PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Han, XD; Tong, J; Zhang, J; Farahvar, A; Wang, E; Yang, JK; Samadani, U; Smith, DH; Huang, JH				Han, Xiaodi; Tong, Jing; Zhang, Jun; Farahvar, Arash; Wang, Ernest; Yang, Jiankai; Samadani, Uzma; Smith, Douglas H.; Huang, Jason H.			Imipramine Treatment Improves Cognitive Outcome Associated with Enhanced Hippocampal Neurogenesis after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessment; controlled cortical impact; medication; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FIBROBLAST-GROWTH-FACTOR; ADULT-MOUSE HIPPOCAMPUS; CENTRAL-NERVOUS-SYSTEM; DENTATE GYRUS; NEUROTROPHIC FACTOR; CELL-PROLIFERATION; GRANULE CELLS; NEURONAL DIFFERENTIATION; ANTIDEPRESSANT TREATMENT	Previous animal and human studies have demonstrated that chronic treatment with several different antidepressants can stimulate neurogenesis, neural remodeling, and synaptic plasticity in the normal hippocampus. Imipramine is a commonly used tricyclic antidepressant (TCA). We employed a controlled cortical impact (CCI) mouse model of traumatic brain injury (TBI) to assess the effect of imipramine on neurogenesis and cognitive and motor function recovery after TBI. Mice were given daily imipramine injections for either 2 or 4 weeks after injury. Bromodeoxyuridine (BrdU) was administered 3-7 days post-brain injury to label the cells that proliferated as a result of the injury. We assessed the effects of imipramine on post-traumatic motor function using a beam-walk test and an assessment of cognitive function: the novel object recognition test (NOR). Histological analyses were performed at 2 and 4 weeks after CCI. Brain-injured mice treated with imipramine showed significantly improved cognitive function compared to a saline-treated group (p < 0.001). However, there was no significant difference in motor function recovery between imipramine-treated and saline-treated mice. Histological examination revealed increased preservation of proliferation of Ki-67- and BrdU-positive cells in the hippocampal dentate gyrus (DG) at 2 and 4 weeks after TBI. Immunofluorescence double-labeling with BrdU and neuron-specific markers at 4 weeks after injury showed that most progenitors became neurons in the DG and astrocytes in the hilus. Notably, treatment with imipramine increased preservation of the total number of newly-generated neurons. Our findings provide direct evidence that imipramine treatment contributes to cognitive improvement after TBI, perhaps by enhanced hippocampal neurogenesis.	[Han, Xiaodi; Tong, Jing; Farahvar, Arash; Wang, Ernest; Yang, Jiankai; Huang, Jason H.] Univ Rochester, Dept Neurosurg, Rochester, NY 14642 USA; [Han, Xiaodi; Tong, Jing; Yang, Jiankai; Huang, Jason H.] Univ Rochester, Ctr Neural Dev & Dis, Rochester, NY 14642 USA; [Han, Xiaodi] Beijing Tiantan Puhua Hosp, Dept Neurosurg, Beijing, Peoples R China; [Zhang, Jun] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China; [Samadani, Uzma] NYU, Dept Neurosurg, New York, NY 10016 USA; [Smith, Douglas H.] Univ Penn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA		Huang, JH (corresponding author), Univ Rochester, Dept Neurol Surg, 601 Elmwood Ave,Box 670, Rochester, NY 14642 USA.	Jason_huang@urmc.rochester.edu	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	University of Rochester; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS-067435]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067435] Funding Source: NIH RePORTER	This work was supported in part by a University of Rochester SPAC grant (to J.H.H.), and by NIH grant R01-NS-067435 (to J.H.H.).	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bachis A, 2008, NEUROPHARMACOLOGY, V55, P1114, DOI 10.1016/j.neuropharm.2008.07.014; Bessa JM, 2009, MOL PSYCHIATR, V14, P764, DOI 10.1038/mp.2008.119; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bowen A, 1999, BRAIN INJURY, V13, P547; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bull ND, 2005, J NEUROSCI, V25, P10815, DOI 10.1523/JNEUROSCI.3249-05.2005; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Castren E, 2007, CURR OPIN PHARMACOL, V7, P18, DOI 10.1016/j.coph.2006.08.009; Chen CPLH, 1996, J NEUROCHEM, V66, P1592, DOI 10.1046/j.1471-4159.1996.66041592.x; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Czeh B, 2001, P NATL ACAD SCI USA, V98, P12796, DOI 10.1073/pnas.211427898; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deb S, 1999, AM J PSYCHIAT, V156, P374; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Encinas JM, 2008, METHOD CELL BIOL, V85, P243, DOI 10.1016/S0091-679X(08)85011-X; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Gaskin S, 2003, HIPPOCAMPUS, V13, P962, DOI 10.1002/hipo.10154; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; KOCSIS JH, 1988, ARCH GEN PSYCHIAT, V45, P253; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Markakis EA, 1999, J COMP NEUROL, V406, P449; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Millan MJ, 2006, PHARMACOL THERAPEUT, V110, P135, DOI 10.1016/j.pharmthera.2005.11.006; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Nakagawa S, 2002, J NEUROSCI, V22, P3673; NIBUYA M, 1995, J NEUROSCI, V15, P7539; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Perera TD, 2007, J NEUROSCI, V27, P4894, DOI 10.1523/JNEUROSCI.0237-07.2007; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rantamaki T, 2007, NEUROPSYCHOPHARMACOL, V32, P2152, DOI 10.1038/sj.npp.1301345; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; ROBINSON RG, 1985, PSYCHOSOMATICS, V26, P769, DOI 10.1016/S0033-3182(85)72790-9; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Sairanen M, 2005, J NEUROSCI, V25, P1089, DOI 10.1523/JNEUROSCI.3741-04.2005; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shapiro LA, 2005, BRAIN RES REV, V48, P43, DOI 10.1016/j.brainresrev.2004.08.003; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAKAHASHI T, 1992, J NEUROCYTOL, V21, P185, DOI 10.1007/BF01194977; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tsankova NM, 2006, NAT NEUROSCI, V9, P519, DOI 10.1038/nn1659; Wang JW, 2008, J NEUROSCI, V28, P1374, DOI 10.1523/JNEUROSCI.3632-07.2008; Wang SH, 2008, BEHAV BRAIN RES, V189, P9, DOI 10.1016/j.bbr.2007.11.028; Warner-Schmidt JL, 2007, P NATL ACAD SCI USA, V104, P4647, DOI 10.1073/pnas.0610282104; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	82	52	56	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					995	1007		10.1089/neu.2010.1563			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600013	21463148	Green Published			2022-02-06	
J	Ro, YS; Shin, SD; Holmes, JF; Song, KJ; Park, JO; Cho, JS; Lee, SC; Kim, SC; Hong, KJ; Park, CB; Cha, WC; Lee, EJ; Kim, YJ; Ahn, KO; Ong, MEH				Ro, Young Sun; Shin, Sang Do; Holmes, James F.; Song, Kyoung Jun; Park, Ju Ok; Cho, Jin Sung; Lee, Seung Chul; Kim, Seong Chun; Hong, Ki Jeong; Park, Chang Bae; Cha, Won Chul; Lee, Eui Jung; Kim, Yu Jin; Ahn, Ki Ok; Ong, Marcus Eng Hock		Traumatic Brain Injury Res Network	Comparison of Clinical Performance of Cranial Computed Tomography Rules in Patients With Minor Head Injury: A Multicenter Prospective Study	ACADEMIC EMERGENCY MEDICINE			English	Article							NEW-ORLEANS CRITERIA; EMERGENCY-DEPARTMENT; CT; MANAGEMENT; VALIDATION; DIAGNOSIS	Objectives: The objective was to compare the predictive performance of three previously derived cranial computed tomography (CT) rules, the Canadian CT Head Rule (CCHR), the New Orleans Criteria (NOC), and National Emergency X-Ray Utilization Study (NEXUS)-II, for detecting clinically important traumatic brain injury (TB!) and the need for neurosurgical intervention in patients with blunt head trauma. Methods: This was a prospective, multicenter, observational cohort study of patients with blunt head trauma from June 2008 to May 2009. The historical and physical examination components of the CCHR, NOC, and NEXUS-II were documented on a data collection form and the performance of each of the three rules was compared. Patient eligibility for each specific rule was defined exactly as previously described for each specific rule. To compare the three decision rules in terms of sensitivity and specificity, an intersection cohort satisfying inclusion criteria of all three decision rules was derived. The primary outcome was clinically important TBI, and the secondary outcome was neurosurgical intervention. The sensitivity and specificity of each rule were calculated with 95% confidence intervals (95% CIs). We also calculated the potential reduction rate in cranial CT scan utilization realized by theoretical implementation of these rules. Results: A total of 7,131 patients were prospectively enrolled, including 692 (9.7%) with clinical TBI. Among the enrolled population, patients eligible for CCHR, NOC, and NEXUS-II totaled 696, 677, and 2,951, respectively. The sensitivity and specificity for clinically important brain injury were as follows: CCHR, 112 of 144 (79.2%, 95% CI = 70.8% to 86.0%) and 228 of 552 (41.3%, 95% CI = 37.3% to 45.5%); NOC, 91 of 99 (91.9%, 95% CI = 84.7% to 96.5%) and 125 of 558 (22.4%, 95% CI = 19.0% to 26.1%); and NEXUS-II, 511 of 576 (88.7%, 95% CI = 85.8% to 91.2%) and 1,104 of 2,375 (46.5%, 95% CI = 44.5% to CI = 59.0% to 100.0%) and 38.3% (95% CI = 34.5% to 41.9%); NOC, 100% (95% CI = 54.1% to 100.0%) and 20.4% (95% CI = 17.4% to 23.7%); and NEXUS-II, 95.1% (95% CI = 90.1% to 98.0%) and 41.4% (95% CI = 39.5% to 43.2%). Among the enrolled population, intersection patients of CCHR, NOC, and NEXUS-II totaled 588. The sensitivity and specificity for clinically important brain injury were as follows: CC FIR, 73 of 98 (74.5%, 95% CI = 64.7% to 82.8%) and 201 of 490 (41.0%, 95% CI = 36.6% to 45.5%); NOC, 89 of 98 (90.8%, 95% CI = 83.3% to 95.7%) and 112 of 490 (22.9%, 95% CI = 19.2% to 26.8%); and NEXUS-II, 82 of 98 (83.7%, 95% CI = 74.8% to 90.4%) and 172 of 490 (35.1%, 95% CI = 30.9% to 39.5%). The potential reduction in emergency CT scans by using these decision rules would have been higher with the NEXUS-II rule (39.6%, 95% CI = 37.8% to 41.4%) than with the CCHR rule (27.0%, 95% CI = 23.7% to 30.3%) or NOC rule (20.2%, 95% CI = 17.2% to 23.3%). Conclusions: For clinically important TBI, the three cranial CT decision rules had much lower sensitivities in this population than the original published studies, while the specificities were comparable to those studies. The sensitivities for neurosurgical intervention, however, were comparable to the original studies. The NEXUS-II rule showed the highest reduction rate for CT scans compared to other rules, but failed to identify all undergoing neurosurgical intervention for their original inclusion cohort. ACADEMIC EMERGENCY MEDICINE 2011; 18:597-604 (C) 2011 by the Society for Academic Emergency Medicine	[Ro, Young Sun; Shin, Sang Do; Park, Chang Bae; Lee, Eui Jung] Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Holmes, James F.] UC Davis Med Ctr, Dept Emergency Med, Davis, CA USA; [Hong, Ki Jeong] Seoul Natl Univ, Dept Emergency Med, Boramae Hosp, Seoul, South Korea; [Park, Ju Ok] Jeju Natl Univ, Dept Emergency Med, Cheju, South Korea; [Cho, Jin Sung] Gachon Univ, Sch Med Sci, Dept Emergency Med, Inchon, South Korea; [Lee, Seung Chul] Dongkuk Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Kim, Seong Chun] Gyeongsang Natl Univ, Coll Med, Dept Emergency Med, Kyoungnam, South Korea; [Hong, Ki Jeong] Daegu Emergency Med Informat Ctr, Gyeongbuk, South Korea; [Cha, Won Chul] Seoguipo Med Ctr, Dept Emergency Med, Cheju, South Korea; [Kim, Yu Jin] Seoul Natl Univ, Dept Emergency Med, Bundang Hosp, Seoul, South Korea; [Ahn, Ki Ok] Seoul Fire Serv Acad Seoul, EMS Educ & Training Ctr, Seoul, South Korea; [Ong, Marcus Eng Hock] Singapore Gen Hosp, Dept Emergency Med, Singapore 0316, Singapore		Shin, SD (corresponding author), Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea.	shinsangdo@snuh.org	안, 기옥/L-5596-2019; Shin, Sang/J-5523-2012	안, 기옥/0000-0002-8446-3269; Hong, Ki Jeong/0000-0003-3334-817X	Korean Centers for Disease Control and Prevention	The Traumatic Brain Injury Research Network of Korea (TBI Network) is an ED-based clinical research network for traumatic brain injury was constructed in 2007 and, at present, seven Ells are participating to this network: Seoul National University Hospital, Dongkuk University Ilsan Hospital, Seoul National University Boramae Medical Center, Jeju National University Hospital, Gyeongsang National University Hospital, Gachon University Gil Hospital, and Seoul National University Bundang Hospital. The Korean Centers for Disease Control and Prevention supported this study financially.	Boyle A, 2004, EMERG MED J, V21, P426, DOI 10.1136/emj.2002.002063; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; MCCAIG LF, 2002, ADV DATA, V327, P1; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell I.G., 2000, ACAD EMERG MED, V7, P572; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sultan HY, 2004, EMERG MED J, V21, P420, DOI 10.1136/emj.2003.011353; *WHO ICECI COORD M, TEST ICECI REV FILED; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	21	52	53	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JUN	2011	18	6					597	604		10.1111/j.1553-2712.2011.01094.x			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	781BP	WOS:000291905900005	21676057				2022-02-06	
J	Scherer, MR; Burrows, H; Pinto, R; Littlefield, P; French, LM; Tarbett, AK; Schubert, MC				Scherer, Matthew R.; Burrows, Holly; Pinto, Robin; Littlefield, Philip; French, Louis M.; Tarbett, Aaron K.; Schubert, Michael C.			Evidence of Central and Peripheral Vestibular Pathology in Blast-Related Traumatic Brain Injury	OTOLOGY & NEUROTOLOGY			English	Article						Blast; Traumatic brain injury; Vestibular function testing; Videonystagmography	NICOTINE-INDUCED NYSTAGMUS; PSYCHIATRIC-DISORDERS; POSITIONAL VERTIGO; DIZZINESS; COMPLAINTS; RESPONSES; HANDICAP; ATAXIA; TESTS	Objective: To prospectively assay the vestibular and oculomotor systems of blast-exposed service members with traumatic brain injury (TBI). Study Design: Prospective, nonblinded, nonrandomized descriptive study. Setting: Tertiary care facility (Department of Defense Medical Center). Patients: Twenty-four service members recovering from blast-related TBI sustained in Iraq or Afghanistan. Interventions: Focused history and physical, videonystagmography (VNG), rotational chair, cervical vestibular-evoked myogenic potentials, computerized dynamic posturography, and self-report measures. Results: Vestibular testing confirms a greater incidence of vestibular and oculomotor dysfunction in symptomatic (vestibularlike dizziness) personnel with blast-related TBI relative to asymptomatic group members. VNG in the symptomatic group revealed abnormal nystagmus or oculomotor findings in 6 of 12 subjects tested. Similarly, rotational chair testing in this group revealed evidence of both peripheral (4/12) and central (2/12) vestibular pathology. By contrast, the asymptomatic group revealed less vestibular impairment with 1 of 10 rotational chair abnormalities. The asymptomatic group was further characterized by fewer aberrant nystagmus findings (4/12 abnormal VNGs). Computerized dynamic posturography testing revealed no significant differences between groups. Self-report measures demonstrated differences between groups. Conclusion: Vestibular function testing confirms a greater incidence of peripheral vestibular hypofunction in dizzy service members with blast-related TBI relative to those who are asymptomatic. Additionally, oculomotor abnormalities and/or nystagmus consistent with central involvement were present in 10 of the 24 study participants tested. The precise cause of these findings remains unknown.	[Scherer, Matthew R.] Univ Maryland, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA; [Burrows, Holly; Pinto, Robin] Army Audiol & Speech Ctr, No Washington, DC USA; [Tarbett, Aaron K.] Walter Reed Army Med Ctr, Optometry Serv, No Washington, DC USA; [French, Louis M.] Walter Reed Army Med Ctr, Traumat Brain Injury Serv, No Washington, DC USA; [Scherer, Matthew R.; Schubert, Michael C.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA		Scherer, MR (corresponding author), Univ Maryland, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA.	Matthew.scherer@us.army.mil	french, louis/AAB-2083-2020	Littlefield, Philip/0000-0002-1890-2278; french, louis/0000-0002-9451-0604			BARBER HO, 1984, OTOLARYNG HEAD NECK, V92, P55, DOI 10.1177/019459988409200112; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bertholon P, 2002, J NEUROL NEUROSUR PS, V72, P366, DOI 10.1136/jnnp.72.3.366; Bertholon P, 2006, ANN OTO RHINOL LARYN, V115, P587, DOI 10.1177/000348940611500804; Brey R, 2008, BALANCE FUNCTION ASS, P254; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Clarke AH, 2001, ACTA OTO-LARYNGOL, P84; COHEN H, 1992, OTOLARYNG HEAD NECK, V107, P638, DOI 10.1177/019459989210700505; Deutschlander A, 2008, NEUROIMAGE, V41, P479, DOI 10.1016/j.neuroimage.2008.03.001; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FERNANDEZ C, 1960, ANN OTOL RHINOL AND LARYNGOL, V69, P94; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gottshall K, 2009, ASS RES OT MIDW M BA; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; GROSSMAN GE, 1988, EXP BRAIN RES, V70, P470; Hoffer M, 2008, VESTIBULAR DIFFERENC; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Honrubia V, 1996, AM J OTOL, V17, P595; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Kattah JC, 2005, ANN NY ACAD SCI, V1039, P540, DOI 10.1196/annals.1325.063; KATTAH JC, 1984, NEUROLOGY, V34, P527, DOI 10.1212/WNL.34.4.527; Kim JS., 2006, J CLIN NEUROL, V2, P58; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Mott FW, 1917, J ROY ARMY MED CORPS, V29, P662; NASHNER LM, 1977, EXP BRAIN RES, V30, P13; NASHNER LM, 1976, EXP BRAIN RES, V26, P59; O'Donnell J, 2000, J TOXICOL-CLIN TOXIC, V38, P659, DOI 10.1081/CLT-100102017; Oh Sun-Young, 2006, J Clin Neurol, V2, P283, DOI 10.3988/jcn.2006.2.4.283; PAIGE GD, 1989, ACTA OTO-LARYNGOL, V108, P1, DOI 10.3109/00016488909107385; Park HJ, 2005, ACTA OTO-LARYNGOL, V125, P852, DOI 10.1080/00016480510033667; Pereira CB, 2000, NEUROLOGY, V55, P1563, DOI 10.1212/WNL.55.10.1563; Polensek SH, 2010, AUDIOL NEURO-OTOL, V15, P241, DOI 10.1159/000255440; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; SAKATA E, 1991, ACTA OTO-LARYNGOL, P254; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Shepard NT, 1996, PRACTICAL MANAGEMENT; Shoman N, 2007, J LARYNGOL OTOL, V121, P166, DOI 10.1017/S0022215106004063; Strupp M, 1998, NEUROLOGY, V51, P838, DOI 10.1212/WNL.51.3.838; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; WAESPE W, 1985, SCIENCE, V228, P199, DOI 10.1126/science.3871968; Walker MF, 1999, ANN NY ACAD SCI, V871, P205, DOI 10.1111/j.1749-6632.1999.tb09186.x; Weathers F.W., 1991, PTSD CHECKLIST MILIT; Yabe I, 2003, J NEUROL, V250, P440, DOI 10.1007/s00415-003-1020-5; YARDLEY L, 1994, SOC SCI MED, V39, P573, DOI 10.1016/0277-9536(94)90100-7; Zapala DA, 2008, J AM ACAD AUDIOL, V19, P257, DOI 10.3766/jaaa.19.3.10	51	52	52	1	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1531-7129	1537-4505		OTOL NEUROTOL	Otol. Neurotol.	JUN	2011	32	4					571	580		10.1097/MAO.0b013e318210b8fa			10	Clinical Neurology; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Otorhinolaryngology	763ME	WOS:000290560600009	21358450				2022-02-06	
J	Shein, NA; Shohami, E				Shein, Na'ama A.; Shohami, Esther			Histone Deacetylase Inhibitors as Therapeutic Agents for Acute Central Nervous System Injuries	MOLECULAR MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SUBEROYLANILIDE HYDROXAMIC ACID; CREB-BINDING-PROTEIN; VALPROIC ACID; MOUSE MODEL; HDAC INHIBITOR; MEDIATED NEUROPROTECTION; INTRACEREBRAL HEMORRHAGE; INFLAMMATORY RESPONSE; ISOFORM SELECTIVITY	Histone deacetylase (HDAC) inhibitors are emerging as a novel class of potentially therapeutic agents for treating acute injuries of the central nervous system (CNS). In this review, we summarize data regarding the effects of HDAC inhibitor administration in models of acute CNS injury and discuss issues warranting clinical trials. We have previously shown that the pan-HDAC inhibitor ITF2357, a compound shown to be safe and effective in humans, improves functional recovery and attenuates tissue damage when administered as late as 24 h after injury. Using a well-characterized, clinically relevant mouse model of closed head injury, we demonstrated that a single dose of ITF2357 administered 24 h after injury improves neurobehavioral recovery and reduces tissue damage. ITF2357-induced functional improvement was found to be sustained up to 14 d after trauma and was associated with augmented histone acetylation. Single postinjury administration of ITF2357 also attenuated injury-induced inflammatory responses, as indicated by reduced glial accumulation and activation as well as enhanced caspase-3 expression within microglia/macrophages after treatment. Because no specific therapeutic intervention is currently available for treating brain trauma patients, the ability to affect functional outcome by postinjury administration of HDAC inhibitors within a clinically feasible timeframe may be of great importance. Furthermore, a growing body of evidence indicates that HDAC inhibitors are beneficial for treating various forms of acute CNS injury including ischemic and hemorrhagic stroke. Because HDAC inhibitors are currently approved for other use, they represent a promising new avenue of treatment, and their use in the setting of CNS injury warrants clinical evaluation. (C) 2011 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2011.00038	[Shein, Na'ama A.; Shohami, Esther] Hebrew Univ Jerusalem, Inst Drug Res, Jerusalem, Israel		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Inst Drug Res, Jerusalem, Israel.	esty@cc.huji.ac.il					Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Atweh GF, 1999, BLOOD, V93, P1790; Avila AM, 2007, J CLIN INVEST, V117, P659, DOI 10.1172/JCI29562; Balasubramanian S, 2009, CANCER LETT, V280, P211, DOI 10.1016/j.canlet.2009.02.013; Barbetti V, 2008, ONCOGENE, V27, P1767, DOI 10.1038/sj.onc.1210820; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Bertrand P, 2010, EUR J MED CHEM, V45, P2095, DOI 10.1016/j.ejmech.2010.02.030; Bieliauskas AV, 2008, CHEM SOC REV, V37, P1402, DOI 10.1039/b703830p; Biermann J, 2010, INVEST OPHTH VIS SCI, V51, P526, DOI 10.1167/iovs.09-3903; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Boutillier AL, 2003, J NEUROCHEM, V84, P814, DOI 10.1046/j.1471-4159.2003.01581.x; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Butler KV, 2008, CURR PHARM DESIGN, V14, P505; Camelo S, 2005, J NEUROIMMUNOL, V164, P10, DOI 10.1016/j.jneuroim.2005.02.022; Candelario-Jalil E, 2009, CURR OPIN INVEST DR, V10, P644; Carlisi D, 2008, INT J ONCOL, V32, P177; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DeFina P, 2009, CLIN NEUROPSYCHOL, V23, P1391, DOI 10.1080/13854040903058978; Dinarello CA, 2010, CELL, V140, P935, DOI 10.1016/j.cell.2010.02.043; Emsley HCA, 2002, J CEREBR BLOOD F MET, V22, P1399, DOI 10.1097/01.WCB.0000037880.62590.28; Endres M, 2000, J NEUROSCI, V20, P3175, DOI 10.1523/JNEUROSCI.20-09-03175.2000; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Gallen Christopher C, 2004, NeuroRx, V1, P165, DOI 10.1602/neurorx.1.1.165; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200; Gaub P, 2010, CELL DEATH DIFFER, V17, P1392, DOI 10.1038/cdd.2009.216; Gerstner T, 2008, EXPERT OPIN PHARMACO, V9, P285, DOI [10.1517/14656566.9.2.285, 10.1517/14656566.9.2.285 ]; Glauben R, 2008, GUT, V57, P613, DOI 10.1136/gut.2007.134650; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Hahnen E, 2008, EXPERT OPIN INV DRUG, V17, P169, DOI 10.1517/13543784.17.2.169; Hildmann C, 2007, APPL MICROBIOL BIOT, V75, P487, DOI 10.1007/s00253-007-0911-2; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Huuskonen J, 2004, BRIT J PHARMACOL, V141, P874, DOI 10.1038/sj.bjp.0705682; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin KL, 2001, J MOL NEUROSCI, V16, P49, DOI 10.1385/JMN:16:1:49; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Khan O, 2008, NAT CLIN PRACT ONCOL, V5, P714, DOI 10.1038/ncponc1238; Kilgore M, 2010, NEUROPSYCHOPHARMACOL, V35, P870, DOI 10.1038/npp.2009.197; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Kim HJ, 2009, J NEUROCHEM, V110, P1226, DOI 10.1111/j.1471-4159.2009.06212.x; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kozikowski AP, 2007, J MED CHEM, V50, P3054, DOI 10.1021/jm070178x; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Langley B, 2008, J NEUROSCI, V28, P163, DOI 10.1523/JNEUROSCI.3200-07.2008; Langley B, 2005, CNS NEUROL DISORD-DR, V4, P41, DOI 10.2174/1568007053005091; Langley B, 2009, STROKE, V40, P2899, DOI 10.1161/STROKEAHA.108.540229; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Levenson JM, 2005, NAT REV NEUROSCI, V6, P108, DOI 10.1038/nrn1604; Lipinski C, 2004, NATURE, V432, P855, DOI 10.1038/nature03193; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Marinova Z, 2009, J NEUROCHEM, V111, P976, DOI 10.1111/j.1471-4159.2009.06385.x; Matalon S, 2010, JAIDS-J ACQ IMM DEF, V54, P1, DOI 10.1097/QAI.0b013e3181d3dca3; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Pape TLB, 2006, J HEAD TRAUMA REHAB, V21, P437, DOI 10.1097/00001199-200609000-00063; Qi X, 2004, MOL PHARMACOL, V66, P899, DOI 10.1124/mol.104.001339; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Rivieccio MA, 2009, P NATL ACAD SCI USA, V106, P19599, DOI 10.1073/pnas.0907935106; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; Ryu H, 2005, J NEUROCHEM, V93, P1087, DOI 10.1111/j.1471-4159.2005.03077.x; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Thomas EA, 2008, P NATL ACAD SCI USA, V105, P15564, DOI 10.1073/pnas.0804249105; Thomas EA, 2009, MOL NEUROBIOL, V40, P33, DOI 10.1007/s12035-009-8067-y; Vecsey CG, 2007, J NEUROSCI, V27, P6128, DOI 10.1523/JNEUROSCI.0296-07.2007; Vojinovic J, 2011, ARTHRITIS RHEUM-US, V63, P1452, DOI 10.1002/art.30238; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Witt KA, 2008, MICROVASC RES, V75, P91, DOI 10.1016/j.mvr.2007.06.004; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yildirim F, 2008, EXP NEUROL, V210, P531, DOI 10.1016/j.expneurol.2007.11.031; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115	91	52	57	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1076-1551	1528-3658		MOL MED	Mol. Med.	MAY-JUN	2011	17	5-6					448	456		10.2119/molmed.2011.00038			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	776HS	WOS:000291525700013	21274503	gold, Green Published			2022-02-06	
J	Hays, AN; Lazaridis, C; Neyens, R; Nicholas, J; Gay, S; Chalela, JA				Hays, Angela N.; Lazaridis, Christos; Neyens, Ron; Nicholas, Joyce; Gay, Sarah; Chalela, Julio A.			Osmotherapy: Use Among Neurointensivists	NEUROCRITICAL CARE			English	Article						Osmotherapy; Cerebral edema; Intracranial pressure; Intracranial hypertension; Traumatic brain injury; Hypertonic saline; Mannitol; Survey; Neurocritical care	TRAUMATIC BRAIN-INJURY; HYPERTONIC SALINE RESUSCITATION; INCREASED INTRACRANIAL-PRESSURE; CEREBRAL-BLOOD-FLOW; INTRACEREBRAL HEMORRHAGE; MANNITOL SOLUTION; OXYGENATION; THERAPY; CARE; HYPOTENSION	Cerebral edema and raised intracranial pressure are common problems in neurological intensive care. Osmotherapy, typically using mannitol or hypertonic saline (HTS), has become one of the first-line interventions. However, the literature on the use of these agents is heterogeneous and lacking in class I studies. The authors hypothesized that clinical practice would reflect this heterogeneity with respect to choice of agent, dosing strategy, and methods for monitoring therapy. An on-line survey was administered by e-mail to members of the Neurocritical Care Society. Multiple-choice questions regarding use of mannitol and HTS were employed to gain insight into clinician practices. A total of 295 responses were received, 79.7% of which were from physicians. The majority (89.9%) reported using osmotherapy as needed for intracranial hypertension, though a minority reported initiating treatment prophylactically. Practitioners were fairly evenly split between those who preferred HTS (54.9%) and those who preferred mannitol (45.1%), with some respondents reserving HTS for patients with refractory intracranial hypertension. Respondents who preferred HTS were more likely to endorse prophylactic administration. Preferred dosing regimens for both agents varied considerably, as did monitoring parameters. Treatment of cerebral edema using osmotically active substances varies considerably between practitioners. This variation could hamper efforts to design and implement multicenter trials in neurocritical care.	[Hays, Angela N.] Med Univ S Carolina, Div Adult Neurol, Dept Neurosci, Charleston, SC 29425 USA		Hays, AN (corresponding author), Med Univ S Carolina, Div Adult Neurol, Dept Neurosci, Charleston, SC 29425 USA.	haysa@musc.edu					Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; Alvarez B, 1998, FREE RADICAL BIO MED, V24, P1331, DOI 10.1016/S0891-5849(98)00005-7; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bhardwaj A, 2007, CURR NEUROL NEUROSCI, V7, P513, DOI 10.1007/s11910-007-0079-2; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gasco J, 2005, ACTA NEUROCHIR SUPPL, V95, P73; Hartl R, 1997, ACT NEUR S, V70, P40; HARTMANN A, 1990, ACT NEUR S, V51, P168; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Himmelseher S, 2007, CURR OPIN ANESTHESIO, V20, P414, DOI 10.1097/ACO.0b013e3282eff9ea; Kalita J, 2004, J NEUROL SCI, V224, P19, DOI 10.1016/j.jns.2004.05.019; Korenkov AI, 2000, NEUROSURG REV, V23, P145, DOI 10.1007/PL00011946; Lee SC, 2005, J CLIN NEUROSCI, V12, P520, DOI 10.1016/j.jocn.2004.07.016; Maioriello AV, 2002, J NEUROSURG, V97, P687, DOI 10.3171/jns.2002.97.3.0687; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Palma L, 2006, J Neurosurg Sci, V50, P63; Poli-De-Figueiredo L. F., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P201; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Rozet I, 2007, ANESTHESIOLOGY, V107, P697, DOI 10.1097/01.anes.0000286980.92759.94; SADICK NS, 1991, J DERMATOL SURG ONC, V17, P65, DOI 10.1111/j.1524-4725.1991.tb01595.x; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Sankar T, 2008, J NEUROSURG, V108, P1010, DOI 10.3171/JNS/2008/108/5/1010; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; SHACKFORD SR, 1988, SURGERY, V104, P553; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048	43	52	56	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2011	14	2					222	228		10.1007/s12028-010-9477-4			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	738SY	WOS:000288663800012	21153930				2022-02-06	
J	Heffernan, DS; Vera, RM; Monaghan, SF; Thakkar, RK; Kozloff, MS; Connolly, MD; Gregg, SC; Machan, JT; Harrington, DT; Adams, CA; Cioffi, WG				Heffernan, Daithi S.; Vera, Roberto M.; Monaghan, Sean F.; Thakkar, Rajan K.; Kozloff, Matthew S.; Connolly, Michael D.; Gregg, Shea C.; Machan, Jason T.; Harrington, David T.; Adams, Charles A., Jr.; Cioffi, William G.			Impact of Socioethnic Factors on Outcomes Following Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Socioethnic factors; Traumatic brain injury; Race; Income; Insurance	SOCIOECONOMIC-STATUS; ETHNIC DISPARITIES; RACIAL-DIFFERENCES; MEDICAL ADVICE; RISK-FACTORS; REHABILITATION; RACE; MORTALITY; ALCOHOL; CARE	Background: Ethnic minorities and low income families tend to be in poorer health and have worse outcomes for a spectrum of diseases. Health care provider bias has been reported to potentially affect the distribution of care away from poorer communities, minorities, and patients with a history of substance abuse. Trauma is perceived as a disease of the poor and medically underserved. Minorities are overrepresented in low income populations and are also less likely to possess health insurance leading to a potential overlapping effect. Traumatic brain injury (TBI) is a predominant cause of mortality and long-term morbidity, which imposes a considerable social and financial burden. We therefore sought to determine the independent effect on outcome after TBI from race, insurance status, intoxication on presentation, and median income. Methods: A 5-year retrospective chart review of admitted trauma patients aged 18 years and older to a Level I trauma center. Zip code of residency was a surrogate marker for socioeconomic status, because median income for each zip code is available from the US Census. Charts review included race, insurance status, mechanisms of trauma, and injuries sustained. Outcomes were placement of tracheostomy, hospital length of stay (HLOS), leaving Against Medical Advice (AMA), and discharge to home versus rehabilitation and mortality. Results: A total of 3,101 TBI patients were included in the analyses. Multivariable logistic and proportional hazard regression analyses were undertaken adjusting for age, gender, Injury Severity Score, and mechanism. Rates of tracheostomy placement were unaffected by race, median income, or insurance status. Race and median income did not affect HLOS, but private insurance was associated with shorter HLOS and intoxication was associated with longer HLOS. Neither race nor intoxication affected rates of AMA, but higher income and private insurance was associated with lower rates of AMA. Non-Caucasian race and lack of insurance had significantly lower likelihood of placement in a rehabilitation center. Mortality was unaffected by race, increased in intoxicated patients, was variably affected by median income, and was lowest in patients with private insurance. Conclusions: An extremely complex interplay exists between socioethnic factors and outcomes after TBI. Few physicians would claim overt discrimination. Tracheostomy, the factor most directed by the surgeon, was unbiased by race, income, or insurance status. The likelihood of placement in a rehabilitation center was significantly impacted by both race and insurance status. Future prospective studies are needed to better address causation.	[Heffernan, Daithi S.; Vera, Roberto M.; Monaghan, Sean F.; Thakkar, Rajan K.; Kozloff, Matthew S.; Connolly, Michael D.; Gregg, Shea C.; Machan, Jason T.; Harrington, David T.; Adams, Charles A., Jr.; Cioffi, William G.] Brown Univ, Alpert Med Sch, Dept Surg, Div Trauma & Surg Crit Care,Rhode Isl Hosp, Providence, RI 02903 USA		Heffernan, DS (corresponding author), Brown Univ, Alpert Med Sch, Dept Surg, Div Trauma & Surg Crit Care,Rhode Isl Hosp, 435 APC Bldg,4th Floor,593 Eddy St, Providence, RI 02903 USA.	dheffernan@brown.edu	Machan, Jason T/D-3897-2013	Machan, Jason T/0000-0003-2048-4914			Alban RF, 2010, AM SURGEON, V76, P1108; Anis AH, 2002, CAN MED ASSOC J, V167, P633; Armenian SH, 1999, DRUG ALCOHOL DEPEN, V56, P1, DOI 10.1016/S0376-8716(99)00027-7; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Braver ER, 2003, ACCIDENT ANAL PREV, V35, P295, DOI 10.1016/S0001-4575(01)00106-3; Cooper L. A., 2003, PATIENT PROVIDER COM; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; Girasek DC, 2010, TRAFFIC INJ PREV, V11, P151, DOI 10.1080/15389580903531598; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; Green AR, 2007, J GEN INTERN MED, V22, P1231, DOI 10.1007/s11606-007-0258-5; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; HERTZMAN C, 1999, POPULATION HLTH HUMA; Kressin NR, 2001, ANN INTERN MED, V135, P352, DOI 10.7326/0003-4819-135-5-200109040-00012; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lim HJ, 2007, J TRAUMA, V63, P902, DOI 10.1097/01.ta.0000240110.14909.71; Lu N, 2004, J HEALTH CARE POOR U, V15, P618, DOI 10.1353/hpu.2004.0053; Lurie N, 2005, CIRCULATION, V111, P1264, DOI 10.1161/01.CIR.0000157738.12783.71; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Nirula R, 2009, J TRAUMA, V66, P255, DOI 10.1097/TA.0b013e31815ede46; NOORDZIJ PC, 1988, ERGONOMICS, V31, P663, DOI 10.1080/00140138808966708; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Reutter LI, 2009, QUAL HEALTH RES, V19, P297, DOI 10.1177/1049732308330246; Saitz R, 1999, AM J MED, V107, P507, DOI 10.1016/S0002-9343(99)00262-4; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Taylor SL, 2006, ANN THORAC SURG, V81, P531, DOI 10.1016/j.athoracsur.2005.08.004; Voas RB, 2009, ACCIDENT ANAL PREV, V41, P522, DOI 10.1016/j.aap.2009.02.004; Weingart SN, 1998, J GEN INTERN MED, V13, P568, DOI 10.1046/j.1525-1497.1998.00169.x; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941; [No title captured]	37	52	53	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2011	70	3					527	533		10.1097/TA.0b013e31820d0ed7			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	732PU	WOS:000288201200007	21610339				2022-02-06	
J	Uttl, B; Kibreab, M				Uttl, Bob; Kibreab, Mekale			Self-Report Measures of Prospective Memory Are Reliable but Not Valid	CANADIAN JOURNAL OF EXPERIMENTAL PSYCHOLOGY-REVUE CANADIENNE DE PSYCHOLOGIE EXPERIMENTALE			English	Article; Proceedings Paper	3rd International Conference on Prospective Memory	JUL, 2010	Vancouver, CANADA			prospective memory; self-reports; measurement; reliability; validity	EVERYDAY PROSPECTIVE MEMORY; TRAUMATIC BRAIN-INJURY; RETROSPECTIVE MEMORY; QUESTIONNAIRE PRMQ; COMPREHENSIVE ASSESSMENT; SUBJECTIVE MEMORY; NORMATIVE DATA; PERFORMANCE; ADULTS; PREDICT	Are self-report measures of prospective memory (ProM) reliable and valid? To examine this question, 240 undergraduate student volunteers completed several widely used self-report measures of ProM including the Prospective Memory Questionnaire (PMQ), the Prospective and Retrospective Memory Questionnaire (PRMQ), the Comprehensive Assessment of Prospective Memory (CAPM) questionnaire, self-reports of retrospective memory (RetM), objective measures of ProM and RetM, and measures of involvement in activities and events, memory strategies and aids use, personality and verbal intelligence. The results showed that both convergent and divergent validity of ProM self-reports are poor, even though we assessed ProM using a newly developed, reliable continuous measure. Further analyses showed that a substantial proportion of variability in ProM self-report scores was due to verbal intelligence, personality (conscientiousness, neuroticism), activities and event involvement (busyness), and use of memory strategies and aids. ProM self-reports have adequate reliability, but poor validity and should not be interpreted as reflecting ProM ability.	[Uttl, Bob] Mt Royal Univ, Dept Psychol, Calgary, AB T3E 6K6, Canada; [Kibreab, Mekale] Univ Calgary, Dept Psychol, Calgary, AB T2N 1N4, Canada		Uttl, B (corresponding author), Mt Royal Univ, Dept Psychol, 4825 Mt Royal Gate SW, Calgary, AB T3E 6K6, Canada.	buttl@mtroyal.ca		Kibreab, Mekale/0000-0001-8813-6006			Chan RCK, 2010, NEUROPSYCHOL REHABIL, V20, P459, DOI 10.1080/09602010903425710; Chau LT, 2007, NEUROPSYCHOL REHABIL, V17, P707, DOI 10.1080/09602010600923926; Costa P. T., 1992, REVISED NEO PERSONAL; Crawford JR, 2003, MEMORY, V11, P261, DOI 10.1080/09658210244000027; Cuttler C, 2007, SCAND J PSYCHOL, V48, P215, DOI 10.1111/j.1467-9450.2007.00570.x; Cuttler C, 2009, J ANXIETY DISORD, V23, P813, DOI 10.1016/j.janxdis.2009.03.006; Delbello R., 2001, PSICOLOGICA, V22, P97; Ellis J, 1999, BRIT J PSYCHOL, V90, P9, DOI 10.1348/000712699161233; Fleming J, 2009, BRAIN IMPAIR, V10, P34, DOI 10.1375/brim.10.1.34; Foster ER, 2009, NEUROPSYCHOLOGY, V23, P347, DOI 10.1037/a0014692; Graf P, 2001, CONSCIOUS COGN, V10, P437, DOI 10.1006/ccog.2001.0504; Graf P, 2002, LIFESPAN DEV HUMAN M, P255; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; Heffernan TM, 2006, J ADOLESCENT HEALTH, V39, P138, DOI 10.1016/j.jadohealth.2005.10.010; Kaplan R. W., 2008, PSYCHOL TESTING PRIN, V7th; Kliegel M, 2006, CURR PSYCHOL, V25, P182, DOI 10.1007/s12144-006-1002-8; Kvavilashvili L, 1998, APPL COGNITIVE PSYCH, V12, P533, DOI 10.1002/(SICI)1099-0720(1998120)12:6<533::AID-ACP538>3.0.CO;2-1; Macan T, 2010, PERS INDIV DIFFER, V48, P725, DOI 10.1016/j.paid.2010.01.015; Mantyla T, 2003, MEM COGNITION, V31, P15, DOI 10.3758/BF03196078; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; Martin M, 2003, AGING CLIN EXP RES, V15, P77; Meeks JT, 2007, CONSCIOUS COGN, V16, P997, DOI 10.1016/j.concog.2006.09.005; Neisser U., 1982, MEMORY OBSERVED REME, P327; Pearman A, 2005, J GERONTOL B-PSYCHOL, V60, pP153, DOI 10.1093/geronb/60.3.P153; RABBITT P, 1995, APPL COGNITIVE PSYCH, V9, pS127, DOI 10.1002/acp.2350090709; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Ronnlund M, 2008, SCAND J PSYCHOL, V49, P11, DOI 10.1111/j.1467-9450.2007.00600.x; Royle J, 2008, DISABIL REHABIL, V30, P114, DOI 10.1080/09638280701223876; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thone-Otto AT, 2008, PROSPECTIVE MEMORY C; Uttl B, 2006, AGING NEUROPSYCHOL C, V13, P141, DOI 10.1080/138255890969618; Uttl B, 2005, DYNAMIC COGNITIVE PROCESSES, P273, DOI 10.1007/4-431-27431-6_12; Uttl B, 2005, PSYCHOL SCI, V16, P460; UTTL B, 2002, MEMORY QUESTIONNAIRE; UTTL B, 2002, WORDS A40 MULTIPLE C; UTTL B, 2002, ACTIVITIES EVENT INV; UTTL B, 2002, MEMORY AIDS QU UNPUB; Uttl B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012539; Uttl B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001568; Waugh N., 1999, THESIS GRIFFITH U BR	43	52	55	1	18	CANADIAN PSYCHOLOGICAL  ASSOC	OTTAWA	141 LAURIER AVE WEST, STE 702, OTTAWA, ONTARIO K1P 5J3, CANADA	1196-1961			CAN J EXP PSYCHOL	Can. J. Exp. Psychol.-Rev. Can. Psychol. Exp.	MAR	2011	65	1			SI		57	68		10.1037/a0022843			12	Psychology, Experimental	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology	739RV	WOS:000288736600009	21443331				2022-02-06	
J	Khaksari, M; Soltani, Z; Shahrokhi, N; Moshtaghi, G; Asadikaram, G				Khaksari, Mohammad; Soltani, Zahra; Shahrokhi, Nader; Moshtaghi, Gholamreza; Asadikaram, Gholamreza			The role of estrogen and progesterone, administered alone and in combination, in modulating cytokine concentration following traumatic brain injury	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article							INFLAMMATORY RESPONSE; CORTICAL CONTUSION; CEREBRAL-ISCHEMIA; OVARIAN HORMONES; FEMALE RATS; EXPRESSION; ESTRADIOL; RECEPTOR; STEROIDS; BARRIER	Cytokines play an important role in the pathophysiology of traumatic brain injury (TBI). This study was designed to determine the effects of administering progesterone (P) and estrogen (E), alone and in combination, on brain water content, blood-brain barrier (BBB) disturbance, and brain level of cytokines following diffuse TBI. Ovariectomized rats were divided into 9 groups, treated with vehicle, E1, E2, P1, P2, E1+P1, E1+P2, E2+P1, and E2+P2. Levels of BBB disruption (5 h), cytokines, and water content (24 h) were evaluated after TBI induced by the Marmarou method. Physiological (E1 and P1) and pharmacological (E2 and P2) doses of estrogen and progesterone were administered 30 min after TBI. Water content in the E1+P2-treated group was higher than in the E1-treated group. The inhibitory effect of E2 on water content was reduced by adding progesterone. The inhibitory effect of E1 and E2 on Evans blue content was reduced by treatment with E1+P1 and E2+P2, respectively. The brain level of IL-1 beta was reduced in E1 and E2, after TBI. In the E2+P2-treated group, this level was higher than in the E2-treated group. The brain level of TGF-beta was also elevated by the administration of progesterone and estrogen alone, and reduced when the hormones were administered in combination. In conclusion, a combined administration of progesterone and estrogen inhibited the decreasing effects of administration of progesterone and estrogen alone on water content and BBB disruption that mediated to change the proinflammatory cytokines.	[Khaksari, Mohammad; Soltani, Zahra] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Bam Int Unit, Kerman, Iran; [Shahrokhi, Nader] Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran; [Moshtaghi, Gholamreza] Kerman Univ Med Sci, Dept Biochem, Kerman, Iran; [Asadikaram, Gholamreza] Rafsanjan Univ Med Sci, Dept Biochem, Rafsanjan, Iran		Khaksari, M (corresponding author), Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran.	khaksar38@yahoo.co.uk	Asadikaram, Gholamreza/AAG-4437-2021; Soltani, Zahra/AAC-1350-2019; Shahrokhi, Nader/AAV-3747-2020; Haddad, Mohammad Khaksari/AAB-9025-2019	Asadikaram, Gholamreza/0000-0002-9100-0756; Soltani, Zahra/0000-0002-8423-6189; Shahrokhi, Nader/0000-0002-0149-7819; Haddad, Mohammad Khaksari/0000-0003-0770-4281; Asadi karam, Gholamreza/0000-0002-6417-5200	neuroscience and physiology research centers of Kerman University of Medical Sciences	The present study was financially supported by the neuroscience and physiology research centers of Kerman University of Medical Sciences.	Baulieu EE, 1996, CELL MOL NEUROBIOL, V16, P143, DOI 10.1007/BF02088173; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chi OZ, 2004, HORM METAB RES, V36, P272, DOI 10.1055/s-2004-814478; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Crandall C, 2006, J WOMENS HEALTH, V15, P14, DOI 10.1089/jwh.2006.15.14; Cutolo M, 2006, ANN NY ACAD SCI, V1089, P538, DOI 10.1196/annals.1386.043; del Zoppo GJ, 2000, THROMB RES, V98, pV73; DeVries HE, 1997, PHARMACOL REV, V49, P143; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Frijns CJM, 2002, STROKE, V33, P2115, DOI 10.1161/01.STR.0000021902.33129.69; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hatthachote P, 1999, ENDOCRINOLOGY, V140, P2533, DOI 10.1210/en.140.6.2533; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Houdeau E, 2007, GASTROENTEROLOGY, V132, P982, DOI 10.1053/j.gastro.2006.12.028; Jonsson Daniel, 2007, Swed Dent J Suppl, P11; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Koski CL, 2004, ENDOCRINOLOGY, V145, P95, DOI 10.1210/en.2003-0803; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu R, 2005, BRAIN RES, V1060, P55, DOI 10.1016/j.brainres.2005.08.048; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; OLSSON T, 1995, IMMUNOL REV, V144, P245, DOI 10.1111/j.1600-065X.1995.tb00072.x; Ospina JA, 2004, AM J PHYSIOL-HEART C, V286, pH2010, DOI 10.1152/ajpheart.00481.2003; POLAN ML, 1989, J CLIN ENDOCR METAB, V69, P1200, DOI 10.1210/jcem-69-6-1200; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schaefer TM, 2005, J IMMUNOL, V175, P6509, DOI 10.4049/jimmunol.175.10.6509; Simpkins J. W., 1997, AM J MED, V103, P19, DOI 10.1016/s0002-9343(97)00260-x; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tibbetts TA, 1999, BIOL REPROD, V60, P1158, DOI 10.1095/biolreprod60.5.1158; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; Yuan K, 2002, J PERIODONTOL, V73, P701, DOI 10.1902/jop.2002.73.7.701	44	52	53	0	7	CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS	OTTAWA	1200 MONTREAL ROAD, BUILDING M-55, OTTAWA, ON K1A 0R6, CANADA	0008-4212			CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	JAN	2011	89	1					31	40		10.1139/Y10-103			10	Pharmacology & Pharmacy; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Physiology	699BB	WOS:000285637800004	21186375	Green Accepted			2022-02-06	
J	Mellergard, P; Aneman, O; Sjogren, F; Saberg, C; Hillman, J				Mellergard, Pekka; Aneman, Oscar; Sjogren, Florence; Saberg, Carina; Hillman, Jan			Differences in Cerebral Extracellular Response of Interleukin-1 beta, Interleukin-6, and Interleukin-10 After Subarachnoid Hemorrhage or Severe Head Trauma in Humans	NEUROSURGERY			English	Article						Interleukins; Interleukin-1; Interleukin-6; Interleukin-10; Microdialysis; Subarachnoid hemorrhage; Traumatic brain injury	NEUROSURGICAL INTENSIVE-CARE; BRAIN-INJURY; INTRACEREBRAL MICRODIALYSIS; CEREBROSPINAL-FLUID; CYTOKINE EXPRESSION; NERVOUS-SYSTEM; INFLAMMATION; PRINCIPLES; CORRELATE; RECOVERY	BACKGROUND: Microdialysis has become a routine method for biochemical surveillance of patients in neurosurgical intensive care units. OBJECTIVE: To analyze the intracerebral extracellular levels of 3 interleukins (ILs) during the 7 days after major subarachnoid hemorrhage or traumatic brain injury). METHODS: Microdialysate from 145 severely injured neurosurgical intensive care unit patients (88 with subarachnoid hemorrhage, 57 with traumatic brain injury) was collected every 6 hours for 7 days. The concentrations of IL-1 beta and IL-6 were determined by fluorescence multiplex bead technology, and IL-10 was determined by enzyme-linked immunosorbent assay. RESULTS: Presented are the response patterns of 3 ILs during the first week after 2 different types of major brain injury. These patterns are different for each IL and also differ with respect to the kind of pathological impact. For both IL-1 beta and IL-6, the initial peaks (mean values for all patients at day 2 being 26.9 +/- 4.5 and 4399 +/- 848 pg/mL, respectively) were followed by a gradual decline, with IL-6 values remaining 100-fold higher compared with IL-1 beta. Female patients showed a stronger and more sustained response. The response of IL-10 was different, with mean values less than 23 pg/mL and with no significant variation between any of the postimpact days. For all 3 ILs, the responses were stronger in subarachnoid hemorrhage patients. The study also indicates that under normal conditions, IL-1 beta, IL-6, and IL-10 are present only at very low concentrations or not at all in the extracellular space of the human brain. CONCLUSION: This is the first report presenting in some detail the human cerebral response of IL-1 beta, IL-6, and IL-10 after subarachnoid hemorrhage and traumatic brain injury. The 3 ILs have different reaction patterns, with the response of IL-1 beta and IL-6 being related to the type of cerebral damage sustained, whereas the IL-10 response was less varied.	[Mellergard, Pekka; Aneman, Oscar; Saberg, Carina; Hillman, Jan] Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden		Mellergard, P (corresponding author), Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.						Ao XP, 2006, METHODS, V38, P331, DOI 10.1016/j.ymeth.2005.11.012; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BENEVISTE H, 1990, PROG NEUROBIOL, V35, P195; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Fulwyler M J, 1990, Methods Cell Biol, V33, P613; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; KEMENY DM, 1992, J IMMUNOL METHODS, V150, P57, DOI 10.1016/0022-1759(92)90065-2; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; Liu S, 2008, BRAIN RES, V1231, P63, DOI 10.1016/j.brainres.2008.07.035; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Sturnegk P, 2007, BRIT J NEUROSURG, V21, P332, DOI 10.1080/02688690701411574; TARKOWSKI E, 1995, STROKE, V26, P1393, DOI 10.1161/01.STR.26.8.1393; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Waelgaard L, 2006, SCAND J IMMUNOL, V64, P345, DOI 10.1111/j.1365-3083.2006.01826.x; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021	32	52	54	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2011	68	1					12	19		10.1227/NEU.0b013e3181ef2a40			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	694IE	WOS:000285288200018	21150751				2022-02-06	
J	Azari, MF; Mathias, L; Ozturk, E; Cram, DS; Boyd, RL; Petratos, S				Azari, Michael F.; Mathias, Louisa; Ozturk, Ezgi; Cram, David S.; Boyd, Richard L.; Petratos, Steven			Mesenchymal Stem Cells for Treatment of CNS Injury	CURRENT NEUROPHARMACOLOGY			English	Article						Mesenchymal Stem Cell; Spinal Cord Injury; Traumatic Brain Injury	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; MARROW STROMAL CELLS; PROMOTE AXONAL REGENERATION; BDNF-PRODUCING FIBROBLASTS; MESSENGER-RNA EXPRESSION; ARTERY OCCLUSION MODEL; ADULT-MOUSE BRAIN; BONE-MARROW; FUNCTIONAL RECOVERY	Brain and spinal cord injuries present significant therapeutic challenges. The treatments available for these conditions are largely ineffective, partly due to limitations in directly targeting the therapeutic agents to sites of pathology within the central nervous system (CNS). The use of stem cells to treat these conditions presents a novel therapeutic strategy. A variety of stem cell treatments have been examined in animal models of CNS trauma. Many of these studies have used stem cells as a cell-replacement strategy. These investigations have also highlighted the significant limitations of this approach. Another potential strategy for stem cell therapy utilises stem cells as a delivery mechanism for therapeutic molecules. This review surveys the literature relevant to the potential of mesenchymal stem cells for delivery of therapeutic agents in CNS trauma in humans.	[Azari, Michael F.; Mathias, Louisa; Ozturk, Ezgi; Cram, David S.; Boyd, Richard L.; Petratos, Steven] Monash Univ, MISCL, Sch Biomed Sci, Fac Med, Clayton, Vic 3800, Australia; [Petratos, Steven] RMIT Univ, Mol Neuropathol & Expt Neurol Lab, Hlth Innovat Res Inst, Bundoora, Vic, Australia; [Petratos, Steven] RMIT Univ, Sch Med Sci, Bundoora, Vic, Australia		Azari, MF (corresponding author), Monash Univ, MISCL, Sch Biomed Sci, Fac Med, Level 3,Bldg 75, Clayton, Vic 3800, Australia.	Michael.Azari@med.monash.edu.au		Azari, Dr Michael F./0000-0003-0674-9322			Azari MF, 2006, J NEUROPATH EXP NEUR, V65, P914, DOI 10.1097/01.jnen.0000235855.77716.25; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bensidhoum M, 2004, BLOOD, V103, P3313, DOI 10.1182/blood-2003-04-1121; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chapel A, 2003, J GENE MED, V5, P1028, DOI 10.1002/jgm.452; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chidgey AP, 2008, NATURE, V453, P330, DOI 10.1038/nature07041; Croft AP, 2006, STEM CELLS, V24, P1841, DOI 10.1634/stemcells.2005-0609; Dasari VR, 2008, NEUROCHEM RES, V33, P134, DOI 10.1007/s11064-007-9426-6; Dasari VR, 2007, NEUROCHEM RES, V32, P2080, DOI 10.1007/s11064-007-9368-z; Dasari VR, 2007, J NEUROTRAUM, V24, P391, DOI 10.1089/neu.2006.0142; Dasari VR, 2008, NEUROBIOL DIS, V32, P486, DOI 10.1016/j.nbd.2008.09.005; Davies Jeannette E, 2008, J Biol, V7, P24, DOI 10.1186/jbiol85; Deumens R, 2008, MOL NEUROBIOL, V37, P52, DOI 10.1007/s12035-008-8016-1; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Dihne M, 2006, STEM CELLS, V24, P1458, DOI 10.1634/stemcells.2005-0413; Eftekharpour E, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E18; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; Ferguson IA, 2001, EUR J NEUROSCI, V13, P1059, DOI 10.1046/j.1460-9568.2001.01482.x; FERON F, 2010, STEM CELLS DEV, V19, P853; FitzGerald J, 2007, J BONE JOINT SURG BR, V89B, P1413, DOI 10.1302/0301-620X.89B11; FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890-196803000-00009; Grill R, 1997, J NEUROSCI, V17, P5560; Han JY, 2007, J KOREAN MED SCI, V22, P242, DOI 10.3346/jkms.2007.22.2.242; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Himes BT, 2001, J NEUROSCI RES, V65, P549, DOI 10.1002/jnr.1185; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Jin Y, 2002, EXP NEUROL, V177, P265, DOI 10.1006/exnr.2002.7980; Jung DI, 2009, J NEUROL SCI, V285, P67, DOI 10.1016/j.jns.2009.05.027; Kang SK, 2006, STEM CELLS DEV, V15, P583, DOI 10.1089/scd.2006.15.583; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; King VR, 1999, NEUROSCIENCE, V92, P935, DOI 10.1016/S0306-4522(99)00072-X; Kobayashi NR, 1997, J NEUROSCI, V17, P9583; Koc ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Kurozumi K, 2005, MOL THER, V11, P96, DOI 10.1016/j.ymthe.2004.09.020; Kurozumi K, 2004, MOL THER, V9, P189, DOI 10.1016/j.ymthe.2003.10.012; Le Blanc K, 2007, LEUKEMIA, V21, P1733, DOI 10.1038/sj.leu.2404777; Le Blanc K, 2006, CURR OPIN IMMUNOL, V18, P586, DOI 10.1016/j.coi.2006.07.004; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977; Macias MY, 2006, EXP NEUROL, V201, P335, DOI 10.1016/j.expneurol.2006.04.035; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A., 2003, NEUROSURGERY, V53, P702; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mitsui T, 2005, EXP NEUROL, V194, P410, DOI 10.1016/j.expneurol.2005.02.022; Murray M, 2002, BRAIN RES REV, V40, P292, DOI 10.1016/S0165-0173(02)00211-4; Nakagami H, 2005, ARTERIOSCL THROM VAS, V25, P2542, DOI 10.1161/01.ATV.0000190701.92007.6d; Nakahara Y, 1996, CELL TRANSPLANT, V5, P191, DOI 10.1016/0963-6897(95)02028-4; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100; Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Sadat S, 2007, BIOCHEM BIOPH RES CO, V363, P674, DOI 10.1016/j.bbrc.2007.09.058; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sykova E, 2006, CELL MOL NEUROBIOL, V26, P1113, DOI 10.1007/s10571-006-9007-2; Tobias CA, 2001, J NEUROTRAUM, V18, P287, DOI 10.1089/08977150151070937; Tome M, 2009, STEM CELLS, V27, P2196, DOI 10.1002/stem.130; Tondreau T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-166; TUSZYNSKI MH, 1994, EXP NEUROL, V126, P1, DOI 10.1006/exnr.1994.1037; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Vallieres L, 2003, J NEUROSCI, V23, P5197; Veeravalli KK, 2009, NEUROBIOL DIS, V36, P200, DOI 10.1016/j.nbd.2009.07.012; Vroemen M, 2003, EUR J NEUROSCI, V18, P743, DOI 10.1046/j.1460-9568.2003.02804.x; Wang H, 2009, STEM CELLS, V27, P1548, DOI 10.1002/stem.81; Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333; Wislet-Gendebien S, 2005, BRAIN RES BULL, V68, P95, DOI 10.1016/j.brainresbull.2005.08.016; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061	77	52	53	2	7	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1570-159X	1875-6190		CURR NEUROPHARMACOL	Curr. Neuropharmacol.	DEC	2010	8	4					316	323					8	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	685IX	WOS:000284623500001	21629440	Green Published, Green Submitted			2022-02-06	
J	Coello, AF; Canals, AG; Gonzalez, JM; Martin, JJA				Fernandez Coello, Alejandro; Gabarros Canals, Andreu; Martino Gonzalez, Juan; Acebes Martin, Juan Jose			Cranial nerve injury after minor head trauma	JOURNAL OF NEUROSURGERY			English	Article						head injury; cranial nerve; minor head trauma	TEMPORAL BONE-FRACTURES; OCULOMOTOR NERVE; FACIAL PALSY; INITIAL SIGN; PARALYSIS; PROGNOSIS; TROCHLEAR; ANOSMIA	Object. There are no specific studies about cranial nerve (CM) injury following mild head trauma (Glasgow Coma Scale Score 14-15) in the literature. The aim of this analysis was to document the incidence of CN injury after mild head trauma and to correlate the initial CT findings with the final outcome 1 year after injury. Methods. The authors studied 49 consecutive patients affected by minor head trauma and CN lesions between January 2000 and January 2006. Detailed clinical and neurological examinations as well as CT studies using brain and bone windows were performed in all patients. Based on the CT findings the authors distinguished 3 types of traumatic injury: no lesion, skull base fracture, and other CT abnormalities. Patients were followed up for I year after head injury. The authors distinguished 3 grades of clinical recovery from CN palsy: no recovery, partial recovery, and complete recovery. Results. Posttraumatic single nerve palsy was observed in 38 patients (77.6%), and multiple nerve injuries were observed in II (22.4%). Cranial nerves were affected in 62 cases. The most affected CN was the olfactory nerve (CN I), followed by the facial nerve (CN VII) and the oculomotor nerves (CNs III, IV, and VI). When more than 1 CN was involved, the most frequent association was between CNs VII and VIII. One year after head trauma, a CN deficit was present in 26 (81.2%) of the 32 cases with a skull base fracture, 12 (60%) of 20 cases with other CT abnormalities, and 3 (30%) of 10 cases without CT abnormalities. Conclusions. Trivial head trauma that causes a minor head injury (Glasgow Coma Scale Score 14-15) can result in CN palsies with a similar distribution to moderate or severe head injuries. The CNs associated with the highest incidence of palsy in this study were the olfactory, facial, and oculomotor nerves. The trigeminal and lower CNs were rarely damaged. Oculomotor nerve injury can have a good prognosis, with a greater chance of recovery if no lesion is demonstrated on the initial CT scan. (DOI: 10.3171/2010.6.JNS091620)	[Fernandez Coello, Alejandro; Gabarros Canals, Andreu; Acebes Martin, Juan Jose] Bellvitge Univ Hosp, Dept Neurosurg, Barcelona, Spain; [Martino Gonzalez, Juan] Marques de Valdecilla Univ Hosp, Dept Neurosurg, Santander, Cantabria, Spain		Coello, AF (corresponding author), Comerc N10bis 2, Barcelona 08003, Spain.	jandrocoello@gmail.com	Fernandez-Coello, Alejandro/A-5772-2019; Fernandez-Coello, Alejandro/AAH-6457-2021	Fernandez-Coello, Alejandro/0000-0003-0418-0339; 			AGUILAR EA, 1987, HEAD NECK-J SCI SPEC, V9, P162, DOI 10.1002/hed.2890090306; Bhatoe CHS, 2007, INDIAN J NEUROTRAUM, V4, P89, DOI 10.1016/S0973-0508(07)80022-0; CHUNG SM, 1996, NEUROTRAUMA, P621; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; ELISEVICH KV, 1984, SURG NEUROL, V22, P565, DOI 10.1016/0090-3019(84)90433-6; EYSTER EF, 1972, J AMER MED ASSOC, V220, P1083, DOI 10.1001/jama.220.8.1083; FELIX H, 1991, ACTA OTO-LARYNGOL, V111, P332, DOI 10.3109/00016489109137396; FUKADO Y, 1981, CRANIAL NERVES, P125; HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202; JAFEK BW, 1989, ARCH NEUROL-CHICAGO, V46, P300, DOI 10.1001/archneur.1989.00520390066018; JENNETT B, 1976, LANCET, V1, P1031; Kaido T, 2006, J CLIN NEUROSCI, V13, P852, DOI 10.1016/j.jocn.2005.08.020; Katzen JT, 2003, J TRAUMA, V54, P1026, DOI 10.1097/01.TA.0000066180.14666.8B; Kaushik V, 2002, CLIN NEUROL NEUROSUR, V105, P42, DOI 10.1016/S0303-8467(02)00101-4; KEANE JR, 1992, NEUROL CLIN, V10, P849, DOI 10.1016/S0733-8619(18)30183-X; Keane JR, 2005, ARCH NEUROL-CHICAGO, V62, P1714, DOI 10.1001/archneur.62.11.1714; KLINE LB, 1984, NEUROSURGERY, V14, P756, DOI 10.1227/00006123-198406000-00021; Leigh AD, 1943, LANCET, V1, P38; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; Li J, 2004, BRAIN INJURY, V18, P315, DOI 10.1080/0269905031000149489; MAHAPATRA AK, 1994, SKULL BASE SURGERY, P305; Mahapatra AK, 2004, IND J NEUROTRAUMA, V1, P33; MAHAPATRA AK, 1992, NEUROL INDIA, V40, P17; MEMON MY, 1971, J NEUROSURG, V35, P461, DOI 10.3171/jns.1971.35.4.0461; Muthu P, 2001, EMERG MED J, V18, P310, DOI 10.1136/emj.18.4.310; Patel P, 2005, INDIAN J NEUROTRAUM, V2, P27, DOI 10.1016/S0973-0508(05)80007-3; RICHARDS BW, 1992, AM J OPHTHALMOL, V113, P489, DOI 10.1016/S0002-9394(14)74718-X; RUSH JA, 1981, ARCH OPHTHALMOL-CHIC, V99, P76, DOI 10.1001/archopht.1981.03930010078006; SOLOMONS NB, 1980, S AFR MED J, V58, P109; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; SYDNOR CF, 1982, OPHTHALMOLOGY, V89, P134; Tiffin PAC, 1996, EYE, V10, P377, DOI 10.1038/eye.1996.77; Turner JWA, 1944, LANCET, V1, P756; WALSH F B, 1957, Br J Ophthalmol, V41, P577, DOI 10.1136/bjo.41.10.577; WALTER KA, 1994, NEUROLOGY, V44, P148, DOI 10.1212/WNL.44.1.148; [No title captured]	37	52	54	1	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					547	555		10.3171/2010.6.JNS091620			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100018	20635856				2022-02-06	
J	Leon-Carrion, J; Martin-Rodriguez, JF; Madrazo-Atutxa, A; Soto-Moreno, A; Venegas-Moreno, E; Torres-Vela, E; Benito-Lopez, P; Galvez, MA; Tinahones, FJ; Leal-Cerro, A				Leon-Carrion, Jose; Francisco Martin-Rodriguez, Juan; Madrazo-Atutxa, Ainara; Soto-Moreno, Alfonso; Venegas-Moreno, Eva; Torres-Vela, Elena; Benito-Lopez, Pedro; Angeles Galvez, Maria; Tinahones, Francisco J.; Leal-Cerro, Alfonso			Evidence of Cognitive and Neurophysiological Impairment in Patients with Untreated Naive Acromegaly	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; HORMONE GH DEFICIENCY; PREFRONTAL CORTEX; LONG-TERM; ALZHEIMERS-DISEASE; CORTICAL RHYTHMS; EPISODIC MEMORY; EEG; QUESTIONNAIRE	Context: Recent studies have suggested that long-term exposure to high levels of GH and IGF-I affect brain and cognitive functions. However, very few human studies have challenged this hypothesis. Objective: The aim of this study is to explore whether GH/IGF-I excess in naive patients with acromegaly alters cognitive functions, particularly memory, and whether these alterations are accompanied by neurophysiological correlates. Design: We conducted a comprehensive neuropsychological and neurophysiological exam on 16 naive acromegaly patients and 16 strictly matched healthy controls. Comparative analyses were carried out on major neurocognitive domains (executive functions, visual/verbal memory, attention, visuoconstructive abilities, and verbal fluency) and on quantitative electroencephalogram and low-resolution brain electromagnetic tomography sources. Results were correlated with GH and IGF-I hormone concentrations. Results: Short-and long-term memory were the most severely impaired cognitive functions. Moreover, memory performance correlated negatively with GH and IGF-I concentrations. No association was detected between depression and memory impairment, and only a marginal association was found with quality of life. Finally, acromegaly patients showed power attenuation in fast frequency electroencephalogram bands, as well as decreased activity in prefrontal and middle temporal cortices, that was associated to cognitive performance. Conclusions: Results provide evidence of cognitive and neurophysiological impairment, characterized by moderate-to-severe memory impairment and decreased neural activity in specific brain areas. High levels of GH and IGF-I in acromegaly patients could be the basis for these findings. (J Clin Endocrinol Metab 95: 4367-4379, 2010)	[Leon-Carrion, Jose] Univ Seville, Human Neuropsychol Lab, Fac Psicol, Dept Expt Psychol, Seville 41018, Spain; [Madrazo-Atutxa, Ainara; Soto-Moreno, Alfonso; Venegas-Moreno, Eva; Leal-Cerro, Alfonso] Univ Seville, Biomed Inst Seville, Univ Hosp Virgen Rocio, Consejo Super Invest Cient, Seville 41018, Spain; Virgen Rocio Univ Hosp, Div Endocrinol, Seville 41013, Spain; [Torres-Vela, Elena] San Cecilio Hosp, Granada 18071, Spain; [Benito-Lopez, Pedro; Angeles Galvez, Maria] Reina Sofia Hosp, Cordoba 14004, Spain; [Tinahones, Francisco J.] Virgen Victoria Hosp, Malaga 29720, Spain		Leon-Carrion, J (corresponding author), Univ Seville, Human Neuropsychol Lab, Fac Psicol, Dept Expt Psychol, C Camilo Jose Cela S-N, Seville 41018, Spain.	leoncarrion@us.es; aleal@ibis-sevilla.es	Tinahones, Francisco Jose/AAB-2882-2020	Martin Rodriguez, Juan Francisco/0000-0003-1392-8775	Novartis Oncology	This work was supported by a grant from Novartis Oncology.	Babiloni C, 2004, NEUROIMAGE, V22, P57, DOI 10.1016/j.neuroimage.2003.09.028; Badia Xavier, 2004, Health Qual Life Outcomes, V2, P13, DOI 10.1186/1477-7525-2-13; Bartke A, 2003, NEUROENDOCRINOLOGY, V78, P210, DOI 10.1159/000073704; Benton A., 1976, MULTILINGUAL APHASIA; Biermasz NR, 2004, J CLIN ENDOCR METAB, V89, P5369, DOI 10.1210/jc.2004-0669; BIGLER ED, 2003, HDB REY OSTERRIETH C, P323; Blumenfeld RS, 2006, J NEUROSCI, V26, P916, DOI 10.1523/JNEUROSCI.2353-05.2006; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; CANAVAN AGM, 1989, NEUROPSYCHOLOGIA, V27, P787, DOI 10.1016/0028-3932(89)90003-1; Chung YH, 2002, BRAIN RES, V946, P307, DOI 10.1016/S0006-8993(02)03041-X; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Colao A, 2004, ENDOCR REV, V25, P102, DOI 10.1210/er.2002-0022; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Fletcher PC, 1998, BRAIN, V121, P1249, DOI 10.1093/brain/121.7.1249; Granada ML, 2008, CLIN ENDOCRINOL, V68, P942, DOI 10.1111/j.1365-2265.2007.03120.x; Henson RNA, 1999, BRAIN, V122, P1367, DOI 10.1093/brain/122.7.1367; Hornberger M, 2008, NEUROLOGY, V71, P1481, DOI 10.1212/01.wnl.0000334299.72023.c8; Jelic V, 2000, NEUROBIOL AGING, V21, P533, DOI 10.1016/S0197-4580(00)00153-6; LAI ZN, 1991, BRAIN RES, V546, P222, DOI 10.1016/0006-8993(91)91485-J; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leon-Carrion J, 2008, CLIN NEUROPHYSIOL, V119, P1506, DOI 10.1016/j.clinph.2008.03.030; Leon-Carrion J, 2009, CLIN ENDOCRINOL, V70, P192, DOI 10.1111/j.1365-2265.2008.03355.x; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Maeshima S, 1997, BRAIN INJURY, V11, P211; Moore MJ, 1998, J NEUROL SCI, V160, pS53, DOI 10.1016/S0022-510X(98)00203-2; Moscovitch M., 2002, HDB MEMORY DISORDERS, V2, P315; O'Kusky JR, 2000, J NEUROSCI, V20, P8435, DOI 10.1523/JNEUROSCI.20-22-08435.2000; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; Pantanetti Paola, 2002, Pituitary, V5, P17, DOI 10.1023/A:1022145116901; Pascual-Marqui RD, 1994, ISBET NEWSLETTER, V5, P4; Richert S, 1987, Schweiz Arch Neurol Psychiatr (1985), V138, P61; Rowles SV, 2005, J CLIN ENDOCR METAB, V90, P3337, DOI 10.1210/jc.2004-1565; Sanz J, 1998, PSICOTHEMA, V10, P303; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sievers C, 2009, PITUITARY, V12, P177, DOI 10.1007/s11102-008-0143-1; Sievers C, 2009, CLIN ENDOCRINOL, V71, P691, DOI 10.1111/j.1365-2265.2009.03555.x; Spalletta G, 2005, AM J GERIAT PSYCHIAT, V13, P108; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; Talairach J., 1988, COPLANAR STEREOTAXIC; Tanriverdi F, 2009, GROWTH HORM IGF RES, V19, P24, DOI 10.1016/j.ghir.2008.05.002; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Tolis G, 2006, NEUROENDOCRINOLOGY, V83, P249, DOI 10.1159/000095535; Turner MS, 2008, CORTEX, V44, P637, DOI 10.1016/j.cortex.2007.01.002; van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1; Webb SM, 2006, EUR J ENDOCRINOL, V155, P269, DOI 10.1530/eje.1.02214; Wechsler D., 1997, WAIS 3 WMS 3 TECHNIC; WERNER S, 2006, SOMATOTROPHIC AXIS B, P267; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	50	52	52	0	10	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	SEP	2010	95	9					4367	4379		10.1210/jc.2010-0394			13	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	647SU	WOS:000281640300054	20554710	Bronze			2022-02-06	
J	Spikman, JM; van der Naalt, J				Spikman, Jacoba M.; van der Naalt, Joukje			Indices of Impaired Self-Awareness in Traumatic Brain Injury Patients with Focal Frontal Lesions and Executive Deficits: Implications for Outcome Measurement	JOURNAL OF NEUROTRAUMA			English	Article						executive functions; frontal lesions; impaired self-awareness; outcome; traumatic brain injury	CLOSED-HEAD-INJURY; DIFFUSE AXONAL INJURY; COMPUTED-TOMOGRAPHY; PREDICTORS; MODERATE; ATTENTION; MILD; MRI; ADULTS; METAANALYSIS	In patients with moderate to severe traumatic brain injury (TBI), impairments of self-awareness are frequently found and associated with worse functional outcome and poor compliance with rehabilitation. The aim of this study was to investigate whether indications of impaired self-awareness could be found in TBI patients with frontal lesions and executive function deficits. Twenty-two TBI patients with focal frontal injuries were compared to 29 TBI patients without focal frontal injuries visible on neuroimaging. No differences were found on several outcome measures, including the Glasgow Outcome Scale-Extended (GOS-E), the Differential Outcome Scale (DOS), and return to work (RTW), although the frontal injury patients were more severely injured as indicated by the Glasgow Coma Scale (GCS) and duration of post-traumatic amnesia (PTA), and had impaired performance on a neuropsychological test of executive functioning. Even more so, the frontal injury group had a significantly lower score on the Sickness Impact Profile (SIP), indicating that they had fewer complaints than the patients without frontal injury, and scored significantly higher on the percentage of recovery (PoR) score, which expresses the extent of recovery as a percentage of their previous level of functioning. In contrast to the non-frontal-injury group, their PoR scores were not related to RTW, reflecting an erroneous perception of their actual working status. The positive results on these different outcome measures, which are partly or entirely self-reported, were seen as an indication of an impaired self-evaluative ability in the frontal injury patients. To determine outcome in a patient with frontal injuries and executive dysfunction, the judgment of several relevant other persons in the patient's life (e.g., partners, therapists, and employers) of the patient's daily life functioning should be sought.	[Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Neuropsychol, NL-9700 RB Groningen, Netherlands; [Spikman, Jacoba M.; van der Naalt, Joukje] Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands		Spikman, JM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Clin Neuropsychol, POB 30-001, NL-9700 RB Groningen, Netherlands.	j.m.spikman@rug.nl		Spikman, Jacoba/0000-0002-6477-0763; van der Naalt, Joukje/0000-0001-9873-2418			Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; JACOBS HM, 1993, THESIS U UTRECHT UTR; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Murrey GJ, 2005, BRAIN INJURY, V19, P599, DOI 10.1080/02699050400025257; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Salthouse TA, 2007, BRAIN COGNITION, V63, P279, DOI 10.1016/j.bandc.2006.09.006; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Silver H, 2009, DEMENT GERIATR COGN, V27, P292, DOI 10.1159/000204916; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; SPSS Inc, 2007, SPSS WIND VERS 16 0; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014; [No title captured]	56	52	52	1	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1195	1202		10.1089/neu.2010.1277			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100004	20380551	Green Submitted			2022-02-06	
J	Topjian, AA; Localio, AR; Berg, RA; Alessandrini, EA; Meaney, PA; Pepe, PE; Larkin, GL; Peberdy, MA; Becker, LB; Nadkarni, VM				Topjian, Alexis A.; Localio, A. Russell; Berg, Robert A.; Alessandrini, Evaline A.; Meaney, Peter A.; Pepe, Paul E.; Larkin, G. Luke; Peberdy, Mary Ann; Becker, Lance B.; Nadkarni, Vinay M.		Natl Registry Cardiopulm Resuscita	Women of child-bearing age have better inhospital cardiac arrest survival outcomes than do equal-aged men	CRITICAL CARE MEDICINE			English	Article						heart arrest; cardiopulmonary resuscitation; gender; women; outcome	HOSPITAL CARDIOPULMONARY-RESUSCITATION; ACUTE MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; TRAUMATIC BRAIN-INJURY; SEX-DIFFERENCES; EXPERIMENTAL STROKE; CEREBRAL-ISCHEMIA; TASK-FORCE; PROGESTERONE	Objectives: Estrogen and progesterone improve neurologic outcomes in experimental models of cardiac arrest and stroke. Our objective was to determine whether women of child-bearing age are more likely than men to survive to hospital discharge after in-hospital cardiac arrest. Design: Prospective, observational study. Setting: Five hundred nineteen hospitals in the National Registry of Cardiopulmonary Resuscitation database. Patients: Patients included 95,852 men and women 15-44 yrs and 56 yrs or older with pulseless cardiac arrests from January 1, 2000 through July 31, 2008. Measurements and Main Results: Patients were stratified a priori by gender and age groups (15-44 yrs and >= 56 yrs). Fixed-effects regression conditioning on hospital was used to examine the relationship between age, gender, and survival outcomes. The unadjusted survival to discharge rate for younger women of child-bearing age (15-44 yrs) was 19% (940/4887) vs. 17% (1203/7025) for younger men (p = .013). The adjusted hospital discharge difference between these younger women and men was 2.8% (95% confidence interval, 1.0% to 4.6%; p = .002), and these younger women also had a 2.6% (95% confidence interval, 0.9% to 4.3%; p = .002) absolute increase in favorable neurologic outcome. For older women compared with men (>= 56 yrs), there were no demonstrable differences in discharge rates (18% vs. 18%; adjusted difference, -0.1%; 95% confidence interval, -0.9% to 0.6%; p = .68) or favorable neurologic outcome (14% vs. 14%; adjusted difference, -0.1%; 95% confidence interval, -0.7% to 0.5%; p = .74). Conclusions: Women of child-bearing age were more likely than comparably aged men to survive to hospital discharge after in-hospital cardiac arrest, even after controlling for etiology of arrest and other important variables. (Crit Care Med 2010; 38:1254-1260)	[Topjian, Alexis A.; Berg, Robert A.; Meaney, Peter A.; Nadkarni, Vinay M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Anesthesia & Crit Care Med, Philadelphia, PA 19104 USA; [Localio, A. Russell] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Alessandrini, Evaline A.] Cincinnati Childrens Hosp, Med Ctr, Div Emergency Med, Cincinnati, OH USA; [Pepe, Paul E.] Univ Texas SW Med Ctr Dallas, Dept Emergency Med, Parkland Hlth Hosp Syst, Dallas, TX 75390 USA; [Larkin, G. Luke] Yale Univ, Sch Med, Dept Surg, Emergency Med Sect, New Haven, CT 06510 USA; [Peberdy, Mary Ann] Virginia Commonwealth Univ, Dept Emergency Med & Internal Med, Richmond, VA USA; [Becker, Lance B.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Becker, Lance B.] Univ Penn, Ctr Resuscitat Sci, Philadelphia, PA 19104 USA		Topjian, AA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Anesthesia & Crit Care Med, Philadelphia, PA 19104 USA.	topjian@email.chop.edu		LARKIN, GREGORY LUKE/0000-0002-8655-7824; Meaney, Peter/0000-0001-9898-6928	Edna G. Kynett Foundation; Philips Medical Systems; Laerdal Medical; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Cardiac Science; BeneChill; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS075363] Funding Source: NIH RePORTER	The Edna G. Kynett Foundation FOCUS Junior Faculty Investigator Award provided funding for design of the study and data analysis.; Dr. Becker has received grant/research support from Philips Medical Systems, Laerdal Medical, NIH, Cardiac Science, and BeneChill. He consulted for Philips Medical Systems, NIH Data Safety Monitoring Board and Protocol Review Committee, and Gaymar Industries. He received patents from Hypothermia Induction and Reperfusion Therapies. He is a special government employee. He has received ownership, equity, and royalties from Cold Core Therapeutics, Inc. He is a member of the American Heart Association. He received speaker honoraria from Zoll Medical, Medtronics, and multiple universities. The remaining authors have not disclosed any potential conflicts of interest.	Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Anderson SE, 2003, PEDIATRICS, V111, P844, DOI 10.1542/peds.111.4.844; Arrich J, 2006, MEDICINE, V85, P288, DOI 10.1097/01.md.0000236954.72342.20; Carr BG, 2009, RESUSCITATION, V80, P30, DOI 10.1016/j.resuscitation.2008.09.001; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Davison A. C., 1997, BOOSTRAP METHODS THE; de Vos R, 1999, ARCH INTERN MED, V159, P845, DOI 10.1001/archinte.159.8.845; Ehlenbach WJ, 2009, NEW ENGL J MED, V361, P22, DOI 10.1056/NEJMoa0810245; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Gan SC, 2000, NEW ENGL J MED, V343, P8, DOI 10.1056/NEJM200007063430102; Glickman SW, 2007, AM HEART J, V154, P1206, DOI 10.1016/j.ahj.2007.08.001; Herlitz J, 2004, RESUSCITATION, V60, P197, DOI 10.1016/j.resuscitation.2003.09.012; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Kim C, 2001, CIRCULATION, V104, P2699, DOI 10.1161/hc4701.099784; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Mahapatra S, 2005, RESUSCITATION, V65, P197, DOI 10.1016/j.resuscitation.2004.10.017; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; MCKINLAY SM, 1992, MATURITAS, V14, P103, DOI 10.1016/0378-5122(92)90003-M; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Noppens RR, 2009, J CEREBR BLOOD F MET, V29, P277, DOI 10.1038/jcbfm.2008.116; Peberdy MA, 2008, JAMA-J AM MED ASSOC, V299, P785, DOI 10.1001/jama.299.7.785; Pell JP, 2000, EUR HEART J, V21, P239, DOI 10.1053/euhj.1999.1629; Perers E, 1999, RESUSCITATION, V40, P133, DOI 10.1016/S0300-9572(99)00022-2; Peterson ED, 2006, JAMA-J AM MED ASSOC, V295, P1912, DOI 10.1001/jama.295.16.1912; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; Vaccarino V, 2005, NEW ENGL J MED, V353, P671, DOI 10.1056/NEJMsa032214; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Vukmir RB, 2003, J WOMENS HEALTH, V12, P667, DOI 10.1089/154099903322404311; Wigginton JG, 2002, CRIT CARE MED, V30, pS131, DOI 10.1097/00003246-200204001-00002; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; ZARITSKY A, 1995, PEDIATRICS, V96, P765; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	40	52	53	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2010	38	5					1254	1260		10.1097/CCM.0b013e3181d8ca43			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	593JD	WOS:000277449100003	20228684	Green Accepted			2022-02-06	
J	Hall, KD; Lifshitz, J				Hall, Kelley D.; Lifshitz, Jonathan			Diffuse traumatic brain injury initially attenuates and later expands activation of the rat somatosensory whisker circuit concomitant with neuroplastic responses	BRAIN RESEARCH			English	Article						Regeneration; Ventral posterior medial; Barrel field; GAP-43; APP; Sport-related concussion	FUNCTIONAL REORGANIZATION; STRUCTURAL PLASTICITY; GENE-EXPRESSION; AXONAL INJURY; ADULT CAT; CORTEX; GAP-43; EXPERIENCE; SEQUELAE; AXOTOMY	Traumatic brain injury can initiate an array of chronic neurological deficits, effecting executive function, language and sensorimotor integration. Mechanical forces produce the diffuse pathology that disrupts neural circuit activation across vulnerable brain regions. The present manuscript explores the hypothesis that the extent of functional activation of brain-injured circuits is a consequence of initial disruption and consequent reorganization. In the rat, enduring sensory sensitivity to whisker stimulation directs regional analysis to the whisker barrel circuit. Adult, male rats were subjected to midline fluid percussion brain or sham injury and evaluated between 1 day and 42 days post-injury. Whisker somatosensory regions of the cortex and thalamus maintained cellular composition as visualized by Nissl stain. Within the first week post-injury, quantitatively less cFos activation was elicited by whisker stimulation, potentially due to axotomy within and surrounding the whisker circuit as visualized by amyloid precursor protein immunohistochemistry. Over six weeks post-injury, cFos activation after whisker stimulation showed a significant linear correlation with time in the cortex (r(2)=0.545; p=0.015), non-significant correlation in the thalamus (r(2)=0.326) and U-shaped correlation in the dentate gyrus (r(2)=0.831), all eventually exceeding sham levels. Ongoing neuroplastic responses in the cortex are evidenced by accumulating growth associated protein and synaptophysin gene expression. In the thalamus, the delayed restoration of plasticity markers may explain the broad distribution of neuronal activation extending into the striatum and hippocampus with whisker stimulation. The sprouting of diffuse-injured circuits into diffuse-injured tissue likely establishes maladaptive circuits responsible for behavioral morbidity. Therapeutic interventions to promote adaptive circuit restructuring may mitigate post-traumatic morbidity. (C) 2010 Elsevier B.V. All rights reserved.	[Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, BBSRB, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Phys Med & Rehabil, Lexington, KY 40536 USA		Lifshitz, J (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, BBSRB, B463,741 S Limestone St, Lexington, KY 40536 USA.	jlifshitz@uky.com			University of Kentucky Chandler Medical Center [F32 HD-049343];  [R01 NINDS-NS065052];  [P30 NINDS-NS051220]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052, P30NS051220] Funding Source: NIH RePORTER	Supported, in part, by R01 NINDS-NS065052, the University of Kentucky Chandler Medical Center, F32 HD-049343 and P30 NINDS-NS051220. Special thanks to Ms. C. Lynn Davis and Amanda M. Lisembee for technical support.	Bergmann M, 1997, EXP BRAIN RES, V117, P80, DOI 10.1007/s002210050201; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bisler S, 2002, J CHEM NEUROANAT, V23, P187, DOI 10.1016/S0891-0618(01)00155-7; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; Carmichael ST, 2003, NEUROSCIENTIST, V9, P64, DOI 10.1177/1073858402239592; Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Chuckowree JA, 2004, NEUROSCIENTIST, V10, P280, DOI 10.1177/1073858404263511; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DeBello WM, 2008, TRENDS NEUROSCI, V31, P577, DOI 10.1016/j.tins.2008.08.006; DI GS, 2005, FASEB J, V19, P153; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; DUNNMEYNELL AA, 1992, J COMP NEUROL, V315, P160, DOI 10.1002/cne.903150204; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feldman DE, 2005, SCIENCE, V310, P810, DOI 10.1126/science.1115807; Franklin JL, 1998, J CELL BIOL, V142, P1313, DOI 10.1083/jcb.142.5.1313; Haidarliu S, 2001, J COMP NEUROL, V429, P372, DOI 10.1002/1096-9861(20010115)429:3<372::AID-CNE2>3.0.CO;2-3; Holtmaat A, 2008, BEHAV BRAIN RES, V192, P20, DOI 10.1016/j.bbr.2008.04.005; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Iarocci G, 2006, J AUTISM DEV DISORD, V36, P77, DOI 10.1007/s10803-005-0044-3; Jain N, 2008, J NEUROSCI, V28, P11042, DOI 10.1523/JNEUROSCI.2334-08.2008; Johansen-Berg H, 2007, CURR BIOL, V17, pR141, DOI 10.1016/j.cub.2006.12.022; Jones EG, 2000, ANNU REV NEUROSCI, V23, P1, DOI 10.1146/annurev.neuro.23.1.1; Jones EG, 1998, SCIENCE, V282, P1121, DOI 10.1126/science.282.5391.1121; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924, DOI 10.1152/ajpheart.2000.279.3.H924; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Povlishock JT, 2001, HEAD TRAUMA, P281; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; VAUDANO E, 1995, J NEUROSCI, V15, P3594; Waite Phil M. E., 1995, P705; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011	57	52	52	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 6	2010	1323						161	173		10.1016/j.brainres.2010.01.067			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	583MJ	WOS:000276680300018	20122903	Green Accepted			2022-02-06	
J	Gilmer, LK; Ansari, MA; Roberts, KN; Scheff, SW				Gilmer, Lesley K.; Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.			Age-related changes in mitochondrial respiration and oxidative damage in the cerebral cortex of the Fischer 344 rat	MECHANISMS OF AGEING AND DEVELOPMENT			English	Article						Aging; Clark-type electrode; Respiration; Cortex; Mitochondria; Oxidative damage	NON-SYNAPTIC MITOCHONDRIA; TRAUMATIC BRAIN-INJURY; NONSYNAPTIC MITOCHONDRIA; ANTIOXIDANT ENZYMES; DEPENDENT CHANGES; NEUROLOGICAL PERFORMANCE; LIPID-PEROXIDATION; TIME-COURSE; COMPLEX I; VITAMIN-E	This study probed possible age-related changes in mitochondrial bioenergetics in naive Fischer 344 rats. Synaptic and extrasynaptic mitochondria were isolated from the cortex of one hemisphere of young (3-5 months), middle (12-14 months), or aged (22-24 months) rats. Respiration parameters were obtained using a Clarke-type electrode. Aged rats displayed no significant alterations in respiration, indicating mitochondria must be more resilient to the aging process than previously thought. Synaptic mitochondria displayed lower respiration capacities than the extrasynaptic fraction. Aged F344 rats appear capable of normal electron transport chain function without declines in ability to produce ATP. Markers of cortical oxidative damage (3-nitrotyrosine [3-NT],4-hydroxynonenal [4-HNE], and protein carbonyls [PC]) were collected from the post-mitochondrial supernatant (PMS) from the contralateral hemisphere, and from mitochondrial samples following respiration analysis. Age-related increases in PC and 3-NT levels were found in synaptic mitochondria, whereas significant extrasynaptic elevations were only found in middle aged rats. These findings support an age-related increase in oxidative damage in the cortex, while proposing the two fractions of mitochondria are differentially affected by the aging process. Levels of oxidative damage that accumulates in the cortex with age does not appear to significantly impair cortical mitochondrial respiration of F344 rats. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Gilmer, Lesley K.; Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Scheff, Stephen W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown Bldg,800 S Limestone, Lexington, KY 40536 USA.	lesleygilmer@uky.edu; mubeen.ansari@uky.edu; knrobe2@email.uky.edu; sscheff@email.uky.edu		Ansari, Mubeen Ahmad/0000-0002-1132-5965	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21981]; NIH-NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1T32 DA 022738-01]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by NIH grant AG21981 and training grant NIH-NIDA 1T32 DA 022738-01.	AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Armeni T, 2003, J BIOENERG BIOMEMBR, V35, P181, DOI 10.1023/A:1023754305218; Atamna H, 2007, MITOCHONDRION, V7, P297, DOI 10.1016/j.mito.2007.06.001; Baek BS, 1999, ARCH PHARM RES, V22, P361, DOI 10.1007/BF02979058; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BENZI G, 1992, NEUROBIOL AGING, V13, P361, DOI 10.1016/0197-4580(92)90109-B; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHIU YJD, 1980, EXP GERONTOL, V15, P511, DOI 10.1016/0531-5565(80)90003-0; Cocco T, 2005, FREE RADICAL BIO MED, V38, P796, DOI 10.1016/j.freeradbiomed.2004.11.034; COLEMAN GL, 1977, J GERONTOL, V32, P258, DOI 10.1093/geronj/32.3.258; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Davey GP, 1997, J NEUROCHEM, V69, P2564; Davey GP, 1996, J NEUROCHEM, V66, P1617; Davies SMK, 2001, FREE RADICAL BIO MED, V31, P181, DOI 10.1016/S0891-5849(01)00576-7; Davis M, 1997, ACT NEUR S, V70, P56; DENNIS SC, 1977, BIOCHEM J, V164, P727, DOI 10.1042/bj1640727; DESHMUKH DR, 1982, MECH AGEING DEV, V20, P343, DOI 10.1016/0047-6374(82)90101-4; DESHMUKH DR, 1980, MECH AGEING DEV, V13, P75, DOI 10.1016/0047-6374(80)90131-1; DESHMUKH DR, 1980, J NEUROCHEM, V34, P1219, DOI 10.1111/j.1471-4159.1980.tb09962.x; DogruAbbasoglu S, 1997, MECH AGEING DEV, V98, P177, DOI 10.1016/S0047-6374(97)00082-1; Erecinska M, 1996, BBA-BIOENERGETICS, V1277, P13, DOI 10.1016/S0005-2728(96)00103-X; FERRANDIZ ML, 1994, BRAIN RES, V644, P335, DOI 10.1016/0006-8993(94)91699-3; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Genova ML, 1997, FEBS LETT, V410, P467; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; GORINI A, 1989, BASIC APPL HISTOCHEM, V33, P139; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMON HJ, 1987, MECH AGEING DEV, V38, P167, DOI 10.1016/0047-6374(87)90076-5; Joseph JA, 2000, MECH AGEING DEV, V116, P141, DOI 10.1016/S0047-6374(00)00128-7; Kaufmann JA, 2001, J NEUROCHEM, V76, P1099, DOI 10.1046/j.1471-4159.2001.00118.x; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kwong LK, 2000, ARCH BIOCHEM BIOPHYS, V373, P16, DOI 10.1006/abbi.1999.1495; LaFrance R, 2005, AGING CELL, V4, P139, DOI 10.1111/j.1474-9726.2005.00156.x; LAI JCK, 1994, METAB BRAIN DIS, V9, P143, DOI 10.1007/BF01999767; LAI JCK, 1977, J NEUROCHEM, V28, P625, DOI 10.1111/j.1471-4159.1977.tb10434.x; LEONG SF, 1984, J NEUROCHEM, V42, P1306, DOI 10.1111/j.1471-4159.1984.tb02788.x; LESLIE SW, 1985, BRAIN RES, V329, P177, DOI 10.1016/0006-8993(85)90523-2; Lesnefsky EJ, 2006, AGEING RES REV, V5, P402, DOI 10.1016/j.arr.2006.04.001; Leuner K, 2007, ANTIOXID REDOX SIGN, V9, P1659, DOI 10.1089/ars.2007.1763; Long JG, 2009, NEUROCHEM RES, V34, P755, DOI 10.1007/s11064-008-9850-2; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Meng QY, 2007, MECH AGEING DEV, V128, P286, DOI 10.1016/j.mad.2006.12.008; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Navarro A, 2005, AM J PHYSIOL-REG I, V289, pR1392, DOI 10.1152/ajpregu.00834.2004; Navarro A, 2004, AM J PHYSIOL-REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003; Navarro A, 2002, AM J PHYSIOL-REG I, V282, pR985, DOI 10.1152/ajpregu.00537.2001; Navarro A, 2004, AM J PHYSIOL-REG I, V287, pR1244, DOI 10.1152/ajpregu.00226.2004; Navarro A, 2008, AM J PHYSIOL-REG I, V294, pR501, DOI 10.1152/ajpregu.00492.2007; Navarro A, 2007, FRONT BIOSCI-LANDMRK, V12, P1154, DOI 10.2741/2133; Nicholls DG, 2002, INT J BIOCHEM CELL B, V34, P1372, DOI 10.1016/S1357-2725(02)00077-8; O'Donnell E, 1998, NEUROBIOL AGING, V19, P461, DOI 10.1016/S0197-4580(98)00082-7; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Petrosillo G, 2008, NEUROCHEM INT, V53, P126, DOI 10.1016/j.neuint.2008.07.001; Petrosillo G, 2008, REJUV RES, V11, P935, DOI 10.1089/rej.2008.0772; Renes J, 2000, BIOCHEM J, V350, P555, DOI 10.1042/0264-6021:3500555; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594; Sahoo A, 1997, INT J DEV NEUROSCI, V15, P939, DOI 10.1016/S0736-5748(97)00049-X; Sandhu SK, 2003, BIOGERONTOLOGY, V4, P19, DOI 10.1023/A:1022473219044; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Sharman EH, 2001, NEUROBIOL AGING, V22, P629, DOI 10.1016/S0197-4580(01)00226-3; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Shin CM, 2002, BRAIN RES, V931, P194, DOI 10.1016/S0006-8993(01)03391-1; Shukitt-Hale B, 1998, EXP GERONTOL, V33, P615, DOI 10.1016/S0531-5565(98)00024-2; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SPANGLER EL, 1994, NEUROBIOL AGING, V15, P319, DOI 10.1016/0197-4580(94)90027-2; Stuart JA, 2005, FREE RADICAL BIO MED, V38, P737, DOI 10.1016/j.freeradbiomed.2004.12.003; Tian LQ, 1998, FREE RADICAL BIO MED, V24, P1477, DOI 10.1016/S0891-5849(98)00025-2; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Van Remmen H, 2001, EXP GERONTOL, V36, P957; VILLA RF, 1989, MECH AGEING DEV, V49, P211, DOI 10.1016/0047-6374(89)90072-9; Walker LM, 2001, TOXICOL SCI, V63, P143, DOI 10.1093/toxsci/63.1.143; WEINDRUCH R, 1991, J GERONTOL, V46, pB87, DOI 10.1093/geronj/46.3.B87; WEINDRUCH RH, 1980, MECH AGEING DEV, V12, P375, DOI 10.1016/0047-6374(80)90070-6; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	83	52	54	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0047-6374	1872-6216		MECH AGEING DEV	Mech. Ageing Dev.	FEB	2010	131	2					133	143		10.1016/j.mad.2009.12.011			11	Cell Biology; Geriatrics & Gerontology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Geriatrics & Gerontology	574LV	WOS:000275991600009	20080122	Green Accepted			2022-02-06	
J	Harris, NG; Mironova, YA; Hovda, DA; Sutton, RL				Harris, Neil G.; Mironova, Yevgeniya A.; Hovda, David A.; Sutton, Richard L.			Pericontusion Axon Sprouting Is Spatially and Temporally Consistent With a Growth-Permissive Environment After Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axon sprouting; Brain-derived neurotrophic factor; Brain trauma; Chondroitin sulfate proteoglycan; Fibronectin; GAP43; Neuroplasticity; Perineuronal nets	CORTICAL IMPACT INJURY; INTRINSIC NEURONAL DETERMINANTS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD INJURY; ADULT-RAT BRAIN; CEREBRAL-CORTEX; EXTRACELLULAR-MATRIX; MESSENGER-RNA; CHONDROITIN-SULFATE; FUNCTIONAL RECOVERY	We previously reported that pericontusional extracellular chondroitin Sulfate proteoglycans (CSPGs) are profoundly reduced for 3 weeks after experimental traumatic brain injury, indicating a potential growth-permissive window for plasticity. Here, we investigate the extracellular environment of sprouting neurons after controlled cortical impact injury in adult rats to determine the spatial and temporal arrangement of inhibitory and growth-promoting molecules in relation to growth-associated protein 43-positive (GAP43+) neurons. Spontaneous cortical sprouting was maximal in pericontused regions at 7 and 14 days after injury but absent by 28 days. Perineuronal nets containing CSPGs were reduced at 7 days after injury in the pericontused region (p < 0.05), which was commensurate with a reduction in extracellular CSPGs. Sprouting was restricted to the perineuronal nets and CSPG-deficient regions at 7 days, indicating that the pericontused region is temporarily and spatially permissive to new growth. At this time point, GAP43+ neurons were associated with brain regions containing cells positive for polysialic acid neural cell adhesion molecule but not with fibronectin-positive cells. Brain-derived neurotrophic factor was reduced in the immediate pericontused region at 7 days. Along with prior Western blot evidence, these data Suggest that a lowered intrinsic growth stimulus, together with a later return of growth-inhibitory CSPGs, may contribute to the ultimate disappearance of sprouting neurons after traumatic brain injury.	[Harris, Neil G.; Mironova, Yevgeniya A.; Hovda, David A.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Harris, NG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Box 957039, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu		Harris, Neil/0000-0002-1965-6750	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055910]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055910] Funding Source: NIH RePORTER	This work was supported by the UCLA Brain Injury Research Center and Award Number R01 NS055910 from the National Institute of Neurological Disorders and Stroke.	Alonso G, 1997, J COMP NEUROL, V384, P181; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Batchelor PE, 2000, EUR J NEUROSCI, V12, P3462, DOI 10.1046/j.1460-9568.2000.00239.x; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 2008, BRAIN RES, V1209, P49, DOI 10.1016/j.brainres.2008.02.098; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bonfanti L, 2006, PROG NEUROBIOL, V80, P129, DOI 10.1016/j.pneurobio.2006.08.003; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bruckner G, 1998, EXP BRAIN RES, V121, P300, DOI 10.1007/s002210050463; Bruckner G, 1996, J NEUROCYTOL, V25, P333, DOI 10.1007/BF02284806; BRUCKNER G, 1994, BRAIN RES, V658, P67; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Carmichael ST, 2001, NEUROBIOL DIS, V8, P910, DOI 10.1006/nbdi.2001.0425; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; Caroni P, 1997, BIOESSAYS, V19, P767, DOI 10.1002/bies.950190906; Carulli D, 2007, J COMP NEUROL, V501, P83, DOI 10.1002/cne.21231; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen S., 2002, J NEUROTRAUM, V19, P1300; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; DANI JW, 1991, NEUROSCIENCE, V40, P277, DOI 10.1016/0306-4522(91)90190-Y; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DELOULME JC, 1990, J CELL BIOL, V111, P1559, DOI 10.1083/jcb.111.4.1559; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Emery DL, 2000, J COMP NEUROL, V424, P521; FAWCETT JW, 1992, TRENDS NEUROSCI, V15, P5, DOI 10.1016/0166-2236(92)90338-9; Feig SL, 2004, J COMP NEUROL, V468, P96, DOI 10.1002/cne.10969; Gascon E, 2007, BRAIN RES REV, V56, P101, DOI 10.1016/j.brainresrev.2007.05.014; Ghiani CA, 2007, GLIA, V55, P966, DOI 10.1002/glia.20521; Gogolla N, 2007, CURR OPIN NEUROBIOL, V17, P516, DOI 10.1016/j.conb.2007.09.002; GREENOUGH WT, 1985, BEHAV NEURAL BIOL, V44, P301, DOI 10.1016/S0163-1047(85)90310-3; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; HARRIS NG, 2003, J CEREB METAB BLOOD, V21, P13; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; HOCKFIELD S, 1990, COLD SH Q B, V55, P505; Hsu JYC, 2005, J NEUROSCI RES, V80, P330, DOI 10.1002/jnr.20472; Huber AB, 2002, J NEUROSCI, V22, P3553; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; JONES TA, 1994, J NEUROSCI, V14, P2140; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; King VR, 2003, EXP NEUROL, V182, P383, DOI 10.1016/S0014-4886(03)00033-5; Kleim JA, 1996, J NEUROSCI, V16, P4529; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KUROKAWA T, 1976, J BIOL CHEM, V251, P5686; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; LOVINGER DM, 1986, BRAIN RES, V399, P205, DOI 10.1016/0006-8993(86)91510-6; Massey JM, 2006, J NEUROSCI, V26, P4406, DOI 10.1523/JNEUROSCI.5467-05.2006; MILLER JA, 1991, NEUROSCI LETT, V121, P211, DOI 10.1016/0304-3940(91)90687-O; Mironova Y, 2009, J NEUROTRAUM, V26, pA43; Moretti FA, 2007, J BIOL CHEM, V282, P28057, DOI 10.1074/jbc.M611315200; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; MURAKAMI T, 1994, ARCH HISTOL CYTOL, V57, P509, DOI 10.1679/aohc.57.509; NEVE RL, 1989, P NATL ACAD SCI USA, V86, P4781, DOI 10.1073/pnas.86.12.4781; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Plunet W, 2002, J NEUROSCI RES, V68, P1, DOI 10.1002/jnr.10176; Rasband W.S, 1997, IMAGEJ US; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Rossi F, 2007, PROG NEUROBIOL, V81, P1, DOI 10.1016/j.pneurobio.2006.12.001; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; STEWART GR, 1987, J NEUROSCI, V7, P3325; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tate CC, 2007, J NEUROTRAUM, V24, P226, DOI 10.1089/neu.2006.0043; TETZLAFF W, 1994, PROG BRAIN RES, V103, P271; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Uryu K, 2001, NEUROSCIENCE, V105, P307, DOI 10.1016/S0306-4522(01)00203-2; Verma P, 2005, J NEUROSCI, V25, P331, DOI 10.1523/JNEUROSCI.3073-04.2005; VITKOVIC L, 1988, P NATL ACAD SCI USA, V85, P8296, DOI 10.1073/pnas.85.21.8296; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wegner F, 2003, EXP NEUROL, V184, P705, DOI 10.1016/S0014-4886(03)00313-3; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; YAMADA K, 1994, ACTA NEUROPATHOL, V88, P553	86	52	56	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	FEB	2010	69	2					139	154		10.1097/NEN.0b013e3181cb5bee			16	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	550FV	WOS:000274114600003	20084019	Green Accepted, Bronze			2022-02-06	
J	Bloomfield, ILM; Espie, CA; Evans, JJ				Bloomfield, Imogen L. M.; Espie, Colin A.; Evans, Jonathan J.			Do sleep difficulties exacerbate deficits in sustained attention following traumatic brain injury?	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Arousal; Cognition; Neuropsychological tests; Frontal lobe; Closed head injury; Sleep initiation and maintenance disorders	INSOMNIA; PERFORMANCE; DEPRIVATION; DISTURBANCE; ACTIGRAPHY; DISORDERS; MEDICINE; FAILURES; CRITERIA; QUALITY	Sustained attention has been shown to be vulnerable following traumatic brain injury (TBI). Sleep restriction and disturbances have been shown to negatively affect Sustained attention. Sleep disorders are common but Under-diagnosed after TBI. Thus, it seems possible that Sleep disturbances may exacerbate neuropsychological deficits for a proportion of individuals who have Sustained a TBI. The aim of this prospective Study Was to examine whether poor sleepers post-TBI had poorer sustained and general attentional functioning than good sleepers post-TBI. Retrospective Subjective, prospective Subjective, and objective measures Were used to assess participants sleep. The results showed that the poor sleep group had significantly poorer Sustained attention ability than the good sleep group. The differences on other measures of attention were not significant. This study Supports the use of measures that capture specific components of attention rather than global measures of attention, and highlights the importance of assessing and treating sleep problems in brain injury rehabilitation. (JINS, 2010, 16, 17-25.)	[Bloomfield, Imogen L. M.; Espie, Colin A.; Evans, Jonathan J.] Univ Glasgow, Sect Psychol Med, Glasgow G12 0XH, Lanark, Scotland		Evans, JJ (corresponding author), Univ Glasgow, Fac Med, Sect Psychol Med, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	jonathan.evans@clinmed.gla.ac.uk	Sanguansri, Luz/B-6630-2011; Lang, Steven/AAE-8102-2021	Sanguansri, Luz/0000-0003-1908-7604; Lang, Steven/0000-0003-1669-9146; Espie, Colin/0000-0002-1294-8734	NHS Education for Scotland; Dr. Mortimer and Theresa Sackler Foundation	We thank all our participants, Headway. Momentum. and the Community Treatment Centre for Brain Injury, Glasgow for their time and contribution. In addition, we thank two anonymous reviewers and Professor Haaland for their constructive and encouraging comC merits. and NHS Education for Scotland and The Dr. Mortimer and Theresa Sackler Foundation for Supporting the project. The information in this manuscript has never been published either electronically or in print. The authors are not aware of any financial, or other. conflicts of interest.	Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Bastien CH, 2003, J PSYCHOSOM RES, V54, P39, DOI 10.1016/S0022-3999(02)00544-5; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Buysse DJ, 2006, SLEEP, V29, P1155, DOI 10.1093/sleep/29.9.1155; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Dinges, 1991, SLEEP SLEEPINESS PER, P97; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-0029-1237117; Edinger JD, 2004, SLEEP, V27, P1567, DOI 10.1093/sleep/27.8.1567; Erman MK, 2001, J CLIN PSYCHIAT, V62, P9; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Field A., 2003, DESIGN REPORT EXPT; GRONWALL DMA, 1974, LANCET, V14, P605; Hauri PJ, 1997, ACTA NEUROL BELG, V97, P113; Kamdar BB, 2004, SLEEP MED, V5, P441, DOI 10.1016/j.sleep.2004.05.003; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P1, DOI 10.1016/S0028-3932(01)00086-0; May CP, 1998, J EXP PSYCHOL HUMAN, V24, P363, DOI 10.1037/0096-1523.24.2.363; Morin CM, 1993, INSOMNIA PSYCHOL ASS; *NAT MED ADV PRESS, 1994, MAN ANX INS; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roth T, 2001, SLEEP MED, V2, P379, DOI 10.1016/S1389-9457(01)00071-5; Sadeh A, 2002, SLEEP MED REV, V6, P113, DOI 10.1053/smrv.2001.0182; Schneider C, 2004, J SLEEP RES, V13, P373, DOI 10.1111/j.1365-2869.2004.00427.x; Spiegel R, 1999, BIOL PSYCHIAT, V45, P435, DOI 10.1016/S0006-3223(98)00042-0; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Versace F, 2006, BIOL PSYCHOL, V71, P248, DOI 10.1016/j.biopsycho.2005.04.003; Wechsler D., 2001, WTAR ADM SCORING MAN; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Zafonte RD, 1996, NEUROREHABILITATION, V7, P189, DOI 10.3233/NRE-1996-7304; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	43	52	53	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2010	16	1					17	25		10.1017/S1355617709990798			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	543LR	WOS:000273579600003	19796442	Green Accepted			2022-02-06	
J	Signoretti, S; Di Pietro, V; Vagnozzi, R; Lazzarino, G; Amorini, AM; Belli, A; D'Urso, S; Tavazzi, B				Signoretti, Stefano; Di Pietro, Valentina; Vagnozzi, Roberto; Lazzarino, Giuseppe; Amorini, Angela M.; Belli, Antonio; D'Urso, Serafina; Tavazzi, Barbara			Transient alterations of creatine, creatine phosphate, N-acetylaspartate and high-energy phosphates after mild traumatic brain injury in the rat	MOLECULAR AND CELLULAR BIOCHEMISTRY			English	Article						Creatine; Energy metabolism; HPLC; Magnetic resonance spectroscopy; N-acetylaspartate; Traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; TRANSPORTER GENE SLC6A8; TEMPORAL WINDOW; MYOCARDIAL-INFARCTION; DEFICIENCY SYNDROME; OXIDATIVE STRESS; SKELETAL-MUSCLE; HEAD-INJURY; METABOLISM; CONCUSSION	In this study, the concentrations of creatine (Cr), creatine phosphate (CrP), N-acetylaspartate (NAA), ATP, ADP and phosphatidylcholine (PC) were measured at different time intervals after mild traumatic brain injury (mTBI) in whole brain homogenates of rats. Anaesthetized animals underwent to the closed-head impact acceleration "weight-drop" model (450 g delivered from 1 m height = mild traumatic brain injury) and were killed at 2, 6, 24, 48 and 120 h after the insult (n = 6 for each time point). Sham-operated rats (n = 6) were used as controls. Compounds of interest were synchronously measured by HPLC in organic solvent deproteinized whole brain homogenates. A reversible decrease of all metabolites but PC was observed, with minimal values recorded at 24 h post-injury (minimum of CrP = 48 h after impact). In particular, Cr and NAA showed a decrease of 44.5 and 29.5%, respectively, at this time point. When measuring NAA in relation to other metabolites, as it is commonly carried out in "in vivo" H-1-magnetic resonance spectroscopy (H-1-MRS), an increase in the NAA/Cr ratio and a decrease in the NAA/PC ratio was observed. Besides confirming a transient alteration of NAA homeostasis and ATP imbalance, our results clearly show significant changes in the cerebral concentration of Cr and CrP after mTBI. This suggests a careful use of the NAA/Cr ratio to measure NAA by H-1-MRS in conditions of altered cerebral energy metabolism. Viceversa, the NAA/PC ratio appears to be a better indicator of actual NAA levels during energy metabolism impairment. Furthermore, our data suggest that, under pathological conditions affecting the brain energetic, the Cr-CrP system is not a suitable tool to buffer possible ATP depletion in the brain, thus supporting the growing indications for alternative roles of cerebral Cr.	[Lazzarino, Giuseppe; D'Urso, Serafina] Univ Catania, Div Biochem & Mol Biol, Dept Chem Sci, I-95125 Catania, Italy; [Signoretti, Stefano] San Camillo Hosp, Div Neurosurg, Dept Neurosci Head & Neck Surg, Rome, Italy; [Di Pietro, Valentina; Amorini, Angela M.; Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, Chair Neurosurg, Rome, Italy; [Belli, Antonio] Univ Southampton, Div Clin Neurosci, Southampton, Hants, England		Lazzarino, G (corresponding author), Univ Catania, Div Biochem & Mol Biol, Dept Chem Sci, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@mbox.unict.it	Signoretti, stefano/AAL-5631-2020; Belli, Antonio/I-3799-2015; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; Belli, Antonio/0000-0002-3211-9933; TAVAZZI, BARBARA/0000-0001-8743-0895; AMORINI, Angela Maria/0000-0003-3525-9955; Di Pietro, Valentina/0000-0001-9430-4723; lazzarino, giuseppe/0000-0002-5917-7279	Italian Ministry of University and Research (MIUR)Ministry of Education, Universities and Research (MIUR) [PRIN [2007JBHZ5F]]; Catholic University of Rome "Sacro Cuore''; University of Catania	This study has been supported by the research grant PRIN [2007JBHZ5F] of the Italian Ministry of University and Research (MIUR) and in part by research funds of Catholic University of Rome "Sacro Cuore'' and University of Catania.	Almeida LS, 2006, SYNAPSE, V60, P118, DOI 10.1002/syn.20280; BAGORY M, 2007, C P IEEE ENG MED BIO, P3458; BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bizzi A, 2002, ANN NEUROL, V52, P227, DOI 10.1002/ana.10246; Bogdanis GC, 1996, J APPL PHYSIOL, V80, P876, DOI 10.1152/jappl.1996.80.3.876; Bottomley PA, 2001, RADIOLOGY, V219, P411, DOI 10.1148/radiology.219.2.r01ma39411; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Carta M, 2006, NEUROSCIENCE, V139, P1163, DOI 10.1016/j.neuroscience.2006.01.027; Cave AC, 2000, CIRCULATION, V101, P2090, DOI 10.1161/01.CIR.101.17.2090; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; De Stefano N, 2007, NEUROLOGY, V69, P1942, DOI 10.1212/01.wnl.0000291557.62706.d3; Fayed N, 2008, EUR J RADIOL, V67, P427, DOI 10.1016/j.ejrad.2008.02.039; FOLCH J, 1957, J BIOL CHEM, V226, P497; Royes LF, 2008, NEUROCHEM INT, V53, P33, DOI 10.1016/j.neuint.2008.04.008; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Galbraith RA, 2006, BRAIN RES, V1101, P85, DOI 10.1016/j.brainres.2006.05.032; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Geeraerts T, 2006, J NEUROTRAUM, V23, P1059, DOI 10.1089/neu.2006.23.1059; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Headrick JP, 1998, J MOL CELL CARDIOL, V30, P1415, DOI 10.1006/jmcc.1998.0710; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V8, P469; JIMING YE, 1996, J SURG RES, V61, P227; Kagan V E, 1998, Methods Mol Biol, V108, P71; Karatzaferi C, 1999, J CHROMATOGR B, V730, P183, DOI 10.1016/S0378-4347(99)00221-2; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Koga Y, 2005, NEUROSCIENCE, V132, P65, DOI 10.1016/j.neuroscience.2005.01.004; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LAZZARINO G, 1991, J MOL CELL CARDIOL, V23, P13, DOI 10.1016/0022-2828(91)90035-K; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; Lorentzon M, 2007, J CARD FAIL, V13, P230, DOI 10.1016/j.cardfail.2006.11.012; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; Mitsumoto H, 2007, NEUROLOGY, V68, P1402, DOI 10.1212/01.wnl.0000260065.57832.87; MONTASSER A, 1994, J NEUROSURG, V80, P301; NEUBAUER S, 1995, J CLIN INVEST, V95, P1092, DOI 10.1172/JCI117756; Salomons GS, 2001, AM J HUM GENET, V68, P1497, DOI 10.1086/320595; Schiaffino MC, 2005, NEUROGENETICS, V6, P165, DOI 10.1007/s10048-005-0002-4; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Seidl R, 2000, LIFE SCI, V67, P421, DOI 10.1016/S0024-3205(00)00630-5; Smith-Palmer T, 2002, J CHROMATOGR B, V781, P93, DOI 10.1016/S1570-0232(02)00617-7; SODERLUND K, 1991, AM J PHYSIOL, V261, pE737, DOI 10.1152/ajpendo.1991.261.6.E737; STATHIS CG, 1994, J APPL PHYSIOL, V76, P1802, DOI 10.1152/jappl.1994.76.4.1802; Stefanello FM, 2007, INT J DEV NEUROSCI, V25, P473, DOI 10.1016/j.ijdevneu.2007.08.004; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8	54	52	53	0	7	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-8177	1573-4919		MOL CELL BIOCHEM	Mol. Cell. Biochem.	JAN	2010	333	1-2					269	277		10.1007/s11010-009-0228-9			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	534AZ	WOS:000272869200031	19688182				2022-02-06	
J	Metting, Z; Rodiger, LA; Stewart, RE; Oudkerk, M; De Keyser, J; van der Naalt, J				Metting, Zwany; Rodiger, Lars A.; Stewart, Roy E.; Oudkerk, Matthijs; De Keyser, Jacques; van der Naalt, Joukje			Perfusion Computed Tomography in the Acute Phase of Mild Head Injury: Regional Dysfunction and Prognostic Value	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; GLASGOW OUTCOME SCALE; ACUTE STROKE; TECHNETIUM-99M-HMPAO SPECT; SUBARACHNOID HEMORRHAGE; DYNAMIC CT; DISABILITY; ISCHEMIA	Objective: Traumatic brain injury is a major Cause of disability and death. Most patients sustain a mild head injury with a subgroup that experiences disabling symptoms interfering with return to work. Brain imaging in the acute phase is not predictive of outcome, as 20% of noncontrast computed tomographic (CT) scans on admission is normal in patients with a suboptimal Outcome. The aim of this study was to perform perfusion CT imaging in the acute phase of mild head injury in patients without intracranial abnormalities on the noncontrast CT, to assess whether these patients had cerebral perfusion abnormalities. Furthermore, the relation between perfusion CT parameters and severity of head injury and Outcome was evaluated. Methods: In patients with mild head injury and normal noncontrast CT, perfusion CT was performed directly after admission. The perfusion data were compared with data of 25 healthy control subjects. Outcome was determined 6 months after injury with the extended Glasgow Coma Outcome Scale score and return to work. Results: Seventy-six patients were included. In patients with a decreased Glasgow Coma Scale score, a significant decrease of cerebral blood flow and cerebral blood volume was detected in the frontal and occipital gray matter. In logistic regression analyses, decreased cerebral blood flow and cerebral blood volume in the Frontal lobes predicted worse outcome according to the extended Glasgow Coma Outcome Scale score. CT perfusion parameters did not predict return to work. Interpretation: In the acute phase of mild head injury, disturbed cerebral perfusion is seen in patients with normal noncontrast CT correlating with severity Of injury and Outcome. Ann Neurol 2009;66:809-816	[Metting, Zwany; De Keyser, Jacques; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Rodiger, Lars A.; Oudkerk, Matthijs] Univ Med Ctr Groningen, Dept Radiol, NL-9700 RB Groningen, Netherlands; [Stewart, Roy E.] Univ Med Ctr Groningen, Dept Hlth Sci, NL-9700 RB Groningen, Netherlands		van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	j.van.der.naalt@neuro.umcg.nl	De Keyser, Jacques/D-3725-2013; De Keyser, Jacques/AAA-8721-2021	De Keyser, Jacques/0000-0002-3394-7757; De Keyser, Jacques/0000-0002-3394-7757; Stewart, Roy/0000-0001-9227-433X; Oudkerk, Matthijs/0000-0003-2800-4110; van der Naalt, Joukje/0000-0001-9873-2418	ZonMw, Den Haag, the NetherlandsNetherlands Organization for Health Research and DevelopmentNetherlands Government	This Study was Supported by ZonMw, Den Haag, the Netherlands.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Audenaert K., 2003, MED SCI MONITOR, V9, P112; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Eastwood JD, 2002, RADIOLOGY, V222, P227, DOI 10.1148/radiol.2221010471; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Esteban JM, 2004, NEURORADIOLOGY, V46, P705, DOI 10.1007/s00234-004-1235-x; FOX PT, 1984, J NEUROPHYSIOL, V51, P1109, DOI 10.1152/jn.1984.51.5.1109; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Klotz E, 1999, EUR J RADIOL, V30, P170, DOI 10.1016/S0720-048X(99)00009-1; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Mayer TE, 2000, AM J NEURORADIOL, V21, P1441; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Muizelaar JP, 1997, STROKE, V28, P1998, DOI 10.1161/01.STR.28.10.1998; Nariai T, 2001, J NEUROTRAUM, V18, P1323, DOI 10.1089/08977150152725623; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; POWERS WJ, 1985, STROKE, V16, P361, DOI 10.1161/01.STR.16.3.361; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROLAND PE, 1987, J NEUROSCI, V7, P2373; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Soustiel JF, 2008, NEURORADIOLOGY, V50, P189, DOI 10.1007/s00234-007-0337-7; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Schaaf I, 2006, NEUROLOGY, V66, P1533, DOI 10.1212/01.wnl.0000216272.67895.d3; van der Schaaf I, 2006, STROKE, V37, P409, DOI 10.1161/01.STR.0000198831.69035.43; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wintermark M, 2005, PEDIATR EMERG CARE, V21, P149; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wintermark M, 2002, ANN NEUROL, V51, P417, DOI 10.1002/ana.10136	47	52	54	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	DEC	2009	66	6					809	816		10.1002/ana.21785			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	540FX	WOS:000273317800014	20035508				2022-02-06	
J	Zhang, YL; Xiong, Y; Mahmood, A; Meng, YL; Qu, CS; Schallert, T; Chopp, M				Zhang, Yanlu; Xiong, Ye; Mahmood, Asim; Meng, Yuling; Qu, Changsheng; Schallert, Timothy; Chopp, Michael			Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit	BRAIN RESEARCH			English	Article						Angiogenesis; Erythropoietin; Hemodilution; Neurogenesis; Traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; MITOCHONDRIAL DYSFUNCTION; ENHANCES NEUROGENESIS; NEUROBLAST MIGRATION; SPATIAL MEMORY; EPOETIN-ALPHA; BLOOD-FLOW; STROKE; ANEMIA; NEURONS	Erythropoietin (EPO) provides neuroprotection and neurorestoration after traumatic brain injury (TBI). The EPO doses used for treatment of TBI significantly increase hematocrit, which may affect the efficacy of EPO therapy for TBI. The aim of this study was to investigate whether normalization of hematocrit would affect EPO efficacy for treatment of TBI. Young adult male Wistar rats were randomly divided into four groups: (1) Sham group (n = 6); (2) TBI+saline group (n = 6); (3) TBI+EPO group (n = 6); and (4) TBI+EPO+hemodilution group (n = 7). TBI was induced by controlled cortical impact over the left parietal cortex. EPO (5,000 U/kg) or saline was administered intraperitoneally at days 1, 2, and 3 postinjury. Neurological function was assessed using a modified neurological severity score (mNSS), footfault and the Morris water maze (MWM) tests. Animals were sacrificed 35 days after injury, and brain sections were stained for immunohistochemistry. Compared to the saline treatment, EPO treatment significantly reduced hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, and significantly improved sensorimotor functional outcome (lowered mNSS and foot faults) and spatial learning (MWM test). Normovolemic hemodilution effectively normalized the hematocrit and did not significantly affect the histological and functional outcome of EPO therapy for TBI. These data for the first time demonstrate that increased hematocrit does not affect therapeutic effects of EPO on histological and long-term functional outcomes in rats after TBI and also suggest that neuroprotection and neurorestoration of EPO treatment are independent of hematocrit. (C) 2009 Elsevier B.V. All rights reserved.	[Zhang, Yanlu; Xiong, Ye; Mahmood, Asim; Meng, Yuling; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA		Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS 62002, PO1 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS042345] Funding Source: NIH RePORTER	This work was supported by NIH grants RO1 NS 62002 and PO1 NS42345.	Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Cheung W, 2001, EUR J CLIN PHARMACOL, V57, P411, DOI 10.1007/s002280100324; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Davis A E, 2000, Crit Care Nurs Q, V23, P1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2007, BRAIN, V130, P2577, DOI 10.1093/brain/awm203; Ge YL, 2007, ACTA ANAESTH SCAND, V51, P1331, DOI 10.1111/j.1399-6576.2007.01448.x; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Li M, 2006, J NEUROSURG ANESTH, V18, P125, DOI 10.1097/00008506-200604000-00006; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lindenblatt N, 2007, ARTERIOSCL THROM VAS, V27, P1191, DOI 10.1161/ATVBAHA.107.141580; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; Milano M, 2007, CRIT REV ONCOL HEMAT, V62, P119, DOI 10.1016/j.critrevonc.2006.11.011; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rosenzweig MQ, 2004, J PAIN SYMPTOM MANAG, V27, P185, DOI 10.1016/j.jpainsymman.2003.06.010; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Shibata J, 2003, BLOOD, V101, P4416, DOI 10.1182/blood-2002-09-2814; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wish JB, 2009, ADV CHRONIC KIDNEY D, V16, P101, DOI 10.1053/j.ackd.2008.12.005; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Xiong Y, 2009, NEUROL RES, V31, P496, DOI 10.1179/174313208X353703; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2009, J CEREBR BLOOD F MET, V29, P1240, DOI 10.1038/jcbfm.2009.55; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	59	52	53	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 6	2009	1294						153	164		10.1016/j.brainres.2009.07.077			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	504ZZ	WOS:000270658500016	19646970	Green Accepted			2022-02-06	
J	Sviri, GE; Aaslid, R; Douville, CM; Moore, A; Newell, DW				Sviri, Gill E.; Aaslid, Rune; Douville, Colleen M.; Moore, Anne; Newell, David W.			Time course for autoregulation recovery following severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						brain injury; autoregulation; blood flow; transcranial Doppler ultrasound; outcome	DYNAMIC CEREBRAL AUTOREGULATION; SEVERE HEAD-INJURY; PRACTICAL SCALE; FLOW	Object. The aim of the present study was to evaluate the time course for cerebral autoregulation (AR) recovery following severe traumatic brain injury (TBI) Methods. Thirty-six patients (27 males and 9 females, mean +/- SEM age 33 +/- 15.1 years) with severe TBI underwent serial dynamic AR studies with leg cuff deflation as a stimulus, until recovery of the AR responses was measured. Results. The AR was impaired (AR index < 2.8) in 30 (83%) of 36 patients on Days 3-5 after injury, and in 19 individuals (53%) impairments were found on Days 9-11 after the injury. Nine (25%) of 36 patients exhibited a poor AR response (AR index < 1) on postinjury Days 12-14, which eventually recovered on Days 15-23. Fifty-eight percent of the patients with a Glasgow Coma Scale score of 3-5, 50% of those with diffuse brain injury, 54% of those with elevated intracranial pressure, and 40% of those with poor outcome had no AR recovery in the first 11 days after injury. Conclusions. Autoregulation recovery after severe TBI can be delayed, and failure to recover during the 2nd week after injury occurs mainly in patients with a lower Glasgow Coma Scale score, diffuse brain injury, elevated ICP, or unfavorable outcome. The finding suggests that perfusion pressure management should be considered in some of the patients for a period of at least 2 weeks. (DOI: 10.3171/2008.10.17686)	[Sviri, Gill E.] Technion Israel Inst Technol, Rambam Med Ctr, Dept Neurol Surg, Haifa, Israel; [Aaslid, Rune; Douville, Colleen M.; Moore, Anne; Newell, David W.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Aaslid, Rune; Douville, Colleen M.; Moore, Anne; Newell, David W.] Swedish Neurosci Inst, Seattle, WA USA		Sviri, GE (corresponding author), Technion Israel Inst Technol, Rambam Maimonides Med Ctr, Dept Neurosurg, POB 31096, Haifa, Israel.	sviri@u.washington.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24 NS02128-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K24NS002128] Funding Source: NIH RePORTER	This work was supported by Midcareer Investigator Award (NIH Grant No. K24 NS02128-01A1) to Dr. Newell.	Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; JENNETT B, 1975, LANCET, V1, P480; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TEASDALE G, 1974, LANCET, V2, P81; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014	14	52	54	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2009	111	4					695	700		10.3171/2008.10.17686			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	503PL	WOS:000270550000011	19392589				2022-02-06	
J	Oshima, T; Lee, S; Sato, A; Oda, S; Hirasawa, H; Yamashita, T				Oshima, Taku; Lee, Sachiko; Sato, Akinobu; Oda, Shigeto; Hirasawa, Hiroyuki; Yamashita, Toshihide			TNF-alpha contributes to axonal sprouting and functional recovery following traumatic brain injury	BRAIN RESEARCH			English	Article						Axon; Brain injury; Motor function; Regeneration; TNF-alpha	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; RAT-BRAIN; MICE LACKING; EXPRESSION; RECEPTOR; PLASTICITY; ELEVATION; RESPONSES; PLASMA	In response to a central nervous system (CNS) injury, microglia and astrocytes release tumor necrosis factor-alpha (TNF-alpha). This proinflammatory cytokine has been implicated in both neuronal cell death and survival. Here, we show that TNF-alpha is involved in the recovery of neuromotor function following traumatic brain injury. Composite neuroscore and accel rotarod were employed to measure neuromotor function. TNF-alpha-deficient (TNF-alpha(-/-)) mice showed no improvement in their locomotor function up to 28 days following controlled cortical impact brain injury. Although collateral sprouting of the unlesioned corticospinal tract, as assessed by retrograde biotin dextran amine labeling, at the cervical spinal cord was observed following injury in the wild-type mice, such changes were not induced in the TNF-alpha(-/-) mice at 4 weeks after injury. These results provide evidence that TNF-alpha is involved in neuroanatomical plasticity and functional recovery following CNS injury. (C) 2009 Elsevier B.V. All rights reserved.	[Lee, Sachiko; Sato, Akinobu; Yamashita, Toshihide] Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Suita, Osaka 5650871, Japan; [Oshima, Taku; Yamashita, Toshihide] Chiba Univ, Grad Sch Med, Dept Neurobiol, Chiba, Japan; [Oshima, Taku; Oda, Shigeto; Hirasawa, Hiroyuki] Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chiba, Japan		Yamashita, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yamashita@molneu.med.osaka-u.ac.jp	Oshima, Taku/AAX-1936-2021	Oshima, Taku/0000-0002-3868-8272; Yamashita, Toshihide/0000-0003-4559-7018	National Institute of Biomedical InnovationNational Institute of Biomedical Innovation [05-12]	This work was supported by a Research Grant from the National Institute of Biomedical Innovation (05-12) and a Grant-in-Aid for Young Scientists (S) from JSPS to T.Y.	BERMPOHL D, 2007, J CEREB BLOOD FLOW M, V27, P1669; Blight AR, 2002, NAT NEUROSCI, V5, P1051, DOI 10.1038/nn939; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17	23	52	61	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 22	2009	1290						102	110		10.1016/j.brainres.2009.07.022			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	496GU	WOS:000269958600008	19616519				2022-02-06	
J	Atkins, CM; Falo, MC; Alonso, OF; Bramlett, HM; Dietrich, WD				Atkins, Coleen M.; Falo, M. Cristina; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton			Deficits in ERK and CREB activation in the hippocampus after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						CREB; Hippocampus; ERK; Traumatic brain injury	FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; PROTEIN-KINASES; RAT; GLUTAMATE; MORPHOLOGY; POTASSIUM; INCREASES; MODERATE	Traumatic brain injury (TBI) activates several protein kinase signaling pathways in the hippocampus that are critical for hippocampal-dependent memory formation. In particular, extracellular signal-regulated kinase (ERK), a protein kinase activated during and necessary for hippocampal-dependent learning, is transiently activated after TBI. However, TBI patients experience hippocampal-dependent cognitive deficits that occur for several months to years after the initial injury. Although basal activation levels of ERK return to sham levels within hours after TBI, we hypothesized that activation of ERK may be impaired after TBI. Adult male Sprague-Dawley rats received either sham surgery or moderate parasagittal fluid-percussion brain injury. At 2, 8, or 12 weeks after surgery, the ipsilateral hippocampi of sham surgery and TBI animals were sectioned into transverse slices. After 2 h of recovery in oxygenated artificial cerebrospinal fluid, the hippocampal slices were stimulated with glutamate or KCl depolarization, then analyzed by western blotting for phosphorylated, activated ERK and one of its downstream effectors, the transcription factor cAMP response element-binding protein (CREB). We found that activation of ERK (p < 0.05) and CREB (p < 0.05) after 30 s of glutamate stimulation or KCl depolarization was decreased in hippocampal slices from animals at 2, 8, or 12 weeks after TBI as compared to sham animals. Basal levels of phosphorylated or total ERK were not significantly altered at 2, 8, or 12 weeks after TBI, although basal levels of phosphorylated CREB were decreased 12 weeks post-trauma. These results suggest that TBI results in chronic signaling deficits through the ERK-CREB pathway in the hippocampus. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Atkins, Coleen M.; Falo, M. Cristina; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA		Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, POB 016960 R-48, Miami, FL 33136 USA.	catkins@med.miami.edu		Atkins, Coleen/0000-0003-4718-7493	USAMRMCU.S. Army Medical Research & Materiel Command (USAMRMC) [PR054538]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS056072]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056072, P50NS030291] Funding Source: NIH RePORTER	This work was supported by USAMRMC PR054538 and NIH grant NS056072.	Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Baron C, 1996, J NEUROCHEM, V66, P1005; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; COLE AE, 1989, SYNAPSE, V4, P11, DOI 10.1002/syn.890040103; COLLINS DR, 1994, NEUROPHARMACOLOGY, V33, P1055, DOI 10.1016/0028-3908(94)90143-0; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Deshpande LS, 2008, NEUROSCI LETT, V441, P115, DOI 10.1016/j.neulet.2008.05.113; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; SCHWARZBACH E, 2006, HIPPOCAMPUS; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sindreu CB, 2007, NEURON, V53, P79, DOI 10.1016/j.neuron.2006.11.024; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Trifilieff P, 2006, LEARN MEMORY, V13, P349, DOI 10.1101/lm.80206; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	51	52	54	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 7	2009	459	2					52	56		10.1016/j.neulet.2009.04.064			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	461GZ	WOS:000267254100002	19416748	Green Accepted			2022-02-06	
J	Zlotnik, A; Gruenbaum, SE; Artru, AA; Rozet, I; Dubilet, M; Tkachov, S; Brotfain, E; Klin, Y; Shapira, Y; Teichberg, VI				Zlotnik, Alexander; Gruenbaum, Shaun E.; Artru, Alan A.; Rozet, Irene; Dubilet, Michael; Tkachov, Sergey; Brotfain, Evgeny; Klin, Yael; Shapira, Yoram; Teichberg, Vivian I.			The Neuroprotective Effects of Oxaloacetate in Closed Head Injury in Rats is Mediated by its Blood Glutamate Scavenging Activity Evidence From the Use of Maleate	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						brain injury; glutamate; maleate; oxaloacetate; neurologic outcome; rat	EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; CEREBROSPINAL-FLUID; CLINICAL-TRIALS; PYRUVATE; RELEASE; METABOLISM; RECEPTORS; BARRIER; EFFLUX	Introduction: Treatment with oxaloacetate after traumatic brain injury has been shown to decrease blood glutamate levels and protect against the neurtotoxic effects of glutamate oil the brain. A number of potential mechanisms have been Suggested to explain oxaloacetate-induced neuroprotection. We hypothesize that the primary mechanism by which intravenous oxaloacetate provides neuroprotection is by activation of the blood glutamate-scavenging enzyme glutamate-oxaloacetate transaminase, increasing thereby the driving force for the efflux of excess glutamate from brain interstitial fluids into blood. If so, coadministration of maleate, a glutamate-oxaloacetate transaminase-blocker is expected to prevent the neuroprotective effects of oxaloacetate. Materials and Methods: A neurological severity score (NSS) was measured 1 hour after closed head injury (CHI) in rats. Then, rats received 30 mu L/min/100 g infusion of saline, or 1 mmol/100 g Solution of oxaloacetate, maleate, or a Mixture of oxaloacetate and maleate. NSS was reassessed at 24 and 48 hour after CHI. Blood glutamate and glucose levels were measured at 0, 60, 90, and 120 minutes. Results: NSS improved significantly at 24 hour (P < 0.001) and 48 hour (P < 0.001) only in the rats treated with oxaloacetate. Blood glutamate decreased significantly in the oxaloacetate-treated group at 90 Minute (at the conclusion of oxaloacetate administration) (P < 0.00001), but not in the control, maleate or oxaloacetate+maleate groups. A strong correlation r(2) = 0.86 Was found to exist between the percent decrease in blood glutamate levels and percent improvement in NSS. Discussion: The results of this study demonstrate that the primary mechanism by which oxaloacetate provides neuroprotective activity after CHI is related to its blood glutamate scavenging activity. Management of blood glutamate concentration may have important implications in the treatment of acute brain conditions, including CHI and stroke.	[Artru, Alan A.; Rozet, Irene] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Zlotnik, Alexander; Gruenbaum, Shaun E.; Dubilet, Michael; Tkachov, Sergey; Brotfain, Evgeny; Shapira, Yoram] Ben Gurion Univ Negev, Soroka Med Ctr, Dept Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel; [Klin, Yael; Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel		Artru, AA (corresponding author), Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA.	artruaa@u.washington.edu					BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Crestanello JA, 1998, SURGERY, V124, P92, DOI 10.1016/S0039-6060(98)70080-7; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Desagher S, 1997, J NEUROSCI, V17, P9060; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; GRAHAM LT, 1966, ANAL BIOCHEM, V15, P487, DOI 10.1016/0003-2697(66)90110-2; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hosoya K, 1999, J NEUROCHEM, V73, P1206, DOI 10.1046/j.1471-4159.1999.0731206.x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Koura SS, 1998, ACT NEUR S, V71, P244; Mongan PD, 2001, AM J PHYSIOL-HEART C, V281, pH854, DOI 10.1152/ajpheart.2001.281.2.H854; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Stoffel M, 2002, J NEUROTRAUM, V19, P467, DOI 10.1089/08977150252932415; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Varma SD, 1998, FREE RADICAL RES, V28, P131, DOI 10.3109/10715769809065799; VELICK SF, 1962, J BIOL CHEM, V237, P2109; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	36	52	53	3	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2009	21	3					235	241		10.1097/ANA.0b013e3181a2bf0b			7	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	464KF	WOS:000267503100009	19543002				2022-02-06	
J	Li, XF; Dai, LY				Li, Xin-Feng; Dai, Li-Yang			Three-Dimensional Finite Element Model of the Cervical Spinal Cord Preliminary Results of Injury Mechanism Analysis	SPINE			English	Article						spinal cord injuries; cervical spine; finite element model; injury mechanism	WHITE-MATTER; SPONDYLOTIC MYELOPATHY; GRAY-MATTER; TRAUMA; TISSUE; DAMAGE; INSUFFICIENCY; BIOMECHANICS; SENSITIVITY; ELASTICITY	Study Design. A three-dimensional finite element investigation. Objectives. To create a three-dimensional finite element model of the cervical spinal cord enlargement and to simulate a hyperextension injury of the cervical cord. Summary of Background Data. Experimental studies are difficult to simulate the complex mechanism of spinal cord injuries. The introduction of three-dimensional modeling technique into neurotrauma studies is essential to further understand mechanical behavior of the nerve tissue during traumatic injuries. Methods. Geometrical reconstruction of cervical spinal cord enlargement was developed based on the morphologic features of each segment of the fresh human cervical cord. After the validation of the model, the pinching condition in the hyperextension injuries was simulated with compressive and extension forces applied on the cervical enlargement model. The average von Mises stress of the 9 anatomic regions, such as anterior funiculus, lateral part of the lateral funiculus, medial part of the lateral funiculus, lateral part of the posterior funiculus, medial part of the posterior funiculus, anterior horn, the bottom of anterior horn, the apex of posterior horn, the cervix cornu posterioris, and caput cornu posterioris was recorded. Results. The force-displacement response of the spinal cord under compression and axial tension loading was close to the experimental results reported in the literature. The stress distribution of the spinal cord according to the numerical simulation and the morphologic features of the in vivo experiment were also in close agreement. Hyperextension injury simulation showed high localized stress at the anterior and posterior horn in the gray matter. Conclusion. The finite element method as a three-dimensional modeling technique can improve the understanding of the biomechanical behavior of the spinal cord. The results of hyperextension injury simulation of the cervical spinal cord probably account for the predominance of the hand weakness in patients with central cord injury.	[Li, Xin-Feng; Dai, Li-Yang] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Orthopaed Surg, Shanghai 200092, Peoples R China; [Li, Xin-Feng] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Orthopaed Surg, Shanghai 200092, Peoples R China		Dai, LY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Orthopaed Surg, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.	chinaspine@163.com	Dai, Li-Yang/C-7121-2009		National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [30672144, 39270663]; The Youth Science Funds of Shanghai Municipal Health Bureau [2008Y059]	National Natural Science Foundation funds were received in support of this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.; Supported by National Natural Science Foundation of China (30672144, 39270663) and The Youth Science Funds of Shanghai Municipal Health Bureau (2008Y059).	Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; BENOIST G, 1979, J NEUROSURG, V51, P834, DOI 10.3171/jns.1979.51.6.0834; BERQUIST TH, 1986, IMAGING ORTHOPEDIC T, P91; Bilston LE, 1996, ANN BIOMED ENG, V24, P67; Carlson GD, 2003, J BONE JOINT SURG AM, V85A, P86, DOI 10.2106/00004623-200301000-00014; CHANG GL, 1981, J TRAUMA, V21, P807, DOI 10.1097/00005373-198109000-00011; CHANG GL, 1988, J BIOMECH ENG-T ASME, V110, P115, DOI 10.1115/1.3108415; Dai L, 1997, INT ORTHOP, V21, P380; DOHRMANN GJ, 1971, J NEUROSURG, V35, P263, DOI 10.3171/jns.1971.35.3.0263; DOHRMANN GJ, 1978, J NEUROSURG, V48, P993, DOI 10.3171/jns.1978.48.6.0993; Fukushima M, 2006, SPINE, V31, P903, DOI 10.1097/01.brs.0000209257.47140.fc; Galle B, 2007, J BIOMECH, V40, P3029, DOI 10.1016/j.jbiomech.2007.03.014; Greaves CY, 2008, ANN BIOMED ENG, V36, P396, DOI 10.1007/s10439-008-9440-0; HUNG TK, 1982, SURG NEUROL, V17, P213, DOI 10.1016/0090-3019(82)90284-1; HUNG TK, 1981, J BIOMECH, V14, P269, DOI 10.1016/0021-9290(81)90072-5; Ichihara K, 2003, J NEUROSURG, V99, P278, DOI 10.3171/spi.2003.99.3.0278; Ichihara K, 2001, J NEUROTRAUM, V18, P361, DOI 10.1089/08977150151071053; Kameyama T, 1996, SPINE, V21, P1285, DOI 10.1097/00007632-199606010-00001; Kato Y, 2008, J NEUROSURG-SPINE, V8, P436, DOI 10.3171/SPI/2008/8/5/436; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Ko HY, 2004, SPINAL CORD, V42, P35, DOI 10.1038/sj.sc.3101538; Levine DN, 1997, J NEUROL NEUROSUR PS, V62, P334, DOI 10.1136/jnnp.62.4.334; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Maiman D J, 1989, J Spinal Disord, V2, P14; Maiman D J, 1989, J Spinal Disord, V2, P6; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; MIYASAKA K, 1992, Brain and Nerve (Tokyo), V44, P241; Ozawa H, 2001, J NEUROSURG, V95, P221, DOI 10.3171/spi.2001.95.2.0221; PANJABI M, 1988, SPINE, V13, P838, DOI 10.1097/00007632-198807000-00024; RAYNOR RB, 1985, SPINE, V10, P193, DOI 10.1097/00007632-198504000-00002; RAYNOR RB, 1968, J TRAUM, V8, P597, DOI 10.1097/00005373-196807000-00011; REBHUN WC, 1984, COMP CONT EDUC PRACT, V6, pS396; SCHNEIDER R, 1961, J NEUROSURG, V18, P348, DOI 10.3171/jns.1961.18.3.0348; SCHNEIDER RC, 1954, J NEUROSURG, V11, P546, DOI 10.3171/jns.1954.11.6.0546; SCHNEIDER RC, 1959, NEUROLOGY, V9, P643, DOI 10.1212/WNL.9.10.643; Scifert Jeffrey, 2002, Pain Physician, V5, P394; SEIBERT CE, 1981, AM J ROENTGENOL, V136, P777, DOI 10.2214/ajr.136.4.777; Seki T, 2002, NEUROSURGERY, V50, P1075, DOI 10.1097/00006123-200205000-00024; SHERMAN JL, 1990, AM J NEURORADIOL, V11, P369; SHIMOMURA Y, 1968, J NEUROSURG, V28, P565, DOI 10.3171/jns.1968.28.6.0565; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; SUZUKI F, 1985, Neurological Surgery, V13, P391; TAYLOR AR, 1951, J BONE JOINT SURG BR, V33, P543, DOI 10.1302/0301-620X.33B4.543; TUNTURI AR, 1978, J NEUROSURG, V48, P975, DOI 10.3171/jns.1978.48.6.0975; Wilcox RK, 2004, EUR SPINE J, V13, P481, DOI 10.1007/s00586-003-0625-9; Wilcox RK, 2003, J BONE JOINT SURG AM, V85A, P2184, DOI 10.2106/00004623-200311000-00020	47	52	62	9	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	MAY 15	2009	34	11					1140	1147		10.1097/BRS.0b013e31819e2af1			8	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	447VO	WOS:000266220300004	19444060				2022-02-06	
J	Makley, MJ; Johnson-Greene, L; Tarwater, PM; Kreuz, AJ; Spiro, J; Rao, V; Celnik, PA				Makley, Michael J.; Johnson-Greene, Lisa; Tarwater, Patrick M.; Kreuz, Andrew J.; Spiro, J.; Rao, V.; Celnik, Pablo A.			Return of Memory and Sleep Efficiency Following Moderate to Severe Closed Head Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						Memory; Sleep disturbance; Brain injury; Rehabilitation	EXCESSIVE DAYTIME SLEEPINESS; POSTTRAUMATIC NARCOLEPSY; GALVESTON ORIENTATION; RATING-SCALE; AMNESIA; DISTURBANCE; IMPAIRMENT; COGNITION; CHILDREN; LIFE	Objective. Sleep disturbance is common in the subacute recovery phase following brain injury. A previous study from the authors' group found 68% of patients with closed head injury (CHI) had disrupted sleep on a rehabilitation unit. In the present study, the authors investigated whether improvement in sleep efficiency correlates with duration of posttraumatic amnesia (PTA) after CHI. Methods. Fourteen CHI patients were enrolled and followed prospectively. Mechanism of injury included motor vehicle accident, fall, and blunt assault. An actigraph was placed on each subject's wrist within 72 hours of admission to the rehabilitation unit and recorded data for the duration of their stay. A minimum of 7 days of continuous actigraphy data was obtained on all subjects. PTA was measured daily using the Orientation Log (O-LOG). Results. Seventy-eight percent of subjects had mean week-1 sleep efficiency scores of <= 63%. Patients admitted having already cleared PTA had significantly better week-1 sleep efficiency scores than those with ongoing amnesia (P=.032). For those patients admitted with ongoing PTA, each 10-unit increase in sleep efficiency score correlated with 1 unit increase in O-LOG score (P=.056). Conclusions. Disrupted sleep is common in the postacute stage following CHI. Improved sleep efficiency correlates with resolution of PTA. Decreased sleep efficiency may negatively affect memory return after traumatic brain injury. Actigraphy is uniquely suited to study the sleep patterns of these patients.	[Makley, Michael J.] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA; [Johnson-Greene, Lisa] Kernan Hosp, Dept Neuropsychol, Baltimore, MD USA; [Tarwater, Patrick M.] Texas Tech Univ, Hlth Sci Ctr, Div Biostat & Epidemiol, Paul L Foster Sch Med, El Paso, TX USA; [Kreuz, Andrew J.] Stevenson Univ, Dept Biol, Stevenson, MD USA; [Spiro, J.; Rao, V.] Johns Hopkins Univ, Dept Psychiat, Baltimore, MD USA; [Celnik, Pablo A.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Dept Neurol, Baltimore, MD USA		Makley, MJ (corresponding author), Univ Maryland, Kernan Hosp, Brain Injury Unit, 2200 Kernan Dr, Baltimore, MD 21207 USA.	mmakley@kernan.umm.edu					Ahmed S, 2000, BRAIN INJURY, V14, P765; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Borak J, 1996, J SLEEP RES, V5, P123, DOI 10.1046/j.1365-2869.1996.d01-60.x; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cohen SD, 2007, CLIN J AM SOC NEPHRO, V2, P919, DOI 10.2215/CJN.00820207; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-0029-1237117; DUYCKAERTS C, 1985, ANN NEUROL, V18, P314, DOI 10.1002/ana.410180307; Feeney DM, 1997, ADV NEUROL, V73, P383; Feuerstein C, 1997, ACTA NEUROL BELG, V97, P96; FODOR IE, 1972, J NEUROL NEUROSUR PS, V35, P818, DOI 10.1136/jnnp.35.6.818; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; Franck LS, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e62; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; GORNY S, 1997, ANN M ASS PROF SLEEP; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lieberman HR, 2005, BIOL PSYCHIAT, V57, P422, DOI 10.1016/j.biopsych.2004.11.014; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Moore BE, 1944, NEW ENGL J MED, V230, P445, DOI 10.1056/NEJM194404132301501; NAEGELE B, 1995, SLEEP, V18, P43; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Ohayon MM, 2004, SLEEP, V27, P1255, DOI 10.1093/sleep/27.7.1255; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RempelClower NL, 1996, J NEUROSCI, V16, P5233; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; ROWLAND LP, 1989, MERRITTS TXB NEUROLO, P904; SADEH A, 1991, PEDIATRICS, V87, P494; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SERIES F, 1994, AM J RESP CRIT CARE, V150, P481, DOI 10.1164/ajrccm.150.2.8049833; Singer C, 2003, SLEEP, V26, P893, DOI 10.1093/sleep/26.7.893; Spira AP, 2008, J AM GERIATR SOC, V56, P45, DOI 10.1111/j.1532-5415.2007.01506.x; Stepanski EJ, 2002, SLEEP, V25, P268, DOI 10.1093/sleep/25.3.268; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; Taragano FE., 1994, J NEUROL REHABIL, V8, P92; TEASDALE G, 1974, LANCET, V2, P81; Walker MP, 2004, NEURON, V44, P121, DOI 10.1016/j.neuron.2004.08.031; Wei JL, 2007, ARCH OTOLARYNGOL, V133, P974, DOI 10.1001/archotol.133.10.974; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	51	52	53	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAY	2009	23	4					320	326		10.1177/1545968308325268			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	428UJ	WOS:000264876100002	19171947				2022-02-06	
J	Zazulia, AR; Videen, TO; Powers, WJ				Zazulia, Allyson R.; Videen, Tom O.; Powers, William J.			Transient Focal Increase in Perihematomal Glucose Metabolism After Acute Human Intracerebral Hemorrhage	STROKE			English	Article						intracerebral hemorrhage; glucose metabolism; fluorodeoxyglucose; positron emission tomography	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; FDG LUMPED CONSTANT; AUTOMATED ALGORITHM; DEOXYGLUCOSE METHOD; PET; GLUTAMATE; ISCHEMIA; RAT; MICRODIALYSIS	Background and Purpose-Progressive perihematomal cell death over 3 to 4 days has been described after experimental intracerebral hemorrhage (ICH). We investigated whether progressive perihematomal damage occurs in human subjects by measuring relative changes in regional cerebral glucose metabolism with (18)F-fluorordeoxyglucose (FDG) positron emission tomography at multiple time points during the first week after ICH. Methods-Thirteen subjects with a median hematoma volume of 22 cm(3) were studied 1.0 +/- 0.3, 2.9 +/- 0.8, and 6.7 +/- 1.6 days after ICH. Normalized mean counts in 5 concentric annular 2-mm-thick perihematomal volumes-of-interest (VOIs) were compared to the initial study. Next, automated searches with 0.5 to 5.0 mL spherical VOIs identified maximum focal changes in normalized counts compared to the initial study. Results-No annular or focal decrease in perihematomal FDG uptake developed. Instead, FDG uptake significantly increased at session #2 in the first 3 2-mm annular VOIs (9.2%+/- 14.2, 7.8%+/- 11.3, 5.9%+/- 9.0), returning to baseline at session #3. The VOI search identified focal regions of increased perihematomal FDG uptake relative to the contralateral control hemispheres in 6 subjects, which accounted for the annular increase. Conclusion-Perihematomal glucose metabolism increased transiently in a subset of patients 2 to 4 days after acute ICH. These transient focal increases in glucose metabolism occurring in the brain after acute ICH demonstrate that there are ongoing processes in response to injury that last for days. Although further studies are needed to elucidate their pathophysiology, these processes may be indicative of a prolonged window for intervention to improve neurological outcome. (Stroke. 2009; 40: 1638-1643.)	[Zazulia, Allyson R.; Videen, Tom O.; Powers, William J.] Washington Univ, Dept Neurol & Neurol Surg, St Louis, MO 63110 USA; [Zazulia, Allyson R.; Videen, Tom O.; Powers, William J.] Washington Univ, Dept Radiol, St Louis, MO 63110 USA; [Powers, William J.] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA		Zazulia, AR (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	zazuliaa@neuro.wustl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS035966, P01NS035966, K23NS044885] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35966, NS044885] Funding Source: Medline		Ardizzone TD, 2004, STROKE, V35, P2587, DOI 10.1161/01.STR.0000143451.14228.ff; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bleeker-Rovers CP, 2008, Q J NUCL MED MOL IM, V52, P17; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Chapman AG, 1998, PROG BRAIN RES, V116, P371, DOI 10.1016/S0079-6123(08)60449-5; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Hasselbalch SG, 1998, J CEREBR BLOOD F MET, V18, P154, DOI 10.1097/00004647-199802000-00005; Hattori N, 2004, J NUCL MED, V45, P775; HUTCHINS GD, 1984, J CEREBR BLOOD F MET, V4, P35, DOI 10.1038/jcbfm.1984.5; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P73; Mackenzie J M, 1999, J Stroke Cerebrovasc Dis, V8, P1, DOI 10.1016/S1052-3057(99)80032-9; Meltzer CC, 2000, EPILEPSIA, V41, P193, DOI 10.1111/j.1528-1157.2000.tb00139.x; Miller CM, 2007, NEUROCRIT CARE, V6, P22, DOI 10.1385/NCC:6:1:22; NAKAI H, 1987, J CEREBR BLOOD F MET, V7, P640, DOI 10.1038/jcbfm.1987.117; Qureshi AI, 2003, CRIT CARE MED, V31, P1482, DOI 10.1097/01.CCM.0000063047.63862.99; REIVICH M, 1979, CIRC RES, V44, P127, DOI 10.1161/01.RES.44.1.127; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Spence AM, 1998, J NUCL MED, V39, P440; SUDA S, 1990, J CEREBR BLOOD F MET, V10, P499, DOI 10.1038/jcbfm.1990.92; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tsuchida T, 1999, J NUCL MED, V40, P1441; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Videen TO, 1999, J COMPUT ASSIST TOMO, V23, P248, DOI 10.1097/00004728-199903000-00014; WISNIEWSKI H, 1961, Acta Med Pol, V2, P379; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	30	52	52	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAY	2009	40	5					1638	1643		10.1161/STROKEAHA.108.536037			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	438UB	WOS:000265579800018	19286594	Bronze			2022-02-06	
J	Hopkins, RO; Jackson, JC				Hopkins, Ramona O.; Jackson, James C.			Short- and Long-Term Cognitive Outcomes in Intensive Care Unit Survivors	CLINICS IN CHEST MEDICINE			English	Article						Cognitive impairments; Critical illness; Critical care outcomes	QUALITY-OF-LIFE; MECHANICALLY VENTILATED PATIENTS; PREDICT FUNCTIONAL DECLINES; EXECUTIVE FUNCTION; INFORMANT QUESTIONNAIRE; MEDICATION ADHERENCE; CLINICAL PREDICTORS; ELDERLY-PATIENTS; OLDER-ADULTS; RISK-FACTORS	Evidence increasingly suggests that cognitive impairment is common in intensive care unit survivors, although the nature, severity, and natural history remain unclear. Although the cognitive impairments improve over time in some individuals, they often fail to completely abate. While the functional correlates of these impairments are under-studied, cognitive impairments may adversely impact quality of life, ability to return to work or to work at previously established levels, and ability to function effectively in emotional and interpersonal domains. The potential etiologies of cognitive impairments in intensive care unit survivors are not fully understood and are likely heterogeneous and vary widely across patients. The contributions of these many factors may be particularly significant in patients with pre-existing vulnerabilities for the development of cognitive impairments, such as mild cognitive impairment, dementia, prior traumatic brain injury, or other comorbid disorders, as well as predisposing genetic factors.	[Hopkins, Ramona O.] Intermt Med Ctr, Murray, UT 84107 USA; [Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] LIDS Hosp, Dept Med, Div Pulm & Crit Care, Salt Lake City, UT USA; [Jackson, James C.] Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN 37212 USA; [Jackson, James C.] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN 37212 USA		Hopkins, RO (corresponding author), Intermt Med Ctr, 5121 S Cottonwood St, Murray, UT 84107 USA.	ramona.hopkins@imail.org					Al-Saidi F, 2003, AM J RESP CRIT CARE, V167, pA737; Allen SC, 2003, AGE AGEING, V32, P299, DOI 10.1093/ageing/32.3.299; [Anonymous], 1988, LANCET, V2, P349; Biederman J, 2006, AM J PSYCHIAT, V163, P1730, DOI 10.1176/appi.ajp.163.10.1730; Boyle PA, 2004, CLIN NEUROPSYCHOL, V18, P75, DOI 10.1080/13854040490507172; Boyle PA, 2002, INT J GERIATR PSYCH, V17, P164, DOI 10.1002/gps.539; Boyle PA, 2003, AM J GERIAT PSYCHIAT, V11, P214, DOI 10.1176/appi.ajgp.11.2.214; BRODY MP, 1969, GERONTOLOGIST, V9, P179; Burton CL, 2006, CLIN NEUROPSYCHOL, V20, P432, DOI 10.1080/13854040590967063; Cahn-Weiner Deborah A, 2002, Appl Neuropsychol, V9, P187, DOI 10.1207/S15324826AN0903_8; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; Christie JD, 2006, J CRIT CARE, V21, P125, DOI 10.1016/j.jcrc.2005.11.004; Dolan MM, 2000, J GERONTOL A-BIOL, V55, pM527, DOI 10.1093/gerona/55.9.M527; Eikelenboom P, 1999, DEMENT GERIATR COGN, V10, P319, DOI 10.1159/000017162; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Evans JD, 2004, SCHIZOPHR RES, V70, P331, DOI 10.1016/j.schres.2004.01.011; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; Galanakis P, 2001, INT J GERIATR PSYCH, V16, P349, DOI 10.1002/gps.327; Galvin JE, 2006, NEUROLOGY, V67, P1942, DOI 10.1212/01.wnl.0000247042.15547.eb; Griffith HR, 2003, NEUROLOGY, V60, P449, DOI 10.1212/WNL.60.3.449; Griffiths RD, 2007, CURR OPIN CRIT CARE, V13, P508, DOI 10.1097/MCC.0b013e3282efae05; Heaton RK, 2004, J INT NEUROPSYCH SOC, V10, P317, DOI 10.1017/S1355617704102130; Hinkin CH, 2002, NEUROLOGY, V59, P1944, DOI 10.1212/01.WNL.0000038347.48137.67; Hopkins R. O., 2005, P AM THORAC SOC, V2, pA36; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 2004, J INT NEUROPSYCH SOC, V10, P1005, DOI 10.1017/S135561770410711X; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; HOPKINS RO, 2005, INT NEUR LOG SOC M S; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; Insel K, 2006, J GERONTOL B-PSYCHOL, V61, pP102, DOI 10.1093/geronb/61.2.P102; Jackson JC, 2007, J TRAUMA, V62, P80, DOI 10.1097/TA.0b013e31802ce9bd; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Jackson JC, 2004, INTENS CARE MED, V30, P2009, DOI 10.1007/s00134-004-2422-2; Jackson JC, 2003, ARCH CLIN NEUROPSYCH, V18, P688; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Jones C, 2003, CRIT CARE MED, V31, P2456, DOI 10.1097/01.CCM.0000089938.56725.33; Jones C, 2006, INTENS CARE MED, V32, P923, DOI 10.1007/s00134-006-0112-y; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; KOPONEN H, 1989, ACTA PSYCHIAT SCAND, V79, P579, DOI 10.1111/j.1600-0447.1989.tb10306.x; KOPONEN H, 1989, J NERV MENT DIS, V177, P226, DOI 10.1097/00005053-198904000-00006; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lee TA, 2005, J ALZHEIMERS DIS, V7, P319; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; MARQUIS K, 2000, AM J RESP CRIT CARE, V161, pA383; Marshall JC, 2001, CRIT CARE MED, V29, pS99, DOI 10.1097/00003246-200107001-00032; MATA GV, 1992, CRIT CARE MED, V20, P1257, DOI 10.1097/00003246-199209000-00012; McCusker J, 2001, CAN MED ASSOC J, V165, P575; McGurk SR, 2006, ADM POLICY MENT HLTH, V33, P598, DOI 10.1007/s10488-006-0070-2; Meagher DJ, 2001, BMJ-BRIT MED J, V322, P144, DOI 10.1136/bmj.322.7279.144; Montuclard L, 2000, CRIT CARE MED, V28, P3389, DOI 10.1097/00003246-200010000-00002; NYGARD L, 2003, ACTA NEUROL SCAND, V179, P542; OKEEFE ST, 1994, BRIT J ANAESTH, V73, P673, DOI 10.1093/bja/73.5.673; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Rahkonen T, 2001, INT J GERIATR PSYCH, V16, P415, DOI 10.1002/gps.356; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; Rockwood K, 1999, AGE AGEING, V28, P551, DOI 10.1093/ageing/28.6.551; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Royall DR, 2000, J GERONTOL A-BIOL, V55, pM541, DOI 10.1093/gerona/55.9.M541; Royall DR, 1998, J AM GERIATR SOC, V46, P1519, DOI 10.1111/j.1532-5415.1998.tb01536.x; Shephard R J, 2001, J Cardiopulm Rehabil, V21, P189, DOI 10.1097/00008483-200107000-00001; Spinella M, 2004, INT J NEUROSCI, V114, P1323, DOI 10.1080/00207450490476011; STARR JM, 1994, DRUG SAFETY, V11, P310, DOI 10.2165/00002018-199411050-00003; SUCHYTA MR, 2005, P AM THORAC SOC, V2, pA46; SUCHYTA MR, 2004, AM J RESP CRIT CARE, V169, pA18; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; Teunissen CE, 2003, J NEUROIMMUNOL, V134, P142, DOI 10.1016/S0165-5728(02)00398-3; Udekwu P, 2001, J AM COLL SURGEONS, V193, P245, DOI 10.1016/S1072-7515(01)00994-2; Uldall KK, 2000, AIDS PATIENT CARE ST, V14, P95, DOI 10.1089/108729100318037; Van Wielingen LE, 2004, AGING MENT HEALTH, V8, P374, DOI 10.1080/13607860410001709728; VANDIXHOORN J, 1989, AM HEART J, V118, P545, DOI 10.1016/0002-8703(89)90271-8; Wadley VG, 2007, J AM GERIATR SOC, V55, P1192, DOI 10.1111/j.1532-5415.2007.01245.x; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7	80	52	54	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0272-5231	1557-8216		CLIN CHEST MED	Clin. Chest Med.	MAR	2009	30	1					143	+		10.1016/j.ccm.2008.11.001			12	Respiratory System	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Respiratory System	413MH	WOS:000263796700010	19186286				2022-02-06	
J	Xiong, YQ; Hall, ED				Xiong, Yiqin; Hall, Edward D.			Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Tempol; Peroxynitrite; Spinal cord injury; Oxidative damage; Protein nitration; Lipid peroxidation; Mitochondrial dysfunction; Cytoskeletal breakdown	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL PERMEABILITY TRANSITION; NERVOUS-SYSTEM TRAUMA; NITRIC-OXIDE; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; NITROXIDE RADICALS; DEPENDENT TOXICITY; CYTOTOXIC PATHWAY; MOUSE MODEL	Evidence suggests that the reactive oxygen species peroxynitrite (PN) is an important player in the pathophysiology of acute spinal cord injury (SCI). In the present study. we examined the ability of tempol, a catalytic scavenger of PN-derived free radicals, to alleviate oxidative damage, mitochondrial dysfunction and cytoskeletal degradation following a severe contusion (200 kdyn force) SCI in female Sprague-Dawley rats. PN-mediated oxidative damage in spinal cord tissue, including protein nitration, protein oxidation and lipid peroxidation was significantly reduced by acute tempol treatment (300 mg/kg, i.p. within 5 min post-injury). Injury-induced mitochondrial respiratory dysfunction, measured after 24 h in isolated mitochondria, was partially reversed by tempol along with an attenuation of oxidative damage to mitochondrial proteins. Mitochondrial dysfunction disrupts intracellular Ca(2+) homeostasis contributing to calpain-mediated axonal cytoskeletal protein (alpha-spectrin, 280 kD) degradation. Increased levels of alpha-spectrin breakdown proteins (SBDP 145 kD and 150 kD) were significantly decreased at 24 h in tempol-treated rats indicative of spinal axonal protection, However, a therapeutic window analysis showed that the axonal cytoskeletal protective effects require tempol dosing within the first hour after injury. Nevertheless, these findings are the first to support the concept that PN is an important neuroprotective target in early secondary SCI, and that there is a mechanistic link between PN-mediated oxidative compromise of spinal cord mitochondrial function, loss of intracellular Ca(2+) homeostasis and calpain-mediated proteolytic axonal damage. (C) 2008 Elsevier Inc. All rights reserved.	[Hall, Edward D.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013; Xiong, Yiqin/H-1710-2012		Kentucky Spinal Cord and Head Injury Research Trust; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220] Funding Source: NIH RePORTER	This study was supported by a grant from the Kentucky Spinal Cord and Head Injury Research Trust and by NIH 1P30 NS051220.	Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Alvarez MN, 2002, METHOD ENZYMOL, V359, P353; Banik NL, 2000, METH MOL B, V144, P195; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crow JP, 1996, ADV EXP MED BIOL, V387, P147; Cuzzocrea S, 2000, BRAIN RES, V875, P96, DOI 10.1016/S0006-8993(00)02582-8; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Denicola A, 2005, TOXICOLOGY, V208, P273, DOI 10.1016/j.tox.2004.11.023; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Genovese T, 2007, FREE RADICAL BIO MED, V43, P763, DOI 10.1016/j.freeradbiomed.2007.05.012; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; KRISHNA MC, 1994, METHOD ENZYMOL, V234, P580; Krishna MC, 1996, J BIOL CHEM, V271, P26026, DOI 10.1074/jbc.271.42.26026; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kruman I, 1997, J NEUROSCI, V17, P5089; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; MEHLHORN RJ, 1992, FREE RADICAL RES COM, V17, P157, DOI 10.3109/10715769209068163; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; MIURA Y, 1993, ARCH BIOCHEM BIOPHYS, V300, P148, DOI 10.1006/abbi.1993.1021; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Stewart VC, 2002, EUR J NEUROSCI, V15, P458, DOI 10.1046/j.0953-816x.2001.01878.x; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Valdez LB, 2000, FREE RADICAL BIO MED, V29, P349, DOI 10.1016/S0891-5849(00)00301-4; Vicente S, 2006, J NEUROSCI RES, V84, P78, DOI 10.1002/jnr.20853; Virag L, 1998, FREE RADICAL BIO MED, V25, P1075, DOI 10.1016/S0891-5849(98)00139-7; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Zeltcer G, 1997, FREE RADICAL RES, V27, P627, DOI 10.3109/10715769709097866; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V279, pC341, DOI 10.1152/ajpcell.2000.279.2.C341	54	52	56	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2009	216	1					105	114		10.1016/j.expneurol.2008.11.025			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	413UK	WOS:000263817800013	19111721	Green Accepted			2022-02-06	
J	Jyoti, A; Sethi, P; Sharma, D				Jyoti, Amar; Sethi, Pallavi; Sharma, Deepak			Curcumin protects against electrobehavioral progression of seizures in the iron-induced experimental model of epileptogenesis	EPILEPSY & BEHAVIOR			English	Article						Iron-induced epilepsy; Curcumin; Video/EEG recording; Seizures; Epilepsy; Epileptogenesis; Post-traumatic epilepsy	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; NEUROTROPHIC FACTOR; LIPID-PEROXIDATION; RAT HIPPOCAMPUS; KINASE-C; COGNITIVE FUNCTION; DIETARY CURCUMIN; EPILEPSY; ACID	The purpose of the study was to investigate whether dietary intake of curcumin can inhibit the onset and progression of seizures and their associated pathophysiology in experimental FeCl3-induced epileptogenesis. Curcumin was considered for this study because it can cross the blood-brain barrier and bind redox-active metal ions. It is also well known for its antioxidative, anticancer, and anti-inflammatory properties. In the present study, seizures were induced by intracortical injection of FeCl3 into young rats. Synchronized video/EEG recordings were obtained to diagnose the progression of seizures. Short-term treatment with a curcumin-supplemented diet (1500 ppm w/w) significantly inhibited the onset of grade III and IV seizures in rats with iron-induced epilepsy. The lower dose of curcumin (500 ppm) was not effective in inhibiting grade III seizures, but retarded the onset and progression of generalized seizures. The seizure-suppressing potential of curcumin is explained by the observed biochemical, behavioral, and ultrastructural results. Our results indicate that curcumin significantly prevents generalization of electroclinical seizure activity as well as the pathogenesis associated with iron-induced epileptogenesis. (C) 2009 Published by Elsevier Inc.	[Jyoti, Amar; Sethi, Pallavi; Sharma, Deepak] Jawaharlal Nehru Univ, Sch Life Sci, Neurobiol Lab, New Delhi 110067, India; [Sethi, Pallavi] Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India		Sharma, D (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, Neurobiol Lab, New Delhi 110067, India.	dpak57@hotmail.com			Council for Scientific and Industrial Research (CSIR)Council of Scientific & Industrial Research (CSIR) - India	Author Amar Jyoti thankfully acknowledges the financial assistance extended by the Council for Scientific and Industrial Research (CSIR) through a junior Research Fellowship and Senior Research Fellowship. We are thankful to Professor Rameshwar Singh for his scientific guidance and constructive comments during this project. The authors are also thankful to staff at the SAIF facility of AIMS for help in electron microscopy.	AKAGAWA K, 1979, J NEUROCHEM, V32, P269, DOI 10.1111/j.1471-4159.1979.tb04544.x; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; Bala K, 2006, BIOGERONTOLOGY, V7, P81, DOI 10.1007/s10522-006-6495-x; Baum L, 2004, J ALZHEIMERS DIS, V6, P367; Bolton MM, 2000, PROG BRAIN RES, V128, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunbech L, 2002, DRUGS, V62, P593, DOI 10.2165/00003495-200262040-00004; Deloncle R, 2001, EXP GERONTOL, V36, P231, DOI 10.1016/S0531-5565(00)00214-X; Fabene PF, 2006, NEUROBIOL DIS, V21, P80, DOI 10.1016/j.nbd.2005.06.013; Farooqui AA, 1998, CELL MOL NEUROBIOL, V18, P599, DOI 10.1023/A:1020261600498; Fiske CH, 1925, J BIOL CHEM, V66, P375; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Kelloff GJ, 1996, J CELL BIOCHEM, P72; Kempaiah RK, 2006, J NUTR BIOCHEM, V17, P471, DOI 10.1016/j.jnutbio.2005.09.005; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Khopde SM, 1998, FREE RADICAL BIO MED, V25, P66, DOI 10.1016/S0891-5849(98)00046-X; Komatsu M, 2000, EPILEPSIA, V41, P1091, DOI 10.1111/j.1528-1157.2000.tb00312.x; Kuhad A, 2007, EUR J PHARMACOL, V576, P34, DOI 10.1016/j.ejphar.2007.08.001; Kumar A, 2007, J MED FOOD, V10, P486, DOI 10.1089/jmf.2006.076; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Lin JK, 2007, ADV EXP MED BIOL, V595, P227; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Mahmmoud YA, 2007, BRIT J PHARMACOL, V150, P200, DOI 10.1038/sj.bjp.0706970; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; Masuda T, 2001, J AGR FOOD CHEM, V49, P2539, DOI 10.1021/jf001442x; Mori A, 1998, EPILEPSY RES, V30, P153, DOI 10.1016/S0920-1211(97)00097-1; Mori A, 2004, ACTA MED OKAYAMA, V58, P111; MORIWAKI A, 1992, ELECTROEN CLIN NEURO, V83, P281, DOI 10.1016/0013-4694(92)90087-X; MORIWAKI A, 1990, NEUROSCI LETT, V110, P72, DOI 10.1016/0304-3940(90)90789-C; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; RACINE RJ, 1972, BRAIN RES, V47, P262, DOI 10.1016/0006-8993(72)90268-5; REDDY ACP, 1994, FOOD CHEM TOXICOL, V32, P279, DOI 10.1016/0278-6915(94)90201-1; RENKAWEK K, 1992, EPILEPSIA, V33, P58, DOI 10.1111/j.1528-1157.1992.tb02283.x; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; Sanchez DJ, 1998, PHYSIOL BEHAV, V63, P345, DOI 10.1016/S0031-9384(97)00433-2; Scheff SW, 2006, J ALZHEIMERS DIS, V9, P101; Sethi P, 2008, NEUROTOXICOLOGY, V29, P1069, DOI 10.1016/j.neuro.2008.08.005; SHARMA D, 1993, NEUROBIOL AGING, V14, P319, DOI 10.1016/0197-4580(93)90117-T; Sharma Varsha, 1999, Indian Journal of Experimental Biology, V37, P468; Shin HJ, 2007, NEUROSCI LETT, V416, P49, DOI 10.1016/j.neulet.2007.01.060; Shukla PK, 2008, NEUROCHEM RES, V33, P1036, DOI 10.1007/s11064-007-9547-y; SINGH R, 1990, EPILEPSIA, V31, P15, DOI 10.1111/j.1528-1157.1990.tb05354.x; Sng JCG, 2006, EUR J NEUROSCI, V23, P1269, DOI 10.1111/j.1460-9568.2006.04641.x; Sreejayan, 1997, J PHARM PHARMACOL, V49, P105, DOI 10.1111/j.2042-7158.1997.tb06761.x; Stadtman E R, 1992, EXS, V62, P64; Sumanont Y, 2007, BIOL PHARM BULL, V30, P1732, DOI 10.1248/bpb.30.1732; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu RM, 1996, ANN NY ACAD SCI, V786, P379, DOI 10.1111/j.1749-6632.1996.tb39078.x; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200	58	52	56	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	FEB	2009	14	2					300	308		10.1016/j.yebeh.2008.11.011			9	Behavioral Sciences; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	412ZB	WOS:000263761600005	19100339				2022-02-06	
J	Greve, K; Heinly, M; Bianchini, K; Love, J				Greve, Kevin W.; Heinly, Matthew T.; Bianchini, Kevin J.; Love, Jeffrey M.			Malingering detection with the Wisconsin Card Sorting Test in mild traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	34th Annual Meeting of the International-Neuropsychological-Society	FEB 01-04, 2006	Boston, MA	Int Neuropsychol Soc		Wisconsin Card Sorting Test; Malingering; Traumatic brain injury; Neuropsychological assessment	VERBAL-LEARNING TEST; NEUROCOGNITIVE DYSFUNCTION; CLASSIFICATION ACCURACY; PATIENT SAMPLES; HEAD-INJURY; PERFORMANCE; SPECIFICITY; INDICATORS; SENSITIVITY	This study evaluates the ability of several Wisconsin Card Sorting Test (WCST; Psychological Assessment Resources, 1990) variables to detect malingering in mild traumatic brain injury (TBI). The sample consisted of 373 TBI patients and 766 general clinical patients. Classification accuracy for seven indicators is reported across a range of injury severity and scores levels. Overall, most WCST scores were ineffective in discriminating malingering from non-malingering mild TBI patients. Failure-to-Maintain-Set, the Suhr Boyer formula, and the King et al. formula detected about 30% of malingerers at cutoffs associated with a false positive error rate of 11%. The clinical interpretation and use of these indicators are discussed.	[Greve, Kevin W.; Heinly, Matthew T.; Bianchini, Kevin J.; Love, Jeffrey M.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Heinly, Matthew T.; Bianchini, Kevin J.; Love, Jeffrey M.] Jefferson Neurobehav Grp, Metairie, LA USA		Greve, K (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; BINDER LM, 1993, PORTLAND DIGIT RECOG; CONDER R, 1992, MANUAL COMPUTERIZED; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; CURTIS KL, CLIN NEUROP IN PRESS; Donders J, 1999, ARCH PHYS MED REHAB, V80, P346, DOI 10.1016/S0003-9993(99)90150-8; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Green P., 1996, WORD MEMORY TEST USE; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2005, ARCH CLIN NEUROPSYCH, V20, P355, DOI 10.1016/j.acn.2004.09.004; Greve KW, 2002, ASSESSMENT, V9, P271, DOI 10.1177/1073191102009003006; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Greve KW, 2002, J CLIN EXP NEUROPSYC, V24, P48, DOI 10.1076/jcen.24.1.48.968; GREVE KW, 2007, EVALUATION MALINGERI, P171; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton RK, 1991, COMPREHENSIVE NORMS; Heaton RK, 1981, MANUAL WISCONSIN CAR; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Hilsabeck RC, 2001, ARCH CLIN NEUROPSYCH, V16, P669, DOI 10.1016/S0887-6177(00)00077-9; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; KNIGHT JA, 1986, 94 M AM PSYCH ASS WA; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LARRABEE GJ, 2007, REFINING DIAGNOSTIC; Miller A., 2000, CLIN NEUROPSYCHOLOGI, V2, P141; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MILLIS SR, 2004, EVALUATION MALINGERE; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; *PSYCH ASS RES, 1990, WISC CARD SORT TEST; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Warrington E, 1984, RECOGNITION MEMORY T, V1; [No title captured]	41	52	52	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	2					343	362	PII 793788043	10.1080/13854040802054169			20	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology; Neurosciences & Neurology	399LS	WOS:000262802000011	18609328				2022-02-06	
J	Horneman, G; Emanuelson, I				Horneman, Goran; Emanuelson, Ingrid			Cognitive outcome in children and young adults who sustained severe and moderate traumatic brain injury 10 years earlier	BRAIN INJURY			English	Article						Children; traumatic brain injury; cognitive long-term outcome	NORMATIVE DATA; HEAD-INJURIES; SHORT-TERM; RECOVERY; CHILDHOOD; DEFICITS; PREDICTORS; SKILLS; COMA; AGE	Objective: This study is a population-based, retrospective follow-up study of neuropsychological functions after severe and moderate TBI. Methods: One hundred and sixty-five survivors of TBI injured in 1987-1991 in the 0-17-year age group were identified. Of the traceable individuals (149), 53 patients who sustained injury at a mean of 9.96 years participated in a neuropsychological investigation 10 years post-injury. A control group of 40 healthy subjects, matched for age and sex was chosen. An extensive neuropsychological test battery was used. Results: The TBI group showed significantly poorer performance in tests of intellectual function, with substantially lower results in verbal tests and in tests of verbal learning and memory, visuo-constructive ability and executive functions. The severely injured group showed substantial recovery. Poor results in visuo-constructive tests and tests of executive functions remained. Conclusions: Severity of injury is an important factor when assessing outcome, even 10 years after childhood TBI. The TBI group obtained poorer results on most of the measurements compared with healthy controls. Verbal function was strongly affected which needs to be taken into consideration when preparing for rehabilitation programmes. Evaluations of final outcome should not be made before the subjects reach adulthood.	[Horneman, Goran] Gothenburg Univ, Dept Psychol, Gothenburg, Sweden; [Emanuelson, Ingrid] Inst Clin Disciplines, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden		Horneman, G (corresponding author), Skeppspromenaden 5, SE-41763 Gothenburg, Sweden.	g.horneman@telia.com					Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; BIRKENKAMP R, 1962, AUFMERKSAMKEITS BELA; Birkenkamp R., 1998, D2 TEST ATTENTION; BOLL T, 1993, CHILDRENS CATEGORY T; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; DROTAR D, 2001, HDB RES PEDIAT CLIN, V22; EKLUND G, 1965, STATISTISK TIDSKRIFT, V3, P355; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; FINLAYSON MAJ, 1976, PERCEPT MOTOR SKILL, V43, P475, DOI 10.2466/pms.1976.43.2.475; FLETCHER EJ, 1995, RECEPTOR CHANNEL, V3, P21; Forrester G., 1991, CLIN NEUROPSYCHOL, V5, P345, DOI [10.1080/13854049108404102, DOI 10.1080/13854049108404102]; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Hill T., 2007, STAT METHODS APPL; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LESSER R, 1976, NEUROPSYCHOLOGIA, V14, P79, DOI 10.1016/0028-3932(76)90009-9; LURIA AR, 1964, NEUROPSYCHOLOGIA, V2, P95, DOI 10.1016/0028-3932(64)90015-6; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Meyers JE., 1995, REY COMPLEX FIGURE T; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MUNGAS D, 1983, J CONSULT CLIN PSYCH, V51, P848, DOI 10.1037/0022-006X.51.6.848; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PILLON B, 1981, NEUROPSYCHOLOGIA, V19, P375, DOI 10.1016/0028-3932(81)90067-1; Rey A., 1964, EXAMEN CLIN PSYCHOL; Romine CB, 2005, APPL NEUROPSYCHOL, V12, P190, DOI 10.1207/s15324826an1204_2; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1991, MANUAL WECHSLER ADUL; WEISS J, SCIENCE, V282, P1652; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Wolfson, 1993, HALSTEAD REITAN NEUR; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; YEUDALL LT, 1986, J CLIN PSYCHOL, V42, P918, DOI 10.1002/1097-4679(198611)42:6<918::AID-JCLP2270420617>3.0.CO;2-Y; [No title captured]; [No title captured]	52	52	54	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	11					907	914	PII 915242694	10.1080/02699050903283239			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300007	20100127				2022-02-06	
J	Maggiore, U; Picetti, E; Antonucci, E; Parenti, E; Regolisti, G; Mergoni, M; Vezzani, A; Cabassi, A; Fiaccadori, E				Maggiore, Umberto; Picetti, Edoardo; Antonucci, Elio; Parenti, Elisabetta; Regolisti, Giuseppe; Mergoni, Mario; Vezzani, Antonella; Cabassi, Aderville; Fiaccadori, Enrico			The relation between the incidence of hypernatremia and mortality in patients with severe traumatic brain injury	CRITICAL CARE			English	Article							POSTTRAUMATIC INTRACRANIAL HYPERTENSION; HYPERTONIC SALINE THERAPY; INTENSIVE-CARE-UNIT; MEDICAL COMPLICATIONS; SODIUM-CHLORIDE; CRITICALLY-ILL; SUBARACHNOID HEMORRHAGE; DIABETES-INSIPIDUS; HEAD-INJURY; PRESSURE	Introduction The study was aimed at verifying whether the occurrence of hypernatremia during the intensive care unit (ICU) stay increases the risk of death in patients with severe traumatic brain injury (TBI). We performed a retrospective study on a prospectively collected database including all patients consecutively admitted over a 3-year period with a diagnosis of TBI (post-resuscitation Glasgow Coma Score <= 8) to a general/neurotrauma ICU of a university hospital, providing critical care services in a catchment area of about 1,200,000 inhabitants. Methods Demographic, clinical, and ICU laboratory data were prospectively collected; serum sodium was assessed an average of three times per day. Hypernatremia was defined as two daily values of serum sodium above 145 mmol/l. The major outcome was death in the ICU after 14 days. Cox proportional-hazards regression models were used, with time-dependent variates designed to reflect exposure over time during the ICU stay: hypernatremia, desmopressin acetate (DDAVP) administration as a surrogate marker for the presence of central diabetes insipidus, and urinary output. The same models were adjusted for potential confounding factors. Results We included in the study 130 TBI patients (mean age 52 years (standard deviation 23); males 74%; median Glasgow Coma Score 3 (range 3 to 8); mean Simplified Acute Physiology Score II 50 (standard deviation 15)); all were mechanically ventilated; 35 (26.9%) died within 14 days after ICU admission. Hypernatremia was detected in 51.5% of the patients and in 15.9% of the 1,103 patient-day ICU follow-up. In most instances hypernatremia was mild (mean 150 mmol/l, interquartile range 148 to 152). The occurrence of hypernatremia was highest (P = 0.003) in patients with suspected central diabetes insipidus (25/130, 19.2%), a condition that was associated with increased severity of brain injury and ICU mortality. After adjustment for the baseline risk, the incidence of hypernatremia over the course of the ICU stay was significantly related with increased mortality (hazard ratio 3.00 (95% confidence interval: 1.34 to 6.51; P = 0.003)). However, DDAVP use modified this relation (P = 0.06), hypernatremia providing no additional prognostic information in the instances of suspected central diabetes insipidus. Conclusions Mild hypernatremia is associated with an increased risk of death in patients with severe TBI. In a proportion of the patients the association between hypernatremia and death is accounted for by the presence of central diabetes insipidus.	[Maggiore, Umberto; Antonucci, Elio; Parenti, Elisabetta; Regolisti, Giuseppe; Cabassi, Aderville; Fiaccadori, Enrico] Univ Parma, Dipartimento Clin Med Nefrol & Sci Prevenz, I-43100 Parma, Italy; [Picetti, Edoardo; Mergoni, Mario; Vezzani, Antonella] Univ Parma, Azienda Osped, Serv Anestesia & Rianimaz 1, I-43100 Parma, Italy		Fiaccadori, E (corresponding author), Univ Parma, Dipartimento Clin Med Nefrol & Sci Prevenz, Via Gramsci 14, I-43100 Parma, Italy.	enrico.fiaccadori@unipr.it	Regolisti, Giuseppe/AAH-4766-2021	Regolisti, Giuseppe/0000-0002-9976-5681; Maggiore, Umberto/0000-0002-7468-9600	Italian Ministry of UniversityMinistry of Education, Universities and Research (MIUR) [20074TCLB8]	The authors would like to warmly thank Nino Stocchetti MD for his insightful suggestions, and Luca Longhi MD for comments. Financial support was from the Italian Ministry of University Grant PRIN 20074TCLB8.	Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Boughey JC, 2004, AM SURGEON, V70, P500; *BRAIN TRAUM FDN I, 2003, GUID MAN SEV TRAUM B; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Detry O, 2006, WORLD J GASTROENTERO, V12, P7405, DOI 10.3748/wjg.v12.i46.7405; EDWARDS OM, 1986, MEDICINE, V65, P281; Forsyth LL, 2008, PHARMACOTHERAPY, V28, P469, DOI 10.1592/phco.28.4.469; Froelich M, 2008, CRIT CARE MED, V36, P642, DOI 10.1097/CCM.0B013E3181629821; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Guesde R, 1998, LANCET, V352, P1178, DOI 10.1016/S0140-6736(98)05456-7; Hadjizacharia P, 2008, J AM COLL SURGEONS, V207, P477, DOI 10.1016/j.jamcollsurg.2008.04.017; Hartl R, 1997, ACT NEUR S, V70, P126; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hoorn EJ, 2008, NEPHROL DIAL TRANSPL, V23, P1562, DOI 10.1093/ndt/gfm831; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hosmer D. W., 1999, APPL SURVIVAL ANAL; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kraft MD, 2005, AM J HEALTH-SYST PH, V62, P1663, DOI 10.2146/ajhp040300; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lindner G, 2007, AM J KIDNEY DIS, V50, P952, DOI 10.1053/j.ajkd.2007.08.016; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Muizelaar JP, 2009, CRIT CARE MED, V37, P1521, DOI 10.1097/CCM.0b013e31819d3ea0; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; O'Quigley J, 2005, STAT MED, V24, P479, DOI 10.1002/sim.1946; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Petit L, 2006, ANN FR ANESTH, V25, P828, DOI 10.1016/j.annfar.2006.04.005; Phongsamran Paula V, 2004, Prog Transplant, V14, P105; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Polderman KH, 1999, CRIT CARE MED, V27, P1105, DOI 10.1097/00003246-199906000-00029; Qureshi AI, 2002, NEUROSURGERY, V50, P749, DOI 10.1097/00006123-200204000-00012; Raghavan M, 2006, NEUROCRIT CARE, V4, P179, DOI 10.1385/NCC:4:2:179; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Royston P, 2007, STATA J, V7, P376, DOI 10.1177/1536867X0700700305; Royston P, 2006, STATA J, V6, P83, DOI 10.1177/1536867X0600600105; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; Stelfox HT, 2008, CRIT CARE, V12, DOI 10.1186/cc7162; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Suarez JI, 1999, J NEUROSURG ANESTH, V11, P178, DOI 10.1097/00008506-199907000-00004; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P457; Tisdall M, 2006, J NEUROSURG ANESTH, V18, P57, DOI 10.1097/01.ana.0000191280.05170.0f; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Valadka AB, 2000, CRIT CARE MED, V28, P1245, DOI 10.1097/00003246-200004000-00069; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wartenberg KE, 2006, CURR OPIN CRIT CARE, V12, P78, DOI 10.1097/01.ccx.0000216571.80944.65; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6	60	52	57	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	4							R110	10.1186/cc7953			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	525OL	WOS:000272225600007	19583864	Green Published, gold			2022-02-06	
J	Stein, DM; Dutton, RP; Kramer, ME; Scalea, TM				Stein, Deborah M.; Dutton, Richard P.; Kramer, Mary E.; Scalea, Thomas M.			Reversal of Coagulopathy in Critically III Patients With Traumatic Brain Injury: Recombinant Factor VIIa is More Cost-Effective Than Plasma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Traumatic brain injury; Coagulopathy; rFVIIa; Cost-effectiveness	ACTIVATED FACTOR-VII; CENTRAL-NERVOUS-SYSTEM; FRESH-FROZEN PLASMA; ADJUNCTIVE THERAPY; INTRACEREBRAL HEMORRHAGE; BLOOD-TRANSFUSION; BLEEDING CONTROL; BLUNT TRAUMA; HEAD-INJURY; WARFARIN	Background: Traumatic brain injury (TBI) is the leading cause of death and disability after trauma. Coagulopathy is common in this patient population and requires rapid reversal to allow for safe neurosurgical intervention and prevent worsening of the primary injury. Typically reversal of coagulopathy is accomplished with the use of plasma. Recombinant factor VIIa (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark) has become increasingly used "off-label" in patients with neurosurgical emergencies to rapidly reverse coagulopathy. We hypothesized that the use of rFVIIa in this patient population would prove to be cost-effective as well as demonstrate clinical benefit. Methods: The trauma registry at the R Adams Cowley Shock Trauma Center was used to identify all coagulopatic trauma patients admitted between January 2002 and December 2007 with relatively isolated TBI (head Abbreviated Injury Scale score of >= 4). The medical records of patients were reviewed and demographics, injury-specific data, medications administered, laboratory values, blood product utilization, neurosurgical procedures. length of stay (LOS), discharge disposition, and outcome data were abstracted. Patients who received rFVIIa for reversal of coagulopathy were compared against those who did not receive rFVIIa. t Tests were used to compare differences between continuous variables, and chi(2) analysis was used to compare categorical variables. A p value of <0.05 was considered significant for all statistical tests. Results: During a 6-year period, there were 179 patients who met inclusion criteria. One hundred eleven patients (62.0%) were treated with conventional therapy alone whereas 68 (38.0%) received rFVIIa. Baseline characteristics between the two groups were similar except that Injury Severity Score and admission International normalized ratio were higher in the rFVIIa group and the rFVIIa group had a higher percentage of patients with head Abbreviated Injury Scale score of 5 injuries, patients who underwent neurosurgical procedures and patients with preinjury warfarin use. There was no difference in total charges between these groups (mean US $63,403 in the conventionally treated group vs. $66,086). When patients who required admission to the intensive care unit were analyzed (n = 110, 50% received rFVIIa), total mean charges and costs were significantly lower in the group that received rFVIIa (mean US $108,900 vs. $77,907). Hospital LOS, days of mechanical ventilation, and plasma utilization were lower in the rFVIIa group. Mortality and thromboembolic complication rates were not different between the two groups. Conclusion: In this study, we were able to demonstrate a significant economic benefit of the use of rFVIIa for reversal of coagulopathy in severely injured patients with TBI. Not all patients with coagulopathy and an anatomic brain injury benefit, but in patients who are neurologically or physiologically compromised, using rFVIIa decreases total charges and costs of hospitalization. This decrease in overall cost is directly attributable to the significant decrease in LOS and decrease in the need for mechanical ventilation. This study demonstrates that in coagulopathic patients with TBI who require intensive care unit admission, rFVIIa is cost-effective and safe. Prospective studies are needed to confirm these findings and establish clinical effectiveness.	[Stein, Deborah M.; Dutton, Richard P.; Kramer, Mary E.; Scalea, Thomas M.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA		Stein, DM (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963			Bartal C, 2007, J TRAUMA, V63, P725, DOI 10.1097/TA.0b013e318031ccca; Bochicchio GV, 2008, WORLD J SURG, V32, P2185, DOI 10.1007/s00268-008-9655-0; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Boulis NM, 1999, NEUROSURGERY, V45, P1113, DOI 10.1097/00006123-199911000-00020; Brody DL, 2005, NEUROCRIT CARE, V2, P263, DOI 10.1385/NCC:2:3:263; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cortiana M, 1986, J Neurosurg Sci, V30, P133; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Dara SI, 2005, CRIT CARE MED, V33, P2667, DOI [10.1097/01.CCM.0000186745.53059.F0, 10.1097/01.CCM.0000151062.00501.60]; Dellinger R Phillip, 2008, Crit Care Med, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Earnshaw SR, 2006, STROKE, V37, P2751, DOI 10.1161/01.STR.0000246611.21999.5d; Etemadrezaie H, 2007, CLIN NEUROL NEUROSUR, V109, P166, DOI 10.1016/j.clineuro.2006.09.001; Freeman WD, 2004, MAYO CLIN PROC, V79, P1495, DOI 10.4065/79.12.1495; Galanaud JP, 2003, PHARMACOECONOMICS, V21, P699, DOI 10.2165/00019053-200321100-00002; Ganguly S, 2006, CLIN LAB HAEMATOL, V28, P309, DOI 10.1111/j.1365-2257.2006.00815.x; Harrison TD, 2005, J TRAUMA, V59, P150, DOI 10.1097/01.TA.0000171470.39742.8E; Hawryluk GWJ, 2006, J NEUROSURG, V105, P859, DOI 10.3171/jns.2006.105.6.859; Hedner U, 2006, SEMIN THROMB HEMOST, V32, P77, DOI 10.1055/s-2006-939557; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Karadimov D, 2003, J NEUROSURG ANESTH, V15, P330, DOI 10.1097/00008506-200310000-00008; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; Kian H, 2007, CHEST, V131, P1308, DOI 10.1378/chest.06-3048; KISSELA BM, 2002, BMC NEUROLOGY, V8, P17; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Loudon B, 2005, INTERN MED J, V35, P463, DOI 10.1111/j.1445-5994.2005.00878.x; Lyseng-Williamson KA, 2007, PHARMACOECONOMICS, V25, P1007, DOI 10.2165/00019053-200725120-00004; May AK, 1997, AM SURGEON, V63, P233; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Morris S, 2007, ANAESTHESIA, V62, P43, DOI 10.1111/j.1365-2044.2006.04896.x; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Perkins JG, 2007, J TRAUMA, V62, P1095, DOI 10.1097/TA.0b013e31804798a4; Powner DJ, 2005, NEUROSURGERY, V57, P823, DOI 10.1227/01.NEU.0000179915.74429.b2; Ranucci M, 2008, ARCH SURG-CHICAGO, V143, P296, DOI 10.1001/archsurg.2007.66; Rizoli SB, 2006, CRIT CARE, V10, DOI 10.1186/cc5133; Rizoli SB, 2006, J TRAUMA, V61, P1419, DOI 10.1097/01.ta.0000243045.56579.74; Roitberg B, 2005, NEUROSURGERY, V57, P832, DOI 10.1227/01.NEU.0000180816.80626.C2; Rudisill CN, 2006, AM J HEALTH-SYST PH, V63, P1641, DOI 10.2146/ajhp060093; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Sorensen B, 2003, BLOOD COAGUL FIBRIN, V14, P469, DOI 10.1097/00001721-200307000-00007; Stein DM, 2008, INJURY, V39, P1054, DOI 10.1016/j.injury.2008.03.032; Stein DM, 2008, J TRAUMA, V64, P620, DOI 10.1097/TA.0b013e3181650fc7; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Steiner T, 2006, NEUROSURGERY, V59, P767, DOI 10.1227/01.NEU.0000232837.34992.32; Tawil I, 2008, J TRAUMA, V64, P849, DOI 10.1097/TA.0b013e318160c08a; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Traynor K, 2004, AM J HEALTH-SYST PH, V61, P866, DOI 10.1093/ajhp/61.9.866; Uhrig L, 2007, PEDIATR CRIT CARE ME, V8, P576, DOI 10.1097/01.PCC.0000282734.17597.00; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; White Christopher E, 2006, Curr Surg, V63, P310, DOI 10.1016/j.cursur.2006.04.013; Yusim Y, 2006, J CLIN ANESTH, V18, P545, DOI 10.1016/j.jclinane.2006.02.012; Zaaroor M, 2008, ACTA NEUROCHIR, V150, P663, DOI 10.1007/s00701-008-1593-y; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	61	52	61	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					63	75		10.1097/TA.0b013e318191bc8a			13	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	395SJ	WOS:000262543500008	19131807				2022-02-06	
J	Muscara, F; Catroppa, C; Anderson, V				Muscara, Frank; Catroppa, Cathy; Anderson, Vicki			The impact of injury severity on executive function 7-10 years following pediatric traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL LOBES; HEAD-INJURY; SHORT-TERM; CHILDHOOD; CHILDREN; OUTCOMES; ADOLESCENCE; ATTENTION; BEHAVIOR; DEFICITS	The impact of pediatric traumatic brain injury (TBI) on executive function (EF) development is well documented, with more severe injury associated with poorer Outcome. Few studies have investigated the impact of pediatric TBI oil EF in the long-term post-injury. The current Study explored the relationship between injury severity and EF in participants with childhood TBI, following the transition into adulthood. The sample included 36 participants who had sustained TBI between 8-12 years of age. At 7-10 years post-injury, they now ranged between 16-22 years of age. Findings indicated that adolescents and young adults who suffered a more severe TBI during childhood tended to display a higher degree of executive dysfunction. but Only in specific EF domains.	[Muscara, Frank; Catroppa, Cathy; Anderson, Vicki] Australian Ctr Child Neuropsychol Studies, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Muscara, Frank; Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Melbourne, Vic 3010, Australia; [Catroppa, Cathy; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Vic, Australia		Muscara, F (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	frank.muscara@meri.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436	Royal Children's Research Institute; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	This research was supported by grants front the Royal Children's Research Institute, and the National Health and Medical Research Council. We also thank the participants and their families who generously contributed their time to this research.	Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; ANDERSON V, 2001, DEV NEUROPSYCHOLOGY; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; CASE R, 1992, BRAIN COGNITION, V20, P51, DOI 10.1016/0278-2626(92)90061-P; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Daniel A., 1983, POWER PRIVILEGE PRES; Delis DC., 2001, DELIS KAPLAN EXECUTI; ESLINGER PJ, 1993, NEUROPSYCHOLOGIA, V31, P17, DOI 10.1016/0028-3932(93)90077-D; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA IP, 2000, BEHAV RATING INVENTO; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Luciana M, 2005, CHILD DEV, V76, P697, DOI 10.1111/j.1467-8624.2005.00872.x; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; Rey A., 1964, EXAMEN CLIN PSYCHOL; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tabachnick B.G., 2001, USING MULTIVARIATE S; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	44	52	53	0	15	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	SEP-OCT	2008	33	5					623	636		10.1080/87565640802171162			14	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	354YW	WOS:000259676800004	18788014				2022-02-06	
J	Yoganandan, N; Li, JR; Zhang, JY; Pintar, FA; Gennarelli, TA				Yoganandan, Narayan; Li, Jianrong; Zhang, Jiangyue; Pintar, Frank A.; Gennarelli, Thomas A.			Influence of angular acceleration-deceleration pulse shapes on regional brain strains	JOURNAL OF BIOMECHANICS			English	Article						rotational accelerations; brain trauma; finite element model; strain; pulse shape	DIFFUSE AXONAL INJURY; HEAD-INJURY; BIOMECHANICS; MODEL; VENTRICLES; CONCUSSION; MOTION; IMPACT	Recognizing the association of an-gular loading with brain injuries and inconsistency in previous studies in the application of the biphasic loads to animal, physical, and experimental models. the present Study examined the role of the acceleration-deceleration pulse shapes on region-specific strains. An experimentally validated two-dimensional finite element model representing the adult male human head was used. The model simulated the skull and falx Lis a linear clastic material, cerebrospinal fluid is a hydrodynamic material, and cerebrum as a linear viscoelastic material. The angular loading matrix consisted coronal plane rotation about a center of rotation that was acccleration-only (4.5 ms duration, 7.8 krad/s/s peak), deceleration-only (20 ms, 1.4 krad/s/s peak), acceleration-deceleration, and deceleration-acceleration pulses. Both biphasic pulses had peaks separated by intervals ranging from 0 to 25 ins. Principal strains were determined at the corpus callosum, base of the postcentral sulcus, and cerebral cortex of the parietal lobe. The cerebrum was divided into 17 regions and peak values of average maximum principal strains were determined. In all simulations. the corpus callosum responded with the highest strains. Strains were the least under all simulations in the lower parietal lobes. In all regions peak strains were the same for both monophase Pulses Suggesting that the angular velocity may be a better metric than peak acceleration or deceleration. In contrast, for the biphasic Pulse, peak strains were region- and pulse-shape specific. Peak values were lower in both biphasic pulses when there was no time separation between the Pulses than the corresponding monophase Pulse. Increasing separation time intervals increased strains, albeit non-uniformly. Acceleration followed by deceleration Pulse produced greater strains in all regions than the other form of biphasic pulse. Thus, pulse shape appears to have an effect on regional strains in the brain. Published by Elsevier Ltd.	[Yoganandan, Narayan] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; VA Med Ctr, Milwaukee, WI 53226 USA		Yoganandan, N (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	yoga@mcw.edu					ABEL J, 1978, P 22 STAPP CAR CRASH, P33; Adams J, 1987, P 31 STAPP CAR CRASH, V96, P1355, DOI DOI 10.4271/872197; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1985, P 30 AM ASS ADV AUT, P447; GENNARELLI TA, 1979, P 23 STAPP CAR CRASH, P563; Gennarelli TA, 1972, P 16 STAPP CAR CRASH, P296; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; HIGGINS LS, 1967, P 11 STAPP CAR CRASH, P35; Holbourn AHS, 1943, LANCET, V2, P438; Huang HM, 1999, J TRAUMA, V47, P538, DOI 10.1097/00005373-199909000-00019; Ivarsson J, 2002, J BIOMECH ENG-T ASME, V124, P422, DOI 10.1115/1.1485752; Ivarsson J, 2000, J BIOMECH, V33, P181, DOI 10.1016/S0021-9290(99)00144-X; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LEE MC, 1987, P 31 STAPP CAR CRASH, P67; Li JR, 2007, BIOMED SCI INSTRUM, V43, P24; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARGULIES SS, 1985, P INT RES COUNCIL BI, P223; Meaney D.F., 1990, P 1990 INT IRCOBI C, P215; MEANEY DF, 1994, P ANN C ASS, P345; MEYERS MA, 1984, MECH METALLURGY; Millan A, 1998, J IMAGING SCI TECHN, V42, P385; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1966, P 10 STAPP CAR CRASH, V10, P314; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; THIBAULT L, 1985, CENTRAL NERVOUS SYST, V1, P371; Thibault L., 1971, P 15 STAPP CAR CRASH; Thibault L.E., 1985, P 10 EXP SAF VEH C N, P79; THIBAULT LE, 1990, P ANN C ASS, P337; UNTERHARNSCHEID.F, 1969, ACTA NEUROPATHALOGIC, P200; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; YOGANANDAN N, 1998, FRONTIERS HEAD NECK; Zhang Jiangyue, 2006, Annu Proc Assoc Adv Automot Med, V50, P1; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhou C, 1995, P STAPP CAR CRASH J, V39, P121, DOI DOI 10.4271/952714; ZHOU C, 1996, P 1996 INT IRCOBI C, P35	42	52	53	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUL 19	2008	41	10					2253	2262		10.1016/j.jbiomech.2008.04.019			10	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	336HF	WOS:000258354200023	18556004				2022-02-06	
J	Register-Mihalik, JK; Mihalik, JP; Guskiewicz, KM				Register-Mihalik, Johna K.; Mihalik, Jason P.; Guskiewicz, Kevin M.			Balance deficits after sports-related concussion in individuals reporting posttraumatic headache	NEUROSURGERY			English	Article						migraine; mild traumatic brain injury; postural stability	POSTURAL STABILITY; NEUROPSYCHOLOGICAL PERFORMANCE; MILD HEAD; MIGRAINE; INJURY; COLLEGIATE; DIZZINESS; SYMPTOMS; WHIPLASH; VERTIGO	OBJECTIVE: Posttraumatic headache (PTH) may affect neurocognition after sports-related concussion. To our knowledge, no studies have examined how PTH affects balance after concussion using dynamic posturography. The purpose of this study is to compare balance after concussion between athletes reporting PTH and athletes not reporting PTH. METHODS: We conducted a retrospective, repeated-measures design with participants grouped by presence of postinjury report of headache. Balance testing was conducted on 108 concussed collegiate athletes (age, 18.83 +/- 1.27 yr; height, 180.92 +/- 10.01 cm; mass, 83.29 +/- 19.62 kg). Presence of PTH during the first postinjury test session (group) and test time (baseline, postinjury) served as the independent variables. The composite equilibrium score and the somatosensory, vestibular, and visual ratio scores served as dependent variables. A 2 X 2 mixed model analysis of variance was used to analyze each outcome measure. RESULTS: Significant decreases in all four measures assessed were noted after concussion compared with preseason baseline measures (P < 0.05). Significant group by test-time interactions were observed, suggesting that composite equilibrium (F-1106 = 6.6089; P = 0.012) and vestibular ratio (F-1106 = 7.156; P = 0.009) scores are affected by the presence of PTH. Athletes reporting PTH also demonstrated worse visual ratio scores compared with individuals not experiencing PTH (F-1106 = 4.26; P = 0.041). No other significant findings were observed for the somatosensory ratio score. CONCLUSION: Current literature proposes that PTH is associated with cognitive deficits. Our study indicates that PTH may also contribute to increased balance deficits. We believe the deficits may be a result of increased sensory organization challenges after injury. Clinicians should be mindful of these findings when managing concussed athletes reporting headache.	[Register-Mihalik, Johna K.; Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Register-Mihalik, Johna K.; Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA		Guskiewicz, KM (corresponding author), Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, 209 Fetzer Gymnasium,Campus Box 8700,South Rd, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Mihalik, Jason P/E-7059-2010	Guskiewicz, Kevin/0000-0002-8682-2130; Register-Mihalik, Johna/0000-0002-4229-4743; Mihalik, Jason/0000-0001-6085-8322			Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CUTRER FM, 1992, HEADACHE, V32, P300, DOI 10.1111/j.1526-4610.1992.hed3206300.x; FORDSMITH CD, 1995, ARCH PHYS MED REHAB, V76, P77, DOI 10.1016/S0003-9993(95)80047-6; Furman JM, 2003, CURR OPIN NEUROL, V16, P5, DOI 10.1097/00019052-200302000-00002; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Giacomini PG, 2004, EUR J PAIN, V8, P579, DOI 10.1016/j.ejpain.2004.02.004; GUIDETTI G, 1984, Acta Oto-Rhino-Laryngologica Belgica, V38, P140; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harno H, 2003, NEUROLOGY, V61, P1748, DOI 10.1212/01.WNL.0000098882.82690.65; HORSTMANN GA, 1988, NEUROSCI LETT, V95, P179, DOI 10.1016/0304-3940(88)90653-2; Hu Ming-Hsia, 1996, Proceedings of the National Science Council Republic of China Part B Life Sciences, V20, P78; KURITZKY A, 1981, HEADACHE, V21, P227, DOI 10.1111/j.1526-4610.1981.hed2105227.x; Lake AE, 1999, J HEAD TRAUMA REHAB, V14, P70, DOI 10.1097/00001199-199902000-00008; Mallinson AI, 1998, AM J OTOL, V19, P814; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; O'Bryant Sid E, 2005, Expert Rev Neurother, V5, P363, DOI 10.1586/14737175.5.3.363; Patel AV, 2007, J ATHL TRAINING, V42, P66; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rossi C, 2005, ACTA NEUROL SCAND, V111, P407, DOI 10.1111/j.1600-0404.2005.00422.x; RUBIN AM, 1995, AM J OTOL, V16, P216; Savundra PA, 1997, CEPHALALGIA, V17, P505, DOI 10.1046/j.1468-2982.1997.1704505.x; Soloman S, 1998, HEADACHE, V38, P772, DOI 10.1046/j.1526-4610.1998.3810772.x; Tang PF, 1998, J GERONTOL A-BIOL, V53, pM140, DOI 10.1093/gerona/53A.2.M140; TOGLIA JU, 1981, ANN OTO RHINOL LARYN, V90, P267, DOI 10.1177/000348948109000315; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x	36	52	52	0	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2008	63	1					76	81		10.1227/01.NEU.0000335073.39728.CE			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	341LM	WOS:000258716000017	18728571				2022-02-06	
J	Gomez-Nicola, D; Valle-Argos, B; Pita-Thomas, DW; Nieto-Sampedro, M				Gomez-Nicola, Diego; Valle-Argos, Beatriz; Pita-Thomas, D. Wolfgang; Nieto-Sampedro, Manuel			Interleukin 15 expression in the CNS: Blockade of its activity prevents glial activation after an inflammatory injury	GLIA			English	Article						cytokines; IL-15; inflammation; lipopolysaccharide; microglia; astrocytes	NATURAL-KILLER-CELLS; RAT-BRAIN; INTRACELLULAR TRAFFICKING; REACTIVE ASTROGLIOSIS; MURINE MICROGLIA; IL-2 RECEPTOR; GROWTH-FACTOR; ALPHA-CHAIN; IN-VIVO; ISOFORMS	Although reactive glia formation after neuronal degeneration or traumatic damage is one of the hallmarks of central nervous system (CNS) injury, we have little information on the signals that direct activation of resting glia. IL-15, a pro-inflammatory cytokine involved in regulating the response of T and B cells, may be also key for the regulation of early inflammatory events in the nervous system. IL-15 was expressed in the CNS, most abundantly in cerebellum and hippocampus, mainly in astrocytes and in some projection neurons. Using a rodent model of acute inflammatory injury [lipopolysaccharide (LPS) injection], we found enhanced expression of IL-15 in both reactive astroglia and microglia, soon after CNS injury. Blockade of IL-15 activity with an antibody to the cytokine, reversed activation of both glial types, suggesting that IL-15 has a major role in the generation of gliotic tissue and in the regulation of neuroimmune responses. Because IL-15 appears to modulate the inflammatory environment acutely generated after CNS injury, regulating IL-15 expression seems a clear antiinflammatory therapy to improve the outcome of neurodegenerative diseases and CNS trauma. (C) 2008 Wiley-Liss, Inc.	[Gomez-Nicola, Diego; Valle-Argos, Beatriz; Pita-Thomas, D. Wolfgang; Nieto-Sampedro, Manuel] CSIC, Inst Cajal, Neural Plast Grp, Funct & Syst Neurobiol Dept, E-28002 Madrid, Spain; [Gomez-Nicola, Diego; Nieto-Sampedro, Manuel] Hosp Nacl Paraplej, Expt Neurol Unit, Toledo, Spain		Nieto-Sampedro, M (corresponding author), CSIC, Inst Cajal, Neural Plast Grp, Funct & Syst Neurobiol Dept, Avda Doctor Arce 37, E-28002 Madrid, Spain.	mns@cajal.csic.es	Gomez-Nicola, Diego/E-7728-2015	Gomez-Nicola, Diego/0000-0002-5316-2682			Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; ARAUJO DM, 1989, BRAIN RES, V498, P257, DOI 10.1016/0006-8993(89)91104-9; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; AWATSUJI H, 1993, J NEUROSCI RES, V35, P305, DOI 10.1002/jnr.490350310; Bauer J, 2001, GLIA, V36, P235, DOI 10.1002/glia.1112; Beck RD, 2005, BRAIN RES, V1041, P223, DOI 10.1016/j.brainres.2005.02.010; BENVENISTE EN, 1986, NATURE, V321, P610, DOI 10.1038/321610a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budagian V, 2006, CYTOKINE GROWTH F R, V17, P259, DOI 10.1016/j.cytogfr.2006.05.001; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Depino AM, 2004, HIPPOCAMPUS, V14, P526, DOI 10.1002/hipo.10164; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.3.CO;2-M; Garcia-Moreno F, 2007, J COMP NEUROL, V500, P419, DOI 10.1002/cne.21128; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Gomez-Nicola D, 2006, J NEUROSCI RES, V83, P754, DOI 10.1002/jnr.20777; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Hanisch UK, 1997, J BIOL CHEM, V272, P28853, DOI 10.1074/jbc.272.46.28853; Hanisch UK, 1995, BRAIN RES REV, V21, P246, DOI 10.1016/0165-0173(95)00015-1; HANISCH UK, 1993, J NEUROSCI, V13, P3368; Hauss-Wegrzyniak B, 1998, BRAIN RES, V794, P211, DOI 10.1016/S0006-8993(98)00227-3; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; Huang Z, 2007, NEUROSCI LETT, V417, P160, DOI 10.1016/j.neulet.2007.01.086; ISHIDA Y, 1989, J EXP MED, V170, P1103, DOI 10.1084/jem.170.4.1103; Jung YO, 2007, IMMUNOL LETT, V109, P21, DOI 10.1016/j.imlet.2006.12.006; Kennedy P, 2000, LAT TRADE, V8, P15; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kurowska M, 2002, ANN NY ACAD SCI, V966, P441, DOI 10.1111/j.1749-6632.2002.tb04245.x; Kurys G, 2000, J BIOL CHEM, V275, P30653, DOI 10.1074/jbc.M002373200; LAPCHAK PA, 1991, NEUROSCIENCE, V44, P173, DOI 10.1016/0306-4522(91)90259-Q; Lee YB, 1996, NEUROREPORT, V7, P1062, DOI 10.1097/00001756-199604100-00022; Lund S, 2006, J NEUROIMMUNOL, V180, P71, DOI 10.1016/j.jneuroim.2006.07.007; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; NIETOSAMPEDRO M, 1987, NEUROCHEM RES, V12, P723, DOI 10.1007/BF00970528; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Nishimura H, 2005, FASEB J, V19, P19, DOI 10.1096/fj.04-2633com; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Pereno R, 2000, ONCOGENE, V19, P5153, DOI 10.1038/sj.onc.1203873; Satoh J, 1998, J NEUROL SCI, V155, P170, DOI 10.1016/S0022-510X(97)00310-9; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Schroeter M, 2005, NEUROMOL MED, V7, P183, DOI 10.1385/NMM:7:3:183; SMITH GM, 1990, DEV BIOL, V138, P377, DOI 10.1016/0012-1606(90)90204-V; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Watkins LR, 2002, PHYSIOL REV, V82, P981, DOI 10.1152/physrev.00011.2002; Yamashita T, 2005, J NEUROCHEM, V94, P459, DOI 10.1111/j.1471-4159.2005.03227.x	53	52	55	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR	2008	56	5					494	505		10.1002/glia.20628			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	275KM	WOS:000254070300002	18240307				2022-02-06	
J	Smits, M; Hunink, MGM; van Rijssel, DA; Dekker, HM; Vos, PE; Kool, DR; Nederkoorn, PJ; Hofman, PAM; Twijnstra, A; Tanghe, HLJ; Dippel, DWJ				Smits, M.; Hunink, M. G. M.; van Rijssel, D. A.; Dekker, H. M.; Vos, P. E.; Kool, D. R.; Nederkoorn, P. J.; Hofman, P. A. M.; Twijnstra, A.; Tanghe, H. L. J.; Dippel, D. W. J.			Outcome after complicated minor head injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; INTEROBSERVER AGREEMENT; COMPUTED-TOMOGRAPHY; STROKE PATIENTS; HIGH-RISK; SCALE; SYMPTOMS; VALIDATION; DISABILITY; MANAGEMENT	BACKGROUND AND PURPOSE: Functional outcome in patients with minor head injury with neurocranial traumatic findings on CT is largely unknown. We hypothesized that certain CT findings may be predictive of poor functional outcome. MATERIALS AND METHODS: All patients from the CT in Head Injury Patients (CHIP) study with neurocranial traumatic CT findings were included. The CHIP study is a prospective, multicenter study of consecutive patients, >= 16 years of age, presenting within 24 hours of blunt head injury, with a Glasgow Coma Scale (GCS) score of 13-14 or a GCS score of 15 and a risk factor. Primary outcome was functional outcome according to the Glasgow Outcome Scale (GOS). Other outcome measures were the modified Rankin Scale (mRS), the Barthel Index (BI), and number and severity of postconcussive symptoms. The association between CT findings and outcome was assessed by using univariable and multivariable regression analysis. RESULTS: GOS was assessed in 237/312 patients (76%) at an average of 15 months after injury. There was full recovery in 150 patients (63%), moderate disability in 70 (30%), severe disability in 7 (3.0%), and death in 10 (4.2%). Outcome according to the mRS and BI was also favorable in most patients, but 82% of patients had postconcussive symptoms. Evidence of parenchymal damage was the only independent predictor of poor functional outcome (odds ratio = 1.89, P =.022). CONCLUSION: Patients with neurocranial complications after minor head injury generally make a good functional recovery, but postconcussive symptoms may persist. Evidence of parenchymal damage on CT was predictive of poor functional outcome.	[Dippel, D. W. J.] Univ Med Ctr Rotterdam, Dept Neurol, Erasmus MC, NL-3000 CA Rotterdam, Netherlands; [Smits, M.; Hunink, M. G. M.; van Rijssel, D. A.; Tanghe, H. L. J.] Univ Med Ctr Rotterdam, Dept Radiol, Erasmus MC, NL-3000 CA Rotterdam, Netherlands; [Hunink, M. G. M.; van Rijssel, D. A.] Univ Med Ctr Rotterdam, Dept Epidemiol & Biostat, Erasmus MC, NL-3000 CA Rotterdam, Netherlands; [Hunink, M. G. M.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Dekker, H. M.] Uni Med Ctr Nijmegen, Dept Radiol, Nijmegen, Netherlands; [Vos, P. E.] Uni Med Ctr Nijmegen, Dept Neurol, Nijmegen, Netherlands; [Kool, D. R.] Univ Amsterdam, Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands; [Nederkoorn, P. J.] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; [Hofman, P. A. M.] Univ Hosp Maastricht, Dept Radiol, Maastricht, Netherlands; [Twijnstra, A.] Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands		Dippel, DWJ (corresponding author), Univ Med Ctr Rotterdam, Dept Neurol, Erasmus MC, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.dippel@erasmusmc.nl	Smits, Marion/AAB-3985-2019; Vos, Pieter/A-6043-2012; Dekker, H.M./L-4262-2015; Dippel, Diederik/AAJ-2192-2020; Smits, Marion/E-4795-2011	Smits, Marion/0000-0001-5563-2871; Dippel, Diederik/0000-0002-9234-3515; 			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALTMAN DG, 1999, PRACTICAL STAT MED R, P349; Atzema C, 2004, ANN EMERG MED, V44, P47, DOI 10.1016/j.annemergmed.2004.02.032; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; de Andrade AF, 2006, SURG NEUROL, V65, pS10, DOI 10.1016/j.surneu.2005.11.034; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; JENNETT B, 1975, LANCET, V1, P480; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; MAHONEY F I, 1965, Md State Med J, V14, P61; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCDANIEL T, 2000, NEUROANAGING CLIN PH, P700; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; NORLUND A, 2006, BMJ-BRIT MED J, V333, P455; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUCLEHILL A, 2002, J NEUROTRAUNIA, V19, P855; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TWIJNSTRA A, GUIDELINES DIAGNOSIS; Udstuen GJ, 2001, SEMIN ULTRASOUND CT, V22, P135, DOI 10.1016/S0887-2171(01)90041-1; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; VANDENBROUCKE JP, 1991, BRIT MED J, V302, P249, DOI 10.1136/bmj.302.6771.249; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276	49	52	52	0	3	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2008	29	3					506	513		10.3174/ajnr.A0852			8	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	275JC	WOS:000254066700019	18065509	hybrid, Green Published			2022-02-06	
J	Ownsworth, T; Little, T; Turner, B; Hawkes, A; Shum, D				Ownsworth, Tamara; Little, Trudi; Turner, Ben; Hawkes, Anna; Shum, David			Assessing emotional status following acquired brain injury: The clinical potential of the depression, anxiety and stress scales	BRAIN INJURY			English	Article						Acquired brain injury; assessment; emotional status	CLOSED-HEAD INJURY; QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; TRIPARTITE MODEL; NORMATIVE DATA; INDIVIDUALS; PREVALENCE; INVENTORY; SYMPTOMS; DISORDER	Primary objective: To investigate the clinical potential of the Depression, Anxiety and Stress Scales (DASS 42) and its shorter version ( DASS 21) for assessing emotional status following acquired brain injury. Methods and procedures: Participants included 23 individuals with traumatic brain injury (TBI), 25 individuals with brain tumour and 29 non-clinical controls. Investigations of internal consistency, test-re-test reliability, theory-consistent differences, sensitivity to change and concurrent validity were conducted. Main outcomes and results: Internal consistency of the DASS was generally acceptable (r > 0.70), with the exception of the anxiety scale for the TBI sample. Test-re-test reliability (1-3 weeks) was sound for the depression scale (r > 0.75) and significant but comparatively lower for other scales (r = 0.60-0.73, p < 0.01). Theory-consistent differences were only evident between the brain tumour sample and non-clinical control sample on the anxiety scale (p < 0.01). Sensitivity to change of the DASS in the context of hospital discharge was demonstrated for depression and stress (p < 0.01), but not for anxiety (p > 0.05). Concurrent validity with the Hospital Anxiety and Depression Scale was significant for all scales of the DASS (p < 0.05). Conclusions: While the results generally support the clinical application of the DASS following ABI, further research examining the factor structure of existing and modified versions of the DASS is recommended.	[Ownsworth, Tamara; Little, Trudi; Shum, David] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; [Ownsworth, Tamara; Little, Trudi; Shum, David] Griffith Univ, Appl Cognit Neurosci Res Ctr, Brisbane, Qld 4111, Australia; [Turner, Ben] Univ Queensland, Sch Hlth & Rehabil Sci, St Lucia, Qld, Australia; [Hawkes, Anna] Canc Council Queensland, Viertel Ctr Res Canc Control, Brisbane, Qld, Australia		Ownsworth, T (corresponding author), Griffith Univ, Sch Psychol, Nathan, Qld 4111, Australia.	t.ownsworth@griffith.edu.au	Hawkes, Anna L/C-6370-2009; Shum, David/A-3914-2008; Ownsworth, Tamara/ABB-6961-2021	Shum, David/0000-0002-4810-9262; Ownsworth, Tamara/0000-0003-1835-7094			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Barker-Collo SL, 2007, ARCH CLIN NEUROPSYCH, V22, P519, DOI 10.1016/j.acn.2007.03.002; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; BECK AT, 1987, MANUAL BECK ANXIETY; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; Cummings J. L., 2002, CONCISE GUIDE NEUROP; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; Domholdt E, 2005, REHABILITATION RES P; Epstein RS, 1994, NEUROPSYCHIATRY TRAU, P3; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Fleming J., 2006, BRAIN IMPAIR, V7, P83, DOI [https://doi.org/10.1375/brim.7.2.83, DOI 10.1375/BRIM.7.2.83, 10.1375/brim.7.2.83]; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Fure B, 2006, INT J GERIATR PSYCH, V21, P382, DOI 10.1002/gps.1482; Giovagnoli AR, 1999, J NEUROL NEUROSUR PS, V67, P358, DOI 10.1136/jnnp.67.3.358; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GORDON WA, 1991, REHABIL PSYCHOL, V36, P71, DOI 10.1037/h0079078; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kaplan CP, 2000, BRAIN INJURY, V14, P251; Karlovits T, 1999, BRAIN INJURY, V13, P845; Keir ST, 2006, SUPPORT CARE CANCER, V14, P1213, DOI 10.1007/s00520-006-0087-9; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lovibond SH., 1995, MANUAL DEPRESSION AN, V2nd; Mainio A, 2006, EUR PSYCHIAT, V21, P194, DOI 10.1016/j.eurpsy.2005.05.008; McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Nunnally J., 1994, PSYCHOMETRIC THEORY; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Pringle AM, 1999, BRIT J NEUROSURG, V13, P46, DOI 10.1080/02688699944177; Rickards H, 2006, CURR OPIN PSYCHIATR, V19, P294, DOI 10.1097/01.yco.0000218601.17722.5b; Schramke CJ, 1998, J CLIN EXP NEUROPSYC, V20, P723, DOI 10.1076/jcen.20.5.723.1117; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHUM D, 2006, PSYCHOL TESTING ASSE; Snaith R., 1994, HOSP ANXIETY DEPRESS; Turner BJ, 2008, DISABIL REHABIL, V30, P1153, DOI 10.1080/09638280701532854; WATSON D, 1995, J ABNORM PSYCHOL, V104, P15, DOI 10.1037/0021-843X.104.1.15; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1016/S0960-9822(02)01374-X, 10.1080/09602010244000444]; WRIGHT J, 2000, FIM TM INTERNET CTR	51	52	53	1	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	11					858	869		10.1080/02699050802446697			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	371RT	WOS:000260849700005	18850344				2022-02-06	
J	Thomas, KE; Stevens, JA; Sarmiento, K; Wald, MM				Thomas, K. E.; Stevens, J. A.; Sarmiento, K.; Wald, M. M.			Fall-related traumatic brain injury deaths and hospitalizations among older adults - United States, 2005	JOURNAL OF SAFETY RESEARCH			English	Article						traumatic brain injury; elderly; fall		Problem: Among older adults, both unintentional falls and traumatic brain injuries (TBI) result in significant morbidity and mortality; however, only limited national data on fall-related TBI are available. Method: To examine the relationship between older adult falls and TBI deaths and hospitalizations, CDC analyzed 2005 data from the National Center for Health Statistics' National Vital Statistics System and the Agency for Healthcare Research and Quality's Nationwide Inpatient Sample. Results: In 2005, among adults ! 65 years, there were 7946 fall-related TBI deaths and an estimated 56,423 hospitalizations for nonfatal fall-related TBI in the United States. Fall-related TBI accounted for 50.3% of unintentional fall deaths and 8.0% of nonfatal fall-related hospitalizations. Summary: These findings underscore the need for greater dissemination and implementation of evidence-based fall prevention interventions. Published by Elsevier Ltd.	[Thomas, K. E.; Stevens, J. A.; Sarmiento, K.; Wald, M. M.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA		Thomas, KE (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mail Stop F-62, Atlanta, GA 30341 USA.	KEThomas@cdc.gov					*AHRQ, 2007, DES HCUP NAT INP SAM; *CDC, 2007, MMWR-MORBID MORTAL W, V55, P1221; *CDC, 2005, WEB BAS INJ STAT QUE; *CDC, 2008, BRIEF AG AM C WASH D; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Marr A., 2004, CENTRAL NERVOUS SYST; *NCHS, 2008, NAT VIT STAT REP, V56; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Stevens JA, 2005, INJURY PREV, V11, P115, DOI 10.1136/ip.2004.005835; Stevens JA, 2001, JAMA-J AM MED ASSOC, V286, P2665, DOI 10.1001/jama.286.21.2665; *US CENS BUR, 2007, RES POP NAT POP EST	11	52	52	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-4375			J SAFETY RES	J. Saf. Res.		2008	39	3					269	272		10.1016/j.jsr.2008.05.001			4	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	327YU	WOS:000257765200003	18571567				2022-02-06	
J	Reid-Arndt, SA; Nehl, C; Hinkebein, J				Reid-Arndt, Stephanie A.; Nehl, Carissa; Hinkebein, Joseph			The Frontal Systems Behaviour Scale (FrSBe) as a predictor of community integration following a traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; community integration; neuropsychological; executive functioning; functional status	BLUNT HEAD-INJURY; DRUG-USE; EXECUTIVE DYSFUNCTION; COGNITIVE IMPAIRMENT; FOCAL LESIONS; REHABILITATION; QUESTIONNAIRE; DEMENTIA; OUTCOMES; IMPACT	Primary objective: This study examined the relationships between the Frontal Systems Behaviour Scale (FrSBe), neuropsychological tests and community integration outcomes among individuals with a history of TBI. Methods: Seventy-six individuals with a history of TBI were consecutively recruited from patients seen in a Neuropsychology clinic in an academic healthcare setting. Participants completed neuropsychological tests, the FrSBe and the Community Integration Questionnaire (CIQ) as part of a standard clinical neuropsychological evaluation. Results: The FrSBe was a significant predictor of community integration (CIQ) outcomes. Specifically, poorer executive functioning (FrSBe Executive Functioning) predicted lower CIQ Total Scores, while increased apathy (FrSBe Apathy) was associated with reduced CIQ Productivity. Regarding neuropsychological tests, only Delayed Memory remained as a predictor: higher scores were associated with enhanced CIQ Total Scores and CIQ Social Integration. Finally, female gender was associated with superior CIQ Total Scores, CIQ Home Integration and CIQ Productivity. Conclusions: While neuropsychological tests of executive functioning failed to add predictive power to models of community integration following TBI with this sample, the FrSBe, a measure of behavioural manifestations of frontal lobe dysfunction, did predict these important functional outcomes. This suggests that use of the FrSBe may enhance the ecological validity of information gathered during a clinical neuropsychological assessment.	[Reid-Arndt, Stephanie A.; Nehl, Carissa; Hinkebein, Joseph] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA		Reid-Arndt, SA (corresponding author), Univ Missouri, Dept Hlth Psychol, 1 Hosp Dr,DC 116-88, Columbia, MO 65212 USA.	reidarndts@health.missouri.edu					Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Cahn-Weiner DA, 2002, NEUROPSY NEUROPSY BE, V15, P79, DOI 10.1097/01.WNN.0000012908.05122.F4; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Davis JD, 2007, J NEUROPSYCH CLIN N, V19, P43, DOI 10.1176/appi.neuropsych.19.1.43; Doninger NA, 2003, REHABIL PSYCHOL, V48, P67, DOI 10.1037/0090-5550.48.2.67; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; EDWARD K, 2002, NEUROREHABILITATION, V17, P297; Gioia GA IP, 2000, BEHAV RATING INVENTO; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Goverover Y, 2005, MULT SCLER J, V11, P203, DOI 10.1191/1352458505ms1153oa; GRAHAM DI, 1999, REHABILITATION ADULT, P19; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hamilton JM, 2003, J NEUROL NEUROSUR PS, V74, P120, DOI 10.1136/jnnp.74.1.120; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Linden MA, 2005, DISABIL REHABIL, V27, P1353, DOI 10.1080/09638280500164180; Long, 1996, ECOLOGICAL VALIDITY, P15; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Millis S R, 1994, Int J Neurosci, V79, P165; NABORS NA, 2000, ANN M INT NEUR SOC; Nyenhuis DL, 2004, CLIN NEUROPSYCHOL, V18, P41, DOI 10.1080/13854040490507145; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ready RE, 2003, AM J GERIAT PSYCHIAT, V11, P222, DOI 10.1176/appi.ajgp.11.2.222; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sbordone RJ, 2001, NEUROREHABILITATION, V16, P199; Schopp LH, 2006, J HEAD TRAUMA REHAB, V21, P213, DOI 10.1097/00001199-200605000-00002; Spinella M, 2004, INT J NEUROSCI, V114, P1323, DOI 10.1080/00207450490476011; Spinella M, 2004, INT J NEUROSCI, V114, P83, DOI 10.1080/00207450490249356; Spinella M, 2003, ADDICT BIOL, V8, P67, DOI 10.1080/1355621031000069909; Stout JC, 2003, AM J GERIAT PSYCHIAT, V11, P683; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Van den Broek M.D., 1999, REV CLIN GERONTOLOGY, V9, P257, DOI 10.1017/S0959259899009363; Velligan DI, 2002, PSYCHIAT RES, V113, P227, DOI 10.1016/S0165-1781(02)00264-0; Verdejo-Garcia A, 2006, J INT NEUROPSYCH SOC, V12, P405, DOI 10.1017/S1355617706060486; Verdejo-Garcia A, 2006, ADDICT BEHAV, V31, P1373, DOI 10.1016/j.addbeh.2005.11.003; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WECHSLER D, 1997, WAIS 3 ADMINISTRATIO; WECHSLER D, 1977, WMS 3 ADMINISTRATION; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Zawacki TM, 2002, J NEUROPSYCH CLIN N, V14, P296, DOI 10.1176/appi.neuropsych.14.3.296; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	53	52	52	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1361	1369		10.1080/02699050701785062			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200004	18066938				2022-02-06	
J	Chlu, WT; Huang, SJ; Tsai, SH; Lin, JW; Tsai, MD; Lin, TJ; Huang, WCW				Chlu, Wen-Ta; Huang, Sheng-Jean; Tsai, Shin-Han; Lin, Jia-Wei; Tsai, Ming-Da; Lin, Tien-Jen; Huang, William C. W.			The impact of time, legislation, and geography on the epidemiology of traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						traumatic head injury; rural and urban; follow up study	HEAD-INJURY; POPULATION; URBAN; COUNTRY; TAIWAN	In 1991. a population-based epidemiologic traumatic brain injury (TBI) study was done in urban and rural areas of Taiwan; this was 5 years;cars before the helmet use law was passed and 8 years before the drink driving law was passed. In order to evaluate the impact of three major determinants (time. geography, and legislation) on the epidemiology of TBI, we conducted a prospective study in 2001 and used the 1991 data to examine the differences in TBI distribution in urban and rural Taiwan a decade after these laws were passed. In 2001, 5754 TBI cases were collected from the urban area of Taipei City. and 1474 TBI cases were collected from the rural area of Hualien County;. The TBI incidence rate in Taipei City in 2001 was estimated to be 218/100,000 population (285/100,000 for males and 152/ 100.000 for females). When compared to the 1991 data, the incidence rate in 2001 had increased by 20%. The TBI incidence rate in Hualien County; in 2001 was estimated to be 417/100.000 population (516/100,000 for males and 306/100,000 for females), this was a 37% increase over the 1991 data. Our Study found that the distribution of causes and age distribution had shifted significantly over the 10-year period. In 2001. the age group With the hi-hest incidence was 20-29 years, while in 1991 it had been the over 70 years age group. While traffic-related TBI had decreased. falls and assaults had increased in 2001. We also found that legislation, such as the helmet law, affects TBI distribution by decreasing the traffic-related TBI rate, decreasing the admission severity of TBI, and reducing TBI-related mortality. Finally. geography plays a crucial role in the outcome of TBI: over the 10 year period, Taipei had an increase in moderately severe outcomes. while Hualien had an increase in more severe outcomes. Comparative studies of TBI in urban and rural areas have shown that time. legislation. and geography are Crucial determinants of TBI epidemiology. Although time and legal interventions seem to have more of an impact. geography does affect TBI outcomes. (c) 2006 Elsevier Ltd. All rights reserved.	Taipei Med Univ, Wan Fang Hosp, Dept Neurosurg, Taipei, Taiwan; Taipei Med Univ, Inst Injury Prevent & Control, Taipei, Taiwan; Taiwan Univ Hosp, Dept Neurosurg, Taipei, Taiwan; Shin Kong Wu Ho Su Mem Hosp, Dept Neurosurg, Taipei, Taiwan; Taipei Med Univ Hosp, Wang Fan Hosp, Taipei, Taiwan		Huang, WCW (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Neurosurg, Taipei, Taiwan.	b870ll6O@tinu.edu.tw					BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; Chiu WT, 1997, J CLIN NEUROSCI, V4, P469, DOI 10.1016/S0967-5868(97)90037-0; CHIU WT, 1995, J CLIN NEUROSCI, V2, P210, DOI 10.1016/S0967-5868(95)80004-2; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; CHIU WT, 1992, J TAIPEI MED COLL, V21, P1; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JENNETT B, 1975, LANCET, V11, P480; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; *MIN TRANSP COMM, 2002, ROC TRAFF ACC ASS; *MIN TRANSP COMM, 2001, ROC TREND MOT US TAI; *MIN TRANSP COMM, 2005, ROC TABL CAT MOT VEH; Schootman M, 1999, BRAIN INJURY, V13, P995; SILVERBAGE CG, 1986, THESIS GOTHENBURG U; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; *TAIW DEP HLTH, 2002, VIT STAT TAIW 2001; TEASDALE G, 1974, LANCET, V2, P81; WASTON GS, 1981, AM J PUBLIC HEALTH, V71, P297; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x; YUAN E, ROC TABLE DISTRIBUTI; YUAN E, 2001, ROC TABLE AGE COMPOS	24	52	54	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	OCT	2007	14	10					930	935		10.1016/j.jocn.2006.08.004			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	217HE	WOS:000249938200003	17646104				2022-02-06	
J	Kuss, O; McLerran, D				Kuss, Oliver; McLerran, Dale			A note on the estimation of the multinomial logistic model with correlated responses in SAS	COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE			English	Article						multinomial logistic model; random effects; marginal models; SAS; GEE	GENERALIZED ESTIMATING EQUATIONS; LINEAR MIXED MODELS; POLYTOMOUS DATA; LOGIT MODEL; REGRESSION	We show how multinomial logistic models with correlated responses can be estimated within SAS software. To achieve this, random effects and marginal models are introduced and the respective SAS code is given. An example data set on physicians' recommendations and preferences in traumatic brain injury rehabilitation is used for illustration. The main motivation for this work are two recent papers that recommend estimating multinomial logistic models with correlated responses by using a Poisson likelihood which is statistically correct but computationally inefficient. (C) 2007 Elsevier Ireland Ltd. All rights reserved.	Univ Halle Wittenberg, Inst Med Epidemiol Biostats & Informat, D-06097 Halle, Germany; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA		Kuss, O (corresponding author), Univ Halle Wittenberg, Inst Med Epidemiol Biostats & Informat, D-06097 Halle, Germany.	Oliver.Kuss@medizin.uni-halle.de; dmclerra@fhcrc.org		Kuss, Oliver/0000-0003-3301-5869			BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; Brownstone D, 1999, J ECONOMETRICS, V89, P109; Chen Z, 2001, AM STAT, V55, P89, DOI 10.1198/000313001750358545; Daniels MJ, 1997, STAT MED, V16, P2311, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2311::AID-SIM654>3.3.CO;2-5; Davidian M, 1995, NONLINEAR MODELS REP; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Hartzel J, 2001, STAT MODEL, V1, P81, DOI 10.1177/1471082X0100100201; Hasenbein U, 2003, DISABIL REHABIL, V25, P136, DOI 10.1080/0963828021000024889; Hedeker D, 2003, STAT MED, V22, P1433, DOI 10.1002/sim.1522; HEDEKER D, 1998, J STAT SOFTW, V80, P647; Hines RJO, 1997, BIOMETRICS, V53, P1552, DOI 10.2307/2533523; Kuss O, 2003, P 18 INT WORKSH STAT, P245; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LIPSITZ SR, 1994, STAT MED, V13, P1149, DOI 10.1002/sim.4780131106; LURNLEY T, 1996, BIOMETRICS, V52, P354; Malchow-Moller N, 2003, APPL ECON LETT, V10, P389, DOI 10.1080/1350485032000082018; McCullagh P., 1989, GEN LINEAR MODELS 2, V2; MILLER ME, 1993, BIOMETRICS, V49, P1033, DOI 10.2307/2532245; Revelt D, 1998, REV ECON STAT, V80, P647, DOI 10.1162/003465398557735; RODRIGUEZ G, 1995, J ROY STAT SOC A STA, V158, P73, DOI 10.2307/2983404; Schabenberger O., 2005, P 30 ANN SAS US GROU; Skrondal A, 2003, PSYCHOMETRIKA, V68, P267, DOI 10.1007/BF02294801; Thiebaut R, 2002, COMPUT METH PROG BIO, V69, P249, DOI 10.1016/S0169-2607(02)00017-2; Williamson JM, 1999, COMPUT METH PROG BIO, V58, P25; WOLFINGER R, 1993, J STAT COMPUT SIM, V48, P233, DOI 10.1080/00949659308811554; Wright S. P., 1998, P 23 ANN SAS US GROU	26	52	52	1	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-2607			COMPUT METH PROG BIO	Comput. Meth. Programs Biomed.	SEP	2007	87	3					262	269		10.1016/j.cmpb.2007.06.002			8	Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Medical Informatics	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering; Medical Informatics	209DK	WOS:000249369000010	17686544				2022-02-06	
J	Luo, J; Shi, RY				Luo, Jian; Shi, Riyi			Polyethylene glycol inhibits apoptotic cell death following traumatic spinal cord injury	BRAIN RESEARCH			English	Article						calcium; mitochondria; oxidative stress; cytochrome c; membrane repair; apoptosis	MITOCHONDRIAL PERMEABILITY TRANSITION; OXIDATIVE STRESS; NEURONAL APOPTOSIS; BRAIN-INJURY; MOLECULAR REPAIR; NERVE MEMBRANES; FREE-RADICALS; CYTOCHROME-C; CNS INJURY; GLUTATHIONE	We have previously shown that local administration of polyethylene glycol (PEG, MW: 2000 Da, 50% by weight), a known membrane repair agent, immediately after trauma in guinea pig spinal cord repairs neuronal membrane disruptions and reduces oxidative injury. Here we report that a similar application of PEG resulted in marked decreases in apoptotic cell death and caspase-3 activity. We suggest that PEG may suppress apoptosis through interactions with mitochondria. This is based on our current findings that in isolated mitochondria, PEG improves mitochondrial function and reduces the release of cytochrome c, a pro-apoptotic cell death factor. This hypothesis is further supported by our previous observation that PEG enters injured cells after spinal cord injury, placing PEG in a position to directly interact with mitochondria. In summary, we conclude that PEG reduces both necrosis and apoptosis through two distinct yet synergistic pathways: repair of disrupted plasma membranes and protection of mitochondria through direct interaction. (C) 2007 Published by Elsevier B.V.	Purdue Univ, Sch Vet Med, Dept Med Sci, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA		Shi, RY (corresponding author), Purdue Univ, Sch Vet Med, Dept Med Sci, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	riyi@purdue.edu	Luo, Jian/B-8449-2014	Luo, Jian/0000-0002-2064-8467			Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gorman AM, 2000, DEV NEUROSCI-BASEL, V22, P348, DOI 10.1159/000017460; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Halestrap AP, 1999, BIOCHEM SOC SYMP, V66, P181, DOI 10.1042/bss0660181; Kaufmann SH, 2000, METHOD ENZYMOL, V322, P3; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Koob AO, 2006, J NEUROSCI RES, V83, P1558, DOI 10.1002/jnr.20837; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lai J C, 1979, Methods Enzymol, V55, P51; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Luo J, 2004, NEUROSCI LETT, V359, P167, DOI 10.1016/j.neulet.2004.02.027; Namura S, 1998, J NEUROSCI, V18, P3659; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; SAVAGE MK, 1994, ARCH BIOCHEM BIOPHYS, V315, P142, DOI 10.1006/abbi.1994.1483; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; WOOD KA, 1995, J NEUROSCI, V15, P5851; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	45	52	60	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 25	2007	1155						10	16		10.1016/j.brainres.2007.03.091			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	187OM	WOS:000247857600002	17512912				2022-02-06	
J	Covassin, T; Weiss, L; Powell, J; Womack, C				Covassin, Tracey; Weiss, Leigh; Powell, John; Womack, Christopher			Effects of a maximal exercise test on neurocognitive function	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PERFORMANCE; IMPACT; INFORMATION; CONCUSSION; VALIDITY	Objective: To examine the effects of a maximal exercise test on cognitive function in recreational athletes. Design: A repeated-measures design was used to compare baseline with post-cognitive function and fatigue symptoms after a maximal exercise test. Setting: Division 1 American Midwestern University, (Michigan State University, Michigan, USA). Participants: 102 male and female recreational athletes. Intervention: Participants in the experimental group (n = 54) were asked to perform a maximal treadmill exercise test to maximal oxygen uptake (VO2 max). Participants in the control group were asked to rest for 15 min. Main outcome measurements: All participants were administered a neuropsychological test battery called Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) before and after exercise to measure neurocognitive function and fatigue symptoms. Results: Results revealed a significant group (control, experimental) xtime (baseline, post-test 1, post-test 2) interaction for verbal memory composite scores (p = 0.025). Specifically, verbal memory composite scores decreased in the experimental group from baseline to post-test 1 (p = 0.00). These values returned to baseline 3 days after the VO2 max test (p = 0.00). Further analysis on verbal memory composite scores demonstrated significant differences on immediate recall memory (p = 0.00) and delayed recall memory (p = 0.00). No significant differences were observed for visual memory (p = 0.54), motor processing speed (p = 0.68) and reaction time (p = 0.44) composite scores between the experimental and control groups. Conclusion: The results of this study suggest that a maximal exercise test attenuated a limiting effect on cognitive function. When utilising a neuropsychological test battery to evaluate a patient who has sustained a head injury, the test should not be administered immediately after a practice or a game session.	Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; James Madison Univ, Harrisonburg, VA 22807 USA		Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 105 IM Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu					Cian C, 2000, J PSYCHOPHYSIOL, V14, P29, DOI 10.1027//0269-8803.14.1.29; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Fery YA, 1997, PERCEPT MOTOR SKILL, V84, P291, DOI 10.2466/pms.1997.84.1.291; FLEURY M, 1987, ERGONOMICS, V30, P945, DOI 10.1080/00140138708969790; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; GUTIN B, 1968, RES QUART, V39, P81; HANCOCK S, 1986, PERCEPT MOTOR SKILL, V62, P491, DOI 10.2466/pms.1986.62.2.491; Hogervorst E, 1996, PERCEPT MOTOR SKILL, V83, P479, DOI 10.2466/pms.1996.83.2.479; HOWLEY ET, 1995, MED SCI SPORT EXER, V27, P1292; ISAACS LD, 1991, J HUM MOVEMENT STUD, V20, P123; IVERSON G, 2002, NEUROPSYCHOLOGIA, V17, P769; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; LEDERC S, 2002, MED SCI SPORT EXER, V34, pS103; LOVELL M, 2005, IMMEDIATE POST CONCU; MCGLYNN GH, 1977, PERCEPT MOTOR SKILL, V44, P1139, DOI 10.2466/pms.1977.44.3c.1139; PAAS FGWC, 1991, ERGONOMICS, V34, P1385, DOI 10.1080/00140139108964879; SALMELA JH, 1986, PERCEPT MOTOR SKILL, V63, P1067, DOI 10.2466/pms.1986.63.3.1067; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Shibuya K, 2004, J SPORT MED PHYS FIT, V44, P215; Shibuya KI, 2004, RESP PHYSIOL NEUROBI, V140, P165, DOI 10.1016/j.resp.2003.11.004; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; WRISBERG C, RES, V47, P839	26	52	52	1	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2007	41	6					370	374		10.1136/bjsm.2006.032334			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	171FI	WOS:000246720100010	17224438	Green Published			2022-02-06	
J	Ganesalingam, K; Sanson, A; Anderson, V; Yeates, KO				Ganesalingam, Kalaichelvi; Sanson, Ann; Anderson, Vicki; Yeates, Keith Owen			Self-regulation as a mediator of the effects of childhood traumatic brain injury on social and behavioral functioning	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; children; self-regulation; social and behavioral functioning; multiple mediators; specific indirect effects	EXECUTIVE FUNCTION; RATING-SCALE; HEAD-INJURY; CHILDREN; ATTENTION; DELAY; GRATIFICATION; PREDICTION; INVENTORY; TERM	This study builds on our earlier investigation (see Ganesalingam et at., 2006). We showed previously that children with moderate to severe traumatic brain injuries (TBI) had poorer self-regulation and social and behavioral functioning than their uninjured peers and that self-regulation predicted significant variance in parent- and teacher-rated social and behavioral outcomes, regardless of the presence or absence of TBI. In this study, we examine self-regulation as a mediator of the relationship between TBI and the outcomes. Participants included 65 children with moderate to severe TBI and 65 children without TBI matched for age and gender. Participants were between 6 and 11 years of age. Children completed an assessment of cognitive, emotional, and behavioral self-regulation, and social and behavioral functioning. Mediation was assessed using a bootstrapping approach (a relatively novel statistical method for assessing specific indirect effects in models with multiple mediators). Analyses indicated that, after controlling for socioeconomic status (SES), aspects of self-regulation accounted for individual variation in the outcomes, and acted as a significant mediator of the effects of TBI on the outcomes. Self-regulatory deficits may reflect the relative vulnerability of the prefrontal cortex to TBI and may help account for post-injury difficulties in social and behavioral functioning.	Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia; Murdoch Childrens Res Ctr, Melbourne, Vic, Australia; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Childrens Res Inst, Columbus, OH USA		Ganesalingam, K (corresponding author), Childrens Hosp, Columbus Childrens Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	GaiiesaKa@chi.osu.edu	Yeates, Keith/AAJ-4223-2020	Sanson, Ann/0000-0003-4910-3310; Yeates, Keith/0000-0001-7680-2892			Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; *AUSTR BUR STAT, 2001, POP AUSTR NZ COMP; Banerjee M., 1997, DEV SOCIAL COGNITION, P241; Barkley R.A., 1997, ADHD NATURE SELF CON; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Benson D.F., 1986, FRONTAL LOBES; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bradley SJ., 2000, AFFECT REGULATION DE; CASEY RJ, 1993, DEV PSYCHOL, V29, P119, DOI 10.1037/0012-1649.29.1.119; CICCHETTI D, 1994, MONOGRAPHS SOC RES C, V59, P228; COOK ET, 1994, J ABNORM CHILD PSYCH, V22, P205, DOI 10.1007/BF02167900; Dagenbach D. E., 1994, INHIBITORY PROCESSES; Dodge KA, 2002, PSYCHOL ASSESSMENT, V14, P60, DOI 10.1037//1040-3590.14.1.60; Eisenberg N, 2000, CHILD DEV, V71, P1367, DOI 10.1111/1467-8624.00233; EISENBERG N, 1995, CHILD DEV, V66, P1360, DOI 10.1111/j.1467-8624.1995.tb00940.x; Eisenberg N, 1997, CHILD DEV, V68, P642, DOI 10.2307/1132116; Eisenberg N., 1992, REV PERSONALITY SOCI, V14, P119; EYBERG SM, 1983, J CLIN CHILD PSYCHOL, V12, P347, DOI 10.1207/s15374424jccp1203_19; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FUNDERBURK BW, 1989, BEHAV ASSESS, V11, P297; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; Gresham FM., 1990, SOCIAL SKILLS RATING; Isquith PK, 2005, MENT RETARD DEV D R, V11, P209, DOI 10.1002/mrdd.20075; KAGAN J, 1966, J ABNORM PSYCHOL, V71, P17, DOI 10.1037/h0022886; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Krueger RF, 1996, J PERS, V64, P107, DOI 10.1111/j.1467-6494.1996.tb00816.x; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Luria A.R., 1973, WORKING BRAIN; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Manly T., 1999, TEST EVERYDAY ATTENT; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1111/1469-7610.00708; MISCHEL W, 1970, J PERS SOC PSYCHOL, V16, P329, DOI 10.1037/h0029815; *NAT HLTH INF MAN, 2001, NAT HLTH PLAN AUSTR; Olson SL, 2005, DEV PSYCHOPATHOL, V17, P25, DOI 10.1017/S0954579405050029; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; RODRIGUEZ ML, 1989, J PERS SOC PSYCHOL, V57, P358, DOI 10.1037/0022-3514.57.2.358; Rothbart M.K., 2006, HDB CHILD PSYCHOL, V6th ed., P99, DOI DOI 10.1002/9780470147658.CHPSY0303; ROTHBART MK, 1989, TEMPERAMENT CHILDHOO, P59; Rueda MR, 2005, DEV NEUROPSYCHOL, V28, P573, DOI 10.1207/s15326942dn2802_2; Saarni C., 1997, EMOTIONAL DEV EMOTIO; Schore A.N., 1994, AFFECT REGULATION OR; Sethi A, 2000, DEV PSYCHOL, V36, P767, DOI 10.1037//0012-1649.36.6.767; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; Shields A., 1998, EMOTION REGULATION C; SHIELDS AM, 1994, DEV PSYCHOPATHOL, V6, P57, DOI 10.1017/S0954579400005885; Sobel M., 1988, COMMON PROBLEMS PROP, P46; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; YEATES KO, IN PRESS PSYCHOL B	56	52	52	0	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2007	13	2					298	311		10.1017/S1355617707070324			14	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	144XD	WOS:000244828800013	17286887				2022-02-06	
J	Sifringer, M; Stefovska, V; Zentner, I; Hansen, B; Stepulak, A; Knaute, C; Marzahn, J; Ikonomidou, C				Sifringer, Marco; Stefovska, Vanya; Zentner, Ingo; Hansen, Berglind; Stepulak, Andrzej; Knaute, Christiane; Marzahn, Jenny; Ikonomidou, Chrysanthy			The role of matrix metalloproteinases in infant traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article							FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; DEVELOPING RAT-BRAIN; KAPPA-B ACTIVATION; SPINAL-CORD-INJURY; GENE KNOCK-OUT; CELL-DEATH; NEURONAL DEGENERATION; INDUCED APOPTOSIS; UNITED-STATES	Matrix metalloproteinases (MMPs) play an essential role in tissue repair, cell death and morphogenesis and may constitute therapeutic targets for acute brain injuries. In this study, we investigated the expression of 72 kDa and 92 kDa collagenases MMP-2 and MMP-9 at transcriptional, functional and protein expression level following traumatic brain injury in infant rats. Seven-day-old Wistar rats were subjected to head trauma using a weight drop device. Pups were sacrificed at defined time points (2-72 h) after trauma and brains were processed for molecular studies (semiquantitative and real-time PCR, Western blot, gelatin zymography) and histology. Trauma triggered widespread cell death in the cortex, basal ganglia and white matter. mRNA levels for MMP-2 and -9 were increased in the brain at 12-72 h after trauma. Protein expression of the analyzed MMPs and activity of MMP-2 were increased at 12 h and peaked at 24 h after trauma. Intraperitoneal injection of GM6001 (Ilomastat), an MMP inhibitor, 2 h after trauma, substantially attenuated traumatic brain injury in a dose-dependent manner. These findings causally link the MMPs to trauma-induced neuronal cell death in the immature rodent brain. MMPs might serve as useful targets for therapeutic approaches aimed at preserving neuronal function in the immature brain in the context of mechanical injury. (c) 2006 Elsevier Inc. All rights reserved.	Tech Univ Dresden, Dept Pediat Neurol, Childrens Hosp, Med Fac Carl Gustav Carus, D-01307 Dresden, Germany; Med Univ Lublin, Dept Biochem & Mol Biol, PL-20093 Lublin, Poland		Ikonomidou, C (corresponding author), Tech Univ Dresden, Dept Pediat Neurol, Childrens Hosp, Med Fac Carl Gustav Carus, Fetscherstasse 74, D-01307 Dresden, Germany.	hrissanthi.ikonomidou@uniklinikum-dresden.de		Stepulak, Andrzej/0000-0002-1872-394X			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Gary DS, 2001, J NEUROCHEM, V76, P1485, DOI 10.1046/j.1471-4159.2001.00173.x; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; HAGG T, 1989, NEURON, V3, P721, DOI 10.1016/0896-6273(89)90241-9; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; James HE, 1999, ACT NEUR S, V73, P85; Kieseier BC, 1998, ANN NEUROL, V43, P427, DOI 10.1002/ana.410430404; Kieseier BC, 1998, BRAIN, V121, P159, DOI 10.1093/brain/121.1.159; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lee SR, 2004, J CEREBR BLOOD F MET, V24, P720, DOI 10.1097/01.WCB.0000122747.72175.47; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Montaner J, 2001, STROKE, V32, P1759, DOI 10.1161/01.STR.32.8.1759; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; MURTOMAKI S, 1995, DEV BIOL, V168, P635, DOI 10.1006/dbio.1995.1108; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Noble LJ, 2002, J NEUROSCI, V22, P7526; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsirka SE, 1997, J NEUROSCI, V17, P543; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	54	52	56	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAR	2007	25	3					526	535		10.1016/j.nbd.2006.10.019			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	145NQ	WOS:000244872200008	17188498				2022-02-06	
J	Sherer, M; Evans, CC; Leverenz, J; Stouter, J; Irby, JW; Lee, JE; Yablon, SA				Sherer, Mark; Evans, Clea C.; Leverenz, Joyce; Stouter, Josephine; Irby, James W., Jr.; Lee, Jae Eun; Yablon, Stuart A.			Therapeutic alliance in post-acute brain injury rehabilitation: Predictors of strength of alliance and impact of alliance on outcome	BRAIN INJURY			English	Article						traumatic brain injury; therapeutic alliance; post-acute brain injury rehabilitation; outcome	FAMILY ASSESSMENT DEVICE; WORKING ALLIANCE; AWARENESS QUESTIONNAIRE; IMPAIRED AWARENESS; PATIENT COMPLIANCE; RATING-SCALE; DEPRESSION; COMMUNITY	Primary objective: To determine factors that influence the strength of therapeutic alliance for patients with traumatic brain injury ( TBI) attending post- acute brain injury rehabilitation ( PABIR) and to examine the association of therapeutic alliance with outcome after PABIR. Research design: Prospective cohort study. Methods and procedures: The study sample consisted of 69 of 95 patients with TBI admitted to the PABIR programme during the study period. Demographic and injury severity data were abstracted from medical records or obtained through interview. Study questionnaires ( the modified California Psychotherapy Alliance Scales - patient, family and clinician forms; the Prigatano Alliance Scale; the Awareness Questionnaire; the Center for Epidemiologic Studies - Depression scale; and the Family Assessment Device - General Functioning Scale) were obtained within 2 weeks of patient admission to the PABIR programme. Main outcomes and results: Study outcomes were functional status ( Disability Rating Scale), programme completion and employment status at discharge from PABIR. Higher levels of family discord were associated with poorer therapeutic alliance. Greater discrepancies between family and clinician ratings of patient functioning were associated with poorer therapeutic alliance and poorer effort in therapies. Poor participation was predictive of programme dropout. Productivity status at discharge was predicted by functional status at admission and degree of therapeutic alliance. Conclusions: Findings indicate that family perceptions and family functioning are important determinants of therapeutic alliance for patients in PABIR. These results indicate that therapists in PABIR programmes should address family perceptions and functioning to facilitate patient bonding with the programme.	Methodist Rehabil Ctr, Jackson, MS USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA		Sherer, M (corresponding author), ABPP Cn Mem Hermann TIRR, 1333 Moursund, Houston, TX 77030 USA.	mark.sherer@memorialhermann.org		Leverenz, James/0000-0002-0896-0749			Bordin ES, 1979, PSYCHOTHER THEORY RE, V16, P252, DOI DOI 10.1037/H0085885; BUSH B, 2000, J INT NEUROPSYCH SOC, V6, P221; Conners GJ, 1997, J CONSULT CLIN PSYCH, V65, P588, DOI 10.1037/0022-006X.65.4.588; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Gaston L., 1994, CALIFORNIA PSYCHOTHE, P85; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; HORVATH AO, 1994, WORKING ALLIANCE THE; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; MARMAR CR, 1989, J NERV MENT DIS, V177, P464, DOI 10.1097/00005053-198908000-00003; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Patalano F, 1997, CONTEMP FAM THER, V19, P497, DOI 10.1023/A:1026178920750; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Raue PJ, 1997, J CONSULT CLIN PSYCH, V65, P582, DOI 10.1037/0022-006X.65.4.582; Safran J. D., 1991, PSYCHOL ASSESSMENT J, V3, P188, DOI DOI 10.1037/1040-3590.3.2.188; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P561, DOI 10.1080/09602010500263084; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P298, DOI 10.1080/09602010500176476; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Weiss M, 1997, J CLIN PSYCHIAT, V58, P196, DOI 10.4088/JCP.v58n0504	26	52	53	0	18	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	7					663	672		10.1080/02699050701481589			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	192LX	WOS:000248204400002	17653940				2022-02-06	
J	Vanderploeg, RD; Belanger, HG; Duchnick, JD; Curtiss, G				Vanderploeg, Rodney D.; Belanger, Heather G.; Duchnick, Jennifer D.; Curtiss, Glenn			Awareness problems following moderate to severe traumatic brain injury: Prevalence, assessment methods, and injury correlates	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						awareness; brain injuries; Glasgow Coma Scale; neurobehavioral manifestations; postinjury deficits; posttraumatic amnesia; rehabilitation; self-awareness; TBI; unawareness	COMPETENCE RATING-SCALE; IMPAIRED SELF-AWARENESS; BEHAVIORS CHANGE INVENTORY; HEAD-INJURY; PRACTICAL SCALE; QUESTIONNAIRE; DEFICITS; FAMILY; CONCORDANCE; LIMITATIONS	We examined the degree to which individuals with a history of moderate to severe traumatic brain injury (TBI) are unaware of their postinjury deficits. We also examined correlates between awareness problems and injury acuteness and severity and whether awareness problems differed across behavioral domains. Self- and significant other (family member) ratings on the Key Behaviors Change Inventory (KBCI) were examined in 36 individuals an average of 2 years post-TBI. Family members reported greater problems postinjury than patients did, depending on the behavior in question and the level of patient awareness overall. Postinjury awareness problems were as prevalent as other behavioral problems measured by the KBCI but were not universally present. Some patients exhibited no awareness problems, others emergent awareness, and a minority poor awareness. Correlations revealed that as time postinjury increased, patients showed more accurate self-awareness than those whose injuries were more recent. Family members and patients agreed about preinjury functioning.	[Vanderploeg, Rodney D.; Belanger, Heather G.; Duchnick, Jennifer D.; Curtiss, Glenn] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Curtiss, Glenn] Def & Vet Brian Injury Ctr, Tampa, FL USA; [Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.; Curtiss, Glenn] Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA		Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, 13000 N Bruce B Downs Blvd 116B, Tampa, FL 33612 USA.	Rodney.Vanderploeg@va.gov	Curtiss, Glenn/ABB-5566-2020				Barco PP, 1991, COGNITIVE REHABILITA, P129; Belanger HG, 2002, CLIN NEUROPSYCHOL, V16, P251, DOI 10.1076/clin.16.3.251.13848; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; DUCHNICK JD, 2002, CLIN NEUROPSYCHOL, V16, P209; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming JM, 1996, BRAIN INJURY, V10, P1; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; KOLITZ BP, 2000, THESIS U S FLORIDA T; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Stuss D., 1991, AWARENESS DEFICIT BR, P63; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Sunderland A, 1984, EVERYDAY MEMORY ACTI, P191; TEASDALE G, 1974, LANCET, V2, P81; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Vanderploeg R. D., 2000, CLIN GUIDE NEUROPSYC, P195	41	52	53	0	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					937	949		10.1682/JRRD.2006.12.0163			13	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	253NL	WOS:000252524800007	18075951	Bronze			2022-02-06	
J	Stulemeijer, M; Van der Werf, SP; Jacobs, B; Biert, J; Van Vugt, AB; Brauer, JMP; Vos, PE				Stulemeijer, Maja; Van der Werf, Sieberen P.; Jacobs, Bram; Biert, Jan; Van Vugt, Arie B.; Brauer, Jolanda M. P.; Vos, Pieter E.			Impact of additional extracranial injuries on outcome after mild traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						head injury; mild traumatic brain injury; multiple trauma; outcome; post-concussion symptoms	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; GENERAL HEALTH; RELIABILITY; COMPLAINTS; SCALE	Many patients with mild traumatic brain injury (MTBI) concurrently sustain extracranial injuries; however, little is known about the impact of these additional injuries on outcome. We assessed the impact of additional injuries on the severity of postconcussional symptoms (PCS) and functional outcome 6 months post-injury. A questionnaire (including the Rivermead Post-Concussion Questionnaire and SF-36) was sent to consecutive MTBI patients (hospital admission Glasgow Coma Score 13-15; age range 18-60 years) admitted to the emergency department of a level-I trauma center, and, to serve as a baseline for PCS, a control group of minor-injury patients (ankle or wrist distortion). Of the 299 MTBI respondents (response rate 52%), 89 had suffered additional injuries (mean Injury Severity Score [ISS] of 14.5 +/- 7.4). After 6 months, 44% of the patients with additional injuries were still in some form of treatment, compared to 14% of patients with isolated MTBI and 5% of the controls. Compared to patients with isolated injury, MTBI patients with additional injuries had resumed work less frequently and reported more limitations in physical functioning. Overall, they did not report higher levels of PCS, despite somewhat more severe head injury. Regardless of the presence of additional injuries, patients that were still in treatment reported significantly more severe PCS, with highest rates in patients with isolated MTBI. In conclusion, many patients with additional extracranial injuries are still in the process of recovery at 6 months after injury. However, despite more severe impact to the head and inferior functional outcomes, these patients do not report more severe PCs.	Univ Nijmegen St Radboud Hosp, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen St Radboud Hosp, Med Ctr, Dept Surg, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen St Radboud Hosp, Med Ctr, Dept Psychol Med, NL-6500 HB Nijmegen, Netherlands		Vos, PE (corresponding author), Univ Nijmegen St Radboud Hosp, Med Ctr, Dept Neurol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	P.Vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012; Biert, J./L-4200-2015				Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kibby M Y, 1997, Appl Neuropsychol, V4, P34, DOI 10.1207/s15324826an0401_4; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	33	52	52	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1561	1569		10.1089/neu.2006.23.1561			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500015	17020490	Green Submitted			2022-02-06	
J	Holshouser, BA; Tong, KA; Ashwal, S; Oyoyo, U; Ghamsary, M; Saunders, D; Shutter, L				Holshouser, Barbara A.; Tong, Karen A.; Ashwal, Stephen; Oyoyo, Udochukwu; Ghamsary, Mark; Saunders, David; Shutter, Lori			Prospective longitudinal proton magnetic resonance spectroscopic imaging in adult traumatic brain injury	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						spectroscopy; magnetic resonance spectroscopy; traumatic brain injury; outcome prediction; diffuse axonal injury	IN-VIVO; AXONAL INJURY; HEAD; DYSFUNCTION	Purpose: To investigate whether longitudinal magnetic resonance proton spectroscopic imaging (MRSI) demonstrates regional metabolite abnormalities after traumatic brain injury (TBI) that predict long-term neurologic outcome. Materials and Methods: Two-dimensional-MRSI (point resolved spectroscopy sequence [PRESS]; TR/TE = 3000/ 144 msec: 10 mm) was acquired prospectively in 42 adults with severe TBI through the level of the corpus callosum 7 4 days after injury. Measurements were repeated in 31 patients six to 12 months after injury. Regional and pooled (all regions combined) mean ratios were compared with control values and then used to predict long-term (six- to -12-month) neurologic outcome (good vs. poor) using a logistic regression model. Results: Initial pooled mean N-acetylaspartate (NAA) ratios were lower (P < 0.01) and choline (Cho)/creatine (Cr) ratios higher (P < 0.01) in all TBI patients compared to controls. Ratios from the corpus callosum region were affected most and predicted long-term dichotomized outcome with 83% accuracy. When repeated at six to 12 months after injury, pooled mean NAA/Cr remained lower (P = 0.03) and Cho/Cr remained higher (P = 0.01) in patients with poor outcomes. Conclusion; The NAA/Cr ratio from the corpus callosum was most, useful for outcome prediction. Chronic alterations of metabolite ratios are likely due to neuronal loss and glial proliferation long after injury.	Loma Linda Univ, Med Ctr, Sch Med, Dept Radiol, Loma Linda, CA 92354 USA; Loma Linda Univ, Med Ctr, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; Loma Linda Univ, Med Ctr, Sch Med, Dept Epidemiol & Biostat, Loma Linda, CA 92354 USA; Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45221 USA; Univ Cincinnati, Med Ctr, Dept Neurol, Cincinnati, OH 45221 USA		Holshouser, BA (corresponding author), Loma Linda Univ, Med Ctr, Sch Med, Dept Radiol, MRI-B624,12354 Anderson St, Loma Linda, CA 92354 USA.	bholshouser@ahs.llumc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			Adams A, 2001, BCS CONF SERIES, P49; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; Baslow MH, 2000, J NEUROCHEM, V75, P453, DOI 10.1046/j.1471-4159.2000.0750453.x; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Graham D.I., 1996, NEUROTRAUMA, P43; GUIMARAES AR, 1995, NEUROSCIENCE, V69, P1095, DOI 10.1016/0306-4522(95)00300-8; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2002, ACT NEUR S, V81, P373; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; 2003, AM ASS NEUR SURG C N	22	52	55	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	JUL	2006	24	1					33	40		10.1002/jmri.20607			8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	061TG	WOS:000238894900004	16755529	Bronze			2022-02-06	
J	Kobori, N; Clifton, GL; Dash, PK				Kobori, Nobuhide; Clifton, Guy L.; Dash, Pramod K.			Enhanced catecholamine synthesis in the prefrontal cortex after traumatic brain injury: Implications for prefrontal dysfunction	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; dopamine; norepinephrine; prefrontal cortex; tyrosine hydroxylase; working memory	TYROSINE-HYDROXYLASE PHOSPHORYLATION; CORTICAL IMPACT MODEL; WORKING-MEMORY; COGNITIVE FUNCTION; CHROMAFFIN CELLS; FRONTAL-CORTEX; ACTIVATION; DEFICITS; KINASE; BIOSYNTHESIS	Traumatic brain injury (TBI)-induced dysfunction of the prefrontal cortex causes many high-level cognitive deficits, including working memory (WM) dysfunction. WM lies at the core of many high-level functions, yet the cellular and molecular mechanisms underlying its dysfunction are poorly understood. Lesion and pharmacological studies in rodents have implicated the medial prefrontal cortex (mPFC), which includes the prelimbic/infralimbic (PL/IL) cortices, in WM tasks. These studies have shown that optimal levels of catecholamine neurotransmission are critical for normalcy of WM function, suggesting that alterations in their synthesis may play a role in WM dysfunction. Using the cortical impact injury model of traumatic brain injury which reproducibly causes working memory deficits in rodents, we have measured the protein levels and activity of tyrosine hydroxylase (TH), the rate-limiting enzyme for catecholamine biosynthesis, and tissue dopamine (DA) and norepinephrine (NE) levels in microdissected PL/IL tissues. Our results show that TBI increases TH protein levels, its activity and tissue DA and NE content in the PL/IL. These findings suggest that altered catecholamine signaling within the PL/IL may contribute to impaired PFC function, and may have implications in the design and implementation of strategies to alleviate prefrontal dysfunction in brain injury patients.	Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Dept Neurobiol & Anat, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurosurg, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Dept Neurobiol & Anat, POB 20708,MSB 7-160, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457, R01NS049160] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, NS049160, NS0523] Funding Source: Medline		Arnsten AFT, 1998, ARCH GEN PSYCHIAT, V55, P362, DOI 10.1001/archpsyc.55.4.362; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Betarbet R, 1997, J NEUROSCI, V17, P6761; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BRITO GNO, 1990, BEHAV BRAIN RES, V36, P127, DOI 10.1016/0166-4328(90)90167-D; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/0897715042441828; Delatour B, 2000, BEHAV BRAIN RES, V109, P113, DOI 10.1016/S0166-4328(99)00168-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunkley PR, 2004, J NEUROCHEM, V91, P1025, DOI 10.1111/j.1471-4159.2004.02797.x; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; Goldman-Rakic PS, 2000, BRAIN RES REV, V31, P295, DOI 10.1016/S0165-0173(99)00045-4; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYCOCK JW, 1993, NEUROCHEM RES, V18, P15, DOI 10.1007/BF00966919; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobori N, 2004, J BIOL CHEM, V279, P2182, DOI 10.1074/jbc.M310734200; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; LEVINE RA, 1984, ANAL BIOCHEM, V143, P205, DOI 10.1016/0003-2697(84)90577-3; Lew JY, 1999, MOL PHARMACOL, V55, P202, DOI 10.1124/mol.55.2.202; Lindgren N, 2002, EUR J NEUROSCI, V15, P769, DOI 10.1046/j.1460-9568.2002.01901.x; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Runyan JD, 2005, LEARN MEMORY, V12, P103, DOI 10.1101/lm.89405; Salvatore MF, 2004, J NEUROCHEM, V90, P245, DOI 10.1111/j.1471-4159.2004.02496.x; Salvatore MF, 2001, J NEUROCHEM, V79, P349, DOI 10.1046/j.1471-4159.2001.00593.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; Toska K, 2002, J NEUROCHEM, V83, P775, DOI 10.1046/j.1471-4159.2002.01172.x; WAYMIRE JC, 1991, J NEUROCHEM, V57, P1313, DOI 10.1111/j.1471-4159.1991.tb08296.x; YAMAUCHI T, 1981, BIOCHEM BIOPH RES CO, V100, P807, DOI 10.1016/S0006-291X(81)80246-X; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.neuro.12.1.415	41	52	53	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2006	23	7					1094	1102		10.1089/neu.2006.23.1094			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	069UG	WOS:000239473200005	16866622				2022-02-06	
J	Liu-Snyder, P; Ben Borgens, R; Shi, R				Liu-Snyder, Peishan; Ben Borgens, Richard; Shi, Riyi			Hydralazine rescues PC12 cells from acrolein-mediated death	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						acrolein; secondary injury; neurotrauma; hydralazine	SPINAL-CORD-INJURY; LIPID-PEROXIDATION PRODUCT; OXIDATIVE STRESS; CYTOTOXICITY; DISRUPTION; ALDEHYDE; ACID	Acrolein, a major lipid peroxidation product, has been associated with both CNS trauma and neurodegenerative diseases. Because of its long half-life, acrolein is a potent endogenous toxin capable of killing healthy cells during the secondary injury process. Traditionally, attempts to intervene in the process of progressive cell death after the primary injury have included scavenging reactive oxygen species (so-called free radicals). The animal data supporting such an approach have generally been positive, but all human clinical trials attempting a similar outcome in human CNS injury have failed. New drugs that might reduce toxicity by scavenging the products of lipid peroxidation present a promising, and little investigated, therapeutic approach. Hydralazine, a well-known treatment for hypertension, has been reported to react with acrolein, forming hydrazone in cell-free systems. In the companion paper, we have established an acrolein-mediated cell injury model using PC12 cells in vitro. Here we test the hypothesis that the formation of hydrazone adducts with acrolein is able to reduce acrolein toxicity and spare a significant percentage of the population of PC12 cells from death. Concentrations of approximately 1 mM of this aldehyde scavenger can rescue over 80% of the population of PC12 cells. This study provides a basis for a new pharmacological treatment to reduce the effects of secondary injury in the damaged and/or diseased nervous system. In particular, we describe the need for new drugs that possess aldehyde scavenging properties but do not interfere with the regulation of blood pressure. (c) 2006 Wiley-Liss, Inc.	Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Sci, W Lafayette, IN 47907 USA; Purdue Univ, Coll Engn, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA		Shi, R (corresponding author), Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Sci, 408 S Univ St, W Lafayette, IN 47907 USA.	riyi@purdue.edu					Burcham PC, 2000, REDOX REP, V5, P47, DOI 10.1179/rer.2000.5.1.47; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Ghilarducci DP, 1995, REV ENVIRON CONTAM T, V144, P95; Harper ME, 2004, ACTA PHYSIOL SCAND, V182, P321, DOI 10.1111/j.1365-201X.2004.01370.x; JAESCHKE H, 1987, BIOCHEM PHARMACOL, V36, P51, DOI 10.1016/0006-2952(87)90381-9; LALICH JJ, 1974, EXP MOL PATHOL, V21, P29, DOI 10.1016/0014-4800(74)90076-8; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; Nardini M, 2002, TOXICOLOGY, V170, P173, DOI 10.1016/S0300-483X(01)00540-6; NORDQUIST JE, 2002, THESIS UPPSALA U; Norton ND, 1997, TOXICOLOGY, V122, P111, DOI 10.1016/S0300-483X(97)00086-3; Picklo MJ, 2001, BBA-MOL BASIS DIS, V1535, P145, DOI 10.1016/S0925-4439(00)00093-4; Rudra PK, 1999, ANTICANCER RES, V19, P461; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P403, DOI 10.3748/wjg.v11.i3.403; Springer JE, 1997, J NEUROCHEM, V68, P2469; Tanel A, 2005, BBA-MOL CELL RES, V1743, P255, DOI 10.1016/j.bbamcr.2004.11.007; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Vasan S, 2003, ARCH BIOCHEM BIOPHYS, V419, P89, DOI 10.1016/j.abb.2003.08.016; Zarkovic Kamelija, 2003, Molecular Aspects of Medicine, V24, P293, DOI 10.1016/S0098-2997(03)00024-4; Zhang DQ, 1999, NEUROSCI LETT, V272, P57, DOI 10.1016/S0304-3940(99)00455-3; ZOLLNER H, 1973, BIOCHEM PHARMACOL, V22, P1171, DOI 10.1016/0006-2952(73)90234-7	25	52	53	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUL	2006	84	1					219	227		10.1002/jnr.20862			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	061UD	WOS:000238897400020	16619236				2022-02-06	
J	Cheng, SKW; Man, DWK				Cheng, S. K. W.; Man, D. W. K.			Management of impaired self-awareness in persons with traumatic brain injury	BRAIN INJURY			English	Article						TBI; impaired self-awareness; training; intervention; feedback	INSTRUMENTAL ACTIVITIES; DEFICITS; UNAWARENESS; ADULTS	Aim: To develop and evaluate a systematic intervention programme for the management of impaired self-awareness (ISD) in people with traumatic brain injury. Methods: This study adopted a pre-test-post-test control group design. Twenty-one patients with traumatic brain injury were randomly assigned to an experimental group and a control group according to their admission sequence. The groups joined a newly developed Awareness Intervention Programme (AIP) and a conventional rehabilitation programme respectively for 4 weeks. Pre- and post-intervention outcome measures taken from the two groups were compared. Wilcoxon Signed-Ranks Tests were conducted to compare the within-group changes of the outcome measures of the Self-Awareness of Deficits Interview (SADI), the Functional Independence Measure (FIM) and the Lawton Instrumental Activities of Daily Living Score ( Lawton IADL) in the control and experimental groups. Mann Whitney U-tests were conducted to compare the across-group differences of improvements of outcome measures between the participants in the two groups. Results: After AIP training, the participants in the experimental group demonstrated significant improvement in their level of awareness as compared to the control group. However, the functional outcomes of the participants in experimental group did not show significant differences. Conclusion: The AIP can promote improvement in the level of self-awareness of people with traumatic brain injury. This new programme can be further developed to extend a better carryover treatment effect to functional improvement in daily activities.	Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China; Hosp Author, MacLehose Med Rehabil Ctr, Occupat Therapy Dept, Hong Kong, Hong Kong, Peoples R China		Man, DWK (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China.	rsdavid@polyu.edu.hk					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; Fiedler R., 1996, FUNCTIONAL ELEVATION, P75; Fleming JM, 1996, BRAIN INJURY, V10, P1; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; Langer KG., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [DOI 10.1080/09602019208401395, 10.1080/09602019208401395]; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LESLIE GP, 2000, FDN CLIN RES APPL PR, P193; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; PRIGATANO GP, 1991, DISTURBANCE SELF AWA, P3; PRIGATANO GP, 1995, BLACKWELL DICT NEURO, P80; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; SODERBACK I, 1992, ARCH PHYS MED REHAB, V73, P1140; Sohlberg M, 2001, COGNITIVE REHABILITA, P269; Sohlberg McKay Moore, 2000, Seminars in Speech and Language, V21, P135; Tham K, 1997, ARCH PHYS MED REHAB, V78, P410, DOI 10.1016/S0003-9993(97)90234-3; Tong AYC, 2002, OTJR-OCCUP PART HEAL, V22, P132, DOI 10.1177/153944920202200402	21	52	53	1	25	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	6					621	628		10.1080/02699050600677196			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	062LU	WOS:000238947100007	16754287				2022-02-06	
J	Kirchhoff, C; Stegmaier, J; Bogner, V; Buhmann, S; Mussack, T; Kreimeier, U; Mutschler, W; Biberthaler, P				Kirchhoff, Chlodwig; Stegmaier, Julia; Bogner, Viktoria; Buhmann, Sonja; Mussack, Thomas; Kreimeier, Uwe; Mutschler, Wolf; Biberthaler, Peter			Intrathecal and systemic concentration of NT-proBNP in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						amino terminal proBNP; cerebrospinal fluid; computerized tomography; intracranial pressure; NT-proBNP; traumatic brain injury	NATRIURETIC-PEPTIDE; DIAGNOSIS; INFLAMMATION; SECRETION; ATRIAL	Outcome of patients suffering from traumatic brain injury (TBI) depends on the development of secondary brain damage. In this context, recent studies underlined the role of the natriuretic peptides-atrial natriuretic peptide and brain natriuretic peptide (BNP)-in aneurysmatic subarachnoidal hemorrhage (SAH). Especially BNP correlates with intracranial pressure and clinical outcome after SAH. Since its role in TBI remains unclear, the intracranial and systemic concentrations of N-terminal (NT)-proBNP were analyzed in patients suffering from severe TBI. We measured NT-proBNP levels in cerebrospinal fluid (CSF) and serum of 14 patients suffering from severe TBI (GCS <= 8 points) and 10 healthy control patients, using proBNP (R) assay (Roche (R) Diagnostics). Samples were collected after placement of a ventricular catheter, and at 12, 24, 48, and 72 h after TBI. CSF/serum albumin ratio (Q < a) was daily calculated. At 90 days after TBI, outcome was evaluated using the Glasgow Outcome Scale (GOS). In patients exhibiting a mean ICP of > 15 mm Hg (n = 6), the serum (800 +/- 150 pg/mL) and CSF levels (55 +/- 9 pg/mL) of NT-proBNP were significantly increased after 24 It, as compared to patients with ICP <= 15 mm of Hg (n = 8) as well as to control group. However, Q(a) as well as GOS did not significantly differ among both groups. For the first time, we evaluated intrathecal and systemic NT-proBNP concentrations in patients suffering from severe TBI. Interestingly, NT-proBNP in CSF and serum was significantly elevated in patients exhibiting an ICP of > 15 mm Hg. Further studies are currently performed to elucidate the physiologic role of NT-proBNP in TBI.	Univ Munich, Chirurg Klin & Poliklin, Klinikum Innenstadt, D-80336 Munich, Germany; Univ Munich, Inst Klin Radiol, Klinikum Grosshadern, D-80336 Munich, Germany; Univ Munich, Anasthesiol Klin, Klinikum Innenstadt, D-80336 Munich, Germany		Kirchhoff, C (corresponding author), Univ Munich, Chirurg Klin & Poliklin, Klinikum Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.	Chlodwig.Kirchhoff@med.uni-muenchen.de					Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Berendes E, 1997, LANCET, V349, P245, DOI 10.1016/S0140-6736(96)08093-2; Berendes E, 2001, ANESTH ANALG, V93, P676, DOI 10.1097/00000539-200109000-00029; Charpentier J, 2004, CRIT CARE MED, V32, P660, DOI 10.1097/01.CCM.0000114827.93410.D8; de Lemos JA, 2003, LANCET, V362, P316, DOI 10.1016/S0140-6736(03)13976-1; Espiner EA, 2002, CLIN ENDOCRINOL, V56, P629, DOI 10.1046/j.1365-2265.2002.01285.x; Farin A, 2004, ACT NEUR S, V89, P101; Fukui S, 2003, J CEREBR BLOOD F MET, V23, P1212, DOI 10.1097/01.WCB.0000088762.02615.30; JENNETT B, 1975, LANCET, V1, P480; Jernberg T, 2003, J AM COLL CARDIOL, V42, P1909, DOI 10.1016/j.jacc.2003.07.015; Lainchbury JG, 2003, J AM COLL CARDIOL, V42, P728, DOI 10.1016/S0735-1097(03)00787-3; Levin ER, 1998, NEW ENGL J MED, V339, P321; Ma KK, 2005, REGUL PEPTIDES, V128, P169, DOI 10.1016/j.regpep.2004.12.025; Mair J, 2001, CLIN CHEM LAB MED, V39, P571, DOI 10.1515/CCLM.2001.093; Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; SAITO Y, 1989, BIOCHEM BIOPH RES CO, V158, P360, DOI 10.1016/S0006-291X(89)80056-7; Sviri GE, 2003, ACTA NEUROCHIR, V145, P851, DOI 10.1007/s00701-003-0101-7; TAKAHASHI K, 1992, PEPTIDES, V13, P121, DOI 10.1016/0196-9781(92)90149-W; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation The American Association of Neurological Surgeons The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P497	22	52	55	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2006	23	6					943	949		10.1089/neu.2006.23.943			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	056TW	WOS:000238549000010	16774478				2022-02-06	
J	Itshayek, E; Rosenthal, G; Fraifeld, S; Perez-Sanchez, X; Cohen, JE; Spektor, S				Itshayek, E; Rosenthal, G; Fraifeld, S; Perez-Sanchez, X; Cohen, JE; Spektor, S			Delayed posttraumatic acute subdural hematoma in elderly patients on anticoagulation 10.1227/0	NEUROSURGERY			English	Article						anticoagulation; delayed subdural hematoma; elderly patients; intracranial injury; Glasgow coma scale; mild traumatic brain injury; subdural hematoma	MILD HEAD-INJURY; COMPUTED-TOMOGRAPHY; BRAIN INJURY; INTRACRANIAL HEMORRHAGE; EXTRADURAL HEMATOMA; EPIDURAL HEMATOMA; HIGH-RISK; TRAUMA; MANAGEMENT; METAANALYSIS	OBJECTIVE: To discuss delayed acute subdural hematoma (DASH), a relatively neglected entity, and to emphasize the potentially elevated risk for DASH among elderly, anticoagulated mild traumatic brain injury (TBI) patients. METHODS: The authors reviewed clinical and radiological data for four patients who had normal neurological examinations and normal computed tomographic scans after mild TBI, and who subsequently developed DASH and deteriorated rapidly. RESULTS: The patients included two men and two women, aged 65 to 86 years, who presented to the emergency department after mild TBI between January 2002 and June 2004. All were treated with chronic anticoagulation or anti-aggregation therapy. They deteriorated owing to DASH from 9 hours to 3 days after TBI. Three of the four patients underwent craniotomy for evacuation of their hematomas. One patient, who suffered only focal neurological deficit, was treated conservatively, and her hematoma gradually resolved. Two patients died and two reached Glasgow Outcome Scores of 3 and 4 after extended inpatient rehabilitation. CONCLUSION: A suspicion of DASH should be raised in elderly, anticoagulated, mild TBI patients, including those who present to the emergency department with Glasgow Coma Scores of 15 and normal computed tomographic scans after injury. Based on our experience, we recommend that elderly, anticoagulated mild TBI patients should be admitted for 24 to 48 hours of observation after injury.	Hebrew Univ Jerusalem, Med Ctr, Dept Neurosurg, IL-91120 Jerusalem, Israel		Itshayek, E (corresponding author), Hebrew Univ Jerusalem, Med Ctr, Dept Neurosurg, Kiryat Hadassah,POB 12000, IL-91120 Jerusalem, Israel.	eyalit@md.huji.ac.il					Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; Atzema C, 2004, ANN EMERG MED, V44, P47, DOI 10.1016/j.annemergmed.2004.02.032; Batchelor J, 2002, EMERG MED J, V19, P515, DOI 10.1136/emj.19.6.515; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Cohen T, 1995, TRAUMA, P689; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DEITCH D, 1989, NEUROLOGY, V39, P985, DOI 10.1212/WNL.39.7.985; DOHERTY DL, 1988, ARCH PHYS MED REHAB, V69, P542; DOMENICUCCI M, 1995, NEUROSURG REV, V18, P109, DOI 10.1007/BF00417668; DRAKE CG, 1961, J NEUROSURG, V18, P597, DOI 10.3171/jns.1961.18.5.0597; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P1787, DOI 10.1136/jnnp.2004.041384; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; FRANCEL P, 1996, NEUROLOGICAL SURG, P1595; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; IUVARABOMMELI A, 1991, SCHWEIZ MED WSCHR, V121, P646; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1981, MANAGEMENT HEAD INQU, P155; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Linkins LA, 2003, ANN INTERN MED, V139, P893, DOI 10.7326/0003-4819-139-11-200312020-00007; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MATHIESEN T, 1995, ACTA NEUROL SCAND, V91, P208; MERTOL T, 1991, British Journal of Neurosurgery, V5, P491, DOI 10.3109/02688699108998478; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; POON WS, 1992, NEUROSURGERY, V30, P681; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; Riesgo P, 1997, SURG NEUROL, V48, P226, DOI 10.1016/S0090-3019(97)00194-8; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SHENKIN HA, 1982, J NEUROSURG, V57, P254, DOI 10.3171/jns.1982.57.2.0254; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wong KS, 2000, NEUROLOGY, V54, P2298, DOI 10.1212/WNL.54.12.2298; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006; Zwimpfer TJ, 1997, J NEUROSURG, V86, P433, DOI 10.3171/jns.1997.86.3.0433	51	52	54	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2006	58	5					851	856		10.1227/01.NEU.0000209653.B2936.96			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	039IC	WOS:000237298200011					2022-02-06	
J	Elie, MC				Elie, MC			Blunt cardiac injury	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						myocardial contusion; myocardial concussion; myocardial rupture; blunt cardiac injury; pericardial tamponade; blunt trauma; echocardiography; pericardiocentesis; cardiogenic failure	MYOCARDIAL CONTUSION; CLINICAL-SIGNIFICANCE; CARDIOGENIC-SHOCK; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; BALLOON COUNTERPULSATION; TRAUMATIC RUPTURE; THORACIC TRAUMA; LEFT-VENTRICLE; CHEST TRAUMA; TROPONIN-I	The diagnosis and management of blunt cardiac injury, formerly known as myocardial contusion, has challenged clinicians for decades. Caused primarily by motor vehicle collisions, significant blunt cardiac injury carries a high mortality rate. Yet no reliable diagnostic test exists to identify those patients at greatest risk for an adverse outcome. A literature search using the MEDLINE database was performed to compose a review of epidemiology, diagnostic intervention, and therapeutic approach. The results of the search indicate that, along with a high index of suspicion, utilizing a combination of electrocardiogram, troponin, and echocardiography for appropriate patients may improve the diagnosis, risk stratification and disposition of patients sustaining blunt cardiac injury.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Emergency Med, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Div Crit Care, Dept Med, Newark, NJ 07103 USA		Elie, MC (corresponding author), 150 Bergen St,M219, Newark, NJ 07103 USA.	eliema@umdnj.edu	Elie-Turenne, Marie-Carmelle/G-6895-2013	Elie-Turenne, Marie-Carmelle/0000-0002-4807-9403			Adams JE, 1996, AM HEART J, V131, P308, DOI 10.1016/S0002-8703(96)90359-2; BAUMGARTEL ED, 1992, ARCH SURG-CHICAGO, V127, P347; Bertinchant JP, 2000, J TRAUMA, V48, P924, DOI 10.1097/00005373-200005000-00018; BIFFL WL, 1994, AM J SURG, V168, P523, DOI 10.1016/S0002-9610(05)80115-1; BODAI BI, 1982, J TRAUMA, V22, P487, DOI 10.1097/00005373-198206000-00008; Bokelman TA, 1996, AM HEART J, V131, P411, DOI 10.1016/S0002-8703(96)90379-8; Bromberg BI, 1996, J PEDIATR-US, V128, P536, DOI 10.1016/S0022-3476(96)70366-9; BRUNEL W, 1988, J INTENSIVE CARE MED, V3, P253; CACHECHO R, 1992, J TRAUMA, V33, P68, DOI 10.1097/00005373-199207000-00014; Caparrelli DJ, 2002, J TRAUMA, V52, P377, DOI 10.1097/00005373-200202000-00028; Chirillo F, 1996, HEART, V75, P301, DOI 10.1136/hrt.75.3.301; Christensen M A, 1993, Am J Crit Care, V2, P28; DOTY DB, 1974, ANN SURG, V180, P452, DOI 10.1097/00000658-197410000-00010; Dowd MD, 1996, J TRAUMA, V40, P61, DOI 10.1097/00005373-199601000-00012; DUBROW TJ, 1989, SURGERY, V106, P267; FEGHALI NT, 1995, CHEST, V108, P1673, DOI 10.1378/chest.108.6.1673; FILDES JJ, 1995, AM SURGEON, V61, P832; FOIL MB, 1990, AM J SURG, V160, P638, DOI 10.1016/S0002-9610(05)80764-0; FRAZEE RC, 1986, J TRAUMA, V26, P510, DOI 10.1097/00005373-198606000-00004; FULDA G, 1991, J TRAUMA, V31, P167, DOI 10.1097/00005373-199131020-00003; GETZ BS, 1986, JAMA-J AM MED ASSOC, V255, P761, DOI 10.1001/jama.255.6.761; HEALEY MA, 1990, J TRAUMA, V30, P137, DOI 10.1097/00005373-199002000-00002; HIRSCH R, 1997, J PEDIATR-US, V6, P872; ILLIG KA, 1991, AM J SURG, V162, P537, DOI 10.1016/0002-9610(91)90105-M; KARALIS DG, 1994, J TRAUMA, V36, P53, DOI 10.1097/00005373-199401000-00008; KATO K, 1994, J TRAUMA, V36, P859, DOI 10.1097/00005373-199406000-00017; KEUNG ECH, 1981, JAMA-J AM MED ASSOC, V245, P144, DOI 10.1001/jama.245.2.144; Lindstaedt M, 2002, J TRAUMA, V52, P479, DOI 10.1097/00005373-200203000-00011; Link MS, 1998, NEW ENGL J MED, V338, P1805, DOI 10.1056/NEJM199806183382504; Maenza RL, 1996, AM J EMERG MED, V14, P237, DOI 10.1016/S0735-6757(96)90165-5; MALANGONI MA, 1994, SURGERY, V116, P628; Mandavia DP, 2001, ANN EMERG MED, V38, P377, DOI 10.1067/mem.2001.118224; MANYARI DE, 1978, CAN MED ASSOC J, V119, P445; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1142, DOI 10.1001/jama.287.9.1142; MATTOX KL, 1975, CIRCULATION, V52, P210; MATTOX KL, 1992, J TRAUMA, V33, P649; MAZZORANA V, 1994, AM SURGEON, V60, P516; Nagy KK, 2001, WORLD J SURG, V25, P108, DOI 10.1007/s002680020372; NEIMAN J, 1992, AM HEART J, V123, P1694, DOI 10.1016/0002-8703(92)90827-I; Nesbitt AD, 2001, LANCET, V357, P1195, DOI 10.1016/S0140-6736(00)04338-5; Orliaguet G, 2001, ANESTHESIOLOGY, V95, P544, DOI 10.1097/00000542-200108000-00041; PARMLEY LF, 1958, CIRCULATION, V18, P371, DOI 10.1161/01.CIR.18.3.371; PASQUALE MD, 1998, PRACTICE MANAGEMENT; Patel AN, 2003, ANN THORAC SURG, V76, P2043, DOI 10.1016/S0003-4975(03)01057-9; Patetsios P, 2000, J TRAUMA, V49, P771, DOI 10.1097/00005373-200010000-00032; Penney DJ, 2002, RESUSCITATION, V55, P337, DOI 10.1016/S0300-9572(02)00234-4; PEVEC WC, 1989, CRIT CARE MED, V17, P837, DOI 10.1097/00003246-198908000-00023; PEVEC WC, 1989, ANN THORAC SURG, V48, P139, DOI 10.1016/0003-4975(89)90203-8; PRETRE R, 1993, ANN THORAC SURG, V56, P1426, DOI 10.1016/0003-4975(93)90708-P; Pretre R, 1997, NEW ENGL J MED, V336, P626, DOI 10.1056/NEJM199702273360906; Relos RP, 2003, CRIT CARE MED, V31, P2598, DOI 10.1097/01.CCM.0000089931.09635.D2; ROBERTS JR, 2004, ROBERTS CLIN PROCEDU; Rozycki GS, 1999, J TRAUMA, V46, P543, DOI 10.1097/00005373-199904000-00002; Rozycki GS, 1996, ANN SURG, V223, P737, DOI 10.1097/00000658-199606000-00012; Salim A, 2001, J TRAUMA, V50, P237, DOI 10.1097/00005373-200102000-00008; Schultz JM, 2004, CRIT CARE CLIN, V20, P57, DOI 10.1016/S0749-0704(03)00092-7; SHORR RM, 1987, ANN SURG, V206, P200, DOI 10.1097/00000658-198708000-00013; Sisley AC, 1998, J TRAUMA, V44, P291, DOI 10.1097/00005373-199802000-00009; SNOW N, 1982, J TRAUMA, V22, P426, DOI 10.1097/00005373-198205000-00015; Spodick DH, 2003, NEW ENGL J MED, V349, P684, DOI 10.1056/NEJMra022643; STURAITIS M, 1986, ARCH INTERN MED, V146, P1765, DOI 10.1001/archinte.146.9.1765; SYMBAS PN, 1991, CURR PROB CARDIOLOGY, V16, P537; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; TSUNG SH, 1976, CLIN CHEM, V22, P173; *US DEP HHS, 2004, VIT HLTH STAT; US Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Health Statistics National Hospital Discharge Survey (NHDS), 2004, NAT HOSP DISCH SURV; Velmahos GC, 2003, J TRAUMA, V54, P45, DOI 10.1097/00005373-200301000-00006; VLAY SC, 1980, AM HEART J, V100, P907, DOI 10.1016/0002-8703(80)90073-3; Weiss RL, 1996, CHEST, V109, P73, DOI 10.1378/chest.109.1.73; Zangwill SD, 2004, PEDIATR CLIN N AM, V51, P1347, DOI 10.1016/j.pcl.2004.04.001	70	52	58	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR	2006	73	2					542	552					11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	020NB	WOS:000235915100005	16568196				2022-02-06	
J	Narotam, PK; Budonrappa, SC; Raynor, SC; Rao, M; Taylon, C				Narotam, PK; Budonrappa, SC; Raynor, SC; Rao, M; Taylon, C			Cerebral oxygenation in major pediatric trauma: its relevance to trauma severity and outcome	JOURNAL OF PEDIATRIC SURGERY			English	Article						brain tissue oxygenation (PbtO(2)); Pediatric Trauma Score; Injury Severity Score; Revised Trauma Score; traumatic brain injury	SEVERE HEAD-INJURY; BRAIN-TISSUE OXYGENATION; PERFUSION-PRESSURE; HEMORRHAGIC-SHOCK; COMATOSE PATIENTS; INSPIRED OXYGEN; TENSION; SCORE; EXPERIENCE; MANAGEMENT	Introduction: Trauma is the commonest cause of death in the pediatric population, which is prone to diffuse primary brain injury aggravated by secondary insults (eg, hypoxia, hypotension). Standard monitoring involves intracranial pressure (ICP) and cerebral perfusion pressure, which do not reflect true cerebral oxygenation (oxygen delivery [Do,]). We explore the merits of a brain tissue oxygen-directed critical care guide. Methods: Sixteen patients with major trauma (Injury Severity Score, > 16/Pediatric Trauma Score [PTS], < 7) had partial pressure of brain tissue oxygen (PbtO(2)) monitor (Licox; Integra Neurosciences, Plainsboro, NJ) placed under local anesthesia using twist-drill craniostomy and definitive management of associated injuries. PbtO(2) levels directed therapy intensity level (ventilator management, inotrops, blood transfusion, and others). Patient demographics, short-term physiological parameters, PbtO(2), ICP, Glasgow Coma Score, trauma scores, and outcomes were analyzed to identify the patients at risk for low DO2. Results: There were 10 males and 6 females (mean age, 14 years) sustaining motor vehicle accident (14), falls (1), and assault (1), with a mean Injury Severity Score of 36 (16-59); PTS, 3 (0-7); and Revised Trauma Score, 5.5 (4-11). Eleven patients (70%) had low DO2 (PbtO(2), < 20 mm Hg) on admission despite undergoing standard resuscitation affected by fraction of inspired oxygen, PaO2, and cerebral perfusion pressure (P=.001). Eubaric hyperoxia improved cerebral oxygenation in the low-DO2 group (P=.044). The Revised Trauma Score (r = 0.65) showed moderate correlation with PbtO(2) and was a significant predictor for low DO2 (P=-001) In patients with PbtO(2) of less than 20 mm Hg, PTS correlated with cerebral oxygenation (r = 0.671, P =.033). The mean 2-hour PbtO(2) and the final PbtO(2) in survivors were significantly higher than deaths (21.6 vs 7.2 mm Hg [P =.009] and 25 vs 11 mm Hg [P =.01]). Although 4 of 6 deaths were from uncontrolled high ICP, PTS and 2-hour low DO2 were significant for roots for mortality. Conclusions: PbtO(2) monitoring allows for early recognition of low-Do, situations, enabling appropriate therapeutic intervention. (c) 2006 Elsevier Inc. All rights reserved.	Creighton Univ, Med Ctr, Div Neurosurg, Div Neurosurg & Trauma, Omaha, NE 68131 USA		Narotam, PK (corresponding author), Creighton Univ, Med Ctr, Div Neurosurg, Div Neurosurg & Trauma, Omaha, NE 68131 USA.	narotam@creighton.edu		Burjonrappa, Sathyaprasad/0000-0002-4743-4047			Bardt TF, 1998, ACT NEUR S, V71, P153; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bullock MR, 2003, J NEUROSURG, V98, P943, DOI 10.3171/jns.2003.98.5.0943; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; EICHELBERGER MR, 1989, ANN EMERG MED, V18, P1053, DOI 10.1016/S0196-0644(89)80930-8; Fandino J, 2000, J CLIN NEUROSCI, V7, P226, DOI 10.1054/jocn.1999.0202; Filippi R, 2000, NEUROSURG REV, V23, P94; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Jodicke A, 2003, J NEUROSURG, V98, P515, DOI 10.3171/jns.2003.98.3.0515; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kiening KL, 1998, ACT NEUR S, V71, P172; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; McKinley BA, 2002, J TRAUMA, V53, P825, DOI 10.1097/00005373-200211000-00004; McKinley Bruce A, 2003, Curr Opin Crit Care, V9, P292, DOI 10.1097/00075198-200308000-00007; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NAYDUCH DA, 1991, J TRAUMA, V31, P452, DOI 10.1097/00005373-199104000-00003; Ott R, 2000, J TRAUMA, V49, P729, DOI 10.1097/00005373-200010000-00023; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RAMENOFSKY ML, 1988, J TRAUMA, V28, P1038, DOI 10.1097/00005373-198807000-00021; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Stocchetti N, 1998, ACT NEUR S, V71, P162; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	41	52	53	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	MAR	2006	41	3					505	513		10.1016/j.jpedsurg.2005.11.069			9	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Surgery	026FU	WOS:000236325600009	16516625				2022-02-06	
J	Shindo, T; Matsumoto, Y; Wang, Q; Kawai, N; Tamiya, T; Nagao, S				Shindo, Tokuhisa; Matsumoto, Yoshihito; Wang, Qinghua; Kawai, Nobuyuki; Tamiya, Takashi; Nagao, Seigo			Differences in the neuronal stem cells survival, neuronal differentiation and neurological improvement after transplantation of neural stem cells between mild and severe experimental traumatic brain injury	JOURNAL OF MEDICAL INVESTIGATION			English	Article						embryonic stem cell; neural stem cell; transplantation; cholinergic; traumatic brain injury		We developed a novel protocol for generation and selective amplification of neural progenitor cells regionally specified to the rostral brain but not the spinal cord from mouse embryonic stem cells (ESCs). The neural progenitors could differentiate in vitro and in vivo in to many cholinergic and a few GABA ergic neurons but rarely into astrocytes. The transplanted neurospheres could survive in the hippocampus (CA3) of animals with mild traumatic brain injury (TBI). Twelve weeks after transplantation (a week after the behavioral test), we found significant cholinergic differentiation recognized as ChAT immunoreactivity in the eGFP+ transplanted cells. Moreover, the grafts contained a few GAD67+ cells. However, we barely found GFAP+ astrocytes within the grafts. Furthermore, presynaptic formations of graft-derived neurons were recognized by immunohistochemistry of near the grafts around CA3. However, these findings were not observed in severe TBI group. So, we examined NGF, BDNF, and FGF-2 mRNA by RT-PCR in 12 mice including normal, mild TBI and severe TBI group. Increases in the neurotrophic factors' mRNA were evident in the hippocampus on the ipsilateral side in the mild TBI group. Statistical analysis revealed significant differences between the mild and severe TBI groups. The data also revealed significant differences between the mild TBI and normal groups. The transplanted neurospheres could survive in the mild TBI animals, but not in the severe TBI group.	[Shindo, Tokuhisa; Matsumoto, Yoshihito; Wang, Qinghua; Kawai, Nobuyuki; Tamiya, Takashi; Nagao, Seigo] Kagawa Univ, Fac Med, Dept Neurol Surg, Kagawa, Japan		Shindo, T (corresponding author), Kagawa Univ, Fac Med, Dept Neurol Surg, Kagawa, Japan.							0	52	60	0	1	UNIV TOKUSHIMA SCH MEDICINE	TOKUSHIMA	3-18-15, KURAMOTO-CHO, TOKUSHIMA, 00000, JAPAN	1343-1420	1349-6867		J MED INVESTIG	J. Med. Investig.	FEB	2006	53	1-2					42	51		10.2152/jmi.53.42			10	Medicine, Research & Experimental	Emerging Sources Citation Index (ESCI)	Research & Experimental Medicine	V3T4Z	WOS:000218572400006	16537995	Bronze			2022-02-06	
J	Rutigliano, D; Egnor, MR; Priebe, CJ; McCormack, JE; Strong, N; Scriven, RJ; Lee, TK				Rutigliano, D; Egnor, MR; Priebe, CJ; McCormack, JE; Strong, N; Scriven, RJ; Lee, TK			Decompressive craniectomy in pediatric patients with traumatic brain injury with intractable elevated intracranial pressure	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	36th Annual Meeting of the American-Pediatric-Surgical-Association	MAY, 2005	Phoenix, AZ	Amer Pediat Surg Assoc		decompressive craniectomy; traumatic brain injury; cerebral perfusion pressure; intracranial pressure; children; adolescents	SEVERE HEAD-INJURY; AGGRESSIVE TREATMENT; CHILDREN; HYPERTENSION; CRANIOTOMY	Background: Care of pediatric traumatic brain injury (TBI) has placed emphasis on maximizing cerebral perfusion to prevent ischemia and reperfusion injury. A subset of patients with TBI will continue to have refractory intracranial pressure (ICP) elevation despite aggressive therapy including ventriculostomy, pentobarbital coma, hypertonic saline, and diuretics. Decompressive craniectomy (DC) is a controversial treatment of severe TBI. It is our hypothesis that DC can enhance survival and minimize secondary brain injury in this patient subset. Methods: Patients younger than 20 years treated at a level I regional trauma center between November 2001 and November 2004, who met inclusion criteria for the Brain Trauma Foundation TBI-trac clinical database were included. All patients with a mechanism of injury consistent with TBI and Glasgow Coma Scale score of less than 9 for at least 6 hours after resuscitation and who did not die in the emergency department are entered into a clinical database. Patients who arrived at the study hospital more than 24 hours after injury are excluded. Results: There were 30 patients with TBI identified. The mean Glasgow Coma Scale score at presentation was 8 with a range of 3 to 13. Six patients underwent DC for intractable elevated ICP. Of 6 patient's postoperative ICP, 5 were less than 20 mm Hg. One patient required a return to the operating room where further debridement of brain was performed. All patients who received a DC survived and were discharged to a TBI rehabilitation facility. Conclusion: Although this is a small sample, DC should be considered in patients with TBI with refractory elevated ICP. Long-term follow-up of this patient population should consist of neuropsychiatric evaluation in conjunction with measurement of social function. (c) 2006 Elsevier Inc. All rights reserved.	SUNY Stony Brook, Hlth Sci Ctr, Dept Surg, Div Pediat Surg, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Neurosurg, Stony Brook, NY 11794 USA		Lee, TK (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Surg, Div Pediat Surg, T-19,090, Stony Brook, NY 11794 USA.	tklee@notes.cc.sunysb.edu					ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GAAB MR, 1990, ACT NEUR S, V51, P326; Gower DJ, 1988, NEUROSURGERY, V90, P187; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Kunze E, 1998, ACT NEUR S, V71, P16; Langlois JA., 2004, TRAUMATIC BRAIN INJU; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PUTTS LH, 1980, INTRACRANIAL PRESSUR, V4, P5; Schwab S, 1997, NEUROLOGY, V48, P412, DOI 10.1212/WNL.48.2.412; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410	24	52	53	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	JAN	2006	41	1					83	87		10.1016/j.jpedsurg.2005.10.010			5	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pediatrics; Surgery	010JZ	WOS:000235189400023	16410113				2022-02-06	
J	Coelho, CA; Grela, B; Corso, M; Gamble, A; Feinn, R				Coelho, CA; Grela, B; Corso, M; Gamble, A; Feinn, R			Microlinguistic deficits in the narrative discourse of adults with traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; discovery; linguistic	CLOSED-HEAD-INJURY; ELICITATION TASK; MILD; ADOLESCENTS; COHESION	Background: Recent studies of microlinguistic impairments in the narrative discourse of adults with traumatic brain injury (TBI) have applied syntactic analyses, with some noting no deficits and others specific problems with sentence formulation. An alternative approach to examining the microlinguistic dysfunction in the discourse of individuals with TBI is through the use of propositional analysis. The advantage of propositional analysis is that it enables one to assess semantic complexity of utterances apart from sentence structure and grammaticality. Aims: The present study applied propositional analysis to the story narratives of participants with TBI and participants with no brain injury (NBI). Specifically, the mean number of propositions within a sentence was tallied, in other words the participants' ability to insert multiple ideas into single surface sentences. It was hypothesized that the participants with TBI would produce fewer propositions per sentence because of organizational problems than the participants with NBI, regardless of level of education. Methods and procedures: Two story narratives ( retelling and generation) previously elicited from the two participant groups ( TBI ( n = 53) and NBI ( n = 42)) were analysed. For each language sample, the number of propositions was tallied and divided by the number of T-units. The resulting number, the propositional complexity index (PCI), was the average number of predicates per sentence. Outcomes and results: Results indicated that the group with TBI produced significantly fewer propositions per T-unit. Conclusions: The present findings are in harmony with the notion that the participants with TBI studied presented with impairments of both micro- and macrolinguistic processes involved with the organization of semantic information in discourse. Clinical implications are discussed.	Univ Connecticut, Dept Commun Sci, Storrs, CT 06269 USA; Univ Connecticut, Ctr Hlth, Farmington, CT USA		Coelho, CA (corresponding author), Univ Connecticut, Dept Commun Sci, Unit 1085, Storrs, CT 06269 USA.	coelho@uconn.edu					Brownell, 1990, DISCOURSE ABILITY BR, P69, DOI 10.1007/978-1-4612-3262-9_4; CANNIZZARO MS, 2000, BRAIN INJURY, V14, P397; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Cohen J, 1977, STAT POWER ANAL BEHA; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; GLOSSER G, 1993, NARRATIVE DISCOURSE IN NEUROLOGICALLY IMPAIRED AND NORMAL AGING ADULTS, P191; Glosser G., 1990, BRAIN LANG, V40, P67; HAGAN C, 1980, REHABILITATION HEAD; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HOLLINGSHEAD A, 1972, UNPUB 4 FACTOR INDEX; Hughes DL., 1997, GUIDE NARRATIVE LANG; HUNT CEL, 1970, J NUCL MATER, V35, P134, DOI 10.1016/0022-3115(70)90040-1; Kamhi AG, 1992, BEST PRACTICES SCH S, P99; Kertesz A., 1982, W APHASIA BATTERY; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; KINTSCH W, 1994, HDB PSYCHOLINGUISTIC, P00721; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; Maths S, 1976, GERIATRIC PSYCHIAT; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P583; PARENTE R., 1996, RETRAINING COGNITION; Peach R. K., 1986, ANN CONV AM SPEECH L; Penn C, 1997, APHASIOLOGY, V11, P601, DOI 10.1080/02687039708248492; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow PC, 2000, BRAIN INJURY, V14, P397; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Ulatowska Hanna K., 1990, DISCOURSE ABILITY BR, P180, DOI 10.1007/978-1-4612-3262-9_8; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; WINTER P, 1976, BEAR FLY; WOLFOLK WB, 1992, B PSYCHONOMIC SOC, V30, P226; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745	36	52	53	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2005	19	13					1139	1145		10.1080/02699050500110678			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	983ZD	WOS:000233270000008	16286327				2022-02-06	
J	Goldstrohm, SL; Arffa, S				Goldstrohm, SL; Arffa, S			Preschool children with mild to moderate traumatic brain injury: An exploration of immediate and post-acute morbidity	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						traumatic brain injury; brain injury; head injury; pediatric neuropsychology; preschool children; TBI	CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL SEQUELAE; SEVERITY; ADOLESCENTS; PREDICTORS; PERFORMANCE; RECOVERY; MEMORY; ADULTS; OLDER	This study explored premorbid, neurocognitive, behavioral, and familial factors in preschoolers, ages 3-6, who experienced a mild to moderate traumatic brain injury (TBI). Twenty-nine children with TBI, 33 children with mild to moderate injuries to other body regions, and 34 non-injured children participated in the study. Neuropsychological assessments and behavioral measures were administered at the time of hospitalization and 6 months later. In comparison to the non-injury children, preschool-aged children with TBI had higher rates of premorbid behavior difficulties, lower premorbid cognitive functioning, and poorer development of pre-academic skills. In addition, parents of children with TBI reported greater situational issues and life stressors than parents of children in the non-injured group. Some neurocognitive recovery was evident in the TBI group, but no differences were recognized in behavioral and family measures at the 6-month follow-up. This study emphasizes the relative effects of premorbid characteristics in later practice of preschool children who sustain TBI. (c) 2005 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA; Watson Inst, Pittsburgh, PA 15143 USA		Goldstrohm, SL (corresponding author), Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, 3811 Ohara St, Pittsburgh, PA 15213 USA.	goldstrohmsl@upmc.edu					Abidin, 1995, PARENTING STRESS IND; Achenbach T. M., 1986, CHILD BEHAV CHECKLIS; Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; ARFFA S, 1995, HEAD INJURY THROUGH; ARFFA S, 1998, PEDIAT NEUROPSYCHIAT; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Bracken B.A., 1984, BRACKEN BASIC CONCEP; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, PSYCHOL MED, V11, P1227; Conners C. K., 1997, CONNERS GLOBAL INDEX; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P279; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; GOTSCHALL CS, 1993, PEDIAT TRAUMA PREVEN, P16; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Kolb B., 1995, BRAIN PLASTICITY BEH; Korkman M, 1997, NEPSY; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1979, CHILD BRAIN, V5, P281; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MATHENY AP, 1987, ANN PROGR CHILD PSYC; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; Paris R., 1974, CLIN NEUROPSYCHOLOGY, P179; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; RUTTER M, 1983, HEAD INJURY DEV NEUR; SEMRUDCLIKEMAN M, 2001, TRAUMATIC BRAIN INJU; SHAFFER D, 1975, OUTCOME SEVERE DAMAG, P191; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; TAYLOR HG, 1995, TRAUMATIC HEAD INJUR; Thorndike R. L., 1986, STANFORD BINET INTEL; TRICKETT PK, 1991, DEV PSYCHOL, V27, P148, DOI 10.1037/0012-1649.27.1.148; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; [No title captured]	57	52	52	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2005	20	6					675	695		10.1016/j.acn.2005.02.005			21	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	950HW	WOS:000230849200001	15967630	Bronze			2022-02-06	
J	Martin, I; McDonald, S				Martin, I; McDonald, S			Evaluating the causes of impaired irony comprehension following traumatic brain injury	APHASIOLOGY			English	Article							CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; FRONTAL-LOBE; LINGUISTIC HUMOR; MIND; COMMUNICATION; CHILDREN; ABILITY; ADOLESCENTS; DEFICITS	Background: Individuals with traumatic brain injury (TBI) are known to have difficulty in understanding non-literal language devices such as irony. There are at least two possible explanations for poor irony comprehension following TBI; first, deficits might be caused by a specific impairment to theory of mind (ToM) and, second, deficits could be attributed to more general impairment in executive functioning (EF). Aims: This study aimed to evaluate the role of ToM and EF in the ability to comprehend non-literal ironic jokes. Methods & Procedures: Participants were 16 individuals who had sustained a TBI and 16 age- and demographic-matched controls. The ability to make inferences about mental states was compared to inferential reasoning capacity more generally. Participants were also assessed on other aspects of EF thought to contribute to inference making (working memory, concept formation, and fluency). The extent to which scores on theses tasks were associated with participants' ability to comprehend ironic jokes was assessed using correlational and regression analyses. Outcomes & Results: Participants with TBI were significantly impaired on tasks measuring both ToM and EF. ToM was not significantly associated with irony comprehension. Instead, inferential reasoning, more broasdly defined, demonstrated the strongest association. None of the component EF tasks were associated with irony comprehension. Conclusion: The results of this study do not support the theory that a specific impairment to ToM causes poor irony comprehension in TBI. In contrast, general inferential reasoning was a strong and significant predictor.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ADAMOVICH BLB, 1991, COGNITIVE REHABILITA; Bach Kent, 1994, FDN SPEECH ACT THEOR, P267; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; BARONCOHEN S, 1994, BRIT J PSYCHIAT, V165, P640, DOI 10.1192/bjp.165.5.640; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Braun C M, 1989, Brain Inj, V3, P345, DOI 10.3109/02699058909004559; Brownell H, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P309; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Courtin C, 1998, PSYCHOLOGICAL PERSPECTIVES ON DEAFNESS, VOL 2, P79; DAVIS HL, 1995, AUST J PSYCHOL, V47, P25, DOI 10.1080/00049539508258765; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J AUTISM DEV DISORD, V31, P47, DOI 10.1023/A:1005661613288; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Docking K, 1999, BRAIN INJURY, V13, P953; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Gibbs RW, 1999, BRAIN LANG, V68, P466, DOI 10.1006/brln.1999.2123; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Gordon ACL, 1998, J EXP CHILD PSYCHOL, V68, P70, DOI 10.1006/jecp.1997.2423; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Grice H. P., 1975, SYNTAX SEMANTICS, P41; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HAVERKATE H, 1990, J PRAGMATICS, V14, P77, DOI 10.1016/0378-2166(90)90065-L; JANOWSKY JS, 1989, NEUROPSYCHOLOGIA, V27, P1043, DOI 10.1016/0028-3932(89)90184-X; JOANETTE Y, 1990, DISCOURSE ABILITY BR; Keenan T, 1998, NEW ZEAL J PSYCHOL, V27, P36; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; Levinson Stephen., 1983, PRAGMATICS; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Martin I, 2004, J AUTISM DEV DISORD, V34, P311, DOI 10.1023/B:JADD.0000029553.52889.15; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MCDONALD S, 2003, NEUROPSYCHOL REHABIL, V14, P285; MENNEL HD, 1997, SEVERE HEAD INJURIES, P19; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Perkins MR, 1998, J PRAGMATICS, V29, P291, DOI 10.1016/S0378-2166(97)00055-6; Peterson CC, 1999, PSYCHOL SCI, V10, P126, DOI 10.1111/1467-9280.00119; Peterson CC, 2000, MIND LANG, V15, P123, DOI 10.1111/1468-0017.00126; PRIGATANO GP, 1986, NEUROPSYCHOGICAL REH; Russell, 1997, AUTISM EXECUTIVE DIS; Russell J, 1999, J CHILD PSYCHOL PSYC, V40, P859, DOI 10.1017/S0021963099004229; Russell J., 1997, AUTISM EXECUTIVE DIS, P256; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; SPERBER D, 1984, J EXP PSYCHOL GEN, V113, P130, DOI 10.1037/0096-3445.113.1.130; SPERBER D, 1987, BEHAV BRAIN SCI, V10, P697, DOI 10.1017/S0140525X00055345; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STUSS DT, 1993, DEMENTIA, V4, P220, DOI 10.1159/000107326; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Wilson D., 1986, RELEVANCE COMMUNICAT; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; [No title captured]	66	52	54	1	24	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	AUG	2005	19	8					712	730		10.1080/02687030500172203			19	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	963NT	WOS:000231811700002					2022-02-06	
J	Chesler, M				Chesler, M			Failure and function of intracellular pH regulation in acute hypoxic-ischemic injury of astrocytes	GLIA			English	Article						lactate; acidosis; Na+-H+ exchange; Na+-Ca2+ exchange; KB-R7943; HOE-694	EXTRACELLULAR CALCIUM ACTIVITY; DIFFUSE CEREBRAL-ISCHEMIA; BRAIN LACTIC-ACIDOSIS; HIPPOCAMPAL-NEURONS; GLUTAMATE NEUROTOXICITY; GLUCOSE PRETREATMENT; NA+-CA2+ EXCHANGER; REPERFUSION INJURY; TRANSIENT HYPOXIA; RAT HIPPOCAMPUS	Astrocytes can die rapidly following ischemic and traumatic injury to the CNS. Brain acid-base status has featured prominently in theories of acute astrocyte injury. Failure of astrocyte pH regulation can lead to cell loss under conditions of severe acidosis. By contrast, the function of astrocyte pH regulatory mechanisms appears to be necessary for acute cell death following the simulation of transient ischemia and reperfusion. Severe lactic acidosis, and the failure of astrocytes to regulate intracellular pH (pH(i)) have been emphasized in brain ischemia under hyperglycemic conditions. Direct measurements of astrocyte pHi after cardiac arrest demonstrated a mean pH(i) of 5.3 in hyperglycemic rats. In addition, both in vivo and in vitro studies of astrocytes have shown similar pH levels to be cytotoxic. Whereas astrocytes exposed to hypoxia alone may require 12-24 h to die, acidosis has been found to exacerbate and speed hypoxic loss of these cells. Recently, astrocyte cultures were exposed to hypoxic, acidic media in which the large ionic perturbations characteristic of brain ischemia were simulated. Upon return to normal saline ("reperfusion"), the majority of cells died. This injury was dependent on external Ca2+ and was prevented by inhibition of reversed Na+-Ca+ exchange, blockade of Na+-H+ exchange, or by low pH of the reperfusion saline. These data suggested that cytotoxic elevation of [Ca2+](i) occurred during reperfusion due to a sequence of activated Na+-H+ exchange, cytosolic Na+ loading, and resultant reversal of Na+-Ca2+ exchange. The significance of this reperfusion model to ischemic astrocyte injury in vivo is discussed. (c) 2005 Wiley-Liss, Inc.	NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Dept Neurosurg, New York, NY 10016 USA		Chesler, M (corresponding author), NYU, Sch Med, Dept Physiol & Neurosci, 550 1St Ave, New York, NY 10016 USA.	mitch.chesler@med.nyu.edu		Chesler, Mitchell/0000-0002-3189-8234			Agrawal SK, 1996, J NEUROSCI, V16, P545; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BALENTINE JD, 1978, LAB INVEST, V39, P236; BALLANYI K, 1994, NEUROREPORT, V6, P33, DOI 10.1097/00001756-199412300-00010; Baxter KA, 1996, J PHYSIOL-LONDON, V493, P457, DOI 10.1113/jphysiol.1996.sp021396; Bevensee MO, 1997, J GEN PHYSIOL, V110, P453, DOI 10.1085/jgp.110.4.453; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; Bondarenko A, 2005, GLIA, V49, P143, DOI 10.1002/glia.20107; Bondarenko A, 2001, GLIA, V34, P134, DOI 10.1002/glia.1048; Bondarenko A, 2001, GLIA, V34, P143, DOI 10.1002/glia.1049; BURTON RF, 1978, RESP PHYSIOL, V33, P51, DOI 10.1016/0034-5687(78)90083-X; BUSA WB, 1984, AM J PHYSIOL, V246, pR409, DOI 10.1152/ajpregu.1984.246.4.R409; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; CHESLER M, 1991, BRAIN RES, V556, P71, DOI 10.1016/0006-8993(91)90548-A; CHESLER M, 1994, EXP NEUROL, V125, P93, DOI 10.1006/exnr.1994.1011; CHESLER M, 1987, AM J PHYSIOL, V253, pR666, DOI 10.1152/ajpregu.1987.253.4.R666; CHESLER M, 1989, J NEUROSCI, V9, P2011; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FRIEDE RL, 1961, EXP NEUROL, V4, P197, DOI 10.1016/0014-4886(61)90041-3; GARCIA JH, 1993, AM J PATHOL, V142, P623; Gido G, 1997, STROKE, V28, P206, DOI 10.1161/01.STR.28.1.206; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; Giffard RG, 2000, J NEUROSCI, V20, P1001, DOI 10.1523/JNEUROSCI.20-03-01001.2000; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; HANSEN AJ, 1988, NEUROCHEM PATHOL, V9, P195; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; Hertz L, 1975, Int Rev Neurobiol, V18, P141, DOI 10.1016/S0074-7742(08)60035-5; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P430, DOI 10.1038/jcbfm.1984.62; HOCHACHKA PW, 1983, SCIENCE, V219, P1391, DOI 10.1126/science.6298937; Hulse RE, 2001, GLIA, V33, P169, DOI 10.1002/1098-1136(200102)33:2<169::AID-GLIA1016>3.0.CO;2-B; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; Karmazyn M, 1999, ANN NY ACAD SCI, V874, P326, DOI 10.1111/j.1749-6632.1999.tb09248.x; KELLEHER JA, 1993, STROKE, V24, P855, DOI 10.1161/01.STR.24.6.855; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMLEE MH, 1992, GLIA, V5, P56, DOI 10.1002/glia.440050109; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KRAIG RP, 1990, J CEREBR BLOOD F MET, V10, P104, DOI 10.1038/jcbfm.1990.13; KRAIG RP, 1985, BRAIN RES, V342, P281, DOI 10.1016/0006-8993(85)91127-8; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; KRAIG RP, 1986, AM J PHYSIOL, V250, pR348, DOI 10.1152/ajpregu.1986.250.3.R348; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; Lascola C, 1997, NEUROSCI BIOBEHAV R, V21, P143, DOI 10.1016/S0149-7634(96)00004-8; Levitsky J, 1998, J CLIN PHARMACOL, V38, P887, DOI 10.1002/j.1552-4604.1998.tb04383.x; LEYBAERT L, 1994, EXP BRAIN RES, V100, P369, DOI 10.1007/BF02738397; LIJIMA T, 1992, J CEREB BLOOD FLOW M, V12, P727; Lukaszevicz AC, 2002, J CEREBR BLOOD F MET, V22, P289, DOI 10.1097/00004647-200203000-00006; Matsuda T, 2001, J PHARMACOL EXP THER, V298, P249; Matsuda T, 1996, EUR J NEUROSCI, V8, P951, DOI 10.1111/j.1460-9568.1996.tb01582.x; McDonald JW, 1998, J NEUROSCI, V18, P6290; MELLER A, 1967, ORGANOMET CHEM REV, V2, P1; MELLERGARD PE, 1991, NEUROREPORT, V2, P695, DOI 10.1097/00001756-199111000-00016; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; MORIYA T, 1994, J NEUROTRAUM, V11, P255, DOI 10.1089/neu.1994.11.255; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; MYERS RE, 1977, ARCH NEUROL-CHICAGO, V34, P65, DOI 10.1001/archneur.1977.00500140019003; NEDERGAARD M, 1991, J NEUROSCI, V11, P2489; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581, DOI 10.1152/ajpregu.1991.260.3.R581; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; NORENBERG MD, 1987, J NEUROPATH EXP NEUR, V46, P154, DOI 10.1097/00005072-198703000-00004; Payne RS, 2003, BRAIN RES, V971, P9, DOI 10.1016/S0006-8993(03)02276-5; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; PETITO CK, 1982, ANN NEUROL, V11, P510, DOI 10.1002/ana.410110511; Phillis JW, 1999, BRAIN RES, V839, P199, DOI 10.1016/S0006-8993(99)01705-9; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; PLUTA R, 1987, RESUSCITATION, V15, P267, DOI 10.1016/0300-9572(87)90005-0; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Rose CR, 1998, J NEUROSCI, V18, P3554; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Schurr A, 2002, NEUROCHEM INT, V41, P1, DOI 10.1016/S0197-0186(01)00142-5; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; Sheldon C, 2002, J NEUROPHYSIOL, V87, P2209, DOI 10.1152/jn.2002.87.5.2209; SHEN H, 1995, NEUROSCI LETT, V185, P115, DOI 10.1016/0304-3940(94)11238-E; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P253, DOI 10.1038/jcbfm.1985.32; SMITH ML, 1986, J CEREBR BLOOD F MET, V6, P574, DOI 10.1038/jcbfm.1986.104; SOCHOCKA E, 1994, BRAIN RES, V638, P21, DOI 10.1016/0006-8993(94)90628-9; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; STYS PK, 1992, J NEUROSCI, V12, P430; Swanson RA, 1997, GLIA, V21, P142, DOI 10.1002/(SICI)1098-1136(199709)21:1<142::AID-GLIA16>3.0.CO;2-S; SWANSON RA, 1995, J CEREBR BLOOD F MET, V15, P417, DOI 10.1038/jcbfm.1995.52; THOMAS RC, 1984, J PHYSIOL-LONDON, V354, pP3; TOMBAUGH GC, 1990, BRAIN RES, V506, P343, DOI 10.1016/0006-8993(90)91277-N; Trafton J, 1996, BRAIN RES, V731, P122, DOI 10.1016/0006-8993(96)00488-X; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; Yao H, 2001, AM J PHYSIOL-CELL PH, V281, pC1205, DOI 10.1152/ajpcell.2001.281.4.C1205; Ying WH, 1999, J NEUROCHEM, V73, P1549, DOI 10.1046/j.1471-4159.1999.0731549.x; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1982, BRAIN RES, V253, P115, DOI 10.1016/0006-8993(82)90678-3; YU ACH, 1989, J CEREBR BLOOD F MET, V9, P20, DOI 10.1038/jcbfm.1989.3; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	99	52	54	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUN	2005	50	4			SI		398	406		10.1002/glia.20141			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	922WW	WOS:000228871600011	15846798				2022-02-06	
J	Ratcliff, G; Colantonio, A; Escobar, M; Chase, S; Vernich, L				Ratcliff, G; Colantonio, A; Escobar, M; Chase, S; Vernich, L			Long-term survival following traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						traumatic brain injury; mortality; standardized mortality ratio; death rate; long-term survival	HEAD INJURIES; UNITED-STATES; ASSOCIATION; SEVERITY; TRENDS; DEATH	Purpose. The study used a retrospective cohort design to establish long-term mortality rates and predictors of mortality for persons after moderate to severe traumatic brain injury (TBI). Method. Consecutive records of persons with moderate to severe TBI who were discharged from a large rehabilitation hospital in Pittsburgh, Pennsylvania in the years 1974 - 1984, 1988 and 1989 were reviewed. Results. Six hundred and forty-two eligible individuals were identified and mortality was ascertained up to 24 years post injury. One hundred and twenty-eight of these individuals were found to be deceased. Poisson regression analyses revealed at least a 2-fold increased risk for mortality compared to the general population. Pre-injury characteristics and levels of disability at discharge from in- patient rehabilitation were among the strongest predictors of mortality. Conclusions. These data constitute evidence for premature death in the post-acute TBI population following a moderate to severe head injury and are discussed in relation to other research in the area.	Neuropsychol HealthSouth Harmarville Rehabil Hosp, Pittsburgh, PA 15240 USA; Univ Toronto, Dept Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Working Order, Pittsburgh, PA USA		Ratcliff, G (corresponding author), Neuropsychol HealthSouth Harmarville Rehabil Hosp, POB 11460 Guys Run Rd, Pittsburgh, PA 15240 USA.			Escobar, Michael/0000-0001-9055-4709; Colantonio, Angela/0000-0003-2094-4765	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33 AGO5856-01A1] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34740-2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33AG005856] Funding Source: NIH RePORTER		Agresti A., 2019, INTRO CATEGORICAL DA; Baguley I, 2000, BRAIN INJURY, V14, P505; Breslow N., 1980, STAT METHODS CANC RE, V1; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; *COUNC CLIN CLASS, 1980, INT CLASS DIS 9 REV; Das-Gupta R, 2002, DISABIL REHABIL, V24, P654, DOI 10.1080/09638280110109282; Dischinger PC, 2001, J TRAUMA, V51, P877, DOI 10.1097/00005373-200111000-00009; FAHY TJ, 1967, LANCET, V2, P475; KINGMA J, 1992, 9201; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; *PA DEP HLTH BUR H, 1996, PENNS VIT STAT TABL; *SAS I INC, 1994, SAS STAT SOFTW REL 6; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; [No title captured]	25	52	54	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1464-5165			DISABIL REHABIL	Disabil. Rehabil.	MAR	2005	27	6					305	314		10.1080/09638280400018338			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	920CL	WOS:000228666400003	16040532				2022-02-06	
J	Genovese, T; Mazzon, E; Muia, C; Patel, NSA; Threadgill, MD; Bramanti, P; De Sarro, A; Thiemermann, C; Cuzzocrea, S				Genovese, T; Mazzon, E; Muia, C; Patel, NSA; Threadgill, MD; Bramanti, P; De Sarro, A; Thiemermann, C; Cuzzocrea, S			Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							ADP-RIBOSE POLYMERASE; FACTOR-KAPPA-B; NITRIC-OXIDE; POTENT INHIBITOR; BRAIN-INJURY; OXIDATIVE STRESS; RAT MODEL; ACTIVATION; SYNTHETASE; 5-AMINOISOQUINOLINONE	Poly(ADP-ribose) polymerase ( PARP), a nuclear enzyme activated by strand breaks in DNA, plays an important role in the tissue injury associated with stroke and neurotrauma. The aim of our study was to evaluate the therapeutic efficacy of in vivo inhibition of PARP in an experimental model of spinal cord trauma, which was induced by the application of vascular clips ( force of 24g) to the dura via a four-level T5-T8 laminectomy. Spinal cord injury in mice resulted in severe trauma characterized by edema, neutrophil infiltration ( measured as an increase in myeloperoxidase activity), and apoptosis ( measured by terminal deoxynucleotidyltransferase-mediated UTP end labeling coloration). Infiltration of spinal cord tissue with neutrophils was associated with a marked increase in immunoreactivity for poly(ADP-ribose) ( PAR), index of PARP activation, in the spinal cord tissue. These inflammatory events were associated with the activation of nuclear factor-kappaB (NF-kappaB) at 4 h after spinal cord damage. Treatment of the mice with the PARP inhibitors 3-aminobenzamide (3-AB) or 5-aminoisoquinolinone (5-AIQ) significantly reduced the degree of 1) spinal cord inflammation and tissue injury ( histological score), 2) PAR formation, 3) neutrophil infiltration, and 4) apoptosis. Treatment with these PARP inhibitors also reduced DNA binding of NF-kappaB and inhibitory kappaB degradation. In a separate set of experiments, we have also demonstrated that PARP inhibitors significantly ameliorated the recovery of limb function ( evaluated by motor recovery score). Taken together, our results clearly demonstrate that treatment with PARP inhibitors reduces the development of inflammation and tissue injury events associated with spinal cord trauma.	Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Torre Biol, I-98100 Messina, Italy; Queen Mary Univ London, William Harvey Res Inst, Ctr Expt Med Nephrol & Crit Care, London, England; Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; Univ Messina, Sch Med, Ctr Studio & Trattamento Neurolesi Lungodegenti, Messina, Italy		Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Torre Biol, Policlin Univ Via C Valeria, I-98100 Messina, Italy.	salvator@unime.it	Threadgill, Michael/C-3925-2009; Mazzon, Emanuela/AAL-4334-2020; Bramanti, Placido/K-5117-2016	Patel, Nimesh/0000-0001-9280-5815; GENOVESE, Tiziana/0000-0002-3335-7327; mazzon, emanuela/0000-0002-5073-717X; Thiemermann, Christoph/0000-0003-4228-9722			Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Besson VC, 2003, FREE RADICAL RES, V37, P1201, DOI 10.1080/10715760310001612568; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Chatterjee PK, 1999, KIDNEY INT, V56, P973, DOI 10.1046/j.1523-1755.1999.00644.x; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Cuzzocrea S, 2002, BRIT J PHARMACOL, V135, P496, DOI 10.1038/sj.bjp.0704463; Cuzzocrea S, 2002, BIOCHEM PHARMACOL, V63, P293, DOI 10.1016/S0006-2952(01)00864-4; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; Di Paola R, 2004, EUR J PHARMACOL, V492, P203, DOI 10.1016/j.ejphar.2004.03.033; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hauschildt S, 1997, ADV EXP MED BIOL, V419, P249; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; Li F, 2004, DIABETOLOGIA, V47, P710, DOI 10.1007/s00125-004-1356-0; Mao JR, 1997, PAIN, V72, P355, DOI 10.1016/S0304-3959(97)00063-8; Mazzon E, 2002, SHOCK, V18, P434, DOI 10.1097/00024382-200211000-00008; McDonald MC, 2000, BRIT J PHARMACOL, V130, P843, DOI 10.1038/sj.bjp.0703391; Mota-Filipe Helder, 2002, Med Sci Monit, V8, pBR444; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; POPOVICH PG, 1994, BRAIN RES, V633, P348, DOI 10.1016/0006-8993(94)91560-1; Schwartz MD, 1996, CRIT CARE MED, V24, P1285, DOI 10.1097/00003246-199608000-00004; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2003, GLIA, V41, P105, DOI 10.1002/glia.10137; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; SUTO MJ, 1991, ANTI-CANCER DRUG DES, V6, P107; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo G, 2002, CIRC RES, V90, P100, DOI 10.1161/hh0102.102657; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wayman N, 2001, EUR J PHARMACOL, V430, P93, DOI 10.1016/S0014-2999(01)01359-0; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Zingarelli B, 2003, EUR J PHARMACOL, V469, P183, DOI 10.1016/S0014-2999(03)01726-6; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	44	52	60	0	1	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	FEB	2005	312	2					449	457		10.1124/jpet.104.076711			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	888IJ	WOS:000226367100005	15452194				2022-02-06	
J	Klinger, L				Klinger, Lisa			Occupational Adaptation: Perspectives of People with Traumatic Brain Injury	JOURNAL OF OCCUPATIONAL SCIENCE			English	Article						Traumatic brain injury; Occupational adaptation; Qualitative research; Self-identity		This paper describes a qualitative study carried out to understand the process of occupational adaptation after traumatic brain injury. Seven people, injured two to seventeen years previously, were interviewed. Transcripts were analysed using the constant comparative method, with peer review, journaling, and a member-checking group to maximize truthfulness. Participants described experiencing a change in self-identity following injury that was related to, and influenced, occupational adaptation. Self-identity and engagement in occupation were closely related. Acceptance of the new self was fundamental to successful occupational adaptation. Participants also shifted environmental contexts of doing to reflect their new persona. Reframing self-identity was thus an important aspect of participants' rehabilitation. These findings resonate with other qualitative studies with brain injury survivors, theories of occupational adaptation, and social psychological perspectives. Yet, the literature on brain injury rehabilitation rarely discusses the need to address self-identity. Occupational science can play an important role by integrating these bodies of literature.	[Klinger, Lisa] Univ Western Ontario, Elborn Coll, Fac Hlth Sci, Sch Occupat Therapy, London, ON N6G 1H1, Canada		Klinger, L (corresponding author), Univ Western Ontario, Elborn Coll, Fac Hlth Sci, Sch Occupat Therapy, London, ON N6G 1H1, Canada.	lklinger@uwo.ca					AquanAssee A, 2003, 2 LIFE 2 CHANCE TEAC; Blundon G, 2000, Can J Occup Ther, V67, P184; Boylan E, 1991, WOMEN AND DISABILITY; Brown N., 1997, J COGNITIVE REHA JUL, P20; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Charmaz K, 2002, OTJR-OCCUP PARTICI H, V22, p31S, DOI 10.1177/15394492020220S105; Christiansen CH, 1999, AM J OCCUP THER, V53, P547, DOI 10.5014/ajot.53.6.547; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Dirette DK, 1999, J HEAD TRAUMA REHAB, V14, P595, DOI 10.1097/00001199-199912000-00008; Holt B, 2001, MONARCH          FEB; Hutchinson SHE, 1996, THESIS; Kielhofner G, 2002, MODEL HUMAN OCCUPATI; Kielhofner G., 2003, WILLARD SPACKMANS OC, P212; Lee S S, 2001, Can J Occup Ther, V68, P41; Lincoln Yvonna S., 1985, NATURALISTIC INQUIRY; Llewellyn G., 2000, CLIN RES OCCUPATIONA, P133; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; McGregor K., 2001, MONARCH          MAR; Myers J., 1989, HIAT HEADLINES, P2; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Osborn C. L., 1998, MY HEAD DOCTORS OWN; PADILLA R, 2003, THE AMERICAN JOURNAL, V57, P413; Rudman DL, 2002, J OCCUP SCI, V9, P12, DOI DOI 10.1080/14427591.2002.9686489; SCHKADE J, 1992, THE AMERICAN JOURNAL, V46, P829; SCHULTZ S, 1992, AM J OCCUP THER, V46, P917, DOI 10.5014/ajot.46.10.917; Schultz S., 2003, WILLARD SPACKMANS OC, P220; SCHWARTZ SM, 1995, THE AMERICAN JOURNAL, V49, P655; Scollard J., 2001, MONARCH          JAN; SPENCER JC, 1996, THE AMERICAN JOURNAL, V50, P526; UNRUH AM, 2004, CANADIAN J OCCUPATIO, V5, P290; Wilcock A. A., 1999, AUST OCCUP THER J, V46, P1, DOI [10.1046/j.1440-1630.1999.00174.x, DOI 10.1177/000841749806500501]; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU; Zemke R., 1996, OCCUPATIONAL SCI EVO	34	52	53	0	0	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1442-7591			J OCCUP SCI	J. Occup. Sci.		2005	12	1					9	16		10.1080/14427591.2005.9686543			8	Social Sciences, Interdisciplinary	Emerging Sources Citation Index (ESCI)	Social Sciences - Other Topics	V75PW	WOS:000211857500002					2022-02-06	
J	Coles, JP; Steiner, LA; Johnston, AJ; Fryer, TD; Coleman, MR; Smieleweski, P; Chatfield, DA; Aigbirhio, F; Williams, GB; Boniface, S; Rice, K; Clark, JC; Pickard, JD; Menon, DK				Coles, JP; Steiner, LA; Johnston, AJ; Fryer, TD; Coleman, MR; Smieleweski, P; Chatfield, DA; Aigbirhio, F; Williams, GB; Boniface, S; Rice, K; Clark, JC; Pickard, JD; Menon, DK			Does induced hypertension reduce cerebral ischaemia within the traumatized human brain?	BRAIN			English	Article						ischaemia; hypertension; cerebral perfusion pressure; positron emission tomography; head injury	POSITRON-EMISSION-TOMOGRAPHY; BLOOD-FLOW; ENERGY-METABOLISM; OXYGEN-METABOLISM; NOREPINEPHRINE; INJURY; PERFUSION; DOPAMINE; O-15; PHENYLEPHRINE	Recent changes in published guidelines for the management of patients with severe head injury are based on data showing that aggressive maintenance of cerebral perfusion pressure (CPP) can worsen outcome due to extracranial complications of therapy. However, it remains unclear whether CPP augmentation could reduce cerebral ischaemia, a finding which might prompt the search for CPP augmentation protocols that avoid these extracranial complications. We studied 10 healthy volunteers and 20 patients within 6 days of closed head injury. All subjects underwent imaging of cerebral blood flow (CBF), blood volume (CBV), oxygen metabolism (CMRO2) and oxygen extraction fraction (OEF) using O-15 PET. In addition, for patients, the EEG power ratio index (PRI), burst suppression ratio and somatosensory evoked potentials (SEP) were obtained and CPP was increased from 68 +/- 4 to 90 +/- 4 mmHg using an infusion of norepinephrine and measurements were repeated. Following elevation of CPP, CBF and CBV were increased and CMRO2 and OEF were reduced (P < 0.001 for all comparisons). Regions with a reduction in CMRO2 were associated with the greatest reduction in OEF (r(2) = 0.3; P < 0.0001). Although CPP elevation produced a significant fall in the ischaemic brain volume (IBV) (from 15 +/- 16 to 5 +/- 4 ml; P < 0.01) and improved flow metabolism coupling, the IBV was small and clinically insignificant in the majority of these patients. However, the reduction in IBV was directly related to the baseline IBV (r(2) = 0.97; P < 0.001) and patients with large baseline IBV showed substantial and clinically significant reductions. CPP augmentation increased the EEG PRI (5.0 +/- 1.5 versus 4.3 +/- 1.4, P < 0.01), implying an overall decrease in neural activity, but these changes did not correlate with the reduction in CMRO2 and there was no change in SEP cortical amplitude (N20-P27). These data provide support for recent changes in recommended CPP levels for head injury management across populations of patients with significant head injury. However, they do not provide guidance on whether the intervention may be more appropriate at earlier stages after injury, or in patients selected because of high baseline IBV. It also remains unclear whether CPP values below 65 mmHg can be safely used in this population. Clarification of the significance of a reduction in CMRO2 and neuronal electrical function will require further study.	Addenbrookes Hosp, Dept Clin Neurophysiol, Cambridge CB2 2QQ, England; Univ Cambridge, Div Anaesthesia, Cambridge, England; Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge, England; Univ Cambridge, Dept Neurosurg, Cambridge, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England		Menon, DK (corresponding author), Addenbrookes Hosp, Dept Clin Neurophysiol, Box 93, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019; Rice, Kenneth M/A-4150-2013	Rice, Kenneth M/0000-0001-5779-4495; Coles, Jonathan/0000-0003-4013-679X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390] Funding Source: UKRI		BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Berridge CW, 1999, NEUROSCIENCE, V93, P1263, DOI 10.1016/S0306-4522(99)00276-6; Berridge CW, 1996, J NEUROSCI, V16, P7010; BONVALLET M, 1954, ELECTROEN CLIN NEURO, V6, P119, DOI 10.1016/0013-4694(54)90011-5; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 2003, GUID CER PERF PRESS; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; CORREIA JA, 1985, J CEREBR BLOOD F MET, V5, P591, DOI 10.1038/jcbfm.1985.88; DAHLGREN N, 1980, BRAIN RES, V184, P143, DOI 10.1016/0006-8993(80)90593-4; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; Gibbs EL, 1942, J BIOL CHEM, V144, P325; HERSCOVITCH P, 1983, J CEREBR BLOOD F MET, V3, P407, DOI 10.1038/jcbfm.1983.66; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; JENNETT B, 1975, LANCET, V1, P480; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; KUSCHINSKY W, 1983, PFLUG ARCH EUR J PHY, V398, P134, DOI 10.1007/BF00581061; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; LEBRUNGRANDIE P, 1983, ARCH NEUROL-CHICAGO, V40, P230, DOI 10.1001/archneur.1983.04050040060010; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483, DOI 10.1152/ajplegacy.1976.231.2.483; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mauguiere F, 1999, EEG CL N SU, P255; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Myburgh JA, 2001, INTENS CARE MED, V27, P276, DOI 10.1007/s001340000793; NAGATA K, 1989, ELECTROEN CLIN NEURO, V72, P16, DOI 10.1016/0013-4694(89)90027-8; PHELPS ME, 1979, J NUCL MED, V20, P328; Robertson C S, 1995, New Horiz, V3, P410; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Sebban C, 1999, BRIT J PHARMACOL, V128, P1045, DOI 10.1038/sj.bjp.0702894; Smielewski Peter, 1800, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Stocchetti N, 1998, ACT NEUR S, V71, P162; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; SUBBARAO KV, 1991, J NEUROSCI RES, V28, P399, DOI 10.1002/jnr.490280312; Talairach J., 1988, COPLANAR STEREOTAXIC; Talmor D, 1998, ANESTH ANALG, V87, P574, DOI 10.1097/00000539-199809000-00014; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P457; TUOR UI, 1986, AM J PHYSIOL, V251, pH824, DOI 10.1152/ajpheart.1986.251.4.H824; *WELLC DEP IM NEUR, 1999, STAT PAR MAPP SPM99	49	52	55	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2004	127		11				2479	2490		10.1093/brain/awh268			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	865LD	WOS:000224703700011	15456706	Bronze			2022-02-06	
J	Fromm, L; Heath, DL; Vink, R; Nimmo, AJ				Fromm, L; Heath, DL; Vink, R; Nimmo, AJ			Magnesium attenuates post-traumatic depression/anxiety following diffuse traumatic brain injury in rats	JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION			English	Article						depression; brain magnesium; neurotrauma; antidepressants; post-traumatic stress	SYMPTOMS; SEQUELAE; ANXIETY	Objective: Magnesium (Mg) declines after traumatic brain injury (TBI), a decline believed associated with ensuing neuronal cell death and subsequent functional impairment. While Mg's effects on motor and cognitive deficits following TBI have been well studied, few studies have addressed post-traumatic depression as an outcome parameter, despite its being a major clinical problem with an incidence of between 6 and 77%. We investigated the incidence of post-traumatic depression/anxiety in an animal model of diffuse TBI, and explored the use of magnesium sulfate (MgSO4) as an interventional treatment. Methods: Diffuse TBI was induced in 32 anesthetized, adult, male Sprague-Dawley rats, using the 2 in impact-acceleration model of injury. At 30 min after injury, half of the rats received 250 mumol/kg i.v.. MgSO4; the other half served as non-treated controls. Before and for 6 weeks after injury, the open-field, spontaneous activity test was used to determine post-traumatic depression/anxiety relative to pre-injury. In this test, animals are placed in a I-meter square box with 100 squares marked on the base. The number of squares entered in a 5-min period is recorded. Incidence of post-traumatic depression/anxiety was defined as the number of animals demonstrating a reduction in spontaneous activity to less than 100 squares in 5 min. Prior to injury, rats typically entered a mean of 201 +/- 12 (SEM) squares over a 5 min observation period. Results: At I week after injury, non-treated animals had a mean core of 62 +/- 13. The incidence of post-traumatic depression/anxiety in these animals was 61%, which is similar to that observed clinically. In contrast, animals treated with MgSO4 had a mean activity score of 144 +/- 23 at I week after TBI and an incidence of depression/anxiety of less than 30%. The significant difference between groups persisted for the entire 6-week observation period. Conclusions: The improvement in post-traumatic depression/anxiety conferred by Mg adds further weight to available evidence of Mg's benefit as a neuroprotective agent after TBI.	Univ Adelaide, Dept Pathol, Adelaide, SA, Australia; James Cook Univ N Queensland, Sch Pharm & Mol Sci, Townsville, Qld 4811, Australia		Vink, R (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA, Australia.	robert.vink@adelaide.edu.au	Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Nimmo, Alan/0000-0002-0718-7934			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; BACHMAN DL, 1992, J HEAD TRAUMA REHAB, V7, P50; Ducrocq F, 2001, ENCEPHALE, V27, P159; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Izumi J, 1997, PHARMACOL BIOCHEM BE, V57, P883, DOI 10.1016/S0091-3057(96)00455-8; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JOSEPH AB, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199504000-00010; Kontinen VK, 1999, PAIN, V80, P341, DOI 10.1016/S0304-3959(98)00230-9; Kulkarni S., 1977, INDIAN J PHARM, V9, P241; Levine J, 2000, BIOL PSYCHIAT, V47, P586, DOI 10.1016/S0006-3223(99)00284-X; Mar A, 2002, PHARMACOL BIOCHEM BE, V73, P703, DOI 10.1016/S0091-3057(02)00881-X; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SCHWARTZ RD, 1994, J NEUROCHEM, V62, P916; Suarez M, 2002, LIFE SCI, V71, P1125, DOI 10.1016/S0024-3205(02)01830-1; Szewczyk B, 2001, POL J PHARMACOL, V53, P641; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Von Horsten S, 1998, PHARMACOL BIOCHEM BE, V60, P71, DOI 10.1016/S0091-3057(97)00467-X; WIDMER J, 1995, J AFFECT DISORDERS, V34, P201, DOI 10.1016/0165-0327(95)00018-I; BRAIN INJ, V15, P563	27	52	54	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0731-5724	1541-1087		J AM COLL NUTR	J. Am. Coll. Nutr.	OCT	2004	23	5					529S	533S		10.1080/07315724.2004.10719396			5	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	863AF	WOS:000224531900017	15466958				2022-02-06	
J	Williams, AJ; Tortella, FC; Lu, XM; Moreton, JE; Hartings, JA				Williams, AJ; Tortella, FC; Lu, XM; Moreton, JE; Hartings, JA			Antiepileptic drug treatment of nonconvulsive seizures induced by experimental focal brain ischemia	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							INTENSIVE-CARE-UNIT; CONVULSIVE STATUS EPILEPTICUS; SODIUM-CHANNEL BLOCKER; CONTINUOUS EEG; THERAPEUTIC WINDOW; SPECTRAL-ANALYSIS; DELTA-ACTIVITY; KINDLED RATS; MODEL; VALPROATE	Nonconvulsive seizures (NCSs) after traumatic and ischemic brain injury are often refractory to antiepileptic drug therapy and are associated with a decline in patient outcome. We recently characterized an in vivo rat model of focal brain ischemia-induced NCS and here sought to evaluate potential pharmacological treatments. Electroencephalographic activity was recorded continuously for 24 h in freely behaving rats subjected to permanent middle cerebral artery occlusion (MCAo). Rats were treated with an antiepileptic drug from one of seven different drug classes at ED50 and 2 x ED50 doses (as reported in other rat seizure models), delivered as a single i.v. injection 20 min post-MCAo. Vehicle-treated rats (n=9) had an 89% incidence of NCS with an average number of NCS of 8.6+/-1.9. The latency to onset of NCS was 32.5+/-3.4 min post-MCAo with an average duration of 49.1+/-8.2 s/event. The high doses of ethosuximide, gabapentin, fos-phenytoin, and valproate significantly reduced the incidence of NCS (11, 14, 14, and 38%, respectively), whereas midazolam, phenobarbital, and dextromethorphan had no significant effect at either dose. Across treatment groups, there was a low but significant correlation between the number of NCS events per animal and volume of brain infarction (r=0.352). Antiepileptic drug therapy that prevented the occurrence of NCS also reduced mortality from 26 to 7%. Based on combined effects on NCS, infarction, neurological recovery, and mortality, ethosuximide and gabapentin were identified as having the best therapeutic profile.	Walter Reed Army Inst Res, Div Neurosci, Dept Appl Neurobiol, Silver Spring, MD 20910 USA; Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA		Williams, AJ (corresponding author), Walter Reed Army Inst Res, Div Neurosci, Dept Appl Neurobiol, Silver Spring, MD 20910 USA.	anthony.williams@na.amedd.army.mil		Hartings, Jed/0000-0001-8583-3471			BERNASCONI R, 1985, J NEURAL TRANSM, V63, P169, DOI 10.1007/BF01252616; Bertrand S, 2003, SYNAPSE, V50, P95, DOI 10.1002/syn.10247; Calabresi P, 2003, ANN NEUROL, V53, P693, DOI 10.1002/ana.10603; Czuczwar SJ, 2001, CNS DRUGS, V15, P339, DOI 10.2165/00023210-200115050-00001; Danober L, 1998, PROG NEUROBIOL, V55, P27, DOI 10.1016/S0301-0082(97)00091-9; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Horn J, 2001, STROKE, V32, P570, DOI 10.1161/01.STR.32.2.570; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Lado FA, 2001, EPILEPSIA, V42, P458, DOI 10.1046/j.1528-1157.2001.30900.x; LEITE JP, 1995, EPILEPSY RES, V20, P93, DOI 10.1016/0920-1211(94)00070-D; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; LOSCHER W, 1993, EUR J PHARMACOL, V238, P191, DOI 10.1016/0014-2999(93)90847-B; Loscher W, 1998, EPILEPSY RES, V30, P69, DOI 10.1016/S0920-1211(97)00098-3; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; Manning JPA, 2004, NEUROSCIENCE, V123, P5, DOI 10.1016/j.neuroscience.2003.09.026; Meltzer CC, 2000, EPILEPSIA, V41, P193, DOI 10.1111/j.1528-1157.2000.tb00139.x; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; Perucca E, 2002, CNS DRUGS, V16, P695, DOI 10.2165/00023210-200216100-00004; RATAUD J, 1994, NEUROSCI LETT, V172, P19, DOI 10.1016/0304-3940(94)90652-1; Rekling JC, 2003, NEUROSCI LETT, V335, P167, DOI 10.1016/S0304-3940(02)01193-X; SHENOY AK, 1982, EPILEPSIA, V23, P399, DOI 10.1111/j.1528-1157.1982.tb05426.x; Tortella FC, 1999, J PHARMACOL EXP THER, V291, P399; Tortella FC, 1997, J PHARMACOL EXP THER, V282, P286; TORTELLA FC, 1986, BRAIN RES, V383, P314, DOI 10.1016/0006-8993(86)90031-4; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Trojnar MK, 2002, POL J PHARMACOL, V54, P557; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Williams AJ, 2003, FUND CLIN PHARMACOL, V17, P581, DOI 10.1046/j.1472-8206.2003.00183.x; Williams AJ, 2002, BRAIN RES, V932, P45, DOI 10.1016/S0006-8993(02)02275-8; Williams AJ, 2001, J PHARMACOL EXP THER, V299, P48; Williams AJ, 2000, J PHARMACOL EXP THER, V294, P378; Yang Y, 2000, NEUROSCI LETT, V285, P119, DOI 10.1016/S0304-3940(00)01048-X; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117; Young GB, 1996, NEUROLOGY, V47, P83	40	52	52	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	OCT	2004	311	1					220	227		10.1124/jpet.104.069146			8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	854IK	WOS:000223896100026	15140918				2022-02-06	
J	Jiang, JF; Borisenko, GG; Osipov, A; Martin, I; Chen, RW; Shvedova, AA; Sorokin, A; Tyurina, YY; Potapovich, A; Tyurin, VA; Graham, SH; Kagan, VE				Jiang, JF; Borisenko, GG; Osipov, A; Martin, I; Chen, RW; Shvedova, AA; Sorokin, A; Tyurina, YY; Potapovich, A; Tyurin, VA; Graham, SH; Kagan, VE			Arachidonic acid-induced carbon-centered radicals and phospholipid peroxidation in cyclo-oxygenase-2-transfected PC12 cells	JOURNAL OF NEUROCHEMISTRY			English	Article						carbon-centered radical formation; cyclo-oxygenase-2 inhibitor; cyclo-oxygenase-2 transfection; PC12 cells; phosphatidylserine oxidation; radical spin-trapping	PROSTAGLANDIN-H SYNTHASE-2; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD NEURONS; OXIDATIVE STRESS; OXYGEN RADICALS; ISCHEMIC BRAIN; CYTOCHROME-C; INDUCIBLE CYCLOOXYGENASE	Cyclo-oxygenase-2 (COX-2) is believed to induce neuronal oxidative stress via production of radicals. While oxygen radicals are not directly involved in COX-2-catalytic cycle, superoxide anion radicals have been repeatedly reported to play a critical role in COX-2-associated oxidative stress. To resolve the controversy, we characterized production of free radicals in PC12 cells in which COX-2 expression was manipulated either genetically or by direct protein transfection and compared them with those generated by a recombinant COX-2 in a cell-free system. Using spin-traps alpha-(4-pyridyl-1-oxide)-N-t-butylnitrone, 5,5-dimethyl-1-pyrroline-N-oxide and 4-((9-acridinecarbonyl) amino)-2,2,6,6- tetramethylpiperidine-1-oxyl (Ac-Tempo), we observed arachidonic acid (AA)-dependent production of carbon-centered radicals by heme-reconstituted recombinant COX-2. No oxygen radicals or thiyl radicals have been detected. COX-2 also catalyzed AA-dependent one-electron co-oxidation of ascorbate to ascorbate radicals. Next, we used two different approaches of COX-2 expression in cells, PCXII cells which express isopropyl-1-thio-beta-D-galactopyranoside inducible COX-2, and PC12 cells transfected with COX-2 using a protein delivery reagent, Chariot. In both models, COX-2-dependent AA-induced generation of carbon-centered radicals was documented using spin-traps and Ac-Tempo. No oxygen radical formation was detected in COX-2-transfected cells by either spin-traps or fluorogenic probe, dihydroethidium. In the presence of ascorbate, AA-induced COX-2-dependent ascorbate radicals were detected. AA caused a significant and selective oxidation of one of the major phospholipids, phosphatidylserine (PS). PS was not a direct substrate for COX-2 but was co-oxidized in the presence of AA. The radical generation and PS oxidation were inhibited by COX-2 inhibitors, niflumic acid, nimesulide, or NS-398. Thus, COX-2 generated carbon-centered radicals but not oxygen radicals or thiyl radicals are responsible for oxidative stress in AA-challenged PC12 cells overexpressing COX-2.	Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; NIOSH, Hlth Effects Lab Div, Morgantown, WV USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA; VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA		Kagan, VE (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, 3343 Forbes Ave, Pittsburgh, PA 15260 USA.	kagan+@pitt.edu	Osipov, Andreyan N/G-4791-2010	Osipov, Andreyan N/0000-0001-5921-9056; Tyurin, Vladimir/0000-0002-3474-1697; Tyurina, Yulia/0000-0003-0287-2091; Kagan, Valerian E./0000-0002-7245-1885; Sorokin, Andrey/0000-0002-5660-0190	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P01NS030318, F05NS043922, P20NS030318, R56NS037459, R01NS037459] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 37459, F05 NS 43922, R01 NS037459, R01 NS037459-07, NS 30318] Funding Source: Medline		Adibhatla RM, 2002, BRAIN RES, V938, P81, DOI 10.1016/S0006-8993(02)02447-2; Appleton I, 1996, Adv Pharmacol, V35, P27, DOI 10.1016/S1054-3589(08)60274-4; Armstead WM, 2003, ANESTHESIOLOGY, V98, P1378, DOI 10.1097/00000542-200306000-00012; ARMSTEAD WM, 1988, AM J PHYSIOL, V255, pH401, DOI 10.1152/ajpheart.1988.255.2.H401; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; BLOUGH NV, 1988, J AM CHEM SOC, V110, P1915, DOI 10.1021/ja00214a041; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BUSIJA DW, 1998, PHARM CEREBRAL ISCHE, P237; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Candelario-Jalil E, 2002, EUR J PHARMACOL, V453, P189, DOI 10.1016/S0014-2999(02)02422-6; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FOLCH J, 1957, J BIOL CHEM, V226, P497; Garrido R, 2001, J NEUROCHEM, V76, P1395, DOI 10.1046/j.1471-4159.2001.00135.x; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; GRUNEWALD RA, 1993, BRAIN RES REV, V18, P123, DOI 10.1016/0165-0173(93)90010-W; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Horakova L, 1997, NEUROPHARMACOLOGY, V36, P177, DOI 10.1016/S0028-3908(96)00165-7; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Jiang JF, 2003, FREE RADICAL BIO MED, V35, P814, DOI 10.1016/S0891-5849(03)00429-5; Kagan V E, 1998, Methods Mol Biol, V108, P71; Kagan VE, 2003, AM J PHYSIOL-LUNG C, V285, pL1, DOI 10.1152/ajplung.00365.2002; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kinouchi H, 1999, J NEUROSURG, V91, P1005, DOI 10.3171/jns.1999.91.6.1005; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; Kontos HA, 2001, STROKE, V32, P2712, DOI 10.1161/hs1101.098653; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; LI Y, 1995, AM J PATHOL, V146, P1045; Love S, 1999, BRAIN PATHOL, V9, P119; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Marnett LJ, 2000, CURR OPIN CHEM BIOL, V4, P545, DOI 10.1016/S1367-5931(00)00130-7; MASON RP, 1980, J BIOL CHEM, V255, P5019; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; MCGOWAN JE, 1994, BIOL NEONATE, V66, P367; Mishra OP, 1999, BRAIN RES BULL, V48, P233, DOI 10.1016/S0361-9230(98)00170-1; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; NELSON CW, 1992, AM J PHYSIOL, V263, pH1356, DOI 10.1152/ajpheart.1992.263.5.H1356; NJUS D, 1991, FEBS LETT, V284, P147, DOI 10.1016/0014-5793(91)80672-P; Nogawa S, 1997, J NEUROSCI, V17, P2746; NOGAWA S, 2002, ACTA NEUROPATHOL, V104, P601; O'Brien PJ, 1978, BIOCHEM SOC T, V6, P1169, DOI 10.1042/bst0061169; Perry George, 2002, Journal of Biomedicine & Biotechnology, V2, P120, DOI 10.1155/S1110724302203010; Rice ME, 1998, NEUROSCIENCE, V82, P1213; SCHREIBER J, 1986, ARCH BIOCHEM BIOPHYS, V249, P126, DOI 10.1016/0003-9861(86)90567-9; SCHREIBER J, 1989, J BIOL CHEM, V264, P7936; Sharikabad MN, 2001, AM J PHYSIOL-HEART C, V280, pH344, DOI 10.1152/ajpheart.2001.280.1.H344; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Takadera T, 2002, NEUROSCI LETT, V317, P61, DOI 10.1016/S0304-3940(01)02449-1; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; TSUNAWAKI S, 1986, J EXP MED, V164, P1319, DOI 10.1084/jem.164.4.1319; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Tyurina YY, 2004, J BIOL CHEM, V279, P6056, DOI 10.1074/jbc.M309929200; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	73	52	55	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2004	90	5					1036	1049		10.1111/j.1471-4159.2004.02577.x			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	847CN	WOS:000223366500002	15312159	Bronze			2022-02-06	
J	Hattori, N; Huang, SC; Wu, HM; Liao, WH; Glenn, TC; Vespa, PM; Phelps, ME; Hovda, DA; Bergsneider, M				Hattori, N; Huang, SC; Wu, HM; Liao, WH; Glenn, TC; Vespa, PM; Phelps, ME; Hovda, DA; Bergsneider, M			Acute changes in regional cerebral F-18-FDG kinetics in patients with traumatic brain injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						neurology; PET; traumatic brain injury; glucose transporter; hexokinase F-18-FDG	POSITRON-EMISSION-TOMOGRAPHY; HEAD-INJURY; GLUCOSE-UTILIZATION; BLOOD-FLOW; METABOLIC-CHANGES; BARRIER CHANGES; RAT-BRAIN; MICRODIALYSIS; PHOSPHORYLATION; PET	During the acute phase after traumatic brain injury (TBI), the metabolic state is regionally heterogeneous. The purpose of this study was to characterize contusional, pericontusional, and remote regions of TBI by estimating glucose transporter and hexokinase activities on the basis of F-18-FDG kinetic modeling. Methods: A standard 2-compartment model was used to measure 18F-FDG kinetic parameters in 21 TBI patients with cerebral contusions studied during the acute phase (3.1 +/- 2.1 [mean +/- SD] d after injury). Nineteen patients also underwent O-15-water PET to measure regional cerebral blood flow (CBF). A control study (F-18-FDG and O-15-water) was done with 18 healthy volunteers. The rate constants K-i, K-1, and k(3) were assumed to represent the uptake, transport, and hexokinase activity of F-18-FDG, respectively; K-i was calculated as K-1 x [k(3)/(k(2) + k(3))]. Results: The areas of contusional and pericontusional tissues located 4.5, 13.5, and 22.5 mm away from the contusion (PC4.5, PC13.5, and PC22.5, respectively) demonstrated significantly reduced K-i values, whereas the K-1 values for remote areas remained normal. The k(3) values were significantly reduced regardless of the distance from the contusion. Pericontusional areas with CT- or MRI-evidenced tissue damage showed significantly lower K-i (P < 0.001), CBF (P < 0.01), and K-1 (P < 0.0001) values than did areas without such damage, whereas the k(3) values did not differ significantly. Seven patients showed regionally increased F-18-FDG uptake (hot spots) in pericontusional areas. The k(3) value for the hot spots (0.086 +/- 0.024/min) was significantly higher than that for the remote cortex (P < 0.01), whereas the K-i, CBF, and K-1 values did not show significant differences. Patients with hot spots showed significantly higher K-i and values in PC4.5 (P < 0.05) and higher k(3) values in PC22.5 (P < 0.05) than did patients without hot spots, whereas the K-1 and CBF values did not differ significantly. Conclusion: Brain tissue F-18-FDG kinetics in TBI patients were consistent with reduced hexokinase activity in the whole brain (including apparently uninjured cortex), whereas glucose transport was impaired only in the area immediately around the contusion. Pericontusional high levels of F-18-FDG uptake observed in a subgroup of patients could have been the result of regionally increased hexokinase activity.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Hattori, N (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Box 956948, Los Angeles, CA 90095 USA.	nhattori@mednet.ucla.edu	Hattori, Naoya/G-2298-2012; Hattori, Naoya/AAR-6405-2020	Glenn, Thomas/0000-0003-4273-3408	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30308] Funding Source: Medline		Alessandri B, 1999, ACT NEUR S, V75, P25; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, ACT NEUR S, V70, P243; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAMPE PC, 1984, BIOCHEMISTRY-US, P89; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; CRANE PD, 1983, J NEUROCHEM, V40, P160, DOI 10.1111/j.1471-4159.1983.tb12666.x; CUNNINGHAM VJ, 1981, BRAIN RES, V221, P319, DOI 10.1016/0006-8993(81)90781-2; DRAPER NR, 1981, APPL REGRESSION ANAL, P157; EICHLING JO, 1974, CIRC RES, V35, P358, DOI 10.1161/01.RES.35.3.358; FOSTER NL, 1987, J CEREBR BLOOD F MET, V7, P415, DOI 10.1038/jcbfm.1987.84; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hattori N, 2003, J NUCL MED, V44, P1709; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HUANG SC, 1983, J CEREBR BLOOD F MET, V3, P141, DOI 10.1038/jcbfm.1983.21; Huang SC, 2004, MOL IMAGING BIOL, V6, P34, DOI 10.1016/j.mibio.2003.12.002; HUANG SC, 1982, J CEREBR BLOOD F MET, V2, P99, DOI 10.1038/jcbfm.1982.11; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; HUANG SC, 1987, FEBS LETT, V216, P128, DOI 10.1016/0014-5793(87)80770-6; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KUWABARA H, 1990, J CEREBR BLOOD F MET, V10, P180, DOI 10.1038/jcbfm.1990.33; LANG DA, 1991, ACTA NEUROCHIR, V109, P5, DOI 10.1007/BF01405689; LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P73; Maes F, 1997, IEEE T MED IMAGING, V16, P187, DOI 10.1109/42.563664; Magistretti PJ, 1996, MOL PSYCHIATR, V1, P445; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; POWELL MJD, 1964, COMPUT J, V7, P155, DOI 10.1093/comjnl/7.2.155; Press W. H., 1992, NUMERICAL RECIPES C, P394; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; ROSENSTEIN JM, 1994, J COMP NEUROL, V350, P229, DOI 10.1002/cne.903500207; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; WORLEY G, 1995, DEV MED CHILD NEUROL, V37, P213; Yamaki T, 1996, J NUCL MED, V37, P1166; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhou Y, 2001, IEEE T NUCL SCI, V48, P125, DOI 10.1109/23.910842	43	52	53	0	3	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	MAY	2004	45	5					775	783					9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	819WZ	WOS:000221348300017	15136626				2022-02-06	
J	Yue, HF; Strauss, KI; Borenstein, MR; Barbe, MF; Rossi, LJ; Jansen, SA				Yue, HF; Strauss, KI; Borenstein, MR; Barbe, MF; Rossi, LJ; Jansen, SA			Determination of bioactive eicosanoids in brain tissue by a sensitive reversed-phase liquid chromatographic method with fluorescence detection	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						eicosanoids	ARACHIDONIC-ACID; CARBOXYLIC-ACIDS; P-450 METABOLITES; CYTOCHROME-P-450; EPOXYGENASE; DERIVATIZATION; ULTRAVIOLET; INJURY	Arachidonic acid (AA) is metabolized to prostaglandins (PGs) via cyclooxygenases (COX) catalysis, and to epoxyeicosatrienoic acids (EETs), dihydroxyeicosatrienoic acids (DiHETrEs), and hydroxyeicosatetraenoic acids (HETEs) via cytochrome P450 (CYP450) enzymes. A reliable and robust fluorescence based HPLC method for these eicosanoids was developed. A new selective reverse-phase solid phase extraction (SPE) procedure was developed for PG, DiHETrEs, HETE, and EETs of interest from rat cortical brain tissue. The eicosanoids were derivatized with 2-(2,3-naphthalimino)ethyl-trifluoromethanesulphonate (NE-OTf), followed by separation and quantification at high sensitivity using reverse-phase HPLC with fluorescent detection, and further identified via LC/MS. The derivatization was studied and optimized to obtain reproducible reactions. Various PGs, DiHETrEs, HETEs, EETs, and AA were sensitively detected and baseline resolved simultaneously. LC/MS under positive electrospray ionization selected ion monitoring (SIM) mode was developed to further identify the peaks of these eicosanoids in cortical brain tissue. The method was applied in the traumatic brain injured rat brain. (C) 2004 Elsevier B.V. All rights reserved.	Temple Univ, Dept Chem, Philadelphia, PA 19122 USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; Temple Univ, Sch Pharm, Philadelphia, PA 19140 USA; Temple Univ, Dept Phys Therapy, Philadelphia, PA 19140 USA; Temple Univ, Dept Anat & Cell Biol, Philadelphia, PA 19140 USA; US FDA, Philadelphia, PA 19106 USA		Jansen, SA (corresponding author), Temple Univ, Dept Chem, 1901 N 13th St, Philadelphia, PA 19122 USA.	suebee@unix.temple.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS038654-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038654] Funding Source: NIH RePORTER		Beare-Rogers J, 2001, PURE APPL CHEM, V73, P685, DOI 10.1351/pac200173040685; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; Cunico R.L., 1998, BASIC HPLC CE BIOMOL, V3rd ed.; Davis BB, 2002, P NATL ACAD SCI USA, V99, P2222, DOI 10.1073/pnas.261710799; DEYL Z, 1998, ADV CHROMATOGRAPHIC, P315; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; GOPEZ JJ, 2003, IN PRESS J NEUROSCIE; Hampson AJ, 2002, J NEUROSCI, V22, P257, DOI 10.1523/JNEUROSCI.22-01-00257.2002; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; Maier KG, 2000, AM J PHYSIOL-HEART C, V279, pH863, DOI 10.1152/ajpheart.2000.279.2.H863; Mukherjee PS, 1996, BIOMED CHROMATOGR, V10, P193, DOI 10.1002/(SICI)1099-0801(199609)10:5<193::AID-BMC591>3.0.CO;2-B; Nithipatikom K, 2000, AM J PHYSIOL-HEART C, V279, pH857, DOI 10.1152/ajpheart.2000.279.2.H857; Nithipatikom K, 2001, ANAL BIOCHEM, V298, P327, DOI 10.1006/abio.2001.5395; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; OHKURA Y, 1994, J CHROMATOGR B, V659, P85, DOI 10.1016/0378-4347(94)00125-1; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; TOYOOKA T, 1995, J CHROMATOGR B, V671, P91, DOI 10.1016/0378-4347(94)00559-N; VanderNoot VA, 2002, ANAL CHEM, V74, P5859, DOI 10.1021/ac025909+; YASAKA Y, 1990, J CHROMATOGR, V508, P133, DOI 10.1016/S0021-9673(00)91246-9; YASAKA Y, 1994, J CHROMATOGR B, V659, P139, DOI 10.1016/S0378-4347(94)80126-6; YUE H, 2002, P 224 ACS M BOST AUG	26	52	55	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	APR 25	2004	803	2					267	277		10.1016/j.jchromb.2003.12.027			11	Biochemical Research Methods; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	809MG	WOS:000220640200012	15063335				2022-02-06	
J	Carroll, LJ; Cassidy, JD; Peloso, PM; Garritty, C; Giles-Smith, L				Carroll, LJ; Cassidy, JD; Peloso, PM; Garritty, C; Giles-Smith, L			Systematic search and review procedures: Results of the who collaborating centre task force on mild traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; systematic review; best-evidence synthesis	HEALTH-CARE	The WHO Collaborating Centre for Neurotrauma Task Force on Mild Traumatic Brain Injury performed a comprehensive search and critical review of the literature published between 1980 and 2002 to assemble the best evidence on the epidemiology, diagnosis, prognosis and treatment of mild traumatic brain injury. Our primary sources of literature were Medline, Cinahl, PsycINFO and Embase. Citations were screened for relevance to mild traumatic brain injury, using a priori criteria, and relevant studies were critically reviewed for scientific merit. We identified 38,806 citations, of which 671 studies were judged relevant to the mandate of the task force. These, plus 70 studies found by hand-searching reference lists and 2 original research reports performed as part of the task force mandate were subjected to critical reviews. After review, 313 (42%) were accepted on scientific merit and comprise our best-evidence synthesis. Ninety percent of the literature on mild traumatic brain injury was found in Medline and another 5% in PsycINFO.	Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB T6G 2E1, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden; Univ Iowa, Ctr Hlth, Dept Internal Med, Iowa City, IA USA; Inst Work & Hlth, Toronto, ON, Canada		Carroll, LJ (corresponding author), Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, 3080 RTF,8308-114 St, Edmonton, AB T6G 2E1, Canada.	lcarroll@ualberta.ca	Garritty, Chantelle Marie/AAC-4136-2022; Garritty, Chantelle/ABG-7790-2020	Carroll, Linda/0000-0003-0876-2336; Giles-Smith, Lori/0000-0002-2248-9164			BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cook DJ, 1997, ANN INTERN MED, V127, P210, DOI 10.7326/0003-4819-127-3-199708010-00006; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Fletcher R.H., 1996, CLIN EPIDEMIOLOGY ES; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; LOWE HJ, 1994, JAMA-J AM MED ASSOC, V271, P1103, DOI 10.1001/jama.271.14.1103; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Slavin R. E., 1986, EDUC RES, V15, P5, DOI [DOI 10.3102/0013189X015009005, 10.3102/0013189X015009005]; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; SPITZER WO, 1995, SPINE, V20, P2372; SPITZER WO, 1995, SPINE, V20, pS1; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633	16	52	52	1	4	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			11	14		10.1080/16501960410023660			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	800QR	WOS:000220043300004	15083867	gold			2022-02-06	
J	Catroppa, C; Anderson, V				Catroppa, C; Anderson, V			Recovery and predictors of language skills two years following pediatric traumatic brain injury	BRAIN AND LANGUAGE			English	Article						traumatic brain injury; children; language; recovery	CLOSED-HEAD-INJURY; CHILDREN; ADOLESCENTS; FAMILY; PERFORMANCE; CHILDHOOD; DISCOURSE	Subtle language processing difficulties may adversely affect scholastic performance, as well as communication and social skills. It is therefore crucial that language skills are monitored following traumatic brain injury (TBI) in childhood. The present study examined language skills in a group of 68 children who had sustained a mild, moderate or severe TBI. Results indicated that during the acute stage a dose-response relationship was evident, where severe TBI was associated with poorest performance and mild TBI with least deficits. By 24 months post-TBI, it was clear that for some language functions, the severe TBI group showed substantial recovery, and at times performed better than the moderate TBI group. Predictors of language and literacy skills at 24 months post TBI included pre-injury communication skills, socio-economic status, age at injury, and Vocabulary, as measured by the Wechsler Intelligence Scale for Children (WISC-111). (C) 2003 Elsevier Science (USA). All rights reserved.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Parkville, Vic 3052, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	catroppc@cryptic.rch.unimelb.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M., 1989, CLIN NEUROPSYCHOLOGY; Didus E, 1999, Pediatr Rehabil, V3, P177; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1987, J LEARN DISABIL, V20, P526, DOI 10.1177/002221948702000904; GADDES WH, 1973, RES MONOGRAPH U VICT, V25; GARDNER M, 1979, MANUAL EXPRESSIVE ON; Goldstein FC, 1992, COGNITIVE DISORDERS; Goldstone BP, 2001, READ TEACH, V55, P362; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hallett T L, 1997, Pediatr Rehabil, V1, P219; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Jordan FM, 1996, BRAIN INJURY, V10, P91, DOI 10.1080/026990596124575; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; MARQUARDT TP, 1988, J LEARN DISABIL, V21, P340, DOI 10.1177/002221948802100605; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Morse S, 1999, Pediatr Rehabil, V3, P139; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; RIVARA JMB, 1995, ARCH PHYSICAL MED RE, V77, P754; Sheslow D., 1990, WIDE RANGE ASSESSMEN; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1992, MANUAL WECHSLER INTE; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME	37	52	52	1	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JAN	2004	88	1					68	78		10.1016/S0093-934X(03)00159-7			11	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	766CB	WOS:000188326900007	14698732				2022-02-06	
J	McCauley, SR; Levin, HS				McCauley, SR; Levin, HS			Prospective memory in pediatric traumatic brain injury: A preliminary study	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; TASK COMPLEXITY; CHILDREN; ADOLESCENTS; CUES; AGE; POPULATION; RETRIEVAL; SEQUELAE; MRI	Prospective memory (PM) performance was investigated in a preliminary study of children and adolescents ages 10-19 in 3 groups: individuals with orthopedic injuries (not involving the head) requiring hospitalization (Ortho, N = 15), mild traumatic brain injury (TBI, N = 17), and severe TBI (N= 15). All participants with TBI were at least 5 years postinjury and participants in the Ortho group were at least 3 years postinjury. The PM task involved reporting words presented in blue during a category decision task in which words were presented in several different colors and participants were to determine which of two categories the word belonged. Participants were asked to make their choices as quickly as possible. After a 10- to 15-min intervening computer task in which all words were presented in black letters, a large proportion of participants with mild or severe TBI failed to indicate any blue words when they appeared. After a reminder to perform the PM task was given to all at the same point in the task, PM performance increased in the Ortho and Mild TBI groups, but remained comparably impaired in the Severe TBI group. Reaction time (RT) data indicated that mean RT was slower with increasing TBI severity. Further, there was a significant cost in RT for performing the PM task during the ongoing category decision task for all groups. The cost in terms of slowed RT increased with greater TBI severity.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA		McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Ste 1144, Houston, TX 77030 USA.	mccauley@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		BEAL CR, 1985, CHILD DEV, V56, P631; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CECI SJ, 1985, CHILD DEV, V56, P152, DOI 10.2307/1130182; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; EINSTEIN GO, 1992, PSYCHOL AGING, V7, P471, DOI 10.1037/0882-7974.7.3.471; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Flannery M A, 1997, Pediatr Rehabil, V1, P239; Guajardo NR, 2000, COGNITIVE DEV, V15, P75, DOI 10.1016/S0885-2014(00)00016-2; HANNAY HJ, 1989, J CLIN EXP NEUROPSYC, V11, P444, DOI 10.1080/01688638908400905; HANNAY HJ, 1979, CONTINUOUS RECOGNITI; Hanten G, 2000, J MEM LANG, V43, P335, DOI 10.1006/jmla.2000.2731; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kreutzer M. A., 1975, MEMORY OBSERVED REME, P343; Kvavilashvili L, 2001, DEV PSYCHOL, V37, P418, DOI 10.1037//0012-1649.37.3.418; KVAVILASHVILI L, 1990, REMEMBERING FORGETTI; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; McCauley S. R., 2000, ANN M COGN NEUR SOC; McCauley S. R., 2001, 3 INT C MEM ICOM 3 V; McDaniel M A, 1993, Memory, V1, P23, DOI 10.1080/09658219308258223; MEACHAM JA, 1980, J EDUC RES, V73, P299; MEACHAM JA, 1976, CATALOG SELECTED DOC, V6, P66; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; NOVACK TA, 1995, CLIN NEUROPSYCHOL, V9, P38; PASSOLUNGHI MC, 1995, INT J BEHAV DEV, V18, P1995; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; SCHWANENFLUGEL PJ, 1994, CHILD DEV, V65, P1546; SCHWEINBERGER SR, 1993, CORTEX, V29, P333, DOI 10.1016/S0010-9452(13)80186-4; SOMMERVILLE SC, 1983, J GENET PSYCHOL, V143, P87; TEASDALE G, 1974, LANCET, V2, P81; WELLMAN HM, 1975, DEV PSYCHOL, V11, P780, DOI 10.1037/0012-1649.11.6.780; WICHMAN H, 1983, HUM FACTORS, V25, P583, DOI 10.1177/001872088302500512; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348	43	52	53	1	6	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					5	20		10.1207/s15326942dn2501&2_2			16	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	774CG	WOS:000188961700002	14984326				2022-02-06	
J	Schmidt, EA; Czosnyka, M; Steiner, LA; Balestreri, M; Smielewski, P; Piechnik, SK; Matta, BF; Pickard, JD				Schmidt, EA; Czosnyka, M; Steiner, LA; Balestreri, M; Smielewski, P; Piechnik, SK; Matta, BF; Pickard, JD			Asymmetry of pressure autoregulation after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral hemodynamics; transcranial Doppler ultrasonography autoregulation; outcome	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; TRANSCRANIAL DOPPLER; CEREBROVASCULAR REACTIVITY; PRACTICAL SCALE; MANAGEMENT; VALIDATION; GRADIENTS	Object. The aim of this study was to assess the asymmetry of autoregulation between the left and right sides of the brain by using bilateral transcranial Doppler ultrasonography in a cohort of patients with head injuries. Methods. Ninety-six patients with head injuries comprised the study population. All significant intracranial mass lesions were promptly removed. The patients were given medications to induce sedation and paralysis, and artificial ventilation. Arterial blood pressure (ABP) and intracranial pressure (ICP) were monitored in an invasive manner. A strategy based on the patient's cerebral perfusion pressure (CPP = ABP - ICP) was applied: CPP was maintained at a level higher than 70 mm Hg and ICP at a level lower than 25 mm Hg. The left and right middle cerebral arteries were insonated daily, and bilateral flow velocities (FVs) were recorded. The correlation coefficient between the CPP and FV, termed Mx, was calculated and time-averaged over each recording period on both sides. An Mx close to 1 signified that slow fluctuations in CPP produced synchronized slow changes in FV, indicating a defective autoregulation. An Mx close to 0 indicated preserved autoregulation. Computerized tomography scans in all patients were reviewed; the side on which the major brain lesion was located was noted and the extent of the midline shift was determined. Outcome was measured 6 months after discharge. The left-right difference in the Mx between the hemispheres was significantly higher in patients who died than in those who survived (0.16 +/- 0.04 compared with 0.08 +/- 0.01; p = 0.04). The left-right difference in the Mx was correlated with a midline shift (r = -0.42; p = 0.03). Autoregulation was worse on the side of the brain where the lesion was located (p < 0.035). Conclusions. The left-right difference in autoregulation is significantly associated with a fatal outcome. Autoregulation in the brain is worse on the side ipsilateral to the lesion and on the side of expansion in cases in which there is a midline shift.	Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Anaesthesiol, Cambridge CB2 2QQ, England; Warsaw Univ Technol, Inst Elect Syst, PL-00661 Warsaw, Poland; Hop Univ Toulouse Purpan, Serv Neurochirurg, Toulouse, France		Czosnyka, M (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, POB 167,Hills Rd, Cambridge CB2 2QQ, England.	mc141@medschl.cam.ac.uk	Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019	Smielewski, Peter/0000-0001-5096-3938; Piechnik, Stefan K./0000-0002-0268-5221	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; ENEVOLDSEN EM, 1977, ACTA NEUROL SCAND, V56, P514; Gooskens I, 2003, ACTA NEUROCHIR, V145, P527, DOI 10.1007/s00701-003-0045-y; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Hu HH, 1999, J CEREBR BLOOD F MET, V19, P460, DOI 10.1097/00004647-199904000-00012; JENNETT B, 1975, LANCET, V1, P480; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MENON DK, 2000, TXB NEUROANAESTHESIA, P17; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Panerai RB, 1998, STROKE, V29, P2341, DOI 10.1161/01.STR.29.11.2341; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Schmidt EA, 2001, J NEUROL NEUROSUR PS, V70, P198, DOI 10.1136/jnnp.70.2.198; SCHMIDT EA, J NEUROIMAGING, V3, P248; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; Smielewski P, 1997, INT J CLIN MONIT COM, V14, P185, DOI 10.1023/A:1016901710584; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STEINER LA, 2002, J NEUROTRAUM, V19, P1301; TEASDALE G, 1974, LANCET, V2, P81; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wolfla CE, 1996, J NEUROSURG, V84, P642, DOI 10.3171/jns.1996.84.4.0642; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233	43	52	52	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2003	99	6					991	998		10.3171/jns.2003.99.6.0991			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	751VX	WOS:000187111700009	14705726				2022-02-06	
J	Kay, AD; Petzold, A; Kerr, M; Keir, G; Thompson, E; Nicoll, JAR				Kay, AD; Petzold, A; Kerr, M; Keir, G; Thompson, E; Nicoll, JAR			Alterations in cerebrospinal fluid apolipoprotein E and amyloid beta-protein after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						A beta; apoE; brain injury; CSF analysis; S100B; Tau	GLOBAL CEREBRAL-ISCHEMIA; ONSET ALZHEIMER-DISEASE; CLOSED-HEAD INJURY; E-DEFICIENT MICE; E GENOTYPE; MOUSE MODEL; PRECURSOR PROTEIN; NEURONAL DAMAGE; TRANSGENIC MICE; E POLYMORPHISM	There is evidence that apolipoprotein E (apoE) and amyloid beta-protein (Abeta), which are implicated in the pathology of chronic neurodegenerative disorders, are involved in the response of the brain to acute injury; however, human in vivo evidence is sparse. We conducted a prospective observational study to determine the magnitude and time-course of alterations in cerebrospinal fluid (CSF) apoE and Abeta concentrations after traumatic brain injury (TBI), and the relationship of these changes to severity of injury and clinical outcome. Enzyme linked immunosorbant assay (ELISA) was used to assay apoE, Abeta(1-40) and Abeta(1-42) in serial CSF samples from 13 patients with TBI and 13 controls. CSF S100B and tau were assayed as surrogate markers of brain injury. There was a significant decrease in CSF apoE (p < 0.001) and A&beta; (p < 0.001) after TBI contrasting the observed elevation in CSF S100B (p < 0.001) and tau (p < 0.001) concentration. There was significant correlation (r = 0.67, p = 0.01) between injury severity and the decrease in Abeta(1-40) concentration after TBI. In vivo, changes in apoE and Abeta concentration occur after TBI and may be important in the response of the human brain to injury.	Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland; Univ London, Inst Neurol & Neurosurg, Dept Neuroimmunol, London, England; Dept Neurosurg, Pittsburgh, PA USA; Ctr Nursing Res, Pittsburgh, PA USA; Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton, Hants, England		Kay, AD (corresponding author), Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.		Petzold, Axel/C-1090-2009; Nicoll, James/I-9253-2017	Petzold, Axel/0000-0002-0344-9749; Nicoll, James/0000-0002-9444-7246			Andreasen N, 2001, ARCH NEUROL-CHICAGO, V58, P373, DOI 10.1001/archneur.58.3.373; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Beffert U, 1999, BRAIN RES, V843, P87, DOI 10.1016/S0006-8993(99)01894-6; BLENNOW K, 1994, NEUROREPORT, V5, P2534, DOI 10.1097/00001756-199412000-00032; Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Fagan AM, 2000, ANN NEUROL, V48, P201, DOI 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.3.CO;2-O; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Goedert M, 1999, PHILOS T ROY SOC B, V354, P1101, DOI 10.1098/rstb.1999.0466; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Ikura M, 2000, NAT STRUCT BIOL, V7, P525, DOI 10.1038/76721; Kay A, 2003, STROKE, V34, P637, DOI 10.1161/01.STR.0000057579.25430.16; KAY A, 2003, J NEUROTRAUM, V109, P536; Koistinaho M, 2002, STROKE, V33, P1905, DOI 10.1161/01.STR.0000020124.61998.BC; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; LUXTON RW, 1989, CLIN CHEM, V35, P1731; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; McColl BW, 2003, AM J PATHOL, V162, P273, DOI 10.1016/S0002-9440(10)63818-7; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nicoll JAR, 2001, NEUROREPORT, V12, P695, DOI 10.1097/00001756-200103260-00016; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; NITSCH RM, 1995, ANN NEUROL, V37, P512, DOI 10.1002/ana.410370414; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; RIFAI N, 1987, CLIN CHEM, V33, P1155; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROSENBERG RN, 1993, NEUROLOGY, V43, P851; Schenk DB, 2000, ARCH NEUROL-CHICAGO, V57, P934, DOI 10.1001/archneur.57.7.934; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Shoji M, 1998, J NEUROL SCI, V158, P134, DOI 10.1016/S0022-510X(98)00122-1; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Sorci G, 1998, BBA-MOL CELL RES, V1448, P277, DOI 10.1016/S0167-4889(98)00134-7; Starck M, 2000, CELL BIOCHEM FUNCT, V18, P9, DOI 10.1002/(SICI)1099-0844(200001/03)18:1<9::AID-CBF841>3.0.CO;2-X; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THOMPSON EJ, 1990, ANN CLIN BIOCHEM, V27, P425, DOI 10.1177/000456329002700503; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	71	52	52	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					943	952		10.1089/089771503770195795			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300003	14588111				2022-02-06	
J	van Loo, M; Moseley, AM; Bosman, JM; de Bie, RA; Hassett, L				van Loo, M; Moseley, AM; Bosman, JM; de Bie, RA; Hassett, L			Inter-rater reliability and concurrent validity of walking speed measurement after traumatic brain injury	CLINICAL REHABILITATION			English	Article							HEMIPLEGIC GAIT; STROKE	Objective: To assess the inter-rater reliability and concurrent validity of walking speed measurement after traumatic brain injury. Design: Twelve subjects each completed five comfortably paced and five fast-paced walking trials. Walking speed was measured simultaneously by five observers using a stopwatch (clinical procedure) and by infrared timing gates (gold standard). Setting: Brain injury rehabilitation unit. Subjects: People with traumatic brain injury who could walk independently and were participating in a rehabilitation programme. Main outcome measures: Walking speed over a 10-metre distance. Results: The inter-rater reliability of walking speed measured using a stopwatch was very high, with an intraclass correlation coefficient of at least 0.998 for both comfortable and fast-paced tests. Concurrent validity was excellent for comfortable and fast tests, with perfect correlations between the stopwatch and infrared timing gate measurement procedures. Conclusions: Physiotherapists can use a stopwatch as a reliable and valid measurement tool to quantify walking speed over a short distance at both comfortable and fast paces in people who have sustained traumatic brain injuries.	Univ Sydney, Dept Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands; Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia		Moseley, AM (corresponding author), Univ Sydney, Dept Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.			Hassett, Leanne/0000-0002-3546-1822			BRANDSTATER ME, 1983, ARCH PHYS MED REHAB, V64, P583; Datta D, 1996, CLIN REHABIL, V10, P227, DOI DOI 10.1177/026921559601000307; EKEOKORO ST, 1994, J HUM MOVEMENT STUD, V10, P107; Evans MD, 1997, ARCH PHYS MED REHAB, V78, P725, DOI 10.1016/S0003-9993(97)90080-0; Gifford R, 1977, J HUM MOVEMENT STUD, V3, P66; HILL KD, 1994, ARCH PHYS MED REHAB, V75, P577; Marks R, 1994, Arthritis Care Res, V7, P50, DOI 10.1002/art.1790070111; MAYERSON NH, 1984, ARCH PHYS MED REHAB, V65, P92; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Wade D, 1992, MEASUREMENT NEUROLOG; WADE DT, 1987, SCAND J REHABIL MED, V19, P25	11	52	53	0	4	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	OCT	2003	17	7					775	779		10.1191/0269215503cr677oa			5	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	736CC	WOS:000186152000012	14606745				2022-02-06	
J	Raghupathi, R; Strauss, KI; Zhang, C; Krajewski, S; Reed, JC; McIntosh, TK				Raghupathi, R; Strauss, KI; Zhang, C; Krajewski, S; Reed, JC; McIntosh, TK			Temporal alterations in cellular Bax : Bcl-2 ratio following traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; beta cl-2; Bax; cell death; head injury	CORTICAL IMPACT INJURY; HUMAN HEAD-INJURY; BCL-X; TRANSGENIC MICE; NEURONAL DEATH; SYMPATHETIC NEURONS; GLOBAL-ISCHEMIA; SUPPRESSOR GENE; MEMORY DEFICITS; UP-REGULATION	Cell death/survival following CNS injury may be a result of alterations in the intracellular ratio of death and survival factors. Using immunohistochemistry, Western analysis and in situ hybridization, the expression of the anti-cell death protein, Bcl-2, and the pro-cell death protein, Bax, was evaluated following lateral fluid-percussion (FP) brain injury of moderate severity (2.3-2.6 atm) in adult male Sprague-Dawley rats. By 2 h post-injury, a marked reduction of cellular Bcl-2-immunoreactivity (IR) and a mild decrease in cellular Bax IR were observed in the temporal and occipital cortices, and in the hippocampal CA3 ipsilateral to the site of impact. These decreases in Bcl-2 and Bax IR appeared to precede the overt cell loss in these regions that was evident at 24 h. Immunoblot analysis supported the immunohistochemical data, with a modest but significant reduction in the intensities of both the Bcl-2 and Bax protein bands at 2 h (p < 0.05 compared to sham levels). However, the Bax:Bcl-2 ratio increased significantly at 2 h (2.28 +/- 0.13) and remained elevated up to 7 days (2.05 +/- 0.13) post-injury compared to sham-injured control tissue (1.62 +/- 0.10, p < 0.05). Furthermore, cortical, but not hippocampal, levels of Bax protein increased by 25% (p < 0.05 compared to sham-injured controls) at 24 h post-injury, and returned to control levels by 7 days. In situ hybridization analysis of Bax mRNA revealed increased cellular grain density in the injured cortex (p < 0.05 compared to sham-injured brains), but not in the CA3 region of the injured hippocampus. No injury-induced changes in the expression of Bcl-2 mRNA were observed in any brain region. Taken together, these data suggest that the association between regional post-traumatic cell death and alterations in the cellular ratio of Bcl-2 and Bax may be, in part, due to alterations in mRNA and/or protein expression of the Bcl-2 family of proteins.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; Burnham Inst, La Jolla, CA 92037 USA		Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, R01NS038654, P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS041561, R01 NS038654, R01NS41561, P50 NS008803, P50-NS08803, R01-NS26818] Funding Source: Medline		ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; CHEN J, 1996, J NEUROCHEM, V67, P1; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHESSELET MF, 1996, IN SITU HYBRIDIZATIO, P79; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DeBilbao F, 1996, NEUROSCIENCE, V71, P1111, DOI 10.1016/0306-4522(95)00505-6; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FULP CT, 2000, SOC NEUR ABST, V30; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gillardon F, 1996, J NEUROSCI RES, V43, P726, DOI 10.1002/(SICI)1097-4547(19960315)43:6<726::AID-JNR9>3.3.CO;2-Z; Gillardon F, 1996, BRAIN RES, V739, P244, DOI 10.1016/S0006-8993(96)00829-3; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hassouna I, 1996, NEUROSCI LETT, V204, P85, DOI 10.1016/0304-3940(96)12323-5; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Honkaniemi J, 1996, MOL BRAIN RES, V42, P79, DOI 10.1016/S0169-328X(96)00121-0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marin MC, 1996, ONCOGENE, V12, P2259; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYASHITA T, 1995, CELL, V80, P293; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RINK A, 1995, AM J PATHOL, V147, P1575; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STRAUSS KI, 1996, J NEUROTRAUM, V13, P620; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	75	52	56	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2003	20	5					421	435		10.1089/089771503765355504			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682MY	WOS:000183096900003	12803975	Green Accepted			2022-02-06	
J	Wilken, JA; Kane, R; Sullivan, CL; Wallin, M; Usiskin, JB; Quig, ME; Simsarian, J; Saunders, C; Crayton, H; Mandler, R; Kerr, D; Reeves, D; Fuchs, K; Manning, C; Keller, M				Wilken, JA; Kane, R; Sullivan, CL; Wallin, M; Usiskin, JB; Quig, ME; Simsarian, J; Saunders, C; Crayton, H; Mandler, R; Kerr, D; Reeves, D; Fuchs, K; Manning, C; Keller, M			The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosis	MULTIPLE SCLEROSIS			English	Article						automated assessment; cognition; cognitive dysfunction; computerized neuropsychological assessment; multiple sclerosis; prediction of cognitive impairment	MILD BRAIN INJURY; MONITORING RECOVERY; IMPAIRMENT; CONCUSSION; MEMORY; PERFORMANCE; EFFICIENCY; DISABILITY; MIGRAINE; PATTERNS	Traditional paper-and-pencil neuropsychological batteries used to document cognitive deficits in multiple sclerosis (MS) patients lack timing precision. This makes it difficult to accurately measure psychomotor slowing, a central cognitive symptom of MS. Additionally, traditional batteries lack multiple alternate forms necessary to control for practice effects when assessing cognition over time. Finally, such batteries are lengthy and expensive. Computerized neuropsychological batteries address many of these shortcomings. They measure response time more precisely, require less administration time, include alternate forms, and are ideal for rapid screening/triage. Although there are normative data on the reliability and validity of computerized measures, there have been no controlled validation studies with MS patients. The current study was designed to validate a computerized neuropsychological battery (ANAM) for use with relapsingremitting (RR) MS patients. Prior to initiation of interferon-beta-1a (Avonex) treatment, subjects participated in a neuropsychological evaluation consisting of traditional and computerized measures. Moderate-to-high correlations were found between computerized and traditional measures. Computerized tests accurately predicted performance on key traditional tests. The battery was also concordant with traditional measures in identifying RR MS patients with and without neurocognitive impairment. Findings are discussed with respect to increased accuracy and accessibility of neuropsychological evaluations for MS patients.	Vet Affairs Med Ctr, Dept Psychol, Washington, DC 20422 USA; Vet Affairs Med Ctr, Dept Neurol, Washington, DC 20422 USA; Vet Affairs Med Ctr, Mental Hlth Serv Line, Baltimore, MD 21201 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA; Neurol Ctr, Fairfax, VA USA; Johns Hopkins Univ, Med Ctr, Dept Neurol, Baltimore, MD 21218 USA; USN, San Diego, CA 92055 USA; Univ Virginia, Med Ctr, Charlottesville, VA 22908 USA		Wilken, JA (corresponding author), Vet Affairs Med Ctr, Dept Psychol, 50 Irving St NW, Washington, DC 20422 USA.		Wallin, Mitchell T./J-8190-2019; KERR, Douglas A/B-9270-2008; Weiderpass, Elisabete/AAP-2747-2021	Wallin, Mitchell T./0000-0003-1061-5714; Weiderpass, Elisabete/0000-0003-2237-0128			AMATO MP, 1995, ARCH NEUROL-CHICAGO, V52, P168, DOI 10.1001/archneur.1995.00540260072019; [Anonymous], 1993, NEUROPSYCHOLOGY, V7, P364, DOI [DOI 10.1037/0894-4105.7.3.364, 10.1037/0894-4105.7.3.364]; Arnett PA, 1997, NEUROPSYCHOLOGY, V11, P535, DOI 10.1037/0894-4105.11.4.535; BEATTY WW, 1995, NEUROPSYCHOLOGY, V9, P198, DOI 10.1037/0894-4105.9.2.198; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DELIS C, 1987, CALIFORNIA VERBAL LE; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; ELPERN SJ, 1984, INT NEUR SOC HOUST T; ELSASS P, 1983, ACTA NEUROL SCAND, V68, P257, DOI 10.1111/j.1600-0404.1983.tb04835.x; Farmer K, 2000, HEADACHE, V40, P657, DOI 10.1046/j.1526-4610.2000.040008657.x; Farmer K, 2001, HEADACHE, V41, P377, DOI 10.1046/j.1526-4610.2001.111006377.x; Gottschalk LA, 2000, COMPR PSYCHIAT, V41, P326, DOI 10.1053/comp.2000.9015; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HEATON RK, 1985, J CONSULT CLIN PSYCH, V53, P103, DOI 10.1037/0022-006X.53.1.103; HEGGE FW, 1985, UNIFIED TRISERVICE C; KABAT, 2001, CLIN NEUROPSYCHOL, V15, P498; Kail R, 1998, J CLIN EXP NEUROPSYC, V20, P98, DOI 10.1076/jcen.20.1.98.1483; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; Krupp LB, 2000, NEUROLOGY, V55, P934, DOI 10.1212/WNL.55.7.934; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; Ling ND, 1998, PERCEPT MOTOR SKILL, V86, P987, DOI 10.2466/pms.1998.86.3.987; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MAHLER ME, 1992, PSYCHIAT CLIN N AM, V15, P427; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1995, CURR OPIN NEUROL, V8, P216, DOI 10.1097/00019052-199506000-00010; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Reeves D, 1992, AUTOMATED NEUROPSYCH, VI; REEVES DL, 1992, ANN M AM PSYCH ASS A; Reitan R, 1985, HALSTEAD REITAN NEUR; Reitan R., 1979, MANUAL ADM NEUROPSYC; RON MA, 1991, PSYCHOL MED, V21, P59, DOI 10.1017/S0033291700014653; Ryan L, 1996, NEUROPSYCHOLOGY, V10, P176, DOI 10.1037/0894-4105.10.2.176; SAMET M, 1986, COMPLEX COGNITIVE AS; THORNE DR, 1985, NEUROBEH TOXICOL TER, V7, P415; Thornton AE, 1997, NEUROPSYCHOLOGY, V11, P357, DOI 10.1037/0894-4105.11.3.357; VANDENBURG W, 1987, ARCH NEUROL-CHICAGO, V44, P494, DOI 10.1001/archneur.1987.00520170024017; Wechsler D., 1997, WECHSLER ADULT INTEL, VIII; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Wishart H, 1997, J CLIN EXP NEUROPSYC, V19, P810, DOI 10.1080/01688639708403762	44	52	54	0	7	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	1352-4585			MULT SCLER	Mult. Scler.	MAR	2003	9	2					119	127		10.1191/1352458503ms893oa			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	666QC	WOS:000182187100002	12708806				2022-02-06	
J	Royo, NC; Shimizu, S; Schouten, J; Stover, JF; McIntosh, TK				Royo, NC; Shimizu, S; Schouten, J; Stover, JF; McIntosh, TK			Pharmacology of traumatic brain injury	CURRENT OPINION IN PHARMACOLOGY			English	Article							CORTICAL IMPACT INJURY; CHANNEL BLOCKER ZICONOTIDE; NITRIC-OXIDE SYNTHASE; RECEPTOR ANTAGONIST; BARRIER BREAKDOWN; OXIDATIVE STRESS; CYCLOSPORINE-A; NMDA RECEPTOR; DOSE-RESPONSE; CELL-DEATH	The intensity of experimental and clinical research to identify a neuroprotective drug for the treatment of traumatic brain injury is motivated by the devastating morbidity and mortality of this condition. Encouraging experimental work has led so far to disappointing clinical trials and the identification of new potential therapeutic targets is critically dependent on a better understanding of the chronic pathophysiology triggered by the initial insult. Future advances in the pharmacological treatment of traumatic brain injury are likely to include the evaluation of sequentially timed therapies combining multiple and targeted agents, and manipulation of the newly discovered neurogenic potential of the adult brain together with the refinement of traditional interventions to block specific cytotoxic cascades.	Univ Penn, Dept Neurosurg, Head Injury Ctr, Philadelphia, PA 19104 USA		Royo, NC (corresponding author), Univ Penn, Dept Neurosurg, Head Injury Ctr, 3320 Smith Walk,105 C Hayden Hall, Philadelphia, PA 19104 USA.	nroyo@mail.med.upenn.edu; joost@mail.med.upenn.edu; saori2@mail.med.upenn.edu; stover@mail.med.upenn.edu; mcintosh@seas.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34790] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS40978] Funding Source: Medline		Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Aoyama N, 2002, BRAIN RES, V934, P117, DOI 10.1016/S0006-8993(02)02366-1; Atlante A, 2001, FEBS LETT, V497, P1, DOI 10.1016/S0014-5793(01)02437-1; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bareyre FM, 2002, J NEUROSCI, V22, P7097; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Beaumont A, 2000, NEUROL RES, V22, P665; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Belayev L, 2002, J NEUROSURG, V96, P1077, DOI 10.3171/jns.2002.96.6.1077; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Chabrier PE, 1999, P NATL ACAD SCI USA, V96, P10824, DOI 10.1073/pnas.96.19.10824; Cheney JA, 2001, J CEREBR BLOOD F MET, V21, P396, DOI 10.1097/00004647-200104000-00008; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Katoh-Semba R, 2002, FASEB J, V16, P1328, DOI 10.1096/fj.02-0143fje; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Khaldi A, 2002, ANN NY ACAD SCI, V962, P53, DOI 10.1111/j.1749-6632.2002.tb04055.x; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LENZLINGER PM, 2002, J NEUROTRAUM, V19, P1276; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newcomer JW, 2001, HIPPOCAMPUS, V11, P529, DOI 10.1002/hipo.1069.abs; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 2001, BRAIN RES, V911, P96; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Stutzmann JM, 2002, CNS DRUG REV, V8, P1; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Wahl F, 1999, ACT NEUR S, V73, P103; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	74	52	57	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4892	1471-4973		CURR OPIN PHARMACOL	Curr. Opin. Pharmacol.	FEB	2003	3	1					27	32		10.1016/S1471-4892(02)00006-1			6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	637EA	WOS:000180497600005	12550738				2022-02-06	
J	Masson, F; Thicoipe, M; Mokni, T; Aye, P; Erny, P; Dabadie, P				Masson, F; Thicoipe, M; Mokni, T; Aye, P; Erny, P; Dabadie, P		Aquitaine Grp Severe Brain Injury	Epidemiology of traumatic comas: a prospective population-based study	BRAIN INJURY			English	Article							SEVERE HEAD-INJURIES; BRAIN INJURY; UNITED-STATES; OLDER ADULTS; MORTALITY; DEATHS; GUIDELINES; FALLS; CARE; PREVENTION	Objective: Most studies on patients with severe brain injury (SBI) are based on data from specialized centres. This prospective epidemiologic study included all patients in a defined region with a coma lasting more than 24 hours or leading to a death. Methods: All patients with a SBI admitted to an emergency department in the region were included during a 1-year period. A data form was completed with initial neurological state, CT scan lesions and associated injuries. Outcome at the end of acute hospitalization was assessed from medical notes. Results: Two hundred and forty-eight patients were registered. Annual incidence was 8.5/100 000 population. Median age was 41 years. Traffic crashes were the most frequent cause (59%). Falls occurred in 30% (16% from a high level, 14% from one level). Initial GCS was above 8 in 31%, and patients with a neurological deterioration were older ( 52 vs 32 years). Death occurred in 52% of the cohort. Outcome was related to CT scan diagnosis, delay before eye opening and delay before obeying commands. Conclusion. This population-based cohort of patients with SBI was different from patients selected in trauma centres. The patients were older, more often injured in falls and their mortality rate remained very high.	Univ Hosp Bordeaux, Dept Anesthesia, Bordeaux, France; Univ Hosp Bordeaux, Dept Emergency, Bordeaux, France; Hosp Bayonne, Dept Emergency, Bayonne, France; Hosp Pau, Dept Emergency, Pau, France		Masson, F (corresponding author), Hop Pellegrin, Serv Reanimat, F-33076 Bordeaux, France.						American Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Baethmann A, 2002, EUR SURG RES, V34, P42, DOI 10.1159/000048886; Braver ER, 1997, JAMA-J AM MED ASSOC, V278, P1437, DOI 10.1001/jama.278.17.1437; Bruder N, 1997, ANN FR ANESTH, V16, P227, DOI 10.1016/S0750-7658(97)86405-2; Carter ND, 2001, SPORTS MED, V31, P427, DOI 10.2165/00007256-200131060-00003; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GENTLEMAN D, 1993, BRIT MED J, V307, P547, DOI 10.1136/bmj.307.6903.547; Gentleman D, 1999, BRIT MED BULL, V55, P910, DOI 10.1258/0007142991902718; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Gubler KD, 1996, J TRAUMA, V41, P952, DOI 10.1097/00005373-199612000-00002; Hannan EL, 2001, J TRAUMA, V50, P1117, DOI 10.1097/00005373-200106000-00023; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kannus P, 2001, J CLIN EPIDEMIOL, V54, P597, DOI 10.1016/S0895-4356(00)00346-2; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LAVECCHIA C, 1994, SOZ PRAVENTIV MED, V39, P150, DOI 10.1007/BF01299659; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MacKenzie E J, 1989, Md Med J, V38, P725; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MCKENZIE EJ, 1988, J TRAUMA, V28, P281; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; *OBS NAT INT SEC R, 1997, BIL ANN STAT COMM AN, P1; Piek J, 1998, INTENS CARE MED, V24, P1221, DOI 10.1007/s001340050748; Rzepka SG, 2001, J CLIN EPIDEMIOL, V54, P627, DOI 10.1016/S0895-4356(00)00337-1; SALMI LR, 1989, ACCIDENT ANAL PREV, V6, P589; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sterling DA, 2001, J TRAUMA, V50, P116, DOI 10.1097/00005373-200101000-00021; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Vollmer DG, 1991, J NEUROSURG S, V75, P37; WINKLER J V, 1984, Journal of Emergency Medicine, V2, P1, DOI 10.1016/0736-4679(84)90038-6; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	45	52	56	1	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	4					279	293		10.1080/0269905021000030805			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	660MP	WOS:000181837200002	12637181				2022-02-06	
J	McCullagh, S; Feinstein, A				McCullagh, S; Feinstein, A			Outcome after mild traumatic brain injury: an examination of recruitment bias	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							MINOR HEAD-INJURY; GLASGOW-COMA-SCALE; FOLLOW-UP; SYMPTOMS; CLASSIFICATION; PREDICTION; AMNESIA; TRIAL	Objectives: Research concerning the natural history after mild traumatic brain injury (TBI) faces a number of methodological challenges, including those related to subject recruitment. The aim of this study was to determine whether subjects who agree to participate in longitudinal research differ from those who do not. The presence of identifiable, selective factors operating during recruitment may be an important source of systematic bias. In Canada, given the presence of universal healthcare coverage, this issue can be examined using population based, administrative databases to obtain information about a cohort that was approached for study enrolment, regardless of whether they ultimately agreed to participate. Methods: A sample of 626 consecutive patients with mild TBI was invited to enrol in TBI outcome research. Those who agreed to participate (n=272) were compared with those who refused (n=354) on demographic, past health, and injury related variables. Thereafter, using encrypted health card data, the two groups were contrasted with respect to pre-injury and post-injury healthcare utilisation. Results: No premorbid differences between the groups emerged. However, all early indices of TBI severity were significantly worse for the participants group (p<0.001). Consistent with these findings, healthcare utilisation rates were no different before injury, but were significantly increased after injury for the participants (p<0.001), even beyond the period of study enrolment (p<0.001). Differences remained even after controlling for those with significant non-TBI injuries. Conclusions: Premorbid factors did not predict whether patients comply with, or refuse study participation. However, the participants group was biased toward those with more significant injuries, which translated into higher rates of healthcare utilisation after injury. These results strike a cautionary note, given the apparent systematic bias influencing enrolment in longitudinal studies of mild TBI.	Sunnybrook & Womens Coll Hosp, Neuropsychiat Program, Toronto, ON M4N 3M5, Canada		McCullagh, S (corresponding author), Sunnybrook & Womens Coll Hosp, Neuropsychiat Program, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	scott.mccullagh@swchsc.on.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Barth JT, 1989, MILD HEAD INJURY, P257; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; Britton A, 1999, J Health Serv Res Policy, V4, P112; CHAN B, 1999, ICES ATLAS REPORTS, P1; CONDON JT, 1986, AUST NZ J PSYCHIAT, V20, P87, DOI 10.3109/00048678609158870; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; EDLUND MJ, 1985, AM J PSYCHIAT, V142, P624; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P468; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HOLDEN G, 1993, SOC WORK HEALTH CARE, V19, P1, DOI 10.1300/J010v19n02_01; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kraus J, 2000, HEAD INJURY, P1; KROENKE K, 1993, ARCH INTERN MED, V153, P2474, DOI 10.1001/archinte.153.21.2474; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P159; Simon G, 1996, PSYCHOSOM MED, V58, P481, DOI 10.1097/00006842-199609000-00010; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; *STAT CAN, 1997, STAT CAN POP CENS 19; VANHEMERT AM, 1993, PSYCHOL MED, V23, P167, DOI 10.1017/S0033291700038952; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 1992, LANCET, V340, P823; [No title captured]	40	52	52	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2003	74	1					39	43		10.1136/jnnp.74.1.39			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	632DA	WOS:000180207400011	12486264	Green Published, Bronze			2022-02-06	
J	Scott, CW; Sobotka-Briner, C; Wilkins, DE; Jacobs, RT; Folmer, JJ; Frazee, WJ; Bhat, RV; Ghanekar, SV; Aharony, D				Scott, CW; Sobotka-Briner, C; Wilkins, DE; Jacobs, RT; Folmer, JJ; Frazee, WJ; Bhat, RV; Ghanekar, SV; Aharony, D			Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; SELECTIVE NONPEPTIDE INHIBITORS; SH-SY5Y NEUROBLASTOMA-CELLS; TRAUMATIC BRAIN INJURY; DEPRIVED PC12 CELLS; POTENT; DEATH; ACTIVATION; SUBSTRATE; CLEAVAGE	Caspase-3 is an intracellular cysteine protease, activated as part of the apoptotic response to cell injury. Its interest as a therapeutic target has led many to pursue the development of inhibitors. To date, only one series of nonpeptidic inhibitors have been described, and these have limited selectivity within the caspase family. Here we report the properties of a series of anilinoquinazolines (AQZs) as potent small molecule inhibitors of caspase-3. The AQZs inhibit human caspase-3 with K-i values in the 90 to 800 nM range. A subset of AQZs are equipotent against caspase-6, although most lack activity against this isoform and caspase-1, -2, -7, and -8. The AQZs inhibit endogenous caspase-3 activity toward a cell permeable, exogenously added substrate in staurosporine-treated SH-SY5Y cells. The AQZs reduce biochemical and cellular features of apoptosis that are thought to be a consequence of caspase-3 activation including DNA fragmentation, TUNEL staining, and the various morphological features that define the terminal stages of apoptotic cell death. Moreover, the AQZs also inhibit apoptosis induced by nerve growth factor withdrawal from differentiated PC12 cells. Thus, the AQZs represent a new and structurally novel class of inhibitors, some of which selectively inhibit caspase-3 and will thereby allow evaluation of the role of caspase-3 activity in various cellular models of apoptosis.	AstraZeneca Pharmaceut, Dept Lead Discovery, St Petersburg 198103, Russia; AstraZeneca Pharmaceut, Neurosci Lab, St Petersburg 198103, Russia; AstraZeneca Pharmaceut, Dept Chem, St Petersburg 198103, Russia		Scott, CW (corresponding author), AstraZeneca Pharmaceut, Dept Lead Discovery, LW208,1800 Concord Pike, St Petersburg 198103, Russia.						Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haviv R, 1997, J NEUROSCI RES, V50, P69, DOI 10.1002/(SICI)1097-4547(19971001)50:1<69::AID-JNR8>3.0.CO;2-J; JACOBS RT, Patent No. 0121598; Karanewsky DS, 1998, BIOORG MED CHEM LETT, V8, P2757, DOI 10.1016/S0960-894X(98)00498-3; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lee D, 2001, J MED CHEM, V44, P2015, DOI 10.1021/jm0100537; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Liu JX, 1999, BIOORG MED CHEM LETT, V9, P3231; Lopez E, 2000, MOL BRAIN RES, V85, P61, DOI 10.1016/S0169-328X(00)00235-7; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nobel CSI, 1997, CHEM RES TOXICOL, V10, P1319, DOI 10.1021/tx970131m; Nuttall ME, 2001, DRUG DISCOV TODAY, V6, P85, DOI 10.1016/S1359-6446(00)01601-9; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Stefanis L, 1998, J NEUROSCI, V18, P9204; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xu DG, 1999, J NEUROSCI, V19, P5026; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2	32	52	56	0	1	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JAN	2003	304	1					433	440		10.1124/jpet.102.039651			8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	626UR	WOS:000179892200053	12490620				2022-02-06	
J	O'Brien, CF				O'Brien, CF			Treatment of spasticity with botulinum toxin	CLINICAL JOURNAL OF PAIN			English	Article						spasticity; neural pathways; demyelination; botulinum toxin	PLACEBO-CONTROLLED TRIAL; TRAUMATIC BRAIN INJURY; UPPER-LIMB SPASTICITY; UPPER EXTREMITY SPASTICITY; DOUBLE-BLIND; CEREBRAL-PALSY; MULTIPLE-SCLEROSIS; MUSCLE SPASTICITY; CERVICAL DYSTONIA; STROKE PATIENTS	Spasticity is an abnormal increase in muscle contraction often caused by damage to central motor pathways that control voluntary movement. During clinical examination, spasticity manifests as an increase in stretch reflexes, producing tendon jerks and resistance appearing as muscle tone. There are many causes of spasticity, including demyelination from multiple sclerosis, congenital damage from diseases such as cerebral palsy, trauma to the brain or spinal cord, hemorrhage or infarction, and other pathologic conditions that interrupt neural pathways. Effects of spasticity range from mild muscle stiffness to severe, painful muscle contractures and repetitive spasms that reduce mobility and substantially impede normal activitics of daily living. Botulinum toxin therapy reduces spasticity and pain associated with several disorders. Local treatment with botulinum toxins can be used as adjunctive therapy, along with oral antispasticity medications, or alone to provide localized decrease in symptoms of spasticity and pain. Botulinum toxin therapy may be particularly useful for patients with spasticity due to stroke, whose treatment can be tailored based on recovery of function over time. In addition, botulinum toxin therapy is safe for pediatric patients, including children with cerebral palsy, who may not be able to tolerate the cognitive side effects of oral medications. Results of studies evaluating botulinum toxin for the treatment of spasticity due to various causes are presented here.	Elan Pharmaceut, San Diego, CA 92121 USA		O'Brien, CF (corresponding author), Elan Pharmaceut, 7475 Lusk Blvd, San Diego, CA 92121 USA.	Christopher.Obrien@elan.com					Bakheit AMO, 2000, STROKE, V31, P2402, DOI 10.1161/01.STR.31.10.2402; Bakheit AMO, 2001, EUR J NEUROL, V8, P559, DOI 10.1046/j.1468-1331.2001.00277.x; Bakheit AMO, 2001, DEV MED CHILD NEUROL, V43, P234, DOI 10.1017/S0012162201000445; Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Bentivoglio AR, 1999, CURR OPIN NEUROL, V12, P447, DOI 10.1097/00019052-199908000-00012; Bhakta BB, 2000, J NEUROL NEUROSUR PS, V69, P217, DOI 10.1136/jnnp.69.2.217; Bhakta BB, 1996, J NEUROL NEUROSUR PS, V61, P30, DOI 10.1136/jnnp.61.1.30; Blitzer A, 2001, LARYNGOSCOPE, V111, P218, DOI 10.1097/00005537-200102000-00006; BORGSTEIN J, 1993, AM J PHYS MED REHAB, V72, P364; Brin M F, 1997, Muscle Nerve Suppl, V6, pS208; Brin MF, 1999, NEUROLOGY, V53, P1431, DOI 10.1212/WNL.53.7.1431; Corry IS, 1999, GAIT POSTURE, V10, P206, DOI 10.1016/S0966-6362(99)00037-5; Dauer WT, 1998, BRAIN, V121, P547, DOI 10.1093/brain/121.4.547; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; Goldstein EM, 2001, J CHILD NEUROL, V16, P16, DOI 10.1177/088307380101600104; Gordon N, 1999, BRAIN DEV-JPN, V21, P147, DOI 10.1016/S0387-7604(98)00099-0; Gormley ME, 2001, J CHILD NEUROL, V16, P113, DOI 10.2310/7010.2001.6901; Gormley ME, 1997, MUSCLE NERVE, pS14; Gracies JM, 1997, MUSCLE NERVE, pS92; GRACIES JM, 1997, MUSCLE NERVE       S, V6, pS61; Graham HK, 2000, GAIT POSTURE, V11, P67, DOI 10.1016/S0966-6362(99)00054-5; Hesse S, 2001, DRUG AGING, V18, P255, DOI 10.2165/00002512-200118040-00003; Hyman N, 2000, J NEUROL NEUROSUR PS, V68, P707, DOI 10.1136/jnnp.68.6.707; Kesselring J, 1997, BAILLIERE CLIN NEUR, V6, P429; Kirazli Y, 1998, AM J PHYS MED REHAB, V77, P510, DOI 10.1097/00002060-199811000-00012; KIRSCHNER J, 2001, J NEUROL S1, V248; Kita M, 2000, DRUGS, V59, P487, DOI 10.2165/00003495-200059030-00006; Koman LA, 2000, J PEDIATR ORTHOPED, V20, P108, DOI 10.1097/00004694-200001000-00022; Lagalla G, 2000, AM J PHYS MED REHAB, V79, P377, DOI 10.1097/00002060-200007000-00010; Lew MF, 2000, NEUROLOGY, V55, pS29; Mahant N, 2000, J CLIN NEUROSCI, V7, P389, DOI 10.1054/jocn.2000.0684; Mayer NH, 1997, MUSCLE NERVE, pS1; METAXIOTIS D, 2002, CLIN ORTHOP RELAT R, V394, P177; OBRIEN C, 2002, INT C 2002 BAS THER; OBrien CF, 1996, DRUG AGING, V9, P332, DOI 10.2165/00002512-199609050-00004; Pavesi G, 1998, J NEUROL NEUROSUR PS, V64, P419, DOI 10.1136/jnnp.64.3.419; Ruiz PJG, 2000, EUR J NEUROL, V7, P191, DOI 10.1046/j.1468-1331.2000.00043.x; Sampaio C, 1997, CLIN REHABIL, V11, P3, DOI 10.1177/026921559701100102; Schapiro R T, 2001, Curr Neurol Neurosci Rep, V1, P299, DOI 10.1007/s11910-001-0034-6; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Simpson DM, 2000, MUSCLE NERVE, V23, P447, DOI 10.1002/(SICI)1097-4598(200004)23:4<447::AID-MUS1>3.0.CO;2-J; Wang HC, 2002, AM J PHYS MED REHAB, V81, P272, DOI 10.1097/00002060-200204000-00005; Watanabe Y, 1998, DISABIL REHABIL, V20, P62, DOI 10.3109/09638289809166055; Wissel J, 2000, J PAIN SYMPTOM MANAG, V20, P44, DOI 10.1016/S0885-3924(00)00146-9; Wong V, 2002, J CHILD NEUROL, V17, P138, DOI 10.1177/088307380201700210; Wong V, 1998, PEDIATR NEUROL, V18, P124, DOI 10.1016/S0887-8994(97)00164-1; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939; 2002, SUGGESTED ADULT MYOB	48	52	53	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	NOV-DEC	2002	18	6		S			S182	S190		10.1097/00002508-200211001-00011			9	Anesthesiology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	614AV	WOS:000179165400011	12569967				2022-02-06	
J	Gorrie, C; Oakes, S; Duflou, J; Blumbergs, P; Waite, PME				Gorrie, C; Oakes, S; Duflou, J; Blumbergs, P; Waite, PME			Axonal injury in children after motor vehicle crashes: Extent, distribution, and size of axonal swellings using beta-APP immunohistochemistry	JOURNAL OF NEUROTRAUMA			English	Article						beta-APP; axons diameter; axonal injury	AMYLOID PRECURSOR PROTEIN; NONMISSILE HEAD-INJURY; TRAUMATIC BRAIN INJURY; CORPUS-CALLOSUM; DAMAGE; TRANSPORT; HUMANS; MARKER; MODEL; NEUROPATHOLOGY	The brains of 32 children (3 months to 16 years) who died as a result of motor vehicle collisions were examined for axonal injury using,beta-APP immunohistochemistry. The extent and distribution of axonal injury was assessed and quantified throughout the forebrain, brainstem and cerebellum. The mean diameter of immunoreactive axons in the corpus callosum was measured for this pediatric group and, for comparison, a small adult sample. beta-APP immunoreactivity was seen in 14 pediatric cases (survival 35 mins to 87 h), most frequently in the parasagittal white matter (12/14), the corpus callosum (11/14), the brainstem (10/14) and cerebellum (9/14). In 2 cases, axon swelling was visualized in the internal capsule after only 35-45-min survival, earlier than has previously been reported. No immunoreactivity was seen in the remaining 18 cases who died within I h. The extent and distribution of axonal injury throughout the brain showed a rapid early increase with increasing survival time and then a slower progression. The diameter of individual callosal axons increased with increasing survival times, rapidly over the first 24 h and then more slowly. There was no statistical difference (p < 0.05) for callosal axon diameters at different survival times between the children and the adults sampled here. The extent and distribution of axonal injury throughout the brain appears to be similar in children to that previously reported in adults. The spatial and temporal spread of axonal damage suggests there may be therapeutic potential for the process to be arrested or slowed in its early stages.	Univ New S Wales, Sch Med Sci, Neural Injury Res Unit, Sydney, NSW 2052, Australia; Sydney Cent Area Hlth Serv, Dept Forens Med, Sydney, NSW, Australia; Inst Med & Vet Sci, Neuropathol Lab, Adelaide, SA 5000, Australia		Gorrie, C (corresponding author), Univ New S Wales, Sch Biomed Sci, Dept Anat, Neural Injury Res Unit, Wallace Wurth Bldg, Sydney, NSW 2052, Australia.		Duflou, Johan/AAK-2331-2020; Gorrie, Catherine/S-6591-2019	Gorrie, Catherine/0000-0001-5934-2492; Duflou, Johan/0000-0001-5863-635X; Oakes, Samantha/0000-0003-1838-2310			ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P485; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Blumbergs PC, 1998, J CLIN NEUROSCI, V5, P123, DOI 10.1016/S0967-5868(98)90026-1; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRODY BA, 1987, J NEUROPATH EXP NEUR, V46, P283, DOI 10.1097/00005072-198705000-00005; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Finnie J, 1999, J CLIN NEUROSCI, V6, P38, DOI 10.1016/S0967-5868(99)90601-X; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Gorrie C, 1999, CHILD NERV SYST, V15, P322, DOI 10.1007/s003810050403; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Koszyca B, 1998, J NEUROTRAUM, V15, P675, DOI 10.1089/neu.1998.15.675; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; POLITIS MJ, 1979, BRAIN RES, V166, P221, DOI 10.1016/0006-8993(79)90209-9; Povlishock J T, 2000, Clin Neurosurg, V46, P113; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RUSS JC, 1994, IMAGE PROCESSING HDB; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Slazinski T, 1994, J Neurosci Nurs, V26, P151; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; TEMPLETON JM, 1993, PEDIAT TRAUMA PREVEN, P20; VIANCOUR TA, 1993, BRAIN RES, V628, P209, DOI 10.1016/0006-8993(93)90957-O; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; WAXMAN SG, 1993, BRAIN RES, V614, P137, DOI 10.1016/0006-8993(93)91027-P; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	52	52	54	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2002	19	10					1171	1182		10.1089/08977150260337976			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	605MJ	WOS:000178681400006	12427326				2022-02-06	
J	Constantinidou, F; Baker, S				Constantinidou, F; Baker, S			Stimulus modality and verbal learning performance in normal aging	BRAIN AND LANGUAGE			English	Article						stimulus modality; working memory; delay; interference; recall retrieval; recognition; learning styles	CLOSED-HEAD INJURY; WORKING-MEMORY; MODERATE; ADULTS; YOUNG	The present study investigated the effects of modality presentation on the verbal learning performance of 26 older adults and 26 younger cohorts. A multitrial free-recall paradigm was implemented incorporating three modalities: Auditory, Visual, and simultaneous Auditory plus Visual. Older subjects learned fewer words than younger subjects but their rate of learning was similar to that of the younger group. The visual presentation of objects (with or without the simultaneous auditory presentation of names) resulted in better learning, recall, and retrieval of information than the auditory presentation alone. (C) 2002 Elsevier Science (USA). All rights reserved.	Miami Univ, Dept Speech Pathol & Audiol, Oxford, OH 45056 USA; Univ Florida, Dept Commun Sci & Disorders, Gainesville, FL USA		Constantinidou, F (corresponding author), Miami Univ, Dept Speech Pathol & Audiol, 2 Bachelor Hall, Oxford, OH 45056 USA.			Constantinidou, Fofi/0000-0002-7928-8363			ALESANDRINI KL, 1981, J EDUC PSYCHOL, V73, P358, DOI 10.1037/0022-0663.73.3.358; Baddeley A, 1999, BRAIN COGNITION, V41, P87, DOI 10.1006/brcg.1999.1097; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Cheema I., 1991, ED PSYCHOL, V11, P193; Constantinidou F, 1999, J MED SPEECH-LANG PA, V7, P283; Constantinidou F, 1996, J GEN PSYCHOL, V123, P173, DOI 10.1080/00221309.1996.9921270; CONSTANTINIDOU F, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199508000-00009; Craik F.I.M., 1991, MEMORY DISORDERS RES; Craik F. I. M., 1986, HUMAN MEMORY COGNITI; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; DELIS DC, 1987, CALIF VERBAL LEARNIN; Diller L, 1974, STUDIES COGNITION RE; ELBERT M, 1980, CONTRASTS PICTURE FI; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; JONES SJ, 1994, Q J EXP PSYCHOL-A, V47, P1001, DOI 10.1080/14640749408401104; Kasniak A.W., 1986, HDB CLIN MEMORY ASSE; King DA, 1998, J INT NEUROPSYCH SOC, V4, P115, DOI 10.1017/S1355617798001155; KIRBY JR, 1988, CONTEMP EDUC PSYCHOL, V13, P169, DOI 10.1016/0361-476X(88)90017-3; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; ODONNELL JP, 1988, J GEN PSYCHOL, V115, P355, DOI 10.1080/00221309.1988.9710572; Paivio A., 1976, MENTAL REPRESENTATIO; Paivio A., 1971, IMAGERY VERBAL PROCE; Richardson A., 1977, J MENTAL IMAGERY; Riding RJ, 1996, EDUC PSYCHOL, V16, P81, DOI 10.1080/0144341960160107; Salthouse T. A, 1992, HDB AGING COGNITION; SCHOFIELD NJ, 1994, COGNITION INSTRUCT, V12, P35, DOI 10.1207/s1532690xci1201_2; SHARPS MJ, 1988, J GERONTOL, V43, pP8, DOI 10.1093/geronj/43.1.P8; SHARPS MJ, 1991, PSYCHOL AGING, V6, P309, DOI 10.1037/0882-7974.6.2.309; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; Thorndike E. L., 1944, TEACHERS BOOK 30000; Wechsler D, 1987, MEMORY SCALE REVISED	32	52	52	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	SEP	2002	82	3					296	311	PII S0093-934X(02)00018-4	10.1016/S0093-934X(02)00018-4			16	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	587WV	WOS:000177667800002	12160526				2022-02-06	
J	Saljo, A; Bao, F; Shi, JS; Hamberger, A; Hansson, HA; Haglid, KG				Saljo, A; Bao, F; Shi, JS; Hamberger, A; Hansson, HA; Haglid, KG			Exposure to short-lasting impulse noise causes neuronal c-Jun expression and induction of apoptosis in the adult rat brain	JOURNAL OF NEUROTRAUMA			English	Article						acoustic energy; apoptosis; brain damage; closed head injury; immediate early gene; impulse noise; pressure waves	PROGRAMMED CELL-DEATH; SPINAL-CORD INJURY; INDUCIBLE TRANSCRIPTION FACTORS; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; METHYL-D-ASPARTATE; PARKINSONS-DISEASE; DNA FRAGMENTATION; SUBSTANTIA-NIGRA; SENSORY NEURONS	Exposure to impulse noise, above a certain intensity, is harmful to auditory function. Effects of impulse noise on the central nervous system (CNS) are largely unexplored, and there is little information on critical threshold values and time factors. We have recently shown that neurofilament proteins are affected in the cerebral cortex and the hippocampus. Now we show that impulse noise induces expression of the immediate early gene c-Jun products, proposed to play a role in the initiation of neuronal death, and apoptosis as revealed by TUNEL staining. Rat brains were investigated immunohistochemically 2 h to 21 days after exposure to impulse noise of 198 dB or 202 dB. c-Jun was expressed in neuronal perikarya in layers II-VI of the temporal cortex, the cingulate and the piriform cortices at 2 h to 21 days after both exposure levels. Granule neurons of the dentate gyrus and the CA1-3 in the hippocampus pyramidal neurons were similarly affected. The elevated expression of c-Jun products remained high at all postexposure times. TUNEL staining was positive among the same nerve cell populations 6 h after exposure and persisted even at 7 days at both exposure levels.	Univ Gothenburg, Dept Anat & Cell Biol, SE-40530 Gothenburg, Sweden; China Med Univ, Inst Brain Res, Shenyang, Peoples R China; Zunyi Med Coll, Dept Pharmacol, Zunyi, Peoples R China		Saljo, A (corresponding author), Univ Gothenburg, Dept Anat & Cell Biol, POB 420, SE-40530 Gothenburg, Sweden.	annette.saljo@anatcell.gu.se					BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Burke RE, 1998, ANN NEUROL, V44, pS126, DOI 10.1002/ana.410440719; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; CERNAK I, 1997, INT REV ARMED FORCES, V70, P114; Cheung NS, 1998, J NEUROSCI RES, V52, P69, DOI 10.1002/(SICI)1097-4547(19980401)52:1<69::AID-JNR7>3.3.CO;2-L; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; COHEN JJ, 1984, J IMMUNOL, V132, P38; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dancer A, 1998, SCAND AUDIOL, V27, P123; DEFELIPE C, 1994, J NEUROSCI, V14, P2911; DRAGUNOW M, 1995, BRAIN RES REV, V21, P1, DOI 10.1016/0165-0173(95)00003-L; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Ferrer I, 1996, EUR J NEUROSCI, V8, P1286, DOI 10.1111/j.1460-9568.1996.tb01297.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HERDEGEN T, 1991, NEUROSCIENCE, V45, P413, DOI 10.1016/0306-4522(91)90237-I; HERDEGEN T, 1992, MOL BRAIN RES, V14, P155, DOI 10.1016/0169-328X(92)90170-G; HERDEGEN T, 1995, J COMP NEUROL, V354, P39, DOI 10.1002/cne.903540105; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Houle JD, 1998, EXP NEUROL, V154, P602, DOI 10.1006/exnr.1998.6954; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; *ISO, 1992, 317 ISO; JENKINS R, 1993, NEUROSCIENCE, V53, P447, DOI 10.1016/0306-4522(93)90208-W; JENKINS R, 1991, NEUROSCI LETT, V129, P107, DOI 10.1016/0304-3940(91)90731-8; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Katano H, 1998, BRAIN RES, V800, P69, DOI 10.1016/S0006-8993(98)00493-4; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI Y, 1995, MOL BRAIN RES, V28, P164, DOI 10.1016/0169-328X(94)00220-9; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Liu XZ, 1997, J NEUROSCI, V17, P5395; Messina A, 1996, J COMP NEUROL, V372, P544, DOI 10.1002/(SICI)1096-9861(19960902)372:4<544::AID-CNE4>3.0.CO;2-4; Mochizuki H, 1996, J NEUROL SCI, V137, P120, DOI 10.1016/0022-510X(95)00336-Z; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Oo TF, 1999, J NEUROCHEM, V72, P557, DOI 10.1046/j.1471-4159.1999.0720557.x; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Pennypacker K, 1997, HISTOL HISTOPATHOL, V12, P1125; Pittman S, 1997, LEUKEMIA RES, V21, P491, DOI 10.1016/S0145-2126(97)00038-6; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; RINK A, 1995, AM J PATHOL, V147, P1575; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Smith BJ, 1997, IEEE DES TEST COMPUT, V14, P7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Wullner U, 1999, ACTA NEUROPATHOL, V97, P408, DOI 10.1007/s004010051005; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F	57	52	53	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2002	19	8					985	991		10.1089/089771502320317131			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	585JC	WOS:000177520800008	12225658				2022-02-06	
J	Cvek, M; Mejare, I; Andreasen, JO				Cvek, M; Mejare, I; Andreasen, JO			Healing and prognosis of teeth with intraalveolar fractures involving the cervical part of the root	DENTAL TRAUMATOLOGY			English	Article						dental trauma; permanent teeth; root fractures	PERMANENT	Healing and long-term prognosis of 94 cervical root fractures were evaluated. The teeth were divided into two groups according to type of fracture: transverse fractures limited to the cervical third of the root (51 incisors) and oblique fractures involving both the cervical and middle parts of the root (43 incisors). Neither the frequency nor the type of fracture healing differed significantly between the two groups. In the material as a whole, healing of the fracture with hard tissue formation was observed in 17 teeth (18%), and healing with interposition of periodontal ligament (PDL) and, in some cases, hard tissue between the fragments in 62 teeth (66%). Fifteen teeth (16%) showed no healing and a radiolucency adjacent to the fracture. Statistical analyses revealed that incomplete root formation and a positive sensibility test at the time of injury were significantly related to both healing and hard tissue repair. The same applied to concussion or subluxation compared with dislocation of coronal fragment, as well as optimal compared with suboptimal reposition of displaced coronal fragments. The type and duration of splinting (or no splinting) appeared to be of no significance for frequency or type of healing of cervical root fractures. During the observation time (mean = 75 months), 19 (44%) of the teeth with transverse fractures and 3 (8%) of those with oblique fractures were lost after healing. In conclusion, fractures in the cervical part of the root had a healing potential and the predictive parameters identified for fractures in other parts of the root seemed to be valid for the healing of cervical root fractures. Transverse fractures appeared to have a significantly poorer long-term prognosis compared to oblique fractures, apparently due to a marked post-treatment mobility, which often led to new luxation caused by even minor impacts.	Eastman Dent Inst, Dept Pedodont, S-11324 Stockholm, Sweden; Rigshosp, Dept Oral & Maxillofacial Surg, DK-2100 Copenhagen, Denmark		Mejare, I (corresponding author), Eastman Dent Inst, Dept Pedodont, Dalagatan 11, S-11324 Stockholm, Sweden.						ANDREASEN FM, 1989, ENDOD DENT TRAUMATOL, V5, P11; ANDREASEN FM, 1994, TXB COLOR ATLAS TRAU, P301; ANDREASEN J O, 1971, Journal of Dentistry for Children, V38, P29; ANDREASEN JO, 1967, J ORAL SURG, V25, P414; Austin LT., 1930, JADA, V17, P1930; BENATI FW, 1994, OKLA DENT ASS J, V85, P30; Cvek M, 2001, DENT TRAUMATOL, V17, P53, DOI 10.1034/j.1600-9657.2001.017002053.x; Feiglin B, 1995, Dent Clin North Am, V39, P53; Lindahl B., 1958, ODONTOL REVY, V9, P10; Ravn J J, 1976, Tandlaegebladet, V80, P391; VERGARAEDWARDS I, 1960, REV STOMAT, V61, P794; YATES JA, 1992, INT ENDOD J, V25, P150, DOI 10.1111/j.1365-2591.1992.tb00778.x; ZACHRISSON BU, 1975, SCAND J DENT RES, V83, P345; Zerman N, 1990, Minerva Stomatol, V39, P307	14	52	52	0	8	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	1600-4469			DENT TRAUMATOL	Dent. Traumatol.	APR	2002	18	2					57	65		10.1034/j.1600-9657.2002.180202.x			9	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	540LU	WOS:000174931100002	12184212				2022-02-06	
J	Belayev, L; Alonso, OF; Liu, YT; Chappell, AS; Zhao, WH; Ginsberg, MD; Busto, R				Belayev, L; Alonso, OF; Liu, YT; Chappell, AS; Zhao, WH; Ginsberg, MD; Busto, R			Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						histopathology; neuroprotection; talampanel; traumatic brain injury	REDUCES HISTOPATHOLOGICAL DAMAGE; RECEPTOR-MEDIATED EXCITOTOXICITY; HIPPOCAMPAL CULTURES; CALCIUM; PERMEABILITY; HYPOTHERMIA; LY-300164; DIAZEPAM; ISCHEMIA; CHANNELS	Talampanel {(R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3] benzodiazepine} is an orally active noncompetitive antagonist of the AMPA subtype of glutamate excitatory amino acid receptors. The purpose of this study was to determine whether treatment with talampanel would protect in a rat model of traumatic brain injury (TBI). Twenty-four hours prior to TBI, a fluid-percussion interface was positioned parasagittally over the right cerebral cortex. On the following day, fasted rats were anesthetized with 3% halothane, 70% nitrous oxide, and a balance of oxygen; mechanically ventilated and physiologically regulated; and subjected to right parieto-occipital parasagittal fluid-percussion injury (1.5-2.0 atm). The agent (talampanel, bolus infusion of 4 mg/kg followed by infusion of 4 mg/kg/h over 72 h) or vehicle was administered i.v. starting at either 30 min or 3 h after trauma. Seven days after TBI, brains were perfusion-fixed, coronal sections at various levels were digitized, and contusion areas were measured. Treatment with talampanel, when instituted 30 min after trauma, significantly reduced total contusion area compared to vehicle-treated rats (0.54 +/- 0.25 vs. 1.79 +/- 0.42 mm(2), respectively). When talampanel treatment was begun at 3 h, the neuroprotective effect of the drug was lost. In addition, treatment with talampanel starting at 30 min significantly attenuated neuronal damage in all three subsectors of the hippocampal CAI sector compared to vehicle-treated rats (normal-neuron counts, right (ipsilateral) medial CAI: 80.3 +/- 2.0 [talampanel] vs. 66.3 +/- 2.1 [vehicle] (mean SEM); middle CAI: 71.5 +/- 2.0 vs. 60.3 +/- 2.2; lateral CAI: 74.5 +/- 3.0 vs. 63.0 +/- 3.2, respectively). By contrast, when talampanel treatment was begun at 3 h, normal pyramidal-neuron counts were almost identical in both groups. Our findings document that talampanel therapy instituted 30 min after trauma significantly reduces histological damage.	Univ Miami, Sch Med, Dept Neurol D4 5, Neurotrauma Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA		Belayev, L (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, Neurotrauma Res Ctr, POB 016960, Miami, FL 33101 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 05820, NS 30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS005820, P50NS005820, P50NS030291] Funding Source: NIH RePORTER		Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Borowicz KK, 1999, EUR J PHARMACOL, V380, P67, DOI 10.1016/S0014-2999(99)00541-5; Borowicz KK, 1999, POL J PHARMACOL, V51, P103; BUCHAN A, 1991, J NEUROSCI, V11, P1049; BUCHAN AM, 1993, STROKE, V24, pI148; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; Lodge D, 1996, NEUROPHARMACOLOGY, V35, P1681, DOI 10.1016/S0028-3908(96)00155-4; MAY PC, 1993, NEUROSCI LETT, V152, P169, DOI 10.1016/0304-3940(93)90510-R; May PC, 1999, NEUROSCI LETT, V262, P219, DOI 10.1016/S0304-3940(99)00084-1; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NAKAYAMA H, 1988, NEUROLOGY, V38, P1667, DOI 10.1212/WNL.38.11.1667; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PELLEGRINIGIAMPIETRO DE, 1992, P NATL ACAD SCI USA, V89, P10499, DOI 10.1073/pnas.89.21.10499; RAINES A, 1990, EPILEPSIA, V31, P313, DOI 10.1111/j.1528-1157.1990.tb05381.x; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; TARNAWA I, 1989, EUR J PHARMACOL, V167, P193, DOI 10.1016/0014-2999(89)90579-7; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	27	52	52	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2001	18	10					1031	1038		10.1089/08977150152693728			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	484NG	WOS:000171696000006	11686490				2022-02-06	
J	Kreutzer, JS; Kolakowksy-Hayner, SA; Ripley, D; Cifu, DX; Rosenthal, M; Bushnik, T; Zafonte, R; Englander, J; High, W				Kreutzer, JS; Kolakowksy-Hayner, SA; Ripley, D; Cifu, DX; Rosenthal, M; Bushnik, T; Zafonte, R; Englander, J; High, W			Charges and lengths of stay for acute and inpatient rehabilitation treatment of traumatic brain injury 1990-1996	BRAIN INJURY			English	Article							MEDICARE PAYMENT SYSTEM; COST-EFFECTIVENESS; CARE; INTEGRATION; DISEASE; TRENDS	This investigation evaluated yearly trends in charges and lengths of stay for patients with brain injury in acute care and rehabilitation settings over a 7 year period. Data was collected from 800 consecutive patients enrolled in four NIDRR Model Systems Traumatic Brain Injury programmes. Acute care daily charges showed almost routine increases, averaging nearly $550 per year. Conversely, lengths of stay generally showed a downward trend, with annual reductions averaging 2.25 days. Admission lengths of stay averaged 22-29 days between 1990-1994. Admissions averaged less than 20 days beginning in 1995, with the 1996 average of 16 days, nearly half that of the 1993 average. Between 1990-1996, average daily rehabilitation charges increased each year, with the rise averaging $83 or 7%. The rise in daily rehabilitation charges was offset by corresponding decreases in lengths of stay averaging 3.65 days or 8% annually. Increases in daily charges for brain injury rehabilitation care were roughly comparable to those for general medical care prices. However, the rate of change in acute care charges was substantially greater, with annual increases averaging 10% more than national medical care prices. The steady downward trend in lengths of stay raises serious concerns about the future availability of health care services to persons with brain injury.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Santa Clara Valley Med Ctr, Dept Rehabil, San Jose, CA 95128 USA; Rehabil Inst Michigan, SE Michigan Traumat Brain Injury Syst, Detroit, MI USA; Inst Rehabil & Res, Brain Injury Rehabil Program, Houston, TX USA		Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Med Coll Virginia Campus,POB 980542, Richmond, VA 23298 USA.	jskreutz@hsc.vcu.edu		Bushnik, Tamara/0000-0003-3328-257X; Cifu, David/0000-0003-1600-9387; Ripley, David/0000-0002-5349-1830			ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BARRY P, 1993, J HEAD TRAUMA REHAB, V8, P48; Barth J T, 2000, Dent Clin North Am, V44, P67; Brown AID, 2000, MED CLIN N AM, V84, P279, DOI 10.1016/S0025-7125(05)70219-4; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; Chan L, 2000, ARCH PHYS MED REHAB, V81, P715, DOI 10.1016/S0003-9993(00)90098-4; Chan L, 1997, NEW ENGL J MED, V337, P978, DOI 10.1056/NEJM199710023371406; Cifu DX, 1999, J NEUROTRAUM, V16, P805, DOI 10.1089/neu.1999.16.805; COPE DN, 1994, J HEAD TRAUMA REHAB, V9, P1, DOI 10.1097/00001199-199409000-00003; Dea RA, 2000, PSYCHIAT QUART, V71, P17, DOI 10.1023/A:1004610616732; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; GALVIN RS, 1998, INTEGRATED HEALTHCAR, V53, P1; GRAVES EJ, 1994, VITAL HLTH STAT 13, V140, P1; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HOLLOWAY R, 1995, ARCH NEUROL-CHICAGO, V55, P25; Kephart W, 1999, AM J MANAG CARE, V5, pS309; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; Lee SJ, 2000, J CLIN ONCOL, V18, P64, DOI 10.1200/JCO.2000.18.1.64; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Miller TR, 2000, MED CARE, V38, P562, DOI 10.1097/00005650-200006000-00003; Phipps EJ, 1999, J HEAD TRAUMA REHAB, V14, P329, DOI 10.1097/00001199-199906000-00014; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Roth A, 2000, CLIN CARDIOL, V23, P271, DOI 10.1002/clc.4960230410; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Taheri PA, 1998, ANN SURG, V227, P720, DOI 10.1097/00000658-199805000-00012; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WACHTER RM, 1995, JAMA-J AM MED ASSOC, V273, P230, DOI 10.1001/jama.273.3.230; Wimo A, 1997, ALZ DIS ASSOC DIS, V11, P191; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746	30	52	53	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2001	15	9					763	774		10.1080/02699050010025786			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400002	11516345				2022-02-06	
J	McCullagh, S; Ouchterlony, D; Protzner, A; Blair, N; Feinstein, A				McCullagh, S; Ouchterlony, D; Protzner, A; Blair, N; Feinstein, A			Prediction of neuropsychiatric outcome following mild trauma brain injury: an examination of the Glasgow Coma Scale	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; POSTTRAUMATIC AMNESIA; RATING-SCALE; PRACTICAL SCALE; GENERAL HEALTH; SEQUELAE; QUESTIONNAIRE; SYMPTOMS; RECOVERY; RISK	The relationship between the Glasgow Coma Scale (GCS) and neuropsychiatric outcome was examined in 57 consecutive subjects with mild traumatic brain injury (TBI) attending a follow-up clinic. Subjects were grouped according to initial GCS score (15 versus 13-14) and contrasted at an average of 5-6 months post-injury. As expected, those with GCS 13-14 had longer PTA (p = 0.001) and a higher rate of abnormal brain CT scans (p = 0.005). However, no significant differences emerged for indices of neuropsychiatric status, including measures of neurobehavioural symptoms/signs, overall psychological distress, psychiatric 'caseness', functional and psychosocial outcome, frequency of common somatic complaints, and rate of return to work. Subsidiary analyses based upon the presence/absence of CT abnormalities and the duration of PTA (<1 hour versus 1-24 hours) also failed to predict outcome, although a trend associating longer PTA with lower functional outcome was observed. Thus, despite early neurosurgical differences, the results suggest that initial GCS scores do not clearly translate into neuropsychiatric sequelae at follow-up within the rubric of GCS 13-15.	Univ Toronto, Sunnybrook & Womens Coll Hosp, Neuropsychiat Program, Toronto, ON M4N 3M5, Canada		McCullagh, S (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hosp, Neuropsychiat Program, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.			Protzner, Andrea/0000-0001-8062-2923			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KRAUS JF, 1989, MILD HEAD INJURY, P8; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Ocana M, 2000, BRAIN COGNITION, V44, P83, DOI 10.1006/brcg.1999.1211; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; *SPSS INC, 1999, SPSS WIND REL 10 0; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Symonds CP, 1943, LANCET, V1, P7; TEASDALE G, 1974, LANCET, V2, P81; Tellier A, 1999, BRAIN INJURY, V13, P463; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	48	52	53	0	0	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2001	15	6					489	497		10.1080/02699050010007353			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	439VE	WOS:000169137600002	11394968				2022-02-06	
J	Yan, P; Li, Q; Kim, GM; Xu, J; Hsu, CY; Xu, XM				Yan, P; Li, Q; Kim, GM; Xu, J; Hsu, CY; Xu, XM			Cellular localization of tumor necrosis factor-alpha following acute spinal cord injury in adult rats	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; rat; spinal cord injury; TNF-alpha	CENTRAL NERVOUS-SYSTEM; TRAUMATIC INJURY; BRAIN INJURY; AXONAL REGENERATION; TNF-ALPHA; EXPRESSION; CYTOKINES; INFLAMMATION; DEMYELINATION; APOPTOSIS	Posttraumatic inflammatory reaction may contribute to secondary injury after traumatic spinal cord injury (SCI). Expression of tumor necrosis factor-alpha (TNF-alpha), a key inflammatory mediator, has been demonstrated in the injured cord. However, the specific cell types that are responsible for TN-alpha expression after SCI remain to be identified. In the present study, cellular sources of TNF-alpha were examined in rats that received a spinal cord impact injury at the 9th thoracic (T9) level. Here we demonstrate that, within hours after SCI, increased TNF-alpha immunoreactivity was localized in neurons, glial cells (including astrocytes, oligodendrocytes, and microglia), and endothelial cells in areas of the spinal cord adjacent to the lesion site. Myelin breakdown was noted in oligodendrocytes that are immunopositive for TNF-alpha. In sham-operated controls, a low level of TNF-alpha immunoreactivity was detected. In antigen-absorption experiments, no TNF-alpha immunoreactivity was detected, indicating the specificity of TNF-alpha immunocytochemistry in the present study. Results suggest that various cell types, including neurons, glial cells, and vascular endothelial cells, contribute to TNF-alpha production in the injured cord.	St Louis Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA		Xu, XM (corresponding author), St Louis Univ, Sch Med, Dept Anat & Neurobiol, 1402 S Grand Blvd, St Louis, MO 63104 USA.			Xu, Xiao-ming/0000-0002-7229-0081; Hsu, Chung Y./0000-0002-5632-2733	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 37230, NS 36350, NS 28995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037230, R01NS036350, R01NS028995] Funding Source: NIH RePORTER		Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DeLeo JA, 1997, BRAIN RES, V759, P50, DOI 10.1016/S0006-8993(97)00209-6; DSOUZA S, 1995, J NEUROSCI, V15, P7293; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HOLETS VR, 1987, BRAIN RES, V408, P141, DOI 10.1016/0006-8993(87)90366-0; JENKINS HG, 1992, J NEUROL SCI, V108, P99, DOI 10.1016/0022-510X(92)90194-P; Li Qun, 1998, Society for Neuroscience Abstracts, V24, P738; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Liu XZ, 1997, J NEUROSCI, V17, P5395; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; Qi Y, 1996, J NEUROSCI RES, V45, P364; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yan P, 1999, J NEUROSCI, V19, P9355	25	52	56	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					563	568		10.1089/089771501300227369			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000009	11393259				2022-02-06	
J	Struchen, MA; Hannay, HJ; Contant, CF; Robertson, CS				Struchen, MA; Hannay, HJ; Contant, CF; Robertson, CS			The relation between acute physiological variables and outcome on the Glasgow outcome scale and disability rating scale following severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral perfusion pressure; intracranial pressure; jugular venous oxygen saturation; mean arterial pressure; outcome; traumatic brain injury	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; INTRACRANIAL HYPERTENSION; CEREBRAL OXYGENATION; AGGRESSIVE TREATMENT; VENOUS DESATURATION; MANAGEMENT; EXPERIENCE; PROGNOSIS; COMA	The relation between outcome and duration of adverse physiological events was studied, using suggested critical physiological values, Subjects were 184 patients with severe traumatic brain injury who received continuous monitoring of intracranial pressure (ICP), mean arterial pressure (MAP), cerebral perfusion pressure (CPP), and jugular venous oxygen satuation, Longer durations of adverse physiological events were significantly related to Glasgow Outcome Scale (GOS) scores and Disability Rating Scale (DRS) scores for all variables at all timepoints postinjury, When analyses excluded patients who died, the relation between adverse physiological events and GOS was nonsignificant; however, duration of ICP, MAP, and CPP still accounted for a significant portion of the variance in DRS scalres, The relative sensitivity of the GOS and DRS is discussed.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Houston, Dept Psychol, Houston, TX USA		Struchen, MA (corresponding author), Brain Injury Res Ctr, 4007EE Bellaire Blvd, Houston, TX 77025 USA.	strucm@tirr.tmc.edu		Hannay, H. Julia/0000-0001-7023-912X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; CONTANT CF, 1993, J NEUROTRAUMA S1, V10, pS57; CROUCH JD, 1991, P 8 INT S INTR PRESS; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1993, CRIT CARE MED, V21, P1242, DOI 10.1097/00003246-199308000-00027; EDDY VA, 1995, AM SURGEON, V61, P24; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Jane J, 1996, NEUROTRAUMA, P793; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; JENNETT B, 1981, MANAGEMENT HEAD INJU, P47; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kanter M J, 1990, Intensive Care World, V7, P16; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LANGFITT TW, 1982, CLIN NEUR, V29, P353; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LEWIS SB, 1995, ANAESTH INTENS CARE, V23, P307, DOI 10.1177/0310057X9502300307; MACCAULEY S, 2000, IN PRESS J INT NEURO; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1987, HEAD INJURY, P159; MARMAROU A, 1989, INTRACRANIAL PRESSUR, V7, P549; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Miller J.D., 1987, CEREBRAL BLOOD FLOW, P119; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1975, J NEUROL NEUROSUR PS, V38, P657, DOI 10.1136/jnnp.38.7.657; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; Rosner M., 1987, CEREBRAL BLOOD FLOW, P425; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; *SPSS, 1994, SPSS PCPLUS VERS 6 1; STRUCHEN MA, 1994, THESIS U HOUSTON; TEASDALE G, 1974, LANCET, V2, P81; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; UZZELL BP, 1989, INTRACRANIAL PRESSUR, V7, P567; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; [No title captured]	58	52	54	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2001	18	2					115	125		10.1089/08977150150502569			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	402PW	WOS:000166998200001	11229706				2022-02-06	
J	Galani, R; Hoffman, SW; Stein, DG				Galani, R; Hoffman, SW; Stein, DG			Effects of the duration of progesterone treatment on the resolution of cerebral edema induced by cortical contusions in rats	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						brain injure; edema; frontal cortex; hormones; progesterone; rats; TB1	TRAUMATIC BRAIN INJURY; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; VASCULAR DISRUPTION; LIPID-PEROXIDATION; GLIAL-CELLS; TIME-COURSE; HORMONES; BARRIER; PERMEABILITY	Purpose: The aim of the present Study was to assess the effect of different durations of administration of progesterone (4 mg/kg) on the resolution of edema 6 days after medial frontal cortex contusions (MFC) in male adult rats. Methods: Animals sustaining injury Were injected with progesterone or its vehicle for 33 days or for 5 days beginning the first hour after Surgery. On the 0 day the rats ere killed and their brain water content as measured. Results: We confirmed the presence of edema six days after MFC. However, both 3 and 5 days of treatment with progesterone significantly reduced edema in the injured brains but the five days of treatment were more effective. The effects of progesterone depend upon the duration of the treatment because there are two waves of edema. The first phase begins within a few hours of the injury and the second starts several day's later. Conclusions: Our data are consistent with earlier findings showing that longer durations of progesterone administration lead to more complete behavioral recovery as well as to an increased number Of surviving neurons.	Emory Univ, Brain Res Lab, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Brain Res Lab, Dept Psychol, 575 Rollins Way, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020				Angele MK, 1999, AM J PHYSIOL-CELL PH, V277, pC35, DOI 10.1152/ajpcell.1999.277.1.C35; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Barzo P, 1997, ACT NEUR S, V70, P119; Borel IM, 1999, SCAND J IMMUNOL, V49, P244, DOI 10.1046/j.1365-3083.1999.00484.x; CHAO HJ, 1994, IEEE COMMUN MAG, V32, P52, DOI 10.1109/35.299838; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; GarciaSegura LM, 1996, FRONT NEUROENDOCRIN, V17, P180, DOI 10.1006/frne.1996.0005; Gomez F, 1998, CLIN IMMUNOL IMMUNOP, V89, P231, DOI 10.1006/clin.1998.4602; Hariri R J, 1994, Neurosurg Clin N Am, V5, P687; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; JUNGTESTAS I, 1992, J STEROID BIOCHEM, V41, P621, DOI 10.1016/0960-0760(92)90394-X; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1994, ACTA NEUROCHIR, P3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MATHEW P, 1994, ACTA NEUROCHIR, P428; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Moran MH, 1998, BRAIN RES, V807, P84, DOI 10.1016/S0006-8993(98)00782-3; Moran MH, 1998, BRAIN RES, V807, P91, DOI 10.1016/S0006-8993(98)00781-1; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Nishio S, 1997, ACT NEUR S, V70, P84; PERSSON L, 1976, ACTA NEUROPATHOL, V35, P333; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Robert R, 1997, NITRIC OXIDE-BIOL CH, V1, P453, DOI 10.1006/niox.1997.0157; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shear D. A., 2000, Journal of Neurotrauma, V17, P967; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SMITH JS, 1998, J NEUROTRAUM, V15, P905; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; STEIN DG, 1993, J NEURAL TRANSP PLAS, V4, P227, DOI 10.1155/NP.1993.227; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; UNTERBERG A, 1988, ACTA NEUROPATHOL, V76, P238, DOI 10.1007/BF00687770; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	56	52	52	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2001	18	4					161	166					6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	525CK	WOS:000174049500003	11847439				2022-02-06	
J	Chapman, SB; McKinnon, L				Chapman, SB; McKinnon, L			Discussion of developmental plasticity: Factors affecting cognitive outcome after pediatric traumatic brain injury	JOURNAL OF COMMUNICATION DISORDERS			English	Article						pediatric traumatic brain injury; language; developmental plasticity; cognition; long-term outcome	CLOSED-HEAD-INJURY; CHILDREN; ADOLESCENTS; DISCOURSE; SYSTEMS; REORGANIZATION	Current research on plasticity has altered the over simplistic view of greater capacity in the developing brain after injury. In another paper in this issue, Dennis provides a model to elucidate the complexity uf the multiple factors that influence recovery after brain injury in children. The authors present a brief summary of findings from their longitudinal research in neurobehavioral recovery after traumatic brain injury in children and adolescents that elaborates on the framework of Dennis. The discussion highlights the psychobiological factors that interact to define developmental plasticity and outlines promising directions for future research to elucidate and promote long-term recovery in pediatric brain-injured populations. (C) 2000 by Elsevier Science Inc.	Univ Texas, Callier Ctr Commun Disorders, Brain Res & Treatment Ctr, Dallas, TX 75235 USA		Chapman, SB (corresponding author), Univ Texas, Callier Ctr Commun Disorders, Brain Res & Treatment Ctr, 1966 Inwood Rd, Dallas, TX 75235 USA.	schapman@utdallas.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS21889-16] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; BATES E, 1992, AC APH M TOR ONT CAN; Booth JR, 1999, PROG NEURO-PSYCHOPH, V23, P669, DOI 10.1016/S0278-5846(99)00025-1; BROOKSHIRE BL, IN PRESS J INT NEURO; BUCHWALD JS, 1990, CLIN PERINATOL, V17, P57, DOI 10.1016/S0095-5108(18)30588-8; CASE R, 1982, J EXP CHILD PSYCHOL, V33, P386, DOI 10.1016/0022-0965(82)90054-6; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, 1997, M AM ASS ADV SCI 199; CHAPMAN SB, 1995, CONSEQUENCES TRAUMAT, P95; CHAPMAN SB, 1996, M AM ASS ADV SCI BAL; CHAPMAN SB, 1999, BRAIN DAM B, P235; Chugani HT, 1996, BRAIN DEV-JPN, V18, P347, DOI 10.1016/0387-7604(96)00032-0; CULHANE KA, 1993, THESIS U HOUSTON HOU; Edeline JM, 1999, PROG NEUROBIOL, V57, P165, DOI 10.1016/S0301-0082(98)00042-2; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Greenough WT, 1999, NAT NEUROSCI, V2, P203, DOI 10.1038/6300; HERTZPANNIER L, 1999, J NEURORADIOLOGY S, V26; Kufera J. A., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI 10.1044/1058-0360.0602.66; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, IN PRESS NEUROLOGY, V54, P647; LEVIN HS, 2000, UNPUB WORD FLUENCY R; LEVIN HS, 1995, 3 INT NEUR S TOR ONT; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; MCKINNON L, 1999, NATL AC NEUR ABSTR, pC81; PENNINGTON BF, 1994, WORKING MEMORY FUNCT; REINIS S, 1980, DEV BRAIN; SPINELLI DN, 1990, CLIN PERINATOL, V17, P77, DOI 10.1016/S0095-5108(18)30590-6; Taylor H., 1995, RECOVERY TRAUMATIC B, P188; THATCHER RW, 1992, BRAIN COGNITION, V20, P24, DOI 10.1016/0278-2626(92)90060-Y; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; [No title captured]	34	52	53	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	JUL-AUG	2000	33	4					333	344		10.1016/S0021-9924(00)00029-0			12	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	354AQ	WOS:000089308000006	11001160				2022-02-06	
J	Chen, T; Qian, YZ; Rice, A; Zhu, JP; Di, X; Bullock, R				Chen, T; Qian, YZ; Rice, A; Zhu, JP; Di, X; Bullock, R			Brain lactate uptake increases at the site of impact after traumatic brain injury	BRAIN RESEARCH			English	Article						C-14-lactate; fluid percussion injury; energy	EXCITATORY AMINO-ACIDS; FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; HUMAN HEAD-INJURY; ENERGY-METABOLISM; BARRIER PERMEABILITY; AEROBIC GLYCOLYSIS; SUBSTRATE DELIVERY; SYNAPTIC FUNCTION; KETONE-BODIES	Although glucose is the main carbohydrate energy substrate for the normal brain, several studies published over the last 10 years now challenge this assumption. The activated brain increases its metabolism to meet increased energy demands by glycolysis after injury. In vitro studies now show that lactate alone can serve as an energy source to maintain synaptic function. In this study, we used C-14-lactate to test the hypothesis that blood lactate is acutely taken up by the injured brain, after fluid percussion injury (FPI) in the rat. 50 mu Ci radioactive lactate was injected i.v. immediately after FPI, in injured and sham rats. After 30 min, the brain was removed, frozen, and cut into 20 mu m sections for autoradiography. Uptake of C-14-label was mainly concentrated at the injury site (2.5 times greater) although uninjured brain also took up the C-14-label. This increased concentration of radioactive lactate at the injury site suggests that the injured brain may use the lactate as an energy source. (C) 2000 Elsevier Science B.V. All rights reserved.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [12587] Funding Source: Medline		ALM A, 1985, OPHTHALMIC RES, V17, P181, DOI 10.1159/000265371; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; CREMER JE, 1979, J NEUROCHEM, V33, P439, DOI 10.1111/j.1471-4159.1979.tb05173.x; CREMER JE, 1982, J NEUROCHEM, V39, P674, DOI 10.1111/j.1471-4159.1982.tb07945.x; CROCKARD HA, 1972, EUR NEUROL, V8, P151, DOI 10.1159/000114569; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DREWES LR, 1973, ARCH NEUROL-CHICAGO, V29, P385, DOI 10.1001/archneur.1973.00490300047005; FERNANDES J, 1982, LANCET, V1, P113; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GJEDDE A, 1975, AM J PHYSIOL, V229, P1165, DOI 10.1152/ajplegacy.1975.229.5.1165; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAMBERGER A, 1995, NEUROL RES, V17, P97, DOI 10.1080/01616412.1995.11740295; Hawkins R A, 1988, Ann N Y Acad Sci, V529, P40, DOI 10.1111/j.1749-6632.1988.tb51418.x; HAWKINS RA, 1984, EUR J CLIN INVEST, V14, P313, DOI 10.1111/j.1365-2362.1984.tb01187.x; HOSSMANN KA, 1973, ARCH NEUROL-CHICAGO, V29, P375, DOI 10.1001/archneur.1973.00490300037004; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KING LR, 1974, J NEUROSURG, V40, P617, DOI 10.3171/jns.1974.40.5.0617; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Larrabee MG, 1996, J NEUROCHEM, V67, P1726; LARRABEE MG, 1995, J NEUROCHEM, V64, P1734; LEAR JL, 1991, J CEREBR BLOOD F MET, V11, P576, DOI 10.1038/jcbfm.1991.106; LJUNGGREN B, 1974, BRAIN RES, V77, P173, DOI 10.1016/0006-8993(74)90782-3; LYINGTUNELL U, 1980, ACTA NEUROL SCAND, V62, P265; MAGISTRETTI PJ, 1993, DEV NEUROSCI-BASEL, V15, P306, DOI 10.1159/000111349; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OLDENDORF W, 1979, STROKE, V10, P577, DOI 10.1161/01.STR.10.5.577; OLDENDORF WH, 1971, EUR NEUROL, V6, P49, DOI 10.1159/000114465; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PERSSON L, 1976, ACTA NEUROPATHOL, V35, P333; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; RICE AC, 1999, J NEUROTRAUM, V16, P955; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; SCHURR A, 1987, BRAIN RES, V421, P1359; SIESJO BK, 1973, ARCH NEUROL-CHICAGO, V29, P400, DOI 10.1001/archneur.1973.00490300062008; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	50	52	52	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 10	2000	861	2					281	287		10.1016/S0006-8993(00)01992-2			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	303GL	WOS:000086414100008	10760489				2022-02-06	
J	Adelson, PD; Dixon, CE; Kochanek, PM				Adelson, PD; Dixon, CE; Kochanek, PM			Long-term dysfunction following diffuse traumatic brain injury in the immature rat	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	15th Annual Meeting of the Neurotrauma-Society	OCT 24-25, 1997	NEW ORLEANS, LOUISIANA	Neurotrauma Soc		cognitive; functional recovery; immature; Morris Water Maze; rats; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; HEAD-INJURY; HIPPOCAMPAL-LESIONS; DEFICITS; CHILDREN; ADOLESCENTS; IMPAIRMENT; MEMORY; MOTOR	Children often suffer sustained cognitive dysfunction after severe diffuse traumatic brain injury (TBI), To study the effects of diffuse injury in the immature brain, we developed a model of severe diffuse impact (DI) acceleration TBI in immature rats and previously described the early motor and cognitive dysfunction posttrauma. In the present study, we investigated the long-term functional ability after DI (150 gm/2 m) compared to sham in the immature (PND 17) rat. Beam balance and inclined plane latencies were measured daily for 10 days after injury to assess gross vestibulomotor function. The Morris water maze (MWM) paradigm was evaluated monthly up to 3 months after DI and sham injuries. Reduced latencies on the balance beam and inclined plane were observed in DI rats (p < 0.05 vs. sham [n = 10 per group]) at 24 h and persisted for 10 days postinjury, DI produced sustained MWM performance deficits (p < 0.05 vs, sham) as indicated by the greater latencies to find the hidden platform remarkably through 90 days after injury. Lastly, the brain and body weights of the injured animals were less than sham (p < 0.05) after 3 months. We conclude that a diffuse TBI in the immature rat: (a) created a consistent, marked, but reversible motor deficit up to 10 days following injury; (b) produced a long-term, sustained performance deficit in the MWM up to 3 months posttrauma; and (c) affected body and brain weight gain in the developing rat through 3 months after injury. This TBI model should be useful for the testing of novel therapies and their effect on long-term outcome and development in the immature rat.	Childrens Hosp Pittsburgh, Dept Pediat Neurosurg, Pittsburgh, PA 15213 USA; Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA USA		Adelson, PD (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat Neurosurg, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 33150, K08 NS01809, NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, P20NS030318, P50NS030318, P01NS030318, K08NS001809] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; ADELSON PD, 1996, J NEUROSURG, V85, P134; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BOKSA P, 1995, PEDIATR RES, V37, P489, DOI 10.1203/00006450-199504000-00018; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; JOHNSTON MV, 1983, ANN NEUROL, V13, P511, DOI 10.1002/ana.410130507; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MOSER E, 1993, J NEUROSCI, V13, P3916; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Piper IR, 1996, J NEUROSCI METH, V69, P171, DOI 10.1016/S0165-0270(96)00046-5; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; WINICK M, 1983, MED CLIN N AM, V54, P1413; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	36	52	54	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2000	17	4					273	282		10.1089/neu.2000.17.273			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	302LA	WOS:000086365500002	10776912				2022-02-06	
J	Sweet, JJ; Wolfe, P; Sattlberger, E; Numan, B; Rosenfeld, JP; Clingerman, S; Nies, KJ				Sweet, JJ; Wolfe, P; Sattlberger, E; Numan, B; Rosenfeld, JP; Clingerman, S; Nies, KJ			Further investigation of traumatic brain injury versus insufficient effort with the California Verbal Learning Test	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	17th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 10-13, 1997	LAS VEGAS, NEVADA	Natl Acad Neuropsychol			RECOGNITION MEMORY TEST; MALINGERED HEAD-INJURY; NEUROPSYCHOLOGICAL EVALUATION; IMPAIRMENT; IDENTIFICATION; VALIDATION	The present study replicates and attemps to extend previous research using the California Verbal Learning Test (CVLT) to identify malingerers. Documented moderate and severe traumatic brain injury patients (n = 42) were compared with clinical malingerers identified by criteria other than the CVLT (n = 21), malingering simulators instructed in realistic potential injury sequelae (n = 25), and normal controls (n = 21). Results of discriminant function analyses for high and low base rates are reported, showing similar results. Also, the four individual cutoff scores (Recognition Hits, Discriminability, Total Words Recalled, Long Delay Cued Recall) from Millis, Putnam, Adams, and Ricker (1995) were evaluated with these groups. Similar specificity rates were found with all four variables, while sensitivity rates were slightly lower than that of Millis. Adjusted cutoffs derived from the new samples resulted in slightly improved overall classification rates. Overall, present findings support those of Millis et al. (1995) with regard to the use of the CVLT in detection of malingering. Exploratory use of Total Instructions and Recognition Hits Compared to Long Delay Free Recall was not promising. Simulators were found to be fairly comparable in performance to actual malingerers, affirming their use in malingering research. (C) 2000 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Northwestern Univ, Evanston Hosp, Neuropsychol Serv, Sch Med, Evanston, IL 60201 USA; IIT, Evanston Hosp, Chicago, IL 60616 USA; Cook Cty Hosp, Chicago, IL 60612 USA		Sweet, JJ (corresponding author), Northwestern Univ, Evanston Hosp, Neuropsychol Serv, Sch Med, 2650 Ridge Ave, Evanston, IL 60201 USA.						DELIS D, 1987, CALIFORNIA VERBAL LE; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; MILLIS S, 1997, J INT NEUROPSYCH SOC, V3, P225; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; REYNOLDS C, 1998, DETECTION MALINGERED; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; [No title captured]; [No title captured]; [No title captured]	21	52	53	1	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2000	15	2					105	113		10.1016/S0887-6177(98)00153-X			9	Psychology, Clinical; Psychology	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	276WD	WOS:000084900600002	14590555	Bronze			2022-02-06	
J	Whalen, MJ; Carlos, TM; Dixon, CE; Robichaud, P; Clark, RSB; Marion, DW; Kochanek, PM				Whalen, MJ; Carlos, TM; Dixon, CE; Robichaud, P; Clark, RSB; Marion, DW; Kochanek, PM			Reduced brain edema after traumatic brain injury in mice deficient in P-selectin and intercellular adhesion molecule-1	JOURNAL OF LEUKOCYTE BIOLOGY			English	Article						controlled cortical impact; inflammation; neutrophil; head injury; platelet	CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; COLONY-STIMULATING FACTOR; DOUBLE MUTANT MICE; NEUTROPHIL ACCUMULATION; ISCHEMIA-REPERFUSION; BACTERIAL-MENINGITIS; ACUTE-INFLAMMATION; CELL-ADHESION; IMMATURE RAT	Platelet (P-) selectin and intercellular adhesion molecule-1 (ICAM-1) mediate accumulation of neutrophils in brain. How-ever, the mechanisms regulating neutrophil accumulation and damage after traumatic brain injury (TBI) are poorly defined. We hypothesized that mice deficient in both P-selectin and ICAM-1 (-/-) would have decreased brain neutrophil accumulation and edema, and improved functional and histopathological outcome after TBI compared with wild-type (+/+), In Protocol I, neutrophils and brain water content were quantified at 24 b after TBI, No difference in brain neutrophil accumulation was observed between groups; however, brain edema was decreased in dual P-selectin and ICAM-1 -/- (P < 0.05 vs. +/+ mice). In Protocol II, after TBI, tests of motor and memory function and histopathology were assessed over 21 days. No difference in motor or memory function or histopathological damage was observed between +/+ and -/- mice, A role for adhesion molecules in the pathogenesis of brain edema independent of leukocyte accumulation in brain is suggested.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanck@smtp.anes.upmc.edu	Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER		Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; CARDEN DL, 1993, J APPL PHYSIOL, V75, P2529, DOI 10.1152/jappl.1993.75.6.2529; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Doerschuk CM, 1996, J IMMUNOL, V157, P4609; Gibbs SAL, 1996, SURGERY, V119, P652, DOI 10.1016/S0039-6060(96)80189-9; Goussev AV, 1998, J NEUROL SCI, V161, P16, DOI 10.1016/S0022-510X(98)00262-7; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KING PD, 1995, J IMMUNOL, V154, P6080; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kyriakides C, 1999, FASEB J, V13, pA21; LINDSBERG PJ, 1995, J NEUROSURG, V82, P269, DOI 10.3171/jns.1995.82.2.0269; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MAUGERI N, 1994, THROMB HAEMOSTASIS, V72, P450; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Mizgerd JP, 1998, J LEUKOCYTE BIOL, V64, P291, DOI 10.1002/jlb.64.3.291; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1990, ACT NEUR S, V51, P49; SHERMAN DG, 1997, NEUROLOGY, V48, pA270; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; SINZ EH, 1997, J NEUROTRAUM, V14, P769; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Soares HD, 1995, J NEUROSCI, V15, P8223; Squadrito F, 1997, BRIT J PHARMACOL, V120, P333, DOI 10.1038/sj.bjp.0700904; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Subramaniam M, 1996, BLOOD, V87, P1238, DOI 10.1182/blood.V87.4.1238.bloodjournal8741238; SUBRAMANIAM M, 1995, J EXP MED, V181, P2277, DOI 10.1084/jem.181.6.2277; Sun XM, 1997, AM J PHYSIOL-GASTR L, V273, pG56, DOI 10.1152/ajpgi.1997.273.1.G56; Suzuki H, 1999, NEUROSCI LETT, V265, P163, DOI 10.1016/S0304-3940(99)00229-3; Suzuki H, 1999, NEUROL RES, V21, P269, DOI 10.1080/01616412.1999.11740930; Tang T, 1996, J CLIN INVEST, V97, P2485, DOI 10.1172/JCI118695; Tomita M, 1996, ACT NEUR S, V66, P32; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Weber JR, 1995, J NEUROIMMUNOL, V63, P63; Weiser MR, 1996, SHOCK, V5, P402, DOI 10.1097/00024382-199606000-00003; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; Whalen M, 1999, CRIT CARE MED, V27, pA103, DOI 10.1097/00003246-199901001-00262; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; YEO EL, 1994, BLOOD, V83, P2498	61	52	61	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0741-5400	1938-3673		J LEUKOCYTE BIOL	J. Leukoc. Biol.	FEB	2000	67	2					160	168		10.1002/jlb.67.2.160			9	Cell Biology; Hematology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Hematology; Immunology	307AH	WOS:000086630800003	10670575	Bronze			2022-02-06	
J	Gomez, PA; Lobato, RD; Boto, GR; De la Lama, A; Gonzalez, PJ; de la Cruz, J				Gomez, PA; Lobato, RD; Boto, GR; De la Lama, A; Gonzalez, PJ; de la Cruz, J			Age and outcome after severe head injury	ACTA NEUROCHIRURGICA			English	Article						age; prognosis; severe head injury; logistic regression	CLINICAL EXAMINATION; PROGNOSIS; PREDICTION; CHILDREN; SURVIVAL; ADULT	The authors analyzed the relationship between patient age and the final outcome in a series of 810 patients aged 14 years or older who were consecutively admitted between 1987 and 1996 after suffering a severe closed head injury. The most relevant clinico-radiological variables were prospectively collected in a Data Bank. Stratified and logistic regression analyses were performed in order to assess the influence of age on adverse outcome and the interaction between patient age and other prognostic indicators. Our results reaffirm that the adverse outcome rate increases steadily with age in severe head injured patients and that age effect on outcome is independent of other prognostic variables. The odds of having an adverse outcome increases significantly over 35 years of age being 10 times higher in patients older than 65 years as compared to those aged 15-25 years (reference age group). The adverse influence of an advanced age on the final outcome has not yet been satisfactorily explained but an older brain may have an impaired ability to recover after a pathological insult as compared to a younger one.	Hosp 12 Octubre, E-28041 Madrid, Spain		Gomez, PA (corresponding author), Hosp 12 Octubre, Carretera de Andalucia Km 5-400, E-28041 Madrid, Spain.		Rodriguez-Boto, Gregorio/AAR-9035-2021; Gomez, Pedro/N-5051-2019	Rodriguez-Boto, Gregorio/0000-0001-6361-5713; Gomez, Pedro/0000-0002-4185-5238; Gonzalez Leon, Pedro/0000-0002-1120-4047			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; AMACHER AL, 1987, NEUROSURGERY, V20, P954; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BULLOCK R, 1995, AANS; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/BF01709556; Frowein R A, 1979, Acta Neurochir Suppl (Wien), V28, P3; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Marshall LF, 1991, J NEUROSURG S, V75, P14; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OVERGAARD J, 1973, LANCET, V2, P631; SCHLESSELMAN, 1982, CASE CONTROL STUDIES; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; Vollmer DG, 1991, J NEUROSURG S, V75, P37; [No title captured]	26	52	54	0	4	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2000	142	4					373	+		10.1007/s007010050445			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	306XX	WOS:000086624900004	10883332				2022-02-06	
J	Assaf, Y; Holokovsky, A; Berman, E; Shapira, Y; Shohami, E; Cohen, Y				Assaf, Y; Holokovsky, A; Berman, E; Shapira, Y; Shohami, E; Cohen, Y			Diffusion and perfusion magnetic resonance imaging following closed head injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						closed head injury; diffusion and perfusion MRI; head trauma; MRI; rat brain	TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; CEREBRAL-ISCHEMIA; EDEMA; MRI; SPECTROSCOPY; METABOLISM; MECHANISMS; LACTATE; STROKE	Diffusion-, perfusion-, T-1-, and T-2-weighted magnetic resonance imaging (MRI) were performed at 1-2 h, 24 h, and 1 week following closed head injury (CHI) in rats, and data was compared with hematoxylin and eosin histology, At 1-2 h, large areas of low perfusion in the damaged hemisphere overestimate the histological damage, In the first 2 h, the histological damage seems to be a superposition of abnormalities in the T1- and diffusion-weighted images, In areas with more than 10% reduction in the apparent diffusion coefficients (ADCs), reduced regional cerebral blood volume (r-CBV) was also observed. The decrease in ADCs and rCBV correlated with r = 0.78. Changes in the MRI parameters revealed the following: (a) Further reduction in ADC occurred from 83 +/- 15% at 1-2 h after trauma to 69 +/- 9% at 24 h, and 1 week later a marked elevation in the ADC values is observed. (b) Blood perfusion measurements performed 1-2 h posttrauma revealed a pronounced reduction in r-CBV (53 +/- 18%) in the damaged hemisphere in all rats, At 24 h postimpact, areas of hyper- and hypoperfusion were observed, One week later, similar perfusion was found in both hemispheres of all rats, (c) T-2 hyperintensity at 24 h overestimated the histological damage found at 1 week. At one week following the trauma, the T-2 hyperintensity underestimated the histological damage. It is concluded that CHI, which is a heterogeneous insult, should be studied by a combination of MRI techniques, The superposition of the abnormalities seen on T-1 and on the diffusion-weighted MR images at early time point represents best the histological damage. Both T-2 and rCBV images are less informative in terms of actual histological damage.	Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Chem, IL-69978 Tel Aviv, Israel; Kaplan Hosp, Dept Anesthesiol, IL-76100 Rehovot, Israel; Soroka Med Hosp, Dept Anesthesiol, Beer Sheva, Israel; Hadassah Univ Hosp, Human Biol Res Ctr, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel		Cohen, Y (corresponding author), Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Chem, IL-69978 Tel Aviv, Israel.	ycohen@ccsg.tau.ac.il		assaf, yaniv/0000-0001-6828-7595			Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BELLIVEAU JW, 1990, MAGNET RESON MED, V14, P538, DOI 10.1002/mrm.1910140311; BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRANTZAWADZKI M, 1987, AM J ROENTGENOL, V148, P579, DOI 10.2214/ajr.148.3.579; BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; DARDZINSKI BJ, 1993, MAGNET RESON MED, V30, P318, DOI 10.1002/mrm.1910300307; DECANNIERE C, 1995, MAGNET RESON MED, V34, P343, DOI 10.1002/mrm.1910340311; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FRAHM J, 1986, MAGNET RESON MED, V3, P321, DOI 10.1002/mrm.1910030217; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gomori J M, 1988, Radiographics, V8, P427; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HOSSMANN KA, 1995, CEREBROVAS BRAIN MET, V7, P187; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Le Bihan D, 1995, DIFFUSION PERFUSION; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; MARMAROU A, 1994, ACTA NEUROCHIR, P421; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1981, BRAIN EDEMA, P99; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Pierce AR, 1997, J CEREBR BLOOD F MET, V17, P183, DOI 10.1097/00004647-199702000-00008; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; STARK DD, 1992, MAGNETIC RESONANCE I; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKAHASHI M, 1993, MAGNET RESON MED, V30, P485, DOI 10.1002/mrm.1910300411; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WELCH KMA, 1995, STROKE, V26, P1983, DOI 10.1161/01.STR.26.11.1983	36	52	52	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1999	16	12					1165	1176		10.1089/neu.1999.16.1165			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	266WC	WOS:000084322400004	10619195				2022-02-06	
J	Bramlett, HM; Dietrich, WD; Green, EJ				Bramlett, HM; Dietrich, WD; Green, EJ			Secondary hypoxia following moderate fluid percussion brain injury in rats exacerbates sensorimotor and cognitive deficits	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion; hypoxia; Morris water maze; rats; sensorimotor task; traumatic brain injury	CONTROLLED CORTICAL IMPACT; HEAD-INJURY; MEMORY; HYPOTHERMIA; DAMAGE; HISTOPATHOLOGY; LOCALIZATION; IMPAIRMENTS; EXPRESSION; HYPOXEMIA	Human head trauma is frequently associated with respiratory problems resulting in secondary hypoxic insult. To document the behavioral consequences of secondary hypoxia in an established model of traumatic brain injury (TBI), intubated anesthetized animals were subjected to fluid percussion (FP) injury (1.87-2.17 atm) followed by 30 min of either normoxic (TBI-NO, n = 10) or hypoxic (TBI-HY, n = 11; pO(2) = 30-40 mm Hg) gas levels. Sham animals (n = 19) underwent all manipulations except for the actual trauma. Animals were tested on various sensorimotor tasks beginning 3 days after FP injury along with cognitive testing on days 22 through 29 posttrauma, The secondary hypoxic insult exacerbated the sensorimotor deficits on beam-walking compared to those animals only receiving trauma. Cognitive impairments were also observed in the TBI-HY group in the hidden platform task compared to FP injury alone. These data indicate that a secondary hypoxic insult exacerbates both sensorimotor and cognitive deficits after TBI, This study provides direct evidence that incidences of hypoxia after brain trauma may potentially result in an increase in neurological deficits for the subpopulation of head injured patients undergoing hypoxic conditions further warranting strict monitoring of these events.	Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; Univ Miami, Dept Psychol, Miami, FL 33101 USA; Univ Miami, Dept Neurol, Miami, FL 33101 USA; Univ Miami, Neurotrauma Res Ctr, Miami, FL 33101 USA		Bramlett, HM (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, POB 016960,Mail Locator R-48, Miami, FL 33101 USA.	hbramlet@miamiproject.med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Chesnut R M, 1995, New Horiz, V3, P366; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; DERYCK M, 1992, BRAIN RES, V573, P44; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; SUTHERLAND RJ, 1988, PSYCHOBIOLOGY, V16, P157; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WHISHAW IQ, 1987, BEHAV BRAIN RES, V24, P125, DOI 10.1016/0166-4328(87)90250-6; ZILLES L, 1985, CORTEX RAT STEREOTAX	43	52	55	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	1999	16	11					1035	1047		10.1089/neu.1999.16.1035			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	260MM	WOS:000083954500002	10595820				2022-02-06	
J	Allen, JW; Knoblach, SM; Faden, AI				Allen, JW; Knoblach, SM; Faden, AI			Combined mechanical trauma and metabolic impairment in vitro induces NMDA receptor-dependent neuronal cell death and caspase-3-dependent apoptosis	FASEB JOURNAL			English	Article						neuronal injury; ischemia; caspases; 3-nitropropionic acid	BRAIN INJURY; 3-NITROPROPIONIC ACID; CEREBRAL-ISCHEMIA; CASPASE-3-LIKE PROTEASE; IN-VITRO; MODEL; ACTIVATION; CULTURES; RAT; INHIBITION	Neuronal necrosis and apoptosis occur after traumatic brain injury (TBI) in animals and contribute to subsequent neurological deficits. In contrast, relatively little apoptosis is found after mechanical injury in vitro, Because in vivo trauma models and clinical head injury have associated cerebral ischemia and/or metabolic impairment, we transiently impaired cellular metabolism after mechanical trauma of neuronal-glial cultures by combining 5-nitropropionic acid treatment with concurrent glucose deprivation, This produced greater neuronal cell death than mechanical trauma alone. Such injury was attenuated by the NMDA receptor antagonist dizocilpine (MK801), In addition, this injury significantly increased the number of apoptotic cells over that accruing from mechanical injury alone. This apoptotic cell. death was accompanied by DNA fragmentation, attenuated by cycloheximide, and associated with an increase in caspase-3-like but not caspase-1-like activity, Cell death was reduced by the pan-caspase inhibitor BAF or the caspase-3 selective inhibitor z-DEVD-fmk, whereas the caspase-1 selective inhibitor z-YVAD-fmk had no effect; z-DEVD-fmk also reduced the number of apoptotic cells after combined injury. Moreover, cotreatment with MK801 and BAF resulted in greater neuroprotection than either drug alone. Thus, in vitro trauma with concurrent metabolic inhibition parallels in vivo TBI, showing both NMDA-sensitive necrosis and caspase-3-dependent apoptosis.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA		Faden, AI (corresponding author), EP-04 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634-07] Funding Source: Medline		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arden S. R., 1997, Society for Neuroscience Abstracts, V23, P2294; BEHRENS MI, 1995, NEUROREPORT, V6, P545, DOI 10.1097/00001756-199502000-00034; BEILHARZ EJ, 1995, MOL BRAIN RES, V29, P1; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Chen J, 1998, J NEUROSCI, V18, P4914; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; CIESLA Z, 1974, MOL GEN GENET, V135, P339, DOI 10.1007/BF00271148; Clark R. S. B., 1998, Society for Neuroscience Abstracts, V24, P251; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HASSEL B, 1995, J NEUROCHEM, V65, P1184; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MIRSA HP, 1978, ARCH BIOCHEM BIOPHYS, V189, P317; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Namura S, 1998, J NEUROSCI, V18, P3659; Nath R, 1998, J NEUROCHEM, V71, P186; Pang Z, 1997, J NEUROSCI, V17, P3064; PATEL MN, 1993, NEUROTOXICOLOGY, V14, P35; RINK A, 1995, AM J PATHOL, V147, P1575; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SIEGEL JH, 1995, TRAUMATIC BRAIN INJU, P85; Sonnewald U, 1996, NEUROCHEM RES, V21, P987, DOI 10.1007/BF02532408; Varming T, 1996, J NEUROSCI RES, V44, P40, DOI 10.1002/(SICI)1097-4547(19960401)44:1<40::AID-JNR5>3.0.CO;2-I; VERITY MA, 1991, MOL CHEM NEUROPATHOL, V15, P217; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	40	52	52	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1875	1882		10.1096/fasebj.13.13.1875			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	WOS:000083063400024	10506592				2022-02-06	
J	Leker, RR; Shohami, E; Abramsky, O; Ovadia, H				Leker, RR; Shohami, E; Abramsky, O; Ovadia, H			Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						stroke; ischemia; dexanabinol; TNF alpha; nitric oxide synthase	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; BRAIN INJURY; NITRIC-OXIDE; FACTOR-ALPHA; TNF-ALPHA; HU-211; RATS; INFLAMMATION; ANTAGONIST	The permanent middle cerebral artery occlusion (PMCAO) model was used to investigate the cerebroprotective effects of the synthetic cannabinoid, dexanabinol (HU-211). Dexanabinol is a noncompetitive N-methyl-D-aspartate antagonist, with antioxidant and anti-TNF alpha properties. Twenty hypertensive rats were subjected to PMCAO. Eight were given 4 mg/kg dexanabinol, i.v., 1 h after PMCAO, eight received vehicle and four were not injected. Five rats underwent sham surgery. Infaret volumes were assessed, as well as TNF alpha oconcentrations and NOS activity in brain homogenates. Dexanabinol significantly decreased infarct volumes. It also significantly lowered TNFa levels in the ipsilateral hemisphere although not to the level of sham operated rats. No effect could be demonstrated on NOS activity. In conclusion, dexanabinol may be a pluripotent cerebroprotective agent. (C) 1999 Elsevier Science B.V. All rights reserved.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Neurol, IL-91010 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel		Leker, RR (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Neurol, IL-91010 Jerusalem, Israel.	leker@cc.huji.ac.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334			Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; BELAYEV L, 1995, MOL CHEM NEUROPATHOL, V25, P19, DOI 10.1007/BF02815084; Biegon A, 1995, Ann N Y Acad Sci, V765, P314, DOI 10.1111/j.1749-6632.1995.tb16597.x; BIEGON A, 1997, J NEUROTRAUM, V17, P758; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; BUCE AJ, 1997, NATURE MED, V7, P788; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; Dalkara T, 1997, INT REV NEUROBIOL, V40, P319; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Gallily R, 1997, J PHARMACOL EXP THER, V283, P918; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; Margaill I, 1997, BRIT J PHARMACOL, V120, P160, DOI 10.1038/sj.bjp.0700889; MCCULLOCH J, 1994, J NEURAL TRANSM-SUPP, P71; Meistrell ME, 1997, SHOCK, V8, P341; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Olesen SP, 1997, ACTA NEUROL SCAND, V95, P219, DOI 10.1111/j.1600-0404.1997.tb00102.x; Sadoshima S, 1997, BRAIN RES, V744, P246, DOI 10.1016/S0006-8993(96)01063-3; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Scherbel U., 1997, J NEUROTRAUM, V14, P781; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; WITYK RJ, 1994, CRIT CARE MED, V22, P1278, DOI 10.1097/00003246-199408000-00012; ZHAI QH, 1997, J NEUROL SCI, V152, P1119	29	52	57	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JAN 15	1999	162	2					114	119		10.1016/S0022-510X(98)00301-3			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	177UB	WOS:000079228500002	10202976				2022-02-06	
J	Joashi, UC; Greenwood, K; Taylor, DL; Kozma, M; Mazarakis, ND; Edwards, AD; Mehmet, H				Joashi, UC; Greenwood, K; Taylor, DL; Kozma, M; Mazarakis, ND; Edwards, AD; Mehmet, H			Poly(ADP ribose) polymerase cleavage precedes neuronal death in the hippocampus and cerebellum following injury to the developing rat forebrain	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; brain; caspase; diaschisis; hypoxia; ischaemia	ISCHEMIC BRAIN INJURY; INTERLEUKIN-1-BETA CONVERTING-ENZYME; APOPTOTIC CELL-DEATH; HYPOXIA-ISCHEMIA; MAGNETIC-RESONANCE; CEREBRAL-ISCHEMIA; INFANT RAT; INHIBITION; ACTIVATION; DIASCHISIS	Transient unilateral forebrain hypoxia-ischaemia (HI) in 14-day-old rats produces infarction and delayed neuronal death in the frontal cortex. Cell death can also be observed in regions distant from the primary injury, a phenomenon known as diaschisis. While apoptosis is involved in selective neuronal death, its role in infarction and diaschisis remains poorly understood, Here, we have investigated the proteolytic cleavage of poly(ADP ribose) polymerase (PARP) and the occurrence of apoptosis in the hippocampus and the cerebellum following either HI or traumatic brain injury. We demonstrate that: (i) in vitro, PARP is cleaved during apoptosis but not necrosis in cultured neuronal (N1E) cells and Swiss 3T3 fibroblasts; (ii) following HI, apoptotic cells can be detected by 4h after injury in the hippocampus; (iii) in the ipsilateral hippocampus the appearance of cells with apoptotic morphology is preceded by a dramatic increase in PARR cleavage in the same region, starting immediately following HI and persisting for 24 h; (iv) HI also induces apoptosis in the cerebellum and, as in the hippocampus, the appearance of cells with apoptotic morphology is preceded by PARP cleavage that is greater on the side Ipsilateral to forebrain injury; and (v) similarly, traumatic brain injury to the forebrain leads to PARR cleavage and apoptosis in the cerebellum. We conclude that HI injury or traumatic injury to the developing rat forebrain leads to PARP cleavage in directly affected areas and in sites distant from the primary injury that precedes the appearance of cells with apoptotic morphology. Our results are consistent with a role for apoptotic cell death in infarction and in diaschisis resulting from forebrain injury to the developing brain.	Hammersmith Hosp, Imperial Coll, Sch Med, Weston Lab,Div Paediat Obstet & Gynaecol, London W12 0NN, England		Mehmet, H (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Weston Lab,Div Paediat Obstet & Gynaecol, Du Cane Rd, London W12 0NN, England.	hmehmet@rpms.ac.uk		Edwards, Anthony David/0000-0003-4801-7066	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; ANSARI B, 1993, J PATHOL, V179, P1; Beilharz Erica J., 1995, Molecular Brain Research, V29, P1, DOI 10.1016/0169-328X(94)00217-3; CHARRIAUTMARLANGUE C, 1995, J CEREBR BLOOD F MET, V15, P385, DOI 10.1038/jcbfm.1995.48; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Edwards AD, 1997, PEDIATR RES, V42, P684, DOI 10.1203/00006450-199711000-00022; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Evan Gerard I., 1994, Trends in Cell Biology, V4, P191, DOI 10.1016/0962-8924(94)90134-1; FERRER I, 1994, BRAIN PATHOL, V4, P115, DOI 10.1111/j.1750-3639.1994.tb00821.x; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; FUKUDA K, 1993, AM J PATHOL, V142, P935; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; GOTO K, 1990, BRAIN RES, V534, P299, DOI 10.1016/0006-8993(90)90144-Z; HAMANO S, 1993, PEDIATR NEUROL, V9, P435, DOI 10.1016/0887-8994(93)90022-5; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harada J, 1997, BRAIN RES, V753, P251, DOI 10.1016/S0006-8993(97)00011-5; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HOCKENBERY D, 1995, AM J PATHOL, V146, P16; INFELD B, 1995, STROKE, V26, P90, DOI 10.1161/01.STR.26.1.90; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leist M, 1997, BIOCHEM BIOPH RES CO, V233, P518, DOI 10.1006/bbrc.1997.6491; LI Y, 1995, AM J PATHOL, V146, P1045; LOREK A, 1994, PEDIATR RES, V36, P699, DOI 10.1203/00006450-199412000-00003; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARLANGUE CC, 1996, J CEREB BLOOD FLOW M, V16, P186; MAZARAKIS ND, 1997, ARCH DIS CHILD, V77, P165; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MEHMET H, 1994, NEUROSCI LETT, V181, P121, DOI 10.1016/0304-3940(94)90574-6; MEYER JS, 1993, NEUROL RES, V15, P362; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROSENBAUM DM, 1994, ANN NEUROL, V36, P864, DOI 10.1002/ana.410360610; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Sirimanne ES, 1996, PEDIATR RES, V39, P591, DOI 10.1203/00006450-199604000-00005; Smolders I, 1997, EUR J PHARMACOL, V319, P21, DOI 10.1016/S0014-2999(96)00830-8; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; WILLIAMS CE, 1992, ANN NEUROL, V31, P14, DOI 10.1002/ana.410310104; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; WYATT JS, 1989, ARCH DIS CHILD-FETAL, V64, P953, DOI 10.1136/adc.64.7_Spec_No.953; WYLLIE AH, 1992, OXFORD TXB PATHOLOGY, P141	50	52	54	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	JAN	1999	11	1					91	100		10.1046/j.1460-9568.1999.00409.x			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	155NY	WOS:000077954300009	9987014				2022-02-06	
J	Haselkorn, JK; Mueller, BA; Rivara, FA				Haselkorn, JK; Mueller, BA; Rivara, FA			Characteristics of drivers and driving record after traumatic and nontraumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							EPILEPSY; DAMAGE; STROKE	Objective: To determine whether individuals with a traumatic brain injury (TBI) or stroke (cerebrovascular accident [CVA]) have an increased risk of subsequent motor vehicle crash or moving violation. Design: A retrospective study comparing the driving records of four cohorts hospitalized with TBI, CVA, isolated extremity fractures (FX), and appendicitis (APPY) with the records of four age-matched, gender-matched, and zip code-matched nonhospitalized cohorts. Setting: Eligible drivers in the state of Washington, 1991 to 1993. Participants/Methods: Four cohorts hospitalized in 1992 with TBI, CVA, FX, or APPY were identified from Washington state hospital discharge data. The state driver's license database identified patients with drivers' licenses. Each hospitalized cohort was compared with its own age-matched, gender-matched, and zip code-matched nonhospitalized cohort. Main Outcome Measures: Crashes and citations for moving violations 12 months after hospitalization adjusted for age, gender, and prior driving record. Results: The relative risks (RRs) of any subsequent crash or receipt of citation were not greater for those with either CVA or TBI than for nonhospitalized individuals, nor were the risks of experiencing two or more of these events in the 12 months after hospitalization significantly elevated. After adjustment for prior driving record, modest elevations were observed only for the risks of subsequent driving violation among those with TBI (RR = 1.3, 1.0-1.7) and among patients with FX (RR = 1.2, 1.1-1.4). Conclusions: The results do not support the hypothesis that individuals who have sustained a brain injury are at increased risk of motor vehicle crashes. Although patients with TBI were more likely to subsequently receive citations than nonhospitalized individuals, a similar increase was observed among patients without brain injury who had FX, suggesting an inability to completely control for driver characteristics that may be related to risk-taking behavior and that are also associated with an increased risk of driving violation. (C)1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Puget Sound Healthcare Syst, Dept Vet Affairs, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA		Haselkorn, JK (corresponding author), Puget Sound Healthcare Syst, Dept Vet Affairs, PMR 117,1660 S Columbian Way, Seattle, WA 98108 USA.						Fox G K, 1992, Disabil Rehabil, V14, P140; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; Hansotia P, 1993, Clin Geriatr Med, V9, P323; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; KAWAI I, 1991, JPN J PSYCHIAT NEUR, V45, P311; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; Lings S, 1991, Int Disabil Stud, V13, P74; NOURI FM, 1993, BRIT MED J, V307, P482, DOI 10.1136/bmj.307.6902.482; *PRACT MAN INF COR, 1996, INT CLASS DIS; RETCHIN SM, 1993, CLIN GERIATR MED, V9, P276; SALINSKY MC, 1992, EPILEPSIA, V33, P469, DOI 10.1111/j.1528-1157.1992.tb01693.x; TAKEDA A, 1991, JPN J PSYCHIAT NEUR, V45, P319; YSANDER L, 1966, BRIT J IND MED, V23, P28	13	52	52	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	1998	79	7					738	742		10.1016/S0003-9993(98)90349-5			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	ZZ388	WOS:000074724400003	9685084				2022-02-06	
J	Rueckert, L; Grafman, J				Rueckert, L; Grafman, J			Sustained attention deficits in patients with lesions of posterior cortex	NEUROPSYCHOLOGIA			English	Article						parietal cortex; vigilance	CLOSED-HEAD-INJURY; UNILATERAL NEGLECT; FRONTAL LESIONS; VIGILANCE; PARIETAL; NETWORK; SYSTEM; TASK	Patients with lesions to posterior cortex were compared to controls, matched for age and education, on tests on sustained attention. One test was a simple reaction time task requiring subjects to respond whenever they saw an 'X'. The other was a Continuous Performance Test that required subjects to respond to an 'X' but refrain from responding to other letters. The patients missed more targets than control subjects on both tests. On the Continuous Performance Test the difference between patients and controls increased with time on task, suggesting a sustained attention deficit similar to that previously observed in patients with right frontal lesions. However, whereas frontal patients showed a tendency toward greater impairment when the rate of stimulus presentation was relatively slow, the posterior patients performed significantly worse when the stimuli were presented at a faster rate. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.	NINDS, Cognit Neurosci Sect, NIH, Chicago, IL USA		Rueckert, L (corresponding author), NE Illinois Univ, Dept Psychol, 5500 N St Louis Ave, Chicago, IL 60625 USA.			Grafman, Jordan H./0000-0001-8645-4457			BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BUCK L, 1966, PSYCHOL BULL, V65, P291, DOI 10.1037/h0023207; Cohen RM, 1988, NEUROPSY NEUROPSY BE, V1, P3; Coull JT, 1996, NEUROPSYCHOLOGIA, V34, P1085, DOI 10.1016/0028-3932(96)00029-2; CRAIG A, 1987, HUM FACTORS, V29, P675, DOI 10.1177/001872088702900607; Damasio H., 1989, LESION ANAL NEUROPSY; DAVIES DR, 1969, HUMAN VIGILANCE PERF; DERENZI DE, 1982, DISORDERS SPACE EXPL; DEUTSCH G, 1987, INT J NEUROSCI, V36, P23, DOI 10.3109/00207458709002136; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GOLDBERG ME, 1987, NEUROPSYCHOLOGIA, V25, P107, DOI 10.1016/0028-3932(87)90047-9; HEILMAN KM, 1977, HEMIINATTENTION HEMI; Hjaltason H, 1996, NEUROPSYCHOLOGIA, V34, P1229, DOI 10.1016/0028-3932(96)00044-9; JENKINS HM, 1958, AM J PSYCHOL, V71, P647, DOI 10.2307/1420323; JERISON HJ, 1963, HUM FACTORS, V5, P211, DOI 10.1177/001872086300500305; JOHNSTON WA, 1966, J EXP PSYCHOL, V22, P736; LOEB M, 1970, ACTA PSYCHOL, V33, P343, DOI 10.1016/0001-6918(70)90146-0; LYNCH JC, 1977, J NEUROPHYSIOL, V40, P362, DOI 10.1152/jn.1977.40.2.362; MACKWORTH JF, 1970, VIGILANCE HABITUATIO; MENNEMEIER MS, 1994, NEUROPSYCHOLOGIA, V32, P703, DOI 10.1016/0028-3932(94)90030-2; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; NICKERSON RA, 1969, J EXP PSYCHOL, V79, P452, DOI 10.1037/h0026889; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Parasuraman R, 1984, VARIETIES ATTENTION, P243; PARASURAMAN R, 1979, SCIENCE, V205, P925; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PETERSEN SE, 1988, ASS RES VISION OPHTH, P22; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RICHER F, 1993, BRAIN COGNITION, V21, P203, DOI 10.1006/brcg.1993.1016; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; SALMASO D, 1982, PERCEPT MOTOR SKILL, V54, P1147, DOI 10.2466/pms.1982.54.3c.1147; SEE JE, 1995, PSYCHOL BULL, V117, P230, DOI 10.1037/0033-2909.117.2.230; SIDDLE DAT, 1972, BRIT J PSYCHOL, V63, P191, DOI 10.1111/j.2044-8295.1972.tb02099.x; WEINSTEIN E, 1977, HEMIINATTENTION HEMI; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212; WURTZ RH, 1980, PROGR PSYCHOBIOLOGY, V9, P32	40	52	52	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	JUL	1998	36	7					653	660		10.1016/S0028-3932(97)00150-4			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	106JN	WOS:000075126300007	9723936				2022-02-06	
J	LaPlaca, MC; Thibault, LE				LaPlaca, MC; Thibault, LE			Dynamic mechanical deformation of neurons triggers an acute calcium response and cell injury involving the N-methyl-D-aspartate glutamate receptor	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						glutamate; MK-801; neuronal injury; nifedipine; traumatic brain injury	TRAUMATIC BRAIN INJURY; SODIUM-CHANNEL BLOCKER; NERVOUS-SYSTEM; NTERA-2 CELLS; IN-VITRO; MODEL; CULTURES; RELEASE; INVITRO; RAT	A biomechanical in vitro model of traumatic brain injury was used to examine cellular response to physical insults and the underlying mechanisms that lead to cell dysfunction. A cell shearing injury device was used to deform human NTera-2 neurons at high loading rates during the investigation of mechanisms of cytosolic free calcium increases, which may be detrimental to a cell. Cytosolic free calcium rose immediately to almost three times baseline and was associated with lactate dehydrogenase release at 24 hr, indicating significant cell injury. Low loading rates did not elicit these responses. A major portion of the calcium increase and subsequent cell injury was dependent on the presence of extracellular free calcium. Blocking the N-methyl-D-aspartate glutamate receptor complex with dizocilipine maleate attenuated calcium increases by 45% in injured neurons and blocked a significant part (50%) of the lactate dehydrogenase release. In addition, pretreatment with nifedipine or riluzole also significantly reduced cytosolic free calcium but did not affect cell injury, whereas tetrodotoxin had no affect on either outcome parameter. These results suggest that the increased membrane permeability and immediate calcium influx associated with this model of mechanical injury trigger several cellular pathways, including N-methyl-D-aspartate receptor-mediated cell damage. (C) 1998 Wiley-Liss, Inc.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Allegheny Univ Hlth Sci, Div Bioengn, Dept Neurosurg, Philadelphia, PA 19102 USA		LaPlaca, MC (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,105C Hayden Hall, Philadelphia, PA 19104 USA.	laplacam@mail.med.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD026979] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD26979] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R491CCR304684] Funding Source: Medline		ADAMS JH, 1982, RECENT ADV NEUROPATH, P165; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BOND M, 1988, CELL CALCIUM, V9, P201, DOI 10.1016/0143-4160(88)90001-2; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHIU FC, 1994, J NEUROSCI RES, V38, P687, DOI 10.1002/jnr.490380611; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GROSS GW, 1983, J NEUROSCI, V3, P1979; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MARTIN D, 1993, EUR J PHARMACOL, V250, P473, DOI 10.1016/0014-2999(93)90037-I; MATTSON MP, 1991, MECH AGEING DEV, V60, P171, DOI 10.1016/0047-6374(91)90129-N; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; Munir M, 1995, J NEUROSCI, V15, P7847; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; ROBINSON MB, 1993, J NEUROCHEM, V61, P2099, DOI 10.1111/j.1471-4159.1993.tb07447.x; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Shi RY, 1989, J NEUROTRAUM, V6, P261, DOI 10.1089/neu.1989.6.261; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; THIBAULT LE, 1992, INT C BIOM IMP IRCOB, P311; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; TYMIANSKI M, 1993, NEURON, V11, P221, DOI 10.1016/0896-6273(93)90180-Y; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	45	52	53	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	APR 15	1998	52	2					220	229		10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZJ002	WOS:000073169700010	9579412				2022-02-06	
J	Kreitner, KF; Botchen, K; Rude, J; Bittinger, F; Krummenauer, F; Thelen, M				Kreitner, KF; Botchen, K; Rude, J; Bittinger, F; Krummenauer, F; Thelen, M			Superior labrum and labral-bicipital complex: MR imaging with pathologic-anatomic and histologic correlation	AMERICAN JOURNAL OF ROENTGENOLOGY			English	Article							GLENOID LABRUM; BUFORD COMPLEX; BICEPS TENDON; SLAP INJURIES; SHOULDER; ARTHROGRAPHY; LESIONS; CADAVERS	OBJECTIVE. The purpose of this study was to analyze the anatomic relationship between the superior labrum, the superior glenoid rim, the superior glenohumeral ligament, and the long head of the biceps tendon. MATERIALS AND METHODS. Seventeen cadaveric shoulder specimens underwent axial, oblique coronal, and oblique sagittal MR imaging on a 1.5-T imager. Unenhanced proton density-and T2-weighted spin-echo images with and without fat suppression, and T1-weighted fat-suppressed spin-echo images after intraarticular injection of gadolinium, were obtained of each specimen. The shoulders were then frozen and sectioned into 4-mm-thick slices, either transversely or oblique coronally. After gross anatomic correlation, histologic analysis was performed on 32 sections. RESULTS. A sublabral recess was present in 12 (71%) of 17 shoulders. MR arthrography was significantly better at showing the sublabral recess than was unenhanced MR imaging. Histologically, the synovial recess in all cases was covered by synovial lining cells. Intralabral altered histologic patterns were found in 20 (63%) of 32 labral sections. In addition to signs of degeneration, five sections of two specimens showed proliferating fibroblasts and vessels, as well as fibrosis, suggesting trauma. The presence or absence of altered intralabral histologic patterns was better assessed with T1-weighted fat-suppressed arthrograms than with unenhanced MR images. We found a close association grossly and histologically between the superior labrum and the biceps tendon. CONCLUSION. The attachment of the superior glenoid labrum to the glenoid rim shows great variability. In MR imaging, an overlap appears to exist between physiologic recesses of the superior labrum and a type 2 superior labrum anterior-posterior lesion. T1-weighted fat-suppressed MR arthrograms provided the best view of the superior labrum and the labral-bicipital complex.	Johannes Gutenberg Univ Mainz, Dept Radiol, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Med Stat & Documentat, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Anat, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55131 Mainz, Germany		Kreitner, KF (corresponding author), Johannes Gutenberg Univ Mainz, Dept Radiol, Langenbeckstr 1, D-55131 Mainz, Germany.						BURKHART S S, 1992, Arthroscopy, V8, P31, DOI 10.1016/0749-8063(92)90132-U; CARTLAND JP, 1992, AM J ROENTGENOL, V159, P787, DOI 10.2214/ajr.159.4.1529844; CHANDNANI VP, 1995, RADIOLOGY, V196, P27, DOI 10.1148/radiology.196.1.7784579; CHANDNANI VP, 1993, AM J ROENTGENOL, V161, P1229, DOI 10.2214/ajr.161.6.8249731; COOPER DE, 1992, J BONE JOINT SURG AM, V74A, P46, DOI 10.2106/00004623-199274010-00007; DePalma AF, 1949, AM ACAD ORTHOPEDIC S, V6, P225; DETRISAC DA, 1987, ARTHROSCOPIC SHOULDE, P71; ERICKSON SJ, 1993, RADIOLOGY, V188, P23, DOI 10.1148/radiology.188.1.7685531; FIELD LD, 1993, AM J SPORT MED, V21, P783, DOI 10.1177/036354659302100605; GRAUER JD, 1992, ARTHROSCOPY, V8, P488, DOI 10.1016/0749-8063(92)90013-2; Gusmer PB, 1996, RADIOLOGY, V200, P519, DOI 10.1148/radiology.200.2.8685350; HABERMEYER P, 1993, ARTHROSKOPIE, V6, P263; HODLER J, 1992, AM J ROENTGENOL, V159, P565, DOI 10.2214/ajr.159.3.1503027; HODLER J, 1992, INVEST RADIOL, V27, P323, DOI 10.1097/00004424-199204000-00015; LOREDO R, 1995, RADIOLOGY, V196, P33, DOI 10.1148/radiology.196.1.7784584; MASSENGILL AD, 1994, RADIOGRAPHICS, V14, P1211, DOI 10.1148/radiographics.14.6.7855336; MONU JUV, 1994, AM J ROENTGENOL, V163, P1425, DOI 10.2214/ajr.163.6.7992740; PALMER WE, 1994, RADIOLOGY, V190, P645, DOI 10.1148/radiology.190.3.8115604; RAMES RD, 1993, ORTHOP CLIN N AM, V24, P45; SMITH AM, 1993, SKELETAL RADIOL, V22, P507; Smith DK, 1996, RADIOLOGY, V201, P251, DOI 10.1148/radiology.201.1.8816553; SNYDER S J, 1990, Arthroscopy, V6, P274, DOI 10.1016/0749-8063(90)90056-J; Tirman PFJ, 1996, AM J ROENTGENOL, V166, P869, DOI 10.2214/ajr.166.4.8610565; Tuite MJ, 1996, RADIOLOGY, V199, P537, DOI 10.1148/radiology.199.2.8668808; WILLIAMS MM, 1994, ARTHROSCOPY, V10, P241, DOI 10.1016/S0749-8063(05)80105-7	25	52	56	0	1	AMER ROENTGEN RAY SOC	RESTON	1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA	0361-803X	1546-3141		AM J ROENTGENOL	Am. J. Roentgenol.	MAR	1998	170	3					599	605		10.2214/ajr.170.3.9490937			7	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	YY262	WOS:000072129500012	9490937				2022-02-06	
J	Janis, LS; Hoane, MR; Conde, D; Fulop, Z; Stein, DG				Janis, LS; Hoane, MR; Conde, D; Fulop, Z; Stein, DG			Acute ethanol administration reduces the cognitive deficits associated with traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						alcohol; Morris water maze; contusion; edema; trauma	FRONTAL CORTICAL CONTUSION; HEAD-INJURY; NEURONS; CORTEX; EXCITOTOXICITY; MICRODIALYSIS; MEMORY; EDEMA	The present study was designed to determine whether a low dose of acute ethanol administration could attenuate cognitive deficits associated with traumatic brain injury. Adult male rats received oral administration of ethanol or drinking water 2 h prior to surgery to produce a blood ethanol concentration of 100 mg% and then received bilateral contusion injuries of the medial prefrontal cortex, Seven days after surgery, the rats began 10 days of testing for acquisition of spatial localization in the Morris water maze where they were required to find a hidden platform to escape from the water, The results indicate that the rats given ethanol at the time of injury later spent significantly less time searching for the hidden platform than their water-treated counterparts, On a memory probe test given on the final day of testing, in which the platform was removed from the pool, rats given the ethanol spent more time in the area where the platform had been located indicating that they learned its location better than the lesion/water controls, In addition, acute ethanol treatment reduced some of the histopathology that typically occurs following severe contusion of the medial frontal cortex but did not attenuate post-traumatic formation of edema, These results indicate that acute ethanol intoxication can reduce the severity of cognitive impairments caused by contusive traumatic brain injury and support the contention that there is a dose-response relationship of acute ethanol intoxication in the setting of traumatic brain injury.	Emory Univ, Sch Med, Dept Neurol, Brain Res Lab, Atlanta, GA 30322 USA; Rutgers State Univ, Inst Anim Behav, Newark, NJ 07102 USA		Stein, DG (corresponding author), Emory Univ, Sch Med, Dept Neurol, Brain Res Lab, 575 Rollins Way, Atlanta, GA 30322 USA.		Stein, Donald/AAJ-5139-2020	Hoane, Michael/0000-0001-7779-2657			BONNICHSEN RK, 1951, SCAND J CLIN LAB INV, V3, P58, DOI 10.3109/00365515109060572; CHANDLER LJ, 1993, J NEUROCHEM, V60, P1578, DOI 10.1111/j.1471-4159.1993.tb03326.x; DEACON TW, 1983, J COMP NEUROL, V220, P168, DOI 10.1002/cne.902200205; DeCrescito V, 1974, Surg Forum, V25, P438; DIXON CE, 1991, J NEUROSCI METH, V15, P1; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; FERRARO TN, 1990, ALCOHOL, V7, P129, DOI 10.1016/0741-8329(90)90073-L; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KARPIAK SE, 1984, J NEUROSCI RES, V12, P485, DOI 10.1002/jnr.490120231; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; LEONARD CM, 1969, BRAIN RES, V12, P321, DOI 10.1016/0006-8993(69)90003-1; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LUSTIG HS, 1992, NEUROSCI LETT, V135, P259, DOI 10.1016/0304-3940(92)90450-L; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; NURMI M, 1994, ALCOHOL, V11, P315, DOI 10.1016/0741-8329(94)90098-1; PACKARD MG, 1992, BEHAV NEUROSCI, V106, P439, DOI 10.1037/0735-7044.106.3.439; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PATRINI C, 1988, ALCOHOL ALCOHOLISM, V23, P455; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; STEWART PA, 1988, BRAIN RES, V443, P12, DOI 10.1016/0006-8993(88)91593-4; STRUBELT O, 1974, ARCH TOXICOL, V32, P83, DOI 10.1007/BF00316229; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKADERA T, 1990, BRAIN RES, V537, P109, DOI 10.1016/0006-8993(90)90346-D; *US DEP TRANSP NAT, 1994, 1994 OCC PROT ID SAM; WIENER SI, 1993, J NEUROSCI, V13, P3802; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	41	52	53	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	1998	15	2					105	115		10.1089/neu.1998.15.105			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	YZ744	WOS:000072287300002	9512086				2022-02-06	
J	Miller, W; Riehl, E; Napier, M; Barber, K; Dabideen, H				Miller, W; Riehl, E; Napier, M; Barber, K; Dabideen, H			Use of physician assistants as surgery/trauma house staff at an American College of Surgeons-verified Level II trauma center	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							NURSE PRACTITIONERS; CARE; RESIDENTS; QUALITY	Background: Historically, surgical physicians staff trauma centers, which provide trauma patients with improved outcomes, Such benefits fuel the expansion of designated trauma centers, Cutbacks in residency programs of surgical specialties, however, necessitate substitutions for traditional trauma providers. Methods: A literature and record review was conducted to examine the use of physician assistants in a large community hospital's verified trauma center, Current and historical outcomes were analyzed regarding the trauma surgeon/physician assistant model. Results: Injury Severity Scores increased 19%, transfer time to the operating room decreased 43%, transfer time to the intensive care unit decreased 51%, and transfer time to the floor decreased 20%, The length of stay for admissions decreased 13%, and the length of stay for neurotrauma intensive care unit patients decreased 33%. Conclusion: The Hurley Medical Center trauma surgeon/ physician assistant model is a viable alternative for verified trauma centers unable to maintain a surgical residency program. Consistency and quality of care indicated by shortened length of stay is a hallmark of such a model providing the highest quality of care.	Hurley Med Ctr, Trauma Serv, Dept Physician Assistants, PA C, Flint, MI 48503 USA; Hurley Med Ctr, Dept Trauma, Flint, MI USA; Hurley Med Ctr, Res Dept, Flint, MI USA		Miller, W (corresponding author), Hurley Med Ctr, Trauma Serv, Dept Physician Assistants, PA C, Flint, MI 48503 USA.						*AM AC PHYS ASS, 1997, INF UPD PROJ NUMB PH; *AM AC PHYS ASS, 1997, PHYS ASS STAT TRENDS; CARZOLI RP, 1994, ARCH PEDIAT ADOL MED, V148, P1271, DOI 10.1001/archpedi.1994.02170120033005; DUBAYBO BA, 1991, CHEST, V99, P89, DOI 10.1378/chest.99.1.89; GOLDFRANK L, 1980, ANN EMERG MED, V9, P96, DOI 10.1016/S0196-0644(80)80338-6; Hooker RS, 1996, AM J EMERG MED, V14, P245, DOI 10.1016/S0735-6757(96)90167-9; JONES PE, 1994, JAMA-J AM MED ASSOC, V271, P1266, DOI 10.1001/jama.271.16.1266; MAXFIELD RG, 1975, TRAUMA, V15, P795; RECORD JC, 1980, J HEALTH POLIT POLIC, V5, P470; RIPORTELLAMULLER R, 1995, HEALTH AFFAIR, V14, P181, DOI 10.1377/hlthaff.14.2.181; SCHULMAN M, 1995, AM J PERINAT, V12, P442, DOI 10.1055/s-2007-994517; SOX HC, 1994, ANN INTERN MED, V121, P714, DOI 10.7326/0003-4819-121-9-199411010-00014; SPISSO J, 1990, J TRAUMA, V30, P660, DOI 10.1097/00005373-199006000-00001	13	52	52	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	1998	44	2					372	376		10.1097/00005373-199802000-00025			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	YZ995	WOS:000072317300026	9498514				2022-02-06	
J	Hicks, RR; Baldwin, SA; Scheff, SW				Hicks, RR; Baldwin, SA; Scheff, SW			Serum extravasation and cytoskeletal alterations following traumatic brain injury in rats - Comparison of lateral fluid percussion and cortical impact models	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						MAP2; blood-brain barrier; head injury	MICROTUBULE-ASSOCIATED PROTEIN-2; HEAD-INJURY; VASCULAR DISRUPTION; HIPPOCAMPAL-LESIONS; BARRIER; DAMAGE; MAP2; IMMUNOREACTIVITY; CONTUSION; NEURONS	Disruption of the blood-brain barrier (BBB) and neuronal cytoskeletal damage were evaluated in two commonly used rat models of traumatic brain injury. Adult rats received a lateral cortical impact (CI) or lateral fluid percussion (FP) injury of mild or moderate severity or a sham procedure. Six hours after trauma, the brains were removed and analyzed with immunocytochemical techniques for alterations in the serum protein, IgG, and the cytoskeletal protein, microtubule-associated protein 2 (MAP2). Both models induced profound alterations in these proteins in the ipsilateral cortex and hippocampus compared to sham-injured controls. Following an injury of moderate severity, the CI injury resulted in greater IgG extravasation in the cortex and hippocampus than the FP injury. Conversely, after a mild injury, IgG extravasation in the hippocampus was greater for FP than CI. All of the animals in the CI group and most of the FP group showed a loss of MAP2 in the hippocampus. The specific subregions within the cortex and hippocampus that were affected by the injury varied between models, despite having identical impact sites. These data demonstrate that there are both similarities and differences between a CI and FP injury on vascular and neuronal cystoskeletal integrity which should be considered when utilizing these animal models to study selected features of human head injury.	Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Hicks, RR (corresponding author), Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; AIHARA N, 1994, J COMP NEUROL, V342, P481, DOI 10.1002/cne.903420402; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BLACK MM, 1989, TRENDS NEUROSCI, V12, P211, DOI 10.1016/0166-2236(89)90124-0; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; BOTHE HW, 1984, ACTA NEUROPATHOL, V64, P37, DOI 10.1007/BF00695604; BRALET J, 1992, BIOCHEM PHARMACOL, V43, P979, DOI 10.1016/0006-2952(92)90602-F; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CZURKO A, 1994, NEUROSCI LETT, V166, P51, DOI 10.1016/0304-3940(94)90838-9; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon C. E., 1995, CENTRAL NERVOUS SYST, P255; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FRIEDRICH P, 1991, FEBS LETT, V295, P5, DOI 10.1016/0014-5793(91)81371-E; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HATAKEYAMA T, 1988, STROKE, V19, P1526, DOI 10.1161/01.STR.19.12.1526; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JANE JA, 1982, HEAD INJURY BASIC CL, P229; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; KITIGAWA K, 1989, NEUROSCIENCE, V31, P401; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Kruger L., 1995, PHOTOGRAPHIC ATLAS R; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moos T, 1996, J HISTOCHEM CYTOCHEM, V44, P591, DOI 10.1177/44.6.8666744; MOSER E, 1993, J NEUROSCI, V13, P3916; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PAXINOS G, 1986, RAT BRAINF STEREOTAX; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SEISJO BK, 1988, CRIT CARE MED, V16, P954; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROSCI, V15, P8223; StubleyWeatherly L, 1996, BRAIN RES, V716, P29, DOI 10.1016/0006-8993(95)01589-2; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SZENTISTVANYI I, 1984, AM J PHYSIOL, V246, pF835, DOI 10.1152/ajprenal.1984.246.6.F835; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; VANDENBRINK WA, 1994, ACT NEUR S, V60, P456; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YOSHIMI K, 1991, BRAIN RES, V560, P149, DOI 10.1016/0006-8993(91)91225-P	60	52	52	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	SEP-DEC	1997	32	1-3					1	16		10.1007/BF02815164			16	Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	YN074	WOS:000071130500001	9437655				2022-02-06	
J	Temple, MD; Hamm, RJ				Temple, MD; Hamm, RJ			Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury	BRAIN RESEARCH			English	Article						D-cycloserine; glycine site; memory; Morris water maze; N-methyl-D-aspartate; rat; treatment	D-ASPARTATE RECEPTOR; CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; EXCITATORY AMINO-ACIDS; GLYCINE RECEPTOR; MEMORY IMPAIRMENT; SPATIAL MEMORY; RATS; HIPPOCAMPAL; ANTAGONIST	The purpose of this study was to determine the effect of augmenting NMDA receptor activation on cognitive deficits produced by traumatic brain injury (TBI). Specifically, D-cycloserine (DCS), a partial agonist of the NMDA-associated glycine site, was tested as a potential cognitive enhancer. Rats were injured using lateral fluid percussion TBI (2.8+/-.10 atm). On days 1-15 post-injury, animals were injected (i.p.) with vehicle (n=8), 10 mg/kg (n=9), or 30 mg/kg (n=8) of DCS. Sham-injured animals treated with either vehicle (n=8) or 30 mg/kg of DCS (n=8) were used for comparison. On days 11-15 post-injury, cognitive function was assessed using the Morris water maze (MWM). Results indicate that the 30 mg/kg dose of DCS significantly attenuated memory deficits as compared to injured vehicle-treated animals (P <0.01). Analysis also revealed that performance of the injured-DCS (30 mg/kg) group was not significantly different from sham-injured animals treated with vehicle (P >0.10). In contrast, the 10 mg/kg dose of DCS was ineffective in reducing injury-induced memory deficits. DCS (30 mg/kg) also significantly improved the spatial memory of sham-injured animals when compared with sham-injured animals treated with vehicle (P <0.05). In conclusion, chronic, post-injury enhancement of the NMDA receptor is an effective strategy for ameliorating TBI-associated cognitive deficits.	VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23284						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline		BAXTER MG, 1994, NEUROBIOL AGING, V15, P207, DOI 10.1016/0197-4580(94)90114-7; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Dixon C. E., 1992, Society for Neuroscience Abstracts, V18, P171; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DSOUZA SW, 1993, ARCH DIS CHILD, V69, P212, DOI 10.1136/adc.69.2.212; EMMETT MR, 1991, NEUROPHARMACOLOGY, V30, P1167, DOI 10.1016/0028-3908(91)90161-4; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FISHKIN RJ, 1993, BEHAV NEURAL BIOL, V59, P150, DOI 10.1016/0163-1047(93)90886-M; FLOOD JF, 1992, EUR J PHARMACOL, V221, P249, DOI 10.1016/0014-2999(92)90709-D; FOSTER AC, 1989, NATURE, V338, P377, DOI 10.1038/338377a0; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HANDELMANN G E, 1987, Society for Neuroscience Abstracts, V13, P705; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOOD WF, 1989, NEUROSCI LETT, V98, P91, DOI 10.1016/0304-3940(89)90379-0; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAYER ML, 1989, NATURE, V338, P425, DOI 10.1038/338425a0; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; ROBINSON G, 1988, Society for Neuroscience Abstracts, V14, P248; SARTER M, 1990, PSYCHOPHARMACOLOGY, V101, P1, DOI 10.1007/BF02253710; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SCHUSTER GM, 1992, EUR J PHARMACOL, V224, P97, DOI 10.1016/0014-2999(92)94825-G; SIRVIO J, 1992, NEUROSCI LETT, V146, P215, DOI 10.1016/0304-3940(92)90081-H; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; WOOD PL, 1995, LIFE SCI, V57, P301, DOI 10.1016/0024-3205(95)00288-H	41	52	53	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 25	1996	741	1-2					246	251		10.1016/S0006-8993(96)00940-7			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VZ081	WOS:A1996VZ08100032	9001729				2022-02-06	
J	Schob, OM; Allen, DC; Benzel, E; Curet, MJ; Adams, MS; Baldwin, NG; Largiader, F; Zucker, KA				Schob, OM; Allen, DC; Benzel, E; Curet, MJ; Adams, MS; Baldwin, NG; Largiader, F; Zucker, KA			A comparison of the pathophysiologic effects of carbon dioxide, nitrous oxide, and helium pneumoperitoneum on intracranial pressure	AMERICAN JOURNAL OF SURGERY			English	Article								BACKGROUND: Previous studies have suggested that diagnostic laparoscopy may be contraindicated in multiple trauma patients with closed head injuries because of the detrimental effects of carbon dioxide (CO2) pneumoperitoneum on intracranial pressure (ICP). In this study we compared the effects of two alternative inflation gases, helium (He) and nitrous oxide (N2O), against the standard agent used in most hospitals, CO2. ICP was monitored in experimental animals both with and without a space occupying intracranial lesion designed to simulate a closed head injury. METHODS: Twenty-four domestic pigs (mean, 30 kg) were divided into four groups (6 CO2, 6 He, 6 N2O, and 6 control animals without insufflation). All animals were monitored for ICP, intraabdominal pressure, mean arterial pressure, end-tidal CO2 (ETCO(2)), and arterial blood gases. These parameters were measured for 30 minutes prior to introducing a pneumoperitoneum and then for 80 minutes thereafter. The measurements were repeated after artificially elevating the ICP with a balloon placed in the epidural space. RESULTS: The mean ICP increased significantly in all groups during peritoneal insufflation compared with the control group (P <0.005). The CO2-insufflated animals also showed a significant increase in PaCO2 (P <0.05) and ETCO(2) (P <0.05), as well as a decrease in pH (P <0.05). After inflating the epidural balloon the ICP remained significantly higher in animals inflated with CO2 as compared with the He and N2O groups (P <0.05). CONCLUSIONS: Peritoneal insufflation with He and N2O resulted in a significantly less increase in ICP as compared with CO2. That difference was most likely due to a metabolically mediated increase in cerebral perfusion (PaCO2) in the CO2 group. Further studies need to be conducted to determine the safety and efficacy of using He and N2O as inflation agents prior to attempting diagnostic or therapeutic laparoscopy in patients with potential closed head injuries.	UNIV NEW MEXICO,SCH MED,DEPT SURG,ALBUQUERQUE,NM 87131; UNIV ZURICH HOSP,DEPT SURG,CH-8091 ZURICH,SWITZERLAND									0	52	52	0	4	CAHNERS PUBL CO	NEW YORK	249 WEST 17 STREET, NEW YORK, NY 10011	0002-9610			AM J SURG	Am. J. Surg.	SEP	1996	172	3					248	252		10.1016/S0002-9610(96)00101-8			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	VK095	WOS:A1996VK09500008	8862077				2022-02-06	
J	Tegner, Y; Lorentzon, R				Tegner, Y; Lorentzon, R			Concussion among Swedish elite ice hockey players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						ice hockey; concussion; management; incidence	HEAD-INJURIES; CEREBRAL CONCUSSION; CONTACT-SPORTS; TRAUMA; GUIDELINES; PREVENTION; MANAGEMENT; IMPACT; MILD	Objective-To evaluate the frequency of concussion in Swedish ice hockey and to establish a uniform grading and treatment model for concussions of different severity. Methods-Frequency of concussion was investigated in two studies, one retrospective and one prospective. In the retrospective study, all Swedish elite ice hockey players (n=265) were asked to answer a questionnaire on the number and treatment of previous concussions. Only concussions diagnosed by a doctor were recorded. The questionnaire was completed by 227 players (86%). In the prospective study, all injuries including concussions occurring during game and practice in the Swedish Elite League (n=12 teams) were recorded during four years. The causes of injury, referees judgements, diagnosis, treatment, and time absent from ice hockey were registered on special cards. Results-In the retrospective study, 51 out of 227 players (22%) in the Swedish Elite League reported at least one concussion. In the prospective study, 52 concussions were reported. The incidence of a concussion is at least one concussion every year/team or a yearly risk of about 5% for a player to sustain a concussion. Most concussions occurred during league play (81%). Body contact (checking or boarding) was the most common cause of concussions. The players were absent from full training and play on a mean of 6 d. Conclusions-As this injury is potentially dangerous it must be treated seriously according to a simple treatment model presented. In cases of repeated concussions during the same season, a longer period of time away from play is suggested. In players who have sustained several concussions over the years a thorough medical examination including EEG, CT/MRI, MRI, and neuropsychological tests should be performed. If any of these is pathological the player should be advised to give up ice hockey.	UNIV UMEA HOSP,DEPT ORTHOPAED SURG,SPORTS MED UNIT,S-90185 UMEA,SWEDEN					Tegner, Yelverton/0000-0003-3628-0705			BRUNO LA, 1987, CLIN SPORT MED, V6, P17; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; CASTALDI CR, 1989, ASTM STP, V1050, P14; Feriencik Kazimir, 1979, Phys Sportsmed, V7, P81, DOI 10.1080/00913847.1979.11948437; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; HASTINGS DE, 1974, ONTARIO MED REV  NOV, P686; HENDERSON JM, 1994, MED CLIN N AM, V78, P289, DOI 10.1016/S0025-7125(16)30160-2; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; INGERSOLL CD, 1993, SPORTS MED, V16, P342, DOI 10.2165/00007256-199316050-00005; JENKINS A, 1986, LANCET, V2, P445; Jorgensen U, 1986, Br J Sports Med, V20, P7; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; MCLATCHIE G, 1994, BRIT MED J, V308, P1620, DOI 10.1136/bmj.308.6944.1620; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MCSHERRY JA, 1989, AM FAM PHYSICIAN, V40, P186; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; REILLY PL, 1975, LANCET, V2, P375; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Ryan A J, 1991, Br J Sports Med, V25, P81; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; *SWED MED ASS, 1985, TREATM CONC SPORTS; Tegner Y, 1991, Br J Sports Med, V25, P87; THORNDIKE A, 1952, NEW ENGL J MED, V247, P554, DOI 10.1056/NEJM195210092471504; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; YARNELL PR, 1970, LANCET, V2, P863; 1990, COLO MED, V87, P4	34	52	52	2	5	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	SEP	1996	30	3					251	255		10.1136/bjsm.30.3.251			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	VJ620	WOS:A1996VJ62000021	8889123	Bronze, Green Published			2022-02-06	
J	Bernert, H; Turski, L				Bernert, H; Turski, L			Traumatic brain damage prevented by the non-N-methyl-D-aspartate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						brain injury; glutamate antagonists; therapeutic time-window	SPINAL-CORD INJURY; FUNCTIONAL DEFICITS; GLOBAL-ISCHEMIA; NMDA RECEPTORS; HIPPOCAMPUS; AMPA	The mechanisms of neuronal degeneration following traumatic head injury are not well understood and no adequate treatment is currently available for the prevention of traumatic brain damage in humans. Traumatic head injury leads to primary (at impact) and secondary (distant) damage to the brain. Mechanical percussion of the rat cortex mimics primary damage seen after traumatic head injury in humans; no animal model mimicking the secondary damage following traumatic head injury has yet been established. Rats subjected to percussion trauma of the cortex showed primary damage in the cortex and secondary damage in the hippocampus. Morphometric analysis demonstrated that both cortical and hippocampal damage was mitigated by pretreatment with either the N-methyl-D-aspartate (NMDA) antagonist 3-((+/-)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate (CPP) or the non-NMDA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX). Neither treatment prevented primary damage in the cortex when therapy was started after trauma. Surprisingly, delayed treatment of rats with NBQX, but not with CPP, beginning between 1 and 7 hr after trauma prevented hippocampal damage. No protection was seen when therapy with NBQX was started 10 hr after trauma. These data indicate that both NMDA- and non-NMDA-dependent mechanisms contribute to the development of primary damage in the cortex, whereas non-NMDA mechanisms are involved in the evolution of secondary damage in the hippocampus in rats subjected to traumatic head injury. The wide therapeutic time-window documented for NBQX suggests that antagonism at non-NMDA receptors may offer a novel therapeutic approach for preventing deterioration of the brain after head injury.			Bernert, H (corresponding author), SCHERING AG,RES LABS,MULLERSTR 170-178,D-13342 BERLIN,GERMANY.						Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Bernert H., 1994, Society for Neuroscience Abstracts, V20, P845; CRUZORIVE LM, 1990, AM J PHYSIOL, V258, pL148, DOI 10.1152/ajplung.1990.258.4.L148; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1994, NEUROBIOLOGY CENTRAL, P227; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FINK ROBERT P., 1967, BRAIN RES, V4, P369, DOI 10.1016/0006-8993(67)90166-7; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GREENBERG J, 1993, HDB HEAD SPINE TRAUM; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; HU BR, 1995, J NEUROCHEM, V64, P277; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; LEHMANN J, 1987, J PHARMACOL EXP THER, V240, P737; LI H, 1993, J CEREBR BLOOD F MET, V13, P933, DOI 10.1038/jcbfm.1993.116; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONAGHAN DT, 1991, EXCITATORY AMINO ACI, P1; MONYER H, 1991, Society for Neuroscience Abstracts, V17, P184; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PELLEGRINIGIAMPIETRO DE, 1992, P NATL ACAD SCI USA, V89, P10499, DOI 10.1073/pnas.89.21.10499; Povlishock John T., 1993, P185; SHEARDOWN MJ, 1993, EUR J PHARMACOL, V236, P347, DOI 10.1016/0014-2999(93)90470-3; TURSKI L, 1988, NEUROL NEUR, V46, P343; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; WRATHALL JR, 1992, EUR J PHARMACOL, V218, P273, DOI 10.1016/0014-2999(92)90179-8; ZILLES K, 1987, CORTEX RAT	31	52	52	0	0	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAY 28	1996	93	11					5235	5240		10.1073/pnas.93.11.5235			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN253	WOS:A1996UN25300012	8643559	hybrid, Green Published			2022-02-06	
J	Biagas, KV; Grundl, PD; Kochanek, PM; Schiding, JK; Nemoto, EM				Biagas, KV; Grundl, PD; Kochanek, PM; Schiding, JK; Nemoto, EM			Posttraumatic hyperemia in immature, mature, and aged rats: Autoradiographic determination of cerebral blood flow	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; immature; aged; head trauma hypoperfusion	PERCUSSION BRAIN INJURY; SEVERE HEAD-INJURIES; INTRACRANIAL-PRESSURE; GLUCOSE-UTILIZATION; METABOLISM; CHILDREN; ISOFLURANE; HALOTHANE; ANESTHESIA; TRAUMA	Clinical studies suggest that increased cerebral blood flow (CBF), or hyperemia, after traumatic brain injury (TBI) is commonly found in children and young adults, but is less often found in adults older than 40 years. However, whether posttraumatic cerebral hyperemia is truly an age-related phenomenon has not been proven, Using a model of focal percussive TBI, we hypothesized that (1) local CBF (ICBF) is increased by 24 after injury, and (2) the magnitude of the ICBF increase is age-related and is greatest in immature rats. Wistar rats that were immature (3.5-4.5 weeks), mature (2-3 months), and aged (14.5-15.5 months) were anesthetized and ventilated, TBI was produced by dropping a weight on the exposed right parietal cortex. LCBF was determined by [C-14]iodoantipyrine autoradiography at 24 h posttrauma in all three age groups, at 48 h posttrauma in immature and mature rats, and at 7 days posttrauma in mature rats. In all age groups, low ICBF (<50 mt 100 g(-1) min(-1)) was present in the area of impact at all times studied. At 24 h, hyperemia was observed (vs, corresponding regions of age-matched control rats) in immature and mature rats (7/17 and 5/17 regions, respectively, both p < 0.05), Tout not in aged rats, Comparisons of ICBF between the three age groups revealed a hyperemic response in the peritrauma region in immature rats, Hyperemia persisted to 48 h in both immature and mature rats (2 and 7 of 17 structures with increased ICBF in immature and mature rats, respectively, both p < 0.05). By 7 days posttrauma no regions of increased ICBF were found. Posttraumatic hyperemia appears to be an age-dependent phenomenon, These results suggest possible age-related differences in vasoreactivity or regional metabolism after TBI.	UNIV PITTSBURGH, SCH MED, DEPT ANESTHESIOL CRIT CARE MED, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SCH MED, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06510 USA; FAIRFAX HOSP, DEPT PEDIAT, FALLS CHURCH, VA 22046 USA		Biagas, KV (corresponding author), UNIV PITTSBURGH, SCH MED, SAFAR CTR RESUSITAT RES, 3434 5TH AVE, PITTSBURGH, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Biagas, Katherine/0000-0002-4669-703X			BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRYAN RM, 1994, J NEUROTRAUM, V11, P104; CHRISTENSEN MS, 1967, BRIT J ANAESTH, V39, P927, DOI 10.1093/bja/39.12.927; CLARK RS, 1995, PEDIATR RES, V57, pA43; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DARBY JM, 1988, NEUROSURGERY, V23, P84, DOI 10.1227/00006123-198807000-00014; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HANSEN TD, 1988, ANESTHESIOLOGY, V69, P332, DOI 10.1097/00000542-198809000-00008; HE Z, 1993, J CEREB BLOOD FLOW M, V13, pS405; HOVDA DA, 1993, J CEREB BLOOD FLOW M, V13, pS574; JAKOBSEN J, 1990, DIABETES, V39, P437, DOI 10.2337/diabetes.39.4.437; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P571, DOI 10.1097/00000542-198910000-00016; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LUCIGNANI G, 1987, J CEREBR BLOOD F MET, V7, P309, DOI 10.1038/jcbfm.1987.68; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARTIN AJ, 1991, J CEREBR BLOOD F MET, V11, P684, DOI 10.1038/jcbfm.1991.121; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NORTON WT, 1973, J NEUROCHEM, V21, P759, DOI 10.1111/j.1471-4159.1973.tb07520.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1993, J CEREB BLOOD FLO S1, V13, pS571; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Scremin O. U., 1995, Society for Neuroscience Abstracts, V21, P762; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SOKAL RR, 1981, BIOMETRY, P413; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; WOLLMAN H, 1964, ANESTHESIOLOGY, V25, P180, DOI 10.1097/00000542-196403000-00012; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	46	52	54	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1996	13	4					189	200		10.1089/neu.1996.13.189			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	UK144	WOS:A1996UK14400002	8860199				2022-02-06	
J	Noble, ER; Smoker, WRK				Noble, ER; Smoker, WRK			The forgotten condyle: The appearance, morphology, and classification of occipital condyle fractures	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article						occipital bone; skull, computed tomography; skull, fractures	INJURIES	PURPOSE: To evaluate the appearance, morphology, and treatment of occipital condyle fractures (OCF). METHODS: Cases were collected by a retrospective and prospective analysis of teaching files and case logs. patients' charts, when available, were reviewed for age, sex, mode of injury, physical examination, Glascow Coma Scale score, and associated injuries. Plain films and CT images were reviewed to determine OCF type and to assess for the presence of associated cervical spine and/or intracranial trauma. RESULTS: Fifteen patients with OCF, 13 occurring in a 43-month period, were identified. Ten patients were involved in motor vehicle accidents. Severity of closed head injury and associated clinical findings were variable. Three patients had associated cervical spine fracture. According to the Anderson and Montesano classification, two patients (13%) had type I OCF, eight patients (54%) had type II OCF, and five (33%) had type III OCF. Fourteen of the fractures were identified on screening trauma head. CT scans. Treatment varied according to the presence of associated injuries and stability of the cervical spine. CONCLUSIONS: Although OCFs are rare, they will be encountered by most radiologists who see a significant amount of trauma. Type II OCFs were the most common fracture type in our series. Type III fractures were the second most common and potentially unstable. CT should be initiated at the level of the C-l ring to screen for the presence of OCF in all patients who have suffered trauma.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT RADIOL,RICHMOND,VA 23298								ADAMS VI, 1992, J FORENSIC SCI, V37, P556; ANDERSON LD, 1974, J BONE JOINT SURG AM, VA 56, P1663, DOI 10.2106/00004623-197456080-00017; ANDERSON PA, 1988, SPINE, V13, P731, DOI 10.1097/00007632-198807000-00004; BELL C, 1817, MIDDLESEX HOSP J, V4, P469; BETTINI N, 1993, SKELETAL RADIOL, V22, P187; BOLENDER N, 1978, AM J ROENTGENOL, V131, P729, DOI 10.2214/ajr.131.4.729; BOZBOGA M, 1992, SPINE, V17, P1119, DOI 10.1097/00007632-199209000-00019; BRIDGMAN SA, 1992, SURG NEUROL, V38, P152, DOI 10.1016/0090-3019(92)90094-4; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; BUCHOLZ RW, 1979, J TRAUMA, V19, P768, DOI 10.1097/00005373-197910000-00009; CLAYMAN DA, 1994, AM J NEURORADIOL, V15, P1309; DEEB ZL, 1988, CT-J COMPUT TOMOGR, V12, P261; DESAI SS, 1990, J TRAUMA, V30, P240, DOI 10.1097/00005373-199002000-00023; GOLDSTEIN SJ, 1982, SURG NEUROL, V17, P350, DOI 10.1016/0090-3019(82)90308-1; HARDINGSMITH J, 1981, J BONE JOINT SURG AM, V63, P1170, DOI 10.2106/00004623-198163070-00016; JONES DN, 1990, AM J NEURORADIOL, V11, P1181; Kissinger P., 1900, ZENTRALBL CHIR, V37, P933; LEVENTHAL MR, 1992, ORTHOPEDICS, V15, P944; MANN FA, 1994, AM J ROENTGENOL, V163, P193, DOI 10.2214/ajr.163.1.8010212; MARIANI PJ, 1990, ANN EMERG MED, V19, P1447, DOI 10.1016/S0196-0644(05)82618-6; MODY BS, 1992, INJURY, V23, P350, DOI 10.1016/0020-1383(92)90194-W; OLSSON R, 1994, ACTA RADIOL, V35, P90; ORBAY T, 1989, SURG NEUROL, V31, P402, DOI 10.1016/0090-3019(89)90076-1; RAILA FA, 1993, SKELETAL RADIOL, V22, P269; SHARMA BS, 1994, CLIN NEUROL NEUROSUR, V96, P197, DOI 10.1016/0303-8467(94)90063-9; SPENCER JA, 1984, NEUROSURGERY, V15, P101, DOI 10.1227/00006123-198407000-00019; STROOBANTS J, 1994, J TRAUMA, V36, P440, DOI 10.1097/00005373-199403000-00037; YOUNG WF, 1994, NEUROSURGERY, V34, P257, DOI 10.1227/00006123-199402000-00008	28	52	54	0	1	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	1996	17	3					507	513					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	UB139	WOS:A1996UB13900018	8881246				2022-02-06	
J	Tenhula, WN; Sweet, JJ				Tenhula, WN; Sweet, JJ			Double cross-validation of the booklet Category Test in detecting malingered traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	14th Annual Meeting of the National-Academy-of-Neuropsychology	NOV, 1994	ORLANDO, FL	Natl Acad Neuropsychol			MEMORY DEFICITS; BELIEVABLE DEFICITS; FAKING; PROSPECTS	Two studies were conducted to determine whether the Category Test (CT), in booklet form, can effectively discriminate between groups of brain-injured, malingering, and normal subjects. Discriminant function analyses and clinical decision rules were used to identify malingering on the CT and the relative effectiveness of these two methods was evaluated. Because each of these methods achieved similar classification rates with both samples of subjects, optimal discriminant functions and clinical decision rules were developed combining the subjects from both studies. Discriminant functions correctly classified from 72.5% to 92.2% of subjects and optimal cut-off scores correctly classified from 64.1% to 91.5% of subjects. Effective identification of malingerers was obtained with both higher than expected base rate (29%) and a much lower, more realistic base rate (4%). Thus, the CT performances of individuals who attempt to malinger sequelae of traumatic brain injury appear to be discriminable from genuine brain-injured patients.	EVANSTON HOSP CORP,NEUROPSYCHOL SERV,EVANSTON,IL 60201; NORTHWESTERN UNIV,SCH MED,EVANSTON,IL 60208								ANDERSON EW, 1956, P ROY SOC MED, V49, P513; ANDERSON EW, 1959, ACTA PSYCHIAT NEUROL, V132, P5; BENTON AL, 1961, ARCH GEN PSYCHIAT, V4, P79; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Bolter J. F., 1985, ANN M NAT AC NEUR PH; DeFilippis NA, 1979, BOOKLET CATEGORY TES; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Halstead W.C., 1947, BRAIN INTELLIGENCE; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Laatsch L., 1991, PSYCHOL ASSESSMENT J, V3, P701; MARTIN NJ, 1992, CLIN NEUROPSYCHOLOGI, V6, P329; MARTIN RC, 1991, ANN M NAT AC NEUR DA; MARTIN RC, 1993, ANN M INT NEUR SOC G; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; MENSCH AJ, 1986, INT J CLIN NEUROPSYC, V8, P59; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; MITTENBERG W, 1990, ANN M INT NEUR SOC K; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; Reitan RM, 1985, HALSTEADREITAN NEURO; SNOW WG, 1992, ANN M INT NEUR SOC S; THOMPSON LL, 1991, ARCH CLIN NEUROPSYCH, V6, P231; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253; [No title captured]; [No title captured]; [No title captured]	37	52	52	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	1996	10	1					104	116		10.1080/13854049608406669			13	Psychology, Clinical; Clinical Neurology; Psychology	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	UM353	WOS:A1996UM35300012					2022-02-06	
J	NAWASHIRO, H; SHIMA, K; CHIGASAKI, H				NAWASHIRO, H; SHIMA, K; CHIGASAKI, H			SELECTIVE VULNERABILITY OF HIPPOCAMPAL CA3 NEURONS TO HYPOXIA AFTER MILD CONCUSSION IN THE RAT	NEUROLOGICAL RESEARCH			English	Article						CLOSED HEAD INJURY; HIPPOCAMPUS; HYPOXIA; SYNAPTOPHYSIN; MICROTUBULE-ASSOCIATED PROTEIN 2	KAINIC ACID; CEREBRAL-ISCHEMIA; BRAIN INJURY; FOREBRAIN ISCHEMIA; DAMAGE; SYNAPTOPHYSIN; MECHANISMS	Immunohistochemical staining for microtubule-associated protein 2 (MAP2) and synaptophysin was used to investigate the effect of hypoxia on hippocampal neurons after mild concussion in the rat. Male Sprague-Dawley rats were divided into four groups: Group 1 (n = 3) was subjected to a mild impact-acceleration closed head injury, group 2 (n = 3) was subjected to 30 min of moderate hypoxia, group 3 (n = 5) was subjected to head trauma followed by 30 min of moderate hypoxia, and group 4 (n = 3) comprised sham-operated controls. All rats were fixed by transcardial perfusion 24 h after insult. No damage was observed in CA1 or CA2 neurons in any of the rats. However, rats in group 3 showed selective damage of hippocampal CA3 neurons manifested by a pycnosis and a marked decrease in MAP2 immunoreactivity. Presynaptic terminals visualized by synaptophysin immunostaining showed no differences among groups. The loss of immunoreactivity for the post-synaptic somal and dendritic protein marker MAP2 from the CA3 subfield 24 h after combined insults indicates an increased vulnerability of pyramidal cells in this brain area.			NAWASHIRO, H (corresponding author), NATL DEF MED COLL, DEPT NEUROSURG, 3-2 NAMIKI, TOKOROZAWA, SAITAMA 359, JAPAN.						AKAI F, 1993, BRAIN RES, V603, P87, DOI 10.1016/0006-8993(93)91302-9; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COYLE JT, 1983, J NEUROCHEM, V41, P1; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; NADLER JV, 1980, BRAIN RES, V182, P1; NAWASHIRO H, 1994, ACTA NEUROCHIR, P440; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; SHIMA K, 1991, ADV EXPT NEUROTRAUMA, V3, P84; SLOVITER RS, 1981, NEUROPHARMACOLOGY, V20, P1003, DOI 10.1016/0028-3908(81)90088-5; TOMIMOTO H, 1992, ACTA NEUROPATHOL, V84, P394; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610	23	52	52	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	DEC	1995	17	6					455	460		10.1080/01616412.1995.11740363			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TJ818	WOS:A1995TJ81800012	8622802				2022-02-06	
J	SMITH, DH; MEANEY, DF; LENKINSKI, RE; ALSOP, DC; GROSSMAN, R; KIMURA, H; MCINTOSH, TK; GENNARELLI, TA				SMITH, DH; MEANEY, DF; LENKINSKI, RE; ALSOP, DC; GROSSMAN, R; KIMURA, H; MCINTOSH, TK; GENNARELLI, TA			NEW MAGNETIC-RESONANCE-IMAGING TECHNIQUES FOR THE EVALUATION OF TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, D.C.	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		DIFFUSION-WEIGHTED IMAGING; MAGNETIZATION TRANSFER IMAGING; TRAUMATIC BRAIN INJURY	DIFFUSE AXONAL INJURY; CLOSED HEAD-INJURY; CEREBRAL-ISCHEMIA; T2-WEIGHTED MRI; WEIGHTED MRI	Although current computerized tomography (CT) and magnetic resonance imaging (MRI) techniques have shown great utility in diagnosing various aspects traumatic brain injury, damage resulting from mild diffuse brain injury often goes undetected with these procedures. Newly developed MRI techniques, including magnetization transfer imaging (MTI) and diffusion-weighted imaging (DWI), have been proposed to have enhanced sensitivities for identifying damage induced by both diffuse and focal brain injury, Results from recent initial studies with experimental models of brain injury suggest that MTI may be useful for evaluating diffuse white matter damage, while DWI may demonstrate regions of focal contusion more acutely and with greater accuracy than conventional MRI procedures.	UNIV PENN, DEPT BIOENGN, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT RADIOL, PHILADELPHIA, PA 19104 USA; HAHNEMANN UNIV, DEPT NEUROSURG, PHILADELPHIA, PA 19102 USA		SMITH, DH (corresponding author), UNIV PENN, DIV NEUROSURG, 105 HAYDEN HALL, 240 S 33RD ST, PHILADELPHIA, PA 19104 USA.		smith, douglas/A-1321-2007; Lenkinski, Robert/F-9045-2014; Alsop, David C/J-5764-2013	Alsop, David C/0000-0002-8206-1995; Lenkinski, Robert/0000-0001-7371-5048; Meaney, David/0000-0002-0954-4122	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALSOP DC, 1994, SOC MAGN RESON MED, V3, P1370; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; FORD JC, 1994, MAGNET RESON MED, V31, P488, DOI 10.1002/mrm.1910310504; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HICKS RR, 1992, J NEUROTRAUM, V9, P388; KIMURA H, 1994, RADIOLOGY P, V193, P461; LENKINSKI RE, 1993, P SOC MAGN RES MED, V3, P1491; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LO EH, 1994, J CEREBR BLOOD F MET, V14, P597, DOI 10.1038/jcbfm.1994.74; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1993, AMD, V169, P169; MINEMATSU K, 1993, NEUROLOGY, V43, P397, DOI 10.1212/WNL.43.2.397; MINEMATSU K, 1992, NEUROLOGY, V42, P235, DOI 10.1212/WNL.42.1.235; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1991, MAGNET RESON MED, V19, P321, DOI 10.1002/mrm.1910190222; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	30	52	55	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					573	577		10.1089/neu.1995.12.573			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000008	8683608				2022-02-06	
J	JOHNSTONE, B; HEXUM, CL; ASHKANAZI, G				JOHNSTONE, B; HEXUM, CL; ASHKANAZI, G			EXTENT OF COGNITIVE DECLINE IN TRAUMATIC BRAIN INJURY BASED ON ESTIMATES OF PREMORBID INTELLIGENCE	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; HALSTEAD-REITAN; WAIS-R; MEMORY; TOMOGRAPHY; CONCUSSION; MILD	Global cognitive impairment following traumatic brain injury (TBI) is common, with some abilities more significantly affected than others. However, due to difficulties in estimating premorbid intelligence, there has been no systematic evaluation of the extent of decline in different cognitive abilities following TBI. Recent studies indicate that the Wide Range Achievement Test-Revised (WRAT-R) Reading subtest is an accurate estimate of premorbid intelligence, suggesting that post-TBI cognitive test scores can be compared to the WRAT-R to estimate the extent of decline that occurs in specific cognitive abilities. The current study estimated the extent of deficit in intelligence, memory, attention, speed of processing, and cognitive flexibility for 97 outpatients with TBI. Extent of decline was calculated by subtracting WRAT-R z-scores from cognitive test z-scores to determine a z-difference score (Z(Diff)) for each cognitive ability. The results suggest that intelligence is least declined following TBI (WAIS-R 3-4-point decline; VIQ Z(Diff) = -0.23: FIQ Z(Diff) = -0.27), followed by attention (WMS-R 5-point decline; Z(Diff) = -0.31), memory (WMS-R 6-9-point decline; Verbal Memory Z(Diff) = -0.41; General Memory Z(Diff) = -0.51; Delay Memory Z(Diff) = -0.57), speed of processing (Trails A 15-16 second decline; Z(Diff) = -1.90) and cognitive flexibility (Trails B 35-52 second decline; Z(Diff) = -2.65). Implications for provision of feedback to individuals with TBI and their families are discussed.			JOHNSTONE, B (corresponding author), UNIV MISSOURI,SCH MED,RUSK REHABIL CTR 501,DEPT PHYS MED & REHABIL,1 HOSP DR,COLUMBIA,MO 65212, USA.			Johnstone, Brick/0000-0001-8845-9649			Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Brooks D. N, 1990, REHABILITATION ADULT, P163; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHRISTENSEN H, 1991, PSYCHOL ASSESSMENT, V3, P147; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Jastak J., 1984, WIDE RANGE ACHIEVEME; KANE RL, 1985, J CLIN EXP NEUROPSYC, V7, P211, DOI 10.1080/01688638508401254; KARPMAN T, 1986, J APPLIED REHABILITA, V17, P28; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; NELSON HG, 1975, BRIT J SOC CLIN PSYC, V14, P257; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; Powell J B, 1991, Arch Clin Neuropsychol, V6, P241, DOI 10.1016/0887-6177(91)90001-P; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Reitan R, 1986, TRAIL MAKING TEST MA; ROLD GH, 1988, CLIN NEUROPSYCHOLOGI, V2, P116; ROTH DL, 1990, J CLIN EXP NEUROPSYC, V12, P834; Shum DHK, 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WIENS AN, 1993, CLIN NEUROPSYCHOL, V7, P70, DOI 10.1080/13854049308401889; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089; [No title captured], DOI DOI 10.1080/13854048808520093	38	52	52	0	4	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1995	9	4					377	384		10.3109/02699059509005777			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QY080	WOS:A1995QY08000005	7640683				2022-02-06	
J	GREENSPAN, AI; MACKENZIE, EJ				GREENSPAN, AI; MACKENZIE, EJ			FUNCTIONAL OUTCOME AFTER PEDIATRIC HEAD-INJURY	PEDIATRICS			English	Article						TRAUMATIC HEAD INJURY; FUNCTIONAL LIMITATIONS; PHYSICAL HEALTH; BEHAVIOR PROBLEMS; SPECIAL EDUCATION	BRAIN INJURY; FOLLOW-UP; CHILDREN; SEVERITY; TRAUMA; SEQUELAE; SCORE	Objectives. To examine the consequences of head injury and the medical, economic, and sociodemographic factors affecting functional status 1 year after injury. Methods. A follow-up was conducted on 95 children (aged 5 to 15) 1 year after they were hospitalized for head injury. Parents were interviewed by phone concerning their child's preinjury and current health status, and the family's economic and social resources during the 1 year postinjury. Inpatient medical records were reviewed to obtain information regarding the characteristics of the injury. Results. We found that study children were more likely than children from the general population to have limitations in physical health, behavioral problems, and to be enrolled in a special education program. These findings were true for all levels of head injury severity, although children with severe head injuries (Abbreviated Injury Scale 5) were more likely to demonstrate these functional limitations than were children with less severe injuries (Abbreviated Injury Scale 2, 3, 4). After controlling for head injury severity, we found that the poorer outcomes were associated with poverty, preinjury chronic health problems, and lower extremity injuries. Conclusions. The large proportion of children who demonstrated functional limitations underscores the importance of evaluating all children hospitalized with head injuries for functional limitations and providing rehabilitation and social services when needed.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR HLTH SERV RES & DEV,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR INJURY PREVENT,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD								ADAY LA, 1984, ACCESS MED CARE; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BIJUR PE, 1990, PEDIATRICS, V86, P337; BULL JP, 1985, ACCIDENT ANAL PREV, V17, P387, DOI 10.1016/0001-4575(85)90093-4; CASEY R, 1986, PEDIATRICS, V78, P497; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; Dunham C M, 1989, Md Med J, V38, P227; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EISEN M, 1980, R2313HEW RAND CORP P; FILEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194; FREEMAN HE, 1987, HLTH AFFAIRS     SPR, P6; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; SIEGEL J, 1990, 3RD SCI ASS; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; ZILL N, 1985, BEHAVIOR PROBLEM SCA; ZILL N, 1985, BEHAVIOR PROBLEMS IN; 1985, ABBREVIATED INJURY S	28	52	52	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics	OCT	1994	94	4	1				425	432					8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	PK840	WOS:A1994PK84000003	7936848				2022-02-06	
J	GOLDSTEIN, FC; LEVIN, HS; PRESLEY, RM; SEARCY, J; COLOHAN, ART; EISENBERG, HM; JANN, B; BERTOLINOKUSNERIK, L				GOLDSTEIN, FC; LEVIN, HS; PRESLEY, RM; SEARCY, J; COLOHAN, ART; EISENBERG, HM; JANN, B; BERTOLINOKUSNERIK, L			NEUROBEHAVIORAL CONSEQUENCES OF CLOSED-HEAD INJURY IN OLDER ADULTS	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							ALZHEIMERS-DISEASE; BEHAVIORAL SEQUELAE; PRACTICAL SCALE; BRAIN INJURY; TRAUMA; POPULATION; CLINICIAN; MILD	This study examined the neurobehavioural effects of closed head injury (CHI) in adults aged 50 years and older. Twenty two mild to moderate CHI patients who were within seven months of the injury were administered measures of language, memory, attention, and executive functioning, Compared with demographically similar normal controls, the patients exhibited significantly poorer functioning on the cognitive domains. Naming and word fluency under timed conditions, verbal and visual memory, and the ability to infer similarities were especially vulnerable. These initial findings indicate that CHI in older adults produces considerable cognitive deficits in the early stages of recovery. Future research should characterise long term outcome and the potential links between head injury and the development of progressive dementia.	EMORY UNIV,SCH MED,DEPT NEUROL,NEUROBEHAV PROGRAM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT NEUROSURG,ATLANTA,GA; EMORY UNIV,SCH MED,DEPT REHABIL MED,ATLANTA,GA; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; UNIV MARYLAND,SCH MED,DEPT NEUROL SURG,BALTIMORE,MD 21201		GOLDSTEIN, FC (corresponding author), EMORY UNIV,WESLEY WOODS HLTH CTR,SCH MED,1841 CLIFTON RD NE,ATLANTA,GA 30329, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Benson D.F., 1986, FRONTAL LOBES; Benton A., 1976, MULTILINGUAL APHASIA; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; DAVIS CS, 1988, J AM GERIATR SOC, V36, P225, DOI 10.1111/j.1532-5415.1988.tb01805.x; DELIS DC, 1988, CALIFORNIA VERBAL LE; DELIS DC, 1986, CALIFORNIA VERBAL LE; DEMARIA EJ, 1987, ANN SURG, V206, P738, DOI 10.1097/00000658-198712000-00009; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GALBRAITH S, 1987, BRIT MED J, V294, P325, DOI 10.1136/bmj.294.6568.325; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Gronwall D, 1989, MILD HEAD INJURY, P153; Gustafson L, 1990, Adv Neurol, V51, P65; HANNAY HJ, 1988, CONTINUOUS RECOGNITI; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1987, HEAD INJURY, V2, P1; LEUERSSEN TG, 1988, J NEUROSURG, V68, P409; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MILLER BL, 1991, NEUROLOGY, V41, P1374, DOI 10.1212/WNL.41.9.1374; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLNEY JW, 1990, PROG BRAIN RES, V86, P37; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; Sarno M, 1985, SPEECH LANGUAGE EVAL, P323; TEASDALE G, 1974, LANCET, V2, P81; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	44	52	52	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	1994	57	8					961	966		10.1136/jnnp.57.8.961			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	PB921	WOS:A1994PB92100016	8057121	Bronze, Green Published			2022-02-06	
J	ARCIA, E; GUALTIERI, CT				ARCIA, E; GUALTIERI, CT			NEUROBEHAVIORAL PERFORMANCE OF ADULTS WITH CLOSED-HEAD INJURY, ADULTS WITH ATTENTION-DEFICIT, AND CONTROLS	BRAIN INJURY			English	Article							HYPERACTIVE-CHILDREN; EVALUATION SYSTEM; RECOVERY; DISORDER	The symptoms experienced by people with mild closed-head injury (mCHI) and by people with attention deficit disorder (ADD) are similar in many aspects. We examined the performance of 26 adults with mCHI, 23 adults with ADD, and 25 matched controls on four functional areas: (1) simple motor response, (2) response speed and attention, (3) complex perceptual-motor performance, and (4) memory and learning. Analyses of variance and multivariate analyses of variance were used to compare the performance of the three groups. Test results were also plotted to examine patterns of performance and similarities between the groups. Both groups with mCHI and ADD had significantly more difficulty than controls with sustained attention. However, whereas the group with mCHI was characterized by generalized slowness in their response times, the group with ADD was characterized by impulsivity or an inability to regulate their attention and responses.	N CAROLINA NEUROPSYCHIAT, CHAPEL HILL, NC 27516 USA		ARCIA, E (corresponding author), UNIV N CAROLINA, FRANK PORTER GRAHAM CHILD DEV CTR, 300 NAT BANK PLAZA, CHAPEL HILL, NC 27514 USA.						ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; ARCIA E, 1991, J SCHOOL PSYCHOL, V29, P337, DOI 10.1016/0022-4405(91)90021-I; ARCIA E, 1992, NEUROTOXICOL TERATOL, V14, P103, DOI 10.1016/0892-0362(92)90058-I; Bailey B. N., 1989, TXB HEAD INJURY, P308; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; CHELUNE GJ, 1986, CHILD PSYCHIAT HUM D, V16, P221, DOI 10.1007/BF00706479; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; EVANS RW, 1986, PSYCHOPHARMACOLOGY, V90, P211; GENTILINI M, 1989, MILD HEAD INJURY, P163; GRONWALL D, 1974, LANCET, V2, P605; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; HECHTMAN L, 1983, AM J ORTHOPSYCHIAT, V53, P532, DOI 10.1111/j.1939-0025.1983.tb03397.x; HOOISMA J, 1990, ADVANCES IN NEUROBEHAVIORAL TOXICOLOGY : APPLICATIONS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH, P245; KLEE SH, 1986, PSYCHIAT ANN, V16, P52, DOI 10.3928/0048-5713-19860101-12; LETZ R, 1990, ADVANCES IN NEUROBEHAVIORAL TOXICOLOGY : APPLICATIONS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH, P189; LETZ R, 1986, UNPUB NEUROBEHAVIORA; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOU HC, 1984, ARCH NEUROL-CHICAGO, V41, P825, DOI 10.1001/archneur.1984.04050190031010; MATTES JA, 1980, COMPR PSYCHIAT, V21, P358, DOI 10.1016/0010-440X(80)90017-6; MENDELSON W, 1971, J NERV MENT DIS, V153, P127; RICHARDSON JTE, 1984, CORTEX, V20, P413, DOI 10.1016/S0010-9452(84)80009-X; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SERGEANT J, 1988, ATTENTION DEFICIT DI, P183; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Swanson JM, 1990, DEV ATTENTION RES TH, P383; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; WOODS D, 1986, PSYCHIAT ANN, V16, P23, DOI 10.3928/0048-5713-19860101-06; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001	31	52	53	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1994	8	5					395	404		10.3109/02699059409150991			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	NW122	WOS:A1994NW12200001	7951202				2022-02-06	
J	COSTER, WJ; HALEY, S; BARYZA, MJ				COSTER, WJ; HALEY, S; BARYZA, MJ			FUNCTIONAL PERFORMANCE OF YOUNG-CHILDREN AFTER TRAUMATIC BRAIN INJURY - A 6-MONTH FOLLOW-UP-STUDY	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						BRAIN INJURIES; INFANT	CLOSED HEAD-INJURY; PEDIATRIC TRAUMA; MORBIDITY; SEQUELAE; SEVERITY; SERVICES; AGE	Objectives, A.follow-up study is reported of 40 children between the ages of 1 month and 5.6 years who had sustained a brain injury either with (n = 11) or without (n = 29) additional injuries. Method. Children and their families were assessed at both 1 and 6 months after hospital discharge with standardized measures of functional performance and family functioning, including the Child Behavior Checklist, the Pediatric Evaluation of Disability Inventory, and the Impact on Family Scale. In addition to within-group analyses, functional outcome was compared to that of a group of 17 children who bad sustained non-central nervous system injuries. Results. Mean scores for both groups of injured children were within the average range at both 1-month and 6-month follow-up testing. There was a general trend toward improved performance across the follow-up period, although only a few of these changes reached statistical significance. The effect of the injury as reported by the family was significantly associated with children's function as reflected by number of behavior problems and increased need for caregiver assistance. Conclusion. Results point to the need for systematic follow-up of young children after brain injury using sensitive measures to enable early identification of children whose further development may be at risk and to provide support to families whose children are displaying changes in functional behavior.	TUFTS UNIV,SCH MED,DEPT REHABIL MED,RES & TRAINING CTR REHABIL & CHILDHOOD TRAUMA,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,INST HLTH,BOSTON,MA 02111; SHRINERS BURN INST,BOSTON,MA		COSTER, WJ (corresponding author), BOSTON UNIV,SARGENT COLL,DEPT OCCUPAT THERAPY,635 COMMONWEALTH AVE,BOSTON,MA 02215, USA.						ACHENBACH TM, 1987, J ABNORM CHILD PSYCH, V15, P629, DOI 10.1007/BF00917246; ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Bagnato S. J., 1989, INFANT YOUNG CHILD, V2, P1; BAGNATO SJ, 1989, TOP EARLY CHILD SPEC, V2, P72; Bagnato SJ, 1986, REM SPEC EDUC, V7, P31, DOI 10.1177/074193258600700507; Bagnato SJ, 1986, DEV NEUROPSYCHOL, V2, P213, DOI 10.1080/87565648609540343; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BLACK P, 1981, BRAIN DYSFUNCTION CH, P171; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CATALDO MF, 1986, CHILD HLTH BEHAVIOR; CLYDESDALE TT, 1990, ARCH PHYS MED REHAB, V71, P469; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HALEY SM, 1992, ADM MANUAL PEDIATRIC; HANFT B, 1988, AM J OCCUP THER, V42, P724, DOI 10.5014/ajot.42.11.724; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LARSON CP, 1988, AM J DIS CHILD, V142, P1052, DOI 10.1001/archpedi.1988.02150100046023; Lehr E, 1990, PSYCHOL MANAGEMENT T; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; MULHERN RK, 1993, J PEDIATR PSYCHOL, V18, P339, DOI 10.1093/jpepsy/18.3.339; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; Paris R., 1974, CLIN NEUROPSYCHOLOGY, P179; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; SINGER L, 1989, FAM RELAT, V38, P444, DOI 10.2307/585751; SOLLEE ND, 1987, J ABNORM CHILD PSYCH, V15, P479, DOI 10.1007/BF00917235; STEIN REK, 1980, MED CARE, V18, P462; SUNDBERG KB, 1992, THESIS BOSTON U; TEASDALE G, 1974, LANCET, V2, P81; TIMKO C, 1992, J PEDIATR PSYCHOL, V17, P705, DOI 10.1093/jpepsy/17.6.705; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008	42	52	52	0	1	AMER OCCUPATION THERAPY ASSN	ROCKVILLE	1383 PICCARD DRIVE PO BOX ROCKVILLE, MD 20850-4375	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	MAR	1994	48	3					211	218		10.5014/ajot.48.3.211			8	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	MW828	WOS:A1994MW82800003	8178914				2022-02-06	
J	PADULA, WV; ARGYRIS, S; RAY, J				PADULA, WV; ARGYRIS, S; RAY, J			VISUAL-EVOKED POTENTIALS (VEP) EVALUATING TREATMENT FOR POSTTRAUMA VISION SYNDROME (PTVS) IN PATIENTS WITH TRAUMATIC BRAIN INJURIES (TBI)	BRAIN INJURY			English	Article								Post-trauma vision syndrome (PTVS), which is characterized by binocular function problems, may bc caused by dysfunction of the ambient visual process which is part of the sensory-motor feedback loop rather than specific oculomotor disturbance. Clinically, PTVS frequently presents with symptoms of diplopia, blur, seeing movement in the spatial environment, vertigo, and hallucination-like experiences. Visual evoked potentials (P100) were used to evaluate an experimental group (n = 10) of subjects who suffered a traumatic brain injury, and a control group (n = 10). A new treatment using prisms and bi-nasal occluders which affected amplitude responses of the VEP was evaluated. The results demonstrate the amplitude of the VEP is a function of cortical binocular integration, and that this is influenced by dysfunction of the ambient visual process. The results also demonstrate that base-in prism and bi-nasal occluders arc an effective means to treat ambient vision disturbances resulting from head trauma which causes PTVS.	GARDEN STATE REHABIL HOSP,TOMS RIVER,NJ								Carrol R., 1984, ARCH OPHTHALMOL-CHIC, V88, P57; CINOTTI A, 1980, J AM GERIATR SOC, V28, P84, DOI 10.1111/j.1532-5415.1980.tb00211.x; FIRSCHING R, 1990, NEUROSURG REV, V13, P141, DOI 10.1007/BF00383655; GIANUTSOS R, J AM OPTOM ASSOC, V69, P573; Halliday A M, 1973, Trans Ophthalmol Soc U K, V93, P315; HART C, 1964, P ROYAL SOC MED, V62; LIEBOWITZ HW, IN PRESS ORG REPRESE; NASHOLD BS, 1972, ARCH OPHTHALMOL-CHIC, V88, P245; PADULA WV, 1988, BEHAVIORAL VISION AP; REGAN D, 1977, OPHTHALMOLOGICA, V175, P159, DOI 10.1159/000308649; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; RUTKOWSKI PC, 1982, J AM ACADEMY OPHTHAL, V73, P660; Soden R, 1983, J Am Optom Assoc, V54, P451; STANWORTH A, 1974, BRIT J OPHTHALMOL, V58, P266, DOI 10.1136/bjo.58.3.266; STREFF J, 1992, NEUROOPTOMETRIC REHA, V2, P1; TREVARTHEN C, 1973, BRAIN, V96, P547, DOI 10.1093/brain/96.3.547; WICK RE, 1968, J AM ACADEMY OPTOMET, V59, P475	17	52	52	0	11	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1994	8	2					125	133		10.3109/02699059409150964			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	NA029	WOS:A1994NA02900002	8193632				2022-02-06	
J	SANDER, D; KLINGELHOFER, J				SANDER, D; KLINGELHOFER, J			CEREBRAL VASOSPASM FOLLOWING POSTTRAUMATIC SUBARACHNOID HEMORRHAGE EVALUATED BY TRANSCRANIAL DOPPLER ULTRASONOGRAPHY	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						VASOSPASM; SUBARACHNOID HEMORRHAGE; HEAD INJURY; INTRACRANIAL PRESSURE; TRANSCRANIAL DOPPLER; CLINICAL OUTCOME	CLOSED HEAD-INJURY; BLOOD-FLOW CHANGES; ULTRASOUND; VELOCITY; SPASM; DIAGNOSIS	We studied the incidence and time course of flow velocity changes suggesting a vasospasm following post-traumatic subarachnoid hemorrhage (SAH) considering the intracranial pressure (ICP) in 38 SAH patients as compared to 30 patients with spontaneous SAH. The first investigation was done within 24 h after onset of hemorrhage and regularly followed up during the clinical course. Additionally, the index of cerebral circulatory resistance was calculated and the ICP was measured using an epidural transducer. A significant correlation between middle cerebral artery maximum mean flow velocity and the quantity of blood seen on a computed tomographic scan in patients with post-traumatic SAH indicates a similar pathogenetic mechanism of the development of vasospasm to that after spontaneous SAH. In contrast, there was a significantly earlier occurrence of mean flow velocities over 120 cm/s following post-traumatic SAH irrespective of the ICP. Therefore, additional factors must be considered in the evaluation of these pathologically raised flow velocities after posttraumatic SAH. In both SAH groups there was a highly significant correlation between clinical outcome and clinical grade on admission, ICP and resistance index. The weak correlation between maximum mean flow velocity and clinical outcome following post-traumatic SAH supports the notion that final clinical outcome of these patients is of multifactorial origin.	TECH UNIV MUNICH, DEPT NEUROL, MOHLSTR 28, W-8000 MUNICH 80, GERMANY								AASLID R, 1986, NEURORADIOLOGY, V28, P11, DOI 10.1007/BF00341759; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BACKMUND H, 1972, NEURORADIOLOGY, V4, P46, DOI 10.1007/BF00344809; BRUCE DA, 1978, PATHOPHYSIOLOGY INCR; BRUNO A, 1988, STROKE, V19, P135, DOI 10.1161/01.STR.19.10.1300; COLD GE, 1980, ACTA ANAESTH SCAND, V24, P245, DOI 10.1111/j.1399-6576.1980.tb01544.x; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; DIETRICH K, 1977, NEUROPADIATRIE, V8, P21, DOI 10.1055/s-0028-1091501; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; GROSSET DG, 1992, STROKE, V23, P674, DOI 10.1161/01.STR.23.5.674; GURUSINGHE NT, 1984, J NEUROSURG, V60, P763, DOI 10.3171/jns.1984.60.4.0763; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; HASSLER W, 1987, HEMODYNAMICS ASPECTS, P9; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JAKOBSEN M, 1990, ACTA NEUROL SCAND, V82, P311; JENNETT B, 1975, LANCET, V1, P480; KLINGELHOFER J, 1991, J NEUROSURG, V75, P752, DOI 10.3171/jns.1991.75.5.0752; LEEDS NE, 1966, ACTA RADIOL DIAGN, V5, P320, DOI 10.1177/02841851660050P135; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; Pourcelot L., 1976, PRESENT FUTURE DIAGN, P141; SEILER RW, 1986, J NEUROSURG, V64, P594, DOI 10.3171/jns.1986.64.4.0594; SEKHAR LN, 1988, NEUROSURGERY, V22, P813, DOI 10.1227/00006123-198805000-00002; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TEASDALE G, 1974, LANCET, V2, P81; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626	34	52	54	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT	1993	119	1					1	7		10.1016/0022-510X(93)90185-2			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MA596	WOS:A1993MA59600001	7902422				2022-02-06	
J	VIGE, X; CARREAU, A; SCATTON, B; NOWICKI, JP				VIGE, X; CARREAU, A; SCATTON, B; NOWICKI, JP			ANTAGONISM BY NG-NITRO-L-ARGININE OF L-GLUTAMATE-INDUCED NEUROTOXICITY IN CULTURED NEONATAL RAT CORTICAL-NEURONS - PROLONGED APPLICATION ENHANCES NEUROPROTECTIVE EFFICACY	NEUROSCIENCE			English	Article							CEREBELLAR GRANULE CELLS; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; OXIDE SYNTHASE; NMDA ANTAGONISTS; RECEPTOR AGONISTS; GYKI 52466; DEATH; RELEASE	The effects of N(G)-nitro-L-arginine on L-glutamate-induced neurotoxicity have been evaluated on primary cultures of neonatal rat cortical neurons. Treatment of cultures with increasing concentrations of L-glutamate during 5 min produced a delayed neuronal death, as measured by lactate dehydrogenase release in the medium 24 h later. Maximal toxicity was obtained with 500 mu M Of L-glutamate. Substantial nitric oxide synthase activity was detected in these cortical cultures. Nitric oxide synthase activity and cellular L-glutamate-induced cyclic guanosine 3',5'-monophosphate accumulation were totally inhibited by 100 mu M N(G)-nitro-L-arginine. Addition of N(G)-nitro-L-arginine (100 mu M) to the medium either 5 min prior to and during L-glutamate exposure (500 mu M, 5 min) or for 24 h after L-glutamate exposure decreased the amino acid-induced neurotoxicity by 23% (not significant) and 43%, respectively. When added 5 min before L-glutamate and just after L-glutamate removal and kept in contact with neurons for the following 24 h, N(G)-nitro-L-arginine (100 mu M) antagonized by 74% the L-glutamate-induced neurotoxicity. This effect was not reversed by a co-application Of L-arginine (1 mM). The neuroprotective effect of N(G)-nitro-L-arginine was concentration-dependent, a half-maximal inhibition of L-glutamate-induced neurotoxicity being observed with the addition (before and after L-glutamate) of 4 mu M of the drug. These results suggest that the neuroprotective effect of N(G)-nitro-L-arginine previously observed in vivo is exerted at the neuronal level. The increased neuroprotective efficacy of N(G)-nitro-L-arginine, with prolonged application indicates that a nitric oxide-dependent delayed neuronal death is taking place during the maturation phase that folloWS L-glutamate exposure.			VIGE, X (corresponding author), SYNTHELABO RECH,LERS,DEPT BIOL,31 AVE PAUL VAILLANT COUTURIER,F-92220 BAGNEUX,FRANCE.						ALHO H, 1988, DEV BRAIN RES, V39, P193, DOI 10.1016/0165-3806(88)90023-5; BERTOLINO M, 1988, NEUROSCI LETT, V84, P351, DOI 10.1016/0304-3940(88)90534-4; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUISSON A, 1992, BRIT J PHARMACOL, V106, P766, DOI 10.1111/j.1476-5381.1992.tb14410.x; CARREAU A, UNPUB DEVL BRAIN RES; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6338; DEMERLEPALLARDY C, 1991, BIOCHEM BIOPH RES CO, V181, P456, DOI 10.1016/S0006-291X(05)81441-X; DIEMER NH, 1992, ACTA NEUROL SCAND, V86, P45, DOI 10.1111/j.1600-0404.1992.tb08052.x; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GARTHWAITE G, 1986, NEUROSCI LETT, V66, P193, DOI 10.1016/0304-3940(86)90189-8; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; IZUMI Y, 1992, NEUROSCI LETT, V135, P227, DOI 10.1016/0304-3940(92)90442-A; KIEDROWSKI L, 1992, J NEUROCHEM, V58, P335, DOI 10.1111/j.1471-4159.1992.tb09315.x; LEPEILLET E, 1992, BRAIN RES, V571, P115; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; LUSTIG HS, 1992, BRAIN RES, V577, P343, DOI 10.1016/0006-8993(92)90295-K; MANEV H, 1989, MOL PHARMACOL, V36, P106; MARAGOS WF, 1987, TRENDS NEUROSCI, V10, P65, DOI 10.1016/0166-2236(87)90025-7; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NOVELLI A, 1987, J NEUROSCI, V7, P40; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V183, P238, DOI 10.1016/0006-291X(92)91634-3; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PAUWELS PJ, 1992, NEUROSCI LETT, V143, P27, DOI 10.1016/0304-3940(92)90225-V; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SCATTON B, 1991, CEREBROVASC DIS, V1, P121, DOI 10.1159/000108829; SCHMIDT HHW, 1991, BIOCHEM BIOPH RES CO, V181, P1372, DOI 10.1016/0006-291X(91)92090-7; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SMITH SE, 1992, STROKE, V23, P861, DOI 10.1161/01.STR.23.6.861; TRIFLETTI RR, 1962, EUR J PHARMACOL, V218, P197; UEHARAKUNUGI Y, 1991, DEV BRAIN RES, V59, P157, DOI 10.1016/0165-3806(91)90095-Z; VIGE X, 1992, BRAIN RES, V591, P345, DOI 10.1016/0006-8993(92)91718-T; WOOD PL, 1990, J NEUROCHEM, V55, P346, DOI 10.1111/j.1471-4159.1990.tb08859.x; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210	45	52	52	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0306-4522			NEUROSCIENCE	Neuroscience	AUG	1993	55	4					893	901		10.1016/0306-4522(93)90306-Z			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LQ427	WOS:A1993LQ42700002	7694182				2022-02-06	
J	ELLIS, EF; DODSON, LY; POLICE, RJ				ELLIS, EF; DODSON, LY; POLICE, RJ			RESTORATION OF CEREBROVASCULAR RESPONSIVENESS TO HYPERVENTILATION BY THE OXYGEN RADICAL SCAVENGER NORMAL-ACETYLCYSTEINE FOLLOWING EXPERIMENTAL TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						BRAIN INJURY; CYCLOOXYGENASE; FREE RADICAL; CATALASE; SUPEROXIDE DISMUTASE; CEREBROVASCULAR REACTIVITY; CAT; RABBIT	ENDOTHELIUM-DEPENDENT RELAXATION; CEREBRAL ARTERIOLAR DILATION; SUPEROXIDE-DISMUTASE; N-ACETYLCYSTEINE; ACUTE HYPERTENSION; CATS; MICROCIRCULATION; ABNORMALITIES; BRADYKININ; RECOVERY	Previous experiments have shown that, following experimental fluid-percussion brain injury, cyclo-oxygenase-dependent formation of oxygen radicals prevents arteriolar vasoconstriction in response to hyperventilation. The oxygen radical scavengers superoxide dismutase and catalase restore normal reactivity; however, they are not routinely available for clinical use. The present study tested whether n-acetylcysteine (Mucomyst), an agent currently available for acetaminophen toxicity, could be used as a radical scavenger to restore reactivity after brain injury. N-acetylcysteine (163 mg/kg) was given intraperitoneally prior to or 30 minutes after fluid-percussion brain injury (2.6 atm) in cats, and reactivity to hyperventilation was tested 1 hour after injury. The authors found either that pre- or postinjury administration led to normal reactivity. Additional experiments supported the hypothesis that n-acetylcysteine is an oxygen radical scavenger, since it reduced or prevented the free radical-dependent cerebral arteriolar dilation normally induced by the topical application of arachidonic acid or bradykinin. The mechanism by which n-acetylcysteine is effective in trauma may involve direct scavenging of radicals or stimulation of glutathione peroxidase activity. The results suggest that n-acetylcysteine may be useful for treatment of oxygen free radical-mediated brain injury.			ELLIS, EF (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,MCV STN BOX 613,RICHMOND,VA 23298, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [23432, 12587, 27214] Funding Source: Medline		AMRUTHESH SC, 1991, IN PRESS J NEUROCHEM; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BAEZ SILVIO, 1966, J APPL PHYSIOL, V21, P299; BERNARD GR, 1984, J CLIN INVEST, V73, P1772, DOI 10.1172/JCI111386; CERCHIARI EL, 1987, STROKE, V18, P869, DOI 10.1161/01.STR.18.5.869; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; ELLIS EF, 1988, AM J PHYSIOL, V255, pH397, DOI 10.1152/ajpheart.1988.255.2.H397; ELLIS EF, 1990, AM J PHYSIOL, V258, pH1780, DOI 10.1152/ajpheart.1990.258.6.H1780; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; ELLIS EF, 1990, LIPID MEDIATORS ISCH, P129; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; HABERL RL, 1989, AM J PHYSIOL, V256, pH1255, DOI 10.1152/ajpheart.1989.256.4.H1255; HALLIWELL B, 1985, FREE RADICAL BIO MED, P67; HEISTAD DD, 1983, HDB PHYSL 2, V0003, P00137; KAMITANI T, 1985, CIRC RES, V57, P545, DOI 10.1161/01.RES.57.4.545; KONTOS HA, 1981, AM J PHYSIOL, V240, pH511, DOI 10.1152/ajpheart.1981.240.4.H511; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; LUCHT WD, 1987, AM J MED SCI, V294, P161, DOI 10.1097/00000441-198709000-00006; MARMAROU A, 1989, INTRACRANIAL PRESSUR, V7, P688; ROSENBLUM WI, 1987, CIRC RES, V61, P601, DOI 10.1161/01.RES.61.4.601; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781; ZHANG XM, 1990, AM J PHYSIOL, V259, pH497, DOI 10.1152/ajpheart.1990.259.2.H497; ZIMENT I, 1986, RESPIRATION, V50, P26, DOI 10.1159/000195085	29	52	53	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	1991	75	5					774	779		10.3171/jns.1991.75.5.0774			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	GM092	WOS:A1991GM09200015	1919701				2022-02-06	
J	HAYES, RL; LYETH, BG; JENKINS, LW; ZIMMERMAN, R; MCINTOSH, TK; CLIFTON, GL; YOUNG, HF				HAYES, RL; LYETH, BG; JENKINS, LW; ZIMMERMAN, R; MCINTOSH, TK; CLIFTON, GL; YOUNG, HF			POSSIBLE PROTECTIVE EFFECT OF ENDOGENOUS OPIOIDS IN TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article											HAYES, RL (corresponding author), VIRGINIA COMMONWEALTH UNIV,DEPT SURG,DIV NEUROSURG,RICHARD ROLAND REYNOLDS NEUROSURG RES LABS,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P50NS012587, P01NS012587] Funding Source: NIH RePORTER		ADLER MW, 1976, J PHARMACOL EXP THER, V198, P655; ARAUJO DM, 1987, J NEUROSCI, V7, P1698; BAKER HJ, 1979, LABORATORY RAT, V1; BASKIN DS, 1982, LIFE SCI, V31, P2201, DOI 10.1016/0024-3205(82)90118-7; BELENKY GL, 1979, BRAIN RES, V177, P414, DOI 10.1016/0006-8993(79)90797-2; BERRY SC, 1984, BRIT J PHARMACOL, V83, P179, DOI 10.1111/j.1476-5381.1984.tb10133.x; CHOI D W, 1987, Society for Neuroscience Abstracts, V13, P1029; CHOI DW, 1987, BRAIN RES, V403, P333, DOI 10.1016/0006-8993(87)90070-9; CHOI DW, 1987, J NEUROSCI, V7, P369; CHURCH J, 1985, EUR J PHARMACOL, V111, P185, DOI 10.1016/0014-2999(85)90755-1; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; COWAN A, 1979, SCIENCE, V206, P465, DOI 10.1126/science.504986; DEWITT D S, 1988, Society for Neuroscience Abstracts, V14, P621; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DRAGUNOW M, 1986, TRENDS PHARMACOL SCI, V7, P128, DOI 10.1016/0165-6147(86)90285-3; FADEN A I, 1983, Current Concepts of Cerebrovascular Disease and Stroke, V18, P27; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1983, STROKE, V14, P169, DOI 10.1161/01.STR.14.2.169; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEESER H R, 1987, Society for Neuroscience Abstracts, V13, P1157; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GEORGE C P, 1987, Society for Neuroscience Abstracts, V13, P1446; HARDY C, 1980, BRAIN RES, V194, P293, DOI 10.1016/0006-8993(80)91347-5; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes R L, 1988, Brain Inj, V2, P31, DOI 10.3109/02699058809150930; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HAYES RL, 1989, MILD HEAD INJURY, P54; Holaday JW, 1984, CENTRAL PERIPHERAL E, P237; HOSOBUCHI Y, 1982, SCIENCE, V215, P69, DOI 10.1126/science.6274019; ITZHAK Y, 1988, OPIATE RECEPTORS, P95; JEFTINIJA S, 1987, Society for Neuroscience Abstracts, V13, P1305; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; JENKINS LW, 1989, MICHIGAN S SERIES TR, V1, P47; KELSEY JE, 1982, BRAIN RES, V253, P337, DOI 10.1016/0006-8993(82)90705-3; LAPCHAK P A, 1987, Society for Neuroscience Abstracts, V13, P1192; LASON W, 1987, Society for Neuroscience Abstracts, V13, P1306; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; Lindgren S O, 1966, Acta Chir Scand Suppl, V360, P1; Long J B, 1986, Cent Nerv Syst Trauma, V3, P295; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, IN PRESS NEUROTRAUMA; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MELDRUM BS, 1985, INT REV NEUROBIOL, V17, P1; MORLEY JE, 1983, NEUROSCI BIOBEHAV R, V7, P281, DOI 10.1016/0149-7634(83)90020-9; Newcombe F, 1980, Int Rehabil Med, V2, P133; NORTH RA, 1979, LIFE SCI, V24, P1527, DOI 10.1016/0024-3205(79)90014-6; OLNEY JW, 1983, NATURE, V301, P520, DOI 10.1038/301520a0; PATERSON SJ, 1983, BRIT MED BULL, V39, P31, DOI 10.1093/oxfordjournals.bmb.a071787; PRINCE D A, 1987, Society for Neuroscience Abstracts, V13, P1446; ROSNER MJ, 1982, 5TH P INT S INTR PRE, P154; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; RUTHERFORD WH, 1977, LANCET, V1, P1; SAPOLSKY RM, 1989, NEUROSCI LETT, V97, P157, DOI 10.1016/0304-3940(89)90156-0; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; STERNAU L, 1987, J CEREB BLOOD FLO S1, V7, P147; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SWAN JH, 1987, J CEREB BLOOD FLO S1, V7, P145; TEASDALE G, 1976, BRIT J ANAESTH, V48, P761, DOI 10.1093/bja/48.8.761; TORTELLA F C, 1987, Society for Neuroscience Abstracts, V13, P208; TORTELLA FC, 1982, LIFE SCI, V31, P881, DOI 10.1016/0024-3205(82)90544-6; TORTELLA FC, 1986, J PHARMACOL EXP THER, V237, P49; TORTELLA FC, 1985, BRAIN RES, V332, P174, DOI 10.1016/0006-8993(85)90403-2; TORTELLA FC, 1985, SCIENCE, V228, P1106, DOI 10.1126/science.2986292; TORTELLA FC, 1986, BRAIN RES, V383, P314, DOI 10.1016/0006-8993(86)90031-4; TORTELLA FC, 1987, INACTIVATION HYPERSE, P33; TURSKI WA, 1983, EXPERIENTIA, V39, P1408, DOI 10.1007/BF01990130; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WHITE JD, 1985, PHYSIOL REV, V65, P553, DOI 10.1152/physrev.1985.65.3.553; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZIMMERMAN R S, 1989, Society for Neuroscience Abstracts, V15, P131	80	52	54	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	1990	72	2					252	261		10.3171/jns.1990.72.2.0252			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CK260	WOS:A1990CK26000013	2295922				2022-02-06	
J	PAPANICOLAOU, AC; LEVIN, HS; EISENBERG, HM; MOORE, BD; GOETHE, KE; HIGH, WM				PAPANICOLAOU, AC; LEVIN, HS; EISENBERG, HM; MOORE, BD; GOETHE, KE; HIGH, WM			EVOKED-POTENTIAL CORRELATES OF POSTTRAUMATIC AMNESIA AFTER CLOSED HEAD-INJURY	NEUROSURGERY			English	Article											PAPANICOLAOU, AC (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 07377, NS 9-2314] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS092314] Funding Source: NIH RePORTER		JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEVIN HS, NEUROPSYCHOLOGY MEMO; Moore BE, 1944, NEW ENGL J MED, V230, P445, DOI 10.1056/NEJM194404132301501; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SQUIRES KC, 1979, HUMAN EVOKED POTENTI, P383; TEASDALE G, 1974, LANCET, V2, P81	11	52	54	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery		1984	14	6					676	678		10.1227/00006123-198406000-00005			3	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	TB473	WOS:A1984TB47300005	6462402				2022-02-06	
J	NOSEWORTHY, JH; MILLER, J; MURRAY, TJ; REGAN, D				NOSEWORTHY, JH; MILLER, J; MURRAY, TJ; REGAN, D			AUDITORY BRAIN-STEM RESPONSES IN POST-CONCUSSION SYNDROME	ARCHIVES OF NEUROLOGY			English	Article									DALHOUSIE UNIV,HALIFAX INFIRM,DEPT PHYSIOL,HALIFAX B35 1B6,NS,CANADA; DALHOUSIE UNIV,HALIFAX INFIRM,DEPT MED,HALIFAX B35 1B6,NS,CANADA; DALHOUSIE UNIV,HALIFAX INFIRM,DEPT BIOPHYS,HALIFAX B35 1B6,NS,CANADA								ACHOR LJ, 1980, ELECTROEN CLIN NEURO, V48, P174, DOI 10.1016/0013-4694(80)90302-8; ACHOR LJ, 1980, ELECTROEN CLIN NEURO, V48, P154, DOI 10.1016/0013-4694(80)90301-6; ALLEN AR, 1978, ELECTROEN CLIN NEURO, V45, P53, DOI 10.1016/0013-4694(78)90341-3; BUCHWALD JS, 1975, SCIENCE, V189, P382, DOI 10.1126/science.1145206; CHIAPPA KH, 1979, ARCH NEUROL-CHICAGO, V36, P81, DOI 10.1001/archneur.1979.00500380051005; CROMPTON MR, 1971, LANCET, V1, P669; CRONWALL DNA, 1974, LANCET, V2, P605; ERICHSEN JE, 1866, RAILWAY OTHER INJURI, P144; GOLDENBERG RA, 1975, J SPEECH HEAR RES, V18, P420, DOI 10.1044/jshr.1803.420; JENNETT B, 1975, BRIT MED J, V3, P267, DOI 10.1136/bmj.3.5978.267; JEWETT DL, 1970, ELECTROEN CLIN NEURO, V28, P609, DOI 10.1016/0013-4694(70)90203-8; KAY DWK, 1971, LANCET, V2, P1052; KHONOFF H, 1977, J NEUROL NEUROSURG P, V40, P1211; LeCount ER, 1920, J AMER MED ASSOC, V74, P501, DOI 10.1001/jama.1920.02620080003002; LEV A, 1972, ARCH KLIN EXP OHR, V201, P79, DOI 10.1007/BF00341066; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; MILLER, 1972, LANCET, V1, P580; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MILLER H, 1966, P R SOC MED, V69, P257; MODLIN HC, 1967, AM J PSYCHIAT, V123, P1008, DOI 10.1176/ajp.123.8.1008; NEVIN NC, THESIS BELFAST; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PAXSON CL, 1976, PEDIATRICS, V57, P893; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; REGLAR J, 1967, BRIT MED J, V3, P67; ROWE MJ, 1978, ELECTROEN CLIN NEURO, V44, P459, DOI 10.1016/0013-4694(78)90030-5; ROWE MJ, 1977, ELECTROEN CLIN NEURO, V43, P454; ROWE MW, UNPUBLISHED; RUTHERFORD WH, 1977, LANCET, V1, P1; STARR A, 1976, ELECTROEN CLIN NEURO, V41, P595, DOI 10.1016/0013-4694(76)90005-5; STARR A, 1975, ARCH NEUROL-CHICAGO, V32, P761, DOI 10.1001/archneur.1975.00490530083009; STOCKARD JJ, 1978, AM J EEG TECHNOL, V27, P316; SYMONDS C, 1962, LANCET, V1, P1; TAYLOR AR, 1966, LANCET, V2, P178; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67; TOGLIA JU, 1976, NEUROLOGY, V26, P808, DOI 10.1212/WNL.26.9.808; Toglia JU, 1969, LATE EFFECTS HEAD IN, P72; VANWOERKOM TCAM, 1977, LANCET, V1, P812; ZETTERHOLM S, 1947, ACTA PSYCHIAT NEUR S, V45, P1; 1969, REPORT MED ASPECTS B	42	52	57	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.		1981	38	5					275	278		10.1001/archneur.1981.00510050041004			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LP323	WOS:A1981LP32300003	7224910				2022-02-06	
J	Rehman, SU; Ikram, M; Ullah, N; Alam, SI; Park, HY; Badshah, H; Choe, K; Kim, MO				Rehman, Shafiq Ur; Ikram, Muhammad; Ullah, Najeeb; Alam, Sayed Ibrar; Park, Hyun Young; Badshah, Haroon; Choe, Kyonghwan; Kim, Myeong Ok			Neurological Enhancement Effects of Melatonin against Brain Injury-Induced Oxidative Stress, Neuroinflammation, and Neurodegeneration via AMPK/CREB Signaling	CELLS			English	Article						rmTBI melatonin; AMPK; CREB; neurodegeneration; amyloid beta; synaptic dysfunction	AMYLOID PRECURSOR PROTEIN; TRANSCRIPTIONAL REGULATION; AMPK ACTIVATION; KINASE; APOPTOSIS; PATHWAY; BETA; DEGENERATION; MECHANISMS; INHIBITION	Oxidative stress and energy imbalance strongly correlate in neurodegenerative diseases. Repeated concussion is becoming a serious public health issue with uncontrollable adverse effects in the human population, which involve cognitive dysfunction and even permanent disability. Here, we demonstrate that traumatic brain injury (TBI) evokes oxidative stress, disrupts brain energy homeostasis, and boosts neuroinflammation, which further contributes to neuronal degeneration and cognitive dysfunction in the mouse brain. We also demonstrate that melatonin (an anti-oxidant agent) treatment exerts neuroprotective effects, while overcoming oxidative stress and energy depletion and reducing neuroinflammation and neurodegeneration. Male C57BL/6N mice were used as a model for repetitive mild traumatic brain injury (rmTBI) and were treated with melatonin. Protein expressions were examined via Western blot analysis, immunofluorescence, and ELISA; meanwhile, behavior analysis was performed through a Morris water maze test, and Y-maze and beam-walking tests. We found elevated oxidative stress, depressed phospho-5'AMP-activated protein kinase (p-AMPK) and phospho- CAMP-response element-binding (p-CREB) levels, and elevated p-NF-kappa B in rmTBI mouse brains, while melatonin treatment significantly regulated p-AMPK, p-CREB, and p-NF-kappa B in the rmTBI mouse brain. Furthermore, rmTBI mouse brains showed a deregulated mitochondrial system, abnormal amyloidogenic pathway activation, and cognitive functions which were significantly regulated by melatonin treatment in the mice. These findings provide evidence, for the first time, that rmTBI induces brain energy imbalance and reduces neuronal cell survival, and that melatonin treatment overcomes energy depletion and protects against brain damage via the regulation of p-AMPK/p-CREB signaling pathways in the mouse brain.	[Rehman, Shafiq Ur; Ikram, Muhammad; Ullah, Najeeb; Alam, Sayed Ibrar; Badshah, Haroon; Kim, Myeong Ok] Gyeongsang Natl Univ, Coll Nat Sci, Div Life Sci & Appl Life Sci BK 21plus, Jinju 52828, South Korea; [Ullah, Najeeb] Khyber Med Univ, Inst Basic Med Sci, Peshawar 25100, Khyber Pakhtunk, Pakistan; [Park, Hyun Young; Choe, Kyonghwan] Maastricht Univ, Med Ctr, Sch Mental Hlth & Neurosci, Alzheimer Ctr Limburg, NL-6229 ER Maastricht, Netherlands		Kim, MO (corresponding author), Gyeongsang Natl Univ, Coll Nat Sci, Div Life Sci & Appl Life Sci BK 21plus, Jinju 52828, South Korea.	mokim@gnu.ac.kr	Ikram, Muhammad/Z-5563-2019; Kim, Myeong Ok/AAS-1488-2021; Ullah, Najeeb/AAU-3677-2021	Ikram, Muhammad/0000-0001-5226-4081; Kim, Myeong Ok/0000-0003-4317-1072; 	Brain Research Program through the National Research Foundation (NRF) of Korea - Ministry of Science, ICT [2016M3C7A1904391]	This research work was supported by the Brain Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Science, ICT (2016M3C7A1904391).	Ahmad A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060850; Ahmad A, 2019, METABOLISM, V90, P31, DOI 10.1016/j.metabol.2018.10.004; Alam SI, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020271; Ali T, 2018, MOL NEUROBIOL, V55, P6076, DOI 10.1007/s12035-017-0798-6; Ali T, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1157-x; Ali T, 2017, MOL NEUROBIOL, V54, P6490, DOI 10.1007/s12035-016-0136-4; Ali T, 2015, J PINEAL RES, V59, P47, DOI 10.1111/jpi.12238; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Badshah H, 2016, J NEUROIMMUNE PHARM, V11, P48, DOI 10.1007/s11481-015-9623-z; Bonnefont-Rousselot D, 2010, TOXICOLOGY, V278, P55, DOI 10.1016/j.tox.2010.04.008; Borriello M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050385; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Cai ZY, 2012, J ALZHEIMERS DIS, V29, P89, DOI 10.3233/JAD-2012-111649; Calvo JR, 2013, J PINEAL RES, V55, P103, DOI 10.1111/jpi.12075; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cenini G., 2019, OXIDATIVE MED CELL L, V2019; Ceolotto G, 2007, ARTERIOSCL THROM VAS, V27, P2627, DOI 10.1161/ATVBAHA.107.155762; Chang JC, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060564; Chen D, 2012, ACTA NEUROCHIR, V154, P1469, DOI 10.1007/s00701-012-1328-y; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Domise M, 2016, EXPERIENTIA SUPPL, V107, P153, DOI 10.1007/978-3-319-43589-3_7; Fiorelli S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040356; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2018, NEUROLOGY, V90, pE1771, DOI 10.1212/WNL.0000000000005522; Ghosh M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0463-9; Hill JL, 2016, J NEUROCHEM, V139, P106, DOI 10.1111/jnc.13726; Hong Y, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020135; Ikram M., 2019, MOL NEUROBIOL; Ikram M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051082; Jo M. G., 2018, MOL NEUROBIOL, P1; Ju TC, 2014, BBA-MOL BASIS DIS, V1842, P1668, DOI 10.1016/j.bbadis.2014.06.012; Kerr NA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010069; Khan A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050680; Khan A, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01383; Kho AR, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050405; Kim JE, 2008, J PHARMACOL SCI, V106, P394, DOI 10.1254/jphs.FP0071857; Kim MJ, 2017, NANOMED-NANOTECHNOL, V13, P2533, DOI 10.1016/j.nano.2017.06.022; Kitagawa K, 2007, FEBS J, V274, P3210, DOI 10.1111/j.1742-4658.2007.05890.x; Lahiri DK, 1999, J PINEAL RES, V26, P137, DOI 10.1111/j.1600-079X.1999.tb00575.x; Li CW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00614; Lin Y. W., 2018, INT J MOL MED; Liou CJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050447; Liu XZ, 2013, J PINEAL RES, V55, P14, DOI 10.1111/jpi.12045; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McGuire J. L., 2018, MOL PSYCHIAT; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Merlo L, 2014, J NEUROTRAUM, V31, P1375, DOI 10.1089/neu.2014.3385; Muhammad T, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030648; Nguyen TLA, 2007, J BIOL CHEM, V282, P20854, DOI 10.1074/jbc.M703060200; Ogeturk M, 2008, TOXICOL IND HEALTH, V24, P201, DOI 10.1177/0748233708093725; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ou ZR, 2018, BRAIN BEHAV IMMUN, V69, P351, DOI 10.1016/j.bbi.2017.12.009; Park JJ, 2019, ACS APPL POLYM MATER, V1, P27, DOI 10.1021/acsapm.8b00019; Peixoto CA, 2017, EXP NEUROL, V298, P31, DOI 10.1016/j.expneurol.2017.08.013; Qin LM, 2016, J NEUROCHEM, V136, P918, DOI 10.1111/jnc.13497; Rehman SU, 2018, IEEE I C ELECT CIRC, P45; Rehman SU, 2018, CEREB CORTEX, V28, P2854, DOI 10.1093/cercor/bhx164; Saito M., 2019, INT J DEV NEUROSCI; Singleton Q, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010063; Subedi L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020194; Thanan R, 2015, INT J MOL SCI, V16, P193, DOI 10.3390/ijms16010193; Thomson DM, 2008, J APPL PHYSIOL, V104, P429, DOI 10.1152/japplphysiol.00900.2007; Toyoda T, 2004, AM J PHYSIOL-ENDOC M, V287, pE166, DOI 10.1152/ajpendo.00487.2003; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu HJ, 2017, CELL MOL NEUROBIOL, V37, P1173, DOI 10.1007/s10571-017-0461-9; Xu J, 2017, ONCOTARGET, V8, P112477, DOI 10.18632/oncotarget.22055; Yamada KH, 2012, J BIOL CHEM, V287, P13182, DOI 10.1074/jbc.M111.302612; Yan P, 2019, INT J NEUROPSYCHOPH, V22, P303, DOI 10.1093/ijnp/pyz001; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14; ZHOU P, 2019, CELLS-BASEL, V8, DOI DOI 10.3390/cells8030213; Zihl J, 2015, J CLIN MED, V4, P1051, DOI 10.3390/jcm4051051	73	51	53	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2073-4409		CELLS-BASEL	Cells	JUL	2019	8	7							760	10.3390/cells8070760			23	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	IN8AC	WOS:000478902000025	31330909	gold, Green Submitted, Green Published			2022-02-06	
J	Gill, J; Latour, L; Diaz-Arrastia, R; Motamedi, V; Turtzo, C; Shahim, P; Mondello, S; DeVoto, C; Veras, E; Hanlon, D; Song, LN; Jeromin, A				Gill, Jessica; Latour, Lawrence; Diaz-Arrastia, Ramon; Motamedi, Vida; Turtzo, Christine; Shahim, Pashtun; Mondello, Stefania; DeVoto, Christina; Veras, Eliseo; Hanlon, David; Song, Linan; Jeromin, Andreas			Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI	NEUROLOGY			English	Article							C-TERMINAL HYDROLASE-L1; TRAUMATIC BRAIN-INJURY; PLASMA-LEVELS; DIAGNOSIS; MARKER	Objectives To determine whether a panel of blood-based biomarkers can discriminate between patients with suspected mild traumatic brain injury (mTBI) with and without neuroimaging findings (CT and MRI). Methods Study participants presented to the emergency department with suspected mTBI (n = 277) with a CT and MRI scan and healthy controls (n = 49). Plasma concentrations of tau, glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1, and neurofilament light chain (NFL) were measured using the single-molecule array technology. Results Concentrations of GFAP, tau, and NFL were higher in patients with mTBI, compared with those of controls (p's < 0.01). GFAP yielded an area under the curve (AUC) of 0.93 (95% confidence interval [CI] 0.90-0.96), confirming its discriminatory power for distinguishing mTBI from controls. Levels of GFAP, tau, and NFL were higher in patients with trauma-related intracranial findings on CT compared with those with normal CT, with the only significant predictor being GFAP (AUC 0.77, 95% CI 0.70-0.84). Among patients with mTBI, tau, NFL, and GFAP differentiated subjects with and without MRI abnormalities with an AUC of 0.83, with GFAP being the strongest predictor. Combining tau, NFL, and GFAP showed a good discriminatory power (AUC 0.80, 95% CI 0.69-0.90) for detecting MRI abnormalities, even in patients with mTBI with a normal CT. Conclusion Our study confirms GFAP as a promising marker of brain injury in patients with acute mTBI. A combination of various biomarkers linked to different pathophysiologic mechanisms increases diagnostic subgroup accuracy. This multimarker strategy may guide medical decision making, facilitate the use of MRI scanning, and prove valuable in the stratification of patients with brain injuries in future clinical trials. Classification of evidence Class I evidence that blood concentrations of GFAP, tau, and NFL discriminate patients with mTBI with and without neuroimaging findings.	[Gill, Jessica; Motamedi, Vida; DeVoto, Christina] Uniformed Serv Univ Hlth Sci, Natl Inst Hlth, Bethesda, MD 20814 USA; [Gill, Jessica; Shahim, Pashtun] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Natl Inst Nursing Res, Bethesda, MD 20814 USA; [Latour, Lawrence; Turtzo, Christine] NINDS, Biomarker Core, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Latour, Lawrence; Turtzo, Christine] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Mondello, Stefania] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy; [Veras, Eliseo; Hanlon, David; Song, Linan; Jeromin, Andreas] Quanterix Corp, Lexington, MA USA		Gill, J (corresponding author), Uniformed Serv Univ Hlth Sci, Natl Inst Hlth, Bethesda, MD 20814 USA.; Gill, J (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Natl Inst Nursing Res, Bethesda, MD 20814 USA.	gillj@mail.nih.gov	Mondello, Stefania/A-1813-2012; Gill, Gill M/Q-2020-2017; Latour, Larry/AAH-5663-2021	Mondello, Stefania/0000-0002-8587-3614; Latour, Larry/0000-0001-6160-5263	National Institute of Nursing Research (NINR) Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); National Institute of Neurological Disease and Stroke (NINDS) Team; Center for Neuroscience and Regenerative Medicine, Acute Studies and Biomarker Core; National Football League and General Electric, Head to Head Grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003120] Funding Source: NIH RePORTER	National Institute of Nursing Research (NINR) Intramural Research Program, National Institute of Neurological Disease and Stroke (NINDS) Team, Center for Neuroscience and Regenerative Medicine, Acute Studies and Biomarker Core, National Football League and General Electric, Head to Head Grant.	Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Korley FK, 2016, J HEAD TRAUMA REHAB, V31, P379, DOI 10.1097/HTR.0000000000000187; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Mondello S, J NEUROTRAUMA; Mondello S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28203; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Peacock WF, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00641; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	14	51	51	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 9	2018	91	15					E1385	E1389		10.1212/WNL.0000000000006321			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HD4LZ	WOS:000452500400003	30209234	Green Published			2022-02-06	
J	Sreedharan, NPN; Ganesan, B; Raveendran, R; Sarala, P; Dennis, B; Boothalingam, RR				Sreedharan, Ninu Preetha Nirmala; Ganesan, Brammya; Raveendran, Ramya; Sarala, Praveena; Dennis, Binu; Boothalingam, Rajakumar R.			Grey Wolf optimisation-based feature selection and classification for facial emotion recognition	IET BIOMETRICS			English	Article						face recognition; gradient methods; feature extraction; evolutionary computation; particle swarm optimisation; neural nets; optimisation; emotion recognition; Grey Wolf optimisation; feature selection; facial emotion recognition; human emotions; facial emotions; elemental facial expressions; fear; recognition process; FER system; pre-processing; scale invariant feature; feature extraction method; facial point; optimal features; NN-particle swarm optimisation	TRAUMATIC BRAIN-INJURY; EXPRESSION RECOGNITION; NEURAL-NETWORKS; INDIVIDUAL-DIFFERENCES; ALGORITHM; SCHIZOPHRENIA; SIFT; ASSOCIATION; CHILDHOOD; DEFICITS	The channels used to convey the human emotions consider actions, behaviours, poses, facial expressions, and speech. An immense research has been carried out to analyse the relationship between the facial emotions and these channels. The goal of this study is to develop a system for Facial Emotion Recognition (FER) that can analyse the elemental facial expressions of human, such as normal, smile, sad, surprise, anger, fear, and disgust. The recognition process of the proposed FER system is categorised into four processes, namely pre-processing, feature extraction, feature selection, and classification. After preprocessing, scale invariant feature transform -based feature extraction method is used to extract the features from the facial point. Further, a meta-heuristic algorithm called Grey Wolf optimisation (GWO) is used to select the optimal features. Subsequently, GWO-based neural network (NN) is used to classify the emotions from the selected features. Moreover, an effective performance analysis of the proposed as well as the conventional methods such as convolutional neural network, NN-Levenberg-Marquardt, NN-Gradient Descent, NN-Evolutionary Algorithm, NN-firefly, and NN-Particle Swarm Optimisation is provided by evaluating few performance measures and thereby, the effectiveness of the proposed strategy over the conventional methods is validated.	[Sreedharan, Ninu Preetha Nirmala; Ganesan, Brammya; Raveendran, Ramya; Sarala, Praveena; Dennis, Binu; Boothalingam, Rajakumar R.] Resbee Info Technol Private Ltd, Thuckalay 629175, India		Sreedharan, NPN (corresponding author), Resbee Info Technol Private Ltd, Thuckalay 629175, India.	research@resbee.org	R, Rajakumar B/AAJ-6031-2020; D, Binu/AAX-5646-2021	R, Rajakumar B/0000-0002-4720-8875; D, Binu/0000-0002-1649-5541			Ahmed F, 2012, ELECTRON LETT, V48, P1203, DOI 10.1049/el.2012.1841; Alqahtani MMJ, 2015, POSTEP PSYCHIATR NEU, V24, P217, DOI 10.1016/j.pin.2015.11.003; Azeem A., 2015, J. appl. res. technol, V13, P402; Balas B, 2015, J EXP CHILD PSYCHOL, V140, P171, DOI 10.1016/j.jecp.2015.07.006; Barnard-Brak L, 2017, PSYCHIAT RES, V249, P109, DOI 10.1016/j.psychres.2016.12.049; Boutorh A, 2016, ENG APPL ARTIF INTEL, V51, P58, DOI 10.1016/j.engappai.2016.01.004; Celik O, 2016, J CLEAN PROD, V116, P1, DOI 10.1016/j.jclepro.2015.12.082; Cruz AC, 2014, IEEE T AFFECT COMPUT, V5, P418, DOI 10.1109/TAFFC.2014.2316151; Fan XJ, 2017, PATTERN RECOGN, V64, P399, DOI 10.1016/j.patcog.2016.12.002; Fasel B, 2002, INT C PATT RECOG, P40, DOI 10.1109/ICPR.2002.1048231; Gaidhane VH, 2016, SADHANA-ACAD P ENG S, V41, P415, DOI 10.1007/s12046-016-0479-6; Gola KA, 2017, NEUROIMAGE-CLIN, V14, P672, DOI 10.1016/j.nicl.2017.01.016; Hargreaves A, 2016, NEUROSCI LETT, V633, P47, DOI 10.1016/j.neulet.2016.09.017; Hernandez-Matamoros A, 2016, KNOWL-BASED SYST, V110, P1, DOI 10.1016/j.knosys.2016.07.011; Jiana J., 2011, PROCEDIA ENG, V15, P5126, DOI 10.1016/j.proeng.2011.08.951; Kobayashi M, 2017, NEUROCOMPUTING, V260, P174, DOI 10.1016/j.neucom.2017.04.025; Komaki GM, 2015, J COMPUT SCI-NETH, V8, P109, DOI 10.1016/j.jocs.2015.03.011; Lee SY, 2015, SCHIZOPHR RES, V165, P60, DOI 10.1016/j.schres.2015.03.026; Lenc L, 2015, COMPUT ELECTR ENG, V46, P256, DOI 10.1016/j.compeleceng.2015.01.014; Lin CH, 2016, ISA T, V64, P405, DOI 10.1016/j.isatra.2016.05.013; Lopes AT, 2017, PATTERN RECOGN, V61, P610, DOI 10.1016/j.patcog.2016.07.026; Meng HY, 2016, IEEE T CYBERNETICS, V46, P916, DOI 10.1109/TCYB.2015.2418092; Mirjalili S, 2016, EXPERT SYST APPL, V47, P106, DOI 10.1016/j.eswa.2015.10.039; Mirjalili S, 2014, ADV ENG SOFTW, V69, P46, DOI 10.1016/j.advengsoft.2013.12.007; Moeini A, 2017, J VIS COMMUN IMAGE R, V45, P20, DOI 10.1016/j.jvcir.2017.02.007; Moeini A, 2016, J VIS COMMUN IMAGE R, V35, P1, DOI 10.1016/j.jvcir.2015.11.006; Neoh SC, 2015, APPL SOFT COMPUT, V34, P72, DOI 10.1016/j.asoc.2015.05.006; Ozturk S., 2017, ELECT PALANGA, V2014, P1; Prado CE, 2015, PERS INDIV DIFFER, V80, P22, DOI 10.1016/j.paid.2015.02.013; Pu XR, 2015, NEUROCOMPUTING, V168, P1173, DOI 10.1016/j.neucom.2015.05.005; Rigon A, 2017, NEUROIMAGE-CLIN, V13, P370, DOI 10.1016/j.nicl.2016.12.010; Russo M, 2015, PSYCHIAT RES, V229, P771, DOI 10.1016/j.psychres.2015.08.004; Sanchez D, 2017, ENG APPL ARTIF INTEL, V64, P172, DOI 10.1016/j.engappai.2017.06.007; Song XH, 2015, SOIL DYN EARTHQ ENG, V75, P147, DOI 10.1016/j.soildyn.2015.04.004; Sonmez EB, 2013, IET COMPUT VIS, V7, P500, DOI 10.1049/iet-cvi.2012.0127; Sun Y, 2014, ELECTRON LETT, V50, P671, DOI 10.1049/el.2014.0441; Tang XW, 2016, PSYCHIAT RES, V246, P353, DOI 10.1016/j.psychres.2016.09.055; Theurel A, 2016, J EXP CHILD PSYCHOL, V150, P252, DOI 10.1016/j.jecp.2016.06.004; Vinay A, 2016, PROCEDIA COMPUT SCI, V79, P543, DOI 10.1016/j.procs.2016.03.069; Wang SF, 2014, IMAGE VISION COMPUT, V32, P682, DOI 10.1016/j.imavis.2014.04.013; Yang ML, 2017, NEUROCOMPUTING, V267, P195, DOI 10.1016/j.neucom.2017.06.007; Yi JZ, 2014, IET COMPUT VIS, V8, P429, DOI 10.1049/iet-cvi.2013.0171; Yu KM, 2013, PATTERN RECOGN, V46, P2144, DOI 10.1016/j.patcog.2013.01.032; Zhang L, 2016, KNOWL-BASED SYST, V111, P248, DOI 10.1016/j.knosys.2016.08.018; Zhang T, 2016, IEEE T MULTIMEDIA, V18, P2528, DOI 10.1109/TMM.2016.2598092; Zhou Q, 2016, CHINESE J ELECTRON, V25, P1034, DOI 10.1049/cje.2016.10.001; Zwick JC, 2017, J AFFECT DISORDERS, V210, P90, DOI 10.1016/j.jad.2016.12.022	47	51	51	2	30	INST ENGINEERING TECHNOLOGY-IET	HERTFORD	MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND	2047-4938	2047-4946		IET BIOMETRICS	IET Biom.	SEP	2018	7	5					490	499		10.1049/iet-bmt.2017.0160			10	Computer Science, Artificial Intelligence	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Computer Science	GR0UL	WOS:000442238900013					2022-02-06	
J	Zhang, K; Shi, ZQ; Zhou, JK; Xing, Q; Ma, SS; Li, QH; Zhang, YT; Yao, MH; Wang, XF; Li, Q; Li, JA; Guan, FX				Zhang, Kun; Shi, Zhenqing; Zhou, Jiankang; Xing, Qu; Ma, Shanshan; Li, Qinghua; Zhang, Yanting; Yao, Minghao; Wang, Xiaofeng; Li, Qian; Li, Jingan; Guan, Fangxia			Potential application of an injectable hydrogel scaffold loaded with mesenchymal stem cells for treating traumatic brain injury	JOURNAL OF MATERIALS CHEMISTRY B			English	Article							SMOOTH-MUSCLE-CELLS; ACID MICRO-PATTERN; HYALURONIC-ACID; TITANIUM SURFACE; IV COLLAGEN; ENDOTHELIALIZATION; STRATEGIES; COCULTURE; PHENOTYPE; RECOVERY	In the past few decades, there have been potential applications for stem cell replacement therapy in the treatment of nervous system damage resulting from diseases or traumatic brain injury (TBI). However, the insufficient number of transplanted stem cells and low survival rate caused by a series of negative conditions limit the therapeutic effect. In this contribution, we developed an injectable hydrogel composed of sodium alginate (SA) and hyaluronic acid (HA) as a tissue scaffold to create a more optimal microenvironment for stem cells after implantation. The gelation time of the HA/SA hydrogel exceeded 6 min, which satisfied the requirements for injection performance, and the high ratios of water content and slower degradation speed affirmed that the HA/SA hydrogel is a preferable stem cell scaffold. As a tissue engineering scaffold, the HA/SA hydrogel exhibited appropriately porous structures for stem cell loading and good rheological behavior, which contributed to stem cell differentiation. The in vitro culture experiment proved that the HA/SA scaffold performed well on hUC-MSCs with higher viability ratio and proliferation. Further in vivo tests indicated that the HA/SA scaffold not only protected the injected human umbilical cord mesenchymal stem cells (hUC-MSCs) so that they could maintain a higher survival ratio, but it also contributed to the regeneration of endogenous nerve cells. In summary, this injectable HA/SA hydrogel has the potential to be used for stem cell tissue engineering and support the physiological function recovery of TBI patients.	[Zhang, Kun; Shi, Zhenqing; Zhou, Jiankang; Xing, Qu; Ma, Shanshan; Li, Qinghua; Zhang, Yanting; Yao, Minghao; Guan, Fangxia] Zhengzhou Univ, Sch Life Sci, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China; [Zhang, Kun; Guan, Fangxia] Zhengzhou Univ, Affiliated Hosp 1, Ctr Stem Cell & Regenerat Med, 40 Univ Rd, Zhengzhou 450052, Henan, Peoples R China; [Wang, Xiaofeng; Li, Qian] Zhengzhou Univ, Natl Ctr Int Res Micronano Molding Technol, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China; [Li, Jingan] Zhengzhou Univ, Sch Mat Sci & Engn, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China		Guan, FX (corresponding author), Zhengzhou Univ, Sch Life Sci, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China.; Guan, FX (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Ctr Stem Cell & Regenerat Med, 40 Univ Rd, Zhengzhou 450052, Henan, Peoples R China.; Li, JA (corresponding author), Zhengzhou Univ, Sch Mat Sci & Engn, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China.	4828713@qq.com; fxguan@126.com			Joint Fund for Fostering Talents of the National Natural Science Foundation of China and Henan province [U1504310]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [NSFC 81471306]; Key Scientific Research Projects of higher education institutions in Henan province [16A430030]; Innovative Research Team in Science and Technology of the University of Henan Province [15IRTSTHN022]; Plan for Scientific Innovation Talent of Henan Province [154200510008]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014M562333, 2015M582206]; Key Project and Special Foundation of Research, Development and Promotion in Henan province [182102310076]; National Center for International Research of Micro-nano Molding Technology & Key Laboratory for Micro Molding Technology of Henan Province [MMT2017-01]	The study was supported by the Joint Fund for Fostering Talents of the National Natural Science Foundation of China and Henan province (U1504310), National Natural Science Foundation of China (NSFC 81471306), Key Scientific Research Projects of higher education institutions in Henan province (16A430030), the Innovative Research Team in Science and Technology of the University of Henan Province (15IRTSTHN022), the Plan for Scientific Innovation Talent of Henan Province (154200510008), China Postdoctoral Science Foundation (2014M562333 and 2015M582206), Key Project and Special Foundation of Research, Development and Promotion in Henan province (No. 182102310076), and National Center for International Research of Micro-nano Molding Technology & Key Laboratory for Micro Molding Technology of Henan Province (MMT2017-01).	Ata MT, 2016, WORLD NEUROSURG, V89, P355, DOI 10.1016/j.wneu.2016.01.040; Benjamin O, 2018, FOOD HYDROCOLLOID, V75, P95, DOI 10.1016/j.foodhyd.2017.08.033; Bhattacharya DS, 2017, J MATER CHEM B, V5, P8183, DOI [10.1039/c7tb01895a, 10.1039/C7TB01895A]; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056/NEJMoa1003548; Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197; Chuang TW, 2009, BIOMATERIALS, V30, P5341, DOI 10.1016/j.biomaterials.2009.06.029; Cox CS, 2018, PEDIATR RES, V83, P325, DOI 10.1038/pr.2017.253; Ferreri AJM, 2017, LANCET HAEMATOL, V4, pE510, DOI 10.1016/S2352-3026(17)30174-6; Gombotz WR, 2012, ADV DRUG DELIVER REV, V64, P194, DOI 10.1016/j.addr.2012.09.007; Graser S, 2015, BONE, V79, P150, DOI [10.1016/J.bone.2015.05.033, 10.1016/j.bone.2015.05.033]; Greer K, 2017, BRAIN RES BULL, V134, P38, DOI 10.1016/j.brainresbull.2017.06.016; Hongo-Kohama M, 2017, INT J GYNECOL PATHOL, V36, P582, DOI 10.1097/PGP.0000000000000373; Huang GY, 2012, BIOFABRICATION, V4, DOI 10.1088/1758-5082/4/4/042001; Hunt NC, 2017, ACTA BIOMATER, V49, P329, DOI 10.1016/j.actbio.2016.11.016; Kim YS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183894; Li JG, 2017, ACS APPL MATER INTER, V9, P30343, DOI 10.1021/acsami.7b07444; Li JG, 2016, COLLOID SURFACE B, V145, P410, DOI 10.1016/j.colsurfb.2016.05.024; Li JG, 2015, COLLOID SURFACE B, V128, P201, DOI 10.1016/j.colsurfb.2015.01.010; Li JA, 2015, J MATER SCI, V50, P3226, DOI 10.1007/s10853-015-8889-0; Li JA, 2014, J BIOMED MATER RES A, V102, P1950, DOI 10.1002/jbm.a.34867; Li JG, 2014, MAT SCI ENG C-MATER, V38, P235, DOI 10.1016/j.msec.2014.02.008; Li JG, 2013, EXP CELL RES, V319, P2663, DOI 10.1016/j.yexcr.2013.05.027; Li JG, 2013, COLLOID SURFACE B, V110, P199, DOI 10.1016/j.colsurfb.2013.04.048; Li JG, 2013, APPL SURF SCI, V273, P24, DOI 10.1016/j.apsusc.2013.01.058; Li YX, 2014, GASTROENTEROLOGY, V146, pS527; Lu X, 2017, EXP THER MED, V13, P2247, DOI 10.3892/etm.2017.4283; Marion Donald W, 2006, Prog Neurol Surg, V19, P171, DOI 10.1159/000095191; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Mitkari B, 2014, BEHAV BRAIN RES, V259, P50, DOI 10.1016/j.bbr.2013.10.030; Morris DC, 2017, NEUROSCI LETT, V659, P7, DOI 10.1016/j.neulet.2017.08.064; Park H, 2013, ACTA BIOMATER, V9, P4779, DOI 10.1016/j.actbio.2012.08.033; Petsa A, 2009, IN VITRO CELL DEV-AN, V45, P573, DOI 10.1007/s11626-009-9227-0; Shin J, 2017, BIOMACROMOLECULES, V18, P3060, DOI 10.1021/acs.biomac.7b00568; Summa M, 2018, EUR J PHARM BIOPHARM, V122, P17, DOI 10.1016/j.ejpb.2017.10.004; Tsang KKT, 2012, BRIT J ORAL MAX SURG, V50, P298, DOI 10.1016/j.bjoms.2011.03.004; Wang YS, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00413; Wu F, 2016, ACS APPL MATER INTER, V8, P109, DOI 10.1021/acsami.5b07427; Xu C, 2017, INT J NEUROSCI, V127, P1124, DOI 10.1080/00207454.2017.1325884; Zhao YZ, 2016, J CONTROL RELEASE, V224, P165, DOI 10.1016/j.jconrel.2016.01.017; Zhu Y, 2017, BIOMATERIALS, V147, P133, DOI 10.1016/j.biomaterials.2017.09.018; Zhuo FL, 2017, MAT SCI ENG C-MATER, V81, P1, DOI 10.1016/j.msec.2017.07.029	41	51	51	8	92	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2050-750X	2050-7518		J MATER CHEM B	J. Mat. Chem. B	MAY 21	2018	6	19					2982	2992		10.1039/c7tb03213g			11	Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Materials Science	GK5RR	WOS:000436234900006	32254333				2022-02-06	
J	Main, BS; Villapol, S; Sloley, SS; Barton, DJ; Parsadanian, M; Agbaegbu, C; Stefos, K; McCann, MS; Washington, PM; Rodriguez, OC; Burns, MP				Main, Bevan S.; Villapol, Sonia; Sloley, Stephanie S.; Barton, David J.; Parsadanian, Maia; Agbaegbu, Chinyere; Stefos, Kathryn; McCann, Mondona S.; Washington, Patricia M.; Rodriguez, Olga C.; Burns, Mark P.			Apolipoprotein E4 impairs spontaneous blood brain barrier repair following traumatic brain injury	MOLECULAR NEURODEGENERATION			English	Article						Apolipoprotein E; Blood brain barrier; Neurovascular unit; Pericyte; MMP-9; CD31; Lectin; TBI	CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; AMYLOID-BETA; NEUROINFLAMMATORY RESPONSE; KERATAN SULFATE; DISRUPTION; PERMEABILITY; EDEMA; MICE	Background: Traumatic Brain Injury (TBI) is a major cause of disability and mortality, to which there is currently no comprehensive treatment. Blood Brain Barrier (BBB) dysfunction is well documented in human TBI patients, yet the molecular mechanisms that underlie this neurovascular unit (NVU) pathology remains unclear. The apolipoprotein-E (apoE) protein has been implicated in controlling BBB integrity in an isoform dependent manner, via suppression of Cyclophilin A (CypA)-Matrix metallopeptidase-9 (MMP-9) signaling cascades, however the contribution of this pathway in TBI-induced BBB permeability is not fully investigated. Methods: We exposed C57Bl/6 mice to controlled cortical impact and assessed NVU and BBB permeability responses up to 21 days post-injury. We pharmacologically probed the role of the CypA-MMP-9 pathway in BBB permeability after TBI using Cyclosporin A (CsA, 20 mg/kg). Finally, as the apoE4 protein is known to be functionally deficient compared to the apoE3 protein, we used humanized APOE mice as a clinically relevant model to study the role of apoE on BBB injury and repair after TBI. Results: In C57Bl/6 mice there was an inverse relationship between soluble apoE and BBB permeability, such that damaged BBB stabilizes as apoE levels increase in the days following TBI. TBI mice displayed acute pericyte loss, increased MMP-9 production and activity, and reduced tight-junction expression. Treatment with the CypA antagonist CsA in C57Bl/6 mice attenuates MMP-9 responses and enhances BBB repair after injury, demonstrating that MMP-9 plays an important role in the timing of spontaneous BBB repair after TBI. We also show that apoe mRNA is present in both astrocytes and pericytes after TBI. We report that APOE3 and APOE4 mice have similar acute BBB responses to TBI, but APOE3 mice display faster spontaneous BBB repair than APOE4 mice. Isolated microvessel analysis reveals delayed pericyte repopulation, augmented and sustained MMP-9 expression at the NVU, and impaired stabilization of Zonula Occludens-1, Occludin and Claudin-5 expression at tight junctions in APOE4 mice after TBI compared to APOE3 mice. Conclusions: These data confirm apoE as an important modulator of spontaneous BBB stabilization following TBI, and highlights the APOE4 allele as a risk factor for poor outcome after TBI.	[Rodriguez, Olga C.] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20057 USA; [Main, Bevan S.; Villapol, Sonia; Sloley, Stephanie S.; Barton, David J.; Parsadanian, Maia; Agbaegbu, Chinyere; Stefos, Kathryn; McCann, Mondona S.; Washington, Patricia M.; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20007 USA; [Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, New Res Buld EG11,3970 Reservoir Rd,NW, Washington, DC 20057 USA		Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20007 USA.; Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Buld EG11,3970 Reservoir Rd,NW, Washington, DC 20057 USA.	mpb37@georgetown.edu	Barton, David J/C-9282-2011; Villapol, Sonia/D-1949-2014	Barton, David J/0000-0003-0976-0383; Villapol, Sonia/0000-0002-6174-4113; McCann, Mondona/0000-0002-6520-7956; Burns, Mark P/0000-0003-4750-2000	National Institute for Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067417, R03NS095038]; Department of Health and Human Services [90AR5005]; Neural Injury and Plasticity pre-doctoral fellowship [T32 NS041218]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS041218, R03NS095038, R01NS081068, R03NS067417] Funding Source: NIH RePORTER	This work was supported by R01NS067417 (MPB) and R03NS095038 (SV) from the National Institute for Neurological Disorders and Stroke (NINDS). The Advanced Rehabilitation Research and Training Program (90AR5005) funded by The Department of Health and Human Services provided fellowship support for BSM and a T32 NS041218 Neural Injury and Plasticity pre-doctoral fellowship supported SSS.	Alata W, 2015, J CEREBR BLOOD F MET, V35, P86, DOI 10.1038/jcbfm.2014.172; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Cao F, 2016, J NEUROTRAUM, V33, P175, DOI 10.1089/neu.2015.3887; Cartagena CM, 2008, J NEUROTRAUM, V25, P1087, DOI 10.1089/neu.2007.0444; Casey CS, 2015, J BIOL CHEM, V290, P14208, DOI 10.1074/jbc.M114.625251; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Cherian L, 2011, J PHARMACOL EXP THER, V337, P451, DOI 10.1124/jpet.110.176602; COLTON CA, 1992, J HISTOCHEM CYTOCHEM, V40, P505, DOI 10.1177/40.4.1372634; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dash PK, 2016, J NEUROSCI, V36, P2809, DOI 10.1523/JNEUROSCI.3197-15.2016; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Enerson BE, 2006, J CEREBR BLOOD F MET, V26, P959, DOI 10.1038/sj.jcbfm.9600249; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Hafezi-Moghadam A, 2007, AM J PHYSIOL-CELL PH, V292, pC1256, DOI 10.1152/ajpcell.00563.2005; Halliday MR, 2016, J CEREBR BLOOD F MET, V36, P216, DOI 10.1038/jcbfm.2015.44; Halliday MR, 2013, JAMA NEUROL, V70, P1198, DOI 10.1001/jamaneurol.2013.3841; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Ho KM, 2014, J NEUROSURG, V121, P674, DOI 10.3171/2014.6.JNS132838; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Lanfranco MF, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2608; Li HX, 2016, BRAIN RES, V1642, P70, DOI 10.1016/j.brainres.2016.03.031; Li SJ, 2015, J TRAUMA ACUTE CARE, V79, P78, DOI 10.1097/TA.0000000000000697; Lin Y, 2012, LAB INVEST, V92, P1623, DOI 10.1038/labinvest.2012.118; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Main BS, 2017, J NEUROCHEM, V141, P75, DOI 10.1111/jnc.13940; Main BS, 2016, GLIA, V64, P1590, DOI 10.1002/glia.23028; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Meng QY, 2017, EBIOMEDICINE, V16, P184, DOI 10.1016/j.ebiom.2017.01.046; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Price L., 2016, TRANSLATIONAL RES TR; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Sangiorgi S, 2013, J NEUROSURG, V118, P763, DOI 10.3171/2012.11.JNS12627; Saw MM, 2014, NEUROCRIT CARE, V20, P209, DOI 10.1007/s12028-013-9933-z; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shelef, 2011, CARDIOVASC PSYCHIAT, V2011, DOI [DOI 10.1155/2011/765923, 10.1155/2011/765923]; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Storck SE, 2016, J CLIN INVEST, V126, P123, DOI 10.1172/JCI81108; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Takata F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-106; Tao X, 2015, NEUROSCIENCE, V291, P26, DOI 10.1016/j.neuroscience.2015.01.070; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teng ZP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06932-3; Tsuji D, 2005, J NEUROCHEM, V92, P1497, DOI 10.1111/j.1471-4159.2005.02986.x; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Washington PM, 2016, J NEUROPATHOL EXP NE; Wilhelmus MMM, 2005, J NEUROSCI, V25, P3621, DOI 10.1523/JNEUROSCI.4213-04.2005; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Winkler EA, 2012, J CEREBR BLOOD F MET, V32, P1841, DOI 10.1038/jcbfm.2012.113; Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006; Yamakawa H, 2003, J CEREBR BLOOD F MET, V23, P371, DOI 10.1097/01.WCB.0000047369.05600.03; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yao XM, 2015, J NEUROTRAUM, V32, P1458, DOI 10.1089/neu.2014.3675; Yuan F, 2016, J NEUROCHEM, V136, P581, DOI 10.1111/jnc.13423; Zehendner CM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13497; Zhang HQ, 2006, ANN NY ACAD SCI, V1086, P81, DOI 10.1196/annals.1377.014; Zhang HQ, 2006, GLYCOBIOLOGY, V16, P702, DOI 10.1093/glycob/cwj115; Zozulya A, 2008, BRAIN RES, V1189, P1, DOI 10.1016/j.brainres.2007.10.099	87	51	52	2	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1750-1326			MOL NEURODEGENER	Mol. Neurodegener.	APR 4	2018	13								17	10.1186/s13024-018-0249-5			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GC6AZ	WOS:000429873800002	29618365	Green Published, gold			2022-02-06	
J	Oddo, M; Poole, D; Helbok, R; Meyfroidt, G; Stocchetti, N; Bouzat, P; Cecconi, M; Geeraerts, T; Martin-Loeches, I; Quintard, H; Taccone, FS; Geocadin, RG; Hemphill, C; Ichai, C; Menon, D; Payen, JF; Perner, A; Smith, M; Suarez, J; Videtta, W; Zanier, ER; Citerio, G				Oddo, Mauro; Poole, Daniele; Helbok, Raimund; Meyfroidt, Geert; Stocchetti, Nino; Bouzat, Pierre; Cecconi, Maurizio; Geeraerts, Thomas; Martin-Loeches, Ignacio; Quintard, Herve; Taccone, Fabio Silvio; Geocadin, Romergryko G.; Hemphill, Claude; Ichai, Carole; Menon, David; Payen, Jean-Francois; Perner, Anders; Smith, Martin; Suarez, Jose; Videtta, Walter; Zanier, Elisa R.; Citerio, Giuseppe			Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations	INTENSIVE CARE MEDICINE			English	Article						Evidence-based medicine; Guidelines; Fluid therapy; Traumatic brain injury; Subarachnoid haemorrhage; Intracerebral haemorrhage; Stroke; Mannitol; Hypertonic; Neurointensive care	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; ANEURYSMAL SUBARACHNOID HEMORRHAGE; INCREASED INTRACRANIAL-PRESSURE; RANDOMIZED CONTROLLED-TRIAL; HYPERTONIC SALINE RESUSCITATION; MULTICENTER PROSPECTIVE COHORT; END-DIASTOLIC VOLUME; ISCHEMIC-STROKE; HEAD-INJURY	Objective: To report the ESICM consensus and clinical practice recommendations on fluid therapy in neurointensive care patients. Design: A consensus committee comprising 22 international experts met in October 2016 during ESICM LIVES2016. Teleconferences and electronic-based discussions between the members of the committee subsequently served to discuss and develop the consensus process. Methods: Population, intervention, comparison, and outcomes (PICO) questions were reviewed and updated as needed, and evidence profiles generated. The consensus focused on three main topics: (1) general fluid resuscitation and maintenance in neurointensive care patients, (2) hyperosmolar fluids for intracranial pressure control, (3) fluid management in delayed cerebral ischemia after subarachnoid haemorrhage. After an extensive literature search, the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system were applied to assess the quality of evidence (from high to very low), to formulate treatment recommendations as strong or weak, and to issue best practice statements when applicable. A modified Delphi process based on the integration of evidence provided by the literature and expert opinions-using a sequential approach to avoid biases and misinterpretations-was used to generate the final consensus statement. Results: The final consensus comprises a total of 32 statements, including 13 strong recommendations and 17 weak recommendations. No recommendations were provided for two statements. Conclusions: We present a consensus statement and clinical practice recommendations on fluid therapy for neurointensive care patients.	[Oddo, Mauro] Univ Lausanne, Fac Biol & Med, Dept Med Surg Intens Care Med, CHUV, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland; [Poole, Daniele] San Martino Hosp, Anesthesia & Intens Care Operat Unit, Belluno, Italy; [Helbok, Raimund] Med Univ Innsbruck, Dept Neurol, Neurol Intens Care Unit, Innsbruck, Austria; [Meyfroidt, Geert] Univ Hosp Leuven, Dept Intens Care Med, Louvain, Belgium; [Stocchetti, Nino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurosci Intens Care Unit, Dept Anesthesia & Crit Care, Milan, Italy; [Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplants, Milan, Italy; [Bouzat, Pierre; Payen, Jean-Francois] CHU Grenoble Alpes, Dept Anesthesia & Crit Care, F-38000 Grenoble, France; [Cecconi, Maurizio] St Georges Univ Hosp, Dept Anaesthesia & Intens Care, London, England; [Geeraerts, Thomas] Univ Toulouse 3 Paul Sabatier, Toulouse Univ Hosp, Dept Anaesthesia & Intens Care, F-31059 Toulouse, France; [Martin-Loeches, Ignacio] St James Univ Hosp, Dept Intens Care Med, Jamess St,POB 580, Dublin 8, Ireland; [Quintard, Herve] CHU Nice, Univ Cote Azur, Serv Reanimat Med Chirurg, Hop Pasteur 2, F-06000 Nice, France; [Quintard, Herve] CNRS, Unite 7275, Sophia Antipolis, France; [Taccone, Fabio Silvio] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Geocadin, Romergryko G.; Suarez, Jose] Johns Hopkins Univ, Neurosci Crit Care, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Geocadin, Romergryko G.; Suarez, Jose] Johns Hopkins Univ, Neurosci Crit Care, Dept Neurol, Baltimore, MD 21205 USA; [Geocadin, Romergryko G.; Suarez, Jose] Johns Hopkins Univ, Neurosci Crit Care, Dept Neurosurg, Baltimore, MD 21205 USA; [Hemphill, Claude] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Ichai, Carole] CHU Nice, Serv Reanimat Polyvalente, Hop Pasteur 2, 30 Voie Romaine,CS 51069, F-06001 Nice 1, France; [Menon, David] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England; [Perner, Anders] Rigshosp, Copenhagen Univ Hosp, Dept Intens Care 4131, Copenhagen, Denmark; [Smith, Martin] Univ Coll London Hosp, Natl Hosp Neurosurg & Neurol, Dept Neuroanesthesia & Neurocrit Care, London, England; [Videtta, Walter] Hosp Nacl Prof Alejandro Posadas, Buenos Aires, DF, Argentina; [Zanier, Elisa R.] IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] ASST Monza, San Gerardo Hosp, Neurointens Care, I-20900 Monza, Italy		Oddo, M (corresponding author), Univ Lausanne, Fac Biol & Med, Dept Med Surg Intens Care Med, CHUV, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Poole, Daniele/X-7210-2019; Bouzat, Pierre/AAC-4105-2019; Helbok, Raimund/AAA-8361-2021; Bouzat, Pierre/L-6881-2014; Zanier, Elisa/AAA-8095-2020; Citerio, Giuseppe/B-1839-2015; Payen, Jean-Francois/L-6667-2014; Cecconi, Maurizio/A-6241-2012; martin-loeches, Prof. Ignacio/Q-6645-2018	Poole, Daniele/0000-0001-5279-9844; Bouzat, Pierre/0000-0003-4667-6738; Zanier, Elisa/0000-0002-3011-8718; Citerio, Giuseppe/0000-0002-5374-3161; Cecconi, Maurizio/0000-0002-4376-6538; Perner, Anders/0000-0002-4668-0123; martin-loeches, Prof. Ignacio/0000-0002-5834-4063			Al-Rawi PG, 2005, ACTA NEUROCHIR SUPPL, V95, P123; Al-Rawi PG, 2010, STROKE, V41, P122, DOI 10.1161/STROKEAHA.109.560698; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Asehnoune K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1918-4; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bentsen G, 2006, CRIT CARE MED, V34, P2912, DOI 10.1097/01.CCM.0000245665.46789.7C; Bereczki D, 2003, STROKE, V34, P1730, DOI 10.1161/01.STR.0000078658.52316.E8; CANDELISE L, 1988, LANCET, V1, P318; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Dhar R, 2012, J NEUROSURG, V116, P648, DOI 10.3171/2011.9.JNS11691; Dharmasaroja PA, 2016, TRANSL STROKE RES, V7, P49, DOI 10.1007/s12975-015-0439-1; Diringer MN, 2012, NEUROSURGERY, V70, P1215, DOI 10.1227/NEU.0b013e3182417bc2; Diringer MN, 2011, NEUROCRIT CARE, V14, P11, DOI 10.1007/s12028-010-9465-8; Egge A, 2001, NEUROSURGERY, V49, P593, DOI 10.1097/00006123-200109000-00012; Ekelund A, 2002, ACTA NEUROCHIR, V144, P703, DOI 10.1007/s00701-002-0959-9; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Ginsberg MD, 2013, LANCET NEUROL, V12, P1049, DOI 10.1016/S1474-4422(13)70223-0; Hartl R, 1997, ACT NEUR S, V70, P126; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Helbok R, 2011, J NEUROL NEUROSUR PS, V82, P378, DOI 10.1136/jnnp.2009.198754; Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752; Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019; Huang ZC, 2002, CLIN NEUROPHYSIOL, V113, P446, DOI 10.1016/S1388-2457(02)00012-3; Ibrahim GM, 2013, NEUROCRIT CARE, V19, P140, DOI 10.1007/s12028-013-9860-z; Ichai C, 2013, INTENS CARE MED, V39, P1413, DOI 10.1007/s00134-013-2978-9; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Ioannidis JPA, 2008, EPIDEMIOLOGY, V19, P640, DOI 10.1097/EDE.0b013e31818131e7; JAFAR JJ, 1986, J NEUROSURG, V64, P754, DOI 10.3171/jns.1986.64.5.0754; Jagannatha AT, 2016, J CLIN NEUROSCI, V27, P68, DOI 10.1016/j.jocn.2015.08.035; Jost SC, 2005, J NEUROSURG, V103, P25, DOI 10.3171/jns.2005.103.1.0025; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Kim CY, 2003, ACTA NEUROCHIR, V145, P571, DOI 10.1007/s00701-003-0024-3; Kissoon NR, 2015, J STROKE CEREBROVASC, V24, P2245, DOI 10.1016/j.jstrokecerebrovasdis.2015.05.027; Kurtz P, 2014, NEUROCRIT CARE, V20, P247, DOI 10.1007/s12028-013-9910-6; Kuwabara K, 2013, J NEUROL, V260, P820, DOI 10.1007/s00415-012-6710-4; Launey Y, 2014, J NEUROTRAUM, V31, P984, DOI 10.1089/neu.2012.2829; Lehmann L, 2013, NEUROCRIT CARE, V18, P5, DOI 10.1007/s12028-012-9764-3; Lennihan L, 2000, STROKE, V31, P383, DOI 10.1161/01.STR.31.2.383; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; Major EH, 2015, IRISH J MED SCI, V184, P159, DOI 10.1007/s11845-014-1080-9; Mangat HS, 2015, J NEUROSURG, V122, P202, DOI 10.3171/2014.10.JNS132545; Manno EM, 1999, NEUROLOGY, V52, P583, DOI 10.1212/WNL.52.3.583; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; Martini RP, 2012, NEUROCRIT CARE, V17, P191, DOI 10.1007/s12028-011-9573-0; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; Misra UK, 2007, EUR J NEUROL, V14, P1118, DOI 10.1111/j.1468-1331.2007.01918.x; MORI K, 1995, STROKE, V26, P1620, DOI 10.1161/01.STR.26.9.1620; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; Mutoh T, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0482-4; Mutoh T, 2014, STROKE, V45, P1280, DOI 10.1161/STROKEAHA.114.004739; Myburgh J, 2007, NEW ENGL J MED, V357, P874; NATH F, 1986, J NEUROSURG, V65, P41, DOI 10.3171/jns.1986.65.1.0041; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Palesch YY, 2006, STROKE, V37, P2107, DOI 10.1161/01.STR.0000231389.34701.b5; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Rabinstein AA, 2011, NEUROCRIT CARE, V15, P354, DOI 10.1007/s12028-011-9585-9; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Roquilly A, 2013, CRIT CARE, V17, DOI 10.1186/cc12686; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Scalfani M. T., 2012, J CRIT CARE, V27, pe527; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; Sekhon MS, 2011, J CRIT CARE, V26, P357, DOI 10.1016/j.jcrc.2010.12.001; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SHIMODA M, 1993, J NEUROSURG, V78, P423, DOI 10.3171/jns.1993.78.3.0423; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Suarez JI, 2004, J NEUROSURG, V100, P585, DOI 10.3171/jns.2004.100.4.0585; Tagami T, 2014, NEUROCRIT CARE, V21, P462, DOI 10.1007/s12028-014-9973-z; Tagami T, 2014, CRIT CARE MED, V42, P1348, DOI 10.1097/CCM.0000000000000163; TANABE T, 1982, ACTA NEUROCHIR, V63, P291, DOI 10.1007/BF01728884; Tisdall M, 2006, J NEUROSURG ANESTH, V18, P57, DOI 10.1097/01.ana.0000191280.05170.0f; Tseng MY, 2008, BRIT J NEUROSURG, V22, P257, DOI 10.1080/02688690701832100; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Videen TO, 2001, NEUROLOGY, V57, P2120, DOI 10.1212/WNL.57.11.2120; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wang X, 2015, STROKE, V46, P2762, DOI 10.1161/STROKEAHA.115.009357; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; YAMAKAMI I, 1987, NEUROSURGERY, V21, P303, DOI 10.1227/00006123-198709000-00004; Ye H, 2013, ACTA CIR BRAS, V28, P106, DOI 10.1590/S0102-86502013000200004; Yoneda H, 2013, STROKE, V44, P2155, DOI 10.1161/STROKEAHA.113.001015	90	51	54	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	APR	2018	44	4					449	463		10.1007/s00134-018-5086-z			15	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE4FR	WOS:000431171300005	29500701	Green Submitted			2022-02-06	
J	Sharma, A; Liaw, K; Sharma, R; Zhang, Z; Kannan, S; Kannan, RM				Sharma, Anjali; Liaw, Kevin; Sharma, Rishi; Zhang, Zhi; Kannan, Sujatha; Kannan, Rangaramanujam M.			Targeting Mitochondrial Dysfunction and Oxidative Stress in Activated Microglia using Dendrimer-Based Therapeutics	THERANOSTICS			English	Article						Hydroxyl PAMAM dendrimer; mitochondria; activated microglia; sub-cellular targeting; oxidative stress; N-acetyl cysteine	TRAUMATIC BRAIN-INJURY; DRUG; SURFACE; NANOPARTICLES; ANTIOXIDANTS; MODEL; TRIPHENYLPHOSPHONIUM; NEUROPROTECTION; NANOCARRIERS; CONJUGATION	Mitochondrial oxidative stress is associated with many neurodegenerative diseases, such as traumatic brain injury (TBI). Targeted delivery of antioxidants to mitochondria has failed to translate into clinical success due to their nonspecific cellular localization, poor transport properties across multiple biological barriers, and associated side effects. These challenges, coupled with the complex function of the mitochondria, create the need for innovative delivery strategies. Methods: Neutral hydroxyl-terminated polyamidoamine (PAMAM) dendrimers have shown significant potential as nanocarriers in multiple brain injury models. N-acetyl cysteine (NAC) is a clinically used antioxidant and anti-inflammatory agent which has shown significant potency when delivered in a targeted manner. Here we present a mitochondrial targeting hydroxyl PAMAM dendrimer-drug construct (TPP-D-NAC) with triphenyl-phosphonium (TPP) for mitochondrial targeting and NAC for targeted delivery to mitochondria in injured glia. Co-localization and mitochondrial content of mitochondria-targeted and unmodified dendrimer were assessed in microglia and macrophages in vitro via immunohistochemistry and fluorescence quantification. Therapeutic improvements of TPP-D-NAC over dendrimer-NAC conjugate (D-NAC) and free NAC were evaluated in vitro in microglia under oxidative stress challenge. In vivo neuroinflammation targeting was confirmed in a rabbit model of TBI. Results: TPP-conjugated dendrimer co-localized significantly more with mitochondria than unmodified dendrimer without altering overall levels of cellular internalization. This targeting capability translated to significant improvements in the attenuation of oxidative stress by TPP-D-NAC compared to D-NAC and free NAC. Upon systemic administration in a rabbit TBI model, TPP-conjugated dendrimer co-localized specifically with mitochondria in activated microglia and macrophages in the white matter of the ipsilateral/injured hemisphere, confirming its BBB penetration and glial targeting capabilities. Conclusion: D-NAC has shown promising efficacy in many animal models of neurodegeneration, and this work provides evidence that modification for mitochondrial targeting can further enhance its therapeutic efficacy, particularly in diseases where oxidative stress-induced glial cell death plays a significant role in disease progression.	[Sharma, Anjali; Liaw, Kevin; Sharma, Rishi; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Ctr Nanomed, Dept Ophthalmol, Wilmer Eye Inst,Sch Med, Baltimore, MD 21231 USA; [Liaw, Kevin; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Zhang, Zhi; Kannan, Sujatha] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Sch Med, Baltimore, MD 21287 USA; [Kannan, Sujatha; Kannan, Rangaramanujam M.] Kennedy Krieger Inc, Hugo W Moser Res Inst, Baltimore, MD 21205 USA; [Kannan, Sujatha; Kannan, Rangaramanujam M.] Johns Hopkins Univ Cerebral Palsy Res Excellence, Kennedy Krieger Inst, Baltimore, MD 21218 USA		Kannan, RM (corresponding author), Wilmer Eye Inst, Ctr Nanomed, Ophthalmol, 400 North Broadway, Baltimore, MD 21231 USA.	krangar1@jhmi.edu		Sharma, Anjali/0000-0003-0748-3001; Zhang, Zhi/0000-0001-6256-9516; Sharma, Rishi/0000-0002-7069-7099	NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB01 8306]; Wilmer Core Grant for Vision Research, Microscopy and Imaging Core Module [EY001865]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB018306] Funding Source: NIH RePORTER	This study was funded by the NIBIB R01EB01 8306 (RM Kannan). We thank the Wilmer Core Grant for Vision Research, Microscopy and Imaging Core Module (Grant #EY001865) for access to the Zen LSM710 confocal microscope.	Battin EE, 2009, CELL BIOCHEM BIOPHYS, V55, P1, DOI 10.1007/s12013-009-9054-7; Bielski ER, 2015, MOL PHARMACEUT, V12, P3043, DOI 10.1021/acs.molpharmaceut.5b00320; Biswas S, 2012, BIOMATERIALS, V33, P4773, DOI 10.1016/j.biomaterials.2012.03.032; Chtistophe M, 2006, CURR PHARM DESIGN, V12, P739, DOI 10.2174/138161206775474242; Dai H, 2010, NANOMEDICINE-UK, V5, P1317, DOI 10.2217/NNM.10.89; DIPIETRO V, 2017, SCI REP UK, V7; Dobrovolskaia MA, 2017, CURR PHARM DESIGN, V23, P3134, DOI 10.2174/1381612823666170309151958; Dobrovolskaia MA, 2012, MOL PHARMACEUT, V9, P382, DOI 10.1021/mp200463e; Dupuis L, 2004, NEURODEGENER DIS, V1, P245, DOI 10.1159/000085063; Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030; Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00029, 10.3389/fnsys.2010.00020]; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm JC, 2016, ANN THORAC SURG, V102, P743, DOI 10.1016/j.athoracsur.2016.02.077; Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009; He HJ, 2018, J AM CHEM SOC, V140, P1215, DOI 10.1021/jacs.7b11582; Heller A, 2012, EUR J PHARM BIOPHARM, V82, P1, DOI 10.1016/j.ejpb.2012.05.014; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hou RCW, 2005, ANN NY ACAD SCI, V1042, P279, DOI 10.1196/annals.1338.050; Hu QS, 2016, TRANSL NEURODEGENER, V5, DOI 10.1186/s40035-016-0060-6; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kambhampati SP, 2015, EUR J PHARM BIOPHARM, V95, P239, DOI 10.1016/j.ejpb.2015.02.013; Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162; Kurtoglu YE, 2009, BIOMATERIALS, V30, P2112, DOI 10.1016/j.biomaterials.2008.12.054; Kwon HJ, 2016, ACS NANO, V10, P2860, DOI 10.1021/acsnano.5b08045; Lesniak WG, 2013, MOL PHARMACEUT, V10, P4560, DOI 10.1021/mp400371r; Li Y, 2017, RSC ADV, V7, P15475, DOI 10.1039/c7ra00713b; Liaw K, 2018, J NANOPART RES, V20, DOI 10.1007/s11051-018-4219-1; Lieven CJ, 2003, ANTIOXID REDOX SIGN, V5, P641, DOI 10.1089/152308603770310310; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Liu XS, 2013, LANGMUIR, V29, P9138, DOI 10.1021/la401556k; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mao PZ, 2010, BBA-MOL BASIS DIS, V1802, P66, DOI 10.1016/j.bbadis.2009.07.002; Marrache S, 2014, P NATL ACAD SCI USA, V111, P10444, DOI 10.1073/pnas.1405244111; Mignani S, 2017, PROG POLYM SCI, V64, P23, DOI 10.1016/j.progpolymsci.2016.09.006; Mignani S, 2013, ADV DRUG DELIVER REV, V65, P1316, DOI 10.1016/j.addr.2013.01.001; Mishra MK, 2014, ACS NANO, V8, P2134, DOI 10.1021/nn404872e; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Nance E, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-1004-5; Nance E, 2016, BIOMATERIALS, V101, P96, DOI 10.1016/j.biomaterials.2016.05.044; Nance E, 2015, J CONTROL RELEASE, V214, P112, DOI 10.1016/j.jconrel.2015.07.009; Nemeth CL, 2017, NANOMED-NANOTECHNOL, V13, P2359, DOI 10.1016/j.nano.2017.06.014; OLSSON B, 1988, EUR J CLIN PHARMACOL, V34, P77, DOI 10.1007/BF01061422; Saovapakhiran A, 2009, BIOCONJUGATE CHEM, V20, P693, DOI 10.1021/bc8002343; Sharma A, 2018, J CONTROL RELEASE, V283, P175, DOI 10.1016/j.jconrel.2018.06.003; Sharma A, 2014, ACS MACRO LETT, V3, P1079, DOI 10.1021/mz5006298; Sharma A, 2014, RSC ADV, V4, P19242, DOI 10.1039/c4ra02713b; Sharma A, 2012, BIOMACROMOLECULES, V13, P239, DOI 10.1021/bm201538j; Sharma A, 2011, MACROMOLECULES, V44, P521, DOI 10.1021/ma102354k; Sharma A, 2011, BIOMATERIALS, V32, P1419, DOI 10.1016/j.biomaterials.2010.10.025; Sharma R, 2018, BIOENG TRANSL MED, V3, P87, DOI 10.1002/btm2.10094; Sharma R, 2017, BIOCONJUGATE CHEM, V28, P2874, DOI 10.1021/acs.bioconjchem.7b00569; Sharma R, 2016, NANOSCALE, V8, P5106, DOI 10.1039/c5nr06757j; Sharma R, 2015, POLYM CHEM-UK, V6, P1436, DOI 10.1039/c4py01761g; Sharma R, 2014, CHEM COMMUN, V50, P13300, DOI 10.1039/c4cc06191h; Sheu SS, 2006, BBA-MOL BASIS DIS, V1762, P256, DOI 10.1016/j.bbadis.2005.10.007; Shi J, 2013, ACS NANO, V7, P10612, DOI 10.1021/nn403069n; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sliwka L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155772; Smith RAJ, 2012, TRENDS PHARMACOL SCI, V33, P341, DOI 10.1016/j.tips.2012.03.010; Sorrentino V, 2018, ANNU REV PHARMACOL, V58, P353, DOI 10.1146/annurev-pharmtox-010716-104908; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Thiagarajan G, 2013, EUR J PHARM BIOPHARM, V84, P330, DOI 10.1016/j.ejpb.2013.01.019; Vekaria HJ, 2017, NEUROCHEM INT, V109, P117, DOI 10.1016/j.neuint.2017.04.004; Wang CX, 2009, ANNU REV GENET, V43, P95, DOI 10.1146/annurev-genet-102108-134850; Yang GB, 2018, NANO LETT, V18, P2475, DOI 10.1021/acs.nanolett.8b00040; Yue YK, 2014, J OCUL PHARMACOL TH, V30, P657, DOI 10.1089/jop.2014.0022; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; Zhang F, 2015, BIOMATERIALS, V52, P507, DOI 10.1016/j.biomaterials.2015.02.053; Zhang Z, 2015, J NEUROTRAUM, V32, P1369, DOI 10.1089/neu.2014.3701	71	51	53	9	20	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1838-7640			THERANOSTICS	Theranostics		2018	8	20					5529	5547		10.7150/thno.29039			19	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	HA2DJ	WOS:000450042300002	30555562	gold, Green Submitted, Green Published			2022-02-06	
J	Wu, LC; Kuo, C; Loza, J; Kurt, M; Laksari, K; Yanez, LZ; Senif, D; Anderson, SC; Miller, LE; Urban, JE; Stitzel, JD; Camarillo, DB				Wu, Lyndia C.; Kuo, Calvin; Loza, Jesus; Kurt, Mehmet; Laksari, Kaveh; Yanez, Livia Z.; Senif, Daniel; Anderson, Scott C.; Miller, Logan E.; Urban, Jillian E.; Stitzel, Joel D.; Camarillo, David B.			Detection of American Football Head Impacts Using Biomechanical Features and Support Vector Machine Classification	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; PHYSICAL-ACTIVITY; ICE HOCKEY; EXPOSURE; PLAYERS; CONCUSSION; SENSORS; SYSTEM; KINEMATICS; MOUTHGUARD	Accumulation of head impacts may contribute to acute and long-term brain trauma. Wearable sensors can measure impact exposure, yet current sensors do not have validated impact detection methods for accurate exposure monitoring. Here we demonstrate a head impact detection method that can be implemented on a wearable sensor for detecting field football head impacts. Our method incorporates a support vector machine classifier that uses biomechanical features from the time domain and frequency domain, as well as model predictions of head-neck motions. The classifier was trained and validated using instrumented mouthguard data from collegiate football games and practices, with ground truth data labels established from video review. We found that low frequency power spectral density and wavelet transform features (10 similar to 30 Hz) were the best performing features. From forward feature selection, fewer than ten features optimized classifier performance, achieving 87.2% sensitivity and 93.2% precision in cross-validation on the collegiate dataset (n = 387), and over 90% sensitivity and precision on an independent youth dataset (n = 32). Accurate head impact detection is essential for studying and monitoring head impact exposure on the field, and the approach in the current paper may help to improve impact detection performance on wearable sensors.	[Wu, Lyndia C.; Kuo, Calvin; Loza, Jesus; Yanez, Livia Z.; Senif, Daniel; Anderson, Scott C.; Camarillo, David B.] Stanford Univ, Stanford, CA 94305 USA; [Kurt, Mehmet] Stevens Inst Technol, Hoboken, NJ 07030 USA; [Laksari, Kaveh] Univ Arizona, Tucson, AZ USA; [Miller, Logan E.; Urban, Jillian E.; Stitzel, Joel D.] Wake Forest Univ, Winston Salem, NC 27109 USA		Wu, LC (corresponding author), Stanford Univ, Stanford, CA 94305 USA.	lyndiacw@stanford.edu	Kuo, Calvin/AAH-1933-2019; Stitzel, Joel/B-4045-2012; Wu, Lyndia/AAQ-1106-2020; Kurt, Mehmet/AAX-3303-2021	Kuo, Calvin/0000-0001-8401-9136; Stitzel, Joel/0000-0001-9762-3033; Wu, Lyndia/0000-0002-8236-032X; Kurt, Mehmet/0000-0002-5618-0296; Miller, Logan/0000-0002-6348-7536	Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center	The authors would like to thank Stanford Athletics, Coach Shaw and the Football Team for their support in this research. We would also like to thank Camarillo Lab interns and Wake Forest University interns who aided in device fabrication, data collection, and video analysis. We would like to express special thanks to the Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center, as well as Mireille Kelley and the iTAKL study for providing support.	Abramowitz M, 1965, HDB MATH FUNCTIONS F; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Altun K, 2010, PATTERN RECOGN, V43, P3605, DOI 10.1016/j.patcog.2010.04.019; [Anonymous], 2015, US SOCC ANN REC REC; Bao L, 2004, LECT NOTES COMPUT SC, V3001, P1, DOI 10.1007/978-3-540-24646-6_1; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Campbell KR, 2016, P 2016 NAT ATHL TRAI; Cortes N, 2017, AM J SPORT MED, V45, P2379, DOI 10.1177/0363546517706703; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Doukas Charalampos, 2008, 2008 Second International Conference on Pervasive Computing Technologies for Healthcare (PervasiveHealth), P103, DOI 10.1109/PCTHEALTH.2008.4571042; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gissane C., 2014, AM J SPORT MED; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haran F. J., 2012, INT J SPORTS MED, V24; Hernandez F., 2014, ANN BIOMED ENG; Huang J, 2005, IEEE T KNOWL DATA EN, V17, P299, DOI 10.1109/TKDE.2005.50; Kuo C., 2017, BIORXIV; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Lustrek . M., 2008, INFORMATICA, V33, P205; Mannini A, 2010, SENSORS-BASEL, V10, P1154, DOI 10.3390/s100201154; Mantyjarvi J., 2001, P IEEE INT C SYST MA, V2, P2, DOI DOI 10.1109/ICSMC.2001.973004.(2001); Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Mez J., 2016, JAMA NEUROL, P4; Motiwale S, 2016, 2016 3RD IEEE EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL AND HEALTH INFORMATICS, P204, DOI 10.1109/BHI.2016.7455870; Musicant D. R., 2003, P 16 INT FLOR ART IN, P356; Najafi B, 2003, IEEE T BIO-MED ENG, V50, P711, DOI 10.1109/TBME.2003.812189; Nevins D, 2016, PROCEDIA ENGINEER, V147, P186, DOI 10.1016/j.proeng.2016.06.211; Nyan MN, 2008, J BIOMECH, V41, P3475, DOI 10.1016/j.jbiomech.2008.08.009; Preece SJ, 2009, PHYSIOL MEAS, V30, pR1, DOI 10.1088/0967-3334/30/4/R01; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Reynolds BB, 2016, AM J SPORT MED, V44, P2947, DOI 10.1177/0363546516648442; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Sae S., 1995, ELECT INSTRUMENTAT 1, V552, P25; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Vasavada AN, 1998, SPINE, V23, P412, DOI 10.1097/00007632-199802150-00002; Vasavada AN, 2008, J BIOMECH, V41, P114, DOI 10.1016/j.jbiomech.2007.07.007; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Wu L.C., 2015, ANN BIOMED ENG; Wu LC, 2014, IEEE T BIO-MED ENG, V61, P2659, DOI 10.1109/TBME.2014.2320153; Wu WM, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.2208	44	51	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	DEC 21	2017	7								855	10.1038/s41598-017-17864-3			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX2OU	WOS:000425901700001	29321637	Green Published, gold			2022-02-06	
J	Kota, DJ; Prabhakara, KS; Toledano-Furman, N; Bhattarai, D; Chen, QZ; DiCarlo, B; Smith, P; Triolo, F; Wenzel, PL; Cox, CS; Olson, SD				Kota, Daniel J.; Prabhakara, Karthik S.; Toledano-Furman, Naama; Bhattarai, Deepa; Chen, Qingzheng; DiCarlo, Bryan; Smith, Philippa; Triolo, Fabio; Wenzel, Pamela L.; Cox, Charles S.; Olson, Scott D.			Prostaglandin E2 Indicates Therapeutic Efficacy of Mesenchymal Stem Cells in Experimental Traumatic Brain Injury	STEM CELLS			English	Article						Mesenchymal stem cells; Inflammation; Immunomodulation; Traumatic brain injury; Prostaglandin E2	VERSUS-HOST-DISEASE; REGULATORY T-CELLS; STROMAL CELLS; AMNIOTIC-FLUID; MICROGLIAL ACTIVATION; MYOCARDIAL-INFARCTION; BARRIER DISRUPTION; IMMUNE-RESPONSE; CLINICAL-TRIALS; IN-VITRO	Traumatic brain injury (TBI) is soon predicted to become the third leading cause of death and disability worldwide. After the primary injury, a complex set of secondary injuries develops hours and days later with prolonged neuroinflammation playing a key role. TBI and other inflammatory conditions are currently being treated in preclinical and clinical trials by a number of cellular therapies. Mesenchymal stem cells (MSC) are of great interest due to their widespread usage, safety, and relative ease to isolate and culture. However, there has been a wide range in efficacy reported using MSC clinically and in preclinical models, likely due to differences in cell preparations and a significant amount of donor variability. In this study, we seek to find a correlation between in vitro activity and in vivo efficacy. We designed assays to explore the responsiveness of MSC to immunological cues to address the immunomodulatory properties of MSC, one of their primary modes of therapeutic activity in TBI. Our results showed intrinsic differences in the immunomodulatory capacity of MSC preparations from different bone marrow and amniotic fluid donors. This difference mirrored the therapeutic capacity of the MSC in an experimental model of TBI, an effect confirmed using siRNA knockdown of COX2 followed by overexpressing COX2. Among the immunomodulatory factors assessed, the therapeutic benefit correlated with the secretion of prostaglandin E2 (PGE(2)) by MSC prior to treatment, suggesting that measurement of PGE(2) could be a very useful potency marker to create an index of predicted efficacy for preparations of MSC to treat TBI. Stem Cells2017;35:1416-1430	[Kota, Daniel J.] Sanford Res, Children Hlth Res Ctr S, Sioux Falls, SD USA; [Prabhakara, Karthik S.; Toledano-Furman, Naama; Bhattarai, Deepa; Chen, Qingzheng; DiCarlo, Bryan; Smith, Philippa; Triolo, Fabio; Wenzel, Pamela L.; Cox, Charles S.; Olson, Scott D.] Univ Texas Houston, Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St MSE R162, Houston, TX 77030 USA		Olson, SD (corresponding author), Univ Texas Houston, Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St MSE R162, Houston, TX 77030 USA.	Scott.D.Olson@uth.tmc.edu	Toledano Furman, Naama/N-1854-2016; Wenzel, Pamela/AAJ-1944-2021	Toledano Furman, Naama/0000-0002-2687-7068; Wenzel, Pamela/0000-0002-4530-015X; Olson, Scott/0000-0001-8032-3755	Clare A. Glassell Family Pediatric Stem Cell Research Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K01DK092365] Funding Source: NIH RePORTER	This study was supported by the Clare A. Glassell Family Pediatric Stem Cell Research Fund. We thank our colleague, Dr. Richard Kulmacz, for kindly providing the SG5-COX2 expression vector.	Abdi R, 2008, DIABETES, V57, P1759, DOI 10.2337/db08-0180; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Ankrum JA, 2014, SCI REP-UK, V4, DOI 10.1038/srep04645; Armin SS, 2006, NEUROL RES, V28, P445, DOI 10.1179/016164106X115053; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Chen PM, 2014, J LEUKOCYTE BIOL, V96, P295, DOI 10.1189/jlb.3A0513-242R; Chinnadurai R, 2014, J IMMUNOL, V192, P1491, DOI 10.4049/jimmunol.1301828; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Darlington PJ, 2011, EXPERT REV NEUROTHER, V11, P1295, DOI [10.1586/ern.11.113, 10.1586/ERN.11.113]; Davis NE, 2012, CURR DIABETES REP, V12, P612, DOI 10.1007/s11892-012-0305-4; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; English K, 2013, IMMUNOL CELL BIOL, V91, P19, DOI 10.1038/icb.2012.56; Fauza D, 2004, BEST PRACT RES CL OB, V18, P877, DOI 10.1016/j.bpobgyn.2004.07.001; Fiorina P, 2009, J IMMUNOL, V183, P993, DOI 10.4049/jimmunol.0900803; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Galipeau J, 2013, CYTOTHERAPY, V15, P2, DOI 10.1016/j.jcyt.2012.10.002; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; Ge W, 2010, TRANSPLANTATION, V90, P1312, DOI 10.1097/TP.0b013e3181fed001; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Harting MT, 2008, BRAIN, V131, DOI 10.1093/brain/awn142; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hsu WT, 2013, J IMMUNOL, V190, P2372, DOI 10.4049/jimmunol.1202996; Iso Y, 2007, BIOCHEM BIOPH RES CO, V354, P700, DOI 10.1016/j.bbrc.2007.01.045; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kota DJ, 2016, STEM CELL TRANSL MED, V5, P33, DOI 10.5966/sctm.2015-0065; Kota DJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep04565; Kota DJ, 2013, DIABETES, V62, P2048, DOI 10.2337/db12-0931; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111; Lee RH, 2012, CELL STEM CELL, V11, P825, DOI 10.1016/j.stem.2012.10.001; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Li D, 2015, INT J MOL MED, V35, P1309, DOI 10.3892/ijmm.2015.2137; Li P, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0361-9; Liao GP, 2014, J SURG RES, V190, P628, DOI 10.1016/j.jss.2014.05.011; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lopez F, 2010, RISK ANAL, V30, P1857, DOI 10.1111/j.1539-6924.2010.01465.x; Luo CF, 2014, CURR STEM CELL RES T, V9, P36; Luz-Crawford P, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt216; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Moorefield EC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026535; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nauta AJ, 2006, J IMMUNOL, V177, P2080, DOI 10.4049/jimmunol.177.4.2080; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Ohsawa K, 2010, GLIA, V58, P790, DOI 10.1002/glia.20963; Ooi YY, 2010, INT IMMUNOPHARMACOL, V10, P1532, DOI 10.1016/j.intimp.2010.09.001; Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104; Prevosto C, 2007, HAEMATOLOGICA, V92, P881, DOI 10.3324/haematol.11240; Prockop DJ, 2010, J CELL MOL MED, V14, P2190, DOI 10.1111/j.1582-4934.2010.01151.x; Prockop DJ, 2009, MOL THER, V17, P939, DOI 10.1038/mt.2009.62; Puissant N, 2005, BRIT J HAEMATOL, V129, P118, DOI 10.1111/j.1365-2141.2005.05409.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rasmusson I, 2003, TRANSPLANTATION, V76, P1208, DOI 10.1097/01.TP.0000082540.43730.80; Ren GW, 2009, STEM CELLS, V27, P1954, DOI 10.1002/stem.118; Rozenberg A, 2016, STEM CELL TRANSL MED, V5, P1506, DOI 10.5966/sctm.2015-0243; Schrepfer S, 2007, TRANSPL P, V39, P573, DOI 10.1016/j.transproceed.2006.12.019; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Tang YH, 2015, ADV FUNCT MATER, V25, P1024, DOI 10.1002/adfm.201402930; Teixeira FG, 2013, CELL MOL LIFE SCI, V70, P3871, DOI 10.1007/s00018-013-1290-8; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Uccelli A, 2010, CURR OPIN IMMUNOL, V22, P768, DOI 10.1016/j.coi.2010.10.012; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Waterman RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010088; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wostradowski T, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0715-3; Yan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084116; Yang B, 2012, STROKE, V43; Ylostalo JH, 2012, STEM CELLS, V30, P2283, DOI 10.1002/stem.1191; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zheng B, 2016, THERANOSTICS, V6, P291, DOI 10.7150/thno.13728; Zhou J, 2014, ARCH GYNECOL OBSTET, V290, P223, DOI 10.1007/s00404-014-3231-7	91	51	54	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	MAY	2017	35	5					1416	1430		10.1002/stem.2603			15	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	ET1HC	WOS:000400017200025	28233425	Bronze			2022-02-06	
J	Emami, P; Czorlich, P; Fritzsche, FS; Westphal, M; Rueger, JM; Lefering, R; Hoffmann, M				Emami, Pedram; Czorlich, Patrick; Fritzsche, Friederike S.; Westphal, Manfred; Rueger, Johannes M.; Lefering, Rolf; Hoffmann, Michael			Impact of Glasgow Coma Scale score and pupil parameters on mortality rate and outcome in pediatric and adult severe traumatic brain injury: a retrospective, multicenter cohort study	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; mortality; outcome; pediatrics	SEVERE HEAD-INJURY; PRACTICAL SCALE; MOTOR SCORE; AGE; ADMISSION; RISK; PREDICTION; CHILDREN; SURVIVAL	OBJECTIVE Prediction of death and functional outcome is essential for determining treatment strategies and allocation of resources for patients with severe traumatic brain injury (TBI). The aim of this study was to evaluate, by using pupillary status and Glasgow Coma Scale (GCS) score, if patients with severe TBI who are <= 15 years old have a lower mortality rate and better outcome than adults with severe TBI. METHODS A retrospective cohort analysis of patients suffering from severe TBI registered in the Trauma Registry of the German Society for Trauma Surgery between 2002 and 2013 was undertaken. Severe TBI was defined as an Abbreviated Injury Scale of the head (AlShead) score of >= 3 and an AIS score for any other part of the body that does not exceed the AlShead score. Only patients with complete data (GCS score, age, and pupil parameters) were included. To assess the impact of GCS score and pupil parameters, the authors also used the recently introduced Eppendorf-Co-logne Scale and divided the study population into 2 groups: children (0-15 years old) and adults (16-55 years old). Each patient's outcome was measured at discharge from the trauma center by using the Glasgow Outcome Scale. RESULTS A total of 9959 patients fulfilled the study inclusion criteria; 888 (8.9%) patients were <= 15 years old (median 10 years). The overall mortality rate and the mortality rate for patients with a GCS of 3 and bilaterally fixed and dilated pupils (19.9% and 16.3%, respectively) were higher for the adults than for the pediatric patients (85% vs 80.9%, respectively), although cardiopulmonary resuscitation rates were significantly higher in the pediatric patients (5.6% vs 8.8%, respectively). In the multivariate logistic regression analysis, no motor response (OR 3.490, 95% CI 2.240-5.435) and fixed pupils (OR 4.197, 95% CI 3.271-5.386) and bilateral dilated pupils (OR 2.848, 95% CI 2.282-3.556) were associated with a higher mortality rate. Patients >= 15 years old had a statistically lower mortality rate (OR 0.536, 95% CI 0.421-0.814; p = 0.001). The rate of good functional outcomes (Glasgow Outcome Scale Score 4 or 5) was higher in pediatric patients than in the adults (72.2% vs 63.1%, respectively). CONCLUSIONS This study found that severe TBI in children aged <= 15 years is associated with a lower mortality rate and superior functional outcome than in adults. Also, children admitted with a missing motor response or fixed and bilaterally dilated pupils also have a lower mortality rate and higher functional outcome than adults with the same initial presentation. Therefore, patients suffering from severe TBI, especially pediatric patients, could benefit from early and aggressive treatment.	[Emami, Pedram; Czorlich, Patrick; Fritzsche, Friederike S.; Westphal, Manfred] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany; [Rueger, Johannes M.; Hoffmann, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Hamburg, Germany; [Lefering, Rolf] Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany		Czorlich, P (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany.	p.czorlich@uke.de	Czorlich, Patrick/H-8934-2019		European Journal of Trauma and Emergency; Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG); Federal Highway Research Institute of the Federal Republic of Germany (BAST); Federal Ministry of Education and Research of the Federal Republic of Germany (BMBF)Federal Ministry of Education & Research (BMBF); AUC GmbH, German Trauma Society	Dr. Lefering was paid by the European Journal of Trauma and Emergency for statistical reviews; he is employed by the University of Witten/Herdecke, which has a service agreement with the Akademie der Unfallchirurgie (AUC)/German Society for Trauma Surgery for scientific assistance, annual audit reports, etc.; he has received sponsoring from the Deutsche Forschungsgemeinschaft (DFG), the Federal Highway Research Institute of the Federal Republic of Germany (BAST), the Federal Ministry of Education and Research of the Federal Republic of Germany (BMBF), and several other research foundations; and he also received payments for lectures at the KKS Dusseldorf and Frankfurt, Mibeg, for education in statistics for study nurses, study physicians, and project managers. The TR-DGU is funded by fees from the participating hospitals. AUC GmbH, a 100% affiliate of the German Trauma Society, collects the fees and runs the registry. There is a cooperation-and-service agreement between the AUC and University Witten/Herdecke (Dr. Lefering), which covers statistical support for scientific analyses using the registry data.	Alharfi IM, 2013, J NEUROTRAUM, V30, P361, DOI 10.1089/neu.2012.2410; [Anonymous], 1971, JAMA-J AM MED ASSOC, V215, P277; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Basso A, 2001, WORLD J SURG, V25, P1174; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Billeter AT, 2014, AM J SURG, V207, P459, DOI 10.1016/j.amjsurg.2013.04.015; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Centers for Disease Control and Prevention, 2013, 013 MORT MULT CAUS M; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Federal Statistical Office of the Federal Republic of Germany, DEST DE; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Gray AT, 1997, ARCH NEUROL-CHICAGO, V54, P579, DOI 10.1001/archneur.1997.00550170055014; Grote S, 2011, J NEUROTRAUM, V28, P527, DOI 10.1089/neu.2010.1433; Hamill V, 2015, J NEUROTRAUM, V32, P689, DOI 10.1089/neu.2014.3670; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hoffmann M, 2012, BRIT J SURG, V99, P122, DOI 10.1002/bjs.7707; Hoffmann M, 2012, J TRAUMA ACUTE CARE, V73, P1607, DOI 10.1097/TA.0b013e318270d572; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1975, LANCET, V1, P480; Lefering R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0476-2; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Majdan M, 2015, J NEUROTRAUM, V32, P101, DOI 10.1089/neu.2014.3438; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; TEASDALE G, 1974, LANCET, V2, P81; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; Timmons SD, 2011, J TRAUMA, V71, P1172, DOI 10.1097/TA.0b013e31822b0f4b; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237	34	51	53	1	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2017	126	3					760	767		10.3171/2016.1.JNS152385			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	EL9FT	WOS:000394926200010	27035177				2022-02-06	
J	Vergara, VM; Mayer, AR; Damaraju, E; Kiehl, KA; Calhoun, V				Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Kiehl, Kent A.; Calhoun, Vince			Detection of Mild Traumatic Brain Injury by Machine Learning Classification Using Resting State Functional Network Connectivity and Fractional Anisotropy	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; magnetic resonance imaging; traumatic brain injury	STRUCTURAL CONNECTIVITY; MRI; FMRI; SCHIZOPHRENIA; ABNORMALITIES; DISRUPTION; COGNITION; DISORDER; THERAPY; TIME	Traumatic brain injury (TBI) may adversely affect a person's thinking, memory, personality, and behavior. While mild TBI (mTBI) diagnosis is challenging, there is a risk for long-term psychiatric, neurologic, and psychosocial problems in some patients that motivates the search for new and better biomarkers. Recently, diffusion magnetic resonance imaging (dMRI) has shown promise in detecting mTBI, but its validity is still being investigated. Resting state functional network connectivity (rsFNC) is another approach that is emerging as a promising option for the diagnosis of mTBI. The present work investigated the use of rsFNC for mTBI detection compared with dMRI results on the same cohort. Fifty patients with mTBI (25 males) and age-sex matched healthy controls were recruited. Features from dMRI were obtained using all voxels, the enhanced Z-score microstructural assessment for pathology, and the distribution corrected Z-score. Features based on rsFNC were obtained through group independent component analysis and correlation between pairs of resting state networks. A linear support vector machine was used for classification and validated using leave-one-out cross validation. Classification achieved a maximum accuracy of 84.1% for rsFNC and 75.5% for dMRI and 74.5% for both combined. A t test analysis revealed significant increase in rsFNC between cerebellum versus sensorimotor networks and between left angular gyrus versus precuneus in subjects with mTBI. These outcomes suggest that inclusion of both common and unique information is important for classification of mTBI. Results also suggest that rsFNC can yield viable biomarkers that might outperform dMRI and points to connectivity to the cerebellum as an important region for the detection of mTBI.	[Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Kiehl, Kent A.; Calhoun, Vince] Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA; [Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Kiehl, Kent A.; Calhoun, Vince] Lovelace Biomed & Environm Res Inst, Albuquerque, NM USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Damaraju, Eswar; Calhoun, Vince] Univ New Mexico, Dept ECE, Albuquerque, NM 87131 USA; [Kiehl, Kent A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA		Vergara, VM (corresponding author), Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	vvergara@mrn.org	Kiehl, Kent A./AAK-3290-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24HD050836/R21NS064464/3R21 NS064464, P20GM103472/1R01EB006841]; Office Of The DirectorNational Science Foundation (NSF)NSF - Office of the Director (OD) [1539067] Funding Source: National Science Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB006841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	The authors thank Joseph Ling, Jill Fries, Vikram Rao, Prashanth Nyalakanti, and Sandeep Panta for help with preprocessing the data. This work was funded by the following NIH grants: R24HD050836/R21NS064464/3R21 NS064464 to A.M. and P20GM103472/1R01EB006841 to V.C.	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Bharath RD, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00513; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun Vince D, 1800, Biol Psychiatry Cogn Neurosci Neuroimaging, V1, P230; Calhoun Vince D, 1800, IEEE Rev Biomed Eng, V5, P60, DOI 10.1109/RBME.2012.2211076; Damaraju E., 2014, 4 BIENN C REST STAT; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Hahn T, 2015, JAMA PSYCHIAT, V72, P68, DOI 10.1001/jamapsychiatry.2014.1741; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Huston JM, 2013, MAGN RESON IMAGING C, V21, P279, DOI 10.1016/j.mric.2012.12.003; K/tter, 2003, NEUROSCIENCE DATABAS, P237, DOI [10.1007/978-1-4615-1079-6_16, DOI 10.1007/978-1-4615-1079-6{\_}16]; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koch MA, 2002, NEUROIMAGE, V16, P241, DOI 10.1006/nimg.2001.1052; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Liu JY, 2009, HUM BRAIN MAPP, V30, P241, DOI 10.1002/hbm.20508; Ma S, 2011, IEEE T BIO-MED ENG, V58, P3406, DOI 10.1109/TBME.2011.2167149; Mayer A., 2014, J NEUROTRAUMA; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Rocca MA, 2013, NEUROTHERAPEUTICS, V10, P511, DOI 10.1007/s13311-013-0189-2; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schmahmann JD, 2006, BRAIN, V129, P290, DOI 10.1093/brain/awh729; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shen H, 2010, NEUROIMAGE, V49, P3110, DOI 10.1016/j.neuroimage.2009.11.011; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Sui J, 2011, NEUROIMAGE, V57, P839, DOI 10.1016/j.neuroimage.2011.05.055; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Timmann D, 2007, CEREBELLUM, V6, P159, DOI 10.1080/14734220701496448; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Vergara V. M., 2016, NEUROIMAGE; Whelan R, 2014, NATURE, V512, P185, DOI 10.1038/nature13402; Yuan K, 2016, BRAIN STRUCT FUNCT, V221, P1427, DOI 10.1007/s00429-014-0982-7; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	53	51	52	2	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2017	34	5					1045	1053		10.1089/neu.2016.4526			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EM6EI	WOS:000395405200009	27676221	Green Published			2022-02-06	
J	Ropper, AE; Thakor, DK; Han, IB; Yu, D; Zeng, X; Anderson, JE; Aljuboori, Z; Kim, SW; Wang, HJ; Sidman, RL; Zafonte, RD; Teng, YD				Ropper, Alexander E.; Thakor, Devang K.; Han, Inbo; Yu, Dou; Zeng, Xiang; Anderson, Jamie E.; Aljuboori, Zaid; Kim, Soo-Woo; Wang, Hongjun; Sidman, Richard L.; Zafonte, Ross D.; Teng, Yang D.			Defining recovery neurobiology of injured spinal cord by synthetic matrix-assisted hMSC implantation	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						spinal cord injury; recovery neurobiology; mesenchymal stromal stem cell; PLGA; locomotion	NEURAL STEM-CELLS; HUMAN BONE-MARROW; STROMAL CELLS; FUNCTIONAL RECOVERY; TISSUE-DAMAGE; INFLAMMATION; SCAFFOLDS; DIFFERENTIATION; POLYMER; REPAIR	Mesenchymal stromal stem cells (MSCs) isolated from adult tissues offer tangible potential for regenerative medicine, given their feasibility for autologous transplantation. MSC research shows encouraging results in experimental stroke, amyotrophic lateral sclerosis, and neurotrauma models. However, further translational progress has been hampered by poor MSC graft survival, jeopardizing cellular and molecular bases for neural repair in vivo. We have devised an adult human bone marrow MSC (hMSC) delivery formula by investigating molecular events involving hMSCs incorporated in a uniquely designed poly(lactic-co-glycolic) acid scaffold, a clinically safe polymer, following inflammatory exposures in a dorsal root ganglion organotypic coculture system. Also, in rat T9-T10 hemisection spinal cord injury (SCI), we demonstrated that the tailored scaffolding maintained hMSC stemness, engraftment, and led to robust motosensory improvement, neuropathic pain and tissue damage mitigation, and myelin preservation. The scaffolded nontransdifferentiated hMSCs exerted multimodal effects of neurotrophism, angiogenesis, neurogenesis, antiautoimmunity, and antiinflammation. Hindlimb locomotion was restored by reestablished integrity of submidbrain circuits of serotonergic reticulospinal innervation at lumbar levels, the propriospinal projection network, neuromuscular junction, and central pattern generator, providing a platform for investigating molecular events underlying the repair impact of nondifferentiated hMSCs. Our approach enabled investigation of recovery neurobiology components for injured adult mammalian spinal cord that are different from those involved in normal neural function. The uncovered neural circuits and their molecular and cellular targets offer a biological underpinning for development of clinical rehabilitation therapies to treat disabilities and complications of SCI.	[Ropper, Alexander E.; Thakor, Devang K.; Han, Inbo; Yu, Dou; Zeng, Xiang; Anderson, Jamie E.; Aljuboori, Zaid; Kim, Soo-Woo; Teng, Yang D.] Vet Affairs Boston Healthcare Syst, Div SCI Res, Boston, MA 02130 USA; [Ropper, Alexander E.; Thakor, Devang K.; Han, Inbo; Yu, Dou; Zafonte, Ross D.; Teng, Yang D.] Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Charlestown, MA 02129 USA; [Ropper, Alexander E.; Thakor, Devang K.; Han, Inbo; Yu, Dou; Zeng, Xiang; Anderson, Jamie E.; Aljuboori, Zaid; Teng, Yang D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Wang, Hongjun] Stevens Inst Technol, Biomed Engn Chem & Biol Sci, Hoboken, NJ 07030 USA; [Sidman, Richard L.] Harvard Med School, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Han, Inbo] CHA Bundang Med Ctr, Dept Neurosurg, Seongnam Si 13496, South Korea; [Kim, Soo-Woo] Harvard Sch Dent Med, Dept Immunol & Infect Dis, Boston, MA 02115 USA		Teng, YD (corresponding author), Vet Affairs Boston Healthcare Syst, Div SCI Res, Boston, MA 02130 USA.; Teng, YD (corresponding author), Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Charlestown, MA 02129 USA.; Teng, YD (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.; Sidman, RL (corresponding author), Harvard Med School, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.	richard_sidman@hms.harvard.edu; yang_teng@hms.harvard.edu	Zeng, Xiang/AAB-6565-2020; Aljuboori, Zaid/AAV-3251-2020; Wang, Hongjun/AAJ-3852-2020; Aljuboori, Zaid/F-2132-2017	Zeng, Xiang/0000-0003-4577-749X; Aljuboori, Zaid/0000-0002-3278-4749; Aljuboori, Zaid/0000-0002-3278-4749	United States Department of Veterans Affairs Rehabilitation Research and Development Grant [1-I01-RX000308-01A1]; Center for the Advancement of Science in Space; National Aeronautics and Space Administration Grant [GA-2015-222]; Cele H. and William B. Rubin Family Fund, Inc. Grant for the Gordon Program; Veterans AffairsUS Department of Veterans Affairs [I01RX000308] Funding Source: NIH RePORTER	Support for this work was provided by United States Department of Veterans Affairs Rehabilitation Research and Development Grant 1-I01-RX000308-01A1, Center for the Advancement of Science in Space and National Aeronautics and Space Administration Grant GA-2015-222, CIMT-DoD Grant (to Y.D.T.), and a Cele H. and William B. Rubin Family Fund, Inc. Grant for the Gordon Program (to Y.D.T. and R.D.Z.).	Alexanian AR, 2010, RESTOR NEUROL NEUROS, V28, P761, DOI 10.3233/RNN-2010-0547; Angeli CA, 2014, BRAIN, V137, P1394, DOI 10.1093/brain/awu038; Assi R, 2016, REGEN MED, V11, P245, DOI 10.2217/rme-2015-0045; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Cantinieaux D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069515; Chastain EML, 2012, IMMUNOL REV, V245, P227, DOI 10.1111/j.1600-065X.2011.01076.x; Committee on Care and Use of Laboratory Animals, 1996, DHHS PUBL, V85-23; Connick P, 2012, LANCET NEUROL, V11, P150, DOI 10.1016/S1474-4422(11)70305-2; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; Cusimano M, 2012, BRAIN, V135, P447, DOI 10.1093/brain/awr339; David S, 2012, INT REV NEUROBIOL, V106, P127, DOI 10.1016/B978-0-12-407178-0.00006-5; DePaul MA, 2015, SCI REP-UK, V5, DOI 10.1038/srep16795; Du Beau A, 2012, NEUROSCIENCE, V227, P67, DOI 10.1016/j.neuroscience.2012.09.037; Egusa H, 2007, TISSUE ENG, V13, P2589, DOI 10.1089/ten.2007.0080; Finnerup NB, 2014, J PAIN, V15, P40, DOI 10.1016/j.jpain.2013.09.008; Flynn JR, 2011, NEUROPHARMACOLOGY, V60, P809, DOI 10.1016/j.neuropharm.2011.01.016; Francois M, 2012, MOL THER, V20, P187, DOI 10.1038/mt.2011.189; Fukuhara K, 2013, CELL REP, V5, P748, DOI 10.1016/j.celrep.2013.10.005; Grayson ACR, 2005, BIOMATERIALS, V26, P2137, DOI 10.1016/j.biomaterials.2004.06.033; Griffin MD, 2013, STEM CELLS, V31, P2033, DOI 10.1002/stem.1452; Grillner S, 2016, CURR BIOL, V25, pR490; Haragopal H, 2015, CELL TRANSPLANT, V24, P645, DOI 10.3727/096368915X687561; Henrique D, 2015, DEVELOPMENT, V142, P2864, DOI 10.1242/dev.119768; Jaderstad J, 2010, P NATL ACAD SCI USA, V107, P5184, DOI 10.1073/pnas.0915134107; Jarocha D, 2015, CELL TRANSPLANT, V24, P661, DOI 10.3727/096368915X687796; Jarocha D, 2014, STEM CELL TRANSL MED, V3, P395, DOI 10.5966/sctm.2013-0141; Kawai R, 2015, NEURON, V86, P800, DOI 10.1016/j.neuron.2015.03.024; Kazanis I, 2010, J NEUROSCI, V30, P9771, DOI 10.1523/JNEUROSCI.0700-10.2010; Kondo S, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-27; Konya D, 2008, REGEN MED, V3, P309, DOI 10.2217/17460751.3.3.309; Kumar AA, 2009, EXP CLIN TRANSPLANT, V7, P241; Kwon BK, 2011, J NEUROTRAUM, V28, P1589, DOI 10.1089/neu.2009.1150; Lavik Erin, 2002, Methods Mol Biol, V198, P89; Lee KD, 2009, J NEUROTRAUM, V26, P2335, DOI 10.1089/neu.2008.0840; Lennon DP, 2012, STEM CELL TRANSL MED, V1, P279, DOI 10.5966/sctm.2011-0011; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pritchard CD, 2010, J NEUROSCI METH, V188, P258, DOI 10.1016/j.jneumeth.2010.02.019; Prockop DJ, 2013, STEM CELLS, V31, P2042, DOI 10.1002/stem.1400; Quertainmont R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039500; Ren GW, 2009, STEM CELLS, V27, P1954, DOI 10.1002/stem.118; Ribeiro TB, 2015, SCI REP-UK, V5, DOI 10.1038/srep16167; Rosenberg LJ, 1999, J NEUROSCI, V19, P464, DOI 10.1523/JNEUROSCI.19-01-00464.1999; Sabelstrom H, 2013, SCIENCE, V342, P637, DOI 10.1126/science.1242576; Saito F, 2012, RESTOR NEUROL NEUROS, V30, P127, DOI 10.3233/RNN-2011-0629; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; Schwab JM, 2014, EXP NEUROL, V258, P121, DOI 10.1016/j.expneurol.2014.04.023; Scruggs BA, 2013, STEM CELLS, V31, P1523, DOI 10.1002/stem.1397; Snyder EY, 2012, NEW ENGL J MED, V366, P1940, DOI 10.1056/NEJMcibr1200138; Tan AM, 2012, J NEUROSCI, V32, P12896, DOI 10.1523/JNEUROSCI.6451-11.2012; Teng YD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004579; Teng YD, 2011, CURR NEUROPHARMACOL, V9, P574, DOI 10.2174/157015911798376299; Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Tester NJ, 2011, SPINAL CORD, V49, P451, DOI 10.1038/sc.2010.128; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Yang C, 2014, NAT MATER, V13, P645, DOI [10.1038/nmat3889, 10.1038/NMAT3889]; Yu D, 2013, P NATL ACAD SCI USA, V110, pE746, DOI 10.1073/pnas.1300083110; Yu D, 2009, STEM CELLS, V27, P1212, DOI 10.1002/stem.26	61	51	53	0	23	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 31	2017	114	5					E820	E829		10.1073/pnas.1616340114			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ4OI	WOS:000393196300020	28096400	Bronze, Green Published			2022-02-06	
J	Grabowski, P; Wilson, J; Walker, A; Enz, D; Wang, SJ				Grabowski, Patrick; Wilson, John; Walker, Alyssa; Enz, Dan; Wang, Sijian			Multimodal impairment-based physical therapy for the treatment of patients with post-concussion syndrome: A retrospective analysis on safety and feasibility	PHYSICAL THERAPY IN SPORT			English	Article						Concussion; Mild traumatic brain injury; Physical therapy; Cardiovascular exercise	SPORT-RELATED CONCUSSION; PREDICT PROTRACTED RECOVERY; TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; EXERCISE; REHABILITATION; SYMPTOMS; EPIDEMIOLOGY; METABOLISM; INACTIVITY	Objective: Demonstrate implementation, safety and feasibility of multimodal, impairment-based physical therapy (PT) combining vestibular/oculomotor and cervical rehabilitation with sub-symptom threshold exercise for the treatment of patients with post-concussion syndrome (PCS). Setting: University hospital outpatient sports medicine facility. Participants: Twenty-five patients (12-20 years old) meeting World Health Organization criteria for PCS following sport-related concussion referred for supervised PT consisting of sub-symptom cardiovascular exercise, vestibular/oculomotor and cervical spine rehabilitation. Design: Retrospective cohort. Main measures: Post-Concussion Symptom Scale (PCSS) total score, maximum symptom-free heart rate (SFHR) during graded exercise testing (GXT), GXT duration, balance error scoring system (BESS) score, and number of adverse events. Results: Patients demonstrated a statistically significant decreasing trend (p < 0.01) for total PCSS scores (pre-PT M = 18.2 (SD = 14.2), post -PT M = 9.1 (SD = 10.8), n = 25). Maximum SFHR achieved on GXT increased 23% (p < 0.01, n = 14), and BESS errors decreased 52% (p<0.01, n = 13). Two patients reported mild symptom exacerbation with aerobic exercise at home, attenuated by adjustment of the home exercise program. Conclusions: Multimodal, impairment-based PT is safe and associated with diminishing PCS symptoms. This establishes feasibility for future clinical trials to determine viable treatment approaches to reduce symptoms and improve function while avoiding negative repercussions of physical inactivity and premature return to full activity. (C) 2016 Elsevier Ltd. All rights reserved.	[Grabowski, Patrick; Enz, Dan] Univ Wisconsin Hosp & Clin, 621 Sci Dr, Madison, WI 53711 USA; [Grabowski, Patrick] Univ Wisconsin, Phys Therapy Program, 1725 State St, La Crosse, WI 54601 USA; [Wilson, John; Walker, Alyssa] Univ Wisconsin, Sch Med & Publ Hlth, 1685 Highland Ave, Madison, WI 53705 USA; [Wang, Sijian] Univ Wisconsin, Dept Biostat, 600 Highland Ave, Madison, WI 53705 USA		Grabowski, P (corresponding author), Univ Wisconsin, Phys Therapy Program, 1725 State St, La Crosse, WI 54601 USA.	pgrabowski@uwlax.edu			Herman and Gwendolyn Shapiro Foundation	Author AW was supported by a research grant from the Herman and Gwendolyn Shapiro Foundation. The foundation had no role in the study.	Alosco ML, 2012, HEALTH PSYCHOL, V31, P754, DOI 10.1037/a0028711; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Ariza-Garcia A, 2013, EUR J CANCER CARE, V22, P738, DOI 10.1111/ecc.12101; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Barnett AG, 2005, INT J EPIDEMIOL, V34, P215, DOI 10.1093/ije/dyh299; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bogdanis GC, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00142; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Browne GJ, 2006, BRIT J SPORT MED, V40, P68, DOI 10.1136/bjsm.2005.020636; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Childs JD, 2008, J ORTHOP SPORT PHYS, V38, pA1, DOI 10.2519/jospt.2008.0303; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Davies R, 2005, BRAIN INJURY, V19, P941, DOI 10.1080/02699050400000565; Ding QX, 2006, EUR J NEUROSCI, V24, P1265, DOI 10.1111/j.1460-9568.2006.05026.x; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; McDonnell MN, 2013, J APPL PHYSIOL, V114, P1174, DOI 10.1152/japplphysiol.01378.2012; McLeod TCV, 2012, J ATHL TRAINING, V47, P221; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Nishijima T, 2013, BEHAV BRAIN RES, V245, P34, DOI 10.1016/j.bbr.2013.02.009; Page P, 2011, INT J SPORTS PHYS TH, V6, P254; Reddy CC, 2011, PM&R, V3, pS396, DOI 10.1016/j.pmrj.2011.07.012; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Rose SC, 2015, BRAIN INJURY, V29, P798, DOI 10.3109/02699052.2015.1004756; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Seifert T, 2011, PROG NEUROBIOL, V95, P406, DOI 10.1016/j.pneurobio.2011.09.008; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Zhang PY, 2013, INT J MOL SCI, V14, P6074, DOI 10.3390/ijms14036074	59	51	51	1	27	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1466-853X			PHYS THER SPORT	Phys. Ther. Sport	JAN	2017	23						22	30		10.1016/j.ptsp.2016.06.001			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	EJ5ML	WOS:000393262200004	27665247				2022-02-06	
J	Kratz, AL; Sander, AM; Brickell, TA; Lange, RT; Carlozzi, NE				Kratz, Anna L.; Sander, Angelle M.; Brickell, Tracey A.; Lange, Rael T.; Carlozzi, Noelle E.			Traumatic brain injury caregivers: A qualitative analysis of spouse and parent perspectives on quality of life	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Caregiver; Quality of life	FAMILY INTERVENTION; REHABILITATION; BURDEN; INDIVIDUALS; ADJUSTMENT; OUTCOMES; HEALTH; IMPACT; NEEDS; TBI	The objective of this qualitative study was to examine how family caregivers of individuals with traumatic brain injury (TBI) describe their quality of life in the context of their caregiving role. Fifty-two caregivers of adults with moderate or severe TBI (n = 31 parents, n = 21 partners/spouses; 77% female; mean age = 57.96 years, range = 34-78 years) were recruited from three data collection sites to participate in focus groups. Thematic content analysis was used to identify two main meta-themes: Caregiver Role Demands and Changes in Person with TBI. Prominent sub-themes indicated that caregivers are (1) overburdened with responsibilities, (2) lack personal time and time for self-care, (3) feel that their life is interrupted or lost, (4) grieve the loss of the person with TBI, and (5) endorse anger, guilt, anxiety, and sadness. Caregivers identified a number of service needs. A number of sub-themes were perceived differently by partner versus parent caregivers. The day-to-day responsibilities of being a caregiver as well as the changes in the person with the TBI present a variety of challenges and sources of distress for caregivers. Although services that address instrumental as well as emotional needs of caregivers may benefit caregivers in general, the service needs of parent and partner caregivers may differ.	[Kratz, Anna L.; Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Sander, Angelle M.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle M.] TIRR Mem Hermanns Brain Injury Res Ctr, Houston, TX USA; [Sander, Angelle M.] Harris Hlth Syst, Dept Phys Med & Rehabil, Houston, TX USA; [Brickell, Tracey A.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Brickell, Tracey A.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada		Kratz, AL (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	alkratz@med.umich.edu			National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [1R01-NR013658-01]; National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [1K01AR064275]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K01AR064275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER	This study was funded by the National Institute of Nursing Research [grant number 1R01-NR013658-01]. During manuscript development, Dr. Kratz was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases [grant number 1K01AR064275].	ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; Averill JB, 2002, QUAL HEALTH RES, V12, P855, DOI 10.1177/104973230201200611; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; Carson P, 1993, J Neurosci Nurs, V25, P165; Catanzaro M., 1988, NURSING RES THEORY P, P437; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; Chwalisz K, 2008, REHABIL PSYCHOL, V53, P387, DOI 10.1037/a0012998; Denzin N.K., 2003, STRATEGIES QUALITATI; Denzin N.K., 2000, HDB QUALITATIVE RES; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Gill CJ, 2011, J HEAD TRAUMA REHAB, V26, P56, DOI 10.1097/HTR.0b013e3182048ee9; Glaser B., 1967, DISCOVERY GROUNDED T; Godwin E, 2014, BRAIN INJURY, V28, P398, DOI 10.3109/02699052.2014.880514; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Hammond FM, 2011, J HEAD TRAUMA REHAB, V26, P69, DOI 10.1097/HTR.0b013e318205174d; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Johnson B P, 1995, J Neurosci Nurs, V27, P113; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Lincoln Yvonna S., 1985, NATURALISTIC INQUIRY; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Miles M., 2020, QUALITATIVE DATA ANA, V4th ed.; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; QSR International Pty Ltd, 2012, NVIVO QUAL DAT AN SO; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Sander A. M., 2005, BRAIN INJURY MED, P1117; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 2012, ARCH PHYS MED REHAB, V93, P842, DOI 10.1016/j.apmr.2011.11.031; Smith A M, 1998, Rehabil Nurs, V23, P252; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; Traumatic Brain Injury Model Systems National Data Center, 2006, TRAUM BRAIN INJ MOD; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x	47	51	51	0	30	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2017	27	1					16	37		10.1080/09602011.2015.1051056			22	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	EB0SL	WOS:000387055700003	26052805	Green Accepted			2022-02-06	
J	Reid, AY; Bragin, A; Giza, CC; Staba, RJ; Engel, J				Reid, Aylin Y.; Bragin, Anatol; Giza, Christopher C.; Staba, Richard J.; Engel, Jerome, Jr.			The progression of electrophysiologic abnormalities during epileptogenesis after experimental traumatic brain injury	EPILEPSIA			English	Article						Lateral fluid percussion injury; Seizure; Electroencephalography; Posttraumatic epilepsy; Biomarker	FLUID PERCUSSION INJURY; SPIKE-WAVE DISCHARGES; SPRAGUE-DAWLEY RATS; POSTTRAUMATIC EPILEPSY; ANIMAL-MODELS; SEIZURE; HIPPOCAMPAL; SEVERITY	Objective: Posttraumatic epilepsy (PTE) accounts for 20% of acquired epilepsies. Experimental models are important for studying epileptogenesis. We previously reported that repetitive high-frequency oscillations with spikes (rHFOSs) occur early after lateral fluid percussion injury (FPI) and may be a biomarker for PTE. The objective of this study was to use multiple electrodes in rat hippocampal and neocortical regions to describe the long-term electroencephalographic and behavioral evolution of rHFOSs and epileptic seizures after traumatic brain injury (TBI). Methods: Adult male rats underwent mild, moderate, or severe FPI or sham injury followed by video-electroencephalography (EEG) recordings with a combination of 16 neocortical and hippocampal electrodes at an early, intermediate, or late time-point after injury, up to 52 weeks. Recordings were analyzed for the presence of rHFOSs and seizures. Results: Analysis was done on 28 rats with FPI and 7 shams. Perilesional rHFOSs were recorded in significantly more rats after severe (70.3%) than mild (20%) injury or shams (14.3%). Frequency of occurrence was significantly highest in the early (10.8/h) versus late group (3.2/h). Late focal seizures originating from the same electrodes were recorded in significantly more rats in the late (87.5%) versus early period (22.2%), occurring almost exclusively in injured rats. Seizure duration increased significantly over time, averaging 19 s at the beginning of the early period and 27 s at the end of the late period. Seizure frequency also increased significantly over time, from 4.4 per week in the early group to 26.4 per week in the late group. Rarely, rats displayed early seizures or generalized seizures. Significance: FPI results in early rHFOSs and later spontaneous focal seizures arising from peri-lesional neocortex, supporting its use as a model for PTE. Epilepsy severity increased over time and was related to injury severity. The association between early rHFOSs and later focal seizures suggests that rHFOSs may be a potential noninvasive biomarker of PTE.	[Reid, Aylin Y.; Bragin, Anatol; Staba, Richard J.; Engel, Jerome, Jr.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Dept Neurosurg & Pediat Neurol, Los Angeles, CA USA; [Giza, Christopher C.; Engel, Jerome, Jr.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp UCLA, Los Angeles, CA USA; [Engel, Jerome, Jr.] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA USA; [Engel, Jerome, Jr.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA		Reid, AY (corresponding author), Univ Hlth Network, Div Neurol, 399 Bathurst St,Off 5W-438, Toronto, ON M5G 1P7, Canada.	aylin.reid@utoronto.ca	Staba, Richard/AAN-3149-2021	Bragin, Anatol/0000-0003-1207-8481; Reid, Aylin Yasmin/0000-0001-6855-9669	Alberta Innovates-Health Solutions; UCLA BIRC [NS05489, NS027544, NS057420]; Child Neurology Foundation/Winokur Family Foundation; Today's and Tomorrow's Children Fund; Thrasher Research Foundation; Citizens United for Research in Epilepsy;  [NS065877];  [NS071048];  [NS033310];  [NS080181]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS033310, K02NS057420, R01NS065877, R01NS027544, R01NS033310, R01NS071048, P20NS080181] Funding Source: NIH RePORTER	The authors would like to thank Mr. Joyel Almajano and Ms. Yan Cai for their technical support. AYR was supported by a Clinical Fellowship award from Alberta Innovates-Health Solutions. AB was supported by NS065877. CCG was supported by UCLA BIRC, NS05489, NS027544, NS057420, Child Neurology Foundation/Winokur Family Foundation, Today's and Tomorrow's Children Fund, and the Thrasher Research Foundation. RJS was supported by NS071048 and Citizens United for Research in Epilepsy. JE was supported by NS033310 and NS080181.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V110, P421; Bolkadze T, 2012, J NEUROTRAUM, V20, P789; Bragin A, 2016, EPILEPSIA, V57, P735, DOI 10.1111/epi.13359; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dudek FE, 2010, EPILEPSY CURR, V10, P91, DOI 10.1111/j.1535-7511.2010.01368.x; Eastman CL, 2015, EXP NEUROL, V264, P150, DOI 10.1016/j.expneurol.2014.12.010; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Langer M, 2011, NEUROPHARMACOLOGY, V61, P1033, DOI 10.1016/j.neuropharm.2011.06.015; LERNERNATOLI M, 1984, EXP NEUROL, V83, P1, DOI 10.1016/0014-4886(84)90040-2; Loscher W, 2015, EPILEPSY BEHAV, V52, P78, DOI 10.1016/j.yebeh.2015.08.037; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Pearce PS, 2014, EPILEPSY BEHAV, V32, P121, DOI 10.1016/j.yebeh.2014.01.004; Prins ML, 2006, BRAIN RES DEV BRAIN, V95, P272; Rakhade SN, 2011, EPILEPSIA, V52, P753, DOI 10.1111/j.1528-1167.2011.02992.x; Rodgers KM, 2015, J NEUROSCI, V35, P9194, DOI 10.1523/JNEUROSCI.0919-15.2015; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; White HS, 2002, NEUROLOGY, V59, pS7, DOI 10.1212/WNL.59.9_suppl_5.S7; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	28	51	51	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	OCT	2016	57	10					1558	1567		10.1111/epi.13486			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EB8QV	WOS:000387656800005	27495360	Green Submitted, Green Accepted			2022-02-06	
J	Dickstein, DL; Pullman, MY; Fernandez, C; Short, JA; Kostakoglu, L; Knesaurek, K; Soleimani, L; Jordan, BD; Gordon, WA; Dams-O'Connor, K; Delman, BN; Wong, E; Tang, CY; DeKosky, ST; Stone, JR; Cantu, RC; Sano, M; Hof, PR; Gandy, S				Dickstein, D. L.; Pullman, M. Y.; Fernandez, C.; Short, J. A.; Kostakoglu, L.; Knesaurek, K.; Soleimani, L.; Jordan, B. D.; Gordon, W. A.; Dams-O'Connor, K.; Delman, B. N.; Wong, E.; Tang, C. Y.; DeKosky, S. T.; Stone, J. R.; Cantu, R. C.; Sano, M.; Hof, P. R.; Gandy, S.			Cerebral [F-18]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy	TRANSLATIONAL PSYCHIATRY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; POSITRON-EMISSION-TOMOGRAPHY; BRAIN-INJURY; ALZHEIMERS-DISEASE; BASAL GANGLIA; BINDING CHARACTERISTICS; BROCAS AREA; PET; FLORBETAPIR; ROBUST	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disorder most commonly associated with repetitive traumatic brain injury (TBI) and characterized by the presence of neurofibrillary tangles of tau protein, known as a tauopathy. Currently, the diagnosis of CTE can only be definitively established postmortem. However, a new positron emission tomography (PET) ligand, [F-18] T807/AV1451, may provide the antemortem detection of tau aggregates, and thus various tauopathies, including CTE. Our goal was to examine [F-18] T807/AV1451 retention in athletes with neuropsychiatric symptoms associated with a history of multiple concussions. Here we report a 39-year-old retired National Football League player who suffered 22 concussions and manifested progressive neuropsychiatric symptoms. Emotional lability and irritability were the chief complaints. Serial neuropsychological exams revealed a decline in executive functioning, processing speed and fine motor skills. Naming was below average but other cognitive functions were preserved. Structural analysis of longitudinally acquired magenetic resonance imaging scans revealed cortical thinning in the left frontal and lateral temporal areas, as well as volume loss in the basal ganglia. PET with [F-18] florbetapir was negative for amyloidosis. The [F-18] T807/AV1451 PET showed multifocal areas of retention at the cortical gray matter-white matter junction, a distribution considered pathognomonic for CTE. [F-18] T807/AV1451 standard uptake value (SUV) analysis showed increased uptake (SUVr >= 1.1) in bilateral cingulate, occipital, and orbitofrontal cortices, and several temporal areas. Although definitive identification of the neuropathological underpinnings basis for [F-18] T807/AV1451 retention requires postmortem correlation, our data suggest that [F-18] T807/AV1451 tauopathy imaging may be a promising tool to detect and diagnose CTE-related tauopathy in living subjects.	[Dickstein, D. L.; Pullman, M. Y.; Hof, P. R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, One Gustave L Levy Pl, New York, NY 10029 USA; [Dickstein, D. L.; Pullman, M. Y.; Hof, P. R.; Gandy, S.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Fernandez, C.; Short, J. A.; Soleimani, L.; Wong, E.; Tang, C. Y.; Sano, M.; Gandy, S.] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA; [Kostakoglu, L.; Knesaurek, K.] Icahn Sch Med Mt Sinai, Dept Nucl Med, New York, NY 10029 USA; [Jordan, B. D.] Burke Rehabilitaiton Hosp, White Plains, NY USA; [Gordon, W. A.; Dams-O'Connor, K.] Icahn Sch Med Mt Sinai, NFL Neurol Program, New York, NY 10029 USA; [Gordon, W. A.; Dams-O'Connor, K.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Delman, B. N.; Wong, E.; Tang, C. Y.] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA; [DeKosky, S. T.] Univ Florida, Dept Neurol, Gainesville, FL USA; [Stone, J. R.] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA; [Stone, J. R.] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA; [Cantu, R. C.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Cantu, R. C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Gandy, S.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA		Dickstein, DL (corresponding author), Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, One Gustave L Levy Pl, New York, NY 10029 USA.; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA.	dickstein@mssm.edu; samuel.gandy@mssm.edu	Dickstein, Dara/AAH-6603-2020	DeKosky, Steven/0000-0003-3743-2758; Fernandez, Corey/0000-0003-3901-5552; Delman, Bradley/0000-0002-9792-8942	Alzheimer's Disease Drug Foundation; NIH grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS 5U01NS086625, NICHD K01HD074651-01A]; Werber Family Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086625] Funding Source: NIH RePORTER	We extend our gratitude to the patient who consented for this investigation. The ligands for both amyloid and tau were a generous gift from Avid Radiopharmaceutical (Philadelphia, PA, USA). This research was supported by a grant from the Alzheimer's Disease Drug Foundation (SG and DLD) and by the NIH grants NINDS 5U01NS086625 (WG and KDO) and NICHD K01HD074651-01A (KDO). The Werber Family Foundation provided additional support.	Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Camus V, 2012, EUR J NUCL MED MOL I, V39, P621, DOI 10.1007/s00259-011-2021-8; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Clark CM, 2012, LANCET NEUROL, V11, P669, DOI 10.1016/S1474-4422(12)70142-4; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; Crosson B, 2003, J INT NEUROPSYCH SOC, V9, P1061, DOI 10.1017/S135561770397010X; Dams-O'Connor K, 2014, J HEAD TRAUMA REHAB, V29, P479, DOI 10.1097/HTR.0000000000000099; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dickerson B, 2014, NEUROLOGY SS8, V10; Fleisher AS, 2011, ARCH NEUROL-CHICAGO, V68, P1404, DOI 10.1001/archneurol.2011.150; Gandy Sam, 2014, F1000Res, V3, P229, DOI 10.12688/f1000research.5372.1; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Goswami R, 2016, BRAIN STRUCT FUNCT, V221, P1911, DOI 10.1007/s00429-015-1012-0; Harada R, 2013, EUR J NUCL MED MOL I, V40, P125, DOI 10.1007/s00259-012-2261-2; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Johnson KA, 2016, ANN NEUROL, V79, P110, DOI 10.1002/ana.24546; Keightley M., 2014, ARCH PHYS MED REHAB, V95, pe68; Kelly JP, 1997, NEUROLOGY, V48, P581; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Lenihan MW, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0541-5; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marquie M, 2015, ANN NEUROL, V78, P787, DOI 10.1002/ana.24517; Martland H., 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2016, JAMA NEUROL, V73, P353, DOI 10.1001/jamaneurol.2015.3998; Millspaugh JA, 1937, US NAVAL MED B, V35, P297; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Monchi O, 2006, ANN NEUROL, V59, P257, DOI 10.1002/ana.20742; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nordberg A, 2013, EUR J NUCL MED MOL I, V40, P104, DOI 10.1007/s00259-012-2237-2; Okamura N, 2016, AGEING RES REV; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Papa L, 2015, BRAIN NEUROTRAUMA MO, DOI [DOI 10.1201/B18126-27, 10.1201/b18126-27]; Rabinovici G, 2015, NEUROLOGY S, V84; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Schuhmann T, 2009, CORTEX, V45, P1111, DOI 10.1016/j.cortex.2008.10.013; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Tateno A, 2015, INT J GERIATR PSYCH, V30, P505, DOI 10.1002/gps.4173; Thompson PW, 2009, J NEUROCHEM, V109, P623, DOI 10.1111/j.1471-4159.2009.05996.x; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Ullman MT, 2006, CORTEX, V42, P480, DOI 10.1016/S0010-9452(08)70382-4; Villemagne VL, 2016, CURR OPIN NEUROBIOL, V36, P43, DOI 10.1016/j.conb.2015.09.002; Wilde EA, 2015, BRAIN IMAGING BEHAV, V9, P367, DOI 10.1007/s11682-015-9444-y; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Zimmer ER, 2014, CAN J NEUROL SCI, V41, P547, DOI 10.1017/cjn.2014.15	59	51	52	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	SEP 27	2016	6								e900	10.1038/tp.2016.175			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Psychiatry	EH9YA	WOS:000392126800001	27676441	gold, Green Published			2022-02-06	
J	Haider, HA; Esteller, R; Hahn, CD; Westover, MB; Halford, JJ; Lee, JW; Shafi, MM; Gaspard, N; Herman, ST; Gerard, EE; Hirsch, LJ; Ehrenberg, JA; LaRoche, SM				Haider, Hiba A.; Esteller, Rosana; Hahn, Cecil D.; Westover, M. Brandon; Halford, Jonathan J.; Lee, Jong W.; Shafi, Mouhsin M.; Gaspard, Nicolas; Herman, Susan T.; Gerard, Elizabeth E.; Hirsch, Lawrence J.; Ehrenberg, Joshua A.; LaRoche, Suzette M.		Critical Care EEG Monitoring Res	Sensitivity of quantitative EEG for seizure identification in the intensive care unit	NEUROLOGY			English	Article							AMPLITUDE-INTEGRATED ELECTROENCEPHALOGRAPHY; NONCONVULSIVE STATUS EPILEPTICUS; CEREBRAL FUNCTION MONITOR; CRITICALLY-ILL CHILDREN; DENSITY SPECTRAL ARRAY; TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; TERMINOLOGY; CRITERIA; ADULTS	Objective: To evaluate the sensitivity of quantitative EEG (QEEG) for electrographic seizure identification in the intensive care unit (ICU). Methods: Six-hour EEG epochs chosen from 15 patients underwent transformation into QEEG displays. Each epoch was reviewed in 3 formats: raw EEG, QEEG + raw, and QEEG-only. Epochs were also analyzed by a proprietary seizure detection algorithm. Nine neurophysiologists reviewed raw EEGs to identify seizures to serve as the gold standard. Nine other neurophysiologists with experience in QEEG evaluated the epochs in QEEG formats, with and without concomitant raw EEG. Sensitivity and false-positive rates (FPRs) for seizure identification were calculated and median review time assessed. Results: Mean sensitivity for seizure identification ranged from 51% to 67% for QEEG-only and 63%-68% for QEEG + raw. FPRs averaged 1/h for QEEG-only and 0.5/h for QEEG + raw. Mean sensitivity of seizure probability software was 26.2%-26.7%, with FPR of 0.07/h. Epochs with the highest sensitivities contained frequent, intermittent seizures. Lower sensitivities were seen with slow-frequency, low-amplitude seizures and epochs with rhythmic or periodic patterns. Median review times were shorter for QEEG (6 minutes) and QEEG + raw analysis (14.5 minutes) vs raw EEG (19 minutes; p = 0.00003). Conclusions: A panel of QEEG trends can be used by experts to shorten EEG review time for seizure identification with reasonable sensitivity and low FPRs. The prevalence of false detections confirms that raw EEG review must be used in conjunction with QEEG. Studies are needed to identify optimal QEEG trend configurations and the utility of QEEG as a screening tool for non-EEG personnel. Classification of evidence review: This study provides Class II evidence that QEEG + raw interpreted by experts identifies seizures in patients in the ICU with a sensitivity of 63%-68% and FPR of 0.5 seizures per hour.	[Haider, Hiba A.; Ehrenberg, Joshua A.; LaRoche, Suzette M.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Esteller, Rosana] Neuropace Inc, Mountain View, CA USA; [Hahn, Cecil D.] Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; [Westover, M. Brandon] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA; [Halford, Jonathan J.] Med Univ South Carolina, Dept Neurol, Charleston, SC USA; [Lee, Jong W.; Shafi, Mouhsin M.; Herman, Susan T.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA; [Gaspard, Nicolas] Univ Libre Bruxelles, Brussels, Belgium; [Gerard, Elizabeth E.] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Chicago, IL 60611 USA; [Hirsch, Lawrence J.] Yale Univ Hosp, New Haven, CT USA		Haider, HA (corresponding author), Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.	hiba.arif@emory.edu	Hahn, Cecil/J-3372-2016; Hahn, Cecil D./F-6218-2011; Lee, Jongwoo/AAI-3617-2020	Hahn, Cecil/0000-0002-0887-8761; Hahn, Cecil D./0000-0002-0887-8761; Lee, Jongwoo/0000-0001-5283-7476; Hyslop, Ann/0000-0002-2971-7131; Halford, Jonathan/0000-0003-1681-6744; gerard, elizabeth/0000-0003-3062-8360; Haider, Hiba/0000-0001-7118-3690; Hirsch, Lawrence/0000-0002-6333-832X; Herman, Susan/0000-0002-6556-083X; Wusthoff, Courtney/0000-0002-1882-5567	NINDS R25 Research Education Training Grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS090900] Funding Source: NIH RePORTER	H. Haider: Supported by an NINDS R25 Research Education Training Grant. R. Esteller, C. Hahn, M. Westover, J. Halford, J. Lee, M. Shafi, N. Gaspard, S. Herman, E. Gerard, L. Hirsch, J. Ehrenberg, and S. LaRoche report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.	Abend NS, 2008, EPILEPSIA, V49, P349, DOI 10.1111/j.1528-1167.2007.01425.x; Akman CI, 2011, EPILEPSY RES, V93, P66, DOI 10.1016/j.eplepsyres.2010.10.018; Beniczky S, 2013, EPILEPSIA, V54, P28, DOI 10.1111/epi.12270; Bourez-Swart MD, 2009, CLIN NEUROPHYSIOL, V120, P1916, DOI 10.1016/j.clinph.2009.08.015; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; El-Dib M, 2009, PEDIATR NEUROL, V41, P315, DOI 10.1016/j.pediatrneurol.2009.05.002; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Gaspard N, 2014, EPILEPSIA, V55, P1366, DOI 10.1111/epi.12653; Halford JJ, 2015, CLIN NEUROPHYSIOL, V126, P1661, DOI 10.1016/j.clinph.2014.11.008; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P96, DOI 10.1097/WNP.0000000000000165; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Husain AM, 2013, 4 LOND INNSBR C STAT; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Kaplan PW, 2007, EPILEPSIA, V48, P39, DOI 10.1111/j.1528-1167.2007.01345.x; LOWENSTEIN DH, 1993, NEUROLOGY, V43, P483, DOI 10.1212/WNL.43.3_Part_1.483; Mazarati AM, 1998, BRAIN RES, V814, P179, DOI 10.1016/S0006-8993(98)01080-4; Moura LMVR, 2014, NEUROLOGY, V83, P56, DOI 10.1212/WNL.0000000000000537; Nitzschke R, 2011, J CLIN MONIT COMPUT, V25, P329, DOI 10.1007/s10877-011-9312-2; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Pensirikul AD, 2013, J CLIN NEUROPHYSIOL, V30, P371, DOI 10.1097/WNP.0b013e31829de01c; Rennie JM, 2004, ARCH DIS CHILD-FETAL, V89, pF37, DOI 10.1136/fn.89.1.F37; Ronner HE, 2009, SEIZURE-EUR J EPILEP, V18, P257, DOI 10.1016/j.seizure.2008.10.010; Shah DK, 2008, PEDIATRICS, V122, P863, DOI 10.1542/peds.2008-1000; Shellhaas RA, 2007, PEDIATRICS, V120, P770, DOI 10.1542/peds.2007-0514; Stewart CP, 2010, NEUROLOGY, V75, P1501, DOI 10.1212/WNL.0b013e3181f9619e; Toet MC, 2002, PEDIATRICS, V109, P772, DOI 10.1542/peds.109.5.772; Topjian AA, 2015, PEDIATR CRIT CARE ME, V16, P461, DOI 10.1097/PCC.0000000000000352; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Williamson CA, 2014, NEUROCRIT CARE, V20, P32, DOI 10.1007/s12028-013-9912-4	33	51	51	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG 30	2016	87	9					935	944		10.1212/WNL.0000000000003034			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DW9LJ	WOS:000383980600020	27466474	Green Published			2022-02-06	
J	Matuszak, JM; McVige, J; McPherson, J; Willer, B; Leddy, J				Matuszak, Jason M.; McVige, Jennifer; McPherson, Jacob; Willer, Barry; Leddy, John			A Practical Concussion Physical Examination Toolbox: Evidence-Based Physical Examination for Concussion	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						concussion; mTBI; physical examination	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; POSTCONCUSSION SYNDROME; VESTIBULAR REHABILITATION; POSTTRAUMATIC-STRESS; KING-DEVICK; HEAD-INJURY; BALANCE; DEPRESSION; DIZZINESS	Context: With heightened awareness of concussion, there is a need to assess and manage the concussed patient in a consistent manner. Unfortunately, concussion physical examination has not been standardized or supported by evidence. Important questions remain about the physical examination. Evidence Acquisition: Review of ClinicalKey, Cochrane, MEDLINE, and PubMed prior to July 2015 was performed using search terms, including concussion, mTBI, physical examination, mental status, cranial nerves, reflexes, cervical, vestibular, and oculomotor. The references of the pertinent articles were reviewed for other relevant sources. Study Design: Clinical review. Level of Evidence: Level 3. Results: The pertinent physical examination elements for concussion include evaluation of cranial nerves, manual muscle testing, and deep tendon reflexes; inspecting the head and neck for trauma or tenderness and cervical range of motion; Spurling maneuver; a static or dynamic balance assessment; screening ocular examination; and a mental status examination that includes orientation, immediate and delayed recall, concentration, mood, affect, insight, and judgment. Other examination elements to consider, based on signs, symptoms, or clinical suspicion, include testing of upper motor neurons, cervical strength and proprioception, coordination, pupillary reactivity, and visual acuity; examination of the jaw, temporomandibular joint, and thoracic spine; fundoscopic evaluation; orthostatic vital signs; assessment of dynamic visual acuity; and screening for depression, anxiety, substance abuse disorders, and preinjury psychiatric difficulties. Conclusion: Various elements of the physical examination, such as screening ocular examination, cervical musculoskeletal examination, static and/or dynamic balance assessment, and mental status examination, appear to have utility for evaluating concussion; however, data on validity are lacking.	[Matuszak, Jason M.] Excelsior Orthopaed, Amherst, NY USA; [McVige, Jennifer] Dent Neurol, Amherst, NY USA; [McPherson, Jacob] Susan Bennett Phys Therapy, North Tonawanda, NY USA; [Willer, Barry; Leddy, John] Univ Buffalo, Jacobs Sch Med, UBMD Orthopaed & Sports Med, Buffalo, NY USA		Matuszak, JM (corresponding author), Excelsior Orthopaed, Amherst, NY USA.; Matuszak, JM (corresponding author), Excelsior Sports Med, Excelsior Orthopaed, 3925 Sheridan Dr, Amherst, NY 14226 USA.	jmatuszak@excelsiorortho.com					Alsalaheen BA, 2012, THESIS; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Anderson NE, 2005, J NEUROL NEUROSUR PS, V76, P545, DOI 10.1136/jnnp.2004.043679; Armstrong B, 2008, SPORTS MED, V38, P101, DOI 10.2165/00007256-200838020-00002; Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; BENOIT BG, 1982, CAN J NEUROL SCI, V9, P321, DOI 10.1017/S0317167100044140; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brandt T, 2005, CLIN NEUROPHYSIOL, V116, P406, DOI 10.1016/j.clinph.2004.08.009; Burgio D L, 1992, J Vestib Res, V2, P221; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; CICERONE CM, 1995, PERCEPT PSYCHOPHYS, V57, P761, DOI 10.3758/BF03206792; Contreras R, 2011, BRAIN RES, V1398, P55, DOI 10.1016/j.brainres.2011.05.004; Cooke J, 2009, QJM-INT J MED, V102, P335, DOI 10.1093/qjmed/hcp020; Crutchfield K, 2014, NEUROLOGY S, V82; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Defense Centers of Excellence for Psychological Traumatic Brain Injury, 2012, ASS MAN DIZZ ASS MIL; Department of Veterans Affairs Department of Defense, 2009, MAN CONC MILD TRAUM; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Faraji F, 2011, OTOL NEUROTOL, V32, P654, DOI 10.1097/MAO.0b013e3182117769; Coello AF, 2010, J NEUROSURG, V113, P547, DOI 10.3171/2010.6.JNS091620; Findling O, 2011, GAIT POSTURE, V34, P473, DOI 10.1016/j.gaitpost.2011.06.021; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Foundation ON, 2013, GUID MILD TRAUM BRAI; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Green W, 2010, OPTOMETRY, V81, P129, DOI 10.1016/j.optm.2009.07.015; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jacobson GP, 2011, EAR HEARING, V32, pE1, DOI 10.1097/AUD.0b013e31822802bb; JOHNSON LN, 1991, J FAM PRACTICE, V33, P381; Kamel H, 2011, NEUROLOGY, V77, P1395, DOI 10.1212/WNL.0b013e3182315249; Kanjwal K, 2010, CARDIOL J, V17, P482; Kardon R, 2014, J NEURO-OPHTHALMOL, V34, pS10, DOI 10.1097/WNO.0000000000000162; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Liu HJ, 2012, ACTA OTO-LARYNGOL, V132, P803, DOI 10.3109/00016489.2012.657359; Longridge NS, 2010, OTOL NEUROTOL, V31, P803, DOI 10.1097/MAO.0b013e3181e3deb2; Martin RM, 2008, CURR REV MUSCULOSKE, V1, P1, DOI 10.1007/s12178-007-9000-5; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mulligan I, 2012, J ORTHOP SPORT PHYS, V42, P625, DOI 10.2519/jospt.2012.3798; Naschitz JE, 2007, POSTGRAD MED J, V83, DOI 10.1136/pgmj.2007.058198; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Page P, 2011, INT J SPORTS PHYS TH, V6, P254; Patel P, 2005, INDIAN J NEUROTRAUM, V2, P27, DOI 10.1016/S0973-0508(05)80007-3; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Richardson LP, 2010, PEDIATRICS, V126, P1117, DOI 10.1542/peds.2010-0852; Rosenthal JF, 2013, HEADACHE, V53, P1564, DOI 10.1111/head.12200; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schneiders AG, 2012, SCAND J MED SCI SPOR, V22, P85, DOI 10.1111/j.1600-0838.2010.01141.x; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004; SELHORST JB, 1985, NEUROSURGERY, V16, P357, DOI 10.1227/00006123-198503000-00013; Shawkat FS, 2000, BRIT J OPHTHALMOL, V84, P175, DOI 10.1136/bjo.84.2.175; Silverberg ND, SCREENING DEPRESSION; Steffen H, 1996, OPHTHALMOLOGY, V103, P1229, DOI 10.1016/S0161-6420(96)30518-6; Szymanowicz D, 2012, J REHABIL RES DEV, V49, P1083, DOI 10.1682/JRRD.2010.07.0129; Thiagarajan P, 2014, J REHABIL RES DEV, V51, P175, DOI 10.1682/JRRD.2013.01.0027; Thiagarajan P, 2014, BRAIN INJURY, V28, P930, DOI 10.3109/02699052.2014.888761; Thiagarajan P, 2014, NEUROREHABILITATION, V34, P129, DOI 10.3233/NRE-131025; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Treleaven J, 2011, SPINE, V36, pS211, DOI 10.1097/BRS.0b013e3182387f78; VARTIAINEN E, 1985, INT J PEDIATR OTORHI, V9, P135, DOI 10.1016/S0165-5876(85)80013-6; Whiteside JW, 2006, AM FAM PHYSICIAN, V74, P1357; Zhou GW, 2015, OTOLARYNG HEAD NECK, V152, P1133, DOI 10.1177/0194599815576720	93	51	51	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	MAY-JUN	2016	8	3					260	269		10.1177/1941738116641394			10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	EG8CM	WOS:000391283300009	27022058	Green Published			2022-02-06	
J	Gaw, CE; Zonfrillo, MR				Gaw, Christopher E.; Zonfrillo, Mark R.			Emergency department visits for head trauma in the United States	BMC EMERGENCY MEDICINE			English	Article						Concussion; Emergency department; Head trauma; National Electronic Injury Surveillance System; Traumatic brain injury	BRAIN-INJURY; CASE ASCERTAINMENT; CONCUSSION; EPIDEMIOLOGY; TRENDS; YOUTH; HOSPITALIZATION; SURVEILLANCE; ACCURACY; OUTCOMES	Background: Head trauma affects millions of Americans each year and has significant morbidity and economic costs to society. The objective of this study is to describe the epidemiology of head traumas presenting to emergency departments in the United States. Methods: The National Electronic Injury Surveillance System-All Injury Program was queried to conduct a retrospective analysis of head traumas treated in U.S. emergency departments. 207,159 cases of nonfatal head trauma from January 1, 2007 to December 31, 2011 were included in this study. Results: An estimated 10,746,629 (95 % confidence interval: 8,368,720-13,124,537) head traumas were treated in U.S. emergency departments (EDs) during the study period, averaging 2,149,326 cases annually. The annual injury rate per 10,000 population increased from 55.2 in 2007 to 85.4 in 2011, with the largest increases seen in children <= 11 years of age and in adults >65 years of age. Traffic-related head trauma accounted for an estimated 1,819,824 visits to U.S. EDs over the study period and was associated with a 1.74 times greater risk of a hospital admission compared to injuries due to non-traffic-related causes. Assaults (95.9 %) were the most common reason for head trauma in cases where injury intent was documented, and 16.9 % of assault-related head trauma occurred in children 0-17 years of age. When analyzed separately from other head traumas, concussions increased by 37.5 % over the study period, and nearly a third (29.9 %) of all concussions were sports-related. Conclusions: The increase in the number and rate of head traumas treated in U.S. EDs warrants continued injury prevention efforts and improvements in injury nomenclature and surveillance.	[Gaw, Christopher E.] Univ Penn, Perelman Sch Med, 3400 Civ Ctr Blvd,Bldg 421, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.] Brown Univ, Dept Emergency Med, Alpert Med Sch, 55 Claverick St,2nd Floor, Providence, RI 02903 USA		Zonfrillo, MR (corresponding author), Brown Univ, Dept Emergency Med, Alpert Med Sch, 55 Claverick St,2nd Floor, Providence, RI 02903 USA.	Zonfrillo@brown.edu	Gaw, Christopher/ABI-2314-2020; Zonfrillo, Mark R./H-9403-2017	Gaw, Christopher/0000-0002-2847-6372; Zonfrillo, Mark R./0000-0002-0610-9563	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08 HD073241, K08HD073241] Funding Source: Medline		Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Eisele JA, 2006, J HEAD TRAUMA REHAB, V21, P537, DOI 10.1097/00001199-200611000-00008; Faul M, 2010, TRAUMATIC BRAIN INJU; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Finkelhor D, 2005, CHILD MALTREATMENT, V10, P5, DOI 10.1177/1077559504271287; Finklestein E, 2006, INCIDENCE EC BURDENS; Garrick JG, 2005, CLIN J SPORT MED, V15, P385, DOI 10.1097/01.jsm.0000181438.48892.1b; HAHN YS, 1983, CHILD BRAIN, V10, P229; Hunt JP, 2000, J TRAUMA, V49, P679, DOI 10.1097/00005373-200010000-00016; Inter-university Consortium for Political and Social Research, 2014, NAT EL INJ SURV SYST; Irie F, 2011, J TRAUMA, V71, P847, DOI 10.1097/TA.0b013e3182032c9a; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; NEISS, 2000, NAT EL INJ SURV SYST; Norrie J, 2010, BRAIN INJURY, V24, P1528, DOI 10.3109/02699052.2010.531687; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Schroeder T., 2001, NEISS SAMPLE DESIGN; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Stevens PK, 2010, J TRAUMA NURS, V17, P183; Straus B., 2014, NY TIMES; Strauss B, 2014, NEW YORK TIMES; Thompson MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092052; Thompson MC, 2014, BRAIN INJURY, V28, P431, DOI 10.3109/02699052.2014.887146; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; U.S. Census Bureau, 2004, US EST90INT 07 INT E; U.S. Census Bureau, 2012, NC EST2011 ALLDATA M; U.S. Census Bureau, 2011, US EST00INT ALLDATA; U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Injury Prevention and Control U.S. Consumer Product Safety Commission, 2011, NAT EL INJ SURV SYST; Underwood E, 2013, SCIENCE, V339, P1367, DOI 10.1126/science.339.6126.1367; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Xiang HY, 2007, BRAIN INJURY, V21, P293, DOI 10.1080/02699050701311034; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	44	51	51	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-227X			BMC EMERG MED	BMC Emerg. Med.	JAN 19	2016	16								5	10.1186/s12873-016-0071-8			10	Emergency Medicine	Emerging Sources Citation Index (ESCI)	Emergency Medicine	DO9QG	WOS:000378121000001	26781953	gold, Green Published			2022-02-06	
J	Ruseva, MM; Ramaglia, V; Morgan, BP; Harris, CL				Ruseva, Marieta M.; Ramaglia, Valeria; Morgan, B. Paul; Harris, Claire L.			An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						traumatic brain injury; complement; therapy; CD59; CRIg	MEMBRANE ATTACK COMPLEX; MYELIN PHAGOCYTOSIS; ALTERNATIVE PATHWAY; HEAD-INJURY; ACTIVATION; INHIBITION; EXPRESSION; SYSTEM; C3; CD59	Activation of complement is a key determinant of neuropathology and disability after traumatic brain injury (TBI), and inhibition is neuroprotective. However, systemic complement is essential to fight infections, a critical complication of TBI. We describe a targeted complement inhibitor, comprising complement receptor of the Ig superfamily (CRIg) fused with complement regulator CD59a, designed to inhibit membrane attack complex (MAC) assembly at sites of C3b/iC3b deposition. CRIg and CD59a were linked via the IgG2a hinge, yielding CD59-2a-CRIg dimer with increased iC3b/C3b binding avidity and MAC inhibitory activity. CD59-2a-CRIg inhibited MAC formation and prevented complement-mediated lysis in vitro. CD59-2a-CRIg dimer bound C3b-coated surfaces with submicromolar affinity (K-D). In experimental TBI, CD59-2a-CRIg administered post-trauma homed to sites of injury and significantly reduced MAC deposition, microglial accumulation, mitochondrial stress, and axonal damage and enhanced neurologic recovery compared with placebo controls. CD59-2a-CRIg inhibited MAC-induced inflammasome activation and IL-1 beta production in microglia. Given the important anti-infection roles of complement opsonization, site-targeted inhibition of MAC should be considered to promote recovery postneurotrauma.	[Ruseva, Marieta M.; Morgan, B. Paul; Harris, Claire L.] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF14 4XN, S Glam, Wales; [Ramaglia, Valeria] Univ Amsterdam, Acad Med Ctr, Dept Genome Anal, NL-1105 AZ Amsterdam, Netherlands		Harris, CL (corresponding author), Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF14 4XN, S Glam, Wales.	harriscl@cardiff.ac.uk		Morgan, Paul/0000-0003-4075-7676	Cardiff University; Brain Foundation of the Netherlands Fellowship [F2010 (1)-05]	We thank Iliana Michailidou for technical support with in situ hybridization. This work was funded by a Cardiff University PhD studentship (to M.M.R.) and Brain Foundation of the Netherlands Fellowship F2010 (1)-05 (to V.R.).	Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208; Baas F, 2014, TRAUMATIC BRAIN INJU, P79; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Burk AM, 2012, SHOCK, V37, P348, DOI 10.1097/SHK.0b013e3182471795; CHARREAU B, 1994, TRANSPLANTATION, V58, P1222, DOI 10.1097/00007890-199412150-00015; Dorado L, 2014, CURR CARDIOL REV, V10, P327, DOI 10.2174/1573403X10666140320144637; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Harris CL, 2003, IMMUNOLOGY, V109, P117, DOI 10.1046/j.1365-2567.2003.01628.x; Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039; Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Lai AY, 2006, J NEUROIMMUNOL, V175, P97, DOI 10.1016/j.jneuroim.2006.03.001; Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Ma YF, 2015, J IMMUNOL, V194, P2855, DOI 10.4049/jimmunol.1303477; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; MERI S, 1990, IMMUNOLOGY, V71, P1; Morgan B P, 2000, Methods Mol Biol, V150, P61; PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477; Plurad DS, 2010, AM SURGEON, V76, P43; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Qiao Q, 2014, FASEB J, V28, P4986, DOI 10.1096/fj.14-258046; Ramaglia V, 2007, J NEUROSCI, V27, P7663, DOI 10.1523/JNEUROSCI.5623-06.2007; Reichert F, 2003, NEUROBIOL DIS, V12, P65, DOI 10.1016/S0969-9961(02)00008-6; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rossi S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-56; Rostami E, 2013, J NEUROTRAUM, V30, P1954, DOI 10.1089/neu.2012.2583; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Ruseva MM, 2014, METHODS MOL BIOL, V1100, P75, DOI 10.1007/978-1-62703-724-2_6; RUSEVA MM, 2009, MOL IMMUNOL, V46, P2865, DOI DOI 10.1016/J.MOLIMM.2009.05.317; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388; Zhang HF, 1999, J CLIN INVEST, V103, P55, DOI 10.1172/JCI4607; Zhang R, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-109	45	51	51	1	7	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	NOV 17	2015	112	46					14319	14324		10.1073/pnas.1513698112			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CW7IA	WOS:000365170400065	26578778	Bronze, Green Published, Green Accepted			2022-02-06	
J	Takahashi, M; Miyata, H; Kametani, F; Nonaka, T; Akiyama, H; Hisanaga, S; Hasegawa, M				Takahashi, Muneaki; Miyata, Haruka; Kametani, Fuyuki; Nonaka, Takashi; Akiyama, Haruhiko; Hisanaga, Shin-ichi; Hasegawa, Masato			Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau	ACTA NEUROPATHOLOGICA			English	Article						Tau; Amyloid precursor protein; Propagation; Alzheimer's disease; Down's syndrome	AMYLOID PRECURSOR PROTEIN; PATHOLOGICAL ALPHA-SYNUCLEIN; TRAUMATIC BRAIN-INJURY; FAMILIAL ALZHEIMERS-DISEASE; LOCUS DUPLICATION; DOWNS-SYNDROME; CEREBROSPINAL-FLUID; MOUSE-BRAIN; RAT; PHOSPHORYLATION	Alzheimer's disease (AD) is characterized by extracellular amyloid beta (A beta) deposition and intracellular tau aggregation. Many studies have indicated some association between these processes, but it remains unknown how the two pathologies are linked. In this study, we investigated whether expression of amyloid precursor protein (APP) influences extracellular seed-dependent intracellular tau accumulation in cultured cells. Treatment of tau-expressing SH-SY5Y cells with A beta fibrils did not induce intracellular tau aggregation. On the other hand, in cells expressing both tau and APP, treatment with tau fibrils or Sarkosyl-insoluble tau from AD brains induced intracellular tau aggregation. The seed-dependent intracellular tau aggregation was not induced by expression of APP lacking the extracellular domain. The amount of phosphorylated tau aggregates in cultured cells was dose dependently elevated in response to increased levels of APP on the cell membrane. Our results indicate that the extracellular region of APP is involved in uptake of tau fibrils into cells, raising the possibility that APP, but not A beta, influences cell-to-cell spreading of tau pathologies in AD by serving as a receptor of abnormal tau aggregates.	[Takahashi, Muneaki; Miyata, Haruka; Kametani, Fuyuki; Nonaka, Takashi; Akiyama, Haruhiko; Hasegawa, Masato] Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Setagaya Ku, Tokyo 1568506, Japan; [Takahashi, Muneaki; Hisanaga, Shin-ichi] Tokyo Metropolitan Univ, Lab Mol Neurosci, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan		Hasegawa, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Setagaya Ku, Tokyo 1568506, Japan.	hasegawa-ms@igakuken.or.jp	Kametani, Fuyuki/G-4752-2011; Nonaka, Takashi/L-8572-2017	Kametani, Fuyuki/0000-0001-9125-7001; Nonaka, Takashi/0000-0002-0830-9403	MEXT KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26117005, 23240050, 24111556]; MHLWMinistry of Health, Labour and Welfare, Japan [12946221]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15H02356, 26111730] Funding Source: KAKEN	This work was supported by MEXT KAKENHI Grant Numbers 26117005, 23240050 (to MH), 24111556 (to TN) and MHLW Grant ID Number 12946221 (to MH).	BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Braak H, 2013, ACTA NEUROPATHOL, V126, P631, DOI [10.1007/s00401-013-1139-0, 10.1007/s00401-013-1153-2]; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Ferrari A, 2003, J BIOL CHEM, V278, P40162, DOI 10.1074/jbc.M308243200; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Frost B, 2009, J BIOL CHEM, V284, P3546, DOI 10.1074/jbc.M805627200; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Guo JL, 2011, J BIOL CHEM, V286, P15317, DOI 10.1074/jbc.M110.209296; Guyant-Marechal L, 2008, NEUROLOGY, V71, P1925, DOI 10.1212/01.wnl.0000339400.64213.56; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Holmes BB, 2013, P NATL ACAD SCI USA, V110, pE3138, DOI 10.1073/pnas.1301440110; Iba M, 2013, J NEUROSCI, V33, P1024, DOI 10.1523/JNEUROSCI.2642-12.2013; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; KAMETANI F, 1994, FEBS LETT, V351, P165, DOI 10.1016/0014-5793(94)00851-5; Kandalepas PC, 2012, J NEUROCHEM, V120, P55, DOI 10.1111/j.1471-4159.2011.07512.x; Kasuga K, 2009, J NEUROL NEUROSUR PS, V80, P1050, DOI 10.1136/jnnp.2008.161703; Kfoury N, 2012, J BIOL CHEM, V287, P19440, DOI 10.1074/jbc.M112.346072; Kume H, 2006, BIOCHEM BIOPH RES CO, V349, P1356, DOI 10.1016/j.bbrc.2006.08.181; Lannfelt L, 2014, J INTERN MED, V275, P284, DOI 10.1111/joim.12168; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Luk KC, 2012, SCIENCE, V338, P949, DOI 10.1126/science.1227157; Luk KC, 2012, J EXP MED, V209, P975, DOI 10.1084/jem.20112457; Mairet-Coello G, 2013, NEURON, V78, P94, DOI 10.1016/j.neuron.2013.02.003; Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8; Masuda-Suzukake M, 2013, BRAIN, V136, P1128, DOI 10.1093/brain/awt037; McNaughton Daniel, 1800, Neurobiol Aging, V33, DOI 10.1016/j.neurobiolaging.2010.10.010; Michel CH, 2014, J BIOL CHEM, V289, P956, DOI 10.1074/jbc.M113.515445; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mougenot AL, 2012, NEUROBIOL AGING, V33, P2225, DOI 10.1016/j.neurobiolaging.2011.06.022; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Nonaka T, 2010, J BIOL CHEM, V285, P34885, DOI 10.1074/jbc.M110.148460; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Paudel HK, 1999, J BIOL CHEM, V274, P8029, DOI 10.1074/jbc.274.12.8029; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierrot N, 2013, EMBO MOL MED, V5, P608, DOI 10.1002/emmm.201202215; Purushothuman S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059740; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rovelet-Lecrux A, 2007, J NEUROL NEUROSUR PS, V78, P1158, DOI 10.1136/jnnp.2006.113514; Rovelet-Lecrux A, 2006, NAT GENET, V38, P24, DOI 10.1038/ng1718; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Saman S, 2012, J BIOL CHEM, V287, P3842, DOI 10.1074/jbc.M111.277061; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Simon D, 2012, FEBS LETT, V586, P47, DOI 10.1016/j.febslet.2011.11.022; Sleegers K, 2006, BRAIN, V129, P2977, DOI 10.1093/brain/awl203; Song YL, 2014, PROTEIN SCI, V23, P1, DOI 10.1002/pro.2385; Taniguchi S, 2005, J BIOL CHEM, V280, P7614, DOI 10.1074/jbc.M408714200; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Wilcock DM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-84; Wu JW, 2013, J BIOL CHEM, V288, P1856, DOI 10.1074/jbc.M112.394528	61	51	53	1	18	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2015	129	6					895	907		10.1007/s00401-015-1415-2			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	CI4GO	WOS:000354706600009	25869641	Green Published, hybrid			2022-02-06	
J	Guo, SX; Zhou, HL; Huang, CL; You, CG; Fang, Q; Wu, P; Wang, XG; Han, CM				Guo, Song-Xue; Zhou, Han-Lei; Huang, Chun-Lan; You, Chuan-Gang; Fang, Quan; Wu, Pan; Wang, Xin-Gang; Han, Chun-Mao			Astaxanthin Attenuates Early Acute Kidney Injury Following Severe Burns in Rats by Ameliorating Oxidative Stress and Mitochondrial-Related Apoptosis	MARINE DRUGS			English	Article							ACUTE-RENAL-FAILURE; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; GELATINASE-ASSOCIATED LIPOCALIN; HYDROGEN-RICH SALINE; EARLY BRAIN-INJURY; CEREBRAL-ISCHEMIA; PROTECTS; MODEL; SURVIVAL; CELLS	Early acute kidney injury (AKI) is a devastating complication in critical burn patients, and it is associated with severe morbidity and mortality. The mechanism of AKI is multifactorial. Astaxanthin (ATX) is a natural compound that is widely distributed in marine organisms; it is a strong antioxidant and exhibits other biological effects that have been well studied in various traumatic injuries and diseases. Hence, we attempted to explore the potential protection of ATX against early post burn AKI and its possible mechanisms of action. The classic severe burn rat model was utilized for the histological and biochemical assessments of the therapeutic value and mechanisms of action of ATX. Upon ATX treatment, renal tubular injury and the levels of serum creatinine and neutrophil gelatinase-associated lipocalin were improved. Furthermore, relief of oxidative stress and tubular apoptosis in rat kidneys post burn was also observed. Additionally, ATX administration increased Akt and Bad phosphorylation and further down-regulated the expression of other downstream pro-apoptotic proteins (cytochrome c and caspase-3/9); these effects were reversed by the PI3K inhibitor LY294002. Moreover, the protective effect of ATX presents a dose-dependent enhancement. The data above suggested that ATX protects against early AKI following severe burns in rats, which was attributed to its ability to ameliorate oxidative stress and inhibit apoptosis by modulating the mitochondrial-apoptotic pathway, regarded as the Akt/Bad/Caspases signalling cascade.	[Guo, Song-Xue; Zhou, Han-Lei; You, Chuan-Gang; Wu, Pan; Wang, Xin-Gang; Han, Chun-Mao] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Burns, Hangzhou 310009, Zhejiang, Peoples R China; [Huang, Chun-Lan] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Plast Surg, Hangzhou 310000, Zhejiang, Peoples R China; [Fang, Quan] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Plast Surg,Binjiang Branch, Hangzhou 310000, Zhejiang, Peoples R China		Han, CM (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Burns, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	11318225@zju.edu.cn; zhlei288@zju.edu.cn; 21418262@zju.edu.cn; 2314053@zju.edu.cn; 21218125@zju.edu.cn; wuzhiqiujin@zju.edu.cn; wangxingang8157@zju.edu.cn; zrssk@zju.edu.cn			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81401591]; Zhejiang Provincial National Natural Science Foundation of China [LQ13H150001]	This work was supported by grants from National Natural Science Foundation of China (NSFC) grant 81401591 and Zhejiang Provincial National Natural Science Foundation of China Grant: LQ13H150001.	Abali A. E., 2014, BURNS IN PRESS; Arora S, 2014, MOL CELL BIOCHEM, V393, P123, DOI 10.1007/s11010-014-2052-0; Arunkumar E, 2012, FOOD FUNCT, V3, P120, DOI 10.1039/c1fo10161g; Billings FT, 2014, CARDIORENAL MED, V4, P12, DOI 10.1159/000357871; Chalah A, 2008, ADV EXP MED BIOL, V615, P25, DOI 10.1007/978-1-4020-6554-5_3; Choi HD, 2011, BRIT J NUTR, V105, P220, DOI 10.1017/S0007114510003454; Coca SG, 2007, AM J KIDNEY DIS, V49, P517, DOI 10.1053/j.ajkd.2006.12.018; Colpaert K, 2008, CRIT CARE, V12, DOI 10.1186/cc7106; Dagher PC, 2012, AM J PHYSIOL-RENAL, V302, pF284, DOI 10.1152/ajprenal.00317.2011; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Elks CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024028; Fang Y, 2011, J BURN CARE RES, V32, pE82, DOI 10.1097/BCR.0b013e318217f84f; Fassett RG, 2009, FUTUR CARDIOL, V5, P333, DOI 10.2217/FCA.09.19; Feng YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054593; Gal AF, 2012, ACTA VET SCAND, V54, DOI 10.1186/1751-0147-54-50; Gao CJ, 2009, BURNS, V35, P547, DOI 10.1016/j.burns.2008.10.006; Gravante G, 2007, APOPTOSIS, V12, P259, DOI 10.1007/s10495-006-0621-8; Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Hong DY, 2013, J BURN CARE RES, V34, pE326, DOI 10.1097/BCR.0b013e31827d1f36; Hong Y, 2012, J NEUROSCI RES, V90, P1670, DOI 10.1002/jnr.22739; Horton JW, 2003, TOXICOLOGY, V189, P75, DOI 10.1016/S0300-483X(03)00154-9; Jiang L, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-53; Kim YJ, 2009, J AGR FOOD CHEM, V57, P8793, DOI 10.1021/jf9019745; Lauver DA, 2005, J PHARMACOL EXP THER, V314, P686, DOI 10.1124/jpet.105.087114; Leblanc M, 1997, BURNS, V23, P160, DOI 10.1016/S0305-4179(96)00085-X; Lee DH, 2010, J CLIN BIOCHEM NUTR, V47, P121, DOI 10.3164/jcbn.10-29; Li PKT, 2013, NAT REV NEPHROL, V9, P133, DOI 10.1038/nrneph.2013.20; Li YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093639; Liu CM, 2012, TOXICOL APPL PHARM, V258, P330, DOI 10.1016/j.taap.2011.11.015; Mariano F, 2008, CRIT CARE, V12, DOI 10.1186/cc6848; Mosier MJ, 2010, J BURN CARE RES, V31, P83, DOI 10.1097/BCR.0b013e3181cb8c87; Mustonen KM, 2008, J BURN CARE RES, V29, P227, DOI 10.1097/BCR.0b013e31815f3196; Nagendraprabhu P, 2011, INVEST NEW DRUG, V29, P207, DOI 10.1007/s10637-009-9342-5; Naguib YMA, 2000, J AGR FOOD CHEM, V48, P1150, DOI 10.1021/jf991106k; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Palipoch S, 2013, AFR J TRADIT COMPLEM, V10, P88, DOI 10.4314/ajtcam.v10i4.15; Palmieri T, 2010, BURNS, V36, P205, DOI 10.1016/j.burns.2009.08.012; Parihar A, 2008, BURNS, V34, P6, DOI 10.1016/j.burns.2007.04.009; Qiu XF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0388-1; Quoilin C, 2014, BBA-BIOENERGETICS, V1837, P1790, DOI 10.1016/j.bbabio.2014.07.005; Rael LT, 2009, J NEUROTRAUM, V26, P1203, DOI 10.1089/neu.2008-0816; Rael LT, 2009, J TRAUMA, V66, P76, DOI 10.1097/TA.0b013e318191bfe0; Rana A, 2001, APOPTOSIS, V6, P83, DOI 10.1023/A:1009680229931; Rong Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI 10.1146/annurev.physiol.70.021507.105852; Sahu BD, 2011, FOOD CHEM TOXICOL, V49, P3090, DOI 10.1016/j.fct.2011.08.018; Sedeek M, 2010, AM J PHYSIOL-RENAL, V299, pF1348, DOI 10.1152/ajprenal.00028.2010; Sener G, 2007, BURNS, V33, P587, DOI 10.1016/j.burns.2006.10.381; Shah SV, 2001, AM J KIDNEY DIS, V37, pS30, DOI 10.1053/ajkd.2001.20736; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Si YN, 2014, EUR REV MED PHARMACO, V18, P1843; Sila A, 2015, EUR J NUTR, V54, P301, DOI 10.1007/s00394-014-0711-2; Small DM, 2012, EXPERT OPIN DRUG MET, V8, P655, DOI 10.1517/17425255.2012.679657; Steinvall I, 2008, CRIT CARE, V12, DOI 10.1186/cc7032; Stoyanoff TR, 2014, TOXICOLOGY, V318, P13, DOI 10.1016/j.tox.2014.01.011; Tasanarong A, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-138; Wagener FADTG, 2009, APOPTOSIS, V14, P1451, DOI 10.1007/s10495-009-0359-1; Yavuz S, 2014, BURNS, V40, P648, DOI 10.1016/j.burns.2013.09.004; Yuan JP, 2011, MOL NUTR FOOD RES, V55, P150, DOI 10.1002/mnfr.201000414; Yuan L, 2011, AM J PHYSIOL-RENAL, V300, pF207, DOI 10.1152/ajprenal.00073.2010; Yuan X, 2014, EXP THER MED, V8, P973, DOI 10.3892/etm.2014.1820; Zhang XS, 2014, MAR DRUGS, V12, P4291, DOI 10.3390/md12084291; Zhang XS, 2014, J NEUROSURG, V121, P42, DOI 10.3171/2014.2.JNS13730	63	51	55	1	15	MDPI AG	BASEL	POSTFACH, CH-4005 BASEL, SWITZERLAND	1660-3397			MAR DRUGS	Mar. Drugs	APR	2015	13	4					2105	2123		10.3390/md13042105			19	Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	CH0NA	WOS:000353715900026	25871290	gold, Green Submitted, Green Published			2022-02-06	
J	Kirk, S; Fallon, D; Fraser, C; Robinson, G; Vassallo, G				Kirk, S.; Fallon, D.; Fraser, C.; Robinson, G.; Vassallo, G.			Supporting parents following childhood traumatic brain injury: a qualitative study to examine information and emotional support needs across key care transitions	CHILD CARE HEALTH AND DEVELOPMENT			English	Article						adolescents; children; co-ordination; information; support; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; OF-LIFE; CHILDREN; SCHOOL; OUTCOMES; ADOLESCENTS; IMPACT; REHABILITATION; PARTICIPATION	IntroductionTraumatic brain injury (TBI) is the leading cause of death and acquired disability in childhood. Research has demonstrated that TBI can lead to long-term physical, cognitive, emotional and behavioural difficulties for children and parental stress. Less is known about how parents experience a childhood brain injury and their information and support needs. This study aimed to examine parents' experiences and support needs following a childhood TBI from the time of the accident to their child's discharge home. MethodsQualitative semi-structured interviews were conducted with 29 parents/carers of children who had experienced a severe TBI. Participants were recruited from one children's tertiary centre in the UK. Data were analysed using the Framework approach. ResultsParents had unmet information and emotional support needs across the care trajectory from the time of the accident to their child's return home. Information needs related to the impact of the TBI on their child; current and future treatment/rehabilitation plans; helping their child and managing their behaviour; accessing services/support. They lacked information and support for care transitions. In different settings parents faced particular barriers to having their information needs met. Parents' felt they needed emotional support in coming to terms with witnessing the accident and the loss of their former child. Lack of community support related not only to service availability but to a general lack of understanding of the impact of TBI on children, particularly when this was invisible. Overall parents felt unsupported in coping with children's behavioural and psychological difficulties. DiscussionTaking a holistic approach to examining parents' experiences and support needs has enabled their changing needs to be highlighted across key care transitions within hospital and community settings and the service implications identified. Improvements in care co-ordination across care transitions are needed to ensure continuity of care and integration of support.	[Kirk, S.; Fallon, D.; Fraser, C.] Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester M13 9PL, Lancs, England; [Robinson, G.; Vassallo, G.] Royal Manchester Childrens Hosp, Paediat Neurol Dept, Manchester M27 1HA, Lancs, England		Kirk, S (corresponding author), Univ Manchester, Sch Nursing Midwifery & Social Work, Jean McFarlane Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.	sue.kirk@manchester.ac.uk	Fraser, Claire/O-9023-2014; Fallon, Debbie/AAA-4553-2019	Fraser, Claire/0000-0003-3684-3168; Kirk, Susan/0000-0002-1485-8804			Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Aitken ME, 2004, ARCH PHYS MED REHAB, V85, P567, DOI 10.1016/j.apmr.2003.06.018; Anaby D, 2012, DEV MED CHILD NEUROL, V54, P339, DOI 10.1111/j.1469-8749.2011.04204.x; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Brown FL, 2013, BRAIN INJURY, V27, P1570, DOI 10.3109/02699052.2013.841996; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Clark Alex, 2008, Clin Child Psychol Psychiatry, V13, P565, DOI 10.1177/1359104508090607; Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Gfroerer SD, 2008, BRAIN INJURY, V22, P649, DOI 10.1080/02699050802227162; Glang A, 2008, NEUROREHABILITATION, V23, P477; Guerriere D, 1997, J Soc Pediatr Nurs, V2, P105, DOI 10.1111/j.1744-6155.1997.tb00067.x; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hoffman JM, 2012, ARCH PHYS MED REHAB, V93, P287, DOI 10.1016/j.apmr.2011.08.041; Jordan J, 2013, BRAIN INJURY, V27, P1063, DOI 10.3109/02699052.2013.794962; Kenardy J, 2012, J CLIN CHILD ADOLESC, V41, P5, DOI 10.1080/15374416.2012.632348; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Latour JM, 2011, INTENS CARE MED, V37, P319, DOI 10.1007/s00134-010-2074-3; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Mealings M, 2012, BRAIN INJURY, V26, P1165, DOI 10.3109/02699052.2012.672785; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Roscigno CI, 2011, QUAL HEALTH RES, V21, P1413, DOI 10.1177/1049732311410988; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Sloper P, 2006, CHILD CARE HLTH DEV, V32, P147, DOI 10.1111/j.1365-2214.2006.00592.x; Spencer L., 2003, QUALITATIVE RES PRAC, P199; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Tasker RC, 2011, BRIT J NEUROSURG, V25, P68, DOI 10.3109/02688697.2010.538770; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Tomlin P, 2002, DEV MED CHILD NEUROL, V44, P828; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Van Houdt S, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-296; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Williams H., 2011, REPAIRING SHATTERED	45	51	51	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1862	1365-2214		CHILD CARE HLTH DEV	Child Care Health Dev.	MAR	2015	41	2					303	313		10.1111/cch.12173			11	Psychology, Developmental; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics	CB6XU	WOS:000349771100014	25039833				2022-02-06	
J	Wade, SL; Kurowski, BG; Kirkwood, MW; Zhang, NH; Cassedy, A; Brown, TM; Nielsen, B; Stancin, T; Taylor, G				Wade, Shari L.; Kurowski, Brad G.; Kirkwood, Michael W.; Zhang, Nanhua; Cassedy, Amy; Brown, Tanya M.; Nielsen, Britt; Stancin, Terry; Taylor, Gerry			Online Problem-Solving Therapy After Traumatic Brain Injury: A Randomized Controlled Trial	PEDIATRICS			English	Article							EXECUTIVE DYSFUNCTION; FUNCTIONAL RECOVERY; ATTENTION PROBLEMS; UNITED-STATES; CHILDREN; OUTCOMES; INTERVENTIONS; PREDICTORS; MILD; ADOLESCENTS	BACKGROUND: Pediatric traumatic brain injury (TBI) contributes to impairments in functioning in everyday settings. Evidence suggests that online family problem-solving therapy (FPST) may be effective in reducing adolescent behavioral morbidity. This article examines the efficacy of Counselor-Assisted Problem Solving (CAPS), a form of online FPST in improving long-term functional outcomes of adolescents with TBI relative to Internet resources only. METHODS: Children, aged 12 to 17 years, who were hospitalized in the previous 7 months for TBI were enrolled in a multisite, assessor-blinded randomized controlled trial. Consented participants were randomly assigned to CAPS or an Internet resource comparison (IRC) condition. Outcomes were assessed at baseline and at follow-ups 6, 12, and 18 months postbaseline. The Child and Functional Assessment Scale and the Iowa Family Interaction Rating Scale (IFIRS) served as primary outcomes of child and family functioning respectively. RESULTS: For the Child and Functional Assessment Scale total, we found a significant group x time interaction, with less impaired functioning for the CAPS group than for the IRC group at the final follow-up. Parent education moderated the efficacy of CAPS on overall rates of impairment and school/work functioning, with the advantage of CAPS over IRC evident at the final follow-up only for participants with less-educated parents. Neither group differences nor group x time interactions were found for the IFIRS. CONCLUSIONS: Relatively brief, online treatment shortly after injury may result in long-term improvements in child functioning, particularly among families of lower socioeconomic status. Clinical implementation of CAPS during the initial months postinjury should be considered.	[Wade, Shari L.; Kurowski, Brad G.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Zhang, Nanhua; Cassedy, Amy] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Epidemiol & Biostat, Cincinnati, OH 45229 USA; [Zhang, Nanhua; Cassedy, Amy] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA; [Brown, Tanya M.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA; [Nielsen, Britt; Stancin, Terry] Metrohlth Med Ctr, Dept Psychiat, Div Pediat Psychol, Cleveland, OH 44109 USA; [Nielsen, Britt; Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Taylor, Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, Gerry] Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Case Med Ctr, Cleveland, OH 44106 USA		Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA.		Nielsen, Britt/S-5796-2019; Zhang, Nanhua/L-7606-2015; Stancin, Terry/L-7993-2019	Zhang, Nanhua/0000-0001-5796-3404	National Institutes of Health grant from the National Institute of Mental Health [R01-MH073764]; Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; National Institute of Disability and Rehabilitation Research, Department of Education [H133G050239]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD074683-01A1]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077, UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	Supported in part by National Institutes of Health grant R01-MH073764 from the National Institute of Mental Health; a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; grant H133G050239 from the National Institute of Disability and Rehabilitation Research, Department of Education; and National Institute of Child Health and Human Development grant 1K23HD074683-01A1. Funded by the National Institutes of Health (NIH).	Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Andrews G., 2010, PLOS ONE, V5, DOI DOI 10.1371/JOURNAL.PONE.0010939; Backeljauw B, 2014, PM&R, V6, P814, DOI 10.1016/j.pmrj.2014.04.004; Blaha RZ, 2015, J HEAD TRAUMA REHAB, V30, pE33, DOI 10.1097/HTR.0000000000000059; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cushing CC, 2010, J PEDIATR PSYCHOL, V35, P937, DOI 10.1093/jpepsy/jsq023; Gan C, 2010, NEUROREHABILITATION, V27, P5, DOI 10.3233/NRE-2010-0577; Hodges K, 1998, J BEHAV HEALTH SER R, V25, P325, DOI 10.1007/BF02287471; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kurowski BG, 2014, JAMA PEDIATR, V168, P523, DOI 10.1001/jamapediatrics.2013.5070; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Micklewright JL, 2012, J INT NEUROPSYCH SOC, V18, P343, DOI 10.1017/S1355617711001792; Penate W, 2012, INT J CLIN HLTH PSYC, V12, P475; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ross KA, 2011, BRAIN INJURY, V25, P1206, DOI 10.3109/02699052.2011.609519; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; TEASDALE G, 1974, LANCET, V2, P81; Todis B, 2008, J HEAD TRAUMA REHAB, V23, P252, DOI 10.1097/01.HTR.0000327257.84622.bc; van 't Hooft I, 2007, NEUROREHABILITATION, V22, P109; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Wade SL, 2014, REHABIL PSYCHOL, V59, P1, DOI 10.1037/a0034911; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Webb MS, 2010, AM J HEALTH PROMOT, V25, P109, DOI 10.4278/ajhp.090123-LIT-25; Wechsler D, 2003, WISC 4 ADM MANUAL; Wechsler D., 2008, WECHSLER ADULT INTEL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Xue Y, 2004, J CLIN CHILD ADOLESC, V33, P516, DOI 10.1207/s15374424jccp3303_9; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387	41	51	52	2	23	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2015	135	2					E487	E495		10.1542/peds.2014-1386			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	CE0PX	WOS:000351507800001	25583911	Green Published			2022-02-06	
J	Wang, Z; Wang, Y; Wang, ZY; Gutkind, JS; Wang, ZL; Wang, F; Lu, J; Niu, G; Teng, GJ; Chen, XY				Wang, Zhe; Wang, Yu; Wang, Zhiyong; Gutkind, J. Silvio; Wang, Zhongliang; Wang, Fu; Lu, Jie; Niu, Gang; Teng, Gaojun; Chen, Xiaoyuan			Engineered Mesenchymal Stem Cells with Enhanced Tropism and Paracrine Secretion of Cytokines and Growth Factors to Treat Traumatic Brain Injury	STEM CELLS			English	Article						Mesenchymal stem cell; CXC chemokine receptor 4; Traumatic brain injury; Imaging; Angiogenesis; Neuron	MARROW STROMAL CELLS; ANTICANCER ACTIVITIES; TISSUE REGENERATION; DELIVERY-SYSTEM; TNF-ALPHA; BONE; MIGRATION; MICE; ENGRAFTMENT; APOPTOSIS	Traumatic brain injury (TBI) is the leading cause of death and disability worldwide. Mesenchymal stem cells (MSCs) are promising for the treatment of various diseases and injuries. Many strategies have been applied to attract MSCs to injury site after systemic infusion. In this study, we evidenced that the CXC chemokine receptor 4 (CXCR4)-SDF1 alpha (stromal cell-derived factor 1 alpha) axis in engineered MSCs serves not only to attract MSC migration to TBI but also to activate Akt kinase signaling pathway in MSCs to promote paracrine secretion of cytokines and growth factors. This leads to enhanced vasculogenesis and neuroprotection at the boundary of TBI for improved blood supply, recovery of axon connectivity, and behavioral ability and results in positive feedback loop to enhance additional MSC tropism to injury. These findings indicate a new aspect of SDF1 alpha in mediating CXCR4 engineered MSCs for brain trauma homing and recovery. This potential mechanism may be applicable to other injuries, where CXCR4-SDF1 alpha interaction is highly associated.	[Wang, Zhe; Wang, Yu; Wang, Zhongliang; Wang, Fu; Lu, Jie; Niu, Gang; Chen, Xiaoyuan] Natl Inst Hlth, Lab Mol Imaging & Nanomed, Natl Inst Biomed Imaging & Bioengn, Bethesda, MD USA; [Wang, Zhiyong; Gutkind, J. Silvio] Natl Inst Hlth, Oral & Pharyngeal Canc Branch, Natl Inst Dent & Craniofacial Res, Bethesda, MD USA; [Wang, Yu; Teng, Gaojun] Zhongda Hosp, Dept Radiol, Jiangsu Key Lab Mol & Funct Imaging, Nanjing 210009, Peoples R China; [Wang, Zhongliang; Wang, Fu] Xidian Univ, Sch Life Sci & Technol, Xian, Shaanxi, Peoples R China		Teng, GJ (corresponding author), Zhongda Hosp, Dept Radiol, Jiangsu Key Lab Mol & Funct Imaging, Nanjing 210009, Peoples R China.	gjteng@vip.sina.com; shawn.chen@nih.gov	Wang, Fu/S-7955-2017; Wang, Zhongliang/J-8674-2012; Gutkind, J. Silvio/J-1201-2016	Wang, Fu/0000-0001-9222-0833; Wang, Zhongliang/0000-0001-9388-149X; Gutkind, J. Silvio/0000-0002-5150-4482	CNRM program at Henry M. Jackson Foundation; Intramural Research Program (IRP), NIBIB/NIH; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER	This work was supported, in part, by CNRM program at Henry M. Jackson Foundation, and the Intramural Research Program (IRP), NIBIB/NIH.	Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bai L, 2012, NAT NEUROSCI, V15, P862, DOI 10.1038/nn.3109; Baraniak PR, 2010, REGEN MED, V5, P121, DOI 10.2217/RME.09.74; Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028; Brenner S, 2004, STEM CELLS, V22, P1128, DOI 10.1634/stemcells.2003-0196; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Carlson KB, 2011, GLIA, V59, P267, DOI 10.1002/glia.21099; Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Iglesias-Bartolome R, 2012, CELL STEM CELL, V11, P401, DOI 10.1016/j.stem.2012.06.007; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Islam O, 2009, CURR NEUROVASC RES, V6, P42, DOI 10.2174/156720209787466028; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Khoo CP, 2011, TISSUE ENG PART C-ME, V17, P895, DOI [10.1089/ten.tec.2011.0150, 10.1089/ten.TEC.2011.0150]; Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349; Lee RH, 2006, BLOOD, V107, P2153, DOI 10.1182/blood-2005-07-2701; Lee RH, 2012, CELL STEM CELL, V11, P825, DOI 10.1016/j.stem.2012.10.001; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Levy O, 2013, BLOOD, V122, pE23, DOI 10.1182/blood-2013-04-495119; Liu HB, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0034608, 10.1371/journal.pone.0050785]; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Nakano-Doi A, 2010, STEM CELLS, V28, P1292, DOI 10.1002/stem.454; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Ranganath SH, 2012, CELL STEM CELL, V10, P244, DOI 10.1016/j.stem.2012.02.005; Sackstein R, 2008, NAT MED, V14, P181, DOI 10.1038/nm1703; Sage EK, 2014, THORAX, V69, P638, DOI 10.1136/thoraxjnl-2013-204110; Sarkar D, 2011, BLOOD, V118, pE184, DOI 10.1182/blood-2010-10-311464; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Stephan MT, 2010, NAT MED, V16, P1035, DOI 10.1038/nm.2198; Tsai LK, 2011, STROKE, V42, P2932, DOI 10.1161/STROKEAHA.110.612788; Wang F, 2014, P NATL ACAD SCI USA, V111, P5165, DOI 10.1073/pnas.1321374111; Wang Z, 2014, ADV HEALTHC MATER, V3, P1326, DOI 10.1002/adhm.201400088; Wang Z, 2014, PHARM RES-DORDR, V31, P1358, DOI 10.1007/s11095-013-1103-7; Wang Z, 2013, BIOMATERIALS, V34, P6194, DOI 10.1016/j.biomaterials.2013.05.004; Wang Z, 2011, PHARM RES-DORDR, V28, P585, DOI 10.1007/s11095-010-0308-2; Wang Z, 2010, SMALL, V6, P2576, DOI 10.1002/smll.201001122; Wang Z, 2010, BIOMATERIALS, V31, P7115, DOI 10.1016/j.biomaterials.2010.05.075; Wang Z, 2010, EXPERT OPIN DRUG DEL, V7, P159, DOI 10.1517/17425240903468696; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Yu XL, 2012, J NEUROL SCI, V316, P141, DOI 10.1016/j.jns.2012.01.001; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061	52	51	55	1	58	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	FEB	2015	33	2					456	467		10.1002/stem.1878			12	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	AZ4RW	WOS:000348211300014	25346537	Bronze			2022-02-06	
J	Wang, Y; West, JD; Bailey, JN; Westfall, DR; Xiao, H; Arnold, TW; Kersey, PA; Saykin, AJ; McDonald, BC				Wang, Yang; West, John D.; Bailey, Jessica N.; Westfall, Daniel R.; Xiao, Hui; Arnold, Todd W.; Kersey, Patrick A.; Saykin, Andrew J.; McDonald, Brenna C.			Decreased Cerebral Blood Flow in Chronic Pediatric Mild TBI: An MRI Perfusion Study	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; PATHOPHYSIOLOGY; 3T	We evaluated cerebral blood flow (CBF) in chronic pediatric mild traumatic brain injury (mTBI) using arterial spin labeling (ASL) magnetic resonance imaging perfusion. mTBI patients showed lower CBF than controls in bilateral frontotemporal regions, with no between-group cognitive differences. Findings suggest ASL may be useful to assess functional abnormalities in pediatric mTBI.	[Wang, Yang] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA; [Wang, Yang; West, John D.; Bailey, Jessica N.; Westfall, Daniel R.; Xiao, Hui; Saykin, Andrew J.; McDonald, Brenna C.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, Indianapolis, IN 46202 USA; [Westfall, Daniel R.] Univ Illinois, Neurosci Program, Urbana, IL USA; [Xiao, Hui] Dongfang Hosp, Dept Radiol, Fuzhou, Fujian, Peoples R China; [Arnold, Todd W.; Kersey, Patrick A.] St Vincent Sports Performance, Carmel, IN USA		Wang, Y (corresponding author), Med Coll Wisconsin, Dept Biophys, Ctr Imaging Res, Dept Radiol,MFRC, 9200 West Wisconsin Ave,G2411, Milwaukee, WI 53226 USA.	yangwang@mcw.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	Indiana State Department of Health Spinal Cord and Brain Injury Fund Research Grant Program; Project Development Team within the ICTSI NIH/NCRR [RR025761]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002529, UL1TR001108] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771, P30AG010133] Funding Source: NIH RePORTER	This work was supported by a grant from the Indiana State Department of Health Spinal Cord and Brain Injury Fund Research Grant Program and by a Project Development Team within the ICTSI NIH/NCRR Grant Number RR025761.	Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Detre JA, 2012, J MAGN RESON IMAGING, V35, P1026, DOI 10.1002/jmri.23581; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Metting Z, 2014, BRAIN COGNITION, V86, P24, DOI 10.1016/j.bandc.2014.01.012; Wang JJ, 2003, J MAGN RESON IMAGING, V18, P404, DOI 10.1002/jmri.10372; Wang Y, 2011, NEUROIMAGE, V54, P1188, DOI 10.1016/j.neuroimage.2010.08.043	10	51	54	2	16	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	JAN 2	2015	40	1			SI		40	44		10.1080/87565641.2014.979927			5	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	CA6IR	WOS:000349015800008	25649779	Green Accepted, Green Published			2022-02-06	
J	Stokum, JA; Sours, C; Zhuo, JC; Kane, R; Shanmuganathan, K; Gullapalli, RP				Stokum, Jesse A.; Sours, Chandler; Zhuo, Jiachen; Kane, Robert; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.			A longitudinal evaluation of diffusion kurtosis imaging in patients with mild traumatic brain injury	BRAIN INJURY			English	Article						ANAM; diffusion kurtosis imaging; longitudinal analysis; mild traumatic brain injury	NEUROPSYCHOLOGICAL ASSESSMENT METRICS; AXONAL INJURY; COGNITIVE IMPAIRMENT; CORPUS-CALLOSUM; MODERATE; WHITE; PERFORMANCE; ATTENUATION; ORIENTATION; SEVERITY	Primary objective: To investigate longitudinal diffusion tensor imaging (DTI) and diffusion kurtosis imaging (DKI) changes in white and grey matter in patients with mild traumatic brain injury (mTBI). Research design: A prospective case-control study. Methods and procedures: DKI data was obtained from 24 patients with mTBI along with cognitive assessments within 10 days, 1 month and 6 months post-injury and compared with age-matched control (n = 24). Fractional anisotropy (FA), mean diffusivity (MD), radial diffusion (lambda(r)), mean kurtosis (MK) and radial kurtosis (K-r) were extracted from the thalamus, internal capsule and corpus callosum. Main outcomes and results: Results demonstrate reduced K-r and MK in the anterior internal capsule in patients with mTBI across the three visits, and reduced MK in the posterior internal capsule during the 10 day time point. Correlations were observed between the change in MK or K-r between 1-6 months and the improvements in cognition between the 1 and 6 month visits in the thalamus, internal capsule and corpus callosum. Conclusions: These data demonstrate that DKI may be sensitive in tracking pathophysiological changes associated with mTBI and may provide additional information to conventional DTI parameters in evaluating longitudinal changes following TBI.	[Stokum, Jesse A.; Sours, Chandler; Zhuo, Jiachen; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Sours, Chandler; Gullapalli, Rao P.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA; [Kane, Robert] Georgetown Univ, Sch Med, Washington, DC USA		Gullapalli, RP (corresponding author), Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, 22 S Greene St, Baltimore, MD 21201 USA.	rgullapalli@umm.edu			US ArmyUnited States Department of Defense [W81XWH-08-1-0725, W81XWH-12-1-0098]	The authors report no conflicts of interest. This work was partly supported by the grants W81XWH-08-1-0725 and W81XWH-12-1-0098 from the US Army.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 1998, J MAGN RESON, V131, P69, DOI 10.1006/jmre.1997.1313; Axer H, 2000, J NEUROSCI METH, V94, P165, DOI 10.1016/S0165-0270(99)00132-6; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Centers for Disease Control and Prevention  National Center for Injury Prevention and Control, 2010, TRAUMATIC BRAIN INJU; Cheung MM, 2009, NEUROIMAGE, V45, P386, DOI 10.1016/j.neuroimage.2008.12.018; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Falangola MF, 2013, MAGN RESON IMAGING, V31, P840, DOI 10.1016/j.mri.2013.02.008; Falangola MF, 2008, J MAGN RESON IMAGING, V28, P1345, DOI 10.1002/jmri.21604; Gong NJ, 2013, MAGN RESON IMAGING, V31, P688, DOI 10.1016/j.mri.2012.10.027; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Grossman Elan J, 2010, Top Magn Reson Imaging, V21, P379, DOI 10.1097/RMR.0b013e31823e65b8; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hui ES, 2008, NEUROIMAGE, V42, P122, DOI 10.1016/j.neuroimage.2008.04.237; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kamagata K, 2013, MAGN RESON IMAGING, V31, P1501, DOI 10.1016/j.mri.2013.06.009; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Niendorf T, 1996, MAGN RESON MED, V36, P847, DOI 10.1002/mrm.1910360607; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Raab P, 2010, RADIOLOGY, V254, P876, DOI 10.1148/radiol.09090819; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reich S, 2005, VALIDATION ANAM TEST; Sours C, 2014, BRAIN IMAGING BEHAV; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; Umene-Nakano W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087890; Vincent AS, 2012, MIL MED, V177, P256, DOI 10.7205/MILMED-D-11-00289; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu EX, 2010, NMR BIOMED, V23, P836, DOI 10.1002/nbm.1506; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	52	51	55	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	1					47	57		10.3109/02699052.2014.947628			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AW1WC	WOS:000346078000007	25259786				2022-02-06	
J	Kore, RA; Abraham, EC				Kore, Rajshekhar A.; Abraham, Edathara C.			Inflammatory cytokines, interleukin-1 beta and tumor necrosis factor-alpha, upregulated in glioblastoma multiforme, raise the levels of CRYAB in exosomes secreted by U373 glioma cells	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						IL-1 beta; TNF-alpha; GBM; Neuroinflammation; Cancer progression; CRYAB	CANCER-RELATED INFLAMMATION; HUMAN BRAIN-TUMORS; B-CRYSTALLIN; EXPRESSION; ROLES; MICROENVIRONMENT; COMMUNICATION; PROGRESSION; BIOGENESIS; INDUCTION	In the brain, levels of inflammatory cytokines, interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), are elevated under traumatic brain injury, neuroinflammatory conditions and glioblastoma multiforme (GBM). In GBM, the levels of small heat shock protein, CRYAB (HspB5) are also reported to be elevated, where it has been shown to exert anti-apoptotic activity. Interestingly, CRYAB is secreted via exosomes by various cells. In order to understand the relation between inflammatory cytokines and CRYAB, U373 glioma cells, were stimulated with proinflammatory cytokines, IL-1 beta and TNF-alpha, and their effect on CRYAB levels in cells and secreted exosomes was studied. Our results show that U373 cells produce and secrete CRYAB via exosomes and that stimulation with IL-1 beta and TNF-alpha, significantly increase the levels of CRYAB in not only the cells but also in the secreted exosomes. In addition, cytokine stimulation of U373 cells brings about changes in the secreted exosomal proteome, many of which are involved in cancer progression. (C) 2014 Elsevier Inc. All rights reserved.	[Kore, Rajshekhar A.; Abraham, Edathara C.] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA		Kore, RA (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham St,Slot 516, Little Rock, AR 72205 USA.	RAKore@uams.edu			NIH/NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY011352-17]; Arkansas IDeA Network for Biomedical Research Excellence [P20GM103429]; UA Center for Protein Structure and Function [P30GM103450]; UAMS Center for Microbial Pathogenesis and Host Inflammatory Responses [P20GM103625]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY011352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103450, P20GM103625, P20GM103429] Funding Source: NIH RePORTER	This study was supported by NIH/NEI Grant R01EY011352-17. The authors would like to acknowledge Jeffrey A. Kamykowski and UAMS Digital Microscopy Core for the electron microscopy images, and the UAMS Proteomics Core supported by the Arkansas IDeA Network for Biomedical Research Excellence (P20GM103429), the UA Center for Protein Structure and Function (P30GM103450), and the UAMS Center for Microbial Pathogenesis and Host Inflammatory Responses (P20GM103625) for proteomics studies. The authors would also like to thank Dr. Samuel G. Mackintosh, Ms. Linley Moreland and Dr. Alan J. Tackett for their help.	Allavena P, 2008, CURR OPIN GENET DEV, V18, P3, DOI 10.1016/j.gde.2008.01.003; AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; Byrum S, 2011, J CUTAN PATHOL, V38, P933, DOI 10.1111/j.1600-0560.2011.01761.x; Byrum Stephanie D, 2013, J Proteomics Bioinform, V6, P43; Cai ZJ, 2012, J IMMUNOL, V188, P5954, DOI 10.4049/jimmunol.1103466; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969; Formolo CA, 2011, J PROTEOME RES, V10, P3149, DOI 10.1021/pr200210w; Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604; Fruhbeis C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00119; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Goplen D, 2010, AM J PATHOL, V177, P1618, DOI 10.2353/ajpath.2010.090063; Gridley DS, 1998, CANCER DETECT PREV, V22, P20, DOI 10.1046/j.1525-1500.1998.00010.x; Guescini M, 2010, J NEURAL TRANSM, V117, P1, DOI 10.1007/s00702-009-0288-8; Gusachenko ON, 2013, BIOCHEMISTRY-MOSCOW+, V78, P1, DOI 10.1134/S000629791301001X; Henderson MC, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00038; Hitotsumatsu T, 1996, CANCER, V77, P352, DOI 10.1002/(SICI)1097-0142(19960115)77:2<352::AID-CNCR19>3.3.CO;2-Q; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; Hosseini Hamideh Mahmoodzadeh, 2013, Inflammation & Allergy Drug Targets, V12, P29; Ilyin SE, 2000, BRAIN RES BULL, V51, P29, DOI 10.1016/S0361-9230(99)00190-2; IWAKI T, 1991, CANCER, V68, P2230, DOI 10.1002/1097-0142(19911115)68:10<2230::AID-CNCR2820681023>3.0.CO;2-7; Kahlert C, 2013, J MOL MED, V91, P431, DOI 10.1007/s00109-013-1020-6; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Kucharzewska P., 2013, P NATL ACAD SCI US; Liu CR, 2006, J IMMUNOL, V176, P1375, DOI 10.4049/jimmunol.176.3.1375; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118; Ohno S, 2013, ADV DRUG DELIVER REV, V65, P398, DOI 10.1016/j.addr.2012.07.019; Polisetty RV, 2011, J PROTEOMICS, V74, P1918, DOI 10.1016/j.jprot.2011.05.002; Putz U, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003084; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Stegh AH, 2008, P NATL ACAD SCI USA, V105, P10703, DOI 10.1073/pnas.0712034105; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Tarassishin L, 2014, J PROTEOMICS, V99, P152, DOI 10.1016/j.jprot.2014.01.024; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tian TA, 2010, J CELL BIOCHEM, V111, P488, DOI 10.1002/jcb.22733; Venugopal C, 2012, J NEURO-ONCOL, V109, P457, DOI 10.1007/s11060-012-0917-1; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Zhou W., 2014, J CANC RES CLIN ONCO	40	51	53	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	OCT 24	2014	453	3					326	331		10.1016/j.bbrc.2014.09.068			6	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	CC3RR	WOS:000350267500007	25261722	Green Accepted			2022-02-06	
J	Kelly, KC; Jordan, EM; Joyner, AB; Burdette, GT; Buckley, TA				Kelly, Kassandra C.; Jordan, Erin M.; Joyner, A. Barry; Burdette, G. Trey; Buckley, Thomas A.			National Collegiate Athletic Association Division I Athletic Trainers' Concussion-Management Practice Patterns	JOURNAL OF ATHLETIC TRAINING			English	Article						baseline testing; head injuries; return to participation	ERROR SCORING SYSTEM; SPORT-RELATED CONCUSSION; MEDICINE PROFESSIONALS; PERFORMANCE; PLAYERS	Context: A cornerstone of the recent consensus statements on concussion is a multifaceted concussion-assessment program at baseline and postinjury and when tracking recovery. Earlier studies of athletic trainers' (ATs') practice patterns found limited use of multifaceted protocols; however, these authors typically grouped diverse athletic training settings together. Objective: To (1) describe the concussion-management practice patterns of National Collegiate Athletic Association (NCAA) Division I ATs, (2) compare these practice patterns to earlier studies, and (3) objectively characterize the clinical examination. Design: Cross-sectional study. Setting: Online survey. Patients or Other Participants: A total of 610 ATs from NCAA Division I institutions, for a response rate of 34.4%. Main Outcome Measure(s): The survey had 3 subsections: demographic questions related to the participant's experiences, concussion-assessment practice patterns, and concussion-recovery and return-to-participation practice patterns. Specific practice-pattern questions addressed balance, cognitive and mental status, neuropsychological testing, and self-reported symptoms. Finally, specific components of the clinical examination were examined. Results: We identified high rates of multifaceted assessments (ie, assessments using at least 3 techniques) during testing at baseline (71.2%), acute concussion assessment (79.2%), and return to participation (66.9%). The specific techniques used are provided along with their adherence with evidence-based practice findings. Respondents endorsed a diverse array of clinical examination techniques that often overlapped objective concussion-assessment protocols or were likely used to rule out associated potential conditions. Respondents were cognizant of the Third International Consensus Statement, the National Athletic Trainers' Association position statement, and the revised NCAA Sports Medicine Handbook recommendations. Conclusions: Athletic trainers in NCAA Division I demonstrated widespread use of multifaceted concussion-assessment techniques and appeared compliant with recent consensus statements and the NCAA Sports Medicine Handbook.	[Kelly, Kassandra C.; Jordan, Erin M.; Joyner, A. Barry; Burdette, G. Trey] Georgia So Univ, Dept Hlth & Kinesiol, Statesboro, GA 30460 USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA		Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, 144 Human Performance Lab,541 South Coll Ave, Newark, DE 19716 USA.	TBuckley@UDel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150			[Anonymous], NCAA DIV 1 INT ATHL; Bey T, 2009, WEST J EMERG MED, V10, P6; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Ferrara Michael S., 2001, J Athl Train, V36, P145; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Impact Applications Inc, IMP TEST FREQ ASK QU; Klossner D, 2010, NATL COLLEGIATE ATHL; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Onate JA, 2000, J ATHL TRAINING, V35, P155; Onate JA, 2007, J ATHL TRAINING, V42, P446; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Schwartz A., 2010, NEW YORK TIMES  0917, pD5; Schwartz A., 2010, SUICIDE REVEALS SIGN, pA1; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	28	51	51	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2014	49	5					665	673		10.4085/1062-6050-49.3.25			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	AY4NN	WOS:000347555600014	25188315	Green Published, Bronze			2022-02-06	
J	Castro, CA; Kintzle, S				Castro, Carl Andrew; Kintzle, Sara			Suicides in the Military: The Post-Modern Combat Veteran and the Hemingway Effect	CURRENT PSYCHIATRY REPORTS			English	Article						Military; Suicide; Veteran; Combat; Interpersonal-psychological theory of suicide; Military transition theory; Modern veteran; Hemingway effect	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; US MILITARY; PERSONNEL; ARMY; PTSD; COMORBIDITY; BEHAVIOR; IRAQ; CARE	Suicides in the military have increased over the last ten years. Much effort has been focused on suicide prevention and treatment, as well as understanding the reasons for the sharp increase in military suicides. Despite this effort, the definitive causes of military suicides remain elusive. Further, highly effective suicide prevention and treatment approaches have not yet been developed. The purpose of this article is to present a short review of the current state of suicide prevention interventions within the context of the military. The root causes of suicidal behavior and the role of combat in the military are each discussed. Interpersonal-psychological theory of suicide and the military transition theory are introduced as guiding frameworks for understanding suicides and suicidal behavior amongst active military personnel and military veterans. The article concludes with a set of recommendations for moving forward in understanding and addressing suicides in the military.	[Castro, Carl Andrew; Kintzle, Sara] Univ So Calif, Sch Social Work, Ctr Innovat & Res Vet & Mil Families, Los Angeles, CA 90015 USA		Castro, CA (corresponding author), Univ So Calif, Sch Social Work, Ctr Innovat & Res Vet & Mil Families, 1150 South Olive,Suite 1400, Los Angeles, CA 90015 USA.	carl.castro@usc.edu; kintzle@usc.edu					Adler AB, 2013, MILITARY BEHAV HLTH, V1, P41, DOI DOI 10.1080/21635781.2012.721063; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; [Anonymous], 2014, GUIDE US MILITARY CA; [Anonymous], 2012, EXCEPT PARENT, V42, P55; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Baker C., 1969, ERNST HEMINGWAY LIFE; Baldessarini RJ, 2004, HARVARD REV PSYCHIAT, V12, P1, DOI 10.1080/10673220490425915; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Bartone Paul T, 2013, Int J Emerg Ment Health, V15, P299; Brenner L.A., 2008, J MENTAL HEALTH COUN, V30, P211, DOI [10.17744/mehc.30.3.n6418tm72231j606, DOI 10.17744/MEHC.30.3.N6418TM72231J606]; Bryan CJ, 2014, J AFFECT DISORDERS, V159, P15, DOI 10.1016/j.jad.2014.02.021; Bryan CJ, 2013, J CLIN PSYCHOL, V69, P64, DOI 10.1002/jclp.21932; Castro CA, 2007, TRAUMATOLOGY, V13, P6, DOI [DOI 10.1177/1534765607309950, 10.1177/1534765607309950]; Castro CA, 2014, S ANN M SOC SO UNPUB; Conner KR, 2013, J ABNORM PSYCHOL, V122, P256, DOI 10.1037/a0030163; Crum-Cianflone N., 2013, MILITARY HLTH CARE P; Department of Veterans Affairs. Epidemiology Program Post Deployment Health Group Office of Public Health Veterans Health Administration, REP VA FAC SPEC OP E; DoDSER 2011 Department of Defense National Center for Telehealth & Technology (T2) Defense Centers of Excellence for Psychological Health & TBI (DCoE) & T2health.org, 2011, DODSER CAL YEAR 2011; DoDSER Department of Defense National Center for Telehealth & Technology (T2) Defense Centers of Excellence for Psychological Health & TBI (DCoE) & T2health.org, 2012, DODSER CAL YEAR 2012; Eaton KM, 2006, SUICIDE LIFE-THREAT, V36, P182, DOI 10.1521/suli.2006.36.2.182; Joiner T., 2005, WHY PEOPLE DIE SUICI, DOI [10.1037/13748-018, DOI 10.1037/13748-018]; Joiner T.E., 2005, WHY PEOPLE DIE SUICI; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; Kaplan MS, 2012, AM J PUBLIC HEALTH, V102, pS131, DOI 10.2105/AJPH.2011.300445; Kemp J, 2012, SUICIDE DATA REPORT; Lambert MT, 1997, J MENT HEALTH ADMIN, V24, P350, DOI 10.1007/BF02832668; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; Mann JJ, 1999, J CLIN PSYCHIAT, V60, P7; McGuffin P, 2001, Crisis, V22, P61, DOI 10.1027//0227-5910.22.2.61; Mental Health Advisory Team (MHAT), 2003, OP IR FREED OIF MENT; Mental Health Advisory Team (MHAT-III), 2006, 0406 MHAT 3 SURG MUL; Mental Health Advisory Team (MHAT-IV), 2006, 0507 MHAT 4 SURG MUL; MSMR Armed Forces Health Surveillance Center, 2014, MED SURVEILL MONTHLY, V21, P1; Murphy Sherry L, 2013, Natl Vital Stat Rep, V61, P1; Nicholson NR, 2009, J ADV NURS, V65, P1342, DOI 10.1111/j.1365-2648.2008.04959.x; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Nock MK, 2013, PSYCHIATRY, V76, P97, DOI 10.1521/psyc.2013.76.2.97; Ramsawh HJ, 2014, J AFFECT DISORDERS, V161, P116, DOI 10.1016/j.jad.2014.03.016; Rosel P, 2000, PSYCHIAT RES-NEUROIM, V99, P173, DOI 10.1016/S0925-4927(00)00076-7; Rudd MD, 2011, PROF PSYCHOL-RES PR, V42, P354, DOI 10.1037/a0025164; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; Schoenbaum M, 2014, JAMA PSYCHIAT, V71, P493, DOI 10.1001/jamapsychiatry.2013.4417; Thomsen CJ, 2011, J PSYCHIATR RES, V45, P1321, DOI 10.1016/j.jpsychires.2011.04.003; Wilson KG, 2013, REHABIL PSYCHOL, V58, P111, DOI 10.1037/a0031390; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900	46	51	52	4	41	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1523-3812	1535-1645		CURR PSYCHIAT REP	Curr. Psychiatry Rep.	AUG	2014	16	8							460	10.1007/s11920-014-0460-1			9	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	AM4CX	WOS:000339801200002	24930521				2022-02-06	
J	Duclos, C; Dumont, M; Blais, H; Paquet, J; Laflamme, E; de Beaumont, L; Wiseman-Hakes, C; Menon, DK; Bernard, F; Gosselin, N				Duclos, Catherine; Dumont, Marie; Blais, Helene; Paquet, Jean; Laflamme, Elyse; de Beaumont, Louis; Wiseman-Hakes, Catherine; Menon, David K.; Bernard, Francis; Gosselin, Nadia			Rest-Activity Cycle Disturbances in the Acute Phase of Moderate to Severe Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; sleep; circadian rhythms; actigraphy; intensive care	MECHANICALLY VENTILATED PATIENTS; CIRCADIAN-RHYTHMS; SLEEP RESTRICTION; HEAD-INJURY; ACTIGRAPHY; CONSEQUENCES; IMPACT; SCALE; CLASSIFICATION; VALIDATION	Background. Sleep-wake disturbances are among the most persistent sequelae after traumatic brain injury (TBI) and probably arise during the hospital stay following TBI. These disturbances are characterized by difficulties sleeping at night and staying awake during the day. Objective. The aim of the present study was to document rest-activity cycle consolidation in acute moderate/severe TBI using actigraphy and to assess its association with injury severity and outcome. Methods. In all, 16 hospitalized patients (27.1 +/- 11.3 years) with moderate/severe TBI wore actigraphs for 10 days, starting in the intensive care unit (ICU) when continuous sedation was discontinued and patients had reached medical stability. Activity counts were summed for daytime (7: 00-21: 59 hours) and nighttime periods (22: 00-6: 59 hours). The ratio of daytime period activity to total 24-hour activity was used to quantify rest-activity cycle consolidation. An analysis of variance was carried out to characterize the evolution of the daytime activity ratio over the recording period. Results. Rest-activity cycle was consolidated only 46.6% of all days; however, a significant linear trend of improvement was observed over time. Greater TBI severity and longer ICU and hospital lengths of stay were associated with poorer rest-activity cycle consolidation and evolution. Patients with more rapid return to consolidated rest-activity cycle were more likely to have cleared posttraumatic amnesia and have lower disability at hospital discharge. Conclusions. Patients with acute moderate/severe TBI had an altered rest-activity cycle, probably reflecting severe fragmentation of sleep and wake episodes, which globally improved over time. A faster return to rest-activity cycle consolidation may predict enhanced brain recovery.	[Duclos, Catherine; Dumont, Marie; Blais, Helene; Paquet, Jean; Laflamme, Elyse; de Beaumont, Louis; Wiseman-Hakes, Catherine; Bernard, Francis; Gosselin, Nadia] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada; [Duclos, Catherine; Dumont, Marie; Wiseman-Hakes, Catherine; Bernard, Francis; Gosselin, Nadia] Univ Montreal, Montreal, PQ, Canada; [de Beaumont, Louis] Univ Quebec Trois Rivieres, Trois Rivieres, PQ GA9 5H7, Canada; [Menon, David K.] Univ Cambridge, Cambridge, England		Gosselin, N (corresponding author), Hop Sacre Coeur, Ctr Adv Res Sleep Med, 5400 Boul Gouin Ouest,Local E-0330, Montreal, PQ H4J 1C5, Canada.	nadia.gosselin@umontreal.ca	Wiseman-Hakes, Catherine/AAC-8303-2021	Wiseman-Hakes, Catherine/0000-0001-8441-884X	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Fonds pour la recherche du Quebec, Sante (FRQS); University of Montreal; Fondation Neurotrauma Marie-Robert; Reseau provincial de recherche en adaptation-readaptation (REPAR); J. A. De Seve foundation; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The research was supported by the Canadian Institutes of Health Research (CIHR), by the Fonds pour la recherche du Quebec, Sante (FRQS), by the University of Montreal (studentship to CD), by the Fondation Neurotrauma Marie-Robert (studentship to CD), by the Reseau provincial de recherche en adaptation-readaptation (REPAR) (studentship to CWH), and by the J. A. De Seve foundation (studentship to CD).	Barion A, 2007, SLEEP MED, V8, P566, DOI 10.1016/j.sleep.2006.11.017; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Beecroft JM, 2008, INTENS CARE MED, V34, P2076, DOI 10.1007/s00134-008-1180-y; Bijwadia JS, 2009, CURR OPIN CRIT CARE, V15, P25, DOI 10.1097/MCC.0b013e3283220dc7; Blood ML, 1997, SLEEP, V20, P388; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chae KY, 2009, SLEEP MED, V10, P621, DOI 10.1016/j.sleep.2008.07.009; Cooper AB, 2000, CHEST, V117, P809, DOI 10.1378/chest.117.3.809; Czeisler CA, 2007, COLD SPRING HARB SYM, V72, P579, DOI 10.1101/sqb.2007.72.064; de Souza L, 2003, SLEEP, V26, P81, DOI 10.1093/sleep/26.1.81; Dispersyn G, 2008, CHRONOBIOL INT, V25, P835, DOI 10.1080/07420520802551386; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Gehlbach BK, 2012, SLEEP, V35, P1105, DOI 10.5665/sleep.1998; Goel N, 2009, SEMIN NEUROL, V29, P320, DOI 10.1055/s-0029-1237117; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Haack M, 2007, SLEEP, V30, P1145, DOI 10.1093/sleep/30.9.1145; Hagen C, 1972, RANCHO LOS AMIGOS LE; Hardin KA, 2009, CHEST, V136, P284, DOI 10.1378/chest.08-1546; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lichstein KL, 2006, SLEEP, V29, P232; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin JL, 2011, CHEST, V139, P1514, DOI 10.1378/chest.10-1872; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mullington JM, 2009, PROG CARDIOVASC DIS, V51, P294, DOI 10.1016/j.pcad.2008.10.003; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Natale V, 2009, SLEEP, V32, P767, DOI 10.1093/sleep/32.6.767; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Padhye NS, 2007, BIOL RES NURS, V9, P30, DOI 10.1177/1099800407303509; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Robillard R, 2011, SLEEP, V34, P335, DOI 10.1093/sleep/34.3.335; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; TEASDALE G, 1974, LANCET, V2, P81; Van Der Werf YD, 2009, NAT NEUROSCI, V12, P122, DOI 10.1038/nn.2253; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P2119, DOI 10.1210/jc.2003-031562; Walker MP, 2004, CELL MOL LIFE SCI, V61, P3009, DOI 10.1007/s00018-004-4351-1; Wang SY, 2010, CANCER NURS, V33, pE11, DOI 10.1097/NCC.0b013e3181b3278e; Wiseman-Hakes C., 2009, CRIT REV PHYS REHABI, V21, P317, DOI [10.1615/CritRevPhysRehabilMed.v21.i3-4.70, DOI 10.1615/CRITREVPHYSREHABILMED.V21.I3-4.70]; Wiseman-Hakes C, 2011, BRAIN INJURY, V25, P1256, DOI 10.3109/02699052.2011.608215	48	51	53	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUN	2014	28	5					472	482		10.1177/1545968313517756			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	AN6SQ	WOS:000340727700009	24379082	Green Submitted			2022-02-06	
J	Zatzick, D; Donovan, DM; Jurkovich, G; Gentilello, L; Dunn, C; Russo, J; Wang, J; Zatzick, CD; Love, J; McFadden, C; Rivara, FP				Zatzick, Douglas; Donovan, Dennis M.; Jurkovich, Gregory; Gentilello, Larry; Dunn, Chris; Russo, Joan; Wang, Jin; Zatzick, Christopher D.; Love, Jeff; McFadden, Collin; Rivara, Frederick P.			Disseminating alcohol screening and brief intervention at trauma centers: a policy-relevant cluster randomized effectiveness trial	ADDICTION			English	Article						Alcohol; policy mandate; motivational interviewing; dissemination and implementation research; traumatic brain injury; American College of Surgeons; screening and brief intervention	POSTTRAUMATIC-STRESS-DISORDER; EMERGENCY-DEPARTMENTS; SUBSTANCE USE; PRIMARY-CARE; INJURY; DRINKING; HEALTH; RISK; ADULTS	Background and Aims In 2005 the American College of Surgeons passed a mandate requiring that level I trauma centers have mechanisms to identify and intervene with problem drinkers. The aim of this investigation was to determine if a multi-level trauma center intervention targeting both providers and patients would lead to higher-quality alcohol screening and brief intervention (SBI) when compared with trauma center mandate compliance without implementation enhancements. Design Cluster randomized trial in which intervention site (site n = 10, patient n = 409) providers received 1-day workshop training on evidence-based motivational interviewing (MI) alcohol interventions and four 30-minute feedback and coaching sessions; control sites (site n = 10, patient n = 469) implemented the mandate without study team training enhancements. Setting Trauma centers in the United States of America. Participants A total of 878 blood alcohol-positive in-patients with and without traumatic brain injury (TBI). Measurements MI skills of providers were assessed with fidelity coded standardized patient interviews. All patients were interviewed at baseline and 6- and 12-months post-injury with the Alcohol Use Disorders Identification Test (AUDIT). Findings Intervention site providers consistently demonstrated enhanced MI skills compared with control providers. Intervention patients demonstrated an 8% reduction in AUDIT hazardous drinking relative to controls over the course of the year after injury (relative risk = 0.88, 95%, confidence interval = 0.79, 0.98). Intervention patients were more likely to demonstrate improvements in alcohol use problems in the absence of traumatic brain injury (TBI) (P = 0.002). Conclusion Trauma center providers can be trained to deliver higher-quality alcohol screening and brief intervention (SBI) than untrained providers, which is associated with modest reductions in alcohol use problems, particularly among patients without TBI.	[Zatzick, Douglas; Gentilello, Larry; Wang, Jin] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Donovan, Dennis M.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Alcohol & Drug Abuse Inst, Seattle, WA 98195 USA; [Jurkovich, Gregory] Denver Hlth Care Colorado, Dept Surg, Denver, CO USA; [Dunn, Chris; Russo, Joan; Love, Jeff; McFadden, Collin] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Zatzick, Christopher D.] Simon Fraser Univ, Business Adm, Burnaby, BC V5A 1S6, Canada; [Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA		Zatzick, D (corresponding author), Dept Psychiat & Behav Sci, 325 Ninth Ave Box 359960, Seattle, WA 98104 USA.	dzatzick@u.washington.edu		Donovan, Dennis/0000-0003-2237-4292	National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01/AA016102]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24/MH086814]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH086814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA016102] Funding Source: NIH RePORTER	Thisworkwas supported by National Institute on Alcohol Abuse and Alcoholism R01/AA016102 and National Institute of Mental Health K24/MH086814 grants to Dr Zatzick. The investigators would like to acknowledge the contribution of Roselyn Peterson BA for her contribution to the preparation of the references and proofreading the submission. She received no additional compensation for her work on the manuscript. The investigators also wish to acknowledge participating trauma centers and trauma surgical champions, including: William 'Bill' Charash MD (Fletcher Allen Healthcare, Burlington, VT); Frederic 'Ric' Cole MD (Legacy Emanuel Hospital and Health Center, Portland, OR); John Griswold MD (Texas Tech University Health Sciences Center, Lubbock, TX); Rajan Gupta MD (Dartmouth-Hitchcock Medical Center, Lebanon, NH); Charles Hu MD (Scottsdale Healthcare, Scottsdale, AZ); Toan Huynh MD (Carolina's Medical Center, Charlotte, NC); Michael E. Lekawa MD (University of California, Irvine, Orange, CA); David Livingston MD (New Jersey Trauma Center, University Hospital, Newark, NJ); Michael Moncure MD(University of Kansas Hospital, Kansas City, KS); Ernest Moore MD (Denver Health, Denver, CO); Lena M. Napolitano MD (University of Michigan, Ann Arbor, MI); Joseph Nold MD (Via Christi Regional Medical Center, Wichita, KS); Steven E. Ross MD (Cooper University Hospital, Camden, NJ); Scott Sagraves, MD (Vidant Medical Center, Greenville, NC); John Sherck MD (Santa Clara Valley Medical Center, San Jose, CA); Steven Steinberg MD (Ohio State University Medical System, Columbus, OH); Ronald Stewart MD (University Health System, San Antonio, TX); Fresca Swaniker MD (Borgess Medical Center, Kalamazoo, MI); Gail T. Tominaga MD (Scripps Memorial Hospital, La Jolla, CA, Trauma Services); and Robert Winchell MD (Maine Medical Center, Portland, ME).	Adams RS, 2012, J SOC WORK PRACT ADD, V12, P28, DOI 10.1080/1533256X.2012.647580; *AM COLL SURG COMM, 2006, RES OPT CAR INJ PAT; American College of Surgeons US Department of Health and Human Services Department of Transportation, 2010, ALC SCREEN BRIEF INT; Babor T., 1989, ALCOHOL USE DISORDER; Bergen GS., 2008, INJURY US 2007 CHART; Bernstein JA, 2010, DRUG ALCOHOL REV, V29, P498, DOI 10.1111/j.1465-3362.2010.00174.x; Bonnie R.J., 1999, REDUCING BURDEN INJU; Bray JW, 2011, MED CARE, V49, P287, DOI 10.1097/MLR.0b013e318203624f; Civil ID, 1985, ABBREVIATED INJURY S; Corrigan JD, 2013, AM J PSYCHIAT, V170, P351, DOI 10.1176/appi.ajp.2012.12121602; Cunningham RM, 2009, ACAD EMERG MED, V16, P1078, DOI 10.1111/j.1553-2712.2009.00552.x; D'Onofrio G, 2012, ANN EMERG MED, V60, P181, DOI 10.1016/j.annemergmed.2012.02.006; D'Onofrio G, 2010, ANN EMERG MED, V56, P551, DOI 10.1016/j.annemergmed.2010.06.562; Donovan DM, 2012, ADDICT SCI CLIN PRAC, V7, DOI 10.1186/1940-0640-7-16; Dunn Chris, 2003, Semin Clin Neuropsychiatry, V8, P188, DOI 10.1016/S1084-3612(03)00025-X; Field CA, 2010, ALCOHOL CLIN EXP RES, V34, P2004, DOI 10.1111/j.1530-0277.2010.01297.x; Field CA, 2010, ADDICTION, V105, P62, DOI 10.1111/j.1360-0443.2009.02737.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gentilello LM, 2005, ANN SURG, V241, P541, DOI 10.1097/01.sla.0000157133.80396.1c; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Gibbons RD, 2010, ANNU REV CLIN PSYCHO, V6, P79, DOI 10.1146/annurev.clinpsy.032408.153550; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; Havard A, 2008, ADDICTION, V103, P368, DOI 10.1111/j.1360-0443.2007.02072.x; Institute of Medicine (US) Committee on Quality of Health Care in America ebrary Inc, 2012, SUBST US DIS US ARM; *J HOPK HLTH SERV, 1989, DET INJ SEV HOSP DIS; Jonas DE, 2012, ANN INTERN MED, V157, P645, DOI 10.7326/0003-4819-157-9-201211060-00544; Klar, 2000, DESIGN ANAL CLUSTER; Koepsell TD, 2011, AM J PREV MED, V40, P191, DOI 10.1016/j.amepre.2010.10.022; Madras BK, 2009, DRUG ALCOHOL DEPEN, V99, P280, DOI 10.1016/j.drugalcdep.2008.08.003; McGlynn EA, 2003, NEW ENGL J MED, V349, P1867; Miller WR, 1995, DRINKER INVENTORY CO; Miller WR, 1996, FORM 90 STRUCTURED A; Moyers TB, 2005, J SUBST ABUSE TREAT, V28, P19, DOI 10.1016/j.jsat.2004.11.001; Murray D. M., 1998, DESIGN ANAL GROUP RA; National Center for Injury Prevention, 2012, CDC 2012; National Institute on Alcohol Abuse and Alcoholism, MOD BING DRINK; Neumann T, 2004, ALCOHOL CLIN EXP RES, V28, P1693, DOI 10.1097/01.ALC.0000145696.58084.08; Nilsen P, 2008, J SUBST ABUSE TREAT, V35, P184, DOI 10.1016/j.jsat.2007.09.008; Oliver I, 2012, IEEE IC COMP COM NET; Perl HI, 2011, ADDICT BEHAV, V36, P590, DOI 10.1016/j.addbeh.2011.01.027; Raghavan R., 2012, DISSEMINATION IMPLEM, P89; Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7; Rogers E., 1995, DIFFUSION INNOVATION, V4th edn.; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2; Rose G., 1992, STRATEGY PREVENTIVE; Roudsari B, 2006, INJURY, V37, P614, DOI 10.1016/j.injury.2006.02.010; Sander AM, 2012, J HEAD TRAUMA REHAB, V27, P319, DOI 10.1097/HTR.0b013e318269838c; Schermer CR, 2006, J TRAUMA, V60, P29, DOI 10.1097/01.ta.0000199420.12322.5d; Sobell LC, 2003, ASSESSING ALCOHOL PR, V2, P75; Soderstrom CA, 1997, JAMA-J AM MED ASSOC, V277, P1769, DOI 10.1001/jama.277.22.1769; Soderstrom CA, 2007, J TRAUMA, V62, P1102, DOI 10.1097/TA.0b013e31804bdb26; Sommers MS, 2006, J TRAUMA, V61, P523, DOI 10.1097/01.ta.0000221756.67126.91; Sommers MS, 2000, ALCOHOL CLIN EXP RES, V24, P1406, DOI 10.1097/00000374-200009000-00012; TEASDALE G, 1974, LANCET, V2, P81; Terrell F, 2008, J AM COLL SURGEONS, V207, P630, DOI 10.1016/j.jamcollsurg.2008.05.021; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Whitlock EP, 2004, ANN INTERN MED, V140, P557, DOI 10.7326/0003-4819-140-7-200404060-00017; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick D, 2013, ANN SURG, V257, P390, DOI 10.1097/SLA.0b013e31826bc313; Zatzick D, 2012, J SUBST ABUSE TREAT, V43, P410, DOI 10.1016/j.jsat.2012.08.009; Zatzick DF, 2013, GEN HOSP PSYCHIAT, V35, P174, DOI 10.1016/j.genhosppsych.2012.11.012; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	64	51	51	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0965-2140	1360-0443		ADDICTION	Addiction	MAY	2014	109	5					754	765		10.1111/add.12492			12	Substance Abuse; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Substance Abuse; Psychiatry	AE4XO	WOS:000333990500014	24450612	Green Accepted			2022-02-06	
J	Cook, JM; Dinnen, S; Simiola, V; Thompson, R; Schnurr, PP				Cook, Joan M.; Dinnen, Stephanie; Simiola, Vanessa; Thompson, Richard; Schnurr, Paula P.			VA Residential Provider Perceptions of Dissuading Factors to the Use of Two Evidence-Based PTSD Treatments	PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE			English	Article						evidence-based treatment; posttraumatic stress disorder; provider perspectives	POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE PROCESSING THERAPY; TRAUMATIC BRAIN-INJURY; PROLONGED EXPOSURE; PSYCHOLOGICAL TREATMENTS; PERSONALITY-DISORDERS; VETERANS; PSYCHOTHERAPY; TRIAL; SURVIVORS	Providers (N = 198) from 38 Department of Veterans Affairs residential posttraumatic stress disorder treatment programs across the United States completed qualitative interviews regarding implementation of 2 evidence-based treatments: prolonged exposure and cognitive processing therapy. As part of this investigation, providers were asked how they decide which patients are appropriate for these treatments. Many indicated that they did not perceive any patient factors that dissuade their use of either evidence-based treatment. However, 3 broad categories emerged surrounding reasons that patients were perceived to be less suitable candidates for the treatments: the presence of psychiatric comorbidities, cognitive limitations, and low levels of patient motivation. Interestingly, providers' perceived reasons for limited or nonuse of a treatment did not correspond entirely to those espoused by treatment developers. Possible solutions to address provider concerns, including educational and motivational interventions, are noted.	[Cook, Joan M.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA; [Dinnen, Stephanie; Simiola, Vanessa] Yale Univ, Sch Med, West Haven, CT 06516 USA; [Cook, Joan M.; Dinnen, Stephanie; Simiola, Vanessa] Natl Ctr PTSD, West Haven, CT USA; [Thompson, Richard] Univ Illinois, Chicago, IL USA; [Schnurr, Paula P.] Natl Ctr PTSD, White River Jct, VT USA; [Schnurr, Paula P.] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA		Cook, JM (corresponding author), Yale Univ, Sch Med, Northeast Program Evaluat Ctr 182, 950 Campbell Ave, West Haven, CT 06516 USA.	joan.cook@yale.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RC1 MH088454] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RC1MH088454] Funding Source: NIH RePORTER		Alvarez J, 2011, J CONSULT CLIN PSYCH, V79, P590, DOI 10.1037/a0024466; Bass JK, 2013, NEW ENGL J MED, V368, P2182, DOI 10.1056/NEJMoa1211853; Beck A., 1985, ANXIETY DISORDERS PH; Becker CB, 2004, BEHAV RES THER, V42, P277, DOI 10.1016/S0005-7967(03)00138-4; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Cloitre M, 2010, AM J PSYCHIAT, V167, P915, DOI 10.1176/appi.ajp.2010.09081247; Cook JM, 2013, J TRAUMA STRESS, V26, P56, DOI 10.1002/jts.21769; Cook JM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-59; Desai R, 2010, LONG JOURNEY HOME; Foa E., 1986, PSYCHOL BULL, V132, P20, DOI DOI 10.1037/0033-2909.99.1.20; Foa E.B., 2007, PROLONGED EXPOSURE T; Foa EB, 2005, J CONSULT CLIN PSYCH, V73, P953, DOI 10.1037/0022-006X.73.5.953; Foa EB, 2002, J CONSULT CLIN PSYCH, V70, P1022, DOI 10.1037//0022-006X.70.4.1022; Foa EB, 2009, EFFECTIVE TREATMENTS, V2nd; Foa EB, 2013, JAMA-J AM MED ASSOC, V310, P488, DOI 10.1001/jama.2013.8268; Frueh BC, 2009, J ANXIETY DISORD, V23, P665, DOI 10.1016/j.janxdis.2009.02.005; Glasgow RE, 2013, HEALTH EDUC BEHAV, V40, P257, DOI 10.1177/1090198113486805; Greenhalgh T, 2005, DIFFUSION INNOVATION, DOI [10.1002/9780470987407, DOI 10.1002/9780470987407]; Hembree EA, 2004, J PERS DISORD, V18, P117, DOI 10.1521/pedi.18.1.117.32767; Hembree EA, 2003, J TRAUMA STRESS, V16, P555, DOI 10.1023/B:JOTS.0000004078.93012.7d; Jaycox LH, 1996, CLIN PSYCHOL PSYCHOT, V3, P176; Karlin BE, 2010, J TRAUMA STRESS, V23, P663, DOI 10.1002/jts.20588; LITZ BT, 1990, BEHAV THERAPIST, V13, P91; McCarthy E, 2011, J TRAUMA STRESS, V24, P474, DOI 10.1002/jts.20660; Murphy RT, 2009, PSYCHOL SERV, V6, P264, DOI 10.1037/a0017577; Rauch SAM, 2009, J TRAUMA STRESS, V22, P60, DOI 10.1002/jts.20380; Resick P. A., 1993, COGNITIVE PROCESSING; Resick P. A., 2008, COGNITIVE PROCESSING; Resick PA, 2008, J CONSULT CLIN PSYCH, V76, P243, DOI 10.1037/0022-006X.76.2.243; Rosenheck R, 1997, J TRAUMA STRESS, V10, P407, DOI 10.1002/jts.2490100306; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schottenbauer MA, 2008, PSYCHIATRY, V71, P134, DOI 10.1521/psyc.2008.71.2.134; Shiner B, 2013, ADM POLICY MENT HLTH, V40, P311, DOI 10.1007/s10488-012-0421-0; Sripada RK, 2013, J TRAUMA STRESS, V26, P369, DOI 10.1002/jts.21813; Steenkamp MM, 2013, CLIN PSYCHOL REV, V33, P45, DOI 10.1016/j.cpr.2012.10.002; Tuerk PW, 2011, J ANXIETY DISORD, V25, P397, DOI 10.1016/j.janxdis.2010.11.002; U.S. Department of Veterans Affairs, 2010, VET HLTH ADM HDB VHA, V1160; U. S. Department of Veterans Affairs & U. S. Department of Defense, 2010, VA DOD CLIN PRACT GU; van Dam D, 2012, CLIN PSYCHOL REV, V32, P202, DOI 10.1016/j.cpr.2012.01.004; van Minnen A, 2012, EUR J PSYCHOTRAUMATO, V3, DOI 10.3402/ejpt.v3i0.18805; Walter KH, 2012, COGNITIVE THER RES, V36, P576, DOI 10.1007/s10608-011-9393-8	41	51	52	1	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0735-7028	1939-1323		PROF PSYCHOL-RES PR	Prof. Psychol.-Res. Pract.	APR	2014	45	2					136	142		10.1037/a0036183			7	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	AF7AF	WOS:000334865100008	25309031	Green Accepted			2022-02-06	
J	Darling, SR; Leddy, JJ; Baker, JG; Williams, AJ; Surace, A; Miecznikowski, JC; Willer, B				Darling, Scott R.; Leddy, John J.; Baker, John G.; Williams, Amy J.; Surace, Anthony; Miecznikowski, Jeffrey C.; Willer, Barry			Evaluation of the Zurich Guidelines and Exercise Testing for Return to Play in Adolescents Following Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; computerized neuropsychological testing; return to play; return to sport; exercise; treadmill	SPORTS-RELATED CONCUSSION; NEUROPSYCHOLOGICAL ASSESSMENT; RETEST RELIABILITY; NORMATIVE DATA; TEST FAILURE; RECOVERY; PERFORMANCE; MANAGEMENT; SYMPTOMS	Objective:To evaluate return to play (RTP) and return to classroom outcomes when the Zurich guidelines are combined with a standardized exercise treadmill test [Buffalo Concussion Treadmill Test (BCTT)] and computerized neuropsychological (cNP) testing in adolescent athletes after concussion.Design:Retrospective chart review and follow-up.Setting:University Sports Medicine Concussion Clinic.Participants:One hundred seventeen athletes (75% male) with sport concussion ages 13 to 19 years and telephone follow-up of 91 (77.8%) athletes and their parents.Interventions:Concussed athletes who were asymptomatic at rest completed Automated Neuropsychological Assessment Metrics or Immediate Post-concussion Assessment and Cognitive Test cNP testing followed by the BCTT on the same day. Athletes then followed the Zurich consensus guidelines for RTP.Main Outcome Measures:The primary outcome measure was the degree of success in RTP, that is, RTP with or without return of concussive symptoms. Secondary outcome measure was return to school with or without symptoms.Results:All athletes returned to sport without exacerbation of symptoms. Telephone follow-up revealed that 38.5% experienced new issues upon return to the classroom. Forty-eight percent of athletes had 1 or more cNP subtests below average (<ninth percentile) when asymptomatic. Ultimately, performance on cNP was not predictive of return to school issues.Conclusions:The BCTT in combination with the Zurich consensus guidelines seems to be safe and successful for RTP. There is evidence to suggest that cNP testing performed in athletes who do not have a preinjury baseline test was not related to RTP or problems upon return to school.	[Darling, Scott R.; Leddy, John J.; Baker, John G.; Surace, Anthony] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14214 USA; [Baker, John G.; Williams, Amy J.] SUNY Buffalo, Dept Nucl Med, Buffalo, NY 14214 USA; [Miecznikowski, Jeffrey C.] SUNY Buffalo, Dept Biostat, Buffalo, NY 14214 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14214 USA		Darling, SR (corresponding author), SUNY Buffalo, Dept Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	sdarling@buffalo.edu			Robert Rich Family Foundation; Program for Understanding Childhood Concussion and Stroke; Buffalo Bills (Ralph Wilson) Team Physician Fund; Buffalo Sabres Foundation	The authors wish to thank the following organizations for financial support of the project described in this article: The Robert Rich Family Foundation, Program for Understanding Childhood Concussion and Stroke, Buffalo Bills (Ralph Wilson) Team Physician Fund and the Buffalo Sabres Foundation.	Baker JG, 2012, REHABIL RES PRACT, DOI [10.1155/2012/70539, DOI 10.1155/2012/70539]; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Coppel DB, 2011, PHYS MED REH CLIN N, V22, P653, DOI 10.1016/j.pmr.2011.08.006; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kirkwood MW, 2012, PSYCHOL ASSESSMENT, V24, P36, DOI 10.1037/a0024628; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McAvoy K, 2009, REAP BENEFITS GOOD C; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory Paul, 2009, Scand J Med Sci Sports, V19, P452, DOI 10.1111/j.1600-0838.2009.00978.x; McGrath N, 2013, BRAIN INJURY, V27, P103, DOI 10.3109/02699052.2012.729282; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Performance CftSoHO, 2009, ANAM4 US MAN VERS 4; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Shrier I, 2012, CLIN J SPORT MED, V22, P211, DOI 10.1097/JSM.0b013e31824cc5f9; Team R.D.C, 2008, R LANG ENV STAT COMP; Wellek S., 2010, TESTING STAT HYPOTHE; [No title captured]	31	51	52	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2014	24	2					128	133		10.1097/JSM.0000000000000026			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	AC0WO	WOS:000332216400005	24184849				2022-02-06	
J	Bian, W; Hess, CP; Chang, SM; Nelson, SJ; Lupo, JM				Bian, Wei; Hess, Christopher P.; Chang, Susan M.; Nelson, Sarah J.; Lupo, Janine M.			Susceptibility-weighted MR imaging of radiation therapy-induced cerebral microbleeds in patients with glioma: a comparison between 3T and 7T	NEURORADIOLOGY			English	Article						Cerebral microbleeds; Radiation therapy; Susceptibility-weighted imaging; 7T	TRAUMATIC BRAIN-INJURY; COGNITIVE IMPAIRMENT; VASCULAR DEMENTIA; GUIDE	Cerebral microbleeds have been observed in normal-appearing brain tissue of patients with glioma years after receiving radiation therapy. The contrast of these paramagnetic lesions varies with field strength due to differences in the effects of susceptibility. The purpose of this study was to compare 3T and 7T MRI as platforms for detecting cerebral microbleeds in patients treated with radiotherapy using susceptibility-weighted imaging (SWI). SWI was performed with both 3T and 7T MR scanners on ten patients with glioma who had received prior radiotherapy. Imaging sequences were optimized to obtain data within a clinically acceptable scan time. Both T2*-weighted magnitude images and SWI data were reconstructed, minimum intensity projection was implemented, and microbleeds were manually identified. The number of microbleeds was counted and compared among datasets. Significantly more microbleeds were identified on SWI than magnitude images at both 7T (p = 0.002) and 3T (p = 0.023). Seven-tesla SWI detected significantly more microbleeds than 3T SWI for seven out of ten patients who had tumors located remote from deep brain regions (p = 0.016), but when the additional three patients with more inferior tumors were included, the difference was not significant. SWI is more sensitive for detecting microbleeds than magnitude images at both 3T and 7T. For areas without heightened susceptibility artifacts, 7T SWI is more sensitive to detecting radiation therapy-induced microbleeds than 3T SWI. Tumor location should be considered in conjunction with field strength when selecting the most appropriate strategy for imaging microbleeds.	[Bian, Wei; Nelson, Sarah J.] Univ Calif Berkeley, San Francisco, CA USA; [Bian, Wei; Nelson, Sarah J.] Univ Calif San Francisco, UCSF Grad Program Bioengn, San Francisco, CA 94143 USA; [Bian, Wei; Hess, Christopher P.; Nelson, Sarah J.; Lupo, Janine M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94158 USA; [Chang, Susan M.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Nelson, Sarah J.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA		Lupo, JM (corresponding author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 1700 4th St,Byers Hall Room 303,UCSF Campus Box 2, San Francisco, CA 94158 USA.	janine.lupo@ucsf.edu		Hess, Christopher/0000-0002-5132-5302	UC Discovery grant [ITL-BIO04-10148]; Graduate Education in Medical Sciences (GEMS); Howard Hughes Medical Institute (HHMI)Howard Hughes Medical Institute; General Electric HealthcareGeneral ElectricGE Healthcare; UCSF REAC Cohn & Simon Memorial Fund; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR026845] Funding Source: NIH RePORTER	The authors would like to thank Andre Cote, Adam Elkhaled, Angela Jakary and Trey Jalbert for their work in MR image acquisition and Bert Jimenez and Mary McPolin for their clinical coordination of patient MR scans. This work was supported by UC Discovery grant ITL-BIO04-10148, which is an academic-industry partnership grant with General Electric Healthcare, a UCSF REAC Cohn & Simon Memorial Fund and a fellowship from the Graduate Education in Medical Sciences (GEMS) training program funded by Howard Hughes Medical Institute (HHMI).	Ayaz M, 2010, J MAGN RESON IMAGING, V31, P142, DOI 10.1002/jmri.22001; Charidimou A, 2013, NEURORADIOLOGY, V55, P655, DOI 10.1007/s00234-013-1175-4; Charidimou A, 2011, FUTUR NEUROL, V6, P587, DOI 10.2217/FNL.11.42; Conijn MMA, 2011, AM J NEURORADIOL, V32, P1043, DOI 10.3174/ajnr.A2450; Cordonnier C, 2007, BRAIN, V130, P1988, DOI 10.1093/brain/awl387; Goos JDC, 2009, STROKE, V40, P3455, DOI 10.1161/STROKEAHA.109.558197; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Jin ZY, 2008, J MAGN RESON IMAGING, V28, P327, DOI 10.1002/jmri.21447; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Liu T, 2012, RADIOLOGY, V262, P269, DOI 10.1148/radiol.11110251; Lupo JM, 2012, INT J RADIAT ONCOL, V82, pE493, DOI 10.1016/j.ijrobp.2011.05.046; Lupo JM, 2009, MAGN RESON IMAGING, V27, P480, DOI 10.1016/j.mri.2008.08.003; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; SHAW EG, 1990, ARCH NEUROL-CHICAGO, V47, P1138, DOI 10.1001/archneur.1990.00530100108023; Shobha N, 2009, CAN J NEUROL SCI, V36, P376, DOI 10.1017/S0317167100007162; Theysohn JM, 2011, J MAGN RESON IMAGING, V33, P782, DOI 10.1002/jmri.22513; VALK PE, 1991, AM J NEURORADIOL, V12, P45; van Norden AGW, 2011, STROKE, V42, P3382, DOI 10.1161/STROKEAHA.111.629634; Werring DJ, 2010, J NEUROL SCI, V299, P131, DOI 10.1016/j.jns.2010.08.034	21	51	53	1	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	FEB	2014	56	2					91	96		10.1007/s00234-013-1297-8			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AA2TF	WOS:000330946300001	24281386	Green Accepted			2022-02-06	
J	Horowitz, M				Horowitz, Michal			Heat Acclimation, Epigenetics, and Cytoprotection Memory	COMPREHENSIVE PHYSIOLOGY			English	Article							THERMAL CONTROL ESTABLISHMENT; TRAUMATIC BRAIN-INJURY; UNDERLYING MOLECULAR-MECHANISMS; SUBMAXILLARY SALIVARY-GLAND; ISCHEMIC CROSS-TOLERANCE; ECCRINE SWEAT GLAND; GENE-EXPRESSION; HISTONE H3; NITRIC-OXIDE; THERMOREGULATORY RESPONSES	Heat acclimation is a within-life phenotypic adaptation to heat. Plasticity of the thermoregulatory system is crucial for the induction of heat acclimation. In the last two decades, it has become clear that heat causes adaptive shifts in gene expression which adjust the protein balance. These changes are part of the evolvement of the acclimated phenotype. The molecular-cellular aspects of some acclimatory mechanisms that have only been explained by physiological-effectorial mechanisms have been discovered. This review attempts to bridge the gap between the classic physiological heat acclimation profile and the molecular/cellular mechanisms underlying the evolvement of the acclimated phenotype. Heat acclimation leads to leftward and rightward shifts in temperature thresholds of heat dissipation organs and thermal injury, respectively, thereby expanding the acclimated dynamic thermoregulatory range. Interactions between ambient temperature and afferent drives from effector organs to the hypothalamic thermoregulatory center with modifications in warm/cold sensitive neuron ratio and excitability contribute to the threshold changes. The altered threshold for thermal injury is associated with progressive enhancement of inducible cytoprotective networks, including HSP70, HSF1, and HIF-1 alpha. These molecules are also important in acclimatory kinetics. Aspects of cross-adaption, cross-tolerance and interference with heat acclimation are explained using molecular-cellular physiological interactions, with the heart, skeletal muscles, and water secretory glands as models. Lastly, the roles of epigenetic mechanisms in transcriptional regulation during induction of the acclimated phenotype, its decay, and reinduction are discussed. Posttranslational histone modifications in the promoters of hsp70 and hsp90 form part of our prototype model of heat-acclimation-mediated cytoprotective memory. (C) 2014 American Physiological Society.	Hebrew Univ Jerusalem, Fac Med Dent, Lab Environm Physiol, Jerusalem, Israel		Horowitz, M (corresponding author), Hebrew Univ Jerusalem, Fac Med Dent, Lab Environm Physiol, Jerusalem, Israel.	m.horowitz@mail.huji.ac.il			ISF, Israel Science FoundationIsrael Science Foundation; BSFUS-Israel Binational Science Foundation; US-Israel binational fundUS-Israel Binational Science Foundation; German Israeli FoundationGerman-Israeli Foundation for Scientific Research and Development	The research of the author, cited in this review was supported over the years by the ISF, Israel Science Foundation, founded by the Israel Academy of Sciences and Humanities, BSF, US-Israel binational fund and German Israeli Foundation Research Grants.	Abbas A, 2010, PHYSIOLOGIST, V53, P24; Adolph E.F., 1964, HDB PHYSL SECTION 4, P27; Alexander R, 2012, HEAT ACCLIMATION MED; [Anonymous], 1773, DIS INCIDENTAL EUROP; Arieli Y, 2003, BRAIN RES, V962, P15, DOI 10.1016/S0006-8993(02)03681-8; ARJONA AA, 1990, COMP BIOCHEM PHYS A, V95, P393, DOI 10.1016/0300-9629(90)90238-N; Assayag M, 2012, AM J PHYSIOL-REG I, V303, pR870, DOI 10.1152/ajpregu.00155.2012; Assayag M, 2010, CELL STRESS CHAPERON, V15, P651, DOI 10.1007/s12192-010-0178-x; ATTIAS J, 1988, J THERM BIOL, V13, P175, DOI 10.1016/0306-4565(88)90030-7; Bae JS, 2006, PFLUG ARCH EUR J PHY, V453, P67, DOI 10.1007/s00424-006-0098-x; Baird NA, 2006, J BIOL CHEM, V281, P38675, DOI 10.1074/jbc.M608013200; BAKER MA, 1982, J PHYSIOL-LONDON, V322, P457, DOI 10.1113/jphysiol.1982.sp014049; BAKER MA, 1993, J PHYSIOL-LONDON, V471, P679, DOI 10.1113/jphysiol.1993.sp019922; Barco A, 2005, NEURON, V48, P123, DOI 10.1016/j.neuron.2005.09.005; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bhusari S, 2008, J THERM BIOL, V33, P157, DOI 10.1016/j.jtherbio.2008.01.001; BLIGH J, 1973, J PHYSIOL-LONDON, V229, pP30; Bolli R, 2007, AM J PHYSIOL-HEART C, V292, pH19, DOI 10.1152/ajpheart.00712.2006; Boulant JA, 2006, J APPL PHYSIOL, V100, P1347, DOI 10.1152/japplphysiol.01064.2005; Boulant JA, 2006, AM J PHYSIOL-REG I, V290, pR1481, DOI 10.1152/ajpregu.00655.2005; BOULANT JA, 1989, NEWS PHYSIOL SCI, V4, P245; Brazaitis M, 2010, EUR J APPL PHYSIOL, V109, P771, DOI 10.1007/s00421-010-1429-3; Bromberg Z, 2004, P 1 INT M PHYS PHARM, P198; BROWN M, 1977, SCIENCE, V196, P998, DOI 10.1126/science.860130; BRUCK K, 1987, PHARMACOL THERAPEUT, V35, P163, DOI 10.1016/0163-7258(87)90106-9; Buckley BA, 2002, J EXP BIOL, V205, P3231; Cairns BR, 2009, NATURE, V461, P193, DOI 10.1038/nature08450; CASSUTO Y, 1968, AM J PHYSIOL, V214, P1147, DOI 10.1152/ajplegacy.1968.214.5.1147; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Cheung SS, 1998, J APPL PHYSIOL, V84, P1731, DOI 10.1152/jappl.1998.84.5.1731; CHRISTMAN JV, 1980, J APPL PHYSIOL, V49, P942, DOI 10.1152/jappl.1980.49.6.942; CHRISTMAN JV, 1985, J APPL PHYSIOL, V58, P1923, DOI 10.1152/jappl.1985.58.6.1923; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Cohen O, 2001, J MOL CELL CARDIOL, V33, pA22, DOI 10.1016/S0022-2828(01)90087-2; Cohen O, 2007, J APPL PHYSIOL, V103, P266, DOI 10.1152/japplphysiol.01351.2006; Dahlhoff EP, 2007, J BIOSCIENCES, V32, P477, DOI 10.1007/s12038-007-0047-7; DEAN JB, 1989, AM J PHYSIOL, V257, pR57, DOI 10.1152/ajpregu.1989.257.1.R57; DERAMBURE PS, 1994, AM J PHYSIOL, V266, pR1876, DOI 10.1152/ajpregu.1994.266.6.R1876; DIETZ TJ, 1992, P NATL ACAD SCI USA, V89, P3389, DOI 10.1073/pnas.89.8.3389; DIETZ TJ, 1994, J EXP BIOL, V188, P333; Dokladny K, 2006, AM J PHYSIOL-GASTR L, V290, pG204, DOI 10.1152/ajpgi.00401.2005; Eynan M, 2002, J APPL PHYSIOL, V93, P2095, DOI 10.1152/japplphysiol.00304.2002; Eynan M, 2012, J APPL PHYSIOL, V113, P595, DOI 10.1152/japplphysiol.00228.2012; FEBBRAIO MA, 1994, J APPL PHYSIOL, V76, P589, DOI 10.1152/jappl.1994.76.2.589; FRANCESCONI R, 1982, J APPL PHYSIOL, V52, P734, DOI 10.1152/jappl.1982.52.3.734; Fregly MJ, 1996, COMPREHENSIVE PH S14, V1, P3; Furuyama F, 1998, PHYSIOL BEHAV, V63, P787, DOI 10.1016/S0031-9384(97)00541-6; Gaffney DK, 2000, RADIAT RES, V154, P461, DOI 10.1667/0033-7587(2000)154[0461:EOMTIL]2.0.CO;2; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Garbuz D, 2003, J EXP BIOL, V206, P2399, DOI 10.1242/jeb.00429; Garrett AT, 2012, EUR J APPL PHYSIOL, V112, P1827, DOI 10.1007/s00421-011-2153-3; Garrett AT, 2011, SPORTS MED, V41, P757, DOI 10.2165/11587320-000000000-00000; Geor RJ, 2000, J APPL PHYSIOL, V89, P2283, DOI 10.1152/jappl.2000.89.6.2283; Gershoni M, 2009, BIOESSAYS, V31, P642, DOI 10.1002/bies.200800139; Gerstberger R, 1999, NEWS PHYSIOL SCI, V14, P30; GOLDSPINK G, 1992, SYM SOC EXP BIOL, V46, P139; Haddad W, 1999, J THERM BIOL, V24, P403, DOI 10.1016/S0306-4565(99)00054-6; Haddad W, 1994, ADV PHARM SCI, P203; Haines TH, 2001, PROG LIPID RES, V40, P299, DOI 10.1016/S0163-7827(01)00009-1; HALES JRS, 1984, J THERM BIOL, V9, P113, DOI 10.1016/0306-4565(84)90048-2; HAMMEL HT, 1963, J APPL PHYSIOL, V18, P1146, DOI 10.1152/jappl.1963.18.6.1146; HAMMEL HT, 1960, AM J PHYSIOL, V198, P481, DOI 10.1152/ajplegacy.1960.198.3.481; Heled Y, 2012, AVIAT SPACE ENVIR MD, V83, P649, DOI 10.3357/ASEM.3241.2012; HENSEL H, 1981, FED PROC, V40, P2830; HIESTAND WA, 1955, P SOC EXP BIOL MED, V88, P94; HINCKEL P, 1987, CAN J PHYSIOL PHARM, V65, P1281, DOI 10.1139/y87-204; Hiranandani N, 2006, J APPL PHYSIOL, V100, P1727, DOI 10.1152/japplphysiol.01244.2005; Hom LL, 2012, CELL STRESS CHAPERON, V17, P29, DOI 10.1007/s12192-011-0283-5; Hori S, 1995, JPN J PHYSIOL, V45, P921, DOI 10.2170/jjphysiol.45.921; HORI T, 1991, JPN J PHYSIOL, V41, P1, DOI 10.2170/jjphysiol.41.1; Horowitz M, 2003, NEWS PHYSIOL SCI, V18, P215, DOI 10.1152/nips.01453.2003; Horowitz M, 2004, J APPL PHYSIOL, V97, P1496, DOI 10.1152/japplphysiol.00306.2004; Horowitz M, 1997, ANN NY ACAD SCI, V813, P617, DOI 10.1111/j.1749-6632.1997.tb51755.x; Horowitz M, 2002, COMP BIOCHEM PHYS A, V131, P475, DOI 10.1016/S1095-6433(01)00500-1; HOROWITZ M, 1988, AM J PHYSIOL, V254, pR109, DOI 10.1152/ajpregu.1988.254.1.R109; HOROWITZ M, 1983, COMP BIOCHEM PHYS A, V75, P105, DOI 10.1016/0300-9629(83)90052-X; HOROWITZ M, 1986, J APPL PHYSIOL, V60, P9, DOI 10.1152/jappl.1986.60.1.9; Horowitz M, 2001, J THERM BIOL, V26, P357, DOI 10.1016/S0306-4565(01)00044-4; HOROWITZ M, 1983, COMP BIOCHEM PHYS A, V74, P945, DOI 10.1016/0300-9629(83)90374-2; HOROWITZ M, 1979, J APPL PHYSIOL, V47, P738, DOI 10.1152/jappl.1979.47.4.738; HOROWITZ M, 1985, COMP BIOCHEM PHYS A, V80, P57, DOI 10.1016/0300-9629(85)90678-4; Horowitz M, 1998, NEWS PHYSIOL SCI, V13, P218; Horowitz M, 1996, J APPL PHYSIOL, V80, P77, DOI 10.1152/jappl.1996.80.1.77; HOROWITZ M, 1993, PFLUG ARCH EUR J PHY, V422, P386, DOI 10.1007/BF00374295; HOROWITZ M, 1986, J MOL CELL CARDIOL, V18, P511, DOI 10.1016/S0022-2828(86)80916-6; HOROWITZ M, 1985, COMP BIOCHEM PHYS A, V82, P577, DOI 10.1016/0300-9629(85)90436-0; Horowitz M, 1999, AM J PHYSIOL-REG I, V277, pR47, DOI 10.1152/ajpregu.1999.277.1.R47; HOROWITZ M, 1976, PFLUG ARCH EUR J PHY, V366, P173, DOI 10.1007/BF00585874; Horowitz M., 1993, Journal of Basic and Clinical Physiology and Pharmacology, V4, P139; Horowitz M, 2006, APS M VIRG BEACH; Horowitz M, 2007, PROG BRAIN RES, V162, P373, DOI 10.1016/S0079-6123(06)62018-9; Horowitz M, 2010, MED SCI SPORT EXER, V42, P2164, DOI 10.1249/MSS.0b013e3181e303b0; Horowitz Michal, 2010, Front Biosci (Schol Ed), V2, P1068; Horowitz M, 2010, ANN NY ACAD SCI, V1188, P199, DOI 10.1111/j.1749-6632.2009.05101.x; Horowitz Michal, 1993, Journal of Basic and Clinical Physiology and Pharmacology, V4, P37; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jousset A., 1884, TRAITE ACCLIMATEMENT, V1584; Kaspler P, 1997, ANN NY ACAD SCI, V813, P620, DOI 10.1111/j.1749-6632.1997.tb51756.x; Kaspler P, 2001, AM J PHYSIOL-REG I, V280, pR1688, DOI 10.1152/ajpregu.2001.280.6.R1688; Kaspler Pavel, 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P153; Kassahn KS, 2009, BIOL REV, V84, P277, DOI 10.1111/j.1469-185X.2008.00073.x; Katz A, 2006, J NEUROSCI, V26, P3899, DOI 10.1523/JNEUROSCI.0371-06.2006; KHUDAIBERDIEV M D, 1979, Fiziologicheskii Zhurnal SSSR Imeni I M Sechenova, V65, P1687; Kisliouk T, 2013, NEUROSCIENCE, V238, P114, DOI 10.1016/j.neuroscience.2013.02.020; Kisliouk T, 2011, EUR J NEUROSCI, V33, P224, DOI 10.1111/j.1460-9568.2010.07493.x; Kisliouk T, 2010, DEV NEUROBIOL, V70, P100, DOI 10.1002/dneu.20763; Kisliouk T, 2009, EUR J NEUROSCI, V30, P1909, DOI 10.1111/j.1460-9568.2009.06957.x; KLOOG Y, 1985, BIOCHIM BIOPHYS ACTA, V845, P428, DOI 10.1016/0167-4889(85)90208-3; Kodesh E, 2011, AM J PHYSIOL-REG I, V301, pR1786, DOI 10.1152/ajpregu.00465.2011; Kodesh E, 2010, MED SCI SPORT EXER, V42, P943, DOI 10.1249/MSS.0b013e3181c3ac3f; Kresfelder TL, 2006, J THERM BIOL, V31, P406, DOI 10.1016/j.jtherbio.2006.02.001; Kuennen M, 2011, AM J PHYSIOL-REG I, V301, pR524, DOI 10.1152/ajpregu.00039.2011; Kultz D, 2003, J EXP BIOL, V206, P3119, DOI 10.1242/jeb.00549; Kultz D, 2001, COMP BIOCHEM PHYS A, V130, P421, DOI 10.1016/S1095-6433(01)00440-8; Labrador M, 2003, GENE DEV, V17, P43, DOI 10.1101/gad.1021403; Labunskay G, 2006, J NEUROBIOL, V66, P56, DOI 10.1002/neu.20191; Ladell WS, 1964, ADAPTATION ENV; LEVI E, 1993, J APPL PHYSIOL, V75, P833, DOI 10.1152/jappl.1993.75.2.833; Lewin B., 2000, GENES 7 OXFORD; Li GH, 2008, EUR J APPL PHYSIOL, V104, P29, DOI 10.1007/s00421-008-0772-0; Li QL, 2011, DNA CELL BIOL, V30, P247, DOI 10.1089/dna.2010.1133; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Lorenzo S, 2010, J APPL PHYSIOL, V109, P1736, DOI 10.1152/japplphysiol.00725.2010; Lorenzo S, 2010, J APPL PHYSIOL, V109, P1140, DOI 10.1152/japplphysiol.00495.2010; LYASHKO VN, 1994, P NATL ACAD SCI USA, V91, P12492, DOI 10.1073/pnas.91.26.12492; LYONS TP, 1995, AVIAT SPACE ENVIR MD, V66, P957; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Maloyan A, 2005, PHYSIOL GENOMICS, V23, P79, DOI 10.1152/physiolgenomics.00279.2004; Maloyan A, 2001, J MOL CELL CARDIOL, V33, pA72, DOI 10.1016/S0022-2828(01)90285-8; Maloyan A, 1999, AM J PHYSIOL-REG I, V276, pR1506, DOI 10.1152/ajpregu.1999.276.5.R1506; Maloyan A, 2002, J APPL PHYSIOL, V93, P107, DOI 10.1152/japplphysiol.01122.2001; Markakis EA, 2004, J NEUROSCI, V24, P2886, DOI 10.1523/JNEUROSCI.4161-03.2004; Maruyama M, 2007, J PHYSIOL SCI, V57, P107, DOI 10.2170/physiolsci.RP014506; Matsuki H, 2013, GENES CELLS, V18, P135, DOI 10.1111/gtc.12023; Matsuzaki K, 2009, PFLUG ARCH EUR J PHY, V458, P661, DOI 10.1007/s00424-009-0654-2; Maughan R, 2004, J SPORT SCI, V22, P917, DOI 10.1080/02640410400005909; Mcgee SL, 2011, J APPL PHYSIOL, V110, P258, DOI 10.1152/japplphysiol.00979.2010; Miova B., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P65; Mirit E, 1999, AM J PHYSIOL-REG I, V276, pR550, DOI 10.1152/ajpregu.1999.276.2.R550; Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100; MITCHELL D, 1976, J APPL PHYSIOL, V40, P768, DOI 10.1152/jappl.1976.40.5.768; Montain SJ, 1998, INT J SPORTS MED, V19, P87, DOI 10.1055/s-2007-971887; Moran D, 1996, J THERM BIOL, V21, P171, DOI 10.1016/0306-4565(95)00042-9; Moseley PL, 1997, J APPL PHYSIOL, V83, P1413, DOI 10.1152/jappl.1997.83.5.1413; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NADEL ER, 1974, J APPL PHYSIOL, V37, P515, DOI 10.1152/jappl.1974.37.4.515; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Nielsen B, 2003, SPORTS MED, V33, P1, DOI 10.2165/00007256-200333010-00001; NIELSEN B, 1993, J PHYSIOL-LONDON, V460, P467, DOI 10.1113/jphysiol.1993.sp019482; NIELSEN B, 1994, ERGONOMICS, V37, P49, DOI 10.1080/00140139408963622; Nielsen B, 1998, INT J SPORTS MED, V19, pS154, DOI 10.1055/s-2007-971984; Norris Carol E, 2002, Prog Mol Subcell Biol, V28, P19; Nowak SJ, 2003, MOL CELL BIOL, V23, P6129, DOI 10.1128/MCB.23.17.6129-6138.2003; Nybo L, 2001, J APPL PHYSIOL, V91, P2017, DOI 10.1152/jappl.2001.91.5.2017; Nybo L, 2001, J APPL PHYSIOL, V91, P1055, DOI 10.1152/jappl.2001.91.3.1055; Obrenovitch TP, 2008, PHYSIOL REV, V88, P211, DOI 10.1152/physrev.00039.2006; Ophir E, 2002, J EXP BIOL, V205, P2627; Oppenheim A, 1996, ISRAEL J MED SCI, V32, pS38; Pandolf KB, 1998, INT J SPORTS MED, V19, pS157, DOI 10.1055/s-2007-971985; PANDOLF KB, 1977, ERGONOMICS, V20, P399, DOI 10.1080/00140137708931642; Patberg KW, 2005, HEART RHYTHM, V2, P1376, DOI 10.1016/j.hrthm.2005.08.021; Patberg KW, 2005, CARDIOVASC RES, V68, P259, DOI 10.1016/j.cardiores.2005.05.028; Patronas P, 1998, BRAIN RES, V798, P127, DOI 10.1016/S0006-8993(98)00405-3; Paz Z, 2004, AUDIOL NEURO-OTOL, V9, P363, DOI 10.1159/000081409; Pierau FK, 1998, PROG BRAIN RES, V115, P63; Rae DE, 2008, MED SCI SPORT EXER, V40, P1193, DOI 10.1249/MSS.0b013e31816a7155; RALL JA, 1990, AM J PHYSIOL, V259, pR197, DOI 10.1152/ajpregu.1990.259.2.R197; Reul JMHM, 2007, PSYCHONEUROENDOCRINO, V32, pS21, DOI 10.1016/j.psyneuen.2007.03.016; Riis ALD, 2005, AM J PHYSIOL-ENDOC M, V288, pE1265, DOI 10.1152/ajpendo.00533.2004; Ritossa F, 1996, CELL STRESS CHAPERON, V1, P97, DOI 10.1379/1466-1268(1996)001<0097:DOTHSR>2.3.CO;2; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; ROBERTS MF, 1977, J APPL PHYSIOL, V43, P133, DOI 10.1152/jappl.1977.43.1.133; Robinson S., THESIS HEBREW U JERU; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; ROWELL LB, 1967, J APPL PHYSIOL, V22, P509, DOI 10.1152/jappl.1967.22.3.509; ROWELL LB, 1974, PHYSIOL REV, V54, P75, DOI 10.1152/physrev.1974.54.1.75; Rowell LB, 1980, HDB PHYSL PERIPHERAL; Rowell LB, 1986, HUMAN CIRCULATION RE, P363, DOI DOI 10.1152/JN.00057.2012; Saeki A, 2000, AM J PHYSIOL-HEART C, V279, pH2855, DOI 10.1152/ajpheart.2000.279.6.H2855; Sailaja BS, 2012, P NATL ACAD SCI USA, V109, pE3687, DOI 10.1073/pnas.1209990110; Samuels SE, 2000, CAN J PHYSIOL PHARM, V78, P557, DOI 10.1139/cjpp-78-7-557; Sandstrom ME, 2008, CELL STRESS CHAPERON, V13, P169, DOI 10.1007/s12192-008-0022-8; SATO F, 1990, J APPL PHYSIOL, V69, P232, DOI 10.1152/jappl.1990.69.1.232; SATO K, 1983, AM J PHYSIOL, V245, pR203, DOI 10.1152/ajpregu.1983.245.2.R203; Sawka MN, 2011, COMPR PHYSIOL, V1, P1883, DOI 10.1002/cphy.c100082; SAWKA MN, 1983, J APPL PHYSIOL, V55, P1147, DOI 10.1152/jappl.1983.55.4.1147; SAWKA MN, 1992, J APPL PHYSIOL, V73, P368, DOI 10.1152/jappl.1992.73.1.368; SAWKA MN, 1996, HDB PHYSIOL SECT 4, V1, P157; SCHAIBLE TF, 1986, J APPL PHYSIOL, V60, P1435, DOI 10.1152/jappl.1986.60.4.1435; SCHMID HA, 1993, AM J PHYSIOL, V264, pR449, DOI 10.1152/ajpregu.1993.264.2.R449; Schulte PM, 2001, COMP BIOCHEM PHYS B, V128, P597, DOI 10.1016/S1096-4959(00)00357-2; Schwimmer H, 2004, MOL BRAIN RES, V130, P95, DOI 10.1016/j.molbrainres.2004.07.011; Schwimmer H, 2004, BRAIN RES, V1006, P177, DOI 10.1016/j.brainres.2004.01.064; Schwimmer H, 2006, J APPL PHYSIOL, V100, P1992, DOI 10.1152/japplphysiol.00850.2005; Seebacher F, 2009, PHYSIOL BIOCHEM ZOOL, V82, P766, DOI 10.1086/605955; Seebacher F, 2010, PHYSIOL BIOCHEM ZOOL, V83, P721, DOI 10.1086/649964; Seebacher F, 2009, J EXP BIOL, V212, P2885, DOI 10.1242/jeb.024430; SELYE H, 1950, BRIT MED J, V1, P1383, DOI 10.1136/bmj.1.4667.1383; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; SENAY LC, 1976, J APPL PHYSIOL, V40, P786, DOI 10.1152/jappl.1976.40.5.786; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Shein NA, 2007, PROG BRAIN RES, V161, P353, DOI 10.1016/S0079-6123(06)61025-X; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; SHIDO O, 1990, J APPL PHYSIOL, V68, P66, DOI 10.1152/jappl.1990.68.1.66; Shmeeda H, 2002, AM J PHYSIOL-REG I, V283, pR389, DOI 10.1152/ajpregu.00423.2001; Shochina M, 1996, J THERM BIOL, V21, P289, DOI 10.1016/S0306-4565(96)00012-5; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Somero GN, 2011, AM J PHYSIOL-REG I, V301, pR1, DOI 10.1152/ajpregu.00719.2010; Sonna LA, 2002, J APPL PHYSIOL, V92, P2208, DOI 10.1152/japplphysiol.01002.2001; Strudler Paul K., 1996, Radiation Research, V145, P107; Sumner FB, 1913, J EXP ZOOL, V15, P315, DOI 10.1002/jez.1400150304; Sundstroem ES, 1925, J BIOL CHEM, Vlxiii; Tattersall GJ, 2012, COMPR PHYSIOL, V2, P2151, DOI 10.1002/cphy.c110055; Taylor N, 2013, COMP PHYSL IN PRESS; Tetievsky A, 2008, PHYSIOL GENOMICS, V34, P78, DOI 10.1152/physiolgenomics.00215.2007; Tetievsky A, 2010, J APPL PHYSIOL, V109, P1552, DOI 10.1152/japplphysiol.00469.2010; Thomson S, 2004, MOL CELL, V15, P585, DOI 10.1016/j.molcel.2004.08.002; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Tirosh S, 2007, DEV NEUROBIOL, V67, P728, DOI 10.1002/dneu.20378; Todd G, 2005, J PHYSIOL-LONDON, V563, P621, DOI 10.1113/jphysiol.2004.077115; Tomanek L, 2002, J EXP BIOL, V205, P677; Tomanek L, 2012, INTEGR COMP BIOL, V52, P648, DOI 10.1093/icb/ics114; TRAVIS KA, 1993, AM J PHYSIOL, V264, pR1200, DOI 10.1152/ajpregu.1993.264.6.R1200; Treinin M, 2003, PHYSIOL GENOMICS, V14, P17, DOI 10.1152/physiolgenomics.00179.2002; Turner BM, 2007, NAT CELL BIOL, V9, P2, DOI 10.1038/ncb0107-2; Tzschentke B, 2007, POULTRY SCI, V86, P1025, DOI 10.1093/ps/86.5.1025; Tzschentke B, 2002, COMP BIOCHEM PHYS A, V131, P825, DOI 10.1016/S1095-6433(02)00020-X; Tzschentke B, 1997, ANN NY ACAD SCI, V813, P87, DOI 10.1111/j.1749-6632.1997.tb51677.x; Umschweif G, 2013, J CEREBR BLOOD F MET, V33, P524, DOI 10.1038/jcbfm.2012.193; Vergauwen L, 2010, COMP BIOCHEM PHYS A, V157, P149, DOI 10.1016/j.cbpa.2010.06.160; Virchow R, 1885, TAG 58 VERS DTSCH XA, P540; Walter I, 2009, J EXP BIOL, V212, P2328, DOI 10.1242/jeb.029009; Wang YJ, 2013, MOL BIOL REP, V40, P3877, DOI 10.1007/s11033-012-1977-1; Weller AS, 2007, EUR J APPL PHYSIOL, V102, P57, DOI 10.1007/s00421-007-0563-z; WYNDHAM CH, 1968, J APPL PHYSIOL, V25, P586, DOI 10.1152/jappl.1968.25.5.586; WYNDHAM CH, 1976, J APPL PHYSIOL, V40, P779, DOI 10.1152/jappl.1976.40.5.779; WYNDHAM CH, 1973, ANNU REV PHYSIOL, V35, P193, DOI 10.1146/annurev.ph.35.030173.001205; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Yakobi A, 2012, ISR SOC PHYSL PHARM; YELLON DM, 1992, J MOL CELL CARDIOL, V24, P113, DOI 10.1016/0022-2828(92)93148-D; Yoshimura H., 1960, ACCLIMATIZATION HEAT; YOUNG AJ, 1985, J APPL PHYSIOL, V59, P1929, DOI 10.1152/jappl.1985.59.6.1929; YOUSEF MK, 1975, AM J PHYSIOL, V229, P427, DOI 10.1152/ajplegacy.1975.229.2.427; Zatsepina OG, 2000, J EXP BIOL, V203, P1017; Zhang HJ, 2003, FASEB J, V17, P2293, DOI 10.1096/fj.03-0139fje	246	51	51	3	78	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2040-4603			COMPR PHYSIOL	Compr. Physiol.	JAN	2014	4	1					199	230		10.1002/cphy.c130025			32	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	AA6HL	WOS:000331199300007	24692139				2022-02-06	
J	Laborey, M; Masson, F; Ribereau-Gayon, R; Zongo, D; Salmi, LR; Lagarde, E				Laborey, Magali; Masson, Francoise; Ribereau-Gayon, Regis; Zongo, Drissa; Salmi, Louis Rachid; Lagarde, Emmanuel			Specificity of Postconcussion Symptoms at 3 Months After Mild Traumatic Brain Injury: Results From a Comparative Cohort Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; postconcussion syndrome; symptom specificity; control group	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; BASE-RATE; QUESTIONNAIRE; COMPLAINTS; OUTCOMES; ISSUES	Objective: To assess the specificity of symptoms included in various symptom lists used to identify postconcussion syndrome (PCS), by using follow-up data comparing patients with mild traumatic brain injury (MTBI) and control patients during the month prior to injury and 3 months later. Setting: The adult emergency department of a teaching hospital in Bordeaux, France. Participants: A cohort of patients with MTBI (n = 536) and a comparison group with nonhead injuries (n = 946). Main measures: Postconcussion symptoms listed in the Rivermead Postconcussion Symptoms Questionnaire (RPQ), the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), and the 10th International Classification of Diseases (ICD-10). Results: Analyses were performed comparing symptom occurrence in patients with MTBI and controls, before and 3 months after injury. Eight symptoms were identified as being specific to MTBI: headache, dizziness, intolerance of stress, forgetfulness, poor concentration, taking longer to think, blurred vision, and personality change. Conclusion: The relevance of symptoms proposed to constitute PCS should be reviewed. A more specific definition of PCS would make diagnosis easier and facilitate prevention as well as treatment of patients with MTBI.	[Laborey, Magali; Salmi, Louis Rachid; Lagarde, Emmanuel] Univ Bordeaux, ISPED, Ctr INSERM, Epidemiol Biostat U897, F-33000 Bordeaux, France; [Laborey, Magali; Masson, Francoise; Ribereau-Gayon, Regis; Zongo, Drissa; Salmi, Louis Rachid; Lagarde, Emmanuel] Ctr INSERM, Epidemiol Biostat U897, INSERM, ISPED, F-33000 Bordeaux, France; [Salmi, Louis Rachid] CHU Bordeaux, F-33000 Bordeaux, France; [Masson, Francoise] Ctr Hosp Univ Bordeaux, Hop Pellegrin, Serv Anesthesie Reanimat, F-33000 Bordeaux, France; [Ribereau-Gayon, Regis] Ctr Hosp Univ Bordeaux, Hop Pellegrin, Serv Med Gen & Posturgences, F-33000 Bordeaux, France		Lagarde, E (corresponding author), 146 Rue Leo Saignat, F-33076 Bordeaux, France.	emmanuel.lagarde@isped.u-bordeaux2.fr	Salmi, Louis-Rachid/T-1982-2019; Regis, RIBEREAU-GAYON/U-5423-2019; Lagarde, Emmanuel/F-7132-2013	Lagarde, Emmanuel/0000-0001-8031-7400	French National Institute for Medical Research (INSERM)Institut National de la Sante et de la Recherche Medicale (Inserm); EHESP School of Public Health	M.L. is the recipient of a doctoral grant from the French National Institute for Medical Research (INSERM) and the EHESP School of Public Health.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Association A. P., 1994, DIAGN STAT MAN MENT; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M, 2010, TRAUMATIC BRAIN INJU; Greene CJ, 2008, J TRAUMA STRESS, V21, P433, DOI 10.1002/jts.20367; Greiffenstein M, 2009, CLIN NEUROPSYCHOL, V23, P286, DOI 10.1080/13854040802104873; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Organization WH, 1992, ICD 10 CLASS MENT BE; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Walker E, 2011, J GEN INTERN MED, V26, P192, DOI 10.1007/s11606-010-1513-8; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	43	51	53	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					E28	E36		10.1097/HTR.0b013e318280f896			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400007	23474878				2022-02-06	
J	McLean, AM; Jarus, T; Hubley, AM; Jongbloed, L				McLean, Alison M.; Jarus, Tal; Hubley, Anita M.; Jongbloed, Lyn			Associations between social participation and subjective quality of life for adults with moderate to severe traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						Community integration; leisure; participation; quality of life; social reintegration; traumatic brain injury	COMMUNITY INTEGRATION QUESTIONNAIRE; PORTLAND ADAPTABILITY INVENTORY; OCCUPATIONAL GAPS; EVERYDAY LIFE; OUTCOMES; SATISFACTION; INDIVIDUALS; HEALTH; DISABILITY; LONELINESS	Purpose: To examine the association between social participation and subjective quality of life (SQOL) for non-employed, community-dwelling adults with moderate to severe traumatic brain injury (TBI) at 1 year or greater post-injury. Method: A correlational study was conducted involving 46 participants. Social participation was measured using the Community Integration Questionnaire, Social Provisions Scale and the Adult Subjective Assessment of Participation. SQOL was measured using the Quality of Life and Health Questionnaire, Abdel-Khalek Happiness Scale and UCLA Loneliness Scale. Results: Higher levels of happiness and global quality of life were each associated with higher levels of enjoyment, satisfaction with performance and higher proportion of activities performed with others. Lower levels of loneliness were associated with higher levels of general social integration and higher levels of perceived social supports. There were no associations found between SQOL and the objective social participation measures of diversity, frequency (intensity) or proportion of activities performed outside of home. Conclusions: Findings contribute to the TBI literature in showing that it is: (a) the more subjective and not objectively measured nature of participation that is associated with SQOL and (b) positive and negative aspects of quality of life show different relationships with social participation variables.	[McLean, Alison M.] GF Strong Rehabil Ctr, Vancouver, BC, Canada; [McLean, Alison M.; Jarus, Tal; Jongbloed, Lyn] Univ British Columbia, Dept Occupat Sci & Occupat Therapy, Vancouver, BC V6T 2B5, Canada; [Hubley, Anita M.] Univ British Columbia, Dept Educ & Counselling Psychol & Special Educ, Vancouver, BC V6T 2B5, Canada		McLean, AM (corresponding author), Univ British Columbia, Dept Occupat Sci & Occupat Therapy, T-325,2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.	almclean@mail.ubc.ca		Jarus, Tal/0000-0003-4124-7782	University of British Columbia's College of Health Disciplines Cedar Lodge Endowment Award; Frederick Banting and Charles Best Canada Graduate Scholarship Master's Award from the Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Thelma Cardwell Scholarship from the Canadian Occupational Therapy Foundation	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This study was supported by an operational grant from The University of British Columbia's College of Health Disciplines Cedar Lodge Endowment Award (awarded to the first and second authors) and the Frederick Banting and Charles Best Canada Graduate Scholarship Master's Award from the Canadian Institutes of Health Research and a Thelma Cardwell Scholarship from the Canadian Occupational Therapy Foundation (both awarded to the first author).	Abdel-Khalek AM, 2006, SOC BEHAV PERSONAL, V34, P139, DOI 10.2224/sbp.2006.34.2.139; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; [Anonymous], 2001, ICF INTRO; Bekhet AK, 2008, NURS FORUM, V43, P207, DOI 10.1111/j.1744-6198.2008.00114.x; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; Blake H, 2009, CLIN REHABIL, V23, P589, DOI 10.1177/0269215508101736; Braden CA, 2012, BRAIN INJURY, V26, P1315, DOI 10.3109/02699052.2012.706351; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Camfield L, 2008, J HEALTH PSYCHOL, V13, P764, DOI 10.1177/1359105308093860; Cicerone KD, 2004, J HEAD TRAUMA REHAB, V19, P494, DOI 10.1097/00001199-200411000-00006; Cohen J., 2013, STAT POWER ANAL BEHA; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Cutrona EC., 1987, ADV PERSONAL RELATIO, V1, P37, DOI DOI 10.1037/0882-7974.1.1.47; Dawson DR, 2000, BRAIN COGNITION, V44, P35; DePalma J A, 2001, Crit Care Nurs Q, V23, P42; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Diener E, 1999, PSYCHOL BULL, V125, P276, DOI 10.1037//0033-2909.125.2.276; Diener E, 2002, PSYCHOL SCI, V13, P81, DOI 10.1111/1467-9280.00415; Diener E., 2006, J HAPPINESS STUD, V7, P397, DOI [10.1007/s10902-006-9000-y, DOI 10.1007/S10902-006-9000-Y, 10.1007/s11482-006-9007-x, DOI 10.1007/S11482-006-9007-X]; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Dolan P, 2008, J ECON PSYCHOL, V29, P94, DOI 10.1016/j.joep.2007.09.001; Dolbier CL, 2000, BEHAV MED, V25, P169, DOI 10.1080/08964280009595746; Dunn DS, 2008, REHABIL PSYCHOL, V53, P413, DOI 10.1037/a0013749; Eriksson G, 2006, J REHABIL MED, V38, P159, DOI 10.1080/16501970500415322; Eriksson G, 2009, J REHABIL MED, V41, P187, DOI 10.2340/16501977-0307; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fischer J., 2007, MEASURES CLIN PRACTI; Fraas M, 2007, BRAIN INJURY, V21, P1267, DOI 10.1080/02699050701721794; Fraas MR, 2009, AM J SPEECH-LANG PAT, V18, P315, DOI 10.1044/1058-0360(2009/08-0008); Geurtsen GJ, 2010, J REHABIL MED, V42, P97, DOI 10.2340/16501977-0508; Grace M, 2001, FRONTAL SYSTEMS BEHA; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; HADORN DC, 1995, J CLIN EPIDEMIOL, V48, P619, DOI 10.1016/0895-4356(94)00186-T; Haggstrom A, 2008, J REHABIL MED, V40, P89, DOI 10.2340/16501977-0138; Hanks RA, 2012, ARCH PHYS MED REHAB, V93, P1297, DOI 10.1016/j.apmr.2012.04.027; Harker WF, 2002, INT J REHABIL RES, V25, P93, DOI 10.1097/00004356-200206000-00003; Heinrich LA, 2006, CLIN PSYCHOL REV, V26, P695, DOI 10.1016/j.cpr.2006.04.002; Hemmingsson H, 2005, AM J OCCUP THER, V59, P569, DOI 10.5014/ajot.59.5.569; Hoofien D, 2001, BRAIN INJURY, V15, P189; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jarus T, 2006, ISRAELI J OCCUP THER, V15, pH93; Johnson K, 1998, BEHAV MODIF, V22, P502, DOI 10.1177/01454455980224004; Johnston MV, 2006, BRAIN INJURY, V20, P391, DOI 10.1080/02699050500487795; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Jumisko Eija, 2005, J Neurosci Nurs, V37, P42; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kean, 2010, NEUROSCI MED, V1, P39; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; KUIPERS P, 1999, J COGNITIVE REHABILI, V17, P6; KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k; Law M, 2002, AM J OCCUP THER, V56, P640, DOI 10.5014/ajot.56.6.640; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; Levasseur M, 2004, DISABIL REHABIL, V26, P1206, DOI 10.1080/09638280412331270371; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; Martelli MF, 2012, NEUROREHABILITATION, V31, P3, DOI 10.3233/NRE-2012-0770; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; McColl MA, 2007, BRAIN IMPAIR, V8, P238, DOI DOI 10.1375/BRIM.8.3.238; McLean AM, 2012, BRAIN INJURY, V26, P83, DOI 10.3109/02699052.2011.635353; Mellor D, 2008, PERS INDIV DIFFER, V45, P213, DOI 10.1016/j.paid.2008.03.020; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Minnes P, 2001, NEUROREHABILITATION, V16, P3; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth T, 2004, NEUROPSYCHOL REHABIL, V14, P535, DOI 10.1080/09602010343000538; Pallant J.F., 2007, SPSS SURVIVAL MANUAL; PAVOT W, 1993, SOC INDIC RES, V28, P1, DOI 10.1007/BF01086714; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Reyes-Garcia V, 2009, HUM NATURE-INT BIOS, V20, P431, DOI 10.1007/s12110-009-9073-5; Ring L, 2007, SOC INDIC RES, V82, P443, DOI 10.1007/s11205-006-9041-y; Rochette A, 2006, DISABIL REHABIL, V28, P1231, DOI 10.1080/09638280600554827; RUSSELL D, 1978, J PERS ASSESS, V42, P290, DOI 10.1207/s15327752jpa4203_11; Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Shrive Fiona M, 2006, BMC Med Res Methodol, V6, P57, DOI 10.1186/1471-2288-6-57; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Statistics Canada, 2008, LOW INC CUT OFFS 200; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Teasell R, 2012, INTRO METHODOLOGY EV; Thomas MD, 2009, BRAIN INJURY, V23, P516, DOI 10.1080/02699050902926333; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Vella-Brodrick DA, 2009, SOC INDIC RES, V90, P165, DOI 10.1007/s11205-008-9251-6; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watanabe TK, 2003, ARCH PHYS MED REHAB, V84, pS23, DOI 10.1053/apmr.2003.50054; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvsaker M, 2001, BRAIN INJ SOURCE, V5; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002; ZUNG WWK, 1967, ARCH GEN PSYCHIAT, V16, P543; [No title captured], DOI DOI 10.1375/BRIM.7.2.107	108	51	51	3	41	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2014	36	17					1409	1418		10.3109/09638288.2013.834986			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	AN8XG	WOS:000340888500004	24059448				2022-02-06	
J	Thiagarajan, P; Ciuffreda, KJ; Capo-Aponte, JE; Ludlam, DP; Kapoor, N				Thiagarajan, Preethi; Ciuffreda, Kenneth J.; Capo-Aponte, Jose E.; Ludlam, Diana P.; Kapoor, Neera			Oculomotor neurorehabilitation for reading in mild traumatic brain injury (mTBI): An integrative approach	NEUROREHABILITATION			English	Article						Traumatic brain injury; mTBI; reading dysfunction; oculomotor deficiency; nearvision symptoms; oculomotor rehabilitation; neuroplasticity; oculomotor learning; eye movements	SUSTAINED-ATTENTION; VISUAL FUNCTION; REHABILITATION; ACCOMMODATION; VERGENCE; MILITARY; VETERANS; BEHAVIOR; DEFICITS; MODEL	BACKGROUND: Considering the extensive neural network of the oculomotor subsystems, traumatic brain injury (TBI) could affect oculomotor control and related reading dysfunction. OBJECTIVE: To evaluate comprehensively the effect of oculomotor-based vision rehabilitation (OBVR) in individuals with mTBI. METHODS: Twelve subjects with mTBI participated in a cross-over, interventional study involving oculomotor training (OMT) and sham training (ST). Each training was performed for 6 weeks, 2 sessions a week. During each training session, all three oculomotor subsystems (vergence/accommodation/version) were trained in a randomized order across sessions. All laboratory and clinical parameters were determined before and after OMT and ST. In addition, nearvision-related symptoms using the Convergence Insufficiency Symptom Survey (CISS) scale and subjective visual attention using the Visual Search and Attention Test (VSAT) were assessed. RESULTS: Following the OMT, over 80% of the abnormal parameters significantly improved. Reading rate, along with the amplitudes of vergence and accommodation, improved markedly. Saccadic eye movements demonstrated enhanced rhythmicity and accuracy. The improved reading-related oculomotor behaviorwas reflected in reduced symptoms and increased visual attention. None of the parameters changed with ST. CONCLUSIONS: OBVR had a strong positive effect on oculomotor control, reading rate, and overall reading ability. This oculomotor learning effect suggests considerable residual neuroplasticity following mTBI.	[Thiagarajan, Preethi; Ciuffreda, Kenneth J.; Ludlam, Diana P.] SUNY State Coll Optometry, Dept Biol & Vis Sci, New York, NY USA; [Capo-Aponte, Jose E.] Womack Army Med Ctr, Optometry Serv, Ft Bragg, NC USA; [Kapoor, Neera] SUNY State Coll Optometry, Dept Clin Sci, New York, NY USA		Thiagarajan, P (corresponding author), Retina Fdn Southwest, 9600 N Cent Expy,Suite 200, Dallas, TX 75231 USA.	pthiagarajan@retinafoundation.org			US Army, DoDUnited States Department of Defense [W81XWH-10- 1-1041, W81XWH12-1-0240]; College of Optometrists in Vision Development (COVD); SUNY Graduate Program	This research was funded by the US Army, DoD, Award # s: W81XWH-10- 1-1041 and W81XWH12-1-0240, the College of Optometrists in Vision Development (COVD), and the SUNY Graduate Program.	ABRAMS SG, 1972, READ RES QUART, V8, P40, DOI 10.2307/746979; Alvarez TL, 2010, OPTOMETRY VISION SCI, V87, P985, DOI 10.1097/OPX.0b013e3181fef1aa; BAKER RS, 1991, SURV OPHTHALMOL, V35, P245, DOI 10.1016/0039-6257(91)90046-I; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Borish I. M., 2006, CLIN REFRACTION; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Bulson R, 2012, J REHABIL RES DEV, V49, P1075, DOI 10.1682/JRRD.2011.02.0017; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chen HW, 2010, PM&R, V2, pS306, DOI 10.1016/j.pmrj.2010.10.006; Chiu YC, 2009, J NEUROSCI, V29, P3930, DOI 10.1523/JNEUROSCI.5737-08.2009; Ciuffreda K, 1983, VERGENCE EYE MOVEMEN, P101; Ciuffreda K. J., 2005, BRAIN INJURY PROFESS, V2, P16; Ciuffreda K. J., 2007, OPTOMETRY, V78, P55; Ciuffreda K. J., 1996, J BEHAV OPTOM, V7, P31; CIUFFREDA K. J., 1992, J BEHAV OPTOM, V3, P3; Ciuffreda K. J., 1994, EYE MOVEMENTS READIN, P163; Ciuffreda KJ, 2006, NEUROREHABILITATION, V21, P9; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; Ciuffreda MA, 2003, J BEHAV OPTOM, V14, P60; Clark B, 1935, J EDUC PSYCHOL, V26, P530, DOI 10.1037/h0053899; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Green W, 2010, OPTOMETRY, V81, P129, DOI 10.1016/j.optm.2009.07.015; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griffin JR., 2002, BINOCULAR ANOMALIES, V4th ed; Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002; Hanrahan, 1997, BIOPHYSICAL FDN HUMA; Hatch S. W., 1998, OPHTHALMIC RES EPIDE, P97; Hibbard M. R., 2001, VISUAL VESTIBULAR CO, P32; Hung GK, 1996, OPHTHAL PHYSL OPT, V16, P31, DOI 10.1016/0275-5408(95)00110-7; HUNG GK, 1986, IEEE T BIO-MED ENG, V33, P1021, DOI 10.1109/TBME.1986.325868; HUNG GK, 1988, OPHTHAL PHYSL OPT, V8, P327, DOI 10.1016/0275-5408(88)90183-4; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; Khan A. A., 2005, DIGITAL SIGNAL PROCE; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; KOTULAK JC, 1987, VISION RES, V27, P1797, DOI 10.1016/0042-6989(87)90108-8; Leigh RJ, 2006, NEUROLOGY EYE MOVEME; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Munoz-Cespedes JM, 2005, NEUROPSYCHOL REV, V15, P169, DOI 10.1007/s11065-005-9178-5; Nag S, 1999, NEUROL INDIA, V47, P32; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Pashler H.E., 1998, PSYCHOL ATTENTION; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Rabbetts RB, 2007, BENNETT RABBETTS CLI; REICHLE ED, 2002, MODELS VISUAL SYSTEM, P565; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Solan HA, 2003, J LEARN DISABIL-US, V36, P556, DOI 10.1177/00222194030360060601; Stark L, 1968, NEUROLOGICAL CONTROL; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Suchoff IB, 2001, VISUAL VESTIBULAR CO; Szymanowicz D, 2012, J REHABIL RES DEV, V49, P1083, DOI 10.1682/JRRD.2010.07.0129; Tannen B., 1995, EYE MOVEMENT BASICS; Taylor E. A., 1966, FUNDAMENTAL READING; Thiagarajan P, J REHABILIT IN PRESS; Thiagarajan P., 2012, THESIS SUNY COLLEGE; Trenerry M. R., 1989, VISUAL SEARCH ATTENT; Warraich Z, 2010, PM&R, V2, pS208, DOI 10.1016/j.pmrj.2010.10.016; Wick B., 2008, CLIN MANAGEMENT BINO; Xu J. J., 2009, J BEHAV OPTOMETRY, V20, P67	62	51	51	0	17	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2014	34	1					129	146		10.3233/NRE-131025			18	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AA4JN	WOS:000331062000015	24284470				2022-02-06	
J	Chen, T; Yang, YF; Luo, P; Liu, W; Dai, SH; Zheng, XR; Fei, Z; Jiang, XF				Chen, Tao; Yang, Yue-fan; Luo, Peng; Liu, Wei; Dai, Shu-hui; Zheng, Xin-rui; Fei, Zhou; Jiang, Xiao-fan			Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson's disease	CELLULAR SIGNALLING			English	Article						Parkinson's disease; Homer; Calcium channel; Endoplasmic reticulum	METABOTROPIC GLUTAMATE RECEPTORS; TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL DYSFUNCTION; NEUROLOGICAL DISEASES; SUBUNIT EXPRESSION; CORTICAL-NEURONS; DOWN-REGULATION; IP3 RECEPTORS; CHANNEL; PROTEINS	Homer1 protein is an important scaffold protein at postsynaptic density and has been demonstrated to play a central role in calcium signaling in the central nervous system. The aim of this study was to investigate the effects of Horner1 knockdown on MPP+ induced neuronal injury in cultured dopamine (DA) neurons. We found that down-regulating Homer1 expression with specific small interfering RNA (siRNA) significantly suppressed LDH release, reduced Propidium iodide (PI) or Hoechst staining, increased the number of tyrosine hydroxylase (TH) positive cells and DA uptake, and attenuated apoptotic and necrotic cell death after MPP+ injury. Homer1 knock-down decreased intracellular reactive oxygen species (ROS) generation through inhibition of intracellular calcium overload, but did not affect the endogenous antioxidant enzyme activities. Calcium imaging was used to examine the changes of intracellular Ca2+ concentration ([Ca2+](cyt)) and Ca2+ in endoplasmic reticulum (ER) ([Ca2+](ER)), and the results showed that Homer1 siRNA transfection attenuated ER Ca2+ release up to 120 min after MPP+ injury. Furthermore, decrease of [Ca2+](cyt) induced by Homer1 knockdown in MPP+ treated neurons was further enhanced by NMDA receptor antagonists MK-801 and AP-5, but not canonical transient receptor potential (TRPC) channel antagonist SKF-96365. L-type calcium antagonist isradipine but not nimodipine further inhibited intracellular calcium overload after MPP+ insult in Homer1 down-regulated neurons. These results suggest that Homer1 knockdown has protective effects against neuronal injury in in vitro PD model by reducing calcium overload mediated ROS generation, and this protection may be dependent at least in part on the regulatory effects on the function of calcium channels in both plasma membrane and ER. (C) 2013 Elsevier Inc. All rights reserved.	[Chen, Tao; Yang, Yue-fan; Luo, Peng; Liu, Wei; Dai, Shu-hui; Zheng, Xin-rui; Fei, Zhou; Jiang, Xiao-fan] Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi Provinc, Peoples R China; [Chen, Tao] 123th Hosp PLA, Dept Neurosurg, Bengbu 233000, Anhui, Peoples R China		Jiang, XF (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi Provinc, Peoples R China.	fmmuzhoufei@163.com; fmmujiangxiaofan@163.com	Yang, Yuefan/AAJ-9136-2020	Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81071034, 81371447, 81301037, 30930093]; National Science & Technology Pillar Program [2012BAI11B02]; Research Foundation of PEA [2010gxjs078, AWS11J008]	This work was financially supported by the National Natural Science Foundation of China (No. 81071034, 81371447, 81301037, and No. 30930093), National Science & Technology Pillar Program (No. 2012BAI11B02) and Research Foundation of PEA (No. 2010gxjs078 and No. AWS11J008).	Abramov AY, 2003, CELL CALCIUM, V33, P101, DOI 10.1016/S0143-4160(02)00203-8; Ary AW, 2007, BRAIN RES, V1184, P295, DOI 10.1016/j.brainres.2007.09.035; Becker C, 2008, NEUROLOGY, V70, P1438, DOI 10.1212/01.wnl.0000303818.38960.44; Ben-Shahar O, 2009, SYNAPSE, V63, P598, DOI 10.1002/syn.20640; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bouron A, 2006, EUR J NEUROSCI, V24, P699, DOI 10.1111/j.1460-9568.2006.04946.x; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Chan CS, 2009, TRENDS NEUROSCI, V32, P249, DOI 10.1016/j.tins.2009.01.006; Chen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055601; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Cristofanilli M, 2006, J PHYSIOL-LONDON, V575, P543, DOI 10.1113/jphysiol.2006.114108; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Duchen MR, 2012, PFLUG ARCH EUR J PHY, V464, P111, DOI 10.1007/s00424-012-1112-0; Gandhi S, 2009, MOL CELL, V33, P627, DOI 10.1016/j.molcel.2009.02.013; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Igosheva N, 2005, NEUROCHEM INT, V47, P216, DOI 10.1016/j.neuint.2005.02.011; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ilijic E, 2011, NEUROBIOL DIS, V43, P364, DOI 10.1016/j.nbd.2011.04.007; Karst H, 2002, EUR J NEUROSCI, V16, P1083, DOI 10.1046/j.1460-9568.2002.02172.x; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kotake Y, 2003, CURR MED CHEM, V10, P2507, DOI 10.2174/0929867033456558; Kupsch A, 1996, BRAIN RES, V741, P185, DOI 10.1016/S0006-8993(96)00917-1; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Liu CY, 2009, J FORMOS MED ASSOC, V108, P599, DOI 10.1016/S0929-6646(09)60380-6; Luo P, 2012, NEUROCHEM INT, V61, P731, DOI 10.1016/j.neuint.2012.06.014; Luo P, 2012, FREE RADICAL RES, V46, P766, DOI 10.3109/10715762.2012.678340; Maret S, 2007, P NATL ACAD SCI USA, V104, P20090, DOI 10.1073/pnas.0710131104; MASLIAH E, 1992, J NEUROPATH EXP NEUR, V51, P404, DOI 10.1097/00005072-199207000-00003; Mattson MP, 2007, AGING CELL, V6, P337, DOI 10.1111/j.1474-9726.2007.00275.x; Nedergaard M, 2010, CELL CALCIUM, V47, P140, DOI 10.1016/j.ceca.2009.11.010; Nedergaard M, 2010, CELL CALCIUM, V47, P101, DOI 10.1016/j.ceca.2009.12.011; Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389; Ritz B, 2010, ANN NEUROL, V67, P600, DOI 10.1002/ana.21937; Scheife RT, 2000, AM J HEALTH-SYST PH, V57, P953, DOI 10.1093/ajhp/57.10.953; Schreibelt G, 2007, BRAIN RES REV, V56, P322, DOI 10.1016/j.brainresrev.2007.07.005; Shiraishi Y, 2003, MOL CELL NEUROSCI, V22, P188, DOI 10.1016/S1044-7431(03)00037-X; Surmeier DJ, 2011, NEUROSCIENCE, V198, P221, DOI 10.1016/j.neuroscience.2011.08.045; Szumlinski KK, 2006, CURR OPIN NEUROBIOL, V16, P251, DOI 10.1016/j.conb.2006.05.002; Szumlinski KK, 2006, NEUROPSYCHOPHARMACOL, V31, P768, DOI 10.1038/sj.npp.1300890; Szumlinski KK, 2004, NEURON, V43, P401, DOI 10.1016/j.neuron.2004.07.019; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Vanden Berghe T, 2010, CELL DEATH DIFFER, V17, P922, DOI 10.1038/cdd.2009.184; Vila M, 2004, NAT MED, V10, pS58, DOI 10.1038/nm1068; Witte ME, 2010, MITOCHONDRION, V10, P411, DOI 10.1016/j.mito.2010.05.014; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yamamoto K, 2005, EUR J NEUROSCI, V22, P1338, DOI 10.1111/j.1460-9568.2005.04278.x; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	49	51	51	2	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0898-6568	1873-3913		CELL SIGNAL	Cell. Signal.	DEC	2013	25	12					2863	2870		10.1016/j.cellsig.2013.09.004			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	268OG	WOS:000328179800056	24036210				2022-02-06	
J	Heinemann, AW; Magasi, S; Bode, RK; Hammel, J; Whiteneck, GG; Bogner, J; Corrigan, JD				Heinemann, Allen W.; Magasi, Susan; Bode, Rita K.; Hammel, Joy; Whiteneck, Gale G.; Bogner, Jennifer; Corrigan, John D.			Measuring Enfranchisement: Importance of and Control Over Participation by People With Disabilities	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Psychometrics; Quality of life; Rehabilitation; Social participation	INTERNATIONAL-CLASSIFICATION; COMMUNITY; HEALTH; PERSPECTIVES; INTEGRATION; COMPONENTS; ISSUES; LIFE	Objective: To evaluate the psychometric properties and validity of an expanded set of community enfranchisement items that are suitable for computer adaptive testing. Design: Survey. Setting: Community setting. Participants: Individuals with disabilities (N=1163) were recruited from an online panel generation company (51%), former rehabilitation inpatients (18%), disability community organizations (13%), a registry of rehabilitation patients (10%), and Traumatic Brain Injury and Spinal Cord Injury Model System facilities (8%). Inclusion criteria were a self-identified disability, aged >= 18 years, and the ability to read and speak English. Interventions: None. Main Outcome Measure: Community enfranchisement. Results: Exploratory and confirmatory factor analyses of the 48 enfranchisement items suggested 2 distinct subsets of items: (1) importance of participation and (2) control over participation. Principal components analysis of the residuals suggested that the 2 item sets are unidimensional. Rating scale analysis provided evidence that the 2 item sets fit the Rasch model. Importance and control were moderately correlated with each other and with disability severity. Conclusions: Importance of participation and control over participation define 2 distinct sets of participation enfranchisement. Preliminary evidence supports their validity. (C) 2013 by the American Congress of Rehabilitation Medicine	[Heinemann, Allen W.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Hammel, Joy] Univ Illinois, Coll Appl Hlth Sci, Chicago, IL USA; [Magasi, Susan; Whiteneck, Gale G.] Craig Hosp, Englewood, CO USA; [Bogner, Jennifer; Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA		Heinemann, AW (corresponding author), Northwestern Univ, Feinberg Sch Med, 345 E Super St, Chicago, IL 60611 USA.	a-heinemann@northwestern.edu	Bogner, Jennifer/E-2773-2011; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326	National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness [H133B040032]	Supported by the National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness grant (no. H133B040032).	Badley EM, 2008, SOC SCI MED, V66, P2335, DOI 10.1016/j.socscimed.2008.01.026; Baum CM, 2011, ARCH PHYS MED REHAB, V92, P169, DOI 10.1016/j.apmr.2010.12.010; Bezruczko N., 2005, RASCH MEASUREMENT HL; Bond T. G., 2007, APPL RASCH MODEL FUN, V2; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Choi SW, 2011, J STAT SOFTW, V39, P1; GIBBONS RD, 1992, PSYCHOMETRIKA, V57, P423, DOI 10.1007/BF02295430; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Heinemann AW, 2011, ARCH PHYS MED REHAB, V92, P564, DOI 10.1016/j.apmr.2010.07.220; Heinemann AW, 2010, ARCH PHYS MED REHAB, V91, pS72, DOI 10.1016/j.apmr.2009.11.031; Hemmingsson H, 2005, AM J OCCUP THER, V59, P569, DOI 10.5014/ajot.59.5.569; Hollingsworth H, 2010, ARCH PHYS MED REHAB, V91, P1174, DOI 10.1016/j.apmr.2010.04.019; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Institute of Medicine, 2007, FUTURE DISABILITY AM; Linacre J. M., 2009, WINSTEPS RASCH PROGR; Magasi S, 2010, ARCH PHYS MED REHAB, V91, pS17, DOI 10.1016/j.apmr.2010.07.011; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; MCDONALD RP, 1981, BRIT J MATH STAT PSY, V34, P100, DOI 10.1111/j.2044-8317.1981.tb00621.x; Muthen B., 1997, ROBUST INFERENCE USI; Muthen L.K., 2017, MPLUS USERS GUIDE, V8th ed.; O'Connor BP, 2000, BEHAV RES METH INS C, V32, P396, DOI 10.3758/BF03200807; Rasch Georg, 1980, PROBABILISTIC MODELS; Seekins T, 2012, DISABIL HEALTH J, V5, P224, DOI 10.1016/j.dhjo.2012.05.002; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Tennant A., 2006, RASCH MEAS T, V20, P1048; Townley G, 2009, J COMMUNITY PSYCHOL, V37, P362, DOI 10.1002/jcop.20301; Ueda S, 2003, DISABIL REHABIL, V25, P596, DOI 10.1080/0963828031000137108; van de Ven L, 2005, DISABIL SOC, V20, P311, DOI 10.1080/09687590500060778; Vargus-Adams JN, 2012, DEV MED CHILD NEUROL, V54, P777, DOI 10.1111/j.1469-8749.2012.04353.x; Whiteneck G, 2006, WORKSH DIS AM NEW LO, P55; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; World Health Organization, 2007, INT CLASS FUNCT DIS; Wright B., 1999, MEASUREMENT ESSENTIA, V2nd	34	51	51	0	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2013	94	11					2157	2165		10.1016/j.apmr.2013.05.017			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	250KV	WOS:000326852600017	23769764				2022-02-06	
J	Kuceyeski, A; Maruta, J; Relkin, N; Raj, A				Kuceyeski, Amy; Maruta, Jun; Relkin, Norman; Raj, Ashish			The Network Modification (NeMo) Tool: Elucidating the Effect of White Matter Integrity Changes on Cortical and Subcortical Structural Connectivity	BRAIN CONNECTIVITY			English	Article						altered brain connectivity; brain networks; fiber tracking; neurodegenerative disorder; traumatic brain injury; altered brain connectivity; brain networks; fiber tracking; neurodegenerative disorder; traumatic brain injury	MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; SMALL-WORLD; ORGANIZATION; INJURY; TRACTOGRAPHY; LOCATION; DAMAGE; ATLAS	Accurate prediction of brain dysfunction caused by disease or injury requires the quantification of resultant neural connectivity changes compared with the normal state. There are many methods with which to assess anatomical changes in structural or diffusion magnetic resonance imaging, but most overlook the topology of white matter (WM) connections that make up the healthy brain network. Here, a new neuroimaging software pipeline called the Network Modification (NeMo) Tool is presented that associates alterations in WM integrity with expected changes in neural connectivity between gray matter regions. The NeMo Tool uses a large reference set of healthy tractograms to assess implied network changes arising from a particular pattern of WM alteration on a region- and network-wise level. In this way, WM integrity changes can be extrapolated to the cortices and deep brain nuclei, enabling assessment of functional and cognitive alterations. Unlike current techniques that assess network dysfunction, the NeMo tool does not require tractography in pathological brains for which the algorithms may be unreliable or diffusion data are unavailable. The versatility of the NeMo Tool is demonstrated by applying it to data from patients with Alzheimer's disease, fronto-temporal dementia, normal pressure hydrocephalus, and mild traumatic brain injury. This tool fills a gap in the quantitative neuroimaging field by enabling an investigation of morphological and functional implications of changes in structural WM integrity.	[Kuceyeski, Amy; Raj, Ashish] Weill Cornell Med Coll, IDEAL, Dept Radiol, 515 E 71st St, New York, NY 10065 USA; [Kuceyeski, Amy; Raj, Ashish] Weill Cornell Med Coll, Brain & Mind Res Inst, New York, NY 10065 USA; [Maruta, Jun] Brain Trauma Fdn, New York, NY USA; [Relkin, Norman] Weill Cornell Med Coll, Dept Neurol, New York, NY 10065 USA; [Relkin, Norman] Weill Cornell Med Coll, Dept Neurosci, New York, NY 10065 USA		Kuceyeski, A (corresponding author), Weill Cornell Med Coll, IDEAL, Dept Radiol, 515 E 71st St, New York, NY 10065 USA.	amk2012@med.cornell.edu	Maruta, Jun/I-3790-2019	Maruta, Jun/0000-0002-5054-6605	Leon Levy Foundation Neuroscience Fellowship; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32 EB012404-01, P41 RR023953-02, P41 RR023953-02S1, R21 EB008138-02]; Department of DefenseUnited States Department of Defense [W81XWH-08-1-0646, W81XWH-08-20177]; James S. McDonnell Foundation; Leon Levy Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 AG19724, P50 AG1657303-75271]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR023953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [F32EB012404, R21EB008138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG016573, P01AG019724] Funding Source: NIH RePORTER	The data processing, analysis and NeMo Tool creation and validation were supported by a Leon Levy Foundation Neuroscience Fellowship as well as the following National Institutes of Health grants: F32 EB012404-01, P41 RR023953-02, P41 RR023953-02S1, and R21 EB008138-02. The normative data used in the TRS and the TBI patient data were collected and maintained with support from the Department of Defense grants W81XWH-08-1-0646 and W81XWH-08-20177, and a James S. McDonnell Foundation grant for the Cognitive Neurobiological Research Consortium in Traumatic Brain Injury. The NPH portion of this study was supported by The Leon Levy Foundation. The authors thank Dr. Bruce Miller and NIH grants P01 AG19724 and P50 AG1657303-75271 for sharing data and Eve LoCastro for help in creating the Tractogram Reference Set. They also thank Xiaobo Shen for his help in packaging and publishing the NeMo Tool and Eve LoCastro for adapting her Brainography visualization software for use within the NeMo Tool.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Akiguchi I, 2008, J NEUROL, V255, P1392, DOI 10.1007/s00415-008-0928-1; Aleman-Gomez Y, 2005, 12 ANN M ORG HUM BRA; Alstott J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000408; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J., 2006, STAT PARAMETRIC MAPP, V1st ed.; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Barabasi AL, 2009, SCIENCE, V325, P412, DOI 10.1126/science.1173299; Bassett DS, 2008, J NEUROSCI, V28, P9239, DOI 10.1523/JNEUROSCI.1929-08.2008; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Charil A, 2003, NEUROIMAGE, V19, P532, DOI 10.1016/S1053-8119(03)00117-4; Chen CL, 2000, ARCH PHYS MED REHAB, V81, P447, DOI 10.1053/mr.2000.3837; Chung MK, 2001, NEUROIMAGE, V14, P595, DOI 10.1006/nimg.2001.0862; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Crofts JJ, 2011, NEUROIMAGE, V54, P161, DOI 10.1016/j.neuroimage.2010.08.032; Evans AC., 2006, P 12 ANN M ORG HUM B; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; Fields RD, 2008, TRENDS NEUROSCI, V31, P361, DOI 10.1016/j.tins.2008.04.001; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Gleichgerrcht E, 2009, BEHAV NEUROL, V21, P181, DOI [10.3233/BEN-2009-0249, 10.1155/2009/516796]; Gondran M, 1984, DISCREET MATH SERIES, V1484; Hattori T, 2012, AM J NEURORADIOL, V33, P97, DOI 10.3174/ajnr.A2706; He Y, 2009, NEUROSCIENTIST, V15, P333, DOI 10.1177/1073858409334423; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Iturria-Medina Y, 2005, 11 ANN M ORG HUM BRA, P26; Johansen-Berg H, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00146; Johansen-Berg H, 2010, CURR OPIN NEUROL, V23, P351, DOI 10.1097/WCO.0b013e32833b7631; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kuceyeski A, 2013, HUM BRAIN MAPP, V34, P3129, DOI 10.1002/hbm.22132; Kuceyeski A, 2012, NEUROIMAGE, V61, P1311, DOI 10.1016/j.neuroimage.2012.03.039; Kuceyeski A, 2011, NEUROIMAGE, V58, P109, DOI 10.1016/j.neuroimage.2011.05.087; Kutzelnigg A, 2005, BRAIN, V128, P2705, DOI 10.1093/brain/awh641; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lo CY, 2010, J NEUROSCI, V30, P16876, DOI 10.1523/JNEUROSCI.4136-10.2010; Mukherjee P, 2005, NEUROIMAG CLIN N AM, V15, P655, DOI 10.1016/j.nic.2005.08.010; Nazzal ME, 2009, DISABIL REHABIL, V31, P1501, DOI 10.1080/09638280802627702; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Otani N, 2004, J CLIN NEUROSCI, V11, P313, DOI 10.1016/j.jocn.2003.02.014; Pagani E, 2007, AM J NEURORADIOL, V28, P411; Pannek K, 2011, NEUROIMAGE, V55, P133, DOI 10.1016/j.neuroimage.2010.12.010; Pfefferbaum A, 2005, NEUROIMAGE, V26, P891, DOI 10.1016/j.neuroimage.2005.02.034; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Przulj N, 2004, KNOWLEDGE DISCOVERY; Raj A, 2012, NEURON, V73, P1204, DOI 10.1016/j.neuron.2011.12.040; Raj A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014832; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Saito M, 2011, DEMENT GER COGN D EX, V1, P202, DOI 10.1159/000328924; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Schulte T, 2012, ALCOHOL CLIN EXP RES, V36, P2017, DOI 10.1111/j.1530-0277.2012.01831.x; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; Sporns O, 2004, NEUROINFORMATICS, V2, P145, DOI 10.1385/NI:2:2:145; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vaessen MJ, 2010, NEUROIMAGE, V51, P1106, DOI 10.1016/j.neuroimage.2010.03.011; Vellinga MM, 2009, J MAGN RESON IMAGING, V29, P768, DOI 10.1002/jmri.21679; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wen W, 2011, J NEUROSCI, V31, P1204, DOI 10.1523/JNEUROSCI.4085-10.2011; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wilson M, 2003, J NEUROL NEUROSUR PS, V74, P203, DOI 10.1136/jnnp.74.2.203; Woolrich Mark W, 2009, Neuroimage, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Yen PS, 2009, SURG NEUROL, V72, P464, DOI 10.1016/j.surneu.2009.05.008; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zhang Y, 2009, BRAIN, V132, P2579, DOI 10.1093/brain/awp071	69	51	51	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	2158-0014	2158-0022		BRAIN CONNECT	Brain Connect.	OCT	2013	3	5					451	463		10.1089/brain.2013.0147			13	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	VG7EK	WOS:000448182800001	23855491	Green Published			2022-02-06	
J	Monaco, CM; Mattiola, VV; Folweiler, KA; Tay, JK; Yelleswarapu, NK; Curatolo, LM; Matter, AM; Cheng, JP; Kline, AE				Monaco, Christina M.; Mattiola, Vincent V.; Folweiler, Kaitlin A.; Tay, Justin K.; Yelleswarapu, Narayana K.; Curatolo, Lauren M.; Matter, Ashley M.; Cheng, Jeffrey P.; Kline, Anthony E.			Environmental enrichment promotes robust functional and histological benefits in female rats after controlled cortical impact injury	EXPERIMENTAL NEUROLOGY			English	Article						Behavior; Controlled cortical impact; Environmental enrichment; Functional recovery; Learning and memory; Morris water maze; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; RECEPTOR AGONIST 8-OH-DPAT; COGNITIVE DEFICITS; SPATIAL MEMORY; NEUROBEHAVIORAL BENEFIT; SYNAPTOPHYSIN LEVELS; NEUROTROPHIC FACTOR; HYPOXIA-ISCHEMIA; CONTUSION INJURY; CLINICAL-TRIALS	Environmental enrichment (EE) consistently induces marked benefits in male rats after traumatic brain injury (TBI), but whether similar efficacy extends to females is not well established. Hence, the aim of this study was to reassess the effect of EE on functional and histological outcome in female rats after brain trauma. Twenty-four normal cycling adult female rats underwent verification of estrous stage prior to controlled cortical impact (CCI) or sham injury and then were assigned to EE or standard (STD) housing. Motor function was assessed with beam-balance/beam-walk and rotarod tasks on post-operative days 1-5 and every other day from 1-19, respectively. Spatial learning/memory was evaluated in a Morris water maze on days 14-19. Morphologically intact hippocampal CA(1/3) cells and cortical lesion volume were quantified 3 weeks after injury. No differences were observed between the EE and STD sham groups in any endpoint measure and thus the data were pooled. In the TBI groups, EE improved beam-balance, beam-walk, rotarod, and spatial learning performance vs. STD (p's<0.05). EE also provided significant histological protection as confirmed by increased CA(1/3) cell survival and decreased cortical lesion size vs. STD. These data demonstrate that EE confers robust benefits in female rats after CCI injury, which parallels numerous studies in males and lends further credence for EE as a preclinical model of neurorehabilitation. (C) 2013 Elsevier Inc. All rights reserved.	[Monaco, Christina M.; Mattiola, Vincent V.; Folweiler, Kaitlin A.; Tay, Justin K.; Yelleswarapu, Narayana K.; Curatolo, Lauren M.; Matter, Ashley M.; Cheng, Jeffrey P.; Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA; [Mattiola, Vincent V.; Folweiler, Kaitlin A.; Tay, Justin K.; Yelleswarapu, Narayana K.; Curatolo, Lauren M.; Matter, Ashley M.; Cheng, Jeffrey P.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA		Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS060005, HD069620]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	Supported, in part, by NIH grants NS060005 and HD069620 (AEK)	BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Faul M, 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Frick KM, 2003, LEARN MEMORY, V10, P187, DOI 10.1101/lm.50703; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Garcia AN, 2011, PM&R, V3, pS18, DOI 10.1016/j.pmrj.2011.03.017; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gomez-Pinilla F, 2011, EUR J NEUROSCI, V33, P383, DOI 10.1111/j.1460-9568.2010.07508.x; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Lambert TJ, 2005, NEUROBIOL LEARN MEM, V83, P206, DOI 10.1016/j.nlm.2004.12.001; Martinez-Cue C, 2002, BEHAV BRAIN RES, V134, P185, DOI 10.1016/S0166-4328(02)00026-8; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Pereira LO, 2008, BRAIN RES, V1218, P257, DOI 10.1016/j.brainres.2008.04.010; Pereira LO, 2009, BRAIN RES, V1247, P188, DOI 10.1016/j.brainres.2008.10.017; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Yelleswarapu NK, 2012, NEUROSCI LETT, V515, P153, DOI 10.1016/j.neulet.2012.03.033	58	51	52	1	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2013	247						410	418		10.1016/j.expneurol.2013.01.007			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	204VO	WOS:000323399600050	23333563	Green Accepted			2022-02-06	
J	Tator, CH				Tator, Charles H.			Concussions and their consequences: current diagnosis, management and prevention	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							SPORT-RELATED CONCUSSION; RECURRENT CONCUSSION; FOOTBALL PLAYERS; HEAD-INJURY; HOCKEY; RETURN; RISK		[Tator, Charles H.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Tator, Charles H.] Toronto Western Hosp, Krembil Neurosci Ctr, Canadian Sports Concuss Project, Toronto, ON, Canada; [Tator, Charles H.] Think First & Parachute Canada, Toronto, ON, Canada		Tator, CH (corresponding author), Univ Toronto, Div Neurosurg, Toronto, ON, Canada.	charles.tator@uhn.ca					Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; [Anonymous], 2000, CLIN J SPORT MED, V10, P209; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoshizaki TB, 2004, NEUROSURGERY, V55, P956, DOI 10.1227/01.NEU.0000137275.50246.0B; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Tator CH, 2001, NEUROLOGICAL SPORTS, P261; Tator CH, 2009, CAN J NEUROL SCI, V36, P405, DOI 10.1017/S031716710000771X; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8	20	51	52	2	54	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946			CAN MED ASSOC J	Can. Med. Assoc. J.	AUG 6	2013	185	11					975	979		10.1503/cmaj.120039			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196ZR	WOS:000322816700029	23877672	gold, Green Published			2022-02-06	
J	Greer, JE; Hanell, A; McGinn, MJ; Povlishock, JT				Greer, John E.; Hanell, Anders; McGinn, Melissa J.; Povlishock, John T.			Mild traumatic brain injury in the mouse induces axotomy primarily within the axon initial segment	ACTA NEUROPATHOLOGICA			English	Article						Diffuse axonal injury; Traumatic brain injury; Axon initial segment	AMYLOID PRECURSOR PROTEIN; SPINAL-CORD-INJURY; CALPAIN-MEDIATED PROTEOLYSIS; OPTIC-NERVE FIBERS; HEAD-INJURY; STRETCH-INJURY; RETROGRADE CONVERSION; TRANSPORTED VESICLES; NEURONAL INJURY; SODIUM-CHANNELS	Traumatic axonal injury (TAI) is a consistent component of traumatic brain injury (TBI), and is associated with much of its morbidity. Increasingly, it has also been recognized as a major pathology of mild TBI (mTBI). In terms of its pathogenesis, numerous studies have investigated the susceptibility of the nodes of Ranvier, the paranode and internodal regions to TAI. The nodes of Ranvier, with their unique composition and concentration of ion channels, have been suggested as the primary site of injury, initiating a cascade of abnormalities in the related paranodal and internodal domains that lead to local axonal swellings and detachment. No investigation, however, has determined the effect of TAI upon the axon initial segment (AIS), a segment critical to regulating polarity and excitability. The current study sought to identify the susceptibility of these different axon domains to TAI within the neocortex, where each axonal domain could be simultaneously assessed. Utilizing a mouse model of mTBI, a temporal and spatial heterogeneity of axonal injury was found within the neocortical gray matter. Although axonal swellings were found in all domains along myelinated neocortical axons, the majority of TAI occurred within the AIS, which progressed without overt structural disruption of the AIS itself. The finding of primary AIS involvement has important implications regarding neuronal polarity and the fate of axotomized processes, while also raising therapeutic implications, as the mechanisms underlying such axonal injury in the AIS may be distinct from those described for nodal/paranodal injury.	[Greer, John E.; Hanell, Anders; McGinn, Melissa J.; Povlishock, John T.] Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu	Hanell, Anders/E-4776-2011	Hanell, Anders/0000-0001-9369-3886	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS077675, NS047463]; NIH-NINDS CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS077675] Funding Source: NIH RePORTER	The authors would like to thank C. Lynn Davis, Jesse Sims and Sue Walker for their technical support. Funding was provided by NIH Grants NS077675 and NS047463. Microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS Center core Grant (5P30NS047463-02).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bender KJ, 2012, ANNU REV NEUROSCI, V35, P249, DOI 10.1146/annurev-neuro-062111-150339; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; BISBY MA, 1977, J NEUROCHEM, V29, P313, DOI 10.1111/j.1471-4159.1977.tb09624.x; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Carter LM, 2008, J NEUROSCI, V28, P14107, DOI 10.1523/JNEUROSCI.2217-08.2008; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duflocq A, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-66; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Grubb MS, 2010, NATURE, V465, P1070, DOI 10.1038/nature09160; Hedstrom KL, 2008, J CELL BIOL, V183, P635, DOI 10.1083/jcb.200806112; Hinman JD, 2013, STROKE, V44, P182, DOI 10.1161/STROKEAHA.112.668749; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Kaphzan H, 2011, J NEUROSCI, V31, P17637, DOI 10.1523/JNEUROSCI.4162-11.2011; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kole MHP, 2012, NEURON, V73, P235, DOI 10.1016/j.neuron.2012.01.007; Kuba H, 2012, J PHYSIOL-LONDON, V590, P5571, DOI 10.1113/jphysiol.2012.237305; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Povlishock JT, 1999, ACT NEUR S, V73, P15; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rasband MN, 2011, SEMIN CELL DEV BIOL, V22, P178, DOI 10.1016/j.semcdb.2010.09.010; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; SMITH RS, 1991, BRAIN RES, V552, P215, DOI 10.1016/0006-8993(91)90085-A; SNYDER RE, 1994, BRAIN RES, V635, P49, DOI 10.1016/0006-8993(94)91422-2; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Sugino K, 2006, NAT NEUROSCI, V9, P99, DOI 10.1038/nn1618; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	77	51	52	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	JUL	2013	126	1					59	74		10.1007/s00401-013-1119-4			16	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	169LK	WOS:000320781500005	23595276	Green Accepted			2022-02-06	
J	Tarapore, PE; Findlay, AM; LaHue, SC; Lee, H; Honma, SM; Mizuiri, D; Luks, TL; Manley, GT; Nagarajan, SS; Mukherjee, P				Tarapore, Phiroz E.; Findlay, Anne M.; LaHue, Sara C.; Lee, Hana; Honma, Susanne M.; Mizuiri, Danielle; Luks, Tracy L.; Manley, Geoffrey T.; Nagarajan, Srikantan S.; Mukherjee, Pratik			Resting state magnetoencephalography functional connectivity in traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cognition; concussion; diffuse axonal injury; functional connectivity; magnetoencephalography; traumatic brain injury	MEG RECORDINGS; HEAD TRAUMA; RECOVERY; EEG; SYNCHRONIZATION; REORGANIZATION; SCHIZOPHRENIA; PLASTICITY; COHERENCY; SYMPTOMS	Object. Traumatic brain injury (TBI) is one of the leading causes of morbidity worldwide. One mechanism by which blunt head trauma may disrupt normal cognition and behavior is through alteration of functional connectivity between brain regions. In this pilot study, the authors applied a rapid automated resting state magnetoencephalography (MEG) imaging technique suitable for routine clinical use to test the hypothesis that there is decreased functional connectivity in patients with TBI compared with matched controls, even in cases of mild TBI. Furthermore, they posit that these abnormal reductions in MEG functional connectivity can be detected even in TBI patients without specific evidence of traumatic lesions on 3-T MR images. Finally, they hypothesize that the reductions of functional connectivity can improve over time across serial MEG scans during recovery from TBI. Methods. Magnetoencephalography maps of functional connectivity in the alpha (8- to 12-Hz) band from 21 patients who sustained a TBI were compared with those from 18 age- and sex-matched controls. Regions of altered functional connectivity in each patient were detected in automated fashion through atlas-based registration to the control database. The extent of reduced functional connectivity in the patient group was tested for correlations with clinical characteristics of the injury as well as with findings on 3-T MRI. Finally, the authors compared initial connectivity maps with 2-year follow-up functional connectivity in a subgroup of 5 patients with TBI. Results. Fourteen male and 7 female patients (17-53 years old, median 29 years) were enrolled. By Glasgow Coma Scale (GCS) criteria, 11 patients had mild, 1 had moderate, and 3 had severe TBI, and 6 had no GCS score recorded. On 3-T MRI, 16 patients had abnormal findings attributable to the trauma and 5 had findings in the normal range. As a group, the patients with TBI had significantly lower functional connectivity than controls (p < 0.01). Three of the 5 patients with normal findings on 3-T MRI showed regions of abnormally reduced MEG functional connectivity. No significant correlations were seen between extent of functional disconnection and injury severity or posttraumatic symptoms (p > 0.05). In the subgroup undergoing 2-year follow-up, the second MEG scan demonstrated a significantly lower percentage of voxels with decreased connectivity (p < 0.05) than the initial MEG scan. Conclusions. A rapid automated resting-state MEG imaging technique demonstrates abnormally decreased functional connectivity that may persist for years after TBI, including cases classified as "mild" by GCS criteria. Disrupted MEG connectivity can be detected even in some patients with normal findings on 3-T MRI. Analysis of follow-up MEG scans in a subgroup of patients shows that, over time, the abnormally reduced connectivity can improve, suggesting neuroplasticity during the recovery from TBI. Resting state MEG deserves further investigation as a prognostic and predictive biomarker for TBI.	[Tarapore, Phiroz E.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94107 USA; [Findlay, Anne M.; LaHue, Sara C.; Lee, Hana; Honma, Susanne M.; Mizuiri, Danielle; Luks, Tracy L.; Nagarajan, Srikantan S.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94107 USA		Mukherjee, P (corresponding author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94107 USA.	pratik@radiology.ucsf.edu		Mukherjee, Pratik/0000-0001-7473-7409	Dana Foundation Brain and Immuno-imaging Program; UCSF Research Evaluation and Allocation Program; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS060776, RC2 NS069409]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060776, RC2NS069409, R21NS076171, R01NS066654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC010145, R01DC004855, R01DC006435] Funding Source: NIH RePORTER	This work was supported by the Dana Foundation Brain and Immuno-imaging Program, UCSF Research Evaluation and Allocation Program, and NIH (Grant Nos. R01 NS060776 and RC2 NS069409).	AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; Bartolomei F, 2006, ANN NEUROL, V59, P128, DOI 10.1002/ana.20710; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Dalal SS, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/758973; Douw L, 2008, EXP NEUROL, V212, P285, DOI 10.1016/j.expneurol.2008.03.013; Eliassen JC, 2008, TOP STROKE REHABIL, V15, P427, DOI 10.1310/tsr1505-427; Faul M, 2010, TRAUMATIC BRAIN INJU; FEIN G, 1988, ELECTROEN CLIN NEURO, V69, P581, DOI 10.1016/0013-4694(88)90171-X; Finkelstein E., 2006, INCIDENCE EC BURDEN; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Guggisberg AG, 2008, ANN NEUROL, V63, P193, DOI 10.1002/ana.21224; Guo CC, 2012, NEUROIMAGE, V61, P1471, DOI 10.1016/j.neuroimage.2012.03.027; Hinkley LBN, 2011, BIOL PSYCHIAT, V70, P1134, DOI 10.1016/j.biopsych.2011.06.029; Hinkley LBN, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.073.2009; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Le Van Quyen M, 2001, J NEUROSCI METH, V111, P83, DOI 10.1016/S0165-0270(01)00372-7; LEE RG, 1995, CAN J NEUROL SCI, V22, P257, DOI 10.1017/S0317167100039445; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LOPESDASILVA FH, 1973, ELECTROEN CLIN NEURO, V35, P627, DOI 10.1016/0013-4694(73)90216-2; Martino J, 2011, ANN NEUROL, V69, P521, DOI 10.1002/ana.22167; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nolte G, 2004, CLIN NEUROPHYSIOL, V115, P2292, DOI 10.1016/j.clinph.2004.04.029; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Nunez PL, 1997, ELECTROEN CLIN NEURO, V103, P499, DOI 10.1016/S0013-4694(97)00066-7; Quigley M, 2001, AM J NEURORADIOL, V22, P294; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Sekihara K, 2004, IEEE T BIO-MED ENG, V51, P1726, DOI 10.1109/TBME.2004.827926; Sekihara K, 2001, IEEE T BIO-MED ENG, V48, P760, DOI 10.1109/10.930901; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Stam CJ, 2002, J CLIN NEUROPHYSIOL, V19, P562, DOI 10.1097/00004691-200212000-00010; Stam CJ, 2003, HUM BRAIN MAPP, V19, P63, DOI 10.1002/hbm.10106; Vrba J, 2001, METHODS, V25, P249, DOI 10.1006/meth.2001.1238; Wang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021976; Westlake KP, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00008; Witte OW, 1997, ADV NEUROL, V73, P207; Zuo XN, 2010, NEUROIMAGE, V49, P2163, DOI 10.1016/j.neuroimage.2009.10.080	40	51	51	0	19	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2013	118	6					1306	1316		10.3171/2013.3.JNS12398			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	150BY	WOS:000319366400031	23600939	Green Accepted			2022-02-06	
J	Fitzgerald, M; Hodgetts, S; Van den Heuvel, C; Natoli, R; Hart, NS; Valter, K; Harvey, AR; Vink, R; Provis, J; Dunlop, SA				Fitzgerald, Melinda; Hodgetts, Stuart; Van den Heuvel, Corinna; Natoli, Riccardo; Hart, Nathan S.; Valter, Krisztina; Harvey, Alan R.; Vink, Robert; Provis, Jan; Dunlop, Sarah A.			Red/near-infrared irradiation therapy for treatment of central nervous system injuries and disorders	REVIEWS IN THE NEUROSCIENCES			English	Article						irradiation therapy; Parkinson's disease; retinal degeneration; trauma - nervous system	LOW-LEVEL LASER; TRAUMATIC BRAIN-INJURY; EMITTING DIODE IRRADIATION; ACUTE ISCHEMIC-STROKE; CYTOCHROME-C-OXIDASE; LIGHT-INDUCED DAMAGE; SPINAL-CORD-INJURY; OPTICAL-PROPERTIES; OXIDATIVE STRESS; ABSORPTION-MEASUREMENTS	Irradiation in the red/near-infrared spectrum (R/NIR, 630-1000 nm) has been used to treat a wide range of clinical conditions, including disorders of the central nervous system (CNS), with several clinical trials currently underway for stroke and macular degeneration. However, R/NIR irradiation therapy (R/NIR-IT) has not been widely adopted in clinical practice for CNS injury or disease for a number of reasons, which include the following. The mechanism/s of action and implications of penetration have not been thoroughly addressed. The large range of treatment intensities, wavelengths and devices that have been assessed make comparisons difficult, and a consensus paradigm for treatment has not yet emerged. Furthermore, the lack of consistent positive outcomes in randomised controlled trials, perhaps due to sub-optimal treatment regimens, has contributed to scepticism. This review provides a balanced precis of outcomes described in the literature regarding treatment modalities and efficacy of R/NIR-IT for injury and disease in the CNS. We have addressed the important issues of specification of treatment parameters, penetration of R/NIR irradiation to CNS tissues and mechanism/s, and provided the necessary detail to demonstrate the potential of R/NIR-IT for the treatment of retinal degeneration, damage to white matter tracts of the CNS, stroke and Parkinson's disease.	[Fitzgerald, Melinda; Hodgetts, Stuart; Harvey, Alan R.] Univ Western Australia, Crawley 6009, Australia; [Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley 6009, Australia; [Hodgetts, Stuart; Harvey, Alan R.] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley 6009, Australia; [Van den Heuvel, Corinna; Vink, Robert] Univ Adelaide, Sch Med Sci, Adelaide, SA 5005, Australia; [Natoli, Riccardo; Valter, Krisztina; Provis, Jan] Australian Natl Univ, ANU Med Sch, Acton 0200, Australia; [Natoli, Riccardo; Valter, Krisztina; Provis, Jan] Australian Natl Univ, John Curtin Sch Med Res, Acton 0200, Australia; [Hart, Nathan S.] Univ Western Australia, Sch Anim Biol, Crawley 6009, Australia		Fitzgerald, M (corresponding author), Univ Western Australia, Crawley 6009, Australia.	lindy.fitzgerald@uwa.edu.au	Vink, Robert/J-7351-2012; Dunlop, Sarah A/G-9357-2013; Hart, Nathan S/B-8564-2011; Vink, Robert/S-5616-2019; Valter, Krisztina/L-3015-2016; Fitzgerald, Melinda/C-4235-2011; Provis, Jan/C-9529-2009	Vink, Robert/0000-0002-4885-0667; Hart, Nathan S/0000-0002-7289-9399; Vink, Robert/0000-0002-4885-0667; Fitzgerald, Melinda/0000-0002-4823-8179; Valter, Krisztina/0000-0002-2033-0408; Hodgetts, Stuart/0000-0002-3318-0410; Provis, Jan/0000-0002-6405-2868; Natoli, Riccardo/0000-0002-9350-0439; , Corinna/0000-0003-0664-8935; Dunlop, Sarah/0000-0002-1306-3962; , Alan/0000-0002-2590-831X	Neurotrauma Research Program (Western Australia); NHMRC, AustraliaNational Health and Medical Research Council of Australia [APP1002347]	This work was supported by the Neurotrauma Research Program (Western Australia). Prof. Dunlop is a Principal Research Fellow of the NH&MRC, Australia (Grant ID: APP1002347). Prof. Nathan Hart would like to acknowledge the support of Prof. Shaun Collin.	Ad N, 2001, INT J CARDIOL, V80, P109, DOI 10.1016/S0167-5273(01)00503-4; Albarracin R, 2012, PHOTOCHEM PHOTOBIOL, V88, P1418, DOI 10.1111/j.1751-1097.2012.01130.x; Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664; Albarracin RS, 2012, ADV EXP MED BIOL, V723, P121, DOI 10.1007/978-1-4614-0631-0_17; Alves G, 2008, J NEUROL, V255, P18, DOI 10.1007/s00415-008-5004-3; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Ankri R, 2010, LASER SURG MED, V42, P760, DOI 10.1002/lsm.20955; ASSIA E, 1989, BRAIN RES, V476, P205, DOI 10.1016/0006-8993(89)91240-7; Balaratnasingam C, 2009, INVEST OPHTH VIS SCI, V50, P2824, DOI 10.1167/iovs.08-3206; Ball KA, 2011, J PHOTOCH PHOTOBIO B, V102, P182, DOI 10.1016/j.jphotobiol.2010.12.002; Banerjee R, 2009, BBA-MOL BASIS DIS, V1792, P651, DOI 10.1016/j.bbadis.2008.11.007; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Biron KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023789; Bjordal JM, 2003, AUST J PHYSIOTHER, V49, P107, DOI 10.1016/S0004-9514(14)60127-6; Bradaric BD, 2012, J NEURAL TRANSM, V119, P59, DOI 10.1007/s00702-011-0684-8; BRAMBILLA R, 2006, CYTOKINES CNS, P299; BROSSEAU L, 2003, COCHRANE DB SYST REV; Brosseau L., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004377; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Camello-Almaraz MC, 2006, J CELL PHYSIOL, V206, P487, DOI 10.1002/jcp.20498; CARTER K, 1982, J BIOL CHEM, V257, P13507; Cauwels RGEC, 2011, EUR ARCH PAEDIATR DE, V12, P118, DOI 10.1007/BF03262791; CHEONG WF, 1990, IEEE J QUANTUM ELECT, V26, P2166, DOI 10.1109/3.64354; Chow RT, 2009, LANCET, V374, P1897, DOI 10.1016/S0140-6736(09)61522-1; Christie A, 2007, PHYS THER, V87, P1697, DOI 10.2522/ptj.20070039; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402; de Lima AG, 2012, INT J RADIAT ONCOL, V82, P270, DOI 10.1016/j.ijrobp.2010.10.012; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Dimauro TM, 2007, U.S. Patent, Patent No. [7, 288, 108, 7288108]; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; EICHLER J, 1977, RADIAT ENVIRON BIOPH, V14, P239, DOI 10.1007/BF01323942; FIRBANK M, 1993, PHYS MED BIOL, V38, P503, DOI 10.1088/0031-9155/38/4/002; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Hartz AMS, 2012, STROKE, V43, P514, DOI 10.1161/STROKEAHA.111.627562; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; HEBEDA KM, 1994, NEUROSURGERY, V35, P720, DOI 10.1227/00006123-199410000-00019; Hegedus B, 2009, PHOTOMED LASER SURG, V27, P577, DOI 10.1089/pho.2008.2297; Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709; Hom J, 2011, AM J NEURORADIOL, V32, P41, DOI 10.3174/ajnr.A2244; Howard RS, 2012, QJM-INT J MED, V105, P551, DOI 10.1093/qjmed/hcs016; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Ishiguro M, 2010, J ORTHOP SCI, V15, P233, DOI 10.1007/s00776-009-1438-4; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Jenkins PA, 2011, PHOTOMED LASER SURG, V29, P785, DOI 10.1089/pho.2011.9895; JOHNSON VE, 2012, EXP NEUROL IN PRESS; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355; Karu TI, 2008, PHOTOMED LASER SURG, V26, P593, DOI 10.1089/pho.2008.2246; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Kaviani A, 2011, PHOTOMED LASER SURG, V29, P109, DOI 10.1089/pho.2009.2680; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014; Kokol R, 2005, HAUTARZT, V56, P570, DOI 10.1007/s00105-004-0864-7; KOMELKOVA LV, 2004, PATOL FIZIOL EKSP TE, V1, P15; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lansberg MG, 2009, STROKE, V40, P2438, DOI 10.1161/STROKEAHA.109.552547; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2002, STROKE, V33, P1411, DOI 10.1161/01.STR.0000015346.00054.8B; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Lapchak PA, 2012, EXPERT REV MED DEVIC, V9, P71, DOI 10.1586/ERD.11.64; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Silva GBL, 2011, PHOTOMED LASER SURG, V29, P27, DOI 10.1089/pho.2009.2699; Lenz P, 1999, APPL OPTICS, V38, P3662, DOI 10.1364/AO.38.003662; Leonarduzzi G, 2011, CURR PHARM DESIGN, V17, P3994, DOI 10.2174/138161211798764906; Leung MCP, 2002, LASER SURG MED, V31, P283, DOI 10.1002/lsm.10096; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Liang HL, 2006, NEUROSCIENCE, V139, P639, DOI 10.1016/j.neuroscience.2005.12.047; Lim J, 2010, J PHOTOCH PHOTOBIO B, V99, P105, DOI 10.1016/j.jphotobiol.2010.03.002; Lim J, 2009, J BIOCHEM MOL TOXIC, V23, P1, DOI 10.1002/jbt.20257; Liu XZ, 1997, J NEUROSCI, V17, P5395; Mason MG, 2006, P NATL ACAD SCI USA, V103, P708, DOI 10.1073/pnas.0506562103; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McCarthy TJ, 2010, PHOTOMED LASER SURG, V28, P663, DOI 10.1089/pho.2009.2581; Medalha CC, 2010, PHOTOMED LASER SURG, V28, P669, DOI 10.1089/pho.2009.2691; MESTER E, 1985, LASER SURG MED, V5, P31, DOI 10.1002/lsm.1900050105; Mitchell Ulrike H., 2011, Physiotherapy Theory and Practice, V27, P345, DOI 10.3109/09593985.2010.511440; Mitra S, 2004, PHYS MED BIOL, V49, P1891, DOI 10.1088/0031-9155/49/10/005; Moftakhar P, 2010, J NEUROPATH EXP NEUR, V69, P1201, DOI 10.1097/NEN.0b013e3181fd252c; Moreira MS, 2009, J PHOTOCH PHOTOBIO B, V97, P145, DOI 10.1016/j.jphotobiol.2009.09.002; MULLER PJ, 1986, PHYS MED BIOL, V31, P1295, DOI 10.1088/0031-9155/31/11/012; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Nashmi R, 2001, BRAIN RES REV, V38, P165, DOI 10.1016/S0165-0173(01)00134-5; Natoli R, 2010, MOL VIS, V16, P1801; Nawashiro H, 2012, PHOTOMED LASER SURG, V30, P231, DOI 10.1089/pho.2011.3044; Neupane J, 2010, PHOTODIAGN PHOTODYN, V7, P44, DOI 10.1016/j.pdpdt.2009.12.006; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; PARRISH JA, 1981, J INVEST DERMATOL, V77, P45, DOI 10.1111/1523-1747.ep12479235; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Peoples Cassandra, 2012, ISRN Neurol, V2012, P850150, DOI 10.5402/2012/850150; Peoples C, 2012, PARKINSONISM RELAT D, V18, P469, DOI 10.1016/j.parkreldis.2012.01.005; PETRATOS S, 2004, NEUROBIOL DIS, V15, P415; Posten W, 2005, DERMATOL SURG, V31, P334, DOI 10.1097/00042728-200503000-00016; PROFIO AE, 1989, APPL OPTICS, V28, P2216, DOI 10.1364/AO.28.002216; Qu C, 2010, ADV EXP MED BIOL, V664, P365, DOI 10.1007/978-1-4419-1399-9_42; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Quirk BJ, 2011, PHOTOMED LASER SURG, V29, P143, DOI 10.1089/pho.2011.3014; Rochkind S, 2009, INT REV NEUROBIOL, V87, P445, DOI 10.1016/S0074-7742(09)87025-6; Rodieck R. W., 1998, 1 STEPS SEEING; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P2379, DOI 10.1167/iovs.10-6010; Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925; SANDEMAN DR, 1986, LASER MED SCI, V3, P47; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Segura T, 2008, EXPERT OPIN PHARMACO, V9, P1071, DOI [10.1517/14656566.9.7.1071, 10.1517/14656560802049322]; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Seme MT, 1999, J PHARMACOL EXP THER, V289, P361; Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207; Shen JF, 2008, J CEREBR BLOOD F MET, V28, P1460, DOI 10.1038/jcbfm.2008.37; Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346; Shi QL, 2007, ALZ DIS ASSOC DIS, V21, P276, DOI 10.1097/WAD.0b013e31815721c3; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; STERENBORG H J C M, 1989, Lasers in Medical Science, V4, P221, DOI 10.1007/BF02032451; Stolik S, 2000, J PHOTOCH PHOTOBIO B, V57, P90, DOI 10.1016/S1011-1344(00)00082-8; Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; STREETER J, 2012, Patent No. 11844205; Sutherland JC, 2002, PHOTOCHEM PHOTOBIOL, V76, P164, DOI 10.1562/0031-8655(2002)076<0164:BEOPL>2.0.CO;2; SVAASAND LO, 1983, PHOTOCHEM PHOTOBIOL, V38, P293, DOI 10.1111/j.1751-1097.1983.tb02674.x; Sykova E, 2008, NEUROCHEM INT, V52, P5, DOI 10.1016/j.neuint.2007.04.007; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tascioglu F, 2010, J INT MED RES, V38, P1233, DOI 10.1177/147323001003800404; Teggi R, 2009, AUDIOL NEURO-OTOL, V14, P115, DOI 10.1159/000161235; Topakian R, 2010, J NEUROL NEUROSUR PS, V81, P192, DOI 10.1136/jnnp.2009.172072; TOSELLI R, 2008, Patent No. 12041405; Tretter L, 2007, J NEUROSCI RES, V85, P3471, DOI 10.1002/jnr.21405; Tsukahara H, 2004, LIFE SCI, V75, P933, DOI 10.1016/j.lfs.2004.01.025; VONBUSSMANN KA, 1993, NEUROREPORT, V4, P247, DOI 10.1097/00001756-199303000-00005; WAN S, 1981, PHOTOCHEM PHOTOBIOL, V34, P679, DOI 10.1111/j.1751-1097.1981.tb09424.x; Whelan HT, 2003, J CLIN LASER MED SUR, V21, P67, DOI 10.1089/104454703765035484; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667; Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Ying R, 2008, BRAIN RES, V1243, P167, DOI 10.1016/j.brainres.2008.09.057; Yousefi-Nooraie R, 2008, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD005107.PUB4; Yu DY, 1999, INVEST OPHTH VIS SCI, V40, P2082; Yu W, 1997, PHOTOCHEM PHOTOBIOL, V66, P866, DOI 10.1111/j.1751-1097.1997.tb03239.x; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	158	51	51	1	29	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	APR	2013	24	2					205	226		10.1515/revneuro-2012-0086			22	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	199CD	WOS:000322971000007	23492552	Green Submitted			2022-02-06	
J	Maghool, F; Khaksari, M; Khachki, AS				Maghool, Fatemeh; Khaksari, Mohammad; Khachki, Ali Siahposht			Differences in brain edema and intracranial pressure following traumatic brain injury across the estrous cycle: Involvement of female sex steroid hormones	BRAIN RESEARCH			English	Article						Traumatic brain injury; Estrous cycle; Brain edema; Intracranial pressure; Cerebral perfusion pressure; Sex steroid hormone	FOCAL CEREBRAL-ISCHEMIA; CONTUSION INJURY; BLOOD-FLOW; PROGESTERONE; RATS; EXPRESSION; GENDER; STROKE; MODEL; FLUID	It has been shown that sex steroid hormones have profound neuroprotective effects in experimental traumatic brain injury (TBI). Because the endogenous hormone levels are proven to differ with estrous cycle stage, we evaluated whether estrous cycle stage affects various outcomes following diffuse TBI. TBI was induced by Marmarou's method in normal cycling and in ovariectomized rats with physiologically relevant restoration of hormonal levels by hormone capsule implantation. Intracranial pressure (ICP) and cerebral perfusion pressure (CPP) were measured before and different times after TBI and brain edema was assessed at 24 h after trauma. Results indicated that after TB!, water content (WC) in traumatic proestrous (TP) rats was less than the one in traumatic non-proestrous (TNP) and ovariectomized (TOVX) and also in high estradiol (HE) and progesterone (HP) was statistically less than in TBI untreated groups.There was no significant difference in WC between high doses hormone treated and TP and also between TNP, TOVX, low estradiol (LE) and progesterone (LP) groups. At 4 h and 24 h after trauma, there was a significant difference in ICP between TP, HE and HP compared to TNP and other TBI nontreated groups. Also in these times, the CPP increased in TP and hormone treated groups compared with TOVX, but the difference between TNP and TOVX was not significant. The results indicate that the estrous cycle has a prominent role in TBI outcome's and the difference in female sex steroid levels might be the reason of the different neuroprotective effects in proestrous and non-proestrous groups. (C) 2012 Elsevier B.V. All rights reserved.	[Maghool, Fatemeh] Kerman Univ Med Sci, Sch Med, Neurosci Res Ctr, Kerman, Iran; [Khaksari, Mohammad; Khachki, Ali Siahposht] Kerman Univ Med Sci, Sch Med, Physiol Res Ctr, Kerman, Iran		Khaksari, M (corresponding author), Kerman Univ Med Sci, Sch Med, Physiol Res Ctr, Kerman, Iran.	Khaksar38@yahoo.co.uk	Haddad, Mohammad Khaksari/AAB-9025-2019; Maghool, Fatemeh/ABI-7612-2020	Haddad, Mohammad Khaksari/0000-0003-0770-4281; 	Kerman Neuroscience Research Center; Kerman Physiology Research Center	This work was supported financially by the Kerman Neuroscience and Kerman Physiology Research Centers. We thank Dr. Nader Shahrokhi and Dr. Aliasghar Pourshanazari for their cooperation in this study and Dr. Nouzar Nakhaee for assisting in the statistical analyses.	Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Azcoitia I, 2003, ANN NY ACAD SCI, V1007, P298, DOI 10.1196/annals.1286.028; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Carswell HVO, 2000, AM J PHYSIOL-HEART C, V278, pH290, DOI 10.1152/ajpheart.2000.278.1.H290; Carswell HVO, 1999, HYPERTENSION, V33, P681, DOI 10.1161/01.HYP.33.2.681; Consiglio AR, 2000, BRAIN RES PROTOC, V5, P109, DOI 10.1016/S1385-299X(99)00062-8; DEPAOLO LV, 1979, BIOL REPROD, V21, P1015, DOI 10.1095/biolreprod21.4.1015; DEPAOLO LV, 1986, BIOL REPROD, V35, P320, DOI 10.1095/biolreprod35.2.320; Deurveilher S, 2008, AM J PHYSIOL-REG I, V295, pR1328, DOI 10.1152/ajpregu.90576.2008; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Duckles SP, 2007, CLIN EXP PHARMACOL P, V34, P801, DOI 10.1111/j.1440-1681.2007.04683.x; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Gabrielian L, 2011, J NEUROTRAUM, V28, P2103, DOI 10.1089/neu.2011.1785; Gibson CL, 2006, J CEREBR BLOOD F MET, V26, P1103, DOI 10.1038/sj.jcbfm.9600270; Gilkes CE., 2009, NEUROSURGERY, V27, P139; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Jover-Mengual T, 2007, ENDOCRINOLOGY, V148, P1131, DOI 10.1210/en.2006-1137; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kovacs EJ, 2005, EXP GERONTOL, V40, P549, DOI 10.1016/j.exger.2005.04.009; Krause DN, 2002, INT CONGR SER, V1235, P395, DOI 10.1016/S0531-5131(02)00211-X; LALORAYA M, 1988, BIOCHEM BIOPH RES CO, V157, P146, DOI 10.1016/S0006-291X(88)80025-1; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; Liao SL, 2001, NEUROSCI LETT, V297, P159, DOI 10.1016/S0304-3940(00)01704-3; Long J. A., 1922, Memoirs of the University of California, V6, P1; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MANDL AM, 1951, J EXP BIOL, V28, P576; Marik P, 1999, J EMERG MED, V17, P711, DOI 10.1016/S0736-4679(99)00055-4; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Marmarou Anthony, 2004, Cleve Clin J Med, V71 Suppl 1, pS6; MATSUDA T, 1991, LIFE SCI, V48, P1627, DOI 10.1016/0024-3205(91)90122-R; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Ono H, 2002, CLIN EXP PHARMACOL P, V29, P73, DOI 10.1046/j.1440-1681.2002.03600.x; Patro A, 2009, INDIAN J NEUROTRAUM, V6, P11, DOI 10.1016/S0973-0508(09)80021-X; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Santizo RA, 2000, STROKE, V31, P2231, DOI 10.1161/01.STR.31.9.2231; Sarkaki A.R., 2011, J NEUROTRAUMA; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Strom JO, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-39; Thompson HJ, 2003, NEUROBIOL DIS, V12, P163, DOI 10.1016/S0969-9961(02)00030-X; Vink R, 2003, ACT NEUR S, V86, P257; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	78	51	53	0	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 25	2013	1497						61	72		10.1016/j.brainres.2012.12.014			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	099FS	WOS:000315607500007	23262351				2022-02-06	
J	Babikian, T; McArthur, D; Asarnow, RF				Babikian, Talin; McArthur, David; Asarnow, Robert F.			Predictors of 1-Month and 1-Year Neurocognitive Functioning from the UCLA Longitudinal Mild, Uncomplicated, Pediatric Traumatic Brain Injury Study	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Mild traumatic brain injury; Concussion; Pediatric; Neurocognition; Brain injury; Outcomes	HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; CHILDREN; OUTCOMES; RECOVERY; BEHAVIOR	Although more severe brain injuries have long been associated with persisting neurocognitive deficits, an increasing body of literature has shown that children/adolescents with single, uncomplicated mild traumatic brain injury (mTBI) do not exhibit long-lasting neurocognitive impairments. Nonetheless, clinical experience and our previous report (Babikian, 2011) showed that a minority of children/adolescents exhibit persistent cognitive problems using performance based measures following what appear to be relatively mild injuries. Predictors of poor neurocognitive outcomes were evaluated in 76 mTBI and 79 Other Injury subjects to determine the relative contributions of indices of injury severity, clinical symptomatology, demographic factors, and premorbid functioning in predicting 1-month and 12-month neurocognitive impairment on computerized or paper and pencil measures. Injury severity indicators or type of injury (head vs. other body part) did not predict either 1-month or 12-month cognitive impairment status. Rather, premorbid variables that antedated the injury (parental education, premorbid behavior and/or learning problems, and school achievement) predicted cognitive impairments. When post-injury neurocognitive impairments are observed in survivors of mild injuries (head or other body part), a sound understanding of their etiology is critical in designing appropriate intervention plans. Clinical and research implications are discussed. (JINS, 2013, 19, 145-154)	[Babikian, Talin; Asarnow, Robert F.] UCLA Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [McArthur, David] UCLA Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA		Babikian, T (corresponding author), UCLA Sch Med, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,Room C8-746, Los Angeles, CA 90095 USA.	tbabikian@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026801]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026801] Funding Source: NIH RePORTER	There are no conflicts of interest to report. This study was funded by NINDS R01NS026801 Neurobehavioral Sequelae of Mild Brain Injury in Children; and NICHD R01HD061504 Reconnection of Neural Networks and Cognitive Recovery After Pediatric TBI.	Achenbach T. M., 1991, CHILD BEHAV CHECKLIS; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Asarnow R, 1995, TRAUMATIC BRAIN INJU, P117; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; BIJUR PE, 1990, PEDIATRICS, V86, P337; Brier GW, 1950, MON WEATHER REV, V78, P1, DOI DOI 10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2; Brooks BL, 2010, PSYCHOL ASSESSMENT, V22, P650, DOI 10.1037/a0019781; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P182, DOI 10.1093/arclin/acq005; Brun R, 2001, WATER RESOUR RES, V37, P1015, DOI 10.1029/2000WR900350; Dunn LM., 1981, PEABODY PICTURE VOCA; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kundu S, 2011, EUR J EPIDEMIOL, V26, P261, DOI 10.1007/s10654-011-9567-4; Moos B.R., 1986, FAMILY ENV SCALE MAN; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; R Development Core Team, 2011, R LANG ENV STAT COMP; Reitan R, 1985, HALSTEAD REITAN NEUR; SATZ P, 1989, PIN TEST PROFESSIONA; Schretlen DJ, 2003, J INT NEUROPSYCH SOC, V9, P864, DOI 10.1017/S1355617703960061; Smith A., 1968, J LEARNING DISORDERS, V3, P83; Soetaert K, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i09; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; WICKENS DD, 1970, PSYCHOL REV, V77, P1, DOI 10.1037/h0028569; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	35	51	51	1	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	FEB	2013	19	2					145	154		10.1017/S135561771200104X			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	085WV	WOS:000314645900004	23157821				2022-02-06	
J	Johnston, DT; Deuster, PA; Harris, WS; MacRae, H; Dretsch, MN				Johnston, Daniel T.; Deuster, Patricia A.; Harris, William S.; MacRae, Holden; Dretsch, Michael N.			Red blood cell omega-3 fatty acid levels and neurocognitive performance in deployed US Servicemembers	NUTRITIONAL NEUROSCIENCE			English	Article						Omega-3; Neurocognition; Omega-3 index; Performance; Military; Brain	N-3 FATTY-ACIDS; RATING DEPRESSION SCALE; TRAUMATIC BRAIN-INJURY; SLEEP QUALITY INDEX; DOCOSAHEXAENOIC ACID; DIETARY-INTAKE; OMEGA-3 INDEX; RISK; VALIDITY; HEALTH	Objective: To explore the cross-sectional relationships between blood eicosapentaenoic acid + docosahexaenoic acid (HSOmega-3 Index (R)) and sleep disorders, depression, anxiety, and neurocognitive performance in Servicemembers deployed to Iraq. Methods: Servicemembers with mild-to-moderate depression by the Patient Health Questionnarie-9 from two US military camps were invited to participate in this study. A battery of validated psychosocial (Pittsburgh Sleep Quality Index, and Zung Depression, Zung Anxiety, Epworth Sleepiness, and Combat Experiences scales) and computerized neurocognitive tests were completed by each participant. Five neurocognitive domain scores were calculated - Processing Speed, Complex Attention, Reaction Time, Cognitive Flexibility (CF), and Executive Function (EF). A drop of blood was also collected on an anti-oxidant-treated filter paper card and sent for HS-Omega-3 Index (R) analysis. An analysis of variance contrast was used to test for linear trends between quartiles of the HS-Omega-3 Index (R) for both EF and CF. Results: The mean HS-Omega-3 Index (R) was 3.5 +/- 0.7% (n = 78). The HS-Omega-3 Index (R) was not significantly associated with scores for anxiety, depression, or sleep, whether assessed as continuous or dichotomous variables, but was directly associated with CF and EF (P < 0.02 and 0.01, respectively), especially in the 81% who reported poor sleep quality. In those with poor sleep quality (n = 63), EF and CF were higher (P = 0.005) in subjects with Omega-3 levels above versus below the mean. Conclusion: Optimal neurocognitive performance is essential during deployment. Our finding that EF and CF were positively related to HS-Omega-3 Index (R) suggests that improving omega-3 status through an increase in omega-3 intake may improve neurocognitive performance and confer an element of resilience to poor sleep.	[Johnston, Daniel T.] USA, Comprehens Soldier Fitness Performance Resilience, Headquarters Dept, Washington, DC 20310 USA; [Deuster, Patricia A.] Uniformed Serv Univ Hlth Sci, Consortium Hlth & Mil Performance, Dept Mil & Emergency Med, Bethesda, MD 20814 USA; [Harris, William S.] Univ S Dakota, Sanford Sch Med, Sioux Falls, SD 57105 USA; [Harris, William S.] OmegaQuant Analyt LLC, Sioux Falls, SD 57105 USA; [Harris, William S.] Hlth Diagnost Lab Inc, Richmond, VA USA; [MacRae, Holden] Pepperdine Univ, Div Nat Sci, Malibu, CA 90265 USA; [Dretsch, Michael N.] USA, Aeromed Res Lab USAARL, Ft Rucker, AL USA		Johnston, DT (corresponding author), 2530 Crystal Dr,Rm 1628, Arlington, VA 22203 USA.	Daniel.Johnston@us.army.mil	Harris, William Stephen/T-1674-2019; Deuster, Patricia A/G-3838-2015	Harris, William Stephen/0000-0003-3042-9353; Deuster, Patricia A/0000-0002-7895-0888			Amin AA, 2008, PSYCHOSOM MED, V70, P856, DOI 10.1097/PSY.0b013e318188a01e; Assies J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010635; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; BIGGS JT, 1978, BRIT J PSYCHIAT, V132, P381, DOI 10.1192/bjp.132.4.381; Bistrian BR, 2011, JPEN-PARENTER ENTER, V35, P556, DOI 10.1177/0148607111416122; Block Robert C, 2008, Open Biomark J, V1, P1, DOI 10.2174/1875318300801010001; Bray RM, 2010, MIL MED, V175, P390, DOI 10.7205/MILMED-D-09-00132; Buysse D J, 1989, Psychiatry Res, V28, P193; Carney RM, 2009, JAMA-J AM MED ASSOC, V302, P1651, DOI 10.1001/jama.2009.1487; Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5; Colangelo LA, 2009, NUTRITION, V25, P1011, DOI 10.1016/j.nut.2008.12.008; CONNOR WE, 1992, NUTR REV, V50, P21; Esposito-Smythers C, 2011, J FAM PSYCHOL, V25, P497, DOI 10.1037/a0024534; Gao Q, 2011, J NUTR HEALTH AGING, V15, P32, DOI 10.1007/s12603-011-0010-z; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Han DH, 2011, PSYCHIAT INVEST, V8, P221, DOI 10.4306/pi.2011.8.3.221; Harris WS, 2004, PREV MED, V39, P212, DOI 10.1016/j.ypmed.2004.02.030; Harris WS, 2012, J NUTR IN PRESS; Hayashino Y, 2010, SLEEP MED, V11, P366, DOI 10.1016/j.sleep.2009.05.021; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Innis SM, 2007, J NUTR, V137, P855, DOI 10.1093/jn/137.4.855; IOM. (Institute of Medicine), 2011, NUTR TRAUM BRAIN INJ; Jackson ML, 2011, PROG BRAIN RES, V190, P53, DOI 10.1016/B978-0-444-53817-8.00003-7; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; Johnson EJ, 2008, NUTR NEUROSCI, V11, P75, DOI 10.1179/147683008X301450; Jugovac D, 2011, EXP PSYCHOL, V1, P11; Kris-Etherton PM, 2000, AM J CLIN NUTR, V71, p179S, DOI 10.1093/ajcn/71.1.179S; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lafourcade M, 2011, NAT NEUROSCI, V14, P345, DOI 10.1038/nn.2736; Lauritzen L, 2001, PROG LIPID RES, V40, P1, DOI 10.1016/S0163-7827(00)00017-5; Lemke SL, 2010, AM J CLIN NUTR, V92, P766, DOI 10.3945/ajcn.2009.29072; Lin PY, 2010, BIOL PSYCHIAT, V68, P140, DOI 10.1016/j.biopsych.2010.03.018; Lucas M, 2011, AM J CLIN NUTR, V93, P1337, DOI 10.3945/ajcn.111.011817; Lucas M, 2010, J AM COLL NUTR, V29, P211, DOI 10.1080/07315724.2010.10719836; Luxton DD, 2010, DEPRESS ANXIETY, V27, P1027, DOI 10.1002/da.20730; Lyche P, 2011, CLIN NEUROPSYCHOL, V25, P359, DOI 10.1080/13854046.2010.547518; Martins JG, 2009, J AM COLL NUTR, V28, P525, DOI 10.1080/07315724.2009.10719785; MIKESELL RH, 1970, PERCEPT MOTOR SKILL, V30, P22, DOI 10.2466/pms.1970.30.1.22; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Milte CM, 2011, PROSTAG LEUKOTR ESS, V84, P153, DOI 10.1016/j.plefa.2011.02.002; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moriguchi T, 2003, J NEUROCHEM, V87, P297, DOI 10.1046/j.1471-4159.2003.01966.x; Najmi S, 2012, DEPRESS ANXIETY, V29, P243, DOI 10.1002/da.20900; Oddy WH, 2011, DEPRESS ANXIETY, V28, P582, DOI 10.1002/da.20822; Owen C, 2008, CURR OPIN PSYCHIATR, V21, P19, DOI 10.1097/YCO.0b013e3282f29841; Ozias MK, 2007, J NUTR, V137, P125, DOI 10.1093/jn/137.1.125; Pascoe MC, 2011, CLIN NUTR, V30, P407, DOI 10.1016/j.clnu.2011.03.013; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Riviere LA, 2011, BRIT J PSYCHIAT, V198, P136, DOI 10.1192/bjp.bp.110.084863; Romera I, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-4; Sands SA, 2005, LIPIDS, V40, P343, DOI 10.1007/s11745-006-1392-2; Srygley JM, 2009, BRAIN RES, V1253, P92, DOI 10.1016/j.brainres.2008.11.067; Sublette ME, 2011, J CLIN PSYCHIAT, V72, P1577, DOI 10.4088/JCP.10m06634; Suganuma H, 2010, NEUROPATHOLOGY, V30, P597, DOI 10.1111/j.1440-1789.2010.01114.x; Tan ZS, 2012, NEUROLOGY, V78, P658, DOI 10.1212/WNL.0b013e318249f6a9; Tassoni D, 2008, ASIA PAC J CLIN NUTR, V17, P220; Thoma P, 2011, PSYCHIAT RES, V189, P373, DOI 10.1016/j.psychres.2011.07.030; Uauy R, 1996, LIPIDS, V31, pS167, DOI 10.1007/BF02637071; van de Rest O, 2008, NEUROLOGY, V71, P430, DOI 10.1212/01.wnl.0000324268.45138.86; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Yurko-Mauro K, 2010, ALZHEIMERS DEMENT, V6, P456, DOI 10.1016/j.jalz.2010.01.013; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V13, P508, DOI 10.1001/archpsyc.1965.01730060026004; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P380	67	51	51	0	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1028-415X	1476-8305		NUTR NEUROSCI	Nutr. Neurosci.	JAN	2013	16	1					30	38		10.1179/1476830512Y.0000000025			9	Neurosciences; Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Nutrition & Dietetics	087OL	WOS:000314771400005	22748167				2022-02-06	
J	Joseph, B; Hadjizacharia, P; Aziz, H; Kulvatunyou, N; Tang, A; Pandit, V; Wynne, J; O'Keeffe, T; Friese, RS; Rhee, P				Joseph, Bellal; Hadjizacharia, Pantelis; Aziz, Hassan; Kulvatunyou, Narong; Tang, Andrew; Pandit, Viraj; Wynne, Julie; O'Keeffe, Terence; Friese, Randall S.; Rhee, Peter			Prothrombin complex concentrate: An effective therapy in reversing the coagulopathy of traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Prothrombin concentrate complex; rFVIIa; traumatic brain injury; coagulopathy of trauma; craniotomy	RECOMBINANT-FACTOR-VIIA; COAGULATION; COMPLICATIONS; EFFICACY; PLASMA	BACKGROUND: Coagulopathy in patients with traumatic brain injury (TBI) is a well-studied concept. Prothrombin complex concentrate (PCC) has been shown to be an effective treatment modality for correction of TBI coagulopathy. However, its use and effectiveness compared with recombinant factor VII (rFVIIa) in TBI has not been established. The purpose of this study was to compare PCC and rFVIIa for the correction of TBI coagulopathy. METHODS: All patients with a TBI and an induced or acquired coagulopathy whom received rFVIIa or PCC at our Level I trauma center during a 4-year period were reviewed. Data collected included demographics, changes in international normalized ratio and blood products transfusion, craniotomy rates, and time to neurosurgical intervention, thromboembolic complications, and mortality differences. RESULTS: The study was composed of 85 TBI patients, of whom 64 patients received PCC while 21 patients received rFVIIa. PCC group were more likely to be on coumadin (44% vs. 14%, p = 0.01). There was a significant decline in packed red blood cell transfusion and fresh frozen plasma after PCC administration (p < 0.01). There was no statistically significant difference in the craniotomy rate (28% vs. 10%, p = 0.1) or the mean time to intervention between the two groups (201 [33] vs. 230 [10], p = 0.9). Mortality rates were lower in the PCC group compared with rFVIIa (67% vs. 47%, p = 0.02). Subsequent thromboembolic event was seen in one patient on rFVIIa. Mean cost of treatment per patient on PCC was $1,007 compared with $5,757 for rFVIIa (p < 0.01). CONCLUSION: PCC is safe and effective for treating coagulopathy in TBI patients, while reducing costs and resource use. PCC should be considered as an effective therapy to treat both acquired and induced coagulopathy in TBI with or without prehospital coumadin use. (J Trauma Acute Care Surg. 2013;74: 248-253. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Hadjizacharia, Pantelis; Aziz, Hassan; Kulvatunyou, Narong; Tang, Andrew; Pandit, Viraj; Wynne, Julie; O'Keeffe, Terence; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Rm 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021	Aziz, Hassan/0000-0003-0406-1946			Aguilar MI, 2007, MAYO CLIN PROC, V82, P82, DOI 10.1016/s0025-6196(11)60970-1; Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670; Beck KH, 2000, INFUS THER TRANSFUS, V27, P144; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Brohi K, 2009, J R Army Med Corps, V155, P320; Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4; Dickneite G, 2010, J TRAUMA, V68, P1151, DOI 10.1097/TA.0b013e3181b06364; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Fries D, 2006, BRIT J ANAESTH, V97, P460, DOI 10.1093/bja/ael191; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hirsh J, 2003, J AM COLL CARDIOL, V41, P1633, DOI 10.1016/S0735-1097(03)00416-9; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Holland L, 2009, TRANSFUSION, V49, P1171, DOI 10.1111/j.1537-2995.2008.02080.x; Joseph B, 2012, J TRAUMA ACUTE CARE, V72, P828, DOI 10.1097/TA.0b013e318247c944; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Levy JH, 2008, ANESTHESIOLOGY, V109, P918, DOI 10.1097/ALN.0b013e3181895bd8; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Meng ZH, 2003, J TRAUMA, V55, P886, DOI 10.1097/01.TA.0000066184.20808.A5; O'Connell KA, 2006, JAMA-J AM MED ASSOC, V295, P293, DOI 10.1001/jama.295.3.293; Pabinger I, 2008, J THROMB HAEMOST, V6, P622, DOI 10.1111/j.1538-7836.2008.02904.x; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Safaoui MN, 2009, AM J SURG, V197, P785, DOI 10.1016/j.amjsurg.2008.04.003; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; Staudinger T, 1999, INTENS CARE MED, V25, P1105, DOI 10.1007/s001340051019; Stein DM, 2008, INJURY, V39, P1054, DOI 10.1016/j.injury.2008.03.032; Stein DM, 2008, J TRAUMA, V64, P620, DOI 10.1097/TA.0b013e3181650fc7; Stein DM, 2009, J TRAUMA, V66, P63, DOI 10.1097/TA.0b013e318191bc8a; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2	28	51	51	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2013	74	1					248	253		10.1097/TA.0b013e3182788a40			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	071VI	WOS:000313623300057	23271101				2022-02-06	
J	Lee, DJ; Gurkoff, GG; Izadi, A; Berman, RF; Ekstrom, AD; Muizelaar, JP; Lyeth, BG; Shahlaie, K				Lee, Darrin J.; Gurkoff, Gene G.; Izadi, Ali; Berman, Robert F.; Ekstrom, Arne D.; Muizelaar, J. Paul; Lyeth, Bruce G.; Shahlaie, Kiarash			Medial Septal Nucleus Theta Frequency Deep Brain Stimulation Improves Spatial Working Memory after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						deep brain stimulation; hippocampus; medial septal nucleus; TBI; theta oscillations	LATERAL FLUID-PERCUSSION; GAMMA OSCILLATIONS; IN-VIVO; HIPPOCAMPAL; RHYTHM; RAT; DYSFUNCTION; MODERATE; NEURONS; MILD	More than 5,000,000 survivors of traumatic brain injury (TBI) live with persistent cognitive deficits, some of which likely derive from hippocampal dysfunction. Oscillatory activity in the hippocampus is critical for normal learning and memory functions, and can be modulated using deep brain stimulation techniques. In this pre-clinical study, we demonstrate that lateral fluid percussion TBI results in the attenuation of hippocampal theta oscillations in the first 6 days after injury, which correlate with deficits in the Barnes maze spatial working memory task. Theta band stimulation of the medial septal nucleus (MSN) results in a transient increase in hippocampal theta activity, and when delivered 1 min prior to training in the Barnes maze, it significantly improves spatial working memory. These results suggest that MSN theta stimulation may be an effective neuromodulatory technique for treatment of persistent learning and memory deficits after TBI.	[Lee, Darrin J.; Gurkoff, Gene G.; Izadi, Ali; Berman, Robert F.; Muizelaar, J. Paul; Lyeth, Bruce G.; Shahlaie, Kiarash] UC Davis Sch Med, Dept Neurol Surg, Sacramento, CA 95817 USA; [Ekstrom, Arne D.] Univ Calif Davis, Davis Sch Med, Dept Psychol, Sacramento, CA 95817 USA		Shahlaie, K (corresponding author), UC Davis Sch Med, Dept Neurol Surg, 4860 Y 0St,Suite 3740, Sacramento, CA 95817 USA.	kiarash.shahlaie@ucdmc.ucdavis.edu	Ekstrom, Arne/A-1329-2013	Ekstrom, Arne/0000-0002-6812-2368; Lyeth, Bruce/0000-0003-4811-1474	Bronte Epilepsy Research Foundation; UC Davis Health System National Board of Advisors	This project was supported by the Bronte Epilepsy Research Foundation, and a "Vision Grant" from the UC Davis Health System National Board of Advisors. We thank Angela Echeverri, Mikhail Melnik, Rebecca Wong, and Heather McConnell for their expert technical assistance.	Addante RJ, 2011, P NATL ACAD SCI USA, V108, P10702, DOI 10.1073/pnas.1014528108; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Belluscio MA, 2012, J NEUROSCI, V32, P423, DOI 10.1523/JNEUROSCI.4122-11.2012; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; Buzsaki G, 2005, HIPPOCAMPUS, V15, P827, DOI 10.1002/hipo.20113; COLOM LV, 1988, BRAIN RES, V460, P329, DOI 10.1016/0006-8993(88)90377-0; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Darling RD, 2011, J NEUROPHYSIOL, V105, P2213, DOI 10.1152/jn.00801.2010; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Ekstrom AD, 2005, HIPPOCAMPUS, V15, P881, DOI 10.1002/hipo.20109; Faul M, 2010, TRAUMATIC BRAIN INJU; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GREEN JD, 1954, J NEUROPHYSIOL, V17, P533, DOI 10.1152/jn.1954.17.6.533; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Igarashi J, 2007, COGN NEURODYNAMICS, V1, P169, DOI 10.1007/s11571-006-9003-8; Jacobs J, 2009, J NEUROSCI, V29, P10203, DOI 10.1523/JNEUROSCI.2187-09.2009; Jensen O, 1996, LEARN MEMORY, V3, P279, DOI 10.1101/lm.3.2-3.279; Kocsis B, 1997, HIPPOCAMPUS, V7, P204, DOI 10.1002/(SICI)1098-1063(1997)7:2<204::AID-HIPO7>3.0.CO;2-M; LANDFIELD PW, 1972, SCIENCE, V175, P87, DOI 10.1126/science.175.4017.87; LAWSON VH, 1993, EXP NEUROL, V120, P132, DOI 10.1006/exnr.1993.1047; Laxton AW, 2010, ANN NEUROL, V68, P521, DOI 10.1002/ana.22089; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lundqvist M, 2011, J COGNITIVE NEUROSCI, V23, P3008, DOI 10.1162/jocn_a_00029; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCNAUGHTON BL, 1977, J COMP NEUROL, V175, P439, DOI 10.1002/cne.901750404; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; MIZUMORI SJY, 1990, BRAIN RES, V528, P12, DOI 10.1016/0006-8993(90)90188-H; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Nyhus E, 2010, NEUROSCI BIOBEHAV R, V34, P1023, DOI 10.1016/j.neubiorev.2009.12.014; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Raghavachari S, 2001, J NEUROSCI, V21, P3175, DOI 10.1523/JNEUROSCI.21-09-03175.2001; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Sederberg PB, 2003, J NEUROSCI, V23, P10809; Shin SS, 2011, BRAIN RES, V1369, P208, DOI 10.1016/j.brainres.2010.10.096; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Suthana N, 2012, NEW ENGL J MED, V366, P502, DOI 10.1056/NEJMoa1107212; Takahashi M, 2009, COGN NEURODYNAMICS, V3, P165, DOI 10.1007/s11571-009-9081-5; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; Vertes RP, 2005, HIPPOCAMPUS, V15, P923, DOI 10.1002/hipo.20118; Vertes RP, 2001, NEUROSCIENCE, V104, P619, DOI 10.1016/S0306-4522(01)00131-2; Vertes RP, 1997, NEUROSCIENCE, V81, P893; Wang XJ, 2002, J NEUROPHYSIOL, V87, P889, DOI 10.1152/jn.00135.2001; WINSON J, 1974, ELECTROEN CLIN NEURO, V36, P291, DOI 10.1016/0013-4694(74)90171-0; Yamamoto T, 2005, ACTA NEUROCHIR SUPPL, V93, P101; Yamamoto T, 2005, NEUROPSYCHOL REHABIL, V15, P406, DOI 10.1080/09602010443000353	56	51	51	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					131	139		10.1089/neu.2012.2646			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000008	23016534				2022-02-06	
J	Siffredi, V; Anderson, V; Leventer, RJ; Spencer-Smith, MM				Siffredi, Vanessa; Anderson, Vicki; Leventer, Richard J.; Spencer-Smith, Megan M.			Neuropsychological Profile of Agenesis of the Corpus Callosum: A Systematic Review	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; INTERHEMISPHERIC-TRANSFER; DEVELOPMENTAL DELAY; PRENATAL-DIAGNOSIS; MENTAL-RETARDATION; FETAL AGENESIS; WHITE-MATTER; CHILDREN; DEFICITS; INFORMATION	Developmental absence (agenesis) of the corpus callosum (AgCC) is a common brain malformation that presents in isolation or in association with other conditions. Variability in aspects of neuropsychological functioning has been reported in small samples of individuals. This study aimed to systematically review the literature to characterize the profile and severity of cognitive impairments in individuals with AgCC across development. A mean general intellectual ability was calculated and neuropsychological functioning was qualitatively examined. We discuss methodological limitations of the literature, inherent heterogeneity of the causes and comorbidities of AgCC, and the developmental aspect of AgCC in opposition to split-brain patients.	[Siffredi, Vanessa; Anderson, Vicki; Leventer, Richard J.; Spencer-Smith, Megan M.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Leventer, Richard J.] Univ Melbourne, Melbourne, Vic, Australia; [Anderson, Vicki; Leventer, Richard J.] Royal Childrens Hosp, Melbourne, Vic, Australia		Spencer-Smith, MM (corresponding author), Karolinska Inst, Dept Neurosci, Dev Cognit Neurosci Lab, Retzius Vag 8, S-17177 Stockholm, Sweden.	megan.spencer-smith@ki.se	Siffredi, Vanessa/AAA-4866-2020	Siffredi, Vanessa/0000-0002-9137-0730; Spencer-Smith, Megan/0000-0002-1047-0829	Victorian Government; Murdoch Childrens Research Institute	This study was supported by the Victorian Government's Operational Infrastructure Support Program. This research was funded by the Murdoch Childrens Research Institute.	Anderson PJ, 2010, STUD NEUROPSYCHOL NE, P3; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Banich Marie T., 1995, P427; Barr MS, 2005, NEUROPSYCHOLOGY, V19, P707, DOI 10.1037/0894-4105.19.6.707; Bedeschi MF, 2006, PEDIATR NEUROL, V34, P186, DOI 10.1016/j.pediatrneurol.2005.08.008; Boyd E, 1993, Clin Dysmorphol, V2, P332; Brown WS, 1999, NEUROPSYCHOLOGIA, V37, P1165, DOI 10.1016/S0028-3932(99)00011-1; Brown WS, 2001, J INT NEUROPSYCH SOC, V7, P302, DOI 10.1017/S1355617701733048; Caille S, 1999, NEUROCASE, V5, P109, DOI 10.1093/neucas/5.2.109; Carroll J.B., 1993, HUMAN COGNITIVE ABIL, DOI DOI 10.1017/CBO9780511571312; Hallak JEC, 2007, ARQ NEURO-PSIQUIAT, V65, P1216, DOI 10.1590/S0004-282X2007000700024; CURATOLO P, 1993, NEUROPEDIATRICS, V24, P77, DOI 10.1055/s-2008-1071518; DAVID AS, 1992, NEUROPSYCHOLOGIA, V30, P161, DOI 10.1016/0028-3932(92)90025-H; de Guise E, 1999, BRAIN, V122, P1049, DOI 10.1093/brain/122.6.1049; Dell'Acqua R, 2005, COGN NEUROPSYCHOL, V22, P1035, DOI 10.1080/02643290442000491; Dennis M., 2006, BRAIN RESERVE CAPACI; Di Stefano M, 1998, NEUROREPORT, V9, P1331; ElAbd S, 1997, DEV MED CHILD NEUROL, V39, P119, DOI 10.1111/j.1469-8749.1997.tb07394.x; Finlay DC, 2000, J CLIN EXP NEUROPSYC, V22, P731, DOI 10.1076/jcen.22.6.731.962; FISCHER M, 1992, ARCH NEUROL-CHICAGO, V49, P271, DOI 10.1001/archneur.1992.00530270085023; Forget J, 2009, EXP BRAIN RES, V192, P443, DOI 10.1007/s00221-008-1602-7; Francesco P, 2006, PEDIATR INT, V48, P298, DOI 10.1111/j.1442-200X.2006.02208.x; Fuchigami T, 1996, ACTA PAEDIATR JAPON, V38, P52; Giedd JN, 1996, DEV BRAIN RES, V91, P274; GOODING CA, 1984, J PEDIATR-US, V104, P509, DOI 10.1016/S0022-3476(84)80538-7; Goodyear PWA, 2001, FETAL DIAGN THER, V16, P139, DOI 10.1159/000053898; Graham JM, 2003, AM J MED GENET A, V123A, P37, DOI 10.1002/ajmg.a.20504; Graham JM, 2008, AM J MED GENET A, V146A, P3011, DOI 10.1002/ajmg.a.32553; GUPTA JK, 1995, PRENATAL DIAG, V15, P301, DOI 10.1002/pd.1970150402; Hannay HJ, 2009, J CLIN EXP NEUROPSYC, V31, P180, DOI 10.1080/13803390802209954; Hetts SW, 2006, AM J ROENTGENOL, V187, P1343, DOI 10.2214/AJR.05.0146; Hines RJ, 2002, NEUROPSYCHOLOGIA, V40, P1804, DOI 10.1016/S0028-3932(02)00032-5; Huang H, 2005, NEUROIMAGE, V26, P195, DOI 10.1016/j.neuroimage.2005.01.019; Huang H, 2009, J NEUROSCI, V29, P4263, DOI 10.1523/JNEUROSCI.2769-08.2009; Huber-Okrainec J, 2005, BRAIN LANG, V93, P349, DOI 10.1016/j.bandl.2004.11.002; Imamura T, 1994, Behav Neurol, V7, P43, DOI 10.3233/BEN-1994-7201; Jancke L, 1997, NEUROPSYCHOLOGIA, V35, P1389, DOI 10.1016/S0028-3932(97)00068-7; Jea A, 2008, CHILD NERV SYST, V24, P685, DOI 10.1007/s00381-008-0626-4; Kamnasaran D, 2005, CLIN INVEST MED, V28, P267; KARNATH HO, 1991, CORTEX, V27, P345, DOI 10.1016/S0010-9452(13)80141-4; Keshavan MS, 2002, LIFE SCI, V70, P1909, DOI 10.1016/S0024-3205(02)01492-3; KESSLER J, 1991, INT J NEUROSCI, V58, P275, DOI 10.3109/00207459108985443; Klaas PA, 1999, J CLIN EXP NEUROPSYC, V21, P837, DOI 10.1076/jcen.21.6.837.851; KOEDA T, 1993, DEV MED CHILD NEUROL, V35, P65; Lamonica DAC, 2009, AM J MED GENET A, V149A, P1041, DOI 10.1002/ajmg.a.32787; LASSONDE M, 1994, ADV BEHAV BIOL, V42, P275; Lawson-Yuen A, 2006, CLIN DYSMORPHOL, V15, P217, DOI 10.1097/01.mcd.0000220609.17284.a9; Lebel C, 2010, NEUROIMAGE, V52, P20, DOI 10.1016/j.neuroimage.2010.03.072; Lee Ying-Ying, 2008, Acta Neurol Taiwan, V17, P194; Lessard N, 2002, BRAIN, V125, P1039, DOI 10.1093/brain/awf096; Lindwall C, 2007, CURR OPIN NEUROBIOL, V17, P3, DOI 10.1016/j.conb.2007.01.008; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Marszal E, 2000, J CHILD NEUROL, V15, P401, DOI 10.1177/088307380001500609; Matlary A, 2004, CLIN DYSMORPHOL, V13, P257, DOI 10.1097/00019605-200410000-00012; Midorikawa A, 2006, CORTEX, V42, P356, DOI 10.1016/S0010-9452(08)70362-9; Motomura N, 2002, PSYCHIAT CLIN NEUROS, V56, P199, DOI 10.1046/j.1440-1819.2002.00944.x; Moutard ML, 2003, CHILD NERV SYST, V19, P471, DOI 10.1007/s00381-003-0781-6; Panos PT, 2001, ARCH CLIN NEUROPSYCH, V16, P507, DOI 10.1016/S0887-6177(00)00061-5; Parraga HC, 2003, INT J PSYCHIAT MED, V33, P107, DOI 10.2190/D4Y1-WNBX-HQW8-HDPL; Paul L.K., 2000, COGNITIVE NEUROPSYCH, V5, P135, DOI [10.1080/135468000395781, DOI 10.1080/135468000395781]; Paul LK, 2004, ARCH CLIN NEUROPSYCH, V19, P215, DOI 10.1016/S0887-6177(03)00024-6; Paul LK, 2003, BRAIN LANG, V85, P313, DOI 10.1016/S0093-934X(03)00062-2; Paul LK, 2007, NAT REV NEUROSCI, V8, P287, DOI 10.1038/nrn2107; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Ramelli GP, 2006, SWISS MED WKLY, V136, P404; Raybaud C, 2010, NEURORADIOLOGY, V52, P447, DOI 10.1007/s00234-010-0696-3; Reddy RP, 2010, NEUROPSYCHOL TRENDS, P29, DOI 10.7358/neur-2010-007-redd; Richards LJ, 2004, CLIN GENET, V66, P276, DOI 10.1111/j.1399-0004.2004.00354.x; Schulte T, 2010, NEUROPSYCHOL REV, V20, P174, DOI 10.1007/s11065-010-9130-1; Semrud-Clikeman M., 2009, CHILD NEUROSPYCHOLOG; Shevell MI, 2002, J CHILD NEUROL, V17, P896, DOI 10.1177/08830738020170122601; Simon A, 2008, NEUROPSYCHOBIOLOGY, V58, P118, DOI 10.1159/000170392; Stickles LJ, 2002, INT J DISABIL DEV ED, V49, P367, DOI [DOI 10.1080/1034912022000028349, 10.1080/1034912022000028349]; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Symington SH, 2010, SOC NEUROSCI-UK, V5, P296, DOI 10.1080/17470910903462419; Taylor M, 1998, J NEUROL NEUROSUR PS, V64, P131, DOI 10.1136/jnnp.64.1.131; VANASSE M, 1994, ADV BEHAV BIOL, V42, P199; Velek M, 1988, Ala Med, V58, P27; [No title captured]	79	51	53	0	27	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	JAN 1	2013	38	1					36	57		10.1080/87565641.2012.721421			22	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	104HX	WOS:000315984000003	23311314				2022-02-06	
J	Lovstad, M; Funderud, I; Endestad, T; Due-Tonnessen, P; Meling, TR; Lindgren, M; Knight, RT; Solbakk, AK				Lovstad, M.; Funderud, I.; Endestad, T.; Due-Tonnessen, P.; Meling, T. R.; Lindgren, M.; Knight, R. T.; Solbakk, A. K.			Executive functions after orbital or lateral prefrontal lesions: Neuropsychological profiles and self-reported executive functions in everyday living	BRAIN INJURY			English	Article						Executive functioning; frontal lobe; neuropsychological; assessment; cognition	TRAUMATIC BRAIN-INJURY; BEHAVIOR RATING INVENTORY; GLASGOW OUTCOME SCALE; VERBAL-LEARNING TEST; FRONTAL LESIONS; PERFORMANCE; CORTEX; MEMORY; CHILDREN; REHABILITATION	Objective: This study examined the effects of chronic focal lesions to the lateral prefrontal cortex (LPFC) or orbitofrontal cortex (OFC) on neuropsychological test performance and self-reported executive functioning in everyday living. Methods: Fourteen adults with OFC lesions were compared to 10 patients with LPFC injuries and 21 healthy controls. Neuropsychological tests with emphasis on measures of cognitive executive function were administered along with the Behavior Rating Inventory of Executive Functions (BRIEF-A) and a psychiatric screening instrument. Results: The LPFC group differed from healthy controls on neuropsychological tests of sustained mental effort, response inhibition, working memory and mental switching, while the BRIEF-A provided more clinically important information on deficits in everyday life in the OFC group compared to the LPFC group. Correlations between neuropsychological test results and BRIEF-A were weak, while the BRIEF-A correlated strongly with emotional distress. Conclusions: It was demonstrated that LPFC damage is particularly prone to cause cognitive executive deficit, while OFC injury is more strongly associated with self-reported dysexecutive symptoms in everyday living. The study illustrates the challenge of identifying executive deficit in individual patients and the lack of strong anatomical specificity of the currently employed methods. There is a need for an integrative methodological approach where standard testing batteries are supplemented with neuropsychiatric and frontal-specific rating scales.	[Lovstad, M.] Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; [Funderud, I.; Endestad, T.; Lindgren, M.; Solbakk, A. K.] Natl Hosp Norway, Oslo Univ Hosp, Dept Neuropsychiat & Psychosomat Med, Oslo, Norway; [Endestad, T.] Univ Oslo, Dept Psychol, N-0316 Oslo, Norway; [Due-Tonnessen, P.] Natl Hosp Norway, Oslo Univ Hosp, Dept Radiol, Oslo, Norway; [Meling, T. R.] Natl Hosp Norway, Oslo Univ Hosp, Dept Neurosurg, Oslo, Norway; [Lindgren, M.] Lund Univ, Dept Psychol, S-22100 Lund, Sweden; [Knight, R. T.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Knight, R. T.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA		Lovstad, M (corresponding author), Sunnaas Rehabil Hosp, Bjornemyrvn 11, N-1450 Nesoddtangen, Norway.	marianne.lovstad@sunnaas.no	Meling, Torstein/Q-2568-2019	Meling, Torstein/0000-0001-6595-0873; Due-Tonnessen, Paulina/0000-0002-3615-1914	South-Eastern Norway Regional Health Authority [SUN-001-SS, 2008047]; Research Council of NorwayResearch Council of Norway [186504/V50]; National Institute of Neurological Disorders (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21135]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS021135, R56NS021135, R01NS021135] Funding Source: NIH RePORTER	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This research is supported by the South-Eastern Norway Regional Health Authority (grants SUN-001-SS and 2008047) and the Research Council of Norway (grant no. 186504/V50 to author AKS) as well as the National Institute of Neurological Disorders (NINDS; grant NS21135 to author RTK). The work forms part of a doctoral thesis to be submitted to the Department of Psychology, University of Oslo, Norway.	Alexander MP, 2003, BRAIN, V126, P1493, DOI 10.1093/brain/awg128; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Anderson V, 2005, J INT NEUROPSYCH SOC, V11, P817, DOI 10.1017/S1355617705051052; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis D. C., 2001, EXAMINERS MANUAL DEL; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90, V3rd ed.; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Fernandez-Duque D, 2000, CONSCIOUS COGN, V9, P288, DOI 10.1006/ccog.2000.0447; Garlinghouse MA, 2010, SCHIZOPHR RES, V120, P71, DOI 10.1016/j.schres.2010.02.1067; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2005, PSYCHOL ASSESS RESOU; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Kaplan CP, 1998, BRAIN INJURY, V12, P199, DOI 10.1080/026990598122674; Kliegel M, 2008, DEV PSYCHOL, V44, P612, DOI 10.1037/0012-1649.44.2.612; Koenigs M., 2006, ORBITOFRONTAL CORTEX, P597; Krueger CE, 2011, NEUROPSYCHOLOGY, V25, P249, DOI 10.1037/a0021681; Lovstad M, 2012, J COGNITIVE NEUROSCI, V24, P378, DOI 10.1162/jocn_a_00099; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Matheson L, 2010, WORK, V36, P413, DOI 10.3233/WOR-2010-1043; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Pearson Education Inc, 2000, CALIFORNIA VERBAL LE; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; Shimamura AP, 1995, ANN NY ACAD SCI, V769, P151, DOI 10.1111/j.1749-6632.1995.tb38136.x; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; STUSS DT, 2007, HUMAN FRONTAL LOBES, P292; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tranel D, 2008, CLIN NEUROPSYCHOL, V22, P242, DOI 10.1080/13854040701218410; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yochim B, 2007, J INT NEUROPSYCH SOC, V13, P704, DOI 10.1017/S1355617707070907; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012	44	51	52	0	32	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1586	1598		10.3109/02699052.2012.698787			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700005	22731818	Green Accepted			2022-02-06	
J	Wada, T; Asano, Y; Shinoda, J				Wada, T.; Asano, Y.; Shinoda, J.			Decreased Fractional Anisotropy Evaluated Using Tract-Based Spatial Statistics and Correlated with Cognitive Dysfunction in Patients with Mild Traumatic Brain Injury in the Chronic Stage	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							DIFFUSE AXONAL INJURY; NONMISSILE HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; VOXELWISE ANALYSIS; SYMPTOMS; DAMAGE	BACKGROUND AND PURPOSE: The relationship between white matter disruption and cognitive dysfunction of patients with mTBI in the chronic stage remains unclear. The aim of this study was to identify white matter integrity by using DTI in patients with mTBI without morphologic traumatic abnormalities seen with conventional imaging and to evaluate the association of such regions with cognitive function. MATERIALS AND METHODS: Diffusion tensor images from 51 consecutive patients with mTBI without morphologic traumatic abnormalities on conventional MRI were processed, and FA maps were generated as a measure of white matter integrity. All subjects underwent cognitive examinations (MMSE and WAIS-R FIQ). Correlations between the skeletonized FA values in the white matter and the cognitive function were analyzed by using regression analysis. RESULTS: In patients with mTBI, significantly decreased FA value clusters in the white matter compared with the healthy controls were found in the superior longitudinal fasciculus, superior frontal gyrus, insula, and fornix. Cognitive examination scores positively correlated with FA values in a number of regions in deep brain structures, which were anatomically close or physiologically intimate to the regions with significant FA value reduction, in patients with mTBI. CONCLUSIONS: The present study shows that patients with mTBI in the chronic stage have certain regions with abnormally reduced white matter integrity in the brain. Although the clinical and pathologic-anatomic correlation of these findings remains to be elucidated, these brain regions are strongly suggested to be related to chronic persistent cognitive impairments in these patients.	[Wada, T.] Gifu Univ, Grad Sch Med, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Kizawa Mem Hosp, Gifu 5050034, Japan; [Wada, T.] Gifu Univ, Grad Sch Med, Dept Clin Brain Sci, Gifu 5050034, Japan		Wada, T (corresponding author), Gifu Univ, Grad Sch Med, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Kizawa Mem Hosp, 630 Shimokobi,Kobi Cho, Gifu 5050034, Japan.	tetsuya-wada@umin.ac.jp					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; JENNETT B, 1978, PRACTITIONER, V221, P76; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Masutani Y, 2003, EUR J RADIOL, V46, P53, DOI 10.1016/S0720-048X(02)00328-5; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McMillan TM, 2004, BRAIN INJURY, V18, P935, DOI 10.1080/02699050410001675915; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Oishi K., 2011, MRI ATLAS HUMAN WHIT, V2nd Edn.; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Rimrodt SL, 2010, CORTEX, V46, P739, DOI 10.1016/j.cortex.2009.07.008; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sosin DM, 1996, BRAIN INJURY, V10, P47; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	40	51	52	0	9	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	DEC	2012	33	11					2117	2122		10.3174/ajnr.A3141			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	063AU	WOS:000312968500016	22723057	hybrid, Green Published			2022-02-06	
J	Ross, DE; Ochs, AL; Seabaugh, JM; Demark, MF; Shrader, CR; Marwitz, JH; Havranek, MD				Ross, David E.; Ochs, Alfred L.; Seabaugh, Jan M.; Demark, Michael F.; Shrader, Carole R.; Marwitz, Jennifer H.; Havranek, Michael D.		Alzheimers Dis Neuroimaging Initia	Progressive brain atrophy in patients with chronic neuropsychiatric symptoms after mild traumatic brain injury: A preliminary study	BRAIN INJURY			English	Article						Traumatic brain injury; magnetic resonance imaging; volumetry; cortical atrophy; longitudinal study; medicolegal; vocational outcome; NeuroQuant (R)	DISABILITY RATING-SCALE; VOLUMETRY; MRI	Introduction: NeuroQuant (R) is a recently developed, FDA-approved software program for measuring brain MRI volume in clinical settings. The aims of this study were as follows: (1) to examine the test-retest reliability of NeuroQuant (R); (2) to test the hypothesis that patients with mild traumatic brain injury (TBI) would have abnormally rapid progressive brain atrophy; and (3) to test the hypothesis that progressive brain atrophy in patients with mild TBI would be associated with vocational outcome. Methods: Sixteen patients with mild TBI were compared to 20 normal controls. Vocational outcome was assessed with the Glasgow Outcome Scale-Extended (GOSE) and Disability Rating Scale (DRS). Results: NeuroQuant (R) showed high test-re-test reliability. Patients had abnormally rapid progressive atrophy in several brain regions and the rate of atrophy was associated with inability to return to work. Conclusions: NeuroQuant (R), is a reliable and valid method for assessing the anatomic effects of TBI. Progression of atrophy may continue for years after injury, even in patients with mild TBI.	[Ross, David E.; Ochs, Alfred L.; Seabaugh, Jan M.; Demark, Michael F.; Shrader, Carole R.] Virginia Inst Neuropsychiat, Midlothian, VA 23114 USA; [Ross, David E.; Ochs, Alfred L.; Marwitz, Jennifer H.] Virginia Commonwealth Univ, Richmond, VA USA; [Havranek, Michael D.] Amicus Visual Solut, Richmond, VA USA		Ross, DE (corresponding author), Virginia Inst Neuropsychiat, 364 Browns Hill Court, Midlothian, VA 23114 USA.	dross@vaneuropsychiatry.org		Ochs, Alfred/0000-0003-3932-876X	Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 AG024904]; National Institute on Aging, the National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AG010129, K01 AG030514]; Dana Foundation; Virginia Institute of Neuropsychiatry; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG030514, P30AG010129, U01AG024904] Funding Source: NIH RePORTER	Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education and the study is co-ordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514 and the Dana Foundation.; Other than the funding for the ADNI normal controls, as noted above, this project was funded by the Virginia Institute of Neuropsychiatry. The authors report no conflicts of interest, including no financial interests or investments with CorTechs Labs (R), maker of NeuroQuant (R).	Bigler E.D., 2005, TXB TRAUMATIC BRAIN, P79, DOI DOI 10.1007/S00417-005-0003-X; Bigler E.D., 2011, TXB TRAUMATIC BRAIN, P73, DOI DOI 10.1177/1753193410381840; Brewer JB, 2009, BEHAV NEUROL, V21, P21, DOI [10.1155/2009/616581, 10.3233/BEN-2009-0226]; Brewer JB, 2009, AM J NEURORADIOL, V30, P578, DOI 10.3174/ajnr.A1402; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Huppertz HJ, 2010, NEUROIMAGE, V49, P2216, DOI 10.1016/j.neuroimage.2009.10.066; Kovacevic S, 2009, ALZ DIS ASSOC DIS, V23, P139, DOI 10.1097/WAD.0b013e318192e745; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Ross DE, J NEUROPSYCHIATRY CL, V24, pE33; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Silver JM, 2011, TXB TRAUMATIC BRAIN, VSecond; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Weiner MW, 2010, ALZHEIMERS DEMENT, V6, P202, DOI 10.1016/j.jalz.2010.03.007; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	23	51	51	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2012	26	12					1500	1509		10.3109/02699052.2012.694570			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	022DL	WOS:000309935400011	22721509				2022-02-06	
J	Boone, DR; Sell, SL; Micci, MA; Crookshanks, JM; Parsley, M; Uchida, T; Prough, DS; DeWitt, DS; Hellmich, HL				Boone, Deborah R.; Sell, Stacy L.; Micci, Maria-Adelaide; Crookshanks, Jeanna M.; Parsley, Margaret; Uchida, Tatsuo; Prough, Donald S.; DeWitt, Douglas S.; Hellmich, Helen L.			Traumatic Brain Injury-Induced Dysregulation of the Circadian Clock	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; SUPRACHIASMATIC NUCLEUS; ALZHEIMERS-DISEASE; RAT HIPPOCAMPUS; GENE-EXPRESSION; HEAD TRAUMA; RHYTHMS; MEMORY; NEURONS; OSCILLATION	Circadian rhythm disturbances are frequently reported in patients recovering from traumatic brain injury (TBI). Since circadian clock output is mediated by some of the same molecular signaling cascades that regulate memory formation (cAMP/MAPK/CREB), cognitive problems reported by TBI survivors may be related to injury-induced dysregulation of the circadian clock. In laboratory animals, aberrant circadian rhythms in the hippocampus have been linked to cognitive and memory dysfunction. Here, we addressed the hypothesis that circadian rhythm disruption after TBI is mediated by changes in expression of clock genes in the suprachiasmatic nuclei (SCN) and hippocampus. After fluid-percussion TBI or sham surgery, male Sprague-Dawley rats were euthanized at 4 h intervals, over a 48 h period for tissue collection. Expression of circadian clock genes was measured using quantitative real-time PCR in the SCN and hippocampus obtained by laser capture and manual microdissection respectively. Immunofluorescence and Western blot analysis were used to correlate TBI-induced changes in circadian gene expression with changes in protein expression. In separate groups of rats, locomotor activity was monitored for 48 h. TBI altered circadian gene expression patterns in both the SCN and the hippocampus. Dysregulated expression of key circadian clock genes, such as Bmal1 and Cry1, was detected, suggesting perturbation of transcriptional-translational feedback loops that are central to circadian timing. In fact, disruption of circadian locomotor activity rhythms in injured animals occurred concurrently. These results provide an explanation for how TBI causes disruption of circadian rhythms as well as a rationale for the consideration of drugs with chronobiotic properties as part of a treatment strategy for TBI.	[Boone, Deborah R.; Sell, Stacy L.; Micci, Maria-Adelaide; Crookshanks, Jeanna M.; Parsley, Margaret; Uchida, Tatsuo; Prough, Donald S.; DeWitt, Douglas S.; Hellmich, Helen L.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX USA		Hellmich, HL (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	Moody Foundation/Mission Connect; Department of Anesthesiology	This study was supported in part by the Moody Foundation/Mission Connect and in part by the Department of Anesthesiology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe M, 2000, NEUROREPORT, V11, P3261, DOI 10.1097/00001756-200009280-00042; Akashi M, 2008, J NEUROSCI, V28, P4619, DOI 10.1523/JNEUROSCI.3410-07.2008; Alamili M, 2010, DAN MED BULL, V57; Llompart-Pou JA, 2010, NEUROCRIT CARE, V13, P211, DOI 10.1007/s12028-010-9399-1; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; BARNES CA, 1977, SCIENCE, V197, P91, DOI 10.1126/science.194313; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Bechtold DA, 2010, TRENDS PHARMACOL SCI, V31, P191, DOI 10.1016/j.tips.2010.01.002; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Benca R, 2009, BRAIN RES REV, V62, P57, DOI 10.1016/j.brainresrev.2009.09.005; Boyce P, 2010, AUST FAM PHYSICIAN, V39, P307; Brambrink AM, 2010, ANESTHESIOLOGY, V112, P834, DOI 10.1097/ALN.0b013e3181d049cd; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chaudhury D, 2005, J BIOL RHYTHM, V20, P225, DOI 10.1177/0748730405276352; Cheeseman JF, 2012, P NATL ACAD SCI USA, V109, P7061, DOI 10.1073/pnas.1201734109; Chen G, 2000, J NEUROCHEM, V75, P1729, DOI 10.1046/j.1471-4159.2000.0751729.x; Chen Z, 2007, CELL CYCLE, V6, P2906, DOI 10.4161/cc.6.23.5041; Craig LA, 2008, BRAIN RES BULL, V76, P141, DOI 10.1016/j.brainresbull.2008.02.013; Dawson D, 1996, PHARMACOL THERAPEUT, V69, P15, DOI 10.1016/0163-7258(95)02020-9; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Eckel-Mahan KL, 2008, NAT NEUROSCI, V11, P1074, DOI 10.1038/nn.2174; Eckel-Mahan KL, 2009, EMBO REP, V10, P584, DOI 10.1038/embor.2009.123; Gamsby JJ, 2009, J BIOL RHYTHM, V24, P193, DOI 10.1177/0748730409334748; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gerstner JR, 2009, J NEUROSCI, V29, P12824, DOI 10.1523/JNEUROSCI.3353-09.2009; Gerstner JR, 2012, FRONTIERS MOL NEUROS, V5, P1; Golombek DA, 2010, PHYSIOL REV, V90, P1063, DOI 10.1152/physrev.00009.2009; Gouin JP, 2010, J AFFECT DISORDERS, V126, P161, DOI 10.1016/j.jad.2010.04.002; Halberg Franz, 2003, J Circadian Rhythms, V1, P2, DOI 10.1186/1740-3391-1-2; Hardeland R, 2003, CHRONOBIOL INT, V20, P921, DOI 10.1081/CBI-120025245; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Iitaka C, 2005, J BIOL CHEM, V280, P29397, DOI 10.1074/jbc.M503526200; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kang TH, 2009, P NATL ACAD SCI USA, V106, P2864, DOI 10.1073/pnas.0812638106; LeSauter J, 1999, J NEUROSCI, V19, P5574; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Maya-Vetencourt JF, 2008, SCIENCE, V320, P385, DOI 10.1126/science.1150516; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004; Mendlewicz J, 2009, CNS DRUGS, V23, P15, DOI 10.2165/11318630-000000000-00000; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569; Phan TH, 2011, J NEUROSCI, V31, P10640, DOI 10.1523/JNEUROSCI.6535-10.2011; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Rawashdeh O, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00027; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Rojo DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023111; Ruby NF, 2008, P NATL ACAD SCI USA, V105, P15593, DOI 10.1073/pnas.0808259105; Sanada K, 2002, J BIOL CHEM, V277, P267, DOI 10.1074/jbc.M107850200; SAS Institute Inc, 2004, SAS STAT US GUID VER; Sassone-Corsi P, 2010, MOL ENDOCRINOL, V24, P2081, DOI 10.1210/me.2010-0359; Schaaf MJM, 2000, MOL BRAIN RES, V75, P342, DOI 10.1016/S0169-328X(99)00314-9; Shieh KR, 2003, NEUROSCIENCE, V118, P831, DOI 10.1016/S0306-4522(03)00004-6; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Sprouse J, 2006, BIOL PSYCHIAT, V60, P896, DOI 10.1016/j.biopsych.2006.03.003; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Ukai-Tadenuma M, 2011, CELL, V144, P268, DOI 10.1016/j.cell.2010.12.019; Uz T, 2005, NEUROSCIENCE, V134, P1309, DOI 10.1016/j.neuroscience.2005.05.003; Volicer L, 2001, AM J PSYCHIAT, V158, P704, DOI 10.1176/appi.ajp.158.5.704; Wang NN, 2008, CELL METAB, V8, P482, DOI 10.1016/j.cmet.2008.10.009; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yin L, 2006, SCIENCE, V311, P1002, DOI 10.1126/science.1121613; Zhang EE, 2009, CELL, V139, P199, DOI 10.1016/j.cell.2009.08.031	68	51	54	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2012	7	10							e46204	10.1371/journal.pone.0046204			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	015NU	WOS:000309454000025	23056261	Green Published, gold			2022-02-06	
J	Payne, SC; Bartlett, CA; Harvey, AR; Dunlop, SA; Fitzgerald, M				Payne, Sophie C.; Bartlett, Carole A.; Harvey, Alan R.; Dunlop, Sarah A.; Fitzgerald, Melinda			Myelin Sheath Decompaction, Axon Swelling, and Functional Loss during Chronic Secondary Degeneration in Rat Optic Nerve	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article							SPINAL-CORD-INJURY; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; EARLY ULTRASTRUCTURAL FINDINGS; CHANNEL BLOCKER LOMERIZINE; OCULAR HYPERTENSION; PROTEOLIPID PROTEIN; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; GLAUCOMA	PURPOSE. To examine chronic changes occurring at 6 months following partial optic nerve (ON) transection, assessing optic axons, myelin, and visual function. METHODS. Dorsal ON axons were transected, leaving ventral optic axons vulnerable to secondary degeneration. At 3 and 6 months following partial transection, toluidine-blue stained sections were used to assess dimensions of the ON injury site. Transmission electron microscopy (TEM) images of ventral ON were used to quantify numbers, diameter, area, and myelin thickness of optic axons. Immunohistochemistry and fluoromyelin staining were used to assess semiquantitatively myelin protein, lipids in ventral ON, and retinal ganglion cells (RGCs) in midventral retina. Visuomotor function was assessed using optokinetic nystagmus. RESULTS. Following partial ON transection, optic axons and function remained disrupted at 6 months. Although ventral ON swelling observed at 3 months (P <= 0.05) receded to normal by 6 months, ultrastructurally, myelinated axons remained swollen (P >= 0.05), and myelin thickness increased (P <= 0.05) due to loosening of lamellae and an increase in the number of intraperiodic lines. Axons with decompacted myelin persisted and were distinguished as having large axonal calibers and thicker myelin sheaths. Nevertheless, progressive loss of myelin lipid staining with fluoromyelin was seen at 6 months. Despite no further loss of ventral optic axons between 3 and 6 months (P >= 0.05), visuomotor function progressively declined at 6 months following partial transection (P <= 0.05). CONCLUSIONS. Continued decompaction of myelin, altered myelin structure, and swelling of myelinated axons are persistent features of the chronic phases of secondary degeneration and likely contribute to progressive loss of visual function. (Invest Ophthalmol Vis Sci. 2012; 53: 6093-6101) DOI: 10.1167/iovs.12-10080	[Payne, Sophie C.; Bartlett, Carole A.; Dunlop, Sarah A.; Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Payne, Sophie C.; Bartlett, Carole A.; Dunlop, Sarah A.; Fitzgerald, Melinda] Univ Western Australia, Western Australian Inst Med Res, Crawley, WA 6009, Australia; [Harvey, Alan R.] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA 6009, Australia		Fitzgerald, M (corresponding author), Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia.	lindy.fitzgerald@uwa.edu.au	Harvey, Alan R/A-4911-2008; Fitzgerald, Melinda/C-4235-2011; Dunlop, Sarah A/G-9357-2013	Fitzgerald, Melinda/0000-0002-4823-8179; , Alan/0000-0002-2590-831X; Dunlop, Sarah/0000-0002-1306-3962	Neurotrauma Research Program (Western Australia); National Health and Medical Research Council, Australia (NHMRC)National Health and Medical Research Council of Australia [572550]; NHMRCNational Health and Medical Research Council of Australia [APP1002347]; University Government; State Government; Commonwealth Government	Supported by the Neurotrauma Research Program (Western Australia) and National Health and Medical Research Council, Australia (NHMRC) Grant 572550 (MF) and from NHMRC Grant APP1002347 (SAD).; We thank Michael Archer for technical assistance with electron microscopy. The authors thank the facilities, scientific, and technical assistance of the Australian Microscopy & Microanalysis Research Facility at the Centre for Microscopy, Characterisation & Analysis, The University of Western Australia, a facility funded by the University, State, and Commonwealth Governments.	Access Economics Pty Limited for the Victorian Neurotrauma Initiative, 2009, EC COST SPIN CORD IN; Bai HQ, 2009, EUR J OPHTHALMOL, V19, P201, DOI 10.1177/112067210901900205; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bizzozero OA, 2001, J NEUROCHEM, V76, P1129, DOI 10.1046/j.1471-4159.2001.00116.x; Bizzozero OA, 2001, NEUROCHEM RES, V26, P1127, DOI 10.1023/A:1012370822754; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BONGARZONE ER, 1995, J NEUROSCI RES, V41, P213, DOI 10.1002/jnr.490410209; BUTT AM, 1995, GLIA, V14, P185, DOI 10.1002/glia.440140304; Casson RJ, 2006, CLIN EXP OPHTHALMOL, V34, P54, DOI 10.1111/j.1442-9071.2006.01146.x; Chabi A, 2012, AM J OPHTHALMOL, V153, P1187, DOI 10.1016/j.ajo.2011.11.008; Crish SD, 2011, NEUROSCIENCE, V176, P1, DOI 10.1016/j.neuroscience.2010.12.036; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fechtner RD, 2004, ACTA OPHTHALMOL SCAN, V82, P42, DOI 10.1046/j.1600-0420.2004.0205.x; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; FRIEDE RL, 1970, BRAIN RES, V19, P165, DOI 10.1016/0006-8993(70)90432-4; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Howell GR, EXP NEUROL; HSIEH ST, 1994, J NEUROSCI, V14, P6392; James ND, 2011, J NEUROSCI, V31, P18543, DOI 10.1523/JNEUROSCI.4306-11.2011; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Karim MD, 2006, CURR EYE RES, V31, P273, DOI 10.1080/02713680500536647; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Kursula P, 2008, AMINO ACIDS, V34, P175, DOI 10.1007/s00726-006-0479-7; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lasiene J, 2008, J NEUROSCI, V28, P3887, DOI 10.1523/JNEUROSCI.4756-07.2008; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Levkovitch-Verbin H, 2001, INVEST OPHTH VIS SCI, V42, P975; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; Mellough CB, 2004, EXP NEUROL, V186, P6, DOI 10.1016/j.expneurol.2003.10.021; Monnier PP, 2011, J NEUROSCI, V31, P10494, DOI 10.1523/JNEUROSCI.0148-11.2011; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Payne SC, 2011, J NEUROTRAUM, V28, P1077, DOI 10.1089/neu.2010.1665; Quek DTL, 2011, AM J OPHTHALMOL, V152, P463, DOI 10.1016/j.ajo.2011.02.023; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Sanli AM, 2012, TURK NEUROSURG, V22, P189, DOI 10.5137/1019-5149.JTN.5193-11.1; Selt M, 2010, BRAIN RES BULL, V81, P467, DOI 10.1016/j.brainresbull.2009.11.004; Sousa AD, 2007, NEURON GLIA BIOL, V3, P169, DOI 10.1017/S1740925X07000415; Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; Tripathi R, 2007, GLIA, V55, P698, DOI 10.1002/glia.20491; Vrabec JP, 2007, EYE, V21, pS11, DOI 10.1038/sj.eye.6702880; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124; Whitmore AV, 2005, PROG RETIN EYE RES, V24, P639, DOI 10.1016/j.preteyeres.2005.04.004; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; Yoles E, 1998, ARCH OPHTHALMOL-CHIC, V116, P906, DOI 10.1001/archopht.116.7.906	60	51	54	0	10	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404	1552-5783		INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	SEP	2012	53	10					6093	6101		10.1167/iovs.12-10080			9	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	016NQ	WOS:000309526200014	22879411				2022-02-06	
J	Scholten, JD; Sayer, NA; Vanderploeg, RD; Bidelspach, DE; Cifu, DX				Scholten, Joel D.; Sayer, Nina A.; Vanderploeg, Rodney D.; Bidelspach, Douglas E.; Cifu, David X.			Analysis of US Veterans Health Administration comprehensive evaluations for traumatic brain injury in Operation Enduring Freedom and Operation Iraqi Freedom Veterans	BRAIN INJURY			English	Article						Traumatic brain injury; health services needs and demand; United States Department of Veterans Affairs	POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; CHRONIC PAIN; BASE RATES; AFGHANISTAN; DEPLOYMENT; ETIOLOGY	Objective: To describe neurobehavioural symptoms in Iraq and Afghanistan war veterans evaluated for traumatic brain injury (TBI) through the Veterans Health Administration (VHA) TBI screening and evaluation programme. Design: An observational study based on VHA administrative data for all veterans who underwent TBI Comprehensive Evaluation between October 2007 and June 2010. Results: 55,070 predominantly white, non-Hispanic, male Veterans with a positive TBI screen had comprehensive TBI evaluations completed during the study period. Moderate-to-severe symptoms were common in the entire sample, both in those with and without a clinician-diagnosed TBI. However, the odds of reporting symptoms of this severity were significantly higher in those diagnosed with TBI compared to those without a TBI diagnosis, with odds ratios ranging from 1.35-2.21. TBI-specialty clinicians believed that in the majority of diagnosed TBI cases both behavioural health conditions and TBI contributed to patients' symptom presentation. Conclusions: The VHAs TBI screening and evaluation process is identifying individuals with ongoing neurobehavioural symptoms. Moderate-to-severe symptoms were more prevalent in veterans with TBI-specialty clinician determined TBI. However, the high rate of symptom reporting also present in individuals without a confirmed TBI suggest that symptom aetiology may be multi-factorial in nature.	[Scholten, Joel D.; Bidelspach, Douglas E.; Cifu, David X.] Dept Vet Affairs, Phys Med & Rehabil Program Off, Washington, DC USA; [Scholten, Joel D.] VA Med Ctr, Dept Phys Med & Rehabil, Washington, DC 20422 USA; [Scholten, Joel D.] Georgetown Univ, Med Ctr, Dept Phys Med & Rehabil, Washington, DC 20007 USA; [Sayer, Nina A.] Minneapolis Vet Affairs Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Sayer, Nina A.] Univ Minnesota, Dept Med & Psychiat, Minneapolis, MN USA; [Vanderploeg, Rodney D.] James A Haley VA, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Neurosci, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Tampa, FL USA; [Bidelspach, Douglas E.] Lebanon VA Med Ctr, Lebanon, VA USA; [Cifu, David X.] Hunter Holmes McGuire VA, Dept Phys Med & Rehabil, Richmond, VA USA; [Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA		Scholten, JD (corresponding author), VA Med Ctr, Dept Phys Med & Rehabil 117, 50 Irving St NW, Washington, DC 20422 USA.	joel.scholten@va.gov	Sayer, Nina/E-3249-2016	Cifu, David/0000-0003-1600-9387	Department of Veterans Affairs (VA) Health Services Research and Development Service (HSR&D) Quality Enhancement Research Initiative (QUERI) Locally Initiated Project [QUERI LIP PLY 10-4218]	The authors report no conflicts of interest. This research was performed at the Minneapolis VA Healthcare System, Minneapolis, MN. This manuscript represents original and valid research that has not been previously published and is not under consideration for publication elsewhere. This research was supported by a Department of Veterans Affairs (VA) Health Services Research and Development Service (HSR&D) Quality Enhancement Research Initiative (QUERI) Locally Initiated Project (QUERI LIP PLY 10-4218). The content of this report presents the findings and conclusions of the authors and does not necessarily represent the VA or HSR&D. The VA had no role in study design, analysis and interpretation of data; writing of the article; or the decision to submit it for publication.	[Anonymous], NON TRADITIONAL REF; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Comprehensive TBI Evaluation User Guide, 2011, COMPR TBI EV US GUID; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Defense and Veterans Brain Injury Center, 2011, DOD WORLDW NUMB TRAU; Environmental Epidemiology Service, 2010, AN VA HLTH CAR UT OP; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Sayer NA, 2011, J HEAD TRAUMA REHAB, V26, P454, DOI 10.1097/HTR.0b013e3181ff393c; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	21	51	51	0	6	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2012	26	10					1177	1184		10.3109/02699052.2012.661914			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	984GR	WOS:000307178600002	22646489				2022-02-06	
J	Kraft, RH; Mckee, PJ; Dagro, AM; Grafton, ST				Kraft, Reuben H.; Mckee, Phillip Justin; Dagro, Amy M.; Grafton, Scott T.			Combining the Finite Element Method with Structural Connectome-based Analysis for Modeling Neurotrauma: Connectome Neurotrauma Mechanics	PLOS COMPUTATIONAL BIOLOGY			English	Article							GRAPH-THEORETICAL ANALYSIS; TRAUMATIC BRAIN-INJURY; DYNAMIC-RESPONSE; CONNECTIVITY; NETWORKS; LESIONS; SYSTEM; TISSUE; STEM	This article presents the integration of brain injury biomechanics and graph theoretical analysis of neuronal connections, or connectomics, to form a neurocomputational model that captures spatiotemporal characteristics of trauma. We relate localized mechanical brain damage predicted from biofidelic finite element simulations of the human head subjected to impact with degradation in the structural connectome for a single individual. The finite element model incorporates various length scales into the full head simulations by including anisotropic constitutive laws informed by diffusion tensor imaging. Coupling between the finite element analysis and network-based tools is established through experimentally-based cellular injury thresholds for white matter regions. Once edges are degraded, graph theoretical measures are computed on the "damaged" network. For a frontal impact, the simulations predict that the temporal and occipital regions undergo the most axonal strain and strain rate at short times (less than 24 hrs), which leads to cellular death initiation, which results in damage that shows dependence on angle of impact and underlying microstructure of brain tissue. The monotonic cellular death relationships predict a spatiotemporal change of structural damage. Interestingly, at 96 hrs post-impact, computations predict no network nodes were completely disconnected from the network, despite significant damage to network edges. At early times (t<24 hrs) network measures of global and local efficiency were degraded little; however, as time increased to 96 hrs the network properties were significantly reduced. In the future, this computational framework could help inform functional networks from physics-based structural brain biomechanics to obtain not only a biomechanics-based understanding of injury, but also neurophysiological insight.	[Kraft, Reuben H.; Dagro, Amy M.] USA, Soldier Protect Sci Branch, Protect Div, Res Lab, Aberdeen Proving Ground, MD USA; [Mckee, Phillip Justin] Dynamic Sci Inc, Aberdeen Proving Ground, MD USA; [Grafton, Scott T.] Univ Calif Santa Barbara, Dept Psychol, Santa Barbara, CA 93106 USA		Kraft, RH (corresponding author), USA, Soldier Protect Sci Branch, Protect Div, Res Lab, Aberdeen Proving Ground, MD USA.	reuben.kraft@gmail.com		Dagro, Amy/0000-0002-3250-3732	U.S. Department of Defense, Department of the ArmyUnited States Department of Defense	This work was funded by the U.S. Department of Defense, Department of the Army. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acar ZA, 2010, J NEUROSCI METH, V190, P258, DOI 10.1016/j.jneumeth.2010.04.031; Alstott J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000408; Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Belytschko T., 2000, NONLINEAR FINITE ELE; Bernick KB, 2011, ACTA BIOMATER, V7, P1210, DOI 10.1016/j.actbio.2010.10.018; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chafi MS, 2011, INT J APPL MECH, V3, P803, DOI 10.1142/S175882511100124X; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Dauguet J, 2007, NEUROIMAGE, V37, P530, DOI 10.1016/j.neuroimage.2007.04.067; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Honey CJ, 2010, NEUROIMAGE, V52, P766, DOI 10.1016/j.neuroimage.2010.01.071; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hosmane S, 2011, LAB CHIP, V11, P3888, DOI 10.1039/c1lc20549h; Iturria-Medina Y, 2011, CEREB CORTEX, V21, P56, DOI 10.1093/cercor/bhq058; Jarbo K, 2012, NEUROIMAGE, V59, P1988, DOI 10.1016/j.neuroimage.2011.09.056; Jirsa VK, 2010, ARCH ITAL BIOL, V148, P189; Kaiser M, 2007, EUR J NEUROSCI, V25, P3185, DOI 10.1111/j.1460-9568.2007.05574.x; Kraft RH, 2011, ARLTR5796; Kuceyeski A, 2011, NEUROIMAGE, V58, P109, DOI 10.1016/j.neuroimage.2011.05.087; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Lee WH, 2012, MED ENG PHYS, V34, P85, DOI 10.1016/j.medengphy.2011.07.002; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mendis K, 1992, THESIS OHIO STATE U; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Morrison B, 2011, STUD MECHANOBIOL TIS, V3, P247, DOI 10.1007/8415_2011_79; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nahum A., 1977, 21 STAPP CAR CRASH C, DOI DOI 10.4271/770922; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Rullmann M, 2009, NEUROIMAGE, V44, P399, DOI 10.1016/j.neuroimage.2008.09.009; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Sanborn B, 2012, J BIOMECH, V45, P434, DOI 10.1016/j.jbiomech.2011.12.017; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Shafieian M, 2011, NORTHEAST BIOENGIN C; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Trexler MM, 2011, J MECH BEHAV BIOMED, V4, P1920, DOI 10.1016/j.jmbbm.2011.06.008; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; WOO EJ, 1994, MED BIOL ENG COMPUT, V32, P530, DOI 10.1007/BF02515311; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yang KH, 2011, STUD MECHANOBIOL TIS, V3, P69, DOI 10.1007/8415_2010_62; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang YC, 2006, NEUROIMAGE, V31, P1513, DOI 10.1016/j.neuroimage.2006.02.027	65	51	52	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1553-734X	1553-7358		PLOS COMPUT BIOL	PLoS Comput. Biol.	AUG	2012	8	8							e1002619	10.1371/journal.pcbi.1002619			15	Biochemical Research Methods; Mathematical & Computational Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Mathematical & Computational Biology	002SA	WOS:000308553500008	22915997	Green Published, gold, Green Submitted			2022-02-06	
J	Wu, JF; Pajoohesh-Ganji, A; Stoica, BA; Dinizo, M; Guanciale, K; Faden, AI				Wu, Junfang; Pajoohesh-Ganji, Ahdeah; Stoica, Bogdan A.; Dinizo, Michael; Guanciale, Kelsey; Faden, Alan I.			Delayed expression of cell cycle proteins contributes to astroglial scar formation and chronic inflammation after rat spinal cord contusion	JOURNAL OF NEUROINFLAMMATION			English	Article						Contusive spinal cord injury; Cell cycle pathway; Cyclin-dependent kinases; Chronic; CR8; Astrogliosis; Inflammation; Rat	FOCAL CEREBRAL-ISCHEMIA; ADHESION MOLECULE L1; CDK INHIBITOR; IN-VITRO; PROVIDES NEUROPROTECTION; NADPH OXIDASE; CLOSE HOMOLOG; BRAIN; MICROGLIA; INJURY	Background: Traumatic spinal cord injury (SCI) induces secondary tissue damage that is associated with astrogliosis and inflammation. We previously reported that acute upregulation of a cluster of cell-cycle-related genes contributes to post-mitotic cell death and secondary damage after SCI. However, it remains unclear whether cell cycle activation continues more chronically and contributes to more delayed glial change. Here we examined expression of cell cycle-related proteins up to 4 months following SCI, as well as the effects of the selective cyclin-dependent kinase (CDKs) inhibitor CR8, on astrogliosis and microglial activation in a rat SCI contusion model. Methods: Adult male rats were subjected to moderate spinal cord contusion injury at T8 using a well-characterized weight-drop model. Tissue from the lesion epicenter was obtained 4 weeks or 4 months post-injury, and processed for protein expression and lesion volume. Functional recovery was assessed over the 4 months after injury. Results: Immunoblot analysis demonstrated a marked continued upregulation of cell cycle-related proteins - including cyclin D1 and E, CDK4, E2F5 and PCNA - for 4 months post-injury that were highly expressed by GFAP(+) astrocytes and microglia, and co-localized with inflammatory-related proteins. CR8 administrated systemically 3 h post-injury and continued for 7 days limited the sustained elevation of cell cycle proteins and immunoreactivity of GFAP, Iba-1 and p22(PHOX) - a key component of NADPH oxidase - up to 4 months after SCI. CR8 treatment significantly reduced lesion volume, which typically progressed in untreated animals between 1 and 4 months after trauma. Functional recovery was also significantly improved by CR8 treatment after SCI from week 2 through week 16. Conclusions: These data demonstrate that cell cycle-related proteins are chronically upregulated after SCI and may contribute to astroglial scar formation, chronic inflammation and further tissue loss.	[Wu, Junfang; Stoica, Bogdan A.; Dinizo, Michael; Guanciale, Kelsey; Faden, Alan I.] Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA; [Wu, Junfang; Stoica, Bogdan A.; Dinizo, Michael; Guanciale, Kelsey; Faden, Alan I.] Univ Maryland, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Baltimore, MD 21201 USA; [Pajoohesh-Ganji, Ahdeah] George Washington Univ, Dept Neurosci, Sch Med, Washington, DC 20037 USA		Wu, JF (corresponding author), Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA.	jwu@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS054221-06]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054221] Funding Source: NIH RePORTER	This project was supported by the National Institutes of Health (NIH) grant no. R01NS054221-06.	Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; Atanasoski S, 2008, MOL CELL NEUROSCI, V37, P519, DOI 10.1016/j.mcn.2007.11.005; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Bettayeb K, 2008, ONCOGENE, V27, P5797, DOI 10.1038/onc.2008.191; Bettayeb Karima, 2010, Genes Cancer, V1, P369, DOI 10.1177/1947601910369817; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Fitch MT, 1999, J NEUROSCI, V19, P8182; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Jakovcevski I, 2007, J NEUROSCI, V27, P7222, DOI 10.1523/JNEUROSCI.0739-07.2007; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kato H, 2003, BRAIN RES BULL, V60, P215, DOI 10.1016/S0361-9230(03)00036-4; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Nagamoto-Combs K, 2010, J NEUROTRAUM, V27, P565, DOI 10.1089/neu.2009.0966; Naphade SB, 2010, ACTA NEUROPATHOL, V119, P123, DOI 10.1007/s00401-009-0616-y; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith ME, 1998, J NEUROSCI RES, V54, P68, DOI 10.1002/(SICI)1097-4547(19981001)54:1<68::AID-JNR8>3.0.CO;2-F; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; Tator C H, 1996, J Spinal Cord Med, V19, P206; Tator CH, 2002, INJURY PREV, V8, pIV33, DOI 10.1136/ip.8.suppl_4.iv33; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Tokumoto YM, 2002, DEV BIOL, V245, P224, DOI 10.1006/dbio.2002.0626; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang W, 2008, J CLIN NEUROSCI, V15, P278, DOI 10.1016/j.jocn.2007.02.004; Wu JF, 2012, CELL CYCLE, V11, P1782, DOI 10.4161/cc.20153; Wu JF, 2011, J NEUROSCI RES, V89, P628, DOI 10.1002/jnr.22598; Wu JF, 2011, NEUROTHERAPEUTICS, V8, P221, DOI 10.1007/s13311-011-0028-2; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zhang Q, 2009, GLIA, V57, P908, DOI 10.1002/glia.20816; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476	58	51	52	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUL 11	2012	9								169	10.1186/1742-2094-9-169			12	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	983LF	WOS:000307120100001	22784881	Green Published, gold			2022-02-06	
J	Zhang, ZR; Zhang, ZY; Wu, YZ; Schluesener, HJ				Zhang, Zhiren; Zhang, Zhi-Yuan; Wu, Yuzhang; Schluesener, Hermann J.			Lesional Accumulation of CD163(+) Macrophages/microglia in Rat Traumatic Brain Injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; CD163; Macrophages; Heme oxygenase-1	ANTIINFLAMMATORY MACROPHAGE PHENOTYPE; HEMOGLOBIN SCAVENGER RECEPTOR; CENTRAL-NERVOUS-SYSTEM; HEME OXYGENASE-1 HO-1; PERIVASCULAR MACROPHAGES; NEUROVASCULAR UNIT; HUMAN MONOCYTES; MICROGLIA; ACTIVATION; EXPRESSION	A robust neuroinflammation, contributing to the development of secondary injury, is a common histopathological feature of traumatic brain injury (TBI). Characterization of leukocytic subpopulations contributing to the early infiltration of the damaged tissue might aid in further understanding of lesion development. Reactive macrophages/microglia can exert protective or damaging effects in TBI. CD163 is considered a marker of M2 (alternatively activated) macrophages. Therefore we investigated the accumulation of CD163(+) macrophages/microglia in the brain of TB! rats. TBI was induced in rats using an open skull weight-drop contusion model and the accumulation of CD163(+) cells was analyzed by immunohistochemistry. In normal rat brains, CD163 was expressed by meningeal, choroid plexus and perivascular macrophages. Significant parenchymal CD163(+) cell accumulation was observed two days post TBI and continuously increased in the investigated survival time. The accumulated CD163(+) cells were mainly distributed to the lesional areas and exhibited macrophage phenotypes with amoeboid morphologic characteristics but not activated microglial phenotypes with hypertrophic morphology and thick processes. Double-labeling experiments showed that most CD163+ cells co-expressed heme oxygenase-1 (HO-1). In addition, in vitro incubating of macrophage RAW264.7 cells or primary peritoneal macrophages with hemoglobin- haptoglobin (Hb-Hp) complex suppressed LPS-induced inflammatory macrophages phenotype and induced CD163 and HO-1 upregulation, indicating that CD163(+) macrophages/microglia in TBI might have anti-inflammatory effects. And further study is necessary to identify functions of these cells in TBI. (C) 2012 Elsevier B.V. All rights reserved.	[Zhang, Zhiren; Wu, Yuzhang] Third Mil Med Univ PLA, Inst Immunol, Chongqing 400038, Peoples R China; [Zhang, Zhiren; Zhang, Zhi-Yuan; Schluesener, Hermann J.] Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany		Zhang, ZR (corresponding author), Third Mil Med Univ PLA, Inst Immunol, Gaotanyan Main St 30, Chongqing 400038, Peoples R China.	zhangzhiren@yahoo.com	Zhang, Zhiren/O-1012-2019; zhang, zhiren/I-1046-2014	Zhang, Zhiren/0000-0002-5238-2835; zhang, zhiren/0000-0002-5238-2835; Zhang, Zhi-Yuan/0000-0001-9067-0670; Wu, Yuzhang/0000-0002-4049-0214	Natural Science Foundation Project of CQ CSTCNatural Science Foundation Project of CQ CSTC [2010BB5025]; National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070954]	This research was partly supported by Natural Science Foundation Project of CQ CSTC (contract No. 2010BB5025) and National Nature Science Foundation of China (No: 81070954).	Abraham NG, 2006, CIRC RES, V99, P911, DOI 10.1161/01.RES.0000249616.10603.d6; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Borda JT, 2008, AM J PATHOL, V172, P725, DOI 10.2353/ajpath.2008.070848; Bover LC, 2007, J IMMUNOL, V178, P8183, DOI 10.4049/jimmunol.178.12.8183; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Fabriek BO, 2005, GLIA, V51, P297, DOI 10.1002/glia.20208; Fairweather D, 2009, J AUTOIMMUN, V33, P222, DOI 10.1016/j.jaut.2009.09.012; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Galea I, 2008, NEUROSCI LETT, V448, P41, DOI 10.1016/j.neulet.2008.09.081; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Inta I, 2008, J NEUROL SCI, V275, P117, DOI 10.1016/j.jns.2008.08.005; Jazwa A, 2010, CURR DRUG TARGETS, V11, P1517, DOI 10.2174/1389450111009011517; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Komohara Y, 2006, J HISTOCHEM CYTOCHEM, V54, P763, DOI 10.1369/jhc.5A6871.2006; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Moestrup SK, 2004, ANN MED, V36, P347, DOI 10.1080/07853890410033171; Moreno JA, 2009, ATHEROSCLEROSIS, V207, P103, DOI 10.1016/j.atherosclerosis.2009.04.033; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046; Nielsen MJ, 2009, BLOOD, V114, P764, DOI 10.1182/blood-2009-01-198309; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Onofre G., 2009, ACTA MED, V52, P57, DOI [DOI 10.14712/18059694.2016.105, 10.14712/18059694.2016.105]; Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Polavarapu R, 2005, J NEUROSCI, V25, P10094, DOI 10.1523/JNEUROSCI.3382-05.2005; Roberts ES, 2004, J NEUROPATH EXP NEUR, V63, P1255, DOI 10.1093/jnen/63.12.1255; Satoh J, 2008, NEUROPATHOLOGY, V28, P561, DOI 10.1111/j.1440-1789.2008.00915.x; Schaer CA, 2006, CIRC RES, V99, P943, DOI 10.1161/01.RES.0000247067.34173.1b; Schaer DJ, 2006, BLOOD, V107, P373, DOI 10.1182/blood-2005-03-1014; Schwartz M, 2003, J CEREBR BLOOD F MET, V23, P385, DOI 10.1097/01.WCB.0000061881.75234.5E; Shibahara S, 2002, ANTIOXID REDOX SIGN, V4, P593, DOI 10.1089/15230860260220094; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; TOPOLL HH, 1989, J PERIODONTAL RES, V24, P106, DOI 10.1111/j.1600-0765.1989.tb00864.x; Ugocsai P, 2006, CYTOM PART A, V69A, P203, DOI 10.1002/cyto.a.20235; Van Gorp H, 2010, MOL IMMUNOL, V47, P1650, DOI 10.1016/j.molimm.2010.02.008; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Zhang XH, 2007, J CEREBR BLOOD F MET, V27, P534, DOI 10.1038/sj.jcbfm.9600368; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; Zheng TS, 2008, J LEUKOCYTE BIOL, V84, P338, DOI 10.1189/jlb.0308165; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; ZWADLO G, 1987, EXP CELL BIOL, V55, P295	49	51	52	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 21	2012	1461						102	110		10.1016/j.brainres.2012.04.038			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	966EF	WOS:000305819700011	22583855				2022-02-06	
J	Debert, CT; Herter, TM; Scott, SH; Dukelow, S				Debert, Chantel T.; Herter, Troy M.; Scott, Stephen H.; Dukelow, Sean			Robotic Assessment of Sensorimotor Deficits After Traumatic Brain Injury	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						proprioception; reaching; rehabilitation; robotics; traumatic brain injury	LIMB POSITION SENSE; MOTOR-PERFORMANCE; UNITED-STATES; CHILDREN; RECOVERY; STROKE; JOINT; KINESTHESIA; RELIABILITY; IMPAIRMENT	Background and Purpose: Robotic technology is commonly used to quantify aspects of typical sensorimotor function. We evaluated the feasibility of using robotic technology to assess visuomotor and position sense impairments following traumatic brain injury (TBI). We present results of robotic sensorimotor function testing in 12 subjects with TBI, who had a range of initial severities (9 severe, 2 moderate, 1 mild), and contrast these results with those of clinical tests. We also compared these with robotic test outcomes in persons without disability. Methods: For each subject with TBI, a review of the initial injury and neuroradiologic findings was conducted. Following this, each subject completed a number of standardized clinical measures (Fugl-Meyer Assessment, Purdue Peg Board, Montreal Cognitive Assessment, Rancho Los Amigos Scale), followed by two robotic tasks. A visually guided reaching task was performed to assess visuomotor control of the upper limb. An arm position-matching task was used to assess position sense. Robotic task performance in the subjects with TBI was compared with findings in a cohort of 170 person without disabilities. Results: Subjects with TBI demonstrated a broad range of sensory and motor deficits on robotic testing. Notably, several subjects with TBI displayed significant deficits in one or both of the robotic tasks, despite normal scores on traditional clinical motor and cognitive assessment measures. Discussion and Conclusions: The findings demonstrate the potential of robotic assessments for identifying deficits in visuomotor control and position sense following TBI. Improved identification of neurologic impairments following TBI may ultimately enhance rehabilitation.	[Debert, Chantel T.; Herter, Troy M.; Dukelow, Sean] Univ Calgary, Hotchkiss Brain Inst, Div Phys Med & Rehabil, Dept Clin Neurosci, Calgary, AB, Canada; [Herter, Troy M.; Scott, Stephen H.] Queens Univ, Dept Anat & Cell Biol, Kingston, ON, Canada		Dukelow, S (corresponding author), Univ Calgary, Hotchkiss Brain Inst, Div Phys Med & Rehabil, Dept Clin Neurosci, Calgary, AB, Canada.	sean.dukelow@albertahealthservices.ca		Debert, Chantel/0000-0002-2704-0438; Dukelow, Sean/0000-0002-0609-981X	CIHRCanadian Institutes of Health Research (CIHR) [MOP 81366, NSP 104015]; Heart and Stroke Foundation of Alberta; Heart and Stroke Foundation of Nunavut; Heart and Stroke Foundation of Northwest Territories; Ontario Research Foundation	Dr Scott is the cofounder and scientific officer of BKIN technologies, the company that manufactures the KINARM robotic device. Funding for this project was made possible through CIHR operating grants (MOP 81366 and NSP 104015); a grant-in-aid from the Heart and Stroke Foundation of Alberta, Nunavut, and Northwest Territories; and a research excellence grant from the Ontario Research Foundation.	Adamo DE, 2009, J AGING PHYS ACTIV, V17, P272, DOI 10.1123/japa.17.3.272; Bickley L., 2007, BATES GUIDE PHYS EXA; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Campbell M, 2000, UNDERSTANDING TRAUMA; Carey LM, 1996, ARCH PHYS MED REHAB, V77, P1271, DOI 10.1016/S0003-9993(96)90192-6; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Coderre AM, 2010, NEUROREHAB NEURAL RE, V24, P528, DOI 10.1177/1545968309356091; Collins DF, 2005, J NEUROPHYSIOL, V94, P1699, DOI 10.1152/jn.00191.2005; Dobkin BH, 2011, NEUROREHAB NEURAL RE, V25, P788, DOI 10.1177/1545968311425908; Dukelow SP, 2010, NEUROREHAB NEURAL RE, V24, P178, DOI 10.1177/1545968309345267; Dukelow SP, 2009, SOC NEUR CHIC IL; Ellis MD, 2008, NEUROREHAB NEURAL RE, V22, P321, DOI 10.1177/1545968307313509; Faul M, 2010, TRAUMATIC BRAIN INJU; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; GANDEVIA SC, 1976, J PHYSIOL-LONDON, V260, P387, DOI 10.1113/jphysiol.1976.sp011521; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Goble DJ, 2005, HUM MOVEMENT SCI, V24, P155, DOI 10.1016/j.humov.2005.05.004; GOODWIN GM, 1972, BRAIN RES, V37, P326, DOI 10.1016/0006-8993(72)90679-8; GOODWIN GM, 1972, SCIENCE, V175, P1382, DOI 10.1126/science.175.4028.1382; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hagen C., 1972, LEVELS COGNITIVE FUN; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Lincoln N.B., 1991, CLIN REHABIL, V5, P273, DOI [DOI 10.1177/026921559100500403, 10.1177/026921559100500403]; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; MATTHEWS PBC, 1982, ANNU REV NEUROSCI, V5, P189, DOI 10.1146/annurev.ne.05.030182.001201; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Scott SH, 1999, J NEUROSCI METH, V89, P119, DOI 10.1016/S0165-0270(99)00053-9; Scott SH, 2011, J REHABIL RES DEV, V48, P335, DOI 10.1682/JRRD.2010.04.0057; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; Singh K, 2003, NAT NEUROSCI, V6, P399, DOI 10.1038/nn1026; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tiffin J, 1948, J APPL PSYCHOL, V32, P234, DOI 10.1037/h0061266; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; WILSON B, 1987, ARCH PHYS MED REHAB, V68, P98; Wolpert DM, 2010, BMC BIOL, V8, DOI [10.1186/1741-7007-8-82, 10.1186/1741-7007-8-92]; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	42	51	51	0	39	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	JUN	2012	36	2					58	67		10.1097/NPT.0b013e318254bd4f			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	946QY	WOS:000304370000003	22592061				2022-02-06	
J	Roozenbeek, B; Chiu, YL; Lingsma, HF; Gerber, LM; Steyerberg, EW; Ghajar, J; Maas, AIR				Roozenbeek, Bob; Chiu, Ya-Lin; Lingsma, Hester F.; Gerber, Linda M.; Steyerberg, Ewout W.; Ghajar, Jamshid; Maas, Andrew I. R.			Predicting 14-Day Mortality after Severe Traumatic Brain Injury: Application of the IMPACT Models in the Brain Trauma Foundation TBI-trac (R) New York State Database	JOURNAL OF NEUROTRAUMA			English	Article						external validation; outcome; prediction models; traumatic brain injury	COMMON DATA ELEMENTS; RECOMMENDATIONS; MODERATE; TRIALS; DESIGN	Prognostic models for outcome prediction in patients with traumatic brain injury (TBI) are important instruments in both clinical practice and research. To remain current a continuous process of model validation is necessary. We aimed to investigate the performance of the International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) prognostic models in predicting mortality in a contemporary New York State TBI registry developed and maintained by the Brain Trauma Foundation. The Brain Trauma Foundation (BTF) TBI-trac (R) database contains data on 3125 patients who sustained severe TBI (Glasgow Coma Scale [GCS] score <= 8) in New York State between 2000 and 2009. The outcome measure was 14-day mortality. To predict 14-day mortality with admission data, we adapted the IMPACT Core and Extended models. Performance of the models was assessed by determining calibration (agreement between observed and predicted outcomes), and discrimination (separation of those patients who die from those who survive). Calibration was explored graphically with calibration plots. Discrimination was expressed by the area under the receiver operating characteristic (ROC) curve (AUC). A total of 2513 out of 3125 patients in the BTF database met the inclusion criteria. The 14-day mortality rate was 23%. The models showed excellent calibration. Mean predicted probabilities were 20% for the Core model and 24% for the Extended model. Both models showed good discrimination with AUCs of 0.79 (Core) and 0.83 (Extended). We conclude that the IMPACT models validly predict 14-day mortality in the BTF database, confirming generalizability of these models for outcome prediction in TBI patients.	[Roozenbeek, Bob; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Roozenbeek, Bob; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Chiu, Ya-Lin; Gerber, Linda M.] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA		Roozenbeek, B (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	b.roozenbeek@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [046291]; New York State Department of Health Bureau of Emergency Medical Services; Brain Trauma Foundation	Development of the IMPACT models was supported by National Institutes of Health grant 046291. The BTF TBI-trac data collection was funded through the New York State Department of Health Bureau of Emergency Medical Services and by the Brain Trauma Foundation.	Brain Trauma Foundation, 2000, MAN PROGN SEV TRAU 1; Brain Trauma Foundation, 1995, GUID MAN SEV HEAD IN; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Edwards P, 2005, LANCET, V365, P1957; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Panczykowski D., 2011, J NEUROTRAUMA; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Steyerberg E.W, 2009, CLIN PREDICTION MODE, VXXVIII; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	24	51	54	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1306	1312		10.1089/neu.2011.1988			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600003	22150207	Green Published			2022-02-06	
J	Yuh, EL; Cooper, SR; Ferguson, AR; Manley, GT				Yuh, Esther L.; Cooper, Shelly R.; Ferguson, Adam R.; Manley, Geoffrey T.			Quantitative CT Improves Outcome Prediction in Acute Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						computer-aided detection; computed tomography; principal component analysis; quantitative CT; traumatic brain injury	COMPUTED-TOMOGRAPHY; MODERATE; CLASSIFICATION	The admission noncontrast head computed tomography (CT) scan has been demonstrated to be one of several key early clinical and imaging features in the challenging problem of prediction of long-term outcome after acute traumatic brain injury (TBI). In this study, we employ two novel approaches to the problem of imaging classification and outcome prediction in acute TBI. First, we employ the novel technique of quantitative CT (qCT) image analysis to provide more objective, reproducible measures of the abnormal features of the admission head CT in acute TBI. We show that the incorporation of quantitative, rather than qualitative, CT features results in a significant improvement in prediction of the 6-month Extended Glasgow Outcome Scale (GOS-E) score over a wide spectrum of injury severity. Second, we employ principal components analysis (PCA) to demonstrate the interdependence of certain predictive variables. Relatively few prior studies of outcome prediction in acute TBI have used a multivariate approach that explicitly takes into account the potential covariance among clinical and CT predictive variables. We demonstrate that several predictors, including midline shift, cistern effacement, subdural hematoma volume, and Glasgow Coma Scale (GCS) score are related to one another. Rather than being independent features, their importance may be related to their status as surrogate measures of a more fundamental underlying clinical feature, such as the severity of intracranial mass effect. We believe that objective computational tools and data-driven analytical methods hold great promise for neurotrauma research, and may ultimately have a role in image analysis for clinical care.	[Yuh, Esther L.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94107 USA; [Cooper, Shelly R.; Ferguson, Adam R.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94107 USA; [Yuh, Esther L.] San Francisco Gen Hosp, San Francisco, CA 94107 USA; [Yuh, Esther L.; Cooper, Shelly R.; Ferguson, Adam R.; Manley, Geoffrey T.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94107 USA		Yuh, EL (corresponding author), Univ Calif San Francisco, Dept Radiol, 185 Berry St,Suite 350, San Francisco, CA 94107 USA.	esther.yuh@ucsf.edu		Cooper, Shelly/0000-0003-0026-6688; Ferguson, Adam/0000-0001-7102-1608	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS067092, NS069537, NS069409]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069537, RC2NS069409, R01NS067092] Funding Source: NIH RePORTER	We thank Pratik Mukherjee, M.D., Ph.D., for evaluation of a subset of computer-aided head CT interpretations for the purpose of determination of interrater reliability for the semi-automated quantitative CT measurements. We gratefully acknowledge support from National Institutes of Health grants NS067092 and NS069537 (PI: A.R.F.) and NS069409 (PI: G.T.M.).	Chesnut R., 2000, J NEUROTRAUM, V17, P557; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Chun KA, 2010, J NEUROTRAUM, V27, P325, DOI 10.1089/neu.2009.1115; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; Laalo JP, 2009, J NEUROTRAUM, V26, P2169, DOI 10.1089/neu.2009.1011; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Nunnally JC., 1978, PSYCHOMETRIC THEORY, V2; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shlens J., 2009, TUTORIAL PRINCIPAL C; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tabachnik BG, 2007, USING MULTIVARIATE S; Yuh EL, 2008, J NEUROTRAUM, V25, P1163, DOI 10.1089/neu.2008.0590	23	51	52	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					735	746		10.1089/neu.2011.2008			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900004	21970562	Green Published			2022-02-06	
J	Post, A; Hoshizaki, B; Gilchrist, MD				Post, Andrew; Hoshizaki, Blaine; Gilchrist, Michael D.			Finite element analysis of the effect of loading curve shape on brain injury predictors	JOURNAL OF BIOMECHANICS			English	Article						Brain injury; Concussion; Finite element modelling	HUMAN HEAD; IMPACT; BIOMECHANICS	Prediction of traumatic and mild traumatic brain injury is an important factor in managing their prevention. Currently, the prediction of these injuries is limited to peak linear and angular acceleration loading curves derived from laboratory reconstructions. However it remains unclear as to what aspect of these loading curves contributes to brain tissue damage. This research uses the University College Dublin Brain Trauma Model (UCDBTM) to analyse three distinct loading curve shapes meant to represent different helmet loading scenarios. The loading curves were applied independently in each axis of linear and angular acceleration and their effect on currently used predictors of TBI and mTBI was examined. Loading curve shape A had a late time to peak. B an early time to peak and C had a consistent plateau. The areas under the curve for all three loading curve shapes were identical. The results indicate that loading curve A produced consistently higher maximum principal strains and Von Mises stress than the other two loading curve types. Loading curve C consistently produced the lowest values of maximum principal strain and Von Mises stress, with loading curve B being lowest in only 2 cases. The areas of peak Von Mises stress and Principal strain also varied depending on loading curve shape and acceleration input. (C) 2011 Elsevier Ltd. All rights reserved.	[Post, Andrew; Hoshizaki, Blaine; Gilchrist, Michael D.] Univ Ottawa, Ottawa, ON K1N 6N5, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, UCD Mech & Mat Engn, Dublin 4, Ireland		Post, A (corresponding author), Univ Ottawa, 200 Lees Ave, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X; Post, Andrew/0000-0002-5960-5552			Adams J H, 1981, Acta Neuropathol Suppl, V7, P26; Bradshaw DRS, 2001, P 17 INT TECHN C ENH; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Gennarelli TA, 1979, P 23 STAPP CAR CRASH; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Hardy W.N., 2001, STAPP CAR CRASH J ST; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; King A., 2003, P IRCOBI C LISB PORT; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; Nahum AM, 1977, P 21 STAPP CAR CRASH; Post A., 2010, P 8 C INT SPORTS ENG; Rousseau P., 2009, J ASTM INT, V6; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Schreiber DI, 1997, P 41 STAPP CAR CRASH; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	23	51	54	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	FEB 23	2012	45	4					679	683		10.1016/j.jbiomech.2011.12.005			5	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	911VR	WOS:000301748800009	22239921	Green Submitted			2022-02-06	
J	Zhu, XX; Tao, LY; Tejima-Mandeville, E; Qiu, JH; Park, J; Garber, K; Ericsson, M; Lo, EH; Whalen, MJ				Zhu, Xiaoxia; Tao, Luyang; Tejima-Mandeville, Emiri; Qiu, Jianhua; Park, Juyeon; Garber, Kent; Ericsson, Maria; Lo, Eng H.; Whalen, Michael J.			Plasmalemma Permeability and Necrotic Cell Death Phenotypes After Intracerebral Hemorrhage in Mice	STROKE			English	Article						apoptosis; inflammation; intracerebral hemorrhage; mice; necrosis; plasmalemma	CONTROLLED CORTICAL IMPACT; HYPOXIA-ISCHEMIA; APOPTOSIS; BRAIN; INHIBITION; NEURONS; MODEL; RAT; NEUROPROTECTION; IDENTIFICATION	Background and Purpose-Traumatic and ischemic brain injury induce plasmalemma permeability and necrosis; however, no studies have examined these aspects of cellular injury in intracerebral hemorrhage models. Methods-In vivo propidium iodide (PI) and YOYO-1 were used to assess plasmalemma damage after collagenase-induced intracerebral hemorrhage in mice. Ex vivo aspartylglutamylvalylaspartic acid, terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling, and electron microscopy were used to assess the relationship between plasmalemma permeability and mode of cell death. Cell types vulnerable to plasmalemma damage were determined by immunohistochemistry. Results-Plasma lemma permeability was first detected in the lesion at 1 to 3 hours and peaked at 48 to 72 hours. Neurons and IBA-1-positive cells with morphological features of monocytes were sensitive, whereas resident microglia and astocytes were resistant to plasmalemma permeability. PI+ cells colocalized with fluorescent-labeled caspase substrates and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling beginning at 3 to 6 hours. At 48 hours, greater than half of injured cells were PI+/aspartylglutamylvalylaspartic acid- or PI+/terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling -suggesting necrosis, and <5% were PI-/terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling+ or PI-/aspartylglutamylvalylaspartic acid+. Electron microscopy confirmed ultrastructural features of necrosis at 24 hours after intracerebral hemorrhage, high mobility group box protein-1 was released from permeable cells, and mice deficient in receptor interacting protein kinase (RIPK) 3, a known necrosis trigger, had 50% less PI+ cells at 24 hours. Permeable cells remained in the brain for at least 24 hours with <10% spontaneous resealing. Conclusions-Necrosis contributes to cell demise after intracerebral hemorrhage. Programmed necrosis and plasmalemma damage may represent novel therapeutic targets to prevent cell death or rescue injured cells after intracerebral hemorrhage. (Stroke. 2012;43:524-531.)	[Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, Charlestown, MA 02129 USA; [Zhu, Xiaoxia; Tao, Luyang; Qiu, Jianhua; Park, Juyeon; Garber, Kent; Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Tejima-Mandeville, Emiri; Lo, Eng H.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Tejima-Mandeville, Emiri; Lo, Eng H.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; [Zhu, Xiaoxia] Fudan Univ, Huashan Hosp, Dept Rheumatol, Shanghai 200433, Peoples R China; [Tao, Luyang] Soochow Univ, Dept Forens Med, Suzhou, Peoples R China; [Ericsson, Maria] Harvard Univ, Sch Med, Electron Microscopy Facil, Boston, MA USA		Whalen, MJ (corresponding author), Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, 149 13th St, Charlestown, MA 02129 USA.	MWhalen@Partners.org			China Natural Science FoundationNational Natural Science Foundation of China (NSFC) [30571909, 30872666, R37-NS37074, P01-NS55104, RO1NS061255, RO1NS064545]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS037074, R01NS064545, P01NS055104, R01NS061255] Funding Source: NIH RePORTER	Supported by the China Natural Science Foundation (30571909 and 30872666, L.T.), R37-NS37074, P01-NS55104 (E.H.L.), and RO1NS061255, RO1NS064545 (M.J.W.).	BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Cadichon SB, 2007, J NEUROSURG, V106, P36, DOI 10.3171/ped.2007.106.1.36; Carloni S, 2007, NEUROBIOL DIS, V27, P354, DOI 10.1016/j.nbd.2007.06.009; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Grossetete M, 2008, J CEREBR BLOOD F MET, V28, P752, DOI 10.1038/sj.jcbfm.9600572; Gurer G, 2009, BRAIN PATHOL, V19, P630, DOI 10.1111/j.1750-3639.2008.00226.x; Hayakawa K, 2010, ANN NY ACAD SCI, V1207, P50, DOI 10.1111/j.1749-6632.2010.05728.x; Hong JR, 1999, J VIROL, V73, P5056, DOI 10.1128/JVI.73.6.5056-5063.1999; Kelly KJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1309, DOI 10.1152/ajpcell.00353.2002; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Li H, 2010, INT J NEUROSCI, V120, P683, DOI 10.3109/00207454.2010.513460; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Ma QY, 2011, J CEREBR BLOOD F MET, V31, P881, DOI 10.1038/jcbfm.2010.167; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Matsushita K, 2000, J CEREBR BLOOD F MET, V20, P396, DOI 10.1097/00004647-200002000-00022; Nguyen AP, 2008, CURR NEUROVASC RES, V5, P171, DOI 10.2174/156720208785425710; Northington FJ, 2001, NEUROBIOL DIS, V8, P207, DOI 10.1006/nbdi.2000.0371; Pisetsky DS, 2011, ANTIOXID REDOX SIGN, V15, P2209, DOI 10.1089/ars.2010.3865; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; Qureshi AI, 2003, NEUROSURGERY, V52, P1041, DOI 10.1227/01.NEU.0000057694.96978.BC; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang XY, 2002, STROKE, V33, P1882, DOI 10.1161/01.STR.0000020121.41527.5D; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhao XR, 2009, STROKE, V40, pS92, DOI 10.1161/STROKEAHA.108.533158	35	51	55	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	FEB	2012	43	2					524	531		10.1161/STROKEAHA.111.635672			8	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	885RK	WOS:000299798300041	22076006	Green Accepted, Bronze			2022-02-06	
J	Caeyenberghs, K; Leemans, A; De Decker, C; Heitger, M; Drijkoningen, D; Linden, CV; Sunaert, S; Swinnen, SP				Caeyenberghs, K.; Leemans, A.; De Decker, C.; Heitger, M.; Drijkoningen, D.; Linden, C. Vander; Sunaert, S.; Swinnen, S. P.			Brain connectivity and postural control in young traumatic brain injury patients: A diffusion MRI based network analysis	NEUROIMAGE-CLINICAL			English	Article						Diffusion tensor imaging; Graph theoretical network analysis; Motor control; Structural network; Traumatic brain injury; Postural control	BEHAVIOR RELATIONSHIPS; STRUCTURAL NETWORKS; ANATOMICAL NETWORK; PARIETAL CORTEX; HEAD-INJURY; MILD HEAD; TRACTOGRAPHY; PATTERNS; IDENTIFICATION; ARCHITECTURE	Our previous research on traumatic brain injury (TBI) patients has shown a strong relationship between specific white matter (WM) diffusion properties and motor deficits. The potential impact of TBI-related changes in network organization of the associated WM structural network on motor performance, however, remains largely unknown. Here, we used diffusion tensor imaging (DTI) based fiber tractography to reconstruct the human brain WM networks of 12 TBI and 17 control participants, followed by a graph theoretical analysis. A force platform was used to measure changes in body posture under conditions of compromised proprioceptive and/ or visual feedback. Findings revealed that compared with controls, TBI patients showed higher betweenness centrality and normalized path length, and lower values of local efficiency, implying altered network organization. These results were not merely a consequence of differences in number of connections. In particular, TBI patients displayed reduced structural connectivity in frontal, parieto-premotor, visual, subcortical, and temporal areas. In addition, the decreased connectivity degree was significantly associated with poorer balance performance. We conclude that analyzing the structural brain networks with a graph theoretical approach provides new insights into motor control deficits following brain injury. (C) 2012 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.	[Caeyenberghs, K.; De Decker, C.; Heitger, M.; Drijkoningen, D.; Swinnen, S. P.] Katholieke Univ Leuven, Res Ctr Movement Control & Neuroplast, Motor Control Lab, B-3001 Heverlee, Belgium; [Leemans, A.] Univ Med Ctr Utrecht, Image Sci Inst, Utrecht, Netherlands; [Linden, C. Vander] Ghent Univ Hosp, Dept Phys Med & Rehabil, Child Rehabil Ctr, Ghent, Belgium; [Sunaert, S.] KULeuven, Univ Hosp, Dept Radiol, Louvain, Belgium; [Swinnen, S. P.] Katholieke Univ Leuven, Leuven Res Inst Neurosci & Dis LIND, B-3001 Heverlee, Belgium		Caeyenberghs, K (corresponding author), Katholieke Univ Leuven, Grp Biomed Sci, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Tervuursevest 101, B-3001 Heverlee, Belgium.	Karen.Caeyenberghs@UGent.be	Leemans, Alexander/A-1784-2011	Leemans, Alexander/0000-0002-9306-6126; Caeyenberghs, Karen/0000-0001-7009-6843	Research Programme of the Research Foundation-Flanders (FWO)FWO [G.0482.010, G.A114.11]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P6/29]; postdoctoral fellowship of the Research Foundation-Flanders (FWO)	This work was supported by a grant from the Research Programme of the Research Foundation-Flanders (FWO) (G.0482.010 and G.A114.11) and Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. Caeyenberghs K. is funded by a postdoctoral fellowship of the Research Foundation-Flanders (FWO).	Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bassett DS, 2011, P NATL ACAD SCI USA, V108, P7641, DOI 10.1073/pnas.1018985108; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2009, BRAIN, V132, P684, DOI 10.1093/brain/awn344; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; COGHILL RC, 1994, J NEUROSCI, V14, P4095; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Descoteaux M, 2009, IEEE T MED IMAGING, V28, P269, DOI 10.1109/TMI.2008.2004424; Desmond JE, 1997, J NEUROSCI, V17, P9675; Frank LR, 2002, MAGN RESON MED, V47, P1083, DOI 10.1002/mrm.10156; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Ginestet CE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021570; Ginestet CE, 2011, NEUROIMAGE, V55, P688, DOI 10.1016/j.neuroimage.2010.11.030; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hagmann P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000597; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060; Jantzen KJ, 2004, P NATL ACAD SCI USA, V101, P6815, DOI 10.1073/pnas.0401300101; Jeurissen B, 2011, HUM BRAIN MAPP, V32, P461, DOI 10.1002/hbm.21032; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; Jones DK, 2011, METHODS MOL BIOL, V711, P127, DOI 10.1007/978-1-61737-992-5_6; Kaiser M, 2006, PLOS COMPUT BIOL, V2, P805, DOI 10.1371/journal.pcbi.0020095; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Leemans A., 2009, 17 ANN M INT SOC MAG, DOI DOI 10.1093/OCCMED/KQR069; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Leunissen I., 2012, HUM BRAIN MAPP, DOI 10.1002/hbm.21508; Liu T, 2008, J NEUROPHYSIOL, V100, P1557, DOI 10.1152/jn.00961.2007; Lo CY, 2010, J NEUROSCI, V30, P16876, DOI 10.1523/JNEUROSCI.4136-10.2010; Molenberghs P, 2007, CEREB CORTEX, V17, P2703, DOI 10.1093/cercor/bhl179; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Pollmann S, 2003, NEUROIMAGE, V18, P310, DOI 10.1016/S1053-8119(02)00036-8; RUBIN AM, 1995, AM J OTOL, V16, P216; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Shu N, 2011, CEREB CORTEX, V21, P2565, DOI 10.1093/cercor/bhr039; Shu N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007228; Sporns O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001049; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Toxopeus CM, 2007, NEUROREPORT, V18, P1557, DOI 10.1097/WNR.0b013e3282efa0a2; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van den Heuvel MP, 2010, J NEUROSCI, V30, P15915, DOI 10.1523/JNEUROSCI.2874-10.2010; van Wijk BCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013701; Vandenberghe R, 2001, NEUROIMAGE, V14, P661, DOI 10.1006/nimg.2001.0860; Vos SB, 2012, NEUROIMAGE, V59, P2208, DOI 10.1016/j.neuroimage.2011.09.086; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Wen W, 2011, J NEUROSCI, V31, P1204, DOI 10.1523/JNEUROSCI.4085-10.2011; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Yantis S, 2002, NAT NEUROSCI, V5, P995, DOI 10.1038/nn921; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	64	51	58	1	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2012	1	1					106	115		10.1016/j.nicl.2012.09.011			10	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V37LG	WOS:000209276700013	24179743	Green Published, gold			2022-02-06	
J	Jamora, CW; Young, A; Ruff, RM				Jamora, Christina Weyer; Young, Ashley; Ruff, Ronald M.			Comparison of subjective cognitive complaints with neuropsychological tests in individuals with mild vs more severe traumatic brain injuries	BRAIN INJURY			English	Article						Neuropsychology; traumatic brain injury; self-report; cognition; post-traumatic stress disorder	STRESS-DISORDER SYMPTOMS; CLOSED-HEAD INJURY; MEMORY PERFORMANCE; CHRONIC PAIN; DEPRESSION	Primary objective: The aim of this study was to examine the complex inter-relationship between subjective reports of cognitive impairments and neuropsychological performances in compensation-seeking individuals with traumatic brain injury (TBI) of differing severities. Specifically, this study examined: (a) the participants' neuropsychological test scores and self-reported ratings according to TBI severity; (b) whether there was a predictive relationship between self-report and cognitive test scores; and (c) the influence of emotional functioning on self-reported cognitive functioning. Research design: A multi-group comparative research design was employed. Methods and procedure: An outpatient sample of 61 patients with TBIs using neuropsychological testing, RNBI (Ruff Neurobehavioral Inventory) and clinical interviews. Main outcomes and results: The mild TBI group exhibited greater attentional impairments, while the moderate-to-severe group exhibited greater memory and learning impairments on neuropsychological tests. The mild group reported more cognitive symptoms than their more severely damaged counterparts. The mild TBI participants reported significantly more symptoms of post-traumatic stress disorder (PTSD). Conclusions: Individuals with moderate-to-severe TBI were more accurate when reporting their memory and learning difficulties, whereas individuals with mild TBI were more accurate when reporting attentional difficulties. It is likely that the occurrence of PTSD worsens the outcome of a mild TBI. There likely is a cumulative effect between the PTSD symptoms and the emotional residuals in the mild TBI population.	[Jamora, Christina Weyer; Ruff, Ronald M.] Univ Calif San Francisco, San Francisco, CA 94143 USA		Jamora, CW (corresponding author), 909 Hyde St,Suite 620, San Francisco, CA 94109 USA.	christina.weyerjamora@ucsf.edu			RNBI	Dr. Ruff receives royalties from the RNBI. All of the other authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Bailey CM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P171, DOI 10.1007/0-387-32565-4_8; Bailey CM, 2009, J HEAD TRAUMA REHAB, V24, P123, DOI 10.1097/HTR.0b013e31819c1caa; Beck AT, 2002, CLINICAL ADVANCES IN COGNITIVE PSYCHOTHERAPY: THEORY AND APPLICATION, P29; Benton AL, 1994, MULTILINGUAL APHASIA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Buitenhuis J, 2006, J PSYCHOSOM RES, V61, P681, DOI 10.1016/j.jpsychores.2006.07.008; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; *C REH MED AM, 1993, J HEAD TRAUMA REHAB, V8, P86; *CDCP, 1996, TRAUM BRAIN INJ US E; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Fargo JD, 2004, EPILEPSY BEHAV, V5, P143, DOI 10.1016/j.yebeh.2003.11.023; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; GASS CS, 1990, PSYCHOL ASSESSMENT J, V2, P175, DOI DOI 10.1037//1040-3590.2.2.175; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Hoffman R. G., 1999, J FORENSIC NEUROPSYC, V1, P3, DOI DOI 10.1300/J151V01N02_02; IVERSON G, 2001, J FORENSIC NEUROPSYC, V6, P371; Johansson SH, 2008, BRAIN INJURY, V22, P999, DOI 10.1080/02699050802530573; KAPUR N, 1983, BRIT J PSYCHOL, V74, P409, DOI 10.1111/j.2044-8295.1983.tb01872.x; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; King NS, 2003, HDB CLIN NEUROPSYCHO, P487; Kizilbash AH, 2002, ARCH CLIN NEUROPSYCH, V17, P57, DOI 10.1016/S0887-6177(00)00101-3; KRAUS JF, 1996, NEUROTRAUMA, P12; Larrabee, 1997, Semin Clin Neuropsychiatry, V2, P196; Larrabee, 2005, FORENSIC NEUROPSYCHO, P209; LEESHALEY P, 1996, ARCH CLIN NEUROPSYCH, V8, P203; Meyers JE., 1995, REY COMPLEX FIGURE T; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Mueller J., 2007, NEUROPSYCHIATRIC PRO; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prudic J, 2000, J ECT, V16, P121, DOI 10.1097/00124509-200006000-00004; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; Roth RS, 2005, ARCH PHYS MED REHAB, V86, P1147, DOI 10.1016/j.apmr.2004.10.041; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff R. M., 2003, RUFF NEUROBEHAVIORAL; Ruff R. M., 1999, RUFF LIGHT TRAIL LEA; Ruff R. M, 1996, RUFF FIGURAL FLUENCY; RUFF RM, 1996, RUFF 2 7 SELECTIVE A; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Taber Katherine H, 2009, J Neuropsychiatry Clin Neurosci, V21, P1, DOI 10.1176/appi.neuropsych.21.1.iv; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	57	51	51	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2012	26	1					36	47		10.3109/02699052.2011.635352			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	858HY	WOS:000297787900004	22149443				2022-02-06	
J	Li, J; Jiang, JY				Li, Jin; Jiang, Ji-yao			Chinese Head Trauma Data Bank: Effect of Hyperthermia on the Outcome of Acute Head Trauma Patients	JOURNAL OF NEUROTRAUMA			English	Article						acute head trauma patients; hyperthermia; outcome	PERCUSSION BRAIN-INJURY; PREDICTION; HYPOTHERMIA	Hyperthermia may accentuate the detrimental consequences of brain injury and worsen the outcome of patients with acute head trauma, especially severe traumatic brain injury (TBI). We explored the effect of different magnitudes and durations of hyperthermia in the first 3 days after injury on the outcome of 7145 patients with acute head trauma, including 1626 with severe TBI. The differences in mortality and unfavorable outcome between the normothermia group, mild fever group, moderate fever group, and high fever group were statistically significant (p < 0.001). The mortality and unfavorable outcome of severe TBI patients in the groups also differed significantly (p < 0.001). The mortality and unfavorable outcome of patients with 1 day, 2 days, and 3 days of high fever were significantly increased (p < 0.01). Our data strongly indicate that both degree and duration of early post-trauma hyperthermia are closely correlated with the outcome of acute TBI patients, especially severely injured ones, which indicates that hyperthermia may play a detrimental role in the delayed mechanisms of damage after acute TBI. Prevention of early hyperthermia after acute head trauma is therefore essential to the management of TBI patients.	[Li, Jin; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Dept Neurosurg, Sch Med, Renji Hosp, Shanghai 200127, Peoples R China		Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Sch Med, Renji Hosp, Shanghai 200127, Peoples R China.	Jiangjyb@online.sh.cn			National Health Science [200802093]; National Key Basic Research ProjectNational Basic Research Program of China [2012CB518100]; Science and Technology Committee of ShanghaiShanghai Science & Technology Committee [10JC1409800, 08411951900]; Program for Shanghai Outstanding Medical Academic Leaders	This work was supported by funding from a National Health Science Grant (no. 200802093), the National Key Basic Research Project (no. 2012CB518100), the Science and Technology Committee of Shanghai (no. 10JC1409800 and 08411951900), and the Program for Shanghai Outstanding Medical Academic Leaders.	Alyagari V, 2007, J NEUROL SCI, V261, P39, DOI 10.1016/j.jns.2007.04.030; Badjatia N, 2009, CRIT CARE MED, V37, pS250, DOI 10.1097/CCM.0b013e3181aa5e8d; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cairns Chris J S, 2002, Curr Opin Crit Care, V8, P106, DOI 10.1097/00075198-200204000-00003; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Childs C, 2006, NEUROCRIT CARE, V5, P10, DOI 10.1385/NCC:5:1:10; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Low D, 2009, J NEUROTRAUM, V26, P1177, DOI [10.1089/neu.2008.0841, 10.1089/neu.2008-0841]; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; TEASDALE G, 1974, LANCET, V2, P81; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	21	51	68	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					96	100		10.1089/neu.2011.1753			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300011	22026424	Green Published			2022-02-06	
J	Lifshitz, J; Lisembee, AM				Lifshitz, Jonathan; Lisembee, Amanda M.			Neurodegeneration in the somatosensory cortex after experimental diffuse brain injury	BRAIN STRUCTURE & FUNCTION			English	Article						Disector; Fractionator; Nucleator	TRAUMATIC AXONAL INJURY; NERVE GROWTH-FACTOR; HEAD-INJURY; OPTICAL FRACTIONATOR; CEREBRAL-CORTEX; TOTAL NUMBER; NEURONS; PLASTICITY; ATROPHY; ADULT	Disruption and consequent reorganization of central nervous system circuits following traumatic brain injury may manifest as functional deficits and behavioral morbidities. We previously reported axotomy and neuronal atrophy in the ventral basal (VB) complex of the thalamus, without gross degeneration after experimental diffuse brain injury in adult rats. Pathology in VB coincided with the development of late-onset aberrant behavioral responses to whisker stimulation, which lead to the current hypothesis that neurodegeneration after experimental diffuse brain injury includes the primary somatosensory barrel cortex (S1BF), which receives projection of VB neurons and mediates whisker somatosensation. Over 28 days after midline fluid percussion brain injury, argyrophilic reaction product within superficial layers and layer IV barrels at 1 day progresses into the cortex to subcortical white matter by 7 days, and selective inter-barrel septa and subcortical white matter labeling at 28 days. Cellular consequences were determined by stereological estimates of neuronal nuclear volumes and number. In all cortical layers, neuronal nuclear volumes significantly atrophied by 42-49% at 7 days compared to sham, which marginally attenuated by 28 days. Concomitantly, the number of healthy neurons was reduced by 34-45% at 7 days compared to sham, returning to control levels by 28 days. Progressive neurodegeneration, including argyrophilic reaction product and neuronal nuclear atrophy, indicates injury-induced damage and reorganization of the reciprocal thalamocortical projections that mediate whisker somatosensation. The rodent whisker barrel circuit may serve as a discrete model to evaluate the causes and consequences of circuit reorganization after diffuse brain injury.	[Lifshitz, Jonathan; Lisembee, Amanda M.] Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Coll Med, Dept Phys Med & Rehabil, Lexington, KY 40536 USA		Lifshitz, J (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Off B463,Biomed & Biol Sci Res Bldg,741 S Limesto, Lexington, KY 40536 USA.	JLifshitz@uky.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065052, P30 NS051220]; Kentucky Spinal Cord and Head Injury Research Trust [7-11]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS065052] Funding Source: NIH RePORTER	We are grateful to Dr. John T. Povlishock, Ms. C. Lynn Davis and Ms. Sue Walker for support and assistance in generating the tissue for stereological analysis. We thank the reviewers for constructive criticisms that improved the manuscript. This work was supported, in part, by the National Institutes of Health research grant (R01 NS065052) and core facility grant (P30 NS051220) and the Kentucky Spinal Cord and Head Injury Research Trust (7-11).	Beltramino C A, 1993, NIDA Res Monogr, V136, P101; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Bothwell S, 2001, J NEUROSCI, V21, P4789, DOI 10.1523/JNEUROSCI.21-13-04789.2001; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; de Olmos S, 2009, NEUROSCIENCE, V164, P1347, DOI 10.1016/j.neuroscience.2009.09.022; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Feldman DE, 2005, SCIENCE, V310, P810, DOI 10.1126/science.1115807; FINCH CE, 1993, TRENDS NEUROSCI, V16, P104, DOI 10.1016/0166-2236(93)90134-8; Giaume C, 2009, NEUROSCIENTIST, V15, P351, DOI 10.1177/1073858409336092; GLASSMAN RB, 1994, EXP NEUROL, V125, P125, DOI 10.1006/exnr.1994.1016; Gogolla N, 2007, CURR OPIN NEUROBIOL, V17, P516, DOI 10.1016/j.conb.2007.09.002; GOLD BG, 1991, J NEUROSCI, V11, P943; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNDERSEN HJG, 1988, J MICROSC-OXFORD, V151, P3, DOI 10.1111/j.1365-2818.1988.tb04609.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mikics E, 2008, PHYSIOL BEHAV, V94, P341, DOI 10.1016/j.physbeh.2008.01.023; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; O'Leary D D, 1994, Curr Opin Neurobiol, V4, P535, DOI 10.1016/0959-4388(94)90054-X; PAXINOS G, 1998, RAT BRAIN STEREOTAXI, V4; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; RICH KM, 1989, J NEUROCYTOL, V18, P569, DOI 10.1007/BF01187077; RICH KM, 1984, J COMP NEUROL, V230, P110, DOI 10.1002/cne.902300110; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Sa MJ, 2000, ACTA NEUROPATHOL, V99, P643, DOI 10.1007/s004010051175; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SOFRONIEW MV, 1993, J NEUROSCI, V13, P5263, DOI 10.1523/JNEUROSCI.13-12-05263.1993; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano GG, 2008, CELL, V135, P422, DOI 10.1016/j.cell.2008.10.008; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Waite P, 1995, RAT NERVOUS SYSTEM; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	64	51	51	0	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653			BRAIN STRUCT FUNCT	Brain Struct. Funct.	JAN	2012	217	1					49	61		10.1007/s00429-011-0323-z			13	Anatomy & Morphology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anatomy & Morphology; Neurosciences & Neurology	922UC	WOS:000302572800005	21597967	Green Accepted			2022-02-06	
J	Schumm, JA; Chard, KM				Schumm, Jeremiah A.; Chard, Kathleen M.			Alcohol and Stress in the Military	ALCOHOL RESEARCH-CURRENT REVIEWS			English	Article						Alcohol consumption; alcohol use and abuse; problematic alcohol use; stress; stress reaction; posttraumatic stress disorder; military personnel; active military; veteran; combat; military sexual trauma; causal pathways; self-medication; genetic vulnerability; co-occurring disorders	SUBSTANCE USE DISORDERS; TRAUMATIC BRAIN-INJURY; ENVIRONMENTAL-INFLUENCES; COMBAT EXPOSURE; BINGE DRINKING; PTSD; IRAQ; PREVALENCE; DEPENDENCE; SYMPTOMS	Although research has independently linked stress experienced by military personnel to both alcohol use and posttraumatic stress disorder, more recently researchers have noted that there also is a significant overlap between stress reactions and alcohol use in veterans and active-duty service members. This overlap seems to be most understood in individuals who have experienced combat or military sexual trauma. This article will provide a brief review of some potential causal mechanisms underlying this relationship, including self-medication and genetic vulnerability models. It also addresses the possible implications for assessment and treatment of military personnel with co-occurring disorders.	[Schumm, Jeremiah A.; Chard, Kathleen M.] Cincinnati Vet Affairs Med Ctr, Posttraumat Stress Disorder & Anxiety Disorders D, Cincinnati, OH USA; [Schumm, Jeremiah A.; Chard, Kathleen M.] Univ Cincinnati, Cincinnati, OH USA		Schumm, JA (corresponding author), Cincinnati Vet Affairs Med Ctr, Posttraumat Stress Disorder & Anxiety Disorders D, Cincinnati, OH USA.		Schumm, Jeremiah/I-9634-2019				Ames G, 2004, ALCOHOL RES HEALTH, V28, P252; Bray RM, 2007, ADDICTION, V102, P1092, DOI 10.1111/j.1360-0443.2007.01841.x; Bremner JD, 1996, AM J PSYCHIAT, V153, P369; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brown PJ, 1999, PSYCHOL ADDICT BEHAV, V13, P115, DOI 10.1037/0893-164X.13.2.115; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Department of Defense Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Departmental Veterans Affairs, 2009, CONS C PRACT REC TRE; Dickstein BD, 2010, J TRAUMA STRESS, V23, P331, DOI 10.1002/jts.20523; FOA EB, 1986, PSYCHOL BULL, V99, P20, DOI 10.1037/0033-2909.99.1.20; Foa EB, 2009, EFFECTIVE TREATMENTS, V2nd; Ford JD, 2007, J COUNS DEV, V85, P475, DOI 10.1002/j.1556-6678.2007.tb00616.x; FREDMAN S.J., 2010, S 44 ANN CONV ASS CO; Gradus JL, 2008, J STUD ALCOHOL DRUGS, V69, P348, DOI 10.15288/jsad.2008.69.348; GRANT BF, 1999, ADDICTIONS COMPREHEN, P9; Harwood HJ, 2009, MIL MED, V174, P728, DOI 10.7205/MILMED-D-03-9008; Hien DA, 2004, AM J PSYCHIAT, V161, P1426, DOI 10.1176/appi.ajp.161.8.1426; Hien DA, 2009, J CONSULT CLIN PSYCH, V77, P607, DOI 10.1037/a0016227; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobsen LK, 2001, AM J PSYCHIAT, V158, P1184, DOI 10.1176/appi.ajp.158.8.1184; Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI 10.1016/j.addbeh.2010.03.023; Khantzian Edward, 1999, TREATING ADDICTION H; Maguen S, 2011, PSYCHOL TRAUMA-US, V3, P21, DOI 10.1037/a0019897; Maguen S, 2010, J TRAUMA STRESS, V23, P86, DOI 10.1002/jts.20434; McLeod DS, 2001, J TRAUMA STRESS, V14, P259, DOI 10.1023/A:1011157800050; Messer SC, 2004, SOC PSYCH PSYCH EPID, V39, P419, DOI 10.1007/s00127-004-0757-1; Miller W.R., 2002, MOTIVATIONAL INTERVI; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Najavits L., 2002, SEEKING SAFETY TREAT; Ouimette PC, 1999, PSYCHOL ADDICT BEHAV, V13, P105, DOI 10.1037/0893-164X.13.2.105; Scherrer JF, 2008, COMPR PSYCHIAT, V49, P297, DOI 10.1016/j.comppsych.2007.11.001; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Stahre MA, 2009, AM J PREV MED, V36, P208, DOI 10.1016/j.amepre.2008.10.017; Suris A, 2008, TRAUMA VIOLENCE ABUS, V9, P250, DOI 10.1177/1524838008324419; TANELLAN T., 2008, INVISIBLE WOUNDS WAR; Xian H, 2000, DRUG ALCOHOL DEPEN, V61, P95, DOI 10.1016/S0376-8716(00)00127-7	36	51	51	0	21	NATL INST ALCOHOL ABUSE  ALCOHOLISM	ROCKVILLE	6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA	1535-7414	1930-0573		ALCOHOL RES-CURR REV	Alcohol Res.-Curr. Rev.		2012	34	4					401	407					7	Substance Abuse	Social Science Citation Index (SSCI)	Substance Abuse	066QB	WOS:000313234200004	23584106				2022-02-06	
J	Lucas, S				Lucas, Sylvia			Headache Management in Concussion and Mild Traumatic Brain Injury	PM&R			English	Article							EPIDEMIOLOGY	Headache is one of the most common symptoms after traumatic brain injury (TBI), and posttraumatic headache (PTH) may be part of a constellation of symptoms that is seen in the postconcussive syndrome. PTH has no defining clinical features; currently it is classified as a secondary headache based on its close temporal relationship to the injury. A growing number of studies are characterizing PTH by using primary headache classifications. Moderate to severe PTH that is often disabling may be classified as migraine or probable migraine and is found in substantial numbers of individuals. Recent data from civilian adult, pediatric, and military populations all find that PTH may be more of a chronic problem than previously thought, with a prevalence of close to half of the injured population. In addition, if PTH definitions are strictly adhered to, then many cases of PTH may be missed, thus underestimating the scope of the problem. New headaches may be reported well after the 7 days required for diagnosis of PTH by the guidelines of the International Classification of Headache Disorders, 2nd edition. A history of headache before a head injury occurs and female gender are possible risk factors for headache after TBI. Treatment of PTH may be acute or preventive, and recommendations are made for the use of migraine-specific acute therapy when indicated. Preventive therapy may be considered when PTH is frequent, disabling, or refractory to acute therapies. Comorbid conditions should be considered when choosing an appropriate preventive therapy. The symptom of headache as a "return to play" or "return to duty" barrier must be viewed in the context of other symptoms of mild TBI. PM R 2011;3:S406-S412	Univ Washington, Med Ctr, Seattle, WA 98195 USA		Lucas, S (corresponding author), Univ Washington, Med Ctr, 1959 NE Pacific St,Box 356097, Seattle, WA 98195 USA.	lucass@uw.edu					Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Blume K, PHYS MED REHABIL CLI; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; GAWEL MJ, 1993, HEADACHE, V33, P96, DOI 10.1111/j.1526-4610.1993.hed3302096.x; Hoffman J, 2011, APMR ABSTRACT 2011; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lerman B, 2011, J NEUROTRAUM, V28, pA16; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; MCBEATH JG, 1994, HEADACHE, V34, P148, DOI 10.1111/j.1526-4610.1994.hed3403148.x; Olesen J, 2006, HEADACHES, P859; Olesen J, 2006, HEADACHES, P441; OLESEN J, 2006, HEADCHES, P251; Packard Russell C, 2005, Curr Pain Headache Rep, V9, P59, DOI 10.1007/s11916-005-0076-6; Ramadan NM, EVIDENCE BASED GUIDE; Rapoport A, 1996, HEADACHE, V36, P14, DOI 10.1046/j.1526-4610.1996.3601014.x; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61	24	51	51	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2011	3	10		3			S406	S412		10.1016/j.pmrj.2011.07.016			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	966YK	WOS:000305873100008	22035683				2022-02-06	
J	Bryan, C; Anestis, M				Bryan, Craig; Anestis, Michael			Reexperiencing Symptoms and the Interpersonal-Psychological Theory of Suicidal Behavior Among Deployed Service Members Evaluated for Traumatic Brain Injury	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						suicide; PTSD; pain; interpersonal-psychological theory	POSTTRAUMATIC-STRESS-DISORDER; RISK; VETERANS; SAMPLES; ADULTS; DEATH; TESTS; PTSD	Recent evidence suggests that military suicide rates now exceed those of the general public. Numerous recent efforts to address this growing concern have focused on the interpersonal psychological theory of suicidal behavior (IPTS). In the current study, we explored the relationships among reexperiencing symptoms of posttraumatic stress disorder and the three components of the IPTS in a sample of deployed military personnel examined for traumatic brain injury. Results indicated that reexperiencing symptoms were directly related to the acquired capability for suicide, but their relationships to perceived burdensomeness and thwarted belongingness were statistically explained by general mental health distress. Results indicate that mental rehearsal of painful and provocative experiences may have an impact on suicide risk. (C) 2011 Wiley Periodicals, Inc. J Clin Psychol 67: 856-865, 2011.	[Bryan, Craig] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA; [Anestis, Michael] Florida State Univ, Tallahassee, FL 32306 USA		Bryan, C (corresponding author), 7550 W IH-10,Suite 1325, San Antonio, TX 78229 USA.	bryanc3@uthscsa.edu		Bryan, Craig/0000-0002-9714-0733			Anestis M., 2009, J MENTAL HLTH COUNSE, V31, P60, DOI DOI 10.17744/MEHC.31.1.U394H1470; ANESTIS MD, J PSYCHIAT IN PRESS; Bender T. W., 2007, IMPULSIVITY SU UNPUB; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner L.A., 2008, J MENTAL HEALTH COUN, V30, P211, DOI [10.17744/mehc.30.3.n6418tm72231j606, DOI 10.17744/MEHC.30.3.N6418TM72231J606]; Briggs N., 2006, DISS ABSTR INT B, V37, p4755B; BRYAN C, J CLIN PSYC IN PRESS; Bryan CJ, 2010, PERS INDIV DIFFER, V48, P347, DOI 10.1016/j.paid.2009.10.023; CelestHealth Solutions, 2008, CELESTHEALTH SOL CLI; Hartl TL, 2005, J NERV MENT DIS, V193, P464, DOI 10.1097/01.nmd.0000168238.13252.b3; HENDIN H, 1991, AM J PSYCHIAT, V148, P586; Joiner T.E., 2005, WHY PEOPLE DIE SUICI; Joiner TE, 2009, J ABNORM PSYCHOL, V118, P634, DOI 10.1037/a0016500; Kopta SM, 2002, PSYCHOTHER RES, V12, P413, DOI 10.1093/ptr/12.4.413; Kotler M, 2001, J NERV MENT DIS, V189, P162, DOI 10.1097/00005053-200103000-00004; Krysinska K, 2010, ARCH SUICIDE RES, V14, P1, DOI 10.1080/13811110903478997; LINEHAN MM, 1983, J CONSULT CLIN PSYCH, V51, P276, DOI 10.1037/0022-006X.51.2.276; Lorge E, 2008, ARMY RESPONDS RISING; Osborne J. W., 2008, BEST PRACTICES QUANT, P239; Osman A, 2001, ASSESSMENT, V8, P443, DOI 10.1177/107319110100800409; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; ROTHBERG JM, 1990, JAMA-J AM MED ASSOC, V264, P2241, DOI 10.1001/jama.264.17.2241; Selby EA, 2007, BEHAV MODIF, V31, P867, DOI 10.1177/0145445507300874; Van Orden KA, 2008, J CONSULT CLIN PSYCH, V76, P72, DOI 10.1037/0022-006X.76.1.72; Van Orden KA, 2010, PSYCHOL REV, V117, P575, DOI 10.1037/a0018697; Weathers F.W., 1993, 9 ANN C ISTSS	26	51	51	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	SEP	2011	67	9					856	865		10.1002/jclp.20808			10	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	811WN	WOS:000294248200003	21520082				2022-02-06	
J	Meng, YL; Xiong, Y; Mahmood, A; Zhang, YL; Qu, CS; Chopp, M				Meng, Yuling; Xiong, Ye; Mahmood, Asim; Zhang, Yanlu; Qu, Changsheng; Chopp, Michael			Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						angiogenesis; cell proliferation; erythropoietin; neurogenesis; rat; sensorimotor; spatial learning; traumatic brain injury	ANEURYSMAL SUBARACHNOID HEMORRHAGE; ENDOTHELIAL GROWTH-FACTOR; ENHANCES NEUROGENESIS; FUNCTIONAL RECOVERY; SPATIAL MEMORY; DOUBLE-BLIND; STROKE; ANGIOGENESIS; CELLS; THERAPY	Object. Delayed (24 hours postinjury) treatment with erythropoietin (EPO) improves functional recovery following experimental traumatic brain injury (TBI). In this study, the authors tested whether therapeutic effects of delayed EPO treatment for TBI are dose dependent in an attempt to establish an optimal dose paradigm for the delayed EPO treatment. Methods. Experimental TBI was performed in anesthetized young adult male Wistar rats using a controlled cortical impact device. Sham animals underwent the same surgical procedure without injury. The animals (8 rats/group) received 3 intraperitoneal injections of EPO (0,1000,3000,5000, or 7000 U/kg body weight, at 24,48, and 72 hours) after TBI. Sensorimotor and cognitive functions were assessed using a modified neurological severity score and foot fault test, and Morris water maze tests, respectively. Animals were killed 35 days after injury, and the brain sections were stained for immunohistochemical analyses. Results. Compared with the saline treatment, EPO treatment at doses from 1000 to 7000 U/kg did not alter lesion volume but significantly reduced hippocampal neuron loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, and significantly improved sensorimotor function and spatial learning. The animals receiving the medium dose of 5000 U/kg exhibited a significant improvement in histological and functional outcomes compared with the lower or higher EPO dose groups. Conclusions. These data demonstrate that delayed (24 hours postinjury) treatment with EPO provides dose-dependent neurorestoration, which may contribute to improved functional recovery after TBI, implying that application of an optimal dose of EPO is likely to increase successful preclinical and clinical trials for treatment of TBI. (DOI: 10.3171/2011.3.JNS101721)	[Meng, Yuling; Xiong, Ye; Mahmood, Asim; Zhang, Yanlu; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA		Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS62002, P01 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS042345] Funding Source: NIH RePORTER	This work was supported by NIH Grant Nos. R01 NS62002 (to Dr. Xiong) and P01 NS42345 (to Drs. Mahmood and Chopp).	BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cariou A, 2008, RESUSCITATION, V76, P397, DOI 10.1016/j.resuscitation.2007.10.003; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Cotena S, 2008, PANMINERVA MED, V50, P185; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2005, NEUROSURGERY, V56, P821, DOI 10.1227/01.NEU.0000156493.00904.7E; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2007, DRUG NEWS PERSPECT, V20, P315, DOI 10.1358/dnp.2007.20.5.1120219; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Jia LF, 2010, STROKE, V41, P2071, DOI 10.1161/STROKEAHA.110.586198; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lieutaud T, 2008, J NEUROTRAUM, V25, P1179, DOI 10.1089/neu.2008.0591; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Minnerup J, 2009, STROKE, V40, P3113, DOI 10.1161/STROKEAHA.109.555789; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nirula R, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/209848; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; Popoli P, 2007, ANN NY ACAD SCI, V1112, P219, DOI 10.1196/annals.1415.033; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Springborg JB, 2007, ACTA NEUROCHIR, V149, P1089, DOI 10.1007/s00701-007-1284-z; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tseng MY, 2009, J NEUROSURG, V111, P171, DOI 10.3171/2009.3.JNS081332; VELLY L, 2010, PHARMACOL THERAPEUT, V28, P445; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2008, J CEREBR BLOOD F MET, V28, P1361, DOI 10.1038/jcbfm.2008.32; Wang L, 2011, J CEREBR BLOOD F MET, V31, P640, DOI 10.1038/jcbfm.2010.138; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077	68	51	55	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2011	115	3					550	560		10.3171/2011.3.JNS101721			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	816FG	WOS:000294583500017	21495821	Green Accepted			2022-02-06	
J	Plurad, DS; Talving, P; Lam, L; Inaba, K; Green, D; Demetriades, D				Plurad, David S.; Talving, Peep; Lam, Lydia; Inaba, Kenji; Green, Donald; Demetriades, Demetrios			Early Vasopressor Use in Critical Injury Is Associated With Mortality Independent From Volume Status	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Critical Care; Vasopressor; Hypovolemia; Resuscitation; Mortality; Hemorrhagic shock; Vasopressin	FLUID RESUSCITATION; HEMORRHAGIC-SHOCK	Background: Complications of excessive crystalloid after critical injury have increased interest in vasopressor support. However, it is hypothesized that vasopressor use in patients who are under-resuscitated is associated with death. We performed this study to determine whether volume status is associated with increased mortality in the critically injured exposed to early vasopressors. Methods: The intensive care unit database at a Level I center was queried for all adult admissions surviving for >24 hours from January 1, 2001, to December 31, 2008. Patients with spinal cord injury and severe traumatic brain injury were excluded. The vasopressor group [Vaso (+)] was exposed to dopamine, epinephrine, phenylephrine, norepinephrine, or arginine vasopressin within 24 hours of admission. Demographic and injury data were studied including intensive care unit admission central venous pressure. Hypovolemia [Hypov (+)] was considered an admission central venous pressure <= 8 mm Hg. The Vaso (+) group was analyzed to determine whether Hypov (+) was independently associated with death. Results: Of 1,349 eligible patients, 26% (351) were Vaso (+). Mortality was 43.6% (153) in the Vaso (+) versus 4.2% (42) in the Vaso (-) group (17.60 [12.10-25.60], <0.01). Vasopressor exposure was associated with death independent of injury severity. In Vaso (+) patients, Hypov (+) was not associated with mortality, whereas Emergency Department admission Glasgow Coma Scale <= 8 and multiple vasopressor use were. Conclusions: Vasopressor exposure early after critical injury is independently associated with death and mortality is increased regardless of fluid status. Although it is not advisable to withhold support with impending cardiovascular collapse, use of any vasopressor during ongoing resuscitation should be approached with extreme caution regardless of volume status.	[Plurad, David S.; Talving, Peep; Lam, Lydia; Inaba, Kenji; Green, Donald; Demetriades, Demetrios] LAC USC Dept Surg, Div Trauma & Surg Crit Care, Los Angeles, CA 90033 USA		Plurad, DS (corresponding author), Navy Trauma Training Ctr, 1200 N State St,Room 1050, Los Angeles, CA 90033 USA.	plurad@usc.edu	Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013; INABA, KENJI/AAC-8532-2020	Talving, Peep/0000-0002-9741-2073; 			Alam HB, 2007, SURG CLIN N AM, V87, P55, DOI 10.1016/j.suc.2006.09.015; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Cavus E, 2008, J TRAUMA, V64, P641, DOI 10.1097/TA.0b013e3181637a6c; Cohn SM, 2007, J TRAUMA, V62, pS56, DOI 10.1097/TA.0b013e318065ab06; Collier B, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2009.05.003; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Devlin JJ, 2008, J TRAUMA, V65, P498, DOI 10.1097/TA.0b013e31817de454; Fangio P, 2005, J TRAUMA, V58, P978, DOI 10.1097/01.TA.0000163435.39881.26; Haas T, 2004, J TRAUMA, V57, P177, DOI 10.1097/01.TA.0000044357.25191.1B; Joshi GP, 2005, ANESTH ANALG, V101, P601, DOI 10.1213/01.ANE.0000159171.26521.31; LANSING A M, 1962, J Trauma, V2, P386, DOI 10.1097/00005373-196207000-00007; Lee JH, 2009, J EMERG MED, V37, P376, DOI 10.1016/j.jemermed.2008.07.004; Meybohm P, 2007, J TRAUMA, V62, P640, DOI 10.1097/01.ta.0000240962.62319.c8; Plurad D, 2007, J TRAUMA, V63, P1, DOI 10.1097/TA.0b013e318068b1ed; Plurad D, 2006, J TRAUMA, V61, P1120, DOI 10.1097/01.ta.0000244737.54032.98; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Sharma RM, 2005, ANESTH ANALG, V101, P833, DOI 10.1213/01.ANE.0000175209.61051.7F; Sperry JL, 2008, J TRAUMA, V64, P9, DOI 10.1097/TA.0b013e31815dd029; Voelckel WG, 2003, CRIT CARE MED, V31, P2552, DOI 10.1097/01.CCM.0000089944.54391.D6; Wenzel V, 2008, BEST PRACT RES-CLIN, V22, P299, DOI 10.1016/j.bpa.2008.02.003	20	51	52	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2011	71	3					565	572		10.1097/TA.0b013e3182213d52			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	818MX	WOS:000294756900014	21908995				2022-02-06	
J	Schneider, HJ; Schneider, M; Kreitschmann-Andermahr, I; Tuschy, U; Wallaschofski, H; Fleck, S; Faust, M; Renner, CIE; Kopczak, A; Saller, B; Buchfelder, M; Jordan, M; Stalla, GK				Schneider, Harald J.; Schneider, Manfred; Kreitschmann-Andermahr, Ilonka; Tuschy, Ulrich; Wallaschofski, Henri; Fleck, Steffen; Faust, Michael; Renner, Caroline I. E.; Kopczak, Anna; Saller, Bernhard; Buchfelder, Michael; Jordan, Martina; Stalla, Guenter K.			Structured Assessment of Hypopituitarism after Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage in 1242 Patients: The German Interdisciplinary Database	JOURNAL OF NEUROTRAUMA			English	Article						growth hormone deficiency; Hypopituitarism; subarachnoid hemorrhage; traumatic brain injury	ANTERIOR-PITUITARY FUNCTION; GROWTH-HORMONE DEFICIENCY; DYSFUNCTION; PREVALENCE; INSUFFICIENCY; ADULTS	Clinical studies have demonstrated that traumatic brain injury (TBI) and aneurysmal subarachnoid hemorrhage (SAH) are frequent causes of long-term disturbances of hypothalamo-pituitary function. This study aimed to assess the prevalence and associated factors of post-traumatic hypopituitarism in a large national registry of patients with TBI and SAH. Data were collected from 14 centers in Germany and Austria treating patients for TBI or SAH and performing endocrine assessments. Data were collected using a structured, internet-based study sheet, obtaining information on clinical, radiological, and hormonal parameters. A total of 1242 patients (825 TBI, age 43.5 +/- 19.7 years; 417 SAH, age 49.7 +/- 11.8 years) were included. We studied the prevalence of hypopituitarism reported based on different definitions of laboratory values and stimulation tests. Stimulation tests for the corticotropic and somatotropic axes were performed in 26% and 22% of the patients, respectively. The prevalence of hypopituitarism in the chronic phase (at least 5 months after the event) by laboratory values, physician diagnoses, and stimulation tests, was 35%, 36%, and 70%, respectively. Hypopituitarism was less common in the acute phase. According to the frequency of endocrine dysfunction, pituitary hormone secretion was impaired in the following sequence: ACTH, LH/FSH, GH, and TSH. TBI patients with abnormal stimulation tests had suffered from more severe TBI than patients with normal stimulation tests. In conclusion, our data confirm that hypopituitarism is a common complication of TBI and SAH. It is possible that patients with a higher likelihood of hypopituitarism were selected for endocrine stimulation tests.	[Schneider, Harald J.] Univ Munich, Med Klin Innenstadt, D-80336 Munich, Germany; [Schneider, Manfred; Kopczak, Anna] Neurol Clin Bad Aibling, Aibling, Germany; [Kreitschmann-Andermahr, Ilonka] RWTH Hosp Aachen, Dept Neurosurg, Aachen, Germany; [Tuschy, Ulrich] Helios Hosp, Div Endocrinol, Dept Med 2, Erfurt, Germany; [Wallaschofski, Henri] Ernst Moritz Arndt Univ Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany; [Fleck, Steffen] Ernst Moritz Arndt Univ Greifswald, Dept Neurosurg, Greifswald, Germany; [Faust, Michael] Univ Hosp Cologne, Dept Internal Med 2, Cologne, Germany; [Renner, Caroline I. E.] Univ Leipzig, NRZ Ctr Neurorehabil, Leipzig, Germany; [Buchfelder, Michael] Univ Hosp Erlangen, Dept Neurosurg, Erlangen, Germany; [Jordan, Martina] ClinSupport GmbH, Erlangen, Germany; [Stalla, Guenter K.] Max Planck Inst Psychiat, Neuroendcrinol Grp, D-80804 Munich, Germany		Schneider, HJ (corresponding author), Univ Munich, Med Klin Innenstadt, Ziemssenstr 1, D-80336 Munich, Germany.	harald.schneider@med.uni-muenchen.de		Renner, Caroline/0000-0003-4047-7017; Kopczak, Anna/0000-0002-5037-2342	Pfizer Pharma GmbHPfizer; PfizerPfizer; NovartisNovartis; LillyEli Lilly; Novo NordiskNovo Nordisk	The authors are grateful to all the centers who contributed patient data to the registry. The database is supported by an independent investigator grant from Pfizer Pharma GmbH. Data storage and statistical analyses were performed by Elmar Beck, Anfomed, Germany. The members of the advisory board of the database were: Prof. Gunther-Karl Stalla, Prof. Ilonka Kreitschmann-Andermahr, Prof. Eberhard Konig, Prof. Michael Buchfelder, and Prof. Eberhard Uhl. The following investigators recruited more than one patient to the database: Dr. Kreitschmann-Andermahr, RWTH Aachen; Dr. Stalla, MPI Munchen; Dr. Konig/Dr. Schneider, Bad Aibling; Dr. Tuschy, Helios-Kliniken Erfurt; Dr. Steube, Neurol. Kl. Bad Neustadt; Dr. Buchfelder/Dr. Kreutzer, Kopfklinik Erlangen; Dr. Sudhoff, Fachklinik Enzensberg; Dr. Faust, Universitat Koln; Dr. Lange, VS Schwenningen; Dr. Oertel, Universitat Giessen; Dr. Renner, Universitat Leipzig; Dr. Fleck/Dr. Wallaschofski, University Greifswald; Dr. Berg, Uni Essen; and Dr. Uhl, Klagenfurt.; H.J.S. received research grants from Pfizer, travel grants from Novartis, Pfizer, and Lilly, speaker fees from Novo Nordisk, Pfizer, and Lilly, and is a member of the German KIMS (Pfizer International Metabolic Survey) board. M.S. received research grants and travel grants from Pfizer and Novo Nordisk. I.K.A. received research grants form Pfizer and Novo Nordisk, and travel grants from Pfizer, Novo Nordisk, and Novartis, and is a member of the German KIMS (Pfizer International Metabolic Survey) board. H.W. received research grants, speaker fees, and travel grants from Pfizer and Novo Nordisc, and is a member of the German KIMS (Pfizer International Metabolic Survey) board. S.F. received travel grants from Novo Nordisk and Pfizer. M.F. is a member of the German KIMS (Pfizer International Metabolic Survey) board. A.K. received travel grants from Pfizer. B.S. is an employee of Pfizer Global Pharmaceuticals. M.B. received research grants, speaker fees, and travel grants from Pfizer, Novo Nordisk, and Novartis, and is a member of the German KIMS (Pfizer International Metabolic Survey) board. M.J. is an employee of Clinsupport, Erlangen. G.K.S. received research grants, speaker fees, and travel grants from Pfizer, Novo Nordisk, and Novartis. C.I.E.R., and U.T. report no conflicts of interest.	Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Klose M, 2010, CLIN ENDOCRINOL, V73, P95, DOI 10.1111/j.1365-2265.2010.03791.x; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Kreitschmann-Andermahr I, 2011, EXP CLIN ENDOCR DIAB, V119, P15, DOI 10.1055/s-0030-1253414; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Pavlovic D, 2010, EUR J NEUROL, V17, P696, DOI 10.1111/j.1468-1331.2009.02910.x; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436	27	51	53	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1693	1698		10.1089/neu.2011.1887			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000002	21671796				2022-02-06	
J	Tsai, MC; Chen, WJ; Tsai, MS; Ching, CH; Chuang, JI				Tsai, Ming Che; Chen, Wei Ju; Tsai, Ming Shi; Ching, Cheng Hsin; Chuang, Jih Ing			Melatonin attenuates brain contusion-induced oxidative insult, inactivation of signal transducers and activators of transcription 1, and upregulation of suppressor of cytokine signaling-3 in rats	JOURNAL OF PINEAL RESEARCH			English	Article						brain contusion; glutathione; inducible nitric oxide synthetase; interleukine-6; melatonin; signal transducers and activators of transcription 1; suppressor of cytokine signaling 1	NF-KAPPA-B; INTRACRANIAL-PRESSURE; CEREBRAL-ISCHEMIA; GENE-EXPRESSION; NITRIC-OXIDE; CELL-DEATH; IN-VIVO; INJURY; STRESS; STAT1	The induction of oxidative stress and inflammation has been closely linked in traumatic brain injury (TBI). Transcriptional factors of signal transducers and activators of transcription (STAT) proteins are redox sensitive and participate in the regulation of cytokine signaling. Previous studies demonstrated that melatonin protects neurons through its antioxidative and anti-inflammatory effects in various neuropathological conditions. However, the effect of melatonin on STAT activity after TBI has not yet been explored. In this study, we used a controlled weight-drop TBI model and found that brain contusion induced oxidative stress (a decreased level of total glutathione and an increased ratio of oxidized glutathione to total glutathione), a reduction in STAT1 DNA-binding activity, and consequently neuronal loss in a contusion depth-dependent manner. A significant increased mRNA expression of suppressor of cytokine signaling (SOCS3), inducible nitric oxide synthetase (iNOS), and interleukine-6 (IL-6), but a decreased protein expression of protein inhibitor of activated STAT (PIAS1), was found 24 hr after brain contusion. SOCS3 and PIAS1 are endogenous negative regulators of STAT1. Moreover, the combination of intraperitoneal and local (presoaked in gelfoam and placed on the traumatic cortex) administration of melatonin had the most pronounced influence in inhibiting all effects except the PIAS1 downregulation induced by brain contusion. The results suggest that SOCS-3 upregulation and oxidative stress may contribute to the STAT1 inactivation after TBI. Melatonin protects neurons from TBI by reducing oxidative stress, STAT1 inactivation, and upregulation of SOCS-3 and pro-inflammatory cytokines.	[Chen, Wei Ju; Ching, Cheng Hsin; Chuang, Jih Ing] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; [Tsai, Ming Che] Chung Shan Med Univ Hosp, Dept Emergency Med, Taichung, Taiwan; [Tsai, Ming Che] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Tsai, Ming Shi] Sinying Hosp, Dept Hlth, Tainan, Taiwan		Chuang, JI (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan.	jichuang@mail.ncku.edu.tw			National Science Council in TaiwanMinistry of Science and Technology, Taiwan [NSC 95-2320-B006-053, NSC96-2320-B-006-043-MY3]	This work was supported by the National Science Council in Taiwan, grant no. NSC 95-2320-B006-053 and NSC96-2320-B-006-043-MY3.	ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Chen ST, 2002, J PINEAL RES, V32, P262, DOI 10.1034/j.1600-079X.2002.01871.x; Choi EY, 2011, J PINEAL RES, V50, P197, DOI 10.1111/j.1600-079X.2010.00829.x; Choi JS, 2008, NEUROSCI LETT, V441, P323, DOI 10.1016/j.neulet.2008.06.051; Chuang JI, 2004, J PINEAL RES, V36, P117, DOI 10.1046/j.1600-079X.2003.00107.x; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Das A, 2010, J PINEAL RES, V48, P157, DOI 10.1111/j.1600-079X.2009.00739.x; Dziennis S, 2008, REV NEUROSCIENCE, V19, P341; Emery B, 2006, P NATL ACAD SCI USA, V103, P7859, DOI 10.1073/pnas.0602574103; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Gorina R, 2007, GLIA, V55, P1313, DOI 10.1002/glia.20542; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hong Y, 2010, J PINEAL RES, V49, P201, DOI 10.1111/j.1600-079X.2010.00786.x; Hoppe JB, 2010, J PINEAL RES, V48, P230, DOI 10.1111/j.1600-079X.2010.00747.x; Hung MW, 2008, J PINEAL RES, V44, P214, DOI 10.1111/j.1600-079X.2007.00514.x; Jung JE, 2009, J NEUROSCI, V29, P7003, DOI 10.1523/JNEUROSCI.1110-09.2009; Kabe Y, 2005, ANTIOXID REDOX SIGN, V7, P395, DOI 10.1089/ars.2005.7.395; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; Kim HS, 2007, CELL SIGNAL, V19, P454, DOI 10.1016/j.cellsig.2006.09.003; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li L, 2010, CANCER RES, V70, P8222, DOI 10.1158/0008-5472.CAN-10-0894; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; Madan E, 2008, BIOCHEM BIOPH RES CO, V377, P1232, DOI 10.1016/j.bbrc.2008.10.158; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; McCormick J, 2006, FASEB J, V20, P2115, DOI 10.1096/fj.06-6188fje; Monroe RK, 2006, FREE RADICAL BIO MED, V41, P493, DOI 10.1016/j.freeradbiomed.2006.04.023; Monroe RK, 2009, NEUROTOXICOLOGY, V30, P589, DOI 10.1016/j.neuro.2009.03.007; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Negi G, 2011, J PINEAL RES, V50, P124, DOI 10.1111/j.1600-079X.2010.00821.x; Osuka K, 2010, BRAIN RES, V1332, P12, DOI 10.1016/j.brainres.2010.03.046; Park SJ, 2009, FREE RADICAL BIO MED, V46, P1694, DOI 10.1016/j.freeradbiomed.2009.03.026; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Reed TT, 2009, J NEUROSCI RES, V87, P408, DOI 10.1002/jnr.21872; Sarafian TA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009532; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shuai K, 2006, CELL RES, V16, P196, DOI 10.1038/sj.cr.7310027; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smith PD, 2009, NEURON, V64, P617, DOI 10.1016/j.neuron.2009.11.021; Spangenburg EE, 2006, J PHYSIOL-LONDON, V572, P839, DOI 10.1113/jphysiol.2005.104315; Stephanou A, 2004, J CELL MOL MED, V8, P519, DOI 10.1111/j.1582-4934.2004.tb00476.x; Takagi Y, 2002, J CEREBR BLOOD F MET, V22, P1311, DOI 10.1097/01.WCB.0000034148.72481.F4; Terui K, 2004, BIOCHEM J, V380, P203, DOI 10.1042/BJ20031891; Timmons SD, 2010, CRIT CARE MED, V38, pS431, DOI 10.1097/CCM.0b013e3181ec57ab; Tocharus J, 2010, J PINEAL RES, V48, P347, DOI 10.1111/j.1600-079X.2010.00761.x; Toklu HZ, 2009, FREE RADICAL RES, V43, P658, DOI 10.1080/10715760902988843; Tsai MC, 2007, SHOCK, V27, P527, DOI 10.1097/01.shk.0000245032.31859.f2; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wang JP, 2002, P NATL ACAD SCI USA, V99, P16209, DOI 10.1073/pnas.252454799; Xie Y, 2009, ENDOCRINOLOGY, V150, P1122, DOI 10.1210/en.2008-1241; Yadav A, 2005, J BIOL CHEM, V280, P31830, DOI 10.1074/jbc.M501316200; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	57	51	53	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0742-3098			J PINEAL RES	J. Pineal Res.	SEP	2011	51	2					233	245		10.1111/j.1600-079X.2011.00885.x			13	Endocrinology & Metabolism; Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	805SC	WOS:000293748300011	21545521				2022-02-06	
J	Kirkwood, MW; Hargrave, DD; Kirk, JW				Kirkwood, Michael W.; Hargrave, David D.; Kirk, John W.			The Value of the WISC-IV Digit Span Subtest in Detecting Noncredible Performance during Pediatric Neuropsychological Examinations	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Digit span; Reliable digit span; Wechsler intelligence scale for children; Symptom validity testing; Response bias; Postconcussion; Mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; WORD MEMORY TEST; CHILDREN; TOMM; POPULATION; CAPACITY; SAMPLE; TESTS; SCALE	In adult populations, research on methodologies to identify negative response bias has grown exponentially in the last two decades. Far less work has focused on methods appropriate for children. Although several recent studies have demonstrated the appropriateness of using stand-alone symptom validity tests with younger populations, a near absence of pediatric work has investigated embedded validity indicators. The present study examined the classification value of several scores derived from the WISC-IV Digit Span subtest. The sample consisted of 274 clinically referred mild traumatic brain injury patients aged 8 through 16 years. Fourteen percent of the participants failed both the Medical Symptom Validity Test and Test of Memory Malingering, which was used as the criterion for noncredible effort. For age-corrected scaled scores, a score of <= 5 resulted in the optimal cut-score, yielding sensitivity of 51% and specificity of 96%. For Reliable Digit Span, the optimal cut-score was <= 6, with sensitivity of 51% and specificity of 92%. Although only moderately sensitive, Digit Span scores are likely to have good utility in identifying noncredible performance in relatively high-functioning older children and adolescents. Indeed, classification statistics produced in this pediatric sample compare favorably with those produced in many real-world adult patients.	[Kirkwood, Michael W.] Childrens Hosp, Concuss Program, Dept Phys Med & Rehabil, Aurora, CO 80045 USA; Univ Colorado, Sch Med, Aurora, CO USA		Kirkwood, MW (corresponding author), Childrens Hosp, Concuss Program, Dept Phys Med & Rehabil, B285,13123 E 16th Ave, Aurora, CO 80045 USA.	kirkwood.michael@tchden.org					Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; BABIKIAN T, 2007, ASSESSMENT FEIGNED C, P00103; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Boone K.B., 2007, ASSESSMENT FEIGNED C; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Cohen J., 2013, STAT POWER ANAL BEHA; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Duncan SA, 2002, ASSESSMENT, V9, P56, DOI 10.1177/1073191102009001007; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Flaro L., 2009, NEUROPSYCHOLOGY MALI, P369; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P., 2004, MANUAL MED SYMPTOM V; Green P., 2007, ASSESSMENT FEIGNED C; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Harrison AG, 2010, ASSESSMENT, V17, P283, DOI 10.1177/1073191109348590; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry G. K., 2005, FORENSIC NEUROPSYCHO, P205; KIRK JW, 2011, CHILD NEUROPSYCHOL, DOI DOI 10.1080/09297049.2010.533166; Kirkwood M. W., PEDIAT FORE IN PRESS; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; McCaffrey R. J., 2009, NEUROPSYCHOLOGY MALI, P377; Suhr J.A., 2007, ASSESSMENT MALINGERE, P131; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler D, 2003, WECHSLER INTELLIGENC; Ylioja SG, 2009, ARCH CLIN NEUROPSYCH, V24, P729, DOI 10.1093/arclin/acp078	42	51	51	1	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2011	26	5					377	384		10.1093/arclin/acr040			8	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	799QC	WOS:000293300200001	21602179	Bronze			2022-02-06	
J	Tavender, EJ; Bosch, M; Green, S; O'Connor, D; Pitt, V; Phillips, K; Bragge, P; Gruen, RL				Tavender, Emma J.; Bosch, Marije; Green, Sally; O'Connor, Denise; Pitt, Veronica; Phillips, Kate; Bragge, Peter; Gruen, Russell L.			Quality and Consistency of Guidelines for the Management of Mild Traumatic Brain Injury in the Emergency Department	ACADEMIC EMERGENCY MEDICINE			English	Article							CLINICAL-PRACTICE GUIDELINES; IMPLEMENTATION; LIMITATIONS; DIAGNOSIS; CHILDREN	Objectives: The objective was to provide an overview of the recommendations and quality of evidence-based clinical practice guidelines (CPGs) for the emergency management of mild traumatic brain injury (mTBI), with a view to informing best practice and improving the consistency of recommendations. Methods: Electronic searches of health databases (MEDLINE, EMBASE, The Cochrane Library, PsycINFO), CPG clearinghouse websites, CPG developer websites, and Internet search engines up to January 2010 were conducted. CPGs were included if 1) they were published in English and freely accessible, 2) their scope included the management of mTBI in the emergency department (ED), 3) the date of last search was within the past 10 years (2000 onward), 4) systematic methods were used to search for evidence, and 5) there was an explicit link between the recommendations and the supporting evidence. Four authors independently assessed the quality of the included CPGs using the Appraisal of Guidelines, Research and Evaluation (AGREE) Instrument. The authors extracted and categorized recommendations according to initial clinical assessment, imaging, management, observation, discharge planning, and patient information and follow-up. Results: The search identified 18 potential CPGs, of which six met the inclusion criteria. The included CPGs varied in scope, target population, size, and guideline development processes. Four CPGs were assessed as "strongly recommended." The majority of CPGs did not provide information about the level of stakeholder involvement (mean AGREE standardized domain score = 57%, range = 25% to 81%), nor did they address the organizational/cost implications of applying the recommendations or provide criteria for monitoring and review of recommendations in practice (mean AGREE standardized domain score = 46.6%, range = 19% to 94%). Recommendations were mostly consistent in terms of the use of the Glasgow Coma Scale (GCS) score (adult and pediatric) to assess the level of consciousness, initial assessment criteria, the use of computed tomography (CT) scanning as imaging investigation of choice, and the provision of patient information. The CPGs defined mTBI in a variety of ways and described different rules to determine the need for CT scanning and therefore used different criteria to identify high-risk patients. Conclusions: Higher-quality CPGs for mTBI are consistent in their recommendations about assessment, imaging, and provision of patient information. There is not, however, an agreed definition of mTBI, and the quality of future CPGs could be improved with better reporting of stakeholder involvement, procedures for updating, and greater consideration of the applicability of the recommendations (cost implications, monitoring procedures). Nevertheless, guideline developers may benefit from adapting existing CPGs to their local context rather than investing in developing CPGs de novo. ACADEMIC EMERGENCY MEDICINE 2011; 18:880-889 (C) 2011 by the Society for Academic Emergency Medicine	[Tavender, Emma J.; Pitt, Veronica; Bragge, Peter; Gruen, Russell L.] Monash Univ, Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia; [Bosch, Marije; Green, Sally; O'Connor, Denise; Phillips, Kate] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3181, Australia		Tavender, EJ (corresponding author), Monash Univ, Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia.	emma.tavender@monash.edu	O'Connor, Denise/ABC-6655-2020	O'Connor, Denise/0000-0002-6836-122X; Green, Sally Elizabeth/0000-0002-9564-9050; Tavender, Emma/0000-0002-7230-712X; Bragge, Peter/0000-0003-0745-5131	Victorian Neurotrauma Initiative; Department of Surgery, Monash UniversityMonash University; Monash UniversityMonash University	The Neurotrauma Evidence Translation Project is funded by the Victorian Neurotrauma Initiative. Emma Tavender is funded by a Faculty Postgraduate Research Scholarship (FPRS), Department of Surgery, Monash University.; Conflict of interest: KP = Transport Accident Commission, Victoria Australia-Clinical Advisor on Client treatment programs; Independent Rehabilitation Services-Rehabilitation of neurotrauma patients; Solicitors-Expert opinion of Neurotrauma patients; Monash University-PhD Scholarship. The other authors have no additional disclosures or conflicts of interest to report.	American College of Radiology, ACR APPR CRIT HEAD T; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brouwers MC, 2010, CAN MED ASSOC J, V182, P1045, DOI 10.1503/cmaj.091714; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US E; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cluzeau F, 2003, QUAL SAF HEALTH CARE, V12, P18; Cluzeau FA, 1999, INT J QUAL HEALTH C, V11, P21, DOI 10.1093/intqhc/11.1.21; CUSHMAN JG, PRACTICE MANAGEMENT; de Andrade AF, 2001, WORLD J SURG, V25, P1186; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Fervers B, 2006, INT J QUAL HEALTH C, V18, P167, DOI 10.1093/intqhc/mzi108; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Grimshaw J, 2006, J GEN INTERN MED, V21, pS14, DOI 10.1111/j.1525-1497.2006.00357.x; Grol R, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c306; Hegarty K, 2009, BRIT J GEN PRACT, V59, P322, DOI 10.3399/bjgp09X420581; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Kamerling SN, 2003, PEDIATR EMERG CARE, V19, P431, DOI 10.1097/01.pec.0000092590.40174.1f; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keris V, 2007, WORLD J SURG, V31, P1352, DOI 10.1007/s00268-007-9002-x; Misso ML, 2008, MED J AUSTRALIA, V189, P394, DOI 10.5694/j.1326-5377.2008.tb02086.x; *MOT ACC AUTH NEW, GUID MILD TRAUM BRAI; National Institute for Health and Clinical Excellence, HEAD INJ TRIAG ASS I; *NEW S WAL DEP HLT, AC MAN HEAD INJ CHIL; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; REED D, ADULT TRAUMA CLIN PR; *ROYAL COLL PAED C, EARL MAN PAT HEAD IN; Rusnak M, 2008, BRATISL MED J, V109, P374; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Scottish Intercollegiate Guidelines Network, 2009, EARL MAN PAT HEAD IN; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; The AGREE Collaboration, AGREE INSTR; Turner T, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-45; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527	40	51	52	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2011	18	8			SI		880	889		10.1111/j.1553-2712.2011.01134.x			10	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Emergency Medicine	807AJ	WOS:000293860400014	21843224	Bronze			2022-02-06	
J	Mustafa, AG; Wang, JA; Carrico, KM; Hall, ED				Mustafa, Ayman G.; Wang, Juan A.; Carrico, Kimberly M.; Hall, Edward D.			Pharmacological inhibition of lipid peroxidation attenuates calpain-mediated cytoskeletal degradation after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						alpha-spectrin; calpain; lipid peroxidation; traumatic brain injury; U-83836E	ALPHA-II-SPECTRIN; ACUTE MITOCHONDRIAL DYSFUNCTION; CONTROLLED CORTICAL IMPACT; EXPERIMENTAL HEAD-INJURY; CYCLOSPORINE-A ANALOG; NA+/K+-PUMP ATPASE; BREAKDOWN PRODUCTS; CEREBROSPINAL-FLUID; OXIDATIVE DAMAGE; MOUSE MODEL	P>Free radical-induced lipid peroxidation (LP) is critical in the evolution of secondary injury following traumatic brain injury (TBI). Previous studies in our laboratory demonstrated that U-83836E, a potent LP inhibitor, can reduce post-TBI LP along with an improved maintenance of mouse cortical mitochondrial bioenergetics and calcium (Ca2+) buffering following severe (1.0 mm; 3.5 m/s) controlled cortical impact TBI (CCI-TBI). Based upon this preservation of a major Ca2+ homeostatic mechanism, we have now performed dose-response and therapeutic window analyses of the ability of U-83836E to reduce post-traumatic calpain-mediated cytoskeletal (alpha-spectrin) proteolysis in ipsilateral cortical homogenates at its 24 h post-TBI peak. In the dose-response analysis, mice were treated with a single i.v. dose of vehicle or U-83836E (0.1, 0.3, 1.3, 3.0, 10.0 or 30.0 mg/kg) at 15 min after injury. U-83836E produced a dose-related attenuation of alpha-spectrin degradation with the maximal decrease being achieved at 3.0 mg/kg. Next, the therapeutic window was tested by delaying the single 3 mg/kg i.v. dose from 15 min post-injury out to 1, 3, 6 or 12 h. No reduction in alpha-spectrin degradation was observed when the treatment delay was 1 h or longer. However, in a third experiment, we re-examined the window with repeated U-83836E dosing (3.0 mg/kg i.v. followed by 10 mg/kg i.p. maintenance doses at 1 and 3 h after the initial i.v. dose) which significantly reduced 24 h alpha-alpha-spectrin degradation even when treatment initiation was withheld until 12 h post-TBI. These results demonstrate the relationship between post-TBI LP, disruptions in neuronal Ca2+ homeostasis and calpain-mediated cytoskeletal damage.	[Mustafa, Ayman G.; Wang, Juan A.; Carrico, Kimberly M.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Mustafa, Ayman G.] Jordan Univ Sci & Technol, Dept Anat, Irbid, Jordan		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone Str,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013	mustafa, ayman/0000-0002-0341-7149	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1P30 NS051220, 1P01 NS058484]; Kentucky Spinal Cord & Head Injury Research Trust; Jordan University of Science and Technology; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058484, P30NS051220, R01NS046566] Funding Source: NIH RePORTER	These studies were supported by NIH grants 1P30 NS051220 and 1P01 NS058484 and funding from the Kentucky Spinal Cord & Head Injury Research Trust and from the Jordan University of Science and Technology.	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Aikman J, 2006, DEV NEUROSCI-BASEL, V28, P457, DOI 10.1159/000094171; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Cardali S, 2006, J Neurosurg Sci, V50, P25; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Durmaz R, 2003, CAN J NEUROL SCI, V30, P143, DOI 10.1017/S0317167100053415; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gadelha FR, 1997, ARCH BIOCHEM BIOPHYS, V345, P243, DOI 10.1006/abbi.1997.0259; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.0.CO;2-H; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Jacquard C, 2006, FASEB J, V20, P1021, DOI 10.1096/fj.05-5085fje; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; KIMURA M, 1992, BRIT J PHARMACOL, V107, P488, DOI 10.1111/j.1476-5381.1992.tb12772.x; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; MUNNS PL, 1995, FREE RADICAL BIO MED, V18, P467, DOI 10.1016/0891-5849(94)00163-E; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Ozsuer H, 2005, NEUROSURG REV, V28, P143, DOI 10.1007/s10143-004-0374-1; Pedersen WA, 1999, EXP NEUROL, V155, P1, DOI 10.1006/exnr.1998.6890; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Racay P, 1997, BIOCHEM MOL BIOL INT, V41, P647; RANDALL RD, 1992, J NEUROSCI, V12, P1882; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROHN TT, 1993, BIOCHEM PHARMACOL, V46, P525, DOI 10.1016/0006-2952(93)90530-A; Rohn TT, 1996, BIOCHEM PHARMACOL, V51, P471, DOI 10.1016/0006-2952(95)02222-8; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Spiteller G, 2006, FREE RADICAL BIO MED, V41, P362, DOI 10.1016/j.freeradbiomed.2006.03.013; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Violi F, 1999, DIABETES-METAB RES, V15, P283, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<283::AID-DMRR42>3.0.CO;2-U; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6	72	51	51	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2011	117	3					579	588		10.1111/j.1471-4159.2011.07228.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	749KJ	WOS:000289464500020	21361959	Green Accepted, Bronze			2022-02-06	
J	Danckwardt, S; Gantzert, AS; Macher-Goeppinger, S; Probst, HC; Gentzel, M; Wilm, M; Grone, HJ; Schirmacher, P; Hentze, MW; Kulozik, AE				Danckwardt, Sven; Gantzert, Anne-Susan; Macher-Goeppinger, Stephan; Probst, Hans Christian; Gentzel, Marc; Wilm, Matthias; Groene, Hermann-Josef; Schirmacher, Peter; Hentze, Matthias W.; Kulozik, Andreas E.			p38 MAPK Controls Prothrombin Expression by Regulated RNA 3 ' End Processing	MOLECULAR CELL			English	Article							TRAUMATIC BRAIN-INJURY; POLY(A) SITE SELECTION; PRE-MESSENGER-RNA; GENE-EXPRESSION; MOLECULAR-MECHANISMS; CANCER DEVELOPMENT; VENOUS THROMBOSIS; PROTEASE NEXIN-1; 3'-END FORMATION; FACTOR CSTF-64	Thrombin is a key protease involved in blood coagulation, complement activation, inflammation, angiogenesis, and tumor invasion. Although induced in many (patho-)physiological conditions, the underlying mechanisms controlling prothrombin expression remained enigmatic. We have now discovered that prothrombin expression is regulated by a post-transcriptional regulatory mechanism responding to stress and inflammation. This mechanism is triggered by external stimuli that activate p38 MAPK. In turn, p38 MAPK upmodulates canonical 3' end processing components and phosphorylates the RNA-binding proteins FBP2 and FBP3, which inhibit 3' end processing of mRNAs, such as prothrombin mRNA, that bear a defined upstream sequence element (USE) in their 3'UTRs. Upon phosphorylation, FBP2 and FBP3 dissociate from the USE, making it accessible to proteins that stimulate 3' end processing. We provide in vivo evidence suggesting the importance of this mechanism in inflammatory hypercoagulation and tumor invasion. Regulated 3' end processing thus emerges as a key mechanism of gene regulation with broad biological and medical implications.	[Danckwardt, Sven; Gantzert, Anne-Susan; Hentze, Matthias W.; Kulozik, Andreas E.] European Mol Biol Lab, Mol Med Partnership Unit, Heidelberg, Germany; [Danckwardt, Sven; Gantzert, Anne-Susan; Kulozik, Andreas E.] Univ Heidelberg, Dept Pediat Oncol Hematol & Immunol, Heidelberg, Germany; [Macher-Goeppinger, Stephan; Schirmacher, Peter] Univ Heidelberg, Inst Pathol, D-6900 Heidelberg, Germany; [Probst, Hans Christian] Johannes Gutenberg Univ Mainz, Inst Immunol, D-6500 Mainz, Germany; [Gentzel, Marc] Max Planck Inst Mol Cell Biol & Genet MPI CBG, Dresden, Germany; [Wilm, Matthias] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 2, Ireland; [Groene, Hermann-Josef] German Canc Res Ctr, Dept Cellular & Mol Pathol, D-6900 Heidelberg, Germany		Hentze, MW (corresponding author), European Mol Biol Lab, Mol Med Partnership Unit, Heidelberg, Germany.	hentze@embl.de; andreas.kulozik@med.uni-heidelberg.de	Kulozik, Andreas/AAO-2432-2020; Hentze, Matthias W/V-3980-2017	Hentze, Matthias W/0000-0002-4023-7876; Gentzel, Marc/0000-0002-4482-6010; PROBST, Hans Christian/0000-0002-7926-0651; Wilm, Matthias/0000-0002-5461-6834	University of Heidelberg; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG); Fritz-Thyssen Stiftung; DFG ForschergruppeGerman Research Foundation (DFG) [FOR 426]; Lautenschlager Research Prize	We are grateful to T. Heise, J. Patton, A. Krainer, B. Blencowe, C. and J. Lutz, H.-J. Chung, D. Levens, A.-B. Shyu, J. Izaquierdo, J. Valcarcel, M. Sattler, A. Lamond, V. Lohmann, B. Jockusch for providing plasmids, cell lines, and antibodies. We thank the Tissue Bank of the National Center for Tumor Diseases (NCT), Heidelberg, Germany, for providing patient samples. We thank P. Ivanov, N. Gehring, S. Breit, G. Neu-Yilik, O. Reddy Bandapalli, and the team of the Molecular Medicine Partnership Unit for advice and discussions. This work was funded by the Young Investigator Award fellowship from the University of Heidelberg (to S.D. and to S.M.G.), by grants from the Deutsche Forschungsgemeinschaft (to S.D. and to A.E.K.), the Fritz-Thyssen Stiftung (to A.E.K.), the DFG Forschergruppe (FOR 426: "Complex RNA-protein interactions in the maturation and function of eukaryotic mRNA"), and funds from the Lautenschlager Research Prize (to A.E.K. and M.W.H.).	Barabino SML, 1999, CELL, V99, P9, DOI 10.1016/S0092-8674(00)80057-4; Blom JW, 2005, JAMA-J AM MED ASSOC, V293, P715, DOI 10.1001/jama.293.6.715; Boccaccio C, 2005, CANCER RES, V65, P8579, DOI 10.1158/0008-5472.CAN-05-2277; Boven LA, 2003, J IMMUNOL, V170, P2638, DOI 10.4049/jimmunol.170.5.2638; Briata P, 2005, MOL CELL, V20, P891, DOI 10.1016/j.molcel.2005.10.021; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Chapman J, 2006, AUTOIMMUN REV, V5, P528, DOI 10.1016/j.autrev.2006.02.011; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Citron BA, 2000, J NEUROTRAUM, V17, P1191, DOI 10.1089/neu.2000.17.1191; Danckwardt S, 2004, BLOOD, V104, P428, DOI 10.1182/blood-2003-08-2894; Danckwardt S, 2008, EMBO J, V27, P482, DOI 10.1038/sj.emboj.7601932; Danckwardt S, 2007, EMBO J, V26, P2658, DOI 10.1038/sj.emboj.7601699; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gehring NH, 2001, NAT GENET, V28, P389, DOI 10.1038/ng578; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Hall-Pogar T, 2007, RNA, V13, P1103, DOI 10.1261/rna.577707; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; Hu L, 2008, CANCER RES, V68, P4666, DOI 10.1158/0008-5472.CAN-07-6276; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Ji Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008419; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kazerouninia A, 2010, RNA, V16, P197, DOI 10.1261/rna.1622010; Kim S, 1998, J NEUROSCI RES, V53, P304, DOI 10.1002/(SICI)1097-4547(19980801)53:3<304::AID-JNR4>3.0.CO;2-E; Kuderer NM, 2009, J CLIN ONCOL, V27, P4902, DOI 10.1200/JCO.2009.22.4584; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Licatalosi DD, 2008, NATURE, V456, P464, DOI 10.1038/nature07488; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lutz CS, 2008, ACS CHEM BIOL, V3, P609, DOI 10.1021/cb800138w; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Miller GJ, 2004, J THROMB HAEMOST, V2, P2107, DOI 10.1111/j.1538-7836.2004.01011.x; Millevoi S, 2009, NUCLEIC ACIDS RES, V37, P4672, DOI 10.1093/nar/gkp470; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; Murakami H, 2003, THROMB RES, V111, P81, DOI 10.1016/S0049-3848(03)00404-3; Nierodzik ML, 2006, CANCER CELL, V10, P355, DOI 10.1016/j.ccr.2006.10.002; Palumbo JS, 2007, BLOOD, V110, P133, DOI 10.1182/blood-2007-01-065995; Pawlicki JM, 2010, TRENDS CELL BIOL, V20, P52, DOI 10.1016/j.tcb.2009.10.004; Petralia GA, 2005, NAT CLIN PRACT ONCOL, V2, P356, DOI 10.1038/ncponc0225; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Riek-Burchardt M, 2002, NEUROSCI LETT, V329, P181, DOI 10.1016/S0304-3940(02)00645-6; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Schulman S, 2000, NEW ENGL J MED, V342, P1953, DOI 10.1056/NEJM200006293422604; Shell SA, 2005, J BIOL CHEM, V280, P39950, DOI 10.1074/jbc.M508848200; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Sullivan KD, 2009, MOL CELL, V34, P322, DOI 10.1016/j.molcel.2009.04.024; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wilhelm BT, 2008, NATURE, V453, P1239, DOI 10.1038/nature07002; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Xiang KH, 2010, NATURE, V467, P729, DOI 10.1038/nature09391; Yin XL, 2010, AM J PATHOL, V176, P1600, DOI 10.2353/ajpath.2010.090406; Zoubine MN, 1996, DEV BIOL, V179, P447, DOI 10.1006/dbio.1996.0274	66	51	54	2	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1097-2765	1097-4164		MOL CELL	Mol. Cell	FEB 4	2011	41	3					298	310		10.1016/j.molcel.2010.12.032			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	722UM	WOS:000287460500008	21292162	Bronze			2022-02-06	
J	Chiodo, S; Tessitore, A; Cortis, C; Lupo, C; Ammendolia, A; Iona, T; Capranica, L				Chiodo, Salvatore; Tessitore, Antonio; Cortis, Cristina; Lupo, Corrado; Ammendolia, Antonio; Iona, Teresa; Capranica, Laura			EFFECTS OF OFFICIAL TAEKWONDO COMPETITIONS ON ALL-OUT PERFORMANCES OF ELITE ATHLETES	JOURNAL OF STRENGTH AND CONDITIONING RESEARCH			English	Article						countermovement jump; handgrip; heart rate; blood lactate	HEART-RATE; RESPONSES; LACTATE; INJURIES; PROFILE; POWER; PRACTITIONERS; RELIABILITY; RECOVERY; EXERCISE	Chiodo, S, Tessitore, A, Cortis, C, Lupo, C, Ammendolia, A, Iona, T, and Capranica, L. Effects of official Taekwondo competitions on all-out performances of elite athletes. J Strength Cond Res 25(2): 334-339, 2011-This study investigated physiological and performance aspects of 15 (4 women and 11 men) elite Taekwondo athletes (24.0 +/- 5.7 years) during their National Championship. The load of the competition was evaluated by means of heart rate (HR) and blood lactate (La). Pre and postmatch countermovement jump (CMJ), and handgrip performances were compared (p < 0.05). The match imposed a high load (HR > 85% of individual HRmax = 92 +/- 12%; La = 6.7 +/- 2.5 mmol.L-1) on athletes. After the match, better (p < 0.0001) CMJ (men: 43.9 +/- 5.2 cm; women: 30.8 +/- 2.3 cm) and worst (p = 0.006) handgrip performances (men: 459 +/- 87 N; women: 337 +/- 70 N) were found with respect to prematch ones (CMJ: men = 40.8 +/- 4.9 cm, women = 28.2 +/- 2.5 cm; handgrip: men = 486 +/- 88 N, women: 337 +/- 70 N). Results indicate that the intermittent activity of the Taekwondo competition elicits a high neuromuscular activation of the lower limbs. Instead, the decreases in grip strength could be because of the repeated concussions on the upper limbs used to protect from the opponent's kicks and punches directed toward the scoring area of the torso. Practically, these results urge coaches to structure training sessions that enable athletes to maintain their upper limb strength during their match.	[Tessitore, Antonio; Cortis, Cristina; Lupo, Corrado; Capranica, Laura] Univ Rome Foro Italico, Dept Human Movement & Sport Sci, Rome, Italy; [Chiodo, Salvatore; Ammendolia, Antonio; Iona, Teresa] Magna Graecia Univ Catanzaro, Expt & Clin Med Dept, Catanzaro, Italy; [Chiodo, Salvatore; Lupo, Corrado] Italian Taekwondo Federat, Rome, Italy		Capranica, L (corresponding author), Univ Rome Foro Italico, Dept Human Movement & Sport Sci, Rome, Italy.	laura.capranica@uniroma4.it	Ammendolia, Antonio/K-2155-2016; CORTIS, Cristina/AAB-9960-2020; Tessitore, Antonio/H-9922-2014; Iona, Teresa/O-6414-2019	Ammendolia, Antonio/0000-0002-2828-2455; CORTIS, Cristina/0000-0001-9643-5532; Tessitore, Antonio/0000-0002-3542-0991; Iona, Teresa/0000-0002-1439-320X; LUPO, Corrado/0000-0002-5372-135X; Lupo, Corrado/0000-0003-1546-8573	FITA; University of Rome Foro Italico	The authors would like to express their gratitude to the Taekwondo athletes who participated in the study and to the General Secretary of the FITA Angelo Cito for his assistance in the organization of the experimental sessions. Furthermore, the technical support of Microgate Italy is greatly appreciated. The study was supported by FITA and the University of Rome Foro Italico.	Aggeloussis N, 2007, J SPORT SCI MED, V6, P6; Amtmann JA, 2008, J STRENGTH COND RES, V22, P645, DOI 10.1519/JSC.0b013e318166018e; Aziz Abdul Rashid, 2002, J Sports Sci Med, V1, P147; BANGSBO J, 1994, J APPL PHYSIOL, V77, P1890, DOI 10.1152/jappl.1994.77.4.1890; BANGSBO J, 2002, SCI SOCCER, P51; Beis K, 2001, EUR J SPORT TRAUMA R, V23, P130; Beis K, 2007, J SPORT SCI MED, V6, P45; BILLOWS D, 2004, J SPORTS SCI, V22, P524; Bishop D, 2001, INT J SPORTS MED, V22, P525, DOI 10.1055/s-2001-17611; Bouhlel E, 2006, SCI SPORT, V21, P285, DOI 10.1016/j.scispo.2006.08.003; Bridge CA, 2007, J STRENGTH COND RES, V21, P718; BROOKS GA, 1991, MED SCI SPORT EXER, V23, P895; Butios S, 2007, J SPORT MED PHYS FIT, V47, P179; Cetin C, 2005, SAUDI MED J, V26, P848; CHUANG TY, 1992, J BIOMECH ENG-T ASME, V114, P346, DOI 10.1115/1.2891394; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; Heller J, 1998, J SPORT SCI, V16, P243, DOI 10.1080/026404198366768; Iide K, 2008, J STRENGTH COND RES, V22, P839, DOI 10.1519/JSC.0b013e31816a5af6; Iwai K, 2008, J STRENGTH COND RES, V22, P350, DOI 10.1519/JSC.0b013e3181635d25; JACKSON AS, 1985, PHYSICIAN SPORTSMED, V13, P76, DOI 10.1080/00913847.1985.11708790; JUBIAK N, 2008, J STRENGTH COND RES, V22, P1194; Kazemi M, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-26; Kazemi M, 2006, J SPORT SCI MED, V5, P114; Koh JO, 2004, CLIN J SPORT MED, V14, P72, DOI 10.1097/00042752-200403000-00004; KOMI PV, 1978, MED SCI SPORT EXER, V10, P261; Koshida S, 2008, J STRENGTH COND RES, V22, P1584, DOI 10.1519/JSC.0b013e31817b03a1; Kravitz L, 2003, J STRENGTH COND RES, V17, P104; Kubo J, 2006, J STRENGTH COND RES, V20, P654; Lin WL, 2006, SCI SPORT, V21, P291, DOI 10.1016/j.scispo.2006.04.005; Markovic G, 2005, COLLEGIUM ANTROPOL, V29, P93; Melhim AF, 2001, BRIT J SPORT MED, V35, P231, DOI 10.1136/bjsm.35.4.231; Peolsson A, 2001, J REHABIL MED, V33, P36; Pieter W, 2000, SCI COACHING OLYMPIC; PIETER W, 1998, KINESIOLOGY, V30, P22, DOI DOI 10.1589/JPTS.28.231; Probst MM, 2007, J STRENGTH COND RES, V21, P451, DOI 10.1519/00124278-200705000-00028; Sbriccoli P, 2007, J STRENGTH COND RES, V21, P738; Slinde F, 2008, J STRENGTH COND RES, V22, P640, DOI 10.1519/JSC.0b013e3181660475; Tessitore A, 2007, J STRENGTH COND RES, V21, P1183; Tessitore A, 2007, J STRENGTH COND RES, V21, P745; Thompson WR, 1991, SPORTS MED TRAINING, V3, P49; Toskovic NN, 2004, J SPORT MED PHYS FIT, V44, P164; Toskovic NN, 2002, J STRENGTH COND RES, V16, P278; Vetter RE, 2007, J STRENGTH COND RES, V21, P819	43	51	52	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1064-8011	1533-4287		J STRENGTH COND RES	J. Strength Cond. Res.	FEB	2011	25	2					334	339		10.1519/JSC.0b013e3182027288			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	709SI	WOS:000286461300007	21233770				2022-02-06	
J	Kemp, K; Gordon, D; Wraith, DC; Mallam, E; Hartfield, E; Uney, J; Wilkins, A; Scolding, N				Kemp, K.; Gordon, D.; Wraith, D. C.; Mallam, E.; Hartfield, E.; Uney, J.; Wilkins, A.; Scolding, N.			Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						fusion; mesenchymal stem cells; Purkinje cells; stem cell; transplantation	MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; BONE-MARROW-CELLS; STROMAL CELLS; NEURONS; ENCEPHALOMYELITIS; CYTOKINES; TRANSPLANTATION; EXPRESSION	Aims: We explored whether cellular fusion and heterokaryon formation between human and rodent cells in the cerebellum of mice occurs after intravenous injection of human bone marrow-derived mesenchymal stem cells (MSCs). The influence of central nervous system inflammation on this process was also assessed. In addition, we examined whether tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma, factors associated with inflammation, increase cellular fusion between human MSCs and rodent cerebellar neurons in vitro. Methods and results: Human MSCs were intravenously injected into mice with experimental autoimmune encephalomyelitis (EAE) and control mice. After 22 days, mouse Purkinje cells expressing human Golgi Zone were found within the Purkinje cell layer of the cerebellum, indicating that fusion and heterokaryon formation had occurred. The numbers of heterokaryons in the cerebellum were markedly increased in mice with EAE compared with control mice. Rodent cerebellar neuronal cells labelled with enhanced green fluorescent proteinin vitro were co-cultured with human bone marrow-derived MSCs in the presence of TNF-alpha and/or IFN-gamma to determine their influence on fusion events. We found that fusion between MSCs and cerebellar neurons did occur in vitro and that the frequency of cellular fusion increased in the presence of TNF-alpha and/or IFN-gamma. Conclusions: We believe that this is the first paper to define fusion and heterokaryon formation between human MSCs and rodent cerebellar neurons in vivo. We have also demonstrated that fusion between these cell populations occurs in vitro. These findings indicate that MSCs may be potential therapeutic agents for cerebellar diseases, and other neuroinflammatory and neurodegenerative disorders.	[Kemp, K.; Gordon, D.; Mallam, E.; Wilkins, A.; Scolding, N.] Univ Bristol, Multiple Sclerosis & Stem Cell Grp, Inst Clin Neurosci, Bristol, Avon, England; [Wraith, D. C.] Univ Bristol, Dept Cellular & Mol Med, Bristol, Avon, England; [Hartfield, E.; Uney, J.] Univ Bristol, Henry Wellcome Labs Integrat Neurosci & Endocrino, Bristol, Avon, England		Kemp, K (corresponding author), Frenchay Hosp, Burden Ctr, MS Labs, 1st Floor, Bristol BS16 1JB, Avon, England.	kevin.kemp@bristol.ac.uk	; Kemp, Kevin/B-9755-2017	Wraith, David/0000-0003-2147-5614; Scolding, Neil/0000-0001-9177-1043; Kemp, Kevin/0000-0003-1465-1309	Multiple Sclerosis Society of Great Britain and Northern Ireland; Wellcome TrustWellcome TrustEuropean Commission; Ataxia UK; Ataxia UK [7160] Funding Source: researchfish	We would like to acknowledge the Multiple Sclerosis Society of Great Britain and Northern Ireland, the Wellcome Trust and Ataxia UK for support.	Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102; Bae JS, 2007, STEM CELLS, V25, P1307, DOI 10.1634/stemcells.2006-0561; Bae JS, 2005, HUM GENE THER, V16, P1006, DOI 10.1089/hum.2005.16.1006; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Bennaceur-Griscelli A, 2001, BLOOD, V97, P435, DOI 10.1182/blood.V97.2.435; Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921; Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood-2002-06-1830; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; English K, 2007, IMMUNOL LETT, V110, P91, DOI 10.1016/j.imlet.2007.04.001; Gordon D, 2008, NEUROSCI LETT, V448, P71, DOI 10.1016/j.neulet.2008.10.040; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Johansson CB, 2008, NAT CELL BIOL, V10, P575, DOI 10.1038/ncb1720; Juedes AE, 2000, J IMMUNOL, V164, P419, DOI 10.4049/jimmunol.164.1.419; Kemp K, 2010, J NEUROCHEM, V114, P1569, DOI 10.1111/j.1471-4159.2009.06553.x; Kozorovitskiy Y, 2003, NAT CELL BIOL, V5, P952, DOI 10.1038/ncb1103-952; LAPHAM LW, 1968, SCIENCE, V159, P310, DOI 10.1126/science.159.3812.310; Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301-472X(03)00110-3; Lee PH, 2008, CLIN PHARMACOL THER, V83, P723, DOI 10.1038/sj.clpt.6100386; Magrassi L, 2007, J NEUROSCI, V27, P9885, DOI 10.1523/JNEUROSCI.2539-07.2007; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A., 2003, NEUROSURGERY, V53, P702; Maitra B, 2004, BONE MARROW TRANSPL, V33, P597, DOI 10.1038/sj.bmt.1704400; MARES V, 1973, BRAIN RES, V53, P273, DOI 10.1016/0006-8993(73)90214-X; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; Nygren JM, 2008, NAT CELL BIOL, V10, P584, DOI 10.1038/ncb1721; O'Neill EJ, 2006, J NEUROIMMUNOL, V178, P1, DOI 10.1016/j.jneuroim.2006.05.030; Okuda Y, 1998, J INTERF CYTOK RES, V18, P415, DOI 10.1089/jir.1998.18.415; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Rice CM, 2004, LANCET, V364, P193, DOI 10.1016/S0140-6736(04)16633-6; Scolding N, 2008, J NEUROL SCI, V265, P111, DOI 10.1016/j.jns.2007.08.009; Singec I, 2008, NAT CELL BIOL, V10, P503, DOI 10.1038/ncb0508-503; Stoll G, 2000, J NEURAL TRANSM-SUPP, P81; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhang J, 2006, J NEUROSCI RES, V84, P587, DOI 10.1002/jnr.20962	43	51	53	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	FEB	2011	37	2					166	178		10.1111/j.1365-2990.2010.01122.x			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	704OR	WOS:000286062800004	20819172	Green Published			2022-02-06	
J	Mannix, RC; Zhang, J; Park, J; Zhang, X; Bilal, K; Walker, K; Tanzi, RE; Tesco, G; Whalen, MJ				Mannix, Rebekah C.; Zhang, Jimmy; Park, Juyeon; Zhang, Xuan; Bilal, Kiran; Walker, Kendall; Tanzi, Rudolph E.; Tesco, Giuseppina; Whalen, Michael J.			Age-dependent effect of apolipoprotein E4 on functional outcome after controlled cortical impact in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; genetics; developmental biology; Alzheimer's disease	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; TRANSGENIC MICE; A-BETA; APOE GENOTYPE; MOUSE MODEL; PEPTIDE; DEPOSITION	The apolipoprotein E4 (APOE4) gene leads to increased brain amyloid beta (Ab) and poor outcome in adults with traumatic brain injury (TBI); however, its role in childhood TBI is controversial. We hypothesized that the transgenic expression of human APOE4 worsens the outcome after controlled cortical impact (CCI) in adult but not immature mice. Adult and immature APOE4 mice had worse motor outcome after CCI (P < 0.001 versus wild type (WT)), but the Morris water maze performance was worse only in adult APOE4 mice (P = 0.028 at 2 weeks, P = 0.019 at 6 months versus WT), because immature APOE4 mice had performance similar to WT for up to 1 year after injury. Brain lesion size was similar in adult APOE4 mice but was decreased (P = 0.029 versus WT) in injured immature APOE4 mice. Microgliosis was similar in all groups. Soluble brain A beta(40) was increased at 48 hours after CCI in adult and immature APOE4 mice and in adult WT (P < 0.05), and was dynamically regulated during the chronic period by APOE4 in adults but not immature mice. The data suggest age-dependent effects of APOE4 on cognitive outcome after TBI, and that therapies targeting APOE4 may be more effective in adults versus children with TBI. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 351-361; doi:10.1038/jcbfm.2010.99; published online 30 June 2010	[Mannix, Rebekah C.] Harvard Univ, Dept Med, Childrens Hosp Boston, Sch Med,Div Emergency Med, Boston, MA 02115 USA; [Zhang, Jimmy; Park, Juyeon; Zhang, Xuan; Bilal, Kiran; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA USA; [Zhang, Jimmy; Park, Juyeon; Zhang, Xuan; Bilal, Kiran; Whalen, Michael J.] Harvard Univ, Dept Pediat, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA; [Walker, Kendall; Tesco, Giuseppina] Tufts Univ, Dept Neurosci, Boston, MA 02111 USA; [Tanzi, Rudolph E.] Massachusetts Gen Hosp, MIND Inst, Dept Neurol, Charlestown, MA USA		Mannix, RC (corresponding author), Harvard Univ, Dept Med, Childrens Hosp Boston, Sch Med,Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	rebekah.Mannix@childrens.harvard.edu	Tanzi, Rudolph/AAE-9622-2019; Mannix, Rebekah/AAD-8702-2020	Tanzi, Rudolph/0000-0002-7032-1454; 	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K12HD052896]; Cure Alzheimer's Fund; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1RO1AGO33016]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS047447]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD052896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447] Funding Source: NIH RePORTER	This work was supported by grants from NICHD 5K12HD052896 (RCM), the Cure Alzheimer's Fund (RET), NIA 1RO1AGO33016 (GT), and NINDS 5RO1NS047447 (MJW).	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Brewer GJ, 1998, NEUROBIOL AGING, V19, P561, DOI 10.1016/S0197-4580(98)00091-8; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Buttini M, 2002, J NEUROSCI, V22, P10539; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Deane R, 2008, J CLIN INVEST, V118, P4002, DOI 10.1172/JCI36663; Ezra Y, 2003, NEUROSCIENCE, V121, P315, DOI 10.1016/S0306-4522(03)00436-6; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hiekikanen H, 2007, BRAIN INJURY, V21, P1307, DOI 10.1080/02699050701739549; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Johnson V. E., 2010, NAT REV NEUROSCI; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kerr ME, 2003, CRIT CARE MED, V31, P2371, DOI 10.1097/01.CCM.0000080484.72004.C4; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Mandrekar S, 2009, J NEUROSCI, V29, P4252, DOI 10.1523/JNEUROSCI.5572-08.2009; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Nagano S, 2004, J BIOL CHEM, V279, P14673, DOI 10.1074/jbc.M313003200; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nicoll JAR, 1996, NEUROPATH APPL NEURO, V22, P515, DOI 10.1111/j.1365-2990.1996.tb01128.x; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Small DH, 2009, NEUROCHEM RES, V34, P1824, DOI 10.1007/s11064-009-9960-5; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Venkitaramani DV, 2007, J NEUROSCI, V27, P11832, DOI 10.1523/JNEUROSCI.3478-07.2007; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Wang DS, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/58406; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE	41	51	52	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2011	31	1					351	361		10.1038/jcbfm.2010.99			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	702BX	WOS:000285870700036	20588316	Green Published, Bronze			2022-02-06	
J	Schiehser, DM; Delis, DC; Filoteo, JV; Delano-Wood, L; Han, SD; Jak, AJ; Drake, AI; Bondi, MW				Schiehser, Dawn M.; Delis, Dean C.; Filoteo, J. Vincent; Delano-Wood, Lisa; Han, S. Duke; Jak, Amy J.; Drake, Angela I.; Bondi, Mark W.			Are self-reported symptoms of executive dysfunction associated with objective executive function performance following mild to moderate traumatic brain injury?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Neuropsychology; Cognition; Behavior; Depression	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; MAJOR DEPRESSIVE DISORDER; GULF-WAR VETERANS; HEAD-INJURY; COGNITIVE COMPLAINTS; MILITARY POPULATION; DEFICITS; IMPAIRMENT; PREDICTORS; SOLDIERS	Background and objective: We examined the relationship between self-reported pre- and post-injury changes in executive dysfunction, apathy, disinhibition, and depression, and performance on neuropsychological tests of executive function, attention/processing speed, and memory in relation to mood levels and effort test performance in individuals in the early stages of recovery from mild to moderate traumatic brain injury (TBI). Method: Participants were 71 noncombat military personnel who were in a semiacute stage of recovery (<3 months post injury) from mild to moderate TBI. Pre- and post-TBI behaviors were assessed with the Frontal Systems Behavior Scale (FrSBe; Grace & Malloy, 2001) and correlated with levels of depressive symptoms, effort test performance, and performance on objective measures of attention, executive function, and memory. Results: Self-reported symptoms of executive dysfunction generally failed to predict performance on objective measures of executive function and memory, although they predicted poorer performance on measures of attention/processing speed. Instead, higher levels of depressive symptomatology best predicted poorer performance on measures of executive function and memory. However, the relationship between memory performance and TBI symptoms was no longer significant when effort performance was controlled. Conclusions: Our findings suggest that, among individuals in early recovery from mild to moderate TBI, self-reported depressive symptoms, rather than patients' cognitive complaints, are associated with objective executive function. However, self-reported cognitive complaints may be associated with objectively measured inattention and slow processing speed.	[Schiehser, Dawn M.; Delis, Dean C.; Filoteo, J. Vincent; Delano-Wood, Lisa; Jak, Amy J.; Bondi, Mark W.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA 92161 USA; [Schiehser, Dawn M.; Delis, Dean C.; Filoteo, J. Vincent; Delano-Wood, Lisa; Jak, Amy J.; Bondi, Mark W.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA 92161 USA; [Schiehser, Dawn M.; Delis, Dean C.; Filoteo, J. Vincent; Delano-Wood, Lisa; Jak, Amy J.; Bondi, Mark W.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Delis, Dean C.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92161 USA; [Han, S. Duke] Rush Univ, Med Ctr, Dept Behav Sci, Chicago, IL 60612 USA; [Drake, Angela I.] USN, Med Ctr, Def & Vet Brain Injury Ctr, Neurosci Dept, San Diego, CA 92152 USA		Bondi, MW (corresponding author), VA San Diego Healthcare Syst, Psychol Serv 116B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	mbondi@ucsd.edu	Han/N-1246-2019		Medical Research Service; Center of Excellence for Stress and Mental Health (CESAMH) of the Department of Veterans Affairs; Defense and Veterans Brain Injury Center, San Diego, California, USA; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24AG026431] Funding Source: NIH RePORTER	This study was supported by Merit Review Research Programs from the Medical Research Service and the Center of Excellence for Stress and Mental Health (CESAMH) of the Department of Veterans Affairs (M. W. B. and D. C. D.) and by the Defense and Veterans Brain Injury Center, San Diego, California, USA. The authors gratefully acknowledge the staff, patients, and volunteers at the Naval Medical Center San Diego and the U. S. Marine Corps Base Camp Pendleton for their assistance with this study. Dean C. Delis is a coauthor of the D-KEFS (Delis-Kaplan Executive Function System) and the California Verbal Learning Test-Second Edition (CVLT-II). There were no other actual or potential conflicts of interest for the authors that could have inappropriately influenced the present work. Subjects were recruited in accordance with Internal Review Board (IRB) approved policies and procedures. Standard ethical and professional guidelines were upheld during the research study and manuscript preparation. The views expressed in this article do not necessarily reflect those of the funding agency, the United States Navy, the United States Marine Corps, the Department of Defense, or the United States Government.	ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andersson S, 2002, NEUROPSY NEUROPSY BE, V15, P184, DOI 10.1097/01.WNN.0000026596.88167.8E; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beer JS, 2006, J COGNITIVE NEUROSCI, V18, P871, DOI 10.1162/jocn.2006.18.6.871; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Defense and Veterans Brain Injury Center, 2010, DEP DEF NUMB TRAUM B; Defense and Veterans Brain Injury Center, 2007, DEF VET BRAIN INJ CT; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Han SD, 2009, J HEAD TRAUMA REHAB, V24, P57, DOI 10.1097/HTR.0b013e3181957055; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Levin H. S., 1987, NEUROBEHAVIORAL SEQU; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Ottowitz WE, 2002, HARVARD REV PSYCHIAT, V10, P86, DOI 10.1080/10673220216210; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sillanpaa MC, 1997, J CLIN EXP NEUROPSYC, V19, P211, DOI 10.1080/01688639708403852; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	52	51	51	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	6					704	714		10.1080/13803395.2011.553587			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	882GA	WOS:000299550100010	21958432	Green Accepted			2022-02-06	
J	Kemp, K; Gray, E; Mallam, E; Scolding, N; Wilkins, A				Kemp, Kevin; Gray, Elizabeth; Mallam, Elizabeth; Scolding, Neil; Wilkins, Alastair			Inflammatory Cytokine Induced Regulation of Superoxide Dismutase 3 Expression by Human Mesenchymal Stem Cells	STEM CELL REVIEWS AND REPORTS			English	Article						Mesenchymal stem cell; Superoxide dismutase 3; Extracellular superoxide dismutase; Inflammation; Central nervous system	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MARROW STROMAL CELLS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; MULTIPLE-SCLEROSIS; NITRIC-OXIDE; IFN-GAMMA; TNF-ALPHA	Increasing evidence suggests that bone marrow derived-mesenchymal stem cells (MSCs) have neuroprotective properties and a major mechanism of action is through their capacity to secrete a diverse range of potentially neurotrophic or anti-oxidant factors. The recent discovery that MSCs secrete superoxide dismutase 3 (SOD3) may help explain studies in which MSCs have a direct anti-oxidant activity that is conducive to neuroprotection in both in vivo and in vitro. SOD3 attenuates tissue damage and reduces inflammation and may confer neuroprotective effects against nitric oxide-mediated stress to cerebellar neurons; but, its role in relation to central nervous system inflammation and neurodegeneration has not been extensively investigated. Here we have performed a series of experiments showing that SOD3 secretion by human bone marrow-derived MSCs is regulated synergistically by the inflammatory cytokines TNF-alpha and IFN-gamma, rather than through direct exposure to reactive oxygen species. Furthermore, we have shown SOD3 secretion by MSCs is increased by activated microglial cells. We have also shown that MSCs and recombinant SOD are able to increase both neuronal and axonal survival in vitro against nitric oxide or microglial induced damage, with an increased MSC-induced neuroprotective effect evident in the presence of inflammatory cytokines TNF-alpha and IFN-gamma. We have shown MSCs are able to convey these neuroprotective effects through secretion of soluble factors alone and furthermore demonstrated that SOD3 secretion by MSCs is, at least, partially responsible for this phenomenon. SOD3 secretion by MSCs maybe of relevance to treatment strategies for inflammatory disease of the central nervous system.	[Kemp, Kevin] Frenchay Hosp, Burden Ctr, MS Labs, Bristol BS16 1JB, Avon, England; [Kemp, Kevin; Gray, Elizabeth; Mallam, Elizabeth; Scolding, Neil; Wilkins, Alastair] Univ Bristol, Multiple Sclerosis & Stem Cell Grp, Inst Clin Neurosci, Bristol, Avon, England		Kemp, K (corresponding author), Frenchay Hosp, Burden Ctr, MS Labs, 1st Floor, Bristol BS16 1JB, Avon, England.	kevin.kemp@bristol.ac.uk	; Kemp, Kevin/B-9755-2017	Scolding, Neil/0000-0001-9177-1043; Kemp, Kevin/0000-0003-1465-1309	Ataxia UK; Ataxia UK [7160] Funding Source: researchfish	This work was carried out using a project grant from Ataxia UK.	Abrams MB, 2009, RESTOR NEUROL NEUROS, V27, P307, DOI 10.3233/RNN-2009-0480; Arnhold S, 2006, EUR J CELL BIOL, V85, P551, DOI 10.1016/j.ejcb.2006.01.015; Baraczka Krisztina, 2003, Acta Microbiologica et Immunologica Hungarica, V50, P339, DOI 10.1556/AMicr.50.2003.4.3; Benveniste EN, 1995, FASEB J, V9, P1577, DOI 10.1096/fasebj.9.15.8529837; BERKOW RL, 1987, J IMMUNOL, V139, P3783; Bowler RP, 2004, AM J RESP CELL MOL, V31, P432, DOI 10.1165/rcmb.2004-0057OC; Broholm H, 2004, ACTA NEUROL SCAND, V109, P261, DOI 10.1111/j.1600-0404.2004.00207.x; Brown GC, 2006, BIOCHEM SOC T, V34, P953, DOI 10.1042/BST0340953; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; Gao F, 2008, J BIOL CHEM, V283, P6058, DOI 10.1074/jbc.M709273200; Ha HY, 2006, BIOCHEM BIOPH RES CO, V348, P450, DOI 10.1016/j.bbrc.2006.07.079; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; HARRIS CA, 1991, J IMMUNOL, V147, P149; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Jensen MB, 2000, J NEUROSCI, V20, P3612, DOI 10.1523/JNEUROSCI.20-10-03612.2000; Kemp K, 2010, J NEUROCHEM, V114, P1569, DOI 10.1111/j.1471-4159.2009.06553.x; Kim YJ, 2009, GLIA, V57, P13, DOI 10.1002/glia.20731; Lanza C, 2009, J NEUROCHEM, V110, P1674, DOI 10.1111/j.1471-4159.2009.06268.x; Laurila JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005786; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; LOB HE, HYPERTENSION, V55, P277; Lubrano V, 2006, CLIN EXP MED, V6, P84, DOI 10.1007/s10238-006-0100-0; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A., 2003, NEUROSURGERY, V53, P702; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; MARKLUND SL, 1992, J BIOL CHEM, V267, P6696; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; Mohamed A, 2003, BIOMED SCI INSTRUM, V39, P440; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; Nozik-Grayck E, 2005, INT J BIOCHEM CELL B, V37, P2466, DOI 10.1016/j.biocel.2005.06.012; Olofsson EM, 2007, MOL VIS, V13, P1285; Park HJ, 2007, EUR J NEUROSCI, V26, P79, DOI 10.1111/j.1460-9568.2007.05636.x; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P5360, DOI 10.1167/iovs.07-0254; Rabbani ZN, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-59; Ratnam DV, 2006, J CONTROL RELEASE, V113, P189, DOI 10.1016/j.jconrel.2006.04.015; Renno T, 1998, MOL CELL NEUROSCI, V12, P376, DOI 10.1006/mcne.1998.0725; RENNO T, 1995, J IMMUNOL, V154, P944; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Ruuls SR, 1996, CLIN EXP IMMUNOL, V103, P467; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; Shi N, 2009, MULT SCLER J, V15, P120, DOI 10.1177/1352458508096871; Smith KJ, 1999, BRAIN PATHOL, V9, P69; STRALIN P, 1994, BIOCHEM J, V298, P347, DOI 10.1042/bj2980347; Stralin P, 2001, AM J PHYSIOL-HEART C, V281, pH1621, DOI 10.1152/ajpheart.2001.281.4.H1621; Stralin P, 2000, ATHEROSCLEROSIS, V151, P433, DOI 10.1016/S0021-9150(99)00427-X; TIKU ML, 1990, J IMMUNOL, V145, P690; Ueda J, 2008, FREE RADICAL BIO MED, V45, P897, DOI 10.1016/j.freeradbiomed.2008.06.016; Vercelli A, 2008, NEUROBIOL DIS, V31, P395, DOI 10.1016/j.nbd.2008.05.016; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006	57	51	53	0	8	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1550-8943			STEM CELL REV REP	Stem Cell Rev. Rep.	DEC	2010	6	4					548	559		10.1007/s12015-010-9178-6			12	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	657PG	WOS:000282424200007	20683679				2022-02-06	
J	Max, JE; Bruce, M; Keatley, E; Delis, D				Max, Jeffrey E.; Bruce, Margaret; Keatley, Eva; Delis, Dean			Pediatric Stroke: Plasticity, Vulnerability, and Age of Lesion Onset	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							UNILATERAL BRAIN-LESIONS; CLOSED-HEAD-INJURY; LOW-BIRTH-WEIGHT; PSYCHIATRIC-DISORDERS; HEMIPLEGIC CHILDREN; CHILDHOOD STROKE; RECOVERY; RELIABILITY; SCHEDULE; VALIDITY	The authors aim to investigate brain plasticity and vulnerability through the study of the relationship of age at the time of brain injury and neurocognitive and psychiatric outcome. Children with early stroke performed more poorly compared with children with late stroke in a wide variety of domains including intellectual function, language, memory, visuospatial function, academic function, and psychiatric problems. The exception to this pattern was that children with late stroke performed more poorly in two of three executive function tests. These findings suggest that in children with focal brain injury, as in those with more diffuse brain insults, younger age at injury predicts worse neurocognitive outcomes, although this may not apply to selected executive function outcomes. Adverse psychiatric outcome after early stroke is less direct but is evident in terms of severity in affected cases. (The Journal of Neuropsychiatry and Clinical Neurosciences 2010; 22:30-39)	[Max, Jeffrey E.; Bruce, Margaret; Keatley, Eva; Delis, Dean] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA		Max, JE (corresponding author), Rady Childrens Hosp, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu			NARSADNARSAD [NIMH K-08MH01800]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER	This work was completed at the Department of Psychiatry, University of California, San Diego. This study was supported in part by a NARSAD Young Investigator Award (Dr. Max) and a Career Development Award (NIMH K-08MH01800) (Dr. Max). We acknowledge: Katherine Mathews, M. D., for help with selection and recruitment of stroke participants; Fred Dietz, M. D., Scott Mubarak, M. D., and Peter Newton, M. D., for selection and recruitment of orthopedic controls; Brigitte Robertson, M. D., for psychiatric assessment interrater reliability studies; Peter Fox, M. D., and Jack Lancaster, Ph.D., for image analysis; Amy Lansing, Ph.D., for database management; Don Slymen, Ph.D., for statistical consultation; and Damien Ihrig for data collection.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; ARAM DM, 1994, NEUROPSYCHOLOGIA, V32, P85, DOI 10.1016/0028-3932(94)90071-X; BANICH MT, 1990, NEUROPSYCHOLOGIA, V28, P35, DOI 10.1016/0028-3932(90)90084-2; Bates E, 1999, CHANGING NERVOUS SYSTEM, P214; Beery K, 1989, VMI DEV TEST VISUAL; Benton AL, 1994, MULTILINGUAL APHASIA; Breslau N, 2000, BIOL PSYCHIAT, V47, P1005, DOI 10.1016/S0006-3223(99)00312-1; Chapman SB, 2003, PEDIATR NEUROL, V29, P34, DOI 10.1016/S0887-8994(03)00012-2; Cohen J., 2013, STAT POWER ANAL BEHA; Delis D.C., 1994, CVLT C CALIFORNIA VE; Delis DC., 2001, DELIS KAPLAN EXECUTI; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FINGER S, 1991, DEV NEUROPSYCHOL, V7, P261, DOI 10.1080/87565649109540494; Ganesan V, 2000, DEV MED CHILD NEUROL, V42, P455, DOI 10.1017/S0012162200000852; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GOODMAN R, 1989, BRIT J PSYCHIAT, V154, P292, DOI 10.1192/bjp.154.3.292; Hammill DD, 1996, TEST WRITTEN LANGUAG; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; HICKS SP, 1984, EARLY BRAIN DAMAGE, P127; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; KENNARD MA, 1942, MT SINAI J MED, V9, P594; Kolb B, 2007, DEV PSYCHOBIOL, V49, P107, DOI 10.1002/dev.20199; LANSDELL H, 1969, J COMP PHYSIOL PSYCH, V69, P734, DOI 10.1037/h0028306; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; LEVINE SC, 1987, DEV MED CHILD NEUROL, V29, P27; Max JE, 2004, J INT NEUROPSYCH SOC, V10, P698, DOI 10.1017/S1355617704105092; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2002, J AM ACAD CHILD PSY, V41, P555, DOI 10.1097/00004583-200205000-00013; MEYERS J, 1995, MEYERS SCORING SYSTE; Mosch SC, 2005, COGN BEHAV NEUROL, V18, P5, DOI 10.1097/01.wnn.0000152207.80819.3c; Pavlovic J, 2006, NEUROPEDIATRICS, V37, P13, DOI 10.1055/s-2006-923932; RIVA D, 1986, NEUROPSYCHOLOGIA, V24, P423, DOI 10.1016/0028-3932(86)90029-1; Schaller BJ, 2007, EXP NEUROL, V205, P9, DOI 10.1016/j.expneurol.2006.01.017; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2004, J INT NEUROPSYCH SOC, V10, P987, DOI 10.1017/S1355617704107078; VARGHAKHADEM F, 1985, BRAIN, V108, P677, DOI 10.1093/brain/108.3.677; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wilkinson, 1984, WIDE RANGE ACHIEVEME; WOODS BT, 1979, ANN NEUROL, V6, P405, DOI 10.1002/ana.410060505; Yakovlev PI, 1967, REGIONAL DEV BRAIN E, P3	50	51	51	0	8	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2010	22	1					30	39		10.1176/appi.neuropsych.22.1.30			10	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	555VO	WOS:000274544500004	20160207				2022-02-06	
J	McAllister, TW				McAllister, Thomas W.			Genetic Factors Modulating Outcome After Neurotrauma	PM&R			English	Article								Wide variation in outcomes after neurotrauma, despite apparently similar injury severity, suggests that host factors may influence the recovery process. Genetically determined individual differences might be one such factor. The study of the genetic modulation of outcome after neurotrauma is at an early stage. Nevertheless, several important components of the response to neurotrauma can be identified in which genetic differences contribute to variability in outcome. These components include genetic modulators of pre- and postinjury cognitive reserve and behavioral homeostasis, and processes that modulate cytotoxic injury cascades (extent of injury) and injury repair. This work reviews what is known of the role of genetic variation in outcome after neurotrauma with a focus on clinical outcomes after traumatic brain injury. Polymorphisms reported to influence outcome after traumatic brain injury that illustrate important underlying mechanisms are emphasized. PM R 2010;2:S241-S252	Dartmouth Med Sch, Sect Neuropsychiat, Dept Psychiat, Lebanon, NH 03756 USA		McAllister, TW (corresponding author), Dartmouth Med Sch, Sect Neuropsychiat, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu			NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176, 1R01HD047242, 1R01HD48638]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS055020]; CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01/CE001254]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD047242, R01HD048638, R01HD048176] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254] Funding Source: NIH RePORTER	Disclosures: 8, grants NICHD R01 HD048176, 1R01HD047242, and 1R01HD48638; NINDS 1R01NS055020; and CDC R01/CE001254	Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320; ADLER LE, 1992, BIOL PSYCHIAT, V32, P607, DOI 10.1016/0006-3223(92)90073-9; ADLER LE, 1993, AM J PSYCHIAT, V150, P1856; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Amouyel P, 1996, NEUROSCI LETT, V217, P203, DOI 10.1016/S0304-3940(96)13092-5; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Ariza M, 2006, J NEUROPSYCH CLIN N, V18, P39, DOI 10.1176/appi.neuropsych.18.1.39; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Bellivier F, 2000, BIOL PSYCHIAT, V48, P319, DOI 10.1016/S0006-3223(00)00891-X; Blum K, 1997, MOL PSYCHIATR, V2, P239, DOI 10.1038/sj.mp.4000261; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Capurso C, 2004, EXP GERONTOL, V39, P1567, DOI 10.1016/j.exger.2004.07.006; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Comings DE, 1998, ALCOHOL, V16, P61, DOI 10.1016/S0741-8329(97)00178-X; Comings DE, 2003, MOL PSYCHIATR, V8, P10, DOI 10.1038/sj.mp.4001095; Comings DE, 1996, PHARMACOGENETICS, V6, P223, DOI 10.1097/00008571-199606000-00004; COOK EH, 1995, AM J HUM GENET, V56, P993; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Deary IJ, 2009, HUM GENET, V126, P215, DOI 10.1007/s00439-009-0655-4; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Dutcher SA, 2001, NEUROL RES, V23, P203, DOI 10.1179/016164101101198343; Ebstein RP, 2000, EUR J PHARMACOL, V410, P205, DOI 10.1016/S0014-2999(00)00852-9; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fisher DE, 2001, APOPTOSIS, V6, P7, DOI 10.1023/A:1009659708549; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Ibelgaufts PDH., HORST IBELGAUFTS COP; Institute of Medicine, 2009, GULF WAR HLTH, V7; Joiner TE, 2003, J AFFECT DISORDERS, V77, P273, DOI 10.1016/S0165-0327(02)00171-4; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kaneko N, 2009, NEUROSCI RES, V63, P155, DOI 10.1016/j.neures.2008.12.001; Kempermann G, 2003, BIOL PSYCHIAT, V54, P499, DOI 10.1016/S0006-3223(03)00319-6; Kempermann G, 2002, E SCHERING RES FDN W, V35, P17; Kempermann G, 2002, BIPOLAR DISORD, V4, P17, DOI 10.1034/j.1399-5618.2002.40101.x; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kulbatski I, 2005, CURR DRUG TARGETS, V6, P111, DOI 10.2174/1389450053345037; Lang UE, 2004, J NEURAL TRANSM, V111, P387, DOI 10.1007/s00702-003-0100-0; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Laws SM, 2002, MOL PSYCHIATR, V7, P768, DOI 10.1038/sj.mp.4001083; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Liljequist R, 1997, BEHAV BRAIN RES, V82, P195, DOI 10.1016/S0166-4328(97)80989-8; Lim KC, 2003, NEUROBIOL AGING, V24, P1135, DOI 10.1016/j.neurobiolaging.2003.09.003; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Lipsky RH, 2003, ANN NY ACAD SCI, V1003, P22, DOI 10.1196/annals.1300.003; Lu B, 2000, PROG BRAIN RES, V128, P231; MacDonald JL, 2009, PROG NEUROBIOL, V88, P170, DOI 10.1016/j.pneurobio.2009.04.002; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Mann JJ, 2000, ARCH GEN PSYCHIAT, V57, P729, DOI 10.1001/archpsyc.57.8.729; Martinez-Lucas P, 2005, INTENS CARE MED, V31, P1168, DOI 10.1007/s00134-005-2715-0; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McAllister, 2004, J NEUROPSYCHIATRY CL, V16, P238; McAllister T, 2009, INT NEUR SOC M SANT; McAllister T, 2008, SINGLE NUCLEOTIDE PO; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2009, J HEAD TRAUMA REHAB, V24, P65, DOI 10.1097/HTR.0b013e3181996e6b; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; McAllister TW, 2005, J NEUROPSYCHIATRY CL, V17, P287; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Mihailescu S, 2000, ARCH MED RES, V31, P131, DOI 10.1016/S0188-4409(99)00087-9; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Morley KI, 2001, BEHAV GENET, V31, P511, DOI 10.1023/A:1013337209957; Mufson EJ, 1999, EXP NEUROL, V158, P469, DOI 10.1006/exnr.1999.7086; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Noble E P, 2000, Pharmacogenomics, V1, P309, DOI 10.1517/14622416.1.3.309; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Parasuraman R, 2002, NEUROPSYCHOLOGY, V16, P254, DOI 10.1037//0894-4105.16.2.254; Pola R, 2002, NEUROREPORT, V13, P1645, DOI 10.1097/00001756-200209160-00015; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Quan N, 2002, HISTOL HISTOPATHOL, V17, P273, DOI 10.14670/HH-17.273; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramasubbu R, 2006, J NEUROPSYCH CLIN N, V18, P96, DOI 10.1176/appi.neuropsych.18.1.96; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Richard F, 2001, NEUROLOGY, V56, P1593, DOI 10.1212/WNL.56.11.1593; ROBERTS GW, 1990, NEUROPATH APPL NEURO, V16, P3, DOI 10.1111/j.1365-2990.1990.tb00927.x; Savitz J, 2006, GENES BRAIN BEHAV, V5, P311, DOI 10.1111/j.1601-183X.2005.00163.x; Saykin A, 2005, ALZH ASS INT C PREV; Schaffer DV, 2004, NEUROMOL MED, V5, P1, DOI 10.1385/NMM:5:1:001; Skaper SD, 2008, CNS NEUROL DISORD-DR, V7, P46, DOI 10.2174/187152708783885174; Stam AH, 2009, J NEUROL NEUROSUR PS, V80, P1125, DOI 10.1136/jnnp.2009.177279; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tanriverdi T, 2006, SURG NEUROL, V65, P7, DOI 10.1016/j.surneu.2005.05.024; Teasdale TW, 1997, BRIT MED J, V315, P569; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; TIRET L, 1992, AM J HUM GENET, V51, P197; Uryu K, 2004, NEUROBIOL AGING S1, V25, pP2; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Uzan M, 2005, ACTA NEUROCHIR, V147, P715, DOI 10.1007/s00701-005-0529-z; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wang JC, 2004, HUM MOL GENET, V13, P1903, DOI 10.1093/hmg/ddh194; Weiland S, 2000, BEHAV BRAIN RES, V113, P43, DOI 10.1016/S0166-4328(00)00199-6; Weinberger DR, 2001, BIOL PSYCHIAT, V50, P825, DOI 10.1016/S0006-3223(01)01252-5; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Wong AHC, 2000, EUR J PHARMACOL, V410, P183; Xie PX, 2009, ARCH GEN PSYCHIAT, V66, P1201, DOI 10.1001/archgenpsychiatry.2009.153; Yudofsky S.C., 2005, TXB TRAUMATIC BRAIN, P27	121	51	53	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	DEC	2010	2	12		2			S241	S252		10.1016/j.pmrj.2010.10.005			12	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	V24LT	WOS:000208412600005	21172686				2022-02-06	
J	Colantonio, A; Saverino, C; Zagorski, B; Swaine, B; Lewko, J; Jaglal, S; Vernich, L				Colantonio, Angela; Saverino, Cristina; Zagorski, Brandon; Swaine, Bonnie; Lewko, John; Jaglal, Susan; Vernich, Lee			Hospitalizations and Emergency Department Visits for TBI in Ontario	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							TRAUMATIC-BRAIN-INJURY; UNITED-STATES; HEAD-INJURY; POPULATION; PATHOPHYSIOLOGY; EPIDEMIOLOGY; TRENDS; CODES; CARE; US	Objective: The aim of this study was to determine the number of annual hospitalizations and overall episodes of care that involve a traumatic brain injury (Tiff) by age and gender in the province of Ontario. To provide a more accurate assessment of the prevalence of TBI, episodes of care included visits to the emergency department (ED), as well as admissions to hospital. Mechanisms of injury for overall episodes were also investigated. Methods: Traumatic brain injury cases from fiscal years 2002/03-2006/07 were identified by means of ICD-10 codes. Data were collected from the National Ambulatory Care Reporting System and the Discharge Abstract Database. Results: The rate of hospitalization was highest for elderly persons over 75 years-of-age. Males generally had higher rates for both hospitalizations and episodes of care than did females. The inclusion of ED visits to hospitalizations had the greatest impact on the rates of TBI in the youngest age groups. Episodes of care for TBI were greatest in youth under the age of 14 and elderly over the age of 85. Falls (41.6%) and being struck by or against an object (31.1%) were the most frequent causes for a TBI. Conclusions: The study provides estimates for TBI from the only Canadian province that has systematically captured ED visits in a national registry. It shows the importance of tracking ED visits, in addition to hospitalizations, to capture the burden of TBI on the health care system. Prevention strategies should include information on ED visits, particularly for those at younger ages.	[Colantonio, Angela; Saverino, Cristina] Univ Toronto, Toronto Rehabil Inst, Dept Occupat Therapy, Toronto, ON M5G 1V7, Canada; [Jaglal, Susan] Univ Toronto, Toronto Rehabil Inst, Dept Phys Therapy, Toronto, ON M5G 1V7, Canada; [Vernich, Lee] Univ Toronto, Dalla Lana Sch Publ Hlth, Res Serv, Toronto, ON M5G 1V7, Canada; [Zagorski, Brandon] Inst Clin Evaluat Sci, Dept Programming & Biostat, Toronto, ON, Canada; [Lewko, John] Laurentian Univ, Ctr Res Human Dev, Sudbury, ON P3E 2C6, Canada; [Swaine, Bonnie] Univ Montreal, Sch Rehabil, Physiotherapy Program, Montreal, PQ, Canada		Colantonio, A (corresponding author), Univ Toronto, Toronto Rehabil Inst, Dept Occupat Therapy, 160-500 Univ Ave,Room 950, Toronto, ON M5G 1V7, Canada.			Jaglal, Susan/0000-0002-2930-1443; Colantonio, Angela/0000-0003-2094-4765	Ontario Neurotrauma Foundation; Institute for Clinical and Evaluative Sciences; Toronto Rehabilitation InstituteUniversity of Toronto; Ontario Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario	The authors thank these :institutions for supporting this project: the Ontario Neurotrauma Foundation, the Institute for Clinical and Evaluative Sciences, and the Toronto Rehabilitation Institute. The Institute for Clinical and Evaluative Sciences and the Toronto Rehabilitation Institute are supported by the Ontario Ministry of Health and Long Term Care.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Boswell JE, 2002, AM J EMERG MED, V20, P177, DOI 10.1053/ajem.2002.32641; Canadian Institute for Health Information (CIHI), 2007, DAT QUAL DOC DISCH A; Canadian Institute of Health Information (CIHI), 2008, DAT QUAL STUD EM DEP, VII; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; *CDCP, 2007, INT COLL EFF INJ STA; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CIHI, 2007, BURD NEUR DIS DIS IN; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Day Heather, 2006, Minn Med, V89, P40; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hillier SL, 1997, BRAIN INJURY, V11, P649; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JUURLINK D, 2006, CAN I HLTH INF DISCH; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Kostylova A, 2005, INJURY PREV, V11, P186, DOI 10.1136/ip.2004.006585; Marr A, 2002, CENTRAL NERVOUS SYST; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; *PHAC, 2002, INJ PREV; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Pickett William, 2004, Chronic Dis Can, V25, P32; RICHARD J, 2001, P STAT CANADA INT S; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Schootman M, 2000, BRAIN INJURY, V14, P373; Selassie AW, 2003, ACAD EMERG MED, V10, P1260, DOI 10.1197/S1069-6563(03)00497-4; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587	38	51	52	0	4	CANADIAN JOURNAL NEUROLOGICAL SCIENCES INC	CALGARY	709-7015 MACLEOD TRAIL SW, CALGARY, AB T2H 2K6, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	NOV	2010	37	6					783	790		10.1017/S0317167100051441			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	686CJ	WOS:000284674100013	21059539	Bronze			2022-02-06	
J	D'Onofrio, G; Jauch, E; Jagoda, A; Allen, MH; Anglin, D; Barsan, WG; Berger, RP; Bobrow, BJ; Boudreaux, ED; Bushnell, C; Chan, YF; Currier, G; Eggly, S; Ichord, R; Larkin, GL; Laskowitz, D; Neumar, RW; Newman-Toker, DE; Quinn, J; Shear, K; Todd, KH; Zatzick, D				D'Onofrio, Gail; Jauch, Edward; Jagoda, Andrew; Allen, Michael H.; Anglin, Deirdre; Barsan, William G.; Berger, Rachel P.; Bobrow, Bentley J.; Boudreaux, Edwin D.; Bushnell, Cheryl; Chan, Yu-Feng; Currier, Glenn; Eggly, Susan; Ichord, Rebecca; Larkin, Gregory L.; Laskowitz, Daniel; Neumar, Robert W.; Newman-Toker, David E.; Quinn, James; Shear, Katherine; Todd, Knox H.; Zatzick, Douglas		Roundtable External Participants; Roundtable Steering Comm; Fed Participants	NIH Roundtable on Opportunities to Advance Research on Neurologic and Psychiatric Emergencies	ANNALS OF EMERGENCY MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; CLINICAL POLICY; DIAGNOSTIC-TEST; CARE; US; STROKE; INTERVENTION; DEPARTMENTS; MANAGEMENT; MEDICINE	Study objective: The Institute of Medicine Committee on the Future of Emergency Care in the United States Health System (2003) identified a need to enhance the research base for emergency care. As a result, a National Institutes of Health (NIH) Task Force on Research in Emergency Medicine was formed to enhance NIH support for emergency care research. Members of the NIH Task Force and academic leaders in emergency care participated in 3 Roundtable discussions to prioritize current opportunities for enhancing and conducting emergency care research. We identify key research questions essential to advancing the science of emergency care and discuss the barriers and strategies to advance research by exploring the collaboration between NIH and the emergency care community. Methods: Experts from emergency medicine, neurology, psychiatry, and public health assembled to review critical,areas in need of investigation, current gaps in knowledge, barriers, and opportunities. Neurologic emergencies included cerebral resuscitation, pain, stroke, syncope, traumatic brain injury, and pregnancy. Mental health topics included suicide, agitation and delirium, substances, posttraumatic stress, violence, and bereavement. Results: Presentations and group discussion firmly established the need for translational research to bring basic science concepts into the clinical arena. A coordinated continuum of the health care system that ensures rapid identification and stabilization and extends through discharge is necessary to maximize overall patient outcomes. There is a paucity of well-designed, focused research on diagnostic testing, clinical decisionmaking, and treatments in the emergency setting. Barriers include the limited number of experienced researchers in emergency medicine, limited dedicated research funding, and difficulties of conducting research in chaotic emergency environments stressed by crowding and limited resources. Several themes emerged during the course of the roundtable discussion, including the need for development of (1) a research infrastructure for the rapid identification, consent, and tracking of research subjects that incorporates innovative informatics technologies, essential for future research; (2) diagnostic strategies and tools necessary to understand key populations and the process of medical decisionmaking, including the investigation of the pathobiology of symptoms and symptom-oriented therapies; (3) collaborative research networks to provide unique opportunities to form partnerships, leverage patient cohorts and clinical and financial resources, and share data; (4) formal research training programs integral for creating new knowledge and advancing the science and practice of emergency medicine; and (5) recognit on that emergency care is part of an integrated system from emergency medical services dispatch to discharge. The NIH Roundtable "Opportunities to Advance Research on Neurological and Psychiatric Emergencies" created a framework to guide future emergency medicine-based research initiatives. Conclusion: Emergency departments provide the portal of access to the health care system for most patients with acute neurologic and psychiatric illness. Emergency physicians and colleagues are primed to investigate neurologic and psychiatric emergencies that will directly improve the delivery of care and patient outcomes. [Ann Emerg Med. 2010;56:551-564.]	[D'Onofrio, Gail; Larkin, Gregory L.] Yale Univ, Sch Med, New Haven, CT 06520 USA; [Jauch, Edward] Med Univ S Carolina, Charleston, SC USA; [Jagoda, Andrew; Chan, Yu-Feng] Mt Sinai Sch Med, New York, NY USA; [Allen, Michael H.] Univ Colorado Denver, Denver, CO USA; [Anglin, Deirdre] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Barsan, William G.] Univ Michigan, Ann Arbor, MI 48109 USA; [Berger, Rachel P.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA; [Bobrow, Bentley J.] Mayo Clin, Coll Med, Rochester, MN 55905 USA; [Boudreaux, Edwin D.] Cooper Univ Hosp, Camden, NJ USA; [Bushnell, Cheryl] Wake Forest Univ, Winston Salem, NC 27109 USA; [Currier, Glenn] Univ Rochester, Med Ctr, Rochester, NY 14627 USA; [Eggly, Susan] Wayne State Univ, Sch Med, Detroit, MI 48202 USA; [Ichord, Rebecca; Neumar, Robert W.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Laskowitz, Daniel] Duke Univ, Med Ctr, Durham, NC 27706 USA; [Newman-Toker, David E.] Johns Hopkins Univ, Baltimore, MD 21218 USA; [Quinn, James] Stanford Univ, Stanford, CA 94305 USA; [Shear, Katherine] Columbia Univ, New York, NY 10027 USA; [Todd, Knox H.] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA; [Zatzick, Douglas] Univ Washington, Sch Med, Seattle, WA 98195 USA		D'Onofrio, G (corresponding author), Dept Emergency Med, 464 Congress Ave,Ste 260, New Haven, CT 06519 USA.	gail.donofrio@yale.edu; jauch@musc.edu; andy.jagoda@mssm.edu; michael.allen@ucdenver.edu; anglin@usc.edu; wbarsan@umich.edu; rachel.p.berger@gmail.com; bobrow.bentley@mayo.edu; boudreaux-edwin@cooperhealth.edu; cbushnel@wfubmc.edu; yu-fengyvonne.chan@mountsinai.org; glenn_currier@urmc.rochester.edu; susaneggly@wayne.edu; ichord@email.chop.edu; gluke.larkin@yale.edu; danl@neuro.duke.edu; neumarr@uphs.upenn.edu; toker@jhu.edu; quinn@stanforid.edu; ks2394@columbia.edu; ktodd@chpnet.org; dzatzick@u.washington.edu	Allen, Michael H/A-8776-2011; Kopp, Jeffrey/O-2681-2015	Allen, Michael H/0000-0002-6479-9793; Jauch, Edward/0000-0002-3533-4364; Eggly, Susan/0000-0002-8137-6098; D'Onofrio, Gail/0000-0002-3833-1871; Kopp, Jeffrey/0000-0001-9052-186X; Boudreaux, Edwin/0000-0002-3223-6371; Quinn, James/0000-0002-3694-2118; Guerrero, Giovanna/0000-0003-4931-8530; LARKIN, GREGORY LUKE/0000-0002-8655-7824			Allen MH, 2005, J PSYCHIAT PRACT S1, V11, P110; Allen Michael H, 2005, J Psychiatr Pract, V11 Suppl 1, P5, DOI 10.1097/00131746-200511001-00002; Barsan WG, 2004, ANN EMERG MED, V44, P407, DOI 10.1016/j.annemergmed.2004.06.024; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bushnell CD, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b664; Claassen CA, 2005, BRIT J PSYCHIAT, V186, P352, DOI 10.1192/bjp.186.4.352; Cunningham RM, 2009, ACAD EMERG MED, V16, P1078, DOI 10.1111/j.1553-2712.2009.00552.x; D'Onofrio G, 2004, ALCOHOL RES HEALTH, V28, P63; Grieve AP, 2005, CLIN TRIALS, V2, P340, DOI 10.1191/1740774505cn094oa; Han JH, 2009, ACAD EMERG MED, V16, P193, DOI 10.1111/j.1553-2712.2008.00339.x; Havard A, 2008, ADDICTION, V103, P368, DOI 10.1111/j.1360-0443.2007.02072.x; Huff JS, 2007, ANN EMERG MED, V49, P431, DOI 10.1016/j.annemergmed.2007.02.001; Hypothermia After Cardiac Arrest Study Group, 2002, NEW ENGL J MED, V346, P550; Kattah JC, 2009, STROKE, V40, P3504, DOI 10.1161/STROKEAHA.109.551234; Larkin GL, 2008, CRISIS, V29, P73, DOI 10.1027/0227-5910.29.2.73; Larkin GL, 2009, ACAD EMERG MED, V16, P1110, DOI 10.1111/j.1553-2712.2009.00545.x; Laskowitz DT, 2009, STROKE, V40, P77, DOI 10.1161/STROKEAHA.108.516377; Levetown M, 2008, PEDIATRICS, V121, pE1441, DOI 10.1542/peds.2008-0565; Lukens TW, 2006, ANN EMERG MED, V47, P79, DOI 10.1016/j.annemergmed.2005.10.002; Lynch JR, 2004, STROKE, V35, P57, DOI 10.1161/01.STR.0000105927.62344.4C; Majersik JJ, 2008, RESUSCITATION, V77, P189, DOI 10.1016/j.resuscitation.2007.11.023; Meert KL, 2007, J PEDIATR-US, V151, P50, DOI 10.1016/j.jpeds.2007.01.050; MEERT KL, 2007, J PEDIAT, V151, pE51; Mitchell C, 2009, INTIMATE PARTNER VIO; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Newman-Toker DE, 2008, MAYO CLIN PROC, V83, P765, DOI 10.4065/83.7.765; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; Quinn J, 2004, ACAD EMERG MED, V11, P1245, DOI 10.1197/j.aem.2004.08.020; Ramchandren S, 2007, AM J NEURORADIOL, V28, P1085, DOI 10.3174/ajnr.A0506; SALTZMAN L, 1999, PREVENTION NCFL VERS; Simon NM, 2007, COMPR PSYCHIAT, V48, P395, DOI 10.1016/j.comppsych.2007.05.002; Todd KH, 2007, ANN EMERG MED, V50, pS37, DOI 10.1016/j.annemergmed.2007.06.146; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; Unden J, 2009, SCAND J CLIN LAB INV, V69, P13, DOI 10.1080/00365510802651833; World Health Organization, 2002, WORLD REPORT VIOLENC; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zatzick DF, 2009, PSYCHIATRY, V72, P346, DOI 10.1521/psyc.2009.72.4.346; 2006, ANN NEUROL, V60, pA12	40	51	52	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	NOV	2010	56	5					551	564		10.1016/j.annemergmed.2010.06.562			14	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	681DY	WOS:000284292800020	21036295				2022-02-06	
J	Tierney, RT; Mansell, JL; Higgins, M; McDevitt, JK; Toone, N; Gaughan, JP; Mishra, A; Krynetskiy, E				Tierney, Ryan T.; Mansell, Jamie L.; Higgins, Michael; McDevitt, Jane K.; Toone, Nieka; Gaughan, John P.; Mishra, Anarug; Krynetskiy, Evgeny			Apolipoprotein E Genotype and Concussion in College Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						polymorphism; MTBI; APOE E2; APOE E4; APOE promoter g-219t	TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; APOE PROMOTER; ASSOCIATION; EPIDEMIOLOGY; SPORTS	Objective: To evaluate the association between apolipoprotein E (APOE) polymorphisms (E2, C/T Arg158Cys; E4, T/C Cys112Arg; and promoter, g-219t) and the history of concussion in college athletes. We hypothesized that carrying 1 or more APOE rare (or minor) allele assessed in this study would be associated with having a history of 1 or more concussions. Design: Multicenter cross-sectional study. Setting: University athletic facilities. Participants: One hundred ninety-six male football (n = 163) and female soccer (n = 33) college athletes volunteered. Interventions: Written concussion history questionnaire and saliva samples for genotyping. Main Outcome Measures: Self-reported history of a documented concussion and rare APOE genotype (E2, E4, promoter). Results: There was a significant association (Wald chi(2) = 3.82; P = 0.05; odds ratio = 9.8) between carrying all APOE rare alleles and the history of a previous concussion. There was also a significant association (Wald chi(2) = 3.96, P = 0.04, odds ratio = 8.4) between carrying the APOE promoter minor allele and experiencing 2 or more concussions. Conclusions: Carriers of all 3 APOE rare (or minor) alleles assessed in this study were nearly 10 times more likely to report a previous concussion and may be at a greater risk of concussion versus noncarriers. Promoter minor allele carriers were 8.4 times more likely to report multiple concussions and may be at a greater risk of multiple concussions versus noncarriers. Research involving larger samples of individuals with multiple concussions and carriers of multiple APOE rare alleles is warranted.	[Tierney, Ryan T.; McDevitt, Jane K.; Toone, Nieka] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Mansell, Jamie L.] Lincoln Univ, Dept Hlth Phys Educ & Recreat, Philadelphia, PA USA; [Higgins, Michael] Towson Univ, Dept Kinesiol, Towson, MD USA; [Gaughan, John P.] Temple Univ, Sch Med, Biostat Consulting Ctr, Philadelphia, PA 19122 USA; [Mishra, Anarug; Krynetskiy, Evgeny] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19122 USA		Tierney, RT (corresponding author), Temple Univ, Dept Kinesiol, 018 Pearson Hall,1800 N Broad St, Philadelphia, PA 19122 USA.	rtierney@temple.edu			Jayne Haines Center for Pharmacogenomics and Drug Safety of the Temple University School of Pharmacy	Supported by the Jayne Haines Center for Pharmacogenomics and Drug Safety of the Temple University School of Pharmacy.	Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Caselli RJ, 2004, NEUROLOGY, V62, P1990, DOI 10.1212/01.WNL.0000129533.26544.BF; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Gennarelli T, 1982, HEAD INJURY BASIC CL, V1982, P129; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; MACCIOCCHI SN, 1999, CLIN SPORTS MED, V45, P138; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROTH SM, 2007, GENETICS PRIMER EXER, V54, P15; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	31	51	51	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2010	20	6					464	468		10.1097/JSM.0b013e3181fc0a81			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	682DC	WOS:000284379100013	21079443				2022-02-06	
J	Xiong, Y; Mahmood, A; Chopp, M				Xiong, Ye; Mahmood, Asim; Chopp, Michael			Neurorestorative Treatments for Traumatic Brain Injury	DISCOVERY MEDICINE			English	Article							MARROW STROMAL CELLS; ERYTHROPOIETIN ENHANCES NEUROGENESIS; HIPPOCAMPAL CA3 REGION; DENTATE GYRUS; THYMOSIN BETA-4; ANGIOGENESIS; RATS; SIMVASTATIN; INCREASE; STROKE	Traumatic brain injury (TBI) remains a major cause of death and permanent disability worldwide, especially in children and young adults. A total of 1.5 million people experience head trauma each year in the United States, with an annual economic cost exceeding $56 billion. Unfortunately, almost all Phase III TBI clinical trials have yet to yield a safe and effective neuroprotective treatment, raising questions regarding the use of neuroprotective strategies as the primary therapy for acute brain injuries. Recent preclinical data suggest that neurorestorative strategies that promote angiogenesis (formation of new blood vessels from pre-existing endothelial cells), axonal remodeling (axonal sprouting and pruning), neurogenesis (generation of new neurons) and synaptogenesis (formation of new synapses) provide promising opportunities for the treatment of TBI. This review discusses select cell-based and pharmacological therapies that activate and amplify these endogenous restorative brain plasticity processes to promote both repair and regeneration of injured brain tissue and functional recovery after TBI. [Discovery Medicine 10(54):434-442, November 2010]	[Xiong, Ye; Mahmood, Asim] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA		Chopp, M (corresponding author), Henry Ford Hlth Syst, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	michael.chopp@gmail.com		Xiong, Ye/0000-0001-9770-6031	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS62002, PO1 NS042259]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259, R01NS062002] Funding Source: NIH RePORTER	The authors' research was supported by NINDS grants RO1 NS62002 and PO1 NS042259.	Becher A, 1999, J NEUROSCI, V19, P1922; Besler Christian, 2008, Expert Rev Cardiovasc Ther, V6, P1071, DOI 10.1586/14779072.6.8.1071; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Chopp M, 2006, ADV EXP MED BIOL, V585, P49; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Crockford D, 2007, ANN NY ACAD SCI, V1112, P385, DOI 10.1196/annals.1415.051; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Harris N, 2010, J NEUROTRAU IN PRESS; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jia LF, 2010, STROKE, V41, P2071, DOI 10.1161/STROKEAHA.110.586198; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Lapchak PA, 2008, EXPERT OPIN INV DRUG, V17, P1175, DOI 10.1517/13543784.17.8.1175 ; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lok J, 2007, NEUROCHEM RES, V32, P2032, DOI 10.1007/s11064-007-9342-9; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Morris DC, 2010, NEUROSCIENCE, V169, P674, DOI 10.1016/j.neuroscience.2010.05.017; Morris DC, 2010, ANN NY ACAD SCI, V1194, P112, DOI 10.1111/j.1749-6632.2010.05469.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun W, 2007, ANN NY ACAD SCI, V1112, P210, DOI 10.1196/annals.1415.013; Walker PA, 2010, STEM CELLS DEV, V19, P867, DOI 10.1089/scd.2009.0188; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2008, J CEREBR BLOOD F MET, V28, P1361, DOI 10.1038/jcbfm.2008.32; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2010, J NEUROSURG IN PRESS; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Yamanaka S, 2007, CELL STEM CELL, V1, P39, DOI 10.1016/j.stem.2007.05.012; Yang XT, 2010, BRAIN RES B IN PRESS; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	74	51	55	0	0	DISCOVERY MEDICINE	TIMONIUM	10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA	1539-6509	1944-7930		DISCOV MED	Discov. Med.	NOV	2010	10	54					434	442					9	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	V27UU	WOS:000208638900007	21122475				2022-02-06	
J	Baki, SGA; Schwab, B; Haber, M; Fenton, AA; Bergold, PJ				Baki, Samah G. Abdel; Schwab, Ben; Haber, Margalit; Fenton, Andre A.; Bergold, Peter J.			Minocycline Synergizes with N-Acetylcysteine and Improves Cognition and Memory Following Traumatic Brain Injury in Rats	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; PLACE AVOIDANCE; SPATIAL INFORMATION; BEHAVIORAL EVIDENCE; MICE; NEURODEGENERATION; SEGREGATION	Background: There are no drugs presently available to treat traumatic brain injury (TBI). A variety of single drugs have failed clinical trials suggesting a role for drug combinations. Drug combinations acting synergistically often provide the greatest combination of potency and safety. The drugs examined (minocycline (MINO), N-acetylcysteine (NAC), simvastatin, cyclosporine A, and progesterone) had FDA-approval for uses other than TBI and limited brain injury in experimental TBI models. Methodology/Principal Findings: Drugs were dosed one hour after injury using the controlled cortical impact (CCI) TBI model in adult rats. One week later, drugs were tested for efficacy and drug combinations tested for synergy on a hierarchy of behavioral tests that included active place avoidance testing. As monotherapy, only MINO improved acquisition of the massed version of active place avoidance that required memory lasting less than two hours. MINO-treated animals, however, were impaired during the spaced version of the same avoidance task that required 24-hour memory retention. Co-administration of NAC with MINO synergistically improved spaced learning. Examination of brain histology 2 weeks after injury suggested that MINO plus NAC preserved white, but not grey matter, since lesion volume was unaffected, yet myelin loss was attenuated. When dosed 3 hours before injury, MINO plus NAC as single drugs had no effect on interleukin-1 formation; together they synergistically lowered interleukin-1 levels. This effect on interleukin-1 was not observed when the drugs were dosed one hour after injury. Conclusions/Significance: These observations suggest a potentially valuable role for MINO plus NAC to treat TBI.	[Baki, Samah G. Abdel] Suny Downstate Med Ctr, Dept Physiol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA		Baki, SGA (corresponding author), Suny Downstate Med Ctr, Dept Physiol, Brooklyn, NY 11203 USA.	pbergold@downstate.edu		Fenton, Andre/0000-0002-5063-1156; Bergold, Peter/0000-0002-6335-1380	Traumatic Brain Injury/Post-Traumatic Stress Disorder [W81XWH-08-1-0293]	This work was supported by a Traumatic Brain Injury/Post-Traumatic Stress Disorder Congressionally Directed Medical Research Programs award W81XWH-08-1-0293 (http://cdmrp.army.mil) to P.J.B. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Cimadevilla JM, 2001, P NATL ACAD SCI USA, V98, P3531, DOI 10.1073/pnas.051628398; Cimadevilla JM, 2001, BRAIN RES BULL, V54, P559, DOI 10.1016/S0361-9230(01)00448-8; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI [10.1517/14728220802517901, 10.1517/14728220802517901 ]; Fenton AA, 1998, P NATL ACAD SCI USA, V95, P11493, DOI 10.1073/pnas.95.19.11493; Frei E., 2003, CANC MED; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kesner RP, 2007, LEARN MEMORY, V14, P771, DOI 10.1101/lm.688207; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kubik S, 2005, J NEUROSCI, V25, P9205, DOI 10.1523/JNEUROSCI.1707-05.2005; Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Moreno S, 2010, J ANTIMICROB CHEMOTH, V65, P827, DOI 10.1093/jac/dkq061; Moussawi K, 2009, NAT NEUROSCI, V12, P182, DOI 10.1038/nn.2250; Paintlia MK, 2004, J NEUROSCI RES, V78, P347, DOI 10.1002/jnr.20261; Pastalkova E, 2006, SCIENCE, V313, P1141, DOI 10.1126/science.1128657; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Russell DG, 2010, SCIENCE, V328, P852, DOI 10.1126/science.1184784; Serrano P, 2008, PLOS BIOL, V6, P2698, DOI 10.1371/journal.pbio.0060318; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vafaei AA, 2007, NEUROBIOL LEARN MEM, V88, P87, DOI 10.1016/j.nlm.2007.02.004; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang S, 2009, AM J NEURORADIOL, V30, P1907, DOI 10.3174/ajnr.A1697; Wesierska M, 2005, J NEUROSCI, V25, P2413, DOI 10.1523/JNEUROSCI.3962-04.2005; Wesierska M, 2009, NEUROBIOL LEARN MEM, V91, P41, DOI 10.1016/j.nlm.2008.09.005; White WB, 2010, NAT REV CARDIOL, V7, P303, DOI 10.1038/nrcardio.2010.55; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8	42	51	51	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2010	5	8							e12490	10.1371/journal.pone.0012490			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	644TX	WOS:000281405300016	20824218	Green Published, gold, Green Submitted			2022-02-06	
J	Schmidt, AT; Hanten, GR; Li, XQ; Orsten, KD; Levin, HS				Schmidt, Adam T.; Hanten, Gerri R.; Li, Xiaoqi; Orsten, Kimberley D.; Levin, Harvey S.			Emotion recognition following pediatric traumatic brain injury: Longitudinal analysis of emotional prosody and facial emotion recognition	NEUROPSYCHOLOGIA			English	Article						Children; Head injury; Emotion processing; Face perception	CLOSED-HEAD INJURY; SHORT-TERM; SOCIAL-BEHAVIOR; PERCEPTION DEFICITS; READING EMOTIONS; CHILDREN; EXPRESSION; OUTCOMES; DAMAGE; ADOLESCENTS	Children with closed head injuries often experience significant and persistent disruptions in their social and behavioral functioning. Studies with adults sustaining a traumatic brain injury (TB!) indicate deficits in emotion recognition and suggest that these difficulties may underlie some of the social deficits. The goal of the current study was to examine if children sustaining a TBI exhibit difficulties with emotion recognition in terms of emotional prosody and face emotion recognition and to determine (1) how these abilities change over time and (2) what, if any, additional factors such as sex, age, and socioeconomic status (SES) affected the findings. Results provide general support for the idea that children sustaining a TBI exhibit deficits in emotional prosody and face emotion recognition performance. Further, although some gains were noted in the TBI group over the two-years following injury, factors such as SES and age at injury influenced the trajectory of recovery. The current findings indicate the relationship between TBI and emotion recognition is complex and may be influenced by a number of developmental and environmental factors. Results are discussed in terms of their similarity to previous investigations demonstrating the influence of environmental factors on behavioral recovery following pediatric TBI, and with regard to future investigations that can further explore the link between emotion recognition deficits and long-term behavioral and psychosocial recovery. (C) 2010 Elsevier Ltd. All rights reserved.	[Schmidt, Adam T.; Hanten, Gerri R.; Li, Xiaoqi; Orsten, Kimberley D.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA		Schmidt, AT (corresponding author), 1709 Dryden Rd,12th Floor, Houston, TX 77030 USA.	ats1978@gmail.com			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; T32 postdoctoral fellowship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD049350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was supported by NINDS grant # NS-21889 to HSL and by a T32 postdoctoral fellowship to ATS.	Adolphs R, 1996, J NEUROSCI, V16, P7678; Adolphs R, 1999, NEUROPSYCHOLOGIA, V37, P1285, DOI 10.1016/S0028-3932(99)00023-8; Adolphs R., 2001, NEUROPSYCHOLOGY, V15; Allerdings MD, 2006, BRAIN COGNITION, V60, P193, DOI 10.1016/j.bandc.2004.09.018; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Ariatti A, 2008, NEUROL SCI, V29, P219, DOI 10.1007/s10072-008-0971-9; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Brazdil M, 2009, NEUROIMAGE, V47, P376, DOI 10.1016/j.neuroimage.2009.03.081; Buchanan TW, 2000, COGNITIVE BRAIN RES, V9, P227, DOI 10.1016/S0926-6410(99)00060-9; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; Charbonneau S, 2003, NEUROPSYCHOLOGIA, V41, P605, DOI 10.1016/S0028-3932(02)00202-6; COPES WS, 1988, J TRAUMA, V28, P78, DOI 10.1097/00005373-198801000-00011; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Dekowska M, 2008, ACTA NEUROBIOL EXP, V68, P229; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Ekman P., 1976, PICTURES FACIAL AFFE; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hanten G, 2000, J MEM LANG, V43, P335, DOI 10.1006/jmla.2000.2731; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hanten G, 2009, TOP LANG DISORD, V29, P236, DOI 10.1097/TLD.0b013e3181b531f0; Hayes CJ, 2007, NEUROPSYCHOLOGIA, V45, P1135, DOI 10.1016/j.neuropsychologia.2006.10.015; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Herba C, 2004, J CHILD PSYCHOL PSYC, V45, P1185, DOI 10.1111/j.1469-7610.2004.00316.x; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Izard C, 2001, PSYCHOL SCI, V12, P18, DOI 10.1111/1467-9280.00304; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kotz SA, 2003, BRAIN LANG, V86, P366, DOI 10.1016/S0093-934X(02)00532-1; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; Leppanen JM, 2001, SCAND J PSYCHOL, V42, P429, DOI 10.1111/1467-9450.00255; Letswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2006, ARCH PHYS MED REHAB, V87, pS1, DOI 10.1016/j.apmr.2006.09.010; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; McClure EB, 2000, PSYCHOL BULL, V126, P424, DOI 10.1037/0033-2909.126.3.424; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 2005, BRAIN IMPAIR, V56, P56; Meletti S, 2009, EPILEPSIA, V50, P1547, DOI 10.1111/j.1528-1167.2008.01978.x; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Moos RH, 1994, LISRES A LIFE STRESS; Pell MD, 2006, BRAIN LANG, V96, P221, DOI 10.1016/j.bandl.2005.04.007; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/PMS.73.8.1139-1150; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; TONKS J, 2007, BRAIN IMPAIR, V8, P143, DOI DOI 10.1375/BRIM.8.2.143; Tonks J, 2008, BRAIN INJURY, V22, P325, DOI 10.1080/02699050801968303; Tonks J, 2007, BRAIN INJURY, V21, P623, DOI 10.1080/02699050701426865; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	70	51	51	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	AUG	2010	48	10					2869	2877		10.1016/j.neuropsychologia.2010.05.029			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	642AU	WOS:000281175900008	20678980	Green Accepted			2022-02-06	
J	Jiang, FX; Yurke, B; Schloss, RS; Firestein, BL; Langrana, NA				Jiang, Frank Xue; Yurke, Bernard; Schloss, Rene S.; Firestein, Bonnie L.; Langrana, Noshir A.			Effect of Dynamic Stiffness of the Substrates on Neurite Outgrowth by Using a DNA-Crosslinked Hydrogel	TISSUE ENGINEERING PART A			English	Article							CELL-ADHESION MOLECULE; CENTRAL-NERVOUS-SYSTEM; MECHANICAL-PROPERTIES; BRAIN-TISSUE; NEURAL DEVELOPMENT; GEL STIFFNESS; SPINAL-CORD; GROWTH; EXTENSION; SURFACES	Central nervous system tissues, like other tissue types, undergo constant remodeling, which potentially leads to changes in their mechanical stiffness. Moreover, mechanical compliance of central nervous system tissues can also be modified under external load such as that experienced in traumatic brain or spinal cord injury, and during pathological processes. Thus, the neuronal responses to the dynamic stiffness of the microenvironment are of significance. In this study, we induced decrease in stiffness by using a DNA-crosslinked hydrogel, and subjected rat spinal cord neurons to such dynamic stiffness. The neurons respond to the dynamic cues as evidenced by the primary neurite structure, and the response from each neurite property (e. g., axonal length and primary dendrite number) is consistent with the behavior on static gels of same substrate rigidity, with one exception of mean primary dendrite length. The results on cell population distribution confirm the neuronal responses to the dynamic stiffness. Quantification on the focal adhesion kinase expression in the neuronal cell body on dynamic gels suggests that neurons also modify adhesion in coping with the dynamic stiffnesses. The results reported here extend the neuronal mechanosensing capability to dynamic stiffness of extracellular matrix, and give rise to a novel way of engineering neurite outgrowth in time dimension.	[Jiang, Frank Xue; Schloss, Rene S.; Langrana, Noshir A.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA; [Yurke, Bernard] Boise State Univ, Dept Mat Sci & Engn, Boise, ID 83725 USA; [Yurke, Bernard] Boise State Univ, Dept Elect & Comp Engn, Boise, ID 83725 USA; [Firestein, Bonnie L.] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; [Langrana, Noshir A.] Rutgers State Univ, Dept Mech & Aerosp Engn, Piscataway, NJ 08854 USA		Langrana, NA (corresponding author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.	langrana@rutgers.edu		Firestein, Bonnie/0000-0002-1679-3565	New Jersey Commission on Spinal Cord Research [07A-019-SCR1]	This study was supported by a grant from the New Jersey Commission on Spinal Cord Research (Grant # 07A-019-SCR1). This work was performed toward the partial fulfillment of the Ph.D. requirements of the first author. We thank Dr. Penelope Georges for assistance in experiments.	ABBOTT NL, 1995, LANGMUIR, V11, P16, DOI 10.1021/la00001a005; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; Bao G, 2003, NAT MATER, V2, P715, DOI 10.1038/nmat1001; BONANOMI D, 2006, INTRACELLULAR MECHAN, P155; BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; BUSKIRK DR, 1980, NATURE, V285, P488, DOI 10.1038/285488a0; Cheng S, 2008, MED ENG PHYS, V30, P1318, DOI 10.1016/j.medengphy.2008.06.003; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; CROSSIN KL, 1989, CLIN CHEM, V35, P738; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; De R, 2007, NAT PHYS, V3, P655, DOI 10.1038/nphys680; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; El-Husseini, 2006, MOL MECH SYNAPTOGENE; Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006-3495(04)74140-5; ESCUIN S, 2006, INTRACELLULAR MECH N, P1; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Fass JN, 2003, BIOPHYS J, V85, P623, DOI 10.1016/S0006-3495(03)74506-8; Fischer TM, 2005, ANN BIOMED ENG, V33, P1229, DOI 10.1007/s10439-005-5509-1; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; GARNER JA, 1986, J NEUROSCI, V6, P3242; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Giniger E, 2002, DIFFERENTIATION, V70, P385, DOI 10.1046/j.1432-0436.2002.700801.x; Goffin JM, 2006, J CELL BIOL, V172, P259, DOI 10.1083/jcb.200506179; Gunn JW, 2005, J BIOMED MATER RES A, V72A, P91, DOI 10.1002/jbm.a.30203; Hachiya NS, 2008, MED HYPOTHESES, V70, P1034, DOI 10.1016/j.mehy.2007.06.043; Heidemann S R, 1991, Curr Opin Neurobiol, V1, P339, DOI 10.1016/0959-4388(91)90050-H; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Huang S, 2005, CANCER CELL, V8, P175, DOI 10.1016/j.ccr.2005.08.009; Janmey PA, 2009, CELL MOTIL CYTOSKEL, V66, P597, DOI 10.1002/cm.20382; Jiang FX, 2010, BIOMATERIALS, V31, P1199, DOI 10.1016/j.biomaterials.2009.10.050; Jiang FX, 2008, ANN BIOMED ENG, V36, P1565, DOI 10.1007/s10439-008-9530-z; JIANG FX, 2009, THESIS RUTGERS U NEW; JIANG X, 2007, OPEN NEUROSCI J, V1, P7; Kostic A, 2007, J CELL SCI, V120, P3895, DOI 10.1242/jcs.009852; LAFONT F, 1993, J CELL SCI, V104, P433; Lahann J, 2005, MRS BULL, V30, P185, DOI 10.1557/mrs2005.50; Leach JB, 2007, J NEURAL ENG, V4, P26, DOI 10.1088/1741-2560/4/2/003; Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178; LEVITAN IB, 1997, NEURON CELL MOL BIOL; LEVITAN IB, 1991, J CELL BIOL, V114, P143; Li L, 2008, ANN BIOMED ENG, V36, P865, DOI 10.1007/s10439-008-9458-3; Li YQ, 2001, BIOTECHNOL PROGR, V17, P348, DOI 10.1021/bp010005f; LIN D, 2006, J MATER RES, V20, P1456, DOI DOI 10.1557/JMR.2005.0186; Lin DC, 2004, J BIOMECH ENG-T ASME, V126, P104, DOI 10.1115/1.1645529; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; MILLER PD, 1994, J NEUROSCI, V14, P4217; Mrksich M, 2005, MRS BULL, V30, P180, DOI 10.1557/mrs2005.49; MULLER D, ROLE NCAM S IN PRESS; Petroll WM, 2004, INVEST OPHTH VIS SCI, V45, P3466, DOI 10.1167/iovs.04-0361; Petroll WM, 2003, CELL MOTIL CYTOSKEL, V55, P254, DOI 10.1002/cm.10126; POOLE AR, 1986, BIOCHEM J, V236, P1; Prag S, 2002, J CELL SCI, V115, P283; Reinhart-King CA, 2005, BIOPHYS J, V89, P676, DOI 10.1529/biophysj.104.054320; Rougon G, 2003, ANNU REV NEUROSCI, V26, P207, DOI 10.1146/annurev.neuro.26.041002.131014; Roy I, 2003, CHEM BIOL, V10, P1161, DOI 10.1016/j.chembiol.2003.12.004; Savtchenko LP, 2004, SYNAPSE, V51, P270, DOI 10.1002/syn.10300; Shreiber DI, 2003, BIOPHYS J, V84, P4102, DOI 10.1016/S0006-3495(03)75135-2; Small DH, 1996, J NEUROCHEM, V67, P889; Solon J, 2007, BIOPHYS J, V93, P4453, DOI 10.1529/biophysj.106.101386; Sparrey CJ, 2008, SPINE, V33, pE812, DOI 10.1097/BRS.0b013e3181894fd3; Sundararaghavan HG, 2009, BIOTECHNOL BIOENG, V102, P632, DOI 10.1002/bit.22074; Suter DM, 2000, J NEUROBIOL, V44, P97, DOI 10.1002/1097-4695(200008)44:2<97::AID-NEU2>3.0.CO;2-U; Sytnyk V, 2006, J CELL BIOL, V174, P1071, DOI 10.1083/jcb.200604145; Toga AW, 2003, ANNU REV BIOMED ENG, V5, P119, DOI 10.1146/annurev.bioeng.5.040202.121611; Trotter JA, 2000, BIOCHEM SOC T, V28, P357, DOI 10.1042/0300-5127:0280357; Tseng Y, 2002, CURR OPIN COLLOID IN, V7, P210, DOI 10.1016/S1359-0294(02)00050-X; TUNG PS, 1992, J CELL PHYSIOL, V152, P410, DOI 10.1002/jcp.1041520224; VANDENPOL AN, 1986, J CELL BIOL, V102, P2281, DOI 10.1083/jcb.102.6.2281; VIIDIK A, 1968, Journal of Biomechanics, V1, P3, DOI 10.1016/0021-9290(68)90032-8; Wang XJ, 2008, LANGMUIR, V24, P5942, DOI 10.1021/la704006z; Willits RK, 2004, J BIOMAT SCI-POLYM E, V15, P1521, DOI 10.1163/1568562042459698; Wottawah F, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.098103; Yang J, 2005, MRS BULL, V30, P189, DOI 10.1557/mrs2005.51; Yeo WS, 2003, J AM CHEM SOC, V125, P14994, DOI 10.1021/ja038265b; Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041; Yousaf MN, 2001, P NATL ACAD SCI USA, V98, P5992, DOI 10.1073/pnas.101112898; Yurke B, 2000, NATURE, V406, P605, DOI 10.1038/35020524; ZHENG J, 1991, J NEUROSCI, V11, P1117	81	51	52	2	31	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3341			TISSUE ENG PT A	Tissue Eng. Part A	JUN	2010	16	6					1873	1889		10.1089/ten.tea.2009.0574			17	Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Engineering; Materials Science	602UQ	WOS:000278164800008	20067396				2022-02-06	
J	Mtchedlishvili, Z; Lepsveridze, E; Xu, H; Kharlamov, EA; Lu, B; Kelly, KM				Mtchedlishvili, Zakaria; Lepsveridze, Eka; Xu, Hong; Kharlamov, Elena A.; Lu, Bo; Kelly, Kevin M.			Increase of GABA(A) receptor-mediated tonic inhibition in dentate granule cells after traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Dentate granule cells; GABA(A) receptor; Diazepam; Furosemide; THIP; Bicuculline; mIPSCs; Synaptic currents; Tonic currents	NUCLEUS BASALIS MAGNOCELLULARIS; AMINOBUTYRIC ACID(A) RECEPTORS; ALPHA-5 SUBUNIT; SYNAPTIC-TRANSMISSION; INCREASED EXPRESSION; NEUROTROPHIC FACTOR; DELTA-SUBUNIT; POSTSYNAPTIC CURRENTS; PERSISTENT ACTIVATION; ALTERED EXPRESSION	Traumatic brain injury (TBI) can result in altered inhibitory neurotransmission, hippocampal dysfunction, and cognitive impairments. GABAergic spontaneous and miniature inhibitory postsynaptic currents (sIPSCs and mIPSCs) and tonic (extrasynaptic) whole cell currents were recorded in control rat hippocampal dentate granule cells (DGCs) and at 90 days after controlled cortical impact (CCI). At 34 degrees C, in CCI DGCs, sIPSC frequency and amplitude were unchanged, whereas mIPSC frequency was decreased (3.10 +/- 0.84 Hz, n = 16, and 2.44 +/- 0.67 Hz, n = 7, p<0.05). At 23 degrees C, 300 nM diazepam increased peak amplitude of mIPSCs in control and CCI DGCs, but the increase was 20% higher in control (26.81 +/- 2.2 pA and 42.60 +/- 1.22 pA, n = 9, p = 0.031) compared to CCI DGCs (33.46 +/- 2.98 pA and 46.13 +/- 1.09 pA, n = 10, p = 0.047). At 34 degrees C, diazepam did not prolong decay time constants (6.59 +/- 0.12 ms and 6.62 +/- 0.98 ms, n = 9, p = 0.12), the latter suggesting that CCI resulted in benzodiazepine-insensitive pharmacology in synaptic GABA(A) receptors (GABA(A)Rs). In CCI DGCs, peak amplitude of mIPSCs was inhibited by 100 mu M furosemide (51.30 +/- 0.80 pA at baseline and 43.50 +/- 5.30 pA after furosemide, n = 5. p<0.001), a noncompetitive antagonist of GABA(A)Rs with an enhanced affinity to alpha 4 subunit-containing receptors. Potentiation of tonic current by the GABA(A)R delta subunit-preferring competitive agonist THIP (1 and 3 mu M) was increased in CCI DGCs (47% and 198%) compared to control DGCs (13% and 162%), suggesting the presence of larger tonic current in CCI DGCs; THIP (1 mu M) had no effect on mIPSCs. Taken together, these results demonstrate alterations in synaptic and extrasynaptic GABAARs in DGCs following CCI. (C) 2010 Elsevier Inc. All rights reserved.	[Mtchedlishvili, Zakaria; Xu, Hong; Lu, Bo; Kelly, Kevin M.] Allegheny Gen Hosp, Allegheny Singer Res Inst, Ctr Res Neurosci, Pittsburgh, PA 15212 USA; [Mtchedlishvili, Zakaria; Kharlamov, Elena A.; Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Neurol, Philadelphia, PA 19104 USA; [Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA; [Lepsveridze, Eka] Ilia Chavchavadze State Univ, Fac Life Sci, Tbilisi, Georgia		Mtchedlishvili, Z (corresponding author), Allegheny Gen Hosp, Allegheny Singer Res Inst, Ctr Res Neurosci, 9J9 ST,320 East North Ave, Pittsburgh, PA 15212 USA.	zmtchedl@wpahs.org	Lepsveridze, Eka/ABC-5582-2021	Harris, Neil/0000-0002-1965-6750	Health Research Formula Fund [RFA 01-07-26]; Pennsylvania Department of Health; Epilepsy Foundation; Georgian National Science Scholars Program	The study was supported by Health Research Formula Fund RFA 01-07-26, Pennsylvania Department of Health (ZM), a Research Grant from the Epilepsy Foundation (ZM), and a grant from the Georgian National Science Scholars Program (EL). We thank Teresa M. Hentosz for assistance in the preparation of the manuscript.	Adkins CE, 2001, J BIOL CHEM, V276, P38934, DOI 10.1074/jbc.M104318200; Alldred MJ, 2005, J NEUROSCI, V25, P594, DOI 10.1523/JNEUROSCI.4011-04.2005; AROLFO MP, 1991, BEHAV NEURAL BIOL, V55, P131, DOI 10.1016/0163-1047(91)80133-Y; Atack JR, 2006, NEUROPHARMACOLOGY, V51, P1023, DOI 10.1016/j.neuropharm.2006.04.018; Bai DL, 2001, MOL PHARMACOL, V59, P814, DOI 10.1124/mol.59.4.814; Banks MI, 1998, J NEUROSCI, V18, P1305; Bianchi MT, 2002, J PHYSIOL-LONDON, V544, P3, DOI 10.1113/jphysiol.2002.020255; Binder DK, 1999, J NEUROSCI, V19, P4616; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Bowser DN, 2002, P NATL ACAD SCI USA, V99, P15170, DOI 10.1073/pnas.212320199; Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806; Bright DP, 2007, J NEUROSCI, V27, P2560, DOI 10.1523/JNEUROSCI.5100-06.2007; BRIONI JD, 1988, PSYCHOPHARMACOLOGY, V96, P505, DOI 10.1007/BF02180032; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brown N, 2002, BRIT J PHARMACOL, V136, P965, DOI 10.1038/sj.bjp.0704795; BUCKMASTER PS, 1995, EUR J NEUROSCI, V7, P1393, DOI 10.1111/j.1460-9568.1995.tb01131.x; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Caraiscos VB, 2004, P NATL ACAD SCI USA, V101, P3662, DOI 10.1073/pnas.0307231101; CASTELLANO C, 1993, PSYCHOPHARMACOLOGY, V111, P134, DOI 10.1007/BF02245514; Cohen AS, 2003, EUR J NEUROSCI, V17, P1607, DOI 10.1046/j.1460-9568.2003.02597.x; COLLINS RC, 1983, BRAIN RES, V280, P25, DOI 10.1016/0006-8993(83)91170-8; Collinson N, 2006, PSYCHOPHARMACOLOGY, V188, P619, DOI 10.1007/s00213-006-0361-z; Collinson N, 2002, J NEUROSCI, V22, P5572; DAHHAOUI M, 1994, PHYSIOL BEHAV, V56, P257, DOI 10.1016/0031-9384(94)90193-7; Das P, 2004, NEUROSCIENCE, V124, P195, DOI 10.1016/j.neuroscience.2003.12.005; Dawson GR, 2006, J PHARMACOL EXP THER, V316, P1335, DOI 10.1124/jpet.105.092320; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Dinocourt C, 2006, EUR J NEUROSCI, V24, P1857, DOI 10.1111/j.1460-9568.2006.05067.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; Elmer E, 1998, NEUROSCIENCE, V83, P351, DOI 10.1016/S0306-4522(97)00387-4; EMFORS P, 1991, NEURONS, V7, P165; Engel AK, 2001, TRENDS COGN SCI, V5, P16, DOI 10.1016/S1364-6613(00)01568-0; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Eugene E, 2007, J NEUROSCI, V27, P14108, DOI 10.1523/JNEUROSCI.2618-07.2007; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Feng HJ, 2008, J NEUROPHYSIOL, V99, P1285, DOI 10.1152/jn.01180.2007; Gao L, 2005, NEUROPHARMACOLOGY, V48, P333, DOI 10.1016/j.neuropharm.2004.10.010; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P2139, DOI 10.1152/jn.1997.77.4.2139; Glykys J, 2008, J NEUROSCI, V28, P1421, DOI 10.1523/JNEUROSCI.4751-07.2008; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Goldschen-Ohm MP, 2010, MOL PHARMACOL, V77, P35, DOI 10.1124/mol.109.058289; Goodkin HP, 2008, J NEUROSCI, V28, P2527, DOI 10.1523/JNEUROSCI.3426-07.2008; Goodkin HP, 2005, J NEUROSCI, V25, P5511, DOI 10.1523/JNEUROSCI.0900-05.2005; Hajos N, 2000, EUR J NEUROSCI, V12, P810, DOI 10.1046/j.1460-9568.2000.00964.x; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; Hamann M, 2002, NEURON, V33, P625, DOI 10.1016/S0896-6273(02)00593-7; Hardingham NR, 1998, J PHYSIOL-LONDON, V507, P249, DOI 10.1111/j.1469-7793.1998.249bu.x; HEINEMANN U, 1992, EPILEPSY RES, P273; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Johansson IM, 2002, BRAIN RES, V934, P125, DOI 10.1016/S0006-8993(02)02414-9; Joshi S, 2009, NEUROSCIENCE, V164, P507, DOI 10.1016/j.neuroscience.2009.08.008; KANEDA M, 1995, J PHYSIOL-LONDON, V485, P419, DOI 10.1113/jphysiol.1995.sp020739; Kant GJ, 1996, PHARMACOL BIOCHEM BE, V53, P317, DOI 10.1016/0091-3057(95)02028-4; Kapur J, 1997, J NEUROSCI, V17, P7532, DOI 10.1523/jneurosci.17-19-07532.1997; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Kittler JT, 2003, CURR OPIN NEUROBIOL, V13, P341, DOI 10.1016/S0959-4388(03)00064-3; Kneussel M, 2000, J PHYSIOL-LONDON, V525, P1, DOI 10.1111/j.1469-7793.2000.t01-4-00001.x; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Korpi ER, 1997, BRIT J PHARMACOL, V120, P741, DOI 10.1038/sj.bjp.0700922; Kozlov AS, 2006, P NATL ACAD SCI USA, V103, P10058, DOI 10.1073/pnas.0603741103; Krazem A, 2001, PHARMACOL BIOCHEM BE, V68, P235, DOI 10.1016/S0091-3057(00)00444-5; Kushmerick C, 2006, J NEUROSCI, V26, P1366, DOI 10.1523/JNEUROSCI.3889-05.2006; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Liu QY, 2000, J NEUROPHYSIOL, V84, P1392, DOI 10.1152/jn.2000.84.3.1392; Llinas R, 2001, ANN NY ACAD SCI, V929, P166; Mangan PS, 2005, MOL PHARMACOL, V67, P775, DOI 10.1124/mol.104.007385; Mann EO, 2010, NAT NEUROSCI, V13, P205, DOI 10.1038/nn.2464; Maubach K, 2003, CNS NEUROL DISORD-DR, V2, P233, DOI 10.2174/1568007033482779; MAYO W, 1993, BRAIN RES, V607, P324, DOI 10.1016/0006-8993(93)91524-V; MAYO W, 1992, BRAIN RES, V589, P109, DOI 10.1016/0006-8993(92)91168-E; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; Micheva KD, 2005, J NEUROSCI, V25, P7481, DOI 10.1523/JNEUROSCI.1801-05.2005; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Mody I, 2004, TRENDS NEUROSCI, V27, P569, DOI 10.1016/j.tins.2004.07.002; Mtchedlishvili Z, 2006, MOL PHARMACOL, V69, P564, DOI 10.1124/mol.105.016683; Naylor DE, 2005, J NEUROSCI, V25, P7724, DOI 10.1523/JNEUROSCI.4944-04.2005; NUSSER Z, 1995, J NEUROSCI, V15, P2948; Nusser Z, 2002, J NEUROPHYSIOL, V87, P2624, DOI 10.1152/jn.2002.87.5.2624; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; Payne HL, 2006, J NEUROSCI, V26, P8600, DOI 10.1523/JNEUROSCI.1088-06.2006; Peng Z, 2002, J COMP NEUROL, V446, P179, DOI 10.1002/cne.10210; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Perrais D, 1999, J NEUROSCI, V19, P578; Pirker S, 2003, J NEUROPATH EXP NEUR, V62, P820, DOI 10.1093/jnen/62.8.820; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Qi ZH, 2007, J BIOL CHEM, V282, P33052, DOI 10.1074/jbc.M707233200; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RAFFALLISEBILLE MJ, 1990, PHARMACOL BIOCHEM BE, V35, P281, DOI 10.1016/0091-3057(90)90156-C; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Richerson GB, 2003, J NEUROPHYSIOL, V90, P1363, DOI 10.1152/jn.00317.2003; Rivera C, 2002, J CELL BIOL, V159, P747, DOI 10.1083/jcb.200209011; Rossi DJ, 1998, NEURON, V20, P783, DOI 10.1016/S0896-6273(00)81016-8; Rudolph U, 2006, CURR OPIN PHARMACOL, V6, P18, DOI 10.1016/j.coph.2005.10.003; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Sassoe-Pognetto M, 2000, J COMP NEUROL, V420, P481, DOI 10.1002/(SICI)1096-9861(20000515)420:4<481::AID-CNE6>3.0.CO;2-5; Shumate MD, 1998, EPILEPSY RES, V32, P114, DOI 10.1016/S0920-1211(98)00045-X; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Silvers JM, 2003, BRAIN RES REV, V43, P275, DOI 10.1016/j.brainresrev.2003.09.002; SOLTESZ I, 1995, J NEUROPHYSIOL, V73, P1763, DOI 10.1152/jn.1995.73.5.1763; Somogyi P, 1996, NEUROPHARMACOLOGY, V35, P1425, DOI 10.1016/S0028-3908(96)00086-X; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Stell BM, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0003.2002; STRINGER JL, 1989, EPILEPSY RES, V4, P177, DOI 10.1016/0920-1211(89)90002-8; Sun CS, 2007, J NEUROSCI, V27, P12641, DOI 10.1523/JNEUROSCI.4141-07.2007; Sun CS, 2004, BRAIN RES, V1029, P207, DOI 10.1016/j.brainres.2004.09.056; Sundstrom-Poromaa I, 2002, NAT NEUROSCI, V5, P721, DOI 10.1038/nn888; Sur C, 1999, MOL PHARMACOL, V56, P110, DOI 10.1124/mol.56.1.110; Terunuma M, 2008, J NEUROSCI, V28, P376, DOI 10.1523/JNEUROSCI.4346-07.2008; Toth Z, 1997, J NEUROSCI, V17, P8106; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; TRAUB RD, 1991, ANN NY ACAD SCI, V627, P277; Turkmen S, 2006, NEUROSCIENCE, V139, P651, DOI 10.1016/j.neuroscience.2005.12.031; Volgushev M, 2004, J NEUROPHYSIOL, V92, P212, DOI 10.1152/jn.01166.2003; Wafford KA, 1996, MOL PHARMACOL, V50, P670; Wall MJ, 1997, EUR J NEUROSCI, V9, P533, DOI 10.1111/j.1460-9568.1997.tb01630.x; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49; Wei WZ, 2003, J NEUROSCI, V23, P10650; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zhan RZ, 2009, J NEUROPHYSIOL, V102, P670, DOI 10.1152/jn.00147.2009	130	51	54	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2010	38	3			SI		464	475		10.1016/j.nbd.2010.03.012			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	595XU	WOS:000277648200017	20304069				2022-02-06	
J	Borges, A; Casselman, J				Borges, Alexandra; Casselman, Jan			Imaging the trigeminal nerve	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						Trigeminal neuropathy; Trigeminal neuralgia; Imaging the trigeminal nerve; Imaging technique; CT; MRI	NEUROVASCULAR COMPRESSION; MICROVASCULAR DECOMPRESSION; CRANIAL NERVES; NEURALGIA; PATHOLOGY; ANATOMY	Of all cranial nerves, the trigeminal nerve is the largest and the most widely distributed in the supra-hyoid neck. It provides sensory input from the face and motor innervation to the muscles of mastication. In order to adequately image the full course of the trigeminal nerve and its main branches a detailed knowledge of neuroanatomy and imaging technique is required. Although the main trunk of the trigeminal nerve is consistently seen on conventional brain studies, high-resolution tailored imaging is mandatory to depict smaller nerve branches and subtle pathologic processes. Increasing developments in imaging technique made possible isotropic sub-milimetric images and curved reconstructions of cranial nerves and their branches and led to an increasing recognition of symptomatic trigeminal neuropathies. Whereas MRI has a higher diagnostic yield in patients with trigeminal neuropathy, CT is still required to demonstrate the bony anatomy of the skull base and is the modality of choice in the context of traumatic injury to the nerve. Imaging of the trigeminal nerve is particularly cumbersome as its long course from the brainstem nuclei to the peripheral branches and its rich anastomotic network impede, in most cases, a topographic approach. Therefore, except in cases of classic trigeminal neuralgia, in which imaging studies can be tailored to the root entry zone, the full course of the trigeminal nerve has to be imaged. This article provides an update in the most recent advances on MR imaging technique and a segmental imaging approach to the most common pathologic processes affecting the trigeminal nerve. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Borges, Alexandra] Ctr Lisboa, Inst Portugues Oncol Francisco Gentil, Dept Radiol, P-1093 Lisbon, Portugal; [Casselman, Jan] AZ St Jan Brugge Antwerpen Hosp, Dept Radiol, Antwerp, Belgium; [Casselman, Jan] AZ St Augustinus Antwerpen Hosp, Dept Radiol, Antwerp, Belgium		Borges, A (corresponding author), Ctr Lisboa, Inst Portugues Oncol Francisco Gentil, Dept Radiol, Rua Prof Lima Basto, P-1093 Lisbon, Portugal.	borgalexandra@gmail.com					Axer H, 2007, J MAGN RESON IMAGING, V26, P905, DOI 10.1002/jmri.21088; Becker M, 2008, NEUROIMAG CLIN N AM, V18, P283, DOI 10.1016/j.nic.2007.11.002; Borges A, 2005, EUR RADIOL, V15, P511, DOI 10.1007/s00330-004-2613-9; Borges A, 2007, EUR RADIOL, V17, P2332, DOI 10.1007/s00330-006-0572-z; Borges A, 2007, EUR RADIOL, V17, P2112, DOI 10.1007/s00330-006-0575-9; Borges A, 2009, NEUROIMAG CLIN N AM, V19, P441, DOI 10.1016/j.nic.2009.06.001; Brisman R, 2004, J NEUROSURG, V100, P848, DOI 10.3171/jns.2004.100.5.0848; Brisman R, 2002, NEUROSURGERY, V50, P1261, DOI 10.1097/00006123-200206000-00015; Carvalho GA, 2000, NEUROSURGERY, V47, P1287, DOI 10.1097/00006123-200012000-00005; CASSELMAN JW, 2004, ER COURS MAGN RES IM; Chavin JM, 2003, OTOLARYNG CLIN N AM, V36, P1079, DOI 10.1016/S0030-6665(03)00124-5; Dandy W., 1934, AM J SURG, V24, P477; Delavelle J, 1998, INT J NEURORADIOL, V4, P445; DEMARCO JK, 1993, NEUROIMAG CLIN N AM, V3, P117; Devor M, 2002, J NEUROSURG, V96, P532, DOI 10.3171/jns.2002.96.3.0532; Fukuda H, 2003, SURG NEUROL, V59, P93, DOI 10.1016/S0090-3019(02)00993-X; Gass A, 1997, NEUROLOGY, V49, P1142, DOI 10.1212/WNL.49.4.1142; Go JL, 2001, SEMIN ULTRASOUND CT, V22, P502, DOI 10.1016/S0887-2171(01)90004-6; Gronseth G, 2008, NEUROLOGY, V71, P1183, DOI 10.1212/01.wnl.0000326598.83183.04; Jannetta PJ, 2003, NEUROSURGERY, V52, P1511, DOI 10.1227/01.NEU.0000068352.22859.82; Kuroiwa T, 1996, Radiat Med, V14, P235; Laine FJ, 1998, NEUROIMAG CLIN N AM, V8, P69; Lakshmi M, 2009, NEUROIMAG CLIN N AM, V19, P393, DOI 10.1016/j.nic.2009.06.004; Larrier D, 2003, OTOLARYNG CLIN N AM, V36, P1041, DOI 10.1016/S0030-6665(03)00127-0; LEBLANC A, 2001, ENCEPHALO PERIPHERAL, P79; LOURYAN S, 2004, ER COURS MAGN RES IM; Love S, 2001, BRAIN, V124, P2347, DOI 10.1093/brain/124.12.2347; LUFKIN R, 2000, TEACHING ATLAS HEAD; Lufkin RB, 2001, MRI HEAD NECK, V2nd; Majoie CBLM, 1997, RADIOLOGY, V204, P455, DOI 10.1148/radiology.204.2.9240535; Maroldi R, 1999, JBR-BTR, V82, P294; MASUR H, 1995, J NEUROL, V242, P93, DOI 10.1007/BF00887823; McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001; Muzammil S, 2009, SOUTH MED J, V102, P534, DOI 10.1097/SMJ.0b013e31819dc79b; Patel NK, 2003, BRIT J NEUROSURG, V17, P60, DOI 10.1080/0268869031000093735; Peker S, 2006, NEUROSURGERY, V59, P354, DOI 10.1227/01.NEU.0000223501.27220.69; WILSONPAWELS, 1998, CRANIAL NERVES ANATO; Yamamoto M, 2004, AM J ROENTGENOL, V182, P385, DOI 10.2214/ajr.182.2.1820385; Yoshino N, 2003, RADIOLOGY, V228, P539, DOI 10.1148/radiol.2282020439; Zakrzewska JM, 2002, CLIN J PAIN, V18, P14, DOI 10.1097/00002508-200201000-00003	40	51	56	4	11	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	MAY	2010	74	2					323	340		10.1016/j.ejrad.2010.02.006			18	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	594UW	WOS:000277565500005	20227216				2022-02-06	
J	Hall, SD; Yamawaki, N; Fisher, AE; Clauss, RP; Woodhall, GL; Stanford, IM				Hall, Stephen D.; Yamawaki, Naoki; Fisher, Alison E.; Clauss, Ralf P.; Woodhall, Gavin L.; Stanford, Ian M.			GABA(A) alpha-1 subunit mediated desynchronization of elevated low frequency oscillations alleviates specific dysfunction in stroke - A case report	CLINICAL NEUROPHYSIOLOGY			English	Article						Magnetoencephalography (MEG); GABA; Theta; Beta; Stroke; Pathological oscillations	TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; VEGETATIVE STATE; ZOLPIDEM; MAGNETOENCEPHALOGRAPHY; IMPROVEMENT; INSOMNIA; SIGNAL	Objective: The paradoxical effects of the hypnotic imidazopyridine zolpidem, widely reported in persistent vegetative state, have been replicated recently in brain-injured and cognitively impaired patients. However, the neuronal mechanisms underlying these benefits are yet to be demonstrated. We implemented contemporary neuroimaging methods to investigate sensorimotor and cognitive improvements, observed in stroke patient JP following zolpidem administration. Methods: We used Magnetic-Resonance-Imaging (MRI) and Magnetic-Resonance-Spectroscopy (MRS) to anatomically and chemically characterize stroke damage. Single-photon-emission-computed-tomography (SPECT) and magnetoencephalography (MEG) were used to identify changes in cerebrovascular perfusion and neuronal network activity in response to sub-sedative doses of zolpidem, zopiclone and placebo. Cognitive improvements were measured using the WAIS-III and auditory-verbal tasks. Results: MRI and MRS revealed a lesion with complete loss of neuronal viability in the left temporal-parietal region; whilst SPECT indicated improved perfusion in the affected hemisphere following zolpidem. MEG demonstrated high-amplitude theta (4-10 Hz) and beta (15-30 Hz) oscillations within the peri-infarct region, which reduced in power coincident with zolpidem uptake and improvements in cognitive and motor function. Conclusions: In JP, functional deficits and pathological oscillations appear coincidentally reduced following administration of low-dose zolpidem. Significance: GABA(A) alpha-1 sensitive desynchronisation of pathological oscillations may represent a biomarker and potential therapeutic target in brain injury. (C) 2009 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Hall, Stephen D.; Yamawaki, Naoki; Woodhall, Gavin L.; Stanford, Ian M.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England; [Fisher, Alison E.] Univ Bristol, Dept Expt Psychol, Bristol, Avon, England; [Clauss, Ralf P.] Royal Surrey Cty Hosp, Dept Nucl Med, Guildford, Surrey, England		Hall, SD (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.	hallsd@aston.ac.uk	Yamawaki, Naoki/AAD-5044-2022	Yamawaki, Naoki/0000-0001-8253-2059; Hall, Stephen/0000-0002-9274-6867; woodhall, gavin/0000-0003-1281-9008; Stanford, Ian M/0000-0002-5677-8538	Regen Therapeutics Plc.; RCUKUK Research & Innovation (UKRI); Wellcome TrustWellcome TrustEuropean Commission; The Dr. Hadwen Trus; Lord Dowding Fund	This work was supported by Regen Therapeutics Plc. and an RCUK Fellowship (SDH). MEG work was supported by The Wellcome Trust and The Dr. Hadwen Trust and the MRI work was supported by The Lord Dowding Fund. We thank Dr. Peter Magill, for helpful comments on the manuscript.	Adjamian P, 2004, CLIN NEUROPHYSIOL, V115, P691, DOI 10.1016/j.clinph.2003.10.023; Basso MR, 2002, CLIN NEUROPSYCHOL, V16, P57, DOI 10.1076/clin.16.1.57.8329; Brown P, 2001, J NEUROSCI, V21, P1033, DOI 10.1523/JNEUROSCI.21-03-01033.2001; Canive JM, 1996, PSYCHOPHARMACOL BULL, V32, P741; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss RP, 2004, ARZNEIMITTELFORSCH, V54, P641; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Daniele A, 1997, LANCET, V349, P1222, DOI 10.1016/S0140-6736(05)62416-6; Dooley M, 2000, DRUGS, V60, P413, DOI 10.2165/00003495-200060020-00014; Farver DK, 2001, ANN PHARMACOTHER, V35, P435; HALL SD, HUM BRAIN M IN PRESS, DOI DOI 10.1002/HBM.20889; Hall-Stoodley L, 2005, TRENDS MICROBIOL, V13, P7, DOI 10.1016/j.tim.2004.11.004; Hillebrand A, 2005, HUM BRAIN MAPP, V25, P199, DOI 10.1002/hbm.20102; Holm KJ, 2000, DRUGS, V59, P865, DOI 10.2165/00003495-200059040-00014; Jarry C, 2002, ANN PHARMACOTHER, V36, P1808; Jensen O, 2005, NEUROIMAGE, V26, P347, DOI 10.1016/j.neuroimage.2005.02.008; Kuhn AA, 2006, EUR J NEUROSCI, V23, P1956, DOI 10.1111/j.1460-9568.2006.04717.x; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Pfurtscheller G, 2001, VISION RES, V41, P1257, DOI 10.1016/S0042-6989(00)00235-2; POZA J, 2007, C P IEEE ENG MED BIO, P6180; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Singh KD, 2002, NEUROIMAGE, V16, P103, DOI 10.1006/nimg.2001.1050; Taniguchi M, 2000, NEUROIMAGE, V12, P298, DOI 10.1006/nimg.2000.0611; Tecchio F, 2006, J NEUROSCI RES, V83, P1077, DOI 10.1002/jnr.20796; Thomson AM, 2000, EUR J NEUROSCI, V12, P425, DOI 10.1046/j.1460-9568.2000.00915.x; Vrba J, 2001, METHODS, V25, P249, DOI 10.1006/meth.2001.1238; Yamamoto T, 2002, ACT NEUR S, V79, P79	29	51	52	0	15	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	APR	2010	121	4					549	555		10.1016/j.clinph.2009.11.084			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	575TK	WOS:000276091100013	20097125				2022-02-06	
J	Siegert, RJ; Jackson, DM; Tennant, A; Turner-Stokes, L				Siegert, Richard J.; Jackson, Diana M.; Tennant, Alan; Turner-Stokes, Lynne			FACTOR ANALYSIS AND RASCH ANALYSIS OF THE ZARIT BURDEN INTERVIEW FOR ACQUIRED BRAIN INJURY CARER RESEARCH	JOURNAL OF REHABILITATION MEDICINE			English	Article						carer; brain injury; burden; Zarit Burden Interview; factor analysis; Rasch analysis	QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; MEASUREMENT MODEL; STROKE PATIENTS; DEPRESSION; CAREGIVERS; CRITERIA; VERSION; IMPACT	Objective: To examine the dimensionality of the Zarit Burden Interview in a sample of carers of adults with acquired brain injury. Design: A cross-sectional UK survey using postal questionnaires. Participants: A sample of 222 carers; 43 men (19.4%) and 179 women (80.6%); mean age 54 years. Types of brain injury included traumatic brain injury (49.5%), stroke (25.9%), brain infection (17.3%), hypoxia (4.1%), and "other" (3.2"A). Methods: Exploratory and confirmatory factor analysis and Rasch analysis. Results: Unidimensionality was tested using confirmatory factor analysis, which showed a poor fit. The underlying structure of the Zarit Burden Interview was explored using principal components analysis and varimax rotation. This revealed 3 factors, although 1 comprised only 2 items. The 2 major factors identified were personal strain and role strain. They were then examined using Rasch analysis, which identified 2 brief and reliable unidimensional scales. There was no evidence of differential item functioning for different types of carer/brain injury. Conclusion: The Zarit Burden Interview is a promising measure for the assessment of burden in carers of people with an acquired brain injury. It offers 2 reliable, brief subscales of personal strain and role strain for this purpose. However, it remains for these 2 brief subscales to be validated clinically in future research.	[Siegert, Richard J.; Jackson, Diana M.; Turner-Stokes, Lynne] Kings Coll London, Dept Palliat Care Policy & Rehabil, London SE5 9RJ, England; [Tennant, Alan] Univ Leeds, Fac Med & Hlth, Leeds, W Yorkshire, England; [Turner-Stokes, Lynne] Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, London, England		Siegert, RJ (corresponding author), Kings Coll London, Guys Kings Coll Hosp, Dept Palliat Care Policy & Rehabil, Sch Med,Weston Educ Ctr, 3rd Floor,Cutcombe Rd,Denmark Hill, London SE5 9RJ, England.	richard.siegert@kcl.ac.uk	Siegert, Richard J./K-2030-2019; Turner-Stokes, Lynne/F-4418-2012; Jackson, Diana/C-3846-2009	Turner-Stokes, Lynne/0000-0002-3302-9462; Siegert, Richard/0000-0002-3074-0929	Department of HealthEuropean Commission [030/0066]; Dunhill Medical TrustDunhill Medical Trust; Luff Foundation	The authors are grateful to all the carers who participated in this research project, and to representatives of Headway, The Encephalitis Society and The Meningitis Trust for their help with recruitment. The project was commissioned and funded by the Department of Health (R&D grant 030/0066), but conducted and written up by an external group of researchers. The views expressed are not necessarily those of the Department of Health. Financial support for the preparation of this manuscript was provided by the Dunhill Medical Trust and the Luff Foundation.	Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS15, DOI 10.1053/apmr.2000.20619; Ankri J, 2005, INT J GERIATR PSYCH, V20, P254, DOI 10.1002/gps.1275; Babakus E., 1988, J ACAD MARKET SCI, V16, P95; Bedard M, 2001, GERONTOLOGIST, V41, P652, DOI 10.1093/geront/41.5.652; Boyer F, 2006, J REHABIL MED, V38, P309, DOI 10.1080/16501970600731578; Cano SJ, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-58; Heinemann AW, 2005, REHABIL PSYCHOL, V50, P6, DOI 10.1037/0090-5550.50.1.6; Hobart JC, 2007, LANCET NEUROL, V6, P1094, DOI 10.1016/S1474-4422(07)70290-9; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Knight B. G., 2000, J CLIN GEROPSYCHOLOG, V6, P249, DOI DOI 10.1023/A:1009530711710; Kreiner S, 2004, COMMUN STAT-THEOR M, V33, P1239, DOI 10.1081/STA-120030148; Molyneux GJ, 2008, INT PSYCHOGERIATR, V20, P1193, DOI 10.1017/S1041610208007515; O'Rourke N, 2003, GERONTOLOGIST, V43, P121, DOI 10.1093/geront/43.1.121; Pallant JF, 2007, BRIT J CLIN PSYCHOL, V46, P1, DOI 10.1348/014466506X96931; PARAG V, 2003, CEREBROVASC DIS, V25, P548; Pomeranz JL, 2008, REHABIL COUNS BULL, V51, P251, DOI 10.1177/0034355208317317; Smith AB, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-19; Tennant A, 2004, VALUE HEALTH, V7, pS22, DOI 10.1111/j.1524-4733.2004.7s106.x; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Thompson B., 2004, EXPLORATORY CONFIRMA; Tooth L, 2008, QUAL LIFE RES, V17, P267, DOI 10.1007/s11136-007-9300-7; van Heugten C, 2006, J REHABIL MED, V38, P153, DOI 10.1080/16501970500441898; Visser-Meily JMA, 2004, CLIN REHABIL, V18, P601, DOI 10.1191/0269215504cr776oa; WHITLATCH CJ, 1991, GERONTOLOGIST, V31, P9, DOI 10.1093/geront/31.1.9; Wright BD., 1982, RATING SCALE ANAL; Zarit S, 1987, INSTRUCTIONS BURDEN	28	51	53	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	APR	2010	42	4					302	309		10.2340/16501977-0511			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	598HY	WOS:000277827500003	20461331	gold, Green Submitted			2022-02-06	
J	Bagnato, S; Boccagni, C; Prestandrea, C; Sant'Angelo, A; Castiglione, A; Galardi, G				Bagnato, S.; Boccagni, C.; Prestandrea, C.; Sant'Angelo, A.; Castiglione, A.; Galardi, G.			Prognostic value of standard EEG in traumatic and non-traumatic disorders of consciousness following coma	CLINICAL NEUROPHYSIOLOGY			English	Article						Level of cognitive functioning (LCF); Synek scale; Altered consciousness; Traumatic brain injury; Vegetative state; Minimally conscious state	PERSISTENT VEGETATIVE STATE; AGE-RELATED DIFFERENCES; SEVERE HEAD-INJURY; BRAIN-DAMAGE; ALPHA-COMA; RECOVERY; SCALE; NEUROPATHOLOGY; POTENTIALS; ADULTS	Objective: To investigate the prognostic value of standard electroencephalogram (EEG) in predicting the improvement of the level of consciousness in patients suffering from severe disturbances of consciousness following coma caused by acute brain injuries. Methods: A standard EEG was recorded at admission in our rehabilitation department in a total of 46 patients with impaired consciousness states following coma (22 patients with traumatic brain injuries, 24 patients with non-traumatic brain injuries). We quantified the EEG abnormalities using the scale of Synek (1988) and correlated them with the basal level of cognitive functioning (LCF) scale score and with its variation after three months. Results: EEG scores correlated with LCF scores at admission (p < 0.01) and with LCF scores' variation after three months (p < 0.01) in patients with traumatic brain injury; EEG scores correlated only with LCF scores variation after three months (p < 0.01) in patients with non-traumatic brain injury. Conclusions: Standard EEG, analysed using the Synek scale, has a good prognostic value in both groups of patients with disorders of consciousness. Significance: This work may have implications for clinical care, rehabilitative programs and medical-legal decisions in patients with impaired consciousness states following coma due to acute brain injuries. (C) 2009 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Bagnato, S.; Boccagni, C.; Sant'Angelo, A.; Castiglione, A.; Galardi, G.] Fdn Ist San Raffaele G Giglio, Rehabil Dept, Neurorehabil Unit, I-90015 Cefalu, PA, Italy; [Bagnato, S.; Boccagni, C.; Prestandrea, C.; Sant'Angelo, A.; Galardi, G.] Fdn Ist San Raffaele G Giglio, Rehabil Dept, Neurophysiol Unit, I-90015 Cefalu, PA, Italy		Galardi, G (corresponding author), Fdn Ist San Raffaele G Giglio, Rehabil Dept, Neurorehabil Unit, I-90015 Cefalu, PA, Italy.	giuseppe.galardi@hsrgiglio.it	Bagnato, Sergio/H-6842-2013	Bagnato, Sergio/0000-0002-6289-1887; Boccagni, Cristina/0000-0002-6317-015X			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Amantini A, 2005, CLIN NEUROPHYSIOL, V116, P229, DOI 10.1016/j.clinph.2004.07.008; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Beaumont JG, 2005, NEUROPSYCHOL REHABIL, V15, P184, DOI 10.1080/09602010443000489; Coleman MR, 2005, J NEUROL NEUROSUR PS, V76, P432, DOI 10.1136/jnnp.2004.045930; Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; DUFFY FH, 1984, ANN NEUROL, V16, P430, DOI 10.1002/ana.410160403; DUFFY FH, 1993, NEUROBIOL AGING, V14, P73, DOI 10.1016/0197-4580(93)90025-7; FAUVAGE B, 1993, CRIT CARE MED, V21, P472, DOI 10.1097/00003246-199303000-00029; Fischer C., 2002, Annales de Readaptation et de Medecine Physique, V45, P448, DOI 10.1016/S0168-6054(02)00295-7; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kaplan PW, 2000, CLIN NEUROPHYSIOL, V111, P584, DOI 10.1016/S1388-2457(99)00303-X; Kaplan PW, 1999, CLIN NEUROPHYSIOL, V110, P205, DOI 10.1016/S1388-2457(98)00046-7; Lescot T, 2009, ANN NY ACAD SCI, V1157, P71, DOI 10.1111/j.1749-6632.2008.04120.x; Monti MM, 2009, ANN NY ACAD SCI, V1157, P81, DOI 10.1111/j.1749-6632.2008.04121.x; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Sancisi E, 2009, BRAIN INJURY, V23, P163, DOI 10.1080/02699050802660446; Sara M, 2007, BRAIN INJURY, V21, P101, DOI 10.1080/02699050601151761; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; Wijdicks EFM, 2005, MAYO CLIN PROC, V80, P1037, DOI 10.4065/80.8.1037; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020; Young GB, 2009, ANN NY ACAD SCI, V1157, P32, DOI 10.1111/j.1749-6632.2009.04471.x; YOUNG GB, 1994, ELECTROEN CLIN NEURO, V91, P93, DOI 10.1016/0013-4694(94)90030-2	30	51	52	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAR	2010	121	3					274	280		10.1016/j.clinph.2009.11.008			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	556AE	WOS:000274557800005	20005157				2022-02-06	
J	Sendroy-Terrill, M; Whiteneck, GG; Brooks, CA				Sendroy-Terrill, Melissa; Whiteneck, Gale G.; Brooks, Cynthia A.			Aging With Traumatic Brain Injury: Cross-Sectional Follow-Up of People Receiving Inpatient Rehabilitation Over More Than 3 Decades	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Brain injury; chronic; Follow-up studies; Outcomes assessment (health care); Rehabilitation	SPINAL-CORD-INJURY; QUALITY-OF-LIFE; FUNCTIONAL INDEPENDENCE MEASURE; SICKNESS IMPACT PROFILE; SEVERE HEAD-INJURY; ENVIRONMENTAL-FACTORS; UPPER EXTREMITY; SHOULDER PAIN; OLDER-ADULTS; HEALTH	Sendroy-Terrill M, Whiteneck GG, Brooks CA. Aging with traumatic brain injury: cross-sectional follow-up of people receiving inpatient rehabilitation over more than 3 decades. Arch Phys Med Rehabil 2010;91:489-97. Objective: To investigate aging with traumatic brain injury (TBI) by determining if long-term outcomes after TBI are predicted by years postinjury and age at injury after controlling for the severity of the injury and sex. Design: Cross-sectional follow-up telephone survey. Setting: Community residents who had received initial treatment in a comprehensive inpatient rehabilitation hospital. Participants: Survivors of TBI (N=243) stratified by years postinjury (in seven 5-year cohorts ranging from I to over 30 years postinjury) and by age at injury (in 2 cohorts of people injured before or after age 30). Interventions: None. Main Outcome Measures: Measures of postconcussive symptoms, major secondary conditions including fatigue (Modified Fatigue Impact Scale), physical and cognitive activity limitations (FIM, Alertness Behavior Subscale of the Sickness Impact Profile, Medical Outcomes Study 12-Item Health Status Survey Short Form), societal participation restrictions (Craig Handicap Assessment and Reporting Technique), environmental barriers (Craig Hospital Inventory of Environmental Factors), and perceived quality of life (Satisfaction with Life Scale). Results: Most problems identified by the outcome measures were reported by one fourth to one half of the study participants. Increasing decades postinjury predicted declines in physical and cognitive functioning, declines in societal participation, and increases in contractures. Increasing age at injury predicted declines in functional independence, increases in fatigue, declines in societal participation, and declines in perceived environmental barriers. Conclusions: This investigation has increased our understanding of the aging process after TBI by demonstrating that both components of aging (years postinjury and age at injury) are predictive of several outcomes after TBI.	[Sendroy-Terrill, Melissa; Whiteneck, Gale G.; Brooks, Cynthia A.] Craig Hosp, Res Dept, Englewood, CO 80113 USA		Sendroy-Terrill, M (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson, Englewood, CO 80113 USA.	msendroy@craighospital.org			National Institute of Disability Rehabilitation and Research [H133A020510]	Supported by an award to Rocky Mountain Regional Brain Injury Model Systems from the National Institute of Disability Rehabilitation and Research (grant no. H133A020510). The opinions expressed are those of the authors and do not necessarily reflect the views of the National Institute of Disability Rehabilitation and Research.	AGRE J, 2000, PHYS MED REHABILITAT, P1591; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ballinger DA, 2000, ARCH PHYS MED REHAB, V81, P1575, DOI 10.1053/apmr.2000.18216; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Brooks D N, 1979, Int Rehabil Med, V1, P160; Chamberlain M. A., 1995, TRAUMATIC BRAIN INJU, P3; Charlifue S, 2004, ARCH PHYS MED REHAB, V85, P1848, DOI 10.1016/j.apmr.2004.03.017; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Colantonio A, 2004, INT J REHABIL RES, V27, P209, DOI 10.1097/00004356-200409000-00006; Craig Hospital Research Department, 2001, CRAIG HOSP INV ENV F; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; GROSWASSER Z, 1977, SCAND J REHABIL MED, V9, P147; Gutierrez DD, 2007, J SPINAL CORD MED, V30, P251, DOI 10.1080/10790268.2007.11753933; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; He W., 2005, 65 US 2005; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hulley S.B., 2001, DESIGNING CLIN RES E; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; KARPMAN T, 1985, J APPL REHABILITATIO, V0017, P00028; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; *KESSL MED REH RES, 2001, TRAUM BRAIN INJ MOD; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lesser I M, 1991, J Neuropsychiatry Clin Neurosci, V3, P33; Levin HS., 1982, NEUROBEHAVIORAL CONS; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Menzel JC, 2008, BRAIN INJURY, V22, P375, DOI 10.1080/02699050802001492; MILLER LL, 1989, COMPUT CHEM, V13, P1, DOI 10.1016/0097-8485(89)80021-X; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Pennings JL, 1993, ARCH SURG-CHICAGO, V128, P93; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; PENTLAND WE, 1991, PARAPLEGIA, V29, P521, DOI 10.1038/sc.1991.75; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Ravesloot C, 1998, CLIN PSYCHOL PSYCHOT, V5, P76, DOI 10.1002/(SICI)1099-0879(199806)5:2<76::AID-CPP156>3.0.CO;2-5; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; ROSENTHAL M, 1990, REHABILITATION ADULT, P190; Ross A M, 1992, J Neurosci Nurs, V24, P88; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SIE IH, 1992, ARCH PHYS MED REHAB, V73, P44; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; *STAT U NY, 1997, GUID UN DAT SYST MED; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TRIESCHMANN RB, 1990, J HEAD TRAUMA REHAB, V5, P57; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Ware J, 1994, SF 36 PHYS MENTAL SU; WATERS RL, 1993, AGING SPINAL CORD IN, P53; Weddell RA, 2006, BRAIN INJURY, V20, P1221, DOI 10.1080/02699050601049783; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, P1793, DOI 10.1016/j.apmr.2004.04.024; Whiteneck G, 2001, COLORADO TRAUMATIC B; Whiteneck GG, 2004, ARCH PHYS MED REHAB, V85, P1324, DOI 10.1016/j.apmr.2003.09.027; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519	88	51	52	1	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2010	91	3					489	497		10.1016/j.apmr.2009.11.011			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	592YM	WOS:000277417900025	20298844				2022-02-06	
J	Togher, L; Power, E; Tate, R; McDonald, S; Rietdijk, R				Togher, Leanne; Power, Emma; Tate, Robyn; McDonald, Skye; Rietdijk, Rachel			Measuring the social interactions of people with traumatic brain injury and their communication partners: The adapted Kagan scales	APHASIOLOGY			English	Article; Proceedings Paper	39th Annual Clinical Aphasiology Conference	MAY 26-30, 2009	Keystone, CO			Traumatic brain injury; Rating scales; Conversation; Assessment; Cognitive-communication	CONVERSATION; IMPAIRMENT; DISCOURSE; ADULTS	Background: Considerable attention has been given to the nature of communication impairments of individuals with TBI (Coelho, 2007; Ylvisaker, Turkstra, Coelho, 2005). However, there have been few data focusing on the way communication partners deal with the often distressing sequelae of TBI. Aims: This study reports inter- and intra-rater reliability of the Adapted Measure of Support in Conversation (MSC) and Measure of Participation in Conversation (MPC) for TBI interactions. Method Procedures: The MSC and MPC were adapted to reflect theoretical models of cognitive-communication support for people with TBI. A total of 10 casual and 10 purposeful TBI interactions were independently rated by two raters to establish inter-rater reliability and by one rater on two separate occasions to determine intra-rater reliability. Outcomes Results: Excellent inter-rater agreement was established on the MSC (ICC = 0.85-0.97) and the MPC (ICC = 0.84-0.89). Intra-rater agreement was also strong (MSC: ICC = 0.80-0.90; MPC: ICC = 0.81-0.92). Over 90% of all ratings scored within 0.5 on a 9-point scale. Conclusions: This is the first scale to measure the communication partner during TBI interactions. It shows promise in evaluating communication partner training programmes.	[Togher, Leanne] Univ Sydney, Natl Hlth & Med Res Council, Fac Hlth Sci, Lidcombe, NSW 1825, Australia; [Tate, Robyn] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia; [McDonald, Skye] Univ New S Wales, Sydney, NSW, Australia		Togher, L (corresponding author), Univ Sydney, Natl Hlth & Med Res Council, Fac Hlth Sci, POB 170, Lidcombe, NSW 1825, Australia.	leanne.togher@usyd.edu.au	Power, Emma/A-9263-2015; Rietdijk, Rachael/J-6573-2012; McDonald, Skye/G-4118-2014; Togher, Leanne/AAC-7083-2019	Power, Emma/0000-0002-2638-0406; Rietdijk, Rachael/0000-0003-4343-4039; McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748			Adamovich B. B., 1992, SCALES COGNITIVE ABI; Bellon ML, 2006, BRAIN INJURY, V20, P1069, DOI 10.1080/02699050600909813; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Kagan Aura, 2004, Top Stroke Rehabil, V11, P67; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Shelton C, 2007, BRAIN INJURY, V21, P1259, DOI 10.1080/02699050701716935; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Togher L, 2009, BRAIN IMPAIR, V10, P188, DOI 10.1375/brim.10.2.188; Turkstra L.S., 2006, BRAIN IMPAIR, V7, P234, DOI [DOI 10.1375/BRIM.7.3.234, 10.1375/brim.7.3.234]; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.3.CO;2-5; World Health Organization, 2007, INT CLASS FUNCT DIS; Ylvisaker M., 1993, STAFF DEV CLIN INTER, P57; Ylvisaker M, 1998, TRAUMATIC BRAIN INJU, P303; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	26	51	51	0	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology		2010	24	6-8					914	927	PII 919045510	10.1080/02687030903422478			14	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	628WL	WOS:000280154900020					2022-02-06	
J	Dickerson, RN; Mitchell, JN; Morgan, LM; Maish, GO; Croce, MA; Minard, G; Brown, RO				Dickerson, Roland N.; Mitchell, Jennifer N.; Morgan, Laurie M.; Maish, George O., III; Croce, Martin A.; Minard, Gayle; Brown, Rex O.			Disparate Response to Metoclopramide Therapy for Gastric Feeding Intolerance in Trauma Patients With and Without Traumatic Brain Injury	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article						metoclopramide; erythromycin; enteral feeding; motility; trauma; traumatic brain injury	CRITICALLY-ILL PATIENTS; EARLY ENTERAL NUTRITION; SEVERE HEAD-INJURY; MECHANICALLY VENTILATED PATIENTS; INTRACRANIAL-PRESSURE; CRITICAL ILLNESS; SEVERITY SCORE; CLINICAL-TRIAL; QT INTERVAL; ERYTHROMYCIN	Patients with traumatic brain injury (TBI) have delayed gastric emptying and often require prokinetic drug therapy to improve enteral feeding tolerance. The authors hypothesized that metoclopramide was less efficacious for improving gastric feeding tolerance for trauma patients with TBI compared to trauma patients Without TBI. A retrospective analysis was conducted of patients admitted to the trauma or neurosurgical intensive care unit who received gastric feeding from January 2006 to April 2008. Gastric feeding intolerance was defined by a gastric residual Volume >200 mL or emesis with abdominal distension or discomfort. Patients with gastric feeding intolerance were given metoclopramide 10 mg intravenously every 6 hours, followed by a dose escalation to 20 mg, and then combination therapy with metoclopramide and erythromycin 250 mg intravenously every 6 hours if intolerance persisted. In total, 882 trauma patients (49% with TBI) were evaluated. TBI patients had a higher incidence of gastric feeding intolerance than those without TBI (18.6% vs 10.4%, P <= .001). Efficacy rates for metoclopramide 10 mg. metoclopramide 20 mg, and metoclopramide-erythromycin were 55%, 62%, and 79%, respectively (P <= .03). Metoclopramide failure occurred in 54% of patients with TBI compared to 35% of patients without TBI, respectively (P <= .02), due to a greater prevalence of tachyphylaxis. Single-drug therapy with metoclopramide was less effective for TBI trauma patients compared to trauma patients without TBI. Combination therapy with erythromycin as first-line therapy for TBI trauma patients with gastric feeding intolerance is indicated if there are no contraindications or significant drug interactions. (JPEN J Parenter Enteral Nutr. 2009;33:646-655)	[Dickerson, Roland N.; Mitchell, Jennifer N.; Brown, Rex O.] Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, Memphis, TN 38163 USA; [Maish, George O., III; Croce, Martin A.; Minard, Gayle] Univ Tennessee, Hlth Sci Ctr, Dept Surg, Memphis, TN 38163 USA; [Morgan, Laurie M.] Reg Med Ctr Memphis, Dept Pharm, Memphis, TN USA		Dickerson, RN (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, 910 Madison Bldg,Room 308, Memphis, TN 38163 USA.	rdickerson@utmem.edu		Dickerson, Roland/0000-0002-2086-6317			Anfinson Theodore J, 2002, Psychopharmacol Bull, V36, P82; Artinian V, 2006, CHEST, V129, P960, DOI 10.1378/chest.129.4.960; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berne JD, 2002, J TRAUMA, V53, P422, DOI 10.1097/00005373-200209000-00004; BLISS DZ, 1992, AM J CLIN NUTR, V55, P753, DOI 10.1093/ajcn/55.3.753; Bochicchio GV, 2006, JPEN-PARENTER ENTER, V30, P503, DOI 10.1177/0148607106030006503; Chapman MJ, 2007, CURR OPIN CRIT CARE, V13, P187, DOI 10.1097/MCC.0b013e3280523a88; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; COOKE RS, 1995, INJURY, V26, P399, DOI 10.1016/0020-1383(95)00064-G; Davies AR, 2002, CRIT CARE MED, V30, P586, DOI 10.1097/00003246-200203000-00016; Deehan S, 2002, J NEUROSURG ANESTH, V14, P157, DOI 10.1097/00008506-200204000-00013; DICKERSON RN, 1990, J AM COLL NUTR, V9, P86; Dickerson RN, 2008, NUTRITION, V24, P536, DOI 10.1016/j.nut.2008.02.008; Esparza J, 2001, INTENS CARE MED, V27, P660, DOI 10.1007/s001340100880; Fruhwald S, 2007, INTENS CARE MED, V33, P36, DOI 10.1007/s00134-006-0452-7; GARRICK T, 1988, GASTROENTEROLOGY, V95, P26, DOI 10.1016/0016-5085(88)90286-7; GUENTER PA, 1991, JPEN-PARENTER ENTER, V15, P277, DOI 10.1177/0148607191015003277; Hawkyard CV, 2007, J ANTIMICROB CHEMOTH, V59, P347, DOI 10.1093/jac/dkl537; Jooste CA, 1999, INTENS CARE MED, V25, P464, DOI 10.1007/s001340050881; Kacker V, 1999, EUR J PHARMACOL, V369, P65, DOI 10.1016/S0014-2999(99)00038-2; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kao CH, 1998, J NUCL MED, V39, P1798; Kearns PJ, 2000, CRIT CARE MED, V28, P1742, DOI 10.1097/00003246-200006000-00007; Klodell CT, 2000, AM J SURG, V179, P168, DOI 10.1016/S0002-9610(00)00297-X; Kompan L, 1999, INTENS CARE MED, V25, P157, DOI 10.1007/s001340050809; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Landzinski J, 2008, JPEN-PARENTER ENTER, V32, P45, DOI 10.1177/014860710803200145; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Liu BA, 2004, NEW ENGL J MED, V351, P1053, DOI 10.1056/NEJMp048192; MacLaren R, 2000, CRIT CARE MED, V28, P438, DOI 10.1097/00003246-200002000-00025; MacLaren R, 2001, CLIN THER, V23, P1855, DOI 10.1016/S0149-2918(00)89081-5; MacLaren R, 2008, JPEN-PARENTER ENTER, V32, P412, DOI 10.1177/0148607108319803; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; Marino LV, 2003, BRIT J NEUROSURG, V17, P24, DOI 10.1080/026889031000093708; MCARTHUR CJ, 1995, INTENS CARE MED, V21, P573, DOI 10.1007/BF01700162; McClave Stephen A., 2002, Journal of Parenteral and Enteral Nutrition, V26, pS80, DOI 10.1177/014860710202600613; Mentec H, 2001, CRIT CARE MED, V29, P1955, DOI 10.1097/00003246-200110000-00018; Montejo JC, 1999, CRIT CARE MED, V27, P1447, DOI 10.1097/00003246-199908000-00006; Mutlu GM, 2001, CHEST, V119, P1222, DOI 10.1378/chest.119.4.1222; Neumann DA, 2002, CRIT CARE MED, V30, P1436, DOI 10.1097/00003246-200207000-00006; Nguyen NQ, 2007, CRIT CARE MED, V35, P2561, DOI 10.1097/01.CCM.0000286397.04815.B1; Nguyen NQ, 2007, CRIT CARE MED, V35, P483, DOI 10.1097/01.CCM.0000253410.36492.E9; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; Nursal TZ, 2007, J CLIN NEUROSCI, V14, P344, DOI 10.1016/j.jocn.2005.11.011; Ott L, 1999, J NEUROTRAUM, V16, P233, DOI 10.1089/neu.1999.16.233; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; Parlak I, 2005, EMERG MED J, V22, P621, DOI 10.1136/emj.2004.014712; POWER I, 1989, ANAESTHESIA, V44, P563, DOI 10.1111/j.1365-2044.1989.tb11442.x; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Ray WA, 2004, NEW ENGL J MED, V351, P1089, DOI 10.1056/NEJMoa040582; Reignier J, 2004, CRIT CARE MED, V32, P94, DOI 10.1097/01.CCM.0000104208.23542.A8; Ritz MA, 2005, INTENS CARE MED, V31, P949, DOI 10.1007/s00134-005-2663-8; Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; STEWART RM, 1995, SURGERY, V117, P68, DOI 10.1016/S0039-6060(05)80232-6; Thor Piotr J, 2003, Med Sci Monit, V9, pCR392; TWYMAN D, 1985, JPEN-PARENTER ENTER, V9, P679, DOI 10.1177/0148607185009006679; van der Voort PHJ, 2001, CRIT CARE, V5, P216, DOI 10.1186/cc1026; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; ZITELLI BJ, 1987, CLIN PEDIATR, V26, P117, DOI 10.1177/000992288702600302	61	51	60	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0148-6071	1941-2444		JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	NOV-DEC	2009	33	6					646	655		10.1177/0148607109335307			10	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	514KN	WOS:000271393400009	19892902				2022-02-06	
J	Moran, LM; Taylor, HG; Ganesalingam, K; Gastier-Foster, JM; Frick, J; Bangert, B; Dietrich, A; Nuss, KE; Rusin, J; Wright, M; Yeates, KO				Moran, Lisa M.; Taylor, H. Gerry; Ganesalingam, Kalaichelvi; Gastier-Foster, Julie M.; Frick, Jessica; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn E.; Rusin, Jerome; Wright, Martha; Yeates, Keith O.			Apolipoprotein E4 as a Predictor of Outcomes in Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies/Society-of-Pediatric-Research	APR 29-MAY 02, 2006	San Francisco, CA	Pediat Acad Soc, Soc Pediat Res		APO E; neuropsychology; pediatric brain injury	E EPSILON-4 ALLELE; HEAD-INJURY; E GENOTYPE; POSTCONCUSSIVE SYMPTOMS; ALZHEIMERS-DISEASE; E POLYMORPHISM; APOE GENOTYPE; ASSOCIATION; CHILDREN; RECOVERY	The epsilon 4 allele of the apolipoprotein E (APOE) gene has been linked to negative outcomes among adults with traumatic brain injury (TBI) across the spectrum of severity, with preliminary evidence suggesting a similar pattern among children. This study investigated the relationship of the APOE epsilon 4 allele to outcomes in children with mild TBI. Participants in this prospective, longitudinal study included 99 children with mild TBI between the ages of 8 and 15 recruited from consecutive admissions to Emergency Departments at two large children's hospitals. Outcomes were assessed acutely in the Emergency Department and at follow-ups at 2 weeks, 3 months, and 12 months post-injury. Among the 99 participants, 28 had at least one epsilon 4 allele. Children with and without an epsilon 4 allele did not differ demographically. Children with an epsilon 4 allele were significantly more likely than those without an epsilon 4 allele to have a Glasgow Coma Scale score of less than 15, but the groups did not differ on any other measures of injury severity. Those with an epsilon 4 allele exhibited better performance than children without an epsilon 4 allele on a test of constructional skill, but the groups did not differ on any other neuropsychological tests. Children with and without an epsilon 4 allele also did not differ on measures of post-concussive symptoms. Overall, the findings suggest that the APOE epsilon 4 allele is not consistently related to the outcomes of mild TBI in children.	[Yeates, Keith O.] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Columbus, OH 43205 USA; [Moran, Lisa M.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Ganesalingam, Kalaichelvi; Gastier-Foster, Julie M.; Dietrich, Ann; Nuss, Kathryn E.; Yeates, Keith O.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Gastier-Foster, Julie M.; Frick, Jessica] Nationwide Childrens Hosp, Dept Lab Med, Columbus, OH 43205 USA; [Gastier-Foster, Julie M.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn E.] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020; Gastier-Foster, Julie/E-3105-2011	Yeates, Keith/0000-0001-7680-2892; Nuss, Kathryn/0000-0003-2185-7364	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD39834, HD44099] Funding Source: Medline		*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; AYR LK, 2007, DISS ABSTR INT B, V68, P4121; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Delis D, 1994, MANUAL CALIFORNIA VE; Eichner JE, 2002, AM J EPIDEMIOL, V155, P487, DOI 10.1093/aje/155.6.487; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Higgins GA, 1997, PHARMACOL BIOCHEM BE, V56, P675, DOI 10.1016/S0091-3057(96)00420-0; JENNETT B, 1975, LANCET, V1, P480; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Jofre-Monseny L, 2008, MOL NUTR FOOD RES, V52, P131, DOI 10.1002/mnfr.200700322; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kuroda MM, 2007, PEDIATRICS, V119, P306, DOI 10.1542/peds.2006-1083; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MITTENBERG W, 1997, CLIN NEUROPSYCHOL, V11, P205; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oria RB, 2005, PEDIATR RES, V57, P310, DOI 10.1203/01.PDR.0000148719.82468.CA; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Quinn TJ, 2004, NEUROPATH APPL NEURO, V30, P569, DOI 10.1111/j.1365-2990.2004.00581.x; SAHAKIAN BJ, 1992, J ROY SOC MED, V85, P399; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wechsler D., 2011, WECHSLER ABBREVIATED; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; [No title captured]	49	51	52	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1489	1495		10.1089/neu.2008.0767			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200006	19645623	Green Published			2022-02-06	
J	Wade, SL; Oberjohn, K; Burkhardt, A; Greenberg, I				Wade, Shari L.; Oberjohn, Karen; Burkhardt, Abby; Greenberg, Ira			Feasibility and Preliminary Efficacy of a Web-Based Parenting Skills Program for Young Children With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acquired brain injury; intervention; online; parenting skills; telehealth; treatment	PSYCHIATRIC-DISORDERS; INTERACTION THERAPY; UNITED-STATES; BEHAVIOR; ADOLESCENTS; REHABILITATION; RESPONSIVENESS; ADAPTATION; PREVALENCE; PREDICTORS	Objective: To report the feasibility and preliminary efficacy of a Web-based parenting skills program to reduce behavior problems following traumatic brain Injury (TBI) in young children. Methods: Families of 9 children between the ages of 3 and 8 years with TBI, injured less than 24 months earlier, participated in a pilot study of a Web-based parenting skills program designed to increase positive parenting skills and to improve caregiver stress management and coping. The program consisted of 10 core sessions and up to 4 supplemental sessions. Each session consisted of self-guided didactic information, video modeling skills, and exercises. Online sessions were followed by synchronous sessions providing in vivo coaching of target skills. Results: Caregivers completed an average of 12 sessions (range 5-24). Ratings of ease of use and satisfaction were high. Paired t tests revealed significant improvements in target parenting behaviors between baseline and session 2 and between sessions 2 and 4. These improvements were maintained at follow-up. Among the 5 families who completed the follow-up assessment, there were trends for reductions in the overall number of behavior problems. Conclusions: This study provides preliminary evidence of the potential feasibility and efficacy of an online parenting skills intervention for improving positive parenting skills and for reducing child behavior problems following early TBI.	[Wade, Shari L.] Univ Cincinnati, Med Ctr, Div Pediat Phys Med & Rehabil, Cincinnati Childrens Hosp,Coll Med, Cincinnati, OH 45229 USA; [Greenberg, Ira] Miami Univ, Oxford, OH 45056 USA		Wade, SL (corresponding author), Univ Cincinnati, Med Ctr, Div Pediat Phys Med & Rehabil, Cincinnati Childrens Hosp,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org			National Institute of Disability and Rehabilitation Research	This project was supported by a Field-initiated research grant from the National Institute of Disability and Rehabilitation Research (Dr Wade). The authors acknowledge the contributions of Erna Olafson, PhD; Erica Pearl, Psyl); and Christopher Kaeponer PhD, in the development and refinement of the intervention materials. Also the authors acknowledge the assistance of Taulina Osinska and Tara Lane in data coding and entry. Results reported in this article were presented in part at the 2 0 0 8 meeting of the Society for Computers in Psychology in Chicago, Illinois.	Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; BOGGS SR, 1990, J CLIN CHILD PSYCHOL, V19, P75, DOI 10.1207/s15374424jccp1901_9; Bradley RH, 2007, DEV PSYCHOL, V43, P1390, DOI 10.1037/0012-1649.43.6.1390; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; BURNS GL, 1991, PSYCHOL ASSESSMENT J, V3, P202, DOI DOI 10.1037/1040-3590.3.2.202; Catroppa C, 2006, Pediatr Rehabil, V9, P89, DOI 10.1080/13638490500155458; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; Eyberg S., 1988, CHILD FAMILY BEHAV T, V10, P33, DOI [10.1300/J019v10n01_04, DOI 10.1300/J019V10N01_04]; Eyberg S. M., 2005, MANUAL DYADIC PARENT; EYBERG SM, 1995, PSYCHOPHARMACOL BULL, V31, P83; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Harwood MD, 2004, J CLIN CHILD ADOLESC, V33, P601, DOI 10.1207/s15374424jccp3303_17; Harwood MD, 2006, J ABNORM CHILD PSYCH, V34, P335, DOI 10.1007/s10802-006-9025-z; Kerr C, 2006, J MED INTERNET RES, V8, DOI 10.2196/jmir.8.3.e13; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Landry SH, 1997, DEV PSYCHOL, V33, P1040, DOI 10.1037/0012-1649.33.6.1040; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; ROTHBAUM F, 1994, PSYCHOL BULL, V116, P55, DOI 10.1037/0033-2909.116.1.55; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Smith KE, 2006, PEDIATRICS, V117, P1608, DOI 10.1542/peds.2005-1284; Steelman LM, 2002, J APPL DEV PSYCHOL, V23, P135, DOI 10.1016/S0193-3973(02)00101-6; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wade SL, 2006, J CONSULT CLIN PSYCH, V51, P178; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	37	51	51	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					239	247		10.1097/HTR.0b013e3181ad6680			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000003	19625863				2022-02-06	
J	Leon-Carrion, J; Martin-Rodriguez, JF; Damas-Lopez, J; Martin, JMBY; Dominguez-Morales, MR				Leon-Carrion, Jose; Francisco Martin-Rodriguez, Juan; Damas-Lopez, Jesus; Manuel Barroso y Martin, Juan; Rosario Dominguez-Morales, Maria			Delta-alpha ratio correlates with level of recovery after neurorehabilitation in patients with acquired brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						Functional assessment; Quantitative EEG; Acquired brain injury; Delta-alpha ratio; Neuropsychological rehabilitation; Long-term outcome	ACUTE ISCHEMIC-STROKE; INDEPENDENT COMPONENT ANALYSIS; MINIMALLY CONSCIOUS STATE; QUANTITATIVE EEG; SYMMETRY-INDEX; INPATIENT REHABILITATION; CEREBRAL INFARCTION; CORTICAL RHYTHMS; DIFFUSION; PERFUSION	Objective: To explore the relationship between three QEEG global indexes and their association with functional outcome after neurorehabilitation in non-acute acquired brain injury (ABI) patients (traumatic brain injury and stroke). Methods: Twenty-one adult ABI patients in post-acute phase were studied. Delta-alpha ratio (DAR), Power Ratio Index (PRI) and Mean Brain Symmetry Index (mBSI) were calculated from resting-state EEG taken at admission. These indexes and other clinical variables were correlated with functional recovery achieved after six months of neurorehabilitation. Results: DAR showed the highest strength of association with the functional outcome measure (rho = -0.65, P = 0.002). The other QEEG indexes and clinical variables showed modest non-significant correlations. A posteriori group analysis showed higher DAR in patients with poor recovery as compared to good recovery patients. Conclusions: Functional recovery after neurorehabilitation appears to be associated with a number of clinical and neurophysiological variables. Among the latter, the ratio between delta and alpha may play a significant role in predicting and monitoring functional rehabilitation outcome. Significance: Neurophysiological assessment of ABI patients may be an important tool in monitoring and predicting outcomes after neurorehabilitation. (C) 2009 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Leon-Carrion, Jose; Manuel Barroso y Martin, Juan] Univ Seville, Sch Psychol, Dept Expt Psychol, Human Neuropsychol Lab, Seville 41018, Andalucia, Spain; [Leon-Carrion, Jose; Francisco Martin-Rodriguez, Juan; Damas-Lopez, Jesus; Rosario Dominguez-Morales, Maria] Ctr Brain Injury Rehabil CRECER, Seville, Spain		Leon-Carrion, J (corresponding author), Univ Seville, Sch Psychol, Dept Expt Psychol, Human Neuropsychol Lab, C Camilo Jose Cela S-N, Seville 41018, Andalucia, Spain.	leoncarrion@us.es	Barroso y Martin, Juan Manuel/AAB-9758-2020	Martin Rodriguez, Juan Francisco/0000-0003-1392-8775	Spanish Ministry of Science and Education as part of the National Plan for Scientific Research, Development and Technological Innovation; European Regional Development Fund (ERDF)European Commission [FIT-300100-2005-37, FIT-300100-2006-77]; Fundacion Cajasol de Sevilla	This study has been funded in part by the Spanish Ministry of Science and Education as part of the National Plan for Scientific Research, Development and Technological Innovation (2004-2007), and co-funded by the European Regional Development Fund (ERDF): FIT-300100-2005-37 and FIT-300100-2006-77, and the Fundacion Cajasol de Sevilla.	Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Babiloni C, 2004, NEUROIMAGE, V22, P57, DOI 10.1016/j.neuroimage.2003.09.028; Baird AE, 2000, CEREBROVASC DIS, V10, P441, DOI 10.1159/000016105; Barber PA, 1998, NEUROLOGY, V51, P418, DOI 10.1212/WNL.51.2.418; Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; COBB WA, 1979, ELECTROEN CLIN NEURO, V47, P251, DOI 10.1016/0013-4694(79)90278-5; DASILVA FHL, 1977, NEUROSCI LETT, V6, P237, DOI 10.1016/0304-3940(77)90024-6; DASILVA FHL, 1980, ELECTROEN CLIN NEURO, V50, P449, DOI 10.1016/0013-4694(80)90011-5; de Vos CC, 2008, J CLIN NEUROPHYSIOL, V25, P77, DOI 10.1097/WNP.0b013e31816ef725; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DOMINGUEZMORALE.MR, 1999, REV ESP NEUROPSICOL, V1, P105; DOODS TA, 1993, ARCH PHYS MED REHAB, V74, P531; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Finnigan SP, 2007, CLIN NEUROPHYSIOL, V118, P2525, DOI 10.1016/j.clinph.2007.07.021; Finnigan SP, 2004, STROKE, V35, P899, DOI 10.1161/01.STR.0000122622.73916.d2; GALINDOLUCAS A, 2001, REV ESP NEUROPSICOL, V3, P82; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Goldman RI, 2002, NEUROREPORT, V13, P2487, DOI 10.1097/00001756-200212200-00022; Gomez CM, 2006, BRAIN RES, V1107, P151, DOI 10.1016/j.brainres.2006.06.019; Goncalves SI, 2006, NEUROIMAGE, V30, P203, DOI 10.1016/j.neuroimage.2005.09.062; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; Hari R, 1997, INT J PSYCHOPHYSIOL, V26, P51, DOI 10.1016/S0167-8760(97)00755-1; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Iriarte J, 2003, J CLIN NEUROPHYSIOL, V20, P249, DOI 10.1097/00004691-200307000-00004; John ER, 2006, CLIN EEG NEUROSCI, V37, P135, DOI 10.1177/155005940603700210; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Leon Carrion J., 2001, REV ESPANOLA NEUROPS, V3, P58; Leon-Carrion J, 2008, CLIN NEUROPHYSIOL, V119, P1506, DOI 10.1016/j.clinph.2008.03.030; Leon-Carrion J, 2008, BRAIN INJURY, V22, P61, DOI 10.1080/02699050701824143; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Lopes da Silva, 2005, ELECTROENCEPHALOGRAP, P339; Machado C, 2004, CLIN EEG NEUROSCI, V35, P116, DOI 10.1177/155005940403500303; Manshanden I, 2002, CLIN NEUROPHYSIOL, V113, P1937, DOI 10.1016/S1388-2457(02)00304-8; Muresanu DF, 2008, J NEUROL SCI, V267, P112, DOI 10.1016/j.jns.2007.10.016; Murri L, 1998, NEUROPHYSIOL CLIN, V28, P249, DOI 10.1016/S0987-7053(98)80115-9; Nadeau SE, 2002, LANCET NEUROL, V1, P126, DOI 10.1016/S1474-4422(02)00044-3; NAGATA K, 1989, ELECTROEN CLIN NEURO, V72, P16, DOI 10.1016/0013-4694(89)90027-8; Niedzwecki CM, 2008, J HEAD TRAUMA REHAB, V23, P209, DOI 10.1097/01.HTR.0000327253.61751.29; NUWER MR, 1987, NEUROLOGY, V37, P1153, DOI 10.1212/WNL.37.7.1153; Prigatano GP, 2000, JAMA-J AM MED ASSOC, V284, P1783, DOI 10.1001/jama.284.14.1783; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P420, DOI 10.1016/0013-4694(83)90224-9; Salenius S, 1995, ELECTROEN CLIN NEURO, V95, P453, DOI 10.1016/0013-4694(95)00155-7; SANDFORD AJ, 1971, BIOL RHYTHMS HUMAN P, P179; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Thatcher RW, 1999, INTRO QUANTITATIVE E, P29; TOLONEN U, 1984, PROG BRAIN RES, V62, P51; Turner-Stokes L, 2002, DISABIL REHABIL, V24, P383, DOI 10.1080/096382801101550; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; van Putten MJAM, 2007, CLIN NEUROPHYSIOL, V118, P2362, DOI 10.1016/j.clinph.2007.07.019; van Putten MJAM, 2004, CLIN NEUROPHYSIOL, V115, P1189, DOI 10.1016/j.clinph.2003.12.002	54	51	54	0	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JUN	2009	120	6					1039	1045		10.1016/j.clinph.2009.01.021			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	463WT	WOS:000267464800005	19398371				2022-02-06	
J	Yang, M; Guo, QJ; Zhang, XT; Sun, SG; Wang, YH; Zhao, LW; Hu, EX; Li, CY				Yang Meng; Guo Qingjie; Zhang Xiangtong; Sun Shugang; Wang Yaohua; Zhao Liwei; Hu Enxi; Li Changyu			Intensive insulin therapy on infection rate, days in NICU, in-hospital mortality and neurological outcome in severe traumatic brain injury patients: A randomized controlled trial	INTERNATIONAL JOURNAL OF NURSING STUDIES			English	Article						Intensive insulin therapy; Severe brain trauma; Hyperglycemia; Nursing	INTERVENTION SCORING SYSTEM; HEAD-INJURY; HYPERGLYCEMIA; MANAGEMENT; GLUCOSE; STRESS; STROKE	Objectives: Evaluate the impact of an intensive insulin therapy and conventional glucose control protocol during staying in neurological intensive care unit (NICU) on infection rate, days in NICU, in-hospital mortality and long-term neurological outcome in severe traumatic brain injury (TBI) patients. Methods: A total of 240 patients with severe TBI (GCS score 3-8) admitted to NICU were prospectively enrolled and randomly assigned either to conventional insulin therapy or to intensive insulin therapy. Patients in intensive glucose control group (n = 121) received continuous insulin infusion to maintain glucose levels between 4.4 mmol/l (80 mg/dl) and 6.1 mmol/l (110 mg/dl). Patients in the conventional treatment group (n = 119) were not given insulin unless glucose levels were greater than 11.1 mmol/l (200 mg/dl). Both groups were treated with insulin infusion to maintain normoglycemia after leaving NICU. Comparison was made against conventional insulin therapy using a randomized trial design. The primary outcomes is the mortality rate at 6 Months follow-up. The second outcomes including ICU infection rate, duration of ICU stay, in-hospital mortality rate and neurologic outcome at 6 months follow-up. Results: There was no significant difference in gender (66% vs. 67% male), age (46 +/- 11 years vs. 45 +/- 10 years), APACHE II score (30 vs. 29), TISS-28 score (47 vs. 46), and Glasgow Coma Score (GCS, 5.3 vs. 5.3) between the two groups. Overall mortality rates at 6 months follow-up were similar in the 2 groups (61 of 117, 52.1% vs. 62 of 116, 53.4%; P = 0.8). The infection rate during the study was significantly higher in patients who received conventional insulin therapy than that in patients who received intensive insulin therapy (46.2% vs. 31.4%; P < 0.05). The days stay in NICU was shorter in intensive insulin control group than that in conventional therapy group [4.2 days vs. 5.6 days (medians) P < 0.05]. The in-hospital mortality during the Study was similar in conventional and intensive therapy groups (34 of 119, 28.6% vs. 35 of 121, 28.9% in the conventional and intensive insulin therapy groups; P = 0.85). The neurologic outcome according to Glasgow Outcome Score (COS) at 6 months (GOS 5 and 4) was better in the intensive insulin therapy group (34 of 117, 29.1%) than that in the conventional therapy group (26 of 116, 22.4%, P < 0.05). Conclusions: Mortality rates at 6 months follow-up are not affected by intensive glucose control in patients with severe TBI. Intensive insulin therapy decreases infection rate and days in NICU and improves the neurological outcome at 6 months follow-up, while has no obvious influence on in-hospital mortality of severe TBI patients. (C) 2009 Elsevier Ltd. All rights reserved.	[Guo Qingjie] Harbin Med Coll, Affiliated Hosp 1, Dept Neurosurg, Harbin, Peoples R China; [Yang Meng; Zhang Xiangtong; Sun Shugang; Wang Yaohua; Zhao Liwei; Hu Enxi; Li Changyu] Harbin Med Coll, Affiliated Hosp 1, Dept Emergency Neurosurg, Harbin, Peoples R China; [Yang Meng; Zhang Xiangtong; Sun Shugang; Wang Yaohua; Zhao Liwei; Hu Enxi; Li Changyu] Harbin Med Coll, Affiliated Hosp 1, Neurol Intens Care Unit, Harbin, Peoples R China		Guo, QJ (corresponding author), Harbin Med Coll, Affiliated Hosp 1, Dept Neurosurg, Harbin, Peoples R China.	guoqingjie188@yahoo.com.cn			Nature Science Foundation of Heilongjiang ProvinceNatural Science Foundation of Heilongjiang Province [D200847]	This research was supported partly by the Nature Science Foundation of Heilongjiang Province (D200847).	ARISTEDIS R, 2000, NEUROSURGERY, V46, P335; Bhalla A, 2003, EUR J NEUROL, V10, P25, DOI 10.1046/j.1468-1331.2003.00504.x; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; HORAN TC, 2004, HOSP EPIDEMIOLOGY IN, P1659; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; MIZOCK BA, 1995, AM J MED, V98, P75, DOI 10.1016/S0002-9343(99)80083-7; Scalea TM, 2007, ANN SURG, V246, P605, DOI 10.1097/SLA.0b013e318155a789; SHANGRAW RE, 1989, METABOLISM, V38, P983, DOI 10.1016/0026-0495(89)90010-3; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Sperry JL, 2007, J TRAUMA, V63, P487, DOI 10.1097/TA.0b013e31812e51fc; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	22	51	56	2	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0020-7489	1873-491X		INT J NURS STUD	Int. J. Nurs. Stud.	JUN	2009	46	6					753	758		10.1016/j.ijnurstu.2009.01.004			6	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	452GB	WOS:000266527100002	19232615				2022-02-06	
J	Herrmann, N; Rapoport, MJ; Rajaram, RD; Chan, F; Kiss, A; Ma, AK; Feinstein, A; McCullagh, S; Lanctot, KL				Herrmann, Nathan; Rapoport, Mark J.; Rajaram, Ryan D.; Chan, Florance; Kiss, Alex; Ma, Andrew K.; Feinstein, Anthony; McCullagh, Scott; Lanctot, Krista L.			Factor Analysis of the Rivermead Post-Concussion Symptoms Questionnaire in Mild-to-Moderate Traumatic Brain Injury Patients	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							DEPRESSION FOLLOWING MILD; VISION-RELATED DISABILITY; MAJOR DEPRESSION; HEAD-INJURY; NEUROPSYCHIATRIC SEQUELAE; PSYCHOLOGICAL DISTRESS; PSYCHIATRIC-DISORDERS; SOMATIC SYMPTOMS; SERTRALINE; SCALE	Posttraumatic brain injury patients with depressive symptoms were compared with nondepressed mild and moderate traumatic brain injury (TBI) patients based on their scores on the Rivermead Post-Concussion Symptoms Questionnaire (RPCSQ). A factor analysis demonstrated that the items of the RPCSQ loaded into three factors: mood and cognition, general somatic, and visual somatic symptom groups. Factor scores based on this model were calculated for each group and it was found that depressed subjects reported a greater severity of all three symptom groups compared to nondepressed patients. These results suggest that depression post-TBI may influence patient perception of postconcussion	[Lanctot, Krista L.] Sunnybrook Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada		Lanctot, KL (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Psychiat, Rm FG05,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Rapoport, Mark/AAD-8581-2020; Lanctot, Krista L./AAY-4820-2020	Lanctot, Krista L./0000-0001-7024-6637	Ontario Mental Health Foundation (OMHF); Ontario Neurotrauma Foundation (ONF)	We would like to acknowledge the support of the Ontario Mental Health Foundation (OMHF) and the Ontario Neurotrauma Foundation (ONF).	Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; de Coster L, 2005, INT J GERIATR PSYCH, V20, P358, DOI 10.1002/gps.1290; de Jonge P, 2006, AM J PSYCHIAT, V163, P138, DOI 10.1176/appi.ajp.163.1.138; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Deb S, 1999, AM J PSYCHIAT, V156, P374; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; First M.B., 1996, STRUCTURED CLIN INTE; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Katon W, 2001, ANN INTERN MED, V134, P917, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00017; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Maskell F, 2007, BRAIN INJURY, V21, P741, DOI 10.1080/02699050701472109; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rees RJ, 2007, NEUROREHABILITATION, V22, P229; Rhee SH, 1999, ARTHRIT CARE RES, V12, P392, DOI 10.1002/1529-0131(199912)12:6<392::AID-ART7>3.0.CO;2-9; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Rutner D, 2006, BRAIN INJURY, V20, P1079, DOI 10.1080/02699050600909904; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Walker JG, 2006, BRIT J HEALTH PSYCH, V11, P303, DOI 10.1348/135910705X68681; Walker JG, 2006, CLIN EXP OPHTHALMOL, V34, P734, DOI 10.1111/j.1442-9071.2006.01340.x; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Waraich P, 2004, CAN J PSYCHIAT, V49, P124, DOI 10.1177/070674370404900208; Watkins LL, 2003, AM HEART J, V146, P48, DOI 10.1016/S0002-8703(03)00083-8; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914	41	51	51	0	10	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	MAY	2009	21	2					181	188					8	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	472SL	WOS:000268152300011	19622689	Bronze			2022-02-06	
J	Church, TE				Church, Thomas E.			Returning Veterans on Campus with War Related Injuries and the Long Road Back Home	JOURNAL OF POSTSECONDARY EDUCATION AND DISABILITY			English	Article								This article reviews the growing numbers of returning military personnel attending higher education based on emerging national trends, including the new GI Educational Bill, amendments to the ADA, and the rising unemployment rate. The trauma of war and the high survival rate have resulted in a high percentage of veterans returning from the Global War on Terror (GWT) who will experience a wide range of health issues as a result of their exposure to combat trauma and blast injuries. Many of these injuries will not be visible and will include physical wounds, post traumatic stress disorder (PTSD), depression, and traumatic brain injuries (TBI) requiring accessible campuses and classroom accommodations. However, many veterans are not utilizing the traditional service providers for students with disabilities in higher education. Therefore colleges and universities need to engage veterans and utilize their strengths in designing welcoming campuses that facilitate success for adult learners.									Abdul-Kadir S., 2008, AOL; American Psychiatric Association, 2004, DIAGN STAT MAN MENT; [Anonymous], 2007, STUD VETS QUART HOM; Bilmes L., 2007, RWP07 001; Center for Disease Control and Prevention, 2007, FACTS MILD TRAUM BRA; Defense and Veterans Brain Injuries Center, 2008, BLAST INJ; DO-IT, 2007, FAC ROOM; Durand M., 2002, ABNORMAL PSYCHOL; Eliscu J., 2008, ROLLING STONE; Evans K., 2009, WALL STREET J, pA1; Fontana A., 2008, ENCY PSYCHOL TRAUMA; Ford J., 2008, ENCY PSYCHOL TRAUMA; Institute of Medicine, 2008, IOM GULF WAR HLTH, VVII; Kaplan A., 2008, PSYCHIAT TIMES, V25, P13; Morgan D., 2008, POST TRAUMATIC STRES; National Association of State Head Injury Administrators, 2007, TRAUM BRAIN INJ FACT; National Institute of Mental Health, 2007, FACTS POST TRAUM STR; Quinn P, 2008, AOL NEWS; Read J., 2008, ENCY PSYCHOL TRAUMA; Remarque E., 2001, THE ROAD BACK; Reyes Gilbert., 2008, ENCY PSYCHOL TRAUMA; Ritchie E., 2008, ENCY PSYCHOL TRAUMA; Roer B., 2007, HIGH RATE PTSD RETUR; Rugaber C., 2008, MERCURY NEWS    1212; Sachs R., 2008, INSIDE HIGHER ED; Shay J., 1994, ACHILLES IN VIETNAM; SHAY Jonathan, 2002, ODYSSEUS IN AM; Stiglitz J.E., 2008, 3 TRILLION DOLLAR WA; Tanielian T., 2008, INVISIBLE WOUNDS WAR	29	51	51	0	0	ASSOC HIGHER EDUCATION & DISABILITY-AHEAD	COLUMBUS	ASSOC HIGHER EDUCATION & DISABILITY-AHEAD, COLUMBUS, OH 00000 USA	2379-7762	2328-3343		J POSTSECOND EDUC DI	J. Postsecond. Educ. Disabil.		2009	22	1			SI		43	52					10	Education, Special	Emerging Sources Citation Index (ESCI)	Education & Educational Research	VE7EM	WOS:000440138000006					2022-02-06	
J	Yu, D; Neeley, WL; Pritchard, CD; Slotkin, JR; Woodard, EJ; Langer, R; Teng, YD				Yu, Dou; Neeley, William L.; Pritchard, Christopher D.; Slotkin, Jonathan R.; Woodard, Eric J.; Langer, Robert; Teng, Yang D.			Blockade of Peroxynitrite-Induced Neural Stem Cell Death in the Acutely Injured Spinal Cord by Drug-Releasing Polymer	STEM CELLS			English	Article						Spinal cord injury; Neural stem cell; Nitric oxide; Peroxynitrite; PLGA scaffold; Neuroinflammation	NITRIC-OXIDE SYNTHASE; 4-BENZOIC ACID PORPHYRIN; ISCHEMIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; FUNCTIONAL RECOVERY; INDUCED APOPTOSIS; OXIDATIVE STRESS; PROGENITOR CELLS; MOTOR-NEURONS; IN-VIVO	Therapeutic impact of neural stem cells (NSCs) for acute spinal cord injury (SCI) has been limited by the rapid loss of donor cells. Neuroinflammation is likely the cause. As there are close temporal-spatial correlations between the inducible nitric oxide (NO) synthase expression and the donor NSC death after neurotrauma, we reasoned that NO-associated radical species might be the in. ammatory effectors which eliminate NSC grafts and kill host neurons. To test this hypothesis, human NSCs (hNSCs: 5 x 10(4) to 2 x 10(6) per milliliter) were treated in vitro with "plain'' medium, 20 mu M glutamate, or donors of NO and peroxynitrite (ONOO-; 100 and 400 mu M of spermine or DETA NONOate, and SIN-1, respectively). hNSC apoptosis primarily resulted from SIN-1 treatment, showing ONOO--triggered protein nitration and the activation of p38 MAPK, cytochrome c release, and caspases. Therefore, cell death following post-SCI (p.i.) NO serge may be mediated through conversion of NO into ONOO-. We subsequently examined such causal relationship in a rat model of dual penetrating SCI using a retrievable design of poly-lactic-co-glycolic acid (PLGA) scaffold seeded with hNSCs that was shielded by drug-releasing polymer. Besides confirming the ONOO--induced cell death signaling, we demonstrated that cotransplantation of PLGA film embedded with ONOO- scavenger, manganese (III) tetrakis (4-benzoic acid) porphyrin, or uric acid (1 mu mol per film), markedly protected hNSCs 24 hours p.i. (total: n = 5 10). Our findings may provide a bioengineering approach for investigating mechanisms underlying the host microenvironment and donor NSC interaction and help formulate strategies for enhancing graft and host cell survival after SCI. STEM CELLS 2009;27:1212-1222	[Yu, Dou; Pritchard, Christopher D.; Slotkin, Jonathan R.; Teng, Yang D.] Harvard Univ, Sch Med, Dept Neurosurg, Brigham & Womens Hosp, Boston, MA 02115 USA; [Yu, Dou; Teng, Yang D.] Vet Affairs Boston Healthcare Syst, Div SCI Res, Boston, MA USA; [Neeley, William L.; Pritchard, Christopher D.; Langer, Robert] New England Baptist Hosp, Dept Chem Engn, Boston, MA USA; [Slotkin, Jonathan R.; Woodard, Eric J.] New England Baptist Hosp, Div Neurol Surg, Boston, MA USA; [Langer, Robert] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Teng, Yang D.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA 02115 USA		Teng, YD (corresponding author), Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.	yang_teng@hms.harvard.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS053935, DE013023, HL060435]; VA biomedical laboratory research; Massachusetts SCI cure research; National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1F32EY018285-01]; New England Baptist Hospital (Teng Lab); NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [F32EY018285] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL060435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE013023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS053935] Funding Source: NIH RePORTER	Support was received from NIH NS053935, the VA biomedical laboratory research grant and Massachusetts SCI cure research grant (Teng Lab); and NIH Ruth L. Kirschstein National Research Service Award 1F32EY018285-01 for W.L.N., NIH DE013023 and HL060435 (Langer Lab). The authors thank InVivo Therapeutics for the support to their labs. We are grateful to Dr. Martin Feelisch and Dr. William D. Eldred of Boston University for advice on the biochemistry and biology of nitric oxide, and Dr. Robert M. Friedlander of Harvard Medical School for help in studying cell death pathways. We greatly appreciate the grant support from New England Baptist Hospital (Teng Lab).	Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bjugstad KB, 2008, EXP NEUROL, V211, P362, DOI 10.1016/j.expneurol.2008.01.025; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Brunori M, 2004, BBA-BIOENERGETICS, V1655, P365, DOI 10.1016/j.bbabio.2003.06.008; Cai ZW, 2003, BRAIN RES, V975, P37, DOI 10.1016/S0006-8993(03)02545-9; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Conti A, 2007, BRAIN RES REV, V54, P205, DOI 10.1016/j.brainresrev.2007.01.013; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Crutcher KA, 2006, J NEUROIMMUNE PHARM, V1, P195, DOI 10.1007/s11481-006-9021-7; DALKARA T, 1994, NEUROPHARMACOLOGY, V33, P1447, DOI 10.1016/0028-3908(94)90048-5; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Deckel AW, 2001, J NEUROSCI RES, V64, P99, DOI 10.1002/jnr.1057; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; Diaz-Ruiz A, 2002, NEUROSCI LETT, V319, P129, DOI 10.1016/S0304-3940(01)02540-X; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; Easton AS, 1998, J PHYSIOL-LONDON, V507, P541, DOI 10.1111/j.1469-7793.1998.541bt.x; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Fischer I, 2000, PROG BRAIN RES, V128, P253; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gibbs SM, 2003, MOL NEUROBIOL, V27, P107, DOI 10.1385/MN:27:2:107; Goldman SA, 2006, PHILOS T R SOC B, V361, P1463, DOI 10.1098/rstb.2006.1886; Grayson ACR, 2005, BIOMATERIALS, V26, P2137, DOI 10.1016/j.biomaterials.2004.06.033; Hachmeister JE, 2006, J NEUROTRAUM, V23, P1766, DOI 10.1089/neu.2006.23.1766; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; HARRIMAN A, 1979, J CHEM SOC FARAD T 2, V75, P1532, DOI 10.1039/f29797501532; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hsieh WY, 2003, J NEUROSCI RES, V71, P272, DOI 10.1002/jnr.10476; Hunt JA, 1997, CHEM BIOL, V4, P845, DOI 10.1016/S1074-5521(97)90117-4; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iarikov DE, 2007, J NEUROTRAUM, V24, P690, DOI 10.1089/neu.2006.0172; Kaji T, 2002, NITRIC OXIDE-BIOL CH, V6, P125, DOI 10.1006/niox.2001.0389; KALCKAR HM, 1947, J BIOL CHEM, V167, P429; Karp JM, 2007, CURR OPIN BIOTECH, V18, P454, DOI 10.1016/j.copbio.2007.09.008; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Keynes RG, 2004, CURR MOL MED, V4, P179, DOI 10.2174/1566524043479176; Kulbatski I, 2005, CURR DRUG TARGETS, V6, P111, DOI 10.2174/1389450053345037; Kwon KJ, 2005, J NEUROSCI RES, V81, P73, DOI 10.1002/jnr.20520; LAZAREWICZ JW, 1988, NEUROPHARMACOLOGY, V27, P765, DOI 10.1016/0028-3908(88)90088-3; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; Liu DX, 2005, J NEUROTRAUM, V22, P1123, DOI 10.1089/neu.2005.22.1123; Liu NK, 2006, ANN NEUROL, V59, P606, DOI 10.1002/ana.20798; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Madhavan L, 2008, STEM CELLS, V26, P254, DOI 10.1634/stemcells.2007-0221; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; Murray M, 2001, NEUROSCIENTIST, V7, P28, DOI 10.1177/107385840100700107; Nakahara S, 2002, J NEUROTRAUM, V19, P1467, DOI 10.1089/089771502320914697; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Peterson DA, 1996, J NEUROSCI, V16, P886; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Raisman G, 2007, NAT REV NEUROSCI, V8, P312, DOI 10.1038/nrn2099; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Shamash S, 2002, J NEUROSCI, V22, P3052, DOI 10.1523/JNEUROSCI.22-08-03052.2002; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; Teng YD, 2006, REGEN MED, V1, P763, DOI 10.2217/17460751.1.6.763; Teng YD, 1998, EUR J NEUROSCI, V10, P798, DOI 10.1046/j.1460-9568.1998.00100.x; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Teng YD, 1997, J NEUROSCI, V17, P4359; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Xu M, 2000, EXP NEUROL, V161, P472, DOI 10.1006/exnr.1999.7278; YU D, 2008, SOC NEUR ABSTR; Zhang YM, 2006, J BIOL CHEM, V281, P9460, DOI 10.1074/jbc.M510650200; Zhou LH, 2006, EXP NEUROL, V197, P84, DOI 10.1016/j.expneurol.2005.08.019	72	51	53	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells		2009	27	5					1212	1222		10.1002/stem.26			11	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	447GL	WOS:000266179500024	19418456	Green Accepted, Bronze			2022-02-06	
J	Lima, FD; Souza, MA; Furian, AF; Rambo, LM; Ribeiro, LR; Martignoni, FV; Hoffmann, MS; Fighera, MR; Royes, LFF; Oliveira, MS; de Mello, CF				Lima, Frederico Diniz; Souza, Mauren Assis; Furian, Ana Flavia; Rambo, Leonardo Magno; Ribeiro, Leandro Rodrigo; Martignoni, Felipe Villa; Hoffmann, Mauricio Scopel; Fighera, Michele Rechia; Freire Royes, Luiz Fernando; Oliveira, Mauro Schneider; de Mello, Carlos Fernando			Na+,K+-ATPase activity impairment after experimental traumatic brain injury: Relationship to spatial learning deficits and oxidative stress	BEHAVIOURAL BRAIN RESEARCH			English	Article						Na+,K+-ATPase; protein carbonylation; TBARS; barnes maze; FPI	POSTTRAUMATIC EPILEPSY; CEREBROSPINAL-FLUID; RAT; ATPASE; TRANSPORT; CHILDREN; INFANTS	Traumatic brain injury (TBI) is a devastating disease that commonly causes persistent mental disturbances and cognitive deficits. Although studies indicate that oxidative stress and functional deficits occurring after TBI are interrelated events. the knowledge of the mechanisms underlying the development of such cognitive deficits has been limited. Thus, in the present study, we investigated the effect of fluid percussion brain injury (FPI) on a spatial learning task and levels of oxidative stress markers, namely, protein carbonylation and thiobarbituric acid-reactive substances (TBARS) and Na+,K+-ATPase activity 1 or 3 months after FPI in rats. Statistical analysis revealed that FPI increased the scape latency and mean number of error in Barnes maze test 1 and 3 months after FPI. We also found that protein carbonylation and TBARS content increased in the parietal cortex 1 and 3 months after FPI In addition, 3 months after FPI, protein carbonylation levels increased both in ipsilateral and contralateral cortices of FPI animals. Indeed, statistical analysis revealed a decrease in Na+,K+-ATPase activity in the cerebral cortex of 1 month FPI animals. Furthermore, the decrease in enzyme activity found 3 months was larger, when compared with 1 month after FPI. These results suggest that cognitive impairment following TBI may result, at least in part, from increase of two oxidative stress markers, protein carbonylation and TBARS that occurs concomitantly to a decrease in Na+,K+-ATPase activity. (C) 2008 Elsevier B.V. All rights reserved.	[Furian, Ana Flavia; Oliveira, Mauro Schneider] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Biol Bioquim, BR-90035003 Porto Alegre, RS, Brazil; [Lima, Frederico Diniz; Souza, Mauren Assis; Furian, Ana Flavia; Martignoni, Felipe Villa; Hoffmann, Mauricio Scopel; Oliveira, Mauro Schneider; de Mello, Carlos Fernando] Univ Fed Santa Maria, Dept Fisiol, Lab Psicofarmacol & Neurotoxicidade, Ctr Ciencias Saude, BR-97105900 Santa Maria, RS, Brazil; [Rambo, Leonardo Magno; Ribeiro, Leandro Rodrigo; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Metodos & Tecnicas Desportivas, Ctr Educ Fis & Desportos, BR-97105900 Santa Maria, RS, Brazil; [Fighera, Michele Rechia] Univ Fed Santa Maria, Dept Pediat, Ctr Ciencias Saude, BR-97105900 Santa Maria, RS, Brazil		Oliveira, MS (corresponding author), Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Biol Bioquim, BR-90035003 Porto Alegre, RS, Brazil.	oliveira.ms@gmail.com	Souza, Mauren/A-7990-2015; Rambo, Leonardo/F-8195-2012; Oliveira, Mauro Schneider/G-3437-2012; Hoffmann, Mauricio/AAM-9899-2020; Mello, Carlos/C-7188-2013; Lima, Frederico Diniz/P-8479-2015; Fighera, Michele R/J-9576-2014	Oliveira, Mauro Schneider/0000-0002-5381-1208; Hoffmann, Mauricio/0000-0003-4232-3169; Mello, Carlos/0000-0002-1326-1045; Lima, Frederico Diniz/0000-0002-3298-2833; Rambo, Leonardo/0000-0002-4769-3663; Ribeiro, Leandro/0000-0002-8442-4075; Fighera, Michele/0000-0002-3111-7530	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [505527/2004-9, 301552/2007-0]; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Research supported by CNPq (grants 505527/2004-9 and 301552/2007-0) and CAPES. Mauro Schneider Oliveira is the recipient of CAPES fellowship. Carlos Fernando de Mello and Ana Flavia Furian are the recipients of CNPq fellowships.	BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dalle-Donne I, 2003, CLIN CHIM ACTA, V329, P23, DOI 10.1016/S0009-8981(03)00003-2; Dean RT, 1997, BIOCHEM J, V324, P1; Dobrota D, 1999, CELL MOL NEUROBIOL, V19, P141, DOI 10.1023/A:1006909927287; IKEDA Y, 1989, Neurological Research, V11, P213; Jamme I, 1995, NEUROREPORT, V7, P333; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morel P, 1998, NEUROCHEM INT, V33, P531, DOI 10.1016/S0197-0186(98)00062-X; Moseley AE, 2007, J NEUROSCI, V27, P616, DOI 10.1523/JNEUROSCI.4464-06.2007; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oliveira MS, 2008, BEHAV BRAIN RES, V187, P200, DOI 10.1016/j.bbr.2007.09.004; Oliveira MS, 2004, NEUROSCIENCE, V128, P721, DOI 10.1016/j.neuroscience.2004.07.012; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Potts Mathew B, 2006, NeuroRx, V3, P143; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Siems WG, 1996, FREE RADICAL BIO MED, V20, P215, DOI 10.1016/0891-5849(95)02041-1; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; YAN LJ, 1995, ANAL BIOCHEM, V228, P349, DOI 10.1006/abio.1995.1362; Zhan H, 2004, NEUROL RES, V26, P35, DOI 10.1179/016164104773026507	35	51	52	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	NOV 21	2008	193	2					306	310		10.1016/j.bbr.2008.05.013			5	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	350NP	WOS:000259359700020	18573545				2022-02-06	
J	Huh, JW; Widing, AG; Raghupathi, R				Huh, Jimmy W.; Widing, Ashley G.; Raghupathi, Ramesh			Midline brain injury in the immature rat induces sustained cognitive deficits, bihemispheric axonal injury and neurodegeneration	EXPERIMENTAL NEUROLOGY			English	Article						traumatic axonal injury; closed head injury; infants; children; mild traumatic brain injury; cognition; neurodegeneration; fluoro-jade	LATERAL FLUID PERCUSSION; MILD HEAD-INJURY; PRESCHOOL-CHILDREN; VULNERABILITY; MODEL; ADOLESCENTS; HIPPOCAMPUS; DYSFUNCTION; PLASTICITY; THALAMUS	infants and children less than 4 years old suffer chronic cognitive deficits following mild, moderate or severe diffuse traumatic brain injury (TBI). It has been suggested that the underlying neuropathologic basis for behavioral deficits following severe TBI is acute brain swelling, subarachnoid hemorrhage and axonal injury. To better understand mechanisms of cognitive dysfunction in mild-moderate TBI, a closed head injury model of midline TBI in the immature rat was developed. Following an impact over the midline suture of the intact skull, 17-day-old rats exhibited short apnea times (3-15 s), did not require ventilatory support and suffered no mortality, Suggestive of mild TBI. Compared to un-injured rats, brain-injured rats exhibited significant learning deficits over the first week post-injury (P < 0.0005), and, significant learning (p < 0.005) and memory deficits (p < 0.05) in the third post-injury week. Between 6 and 72 h, blood-brain barrier breakdown, extensive traumatic axonal injury in the subcortical white matter and thalamus, and focal areas of neurodegeneration in the cortex and hippocampus were observed in both hemispheres of the injured brain. At 8 to 18 days post-injury, reactive astrocytosis in the cortex, axonal degeneration in the subcortical white matter tracts, and degeneration of neuronal cell bodies and processes in the thalamus of both hemispheres were observed; however, cortical volumes were not different between un-injured and injured rat brains. These data Suggest that diffuse TBI in the immature rat can lead to ongoing degeneration of both cell soma and axonal compartments of neurons, which may contribute, in part, to the observed Sustained cognitive deficits. (C) 2008 Elsevier Inc. All rights reserved.	[Widing, Ashley G.; Raghupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; [Huh, Jimmy W.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA		Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	rramesh@drexelmed.edu	Raghupathi, Ramesh/AAX-5538-2021		The Endowed Chair of Critical Care Medicine; Children's Hospital of Philadelphia; University of Pennsylvania; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08-NS053651, R01-NS41561]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, K08NS053651] Funding Source: NIH RePORTER	The authors acknowledge expert technical assistance from Michael Franklin. These studies were supported, in part, by The Endowed Chair of Critical Care Medicine, the Florence RC Murray grant from the Children's Hospital of Philadelphia (JWH, RR), a Research Foundation grant from the University of Pennsylvania (JWH, RR), and NINDS grants K08-NS053651 (JWH) and R01-NS41561 (RIZ).	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2000, BRAIN INJURY, V14, P679; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Butler TL, 2002, BRAIN RES, V929, P252, DOI 10.1016/S0006-8993(01)03371-6; Chiaretti A, 1998, Pediatr Med Chir, V20, P393; Ciurea AV, 2005, ACT NEUR S, V93, P209; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Rasband W. S., 1997, IMAGE J; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	39	51	53	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2008	213	1					84	92		10.1016/j.expneurol.2008.05.009			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	344QX	WOS:000258943500010	18599043	Green Accepted			2022-02-06	
J	Todis, B; Glang, A				Todis, Bonnie; Glang, Ann			Redefining success: Results of a qualitative study of postsecondary transition outcomes for youth with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						postsecondary education; special education; TBI transition outcomes	MODERATE; CHILDREN; FAMILY	Objectives: Identify factors that influence postsecondary education outcomes for students with traumatic brain injury (TBI). Design: Qualitative longitudinal. Participants: Thirty-three young adults with TBI, their parents, and knowledgeable others. Results: Students with TBI who received transition services that linked them with disability services and support agencies were more likely to complete postsecondary programs. Internal factors such as positive attitude and determination were also associated with success. Conclusions: Survey items measuring constructs such as "use of accommodations," "enrolled in special education," and "high school graduation" mask a range of experiences. Transition supports geared to the postsecondary education goals of students with TBI are needed.	[Todis, Bonnie; Glang, Ann] Teaching Res Inst, Eugene, OR 97401 USA		Todis, B (corresponding author), Teaching Res Inst, 99 W l0th Ave,Suite 370, Eugene, OR 97401 USA.	todisb@wou.edu					Backhouse M, 1999, AUST OCCUP THER J, V46, P99, DOI DOI 10.1046/J.1440-1630.1999.00183.X; Benz MR, 1997, EXCEPT CHILDREN, V63, P151, DOI 10.1177/001440299706300201; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Braga WL, 2000, INT HDB NEUROPSYCHOL, P283; Cairns RB., 1994, LIFELINES RISKS PATH; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; GARMEZY N, 1988, STUDIES PSYCHOSOCIAL, P29; GLANG A, 2003, RESILIENCE STUDENTS; Hasazi SB, 1999, EXCEPT CHILDREN, V65, P555; KEOUGH B, 1993, LEARNING DISABILITIE, V8, P3; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; Lincoln Yvonna S., 1985, NATURALISTIC INQUIRY; Miles M. B., 1994, QUALITATIVE DATA ANA, V2nd; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; *QSR INT PY LTD, 2002, N6 QSR; RUTTER M, 1998, STUDIES PSYCHOSOCIAL; STAINBACK S, 1984, EXCEPT CHILDREN, V50, P400, DOI 10.1177/001440298405000502; Stewart Debra, 2006, Phys Occup Ther Pediatr, V26, P5, DOI 10.1300/J006v26n04_02; Stewart-Scott AM, 1998, BRAIN INJURY, V12, P317, DOI 10.1080/026990598122629; TEASDALE G, 1974, LANCET, V2, P81; TODIS B, 1998, RESILIENCE STUDENTS; TODIS B, 2000, J HEAD TRAUMA REHABI; *US DEP ED, 2004, 26 ANN REP C IMPL IN; Wagner M., 2005, HIGH SCH 1 LOOK POST; Wehmeyer M, 1997, EXCEPT CHILDREN, V63, P245, DOI 10.1177/001440299706300207; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	31	51	51	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2008	23	4					252	263		10.1097/01.HTR.0000327257.84622.bc			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	331KU	WOS:000258011900007	18650769				2022-02-06	
J	Buss, A; Pech, K; Kakulas, BA; Martin, D; Schoenen, J; Noth, J; Brook, GA				Buss, A.; Pech, K.; Kakulas, B. A.; Martin, D.; Schoenen, J.; Noth, J.; Brook, G. A.			TGF-beta 1 and TGF-beta 2 expression after traumatic human spinal cord injury	SPINAL CORD			English	Article						spinal cord injury; Wallerian degeneration; scar; inflammation	GROWTH-FACTOR-BETA; TGF-BETA; ALZHEIMERS-DISEASE; NERVOUS-SYSTEM; MESSENGER-RNA; RAT-BRAIN; LOCALIZATION; SCAR; DEGENERATION; REGENERATION	Study design: Immunohistochemical investigation in control and lesioned human spinal cords. Objectives: To assess the spatial and temporal expression patterns of transforming growth factor-beta 1 and -beta 2 (TGF-beta 1 and TGF-beta 2) in the human spinal cord after traumatic injury. Setting: Germany, Aachen, Aachen University Hospital. Methods: Sections from human spinal cords from 4 control patients and from 14 patients who died at different time points after traumatic spinal cord injury (SCI) were investigated immunohistochemically. Results: In control cases, TGF-beta 1 was confined to occasional blood vessels, intravascular monocytes and some motoneurons, whereas TGF-beta 2 was only found in intravascular monocytes. After traumatic SCI, TGF-beta 1 immunoreactivity was dramatically upregulated by 2 days after injury (the earliest survival time investigated) and was detected within neurons, astrocytes and invading macrophages. The staining was most intense over the first weeks after injury but gradually declined by 1 year. TGF-beta 2 immunoreactivity was first detected 24 days after injury. It was located in macrophages and astrocytes and remained elevated for up to 1 year. In white matter tracts undergoing Wallerian degeneration, there was no induction of either isoform. Conclusion: The early induction of TGF-beta 1 at the point of SCI suggests a role in the acute inflammatory response and formation of the glial scar, while the later induction of TGF-beta 2 may indicate a role in the maintenance of the scar. Neither of these TGF-beta isoforms appears to contribute to the astrocytic scar formation in nerve fibre tracts undergoing Wallerian degeneration.	[Buss, A.; Pech, K.; Noth, J.; Brook, G. A.] Rhein Westfal TH Aachen, Dept Neurol, Aachen Univ Hosp, D-52074 Aachen, Germany; [Kakulas, B. A.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia; [Martin, D.] Univ Liege, Dept Neurosurg, Sart Tilman Hosp, Liege, Belgium; [Schoenen, J.] Univ Liege, Dept Neurol, Liege, Belgium; [Schoenen, J.] Univ Liege, Dept Neuroanat, Liege, Belgium; [Brook, G. A.] Rhein Westfal TH Aachen, Dept Neuropathol, Aachen Univ Hosp, D-52074 Aachen, Germany		Buss, A (corresponding author), Rhein Westfal TH Aachen, Dept Neurol, Aachen Univ Hosp, Pauwelsstr 30, D-52074 Aachen, Germany.	abuss@ukaachen.de		MARTIN, Didier/0000-0001-7325-4958			Ashcroft GS, 1999, MICROBES INFECT, V1, P1275, DOI 10.1016/S1286-4579(99)00257-9; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Bunge R P, 1997, Adv Neurol, V72, P305; Buss A, 2004, BRAIN, V127, P34, DOI 10.1093/brain/awh001; De Groot CJA, 1999, J NEUROPATH EXP NEUR, V58, P174, DOI 10.1097/00005072-199902000-00007; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FLANDERS KC, 1995, NEUROLOGY, V45, P1561, DOI 10.1212/WNL.45.8.1561; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; Mangasser-Stephan K, 1999, CELL TISSUE RES, V297, P363, DOI 10.1007/s004410051364; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; PERESS NS, 1995, J NEUROPATH EXP NEUR, V54, P802, DOI 10.1097/00005072-199511000-00007; ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81; ROGISTER B, 1993, J NEUROSCI RES, V34, P32, DOI 10.1002/jnr.490340105; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Unsicker K, 2002, ADV EXP MED BIOL, V513, P353; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004	23	51	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	MAY	2008	46	5					364	371		10.1038/sj.sc.3102148			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	295VS	WOS:000255502600009	18040277	Bronze			2022-02-06	
J	Dottori, M; Leung, J; Turnley, AM; Pebay, A				Dottori, Mirella; Leung, Jessie; Turnley, Ann M.; Pebay, Alice			Lysophosphatidic acid inhibits neuronal differentiation of neural stem/progenitor cells derived from human embryonic stem cells	STEM CELLS			English	Article						embryonic stem cells; embryonic stem cell biology; in vitro differentiation; neural stem cell; neural differentiation; signal transduction	PROTEIN-COUPLED RECEPTORS; MORPHOLOGICAL-CHANGES; PROLIFERATION; LPA; SPHINGOSINE-1-PHOSPHATE; IDENTIFICATION; NEUROBLASTS; MAINTENANCE; PROGENITORS; EXPRESSION	Lysophospholipids are signaling molecules that play broad and major roles within the nervous system during both early development and neural injury. We used neural differentiation of human embryonic stem cells (hESC) as an in vitro model to examine the specific effects of lysophosphatidic acid (LPA) at various stages of neural development, from neural induction to mature neurons and glia. We report that LPA inhibits neurosphere formation and the differentiation of neural stem cells (NSC) toward neurons, without modifying NSC proliferation, apoptosis, or astrocytic differentiation. LPA acts through the activation of the Rho/ROCK and the phosphatidylinositol 3-kinase/Akt pathways to inhibit neuronal differentiation. This study is the first demonstration of a role for LPA signaling in neuronal differentiation of hESC. As LPA concentrations increase during inflammation, the inhibition of neuronal differentiation by LPA might contribute to the low level of neurogenesis observed following neurotrauma.	[Dottori, Mirella; Leung, Jessie; Turnley, Ann M.; Pebay, Alice] Univ Melbourne, Ctr Neurosci, Parkville, Vic 3010, Australia; [Dottori, Mirella; Pebay, Alice] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3010, Australia		Pebay, A (corresponding author), Univ Melbourne, Ctr Neurosci, Parkville, Vic 3010, Australia.	apebay@unimelb.edu.au	Turnley, Ann/A-8125-2010	Turnley, Ann/0000-0002-8442-127X; Pebay, Alice/0000-0002-7408-9453; Dottori, Mirella/0000-0003-0598-4195			Brault S, 2007, AM J PHYSIOL-REG I, V292, pR1174, DOI 10.1152/ajpregu.00619.2006; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; CONTOS JJ, 1920, P NATL ACAD SCI USA, V97, P13384; Davidson KC, 2007, MOL CELL NEUROSCI, V36, P408, DOI 10.1016/j.mcn.2007.07.013; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Fukushima N, 2004, J CELL BIOCHEM, V92, P993, DOI 10.1002/jcb.20093; Fukushima N, 2000, DEV BIOL, V228, P6, DOI 10.1006/dbio.2000.9930; Fukushima N, 2007, NEUROCHEM INT, V50, P302, DOI 10.1016/j.neuint.2006.09.008; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; Goetzl EJ, 1999, CANCER RES, V59, P4732; Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Holtsberg FW, 1998, J NEUROCHEM, V70, P66; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Keller JN, 1997, J NEUROCHEM, V69, P1073; Keller JN, 1996, J NEUROCHEM, V67, P2300; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Kotarsky K, 2006, J PHARMACOL EXP THER, V318, P619, DOI 10.1124/jpet.105.098848; Lee CW, 2007, J BIOL CHEM, V282, P4310, DOI 10.1074/jbc.M610826200; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Moller T, 2001, J BIOL CHEM, V276, P25946, DOI 10.1074/jbc.M102691200; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Pebay A, 2005, STEM CELLS, V23, P1541, DOI 10.1634/stemcells.2004-0338; Pebay A, 1999, GLIA, V28, P25, DOI 10.1002/(SICI)1098-1136(199910)28:1<25::AID-GLIA3>3.0.CO;2-D; Pebay A, 2007, PROSTAG OTH LIPID M, V84, P83, DOI 10.1016/j.prostaglandins.2007.08.004; Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Rhee HJ, 2006, NEUROREPORT, V17, P523; Steiner MR, 2002, BBA-MOL CELL BIOL L, V1582, P154, DOI 10.1016/S1388-1981(02)00150-6; Svetlov SI, 2004, STEM CELLS DEV, V13, P685, DOI 10.1089/scd.2004.13.685; Takuwa Y, 2002, J BIOCHEM, V131, P767, DOI 10.1093/oxfordjournals.jbchem.a003163; Wada K, 2006, J BIOL CHEM, V281, P12673, DOI 10.1074/jbc.M513786200; Ward JE, 2004, BRIT J PHARMACOL, V141, P517, DOI 10.1038/sj.bjp.0705630; Weiner JA, 1998, J COMP NEUROL, V398, P587; Yanagida K, 2007, J BIOL CHEM, V282, P5814, DOI 10.1074/jbc.M610767200; zu Heringdorf DM, 2007, BBA-BIOMEMBRANES, V1768, P923, DOI 10.1016/j.bbamem.2006.09.026	39	51	51	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	MAY	2008	26	5					1146	1154		10.1634/stemcells.2007-1118			9	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	305SB	WOS:000256197000007	18308941				2022-02-06	
J	Bragadeesh, T; Jayaweera, AR; Pascotto, M; Micari, A; Le, DE; Kramer, CM; Epstein, FH; Kaul, S				Bragadeesh, T.; Jayaweera, A. R.; Pascotto, M.; Micari, A.; Le, D. E.; Kramer, C. M.; Epstein, F. H.; Kaul, S.			Post-ischaemic myocardial dysfunction (stunning) results from myofibrillar oedema	HEART			English	Article							REPERFUSION INJURY; SARCOMERE-LENGTH; FORCE GENERATION; SKELETAL-MUSCLE; ISCHEMIA; CARDIOMYOCYTES; ULTRASTRUCTURE; LATTICE; BINDING; CELLS	Objective: To test the hypothesis that myocardial stunning is due to myofibrillar oedema. Methods: Experiments were performed in anaesthetised closed-chest pigs. In 15 pigs (group 1), myocardial stunning was produced by repetitive ischaemia and reperfusion; 5 pigs each were studied at 2 hours, 2 days, and 5 days later. Circumferential left ventricular (LV) midwall myocardial strain (E-cc) was estimated in vivo using tagged magnetic resonance imaging. Myocardial water content (MWC) was measured post mortem, from which interfilament lattice distance (d) was calculated. In 6 pigs (group 2), myocardial dysfunction was produced by intracoronary administration of a mast cell degranulator. Animals were euthanised immediately upon induction of regional LV dysfunction to avoid development of inflammation. In 4 pigs (group 3), transmission electron microscopy (EM) was performed to quantify d in stunned versus normal myocardium. Results: In group 1 pigs, MWC was raised in the stunned compared with normal myocardium (p < 0.02) and decreased over time. An inverse relation was found between Ecc and MWC in the stunned myocardium (r = -0.81) and between Ecc and d (r= -0.90). A similar relation was noted between wall thickening and increase in MWC in group 2 (r= -0.84) pigs. In group 3 pigs, d on EM was significantly lower (40 (3) nmol/ l) in normal myocardium than in stunned myocardium (46.4 (4) nmol/ l), p < 0.001. Conclusions: Ischaemia-reperfusion results in myocardial oedema, with consequent myocyte swelling and myofibrillar oedema. The latter leads to an increase in d, causing myosin heads to either fail to latch, or to latch improperly, onto the actin filament with poor force generation, leading to myocardial dysfunction. As the myocardial oedema abates, myocyte function improves.	[Bragadeesh, T.; Jayaweera, A. R.; Pascotto, M.; Micari, A.; Le, D. E.; Kaul, S.] OHSU, UHN62, Div Cardiovasc, Portland, OR 97239 USA; [Kramer, C. M.; Epstein, F. H.] Univ Virginia, Div Radiol, Charlottesville, VA USA		Kaul, S (corresponding author), OHSU, UHN62, Div Cardiovasc, 3181 SW Sam Jackson,Pk Rd, Portland, OR 97239 USA.	kauls@ohsu.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K08-HL74289] Funding Source: Medline; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R01-EB-002069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL074289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB002069] Funding Source: NIH RePORTER		BERNE RM, PHYSIOLOGY, pCH1; Bolli R, 1998, BASIC RES CARDIOL, V93, P156, DOI 10.1007/s003950050079; Chandrashekhar Y, 1999, J AM COLL CARDIOL, V34, P594, DOI 10.1016/S0735-1097(99)00222-3; Decker RS, 2005, CIRCULATION, V111, P906, DOI 10.1161/01.CIR.0000155609.95618.75; DIBONA DR, 1980, CIRC RES, V47, P653, DOI 10.1161/01.RES.47.5.653; Dumont EAWJ, 2000, CIRCULATION, V102, P1564, DOI 10.1161/01.CIR.102.13.1564; Fuchs F, 1996, J MOL CELL CARDIOL, V28, P1375, DOI 10.1006/jmcc.1996.0129; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GUTTMAN MA, 1994, IEEE T MED IMAGING, V13, P74, DOI 10.1109/42.276146; JENNINGS RB, 1985, CIRC RES, V56, P262, DOI 10.1161/01.RES.56.2.262; Kennedy J., 1993, RECOVERY PROCESSES B, V1st; Kim D, 2003, MAGNET RESON MED, V50, P813, DOI 10.1002/mrm.10589; KLONER RA, 1974, AM J PATHOL, V74, P399; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; KLONER RA, 1983, CIRCULATION, V68, P8; KOIBUCHI Y, 1985, EUR J PHARMACOL, V115, P163; Lan GH, 2005, BIOPHYS J, V88, P4107, DOI 10.1529/biophysj.104.056846; Martyn DA, 2004, BIOPHYS J, V86, P1002, DOI 10.1016/S0006-3495(04)74175-2; Millman BM, 1998, PHYSIOL REV, V78, P359, DOI 10.1152/physrev.1998.78.2.359; Mizutani S, 2006, ANN THORAC SURG, V81, P154, DOI 10.1016/j.athoracsur.2005.06.057; PIAZZESI G, 1993, ADV EXP MED BIOL, V332, P691; PIAZZESI G, 1994, J PHYSIOL-LONDON, V476, P531, DOI 10.1113/jphysiol.1994.sp020152; Pomar F, 1995, EUR HEART J, V16, P1482, DOI 10.1093/oxfordjournals.eurheartj.a060768; SCHIERWAGEN C, 1990, J PHARMACOL METHOD, V23, P179, DOI 10.1016/0160-5402(90)90061-O; Sklenar J, 1992, J Am Soc Echocardiogr, V5, P33; STAHL LD, 1987, J AM COLL CARDIOL, V96, P1339; THALLER S, 2004, J THEOR BIOL, V31, P19; Turschner O, 2004, EUR HEART J, V25, P794, DOI 10.1016/j.ehj.2004.01.006; ZERHOUNI EA, 1998, RADIOLOGY, V69, P59; ZHAO MJ, 1992, J MOL CELL CARDIOL, V24, P269, DOI 10.1016/0022-2828(92)93164-F	30	51	53	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1355-6037			HEART	Heart	FEB	2008	94	2					166	171		10.1136/hrt.2006.102434			6	Cardiac & Cardiovascular Systems	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	256QX	WOS:000252745800011	17639092				2022-02-06	
J	Kennedy, MRT; Krause, MO; Turkstra, LS				Kennedy, Mary R. T.; Krause, Miriam O.; Turkstra, Lyn S.			An electronic survey about college experiences after traumatic brain injury	NEUROREHABILITATION			English	Article						College; post-secondary education; study skills; cognition; psychosocial; services; higher education	HEAD-INJURY; STUDENTS	For many with traumatic brain injury (TBI), going to college is a realistic goal; however there is little documentation of the challenges faced by those with TBI who attend college. The primary purposes of this study were to document the academic challenges (studying, in-class experiences, time management, psychosocial aspects) reported by adults with TBI, and to investigate relationships between these challenges and the physical, cognitive and psychosocial consequences of TBI. An electronic anonymous survey was distributed. Of the 35 respondents with TBI, nearly all reported the need to review material more and a majority reported that others do not understand their problems. In-class experiences of being nervous before tests, forgetting what is said in class, and getting overwhelmed in class were also reported by a majority. Those who reported more physical, cognitive and psychosocial consequences of their injury also identified more academic challenges as well, although cognitive consequences alone predicted academic challenges better than all of the consequences combined. Psychosocial aspects also predicted academic challenges to a lesser extent. In spite of these findings, nearly half of the respondents had not heard of or had never accessed campus disability services. To develop effective on-campus service delivery models, additional research is needed to understand why students do or do not make use of existing services.	[Kennedy, Mary R. T.] Univ Minnesota, Dept Speech Language Hearing Sci, Minneapolis, MN 55455 USA; [Turkstra, Lyn S.] Univ Wisconsin, Madison, WI USA		Kennedy, MRT (corresponding author), Univ Minnesota, Dept Speech Language Hearing Sci, 115 Shevlin Hall,164 Pillsbury Dr SE, Minneapolis, MN 55455 USA.	kenne047@umn.edu	Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921; Krause, Miriam/0000-0002-6798-3991			BUETHE C, 1989, J COLL STUDENT DEV, V30, P172; Cook J, 1991, J HEAD TRAUMA REHAB, V6, P64, DOI [10.1097/00001199-199103000-00011, DOI 10.1097/00001199-199103000-00011]; Gerberich SG, 1997, NEUROEPIDEMIOLOGY, V16, P1, DOI 10.1159/000109665; Harris JR, 1997, J HEAD TRAUMA REHAB, V12, P67, DOI 10.1097/00001199-199704000-00007; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JOHNSTONE B, 1994, J CLIN PSYCHOL MED S, V1, P375, DOI 10.1007/BF01991080; Laforce R, 2001, PERCEPT MOTOR SKILL, V93, P281, DOI 10.2466/PMS.93.5.281-288; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Malec J., 2005, MAYO PORTLAND ADAPTA; Marschark M, 2000, J HEAD TRAUMA REHAB, V15, P1227, DOI 10.1097/00001199-200012000-00004; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Prince S, 2002, J MED SPEECH-LANG PA, V10, P19; Savage RC, 1987, J HEAD TRAUMA REHAB, V2, P1; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Stewart-Scott AM, 1998, BRAIN INJURY, V12, P317, DOI 10.1080/026990598122629; TURKSTRA L, 2004, PERSPECTIVES, V14, P19	16	51	51	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2008	23	6					511	520					10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	391CI	WOS:000262210200007	19127004				2022-02-06	
J	Brown, CN; Guskiewicz, KM; Bleiberg, J				Brown, Cathleen N.; Guskiewicz, Kevin M.; Bleiberg, Joseph			Athlete characteristics and outcome scores for computerized neuropsychological assessment: A preliminary analysis	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; cognitive testing	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN INJURY; CONFIDENCE-INTERVALS; COGNITIVE ASSESSMENT; SPORTS CONCUSSION; TEST-PERFORMANCE; NCAA CONCUSSION; TEST PROTOCOL; MILD; RECOVERY	Context. Computerized neuropsychological testing is used in athletics; however, normative data on an athletic population are lacking. Objective: To investigate factors, such as sex, SAT score, alertness, and sport, and their effects on baseline neuropsychological test scores. A secondary purpose was to begin establishing preliminary reference data for nonsymptomatic collegiate athletes. Design: Observational study. Setting: Research laboratory. Patients or Other Participants: The study population comprised 327 National Collegiate Athletic Association Division I athletes from 12 men's and women's sports. Main Outcome Measure(s): Athletes were baseline tested before their first competitive season. Athletes completed demographics forms and self-reported history of concussion (11 or no concussion and 2 or more concussions) and SAT scores (< 1000, 1000 to 1200, and > 1200). The 108 women had a mean age of 18.39 +/- 0.09 years, height of 167.94 +/- 0.86 cm, and mass of 62.36 +/- 1.07 kg. The 219 men had a mean age of 18.49 +/- 0.07 years, height of 183.24 +/- 1.68 cm, and mass of 88.05 +/- 1.82 kg. Sports participation included women's soccer, lacrosse, basketball, and field hockey; men's football, soccer, lacrosse, and wrestling; and women's and men's track and cheerleading. We used the Automated Neuropsychological Assessment Metrics (Army Medical Research and Materiel Command, Ft Detrick, MID) and measured throughput scores (the number of correct responses per minute) as the dependent variable for each subtest, with higher scores reflecting increased speed and accuracy of responses. Subsets included 2 simple reaction time (SRT) tests, math processing (MTH), Sternberg memory search (ST6), matching to sample pairs (MSP), procedural reaction time (PRO), code digit substitution (CDS), and the Stanford sleep scale Likert-type score. Results: Women scored better than men on the ST6 (P <.05), while men scored significantly better than women on the SRT and MSP tests. The highest-scoring SAT group performed better than other SAT groups on selected subtests (SRT, MTH, ST6, MSP, and CDS) (P <.05), and athletes tested during their season were more likely to score lower on the alertness scale (chi(2)(2)[n = 322] = 11.32, P =.003). The lowest alertness group performed worse on the MSP and CDS subtests (P <.05). No differences were found between the group with a history of 1 or no concussion and the group with a history of 2 or more concussions (P >.05). Conclusions: Performance on computerized neuropsychological tests may be affected by a number of factors, including sex, SAT scores, alertness at the time of testing, and the athlete's sport. To avoid making clinical misinterpretations, clinicians should acknowledge that individual baselines vary over time and should account for this variation.	[Brown, Cathleen N.] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Chapel Hill, NC USA; [Bleiberg, Joseph] Natl Rehabil Hosp, Washington, DC USA		Brown, CN (corresponding author), Univ Georgia, Dept Kinesiol, 330 River Rd, Athens, GA 30602 USA.	browncn@uga.edu	Brown, Cathleen/A-6626-2013	Brown, Cathleen/0000-0002-3414-7938; Guskiewicz, Kevin/0000-0002-8682-2130			Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Beatty WW, 2003, J CLIN EXP NEUROPSYC, V25, P1065, DOI 10.1076/jcen.25.8.1065.16732; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BLEIBERG J, 2005, ANAM SPORTS MED BATT, P12; Brown CN, 2003, J ATHL TRAINING, V38, pS24; BROWN CN, 2004, J ATHL TRAINING, V39, pS17; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Heaton RK, 1996, NEUROPSYCHOLOGICAL A, P141; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; *INJ SURV SYST, SPORT SPEC INJ DAT 2; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Marshall SW, 2004, J SCI MED SPORT, V7, P135, DOI 10.1016/S1440-2440(04)80002-1; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Poole C, 2001, EPIDEMIOLOGY, V12, P291, DOI 10.1097/00001648-200105000-00005; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; Purnell MT, 2002, J SLEEP RES, V11, P219, DOI 10.1046/j.1365-2869.2002.00309.x; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Rollinson DC, 2003, ANN EMERG MED, V41, P400, DOI 10.1067/mem.2003.77; Sefton J. M., 2004, J ATHL TRAINING, V39, pS52; Sosin DM, 1996, BRAIN INJURY, V10, P47; The College Board, 2004, 2004 COLL BOUND SEN; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wilken JA, 2003, MULT SCLER, V9, P119, DOI 10.1191/1352458503ms893oa; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; Wolfe R, 2004, J SCI MED SPORT, V7, P138, DOI 10.1016/S1440-2440(04)80003-3; ZURI RE, 2004, J ATHL TRAINING, V39, pS57	46	51	51	0	25	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2007	42	4					515	523					9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	251AQ	WOS:000252343100012	18174940				2022-02-06	
J	Vallat-Azouvi, C; Weber, T; Legrand, L; Azouvi, P				Vallat-Azouvi, Claire; Weber, Thomas; Legrand, Ludovic; Azouvi, Philippe			Working memory after severe traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						head injury; executive functions; attention; divided attention; central executive; short-term memory	DUAL-TASK PERFORMANCE; CLOSED-HEAD INJURY; CENTRAL EXECUTIVE COMPONENT; DIVIDED ATTENTION; NEUROPSYCHOLOGICAL DEFICITS; SELECTIVE IMPAIRMENT; LOAD	The aim of the present study was to assess the functioning of the different subsystems of working memory after severe traumatic brain injury (TBI). A total of 30 patients with severe chronic TBI and 28 controls received a comprehensive assessment of working memory addressing the phonological loop (forward and backward digit span; word length and phonological similarity effects), the visuospatial sketchpad (forward and backward visual spans), and the central executive (tasks requiring simultaneous storage and processing of information, dual-task processing, working memory updating). Results showed that there were only marginal group differences regarding the functioning of the two slave systems, whereas patients with severe TBI performed significantly poorer than controls on most central executive tasks, particularly on those requiring a high level of controlled processing. These results suggest that severe TBI is associated with an impairment of executive aspects of working memory. The anatomic substrate of this impairment remains to be elucidated. It might be related to a defective activation of a distributed network, including the dorsolateral prefrontal cortex.	Hop Raymond Poincare, Serv Med Phys & Readaptat, Garches 92380, France; Hop Raymond Poincare, UGECAM, Antenne UEROS, Garches, France; INSERM, U 731, Paris, France; Univ Versailles St Quentin, Serv Med Phys Readaptat, Garches, France; Hop Raymond Poincare, AP HP, Garches, France; Univ Paris 06, Fac Med, Lab Physiol & Physiopathol Motricite, Paris, France		Azouvi, P (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, Garches 92380, France.	philippe.azouvi@rcp.aphp.fr					Allain P, 2001, BRAIN COGNITION, V45, P21, DOI 10.1006/brcg.2000.1249; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 1998, CURR OPIN NEUROBIOL, V8, P234, DOI 10.1016/S0959-4388(98)80145-1; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley A., 2002, PRINCIPLES FRONTAL L, P246, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0016; Baddeley A.D., 1986, WORKING MEMORY; Baddeley AD, 2001, BRAIN, V124, P1492, DOI 10.1093/brain/124.8.1492; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BROOKS D N, 1975, Cortex, V11, P329; Brouwer W, 2001, BRAIN COGNITION, V46, P54, DOI 10.1016/S0278-2626(01)80033-6; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Greene JDW, 1995, NEUROPSYCHOLOGIA, V33, P1647, DOI 10.1016/0028-3932(95)00046-1; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Logie RH, 1996, MEM COGNITION, V24, P305, DOI 10.3758/BF03213295; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; MORRIS N, 1990, BRIT J PSYCHOL, V81, P111, DOI 10.1111/j.2044-8295.1990.tb02349.x; NORMAN DA, 1980, N99 U CAL SAN DIEG; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEASDALE G, 1974, LANCET, V2, P81; Vallat C, 2005, BRAIN INJURY, V19, P1157, DOI 10.1080/02699050500110595; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; WITHAAR FK, 2000, UNPUB DIVIDED ATTENT	56	51	55	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2007	13	5					770	780		10.1017/S1355617707070993			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	205UQ	WOS:000249140500004	17697408				2022-02-06	
J	Johnson, MD; Kao, OE; Kipke, DR				Johnson, Matthew D.; Kao, Olivia E.; Kipke, Daryl R.			Spatiotemporal pH dynamics following insertion of neural microelectrode arrays	JOURNAL OF NEUROSCIENCE METHODS			English	Article						pH; brain trauma; insertion speed; microelectrode array; iridium oxide; potentiometry	TRAUMATIC BRAIN-INJURY; CORTICAL IMPACT MODEL; IRIDIUM OXIDE; SPREADING DEPRESSION; CEREBRAL-CORTEX; INTRACEREBRAL MICRODIALYSIS; HIPPOCAMPAL SLICES; DOPAMINE RELEASE; AMINO-ACIDS; SPINAL-CORD	Insertion trauma is a critical issue when assessing intracortical electrophysiological and neurochemical recordings. Previous reports document a wide variety of insertion techniques with speeds ranging from 10 mu m/s to 10 m/s. We hypothesize that insertion speed has an effect on tissue trauma induced by implantation of a neural probe. In order to monitor the neural interface during and after probe insertion, we have developed a silicon-substrate array with hydrous iridium oxide microelectrodes for potentiometric recording of extracellular pH (pH,), a measure of brain homeostasis. Microelectrode sites were sensitive to pH in the super-Nernstianrange (-85.9 mV/pH unit) and selective over other analytes including ascorbic acid, Na+, K+, Ca2+, and Mg2+. Following insertion, arrays recorded either triphasic or biphasic pH., responses, with a greater degree of prolonged acidosis for insertions at 50 mu m/s than at 0.5 mm/s or 1.0 mm/s (p < 0.05). Spatiotemporal analysis of the recordings also revealed micro-scale variability in the pH, response along the array, even when using the same insertion technique. Implants with more intense acidosis were often associated histologically with blood along the probe tract. The potentiometric microsensor array has implications not only as a useful tool to measure extracellular pH, but also as a feedback tool for delivery of pharmacological agents to treat surgical brain trauma. (c) 2006 Elsevier B.V. All rights reserved.	Univ Michigan, Dept Biomol Engn, Ann Arbor, MI 48109 USA		Kipke, DR (corresponding author), Univ Michigan, Dept Biomol Engn, 2149 LBME Bldg,1101 Beal Ave, Ann Arbor, MI 48109 USA.	dkipke@umich.edu	Johnson, Matthew/B-6276-2015	Johnson, Matthew/0000-0001-9686-5540	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB005022, R01EB000230] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41-EB00230, R21-EB005022] Funding Source: Medline		AMMANN D, 1981, ANAL CHEM, V53, P2267, DOI 10.1021/ac00237a031; ANDERSON DJ, 1989, IEEE T BIO-MED ENG, V36, P693, DOI 10.1109/10.32101; Bai Q, 2000, IEEE T BIO-MED ENG, V47, P281, DOI 10.1109/10.827288; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Benabid AL, 2003, CURR OPIN NEUROBIOL, V13, P696, DOI 10.1016/j.conb.2003.11.001; BENVENISTE H, 1987, J NEUROCHEM, V49, P729, DOI 10.1111/j.1471-4159.1987.tb00954.x; BENVENISTE H, 1987, ACTA NEUROPATHOL, V74, P234, DOI 10.1007/BF00688186; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Bezbaruah AN, 2002, ANAL CHEM, V74, P5726, DOI 10.1021/ac020326l; Biran R, 2005, EXP NEUROL, V195, P115, DOI 10.1016/j.expneurol.2005.04.020; Bjornsson CS, 2006, J NEURAL ENG, V3, P196, DOI 10.1088/1741-2560/3/3/002; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BURKE LD, 1984, J ELECTROANAL CHEM, V175, P119, DOI 10.1016/S0022-0728(84)80350-2; BURKE LD, 1984, J ELECTROCHEM SOC, V131, pC298; CALDWELL PC, 1954, J PHYSIOL-LONDON, V126, P169, DOI 10.1113/jphysiol.1954.sp005201; CAMP DM, 1992, J NEUROCHEM, V58, P1706, DOI 10.1111/j.1471-4159.1992.tb10044.x; CASPERS H, 1972, EPILEPSIA, V13, P699, DOI 10.1111/j.1528-1157.1972.tb04403.x; Cham JG, 2005, J NEUROPHYSIOL, V93, P570, DOI 10.1152/jn.00369.2004; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; Clapp-Lilly KL, 1999, J NEUROSCI METH, V90, P129, DOI 10.1016/S0165-0270(99)00064-3; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; DESALLES AAF, 1987, NEUROSURGERY, V20, P297, DOI 10.1227/00006123-198702000-00017; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ENDRES W, 1986, NEUROSCI LETT, V72, P54, DOI 10.1016/0304-3940(86)90617-8; FOG A, 1984, SENSOR ACTUATOR, V5, P137, DOI 10.1016/0250-6874(84)80004-9; GOLDSMITH JD, 1995, HEARING RES, V83, P80, DOI 10.1016/0378-5955(94)00193-T; Grant SA, 2000, CRIT REV BIOMED ENG, V28, P159, DOI 10.1615/CritRevBiomedEng.v28.i12.270; GRICHTCHENKO II, 1994, NEUROSCIENCE, V62, P1057, DOI 10.1016/0306-4522(94)90343-3; Groothuis DR, 1998, BRAIN RES, V803, P218, DOI 10.1016/S0006-8993(98)00572-1; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Hendrikse J, 1998, SENSOR ACTUAT B-CHEM, V53, P97, DOI 10.1016/S0925-4005(98)00298-6; Holson RR, 1998, BRAIN RES, V808, P182, DOI 10.1016/S0006-8993(98)00816-6; HOUSE PA, 2006, NEUROSURG FOCUS, V20; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; ICHIKAWA K, 1989, J APPL PHYSIOL, V67, P193, DOI 10.1152/jappl.1989.67.1.193; JENSEN W, 2003, P IEEE ENG MED BIOL; Johnson MD, 2005, IEEE T NEUR SYS REH, V13, P160, DOI 10.1109/TNSRE.2005.847373; JOHNSON MD, 2006, P IEEE ENG MED BIOL; JONES KE, 1992, ANN BIOMED ENG, V20, P423, DOI 10.1007/BF02368134; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KEMPSKI O, 1988, NEUROCHEM PATHOL, V9, P109; Khan AS, 2003, TRAC-TREND ANAL CHEM, V22, P503, DOI 10.1016/S0165-9936(03)00908-7; Kimelberg Harold K., 1998, P651; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KINLEN PJ, 1994, SENSOR ACTUAT B-CHEM, V22, P13, DOI 10.1016/0925-4005(94)01254-7; Kipke DR, 2003, IEEE T NEUR SYS REH, V11, P151, DOI 10.1109/TNSRE.2003.814443; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; LaManna J C, 1986, Adv Exp Med Biol, V200, P253; Liu X, 1999, IEEE Trans Rehabil Eng, V7, P315, DOI 10.1109/86.788468; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; McCreery D, 2004, IEEE T NEUR SYS REH, V12, P195, DOI 10.1109/TNSRE.2004.827223; McIntosh TK, 1996, LAB INVEST, V74, P315; Menna G, 2000, J NEUROPHYSIOL, V83, P1338, DOI 10.1152/jn.2000.83.3.1338; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nicolelis MAL, 2003, P NATL ACAD SCI USA, V100, P11041, DOI 10.1073/pnas.1934665100; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OLTHUIS W, 1990, SENSOR ACTUAT B-CHEM, V2, P247, DOI 10.1016/0925-4005(90)80150-X; Otto KJ, 2006, IEEE T BIO-MED ENG, V53, P333, DOI 10.1109/TBME.2005.862530; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAPESCHI G, 1981, J MED ENG TECHNOL, V5, P86, DOI 10.3109/03091908109042445; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Peters JL, 2004, J NEUROSCI METH, V137, P9, DOI 10.1016/j.jneumeth.2004.02.006; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Prochazka A, 2001, J PHYSIOL-LONDON, V533, P99, DOI 10.1111/j.1469-7793.2001.0099b.x; Purushothaman G, 2006, J NEUROSCI METH, V153, P86, DOI 10.1016/j.jneumeth.2005.10.015; Rennaker RL, 2005, J NEUROSCI METH, V142, P169, DOI 10.1016/j.jneumeth.2004.08.009; ROBBLEE LS, 1983, J ELECTROCHEM SOC, V130, P731, DOI 10.1149/1.2119793; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROUSCHE PJ, 1992, ANN BIOMED ENG, V20, P413, DOI 10.1007/BF02368133; SCHELLER D, 1992, NEUROSCI LETT, V135, P83, DOI 10.1016/0304-3940(92)90141-S; Schwartz AB, 2004, ANNU REV NEUROSCI, V27, P487, DOI 10.1146/annurev.neuro.27.070203.144233; Siesjo BK, 1996, ADV NEUROL, V71, P209; Szarowski DH, 2003, BRAIN RES, V983, P23, DOI 10.1016/S0006-8993(03)03023-3; Theodore WH, 2004, LANCET NEUROL, V3, P111, DOI 10.1016/S1474-4422(03)00664-1; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; URBANICS R, 1978, PFLUG ARCH EUR J PHY, V378, P47, DOI 10.1007/BF00581957; Vetter RJ, 2004, IEEE T BIO-MED ENG, V51, P896, DOI 10.1109/TBME.2004.826680; VOIPIO J, 1995, J NEUROPHYSIOL, V74, P633, DOI 10.1152/jn.1995.74.2.633; VOIPIO J, 1993, PFLUG ARCH EUR J PHY, V423, P193, DOI 10.1007/BF00374394; Watson CJ, 2006, ANAL CHEM, V78, P1391, DOI 10.1021/ac0693722; WESTERINK BHC, 1988, J NEUROCHEM, V51, P683, DOI 10.1111/j.1471-4159.1988.tb01798.x; Williams JC, 1999, BRAIN RES PROTOC, V4, P303, DOI 10.1016/S1385-299X(99)00034-3	84	51	51	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 15	2007	160	2					276	287		10.1016/j.jneumeth.2006.09.023			12	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	146NG	WOS:000244940600012	17084461				2022-02-06	
J	Sohlberg, MM; Kennedy, M; Avery, J; Coelho, C; Turkstra, L; Ylvisaker, M; Yorkston, K				Sohlberg, McKay Moore; Kennedy, Mary; Avery, Jack; Coelho, Carl; Turkstra, Lyn; Ylvisaker, Mark; Yorkston, Kathryn			Evidence-based practice for the use of external aids as a memory compensation technique	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; PRACTICE GUIDELINES; ASSISTIVE TECHNOLOGY; PAGING SYSTEM; HEAD-INJURY; REHABILITATION; IMPAIRMENTS; REMEDIATION; THERAPY; PATIENT		Univ Oregon, Eugene, OR 97403 USA; Univ Minnesota, Minneapolis, MN USA; Univ Connecticut, Storrs, CT USA; Univ Wisconsin, Madison, WI USA; Coll St Rose, Albany, NY USA; Univ Washington, Seattle, WA 98195 USA		Sohlberg, MM (corresponding author), Univ Oregon, Eugene, OR 97403 USA.	mckay@uoregon.edu	Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921			ADAMS KM, 2003, BRAIN IMPAIRMENT, V4, P31; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Cole E, 1999, NEUROREHABILITATION, V12, P39; Crowe SF, 2003, NEUROPSYCHOL REHABIL, V13, P497, DOI 10.1080/09602010343000075; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Fluharty George, 1993, Brain Injury, V7, P85, DOI 10.3109/02699059309008160; Golper L., 2001, EVIDENCE BASED PRACT; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; HART T, 2004, J HEAD TRAUMA REHAB, V18, P725; Kennedy MRT, 2002, J MED SPEECH-LANG PA, V10, pIX; Kerns K A, 1998, Pediatr Rehabil, V2, P77; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, REHABIL PSYCHOL, V49, P200, DOI 10.1037/0090-5550.49.3.200; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; KIRSCH NL, 1992, J HEAD TRAUMA REHAB, V7, P13, DOI DOI 10.1097/00001199-199209000-00004; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; Miller S.A., 2002, COGNITIVE DEV, V4th; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; TURKSTRA L, 2003, TECHNICAL REPORT USE; TURKSTRA L, 2005, SEMINARS SPEECH LANG, V26; TURKSTRA L, 2005, J MED SPEECH LANGUAG; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; World Health Organization, 2007, INT CLASS FUNCT DIS; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; Yorkston KM, 2001, J MED SPEECH-LANG PA, V9, P243; ZENCIUS A, 1990, Brain Injury, V4, P33, DOI 10.3109/02699059009026146	41	51	51	1	29	DELMAR CENGAGE LEARNING	FLORENCE	PO BOX 6904, FLORENCE, KY 41022-6904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	MAR	2007	15	1					XV	LI					37	Audiology & Speech-Language Pathology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Neurosciences & Neurology	157PF	WOS:000245731700003					2022-02-06	
J	Haqqani, AS; Hutchison, JS; Ward, R; Stanimirovic, DB				Haqqani, Arsalan S.; Hutchison, James S.; Ward, Roxanne; Stanimirovic, Danica B.		Canadian Critical Care Translational	Protein biomarkers in serum of pediatric patients with severe traumatic brain injury identified by ICAT-LC-MS/MS	JOURNAL OF NEUROTRAUMA			English	Article						proteomics; S100 beta; serum biomarkers; traumatic head injury	NEURON-SPECIFIC ENOLASE; BARRIER DISRUPTION; GENE-EXPRESSION; ISCHEMIC-STROKE; POSSIBLE MARKER; HEAD-INJURY; DAMAGE; BLOOD; CHILDREN; S-100-BETA	This report is a feasibility study on the utility of gel-free proteomics in identifying peripheral biomarkers of brain injury. The study was performed in six pediatric patients admitted to the intensive care unit for severe traumatic brain injury (TBI). Serum samples collected at admission (less than 8 h after injury) were used for determining the levels of S100 beta by enzyme-linked immunosorbent assay (ELISA) and for proteomics analyses. Serum samples were depleted of high abundant albumin and immunoglobulin, and were compared to a pooled reference from several healthy individuals. After labeling and separation on an ionic column, six different serum fractions were analyzed using Isotope-Coded Affinity Tag (ICAT), followed by tandem mass spectrometry (MS/MS) protein sequencing and identification. Ninety-five unique, differentially expressed proteins were identified, including several with a likely brain origin. Several proteins with pattern similarity to S100 beta identified by hierarchical clustering could be considered for evaluation in a larger patient sample as potential peripheral markers of TBI.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R7, Canada; Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Integrat Biol Program, Toronto, ON M5G 1X8, Canada; Childrens Hosp Eastern Ontario, Res Inst, Chalmers Grp, Ottawa, ON K1H 8L1, Canada		Stanimirovic, DB (corresponding author), Natl Res Council Canada, Inst Biol Sci, 1200 Montreal Rd,Bldg M-54, Ottawa, ON K1A 0R7, Canada.	danica.stanimirovic@nrc-cnrc.gc.ca					Alaiya A, 2005, J PROTEOME RES, V4, P1213, DOI 10.1021/pr050149f; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Cooper E. H., 1994, International Journal of Biological Markers, V9, P205; Delahunty C, 2005, METHODS, V35, P248, DOI 10.1016/j.ymeth.2004.08.016; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Haqqani AS, 2005, FASEB J, V19, P1809, DOI 10.1096/fj.05-3793com; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Konig R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh027; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Marchi N, 2003, J NEUROSCI, V23, P1949; Matsumoto H, 2001, EUR J BIOCHEM, V268, P3259, DOI 10.1046/j.1432-1327.2001.02221.x; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Mohammed MQ, 2001, MED ONCOL, V18, P109; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Omenn GS, 2005, PROTEOMICS, V5, P3226, DOI 10.1002/pmic.200500358; Pelsers MMAL, 2005, CLIN CHEM LAB MED, V43, P802, DOI 10.1515/CCLM.2005.135; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Tang Y, 2006, J CEREBR BLOOD F MET, V26, P1089, DOI 10.1038/sj.jcbfm.9600264; Veenstra TD, 2004, DRUG DISCOV TODAY, V9, P889, DOI 10.1016/S1359-6446(04)03246-5; Vogelbaum MA, 2005, CANCER-AM CANCER SOC, V104, P817, DOI 10.1002/cncr.21220; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Zhong Y, 2004, CEREB CORTEX, V14, P1144, DOI 10.1093/cercor/bhh074	38	51	54	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					54	74		10.1089/neu.2006.0079			21	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100006	17263670				2022-02-06	
J	Hu, Y; Cui, Q; Harvey, AR				Hu, Ying; Cui, Qi; Harvey, Alan R.			Interactive effects of C3, cyclic AMP and ciliary neurotrophic factor on adult retinal ganglion cell survival and axonal regeneration	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						optic nerve injury; neurotrauma; cyclic nucleotides; cytokines; C3 transferase	MYELIN-ASSOCIATED GLYCOPROTEIN; SIGNAL-REGULATED KINASE; PERIPHERAL-NERVE GRAFTS; OPTIC-NERVE; IN-VIVO; MEDIATED EXPRESSION; INHIBITORY-ACTIVITY; NEURITE OUTGROWTH; SCHWANN-CELLS; RHO	We tested whether combined therapy involving Rho inactivation, elevation of cAMP and supply of ciliary neurotrophic factor (CNTF) (i) increased axotomized adult retinal ganglion cell (RGC) survival and (ii) promoted axonal regeneration into peripheral nerve (PN) autografted onto the cut optic nerve. PN-grafted eyes were injected with combinations of a Rho-inactivating enzyme C3 transferase (C3-11), CNTF and a cell-permeant analogue of cAMP (CPT-cAMP). Four weeks after PN transplantation, RGC survival was quantified using beta-III tubulin immunohistochemistry. Regeneration was assessed using retrograde fluorogold tracing and pan-neurofilament immunostaining of grafts. Treatment with C3-11 increased RGC survival but co-injection with CPT-cAMP, CNTF or combined CNTF/CPT-cAMP did not further enhance RGC viability. There were greater numbers of regenerating RGCs after multiple C3-11 injections and regeneration was further and significantly increased after intravitreal injections of all three factors. In the combined C3-11/CNTF/CPT-cAMP treatment group about 15% of RGCs remained viable of which more than half regenerated an axon. These data emphasize the power of combinatorial pharmacotherapeutic and transplant strategies in the treatment of neurotrauma. (c) 2006 Elsevier Inc. All rights reserved.	Univ Western Australia, Sch Anat & Human Biol M309, Perth, WA 6009, Australia		Harvey, AR (corresponding author), Univ Western Australia, Sch Anat & Human Biol M309, 35 Stirling Highway, Perth, WA 6009, Australia.	arharvey@anhb.uwa.edu.au	Ying, Hu/F-3581-2010; Harvey, Alan R/A-4911-2008	, Alan/0000-0002-2590-831X			Ahmed Z, 2006, BRAIN, V129, P1517, DOI 10.1093/brain/awl080; BAHR M, 1995, EXP NEUROL, V134, P87, DOI 10.1006/exnr.1995.1039; Bandtlow CE, 2003, EXP GERONTOL, V38, P79, DOI 10.1016/S0531-5565(02)00165-1; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bertrand J, 2007, NEUROBIOL DIS, V25, P65, DOI 10.1016/j.nbd.2006.08.008; Bertrand J, 2005, J NEUROSCI, V25, P1113, DOI 10.1523/JNEUROSCI.3931-04.2005; Borisoff JF, 2003, MOL CELL NEUROSCI, V22, P405, DOI 10.1016/S1044-7431(02)00032-5; Bregman BS, 2002, PROG BRAIN RES, V137, P257; Bruce JH, 2000, J NEUROTRAUM, V17, P781, DOI 10.1089/neu.2000.17.781; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Castro C, 2006, EXP NEUROL, V200, P19, DOI 10.1016/j.expneurol.2006.02.001; Chen H, 2004, BRAIN RES, V1011, P99, DOI 10.1016/j.brainres.2004.03.024; CHO EYP, 1987, BRAIN RES, V419, P369, DOI 10.1016/0006-8993(87)90610-X; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Cui Q, 2004, J NEUROTRAUM, V21, P617, DOI 10.1089/089771504774129946; Cui Q, 2002, INVEST OPHTH VIS SCI, V43, P1954; Cui Q, 1999, INVEST OPHTH VIS SCI, V40, P760; Danias J, 2002, INVEST OPHTH VIS SCI, V43, P587; Dergham P, 2002, J NEUROSCI, V22, P6570; Desagher S, 2005, J BIOL CHEM, V280, P5693, DOI 10.1074/jbc.M408971200; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Dusart I, 2005, BRAIN RES REV, V49, P300, DOI 10.1016/j.brainresrev.2004.11.007; FILBIN MT, 1995, CURR OPIN NEUROBIOL, V5, P588, DOI 10.1016/0959-4388(95)80063-8; Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004; Fouad K, 2005, J NEUROSCI, V25, P1169, DOI 10.1523/JNEUROSCI.3562-04.2005; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Frade JM, 1999, DEVELOPMENT, V126, P683; Gao Y, 2004, NEURON, V44, P609, DOI 10.1016/j.neuron.2004.10.030; Gao Y, 2003, J NEUROSCI, V23, P11770; Gillon RS, 2003, J NEUROSCI RES, V74, P524, DOI 10.1002/jnr.10788; Goldberg JL, 2002, NEURON, V33, P689, DOI 10.1016/S0896-6273(02)00602-5; Grandpre T, 2001, NEUROSCIENTIST, V7, P377, DOI 10.1177/107385840100700507; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Hou B, 2004, INVEST OPHTH VIS SCI, V45, P662, DOI 10.1167/iovs.03-0281; Hu Y, 2005, MOL THER, V11, P906, DOI 10.1016/j.ymthe.2005.01.016; Isenmann S, 1998, EUR J NEUROSCI, V10, P2751, DOI 10.1046/j.1460-9568.1998.00325.x; Isenmann S, 2003, PROG RETIN EYE RES, V22, P483, DOI 10.1016/S1350-9462(03)00027-2; Kanekura K, 2005, J BIOL CHEM, V280, P4532, DOI 10.1074/jbc.M410508200; Kitaoka Y, 2004, BRAIN RES, V1018, P111, DOI 10.1016/j.brainres.2004.05.070; Klocker N, 1997, NEUROREPORT, V8, P3439; Klocker N, 1998, J NEUROSCI, V18, P1038; Kobayashi K, 2004, J NEUROSCI, V24, P3480, DOI 10.1523/JNEUROSCI.0295-04.2004; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Kuramoto H, 1997, MOL CHEM NEUROPATHOL, V31, P85, DOI 10.1007/BF02815163; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li YM, 2003, J NEUROSCI, V23, P7830; Lindqvist N, 2004, EXP NEUROL, V187, P487, DOI 10.1016/j.expneurol.2004.02.002; Logan A, 2006, BRAIN, V129, P490, DOI 10.1093/brain/awh706; Loucks FA, 2006, J NEUROCHEM, V97, P957, DOI 10.1111/j.1471-4159.2006.03802.x; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Morgenstern DA, 2003, MOL CELL NEUROSCI, V24, P787, DOI 10.1016/S1044-7431(03)00245-8; MUIR D, 1989, J CELL BIOL, V109, P2353, DOI 10.1083/jcb.109.5.2353; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nakazawa T, 2002, INVEST OPHTH VIS SCI, V43, P3319; NG TF, 1995, J NEUROCYTOL, V24, P487, DOI 10.1007/BF01179974; Nickells RW, 2004, BRAIN RES BULL, V62, P439, DOI 10.1016/j.brainresbull.2003.07.007; Orlando KA, 2006, EXP CELL RES, V312, P5, DOI 10.1016/j.yexcr.2005.09.012; Oshitari T, 2003, NEUROREPORT, V14, P289, DOI 10.1097/00001756-200302100-00027; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; PARK K, 2006, P AUS NEUROSCI SOC, V17, P155; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Saito K., 1997, Geophysical Magazine, Series 2, V2, P109; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Schafer M, 1996, NEURON, V16, P1107, DOI 10.1016/S0896-6273(00)80137-3; Selles-Navarro I, 2001, EXP NEUROL, V167, P282, DOI 10.1006/exnr.2000.7573; Shearer MC, 2003, MOL CELL NEUROSCI, V24, P913, DOI 10.1016/j.mcn.2003.09.004; Shen SL, 1999, NEURON, V23, P285, DOI 10.1016/S0896-6273(00)80780-1; Shen YJ, 1998, MOL CELL NEUROSCI, V12, P79, DOI 10.1006/mcne.1998.0700; Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6; SO KF, 1985, BRAIN RES, V328, P349, DOI 10.1016/0006-8993(85)91047-9; Spencer T, 2004, J ANAT, V204, P49, DOI 10.1111/j.1469-7580.2004.00259.x; Torigoe K, 1998, EXP NEUROL, V150, P254, DOI 10.1006/exnr.1997.6775; Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285; Winton MJ, 2002, J BIOL CHEM, V277, P32820, DOI 10.1074/jbc.M201195200; Yan Q, 1999, J NEUROBIOL, V38, P382, DOI 10.1002/(SICI)1097-4695(19990215)38:3<382::AID-NEU7>3.0.CO;2-5; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zuo J, 1998, J NEUROBIOL, V34, P41, DOI 10.1002/(SICI)1097-4695(199801)34:1<41::AID-NEU4>3.3.CO;2-4	88	51	53	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	JAN	2007	34	1					88	98		10.1016/j.mcn.2006.10.005			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	127PG	WOS:000243598200010	17126028				2022-02-06	
J	Huh, JW; Widing, AG; Raghupath, R				Huh, Jimmy W.; Widing, Ashley G.; Raghupath, Ramesh			Repetitive mild non-contusive brain trauma in immature rats exacerbates traumatic axonal injury and axonal calpain activation: A preliminary report	JOURNAL OF NEUROTRAUMA			English	Article						calpains; children; cognition; infants; inflicted brain injury; shaken-impact syndrome; traumatic axonal injury	SHAKEN-BABY SYNDROME; HEAD-INJURY; NERVOUS-SYSTEM; MODEL; VULNERABILITY; CHILDREN; INFANTS; IMPACT; NEUROPATHOLOGY; PROTEOLYSIS	Infants who experience inflicted brain injury (shaken-impact syndrome) present with subdural hematoma, brain atrophy, and ventriculomegaly, pathologic features that are suggestive of multiple incidences of brain trauma. To develop a clinically relevant model of inflicted brain injury in infants, the skulls of anesthetized 11-day-old rat pups were subjected to one, two, or three successive mild impacts. While skull fractures were not observed, a single impact to the intact skull resulted in petechial hemorrhages in the subcortical white matter, and double or triple impacts led to hemorrhagic tissue tears at 1 day postinjury. Whereas the singly impacted brain did not exhibit overt damage at 7 days, two impacts resulted in an enlarged ventricle and white matter atrophy; three impacts to the brain led to similar pathology albeit at 3 days postinjury. By 7 days, cortical atrophy was observed following three impacts. Reactive astrocytes were visible in the deep cortical layers below the impact site after two impacts, and through all cortical layers after three impacts. Swellings were observed in intact axons in multiple white matter tracts at 1 day following single impact and progressed to axonal disconnections by 3 days. In contrast, double or triple impacts resulted in axonal disconnections by 1 day postinjury; in addition, three impacts led to extensive axonal injury in the dorsolateral thalamus by 3 days. Calpain activation was observed in axons in subcortical white matter tracts in all brain-injured animals at 1 day and increased with the number of impacts. Despite these pathologic alterations, neither one nor two impacts led to acquisition deficits on the Morris water maze. While indicative of the graded nature of the pathologic response, these data suggest that repetitive mild brain injury in the immature rat results in pathologic features similar to those following inflicted brain injuries in infants.	Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA		Raghupath, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	rramesh@drexelmed.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, K08NS053651] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS 053651, R01 NS 41561] Funding Source: Medline		Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Gutierrez Farley L, 2004, J Psychosoc Nurs Ment Health Serv, V42, P22; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Marin-Padilla M, 2002, ACTA NEUROPATHOL, V103, P321, DOI 10.1007/s00401-001-0470-z; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Reichard RR, 2003, J NEUROTRAUM, V20, P347, DOI 10.1089/089771503765172309; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1	44	51	51	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					15	27		10.1089/neu.2006.0072			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100003	17263667				2022-02-06	
J	Lescot, T; Degos, V; Zouaoui, A; Preteux, F; Coriat, P; Puybasset, L				Lescot, Thomas; Degos, Vincent; Zouaoui, Abderrezak; Preteux, Francoise; Coriat, Pierre; Puybasset, Louis			Opposed effects of hypertonic saline on contusions and noncontused brain tissue in patients with severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						head trauma; specific gravity; computed tomography; contusion; blood-brain barrier	CEREBRAL-BLOOD-FLOW; ELEVATED INTRACRANIAL-PRESSURE; IMMUNE FUNCTION; HEAD-INJURY; BARRIER; HYPERTENSION; RAT; MANNITOL; VOLUME; EDEMA	Objective. The aim of this study was to quantify the effect of hypertonic saline solution on contused and noncontused brain tissue in patients with traumatic brain injury. We hypothesize that hypertonic saline would increase the volume of brain contusion while decreasing the volume of noncontused hemispheric areas. Design: Prospective observational study. Setting. Neurosciences critical care unit of a university hospital. Patients: Fourteen traumatic brain injury patients with increased intracranial pressure. Interventions. A computed tomography scan was performed before and after a 20-min infusion of 40 mL of 20% saline. Measurements and Main Results. The volume, weight, and specific gravity of contused and noncontused hemispheric areas were assessed from computed tomography DICOM images by using a custom-designed software (BrainView). Physiologic variables and natremia were measured before and after infusion. Hypertonic saline significantly increased natremia from 143 +/- 5 to 146 +/- 5 mmol/L and decreased intracranial pressure from 23 +/- 3 to 17 +/- 5 mm Hg. The volume of the noncontused hemispheric areas decreased by 13 +/- 8 mL whereas the specific gravity increased by 0.029 +/- 0.027%. The volume of contused hemispheric tissue increased by 5 +/- 5 mL without any concomitant change in density. There was a wide interindividual variability in the response of the noncontused hemispheric tissue with changes in specific gravity varying between -0.0124% and 0.0998%. Conclusions. Three days after traumatic brain injury, the blood-brain barrier remains semipermeable in noncontused areas but not in contusions. Further studies are needed to tailor the use of hypertonic saline in patients with traumatic brain injury according to the volume of contusions assessed on computed tomography.	Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Anesthesiol & Crit Care, Paris, France; Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Neuroradiol, Paris, France; Univ Paris 06, Paris, France; Inst Natl Telecommun, Artemis Project Unit, F-91011 Evry, France		Lescot, T (corresponding author), Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Anesthesiol & Crit Care, Paris, France.						Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beaumont A, 2002, ACT NEUR S, V81, P217; Daneyemez M, 1999, NEUROSCIENCE, V92, P783, DOI 10.1016/S0306-4522(99)00035-4; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Hartl R, 1997, ACT NEUR S, V70, P126; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Junger WG, 1997, SHOCK, V8, P235, DOI 10.1097/00024382-199710000-00001; JUNGER WG, 1994, CIRC SHOCK, V42, P190; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; KUSHI H, 1994, ACTA NEUROCHIR, P472; Lescot T, 2005, INTENS CARE MED, V31, P1042, DOI 10.1007/s00134-005-2709-y; Loomis WH, 2001, AM J PHYSIOL-CELL PH, V281, pC840, DOI 10.1152/ajpcell.2001.281.3.C840; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2000, ACT NEUR S, V76, P349; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; MUIZELAAR JP, 1986, STROKE, V17, P44, DOI 10.1161/01.STR.17.1.44; Saltarini M, 2002, Eur J Emerg Med, V9, P262, DOI 10.1097/00063110-200209000-00011; Schatzmann C, 1998, ACT NEUR S, V71, P31; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; VANDENBRINK WA, 1994, ACT NEUR S, V60, P456; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64	26	51	54	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2006	34	12					3029	3033		10.1097/01.CCM.0000243797.42346.64			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110QH	WOS:000242393100023	16971850				2022-02-06	
J	Shen, F; Tay, TE; Li, JZ; Nigen, S; Lee, PVS; Chan, HK				Shen, F.; Tay, T. E.; Li, J. Z.; Nigen, S.; Lee, P. V. S.; Chan, H. K.			Modified Bilston nonlinear viscoelastic model for finite element head injury studies	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						traumatic brain injury; rheological test; material properties; finite element simulation; impact biomechanics	HUMAN BRAIN-TISSUE; CONSTITUTIVE MODEL; SHEAR; DEFORMATION	This paper proposes a modified nonlinear viscoelastic Bilston model (Bilston et al., 2001, Biorheol., 38, pp. 335-345). for the modeling of brain tissue constitutive properties. The modified model can be readily implemented in a commercial explicit finite element (FE) code, PamCrash. Critical parameters of the model have been determined through a series of rheological tests on porcine brain tissue samples and the time-temperature superposition (TTS) principle has been used to extend the frequency to a high region. Simulations by using PamCrash are compared with the test results. Through the use of the TTS principle, the mechanical and rheological behavior at high frequencies up to 10(4) rad/s may be obtained. This is important because the properties of the brain tissue at high frequencies and impact rates are especially relevant to studies of traumatic head injury. The averaged dynamic modulus ranges from 130 Pa to 1500 Pa and loss modulus ranges from 35 Pa to 800 Pa in the frequency regime studied (0.01 rad/s to 3700 rad/s). The errors between theoretical predictions and averaged relaxation test results are within 20% for strains up to 20%. The FEM simulation results are in good agreement with experimental results. The proposed model will be especially useful for application to FE analysis of the head under impact loads. More realistic analysis of head injury can be carried out by incorporating the nonlinear viscoelastic constitutive law for brain tissue into a commercial FE code.	Natl Univ Singapore, Div Bioengn, Singapore 117576, Singapore; Def Med & Environm Res Inst, Singapore 117510, Singapore		Shen, F (corresponding author), Natl Univ Singapore, Div Bioengn, 9 Engn Dr 1, Singapore 117576, Singapore.	mpesf@nus.edu.sg	Lee, Peter/D-3506-2014	Lee, Peter/0000-0003-3666-4872; Tay, Tong-Earn/0000-0002-2846-1947			Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bilston LE, 2001, BIORHEOLOGY, V38, P335; BRANDS D. W. A., 2000, P STAPP CAR CRASH C, V44, P249; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; BYCROFT GN, 1973, J BIOMECH, V6, P487, DOI 10.1016/0021-9290(73)90007-9; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; European Transport Safety Council, 1999, RED SEV ROAD INJ POS; FRANKE EK, 1954, 5424 WRIGHT PATT AIR; KLEIVEN S, 2002, THESIS ROYAL I TECHN; Kyriacou SK, 2002, BIOMECH MODEL MECHAN, V1, P151, DOI 10.1007/s10237-002-0013-0; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MENDIS KK, 1995, ASME, V117, P279; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; MISRA JC, 1984, J BIOMECH, V17, P459, DOI 10.1016/0021-9290(84)90014-9; Nasseri S, 2002, RHEOL ACTA, V41, P180, DOI 10.1007/s003970200017; PAMIDI MR, 1978, ASME, V100, P44; Peters GWM, 1997, BIORHEOLOGY, V34, P127, DOI 10.1016/S0006-355X(97)00009-7; Phan-Thien N, 2000, J NON-NEWTON FLUID, V95, P343, DOI 10.1016/S0377-0257(00)00175-0; PhanThien N, 1997, RHEOL ACTA, V36, P38, DOI 10.1007/BF00366722; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Trosseille X, 1992, 36 STAPP CAR CRASH C; Voo L, 1996, MED BIOL ENG COMPUT, V34, P375, DOI 10.1007/BF02520009; Zhang LM, 2001, CARBOHYD POLYM, V45, P1, DOI 10.1016/S0144-8617(00)00276-9	29	51	52	0	8	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	OCT	2006	128	5					797	801		10.1115/1.2264393			5	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	094YA	WOS:000241274000022	16995770				2022-02-06	
J	Goldman, SA; Windrem, MS				Goldman, Steven A.; Windrem, Martha S.			Cell replacement therapy in neurological disease	PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES			English	Article						leucodystrophy; oligodendrocyte; glial progenitor cell; transplantation; neural stem cell	EMBRYONIC STEM-CELLS; NEURAL PROGENITOR CELLS; FETAL NIGRAL TRANSPLANTATION; ADULT MAMMALIAN FOREBRAIN; SUBCORTICAL WHITE-MATTER; SPINAL-CORD; DOPAMINERGIC-NEURONS; IN-VITRO; PRECURSOR CELLS; DIRECTED DIFFERENTIATION	Diseases of the brain and spinal cord represent especially daunting challenges for cell-based strategies of repair, given the multiplicity of cell types within the adult central nervous system, and the precision with which they must interact in both space and time. Nonetheless, a number of diseases are especially appropriate for cell-based therapy, in particular those in which single phenotypes are lost, and in which the re-establishment of vectorially specific connections is not entirely requisite for therapeutic benefit. We review here a set of potential therapeutic indications that meet these criteria as potentially benefiting from the transplantation of neural stem and progenitor cells. These include: (i) transplantation of phenotypically restricted neuronal progenitor cells into diseases of a single neuronal phenotype, such as Parkinson's disease; (ii) implantation of mixed progenitor pools into diseases characterized by the loss of a limited number of discrete phenotypes, such as spinal cord injury and the motor neuronopathies; (iii) transplantation of glial and nominally oligodendrocytic progenitor cells as a means of treating disorders of myelin; and (iv) transplantation of neural stem cells as a means of treating lysosomal storage disorders and other diseases of enzymatic deficiency. Among the diseases potentially approachable by these strategies, the myelin disorders, including the paediatric leucodystrophies as well as adult traumatic and inflammatory demyelinations, may present the most compelling targets for cell-based neurological therapy.	Univ Rochester, Med Ctr, Div Cell & Gene Therapy, Dept Neurol, Rochester, NY 14642 USA; Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA		Goldman, SA (corresponding author), Univ Rochester, Med Ctr, Div Cell & Gene Therapy, Dept Neurol, 601 Elmwood Ave,POB 645, Rochester, NY 14642 USA.	steven_goldman@urmc.rochester.edu		Goldman, Steven/0000-0002-5498-4303			Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; Back SA, 2004, SEMIN PERINATOL, V28, P405, DOI 10.1053/j.semperi.2004.10.010; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHMIELNICKI E, 2005, NEURODEGENER DIS, P347; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Follett PL, 2004, J NEUROSCI, V24, P4412, DOI 10.1523/JNEUROSCI.0477-04.2004; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gao Y, 2004, NEURON, V44, P609, DOI 10.1016/j.neuron.2004.10.030; Gold PE, 2002, PSYCHOL SCI, P2, DOI 10.1111/1529-1006.00006; Goldman S, 2005, NAT BIOTECHNOL, V23, P862, DOI 10.1038/nbt1119; Goldman SA, 2005, NEUROLOGY, V64, P1675, DOI 10.1212/01.WNL.0000165312.12463.BE; Goldman SA, 2004, CURR OPIN MOL THER, V6, P466; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; Gritti A, 1996, J NEUROSCI, V16, P1091; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Han SSW, 2004, GLIA, V45, P1, DOI 10.1002/glia.10282; Hauser RA, 1999, ARCH NEUROL-CHICAGO, V56, P179, DOI 10.1001/archneur.56.2.179; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hu FH, 2004, SEMIN PERINATOL, V28, P371, DOI 10.1053/j.semperi.2004.10.001; Hudson L, 2004, MYELIN BIOL DISORDER, P867; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Kawaguchi A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/mcne.2000.0925; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kaye EM, 2001, PEDIATR NEUROL, V24, P11, DOI 10.1016/S0887-8994(00)00232-0; Kerr DA, 2003, J NEUROSCI, V23, P5131; Keyoung HM, 2001, NAT BIOTECHNOL, V19, P843, DOI 10.1038/nbt0901-843; Kim DW, 2006, STEM CELLS, V24, P557, DOI 10.1634/stemcells.2005-0233; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kordower JH, 1998, MOVEMENT DISORD, V13, P383, DOI 10.1002/mds.870130303; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; Lindvall O, 1999, MOVEMENT DISORD, V14, P201, DOI 10.1002/1531-8257(199903)14:2<201::AID-MDS1001>3.3.CO;2-H; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Nakano T, 2005, DEV BIOL, V283, P474, DOI 10.1016/j.ydbio.2005.04.017; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Nistor GI, 2005, GLIA, V49, P385, DOI 10.1002/glia.20127; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; PALMER T, 2006, NEURAL DEV STEM CELL, P343; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Park S, 2004, NEUROSCI LETT, V359, P99, DOI 10.1016/j.neulet.2004.01.073; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pellegatta S, 2006, NEUROBIOL DIS, V21, P314, DOI 10.1016/j.nbd.2005.07.016; Piccini P, 2005, BRAIN, V128, P2977, DOI 10.1093/brain/awh649; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; Pluchino S, 2004, CURR OPIN NEUROL, V17, P247, DOI 10.1097/00019052-200406000-00003; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Powers J., 2004, MYELIN BIOL DISORDER, P663; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Robinson S, 2005, NEUROBIOL DIS, V18, P568, DOI 10.1016/j.nbd.2004.10.024; Roy NS, 2004, NAT BIOTECHNOL, V22, P297, DOI 10.1038/nbt944; Roy NS, 2005, EXP NEUROL, V196, P224, DOI 10.1016/j.expneurol.2005.06.021; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Roy NS, 2000, NAT MED, V6, P271; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Studer L, 2000, J NEUROSCI, V20, P7377; Svendsen CN, 1999, BRAIN PATHOL, V9, P499, DOI 10.1111/j.1750-3639.1999.tb00538.x; Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Urayama A, 2004, P NATL ACAD SCI USA, V101, P12658, DOI 10.1073/pnas.0405042101; vanderKnaap MS, 1997, NEUROLOGY, V48, P845, DOI 10.1212/WNL.48.4.845; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Wang S, 2000, DEV NEUROSCI-BASEL, V22, P167, DOI 10.1159/000017437; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Weiss S, 1996, J NEUROSCI, V16, P7599; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Windrem M, 2002, CONT NEUROS, P69; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Windrem MS, 2002, J NEUROSCI RES, V69, P966, DOI 10.1002/jnr.10397; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; [No title captured]	100	51	58	0	7	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	0962-8436	1471-2970		PHILOS T R SOC B	Philos. Trans. R. Soc. B-Biol. Sci.	SEP 29	2006	361	1473					1463	1475		10.1098/rstb.2006.1886			13	Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics	090RJ	WOS:000240968400002	16939969	Green Published			2022-02-06	
J	Sakellaris, G; Kotsiou, M; Tamiolaki, M; Kalostos, G; Tsapaki, E; Spanaki, M; Spilioti, M; Charissis, G; Evangeliou, A				Sakellaris, G.; Kotsiou, M.; Tamiolaki, M.; Kalostos, G.; Tsapaki, E.; Spanaki, M.; Spilioti, M.; Charissis, G.; Evangeliou, A.			Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: An open label randomized pilot study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						creatine; traumatic; brain injury; pediatric; outcome	SEVERE HEAD-INJURY; MITOCHONDRIAL ENCEPHALOMYOPATHIES; RAT; SUPPLEMENTATION; MONOHYDRATE; DISABILITY; PROTECTS; DEFICIENCY; MUSCLE; DAMAGE	Background. There has been an enormous focus on the discovery and development of neuroprotective agents that might have clinical relevance after traumatic brain injury (TBI). Based on experimental facts, we studied administration of creatine to patients with TBI. Methods. A prospective, randomized, comparative, open-labeled pilot study of the possible neuroprotective effect of creatine was performed on 39 children and adolescents, aged between 1 to 18 years old, with TBI. The creatine was administered for 6 months, at a dose of 0.4 gr/kg in an oral suspension form every day. For categorical variables, we used the chi(2) test to identify differences between controls and cases. Statistical significance was defined as a p value < 0.05 and not statistically significant if p value > 0.1. Results. The administration of creatine to children with TBI improved results in several parameters, including duration of post-traumatic amnesia (PTA), duration of intubation, intensive care unit (ICU) stay, disability, good recovery, self care, communication, locomotion, sociability, personality/behavior and neurophysical, and cognitive function. Significant improvement was recorded in the categories of Cognitive (p < 0.001), personatity/behavior (p < 0.001), Self Care (p = 0.029), and communication (p = 0.018) aspects in all patients. No side effects were seen because of creatine administration. Conclusion. Preliminary data suggest that the administration of creatine may be beneficial to patients with traumatic brain injury.	Univ Hosp Heraklio, Dept Paediat Surg, Iraklion, Greece; Univ Hosp Heraklio, Dept Paediat, Iraklion, Greece; Univ Hosp Heraklio, Dept Neurosurg, Iraklion, Greece; Univ Hosp Heraklio, Paediat Intens Care Unit, Iraklion, Greece; Hippokratio Gen Hosp, Paediat Intens Care Unit, Thessaloniki, Greece		Sakellaris, G (corresponding author), Venizelou 105, GR-70014 Hersonissou P, Greece.	gsakell@mycosmos.gr					Bachmann C, 2004, MOL GENET METAB, V81, pS52, DOI 10.1016/j.ymgme.2003.10.014; Balestrino M, 1999, BRAIN RES, V816, P124, DOI 10.1016/S0006-8993(98)01131-7; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Berger R, 2004, J SOC GYNECOL INVEST, V11, P9, DOI 10.1016/j.jsgi.2003.07.002; Borchert A, 1999, MUSCLE NERVE, V22, P1299; Borges N, 2004, INT J NEUROSCI, V114, P217, DOI 10.1080/00207450490249419; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; EPPENBERGEREBERHARDT M, 1991, J CELL BIOL, V113, P289, DOI 10.1083/jcb.113.2.289; Felber S, 2000, NEUROL RES, V22, P145, DOI 10.1080/01616412.2000.11741051; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; GORDON A, 1995, CARDIOVASC RES, V30, P413, DOI 10.1016/0008-6363(95)00062-3; Holtzman D, 1998, PEDIATR RES, V44, P410, DOI 10.1203/00006450-199809000-00024; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Komura K, 2003, PEDIATR NEUROL, V28, P53, DOI 10.1016/S0887-8994(02)00469-1; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Schulze A, 2003, ANN NEUROL, V53, P248, DOI 10.1002/ana.10455; SPLAINGARD ML, 1989, ARCH PHYS MED REHAB, V70, P318; Stockler S, 1997, METABOLISM, V46, P1189, DOI 10.1016/S0026-0495(97)90215-8; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C; TEGAS JJ, 1990, J PEDIATR SURG, V25, P92; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631	25	51	52	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2006	61	2					322	329		10.1097/01.ta.0000230269.46108.d5			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	075UW	WOS:000239911800017	16917445				2022-02-06	
J	Gillingwater, TH; Ingham, CA; Parry, KE; Wright, AK; Haley, JE; Wishart, TM; Arbuthnott, GW; Ribchester, RR				Gillingwater, Thomas H.; Ingham, Cali A.; Parry, Katherine E.; Wright, Ann K.; Haley, Jane E.; Wishart, Thomas M.; Arbuthnott, Gordon W.; Ribchester, Richard R.			Delayed synaptic degeneration in the CNS of Wld(s) mice after cortical lesion	BRAIN			English	Article						synapse; neurodegeneration; neuroprotection; brain; Alzheimer's disease; electron microscopy	TRAUMATIC BRAIN-INJURY; WALLERIAN DEGENERATION; NEUROMUSCULAR-JUNCTIONS; ALZHEIMERS-DISEASE; CORTICOSPINAL TRACT; AXON DEGENERATION; PROTEIN-SYNTHESIS; MUTANT; SYNAPSES; MODEL	Therapies that might delay degeneration of synapses offer an appealing strategy for treatment of neurodegenerative diseases, including Alzheimer's disease and related dementias, prion diseases, schizophrenia and amyotrophic lateral sclerosis. Analysis of mouse mutants provides one possible avenue towards identifying relevant mechanisms. Here, we used quantitative and serial section electron microscopy to find out whether the onset and time course of pre-synaptic nerve terminal degeneration is delayed in the striatum of Wallerian degeneration slow (Wld(s)) mutant mice. Synaptic degeneration was observed within 48 h of cortical ablation in wild-type mice but was delayed by approximately 1 week in Wld(s) mice. However, the morphological characteristics of degenerating nerve terminals in wild-type and Wld(s) mice were indistinguishable, in contrast to the differences reported previously in studies of the PNS. Surprisingly, the delayed onset of synaptic degeneration was accompanied by an increased incidence of complex synaptic morphologies on post-synaptic spines in the denervated Wld(S) striatum indicating an enhanced plastic response at both injured and uninjured synapses. The data suggest that targeting Wallerian-like mechanisms of synaptic degeneration could lead to the development of new therapies for the treatment of CNS disorders where synapse loss is a primary feature.	Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland; Univ Edinburgh, Neurosci Res Ctr, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Div Vet Biomed Sci, Edinburgh, Midlothian, Scotland		Gillingwater, TH (corresponding author), Univ Edinburgh, Ctr Integrat Physiol, Hugh Robson Bldg, Edinburgh EH8 9XD, Midlothian, Scotland.	T.Gillingwater@ed.ac.uk	Gillingwater, Thomas/G-2880-2011; Arbuthnott, Gordon W/A-4606-2015	Arbuthnott, Gordon W/0000-0002-3386-8362; Haley, Jane/0000-0001-6178-2673; wishart, thomas/0000-0002-1973-6654; Gillingwater, Thomas/0000-0002-0306-5577; Ribchester, Richard/0000-0003-2670-6995	Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/D001722/1] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission [GR066272] Funding Source: Medline		Adalbert R, 2005, EUR J NEUROSCI, V21, P271, DOI 10.1111/j.1460-9568.2004.03833.x; Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Alvarez J, 2000, PROG NEUROBIOL, V62, P1, DOI 10.1016/S0301-0082(99)00062-3; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bernard V, 1997, J NEUROSCI, V17, P819; BROWN MC, 1991, NEURON, V6, P359, DOI 10.1016/0896-6273(91)90245-U; Burbach GJ, 2004, GLIA, V48, P76, DOI 10.1002/glia.20057; Cadet JL, 2003, FASEB J, V17, P1775, DOI 10.1096/fj.03-0073rev; Carroll SL, 1998, J NEUROPATH EXP NEUR, V57, P915, DOI 10.1097/00005072-199810000-00004; Cesa R, 2005, EUR J NEUROSCI, V22, P579, DOI 10.1111/j.1460-9568.2005.04244.x; CHEN S, 1990, BRAIN RES, V520, P103, DOI 10.1016/0006-8993(90)91695-D; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Coleman MP, 2004, CNS NEUROL DISORD-DR, V3, P227, DOI 10.2174/1568007043337436; Coleman P, 2004, NEUROLOGY, V63, P1155, DOI 10.1212/01.WNL.0000140626.48118.0A; Cunningham C, 2003, EUR J NEUROSCI, V17, P2147, DOI 10.1046/j.1460-9568.2003.02662.x; DECKWERTH TL, 1994, DEV BIOL, V165, P63, DOI 10.1006/dbio.1994.1234; ERB DE, 1991, EXP BRAIN RES, V83, P253; Fang C, 2005, NEUROSCIENCE, V135, P1107, DOI 10.1016/j.neuroscience.2005.06.078; Ferri A, 2003, CURR BIOL, V13, P669, DOI 10.1016/S0960-9822(03)00206-9; Fischer LR, 2005, NEUROBIOL DIS, V19, P293, DOI 10.1016/j.nbd.2005.01.008; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.3.CO;2-L; Frankle W. Gordon, 2003, Neuron, V39, P205, DOI 10.1016/S0896-6273(03)00423-9; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Ganeshina O, 2004, NEUROSCIENCE, V125, P615, DOI 10.1016/j.neuroscience.2004.02.025; Gillingwater TH, 2004, J CEREBR BLOOD F MET, V24, P62, DOI 10.1097/01.WCB.0000095798.98378.34; Gillingwater TH, 2006, HUM MOL GENET, V15, P625, DOI 10.1093/hmg/ddi478; Gillingwater TH, 2003, J NEUROCYTOL, V32, P863, DOI 10.1023/B:NEUR.0000020629.51673.f5; Gillingwater TH, 2003, J ANAT, V203, P265, DOI 10.1046/j.1469-7580.2003.00214.x; Gillingwater TH, 2002, J PHYSIOL-LONDON, V543, P739, DOI 10.1113/jphysiol.2002.022343; Gillingwater TH, 2001, J PHYSIOL-LONDON, V534, P627, DOI 10.1111/j.1469-7793.2001.00627.x; Gilman CP, 2003, NEUROMOL MED, V3, P159, DOI 10.1385/NMM:3:3:159; GREENOUGH WT, 1978, SCIENCE, V202, P1096, DOI 10.1126/science.715459; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; Ingham CA, 1998, J NEUROSCI, V18, P4732; Ishimaru H, 2001, BRAIN RES, V903, P94, DOI 10.1016/S0006-8993(01)02439-8; Jourdain P, 2002, J NEUROSCI, V22, P3108, DOI 10.1523/JNEUROSCI.22-08-03108.2002; KEMP JM, 1971, PHILOS T R SOC B, V262, P413, DOI 10.1098/rstb.1971.0104; LaFontaine MA, 2002, NEUROCHEM RES, V27, P417, DOI 10.1023/A:1015560116208; Laser H, 2006, MOL BIOL CELL, V17, P1075, DOI 10.1091/mbc.E05-04-0375; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; LUDWIN SK, 1992, J NEUROL SCI, V109, P140, DOI 10.1016/0022-510X(92)90160-M; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Martin KC, 2004, CURR OPIN NEUROBIOL, V14, P305, DOI 10.1016/j.conb.2004.05.009; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McNeill TH, 2003, J COMP NEUROL, V467, P32, DOI 10.1002/cne.10907; Meshul CK, 2000, EXP NEUROL, V165, P191, DOI 10.1006/exnr.2000.7467; Mi WQ, 2005, BRAIN, V128, P405, DOI 10.1093/brain/awh368; MILEDI R, 1970, J PHYSIOL-LONDON, V207, P507, DOI 10.1113/jphysiol.1970.sp009076; PARENT A, 1995, BRAIN RES REV, V20, P91, DOI 10.1016/0165-0173(94)00007-C; PERRY VH, 1991, EUR J NEUROSCI, V3, P102, DOI 10.1111/j.1460-9568.1991.tb00815.x; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; RIBCHESTER RR, 1995, EUR J NEUROSCI, V7, P1641, DOI 10.1111/j.1460-9568.1995.tb01159.x; Sajadi A, 2004, CURR BIOL, V14, P326, DOI 10.1016//j.cub.2004.01.053; Samsam M, 2003, J NEUROSCI, V23, P2833; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sasaki S, 1996, NEUROSCI LETT, V204, P53, DOI 10.1016/0304-3940(96)12314-4; SCHEFF SW, 1993, ANN NEUROL, V33, P190, DOI 10.1002/ana.410330209; Scheff SW, 2003, NEUROBIOL AGING, V24, P1029, DOI 10.1016/j.neurobiolaging.2003.08.002; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SMALL JV, 1968, P 4 EUR REG C EL MIC; SOMOGYI P, 1981, J COMP NEUROL, V195, P567, DOI 10.1002/cne.901950403; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Steward O, 1997, J COMP NEUROL, V380, P70, DOI 10.1002/(SICI)1096-9861(19970331)380:1<70::AID-CNE5>3.0.CO;2-Q; Subang MC, 1997, J NEUROSCI RES, V49, P563, DOI 10.1002/(SICI)1097-4547(19970901)49:5<563::AID-JNR6>3.0.CO;2-9; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sutton MA, 2005, J NEUROBIOL, V64, P116, DOI 10.1002/neu.20152; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Tsai J, 2004, NAT NEUROSCI, V7, P1181, DOI 10.1038/nn1335; Upadhya SC, 2006, NEUROCHEM INT, V48, P296, DOI 10.1016/j.neuint.2005.11.003; Velde CV, 2004, NEUROMOL MED, V5, P193, DOI 10.1385/NMM:5:3:193; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Wang MS, 2001, ANN NEUROL, V50, P773, DOI 10.1002/ana.10039; Wang MS, 2002, ANN NEUROL, V52, P442, DOI 10.1002/ana.10300; Zhou L, 1998, ANN NEUROL, V44, P99, DOI 10.1002/ana.410440116	76	51	51	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUN	2006	129		6				1546	1556		10.1093/brain/awl101			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	052HN	WOS:000238224900020	16738060	Bronze			2022-02-06	
J	Testa, JA; Malec, JF; Moessner, AM; Browt, AW				Testa, Julie A.; Malec, James F.; Moessner, Anne M.; Browt, Allen W.			Predicting family functioning after TBI - Impact of neurobehavioral factors	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; depression; family functioning; rehabilitation	TRAUMATIC BRAIN-INJURY; DEPRESSION; REHABILITATION; CAREGIVERS	Objective: To identify risk factors for poor family functioning and neurobehavioral problems after traumatic brain injury (TBI) or orthopedic injuries (OI). Design: Longitudinal analyses of data from an inception cohort. Participants: Seventy-five patients with moderate/severe TBI, 47 patients with mild TBI, and 44 patients with OI at discharge; and 49 patients with moderate/severe TBI, 24 patients with mild TBI, and 33 patients with OI at 1-year follow-up. Outcome measures: Measures of family functioning (Family Assessment Device) and Neurobehavioral Functioning Index at hospital discharge and 1-year follow-up. Results: At discharge, patients with moderate/severe TBI had more symptoms of depression, memory/attention problems, and motor impairments than patients with OI and greater communication difficulties than patients with OI or mild TBI. At follow-up, patients with moderate/severe TBI continued to have more problems in memory/attention, depression, and communication. Approximately one third of each group had unhealthy family functioning at each assessment period. Few patients reported both impaired family functioning and clinical depression. Distressed family functioning correlated strongly with increased rates of neurobehavioral symptoms. Family dysfunction at follow-up was best predicted by family dysfunction at discharge and depression or memory/attention deficits at follow-up. Conclusions: After TBI, patients at the greatest risk for distress at follow-up were those with family dysfunction at discharge and continued neurobehavioral problems. High-risk families need to be identified so that necessary referrals and/or treatment can be offered.	Mayo Clin & Mayo Fdn, Dept Psychiat & Psychol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Nursing, Rochester, MN 55905 USA		Testa, JA (corresponding author), Mayo Clin & Mayo Fdn, Dept Psychiat & Psychol, 200 1st St SW, Rochester, MN 55905 USA.	testa.julie@mayo.edu		Brown, Allen W./0000-0001-7228-3351	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A020507] Funding Source: Medline		Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Anderson-Parente JK., 1990, COGN REHABIL, V8, P22; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kabacoff R.I., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	29	51	52	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2006	21	3					236	247		10.1097/00001199-200605000-00004			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	044YL	WOS:000237709600004	16717501				2022-02-06	
J	Zhang, Z; Ottens, AK; Larner, SF; Kobeissy, FH; Williams, ML; Hayes, RL; Wang, KKW				Zhang, Zhiqun; Ottens, Andrew K.; Larner, Stephen F.; Kobeissy, Firas H.; Williams, Melissa L.; Hayes, Ronald L.; Wang, Kevin K. W.			Direct Rho-associated kinase inhibiton induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells	CELLULAR & MOLECULAR BIOLOGY LETTERS			English	Article						neurite outgrowth; ROCK; Y-27632; PC-12; cofilin; actin dynamics	NERVE GROWTH-FACTOR; MYELIN-ASSOCIATED GLYCOPROTEIN; ACTIVATED PROTEIN-KINASE; PHEOCHROMOCYTOMA CELLS; LIM-KINASE; SIGNAL-TRANSDUCTION; MYOSIN PHOSPHATASE; AXON REGENERATION; PC12 CELLS; PHOSPHORYLATION	Axons fail to regenerate in the adult central nervous system (CNS) following injury. Developing strategies to promote axonal regeneration is therapeutically attractive for various CNS pathologies such as traumatic brain injury, stroke and Alzheimer's disease. Because the RhoA pathway is involved in neurite outgrowth, Rho-associated kinases (ROCKs), downstream effectors of GTP-bound Rho, are potentially important targets for axonal repair strategies in CNS injuries. We investigated the effects and downstream mechanisms of ROCK inhibition in promoting neurite outgrowth in a PC-12 cell model. Robust neurite outgrowth (NOG) was induced by ROCK inhibitors Y-27632 and H-1152 in a time- and dose-dependent manner. Dramatic cytoskeletal reorganization was noticed upon ROCK inhibition. NOG initiated within 5 to 30 minutes followed by neurite extension between 6 and 10 hours. Neurite processes were then sustained for over 24 hours. Rapid cofilin dephosphorylation was observed within 5 minutes of Y-27632 and H-1152 treatment. Re-phosphorylation was observed by 6 hours after Y-27632 treatment, while H-1152 treatment produced sustained cofilin dephosphorylation for over 24 hours. The results suggest that ROCK-mediated dephosphorylation of cofilin plays a role in the initiation of NOG in PC-12 cells.	Univ Florida, Ctr Neuroprote & Biomarkers Res, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, McKnight Brain Inst, Gainesville, FL 32610 USA		Wang, KKW (corresponding author), Univ Florida, Ctr Neuroprote & Biomarkers Res, McKnight Brain Inst, POB 100256,100 S Newell Dr, Gainesville, FL 32610 USA.	kwang@psychiatry.ufl.edu	Kobeissy, Firas/E-7042-2017; Ottens, Andrew/K-3352-2012; duan, hf/F-9166-2011	Kobeissy, Firas/0000-0002-5008-6944; Ottens, Andrew/0000-0002-2118-3796; Wang, Kevin/0000-0002-9343-6473			Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Amano M, 2003, J NEUROCHEM, V87, P780, DOI 10.1046/j.1471-4159.2003.02054.x; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Birkenfeld J, 2001, J NEUROCHEM, V78, P924, DOI 10.1046/j.1471-4159.2001.00500.x; Bonini S, 2003, INT ARCH ALLERGY IMM, V131, P80, DOI 10.1159/000070922; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Brabeck C, 2003, ARCH NEUROL-CHICAGO, V60, P1245, DOI 10.1001/archneur.60.9.1245; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; Ellezam B, 2002, PROG BRAIN RES, V137, P371; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Fujita A, 2001, NEUROREPORT, V12, P3599, DOI 10.1097/00001756-200111160-00045; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hashimoto R, 1998, BIOCHEM BIOPH RES CO, V245, P407, DOI 10.1006/bbrc.1998.8446; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; Ikenoya M, 2002, J NEUROCHEM, V81, P9, DOI 10.1046/j.1471-4159.2002.00801.x; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; Kwon Brian K, 2002, Mol Interv, V2, P244, DOI 10.1124/mi.2.4.244; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; McKerracher L, 2004, NAT MED, V10, P1052, DOI 10.1038/nm1004-1052; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Nakajima M, 2003, CANCER CHEMOTH PHARM, V52, P319, DOI 10.1007/s00280-003-0641-9; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Obara Y, 2002, J PHARMACOL EXP THER, V301, P803, DOI 10.1124/jpet.301.3.803; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Ozdinler PH, 2001, J COMP NEUROL, V438, P377; Park YH, 2003, J NEUROCHEM, V87, P1546, DOI 10.1046/j.1471-4159.2003.02127.x; Petruska JC, 2004, NEUROSCI LETT, V361, P168, DOI 10.1016/j.neulet.2003.12.012; Revenu C, 2004, NAT REV MOL CELL BIO, V5, P635, DOI 10.1038/nrm1437; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sasaki Y, 2002, PHARMACOL THERAPEUT, V93, P225, DOI 10.1016/S0163-7258(02)00191-2; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Tojima T, 2004, PROG NEUROBIOL, V72, P183, DOI 10.1016/j.pneurobio.2004.03.002; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yamashita T, 2005, MOL NEUROBIOL, V32, P105, DOI 10.1385/MN:32:2:105; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	47	51	54	0	5	CELLULAR & MOLECULAR BIOLOGY LETTERS	WROCLAW	UNIV WROCLAW, INST BIOCHEM, DEPT GENETIC BIOCHEMISTRY, PRZBYSZEWSKIEGO 63/77, 51-148 WROCLAW, POLAND	1425-8153			CELL MOL BIOL LETT	Cell. Mol. Biol. Lett.	MAR	2006	11	1					12	29		10.2478/s11658-006-0002-x			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	063XB	WOS:000239052100002	16847745	Green Published			2022-02-06	
J	Gao, WM; Chadha, MS; Kline, AE; Clark, RSB; Kochanek, PM; Dixon, CE; Jenkins, LW				Gao, WM; Chadha, MS; Kline, AE; Clark, RSB; Kochanek, PM; Dixon, CE; Jenkins, LW			Immunohistochemical analysis of histone H3 acetylation and methylation - Evidence for altered epigenetic signaling following traumatic brain injury in immature rats	BRAIN RESEARCH			English	Article						epigenetic; hippocampus; pediatric; posttranslational modification; acetylation; methylation	CONTROLLED CORTICAL IMPACT; GENE-EXPRESSION; PATHWAYS; KINASE; HIPPOCAMPUS; NEURONS; MILD; CODE	Posttranslational modifications (PTMs) of histone proteins may result in altered epigenetic signaling after pediatric traumatic brain injury (TBI). Hippocampal histone H3 acetylation and methylation in immature rats after moderate TBI were measured and decreased only in CA3 at 6 h and 24 h with persistent methylation decreases up to 72 h after injury. Decreased histone H3 acetylation and methylation suggest altered hippocampal CA3 epigenetic signaling during the first hours to days after TBI. (c) 2005 Elsevier B.V. All rights reserved.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA		Jenkins, LW (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 201 Hill Bldg,3434 5th Ave, Pittsburgh, PA 15260 USA.	ljenkins@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040686, T-32 HD 40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042648-04, NS42648, R01 NS042648] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042648] Funding Source: NIH RePORTER		Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Crosio C, 2003, J CELL SCI, V116, P4905, DOI 10.1242/jcs.00804; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Dunn BK, 2003, ANN NY ACAD SCI, V983, P1, DOI 10.1111/j.1749-6632.2003.tb05957.x; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Korzus E, 2004, NEURON, V42, P961, DOI 10.1016/j.neuron.2004.06.002; Levenson JM, 2005, NAT REV NEUROSCI, V6, P108, DOI 10.1038/nrn1604; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; SWANK MW, 2001, INCREASED HISTONE AC	23	51	52	1	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 27	2006	1070	1					31	34		10.1016/j.brainres.2005.11.038			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	023BB	WOS:000236099000004	16406269	Green Accepted			2022-02-06	
J	Coles, JP; Fryer, TD; Bradley, PG; Nortje, J; Smielewski, P; Rice, K; Clark, JC; Pickard, JD; Menon, DK				Coles, JP; Fryer, TD; Bradley, PG; Nortje, J; Smielewski, P; Rice, K; Clark, JC; Pickard, JD; Menon, DK			Intersubject variability and reproducibility of O-15 PET studies	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral blood flow; cerebral metabolism; head injury; positron emission tomography	CEREBRAL BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; STEADY-STATE TECHNIQUE; OXYGEN UTILIZATION; HEAD-INJURY; INVIVO MEASUREMENT; NORMAL VALUES; HYPERVENTILATION; METABOLISM	Oxygen-15 positron emission tomography (O-15 PET) can provide important data regarding patients with head injury. We provide reference data on intersubject variability and reproducibility of cerebral blood flow (CBF), cerebral blood volume (CBV), cerebral metabolism (CMRO2) and oxygen extraction fraction (OEF) in patients and healthy controls, and explored alternative ways of assessing reproducibility within the context of a single PET study. In addition, we used independent measurements of CBF and CMRO2 to investigate the effect of mathematical correlation on the relationship between flow and metabolism. In patients, intersubject coefficients of variation (CoV) for CBF, CMRO2 and OEF were larger than in controls (32.9% +/- 2.2%, 23.2% +/- 2.0% and 22.5% +/- 3.4% versus 13.5% +/- 1.4%, 12.8% +/- 1.1% and 7.3% +/- 1.2%), while CoV for CBV were lower (15.2% +/- 2.1% versus 22.5% +/- 2.8%) (P < 0.001). The CoV for the test-retest reproducibility of CBF, CBV, CMRO2 and OEF in patients were 2.1% +/- 1.5%, 3.8% +/- 3.0%, 3.7% +/- 3.0% and 4.6% +/- 3.5%, respectively. These were much lower than the intersubject CoV figures, and were similar to alternative measures of reproducibility obtained by fractionating data from a single study. The physiological relationship between flow and metabolism was preserved even when mathematically independent measures were used for analysis. These data provide a context for the design and interpretation of interventional PET studies. While ideally each centre should develop its own bank of such data, the figures provided will allow initial generic approximations of sample size for such studies.	Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Addenbrookes Hosp, MRC, Biostat Unit, Inst Publ Hlth, Cambridge, England		Coles, JP (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	jpc44@wbic.cam.ac.uk	Rice, Kenneth M/A-4150-2013	Rice, Kenneth M/0000-0001-5779-4495; Smielewski, Peter/0000-0001-5096-3938; Coles, Jonathan/0000-0003-4013-679X	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G9439390] Funding Source: Medline		Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; BERGSTROM M, 1983, J COMPUT ASSIST TOMO, V7, P42, DOI 10.1097/00004728-198302000-00008; Carriere Isabelle, 2002, BMC Med Res Methodol, V2, P15, DOI 10.1186/1471-2288-2-15; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; LAMMERTSMA AA, 1988, J CEREBR BLOOD F MET, V8, P411, DOI 10.1038/jcbfm.1988.77; LAMMERTSMA AA, 1981, J COMPUT ASSIST TOMO, V5, P544, DOI 10.1097/00004728-198108000-00016; LAMMERTSMA AA, 1992, J CEREBR BLOOD F MET, V12, P291, DOI 10.1038/jcbfm.1992.39; LAMMERTSMA AA, 1983, J CEREBR BLOOD F MET, V3, P425, DOI 10.1038/jcbfm.1983.68; LAMMERTSMA AA, 1984, J CEREBR BLOOD F MET, V4, P317, DOI 10.1038/jcbfm.1984.47; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; LEBRUNGRANDIE P, 1983, ARCH NEUROL-CHICAGO, V40, P230, DOI 10.1001/archneur.1983.04050040060010; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; MATTHEW E, 1993, J CEREBR BLOOD F MET, V13, P748, DOI 10.1038/jcbfm.1993.95; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PHELPS ME, 1979, J NUCL MED, V20, P328; Smielewski Peter, 1800, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Stearns C, 1995, J NUCL MED, V36, P105; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Talairach J, 1998, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81	30	51	52	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2006	26	1					48	57		10.1038/sj.jcbfm.9600179			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	021HY	WOS:000235975500005	15988475	Bronze			2022-02-06	
J	Barut, S; Unlu, YA; Karaoglan, A; Tuncdemir, M; Dagistanli, FK; Ozturk, M; Colak, A				Barut, S; Unlu, YA; Karaoglan, A; Tuncdemir, M; Dagistanli, FK; Ozturk, M; Colak, A			The neuroprotective effects of z-DEVD.fmk, a caspase-3 inhibitor, on traumatic spinal cord injury in rats	SURGICAL NEUROLOGY			English	Article						apoptotic cell death; caspase 3; programmed cell death; spinal cord injury; z-DEVD.fmk	CELL-DEATH; NEURONAL APOPTOSIS; BRAIN-INJURY; ACTIVATION; IDENTIFICATION; EXPRESSION; ISCHEMIA; NECROSIS; HOMOLOG; ICE	Background: Apoptosis is one of the most important forms of cell death seen in a variety of physiological and pathological conditions, including traumatic injuries. This type of cell death occurs via mediators known as caspases. Previous studies have investigated the roles that apoptosis and different caspases play in the pathogenesis of secondary damage after spinal cord injury (SCI). The aim of this research was to assess the neuroprotective effect of z-DEVD.frnk, a caspase-3 inhibitor, in a rat model of SCI. Methods: Forty-five Wistar albino rats were studied in 3 groups of 15 animals: sham-operated control animals (group 1); trauma-only control animals (group 2); and rats subjected to trauma + z-DEVD.ftnk treatment (group 3). Spinal cord injury was produced at the thoracic level using the weight-drop technique. Responses to injury and the efficacy of z-DEVD.fmk were assessed by light microscopy and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling staining in cord tissues collected at 4 and 24 hours posttrauma. Five rats from each group were used to assess functional recovery at 7 days after SCI. The functional evaluations were done using the inclined-plane technique and a modified Tarlov motor grading scale. Results: At 4 hours postinjury, the mean apoptotic index in groups 1, 2, and 3 was 0, 33.01 +/- 6.62, and 16.40 +/- 4.91, respectively. The group 3 count was significantly lower than the group 2 count (P <.01). At 24 hours postinjury, light microscopic examination of group 2 tissues showed widespread hemorrhage, necrosis, polymorphonuclear leukocyte infiltration, and vascular thrombi. The group 3 tissues showed similar features. The prominent findings in group 2 were hemorrhage and necrosis, whereas the prominent findings in group 3 were focal hemorrhage and leukocyte infiltration. The mean inclined-plane angles in groups 1, 2, and 3 were 64.5 +/- 1.0, 41.5 +/- 1.3, and 47 +/- 2.0, respectively. Motor scale results in all groups showed a similar trend. Conclusion: Local application of z-DEVD.fmk after SCI in rats reduces secondary tissue injury and helps preserve motor function. These effects can be explained by inhibition of apoptotic death in all cell types in the spinal cord. (c) 2005 Elsevier Inc. All rights reserved.	Taksim Educ & Res Hosp, Neurosurg Clin, TR-34144 Istanbul, Turkey; Istanbul Univ, Cerrahpasa Sch Med, Dept Med Biol, TR-34144 Istanbul, Turkey		Colak, A (corresponding author), Terakki Caddesi 47-7, Istanbul, Turkey.	drahmetcolak@yahoo.com	dagistanli, Fatma Kaya/D-7548-2019; DAGISTANLI, Fatma/ABE-3173-2021; Tuncdemir, Matem/P-3054-2018	DAGISTANLI, Fatma/0000-0002-4672-8721; Tuncdemir, Matem/0000-0002-5300-4449			Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Bresnahan J. C., 1996, Society for Neuroscience Abstracts, V22, P1185; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; CROVE MJ, 1997, NAT MED, V3, P73; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Katoh K, 1996, NEUROSCI LETT, V216, P9; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li H, 2000, STROKE, V31, P176, DOI 10.1161/01.STR.31.1.176; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Namura S, 1998, J NEUROSCI, V18, P3659; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; RINK A, 1995, AM J PATHOL, V147, P1575; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rudel T, 1999, HERZ, V24, P236, DOI 10.1007/BF03044967; Samali A, 1999, CELL DEATH DIFFER, V6, P495, DOI 10.1038/sj.cdd.4400520; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Tarlov I.M., 1957, SPINAL CORD COMPRESS; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Van de Craen M, 1998, CELL DEATH DIFFER, V5, P838, DOI 10.1038/sj.cdd.4400444; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257	41	51	58	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	SEP	2005	64	3					213	220		10.1016/j.surneu.2005.03.042			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	961UI	WOS:000231686900006	16099247				2022-02-06	
J	Clausen, H; McCrory, P; Anderson, V				Clausen, H; McCrory, P; Anderson, V			The risk of chronic traumatic brain injury in professional boxing: change in exposure variables over the past century	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							BOXERS; SPORTS; DAMAGE	Objectives: To determine if boxing exposure has changed over time and hence if current professional boxers are at the same risk of developing chronic traumatic brain injury (CTBI) as historical controls. Design: Literature review of published studies and analysis of data of active professional boxers. Subjects: Professional boxers in the United Kingdom and Australia. Main outcome measures: Boxing history and participation in sparring and professional bouts. Results: Since the 1930s, the average duration of a professional boxer's career has dropped from 19 years to five years, and the mean number of career bouts has reduced from 336 to 13. This is despite no significant decline in participation rates from 1931 until 2002. Conclusions: The incidence of boxing related CTBI will diminish in the current era of professional boxing because of the reduction in exposure to repetitive head trauma and increasing medical monitoring of boxers, with preparticipation medical and neuroimaging assessments resulting in the detection of early and potentially pre-symptomatic cases of CTBI.	Univ Melbourne, Parkville, Vic 3052, Australia		McCrory, P (corresponding author), POB 93, Melbourne, Vic 3916, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019				*A L BLACK, 2003, WHIT ALM; *ABS, 2002, 31010 ABS; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY E, 1937, MED ANN, P318; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HOGG JM, 2003, AUSTR BOXING RECORDS; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; Kemp P L, 1995, J R Nav Med Serv, V81, P182; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAWDSLEY C, 1963, LANCET          1019, P796; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ravdin LD, 2003, CLIN J SPORT MED, V13, P21, DOI 10.1097/00042752-200301000-00005; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SPILLANE JD, 1962, BRIT MED J, P1205	21	51	53	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2005	39	9					661	664		10.1136/bjsm.2004.017046			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	957UF	WOS:000231398100021	16118306	Bronze, Green Published			2022-02-06	
J	Yu, CG; Yezierski, RP				Yu, CG; Yezierski, RP			Activation of the ERK1/2 signaling cascade by excitotoxic spinal cord injury	MOLECULAR BRAIN RESEARCH			English	Article						spinal cord injury; glutamate receptor; ERK; gene expression; pain; excitotoxicity	NF-KAPPA-B; METABOTROPIC GLUTAMATE RECEPTORS; INFLAMMATORY PAIN HYPERSENSITIVITY; TRAUMATIC BRAIN-INJURY; MAP KINASE ACTIVATION; RAT STRIATAL NEURONS; PROTEIN-KINASE; TRANSCRIPTION FACTOR; REGULATED KINASE; GENE-EXPRESSION	The role of the ERK1/2 signal transduction pathway and related transcription factors in the regulation of gene expression and pain behavior following excitotoxic spinal cord injury (SCI) was examined. Specifically, phosphorylation of ERK1/2, activation of transcription factors NF-kappa B, ELK-1, and CREB, and gene expression of the neurokinin-1 receptor and NMDA receptor subunits NR1 and NR-2A were investigated. Excitotoxic injury was produced by intraspinal injection of quisqualic acid (QUIS) in male Sprague-Dawley rats. Western blots were used to evaluate phosphorylation and activation of ERK1/2 and transcription factors using phospho-specific or total antibodies. Real-time PCR was used to evaluate gene expression of NK-1R, NR-1, and NR-2A. Assessment of excessive grooming behavior was used to evaluate the presence of spontaneous pain behavior. Excitotoxic spinal injury resulted in: (1) increased phosphorylation of ERK1/2; (2) increased activation of NF-kappa B and phosphorylation of ELK-1; and (3) increased gene expression for the NK-1 receptor and NR1 and NR-2A subunits of the NMDA receptor. Blockade of the ERK cascade with the MEK inhibitor PD98059 inhibited phosphorylation of ELK-1, activation of NF-kappa B and gene expression of NR1, NR-2A and NK-1R, and prevented the development of excessive grooming behavior. The results have shown that excitotoxic spinal injury leads to the injury-induced activation of the ERK -> ELK-1 and NF-kappa B signaling cascades and transcriptional regulation of receptors important in the development of chronic pain. Blockade of this intracellular kinase cascade prevented the onset of injury-induced pain behavior. (c) 2005 Elsevier B.V. All rights reserved.	Univ Florida, Dept Orthodont & Neurosci, Coll Dent, Gainesville, FL 32610 USA; Univ Florida, Mcknight Brain Inst, Comprehens Ctr Pain Res, Gainesville, FL 32610 USA		Yezierski, RP (corresponding author), Univ Florida, Dept Orthodont & Neurosci, Coll Dent, 1600 SW Archer Rd,POB 100444, Gainesville, FL 32610 USA.	RYEZIERSKI@dental.ufl.edu	Yu, Chen Guang/C-6176-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040096] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40096] Funding Source: Medline		Abraham KE, 2001, NEUROSCIENCE, V104, P863, DOI 10.1016/S0306-4522(01)00134-8; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; BACUERLE PA, 1996, CELL, V87, P13; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Begon S, 2001, BRIT J PHARMACOL, V134, P1227, DOI 10.1038/sj.bjp.0704354; Bethea JR, 1998, J NEUROSCI, V18, P3251; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Caudle RM, 2003, NEUROSCI LETT, V349, P37, DOI 10.1016/S0304-3940(03)00700-6; Choe ES, 2002, NEUROSCIENCE, V114, P557, DOI 10.1016/S0306-4522(02)00318-4; Choe ES, 2002, INT J MOL MED, V9, P3; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Curtis J, 1999, J NEUROSCI RES, V58, P88, DOI 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.0.CO;2-R; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Eide PK, 1998, SPINAL CORD, V36, P601, DOI 10.1038/sj.sc.3100737; Fairbanks CA, 2000, P NATL ACAD SCI USA, V97, P10584, DOI 10.1073/pnas.97.19.10584; Ferrer I, 2001, MOL BRAIN RES, V94, P48, DOI 10.1016/S0169-328X(01)00198-X; Fiebich BL, 2000, J NEUROCHEM, V75, P2020, DOI 10.1046/j.1471-4159.2000.0752020.x; Fundytus ME, 2001, CNS DRUGS, V15, P29, DOI 10.2165/00023210-200115010-00004; Galan A, 2003, MOL BRAIN RES, V116, P126, DOI 10.1016/S0169-328X(03)00284-5; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Grossman SD, 2000, J NEUROCHEM, V75, P174, DOI 10.1046/j.1471-4159.2000.0750174.x; Hao JX, 2003, J REHABIL MED, V35, P81, DOI 10.1080/16501960310010197; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; Ji RR, 2002, J NEUROSCI, V22, P478, DOI 10.1523/JNEUROSCI.22-02-00478.2002; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Karim F, 2001, J NEUROSCI, V21, P3771, DOI 10.1523/JNEUROSCI.21-11-03771.2001; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kawasaki Y, 2004, J NEUROSCI, V24, P8310, DOI 10.1523/JNEUROSCI.2396-04.2004; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Lee KM, 2004, EUR J NEUROSCI, V19, P3375, DOI 10.1111/j.0953-816X.2004.03441.x; Liu AG, 2004, J BIOL CHEM, V279, P17449, DOI 10.1074/jbc.M311267200; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; Loop T, 2002, ANESTHESIOLOGY, V96, P1202, DOI 10.1097/00000542-200205000-00025; Ma VY, 1998, BRAIN RES, V797, P243, DOI 10.1016/S0006-8993(98)00380-1; Ma WY, 2002, PAIN, V99, P175, DOI 10.1016/S0304-3959(02)00097-0; Mao LM, 2004, EUR J NEUROSCI, V19, P1207, DOI 10.1111/j.1460-9568.2004.03223.x; Mills CD, 2002, J NEUROTRAUM, V19, P23, DOI 10.1089/089771502753460213; Mills CD, 2002, EXP NEUROL, V173, P153, DOI 10.1006/exnr.2001.7828; Mills CD, 2001, EXP NEUROL, V170, P244, DOI 10.1006/exnr.2001.7721; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Obata K, 2004, LIFE SCI, V74, P2643, DOI 10.1016/j.lfs.2004.01.007; Obata K, 2003, J NEUROSCI, V23, P4117, DOI 10.1523/jneurosci.23-10-04117.2003; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604; Quartara L, 1998, NEUROPEPTIDES, V32, P1, DOI 10.1016/S0143-4179(98)90015-4; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Richter M, 2002, GENE, V295, P135, DOI 10.1016/S0378-1119(02)00833-8; Riedel W, 2001, Z RHEUMATOL, V60, P404, DOI 10.1007/s003930170003; Roberts JR, 2002, CRYOBIOLOGY, V44, P161, DOI 10.1016/S0011-2240(02)00018-4; Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116; Simeonidis S, 2003, P NATL ACAD SCI USA, V100, P2957, DOI 10.1073/pnas.0530112100; Subramaniam S, 2004, J CELL BIOL, V165, P357, DOI 10.1083/jcb.200403028; THOMPSON SWN, 1994, J NEUROSCI, V14, P3672; Varney MA, 2002, CNS NEUROL DISORD-DR, V1, P283, DOI 10.2174/1568007023339300; Wang X, 1998, BIOCHEM J, V333, P230; Wu X, 2004, J NEUROCHEM, V90, P807, DOI 10.1111/j.1471-4159.2004.02526.x; Yezierski R P, 2000, Prog Brain Res, V129, P429; Yezierski RP, 2004, NEUROSCI LETT, V361, P232, DOI 10.1016/j.neulet.2003.12.035; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445; Yu CG, 2003, J PAIN, V4, P129, DOI 10.1054/jpai.2003.11; YU CG, 2003, 33 NEUR M NEW ORL; ZIMMER M, 1995, GENE, V159, P219, DOI 10.1016/0378-1119(95)00044-7	70	51	55	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	AUG 18	2005	138	2					244	255		10.1016/j.molbrainres.2005.04.013			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	958VH	WOS:000231475800016	15922485				2022-02-06	
J	Magee, WL				Magee, WL			Music therapy with patients in low awareness states: Approaches to assessment and treatment in multidisciplinary care	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Conference of the International-Neuropsychological-Society	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc			TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; REHABILITATION; STROKE; SPEECH; INSTRUCTION; PEOPLE; MOOD	This paper outlines the rationale for and role of music therapy as a clinical intervention and diagnostic tool in multidisciplinary (MDT) rehabilitation programmes for patients in low awareness states. A review of the literature indicates that music is a useful clinical tool in stimulating a range of behavioural, physiological and expressive responses in patients in low awareness states. Referral criteria for music therapy with this patient group are provided, along with suggested methods for collaborative multidisciplinary work. A case vignette is presented of a client whose diagnosis of vegetative state (VS) was contradicted by her purposeful responses within music therapy assessment, contributing towards a changed diagnosis to minimally conscious state (MCS). The case illustrates the particular role of music therapy in assisting with diagnosis in complex cases. Music therapy provides a clinical forum in which recovery of function can be assessed in an informal way, using a medium which does not rely on language, is non-evasive and elicits emotional responses.	Univ Sheffield, Sheffield, S Yorkshire, England			drwmagee@rhn.org.uk	Magee, Wendy L./AAP-6839-2020	Magee, Wendy L./0000-0003-4350-1289			ALDRIDGE D, 1990, J ROY SOC MED, V83, P345, DOI 10.1177/014107689008300602; ALDRIDGE D, 1991, ART PSYCHOTHER, V18, P359, DOI 10.1016/0197-4556(91)90077-N; Baker F, 2001, J MUSIC THER, V38, P170, DOI 10.1093/jmt/38.3.170; Baker F.A., 2000, MUSIC THER PERSPECT, V18, P110, DOI [10.1093/mtp/18.2.110, DOI 10.1093/MTP/18.2.110]; Blacking J., 1976, MUSICAL IS MAN; BOYLE ME, 1983, J APPL BEHAV ANAL, V16, P3, DOI 10.1901/jaba.1983.16-3; Boyle ME, 1995, LONELY WATERS P INT, P163; Bruscia K.E., 1998, DEFINING MUSIC THERA; Burke D, 2000, BRAIN INJURY, V14, P463; COHEN NS, 1988, J MUSIC THER, V25, P85, DOI 10.1093/jmt/25.2.85; COHEN NS, 1992, J MUSIC THER, V29, P87, DOI 10.1093/jmt/29.2.102; COHEN NS, 1993, J MUSIC THER, V30, P81, DOI 10.1093/jmt/30.2.81; FACHNER J, 2004, DIALOGUE DEBATE P 10; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; GUSTORFF D, 2002, INFO CD ROM, V4, P353; Hurt CP, 1998, J MUSIC THER, V35, P228, DOI 10.1093/jmt/35.4.228; ITO S, 2000, P 9 ANN M SOC TREATM, V9, P25; JOCHIMS S, 1995, ART PSYCHOTHER, V22, P21, DOI 10.1016/0197-4556(94)00061-U; Kennelly J, 1997, AUSTR J MUSIC THERAP, V8, P18; Magee W., 1999, MUSIC THERAPY PERSPE, V17, P20, DOI DOI 10.1093/MTP/17.1.20; Magee W., 2002, MUSICAL IDENTITIES, P179; Magee WL, 2002, J MUSIC THER, V39, P20, DOI 10.1093/jmt/39.1.20; Malec JF, 1996, BRAIN INJURY, V10, P781, DOI 10.1080/026990596123909; McIntosh, 1997, J NEUROLOGICAL REHAB, V11, P131; McIntosh GC, 1993, CANADIAN J NEUROLOGI, V20, P168; McIntosh GC, 1995, J NEUROLOGIC REHABIL, V9, P131; MOCHIZUKI E, 2002, P 11 ANN M SOC TREAT, V11, P69; MOCHIZUKI E, 2003, P 12 ANN M SOC TREAT, V12, P117; Nayak S, 2000, REHABIL PSYCHOL, V45, P274, DOI 10.1037/0090-5550.45.3.274; Noda R, 2004, BRAIN INJURY, V18, P509, DOI 10.1080/02699050310001645810; O'Callaghan C., 1999, MUSIC THERAPY PERSPE, V17, P32; OYAMA A, 2003, P 12 ANN M SOC TREAT, V12, P121; Papousek H., 1996, MUSICAL BEGINNINGS O, P37, DOI DOI 10.1093/ACPROF:OSO/9780198523321.003.0002; Pilon MA, 1998, BRAIN INJURY, V12, P793, DOI 10.1080/026990598122188; Prassas S, 1997, GAIT POSTURE, V6, P218, DOI 10.1016/S0966-6362(97)00010-6; Purdie H, 1997, INT J REHABIL RES, V20, P325, DOI 10.1097/00004356-199709000-00009; Rosenfeld JV, 1999, MUSICMEDICINE 3 EXPA, V3, P35; SATO Y, 2002, P 11 ANN M SOC TREAT, V11, P73; SERGENT J, 1992, SCIENCE, V257, P106, DOI 10.1126/science.1621084; Sloboda J. A., 1991, COGNITIVE BASES MUSI, P33; Sloboda J.A., 1991, PSYCHOL MUSIC, V19, P110, DOI [DOI 10.1177/0305735691192002, 10.1177/0305735691192002]; Tamplin J., 2000, AUSTR J MUSIC THERAP, V11, P38; THAUT M H, 1992, Neurology, V42, P208; Thaut MH, 1997, J NEUROL SCI, V151, P207, DOI 10.1016/S0022-510X(97)00146-9; Thaut MH, 1993, PHYS THER, V73, P107; Thaut MH, 1995, J STROKE CEREBROVASC, V5, P100; Thaut MH, 1993, J NEUROL REHABIL, V7, P9, DOI DOI 10.1177/136140969300700103; Thaut MH, 1997, J NEUROL SCI, V151, P7; Trevarthen C., 2002, MUSICAL IDENTITIES, P21; Trevarthen C., 2000, MUSIC SCI, V1999-2000, P155, DOI 10.1177/10298649000030S109; TSUNAKAWA K, 2000, P 9 ANN M SOC TREATM, V9, P31; Wilson BA, 2001, BRAIN INJURY, V15, P1083, DOI 10.1080/02699050110082197; Wilson S. L., 1992, CLIN REHABIL, V6, P181, DOI [10.1177/026921559200600301, DOI 10.1177/026921559200600301]; YAMAMOTO K, 2003, P 12 ANN M SOC TREAT, V12, P109	55	51	52	1	18	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					522	536		10.1080/09602010443000461			15	Neurosciences; Psychology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900037	16350993				2022-02-06	
J	Broglio, SP; Tomporowski, PD; Ferrara, MS				Broglio, SP; Tomporowski, PD; Ferrara, MS			Balance performance with a cognitive task: A dual-task testing paradigm	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						concussion; postural control; cognitive function; task-switch; neurocom	COLLEGIATE FOOTBALL PLAYERS; POSTURAL CONTROL; ATTENTIONAL DEMANDS; EXECUTIVE CONTROL; CONCUSSION; STABILITY; RECOVERY	Purpose: Athletic performance demands simultaneous use of cognitive and postural control capabilities. Decrements to both systems have been observed following concussion. This study evaluated a dual-task methodology to establish the tenability of using this testing model in concussed athletes. Methods: Nonconcussed subjects were assessed over 2 d. Subjects were introduced to the task-switching cognitive assessment test and a NeuroCom Smart Balance Master postural control assessment protocol on day 1. In the following session, subjects were evaluated on postural control and cognitive function tests independently (single task), and then concurrently (dual task). Results: Significant improvements were seen in three of the four balance conditions and in three of the four reaction times when the cognitive and balance task were performed simultaneously (P < 0.05). No significant balance by cognitive task interaction was revealed (P > 0.05): however. significant differences existed in reaction time based on stimulus position and increasing balance demands (P < 0.05). Conclusion: Combining the cognitive and balance assessments resulted in healthy subjects showing improved performance when compared with individual task performance. The dual-task methodology brought about systematic changes to reaction time in relation to increasing balance demands. The ability of this protocol to detect changes in postural control or cognitive function following concussive injury requires further study.	Univ Georgia, Dept Exercise Sci, St Marys Athlet Training Res & Educ Lab, Athens, GA 30602 USA; Univ Georgia, Dept Exercise Sci, Cognit & Skill Acquist Lab, Athens, GA 30602 USA		Broglio, SP (corresponding author), Univ Georgia, Dept Exercise Sci, St Marys Athlet Training Res & Educ Lab, 300 River Rd, Athens, GA 30602 USA.	sbroglio@coe.uga.edu					Andersson G, 2002, BRAIN RES BULL, V58, P135, DOI 10.1016/S0361-9230(02)00770-0; Arbuthnott K, 2000, CAN J EXP PSYCHOL, V54, P33, DOI 10.1037/h0087328; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dault MC, 2001, GAIT POSTURE, V14, P248, DOI 10.1016/S0966-6362(01)00130-8; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUYTON A, 2000, TXB MED PHYSL, P622; Hunter MC, 2001, GAIT POSTURE, V13, P41, DOI 10.1016/S0966-6362(00)00089-8; Kramer AF, 2001, HUMAN FACTORS INTERVENTIONS FOR THE HEALTH CARE OF OLDER ADULTS, P91; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maki BE, 1996, J VESTIBUL RES-EQUIL, V6, P53; MARTIN JH, 1996, NEUROANATOMY TEXT AT, P328; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Melzer I, 2001, GERONTOLOGY, V47, P189, DOI 10.1159/000052797; *NEUR INT, 2001, NEUR SYST OP MAN, pPO1; PETERSON C, 2002, THESIS U GEORGIA ATH; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Riemann BL, 2000, PROPRIOCEPTION AND NEUROMUSCULAR CONTROL IN JOINT STABILITY, P37; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; Shumway-Cook A, 2000, J GERONTOL A-BIOL, V55, pM10; ShumwayCook A, 1997, J GERONTOL A-BIOL, V52, pM232, DOI 10.1093/gerona/52A.4.M232; Tomporowski PD, 2003, EDUC GERONTOL, V29, P447, DOI 10.1080/713844359; Vuillerme N, 2000, NEUROSCI LETT, V291, P77, DOI 10.1016/S0304-3940(00)01374-4; WOLFSON L, 1994, J GERONTOL, V49, pM160, DOI 10.1093/geronj/49.4.M160	31	51	51	2	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	APR	2005	37	4					689	695		10.1249/01.MSS.0000159019.14919.09			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	913QC	WOS:000228166900024	15809571				2022-02-06	
J	Rice, SA; Blackman, JA; Braun, S; Linn, RT; Granger, CV; Wagner, DP				Rice, SA; Blackman, JA; Braun, S; Linn, RT; Granger, CV; Wagner, DP			Rehabilitation of children with traumatic brain injury: Descriptive analysis of a nationwide sample using the WeeFIM	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; disabled children; rehabilitation; treatment outcome	FUNCTIONAL INDEPENDENCE MEASURE; DEVELOPMENTAL-DISABILITIES; STABILITY	Objective: To describe functional capability at admission and discharge of children with traumatic brain injury (TBI) in rehabilitation settings. Design: Descriptive analysis. Setting: Inpatient pediatric rehabilitation hospitals in the United States. Participants: Children (N = 3815) in 56 pediatric inpatient rehabilitation facilities who were discharged during 1999 to 2001. Interventions: Not applicable. Main Outcome Measures: Admission and discharge WeeFIM scores. Results: Admission and discharge WeeFIM scores correlated positively with age at admission, time from injury to rehabilitation admission, and length of stay (LOS). Higher admission WeeFIM scores correlated with shorter LOS, shorter time from injury to admission to rehabilitation, and higher discharge WeeFIM scores. Conclusions: Children with TBI demonstrated significant improvement in functional measures during rehabilitation. Discharge function and LOS correlated with admission severity, with children who had higher functional status and shorter time between injury and rehabilitation care having higher discharge function and shorter LOS. (c) 2005 by American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA; Univ Arizona, Dept Hlth Evaluat Sci, Tucson, AZ 85724 USA; Univ Virginia, Charlottesville, VA USA; SUNY Buffalo, Dept Rehabil Med, Buffalo, NY USA		Rice, SA (corresponding author), Univ Arizona, Dept Pediat, 1501 N Campbell, Tucson, AZ 85724 USA.	srice@peds.arizona.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD040756] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007956] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5 T32 HL 7956-4] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1 F32 HD40756-01A1] Funding Source: Medline		[Anonymous], 2000, WEEFIM SYST CLIN GUI; Azaula M, 2000, ARCH PHYS MED REHAB, V81, P307, DOI 10.1016/S0003-9993(00)90076-5; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; *MATHS, 1999, S PLUS 2000 US GUID; Msall ME., 1993, PHYS MED REH CLIN N, V4, P517; Ottenbacher KJ, 1996, DEV MED CHILD NEUROL, V38, P907; Ottenbacher KJ, 1997, ARCH PHYS MED REHAB, V78, P1309, DOI 10.1016/S0003-9993(97)90302-6; Ottenbacher KJ, 2000, AM J PHYS MED REHAB, V79, P114, DOI 10.1097/00002060-200003000-00002; Ottenbacher KJ, 2000, ARCH PHYS MED REHAB, V81, P1317, DOI 10.1053/apmr.2000.9387; Ziviani Jenny, 2001, Physical and Occupational Therapy in Pediatrics, V21, P91	10	51	52	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2005	86	4					834	836		10.1016/j.apmr.2004.11.006			3	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	914ON	WOS:000228237300034	15827941				2022-02-06	
J	Glantz, L; Avramovich, A; Trembovler, V; Gurvitz, V; Kohen, R; Eidelman, LA; Shohami, E				Glantz, L; Avramovich, A; Trembovler, V; Gurvitz, V; Kohen, R; Eidelman, LA; Shohami, E			Ischemic preconditioning increases antioxidants in the brain and peripheral organs after cerebral ischemia	EXPERIMENTAL NEUROLOGY			English	Article						biological oxidation potential; brain ischemia; reactive oxygen species; uric acid; ascorbic acid	CLOSED-HEAD INJURY; EXTRACELLULAR ASCORBATE RELEASE; AKT/PROTEIN KINASE-B; ARTERY OCCLUSION; NITRIC-OXIDE; URIC-ACID; IN-VIVO; FOREBRAIN ISCHEMIA; OXIDATIVE STRESS; FOCAL ISCHEMIA	Background and purpose. Low molecular weight antioxidants (LMWA), which reflect tissue reducing power, are among the endogenous mechanisms for neutralizing reactive oxygen species (ROS). Ischemic preconditioning (IPC) was associated with decreased oxidative stress. We examined the effect of focal ischemia on LMWA and on prostaglandin E-2 (PGE(2), a product of arachidonic acid oxidation) in the brain, heart, liver, and lungs of rats subjected to 90 min of ischemia and in IPC rats subjected to similar insult. Methods. Transient right middle cerebral artery occlusion (MCAO) was performed for 90 min and at 0, 5, 30, 60, or 240 min of reperfusion, LMWA and PGE2 were evaluated by cyclic voltametry (CV) and radioimmunoassay, respectively. IPC was induced by 2 min of MCAO, 24 h prior to the major ischemic episode. Results. LMWA decreased at 5 min of reperfusion in the brain, heart, liver, and lung and rose 4 h later only in the brain. PGE2 levels increased three to fivefold in all tissues examined. Surprisingly, in IPC rats a dramatic increase of LMWA occurred at 5 min of reperfusion in the brain and in the peripheral organs. Uric acid, but not ascorbic, is the major LMWA increased. Conclusions. We propose that after ischemia, ROS rapidly consume the antioxidants reserves in the brain and also in peripheral organs, suggesting that the whole body is under oxidative stress. Moreover, part of the neuroprotection afforded by IPC is mediated by the brain's ability to mobilize antioxidants, especially uric acid, that attenuate the massive ROS-mediated oxidative stress. (C) 2004 Elsevier Inc. All rights reserved.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Pharmaceut, IL-91120 Jerusalem, Israel		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Kohen, Ron/ABC-2281-2021	Kohen, Ron/0000-0001-7268-9845			Ames BN, 1993, FREE RADICAL BIO MED, V6, P303; Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Back T, 1998, CELL MOL NEUROBIOL, V18, P621, DOI 10.1023/A:1020265701407; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 2003, STROKE, V34, P758, DOI 10.1161/01.STR.0000056169.45365.15; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Cheung RTF, 1997, BRAIN RES, V747, P181, DOI 10.1016/S0006-8993(96)01137-7; Chua HC, 1999, CLIN NEUROL NEUROSUR, V101, P44; Davenport RJ, 1996, STROKE, V27, P421, DOI 10.1161/01.STR.27.3.421; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; HILLERED L, 1988, NEUROSCI LETT, V95, P286, DOI 10.1016/0304-3940(88)90672-6; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Kato H, 1999, CELL MOL NEUROBIOL, V19, P93, DOI 10.1023/A:1006920725663; Klingelhofer J, 1997, BAILLIERE CLIN NEUR, V6, P309; Kontos HA, 2001, STROKE, V32, P2712, DOI 10.1161/hs1101.098653; Leker RR, 2002, EXP NEUROL, V176, P355, DOI 10.1006/exnr.2002.7910; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Mathews KS, 2000, J NEUROSCI METH, V102, P43, DOI 10.1016/S0165-0270(00)00277-6; MIELE M, 1994, NEUROSCIENCE, V62, P87, DOI 10.1016/0306-4522(94)90316-6; Moor E, 2001, NEUROSCI LETT, V316, P169, DOI 10.1016/S0304-3940(01)02394-1; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724; Paciaroni M, 2000, EUR NEUROL, V43, P30, DOI 10.1159/000008125; Prass K, 2002, J CEREBR BLOOD F MET, V22, P520, DOI 10.1097/00004647-200205000-00003; RADI R, 1991, J BIOL CHEM, V266, P4244; Rauca C, 2000, BRAIN RES, V868, P147, DOI 10.1016/S0006-8993(00)02388-X; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; RYAN M, 1997, ANN CLIN BIOCHEM, V35, P553; Saito A, 2003, J NEUROSCI, V23, P1710; SEVANIAN A, 1991, AM J CLIN NUTR, V54, pS1129, DOI 10.1093/ajcn/54.6.1129s; SHOHAMI E, 1982, STROKE, V13, P494, DOI 10.1161/01.STR.13.4.494; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIMON RP, 1993, NEUROL CLIN, V11, P309, DOI 10.1016/S0733-8619(18)30155-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tayag EC, 1996, BRAIN RES, V733, P287, DOI 10.1016/0006-8993(96)00669-5; UEMURA Y, 1991, STROKE, V22, P1548, DOI 10.1161/01.STR.22.12.1548; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yu ZF, 1998, J NEUROSCI RES, V53, P613, DOI 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1; Yusa T, 2000, NEUROSCI LETT, V293, P123, DOI 10.1016/S0304-3940(00)01501-9; Yusa T, 2001, BRAIN RES, V897, P104, DOI 10.1016/S0006-8993(01)02099-6	44	51	54	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2005	192	1					117	124		10.1016/j.expneurol.2004.11.012			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	899LZ	WOS:000227147200013	15698625				2022-02-06	
J	Rowland, SM; Lam, CS; Leahy, B				Rowland, SM; Lam, CS; Leahy, B			Use of the Beck Depression Inventory-II (BDI-II) with persons with traumatic brain injury: Analysis of factorial structure	BRAIN INJURY			English	Article							INDIVIDUALS; RECOVERY	Primary objective: To determine the factorial structure of the BDI-II in a TBI sample and possible predictor variables of depression following TBI. Research design: Principle components analysis with orthogonal rotation and linear regression analyses. Methods and procedures: Fifty-one individuals with traumatic brain injury (TBI) participated in this study. The factorial structure of the BDI-II, a 21-item self-report measure of depression, was examined with individuals in the early stages following TBI. Time since injury, severity of injury, location of lesion and previous substance abuse were examined as possible predictors of depression following TBI. Results: A three-factor structure of the BDI-II was found for the TBI sample, which included Negative Self-Evaluation, Symptoms of Depression and Vegetative Symptoms of Depression. Time since injury was the only significant predictor of depression following; TBI. Conclusion: Using the BDI-II, symptoms of depression after TBI fall into three key categories. With time since injury being the only significant predictor of depression following TBI, it appears that the depression could be more of a result of psychosocial factors than neurobiological factors. It was concluded that BDI-II can be useful in identifying symptoms of depression in the early stages following TBI.	IIT, Inst Psychol, CRC, Chicago, IL 60616 USA		Lam, CS (corresponding author), IIT, Inst Psychol, CRC, 3101 S Dearborn St, Chicago, IL 60616 USA.	lam@iit.edu					American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Christensen BK, 1995, J INT NEUROPSYCH SOC, V1, P121; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KATHOL RG, 1990, PSYCHOSOMATICS, V31, P434, DOI 10.1016/S0033-3182(90)72140-8; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Leahy B, 2003, CLIN NEUROPSYCHOL, V17, P474, DOI 10.1076/clin.17.4.474.27941; Levin H. S., 2000, CEREBRAL REORGANIZAT; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Sprinkle SD, 2002, J COUNS PSYCHOL, V49, P381, DOI 10.1037//0022-0167.49.3.381; Steer RA, 1998, J PSYCHOPATHOL BEHAV, V20, P127, DOI 10.1023/A:1023091529735; Stevens JP., 1996, APPL MULTIVARIATE ST; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Velicer WF, 1998, PSYCHOL METHODS, V3, P231, DOI 10.1037/1082-989X.3.2.231	27	51	51	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2005	19	2					77	83		10.1080/02699050410001719988			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	990JR	WOS:000233739600001	15841751				2022-02-06	
J	Van Geel, WJA; Rosengren, LE; Verbeek, MM				Van Geel, WJA; Rosengren, LE; Verbeek, MM			An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid	JOURNAL OF IMMUNOLOGICAL METHODS			English	Article						cerebrospinal fluid; neurofilament light chain; immunoassay; brain damage	PROTEIN	Neurofilament light chain is a component of the axonal cytoskeleton. The concentration of the neurofilament light chain in cerebrospinal fluid may reflect axonal damage or the extent of white matter damage. In this study we describe a sensitive immunoassay for the detection of neurofilament light chain in cerebrospinal fluid using commercially available materials. The detection limit of the assay was 5 ng/l and the assay was linear up to 390 ng/l. Mean recovery was 91.5% and inter-assay and intra-assay coefficients of variation were below 18%. Strongly increased levels of neurofilament light chain were observed in patients with cerebrovascular accidents, subarachnoid hemorrhage and severe traumatic brain injury, suggesting the occurrence of axonal damage in these conditions. (C) 2004 Elsevier B.V. All rights reserved.	Univ Nijmegen, Med Ctr, Dept Neurol, Lab Pediat & Neurol, NL-6500 HB Nijmegen, Netherlands; Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, S-41345 Gothenburg, Sweden; Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands		Verbeek, MM (corresponding author), Univ Nijmegen, Med Ctr, Dept Neurol, Lab Pediat & Neurol, 319 LKN,POB 9101, NL-6500 HB Nijmegen, Netherlands.	m.verbeek@cukz.umcn.nl	Verbeek, Marcel M/D-1971-2010	Verbeek, Marcel M/0000-0003-4635-7876; Rosengren, Lars/0000-0003-0505-8896			Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Carpenter DA, 1996, J CELL SCI, V109, P2493; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; HOLMBERG B, 1998, MOL DISORD, V13, P170; Kay A, 2003, STROKE, V34, pE240, DOI 10.1161/01.STR.0000100157.88508.2F; LAMERS KJB, 1995, ACTA NEUROL SCAND, V92, P247; Lycke JN, 1998, J NEUROL NEUROSUR PS, V64, P402, DOI 10.1136/jnnp.64.3.402; Norgren N, 2003, BRAIN RES, V987, P25, DOI 10.1016/S0006-8993(03)03219-0; Nylen K, 2002, J NEUROSCI RES, V67, P844, DOI 10.1002/jnr.10180; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Sjogren M, 2000, NEUROLOGY, V54, P1960, DOI 10.1212/WNL.54.10.1960; Sjogren M, 2001, J NEUROSCI RES, V66, P510, DOI 10.1002/jnr.1242; Sjogren M, 2001, CLIN CHEM, V47, P1776; Tullberg M, 1998, NEUROLOGY, V50, P1122, DOI 10.1212/WNL.50.4.1122; Tullberg M, 2002, ACTA NEUROL SCAND, V105, P417, DOI 10.1034/j.1600-0404.2002.01189.x; VANENGELEN BGM, 1992, CLIN CHEM, V38, P813; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC	19	51	51	1	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-1759	1872-7905		J IMMUNOL METHODS	J. Immunol. Methods	JAN	2005	296	1-2					179	185		10.1016/j.jim.2004.11.015			7	Biochemical Research Methods; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Immunology	898ZW	WOS:000227115700018	15680162				2022-02-06	
J	Ahn, MJ; Sherwood, ER; Prough, DS; Lin, CY; DeWitt, DS				Ahn, MJ; Sherwood, ER; Prough, DS; Lin, CY; DeWitt, DS			The effects of traumatic brain injury on cerebral blood flow and brain tissue nitric oxide levels and cytokine expression	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; cytokine; nitric oxide; rats; traumatic brain injury	TUMOR-NECROSIS-FACTOR; CORTICAL IMPACT INJURY; FLUID-PERCUSSION INJURY; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; L-ARGININE; RAT-BRAIN; SYNTHASE EXPRESSION; FACTOR-ALPHA; TNF-ALPHA	Adult, finale, Sprague-Dawley rats were anesthetized, intubated, and mechanically ventilated with 1.5-2.0% isoflurane in oxygen (30%) and air. Rats were prepared for fluid percussion traumatic brain injury (TBI), laser Doppler flowmetry, and measurement of brain tissue nitric oxide (NO) levels using an ISO-NO electrode system. After preparation, isoflurane was reduced to 1.5%, and the rats were randomly assigned to receive sham (n = 6), moderate (1.9 atm, n = 6), or severe (2.8 atm, n = 6) parasagittal fluid percussion TBI. CBF and brain tissue NO levels were measured for 4 h, and then isoflurane levels were increased to 4.0% and the rats were decapitated and the brains were removed. Total RNA was isolated from rat brains and cytokine expression was determined. Laser Doppler flow velocity remained constant in the sham-injured rats but decreased significantly in rats subjected to moderate (p < 0.05) or severe (p < 0.05) TBI. Brain tissue NO levels remained constant in the sham-injured rats but decreased significantly (p < 0.01) after moderate TBI. Severe TBI produced slight, insignificant reductions in NO levels. Cytokine expression was very low in the sham-injured rats. TBI-induced expression of mRNAs for interleukin-1 alpha (IL-1alpha), IL-1beta, IL-6, and tumor necrosis factor-alpha (TNFalpha). IL-lalpha and 1L-1beta mRNA expression increased significantly (p < 0.05 vs. sham-injury) after severe TBI and IL-6 and TNFa mRNA expression increased significant (p < 0.05 vs. sham-injury) after both moderate and severe TBI. Other cytokine mRNA expression was unchanged after TBI.	Univ Texas, Med Branch, Dept Anesthesiol, Charles R Allen Res Labs, Galveston, TX 77555 USA		DeWitt, DS (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, Charles R Allen Res Labs, 301 Univ Blvd, Galveston, TX 77555 USA.	ddewitt@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019355] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19355] Funding Source: Medline		Al-Turki A, 1998, CRIT CARE MED, V26, P917, DOI 10.1097/00003246-199805000-00029; Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; Armstead WM, 2000, AM J PHYSIOL-HEART C, V279, pH2188, DOI 10.1152/ajpheart.2000.279.5.H2188; Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Armstead WM, 1998, J NEUROTRAUM, V15, P721, DOI 10.1089/neu.1998.15.721; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BONVENTO G, 1994, J CEREBR BLOOD F MET, V14, P699, DOI 10.1038/jcbfm.1994.90; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brian JE, 1996, CLIN EXP PHARMACOL P, V23, P449, DOI 10.1111/j.1440-1681.1996.tb02760.x; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DeWitt D. S., 2000, Journal of Neurotrauma, V17, P993; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DING AH, 1988, J IMMUNOL, V141, P2407; FABIAN RH, 1995, J CEREBR BLOOD F MET, V15, P242, DOI 10.1038/jcbfm.1995.30; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Faraci FM, 1998, J CEREBR BLOOD F MET, V18, P1047, DOI 10.1097/00004647-199810000-00001; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Golding EM, 2002, STROKE, V33, P661; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gulbenkian S, 2001, PEPTIDES, V22, P995, DOI 10.1016/S0196-9781(01)00408-9; HABERL RL, 1989, AM J PHYSIOL, V256, pH1247, DOI 10.1152/ajpheart.1989.256.4.H1247; Hlatky R, 2003, J CEREBR BLOOD F MET, V23, P582, DOI 10.1097/01.WCB.0000059586.71206.F3; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; LEON A, 1990, STROKE, V21, P95; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Monroy M, 2001, AM J PHYSIOL-HEART C, V280, pH1448, DOI 10.1152/ajpheart.2001.280.4.H1448; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MORIKAWA E, 1992, BRIT J PHARMACOL, V107, P905, DOI 10.1111/j.1476-5381.1992.tb13382.x; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; PELLIGRINO DA, 1993, J CEREBR BLOOD F MET, V13, P80, DOI 10.1038/jcbfm.1993.10; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Sherwood ER, 2001, CLIN SCI, V101, P541, DOI 10.1042/CS20010074; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STERN MD, 1977, AM J PHYSIOL, V232, pH441, DOI 10.1152/ajpheart.1977.232.4.H441; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Varma TK, 2002, CLIN DIAGN LAB IMMUN, V9, P530, DOI 10.1128/CDLI.9.3.530-543.2002; Varma TK, 2001, INFECT IMMUN, V69, P5249, DOI 10.1128/IAI.69.9.5249-5263.2001; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; WHITE PF, 1974, ANESTHESIOLOGY, V40, P52, DOI 10.1097/00000542-197401000-00012; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	82	51	60	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2004	21	10					1431	1442		10.1089/neu.2004.21.1431			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	867BT	WOS:000224817800007	15672633				2022-02-06	
J	Bauer, R; Fritz, H				Bauer, R; Fritz, H			Pathophysiology of traumatic injury in the developing brain: an introduction and short update	EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	4th International Congress of Pathophysiology	JUN 29-JUL 05, 2002	BUDAPEST, HUNGARY			pediatric TBI; pathogenetic models; review	PEDIATRIC HEAD-INJURY; DEFICIT HYPERACTIVITY DISORDER; CONTROLLED CORTICAL IMPACT; AQUAPORIN-4 WATER CHANNEL; CEREBRAL-BLOOD-FLOW; COMA DATA-BANK; RAT-BRAIN; DOPAMINE TRANSPORTER; HYDROGEN-PEROXIDE; STRIATAL DOPAMINE	Current understanding about the main peculiarities in pathophysiology of immature brain traumatic injury involves marked developmental discrepancy of biomechanical properties, aspects of altered features in water and electrolyte homeostasis as well as maturation dependent differences in structural and functional responses of major transmitter systems. Based on the fact that traumatic brain injury (TBI) is one of the major causes of morbidity and mortality in infants and children, the currently available epidemiological data are reviewed in order to. gain insights about scope and dimension of health care engagement and derive the requirements for reinforced pathogenetic research. To this end, the main aspects of peculiarities in primary and secondary TBI mechanisms in the immature/developing brain are discussed, including structural and functional conditions resulting in a markedly diminished shear resistance of the immature brain tissue. As such, the immature brain tissue appears to be more susceptible to mechanical alterations, because similar mechanical load induces a more intense brain tissue displacement. Furthermore, available indications for increased incidence of brain swelling in the immature brain after TBI are reviewed, focusing on the inter relationship between the age-dependent differences in extracellular space and aquaporin-4 expression during brain maturation. The developmental differences of TBI induced cerebrovascular response as well as some relevant aspects of altered neurotransmission following TBI of the immature brain in regard to the glutamatergic and dopaminergic transmitter system are assessed. Thus, this mini-review highlights some progress but also an increased necessity for expanded pathogenetic research on a clinical scale in order to develop a solid foundation for adequate therapeutic strategies for the different life-threatening consequences of TBI in infancy and childhood, which mainly have failed up to now. (C) 2004 Elsevier GmbH. All rights reserved.	Univ Jena, Univ Klinikum Jena, Inst Pathophysiol & Pathobiochem, D-07740 Jena, Germany; Univ Jena, Univ Klinikum Jena, Dept Anesthesiol & Intens Care Med, D-07740 Jena, Germany		Bauer, R (corresponding author), Univ Jena, Univ Klinikum Jena, Inst Pathophysiol & Pathobiochem, D-07740 Jena, Germany.	Reinhard.Bauer@mti.uni-jena.de					Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 2002, CRIT CARE MED, V30, pS383, DOI 10.1097/00003246-200211001-00001; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1080/713773978; Bauer R, 1999, DEV BRAIN RES, V112, P89, DOI 10.1016/S0165-3806(98)00167-9; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BEHRING EA, 1952, J NEUROSURG, V9, P275; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; BUTT AM, 1990, J PHYSIOL-LONDON, V429, P47, DOI 10.1113/jphysiol.1990.sp018243; Dobbing J., 1981, SCI F PAEDIATRICS, P744; DODSON RF, 1977, J NEUROL SCI, V33, P161, DOI 10.1016/0022-510X(77)90190-3; Dougherty DD, 1999, LANCET, V354, P2132, DOI 10.1016/S0140-6736(99)04030-1; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Dziegielewska KM, 2000, CELL MOL NEUROBIOL, V20, P41, DOI 10.1023/A:1006943926765; EICHELBERGER MR, 1988, J TRAUMA, V28, P430, DOI 10.1097/00005373-198804000-00002; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Ernst M, 1999, AM J PSYCHIAT, V156, P1209; Feher G, 1996, DEV BRAIN RES, V91, P209, DOI 10.1016/0165-3806(95)00178-6; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Ferriero DM, 2001, DEV NEUROSCI-BASEL, V23, P198, DOI 10.1159/000046143; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; Graham DI, 2001, BRAIN, V124, P1261, DOI 10.1093/brain/124.7.1261; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Jackson PS, 1997, PEDIATR NEUROSURG, V27, P286, DOI 10.1159/000121272; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P114; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Knott GW, 1997, J PHYSIOL-LONDON, V499, P179, DOI 10.1113/jphysiol.1997.sp021919; Kochanek PM, 2001, PEDIATR CLIN N AM, V48, P661, DOI 10.1016/S0031-3955(05)70333-3; Konrad KN, 2000, BRAIN INJURY, V14, P859; KRAUS JF, 1987, PEDIATRICS, V79, P501; Krause KH, 2000, NEUROSCI LETT, V285, P107, DOI 10.1016/S0304-3940(00)01040-5; LEHMENKUHLER A, 1993, NEUROSCIENCE, V55, P339, DOI 10.1016/0306-4522(93)90503-8; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Nico B, 2001, J CELL SCI, V114, P1297; Nielsen S, 1997, J NEUROSCI, V17, P171; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; Saunders NR, 2000, CELL MOL NEUROBIOL, V20, P29, DOI 10.1023/A:1006991809927; SCHULZE C, 1992, DEV BRAIN RES, V69, P85, DOI 10.1016/0165-3806(92)90125-G; SLIVKA A, 1985, J BIOL CHEM, V260, P5466; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tang YP, 1997, EUR J NEUROSCI, V9, P1720, DOI 10.1111/j.1460-9568.1997.tb01529.x; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vles JSH, 2003, NEUROPEDIATRICS, V34, P77; Walter B., 2001, Pfluegers Archiv European Journal of Physiology, V441, pR111; Walter B, 2004, J NEUROTRAUM, V21, P1076, DOI 10.1089/0897715041651024; WARD JD, 1994, PEDIATR NEUROSURG, V20, P183, DOI 10.1159/000120784; Ward JD, 1996, NEUROTRAUMA, P859; WEGMAN ME, 1982, PEDIATRICS, V70, P835; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003	86	51	54	0	5	URBAN & FISCHER VERLAG	JENA	BRANCH OFFICE JENA, P O BOX 100537, D-07705 JENA, GERMANY	0940-2993			EXP TOXICOL PATHOL	Exp. Toxicol. Pathol.	OCT	2004	56	1-2					65	73		10.1016/j.etp.2004.04.002			9	Pathology; Toxicology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Pathology; Toxicology	872QF	WOS:000225221900009	15581277				2022-02-06	
J	Selassie, AW; Pickelsimer, EE; Frazier, L; Ferguson, PL				Selassie, AW; Pickelsimer, EE; Frazier, L; Ferguson, PL			The effect of insurance status, race, and gender on ED disposition of persons with traumatic brain injury	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						brain injury; emergency department; insurance status; race and gender	PROSPECTIVE-PAYMENT SYSTEM; SOCIOECONOMIC-STATUS; HEALTH-INSURANCE; MYOCARDIAL-INFARCTION; EMERGENCY-DEPARTMENT; RACIAL-DIFFERENCES; SEX-DIFFERENCES; UNITED-STATES; MEDICAL-CARE; RATES	The objective of this study was to assess the effect of insurance status and demographic characteristics on ED disposition among patients with traumatic brain injury (TBI). Statewide hospital discharge and ED datasets in South Carolina, 1996-2001, were analyzed by primary or secondary diagnosis of TBI in a multivariable logistic regression model. Of 70,671 unduplicated patients with TBI evaluated in the ED, 76% were treated and released; 26% had no insurance. The strongest predictors of hospital admission were TBI severity and preexisting health conditions. However, the uninsured and black females were less likely to be hospitalized after adjusting for demographic, clinical, and hospital characteristics (odds ratio [OR], 0.52; 95% confidence interval [CI], 0.48-0.55 and OR, 0.79; CI, 0.72-0.87, respectively). Although this study does not infer causality, insurance status, race, and gender were significant predictors of hospital admission. These results suggest that inpatient resources are not equitably used. (C) 2004 Elsevier Inc. All rights reserved.	Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA; S Carolina Dept Hlth & Environm Control, Div Injury & Disabil Prevent, Columbia, SC 29201 USA		Selassie, AW (corresponding author), Med Univ S Carolina, Dept Biometry & Epidemiol, 135 Cannon St,POB 250835, Charleston, SC 29425 USA.	selassie@musc.edu			ODCDC CDC HHS [U17/CCU414981, U17/CCU411892] Funding Source: Medline		*ASS ADV AUT MED, 1990, ABBR INJ SCAL REV PL; ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Baker DW, 2000, ARCH INTERN MED, V160, P1269, DOI 10.1001/archinte.160.9.1269; BAKER DW, 1994, JAMA-J AM MED ASSOC, V271, P1909, DOI 10.1001/jama.271.24.1909; Baker SP, 1992, THE INJURY FACT BOOK, VSecond; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; BENNETT CL, 1991, CANCER, V67, P2633, DOI 10.1002/1097-0142(19910515)67:10<2633::AID-CNCR2820671039>3.0.CO;2-9; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; Breslow N.E., 1980, STAT METHODS CANC RE, P192; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CAMPBELL JA, 1998, P60208 CENS BUR US D; Canto JG, 2000, ARCH INTERN MED, V160, P817, DOI 10.1001/archinte.160.6.817; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; Cubbin C, 2000, J EPIDEMIOL COMMUN H, V54, P517, DOI 10.1136/jech.54.7.517; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; DARLINGTON GA, 1998, ENCY BIOSTATISTICS, P788; *DEP DIS SPEC NEED, 1999, S CAR TRAUM HEAD SPI; *DIV INJ DIS PREV, 1999, TRAUM BRAIN INJ SURV; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; Faulkner LA, 1997, AM J PREV MED, V13, P453, DOI 10.1016/S0749-3797(18)30141-7; FLEISS JL, 1998, STAT METHODS RATES P, P58; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; GOLDFARB MG, 1992, HEALTH SERV RES, V27, P385; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; Harris D. Robert, 1997, Ethnicity and Disease, V7, P91; HIMMELSTEIN DU, 1995, AM J PUBLIC HEALTH, V85, P341, DOI 10.2105/AJPH.85.3.341; HOLL JL, 1995, ARCH PEDIAT ADOL MED, V149, P398, DOI 10.1001/archpedi.1995.02170160052008; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; Kressin NR, 2001, ANN INTERN MED, V135, P352, DOI 10.7326/0003-4819-135-5-200109040-00012; Kuttner R, 1999, NEW ENGL J MED, V340, P163, DOI 10.1056/NEJM199901143400226; Lee AJ, 1997, MED CARE, V35, P1173, DOI 10.1097/00005650-199712000-00002; MacKenzie EJ, 2000, J ORTHOP TRAUMA, V14, P455, DOI 10.1097/00005131-200009000-00001; MacKenzie EJ, 2003, JAMA-J AM MED ASSOC, V289, P1515, DOI 10.1001/jama.289.12.1515; Marcin JP, 2003, AM J PUBLIC HEALTH, V93, P461, DOI 10.2105/AJPH.93.3.461; Mayberry RM, 2000, MED CARE RES REV, V57, P108, DOI 10.1177/107755800773743628; MCCARTHY ML, 1995, J TRAUMA, V39, P828, DOI 10.1097/00005373-199511000-00005; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; MILLS RJ, 2002, P60220 US DEP COMM; MILLS RJ, 2001, P60215 US DEP COMM; MISHEL L, 1998, STATE WORKING AM 199, P248; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; Pappas G, 1997, AM J PUBLIC HEALTH, V87, P811, DOI 10.2105/AJPH.87.5.811; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; ROWLAND D, 1998, FUTURE US HEALTHCARE, P25; *SAS I INC, 2000, STAT AN SOFTW VERS 8; Schneider EC, 2001, ANN INTERN MED, V135, P328, DOI 10.7326/0003-4819-135-5-200109040-00009; Schoen C, 1997, HEALTH AFFAIR, V16, P163, DOI 10.1377/hlthaff.16.5.163; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; SCHWAB CW, 1988, J TRAUMA, V28, P939, DOI 10.1097/00005373-198807000-00006; Sox CM, 1998, AM J MED, V105, P506, DOI 10.1016/S0002-9343(98)00324-6; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Svenson JE, 2001, AM J EMERG MED, V19, P19, DOI 10.1053/ajem.2001.18041; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; THURMAN SJ, 1995, GUIDELINES SURVEILLA; *US CENS BUR, 1997, CURR POP SURV; *US CENS BUR, 1996, CURR POP SURV; *US CENS BUR, 1998, CURR POP SURV; *US DHHS, 1996, INT CLASS DIS CLIN M; *US DHHS CDCP DIV, 1999, REH RES DIS PREV TRA; Weissman J.S., 1994, FALLING SAFETY NET I; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WRENN K, 1985, NEW ENGL J MED, V312, P373, DOI 10.1056/NEJM198502073120611	69	51	51	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	OCT	2004	22	6					465	473		10.1016/j.ajem.2004.07.024			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	872TH	WOS:000225230900006	15520941				2022-02-06	
J	Pannu, R; Won, JS; Khan, M; Singh, AK; Singh, I				Pannu, R; Won, JS; Khan, M; Singh, AK; Singh, I			A novel role of lactosylceramide in the regulation of lipopolysaccharide/interferon-gamma-mediated inducible nitric oxide synthase gene expression: Implications for neuroinflammatory diseases	JOURNAL OF NEUROSCIENCE			English	Article						iNOS; astrocytes; lactosylceramide; lipopolysaccharide; interferon-gamma; spinal cord injury	TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE-CELLS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CREUTZFELDT-JAKOB-DISEASE; TRAUMATIC BRAIN-INJURY; C-FOS EXPRESSION; MULTIPLE-SCLEROSIS	In the present study a possible role of glycosphingolipids (GSLs) in inducible nitric oxide synthase ( iNOS) gene expression and nitric oxide ( NO) production after spinal cord injury (SCI) in rats has been established. In primary rat astrocytes lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) treatment increased the intracellular levels of lactosylceramide ( LacCer) and induced iNOS gene expression. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol . HCI ( PDMP), a glucosylceramide synthase and LacCer synthase ( galactosyltransferase, GalT-2) inhibitor, inhibited LPS/IFN-gamma induced iNOS expression, which was reversed by exogenously supplied LacCer, but not by other glycosphingolipids. LPS/IFN-gamma caused a rapid increase in the activity of GalT-2 and synthesis of LacCer. Silencing of GalT-2 gene with the use of antisense oligonucleotides resulted in decreased LPS/IFN-gamma-induced iNOS, TNF-alpha, and IL-1beta gene expression. The PDMP-mediated reduction in LacCer production and inhibition of iNOS expression correlated with decreased Ras and ERK1/2 activation along with decreased IkappaB phosphorylation, NF-kappaB DNA binding activity, and NF-kappaB-luciferase reporter activity. LacCer-mediated Ras activation was redox-mediated and was attenuated by antioxidants N-acetyl cysteine (NAC) and pyrrolidine dithiocarbamate ( PDTC). In vivo administration of PDMP after SCI resulted in improved functional outcome ( Basso, Beattie, Bresnahan score); inhibition of iNOS, TNF-alpha, and IL-1beta expression; decreased neuronal apoptosis; and decreased tissue necrosis and demyelination. The in vivo studies supported the conclusions drawn from cell culture studies and provided evidence for the possible role of GalT-2 and LacCer in SCI-induced inflammation and pathology. To our knowledge this is the first report of a role of LacCer in iNOS expression and the advantage of GSL depletion in attenuating post-SCI inflammation to improve the outcome of SCI.	Med Univ S Carolina, Dept Pediat, Div Dev Neurogenet, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph h Johnson Vet Affairs Med Ctr, Dept Pathol, Charleston, SC 29425 USA		Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, Div Dev Neurogenet, 316 CSB, Charleston, SC 29425 USA.	singhi@musc.edu		Won, Jeseong/0000-0003-2408-0386	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-22576, NS-37766, R01 NS022576, R01 NS040144, R01 NS034741, NS-34741, R37 NS022576, NS-40144, NS-40810, R01 NS037766, R01 NS040810] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037766, R01NS040144, R01NS022576, R01NS040810, R37NS022576, R01NS034741] Funding Source: NIH RePORTER		Akiyama H, 2000, ALZ DIS ASSOC DIS, V14, pS47, DOI 10.1097/00002093-200000001-00008; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; ANDO S, 1984, JPN J EXP MED, V54, P229; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; BLIGHT AR, 1983, NEUROSCIENCE, V10, P1471, DOI 10.1016/0306-4522(83)90128-8; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brugg B, 1996, J NEUROCHEM, V66, P733; Castro-Palomino JC, 2001, CHEM-EUR J, V7, P2178, DOI 10.1002/1521-3765(20010518)7:10<2178::AID-CHEM2178>3.0.CO;2-E; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Chatterjee S, 1997, GLYCOBIOLOGY, V7, P703, DOI 10.1093/glycob/7.5.703; Dawson T M, 1993, NIDA Res Monogr, V136, P258; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Fern R, 2001, Prog Brain Res, V132, P405; Gilg AG, 2000, J NEUROPATH EXP NEUR, V59, P1063, DOI 10.1093/jnen/59.12.1063; Giri S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0798com; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hakomori S, 2003, METHOD ENZYMOL, V363, P191; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Inokuchi J, 1998, ACTA BIOCHIM POL, V45, P479, DOI 10.18388/abp.1998_4241; Iwabuchi K, 2002, BLOOD, V100, P1454, DOI 10.1182/blood.V100.4.1454.h81602001454_1454_1464; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAWAI K, 1994, NEUROSCI LETT, V174, P225, DOI 10.1016/0304-3940(94)90027-2; Khan M, 1998, J NEUROCHEM, V71, P78; KIERNAN JA, 1990, TRENDS PHARMACOL SCI, V11, P316, DOI 10.1016/0165-6147(90)90233-X; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LASSMANN H, 1979, ARCH NEUROL-CHICAGO, V36, P490, DOI 10.1001/archneur.1979.00500440060011; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; Liu XZ, 1997, J NEUROSCI, V17, P5395; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Marcus JS, 2003, GLIA, V41, P152, DOI 10.1002/glia.10168; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; Ohtani Y, 1996, NEURODEGENERATION, V5, P331, DOI 10.1006/neur.1996.0045; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; RENNO T, 1995, J IMMUNOL, V154, P944; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Sequeira SM, 1997, NITRIC OXIDE-BIOL CH, V1, P315, DOI 10.1006/niox.1997.0144; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Simon BM, 2002, CELL DEATH DIFFER, V9, P758, DOI 10.1038/sj.cdd.4401027; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; Won JS, 2004, J NEUROCHEM, V88, P583, DOI 10.1046/j.1471-4159.2003.02165.x; Won JS, 2001, BRAIN RES, V903, P207, DOI 10.1016/S0006-8993(01)02452-0; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; WRATHALL JR, 1992, J NEUROTRAUM, V9, pS129; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yeh LH, 2001, J VASC RES, V38, P551, DOI 10.1159/000051091; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; YU RK, 1974, J NEUROCHEM, V23, P169, DOI 10.1111/j.1471-4159.1974.tb06931.x; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	70	51	51	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 30	2004	24	26					5942	5954		10.1523/JNEUROSCI.1271-04.2004			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	833PZ	WOS:000222351900011	15229242	Green Published, Bronze			2022-02-06	
J	Wade, SL; Wolfe, CR; Pestian, JP				Wade, SL; Wolfe, CR; Pestian, JP			A Web-based family problem-solving intervention for families of children with traumatic brain injury	BEHAVIOR RESEARCH METHODS INSTRUMENTS & COMPUTERS			English	Article; Proceedings Paper	33rd Annual Meeting of the Society-for-Computers-in-Psychology	NOV   06, 2003	Vancouver, CANADA	Soc Comp Psychol			SHORT-TERM; COMPUTER; PREDICTORS; ADOLESCENTS; TELEHEALTH; ADAPTATION; DISORDERS; BEHAVIOR; INTERNET; OUTCOMES	We developed a Web-based intervention for pediatric traumatic brain injury (TBI) and examined its feasibility for participants with limited computer experience. Six families, including parents, siblings, and children with TBI, were given computers, Web cameras, and high-speed Internet access. Weekly videoconferences with the therapist were conducted after participants completed on-line interactive experiences on problem solving, communication, and TBI-specific behavior management. Families were assigned to videoconference with NetMeeting (iBOT cameras) or ViaVideo. Participants ranked the Web site and videoconferences as moderately to very easy to use. ViaVideo participants rated videoconferencing significantly more favorably relative to face-to-face meetings than did NetMeeting participants. Both the Web site and videoconferencing were rated as very helpful. All families demonstrated improved outcomes on one or more target behaviors, including increased understanding of the injury and improved parent-child relationships. All parents and siblings and all but 1 child with TBI said they would recommend the program to others. We conclude that a face-to-face intervention can be successfully adapted to the Web for families with varied computer experience.	Univ Cincinnati, Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA		Wade, SL (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD040942] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40942-02] Funding Source: Medline		Agnew-Davies R, 1998, BRIT J CLIN PSYCHOL, V37, P155, DOI 10.1111/j.2044-8260.1998.tb01291.x; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Farmer JE, 2001, CLIN PEDIATR, V40, P93, DOI 10.1177/000992280104000205; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gega L, 2004, J CLIN PSYCHOL, V60, P147, DOI 10.1002/jclp.10241; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; GREIST JH, 1973, AM J PSYCHIAT, V130, P1327, DOI 10.1176/ajp.130.12.1327; Greist JH, 1998, PSYCHIAT SERV, V49, P887, DOI 10.1176/ps.49.7.887; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Hewson CM, 1996, BEHAV RES METH INSTR, V28, P186, DOI 10.3758/BF03204763; Joinson, 1998, PSYCHOL INTERNET INT, P43; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kleiner KD, 2002, PEDIATRICS, V109, P740, DOI 10.1542/peds.109.5.740; Maheu MM, 2003, PSYCHOTHERAPY, V40, P20, DOI 10.1037/0033-3204.40.1-2.20; MAHEU MM, 2000, TELEHEALTHNET; Marks I, 1998, CLIN PSYCHOL-SCI PR, V5, P151, DOI 10.1111/j.1468-2850.1998.tb00141.x; Marks M, 1993, NeuroRehabilitation, V3, P1, DOI 10.3233/NRE-1993-3303; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; RABASCA L, 2000, MONITOR PSYCHOL, V31, P28; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROTONDI AJ, J HEAD TRAUMA; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Schopp L, 2000, PROF PSYCHOL-RES PR, V31, P179, DOI 10.1037/0735-7028.31.2.179; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SINGER GHS, 1997, CHILDREN ACQUIRED BR, P235; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Sturges JW, 1998, PROF PSYCHOL-RES PR, V29, P183, DOI 10.1037/0735-7028.29.2.183; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 2004, J PEDIATR PSYCHOL, V29, P269, DOI 10.1093/jpepsy/jsh035; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WADE SL, 2004, UNPUB FAMILY INTERVE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; [No title captured]	43	51	51	1	8	PSYCHONOMIC SOC INC	AUSTIN	1710 FORTVIEW RD, AUSTIN, TX 78704 USA	0743-3808			BEHAV RES METH INS C	Behav. Res. Methods Instr. Comput.	MAY	2004	36	2					261	269		10.3758/BF03195572			9	Psychology, Mathematical; Psychology, Experimental	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Psychology	842TH	WOS:000223026600012	15354692	Bronze			2022-02-06	
J	Vasa, RA; Grados, M; Slomine, B; Herskovits, EH; Thompson, RE; Salorio, C; Christensen, J; Wursta, C; Riddle, MA; Gerring, JP				Vasa, RA; Grados, M; Slomine, B; Herskovits, EH; Thompson, RE; Salorio, C; Christensen, J; Wursta, C; Riddle, MA; Gerring, JP			Neuroimaging correlates of anxiety after pediatric traumatic brain injury	BIOLOGICAL PSYCHIATRY			English	Article						traumatic brain injury; orbitofrontal cortex; temporal lobe; anxiety; children	CLOSED-HEAD INJURY; UNILATERAL TEMPORAL LOBECTOMY; OBSESSIVE-COMPULSIVE DISORDER; HUMAN AMYGDALA; ORBITOFRONTAL CORTEX; CONDITIONED FEAR; FRONTAL LESIONS; CHILDREN; EMOTION; PSYCHOPATHOLOGY	Background: Anxiety disorders are common after traumatic brain injury (TBI). Data on the neural correlates of these conditions are lacking. This study examines the relationship between brain damage, particularly to the orbitofrontal cortex (OFC) and temporal lobe, and anxiety symptoms and disorders. Methods: Ninety-five children and adolescents were followed for one year postinjury. Preinjury and one-year postinjury anxiety status were obtained from the parent. Magnetic resonance imaging was performed to evaluate brain lesions. The primary analysis used regression models to determine relationships between brain lesions and anxiety outcomes. As a secondary analysis, previously reported posttraumatic stress disorder (PTSD) data were reanalyzed using similar methods for purposes of comparison. Results: The primary analysis showed that greater volume and number of OFC lesions correlated with decreased risk for anxiety, whereas lesions in other brain areas did not correlate with anxiety. Consistent with prior data, the secondary analysis showed an inverse correlation between OFC damage and PTSD; temporal lobe damage was positively correlated with PTSD. Conclusions: After pediatric TBI greater damage to the OFC is associated with decreased risk for anxiety outcomes. Similar to adult data, these findings implicate OFC dysfunction in childhood anxiety. Temporal lobe damage did not correlate with anxiety, in contrast to the findings for PTSD.	Kennedy Krieger Res Inst, Baltimore, MD 21211 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Univ Penn, Sch Med, Dept Radiol, Philadelphia, PA 19104 USA		Vasa, RA (corresponding author), Kennedy Krieger Res Inst, 3901 Greenspring Ave, Baltimore, MD 21211 USA.			Grados, Marco/0000-0002-6189-6264	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR 00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH 00997] Funding Source: Medline		Adolphs R, 1999, NEUROPSYCHOLOGIA, V37, P1111, DOI 10.1016/S0028-3932(99)00039-1; Anderson AK, 2001, NATURE, V411, P305, DOI 10.1038/35077083; Armony JL, 1997, ANN NY ACAD SCI, V821, P259, DOI 10.1111/j.1749-6632.1997.tb48285.x; Astrom M, 1996, STROKE, V27, P270, DOI 10.1161/01.STR.27.2.270; Baird AA, 1999, J AM ACAD CHILD PSY, V38, P195, DOI 10.1097/00004583-199902000-00019; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; BREMNER JD, 2000, CURR PSYCHIAT REP, V4, P254; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BUTTER CM, 1970, J COMP PHYSIOL PSYCH, V72, P132, DOI 10.1037/h0029303; Cassidy John W., 1994, P43; CASTILLO CS, 1993, J NERV MENT DIS, V181, P100, DOI 10.1097/00005053-199302000-00005; Chua P, 1999, NEUROIMAGE, V9, P563, DOI 10.1006/nimg.1999.0407; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Damasio H., 1989, LESION ANAL NEUROPSY; Davatzikos C, 1998, HUM BRAIN MAPP, V6, P334; DAVIDSON RJ, 1989, J ABNORM PSYCHOL, V98, P127, DOI 10.1037/0021-843X.98.2.127; De Bellis MD, 2000, BIOL PSYCHIAT, V48, P51, DOI 10.1016/S0006-3223(00)00835-0; De Bellis MD, 2001, BIOL PSYCHIAT, V50, P305, DOI 10.1016/S0006-3223(01)01105-2; Funayama ES, 2001, J COGNITIVE NEUROSCI, V13, P721, DOI 10.1162/08989290152541395; Gallagher M, 1999, J NEUROSCI, V19, P6610; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; Hackett TA, 2001, J COMP NEUROL, V441, P197, DOI 10.1002/cne.1407; Hatfield T, 1996, J NEUROSCI, V16, P5256; Heilman KM, 1997, J NEUROPSYCH CLIN N, V9, P439, DOI 10.1176/jnp.9.3.439; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; HERSKOVITZ EH, 2002, RADIOLOGY, V21, P389; *INT SOL GROUP, 1995, ALL SOFTW; KAGAN J, 1987, CHILD DEV, V58, P1459, DOI 10.1111/j.1467-8624.1987.tb03858.x; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LABAR KS, 1995, J NEUROSCI, V15, P6846; LaBar KS, 1998, NEURON, V20, P937, DOI 10.1016/S0896-6273(00)80475-4; LaBar KS, 1996, BEHAV NEUROSCI, V110, P991, DOI 10.1037/0735-7044.110.5.991; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; Machado CJ, 2003, J CHILD PSYCHOL PSYC, V44, P64, DOI 10.1111/1469-7610.00103; Malizia AL, 1999, J PSYCHOPHARMACOL, V13, P372, DOI 10.1177/026988119901300418; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; MORGAN MA, 1995, BEHAV NEUROSCI, V109, P681, DOI 10.1037/0735-7044.109.4.681; Morris JS, 1998, BRAIN, V121, P47, DOI 10.1093/brain/121.1.47; Pine DS, 1999, J CHILD ADOL PSYCHOP, V9, P1, DOI 10.1089/cap.1999.9.1; RABEHESKETH S, 2000, HDB STAT ANAL USING; RAUCH SL, 1995, ARCH GEN PSYCHIAT, V52, P20; RAUCH SL, 1994, ARCH GEN PSYCHIAT, V51, P62; Rauch SL, 1997, BIOL PSYCHIAT, V42, P446, DOI 10.1016/S0006-3223(97)00145-5; Rauch SL, 2003, ANN NY ACAD SCI, V985, P389; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; Salloway S, 1997, J NEUROPSYCH CLIN N, V9, P403; Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407; SCHWARTZ ML, 1991, J COMP NEUROL, V307, P144, DOI 10.1002/cne.903070113; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P690; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; Szeszko PR, 1999, ARCH GEN PSYCHIAT, V56, P913, DOI 10.1001/archpsyc.56.10.913; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 2001, ARCH GEN PSYCHIAT, V58, P1057, DOI 10.1001/archpsyc.58.11.1057; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; WEINGARTEN SM, 1999, SCI PRACT NEUROPSYCH, P446; WILSON J T L, 1990, Brain Injury, V4, P349; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zald DH, 1996, J NEUROPSYCH CLIN N, V8, P249	66	51	52	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	FEB 1	2004	55	3					208	216		10.1016/S0006-3223(03)00708-X			9	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	767HK	WOS:000188434000002	14744460				2022-02-06	
J	Brookshire, B; Levin, HS; Song, JX; Zhang, LF				Brookshire, B; Levin, HS; Song, JX; Zhang, LF			Components of executive function in typically developing and head-injured children	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							PREFRONTAL CORTEX; BRAIN-DAMAGE; MEMORY; WORKING; PERFORMANCE; INHIBITION; ATTENTION; COGNITION; BEHAVIOR; DEFICITS	To identify the key components of executive functions (EFs) in children following traumatic brain injury (TBI), data from a series of EF tests administered to 286 pediatric TBI patients at least 3 years postinjury were subjected to an exploratory factor analysis. A 5-factor model included discourse, EFs (e.g., problem solving, planning), processing speed (e.g., coding), declarative memory, and motor speed. Confirmatory factor analysis based on data obtained from 265 pediatric TBI patients at 3 months postinjury disclosed that the 5-factor model provided a good fit to the data. A second exploratory analysis of the 3-month postinjury data disclosed a 4-factor model in which processing speed and motor speed measures loaded on a common factor. Severity of TBI and age at test had significant effects on all factors in both the 5- and 4-factor models. Adaptive functioning, as measured by the Vineland Adaptive Behavioral Scale-Revised, was moderately related to factor scores at 3 years or longer postinjury, but weakly related to factor scores obtained at 3 months postinjury. The factor scores could be used in clinical trials to facilitate data reduction and appear to have validity as indicators of TBI outcome.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA; Bayer Pharmaceut, Dept Biometry, West Haven, CT USA		Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Ste 1144, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 2002, PRINCIPLES FRONTAL L, P504; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; Bentler PM, 1989, EQS STRUCTURAL EQUAT; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Borkowski J. G., 1996, ATTENTION MEMORY EXE, P235; Braver TS, 2001, NEUROIMAGE, V14, P48, DOI 10.1006/nimg.2001.0791; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Ciccetti D., 1984, VINELAND ADAPTIVE BE; DENCKLA MB, 1974, CORTEX, V10, P184; DENNEY DR, 1973, DEV PSYCHOL, V9, P275, DOI 10.1037/h0035092; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, DISCOURSE ABILITY BR, P199; Diamond A, 1997, MONOGR SOC RES CHILD, V62, P1; DIAMOND A, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P339; DREWE E A, 1975, Cortex, V11, P8; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Dunn LM., 1981, PEABODY PICTURE VOCA; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Giedd JN, 1996, CEREB CORTEX, V6, P551, DOI 10.1093/cercor/6.4.551; Gioia GA IP, 2000, BEHAV RATING INVENTO; GOLDMAN PS, 1974, CNS PLASTICITY RECOV, P149; Goldman-Rakic P., 1998, PREFRONTAL CORTEX EX, P87; Grafman J, 1999, LANCET, V354, P1921, DOI 10.1016/S0140-6736(99)90438-5; Graham S., 1996, ATTENTION MEMORY EXE, P349; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HISCOCK M, 1987, BRAIN COGNITION, V6, P24, DOI 10.1016/0278-2626(87)90044-3; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; JENNETT B, 1975, LANCET, V1, P480; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Krasnegor N.A., 1996, ATTENTION MEMORY EXE, P263; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2001, NEUROPSYCHOLOGY, V15, P557, DOI 10.1037//0894-4105.15.4.557; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; Luria A.R., 1966, HIGHER CORTICAL FUNC; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; Matthews CG., 1964, INSTRUCTION MANUAL A; MAZZOCCO MMM, 1993, J DEV BEHAV PEDIATR, V14, P328; Miller EK, 2000, NEUROIMAGE, V11, P447, DOI 10.1006/nimg.2000.0574; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Pennington B., 1996, ATTENTION MEMORY EXE, P327; Petrides M, 2000, EXP BRAIN RES, V133, P44, DOI 10.1007/s002210000399; PORTEUS SD, 1964, PORTEUS MAZE TEST 50; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Reynolds C. R., 1998, BEHAV ASSESSMENT SYS; Roberts RJ, 1996, DEV NEUROPSYCHOL, V12, P105, DOI 10.1080/87565649609540642; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; TEASDALE G, 1974, LANCET, V2, P81; Vaughn ML, 1997, J CLIN CHILD PSYCHOL, V26, P349, DOI 10.1207/s15374424jccp2604_3; Wechsler D, 1974, WISC R MANUAL WECHSL; [No title captured]	64	51	51	0	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					61	83		10.1207/s15326942dn2501&2_5			23	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	774CG	WOS:000188961700005	14984329				2022-02-06	
J	Pearse, DD; Chatzipanteli, K; Marcillo, AE; Bunge, MB; Dietrich, WD				Pearse, DD; Chatzipanteli, K; Marcillo, AE; Bunge, MB; Dietrich, WD			Comparison of NOS inhibition by antisense and pharmacological inhibitors after spinal cord injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						aminoguanidine; antisense; inducible nitric oxide synthase; spinal cord injury; 140OW	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; L-ARGININE; IN-VIVO; AMINOGUANIDINE TREATMENT; INFLAMMATORY RESPONSE; SELECTIVE-INHIBITION; CEREBROSPINAL-FLUID; MOUSE PLEURISY	Inducible nitric oxide synthase (iNOS) is a key mediator of inflammation during pathological conditions. We examined, through the use of selective iNOS inhibitors, the role of iNOS in specific pathophysiological processes after spinal cord injury (SCI), including astrogliosis, blood-spinal cord barrier (BSCB) permeability, polymorphonuclear leukocyte infiltration, and neuronal cell death. Administration of iNOS antisense oligonucleotides (ASOs) (intraspinally at 3 h) or the pharmacological inhibitors, N-[3(Aminomethyl) benzyl] acetamidine (1400W) (i.v./i.p. 3 and 9 h) or aminoguanidine (i.p. at 3 and 9 h) after moderate contusive injury decreased the number of iNOS immunoreactive cells at the injury site by 65.6% (iNOS ASOs), 62.1% (1400W), or 59% (aminoguanidine) 24 h postinjury. iNOS activity was reduced 81.8% (iNOS ASOs), 56.7% (1400W), or 67.9% (aminoguanidine) at this time. All iNOS inhibitors reduced the degree of BSCB disruption (plasma leakage of rat immunoglobulins), with iNOS ASO inhibition being more effective (reduced by 58%). Neutrophil accumulation within the injury site was significantly reduced by iNOS ASOs and 1400W by 78.8% and 20.9%, respectively. Increased astrogliosis was diminished with iNOS ASOs but enhanced following aminoguanidine. Detection of necrotic and apoptotic neuronal cell death by propidium iodide and an FITC-conjugated Annexin V antibody showed that iNOS inhibition could significantly retard neuronal cell death rostral and caudal to the injury site. These novel findings indicate that acute inhibition of iNOS is beneficial in reducing several pathophysiological processes after SCI. Furthermore, we demonstrate that the antisense inhibition of iNOS is more efficacious than currently available pharmacological agents.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terrace,R-48, Miami, FL 33136 USA.	DDietrich@miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038665] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P0I NS38665] Funding Source: Medline		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Bacso Z, 2000, CANCER RES, V60, P4623; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; BELENKY SN, 1993, J LEUKOCYTE BIOL, V53, P498, DOI 10.1002/jlb.53.5.498; Bethea JR, 1998, J NEUROSCI, V18, P3251; BOADO RJ, 1995, DRUG METAB DISPOS, V23, P1297; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Campbell IL, 1996, J NEUROIMMUNOL, V71, P31, DOI 10.1016/S0165-5728(96)00129-4; Cartwright JE, 2000, BRIT J PHARMACOL, V131, P131, DOI 10.1038/sj.bjp.0703539; Cassina P, 2002, J NEUROSCI RES, V67, P21, DOI 10.1002/jnr.10107; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHI OZ, 1994, PHARMACOLOGY, V48, P367, DOI 10.1159/000139202; Chu D, 2002, NEUROCHEM RES, V27, P97, DOI 10.1023/A:1014858707218; Cifone MG, 1999, BLOOD, V93, P3876, DOI 10.1182/blood.V93.11.3876.411k25_3876_3884; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DING AH, 1988, J IMMUNOL, V141, P2407; Fiscus RR, 2002, NEUROSIGNALS, V11, P175, DOI 10.1159/000065431; Franco-Penteado CF, 2001, BIOCHEM PHARMACOL, V61, P1305, DOI 10.1016/S0006-2952(01)00573-1; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GILLARDON F, 1994, EUR J NEUROSCI, V6, P880, DOI 10.1111/j.1460-9568.1994.tb00999.x; Gloor SM, 2001, BRAIN RES REV, V36, P258, DOI 10.1016/S0165-0173(01)00102-3; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HALIM A, 1995, THROMB RES, V77, P321, DOI 10.1016/0049-3848(95)93835-N; Hamilton LC, 1998, BRIT J PHARMACOL, V125, P335, DOI 10.1038/sj.bjp.0702077; Hinz B, 2000, BIOCHEM BIOPH RES CO, V271, P353, DOI 10.1006/bbrc.2000.2632; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; Huang DY, 2000, FASEB J, V14, P407, DOI 10.1096/fasebj.14.2.407; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JANIGRO D, 1994, CIRC RES, V75, P528, DOI 10.1161/01.RES.75.3.528; Kankuri E, 2001, J PHARMACOL EXP THER, V298, P1128; KAPLAN SS, 1989, BLOOD, V74, P1885; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Larfars G, 1999, BLOOD, V93, P1399, DOI 10.1182/blood.V93.4.1399.404k07_1399_1405; LARROUY B, 1992, GENE, V121, P189, DOI 10.1016/0378-1119(92)90121-5; Liu C, 2001, Chin J Traumatol, V4, P231; Liu CL, 2002, CHINESE MED J-PEKING, V115, P740; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Menchen LA, 2001, LIFE SCI, V69, P479, DOI 10.1016/S0024-3205(01)01139-0; MenezesdeLimaJunior O, 1997, J LEUKOCYTE BIOL, V62, P778, DOI 10.1002/jlb.62.6.778; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1989, BIOCHEM SOC T, V17, P642, DOI 10.1042/bst0170642; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Nagayama T, 2000, J NEUROCHEM, V75, P1716, DOI 10.1046/j.1471-4159.2000.0751716.x; Nakahara S, 2002, J NEUROTRAUM, V19, P1467, DOI 10.1089/089771502320914697; Nishisho T, 1996, NEUROSURGERY, V39, P950, DOI 10.1097/00006123-199611000-00014; Okamura T, 2001, HYPERTENS RES, V24, P47, DOI 10.1291/hypres.24.47; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Pan W, 2001, Arch Physiol Biochem, V109, P350, DOI 10.1076/apab.109.3.350.9342; Pan WH, 1997, EXP NEUROL, V146, P367, DOI 10.1006/exnr.1997.6533; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Parmentier-Batteur S, 2001, J CEREBR BLOOD F MET, V21, P15, DOI 10.1097/00004647-200101000-00003; Paterson I S, 1993, Ann Vasc Surg, V7, P68, DOI 10.1007/BF02042662; Perez-Sala D, 2001, AM J PHYSIOL-RENAL, V280, pF466, DOI 10.1152/ajprenal.2001.280.3.F466; Peters CM, 2003, EXP NEUROL, V180, P1, DOI 10.1016/S0014-4886(02)00023-7; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Tasaka Y, 1996, ENDOCR J, V43, P725, DOI 10.1507/endocrj.43.725; TAYLOR WF, 1993, AM J PHYSIOL, V264, pH1355, DOI 10.1152/ajpheart.1993.264.5.H1355; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vianna RMJ, 1998, BRIT J PHARMACOL, V123, P281, DOI 10.1038/sj.bjp.0701590; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; West AR, 2002, SYNAPSE, V44, P227, DOI 10.1002/syn.10076; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317	79	51	51	1	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	NOV	2003	62	11					1096	1107		10.1093/jnen/62.11.1096			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	744CV	WOS:000186611100002	14656068	Bronze			2022-02-06	
J	Ibarra, A; Correa, D; Willms, K; Merchant, MT; Guizar-Sahagun, G; Grijalva, I; Madrazo, I				Ibarra, A; Correa, D; Willms, K; Merchant, MT; Guizar-Sahagun, G; Grijalva, I; Madrazo, I			Effects of cyclosporin-A on immune response, tissue protection and motor function of rats subjected to spinal cord injury	BRAIN RESEARCH			English	Article						autoimmunity; cellular response; demyelination; neuroprotection; paraplegia	TRAUMATIC BRAIN-INJURY; PROMOTES AXONAL REGENERATION; CENTRAL-NERVOUS-SYSTEM; MYELIN BASIC-PROTEIN; TRANSVERSE SECTION; LIPID-PEROXIDATION; FOREBRAIN ISCHEMIA; RATING-SCALE; ADULT-RATS; DAMAGE	The aim of this work was to test the effect of cyclosporin-A (CsA) on some immunological, morphological and functional aspects developed after spinal cord injury. The specific cellular immune response against spinal cord constituents, the amount of spared tissue and myelination at the site of injury, and the motor function outcome were assessed in a first series of experiments. Rats were subjected to spinal cord compression and treated with cyclosporin-A before lesion and during the entire study. A specific lymphocyte response against spinal cord antigens was found in untreated spinal cord injured rats but not in cyclosporine-A treated injured rats. A significantly better myelination index was also found in injured cyclosporin-A-treated rats, as compared to untreated animals. The amount of spared spinal cord tissue at the epicenter was not significantly different comparing CsA-treated with vehicle-treated rats. Looking for a potential therapeutic use of CsA, in a second series of experiments, rats were subjected to spinal cord contusion and treated with cyclosporin-A from 1 to 72 h after lesion. Motor recovery and red nuclei neurons survival, were evaluated, and found to be significantly better in spinal cord injured rats treated with cyclosporin-A than in injured-untreated rats. This work confirms the existence of an autoimmune cellular reaction after injury that can be inhibited by cyclosporin-A treatment. Furthermore, cyclosporin-A promotes neuroprotection by diminishing both demyelination and neuronal cell death, resulting in a better motor outcome after spinal cord injury. (C) 2003 Elsevier B.V. All rights reserved.	Ctr Med Nacl Siglo XXI, IMSS, Unidad Invest Med Enfermedades Neurol, Mexico City, DF, Mexico; Proyecto Camina AC, Mexico City 14050, DF, Mexico; Inst Nacl Pediat, SSA, Mexico City, DF, Mexico; Univ Nacl Autonoma Mexico, Fac Med, Dept Microbiol & Immunoparasitol, Mexico City, DF, Mexico		Ibarra, A (corresponding author), Ctr Med Nacl Siglo XXI, IMSS, Unidad Invest Med Enfermedades Neurol, Mexico City, DF, Mexico.	iantonio65@yahoo.com		Guizar-Sahagun, Gabriel/0000-0002-2722-5758; Ibarra, Antonio/0000-0003-2489-4689			Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; BANIK NL, 1992, CRIT REV NEUROBIOL, V6, P257; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Bluml S, 1999, EXP NEUROL, V158, P121, DOI 10.1006/exnr.1999.7073; Borlongan CV, 2002, BRAIN RES, V956, P211, DOI 10.1016/S0006-8993(02)03474-1; CAMPAGNOLO DI, 1994, AM J PHYS MED REHAB, V73, P387, DOI 10.1097/00002060-199411000-00003; Cruse JM, 2000, EXP MOL PATHOL, V68, P38, DOI 10.1006/exmp.1999.2292; DAWSON TM, 1994, J NEUROSCI, V14, P5147; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Diaz-Ruiz A, 2000, NEUROREPORT, V11, P1765, DOI 10.1097/00001756-200006050-00033; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FERINGA ER, 1975, ARCH NEUROL-CHICAGO, V32, P676, DOI 10.1001/archneur.1975.00490520046007; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; GOLDMAN L, 1968, BIOPHYS J, V8, P596, DOI 10.1016/S0006-3495(68)86510-5; GRIJALVA I, 1994, NEURODEGENERATION, V3, P159; GUIZARSAHAGUN G, 1994, RESTOR NEUROL NEUROS, V7, P61, DOI 10.3233/RNN-1994-7201; GUIZARSAHAGUN G, 1994, SURG NEUROL, V41, P241, DOI 10.1016/0090-3019(94)90131-7; HALL DE, 1994, FREE RADICAL DAMAGE, P217; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI200112837; Hauben E, 2002, EUR J NEUROSCI, V16, P1731, DOI 10.1046/j.1460-9568.2002.02241.x; Ibarra A, 1996, J NEUROTRAUM, V13, P267, DOI 10.1089/neu.1996.13.267; Ibarra A, 1996, J NEUROTRAUM, V13, P569, DOI 10.1089/neu.1996.13.569; Ibarra A, 2000, NEUROSCIENCE, V96, P3, DOI 10.1016/S0306-4522(99)00541-2; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; KHAN M, 1983, CAN J NEUROL SCI, V10, P161, DOI 10.1017/S031716710004484X; KHAN M, 1985, CAN J NEUROL SCI, V12, P259, DOI 10.1017/S0317167100047120; Kil K, 1999, J NEUROIMMUNOL, V98, P201, DOI 10.1016/S0165-5728(99)00057-0; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Loy DN, 2002, EXP NEUROL, V177, P575, DOI 10.1006/exnr.2002.7959; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P102, DOI 10.1097/00002060-199903000-00002; Miyata K, 2001, NEUROSCIENCE, V105, P571, DOI 10.1016/S0306-4522(01)00225-1; MIZRACHI Y, 1983, PARAPLEGIA, V21, P287, DOI 10.1038/sc.1983.48; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Montgomerie JZ, 1997, CLIN INFECT DIS, V25, P1285, DOI 10.1086/516144; MORRIS RE, 1995, THER DRUG MONIT, V17, P564, DOI 10.1097/00007691-199512000-00003; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Ouary S, 2000, NEUROSCIENCE, V97, P521, DOI 10.1016/S0306-4522(00)00020-8; Palladini G, 1996, J BRAIN RES, V37, P145; PALLADINI G, 1987, EXP NEUROL, V95, P639, DOI 10.1016/0014-4886(87)90305-0; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; ROITT I, 1996, IMMUNOLOGY, P122; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038; Schnell L, 1997, EUR J NEUROSCI, V9, P1000, DOI 10.1111/j.1460-9568.1997.tb01450.x; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Schwartz M, 2001, J NEUROIMMUNOL, V113, P185, DOI 10.1016/S0165-5728(00)00447-1; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SMOLEN AJ, 1983, J NEUROCYTOL, V12, P739, DOI 10.1007/BF01258148; Springer JE, 2000, J NEUROSCI, V20, P7246; STERNBERG EM, 1992, BRAIN RES, V570, P54, DOI 10.1016/0006-8993(92)90563-O; Sugawara T, 1999, NEUROREPORT, V10, P3949, DOI 10.1097/00001756-199912160-00041; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Teichner A, 1993, J Hirnforsch, V34, P343; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; WILLIAMS RW, 1983, J NEUROSCI, V3, P1554; WRATHALL JR, 1992, J NEUROTRAUM, V9, pS129; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zeman RJ, 1999, EXP NEUROL, V159, P267, DOI 10.1006/exnr.1999.7146; [No title captured]	77	51	59	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 25	2003	979	1-2					165	178		10.1016/S0006-8993(03)02898-1			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	705LT	WOS:000184397100020	12850583				2022-02-06	
J	Rugg-Gunn, FJ; Eriksson, SH; Boulby, PA; Symms, MR; Barker, GJ; Duncan, JS				Rugg-Gunn, FJ; Eriksson, SH; Boulby, PA; Symms, MR; Barker, GJ; Duncan, JS			Magnetization transfer imaging in focal epilepsy	NEUROLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; CEREBRAL CORTICAL DYSPLASIA; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; WHITE-MATTER; TRANSFER RATIO; NEOCORTICAL EPILEPSY; NEURONAL MIGRATION; MR; ABNORMALITIES	Objectives: To test the hypothesis that magnetization transfer imaging (MTI), analyzed on a voxel-by-voxel basis, would identify areas of abnormal magnetization transfer ratio (MTR) in patients with focal epilepsy. Methods: The authors used MTI maps and statistical parametric mapping (SPM) to objectively compare the cerebral structures of 15 patients with malformations of cortical development (MCD), 10 with partial seizures and acquired lesions, and 42 with partial seizures and normal conventional MRI with those of 30 control subjects. Results: Significant reductions of MTR were identified in all 10 patients with acquired nonprogressive cerebral lesions and partial seizures. In all, the areas of decreased MTR concurred with abnormalities identified on visual inspection of conventional MRI. In 13 of the 15 patients with MCD, SPM detected regions of significantly reduced MTR, all of which corresponded to abnormalities identified on visual inspection of conventional MRI. In addition, in both groups, there were areas that were normal on conventional imaging that demonstrated abnormal MTR. There was a significant reduction of MTR in 15 of the 42 patients with cryptogenic focal epilepsy. In all of these, the areas of reduced MTR concurred with epileptiform EEG abnormality and clinical seizure semiology. Conclusions: Magnetization transfer imaging analyzed using statistical parametric mapping was sensitive in identifying malformations of cortical development and acquired cerebral lesions. Abnormalities of magnetization transfer ratio in individual MRI-negative patients suggest that minor structural disorganization exists in occult epileptogenic cerebral lesions.	Natl Soc Epilepsy, MRI Unit, Gerrards Cross SL9 0RJ, Bucks, England; UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London, England; UCL, Inst Neurol, NMR Res Unit, London, England; UCL, Inst Neurol, Dept Neuroinflammat, London, England		Duncan, JS (corresponding author), Natl Soc Epilepsy, MRI Unit, Gerrards Cross SL9 0RJ, Bucks, England.	j.duncan@ion.ucl.ac.uk	Barker, Gareth J/C-9616-2009	Barker, Gareth J/0000-0002-5214-7421; Duncan, John S/0000-0002-1373-0681			Adams JH, 1992, GREENFIELDS NEUROPAT, P106; ALLEN IV, 1979, J NEUROL SCI, V41, P81, DOI 10.1016/0022-510X(79)90142-4; Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barker GJ, 1996, MAGN RESON IMAGING, V14, P403, DOI 10.1016/0730-725X(96)00019-7; BARKOVICH AJ, 1988, AM J ROENTGENOL, V150, P179, DOI 10.2214/ajr.150.1.179; BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BOULBY PA, 2000, P 16 M EUR SOC MAGN, P483; Brochet B, 1999, NEUROLOGY, V53, pS12; Burke JW, 1996, AM J NEURORADIOL, V17, P773; CASCINO GD, 1992, EPILEPSY RES, V11, P51, DOI 10.1016/0920-1211(92)90021-K; Castillo M, 1996, RADIOGRAPHICS, V16, P241, DOI 10.1148/radiographics.16.2.8966284; Cendes F, 1997, ANN NEUROL, V42, P737, DOI 10.1002/ana.410420510; Dousset V, 1997, AM J NEURORADIOL, V18, P895; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; Duncan JS, 1997, BRAIN, V120, P339, DOI 10.1093/brain/120.2.339; DUONG T, 1994, ACTA NEUROPATHOL, V87, P493, DOI 10.1007/BF00294176; Ferini-Strambi L, 2000, NEUROLOGY, V54, P2331, DOI 10.1212/WNL.54.12.2331; Filippi M, 1998, ANN NEUROL, V43, P809, DOI 10.1002/ana.410430616; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GASS A, 1994, ANN NEUROL, V36, P62, DOI 10.1002/ana.410360113; Hammers A, 2001, BRAIN, V124, P1555, DOI 10.1093/brain/124.8.1555; HARDING BN, 1992, GREENFIELDS NEUROPAT, P521; Jay V, 1998, CHILD NERV SYST, V14, P15, DOI 10.1007/s003810050167; Juhasz C, 2001, NEUROLOGY, V56, P1650, DOI 10.1212/WNL.56.12.1650; KUCHARCZYK W, 1994, RADIOLOGY, V192, P521, DOI 10.1148/radiology.192.2.8029426; Lemieux L, 1999, MAGN RESON MED, V42, P127; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Li LM, 2000, AM J NEURORADIOL, V21, P1853; MANZ HJ, 1979, ACTA NEUROPATHOL, V45, P97, DOI 10.1007/BF00691886; MARCHAL G, 1989, ARCH NEUROL-CHICAGO, V46, P430, DOI 10.1001/archneur.1989.00520400090025; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.0.CO;2-6; Mehta RC, 1996, AM J NEURORADIOL, V17, P1051; MEHTA RC, 1995, AM J NEURORADIOL, V16, P2085; MITCHISON G, 1991, P ROY SOC B-BIOL SCI, V245, P151, DOI 10.1098/rspb.1991.0102; PALMINI A, 1995, ANN NEUROL, V37, P476, DOI 10.1002/ana.410370410; Plummer D., 1992, RIV NEURORADIOL, V5, P489, DOI DOI 10.1177/197140099200500413; PRAGER JM, 1994, AM J NEURORADIOL, V15, P1497; Richardson MP, 1998, NEUROLOGY, V51, P485, DOI 10.1212/WNL.51.2.485; Rugg-Gunn FJ, 2002, LANCET, V359, P1748, DOI 10.1016/S0140-6736(02)08615-4; Rugg-Gunn FJ, 2001, BRAIN, V124, P627, DOI 10.1093/brain/124.3.627; Silver NC, 1997, J NEUROL NEUROSUR PS, V62, P223, DOI 10.1136/jnnp.62.3.223; Sinson G, 2001, AM J NEURORADIOL, V22, P143; SISODIYA SM, 1995, BRAIN, V118, P1039, DOI 10.1093/brain/118.4.1039; Sisodiya SM, 1997, BRAIN, V120, P271, DOI 10.1093/brain/120.2.271; SYMMS M, 1996, P 4 M INT SOC MAGN R, P588; THEODORE WH, 1990, NEUROLOGY, V40, P797, DOI 10.1212/WNL.40.5.797; TOFTS PS, 1995, AM J NEURORADIOL, V16, P1862; van Waesberghe JHTM, 1999, ANN NEUROL, V46, P747; VANWAESBERGHE JHT, 1998, MULT SCLER, V4, P272; Woermann FG, 1999, BRAIN, V122, P2101, DOI 10.1093/brain/122.11.2101; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; WOLFF SD, 1994, RADIOLOGY, V192, P593, DOI 10.1148/radiology.192.3.8058919; Woo TU, 1996, CEREB CORTEX, V6, P446, DOI 10.1093/cercor/6.3.446; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; ZENTNER J, 1995, J NEUROL NEUROSUR PS, V58, P666, DOI 10.1136/jnnp.58.6.666	59	51	54	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 27	2003	60	10					1638	1645		10.1212/01.WNL.0000065891.93179.CC			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	682LD	WOS:000183092400017	12771255				2022-02-06	
J	Temkin, NR; Machamer, JE; Dikmen, SS				Temkin, NR; Machamer, JE; Dikmen, SS			Correlates of functional status 3-5 years after traumatic brain injury with CT abnormalities	JOURNAL OF NEUROTRAUMA			English	Article						craniocerebral trauma; criterion-related validity; functional status; head injury; health status; measurement development; outcome assessment; traumatic brain injury	GLASGOW-OUTCOME-SCALE; HEAD-INJURY; POSTTRAUMATIC SEIZURES; ALCOHOL-USE; DEPRESSION; RECOVERY	The Functional Status Examination (FSE) is a relatively new measure of functional outcome after traumatic brain injury (TBI). This study examines functional status limitations and what contributes to them to further enhance interpretability of the FSE and to continue its development as an outcome measure. The measure was given to 209 adults sustaining TBI with CT abnormalities who were followed prospectively until three to five years after injury. Relationships between functional status change as assessed by the FSE and characteristics of the injury and pre-injury characteristics of the person injured were evaluated as were relationships with concurrent measures of neuropsychological, emotional, and psychosocial functioning, health status, quality of life, and other functional status measures. Groups based on degree of functional status limitations due to the injury differ significantly on injury severity, especially length of impaired consciousness. They do not differ on most pre-injury characteristics of the person injured, although pre-existing conditions, primarily alcohol abuse, are more common in those with more negative functional changes after injury. All concurrent measures examined differ significantly among FSE groups with strongest relationships with measures of quality of life, psychosocial functioning, and other measures of health status and functional status (each p < 0.001). The Functional Status Examination shows promise as a measure reflecting a broad range of functional limitations. The FSE is an excellent tool combining clinical relevance, face validity, strong relationships to other measures of relevant constructs (criterion-related validity), and reasonable sensitivity to TBI severity even long after the injury and in a mostly moderately injured group.	Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Dept Biostat, Seattle, WA 98104 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA		Temkin, NR (corresponding author), Univ Washington, Dept Neurol Surg, Box 359924,325 9th Ave, Seattle, WA 98104 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19463] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019463] Funding Source: NIH RePORTER		[Anonymous], 1997, FED REGISTER, V62, P66113; BOMBARDIER C, IN PRESS ARCH PHYS M; Cherner M, 2001, ARCH PHYS MED REHAB, V82, P780, DOI 10.1053/apmr.2001.23263; DELIS D, 1987, CALIFORNIA VERBAL LE; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reitan R.M., 1993, HALSTEADREITAN NEURO; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Ware J.E., 1993, SF 36 HLTH SURVEY MA; *WHO, 1993, WHO INT CLASS IMP DI; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	28	51	56	0	9	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2003	20	3					229	241		10.1089/089771503321532815			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	661GU	WOS:000181883500001	12820677				2022-02-06	
J	Hamberger, A; Huang, YL; Zhu, H; Bao, F; Ding, M; Blennow, K; Olsson, A; Hansson, HA; Viano, D; Haglid, KG				Hamberger, A; Huang, YL; Zhu, H; Bao, F; Ding, M; Blennow, K; Olsson, A; Hansson, HA; Viano, D; Haglid, KG			Redistribution of neurofilaments and accumulation of beta-amyloid protein after brain injury by rotational acceleration of the head	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid; closed head injury; cytoskeleton; diffuse axonal injury; immunocytochemistry; inertial brain trauma; neurofilament subunits	PRESSURE WAVE INJURIES; DIFFUSE AXONAL INJURY; ADULT-RAT BRAIN; PRECURSOR PROTEINS; NF-L; PHOSPHORYLATION; SUBUNITS; NEURONS; DAMAGE; IMPACT	Rotational acceleration of the head, as occurs in falls, car crashes, and sport injuries, may result in diffuse brain damage, with acute and chronic neurological and psychiatric symptoms. The present study addresses the effects of rotational trauma on the neuronal cytoskeleton, which stabilizes perikaryal, dendritic and axonal shape and function. The study focuses upon the distribution of (1) the phosphorylated form of the heavy neurofilament subunit, (2) the light neurofilament subunit, and (3) beta-amyloid, a marker for brain injury. While normally restricted to axons, the phosphorylated heavy neurofilament subunits were drastically decreased in the axons after rotational trauma. Instead, they accumulated in the neuronal perikarya, normally devoid of the phosphorylated subunit. This alteration was seen, not only in the cerebral cortex, but also in the hippocampus, the cervical spinal cord, the cerebellum, the cranial nerves and the pyramidal tract. The distribution of the light subunit of neurofilaments was also altered post trauma. Only a weak beta-amyloid immunoreactivity was detected in the brains of control animals. Promptly after the trauma, a large number of B-amyloid positive neurons appeared. Intensely co-localized immunoreactivity for the light subunit of neurofilaments and of beta-amyloid was seen 3 days after the rotational trauma axons of in the subcortical white matter and in the granule cell layer of the dentate gyrus as well as in neurons of the hypoglossal nucleus. The reported alterations in the central nervous system neurons are similar to those in the human brain after closed head injury and in chronic degenerative diseases. Regions of importance for social behavior, memory and body movement were affected.	Univ Gothenburg, Inst Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Inst Clin Neurosci, SE-40530 Gothenburg, Sweden; Chalmers Univ Technol, S-41296 Gothenburg, Sweden		Hamberger, A (corresponding author), Univ Gothenburg, Inst Anat & Cell Biol, POB 420, SE-40530 Gothenburg, Sweden.						CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; EYER J, 1988, BIOCHEM J, V252, P655, DOI 10.1042/bj2520655; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; HEDREEN JC, 1994, J NEUROPATH EXP NEUR, V53, P663, DOI 10.1097/00005072-199411000-00013; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; KARLSSON JE, 1989, J NEUROCHEM, V53, P759, DOI 10.1111/j.1471-4159.1989.tb11770.x; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Meier J, 1999, J NEUROPATH EXP NEUR, V58, P1099, DOI 10.1097/00005072-199910000-00009; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; OMMAYA AK, 1984, BIOMECHANICS IMPACT, P117; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Pierce JES, 1996, J NEUROSCI, V16, P1083; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; SELKOE DJ, 1999, ALZHEIMER DIS, P293; SHAW G, 1986, EUR J CELL BIOL, V42, P1; Siegel GJ, 1999, BASIC NEUROCHEMISTRY; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; SUNESON A, 1989, J TRAUMA, V29, P10, DOI 10.1097/00005373-198901000-00003; Terry R., 1999, ALZHEIMER DIS, V2nd Edn, P187; Torack RM, 2001, NEUROPATH APPL NEURO, V27, P444, DOI 10.1046/j.1365-2990.2001.00355.x; Viano D., 1997, INT J CRASHWORTHINES, V2, P191; VOGELSBERGRAGAG.V, 1999, ALZHEIMERS DIS, P359; WANG S, 1991, BRAIN RES, V541, P334, DOI 10.1016/0006-8993(91)91034-X; WANG S, 1994, J NEUROCHEM, V62, P739; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F	46	51	54	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2003	20	2					169	178		10.1089/08977150360547080			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	652XV	WOS:000181406900004	12675970				2022-02-06	
J	Chan, JHM; Tsui, EYK; Peh, WCG; Fong, D; Fok, KF; Leung, KM; Yuen, MK; Fung, KKL				Chan, JHM; Tsui, EYK; Peh, WCG; Fong, D; Fok, KF; Leung, KM; Yuen, MK; Fung, KKL			Diffuse axonal injury: detection of changes in anisotropy of water diffusion diffusion-weighted imaging	NEURORADIOLOGY			English	Article						head injury; diffuse axonal injury; diffusion-weighted imaging	TRAUMATIC BRAIN INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; HEAD-INJURY; HISTOPATHOLOGIC CORRELATION; MULTIPLE-SCLEROSIS; CORPUS-CALLOSUM; MR; COEFFICIENT; EDEMA; PIG	Myelinated axons of white matter demonstrate prominent directional differences in water diffusion. We performed diffusion-weighted imaging on ten patients with head injury to explore the feasibility of using water diffusion anisotropy for quantitating diffuse axonal injury. We showed significant decrease in diffusion anisotropy indices in areas with or without signal abnormality on T2 and T2*-weighted images. We conclude that the water diffusion anisotropy sensitive index a potentially useful, and quantitative way of diagnosing and assessing patients with diffuse axonal injury.	Tuen Mun Hosp, Dept Diagnost Radiol, Tuen Mun, Hong Kong, Peoples R China; Singapore Gen Hosp, Dept Diagnost Radiol, Singapore 0316, Singapore; Tuen Mun Hosp, Dept Neurosurg, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Optometry & Radiog, Hong Kong, Hong Kong, Peoples R China		Chan, JHM (corresponding author), Tuen Mun Hosp, Dept Diagnost Radiol, Tsing Chung Koon Rd, Tuen Mun, Hong Kong, Peoples R China.	jchm888@yahoo.com		Yuen, MK Ernest/0000-0003-4977-7120; Peh, Wilfred CG/0000-0002-9976-5462			ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Ge YL, 2002, J COMPUT ASSIST TOMO, V26, P62, DOI 10.1097/00004728-200201000-00009; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.0.CO;2-6; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1080/028418501127346990; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Tievsky AL, 1999, AM J NEURORADIOL, V20, P1491; Yang Q, 1999, STROKE, V30, P2382, DOI 10.1161/01.STR.30.11.2382	26	51	52	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	JAN	2003	45	1					34	38		10.1007/s00234-002-0891-y			5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	644CU	WOS:000180901000006	12525952				2022-02-06	
J	Lang, EW; Lagopoulos, J; Griffith, J; Yip, K; Mudaliar, Y; Mehdorn, HM; Dorsch, NWC				Lang, EW; Lagopoulos, J; Griffith, J; Yip, K; Mudaliar, Y; Mehdorn, HM; Dorsch, NWC			Noninvasive cerebrovascular autoregulation assessment in traumatic brain injury: Validation and utility	JOURNAL OF NEUROTRAUMA			English	Article						cerebral perfusion pressure; dynamic cerebral pressure autoregulation; intracranial pressure; severe traumatic brain injury; transcranial Doppler ultrasound	BLOOD-FLOW VELOCITY; CEREBRAL AUTOREGULATION; TRANSCRANIAL DOPPLER; HEAD-INJURY; PHASE RELATIONSHIP; PRESSURE; THRESHOLDS; HUMANS	A moving correlation index (Mx-CPP) of cerebral perfusion pressure (CPP) and mean middle cerebral artery blood flow velocity (CBFV) allows continuous monitoring of dynamic cerebral autoregulation (CA) in patients with severe traumatic brain injury (TBI). In this study we validated Mx-CPP for TBI, examined its prognostic relevance, and assessed its relationship with arterial blood pressure (ABP), CPP, intracranial pressure (ICP), and CBFV. We tested whether using ABP instead of CPP for Mx calculation (Mx-ABP) produces similar results. Mx was calculated for each hemisphere in 37 TBI patients during the first 5 days of treatment. All patients received sedation and analgesia. CPP and bilateral CBFV were recorded, and GOS was estimated at discharge. Both Mx indices were calculated from 10,000 data points sampled at 57.411z. Mx-CPP > 0.3 indicates impaired CA; in these patients CPP had a significant positive correlation with CBFV, confirming failure of CA, while in those with Mx < 0.3, CPP was not correlated with CBFV, indicating intact CA. These findings were confirmed for Mx-ABP. We found a significant correlation between impaired CA, indicated by Mx-CPP and Mx-ABP, and poor outcome for TBI patients. ABP, CPP, ICP, and CBFV were not correlated with CA but it must be noted that our average CPP was considerably higher than in other studies. This study confirms the validity of this index to demonstrate CA preservation or failure in TBI. This index is also valid if ABP is used instead of CPP, which eliminates the need for invasive ICP measurements for CA assessment. An unfavorable outcome is associated with early CA failure. Further studies using the Mx-ABP will reveal whether CA improves along with patients' clinical improvement.	Univ Sydney, Dept Neurosurg, Westmead Hosp, Sydney, NSW 2145, Australia; Univ Sydney, Dept Neurol, Westmead Hosp, Sydney, NSW 2145, Australia; Univ Sydney, Dept Intens Care, Westmead Hosp, Sydney, NSW 2145, Australia; Univ Kiel, Dept Neurosurg, Kiel, Germany		Lang, EW (corresponding author), Univ Sydney, Dept Neurosurg, Westmead Hosp, CD Wing,Level 5, Sydney, NSW 2145, Australia.	keeflang@optusnet.com.au	Mehdorn, Maximilian/D-2495-2010				AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; BULLOCK R, 1996, GUIDELINES MANAGEMEN; Carey BJ, 2000, STROKE, V31, P2895, DOI 10.1161/01.STR.31.12.2895; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Heckmann JG, 1999, NEUROL RES, V21, P457, DOI 10.1080/01616412.1999.11740959; JENNETT B, 1975, LANCET, V1, P480; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; Lewis SB, 2001, NEUROSURGERY, V48, P369, DOI 10.1097/00006123-200102000-00026; LING J, 1995, J CLIN MONITOR, V11, P123, DOI 10.1007/BF01617734; Lipsitz LA, 2000, STROKE, V31, P1897, DOI 10.1161/01.STR.31.8.1897; MCHENRY LC, 1974, STROKE, V5, P695, DOI 10.1161/01.STR.5.6.695; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; RINGELSTEIN RB, 1989, PRACTICAL GUIDE TRAN; SCHNITTGER C, 1997, NEW TRENDS CEREBRAL, P638; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; SYMON L, 1971, EUR NEUROL, V6, P11, DOI 10.1159/000114458; Wallis SJ, 1996, STROKE, V27, P2287, DOI 10.1161/01.STR.27.12.2287	29	51	55	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2003	20	1					69	75		10.1089/08977150360517191			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	641BB	WOS:000180723200006	12614589				2022-02-06	
J	Kinoshita, K; Kraydieh, S; Alonso, O; Hayashi, N; Dietrich, WD				Kinoshita, K; Kraydieh, S; Alonso, O; Hayashi, N; Dietrich, WD			Effect of posttraumatic hyperglycemia on contusion volume and neutrophil accumulation after moderate fluid-percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						fluid-percussion; hyperglycemia; inflammation; neutrophil accumulation; secondary injury; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; ISCHEMIC CELL-DAMAGE; CULTURED ENDOTHELIAL-CELLS; CONTROLLED CORTICAL IMPACT; ADHESION MOLECULES; OXIDATIVE STRESS; POLYMORPHONUCLEAR LEUKOCYTES; GLUCOSE-CONCENTRATION; FOREBRAIN ISCHEMIA; REPERFUSION INJURY	The purpose of this study was to evaluate the effects of posttraumatic hyperglycemia on contusion volume and neutrophil accumulation following moderate traumatic brain injury (TBI) in rats. A parasagittal fluid-percussion (F-P) brain injury (1.8-2.1 atm) was induced in male Sprague-Dawley rats. Rats were then randomized into four trauma groups (n = 7/group) by the timing of dextrose injection (2.0 gm/kg/ip), which included (1) early (E) group: 5 min after TBI; (2) delayed (D) group: 4 h after TBI; (3) 24-h group: 24 h after TBI; or (4) control (C) group: no dextrose injection. A sham operated control group also received dextrose to document physiological parameters (n = 4). Rats were perfusion fixed 3 days following TBI, and the brains were processed for routine histopathological and immunocytochemical analysis. Contusion areas and volumes, as well as the frequency of myeloperoxidase immunoreactive polymorphonuclear leukocytes (PMNLs) were determined. Dextrose injections significantly increased blood glucose levels (p < 0.005) in all treated groups. Although acute hyperglycemia following TBI did not significantly affect total contusion volume, contusion area was significantly elevated in the early treatment group. In addition, early posttraumatic hyperglycemia enhanced neutrophil accumulation in the area of the cortical contusion (p < 0.005). In contrast, delayed induced hyperglycemia (i.e., 4 h, 24 h) did not significantly affect histopathological outcome or neutrophil accumulation. Taken together, these findings indicate that acute but not delayed hyperglycemia aggravates histopathological outcome and increased accumulation of PMNLs. Posttraumatic hyperglycemia in the acute phase may worsen traumatic outcome by enhancing secondary injury processes, including inflammation.	Univ Miami, Sch Med, Miami Project Cure Paralysis R 48, Miami, FL 33101 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis R 48, POB 016960, Miami, FL 33101 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30261] Funding Source: Medline		Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BAUMGARTNERPARZER SM, 1995, DIABETOLOGIA, V38, P1367; BEYNON HLC, 1993, CLIN EXP IMMUNOL, V91, P314; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Ceriello A, 1996, METABOLISM, V45, P498, DOI 10.1016/S0026-0495(96)90226-7; Ceriello A, 1997, DIABETIC MED, V14, pS45, DOI 10.1002/(SICI)1096-9136(199708)14:3+<S45::AID-DIA444>3.3.CO;2-I; Ceriello A, 1998, HORM METAB RES, V30, P146, DOI 10.1055/s-2007-978854; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DECOURTENMYERS G, 1988, STROKE, V19, P623, DOI 10.1161/01.STR.19.5.623; DECOURTENMYERS GM, 1989, STROKE, V20, P1707, DOI 10.1161/01.STR.20.12.1707; DECOURTENMYERS GM, 1994, J CEREBR BLOOD F MET, V14, P227, DOI 10.1038/jcbfm.1994.29; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1993, STROKE, V24, P111, DOI 10.1161/01.STR.24.1.111; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; FOLBERGROVA J, 1992, J CEREBR BLOOD F MET, V12, P25, DOI 10.1038/jcbfm.1992.4; Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563; GINSBERG MD, 1987, STROKE, V18, P570, DOI 10.1161/01.STR.18.3.570; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; Gisselsson L, 1999, J CEREBR BLOOD F MET, V19, P288, DOI 10.1097/00004647-199903000-00007; GLABINSKI AR, 1995, INT J DEV NEUROSCI, V13, P153, DOI 10.1016/0736-5748(95)00017-B; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; HARIK SI, 1988, J NEUROCHEM, V51, P1924, DOI 10.1111/j.1471-4159.1988.tb01179.x; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Hartleb M, 1997, LIVER, V17, P1; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; HURN PD, 1991, AM J PHYSIOL, V261, pH853, DOI 10.1152/ajpheart.1991.261.3.H853; Jean WC, 1998, NEUROSURGERY, V43, P1382, DOI 10.1097/00006123-199812000-00076; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; Kawai N, 1997, STROKE, V28, P149, DOI 10.1161/01.STR.28.1.149; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kent TA, 2001, STROKE, V32, P2318, DOI 10.1161/hs1001.096588; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; Kishimoto T K, 1994, Adv Pharmacol, V25, P117, DOI 10.1016/S1054-3589(08)60431-7; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KRAFT SA, 1990, STROKE, V21, P447, DOI 10.1161/01.STR.21.3.447; KRAIG RP, 1986, AM J PHYSIOL, V250, P348; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Li PA, 1997, ACTA PHYSIOL SCAND, V161, P567, DOI 10.1046/j.1365-201X.1997.00264.x; Lin BW, 1998, ACTA NEUROPATHOL, V96, P610, DOI 10.1007/s004010050942; Lin BW, 2000, NEUROSCI LETT, V278, P1, DOI 10.1016/S0304-3940(99)00889-7; Marfella R, 2000, CIRCULATION, V101, P2247, DOI 10.1161/01.CIR.101.19.2247; MARMAROU A, 1992, J NEUROTRAUM, V9, P551; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; McIntosh TK, 1996, LAB INVEST, V74, P315; MCLEOD DS, 1995, AM J PATHOL, V147, P642; MERGUERIAN P, 1981, CRIT CARE MED, V9, P939; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; MYERS RE, 1977, ARCH NEUROL-CHICAGO, V34, P65, DOI 10.1001/archneur.1977.00500140019003; Myers RE, 1979, ADV PERINATAL NEUROL, V1, P85; NEDERGAARD M, 1987, BRAIN RES, V408, P79, DOI 10.1016/0006-8993(87)90360-X; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NORDSTROM C, 1976, ACTA PHYSL SCAND, V98, P248; PALJARVI L, 1983, ACTA NEUROPATHOL, V60, P232, DOI 10.1007/BF00691871; Panes J, 1996, CIRCULATION, V93, P161, DOI 10.1161/01.CIR.93.1.161; Pieper GM, 1997, J CARDIOVASC PHARM, V30, P528, DOI 10.1097/00005344-199710000-00019; PIEPER GM, 1995, AM J PHYSIOL-HEART C, V269, pH845, DOI 10.1152/ajpheart.1995.269.3.H845; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; RICHARDSON M, 1994, ARTERIOSCLER THROMB, V14, P760, DOI 10.1161/01.ATV.14.5.760; ROBERTSON C, 1992, STROKE, V23, P564, DOI 10.1161/01.STR.23.4.564; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Siesjo BK, 1996, ACT NEUR S, V66, P8; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P253, DOI 10.1038/jcbfm.1985.32; SMITH ML, 1988, ACTA NEUROPATHOL, V76, P253, DOI 10.1007/BF00687772; Soares HD, 1995, J NEUROSCI, V15, P8223; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; TONNESEN MG, 1988, MOL CELLULAR BIOL WO, P149; Vink R, 1997, J CEREBR BLOOD F MET, V17, P50, DOI 10.1097/00004647-199701000-00007; WAGNER KR, 1992, J CEREBR BLOOD F MET, V12, P213, DOI 10.1038/jcbfm.1992.31; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WARNER DS, 1995, STROKE, V26, P655, DOI 10.1161/01.STR.26.4.655; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; ZASSLOW MA, 1989, STROKE, V20, P519, DOI 10.1161/01.STR.20.4.519; ZILLES KJL, 1985, CORTEX BRAIN STEREOT	93	51	55	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2002	19	6					681	692		10.1089/08977150260139075			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	569EZ	WOS:000176588900001	12165130				2022-02-06	
J	Rapoport, M; McCauley, S; Levin, H; Song, J; Feinstein, A				Rapoport, M; McCauley, S; Levin, H; Song, J; Feinstein, A			The role of injury severity in neurobehavioral outcome 3 months after Traumatic Brain Injury	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article							CLOSED-HEAD-INJURY; RATING-SCALE; BEHAVIORAL SEQUELAE; DISORDERS; RECOVERY; DEPRESSION; VALIDITY	Objective/Background: To assess neurobehavioral outcome using the Neurobehavioral Rating Scale-Revised (NRS-R), an instrument with established specificity and validity in Traumatic Brain Injury (TBI) in a sample including the full spectrum of TBI severity 3 months after injury. Method: A cohort group of 102 subjects with mild TBI, 41 with moderate TBI, and 139 with severe TBI, from multiple academic trauma centers, were assessed using the NRS-R and the Glasgow Outcome Scale. Results: Principal components analysis of the NRS-R resulted in a 3-factor model: (1) Cognitive, (2) Emotional, and (3) Hyperarousal. At 3 months, subjects with severe TBI show greater difficulties in cognitive and hyper-arousal, but not emotional domains, than those with mild to moderate TBI. More than one third of subjects in all injury severity groups showed evidence of anxiety, depression, irritability, mental fatigability, and memory dysfunction. Scores on the NRS-R were related to outcome on the Glasgow Outcome Scale. Conclusions: Three months after injury, subjects with severe TBI have more dysfunction in cognitive and behavioral (but not emotional) domains than those with mild-to-moderate TBI. The NRS-R is a useful tool for assessing the full spectrum of neurobehavioral dysfunction at all ranges of TBI severity.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA		Rapoport, M (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, FG37-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	mark.rapoport@swchsc.on.ca	Rapoport, Mark/AAD-8581-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; ODCDC CDC HHS [R49CCR 612707] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Brooks D N, 1979, Int Rehabil Med, V1, P166; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; EPSTEIN RS, 1994, NEUROPSYCHIATRY TRAU, P25; GUALTIERI CT, 1991, J CLIN PSYCHOPHARM, V11, P280, DOI 10.1097/00004714-199108000-00027; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1986, NEUROPSYCHOLOGIC REH; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Silver Jonathan M., 1994, P313; Smeltzer Donald J., 1994, P251; Stevens JP., 1996, APPL MULTIVARIATE ST; Tabachnick B. G., 1989, USING MULTIVARIATE S; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643	42	51	53	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	JUN	2002	15	2					123	132		10.1097/01.WNN.0000016801.80266.36			10	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	560XW	WOS:000176107500008	12050475				2022-02-06	
J	Paschall, MJ; Fishbein, DH				Paschall, MJ; Fishbein, DH			Executive cognitive functioning and aggression: a public health perspective	AGGRESSION AND VIOLENT BEHAVIOR			English	Article						aggression; violence; executive function; cognition; public health; treatment	TRAUMATIC BRAIN-INJURY; DEFICIT-HYPERACTIVITY DISORDER; UNITED-STATES; FOLLOW-UP; ANTISOCIAL-BEHAVIOR; VIOLENT BEHAVIOR; CONDUCT DISORDER; HEAD-INJURY; CHILD-DEVELOPMENT; MALE-ADOLESCENTS	A large body of research from diverse fields suggests that impaired executive cognitive functioning (ECF) may play an important role in the etiology of aggression and violent behavior (AVB). A number of studies examining subjects without significant psychopathology has found compelling evidence for a relationship between subclinical impaired ECF and AVB. These findings provide an empirical foundation for research on the epidemiology of impaired ECF as a risk factor for AVB in the general population, Unfortunately, however, most research on the ECF-AVB relationship has been limited to clinical, incarcerated, and other small nonrepresentative samples of human subjects. Thus, little is known about the public health significance of impaired ECF and its implications for behavioral disorders. Research is reviewed that may shed light on the epidemiology of impaired ECF and its relationship to AVB. Other conditions that correlate with, define, or contribute to ECF impairments that may also relate to AVB are discussed. Because ECF is considered to be malleable, an introduction to interventions with potential to improve ECF and, in turn, AVB is included. Finally, an agenda, along with a conceptual framework to guide this work, is proposed for future research on the ECF-AVB relationship from a public health perspective, with attention to anticipated methodological and ethical challenges. (C) 2002 Elsevier Science Ltd. All rights reserved.	Pacific Inst Res & Evaluat, Chapel Hill, NC 27514 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA		Paschall, MJ (corresponding author), Pacific Inst Res & Evaluat, 104 S Estes Dr,Suite 206, Chapel Hill, NC 27514 USA.	paschall@pire.org		fishbein, diana/0000-0003-1644-2762			Alderman N, 1997, BRAIN INJURY, V11, P79, DOI 10.1080/026990597123683; ALDERMAN N, 1991, NEUROPSYCHOL REHABIL, V1, P65, DOI DOI 10.1080/09602019108401380; ALDERMAN N, 1990, COGNITIVE REHABILITA, P204; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; Barratt ES, 1997, BIOL PSYCHIAT, V41, P1045, DOI 10.1016/S0006-3223(96)00175-8; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BIERMAN KL, 1992, DEV PSYCHOPATHOL, V4, P509, DOI 10.1017/S0954579400004855; BOTVIN GJ, 1995, JAMA-J AM MED ASSOC, V273, P1106, DOI 10.1001/jama.273.14.1106; BROWN CS, 1994, CNS DRUGS, V1, P95, DOI 10.2165/00023210-199401020-00002; BROWN M, 1989, J METAMORPH GEOL, V7, P1, DOI 10.1111/j.1525-1314.1989.tb00569.x; Burgess P. W., 1990, COGNITIVE REHABILITA, P183; BUSCH KG, 1990, J CLIN PSYCHOL, V46, P472, DOI 10.1002/1097-4679(199007)46:4<472::AID-JCLP2270460416>3.0.CO;2-F; Disney ER, 1999, AM J PSYCHIAT, V156, P1515, DOI 10.1176/ajp.156.10.1515; DUNCAN GJ, 1994, CHILD DEV, V65, P296, DOI 10.2307/1131385; Eggert L L, 1994, Am J Health Promot, V8, P202; Elia J, 1999, NEW ENGL J MED, V340, P780, DOI 10.1056/NEJM199903113401007; Ellickson PL, 2000, AM J PUBLIC HEALTH, V90, P566, DOI 10.2105/AJPH.90.4.566; Embry DD, 1996, AM J PREV MED, V12, P91, DOI 10.1016/S0749-3797(18)30241-1; FABIANO E, 1990, PRELIMINARY ASSESSME; FABIANO E, 1990, REHABILITATION CLEAR; Fabiano E. A., 1991, CORRECTIONS TODAY, V53, P102; Fishbein D, 2000, Prev Sci, V1, P89, DOI 10.1023/A:1010090114858; Giancola PR, 1998, J ABNORM PSYCHOL, V107, P629, DOI 10.1037/0021-843X.107.4.629; Giancola PR, 1995, AGGRESSIVE BEHAV, V21, P431, DOI 10.1002/1098-2337(1995)21:6<431::AID-AB2480210604>3.0.CO;2-Q; GIANCOLA PR, 2000, SCI TREATMENT PREVEN; GINACOLA PR, 1994, J ABNORM PSYCHOL, V103, P832; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Green MA, 1996, PROG PHOTOVOLTAICS, V4, P1; Greenberg M.T., 1999, PREVENTING MENTAL DI; GREENBERG MT, 1995, DEV PSYCHOPATHOL, V7, P117, DOI 10.1017/S0954579400006374; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAMMOND R, 1991, J HEALTH CARE POOR U, V2, P359; HAWKINS DF, 1993, HEALTH AFFAIR, V12, P80, DOI 10.1377/hlthaff.12.4.80; Hawkins KA, 2000, AGGRESS VIOLENT BEH, V5, P147, DOI 10.1016/S1359-1789(98)00033-0; HEILBRUN AB, 1990, J PERS ASSESS, V54, P617, DOI 10.1207/s15327752jpa5403&4_16; Hermann D., 1996, RETRAINING COGNITION; Hetherington E.M., 1994, SEPARATE SOCIAL WORL; Higgins ST, 2000, J CONSULT CLIN PSYCH, V68, P64, DOI 10.1037/0022-006X.68.1.64; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; KAKAR S, 1996, CHILD ABUSE DELINQUE; Kann L, 1998, MMWR CDC Surveill Summ, V47, P1; Kellam SG, 1998, DEV PSYCHOPATHOL, V10, P165, DOI 10.1017/S0954579498001564; Kellam SG, 1998, AM J PUBLIC HEALTH, V88, P1490, DOI 10.2105/AJPH.88.10.1490; KELLAM SG, 1994, DEV PSYCHOPATHOL, V6, P463, DOI 10.1017/S0954579400006052; KORENMAN S, 1995, CHILD YOUTH SERV REV, V17, P127, DOI 10.1016/0190-7409(95)00006-X; LAROSE S, 1989, PERCEPT MOTOR SKILL, V69, P851, DOI 10.2466/pms.1989.69.3.851; LAU MA, 1995, J ABNORM PSYCHOL, V104, P150, DOI 10.1037/0021-843X.104.1.150; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LEWIS DO, 1982, J ADOLESCENT HEALTH, V3, P160, DOI 10.1016/S0197-0070(82)80119-8; LEWIS DO, 1988, AM J PSYCHIAT, V44, P527; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Loeber R., 1998, NEW PERSPECTIVES ADO, P90, DOI [DOI 10.1017/CBO9780511571138.005, DOI 10.1017/CBO978051138.005]; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; Lyketsos CG, 1999, AM J PSYCHIAT, V156, P58, DOI 10.1176/ajp.156.1.58; Manchester D, 1997, BRAIN INJURY, V11, P605, DOI 10.1080/026990597123296; Mateer C. A., 1999, COGNITIVE NEUROREHAB, P314; McDermott PA, 1996, J ABNORM CHILD PSYCH, V24, P53, DOI 10.1007/BF01448373; McDermott PA, 1997, YOUTH SOC, V28, P387, DOI 10.1177/0044118X97028004001; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McLoyd VC, 1998, AM PSYCHOL, V53, P185, DOI 10.1037/0003-066X.53.2.185; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; MILNER B, 1995, ADV NEUROL, V66, P67; MOFFITT TE, 1994, CRIMINOLOGY, V32, P277, DOI 10.1111/j.1745-9125.1994.tb01155.x; Moffitt TE, 1989, DEV PSYCHOPATHOL, V1, P105; MOFFITT TE, 1991, NEUROPSYCHOLOGY AGGR, P131; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; MYERS WC, 1995, J AM ACAD CHILD PSY, V34, P1483, DOI 10.1097/00004583-199511000-00015; NEWMAN JP, 1987, J RES PERS, V21, P464, DOI 10.1016/0092-6566(87)90033-X; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; Paschall MJ, 1996, J YOUTH ADOLESCENCE, V25, P177, DOI 10.1007/BF01537343; Paschall MJ, 1998, J RES CRIME DELINQ, V35, P148, DOI 10.1177/0022427898035002002; Paschall MJ, 1998, J CONSULT CLIN PSYCH, V66, P825, DOI 10.1037/0022-006X.66.5.825; Pineda DA, 2000, INT J NEUROSCI, V101, P133, DOI 10.3109/00207450008986497; RAINE A, 1997, NATO ASI SERIES A; Raine A, 1993, PSYCHOPATHOLOGY CRIM; RANTAKALLIO P, 1992, ARCH DIS CHILD, V67, P1459, DOI 10.1136/adc.67.12.1459; Reiss A. J., 1993, UNDERSTANDING PREVEN; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Rothwell NA, 1999, BRAIN INJURY, V13, P521; SAMPSON RJ, 1987, AM J SOCIOL, V93, P348, DOI 10.1086/228748; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; SCHONFELD IS, 1988, CHILD DEV, V59, P993, DOI 10.1111/j.1467-8624.1988.tb03252.x; Schroder J, 1998, J NEURAL TRANSM-SUPP, P51; SEGUIN JR, 1995, J ABNORM PSYCHOL, V104, P614, DOI 10.1037/0021-843X.104.4.614; SHURE MB, 1982, AM J COMMUN PSYCHOL, V10, P341, DOI 10.1007/BF00896500; Silberstein RB, 1998, ARCH GEN PSYCHIAT, V55, P1105, DOI 10.1001/archpsyc.55.12.1105; Smith CA, 1997, WAKE CHILDHOOD MALTR; SNYDER HN, 1999, 178257 NCJ US DEP JU; SPARACELLI S, 1995, VIOLENCE VICTIMS, V10, P163; Spoth R, 1998, J CONSULT CLIN PSYCH, V66, P385, DOI 10.1037/0022-006X.66.2.385; Thompson EA, 1997, J DRUG EDUC, V27, P19, DOI 10.2190/G6XY-U2CQ-GFQF-PNEV; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WebsterStratton C, 1997, J CONSULT CLIN PSYCH, V65, P93, DOI 10.1037/0022-006X.65.1.93; WIDOM CS, 1994, CHILD ABUSE NEGLECT, V18, P303, DOI 10.1016/0145-2134(94)90033-7; WILSON BA, 1997, J INT NEUROPSYCH SOC, V3, P196	95	51	53	1	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-1789	1873-6335		AGGRESS VIOLENT BEH	Aggress. Violent Behav.	MAY-JUN	2002	7	3					215	235	PII S1359-1789(00)00044-6	10.1016/S1359-1789(00)00044-6			21	Criminology & Penology; Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Criminology & Penology; Psychology	563NX	WOS:000176263400002					2022-02-06	
J	Kumar, A; Zou, LL; Yuan, XQ; Long, Y; Yang, K				Kumar, A; Zou, LL; Yuan, XQ; Long, Y; Yang, K			N-methyl-D-aspartate receptors: Transient loss of NR1/NR2A/NR2B subunits after traumatic brain injury in a rodent model	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						N-methyl-D-aspartate receptor; hippocampus; brain injury; memory; rodent model	CORTICAL IMPACT INJURY; NMDA RECEPTORS; RAT-BRAIN; MEDIATED REGULATION; CALPAIN ACTIVATION; MESSENGER-RNA; EXPRESSION; MEMORY; CELLS; NR1	Hippocampal N-methyl-D-aspartate (NMDA) receptor subunits, by virtue of their involvement in excitotoxic injury as well as memory association, may play an important role in the pathophysiologic mechanisms of traumatic brain injury (TBI). In this study, temporal changes in NMDA receptor subunit (NR1, NR2A, and NR2B) levels in rat hippocampus after TBI were investigated by Western blot and mRNA expression levels by RT-PCR methods. Sprague-Dawley rats (250-350 g) were employed, and a controlled cortical impact injury device was used to produce the TBI in rodents. At different postinjury time points (2, 6, 12, 24, and 48 hr), the rat hippocampi were dissected out for protein and RNA preparation. Western blot analysis revealed significant decreases of NR1, NR2A, and NR2B subunit proteins at 6 and 12 hr postinjury in rat hippocampus. Complete recovery of NR1, NR2A, and NR2B subunit protein to the levels of sham controls was observed at 24 hr postinjury. However, RT-PCR analysis did not show any significant change in the mRNA levels at 2, 6, and 12 hr postinjury in comparison with sham controls, suggesting nontranscriptional change in the levels of these subunits. Thus, TBI can produce transient degradation of NMDA receptor subunits in the hippocampus, which might contribute to temporary memory impairment after injury. (C) 2002 Wiley-Liss, Inc.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Dept Vet Affairs Med Ctr, Neurol Care Line, Houston, TX USA		Yang, K (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS35502-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035502] Funding Source: NIH RePORTER		Bi XN, 1996, BRAIN RES, V726, P98, DOI 10.1016/0006-8993(95)01360-1; Bi XN, 1998, BRAIN RES, V790, P245, DOI 10.1016/S0006-8993(98)00067-5; Bi XN, 2000, METH MOL B, V144, P203; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gellerman DM, 1997, J NEUROCHEM, V69, P131; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kim WT, 1998, BRAIN RES, V799, P49, DOI 10.1016/S0006-8993(98)00464-8; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Lu XY, 2001, J NEUROCHEM, V77, P1553, DOI 10.1046/j.1471-4159.2001.00359.x; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nakao Y, 2001, J THORAC CARDIOV SUR, V122, P136, DOI 10.1067/mtc.2001.114101; Takagi N, 1997, J NEUROCHEM, V69, P1060; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Zhang L, 1997, J NEUROCHEM, V69, P1983; Zou LL, 1999, GENE THER, V6, P994, DOI 10.1038/sj.gt.3300936	25	51	79	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAR 15	2002	67	6					781	786		10.1002/jnr.10181			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	526ZC	WOS:000174158700010	11891792				2022-02-06	
J	Lengenfelder, J; Schultheis, MT; Al-Shibabi, T; Mourant, R; DeLuca, J				Lengenfelder, J; Schultheis, MT; Al-Shibabi, T; Mourant, R; DeLuca, J			Divided attention and driving: A pilot study using virtual reality technology	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injured; divided attention; driving; virtual reality	TRAUMATIC BRAIN INJURY; DUAL-TASK PERFORMANCE; HEAD-INJURY; DAMAGE; ENVIRONMENTS; IMPAIRMENTS; PREDICTION; EXPOSURE	Background: Virtual reality (VR) was used to investigate the influence of divided attention (simple versus complex) on driving performance (speed control). Design: Three individuals with traumatic brain injury (TBI) and three healthy controls (HC), matched for age, education, and gender, were examined. Results: Preliminary results revealed no differences on driving speed between TBI and HC, In contrast, TBI subjects demonstrated a greater number of errors on a secondary task performed while driving, Conclusion: The findings suggest that VR may provide an innovative medium for direct evaluation of basic cognitive functions (ie, divided attention) and its impact on everyday tasks (ie, driving) not previously available through traditional neuropsychological measures.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Northeastern Univ, Virtual Environm Lab, Boston, MA 02115 USA		Schultheis, MT (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	mschultheis@kmrrec.org		Schultheis, Maria/0000-0002-6558-548X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD7522-01, HD08589-01] Funding Source: Medline		Adcock RA, 2000, P NATL ACAD SCI USA, V97, P3567, DOI 10.1073/pnas.060588897; Ball K, 1993, J Am Optom Assoc, V64, P71; Ball K, 1998, UFOV USEFUL FIELD VI; Bieliauskas LA, 1998, CLIN NEUROPSYCHOL, V12, P206, DOI 10.1076/clin.12.2.206.1994; BOAKE C, 1993, ARCH PHYS MED REHAB, V74, P1246; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brown D. J., 1998, P 2 EUR C DIS VIRT R, P11; Brown DJ, 1997, COMMUN ACM, V40, P72, DOI 10.1145/257874.257891; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Cox D J, 1998, J Am Board Fam Pract, V11, P264; FINKELMAN JM, 1977, J APPL PSYCHOL, V62, P713, DOI 10.1037/0021-9010.62.6.713; Fisk GD, 1998, BRAIN INJURY, V12, P683; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Haikonen S, 1998, Appl Neuropsychol, V5, P24, DOI 10.1207/s15324826an0501_3; Hinkin CH, 2000, J CLIN EXP NEUROPSYC, V22, P16, DOI 10.1076/1380-3395(200002)22:1;1-8;FT016; Hoffman HG, 2000, PAIN, V85, P305, DOI 10.1016/S0304-3959(99)00275-4; Kostyniuk L. P, 1998, UMTRI9852; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; LEVINE O, 1998, P HUM FACT ERG SOC 4, P1136; Lewis R, 1979, MANUAL REPEATABLE CO; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MOSCOWITZ H, 1973, J SAFETY RES, V5, P185; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Rizzo AA, 1997, ST HEAL T, V44, P123; ROTHBAUM BO, 1995, AM J PSYCHIAT, V152, P626; SATAVA RM, 1996, P MED MEETS VIRT REA, P100; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Schultheis MT, 2001, NEUROLOGY, V56, P1089, DOI 10.1212/WNL.56.8.1089; SIVAK M, 1995, HS041692 U MICH TRAN; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; WESTWOOD JD, 2000, MED MEETS VIRTUAL RE, P207; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5	45	51	53	4	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2002	17	1					26	37		10.1097/00001199-200202000-00005			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	519MM	WOS:000173730100006	11860327				2022-02-06	
J	Hutchinson, PJ; O'Connell, MT; Al-Rawi, PG; Kett-White, CR; Gupta, AK; Maskell, LB; Pickard, JD; Kirkpatrick, PJ				Hutchinson, PJ; O'Connell, MT; Al-Rawi, PG; Kett-White, CR; Gupta, AK; Maskell, LB; Pickard, JD; Kirkpatrick, PJ			Increases in GABA concentrations during cerebral ischaemia: a microdialysis study of extracellular amino acids	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; TRANSIENT FOREBRAIN ISCHEMIA; SUBSTANTIA-NIGRA-RETICULATA; TRAUMATIC BRAIN-INJURY; IN-VIVO; NEURONAL DAMAGE; INTRACEREBRAL MICRODIALYSIS; GENERAL-ANESTHETICS; RAT HIPPOCAMPUS; GLUTAMATE	Objectives: Increases in the extracellular concentration of the excitatory amino acids glutamate and aspartate during cerebral ischaemia in patients are well recognised. Less emphasis has been placed on the concentrations of the inhibitory amino acid neurotransmitters, notably gamma-amino-butyric acid (GABA), despite evidence from animal studies that GABA may act as a neuroprotectant in models of ischaemia, The objective of this study was to investigate the concentrations of various excitatory, inhibitory and non-transmitter amino acids under basal conditions and during periods of cerebral ischaemia in patients with head injury or a subarachnoid haemorrhage. Methods: Cerebral microdialysis was established in 12 patients with head injury (n=7) or subarachnoid haemorrhage (n=5). Analysis was performed using high performance liquid chromatography for a total of 19 (excitatory, inhibitory and non-transmitter) amino acids. Patients were monitored in neurointensive care or during aneurysm clipping. Results: During stable periods of monitoring the concentrations of amino acids were relatively constant enabling basal values to be established. In six patients, cerebral ischaemia was associated with increases (up to 1350 fold) in the concentration of GABA, in addition to the glutamate and aspartate. Parallel increases in the concentration of glutamate and GABA were found (r=0.71, p<0.005). Conclusions: The results suggest that, in the human brain, acute cerebral ischaemia is not accompanied by an imbalance between excitatory and inhibitory amino acids, but by an increase in all neurotransmitter amino acids. These findings concur with the animal models of ischaemia and raise the possibility of an endogenous GABA mediated neuroprotective mechanism in humans.	Univ Cambridge, Addenbrookes Hosp, Acad Dept Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England		Hutchinson, PJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Acad Dept Neurosurg, Box 167, Cambridge CB2 2QQ, England.	p.hutch@which.net		O'Connell, Mark/0000-0001-6272-8767	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI		Antkowiak B, 1999, ANESTHESIOLOGY, V91, P500, DOI 10.1097/00000542-199908000-00025; Bachli H, 1996, NEUROL RES, V18, P370; BALDWIN HA, 1994, BRIT J PHARMACOL, V112, P188, DOI 10.1111/j.1476-5381.1994.tb13050.x; Belelli D, 1999, NEUROCHEM INT, V34, P447, DOI 10.1016/S0197-0186(99)00037-6; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BOURDELAIS AJ, 1992, J NEUROCHEM, V58, P2311, DOI 10.1111/j.1471-4159.1992.tb10979.x; BULLOCK R, 1994, J NEUROSURG, V80, P595; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; CAMPBELL K, 1993, BRAIN RES, V614, P241, DOI 10.1016/0006-8993(93)91041-P; CHOI DW, 1987, J NEUROSCI, V7, P357; CROSS AJ, 1991, BRIT J PHARMACOL, V104, P406, DOI 10.1111/j.1476-5381.1991.tb12443.x; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DURING MJ, 1993, LANCET, V341, P1607; FINKJENSEN A, 1992, EUR J PHARMACOL, V220, P197, DOI 10.1016/0014-2999(92)90748-S; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GRAHAM SH, 1990, NEUROSCI LETT, V110, P124, DOI 10.1016/0304-3940(90)90799-F; Green AR, 1998, PHARMACOL TOXICOL, V83, P90, DOI 10.1111/j.1600-0773.1998.tb01449.x; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HAGBERG H, 1987, NEUROSCI LETT, V78, P311, DOI 10.1016/0304-3940(87)90379-X; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412, DOI 10.1152/jn.1996.76.4.2412; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 1999, NEUROL RES, V21, P352, DOI 10.1080/01616412.1999.11740943; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; JENNETT B, 1975, LANCET, V1, P480; JOHANSEN FF, 1991, ACTA NEUROL SCAND, V84, P1; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; KANTHAN R, 1995, STROKE, V26, P870, DOI 10.1161/01.STR.26.5.870; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MASSIEU L, 1995, J NEUROCHEM, V64, P2262; Matsumoto K, 1996, J CEREBR BLOOD F MET, V16, P114, DOI 10.1097/00004647-199601000-00014; MELDRUM B, 1985, BRIT J ANAESTH, V57, P44, DOI 10.1093/bja/57.1.44; Mendelowitsch A, 1998, ACTA NEUROCHIR, V140, P349, DOI 10.1007/s007010050108; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; *MRC, 1998, NEUR AC BRAIN INJ TR; NAKATA N, 1993, STROKE, V24, P458, DOI 10.1161/01.STR.24.3.458; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; OLNEY JW, 1971, J NEUROPATH EXP NEUR, V30, P75, DOI 10.1097/00005072-197101000-00008; Orser BA, 1998, TOXICOL LETT, V101, P217, DOI 10.1016/S0378-4274(98)00188-X; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; POTASHNER SJ, 1979, J NEUROCHEM, V32, P103, DOI 10.1111/j.1471-4159.1979.tb04516.x; RAVINDRAN J, 1994, NEUROSCI LETT, V176, P209, DOI 10.1016/0304-3940(94)90084-1; Robertson CS, 1998, NEUROL RES, V20, pS91; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SHUAIB A, 1994, BRAIN RES, V666, P99, DOI 10.1016/0006-8993(94)90287-9; SHUAIB A, 1992, BRAIN RES, V590, P13, DOI 10.1016/0006-8993(92)91076-Q; SHUAIB A, 1993, EXP NEUROL, V123, P284, DOI 10.1006/exnr.1993.1160; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SMITH SE, 1994, J NEURAL TRANSM-GEN, V97, P161, DOI 10.1007/BF01277951; STERNAU LL, 1989, STROKE, V20, P281, DOI 10.1161/01.STR.20.2.281; SYDSERFF SG, 1995, BRIT J PHARMACOL, V114, P1631, DOI 10.1111/j.1476-5381.1995.tb14950.x; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Teasdale GM, 1997, ACTA NEUROCHIR, V139, P797, DOI 10.1007/BF01411397; Timmerman W, 1997, SYNAPSE, V27, P242, DOI 10.1002/(SICI)1098-2396(199711)27:3<242::AID-SYN9>3.0.CO;2-D; TIMMERMAN W, 1992, N-S ARCH PHARMACOL, V345, P661, DOI 10.1007/BF00164580; TORP R, 1993, EXP BRAIN RES, V96, P365, DOI 10.1007/BF00234106; UCHIYAMATSUYUKI Y, 1994, J NEUROCHEM, V62, P1074; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wahlgren NG, 1999, STROKE, V30, P21, DOI 10.1161/01.STR.30.1.21; WESTERINK BHC, 1989, N-S ARCH PHARMACOL, V339, P603, DOI 10.1007/BF00168650; Wilson CL, 1996, EPILEPSY RES, V26, P245, DOI 10.1016/S0920-1211(96)00057-5; YOU ZB, 1994, NEUROREPORT, V5, P2301, DOI 10.1097/00001756-199411000-00024; Zhang Jianjun, 1994, Chinese Medical Sciences Journal, V9, P225	78	51	57	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2002	72	1					99	105		10.1136/jnnp.72.1.99			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	506LD	WOS:000172973300019	11784833	Green Published, Bronze			2022-02-06	
J	Chapman, J; Korczyn, AD; Karussis, DM; Michaelson, DM				Chapman, J; Korczyn, AD; Karussis, DM; Michaelson, DM			The effects of APOE genotype on age at onset and progression of neurodegenerative diseases	NEUROLOGY			English	Article							APOLIPOPROTEIN-E EPSILON-4; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN INJURY; MOTOR-NEURON DISEASE; AMYLOID BETA-PROTEIN; E TYPE-4 ALLELE; ALZHEIMERS-DISEASE; MULTIPLE-SCLEROSIS; COGNITIVE DECLINE; E POLYMORPHISM	APOE genotype influences the age at onset of some neurodegenerative diseases such as AD and the rate of progression in others such as MS. The authors hypothesize that APOE genotype ubiquitously determines the efficacy of neuronal maintenance and repair in these diseases and that the seemingly divergent clinical effects are due to the stage of disease at which the diagnosis is made. Early diagnosis facilitates the measurement of effects on disease progression rate, whereas late diagnosis results in a marked effect of APOE genotype on disease onset.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69789 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Neurol, IL-69978 Tel Aviv, Israel; Hadassah Med Ctr, Dept Neurol, IL-91120 Jerusalem, Israel		Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69789 Tel Aviv, Israel.		Chapman, Joab/E-4598-2010; Korczyn, Amos D/C-3461-2017	Korczyn, Amos D/0000-0003-0125-2579			AlChalabi A, 1996, LANCET, V347, P159, DOI 10.1016/S0140-6736(96)90343-8; Arai H, 1997, GERONTOLOGY, V43, P2; BASUN H, 1995, NEUROSCI LETT, V183, P32, DOI 10.1016/0304-3940(94)11107-T; Basun H, 1996, STROKE, V27, P1310, DOI 10.1161/01.STR.27.8.1310; Birnbaum M, 2000, NEUROLOGY, V54, pA341; Breitner JCS, 1999, NEUROLOGY, V53, P321, DOI 10.1212/WNL.53.2.321; Buttini M, 1999, J NEUROSCI, V19, P4867; Camicioli R, 1999, DEMENT GERIATR COGN, V10, P437, DOI 10.1159/000017186; Chapman J, 1999, ARCH NEUROL-CHICAGO, V56, P1484, DOI 10.1001/archneur.56.12.1484; Chapman J, 2000, NEUROLOGY, V54, pA348; Chapman J, 1998, NEUROLOGY, V51, P548, DOI 10.1212/WNL.51.2.548; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Craft S, 1998, NEUROLOGY, V51, P149, DOI 10.1212/WNL.51.1.149; DalForno G, 1996, ARCH NEUROL-CHICAGO, V53, P345; Evangelou N, 1999, J NEUROL NEUROSUR PS, V67, P203, DOI 10.1136/jnnp.67.2.203; Fazekas F, 2000, J NEUROL NEUROSUR PS, V69, P25, DOI 10.1136/jnnp.69.1.25; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GEARING M, 1995, NEUROLOGY, V45, P1985, DOI 10.1212/WNL.45.11.1985; GomezIsla T, 1996, ANN NEUROL, V39, P62, DOI 10.1002/ana.410390110; Growdon JH, 1996, NEUROLOGY, V47, P444, DOI 10.1212/WNL.47.2.444; Harhangi BS, 2000, NEUROLOGY, V54, P1272, DOI 10.1212/WNL.54.6.1272; Helisalmi S, 1996, NEUROSCI LETT, V205, P61, DOI 10.1016/0304-3940(96)12373-9; Hogh P, 2000, MULT SCLER J, V6, P226, DOI 10.1191/135245800678827851; Holmes C, 1996, J NEUROL NEUROSUR PS, V61, P580, DOI 10.1136/jnnp.61.6.580; Hyman BT, 1996, ANN NY ACAD SCI, V802, P1, DOI 10.1111/j.1749-6632.1996.tb32592.x; Inzelberg R, 1998, ALZ DIS ASSOC DIS, V12, P45, DOI 10.1097/00002093-199803000-00007; Jonker C, 1998, ARCH NEUROL-CHICAGO, V55, P1065, DOI 10.1001/archneur.55.8.1065; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kanai M, 1999, NEUROSCI LETT, V267, P65, DOI 10.1016/S0304-3940(99)00323-7; Kehoe P, 1999, J MED GENET, V36, P108; Kurz A, 1996, NEUROLOGY, V47, P440, DOI 10.1212/WNL.47.2.440; Kurz A, 1996, J NEUROL, V243, P452, DOI 10.1007/BF00900498; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; MARTINOLI MG, 1995, ACTA NEUROPATHOL, V90, P239; Moulard B, 1996, J NEUROL SCI, V139, P34, DOI 10.1016/0022-510X(96)00085-8; MUI S, 1995, ANN NEUROL, V38, P460, DOI 10.1002/ana.410380318; Murman DL, 1996, DEMENTIA, V7, P251, DOI 10.1159/000106888; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oliveri RL, 1999, NEUROSCI LETT, V277, P83, DOI 10.1016/S0304-3940(99)00853-8; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Roses AD, 1997, ANN NY ACAD SCI, V826, P200, DOI 10.1111/j.1749-6632.1997.tb48471.x; ROSES AD, 1996, A REV MED, V47, P378; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schiefermeier M, 2000, BRAIN, V123, P585, DOI 10.1093/brain/123.3.585; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Slooter AJC, 1999, J NEUROL, V246, P304, DOI 10.1007/s004150050351; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Smith RG, 1996, LANCET, V348, P334, DOI 10.1016/S0140-6736(05)64502-3; Stern Y, 1997, ANN NEUROL, V41, P615, DOI 10.1002/ana.410410510; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Sylantiev C, 1998, NEUROLOGY, V50, pA150; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TERRY RD, 1994, PROG BRAIN RES, V101, P383; Whitehead AS, 1996, J NEUROL NEUROSUR PS, V61, P347, DOI 10.1136/jnnp.61.4.347	58	51	53	2	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	OCT 23	2001	57	8					1482	1485		10.1212/WNL.57.8.1482			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	484GH	WOS:000171681500023	11673593				2022-02-06	
J	Yan, HQ; Kline, AE; Ma, XC; Hooghe-Peters, EL; Marion, DW; Dixon, CE				Yan, HQ; Kline, AE; Ma, XC; Hooghe-Peters, EL; Marion, DW; Dixon, CE			Tyrosine hydroxylase, but not dopamine beta-hydroxylase, is increased in rat frontal cortex after traumatic brain injury	NEUROREPORT			English	Article						dopamine beta-hydroxylase (DBH); frontal cortex; immunohistochemistry; rat; traumatic brain injury (TBI); tyrosine hydroxylase (TH); Western blot	WATER MAZE PERFORMANCE; PREFRONTAL CORTEX; NORADRENALINE; INNERVATION	Chronic frontal lobe functional deficits after traumatic brain injury (TBI) may be associated with altered catecholamine systems in the frontal cortex. To test this, tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH) levels were examined by immunohistochemistry and Western blot at 1, 7, 14, and 28 days after TBI or sham surgery. No alterations in DBH levels were observed by Western blot at any time point examined, but there was a significant increase in TH expression 28 days after TBI (optical density 334 +/- 68% or 3.3-fold, ipsilateral and 218 +/- 39% or 2.2-fold. contralateral) relative to the sham controls. The increase in TH may reflect a compensatory response of dopaminergic neurons to upregulate their synthesizing capacity and increase the efficiency of dopamine neurotransmission chronically after TBI. NeuroReport 12:2323-2327 (C) 2001 Lippincott Williams & Wilkins.	Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Free Univ Brussels, Dept Pharmacol, B-1090 Brussels, Belgium		Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40125, NS 33150, NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, R01NS040125, R01NS033150, P50NS030318] Funding Source: NIH RePORTER		BERGER B, 1976, BRAIN RES, V106, P133, DOI 10.1016/0006-8993(76)90078-0; BLANCHARD V, 1995, J NEUROCHEM, V64, P1669; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FRITSCHY JM, 1990, J CHEM NEUROANAT, V3, P309; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVITT P, 1978, BRAIN RES, V139, P219, DOI 10.1016/0006-8993(78)90925-3; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; ROSIN DL, 1992, NEUROSCIENCE, V48, P831, DOI 10.1016/0306-4522(92)90271-3; Soriano MA, 1997, NEUROBIOL DIS, V4, P376, DOI 10.1006/nbdi.1997.0166; Venator DK, 1999, NEUROSCIENCE, V93, P497, DOI 10.1016/S0306-4522(99)00131-1; VERNEY C, 1993, J COMP NEUROL, V336, P331, DOI 10.1002/cne.903360303; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	20	51	56	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	AUG 8	2001	12	11					2323	2327		10.1097/00001756-200108080-00009			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	457MP	WOS:000170141600010	11496104				2022-02-06	
J	Clark, RSB; Chen, MZ; Kochanek, PM; Watkins, SC; Jin, KL; Draviam, R; Nathaniel, PD; Pinto, R; Marion, DW; Graham, SH				Clark, RSB; Chen, MZ; Kochanek, PM; Watkins, SC; Jin, KL; Draviam, R; Nathaniel, PD; Pinto, R; Marion, DW; Graham, SH			Detection of single- and double-strand DNA breaks after traumatic brain injury in rats: Comparison of in situ labeling techniques using DNA polymerase 1, the Klenow fragment of DNA polymerase 1, and terminal deoxynucleotidyl transferase	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; controlled cortical impact; Klenow; PANT; TUNEL	CORTICAL IMPACT INJURY; APOPTOTIC CELL-DEATH; CLOSED-HEAD INJURY; NEURONAL APOPTOSIS; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASE; MITOCHONDRIAL DYSFUNCTION; ENDONUCLEASE ACTIVITY; CEREBRAL-ISCHEMIA; DAMAGING AGENTS	DNA damage is a common sequela of traumatic brain injury (TBI). Available techniques for the in situ identification of DNA damage include DNA polymerase I-mediated biotin-dATP nick-translation (PANT), the Klenow fragment of DNA polymerase I-mediated biotin-dATP nick-end labeling (Klenow), and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL). While TUNEL has been widely utilized to detect primarily double-strand DNA breaks, the use of PANT to detect primarily single-strand DNA breaks and Klenow to detect both single- and double-strand DNA breaks has not been reported after TBI. Accordingly, coronal brain sections from naive rats and rats at 0, 0.5, 1, 2, 6, 24, and 72 h (n = 3-5/group) after controlled cortical impact with imposed secondary insult were processed using the PANT, Klenow, and TUNEL methods. Cells with DNA breaks were detected by PANT in the ipsilateral hemisphere as early as 0.5 h after injury and were maximal at 6 h (cortex = 66.3 +/- 15.8, dentate gyrus 58.6 +/- 12.8, CAI = 15.8 +/- 5.9, CA3 = 12.8 +/- 4.2 cells/ x 400 field, mean +/- SEM, all p < 0.05 versus naive). Cells with DNA breaks were detected by Klenow as early as 30 min and were maximal at 24 h (cortex = 56.3 +/- 14.3, dentate gyrus 78.0 +/- 16.7, CA1 = 25.8 +/- 4.7, CA3 = 29.3 +/- 15.1 cells/ x 400 field, all p < 0.05 versus naive). Cells with DNA breaks were not detected by TUNEL until 2 h and were maximal at 24 h (cortex = 47.7 +/- 21.4, dentate gyrus 63.0 +/- 11.9, CA1 = 5.6 +/- 5.4, CA3 = 6.9 +/- 3.7 cells/x400 field, cortex and dentate gyrus p < 0.05 versus naive). Dual-label immunofluorescence revealed that PANT-positive cells were predominately neurons. These data demonstrate that TBI results in extensive DNA damage, which includes both single- and double-strand breaks in injured cortex and hippocampus. The presence of multiple types of DNA breaks implicate several pathways in the evolution of DNA damage after TBI.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA		Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@anes.upmc.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021; Watkins, Simon/ABG-2590-2021	Kochanek, Patrick M/0000-0002-2627-913X; Watkins, Simon/0000-0003-4092-1552	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD028836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001946, R01NS038620, P50NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD28836] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS30318, R01 NS 38620, KO8 NS01946] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BRYANT PE, 1985, INT J RADIAT BIOL, V48, P55, DOI 10.1080/09553008514551061; CHARRIAUTMARLANGUE C, 1995, J CEREBR BLOOD F MET, V15, P385, DOI 10.1038/jcbfm.1995.48; Chavez JC, 2000, J APPL PHYSIOL, V89, P1937, DOI 10.1152/jappl.2000.89.5.1937; Chen J, 1997, J NEUROCHEM, V69, P232; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; COULTON GR, 1992, J CELL SCI, V102, P653; Didier M, 1996, J NEUROSCI, V16, P2238; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Edwards M, 1998, J NEUROSCI RES, V54, P635, DOI 10.1002/(SICI)1097-4547(19981201)54:5<635::AID-JNR8>3.3.CO;2-8; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gobbel GT, 1998, J NEUROSCI, V18, P147; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P475, DOI 10.1016/0006-291X(73)90736-5; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; Jin KL, 1999, J NEUROCHEM, V72, P1204, DOI 10.1046/j.1471-4159.1999.0721204.x; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Lan J, 2000, J NEUROCHEM, V74, P302, DOI 10.1046/j.1471-4159.2000.0740302.x; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; MacManus JP, 1999, J CEREBR BLOOD F MET, V19, P502, DOI 10.1097/00004647-199905000-00004; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; Nagayama T, 2000, J NEUROCHEM, V75, P1716, DOI 10.1046/j.1471-4159.2000.0751716.x; Park DS, 1998, J NEUROSCI, V18, P830; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Pearigen P, 1996, BRAIN RES, V725, P184; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; RADFORD IR, 1985, INT J RADIAT BIOL, V48, P45, DOI 10.1080/09553008514551051; RINK A, 1995, AM J PATHOL, V147, P1575; Rossiter JP, 1996, EXP NEUROL, V138, P33, DOI 10.1006/exnr.1996.0044; Shackelford DA, 1999, J NEUROSCI, V19, P4727; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Tagaya M, 1997, STROKE, V28, P1245, DOI 10.1161/01.STR.28.6.1245; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WARD JF, 1985, RADIAT RES, V103, P383, DOI 10.2307/3576760; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan JL, 2000, CANCER RES, V60, P4372; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	56	51	52	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2001	18	7					675	689		10.1089/089771501750357627			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	457CK	WOS:000170119400004	11497094				2022-02-06	
J	Esselman, PC; Ptacek, JT; Kowalske, K; Cromes, GF; deLateur, BJ; Engrav, LH				Esselman, PC; Ptacek, JT; Kowalske, K; Cromes, GF; deLateur, BJ; Engrav, LH			Community integration after burn injuries	JOURNAL OF BURN CARE & REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; QUESTIONNAIRE; RETURN; WORK	Evaluation of community integration is a meaningful outcome criterion after major burn injury. The Community Integration Questionnaire (CIQ) was administered to 463 individuals with major burn injuries. The CIQ results in Total, Home Integration, Social Integration, and Productivity scores. The purposes of this study were to determine change in CIQ scores over time and what burn injury and demographic factors predict CIQ scores. The CIQ scores did not change significantly from 6 to 12 to 24 months postburn injury. Home integration scores were best predicted by sex and living situation; Social Integration scores by marital status; and Productivity scores by functional outcome, burn severity, age, and preburn work factors. The data demonstrate that individuals with burn injuries have significant difficulties with community integration due to burn and nonburn related factors. CIQ scores did not improve over time but improvement may have occurred before the initial 6-month postburn injury follow-up in this study.	Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98104 USA; Bucknell Univ, Dept Psychol, Lewisburg, PA 17837 USA; Univ Texas, SW Med Ctr, Dept Phys Med & Rehabil, Dallas, TX USA; Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD USA; Univ Washington, Dept Surg, Div Plast Surg, Seattle, WA 98195 USA		Esselman, PC (corresponding author), Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA.						BLADES B, 1982, J TRAUMA, V22, P872, DOI 10.1097/00005373-198210000-00012; BLALOCK SJ, 1994, J TRAUMA, V36, P508, DOI 10.1097/00005373-199404000-00009; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; ENGRAV LH, 1987, PLAST RECONSTR SURG, V79, P927, DOI 10.1097/00006534-198706000-00012; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HAMILTON BB, 1987, REHABILITATION OUTCO, P135; HELM P A, 1992, Journal of Burn Care and Rehabilitation, V13, P53, DOI 10.1097/00004630-199201000-00012; KOWALSKE K, 1998, J BURN CARE REHABIL, V19, pS150; MUNSTER AM, 1987, J TRAUMA, V27, P425, DOI 10.1097/00005373-198704000-00015; PATTERSON DR, 1993, PSYCHOL BULL, V113, P362, DOI 10.1037/0033-2909.113.2.362; Saffle Jeffrey R., 1996, Journal of Burn Care and Rehabilitation, V17, P353, DOI 10.1097/00004630-199607000-00013; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Staley Marlys, 1996, Journal of Burn Care and Rehabilitation, V17, P362, DOI 10.1097/00004630-199607000-00014; Tanttula K, 1997, BURNS, V23, P341, DOI 10.1016/S0305-4179(97)89876-2; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; Wrigley Michael, 1995, Journal of Burn Care and Rehabilitation, V16, P445	20	51	52	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0273-8481			J BURN CARE REHABIL	J. Burn Care Rehabil.	MAY-JUN	2001	22	3					221	227		10.1097/00004630-200105000-00007			7	Emergency Medicine; Rehabilitation; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Emergency Medicine; Rehabilitation; Surgery	606TP	WOS:000178749800004	11403244				2022-02-06	
J	Lenzlinger, PM; Hans, VHJ; Joller-Jemelka, HI; Trentz, O; Morganti-Kossmann, MC; Kossmann, T				Lenzlinger, PM; Hans, VHJ; Joller-Jemelka, HI; Trentz, O; Morganti-Kossmann, MC; Kossmann, T			Markers for cell-mediated immune response are elevated in cerebrospinal fluid and serum after severe traumatic brain injury in humans	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; cellular immunity; cerebrospinal fluid; human brain injuries; immune markers; microglia activation; T-cell activation	SEVERE HEAD-INJURY; TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; SPINAL-CORD INJURY; RAT-BRAIN; BETA-2-MICROGLOBULIN LEVELS; INTERLEUKIN-2 RECEPTOR; INFLAMMATORY RESPONSE; MESSENGER-RNA; INTERFERON-GAMMA	The brain is believed to be an immunologically privileged organ, sheltered from the systemic immunological defense by the blood-brain barrier (BBB). However, there is increasing evidence for a marked inflammatory response in the brain after traumatic brain injury (TBI), Markers for cellular immune activation, neopterin, beta2-microglobulin (beta 2M), and soluble interleukin-2 receptor (sIL-2R), were measured for up to 3 weeks in cerebrospinal fluid (CSF) and serum of 41 patients with severe TBI in order to elucidate the time course and the origin of the cellular immune response following TBI. Neopterin gradually increased during the first posttraumatic week in both CSF and serum. Concentrations in CSF were generally higher than in serum, suggesting intrathecal release of this marker. beta 2M showed similar kinetics but with higher serum than CSF concentrations. Nonetheless, intrathecal release as assessed by the beta 2M index could be postulated for most of the patients. The mean levels of sIL-2R in both CSF and serum were elevated during the whole study period, serum concentrations being up to 2 x 10(4) times higher than in CSF. No significant intrathecal production of sIL-2R could be detected. The present data shows that severe TBI leads to a marked cell-mediated immune response within the brain and in the systemic circulation. In the intrathecal compartment the activated cells appear to be predominantly of the macrophage/microglia lineage, while the immune activation in the systemic circulation seems to involve mainly T-lymphocytes.	Univ Zurich Hosp, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Internal Med, Div Clin Immunol, Zurich, Switzerland; Univ Hosp, Inst Neuropathol, Bonn, Germany		Lenzlinger, PM (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			ADACHI N, 1991, EUR NEUROL, V31, P181, DOI 10.1159/000116674; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; BALOGH D, 1992, BURNS, V18, P185, DOI 10.1016/0305-4179(92)90068-6; BANATI RB, 1993, GLIA, V7, P11; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CHUGANI DC, 1991, J NEUROSCI, V11, P256; COHEN J, 1991, HUM REPROD, V6, P118, DOI 10.1093/oxfordjournals.humrep.a137244; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hagberg L, 2000, J NEUROIMMUNOL, V102, P51, DOI 10.1016/S0165-5728(99)00150-2; Hamerlinck FFV, 1999, EXP DERMATOL, V8, P167, DOI 10.1111/j.1600-0625.1999.tb00367.x; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; IMAMOTO K, 1981, GLIAL NEURONAL CEL A, V59, P125; JENNETT B, 1975, LANCET, V1, P480; KITTUR SD, 1990, ANN NEUROL, V28, P168, DOI 10.1002/ana.410280209; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOREMATSU K, 1994, J CEREBR BLOOD F MET, V14, P825, DOI 10.1038/jcbfm.1994.103; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KREUTZBERG GW, 1995, ARZNEIMITTEL-FORSCH, V45-1, P357; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAMELIN JP, 1982, CLIN IMMUNOL IMMUNOP, V24, P55, DOI 10.1016/0090-1229(82)90088-5; LINK H, 1977, SCAND J CLIN LAB INV, V37, P397, DOI 10.3109/00365517709091498; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARTINEZ M, 1993, J NEUROIMMUNOL, V48, P235, DOI 10.1016/0165-5728(93)90197-7; MATHIESEN T, 1990, J NEUROSURG, V73, P69, DOI 10.3171/jns.1990.73.1.0069; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.iy.11.040193.001333; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; NILSSON K, 1974, TRANSPLANT REV, V21, P53; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; OTT M, 1993, J NEUROL, V241, P108, DOI 10.1007/BF00869773; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1992, J NEUROTRAUM, V9, P1, DOI 10.1089/neu.1992.9.1; QUATTROCCHI KB, 1992, J NEUROSURG, V77, P694, DOI 10.3171/jns.1992.77.5.0694; REIBER H, 1980, J NEUROL, V224, P89, DOI 10.1007/BF00313347; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rostworowski M, 1997, J NEUROSCI, V17, P3664; RUBIN LA, 1990, ANN INTERN MED, V113, P619, DOI 10.7326/0003-4819-113-8-619; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Soares HD, 1995, J NEUROSCI, V15, P8223; SONNERBORG AB, 1989, AIDS, V3, P277, DOI 10.1097/00002030-198905000-00005; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TENHUNEN R, 1978, ACTA NEUROL SCAND, V58, P366; Teodorczyk-Injeyan J A, 1989, J Burn Care Rehabil, V10, P112, DOI 10.1097/00004630-198903000-00003; TEODORCZYKINJEYAN JA, 1989, CLIN IMMUNOL IMMUNOP, V51, P205, DOI 10.1016/0090-1229(89)90020-2; TEODORCZYKINJEYAN JA, 1991, CLIN EXP IMMUNOL, V85, P515; THOMAS WE, 1992, BRAIN RES REV, V17, P61; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMASHITA K, 1994, J NEUROCHEM, V63, P1042; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; Zhang ZY, 1996, J COMP NEUROL, V371, P485; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	83	51	54	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					479	489		10.1089/089771501300227288			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000001	11393251				2022-02-06	
J	Petrov, T; Rafols, JA				Petrov, T; Rafols, JA			Acute alterations of endothelin-1 and iNOS expression and control of the brain microcirculation after head trauma	NEUROLOGICAL RESEARCH			English	Article						microvessels; blood flow; autoregulation; immunocytochemistry; in situ hybridization; ultrastructure	NITRIC-OXIDE SYNTHASE; CEREBRAL BLOOD-FLOW; INJURY; LOCALIZATION; ISCHEMIA; CORTEX; MODEL; CELLS; RATS	The biosynthetic equilibrium between endothelin-l (ET-1, a vasoconstricting agent) and nitric oxide (NO, a gas with varodilating effects) is thought to play a role in the autoregulation of microvessel contractility and maintenance of adequate perfusion after traumatic brain injury. ET-1 is a constitutively expressed peptide, while the gene that encodes for the inducible nitric oxide synthase (iNOS, an enzyme responsible for the synthesis of excessive and toxic amounts of NO) is solely activated after brain injury. We employed the Marmarou acceleration impact model of brain injury (400 g from 2 m) to study the effect of closed head trauma on the rat brain microcirculation. Following head trauma we analyzed changes of cerebral cortex perfusion using laser Doppler flowmetry and ultrastructural alterations of endothelial cells. We temporally correlated these changes with the expression of ET-1 (immunocytochemistry) and iNOS (in situ hybridization) to assess the role of these vasoactive agents in vascular contractility and cortical perfusion. Cortical perfusion was reduced by similar to 50% during the second hour as compared to values during preceding time points after TBI, reached a peak minutes before 3 h, and subsequently showed a trend towards normalization. A significant reduction in the lumen of microvessels and severe distortion of their shape were observed after the fourth hour post-trauma. At the same time period ET-1 expression in endothelial cells was stronger than in microvessels of control animals. ET-I expression was further increased at 24 h after TBI. iNOS mRNA synthesis was strongly upregulated in the same cells at 4 h but was undetectable at 24 h post trauma. Our combined functional, cellular and molecular approach supports the notion that ET-1 and iNOS are expressed differentially in time within individual endothelial cells of cortical microvessels for the control of cortical blood flow following closed head trauma. This differential expression further indicates a reciprocal interaction in the synthesis of these two molecules which may underlie the control of microvascular autoregulation.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA		Petrov, T (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	tpetrov@med.wayne.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39860] Funding Source: Medline		BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CAZABON SM, 1998, INTRO BLOOD BRAIN BA, P338; CULOTTA E, 1992, SCIENCE, V258, P1862, DOI 10.1126/science.1361684; EHRENREICH H, 1995, CLEV CLIN J MED, V62, P105, DOI 10.3949/ccjm.62.2.105; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MASAKI T, 1995, ANNU REV PHARMACOL, V35, P235, DOI 10.1146/annurev.pa.35.040195.001315; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; MULDOON LL, 1991, AM J PHYSIOL, V260, pC1273, DOI 10.1152/ajpcell.1991.260.6.C1273; Petrov T., 1999, Society for Neuroscience Abstracts, V25, P822; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RADOMSKI MW, 1995, ANN MED, V27, P321, DOI 10.3109/07853899509002585; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Sharma AC, 1998, NEUROL RES, V20, P632; Strijbos PJLM, 1996, J NEUROSCI, V16, P5004; Takahashi A, 1997, ACTA NEUROPATHOL, V93, P354, DOI 10.1007/s004010050627; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; You SJ, 1997, GLIA, V20, P87, DOI 10.1002/(SICI)1098-1136(199706)20:2<87::AID-GLIA1>3.0.CO;2-1; Yuan XQ, 1991, J NEUROTRAUM, V8, P219, DOI 10.1089/neu.1991.8.219; Zimmermann M, 1998, NEUROSURGERY, V43, P863, DOI 10.1097/00006123-199810000-00083	27	51	53	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR-APR	2001	23	2-3					139	143		10.1179/016164101101198479			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	422DX	WOS:000168104200005	11320592				2022-02-06	
J	Leclerc, S; Lassonde, M; Delaney, JS; Lacroix, VJ; Johnston, KM				Leclerc, S; Lassonde, M; Delaney, JS; Lacroix, VJ; Johnston, KM			Recommendations for grading of concussion in athletes	SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; TRAUMATIC BRAIN-INJURY; CEREBRAL CONCUSSION; COLLEGE FOOTBALL; SPORTS; SYMPTOMS; PERFORMANCE; GUIDELINES; RECOVERY; DURATION	Mild sports-related concussions, in which there is no loss of consciousness, account for >75% of all sports-related brain injury. Universal agreement on concussion definition and severity grading does not exist. Grading systems represent expertise of clinicians and researchers yet scientific evidence is lacking. Most used loss of consciousness and post-traumatic amnesia as markers for grading concussion. Although in severe head injury these parameters may have been proven important for prognosis, no study has done the same for sport-related concussion. Post-concussion symptoms are often the main features to help in the diagnosis of concussion in sport. Neuropsychological testing is meant to help physicians and health professionals to have objective indices of some of the neurocognitive symptoms. It is the challenge of physicians, therapists and coaches involved in the care of athletes to know the symptoms of concussion, recognise them when they occur and apply basic, neuropsychological testing to help detect this injury. It is, therefore, recommended to be familiar with one grading system and use it consistently, even though it may not be scientifically validated. Then good clinical judgement and the ability to recognise post-concussion signs and symptoms will assure that an athlete never returns to play while symptomatic.	McGill Univ, McGill Sport Med Clin, Montreal, PQ, Canada; Univ Montreal, Neuropsychol Dept, Montreal, PQ, Canada; McGill Univ, Dept Neurosurg, McGill Univ Hlth Ctr, Montreal, PQ H3A 2T5, Canada		Leclerc, S (corresponding author), 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.						ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Barth JT, 1989, MILD HEAD INJURY, P257; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1997, CLIN J SPORT MED, V7, P83, DOI 10.1097/00042752-199704000-00001; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; GERSOFF W, 1991, SPORTS MED SCH AGE A, P45; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1992, NZ J SPORTS MED, V20, P19; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; JENNETT B, 1975, LANCET, V1, P480; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; JOHNSTON KM, IN PRESS CLIN J SPOR; Jones M, 2001, NEUROIMAGE, V13, P1002, DOI 10.1006/nimg.2001.0808; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KULUND D, 1982, INJURED ATHLETE, P225; Leblanc Kim Edward, 1999, Comprehensive Therapy, V25, P39, DOI 10.1007/BF02889833; Leclerc S., 1999, Medicine and Science in Sports and Exercise, V31, pS400, DOI 10.1097/00005768-199905001-02048; LECLERC S, 2001, PASHBY SPORT CONCUSS; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Maroon J C, 1980, Clin Neurosurg, V27, P414; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McCrory PR, 1999, BRIT J SPORT MED, V33, P297; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Meeuwisse WH, 2000, CLIN J SPORT MED, V10, P157, DOI 10.1097/00042752-200007000-00001; Mesulam M., 1985, PRINCIPLES BEHAV NEU; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OMMAYA A, 1990, SPORTS NEUROLOGY, P84; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; SAAL JA, 1991, SPORTS MED, V12, P132, DOI 10.2165/00007256-199112020-00005; Schneider R. C., 1973, HEAD NECK INJURIES F, P163; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; VEGSO JJ, 1991, ATHLETIC INJURIES HE, P225; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	63	51	51	0	14	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.		2001	31	8					629	636		10.2165/00007256-200131080-00007			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	453VM	WOS:000169937200008	11475324				2022-02-06	
J	Killgore, WDS; DellaPietra, L				Killgore, WDS; DellaPietra, L			Using the WMS-III to detect malingering: Empirical validation of the Rarely Missed Index (RMI)	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SIMULATED MEMORY IMPAIRMENT; TRAUMATIC BRAIN-INJURY; FORCED-CHOICE METHOD; REY 15-ITEM TEST; NEUROPSYCHOLOGICAL TESTS; HEAD-INJURY; DEFICITS; PERFORMANCE; HISCOCK	To detect malingering during memory assessment, we evaluated item response biases to the Logical Memory Delayed Recognition (LMDR) subtest of the WMS-III. In a sample of 50 healthy volunteers who were completely naive to the content of the Logical Memory stories, 6 LMDR items were correctly endorsed above chance probabilities. These 6 rarely missed items significantly discriminated 51 patients with neurological impairment from 36 volunteers who attempted to feign head injury and poor cognitive performance. A weighted combination of the 6 items was summed to form a single Rarely Missed Index (RMI). The RMI accurately classified over 98% of participants acid demonstrated high sensitivity (97%) and specificity (100%) in discriminating between analog malingerers and patients. Because the RMI is calculated directly from the LMDR items, it has the advantage of requiring no additional administration time or materials, and thus may serve as a quick screen for dissimulation that can be obtained without additional testing.	Harvard Univ, McLean Hosp, Sch Med, Brain Imaging Ctr,Cognit Neuroimaging Lab, Belmont, MA 02478 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA		Killgore, WDS (corresponding author), Harvard Univ, McLean Hosp, Sch Med, Brain Imaging Ctr,Cognit Neuroimaging Lab, 115 Mill St, Belmont, MA 02478 USA.			Killgore, William/0000-0002-5328-0208			ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; ELLWANGER J, 1993, J CLIN EXPT NEUROPSY, V21, P866; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; KILLGORE WDS, 1998, 18 ANN M NAT ACAD NE; Lee G. P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI DOI 10.1037/1040-3590.4.1.43; Martin RC, 1998, CLIN NEUROPSYCHOL, V12, P84, DOI 10.1076/clin.12.1.84.1722; MILLIS SR, 1995, CLIN NEUROPSYCHOL, V9, P241, DOI 10.1080/13854049508400486; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; MOSTELLER F, 1968, HDB SOCIAL PSYCHOLOG, V2, P133; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; *PSYCH CORP, 1997, WECHSL MEM SCAL; Rey A., 1964, EXAMEN CLIN PSYCHOL; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; ZISKIN J, 1988, COPING PSYCHIAT PRAC; [No title captured]	32	51	51	1	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2000	22	6					761	771					11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	403QT	WOS:000167054500005	11320434				2022-02-06	
J	Jaworski, DM				Jaworski, DM			Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to acute intracranial injury	CELL AND TISSUE RESEARCH			English	Article						glia; glioma; pituitary adenylate cyclase-activating polypeptide; reactive gliosis; receptor; vasoactive intestinal peptide; traumatic brain injury; rat (Sprague Dawley); human	VASOACTIVE-INTESTINAL-PEPTIDE; TERMINAL EXTRACELLULAR DOMAIN; HUMAN NEUROBLASTOMA-CELLS; MOLECULAR-CLONING; DIFFERENTIAL EXPRESSION; FUNCTIONAL EXPRESSION; TISSUE DISTRIBUTION; INTERLEUKIN-6 IL-6; UP-REGULATION; I RECEPTOR	Pituitary adenylate cyclase-activating polypeptide (PACAP) is a bioactive peptide with diverse activities in the nervous system. In addition to its more classic role as a neurotransmitter, PACAP functions as a neurotrophic factor. PACAP exerts these activities by binding to PACAP-selective (PAC1) or nonselective (VPAC1, VPAC2) receptors (-R). Glial cells also exhibit PACAP binding, which is associated with the increased proliferation of astrocytes. The present report demonstrates a distinct spatiotemporal regulation of PACAP, PAC1-R, VPAC1-R, and VPAC2-R expression in primary cultured rat astrocytes. To determine the role of PACAP and PAC1-R expression on glial proliferation, two in vivo models were examined - human brain tumors of glial origin and the reactive gliosis induced by a penetrating stab wound to the mature rat brain. Relative to normal human brain, PAC1-R expression is significantly upregulated in glioma, particularly oligodendrogliomas. While similar polymerase chain reaction (PCR) analysis does not detect PACAP expression, in situ hybridization studies reveal PACAP expression in a limited number of cells within the tumor. In sharp contrast, neither PACAP nor PAC1-R expression are upregulated consequent to injury. These results suggest a distinct role for PACAP and PAC1-R in glioma development and nervous system response to injury.	Univ Vermont, Coll Med, Dept Anat & Neurobiol, Burlington, VT 05405 USA		Jaworski, DM (corresponding author), Univ Vermont, Coll Med, Dept Anat & Neurobiol, Given C454, Burlington, VT 05405 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35874] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS035874] Funding Source: NIH RePORTER		ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Ashur-Fabian O, 1997, J MOL NEUROSCI, V9, P211, DOI 10.1007/BF02800503; Banks WA, 1996, ANN NY ACAD SCI, V805, P270; BARRES BA, 1991, J NEUROSCI, V11, P3685; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; Brandenburg CA, 1997, J NEUROSCI, V17, P4045; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; BRENNEMAN DE, 1987, J CELL BIOL, V104, P1603, DOI 10.1083/jcb.104.6.1603; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Ciani E, 1999, MOL BRAIN RES, V69, P290, DOI 10.1016/S0169-328X(99)00116-3; CORNELLBELL AH, 1991, CELL CALCIUM, V12, P185, DOI 10.1016/0143-4160(91)90020-F; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; DEUTSCH PJ, 1993, J NEUROSCI RES, V35, P312, DOI 10.1002/jnr.490350311; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Gillardon F, 1998, MOL BRAIN RES, V61, P207, DOI 10.1016/S0169-328X(98)00202-2; GOTTSCHALL PE, 1994, BRAIN RES, V637, P197, DOI 10.1016/0006-8993(94)91233-5; GOZES I, 1991, J PHARMACOL EXP THER, V257, P959; Grimaldi M, 1999, EUR J NEUROSCI, V11, P2767, DOI 10.1046/j.1460-9568.1999.00693.x; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HOSOYA M, 1992, BIOCHIM BIOPHYS ACTA, V1129, P199, DOI 10.1016/0167-4781(92)90488-L; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JAWORSKI DM, 1994, J CELL BIOL, V125, P495, DOI 10.1083/jcb.125.2.495; Jaworski DM, 1999, EXP NEUROL, V157, P327, DOI 10.1006/exnr.1999.7062; Larsen JO, 1997, MOL BRAIN RES, V46, P109, DOI 10.1016/S0169-328X(96)00279-3; Lu NR, 1997, P NATL ACAD SCI USA, V94, P3357, DOI 10.1073/pnas.94.7.3357; Lu NR, 1998, J NEUROSCI RES, V53, P651, DOI 10.1002/(SICI)1097-4547(19980915)53:6<651::AID-JNR3>3.0.CO;2-4; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; Ma W, 1999, NEUROSCIENCE, V93, P335, DOI 10.1016/S0306-4522(99)00145-1; MAY V, 1995, J NEUROCHEM, V65, P978; Moller K, 1997, BRAIN RES, V775, P166, DOI 10.1016/S0006-8993(97)00923-2; Moroo I, 1998, BRAIN RES, V795, P191, DOI 10.1016/S0006-8993(98)00291-1; OGI K, 1993, BIOCHEM BIOPH RES CO, V196, P1511, DOI 10.1006/bbrc.1993.2423; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROBBERECHT P, 1994, PEPTIDES, V15, P661, DOI 10.1016/0196-9781(94)90092-2; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SUZUKI N, 1994, EUR J BIOCHEM, V223, P147, DOI 10.1111/j.1432-1033.1994.tb18976.x; Tanaka J, 1997, REGUL PEPTIDES, V72, P1, DOI 10.1016/S0167-0115(97)01038-0; TATSUNO I, 1991, PEPTIDES, V12, P617, DOI 10.1016/0196-9781(91)90110-B; Tatsuno I, 1996, ANN NY ACAD SCI, V805, P482; Vertongen P, 1997, NEUROPEPTIDES, V31, P409, DOI 10.1016/S0143-4179(97)90033-0; Vertongen P, 1996, NEUROPEPTIDES, V30, P491, DOI 10.1016/S0143-4179(96)90015-3; VERTONGEN P, 1995, PEPTIDES, V16, P713, DOI 10.1016/0196-9781(95)00036-J; Vertongen P, 1996, J CELL PHYSIOL, V167, P36, DOI 10.1002/(SICI)1097-4652(199604)167:1<36::AID-JCP4>3.0.CO;2-D; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; WASCHEK JA, 1995, DEV NEUROSCI-BASEL, V17, P1, DOI 10.1159/000111268; Zhang YZ, 1998, NEUROREPORT, V9, P2833, DOI 10.1097/00001756-199808240-00027; Zhang YZ, 1996, NEUROSCIENCE, V74, P1099, DOI 10.1016/S0306-4522(96)00168-6; Zhou XR, 1999, J NEUROSCI RES, V57, P953, DOI 10.1002/(SICI)1097-4547(19990915)57:6<953::AID-JNR21>3.3.CO;2-I; Zupan V, 1998, J NEUROCHEM, V70, P2165	55	51	52	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0302-766X			CELL TISSUE RES	Cell Tissue Res.	MAY	2000	300	2					219	230		10.1007/s004410000184			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KZ	WOS:000087455800002	10867818				2022-02-06	
J	Gerring, J; Brady, K; Chen, A; Quinn, C; Herskovits, E; Bandeen-Roche, K; Denckla, MB; Bryan, RN				Gerring, J; Brady, K; Chen, A; Quinn, C; Herskovits, E; Bandeen-Roche, K; Denckla, MB; Bryan, RN			Neuroimaging variables related to development of Secondary Attention Deficit Hyperactivity Disorder after closed head injury in children and adolescents	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; INFARCTION; ADHD; RISK	Objective: To characterize children who develop Secondary Attention Deficit Hyperactivity Disorder (S-ADHD) after severe and moderate closed head injury (CHI) according to neuroimaging variables. Method: Ninety-nine children fi-om 4-19 years who suffered severe and moderate CHI were prospectively followed for a year after injury. Premorbid psychiatric status was determined by administration to the parent of a structured psychiatric interview. This interview was readministered 1 year after injury to determine the presence of post-dosed head injury S-ADHD. An MRI was performed 3 months after injury to define lesion locations and volumes. Results: A set of multiple logistic regression models determined that the odds of developing S-ADHD were 3.64 times higher among children with thalamus injury, and 3.15 times higher among children with basal ganglia injury. There was no significant difference in lesion volumes in any of the locations of interest between the group who developed S-ADHD and the group who did not develop S-ADHD. Conclusion: The data support an association between S-ADHD and injury in either or both the thalamus and basal ganglia, but they do not definitively demonstrate whether injury in either structure has an effect on S-ADHD in the absence of injury in the other.	Kennedy Krieger Res Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Sch Publ Hlth, Baltimore, MD USA; NIH, Bethesda, MD 20892 USA		Gerring, J (corresponding author), Kennedy Krieger Res Inst, 707 N Broadway, Baltimore, MD 21205 USA.		Bryan, R. Nick/P-1661-2014		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO-RR00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; ASIXAINEN I, 1996, BRAIN INJURY, V10, P883; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BIEDERMAN J, 1995, ARCH GEN PSYCHIAT, V52, P464; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Castellanos FX, 1997, CHILD ADOL PSYCH CL, V6, P383, DOI 10.1016/S1056-4993(18)30310-9; Damasio H., 1989, LESION ANAL NEUROPSY; ESLINGER PJ, 1991, NEUROLOGY, V41, P450, DOI 10.1212/WNL.41.3.450; GENTILINI M, 1987, J NEUROL NEUROSUR PS, V50, P900, DOI 10.1136/jnnp.50.7.900; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; *ISG TECHN, 1995, ALL SOFTW; Kaplan DM, 1997, PSYCHIAT RES-NEUROIM, V76, P15, DOI 10.1016/S0925-4927(97)00055-3; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Moore BD, 1996, NEUROLOGY, V46, P1660, DOI 10.1212/WNL.46.6.1660; Pagano M., 1993, PRINCIPLES BIOSTATIS; SANDSON TA, 1991, ARCH NEUROL-CHICAGO, V48, P1300, DOI 10.1001/archneur.1991.00530240106031; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; Talairach J., 1988, COPLANAR STEREOTAXIC; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; WILSON DS, 1992, EVOL ECOL, V6, P331, DOI 10.1007/BF02270969; WILSON J T L, 1990, Brain Injury, V4, P349; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	30	51	51	0	4	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2000	14	3					205	218					14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	294EE	WOS:000085897700001	10759038				2022-02-06	
J	Spikman, JM; Deelman, BG; van Zomeren, AH				Spikman, JM; Deelman, BG; van Zomeren, AH			Executive functioning, attention and frontal lesions in patients with chronic CHI	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; TRAUMATIC BRAIN INJURY; CARD SORTING TEST; STRATEGY APPLICATION; REACTION-TIME; LOBE LESIONS; PERFORMANCE; DEFICITS; RECOVERY; DAMAGE	To study the presence and nature of dysexecutive problems after CHI, a series of unstructured tasks tapping executive functioning were selected. These were administered to a group of 51 participants with CHI in the chronic stage (i.e. several years post-injury) and to 45 healthy controls. In addition, well-known structured tests of attention and planning were administered. Of the executive tasks, only the Executive Route Finding task showed a significant difference between both groups. A multivariate analysis on the attention tests showed a significant difference between groups, indicating that patients in the chronic stage still process information slower than controls. Within the patient group, patients with and without frontal focal lesions were also compared on executive and attention tests. No differences were found with respect to the latter. However, patients with frontal lesions performed worse on a measure of the Executive Route Finding task. It is concluded that patients with CHI, especially when they have frontal damage, have to rely more heavily on externally provided cues, but this dysexecutive problem can only be demonstrated in tasks that resemble daily life tasks by providing very little structure.	Groningen State Univ, Dept Clin Psychol, Groningen, Netherlands; Groningen State Univ, Dept Neuropsychol, Groningen, Netherlands; Acad Hosp Groningen, Dept Neuropsychol, Groningen, Netherlands		Spikman, JM (corresponding author), Acad Ziekenhuis, Dept Clin Psychol, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.	j.m.spikman@ppsw.rug.nl		Spikman, Jacoba/0000-0002-6477-0763			Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A.D., 1986, WORKING MEMORY; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; BROUWER WH, 1985, THESIS STATE U GRONI; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Damasio A., 1994, DESCARTES ERROR EMOT; Fuster JM., 1980, PREFRONTAL CORTEX; GOLDBERG E, 1986, J CLIN EXP NEUROPSYC, V8, P710, DOI 10.1080/01688638608405191; Grant D. A., 1948, WISCONSIN CARD SORTI; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luria A.R., 1966, HIGHER CORTICAL FUNC; Luria A.R., 1973, WORKING BRAIN; Luria AR, 1963, RESTORATION FUNCTION; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V0005, P00213, DOI DOI 10.1037/0894-4105.5.3.213; Mesulam M., 1985, PRINCIPLES BEHAV NEU; Miller E, 1970, Cortex, V6, P121; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; Salthouse T.A., 1982, ADULT COGNITION EXPT; Scheerer M., 1941, PSYCHOL MONOGRAPHS, P53; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; SPIKMAN JM, UNPUB CONSTRUCT VALI; STOLTZE A, 1991, THESIS U KONSTANZ; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; STUSS DT, 1983, LOCALIZATION NEUROPS, P429; TREXLER LE, 1988, BRAIN COGNITION, V8, P291, DOI 10.1016/0278-2626(88)90056-5; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VELTMAN JC, 1996, NEUROPSYCHOLOGY, V10, P1; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; VILKKI J, 1995, APPL NEUROPSYCHOL, V2, P1; Von Cramon DY, 1992, NEUROPSYCHOL REHABIL, P203; Walsh KW., 1991, UNDERSTANDING BRAIN; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU; [No title captured]; [No title captured]; [No title captured]	60	51	53	0	8	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2000	22	3					325	338		10.1076/1380-3395(200006)22:3;1-V;FT325			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	327UB	WOS:000087811000003	10855041				2022-02-06	
J	Taylor, HG; Klein, N; Minich, NM; Hack, M				Taylor, HG; Klein, N; Minich, NM; Hack, M			Verbal memory deficits in children with less than 750 g birth weight	CHILD NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; SCHOOL-AGE OUTCOMES; INTRAVENTRICULAR HEMORRHAGE; PRETERM INFANTS; LEARNING TEST; INTRACRANIAL HEMORRHAGE; STANDARDIZATION SAMPLE; COGNITIVE-ABILITIES; PERFORMANCE; ACHIEVEMENT	Numerous studies have documented memory deficits in very low birthweight (VLBW, < 1500 g) children, yet we know little about the nature of these memory problems. To clarify memory sequelae and examine memory deficits in relation to the degree of low birth weight, we administered the California Verbal Learning Test-Children's Version (CVLT-C) to a regional sample of 57 < 750 g birthweight children and to groups of 53 750-1499 g birthweight children and 49 term-born controls. Group comparisons revealed significant differences between the < 750 g birthweight group and term-born children on measures of list learning, delayed recall, and inaccurate recall. In addition, the percentage improvement in correct recognitions relative to long-term delayed recall was greater in the < 750 g group than in the term-born controls. Similar differences were observed between VLBW children with and without abnormal neonatal cerebral ultrasounds (high-and low-risk groups). Differences in learning rate between the VLBW and term-born groups, and between high-and low-risk VLBW children, were evident even when vocabulary skill was covaried or when children with neurosensory deficits or IQ < 80 were excluded from analysis. The findings document deficits in verbal memory in the subset of VLBW children at greatest biological risk, and suggest that acquisition processes are selectively impaired.	Case Western Reserve Univ, Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Cleveland State Univ, Dept Educ, Cleveland, OH 44115 USA		Taylor, HG (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.	dsg5@po.cwru.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD26554] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD026554] Funding Source: NIH RePORTER		BAKER LL, 1988, RADIOLOGY, V168, P809, DOI 10.1148/radiology.168.3.3406411; Breslau N, 1996, BIOL PSYCHIAT, V40, P389, DOI 10.1016/0006-3223(95)00399-1; CHAPMAN LJ, 1978, J PSYCHIAT RES, V14, P303, DOI 10.1016/0022-3956(78)90034-1; CIONI G, 1992, BEHAV BRAIN RES, V49, P7, DOI 10.1016/S0166-4328(05)80190-1; Dammann O, 1996, DEV MED CHILD NEUROL, V38, P97; Delis DC., 1994, CALIFORNIA VERBAL LE; Donders J, 1999, DEV NEUROPSYCHOL, V15, P395, DOI 10.1080/87565649909540757; Donders J, 1999, J INT NEUROPSYCH SOC, V5, P26, DOI 10.1017/S1355617799511041; Fletcher JM, 1997, DEV MED CHILD NEUROL, V39, P596; FORD LM, 1989, CLIN PEDIATR, V28, P302, DOI 10.1177/000992288902800702; FRISK V, 1994, DEV NEUROPSYCHOL, V10, P313, DOI 10.1080/87565649409540586; GADIAN DG, IN PRESS BRAIN; HACK M, 1992, J DEV BEHAV PEDIATR, V13, P412; HACK M, 1995, FUTURE CHILD, V5, P176, DOI 10.2307/1602514; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; Hall A, 1995, DEV MED CHILD NEUROL, V37, P1037; HERRGARD E, 1993, DEV MED CHILD NEUROL, V35, P1083; HOFFMAN N, IN PRESS ARCH CLIN N; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; KAUFMAN AS, 1988, J CLIN CHILD PSYCHOL, V17, P359, DOI 10.1207/s15374424jccp1704_10; KLEBANOV PK, 1994, J DEV BEHAV PEDIATR, V15, P248, DOI 10.1097/00004703-199408000-00005; KLEIN N, 1985, PEDIATRICS, V75, P531; KLEIN NK, 1989, J DEV BEHAV PEDIATR, V10, P32; LANDRY SH, 1993, J CLIN EXP NEUROPSYC, V15, P205, DOI 10.1080/01688639308402558; Lou HC, 1996, ACTA PAEDIATR, V85, P1266, DOI 10.1111/j.1651-2227.1996.tb13909.x; Maalouf EF, 1999, J PEDIATR-US, V135, P351, DOI 10.1016/S0022-3476(99)70133-2; MASSMAN PJ, 1990, J CLIN EXP NEUROPSYC, V12, P729, DOI 10.1080/01688639008401015; Mattson SN, 1996, ALCOHOL CLIN EXP RES, V20, P810, DOI 10.1111/j.1530-0277.1996.tb05256.x; Mattson SN, 1999, J INT NEUROPSYCH SOC, V5, P462, DOI 10.1017/S1355617799555082; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PENNINGTON BF, 1994, MAC FDN MEN, P243; RAZ S, 1995, NEUROPSYCHOLOGY, V9, P91, DOI 10.1037/0894-4105.9.1.91; RICKARDS AL, 1993, J DEV BEHAV PEDIATR, V14, P363; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; ROSS G, 1991, PEDIATRICS, V88, P1125; Ross G, 1996, BRAIN COGNITION, V32, P1, DOI 10.1006/brcg.1996.0054; SAIGAL S, 1990, J PEDIATR-US, V116, P409, DOI 10.1016/S0022-3476(05)82835-5; Sattler JM, 1992, ASSESSMENT CHILDREN, Vthird; SELZER SC, 1992, J PEDIATR PSYCHOL, V17, P407, DOI 10.1093/jpepsy/17.4.407; Squire Larry R., 1995, P825; Stewart AL, 1999, LANCET, V353, P1653, DOI 10.1016/S0140-6736(98)07130-X; Taylor HG, 1998, J DEV BEHAV PEDIATR, V19, P235; TAYLOR HG, IN PRESS DEV NEUROPS; TAYLOR HG, IN PRESS CHILD DEV; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; WECHSLER D, 1991, WISC, V3; Whitaker AH, 1996, PEDIATRICS, V98, P719; Whitfield MF, 1997, ARCH DIS CHILD-FETAL, V77, pF85, DOI 10.1136/fn.77.2.F85; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; WOLKE D, 1994, EUR J PEDIATR, V153, P906, DOI 10.1007/s004310050239; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YEATES KO, 1995, J PEDIATR PSYCHOL, V20, P801, DOI 10.1093/jpepsy/20.6.801; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555; [No title captured]	54	51	52	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.		2000	6	1					49	63		10.1076/0929-7049(200003)6:1;1-B;FT049			15	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	353BN	WOS:000089254000005	10980668				2022-02-06	
J	Beaumont, A; Marmarou, A; Czigner, A; Yamamoto, M; Demetriadou, K; Shirotani, T; Marmarou, C; Dunbar, J				Beaumont, A; Marmarou, A; Czigner, A; Yamamoto, M; Demetriadou, K; Shirotani, T; Marmarou, C; Dunbar, J			The impact-acceleration model of head injury: Injury severity predicts motor and cognitive performance after trauma	NEUROLOGICAL RESEARCH			English	Article						Impact Acceleration Model; traumatic brain injury; diffuse axonal injury; secondary insult; neuropsychological tests; motor deficits; cognitive deficits	CONTROLLED CORTICAL IMPACT; CONCUSSIVE BRAIN INJURY; RATING-SCALE; RATS; RECOVERY; DEFICITS; IMPAIRMENT; SEQUELAE; MODERATE; MEMORY	This study examines neuropsychological dysfunction after varying severities of the Impact Acceleration Model of diffuse traumatic brain injury. Adult rats (340 g-400 g) were divided into five groups, and exposed to varying degrees of Impact Acceleration Injury (1 m, 2 m, 2.1 m/500 g and second insult). After injury, animals were allowed to recover; acute neurological reflexes, beam walk score, beam balance score, inclined plane store, and Morris Water Maze score were then assessed at multiple time points. Injury of all severities caused significant motor and cognitive deficits. With milder injuries these effects were transient; however, with more severe injuries no recovery in function was seen. The addition of hypoxia and hypotension made a moderate injury worse than a severe injury. The acute neurological reflexes, the beam balance test and the inclined plane test distinguished between the more severely injured groups, but were affected less by mild injury. The beam walk test was sensitive to mild injury, but appeared unable to distinguish between the severe groups. The Morris Water Maze was sensitive for all injury groups, bur appeared to adopt a different response profile with secondary insult. This study has for the first time characterized the degree of motor and cognitive deficits in rodents exposed to differing severities of impact Acceleration Injury. These data confirm that the tests considered, and the Injury Model used provide a useful system for the consideration of potential therapies which might ameliorate neuropsychological deficits in diffuse brain injury.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980508,Sanger Hall,Room 8004,1101 E Marshall, Richmond, VA 23298 USA.		Beaumont, Andrew/AAJ-7457-2020				Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Golden CJ, 1985, LURIA NEBRASKA NEURO; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1988, BRAIN INJURY, V2, P51; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1985, STATUS REPORT CENTRA, P281; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARION DW, 1993, J NEUROSURG, V78, pA347; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Miller JR, 1989, MILD MODERATE HEAD I, P125; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHIROTANI T, 1994, INTRACRANIAL PRESSUR, V9, P409; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487	38	51	54	0	11	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	DEC	1999	21	8					742	754		10.1080/01616412.1999.11741008			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	260KA	WOS:000083947500006	10596383				2022-02-06	
J	Spikman, JM; Timmerman, ME; van Zomeren, AH; Deelman, BG				Spikman, JM; Timmerman, ME; van Zomeren, AH; Deelman, BG			Recovery versus retest effects in attention after closed head injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							DEFICITS; PERFORMANCE; MEMORY; TESTS	Recovery in 60 patients with a closed-head injury (CHI) in the first year posttrauma was assessed repeatedly with a series of attention tests. A matched group of healthy subjects was tested at the same intervals to allow us to control for practice effects. The results of a multilevel analysis for longitudinal data show retest effects in all but one of the tests. Patients performed more poorly on all tests, but their results on each test appeared to show recovery over time. The indicator of recovery was an improvement in test performance that was greater than the retest effect shown by the controls. On most tests, the performance of the more severely injured patients was initially worse, but showed more recovery over time. Test results differed with respect to changes over time, sensitivity to severity of injury, and subject specific characteristics Like age and vocational level. Recovery rate was not related to age or vocational status. Despite their recovery, the patient group was still impaired 1 year posttrauma on all tests sensitive to mental slowness. Outcome after 1 year, scored on a modified Glasgow Outcome Scale, was predicted to a small extent by PTA duration and initial performance on the RT-Distraction task. Return to work 2 to 5 years posttrauma was predicted by initial performance and improvement over time on the Stroop Color Word Test.	Acad Ziekenhuis, Dept Neuropsychol, NL-9713 GZ Groningen, Netherlands; Groningen State Univ, Dept Neuropsychol, Groningen, Netherlands; Groningen State Univ, Heymans Inst Psychol, Groningen, Netherlands		Spikman, JM (corresponding author), Acad Ziekenhuis, Dept Neuropsychol, Poortweg 4,Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.			Spikman, Jacoba/0000-0002-6477-0763			BERG IJ, 1993, THESIS STATE U GRONI; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; BROUWER WH, 1985, THESIS STATE U GRONI; Bryk, 1992, HIERARCHICAL LINEAR; BRYK AS, 1987, PSYCHOL BULL, V101, P147, DOI 10.1037/0033-2909.101.1.147; DEELMAN BG, 1990, TRAUMATIC BRAIN INJU; DEJONG P, 1991, THESIS FREE U AMSTER; DELAND N, 1995, THESIS U MONTREAL; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; FEINSTEIN A, 1994, J CLIN EXP NEUROPSYC, V16, P436, DOI 10.1080/01688639408402654; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Goldstein H., 1995, MULTILEVEL STAT MODE; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HAYS WL, 1988, STATISTICS; Heaton R.K., 1981, WISCONSIN CARD SORTI; JENNETT B, 1975, LANCET, V1, P480; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luria A.R., 1966, HIGHER CORTICAL FUNC; Luria A.R., 1973, WORKING BRAIN; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RASBASH J, 1995, MLN COMMAND REFERENC; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Salthouse T.A., 1982, ADULT COGNITION EXPT; SCHACTER DL, 1986, J CLIN EXP NEUROPSYC, V8, P727, DOI 10.1080/01688638608405192; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Snijders T, 1996, QUAL QUANT, V30, P405; Snijders T. A., 2011, MULTILEVEL ANAL INTR; SPIKMAN JM, 1995, J CLIN EXP NEUROPSYC, V17, P29, DOI 10.1080/13803399508406578; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; SPIKMAN JM, 1999, UNPUB CONSTRUCT VALI; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1983, LOCALIZATION NEUROPS, P429; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; VAKIL E, 1994, J CLIN EXP NEUROPSYC, V16, P539, DOI 10.1080/01688639408402665; VANDERNAALT J, J NEUROLOGY NEUROSUR, V62; VANZOMEREN AH, 1981, THESIS STATE U GRONI; Verhage F, 1964, INTELLIGENTIE LEEFTI; Zomeren A.H., 1994, CLIN NEUROPSYCHOLOGY; ZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452; ZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995; [No title captured]; [No title captured]; [No title captured]	51	51	51	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1999	21	5					585	605		10.1076/jcen.21.5.585.874			21	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	264XG	WOS:000084207900001	10572280				2022-02-06	
J	Lomnitski, L; Chapman, S; Hochman, A; Kohen, R; Shohami, E; Chen, Y; Trembovler, V; Michaelson, DM				Lomnitski, L; Chapman, S; Hochman, A; Kohen, R; Shohami, E; Chen, Y; Trembovler, V; Michaelson, DM			Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						Alzheimer's disease; apolipoprotein E; oxidation stress; antioxidant; mouse; brain	CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; BRAIN; GLUTATHIONE; RAT; ALPHA; ACID; PEROXIDASE	Apolipoprotein E deficient mice have distinct memory deficits and neurochemical derangements and their recovery from closed head injury is impaired. In the present study, we examined the possibility that the neuronal derangements of apolipoprotein E deficient mice are associated with oxidative stress, which in turn affects their ability to recover from close head injury. It was found that brain phospholipid levels in apolipoprotein E deficient mice are lower than those of the controls (55 +/- 15% of control, P < 0.01), that the cholesterol levels of the two mice groups are similar and that the levels of conjugated dienes of the apolipoprotein E deficient mice are higher than those of control mice (132 +/- 15% of P < 0.01). Brains of apolipoprotein E deficient mice had higher Mn-superoxide dismutase (134 +/- 7%), catalase (122 +/- 8%) and glutathione reductase (167 +/- 7%) activities than control (P < 0.01), whereas glutathione peroxidase activity and the levels of reduced glutathione and ascorbic acid were similar in the two mouse groups, Closed head injury increased catalase and glutathione peroxidase activities in both mouse groups, whereas glutathione reductase increased only in control mice. The superoxide dismutase activity was unaffected in both groups. These findings suggest that the antioxidative metabolism of apolipoprotein E deficient mice is altered both prior to and following head injury and that antioxidative mechanisms may play a role in mediating the neuronal maintenance and repair derangements of the apolipoprotein E deficient mice. (C) 1999 Elsevier Science B.V. All rights reserved.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Dept Pharm, Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel		Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	dmichael@ccsg.tau.ac.il					ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749; Aviram M, 1996, EUR J CLIN CHEM CLIN, V34, P599; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; BENBASSAT A, 1980, BIOCHIM BIOPHYS ACTA, V611, P1, DOI 10.1016/0005-2744(80)90036-4; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BLIGH BG, 1959, CAN J BIOCH PHYSL, V37, P497; BOCHICCHIO M, 1990, INTENS CARE MED, V16, P444, DOI 10.1007/BF01711223; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Chapman S, 1998, J NEUROCHEM, V70, P708; Chen L, 1994, Int J Neurosci, V75, P83; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHN Y, 1997, NEUROSCIENCE, V30, P1255; Fiske CH, 1925, J BIOL CHEM, V66, P375; Flohe L., 1984, METHOD ENZYMOL, V105, P115; GENIS I, 1995, NEUROSCI LETT, V199, P5, DOI 10.1016/0304-3940(95)12007-Q; GINSBERG L, 1993, MOL CHEM NEUROPATHOL, V19, P37, DOI 10.1007/BF03160167; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAJIMOHAMMADREZ.I, 1992, NEUROSCI LETT, V112, P333; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HOCHMAN A, 1987, J BIOL CHEM, V262, P6871; Hochman A, 1998, J NEUROCHEM, V71, P741; Hussain S, 1995, INT J DEV NEUROSCI, V13, P811, DOI 10.1016/0736-5748(95)00071-2; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; Johansson K, 1997, LANCET, V349, P1143, DOI 10.1016/S0140-6736(97)24016-X; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Mahley RW, 1996, ANN NY ACAD SCI, V777, P139, DOI 10.1111/j.1749-6632.1996.tb34412.x; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MOTCHNIK PA, 1994, METHOD ENZYMOL, V234, P269; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Otero G, 1996, MOL CARCINOGEN, V17, P175, DOI 10.1002/(SICI)1098-2744(199612)17:4<175::AID-MC1>3.0.CO;2-D; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; PAPPOLLA MA, 1992, AM J PATHOL, V140, P621; PATTICHIS K, 1994, ANAL BIOCHEM, V221, P428, DOI 10.1006/abio.1994.1441; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; RECKNAGEL RO, 1984, METHOD ENZYMOL, V105, P331; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Tayag EC, 1996, BRAIN RES, V733, P287, DOI 10.1016/0006-8993(96)00669-5; VIANI P, 1991, J NEUROCHEM, V56, P253, DOI 10.1111/j.1471-4159.1991.tb02589.x; Wells K, 1995, NEUROCHEM RES, V20, P1329, DOI 10.1007/BF00992508	47	51	52	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439	0006-3002		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	MAR 30	1999	1453	3					359	368		10.1016/S0925-4439(99)00010-1			10	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Cell Biology	185BX	WOS:000079649200006	10101254	Bronze			2022-02-06	
J	Ray, SK; Shields, DC; Saido, TC; Matzelle, DC; Wilford, GG; Hogan, EL; Banik, NL				Ray, SK; Shields, DC; Saido, TC; Matzelle, DC; Wilford, GG; Hogan, EL; Banik, NL			Calpain activity and translational expression increased in spinal cord injury	BRAIN RESEARCH			English	Article						calpain; calpastatin; calcium; neutral proteinase; spinal cord injury	ACTIVATED NEUTRAL PROTEINASE; TRAUMATIC BRAIN INJURY; DEGRADATION; RAT; PROTEOLYSIS; INHIBITOR	Calpain, a calcium-activated neutral proteinase, has been implicated in myelin and cytoskeletal protein degradation following spinal cord injury. In the present study, we examined the activity and transcriptional expression of calpain in spinal cord injury lesions via Western blotting analysis and RT-PCR, respectively. No increases in transcriptional expression of calpain or calpastatin, the endogenous inhibitor, were observed in the lesion at 1, 4, 24, and 72 h following injury. However, calpain activity (as measured by calpain-specific degradation of the endogenous substrate fodrin) was marginally increased at 4 h and significantly increased by 129.8% at 48 h compared to sham controls after injury. Calpain translational expression was localized in injured spinal cords using double immunofluorescent labeling which revealed increased calpain expression in astrocytes compared to sham controls. These results suggest that calpain produced by astrocytes located in or near spinal cord injury lesions may participate in myelin/axon degeneration following injury. (C) 1999 Published by Elsevier Science B.V. All rights reserved.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA; RIKEN, Brain Sci Inst, Wako, Saitama 3500198, Japan		Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol, 171 Ashley Ave, Charleston, SC 29425 USA.	baniknl@musc.edu	Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-31622] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031622] Funding Source: NIH RePORTER		Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; BALENTINE JD, 1985, TRAUMA CENTRAL NERVO, P285; BANAYSCHWARTZ M, 1994, NEUROCHEM RES, V19, P563, DOI 10.1007/BF00971331; Banik N, 1997, J NEUROCHEM, V69, pS144; Banik Naren L., 1992, P571; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P92; CHAKRABARTI AK, 1988, J NEUROSCI RES, V20, P351, DOI 10.1002/jnr.490200309; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HATA A, 1989, J BIOL CHEM, V264, P6404; HOGAN EL, 1985, HDB NEUROCHEMISTRY, V10, P285; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIXON RA, 1986, J NEUROSCI, V6, P1264; Perot P L Jr, 1987, Cent Nerv Syst Trauma, V4, P149; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Shields DC, 1998, BRAIN RES, V794, P68, DOI 10.1016/S0006-8993(98)00193-0; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Yano T, 1997, EUR J BIOCHEM, V245, P260, DOI 10.1111/j.1432-1033.1997.00260.x; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1	33	51	52	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JAN 23	1999	816	2					375	380		10.1016/S0006-8993(98)01128-7			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	158WH	WOS:000078140100013	9878837				2022-02-06	
S	Bullock, MR; Merchant, RE; Carmack, CA; Doppenberg, E; Shah, AK; Wilner, KD; Ko, G; Williams, SA		Trembly, B; Slikker, W		Bullock, MR; Merchant, RE; Carmack, CA; Doppenberg, E; Shah, AK; Wilner, KD; Ko, G; Williams, SA			An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage	NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	4th International Conference on Neuroprotective Agents - Clinical and Experimental Aspects	NOV 15-19, 1998	ANNAPOLIS, MARYLAND	US FDA, Natl Ctr Toxicol Res, Dept Vet Affairs Med Ctr			EXPERIMENTAL BRAIN INJURY; REGIONAL CEREBRAL EDEMA; ANTAGONIST; RAT; CP101,606; CP-98,113; DAMAGE	CP-101,606 is a postsynaptic antagonist of N-methyl-D-aspartate (NMDA) receptors bearing the NR2B subunit, When administered intravenously (i.v.), it decreases the effects of traumatic brain injury (TBI) and focal ischemia in animal models. Therapeutic plasma concentrations (200 ng/ml) in animals, have been well tolerated in healthy human volunteers. The purpose of the present dose escalation study was to assess the safety, tolerability, and pharmacokinetics of CP-101,606 in subjects who had suffered either an acute severe TBI (Glasgow Coma Scale 3-8) or spontaneous intracerebral hemorrhage, Thirty patients, 20 with a TBI and 10 with a stroke, were enrolled in the trial and began receiving an i.v. infusion of CP-101,606 for 2 hours, 24 hours, or 72 hours within 12 hours of brain injury. For the first two hours,the drug was given a rate of 0.75 mg/kg/hr and then stopped (n = 17) dr continued for 22 (n = 2) or 70 hours (n = 11) at 0.37 mg/kg/hr, Plasma and cerebrospinal fluid (CSF) were collected at serial times during and after treatment. There were no consistent changes in blood pressure or pulse nor any clinically significant hematological or electrocardiogram (ECG) abnormalities attributable to CP-101,606, No adverse events or behavioral changes were considered to be related to the drug. Plasma concentrations of CP-101,606 over 200 ng/ml were rapidly achieved in the blood and CSF within two hours and were sustained there as long as the drug was infused. CSF concentrations were slightly higher than that in plasma by the end of infusion suggesting good penetration of CP-101,606 into the CSF, Outcome in the severe TBI patients, as measured by the Glasgow Outcome Score at six months, suggested that a two-hour infusion yielded a range of scores similar to contemporary patients with a severe TBI treated at our hospital while the outcomes of the patients treated with either a 24- or 72-hour infusion were better on average. Thus, these results indicate that CP-101,606 infused for up to 72 hours is well tolerated, penetrates the CSF and brain, and may improve outcome in the brain-injured patient.	Virginia Commonwealth Univ, Div Neurosurg, MCV Stn, Med Coll Virginia, Richmond, VA 23298 USA; Pfizer Inc, Div Cent Res, Groton, CT 06340 USA		Merchant, RE (corresponding author), Virginia Commonwealth Univ, Div Neurosurg, MCV Stn, Med Coll Virginia, Box 980631, Richmond, VA 23298 USA.						Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Di X, 1997, STROKE, V28, P2244, DOI 10.1161/01.STR.28.11.2244; Menniti F, 1997, EUR J PHARMACOL, V331, P117, DOI 10.1016/S0014-2999(97)10092-9; MENNITI FS, 1998, UNPUB EUR J PHARM; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; PAGNOZZI MJ, 1995, SOC NEUR ABSTR 1 S, V21; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409	8	51	51	0	1	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-222-3	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	890						51	58		10.1111/j.1749-6632.1999.tb07980.x			8	Biochemistry & Molecular Biology; Multidisciplinary Sciences; Clinical Neurology; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BP50F	WOS:000085330700005	10668413				2022-02-06	
J	Berrouane, Y; Daudenthun, I; Riegel, B; Emery, MN; Martin, G; Krivosic, R; Grandbastien, B				Berrouane, Y; Daudenthun, I; Riegel, B; Emery, MN; Martin, G; Krivosic, R; Grandbastien, B			Early onset pneumonia in neurosurgical intensive care unit patients	JOURNAL OF HOSPITAL INFECTION			English	Article						neuro-surgical intensive care unit; nosocomial pneumonia; early onset pneumonia; incidence	RISK-FACTORS; NOSOCOMIAL PNEUMONIA; VENTILATED PATIENTS; TRAUMA PATIENTS; CONSCIOUSNESS; MULTICENTER; PROGNOSIS	To investigate early onset pneumonia in a neurosurgical intensive care unit, we studied a cohort of patients over a 13-month period and compared neurotrauma (T) with non-neurotrauma (NT) patients. Data were abstracted from the infection surveillance database. Five hundred and sixty-five adults were hospitalized in the neurosurgical intensive care unit. 57.9% had trauma and 129 patients developed 152 episodes of pneumonia. Incidence rates, restricted to the 129 first episodes of pneumonia, were 20.1 versus 15.7/1000 patient days and 34.2 versus 27.9/1000 ventilation days, in the T and NT groups respectively. In both groups, the distribution of risk stratified by hospital days was bimodal, being highest during the first three days. However, the risk was higher for T patients (at day 3, 20/1000 ventilation days versus 10.2/1000 ventilation days). The daily risk peaked again at days 5 and 6, and thereafter remained low. Pneumonia occurring within the first three days, or early onset pneumonia (EOP), was associated with trauma (P=0.036) and, in the NT group only, with a Glasgow coma scale score lower than 9 (P=0.062). EOP was caused by Staphylococcus aureus (33%), Haemophilus spp. (23%), other Gram-positive cocci (22%), and other Gram-negative bacilli (GNB) (19%); whereas after the third day GNB other than Haemophilus spp. accounted for 45.4% of isolates (P=0.11). This large series confirms the high incidence of EOP in neurosurgical intensive care units, particularly among trauma patients, in relation to risk factors different from those seen in other intensive care patients. Further studies are needed to elaborate specific preventive measures during early care.	Ctr Hosp Reg Univ Lille, Lab Bacteriol Hyg, Lille, France; Ctr Hosp Reg Univ Lille, Lab Anesthesie Reanimat Chirurg 1, Lille, France; Ctr Hosp Reg Univ Lille, Serv Epidemiol & Sante Publ, Lille, France; Ctr Hosp Reg Univ Lille, Unite Lutte Contre Infect Nosocomiales, Lille, France		Berrouane, Y (corresponding author), CHRU Lille, Hop A Calmette, Lab Bacteriol Hyg, Bd Du Pr J Leclercq, F-59037 Lille, France.						ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; BARREIRO B, 1995, EUR RESPIR J, V8, P1543; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; *CONS SUP HYG PUBL, 1992, B EPIDEMIOLOGIQUE HE, P11; FREEMAN J, 1996, HOSP EPIDEMIOLOGY IN, P12; GARIBALDI RA, 1981, AM J MED, V70, P677, DOI 10.1016/0002-9343(81)90595-7; GARNER JS, 1988, AM J INFECT CONTROL, V16, P28; George DL, 1996, HOSP EPIDEMIOLOGY IN, P175; GROSS PA, 1991, AM J MED, V91, pS16, DOI 10.1016/0002-9343(91)90338-X; HANSON LC, 1992, AM J MED, V92, P161, DOI 10.1016/0002-9343(92)90107-M; HONGHAO A, 1992, AM REV RESPIR DIS, V146, P290; INGLIS TJJ, 1993, J HOSP INFECT, V25, P207, DOI 10.1016/0195-6701(93)90039-3; JARVIS WR, 1991, AM J MED S3B, V91, P185; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; LANGER M, 1987, INTENS CARE MED, V13, P342; LEGALL JR, 1984, CRIT CARE MED, V12, P975; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; MEERT KL, 1995, CRIT CARE MED, V23, P822, DOI 10.1097/00003246-199505000-00008; RELLO J, 1992, CHEST, V102, P525, DOI 10.1378/chest.102.2.525; TEASDALE G, 1974, LANCET, V2, P81; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523	24	51	54	0	0	W B SAUNDERS CO LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0195-6701			J HOSP INFECT	J. Hosp. Infect.	DEC	1998	40	4					275	280		10.1016/S0195-6701(98)90303-6			6	Public, Environmental & Occupational Health; Infectious Diseases	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Infectious Diseases	147CR	WOS:000077470800003	9868618				2022-02-06	
J	Chae, J; Hart, R				Chae, J; Hart, R			Comparison of discomfort associated with surface and percutaneous intramuscular electrical stimulation for persons with chronic hemiplegia	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						pain; neuromuscular stimulation; hemiplegia	FUNCTIONAL NEUROMUSCULAR STIMULATION; UPPER-EXTREMITY FNS; HEMIPARETIC PATIENTS; STROKE PATIENTS; GRASP SYNTHESIS; MOTOR CONTROL; MESH-GLOVE; HUMAN-SKIN; PAIN; FIBERS	Neuromuscular stimulation may facilitate motor recovery after stroke or brain injury, reduce shoulder pain associated with hemiplegia, and reduce cerebral spasticity However, the discomfort of surface neuromuscular stimulation significantly limits the clinical implementation of this modality for persons with hemiplegia, The study contained herein tests the hypothesis that stroke and brain injury survivors with chronic hemiplegia (>6 mo) and intact sensation tolerate percutaneous intramuscular stimulation better than surface stimulation. Four stroke and two traumatic brain injury survivors participated in the study contained within this article. Each subject received three pairs of percutaneous and surface stimulations of the paretic finger extensors. The order of the type of stimulation within each pair was randomly assigned. The stimulation parameters for each type of stimulation were normalized to produce the same torque at the metacarpophalangeal joint. Subjects rated their perceived level of discomfort using a 10-cm visual analog scale and the McGill Pain Questionnaire. A blinded evaluator administered the pain measures, Percutaneous stimulation was associated with significantly lower discomfort as reflected by the visual analog scale (0.74 v 3.3; 95% confidence interval of difference, -3.84, -1.28). The McGill Pain Questionnaire produced similar results with percutaneous stimulation associated with a significantly fewer number of words chosen to describe the discomfort (0.87 v 3.30; 95% confidence interval of difference, -3.50, -1.30) and significantly lower Pain Rating index (1.47 v 6.27; 95% confidence interval of difference, -7.77, -1.83). Data suggest that percutaneous intramuscular stimulation is significantly better tolerated than surface stimulation and that percutaneous stimulation may enhance patient compliance with neuromuscular stimulation treatments.	Case Western Reserve Univ, Metrohlth Med Ctr, Ctr Phys Med & Rehabil, Cleveland, OH 44109 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Dept Phys Med & Rehabil, Cleveland, OH 44109 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Dept Orthoped, Cleveland, OH 44109 USA; Vet Affairs Med Ctr, Cleveland, OH USA		Chae, J (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Ctr Phys Med & Rehabil, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K12 HD01097-01A1] Funding Source: Medline		ADRIAENSEN H, 1983, J NEUROPHYSIOL, V49, P111, DOI 10.1152/jn.1983.49.1.111; ALFIERI V, 1982, SCAND J REHABIL MED, V14, P177; BAKER LL, 1986, PHYS THER, V66, P1930, DOI 10.1093/ptj/66.12.1930; BAKER LL, 1988, CLIN ORTHOP RELAT R, P75; BAKER LL, 1979, PHYS THER, V59, P1495, DOI 10.1093/ptj/59.12.1495; BESSOU P, 1969, J NEUROPHYSIOL, V32, P1025, DOI 10.1152/jn.1969.32.6.1025; BOWMAN BR, 1979, ARCH PHYS MED REHAB, V60, P497; BUCKETT JR, 1988, IEEE T BIO-MED ENG, V35, P897, DOI 10.1109/10.8669; CHAE J, 1998, REHABILITATION MED P, P611; DELITTO A, 1986, PHYS THER, V66, P1704, DOI 10.1093/ptj/66.11.1704; Dimitrijevic MM, 1996, ARCH PHYS MED REHAB, V77, P252; DIMITRIJEVIC MM, 1994, SCAND J REHABIL MED, V26, P187; DUBNER R, 1977, PAIN TRIGEMINAL REGI, P57; FAGHRI PD, 1994, ARCH PHYS MED REHAB, V75, P73; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; GEORGOPOULOS AP, 1977, BRAIN RES, V128, P547, DOI 10.1016/0006-8993(77)90181-0; Glanz M, 1996, ARCH PHYS MED REHAB, V77, P549, DOI 10.1016/S0003-9993(96)90293-2; GRACANIN F, 1975, ARCH PHYS MED REHAB, V56, P243; HALLIN RG, 1982, J NEUROL NEUROSUR PS, V45, P313, DOI 10.1136/jnnp.45.4.313; HANDA Y, 1987, MED PROG TECHNOL, V12, P51; Handa Y, 1989, AUTOMEDICA, V1, P221; HANDA Y, 1984, P 8 INT S ECHE DUBR, P169; HANSEN G, 1979, SCAND J REHABIL MED, V11, P189; KEITH MW, 1988, CLIN ORTHOP RELAT R, P25; KILGORE K, 1994, P 16 ANN INT C IEEE; KILGORE KL, 1993, MED BIOL ENG COMPUT, V31, P607, DOI 10.1007/BF02441809; Kilgore KL, 1997, J BONE JOINT SURG AM, V79A, P533, DOI 10.2106/00004623-199704000-00008; KILGORE KL, 1993, MED BIOL ENG COMPUT, V31, P615, DOI 10.1007/BF02441810; Kobetic R., 1994, IEEE Transactions on Rehabilitation Engineering, V2, P66, DOI 10.1109/86.313148; KOBETIC R, 1994, HUMAN WALKING, P225; KRAFT GH, 1992, ARCH PHYS MED REHAB, V73, P220; LAMOTTE RH, 1978, J NEUROPHYSIOL, V41, P509, DOI 10.1152/jn.1978.41.2.509; LEVIN M F, 1989, Society for Neuroscience Abstracts, V15, P916; LEVIN MF, 1992, ELECTROEN CLIN NEURO, V85, P131, DOI 10.1016/0168-5597(92)90079-Q; Lieberson W.H., 1961, ARCH PHYS MED REHAB, V42, P101; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Memberg W. D., 1993, IEEE Transactions on Rehabilitation Engineering, V1, P126, DOI 10.1109/86.242426; MENSE S, 1977, J PHYSIOL-LONDON, V267, P75, DOI 10.1113/jphysiol.1977.sp011802; MENSE S, 1983, J PHYSIOL-LONDON, V342, P383, DOI 10.1113/jphysiol.1983.sp014857; MENSE S, 1981, BRAIN RES, V225, P95, DOI 10.1016/0006-8993(81)90320-6; MERLETTI R, 1978, SCAND J REHABIL MED, V10, P147; MERLETTI R, 1975, ARCH PHYS MED REHAB, V56, P507; PAINTAL AS, 1960, J PHYSIOL-LONDON, V152, P250, DOI 10.1113/jphysiol.1960.sp006486; Peckham P., 1992, NEURAL PROSTHESES RE, P162; REBERSEK S, 1973, ARCH PHYS MED REHAB, V54, P378; Shimada Y, 1996, ARCH PHYS MED REHAB, V77, P1014, DOI 10.1016/S0003-9993(96)90061-1; SMITH BT, 1994, ARCH PHYS MED REHAB, V75, P939; TAKEBE K, 1975, ARCH PHYS MED REHAB, V56, P237; VANHEES J, 1972, BRAIN RES, V48, P397, DOI 10.1016/0006-8993(72)90198-9; VODOVNIK L, 1965, Arch Phys Med Rehabil, V46, P187; WINCHESTER P, 1983, PHYS THER, V63, P1096, DOI 10.1093/ptj/63.7.1096; WONG RA, 1986, PHYS THER, V66, P1209, DOI 10.1093/ptj/66.8.1209	52	51	52	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV-DEC	1998	77	6					516	522		10.1097/00002060-199811000-00013			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	147RZ	WOS:000077487100010	9862539				2022-02-06	
J	Mautes, AEM; Kim, DH; Sharp, FR; Panter, S; Sato, M; Maida, N; Bergeron, M; Guenther, K; Noble, LJ				Mautes, AEM; Kim, DH; Sharp, FR; Panter, S; Sato, M; Maida, N; Bergeron, M; Guenther, K; Noble, LJ			Induction of heme oxygenase-1 (HO-1) in the contused spinal cord of the rat	BRAIN RESEARCH			English	Article						heat shock protein; heme oxygenase; contusion injury; microglia; macrophage	TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN INJURY; HSP32 MESSENGER-RNA; HEAT-SHOCK; CEREBRAL-ISCHEMIA; PROTEIN; EXPRESSION; STRESS; GENE; FIBROBLASTS	The induction of heme oxygenase-1 (HO-1) was studied in intact spinal cords and injured spinal cords after a moderate, thoracic contusion injury. HO-1 was immunolocalized in the normal cord and along the axis of the cord at 1, 2, 3 and 4 days after contusion. Induction of this enzyme in astrocytes and microglia/macrophages was evaluated using immunofluorescent double labeling with monoclonal antibodies to HO-1 and either glial fibrillary acidic protein or the complement C3bi receptor. HO-1 was expressed in neurons in the normal spinal cord. After contusion, HO-1 was induced in both gray and white matter at the impact site. In segments of cord that were 1 cm proximal or distal to the injury, HO-1 was primarily induced in the dorsal columns and occasionally in the lateral white matter. This pattern of induction was noted at all time points. The HO-1 was induced primarily in microglia/macrophages. The distribution of the HO-1 positive cells closely correlated with the pattern of intraparenchymal hemorrhage. These findings demonstrate acute induction of HO-1 in non-neuronal cells in the injured spinal cord. Induction of HO-1 in glia may be a consequence of multiple factors including exposure to heme proteins, hypoxia and oxidative stress. (C) 1998 Elsevier Science B.V. All rights reserved.	Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco State Univ, Grad Program Phys Therapy, San Francisco, CA USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Vet Adm Med Ctr, San Francisco, CA 94121 USA		Noble, LJ (corresponding author), Univ Calif San Francisco, Dept Neurosurg, 521 Parnassus Ave,Room C224, San Francisco, CA 94143 USA.			Rui, Yanning/0000-0002-4482-5579; Kim, Dong/0000-0002-1523-6396	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS23324] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023324] Funding Source: NIH RePORTER		ALAM J, 1992, J BIOL CHEM, V267, P21894; ANATHAN J, 1986, SCIENCE, V232, P522; APPLEGATE LA, 1991, CANCER RES, V51, P974; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; DWYER BE, 1995, NEUROREPORT, V6, P973, DOI 10.1097/00001756-199505090-00006; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; KEYSE SM, 1990, CARCINOGENESIS, V11, P787, DOI 10.1093/carcin/11.5.787; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kim DH, 1996, NEUROREPORT, V7, P2221, DOI 10.1097/00001756-199609020-00033; MAINES MD, 1984, CRC CR REV TOXICOL, V12, P241, DOI 10.3109/10408448409021604; MAINES MD, 1993, J PHARMACOL EXP THER, V264, P457; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1996, J NEUROSURG, V85, P892, DOI 10.3171/jns.1996.85.5.0892; MAUTES A, 1996, 14 ANN M NEUR SOC WA; MULLER RM, 1987, J BIOL CHEM, V262, P6795; Nimura T, 1996, MOL BRAIN RES, V37, P201, DOI 10.1016/0169-328X(95)00315-J; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; OKINAGA S, 1993, EUR J BIOCHEM, V212, P167, DOI 10.1111/j.1432-1033.1993.tb17647.x; PANNIZON KL, 1996, NEUROREPORT, V7, P662; PASCHEN W, 1994, NEUROSCI LETT, V180, P5, DOI 10.1016/0304-3940(94)90900-8; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; Takeda A, 1996, NEUROSCI LETT, V205, P169, DOI 10.1016/0304-3940(96)12405-8; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131	34	51	51	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 8	1998	795	1-2					17	24		10.1016/S0006-8993(98)00230-3			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	100FY	WOS:000074806500003	9622586				2022-02-06	
J	Harvey, AG; Bryant, RA				Harvey, AG; Bryant, RA			Acute stress disorder after mild traumatic brain injury	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article								The debate continues over whether a posttraumatic response occurs in those who have sustained a traumatic brain injury (TBI). The aim of this study was to investigate the incidence of acute stress disorder (ASD) in the mild TBI population. Patients who sustained a mild TBI after a motor vehicle accident (N = 79) were assessed for the presence of ASD. ASD was diagnosed in 13.9% of patients, and 5.1% were diagnosed with subsyndromal ASD. Dissociative, reexperiencing, and avoidance symptoms were found to have moderate to high predictive power. This study highlights the significant number of patients who experience an acute trauma response after TBI and raises the possibility that those with ASD denote those for whom an early intervention may prevent longer-term psychopathology. Diagnostic difficulties in defining ASD after TBI are discussed.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Harvey, AG (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; *ASS ADV AUT MED, 1990, ABBR INJ SCALE; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; BRYANT RA, 1997, PSYCHOMETRIC PROPERT; BRYANT RA, IN PRESS J CONSULT C; CREAMER M, 1992, J ABNORM PSYCHOL, V101, P452, DOI 10.1037/0021-843X.101.3.452; FEINSTEIN A, 1989, AM J PSYCHIAT, V146, P665; FLEMINGER S, 1993, BIOL PSYCHIAT, V33, P22, DOI 10.1016/0006-3223(93)90274-H; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HARVEY AG, IN PRESS J CONSULT C; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SIVEC HJ, 1995, CLIN PSYCHOL REV, V15, P297, DOI 10.1016/0272-7358(95)00012-E	21	51	53	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	JUN	1998	186	6					333	337		10.1097/00005053-199806000-00002			5	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	ZV640	WOS:000074326100002	9653416				2022-02-06	
J	Rosenbower, TJ; Morris, JA; Eddy, VA; Ries, WR				Rosenbower, TJ; Morris, JA; Eddy, VA; Ries, WR			The long-term complications of percutaneous dilatational tracheostomy	AMERICAN SURGEON			English	Article; Proceedings Paper	65th Annual Scientific Meeting and Postgraduate Course Program of the Southeastern-Surgical-Congress	FEB 01-05, 1997	NASHVILLE, TENNESSEE	SE Surg Congress			CRITICALLY ILL PATIENTS; INTENSIVE-CARE UNIT; DILATIONAL TRACHEOSTOMY; BEDSIDE PROCEDURE; TRACHEOTOMY; TRIAL	Percutaneous dilatational tracheostomy was adopted at our institution, because it was demonstrated to be more cost effective than standard open tracheostomy in critically ill patients. The objective of this study was to evaluate the long-term outcome and complication rate of percutaneous dilatational tracheostomy in critically ill patients. We performed a consecutive case study of all Level I trauma patients from August 1991 to May 1994 who underwent percutaneous dilatational tracheostomy. All patients were prospectively evaluated by a standard questionnaire a minimum of 1 year after the procedure. All symptomatic patients were offered fiberoptic laryngoscopy. Descriptive statistical methods and the Student's T test were used to analyze the data. Of 7054 consecutive trauma admissions, 237 tracheostomies were performed. A total of 143 tracheostomies (60%) were open, and 95 (40%) were percutaneous. Of the 95 patients, 20 were lost to follow-up, 12 died from causes unrelated to the procedure, 6 had severe traumatic brain injuries and were unable to participate, and 2 patients required conversion to an open procedure. This left a study group of 55 patients. At a minimum of 1 year follow-up, 40 patients (73%) were asymptomatic. Of the 15 (27%) symptomatic patients, two patients had acute airway compromise after decannulation secondary to subglottic stenosis. Both were recannulated and subsequently decannulated uneventfully. Six patients declined fiberoptic laryngoscopy, because their symptoms were minimal (minor voice changes in three and intermittent hoarseness in three). Nine patients underwent fiberoptic laryngoscopy, and all examinations were normal. The mean cost of standard open tracheostomy at our institution is $1134 (58%) more than the mean cost of percutaneous dilatational tracheostomy. Of the study group patients undergoing percutaneous dilatational tracheostomy, 27 per cent complained of symptoms a minimum of 1 year posttracheostomy, Of these patients, 60 per cent underwent fiberoptic laryngoscopy, and no subglottic lesions were identified. Our findings suggest that percutaneous dilatational tracheostomy is a safe, cost-effective alternative to standard tracheostomy in critically ill patients.	Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Otolaryngol, Nashville, TN 37212 USA		Rosenbower, TJ (corresponding author), 1103 N Elm St, Greensboro, NC 27401 USA.						BODENHAM A, 1991, ANAESTHESIA, V46, P570, DOI 10.1111/j.1365-2044.1991.tb09659.x; CIAGLIA P, 1992, CHEST, V101, P464, DOI 10.1378/chest.101.2.464; CIAGLIA P, 1985, CHEST, V87, P715, DOI 10.1378/chest.87.6.715; DEVITA MA, 1990, CRIT CARE MED, V18, P1328, DOI 10.1097/00003246-199012000-00004; FRIEDMAN Y, 1993, CHEST, V104, P532, DOI 10.1378/chest.104.2.532; GRIGGS WM, 1990, SURG GYNECOL OBSTET, V170, P543; HAZARD P, 1991, CRIT CARE MED, V19, P1018, DOI 10.1097/00003246-199108000-00008; HAZARD PB, 1988, ANN THORAC SURG, V46, P63, DOI 10.1016/S0003-4975(10)65854-7; HEFFNER JE, 1986, CHEST, V90, P430, DOI 10.1378/chest.90.3.430; IVATURY R, 1992, J TRAUMA, V32, P133, DOI 10.1097/00005373-199202000-00004; MARELLI D, 1990, J TRAUMA, V30, P433, DOI 10.1097/00005373-199030040-00012; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; MYERS EN, 1991, CLIN CHEST MED, V12, P589; PAUL A, 1989, ANN THORAC SURG, V47, P314, DOI 10.1016/0003-4975(89)90301-9; RILEY H, 1993, COMPLICATIONS HEAD N, P257; SCHACHNER A, 1989, CRIT CARE MED, V17, P1052, DOI 10.1097/00003246-198910000-00017; STOCK MC, 1986, CRIT CARE MED, V14, P861, DOI 10.1097/00003246-198610000-00005; TOURSARKISSIAN B, 1994, ANN THORAC SURG, V57, P862, DOI 10.1016/0003-4975(94)90191-0; WOOD DE, 1991, CLIN CHEST MED, V12, P597	19	51	51	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	JAN	1998	64	1					82	86					5	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	YT981	WOS:000071667500028	9457043				2022-02-06	
J	Ersahin, Y; Mutluer, S; Saydam, S; Barcin, E				Ersahin, Y; Mutluer, S; Saydam, S; Barcin, E			Cerebellar mutism: Report of two unusual cases and review of the literature	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						brain stem surgery; cerebellar injury; head injury; mutism; posterior cranial fossa; brain tumour	POSTERIOR-FOSSA SURGERY; TRANSIENT MUTISM; TRAUMATIC MUTISM; DENTATE NUCLEUS; CHILDREN; REMOVAL; TUMOR; MEDULLOBLASTOMA; DYSARTHRIA; LESIONS	Mutism is not a common condition following cerebellar damage. Mutism following posterior cranial fossa surgery was first reported by Rekate et al. and Yonemasu in 1985. Since then, many case reports of mutism have appeared in the English literature. Very few cases developed mutism following brain stem surgery. Although mutism has been described in patients with head injury, only one case of mutism caused by a cerebellar injury has been reported, to our knowledge. We report on two patients in which the cerebellar mutism following a radical excision of an exophytic brain stem glioma and cerebellar injury developed. We reviewed the relevant literature and discussed the mechanism of cerebellar mutism. (C) 1997 Elsevier Science B.V.	EGE UNIV,FAC MED,DEPT NEUROSURG,DIV PAEDIAT NEUROSURG,IZMIR,TURKEY								ALJARALLAH A, 1994, J SURG ONCOL, V55, P126, DOI 10.1002/jso.2930550214; AMMIRATI M, 1989, CHILD NERV SYST, V5, P12, DOI 10.1007/BF00706739; ASAMOTO M, 1994, CHILD NERV SYST, V10, P275, DOI 10.1007/BF00301168; CAKIR Y, 1994, SURG NEUROL, V41, P342, DOI 10.1016/0090-3019(94)90188-0; CATSMANBERREVOETS CE, 1992, DEV MED CHILD NEUROL, V34, P1102; CRUTCHFIELD JS, 1994, J NEUROSURG, V81, P115, DOI 10.3171/jns.1994.81.1.0115; D'Avanzo R, 1993, Acta Neurol (Napoli), V15, P289; DAILEY AT, 1995, J NEUROSURG, V83, P467, DOI 10.3171/jns.1995.83.3.0467; DIETZE DD, 1990, PEDIATR NEUROSURG, V16, P25; Ersahin Y, 1996, NEUROSURGERY, V38, P60; FERRANTE L, 1990, J NEUROSURG, V72, P959, DOI 10.3171/jns.1990.72.6.0959; FERRARA VL, 1985, SURG NEUROL, V23, P573, DOI 10.1016/0090-3019(85)90005-9; FRAIOLI B, 1975, APPL NEUROPHYSIOL, V38, P81; FRIM DM, 1995, NEUROSURGERY, V36, P854, DOI 10.1227/00006123-199504000-00031; HERB E, 1992, NEUROPEDIATRICS, V23, P144, DOI 10.1055/s-2008-1071330; Humphreys RP, 1989, CONCEPTS PEDIATR NEU, P57; NAGATANI K, 1991, SURG NEUROL, V36, P307, DOI 10.1016/0090-3019(91)90094-P; Ozek MM, 1993, TURK NEUROSURG, V3, P37; REKATE HL, 1985, ARCH NEUROL-CHICAGO, V42, P697, DOI 10.1001/archneur.1985.04060070091023; SALVATI M, 1991, CLIN NEUROL NEUROSUR, V93, P313, DOI 10.1016/0303-8467(91)90096-8; SIEGFRIE.J, 1970, CONFIN NEUROL, V32, P1; VANDONGEN HR, 1994, NEUROLOGY, V44, P2040, DOI 10.1212/WNL.44.11.2040; VOLCAN I, 1986, ARCH NEUROL-CHICAGO, V43, P313, DOI 10.1001/archneur.1986.00520040003002; VONCRAMON D, 1981, NEUROPSYCHOLOGIA, V19, P801, DOI 10.1016/0028-3932(81)90092-0; VUILLEUMIER P, 1995, NEUROCHIRURGIE, V41, P98; YOKOTA H, 1990, Neurological Surgery, V18, P67; Yonemasu Y, 1985, 13 ANN M JAP SOC PED	27	51	52	0	1	VAN GORCUM CO BV	ASSEN	PO BOX 43, 9400 AA ASSEN, NETHERLANDS	0303-8467			CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	MAY	1997	99	2					130	134		10.1016/S0303-8467(96)00597-5			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	XG391	WOS:A1997XG39100010	9213058				2022-02-06	
J	Feldman, Z; Robertson, CS				Feldman, Z; Robertson, CS			Monitoring of cerebral hemodynamics with jugular bulb catheters	CRITICAL CARE CLINICS			English	Article							VENOUS OXYGEN-SATURATION; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; FLUID-PERCUSSION INJURY; BLOOD-FLOW VELOCITY; CARDIOPULMONARY BYPASS; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; METABOLISM; HYPOXIA	Jugular venous oxygen saturation (SjvO(2)) monitoring is useful for detecting episodes of cerebral hypoxia/ischemia in patients with head injury, patients undergoing neurosurgical procedures, and patients undergoing cardiopulmonary bypass. The use of SjvO(2) monitoring can direct the treatment of ischemic episodes and identify the optimal level of cerebral perfusion pressure and PCO2 for the individual patient.			Feldman, Z (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,6560 FANNIN,SUITE 900,HOUSTON,TX 77030, USA.			Feldman, Zeev/0000-0002-9719-3894	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BANKIER AA, 1995, AM J ROENTGENOL, V164, P437, DOI 10.2214/ajr.164.2.7839985; BUSIJA DW, 1988, AM J PHYSIOL, V255, pH343, DOI 10.1152/ajpheart.1988.255.2.H343; CALON B, 1995, J NEUROSURG, V83, P910, DOI 10.3171/jns.1995.83.5.0910; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1992, SURG NEUROL, V38, P433, DOI 10.1016/0090-3019(92)90111-Y; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHAN KH, 1992, NEUROSURGERY, V30, P697; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183, DOI 10.1152/jappl.1967.23.2.183; CROUGHWELL N, 1992, J THORAC CARDIOV SUR, V103, P549; CROUGHWELL ND, 1995, J CARDIAC SURG, V10, P503, DOI 10.1111/j.1540-8191.1995.tb00685.x; CROUGHWELL ND, 1994, ANN THORAC SURG, V58, P1702, DOI 10.1016/0003-4975(94)91666-7; CROUGHWELL ND, 1992, ANN THORAC SURG, V53, P827, DOI 10.1016/0003-4975(92)91445-F; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; DENYS BG, 1991, CRIT CARE MED, V19, P1516, DOI 10.1097/00003246-199112000-00013; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; FINNERTY FA, 1954, J CLIN INVEST, V33, P1227, DOI 10.1172/JCI102997; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GARLICK R, 1987, SCAND J CLIN LAB INV, V47, P47; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GIBBS EL, 1945, AM J PSYCHIAT, V102, P184, DOI 10.1176/ajp.102.2.184; GIBBS EL, 1934, ANAT REC, V54, P419; GOETTING MG, 1991, INTENS CARE MED, V17, P195, DOI 10.1007/BF01709876; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GOPINATH SP, UNPUB ANESTH ANALG; HATIBOGLU MT, 1992, J ANAT, V180, P191; HAYMAN AL, IN PRESS EMERGENCY R; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JAKOBSEN M, 1989, J CEREBR BLOOD F MET, V9, P717, DOI 10.1038/jcbfm.1989.101; JOHANNSSON H, 1975, ACTA PHYSIOL SCAND, V93, P269, DOI 10.1111/j.1748-1716.1975.tb05815.x; KATAYAMA Y, 1994, J NEUROSURG, V80, P826, DOI 10.3171/jns.1994.80.5.0826; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; Lennox WG, 1935, ARCH NEURO PSYCHIATR, V34, P1001, DOI 10.1001/archneurpsyc.1935.02250230073006; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; LYONS C, 1964, ANN SURG, V160, P561, DOI 10.1097/00000658-196410000-00001; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MATTA BF, 1994, ANESTH ANALG, V79, P745; MCCORMICK PW, 1991, CRIT CARE MED, V19, P89, DOI 10.1097/00003246-199101000-00020; MELDRUM BS, 1976, BRAIN, V99, P523, DOI 10.1093/brain/99.3.523; MEYER JS, 1965, NEUROLOGY, V15, P892, DOI 10.1212/WNL.15.10.892; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P435; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NAKAJIMA T, 1992, ANESTH ANALG, V74, P630; NAKAJIMA T, 1993, ANESTH ANALG, V77, P1111; NILSSON B, 1978, CIBA F S, V56, P199; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OKADA M, 1993, JAPANESE J THORACIC, V46, P668; PAULSON OB, 1973, J APPL PHYSIOL, V35, P111, DOI 10.1152/jappl.1973.35.1.111; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PIERCE EC, 1962, J CLIN INVEST, V41, P1664, DOI 10.1172/JCI104623; RAICHLE ME, 1976, ARCH NEUROL-CHICAGO, V33, P523, DOI 10.1001/archneur.1976.00500080001001; RITTER AM, IN PRESS J CLIN MONI; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Rosner M., 1987, CEREBRAL BLOOD FLOW, P425; SAPPIRE KJ, UNPUB J THORAC CARDI; SENDFF MG, 1985, INTENS CARE MED, P16; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHENKIN HA, 1948, ARCH NEURO PSYCHIATR, V60, P240, DOI 10.1001/archneurpsyc.1948.02310030021002; Souter M. J., 1995, Journal of Neurotrauma, V12, P471; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Stocchetti N, 1991, Minerva Anestesiol, V57, P319; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927	76	51	61	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0749-0704			CRIT CARE CLIN	Crit. Care Clin.	JAN	1997	13	1					51	&		10.1016/S0749-0704(05)70296-7			28	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE065	WOS:A1997WE06500005	9012576				2022-02-06	
J	Rzigalinski, BA; Liang, S; McKinney, JS; Willoughby, KA; Ellis, EF				Rzigalinski, BA; Liang, S; McKinney, JS; Willoughby, KA; Ellis, EF			Effect of Ca2+ on in vitro astrocyte injury	JOURNAL OF NEUROCHEMISTRY			English	Article						extracellular Ca2+; intracellular free Ca2+; astrocyte injury; traumatic brain injury	BRAIN INJURY; PLASMA-MEMBRANE; CALCIUM ENTRY; CELLS; NEURONS; STORES; ACID; NEUROTOXICITY; METABOLISM; ANNEXINS	Current literature suggests that a massive influx of Ca2+ into the cells of the CNS induces cell damage associated with traumatic brain injury (TBI). Using an in vitro model for stretch-induced cell injury developed by our laboratory, we have investigated the role of extracellular Ca2+ in astrocyte injury. The degree of injury was assessed by measurement of propidium iodide uptake and release of lactate dehydrogenase. Based on results of in vivo models of TBI developed by others, our initial hypothesis was that decreasing extracellular Ca2+ would result in a reduction in astrocyte injury. Quite unexpectedly, our results indicate that decreasing extracellular Ca2+ to levels observed after in vivo TBI increased astrocyte injury. Elevating the extracellular Ca2+ content to twofold above physiological levels (2 mM) produced a reduction in cell injury. The reduction in injury afforded by Ca2+ could not be mimicked with Ba2+, Mn2+, Zn2+, or Mg2+, suggesting that a Ca2+-specific mechanism is involved. Using Ca-45(2+), we demonstrate that injury induces a rapid influx of extracellular Ca2+ into the astrocyte, achieving an elevation in total cell-associated Ca2+ content two- to threefold above basal levels. Pharmacological elevation of intracellular Ca2+ levels with the Ca2+ ionophore A231 87 or thapsigargin before injury dramatically reduced astrocyte injury. Our data suggest that, contrary to popular assumptions, an elevation of total cell-associated Ca2+ reduces astrocyte injury produced by a traumatic insult.			Rzigalinski, BA (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,BOX 980613,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27214] Funding Source: Medline		ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; BARRETT JN, 1994, T AM SOC NEUROCHEM, V25, P207; BERLIN RD, 1993, CELL CALCIUM, V14, P379, DOI 10.1016/0143-4160(93)90042-5; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DAWIDOWICZ EA, 1987, ANNU REV BIOCHEM, V56, P43, DOI 10.1146/annurev.bi.56.070187.000355; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; ERNST JD, 1994, BIOCHEM BIOPH RES CO, V200, P867, DOI 10.1006/bbrc.1994.1531; FINEMAN I, 1990, Society for Neuroscience Abstracts, V16, P778; FLOTT B, 1991, GLIA, V4, P293, DOI 10.1002/glia.440040307; FRANKLIN JL, 1995, J NEUROSCI, V15, P643; GIULIAN D, 1994, NEUROBIOLOGY CNS TRA, P155; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HANSSON E, 1995, FASEB J, V9, P343, DOI 10.1096/fasebj.9.5.7534736; HOLZWARTH JA, 1994, J NEUROSCI, V14, P1879; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; INOUE M, 1992, J LIPID RES, V33, P985; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KLINGMAN JG, 1990, J NEUROSCI METH, V31, P47, DOI 10.1016/0165-0270(90)90008-4; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; LAMB RG, 1995, J NEUROTRAUM, V12, P969; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MICHEL PP, 1994, EUR J NEUROSCI, V6, P577, DOI 10.1111/j.1460-9568.1994.tb00302.x; NAKANISHI K, 1994, BRAIN RES, V659, P169, DOI 10.1016/0006-8993(94)90876-1; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RZIGALINSKI BA, 1996, FASEB J, V10, pA280; SCHOOTEMEIJER A, 1994, EUR J BIOCHEM, V224, P423, DOI 10.1111/j.1432-1033.1994.00423.x; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SHINITZKY M, 1994, PHYSL MEMBRANE FLUID, P1; SJOLIN C, 1994, BIOCHEM J, V300, P325; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; TAVALIN SJ, 1995, J NEUROTRAUM, V12, P144; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSUDA K, 1987, HYPERTENSION, V9, P19; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; XIE XY, 1991, J NEUROSCI, V11, P3257; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	51	51	53	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	JAN	1997	68	1					289	296					8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	VY893	WOS:A1997VY89300035	8978737				2022-02-06	
J	Godfrey, HPD; Knight, RG; Partridge, FM				Godfrey, HPD; Knight, RG; Partridge, FM			Emotional adjustment following traumatic brain injury: A stress appraisal-coping formulation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adjustment; brain injury; rehabilitation; stress	CLOSED-HEAD-INJURY; SOCIAL-INTERACTION; MANAGEMENT; DISORDER	This article conceptualizes emotional adjustment to traumatic brain injury (TBI) within a stress-appraisal-coping (SAG) model. In this model the emotional adjustment of the individual with TBI is seen as a response to neuropsychological symptoms and associated losses. This response is mediated, however, by the individual's coping skills, social support, and appraisal (insight). Evidence regarding the course of emotional dysfunction following TBI and the role of mediating variables is reviewed and found to provide strong preliminary support for the model. In addition, the effects of neuropsychological symptoms on mediators of emotional adjustment are discussed. Finally, the implications of the SAC model for rehabilitation are discussed and recent rehabilitation outcome findings presented.			Godfrey, HPD (corresponding author), UNIV OTAGO,DEPT PSYCHOL,CLIN PSYCHOL RES & TRAINING CTR,POB 56,DUNEDIN,NEW ZEALAND.						BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BOND G, 1993, THESIS U OTAGO; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Falloon I.R.H., 1984, FAMILY CARE SCHIZOPH; FOLEY FW, 1987, J CONSULT CLIN PSYCH, V55, P919, DOI 10.1037/0022-006X.55.6.919; Folkman S., 1984, STRESS; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GODFREY H P D, 1991, Brain Injury, V5, P207, DOI 10.3109/02699059109008091; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; GODFREY HPD, 1991, J CLIN EXP NEUROPSYC, V13, P428; Janis I. L., 1958, PSYCHOL STRESS; Kahneman D., 1973, ATTENTION EFFORT; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Lazarus R., 1966, PSYCHOL STRESS COPIN; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1986, REHABIL PSYCHOL, V31, P217; SERLE H, 1957, STRESS LIFE; SKINNER BF, 1983, AM PSYCHOL, V38, P239, DOI 10.1037/0003-066X.38.3.239; Smith LM, 1995, FAMILY SUPPORT PROGR; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TAYLOR SE, 1988, PSYCHOL BULL, V103, P193, DOI 10.1037/0033-2909.103.2.193; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WOLFOLK R, 1984, PRINCIPLES PRACTICE; Zarit SH., 1985, HIDDEN VICTIMS ALZHE; [No title captured]	35	51	52	0	13	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1996	11	6					29	40		10.1097/00001199-199612000-00006			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	VW427	WOS:A1996VW42700005					2022-02-06	
J	Gehrmann, J				Gehrmann, J			Microglia: A sensor to threats in the nervous system?	RESEARCH IN VIROLOGY			English	Article; Proceedings Paper	5th Rhine-Main Symposium on Macrophages and HIV	MAY, 1995	FRANKFURT, GERMANY	Natl Agcy AIDS Res, INSERM, BMBFT, DLR		CNS; AIDS; microglia; astrocytes; HIV encephalitis; neurotoxicity; cell death; apoptosis	COLONY-STIMULATING FACTOR; MARROW-DERIVED ELEMENTS; MULTINUCLEATED GIANT-CELLS; IMMUNE-DEFICIENCY-SYNDROME; RAT FACIAL NUCLEUS; ADULT-MOUSE BRAIN; MONOCLONAL-ANTIBODIES; PERIVASCULAR CELLS; RESIDENT MICROGLIA; AMEBOID MICROGLIA	The parenchymal microglia are now believed to settle the CNS antenatally, being derived from a bone marrow precursor cell. Based on developmental and pathophysiological studies, at least four different types of parenchymal microglia can be distinguished: (i) the amoeboid microglia which are mainly found perinatally in white matter areas such as the corpus callosum, i.e. the so-called ''fountains of microglia'', (ii) the ramified, resting microglia in the adult CNS, (iii) the activated, non-phagocytic microglia found in areas of secondary reaction due to nerve transection and (iv) the phagocytic microglia, found in areas of trauma, infection or neuronal necrosis. In addition, there are perivascular cells enclosed in the basal lamina which have a high turnover with a bone marrow precursor pool. While the function of resting microglia is still largely unknown, it is clear from observations in neuropathology that microglia are among the first cell types in the brain to respond to injuries. Their reaction pattern to injury has been termed a graded response, since the transformation of resting cells into phagocytes is under strict control in vivo. Microglial activation is a key cellular response in many infectious, inflammatory, traumatic, neoplastic, ischaemic and degenerative conditions in the CNS. In HIV encephalitis, the microglial involvement is striking, and approximately 25% of microglia contain viral DNA or RNA. Based on natural homing mechanisms with bone marrow precursor cells, HIV-infected monocytes/macrophages may home at an early stage to the CNS perivascular space and eventually spread the infection to resident microglia in the CNS which may be difficult to reach by pharmacological intervention. Further understanding of the mechanisms regulating microglial proliferation and activation in vivo may help to develop therapies targeting the potentially harmful microglial response in the injured CNS.			Gehrmann, J (corresponding author), UNIV ZURICH HOSP,DEPT PATHOL,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND.						BANATI RB, 1991, J NEUROSCI RES, V30, P593, DOI 10.1002/jnr.490300402; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; BUDKA H, 1986, ACTA NEUROPATHOL, V69, P253, DOI 10.1007/BF00688301; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Del Rio-Hortega P., 1932, CYTOLOGY CELLULAR PA, P481; DICKSON DW, 1991, LAB INVEST, V64, P135; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; FERRER I, 1990, NEUROSCIENCE, V39, P451, DOI 10.1016/0306-4522(90)90281-8; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEHRMANN J, 1993, GLIA, V7, P50, DOI 10.1002/glia.440070110; GEHRMANN J, 1992, J CEREBR BLOOD F MET, V12, P257, DOI 10.1038/jcbfm.1992.36; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; GEHRMANN J, 1991, RESTOR NEUROL NEUROS, V2, P181, DOI 10.3233/RNN-1991-245605; GEHRMANN J, 1991, J COMP NEUROL, V313, P409, DOI 10.1002/cne.903130302; GEHRMANN J, 1995, J NEUROPATH EXP NEUR, V54, P680, DOI 10.1097/00005072-199509000-00010; GEHRMANN J, 1995, NEUROPATH APPL NEURO, V21, P277, DOI 10.1111/j.1365-2990.1995.tb01062.x; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; GEHRMANN J, 1992, LAB INVEST, V67, P100; GEHRMANN J, 1994, CURR DIAG PATHOL, V1, P121; Gehrmann Jochen, 1995, P883; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GOSZTONYI G, 1994, J NEUROPATH EXP NEUR, V53, P521, DOI 10.1097/00005072-199409000-00012; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GRAEBER MB, 1992, J NEUROPATH EXP NEUR, V51, P303, DOI 10.1097/00005072-199205000-00009; GRAEBER MB, 1989, J NEUROSCI RES, V22, P103, DOI 10.1002/jnr.490220114; HAO C, 1990, J NEUROSCI RES, V27, P314, DOI 10.1002/jnr.490270310; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; JORDAN CA, 1991, J VIROL, V65, P736, DOI 10.1128/JVI.65.2.736-742.1991; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; KIEFER R, 1994, NEUROSCI LETT, V166, P161, DOI 10.1016/0304-3940(94)90475-8; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; KRALL WJ, 1994, BLOOD, V83, P2737; KREUTZBERG GW, 1966, ACTA NEUROPATHOL, V7, P149, DOI 10.1007/BF00686781; KURE K, 1990, AM J PATHOL, V136, P1085; LASSMANN H, 1991, J NEUROSCI RES, V28, P236, DOI 10.1002/jnr.490280211; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X; MAJNO G, 1995, AM J PATHOL, V146, P3; MALIPIERO UV, 1990, J IMMUNOL, V144, P3816; MATSUMOTO Y, 1986, J IMMUNOL, V136, P3668; MATSUMOTO Y, 1987, J NEUROIMMUNOL, V17, P71, DOI 10.1016/0165-5728(87)90032-4; MORIOKA T, 1992, GLIA, V6, P75, DOI 10.1002/glia.440060110; NGUYEN KB, 1994, J AUTOIMMUN, V7, P145, DOI 10.1006/jaut.1994.1011; Nissl F., 1899, ARCH PSYCH, V32, P1; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PETITO CK, 1995, AM J PATHOL, V146, P1121; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; RAIVICH G, 1994, GLIA, V11, P129, DOI 10.1002/glia.440110208; REID DM, 1993, NEUROSCIENCE, V56, P529, DOI 10.1016/0306-4522(93)90353-H; RINAMAN L, 1993, J NEUROSCI, V13, P685; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SHARER LR, 1985, HUM PATHOL, V16, P760, DOI 10.1016/S0046-8177(85)80245-8; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; STREIT WJ, 1989, J NEUROIMMUNOL, V21, P117, DOI 10.1016/0165-5728(89)90167-7; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; SUZUMURA A, 1990, J NEUROIMMUNOL, V30, P111, DOI 10.1016/0165-5728(90)90094-4; THERY C, 1990, J NEUROSCI RES, V26, P129, DOI 10.1002/jnr.490260117; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; UNGER ER, 1993, J NEUROPATH EXP NEUR, V52, P460, DOI 10.1097/00005072-199309000-00004; VASS K, 1993, LAB INVEST, V69, P275; VASS K, 1990, AM J PATHOL, V137, P789; WILLIAMS AE, 1990, NEUROPATH APPL NEURO, V16, P377, DOI 10.1111/j.1365-2990.1990.tb01274.x	76	51	53	0	4	EDITIONS SCIENTIFIQUES ELSEVIER	PARIS CEDEX 15	141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE	0923-2516			RES VIROLOGY	Res. Virol.	MAR-JUN	1996	147	2-3					79	88		10.1016/0923-2516(96)80220-2			10	Virology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Virology	UC606	WOS:A1996UC60600002	8901425				2022-02-06	
J	Regan, RF; Panter, SS; Witz, A; Tilly, JL; Giffard, RG				Regan, RF; Panter, SS; Witz, A; Tilly, JL; Giffard, RG			Ultrastructure of excitotoxic neuronal death in murine cortical culture	BRAIN RESEARCH			English	Article						ischemic brain injury; traumatic brain injury; glutamate receptor; neuronal death	PROGRAMMED CELL-DEATH; NERVE GROWTH-FACTOR; INTERNUCLEOSOMAL DNA CLEAVAGE; PROTEIN-SYNTHESIS; CEREBRAL-ISCHEMIA; GLUTAMATE NEUROTOXICITY; SYMPATHETIC NEURONS; GEL-ELECTROPHORESIS; FACTOR DEPRIVATION; RAT HIPPOCAMPUS	Ischemic and traumatic brain injury are likely to involve neuronal injury triggered by glutamate receptor overactivation. Although excitotoxic neuronal injury has been widely studied in the setting of primary culture, the extent to which these in vitro injury paradigms resemble in vivo ischemic injury morphologically has not previously been well studied. We studied glutamate receptor mediated neuronal death by transmission electron microscopy and light microscopy. Morphologic characteristics of neurons injured by 10 min exposure to 500 mu M glutamate include rapid swelling of mitochondria and endoplasmic reticulum, and cytoplasmic and nuclear lucency. Both alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and kainic acid caused vacuolation, dilatation of the endoplasmic reticulum, cytoplasmic condensation and random condensation of chromatin with preserved mitochondria. None of these injuries was ameliorated by cycloheximide or actinomycin D; all were significantly lessened by aurintricarboxylic acid. Gel electrophoresis showed no increase in DNA fragmentation over control. The morphologic changes seen with alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and kainate are distinct from the changes induced by glutamate. Excitotoxic injury in this system due to high concentrations of glutamate resembles necrosis while the other agonists produce a different form of cell death which is neither necrosis nor apoptosis.	STANFORD UNIV,SCH MED,DEPT ANESTHESIA,STANFORD,CA 94305; LETTERMAN ARMY INST RES,DIV BLOOD RES,SAN FRANCISCO,CA 94129; HARVARD UNIV,SCH MED,DEPT OBSTET GYNECOL & REPROD BIOL,VINCENT CTR REPROD BIOL,BOSTON,MA 02115					Giffard, Rona/0000-0003-2173-4436			BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BELIZARIO JE, 1993, BRIT J CANCER, V67, P1229, DOI 10.1038/bjc.1993.230; BINASTEIN M, 1976, MOL PHARMACOL, V12, P191; BOE R, 1991, EXP CELL RES, V195, P237, DOI 10.1016/0014-4827(91)90523-W; BROWN AW, 1973, ACTA NEUROPATHOL, V23, P9, DOI 10.1007/BF00689000; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; CHARRIAUTMARLANGUE C, 1995, J CEREBR BLOOD F MET, V15, P385, DOI 10.1038/jcbfm.1995.48; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1988, J NEUROSCI, V8, P185; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLLINS RJ, 1992, INT J RADIAT BIOL, V61, P451, DOI 10.1080/09553009214551201; CSERNANSKY CA, 1994, J NEUROSCI RES, V38, P101, DOI 10.1002/jnr.490380113; DESHPANDE J, 1992, EXP BRAIN RES, V88, P91, DOI 10.1007/BF02259131; DESSI F, 1993, J NEUROCHEM, V60, P1953, DOI 10.1111/j.1471-4159.1993.tb13427.x; DIETRICH WD, 1992, ACTA NEUROPATHOL, V84, P630, DOI 10.1007/BF00227740; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DUGAN LL, 1995, J NEUROSCI, V15, P4545; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; GIANNAKIS C, 1991, BIOCHEM BIOPH RES CO, V181, P915, DOI 10.1016/0006-291X(91)91278-K; GOTO K, 1990, BRAIN RES, V534, P299, DOI 10.1016/0006-8993(90)90144-Z; HERON A, 1993, J NEUROCHEM, V61, P1973, DOI 10.1111/j.1471-4159.1993.tb09843.x; HORNUNG JP, 1989, J COMP NEUROL, V283, P425, DOI 10.1002/cne.902830310; IGNATOWICZ E, 1991, NEUROREPORT, V2, P651, DOI 10.1097/00001756-199111000-00004; IKONOMIDOU C, 1989, J NEUROSCI, V9, P1693; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; LEDDACOLUMBANO GM, 1992, AM J PATHOL, V140, P545; LEPPIN C, 1992, BRAIN RES, V581, P168, DOI 10.1016/0006-8993(92)90359-H; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LIN JK, 1992, CANCER RES, V52, P385; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MASTERS JN, 1989, ENDOCRINOLOGY, V124, P3083, DOI 10.1210/endo-124-6-3083; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; NAVASCUES J, 1988, J COMP NEUROL, V278, P34, DOI 10.1002/cne.902780103; NISHIKAWA Y, 1989, ACTA NEUROPATHOL, V78, P1, DOI 10.1007/BF00687395; OLNEY JW, 1969, J NEUROPATH EXP NEUR, V28, P455, DOI 10.1097/00005072-196907000-00007; PAPAS S, 1992, EUR J NEUROSCI, V4, P758, DOI 10.1111/j.1460-9568.1992.tb00185.x; PETITO CK, 1984, J CEREBR BLOOD F MET, V4, P194, DOI 10.1038/jcbfm.1984.28; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; RATAN RR, 1994, J NEUROCHEM, V62, P376; Regan R. F., 1993, Society for Neuroscience Abstracts, V19, P1344; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SELLINS KS, 1991, RADIAT RES, V126, P88, DOI 10.2307/3578175; SHIGENO T, 1990, NEUROSCI LETT, V120, P117, DOI 10.1016/0304-3940(90)90182-9; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; STRAIN SM, 1991, NEUROSCIENCE, V44, P343, DOI 10.1016/0306-4522(91)90059-W; TAKANO YS, 1991, J PATHOL, V163, P329, DOI 10.1002/path.1711630410; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALLEN CA, 1983, CELL TISSUE KINET, V16, P357; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZEEVALK GD, 1993, J NEUROCHEM, V61, P386, DOI 10.1111/j.1471-4159.1993.tb03585.x	67	51	52	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	DEC 24	1995	705	1-2					188	198		10.1016/0006-8993(95)01170-6			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TQ998	WOS:A1995TQ99800023	8821749				2022-02-06	
J	SHATNEY, CH; BRUNNER, RD; NGUYEN, TQ				SHATNEY, CH; BRUNNER, RD; NGUYEN, TQ			THE SAFETY OF OROTRACHEAL INTUBATION IN PATIENTS WITH UNSTABLE CERVICAL-SPINE FRACTURE OR HIGH SPINAL-CORD INJURY	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	47th Annual Meeting of the Southwestern Surgical Congress	APR 23-26, 1995	SAN ANTONIO, TX				AIRWAY MANAGEMENT; ENDOTRACHEAL INTUBATION; TRAUMA PATIENTS; NASOTRACHEAL; INDUCTION	BACKGROUND: The potential merits and dangers of orotracheal and nasotracheal intubation in patients with injury to the cervical spine or spinal cord continue to be debated. To address this issue, a prospective study was conducted at a level 1 trauma center in patients with respiratory embarrassment and either or both of these injuries. MATERIALS AND METHODS: Over a 7-year period, all such patients underwent neurologic examination by a trauma surgeon on arrival at the trauma center, immediately after endotracheal intubation, and at frequent intervals throughout hospitalization. Cervical immobilization was maintained manually during endotracheal intubation, When necessary, patients were sedated or paralyzed with short-acting pharmacologic agents. RESULTS: During the study period, there were 81 patients with 98 cervical vertebral body fractures, but without evidence of spinal cord injury on initial examination, Sixty-seven patients (83%) were legally intoxicated, and 12 patients had closed head injury. Endotracheal intubation was performed in 26 patients with unstable fractures, and 22 patients were intubated via the oral route. No patient manifested a subsequent neurologic deficit. Sixty-nine additional patients presented with high spinal cord injury; 16 had no cervical spine fracture, and 53 patients had 61 fractures of the cervical vertebrae. Sixty patients (87%) were intoxicated, and 8 patients had closed head injury. Endotracheal intubation was performed in 29 of these patients, and 26 patients were intubated via the oral route. No patient experienced further neurologic deficit following endotracheal intubation. CONCLUSION: In trauma victims with or at high risk of cervical spinal cord injury, orotracheal intubation is a rapid, safe means of achieving airway control.	UNIV FLORIDA,HLTH SCI CTR,DEPT SURG,JACKSONVILLE,FL; UNIV FLORIDA,HLTH SCI CTR,DEPT NEUROSURG,JACKSONVILLE,FL								APRAHAMIAN C, 1984, ANN EMERG MED, V13, P584, DOI 10.1016/S0196-0644(84)80278-4; BIVINS HG, 1988, ANN EMERG MED, V17, P25, DOI 10.1016/S0196-0644(88)80498-0; CRISWELL JC, 1994, ANAESTHESIA, V49, P900, DOI 10.1111/j.1365-2044.1994.tb04271.x; DINNER M, 1987, ANESTH ANALG, V66, P461; DRONEN SC, 1987, ANN EMERG MED, V16, P650, DOI 10.1016/S0196-0644(87)80063-X; HASTINGS RH, 1993, ANESTHESIOLOGY, V78, P580, DOI 10.1097/00000542-199303000-00022; HASTINGS RH, 1991, ANESTH ANALG, V73, P471; KAPP JP, 1975, J NEUROSURG, V42, P731, DOI 10.3171/jns.1975.42.6.0731; KNOPP RK, 1990, ANN EMERG MED, V19, P603, DOI 10.1016/S0196-0644(05)82203-6; LIGIER B, 1991, SURG GYNECOL OBSTET, V173, P477; MAJERNICK TG, 1986, ANN EMERG MED, V15, P417, DOI 10.1016/S0196-0644(86)80178-0; MAULL KI, 1977, SOUTHERN MED J, V70, P477, DOI 10.1097/00007611-197704000-00033; MESCHINO A, 1992, CAN J ANAESTH, V39, P114, DOI 10.1007/BF03008639; NORWOOD S, 1994, J AM COLL SURGEONS, V179, P646; REDAN JA, 1991, J TRAUMA, V31, P371, DOI 10.1097/00005373-199103000-00010; RHEE KJ, 1990, ANN EMERG MED, V19, P511, DOI 10.1016/S0196-0644(05)82179-1; ROSEN P, 1989, Journal of Emergency Medicine, V7, P387, DOI 10.1016/0736-4679(89)90312-0; SCANNEL G, 1993, ARCH SURG-CHICAGO, V128, P903; TALUCCI RC, 1988, AM SURGEON, V54, P185; TINTINALLI JE, 1981, ANN EMERG MED, V10, P142, DOI 10.1016/S0196-0644(81)80379-4; WALLS RM, 1992, CAN J SURG, V35, P27; WOOD PR, 1992, ANAESTHESIA, V47, P792, DOI 10.1111/j.1365-2044.1992.tb03259.x; WRIGHT SW, 1992, AM J EMERG MED, V10, P104, DOI 10.1016/0735-6757(92)90039-Z	23	51	53	0	1	CAHNERS PUBL CO	NEW YORK	249 WEST 17 STREET, NEW YORK, NY 10011	0002-9610			AM J SURG	Am. J. Surg.	DEC	1995	170	6					676	680		10.1016/S0002-9610(99)80040-3			5	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	TH942	WOS:A1995TH94200032	7492025				2022-02-06	
J	LAORR, A; GREENSPAN, A; ANDERSON, MW; MOEHRING, HD; MCKINLEY, T				LAORR, A; GREENSPAN, A; ANDERSON, MW; MOEHRING, HD; MCKINLEY, T			TRAUMATIC HIP DISLOCATION - EARLY MRI FINDINGS	SKELETAL RADIOLOGY			English	Article						HIP; MRI STUDIES; MUSCLE, INJURIES; BONE, INJURIES; HIP DISLOCATION	POSTERIOR DISLOCATION; FEMORAL-HEAD; AVASCULAR NECROSIS; MUSCLE TEARS; FRACTURES; INJURIES; KNEE	Purpose. Objective of this study was to present the spectrum of early magnetic resonance imaging (MRI) findings following traumatic dislocation of the femoral head, and to identify any associated injuries that may have therapeutic or prognostic significance and be better delineated by MRI than by conventional radiography. Patients and methods. Prospective MRI of both hips was performed on 18 patients (14 male, 4 female; age range 14-54 years; average age 30.5 years) within 5 weeks of a traumatic femoral head dislocation. The interval between the time of injury and the imaging studies ranged from 2 to 35 days (average 13.2 days). Posterior dislocation was present in 14 patients and anterior dislocation in 4 patients. In the majority of cases, we performed axial T1, coronal T1, and coronal T2* (MPGR) sequences. Images were retrospectively evaluated by consensus of three radiologists for possible abnormalities of the bone and cartilage, joint space, and soft tissues. Because all patients were treated with closed reduction, surgical correlation was not obtained. Results. All patients had a joint effusion or hemarthrosis. Of the 14 patients with posterior dislocation, isolated femoral head contusions (trabecular microfractures) were identified in 6 patients. Four patients had small femoral head fractures, and one had an osteochondral defect. Acetabular lip fractures were seen in six patients, and one patient had a labral tear. Four patients had intra-articular loose bodies and one had ligamentum teres entrapment. Twelve patients had iliofemoral ligament injury. All patients had muscle injury involving the gluteal region and medial fascial compartment, and 13 patients had anterior fascial compartment muscle injury. Seven patients with posterior dislocation had posterior fascial compartment injury. Of the four patients with anterior dislocation, two had bony contusion, two had cortical infraction, one had a labral tear, and all four had an iliofemoral ligament injury. All four patients in this group had muscle injury of the gluteal region and of the anterior and medial fascial compartments.	UNIV CALIF DAVIS, MED CTR, DEPT RADIOL, SACRAMENTO, CA 95817 USA; UNIV CALIF DAVIS, MED CTR, DEPT ORTHOPAED, SACRAMENTO, CA 95817 USA								ALLARD JC, 1992, MAGN RESON IMAGING, V10, P155, DOI 10.1016/0730-725X(92)90385-D; COOPER DE, 1991, AM J SPORT MED, V19, P322, DOI 10.1177/036354659101900319; DESMET AA, 1990, SKELETAL RADIOL, V19, P283, DOI 10.1007/BF00191673; DESMET AA, 1993, SKELETAL RADIOL, V22, P479, DOI 10.1007/BF00209094; DEUTSCH AL, 1989, RADIOLOGY, V170, P113, DOI 10.1148/radiology.170.1.2909083; ENSIGN MF, 1990, SEMIN ULTRASOUND CT, V11, P288; EPSTEIN HC, 1972, J BONE JOINT SURG AM, VA 54, P1561; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, V92, P116; FLECKENSTEIN JL, 1989, RADIOLOGY, V172, P793, DOI 10.1148/radiology.172.3.2772190; HOUGAARD K, 1986, ARCH ORTHOP TRAUM SU, V106, P32, DOI 10.1007/BF00435649; HOUGAARD K, 1987, J BONE JOINT SURG BR, V69, P556, DOI 10.1302/0301-620X.69B4.3611158; KUM C K, 1990, SMJ Singapore Medical Journal, V31, P22; LYNCH TCP, 1989, RADIOLOGY, V171, P761, DOI 10.1148/radiology.171.3.2717748; MEYERS MH, 1988, CLIN ORTHOP RELAT R, P51; MINK JH, 1989, RADIOLOGY, V170, P823, DOI 10.1148/radiology.170.3.2916038; MIROVSKY Y, 1988, J TRAUMA, V28, P1597, DOI 10.1097/00005373-198811000-00016; MITCHELL DG, 1986, RADIOLOGY, V161, P199, DOI 10.1148/radiology.161.1.3763867; MITCHELL DG, 1989, CLIN ORTHOP RELAT R, V244, P60; NERUBAY J, 1976, CLIN ORTHOP RELAT R, P129; PIGGOT J, 1961, J BONE JOINT SURG BR, V43, P38; RICHARDSON P, 1990, AM J ROENTGENOL, V155, P93, DOI 10.2214/ajr.155.1.2112874; RIEGER H, 1991, ARCH ORTHOP TRAUM SU, V110, P114, DOI 10.1007/BF00393886; SHELLOCK FG, 1994, APPL RADIOL, V23, P11; SHERLOCK DA, 1988, J TRAUMA, V28, P411, DOI 10.1097/00005373-198803000-00021; SLATIS P, 1974, INJURY, V5, P188, DOI 10.1016/S0020-1383(74)80003-3; Snell RS, 1992, CLIN ANATOMY MED STU, P764; UPADHYAY SS, 1985, J BONE JOINT SURG BR, V67, P232, DOI 10.1302/0301-620X.67B2.3884614; UPADHYAY SS, 1983, J BONE JOINT SURG BR, V65, P150, DOI 10.1302/0301-620X.65B2.6826619; VONLAER L, 1986, FRAKTUREN LUXATIONEN, P142; WINGSTRAND H, 1986, ACTA ORTHOP SCAND, V57, P305, DOI 10.3109/17453678608994397; YANG RS, 1991, CLIN ORTHOP RELAT R, P218	31	51	52	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2348	1432-2161		SKELETAL RADIOL	Skeletal Radiol.	MAY	1995	24	4					239	245					7	Orthopedics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Radiology, Nuclear Medicine & Medical Imaging	QY621	WOS:A1995QY62100001	7644933				2022-02-06	
J	SIOUTOS, PJ; OROZCO, JA; CARTER, LP; WEINAND, ME; HAMILTON, AJ; WILLIAMS, FC				SIOUTOS, PJ; OROZCO, JA; CARTER, LP; WEINAND, ME; HAMILTON, AJ; WILLIAMS, FC			CONTINUOUS REGIONAL CEREBRAL CORTICAL BLOOD-FLOW MONITORING IN HEAD-INJURED PATIENTS	NEUROSURGERY			English	Article						BRAIN ISCHEMIA; CEREBRAL BLOOD FLOW; THERMAL DIFFUSION FLOWMETRY; TRAUMATIC BRAIN INJURY	TRAUMATIC BRAIN INJURY; XENON ENHANCED CT; THERMAL-DIFFUSION; INTRAOPERATIVE MEASUREMENT; INTRAVENTRICULAR PRESSURE; COMATOSE PATIENTS; METABOLISM; ISCHEMIA; CLEARANCE; PERFUSION	CONTINUOUS REGIONAL CEREBRAL cortical blood flow (rCoBF) was monitored with thermal diffusion flowmetry in 56 severely head-injured patients. Adequate, reliable data were accumulated from 37 patients (21 acute subdural hematomas, 10 cerebral contusions, 4 epidural hematomas, and 2 intracerebral hematomas). The thermal sensor was placed at the time of either craniotomy or burr hole placement. In 15 patients, monitoring was initiated within 8 hours of injury. One-third of the comatose patients monitored within 8 hours had rCoBF measurements of 18 ml per 100 g per minute or less, consistent with previous reports of significant ischemia in the early postinjury period. Initial rCoBF measurements were similar in the patients with Glasgow Coma Scale scores of 3 to 7 and in those with scores of 8 or greater. In patients with poor outcomes, rCoBF measurements did not change significantly from initial measurements; however, in those patients who had better outcomes, final rCoBF measurements were higher than initial rCoBF measurements. The patients who had better outcomes experienced normalization of rCoBF during the period of monitoring, and patients with poor outcomes had markedly reduced final rCoBF. These changes were statistically significant. When management was based strictly upon the intracranial pressure, examples of inappropriate treatment were found. For example, hyperemia and increased intracranial pressure treated with mannitol caused further rCoBF increase, and elevated intracranial pressure with low cerebral blood flow treated with hyperventilation increased the severity of ischemia. In 3 (5%) of 56 patients, wound infections developed. Continuous rCoBF monitoring in head-injured patients offers new therapeutic and prognostic insights into their management.	UNIV OKLAHOMA,SCH MED,DEPT NEUROSURG,OKLAHOMA CITY,OK; UNIV ARIZONA,SCH MED,DEPT SURG,NEUROSURG SECT,TUCSON,AZ								AGNOLI A, 1969, CEREBRAL BLOOD FLOW, P31; ARBIT E, 1989, NEUROSURGERY, V24, P166, DOI 10.1227/00006123-198902000-00003; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BARCLAY L, 1985, BIOL PSYCHIAT, V20, P146, DOI 10.1016/0006-3223(85)90074-5; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CARTER LP, 1973, STROKE, V4, P917, DOI 10.1161/01.STR.4.6.917; CARTER LP, 1973, J NEUROL NEUROSUR PS, V36, P906, DOI 10.1136/jnnp.36.6.906; CARTER LP, 1983, NEUROSURGERY, V12, P620; CARTER LP, 1978, NEUROSURGERY, V2, P223; CARTER LP, 1981, STROKE, V12, P513, DOI 10.1161/01.STR.12.4.513; DICKMAN CA, 1991, NEUROSURGERY, V28, P467, DOI 10.1227/00006123-199103000-00026; DRAYER BP, 1978, STROKE, V9, P123, DOI 10.1161/01.STR.9.2.123; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; GAINES C, 1983, STROKE, V14, P66, DOI 10.1161/01.STR.14.1.66; GOKASLAN ZL, 1989, J NEUROSURG, V70, pA323; GOPINATH SP, 1993, 1993 AANS ANN M BOST; GUR D, 1982, STROKE, V13, P750, DOI 10.1161/01.STR.13.6.750; HERSCHOVICH P, 1987, CEREBRAL BLOOD FLOW, P257; JENNETT B, 1975, LANCET, V1, P480; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KETY SS, 1945, AM J PHYSIOL, V143, P53, DOI 10.1152/ajplegacy.1945.143.1.53; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; MALLETT BL, 1965, CLIN SCI, V29, P179; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MEYER JS, 1981, STROKE, V12, P426, DOI 10.1161/01.STR.12.4.426; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROSENBLUM BR, 1987, J NEUROSURG, V66, P396, DOI 10.3171/jns.1987.66.3.0396; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; TURNER R, 1993, MAGNET RESON MED, V29, P277, DOI 10.1002/mrm.1910290221	38	51	52	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1995	36	5					943	949		10.1227/00006123-199505000-00009			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	QV351	WOS:A1995QV35100031	7791986				2022-02-06	
J	DIXON, CE; BAO, JL; BERGMANN, JS; JOHNSON, KM				DIXON, CE; BAO, JL; BERGMANN, JS; JOHNSON, KM			TRAUMATIC BRAIN INJURY REDUCES HIPPOCAMPAL HIGH-AFFINITY [H-3] CHOLINE UPTAKE BUT NOT EXTRACELLULAR CHOLINE LEVELS IN RATS	NEUROSCIENCE LETTERS			English	Article						CHOLINE; HIGH AFFINITY CHOLINE UPTAKE; HIPPOCAMPUS; MICRODIALYSIS; BRAIN INJURY	CONTROLLED CORTICAL IMPACT; MEMORY	Hippocampal cholinergic hypofunction may contribute to memory deficits following experimental traumatic brain injury. These studies examined two important factors in acetylcholine synthesis: choline availability and neuronal uptake. No reductions in basal extracellular choline levels, using microdialysis, were observed 2 weeks after cortical impact injury. However, studies of high affinity [H-3]choline uptake in the hippocampus, measured in a synaptosomal preparation, found a reduction in the maximum velocity of choline uptake (V-max), while no differences in affinity constants (K-m) were found. The results suggest that post-traumatic cholinergic deficits are not attributable to decreased availability of choline, but may be associated with either a decreased ability of cholinergic neurons to take up choline and/or a loss of cholinergic neurons.	UNIV TEXAS,MED BRANCH,DEPT PHARMACOL & TOXICOL,GALVESTON,TX 77555		DIXON, CE (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,6431 FANNIN ST,SUITE 7148,HOUSTON,TX 77030, USA.		Johnson, Kenneth/E-7944-2014		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49-CCR303547] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458, P01 NS31998] Funding Source: Medline		BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Dixon C. E., 1993, Society for Neuroscience Abstracts, V19, P1486; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1991, J NEUROSCI METH, V39, P253; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; JOHNSON KM, 1978, PHARMACOLOGY, V17, P83, DOI 10.1159/000136839; LEONARD JR, IN PRESS J NEUROTRAU; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MASH DC, 1985, SCIENCE, V228, P1115, DOI 10.1126/science.3992249; MOGHADDAM B, 1989, SYNAPSE, V4, P156, DOI 10.1002/syn.890040209; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	15	51	53	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	OCT 24	1994	180	2					127	130		10.1016/0304-3940(94)90503-7			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PQ428	WOS:A1994PQ42800011	7700564				2022-02-06	
J	CARDENAS, DD; MCLEAN, A; FARRELLROBERTS, L; BAKER, L; BROOKE, M; HASELKORN, J				CARDENAS, DD; MCLEAN, A; FARRELLROBERTS, L; BAKER, L; BROOKE, M; HASELKORN, J			ORAL PHYSOSTIGMINE AND IMPAIRED MEMORY IN ADULTS WITH BRAIN INJURY	BRAIN INJURY			English	Article							ALZHEIMERS PRESENILE-DEMENTIA; HEAD-INJURY; MNESIC PERFORMANCES; SCOPOLAMINE; DISEASE	The purpose of this study was to examine the effects of physostigmine, a cholinergic agonist, on memory loss after traumatic brain injury (TBI), as compared to placebo or scopolamine, a cholinergic antagonist, using a double-blind, placebo-controlled design. Each subject received each active drug and placebo. Neuropsychological measures (Wechsler Memory Scale I and II, Selective Reminding Test, Trail-Making Test, Parts A and B, Digit Symbol, and Memory Questionnaire) and measures of clinical balance were completed at baseline, after each drug phase, and at 1 month follow-up. Thirty-six subjects completed the study with results showing an improvement in memory scores in 44% of subjects (responders) while taking oral physostigmine. The most sensitive measure was the Selective Reminding Test, specifically Long-term Storage. The impact of drugs on standing balance as compared to placebo was improved standing time in the responders: (1) with physostigmine when standing tandem with eyes closed (p<0.05), and (2) with scopolamine when standing on one foot with eyes closed (p<0.05). Results support the potential benefit of cholinergic agonists on memory after TBI and the need for further research of possible clinical markers for the drug.	NEUROCARE INC,CONCORD,CA; VET ADM MED CTR,SEATTLE,WA; TUFTS UNIV,SCH MED,BOSTON,MA 02111		CARDENAS, DD (corresponding author), UNIV WASHINGTON,DEPT REHABIL MED,RJ-30,SEATTLE,WA 98195, USA.						BARTUS RT, 1979, SCIENCE, V206, P1087, DOI 10.1126/science.227061; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROOKS DN, 1975, CORTEX, V11, P328; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Butler PF, 1932, J AMER MED ASSOC, V99, P1329, DOI 10.1001/jama.1932.02740680025006; CAINE ED, 1981, PSYCHOPHARMACOLOGY, V74, P74, DOI 10.1007/BF00431761; CALTAGIRONE C, 1982, INT J NEUROSCI, V16, P247, DOI 10.3109/00207458209147153; CALTAGIRONE C, 1983, INT J NEUROSCI, V18, P143, DOI 10.3109/00207458308985888; COYE MJ, 1986, J OCCUP MED, V28, P519; DAVIS KL, 1978, LIFE SCI, V23, P1729, DOI 10.1016/0024-3205(78)90100-5; DAVIS KL, 1978, SCIENCE, V201, P272, DOI 10.1126/science.351807; DEUTSCH JA, 1971, SCIENCE, V174, P788, DOI 10.1126/science.174.4011.788; Drachman D. A., 1979, NUTR BRAIN, V5, P351; Grober E, 1989, J Cogn Neurosci, V1, P327, DOI 10.1162/jocn.1989.1.4.327; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; LEVIN ED, 1990, BEHAV NEURAL BIOL, V54, P271, DOI 10.1016/0163-1047(90)90639-N; Levin HS., 1982, NEUROBEHAVIORAL CONS; Martin HE, 1925, J AMER MED ASSOC, V84, P1407, DOI 10.1001/jama.1925.02660450015009; McLean A Jr, 1987, Brain Inj, V1, P145, DOI 10.3109/02699058709034453; MOHS R, 1980, AGING 1980S, P181; MOHS RC, 1982, ALZHEIMERS DISEASE R, P351; PARROTT AC, 1987, NEUROPSYCHOBIOLOGY, V17, P53, DOI 10.1159/000118371; PETERS BH, 1982, AGING ALZHEIMERS DIS, P421; PIETERKARK RA, 1977, NEUROLOGY, V27, P70; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; REUSCH J, 1944, AM J PSYCHIAT, V100, P480; RIDLEY RM, 1988, BRAIN RES, V456, P71, DOI 10.1016/0006-8993(88)90348-4; Ritvo M, 1927, AM J ROENTGENOL RADI, V18, P301; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHARPLESS NS, 1985, LANCET, V1, P1397; SMITH CM, 1982, ALZHEIMERS DISEASE R, P405; SULLIVAN EV, 1982, ALZHEIMERS DISEASE R, P361; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; THAL LJ, 1983, ANN NEUROL, V13, P491, DOI 10.1002/ana.410130504; THAL LJ, 1983, NEW ENGL J MED, V308, P720; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; ZEISEL S, 1981, NATURE, V293, P187, DOI 10.1038/293187a0	41	51	52	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1994	8	7					579	587		10.3109/02699059409151010			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	PH426	WOS:A1994PH42600001	7804294				2022-02-06	
J	SMALHEISER, NR; SWANSON, DR				SMALHEISER, NR; SWANSON, DR			ASSESSING A GAP IN THE BIOMEDICAL LITERATURE - MAGNESIUM-DEFICIENCY AND NEUROLOGIC DISEASE	NEUROSCIENCE RESEARCH COMMUNICATIONS			English	Article						MAGNESIUM; NMDA RECEPTOR; EXCITOTOXICITY; DIET; INFORMATION RETRIEVAL	AMYOTROPHIC-LATERAL-SCLEROSIS; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; LOW CALCIUM-MAGNESIUM; DEPRIVATION ENCEPHALOPATHY; MULTIPLE-SCLEROSIS; KII PENINSULA; YOUNG-RATS; MIGRAINE; NEURONS	Recent studies have focused great attention upon the role of NMDA receptor-mediated excitotoxicity in the pathogenesis of a variety of acute and chronic neurologic diseases, and upon the role of endogenous Mg ions in regulating this process. Yet, very few studies have sought to ascertain whether exogenous, e.g., dietary, manipulations of Mg levels can modulate brain function or the expression of neurologic diseases (apart from hyperexcitability and seizures that are elicited directly when Mg levels are extremely low). We argue that this issue is important, and should be addressed in existing animal models of acute and chronic CNS insults.	UNIV CHICAGO, INFORMAT SCI, CHICAGO, IL 60637 USA		SMALHEISER, NR (corresponding author), UNIV CHICAGO, DEPT PEDIAT, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.						ABELE AE, 1990, NEURON, V4, P413, DOI 10.1016/0896-6273(90)90053-I; ADAM WR, 1989, CLIN EXP PHARMACOL P, V16, P33, DOI 10.1111/j.1440-1681.1989.tb01906.x; Altura B M, 1991, Magnes Trace Elem, V10, P182; ALTURA BM, 1978, BLOOD VESSELS, V15, P5; ARSENIAN MA, 1993, PROG CARDIOVASC DIS, V35, P271, DOI 10.1016/0033-0620(93)90008-2; BARBEAU A, 1972, EXPERIENTIA, V28, P289, DOI 10.1007/BF01928694; Castelli S, 1993, Pediatr Med Chir, V15, P481; CEVETTE MJ, 1989, OTOLARYNG HEAD NECK, V101, P537, DOI 10.1177/019459988910100504; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHUTKOW JG, 1979, J NEURAL TRANSM, V44, P297, DOI 10.1007/BF01250324; CHUTKOW JG, 1972, AM J PHYSIOL, V223, P1407, DOI 10.1152/ajplegacy.1972.223.6.1407; CHUTKOW JG, 1974, NEUROLOGY, V24, P780, DOI 10.1212/WNL.24.8.780; Costello R B, 1992, Magnes Res, V5, P61; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DEPOORTERE H, 1993, NEUROPSYCHOBIOLOGY, V27, P237, DOI 10.1159/000118988; Durlach J, 1989, Magnes Res, V2, P195; Durlach J, 1990, Magnes Res, V3, P217; ELIN RJ, 1988, YEARBOOK CHICAGO, V34, P161; FACCHINETTI F, 1991, HEADACHE, V31, P298, DOI 10.1111/j.1526-4610.1991.hed3105298.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; GALLAI V, 1992, HEADACHE, V32, P132, DOI 10.1111/j.1526-4610.1992.hed3203132.x; GALLAI V, 1993, CEPHALALGIA, V13, P94, DOI 10.1046/j.1468-2982.1993.1302094.x; Galland L, 1991, Magnes Trace Elem, V10, P287; GARRUTO RM, 1985, NEUROLOGY, V35, P193, DOI 10.1212/WNL.35.2.193; GLICK JL, 1990, MED HYPOTHESES, V31, P211, DOI 10.1016/0306-9877(90)90095-V; GOLDBERG P, 1986, MED HYPOTHESES, V21, P193, DOI 10.1016/0306-9877(86)90010-1; GOTO I, 1986, BRAIN RES, V372, P31, DOI 10.1016/0006-8993(86)91455-1; GUIDERI G, 1985, J AM COLL NUTR, V4, P139; GUNTHER T, 1988, BIOL TRACE ELEM RES, V16, P43, DOI 10.1007/BF02795332; GUNTHER T, 1981, TERATOLOGY, V24, P225, DOI 10.1002/tera.1420240213; ISHIGAMI M, 1991, ALCOHOL CLIN EXP RES, V15, P757, DOI 10.1111/j.1530-0277.1991.tb00594.x; Joachims Z, 1993, Schriftenr Ver Wasser Boden Lufthyg, V88, P503; KANOFSKY JD, 1991, INT J NEUROSCI, V61, P87, DOI 10.3109/00207459108986275; KASSOUNY ME, 1985, INT J VITAM NUTR RES, V55, P295; KIMURA M, 1977, J NEUROCHEM, V28, P389, DOI 10.1111/j.1471-4159.1977.tb07759.x; Kubena K S, 1990, Magnes Res, V3, P219; KUMAMOTO T, 1979, EXPERIENTIA, V35, P1604, DOI 10.1007/BF01953218; LANDFIELD PW, 1984, BRAIN RES, V322, P167, DOI 10.1016/0006-8993(84)91199-5; LERMA A, 1993, ANN NUTR METAB, V37, P210, DOI 10.1159/000177770; Luthringer C, 1988, Magnes Res, V1, P163; MANSMANN HC, 1993, PEDIATR ASTHMA ALLER, V7, P211, DOI 10.1089/pai.1993.7.211; Marier JR, 1982, MAGNESIUM, V1, P3; MAUSKOP A, 1993, HEADACHE, V33, P135, DOI 10.1111/j.1526-4610.1993.hed3303135.x; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCCREARY PA, 1966, P SOC EXP BIOL MED, V121, P1130; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Mitani K, 1992, Magnes Res, V5, P203; Morris M E, 1992, Magnes Res, V5, P303; MURAKAMI M, 1975, ENDOKRINOLOGIE, V66, P268; NAKAGAWA S, 1980, WAKAYAMA MED REP, V22, P1; NAKANISHI H, 1991, EUR J PHARMACOL, V204, P29, DOI 10.1016/0014-2999(91)90831-A; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OPAVSKY J, 1991, Acta Universitatis Palackianae Olomucensis Facultatis Medicae, V131, P157; POENARU S, 1984, MAGNESIUM-B, V6, P142; RAMADAN NM, 1989, HEADACHE, V29, P416, DOI 10.1111/j.1526-4610.1989.hed2907416.x; Rayssiguier Y, 1984, Magnesium, V3, P226; ROOT EJ, 1988, NUTR REP INT, V37, P959; SARCHIELLI P, 1992, CEPHALALGIA, V12, P21, DOI 10.1046/j.1468-2982.1992.1201021.x; SAUL RF, 1991, ARCH NEUROL-CHICAGO, V38, P650; SCHOENEN J, 1991, CEPHALALGIA, V11, P97, DOI 10.1046/j.1468-2982.1991.1102097.x; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SEELIG MS, 1964, AM J CLIN NUTR, V14, P342, DOI 10.1093/ajcn/14.6.342; SEELIG MS, 1993, J AM COLL NUTR, V12, P442, DOI 10.1080/07315724.1993.10718335; SHILS ME, 1969, MEDICINE, V48, P61, DOI 10.1097/00005792-196901000-00003; SHILS ME, 1988, ANNU REV NUTR, V8, P429, DOI 10.1146/annurev.nu.08.070188.002241; SINGH NP, 1979, ARCH ENVIRON HEALTH, V34, P168, DOI 10.1080/00039896.1979.10667391; SMITT PAES, 1989, J NEUROL SCI, V91, P231, DOI 10.1016/0022-510X(89)90056-7; SREBRO Z, 1972, ACTA NEUROPATHOL, V21, P258, DOI 10.1007/BF00688505; STAFFORD RE, 1993, BIOCHEM BIOPH RES CO, V196, P596, DOI 10.1006/bbrc.1993.2291; SWANSON DR, 1986, PERSPECT BIOL MED, V30, P7; SWANSON DR, 1993, LIBR TRENDS, V41, P606; SWANSON DR, 1990, PERSPECT BIOL MED, V33, P157; SWANSON DR, 1990, B MED LIBR ASSOC, V78, P29; SWANSON DR, 1988, PERSPECT BIOL MED, V31, P526; Taubert K, 1991, Z Arztl Fortbild (Jena), V85, P67; Thomas J, 1992, Magnes Res, V5, P127; TOUITOU Y, 1987, CLIN CHEM, V33, P518; TRAVIESA DC, 1974, J NEUROL NEUROSUR PS, V37, P959, DOI 10.1136/jnnp.37.8.959; WEGLICKI WB, 1992, AM J PHYSIOL, V263, pR734; WHETSELL WO, 1993, LAB INVEST, V68, P372; WONG ET, 1983, AM J CLIN PATHOL, V79, P348, DOI 10.1093/ajcp/79.3.348; YASUI M, 1990, ACTA NEUROL SCAND, V81, P197; YASUI M, 1990, J NEUROL SCI, V99, P177, DOI 10.1016/0022-510X(90)90154-F; YASUI M, 1992, EUR NEUROL, V32, P95, DOI 10.1159/000116800; Yasui M, 1992, Magnes Res, V5, P295; YASUI M, 1991, BIOL TRACE ELEM RES, V31, P293, DOI 10.1007/BF02990198; YASUI M, 1991, NEUROTOXICOLOGY, V12, P615; YOSHIDA S, 1990, BIOMED RES-TOKYO, V11, P11, DOI 10.2220/biomedres.11.11	92	51	52	2	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0893-6609			NEUROSCI RES COMMUN	Neurosci. Res. Commun.	JUL-AUG	1994	15	1					1	9					9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PA792	WOS:A1994PA79200001					2022-02-06	
J	SIETSEMA, JM; NELSON, DL; MULDER, RM; MERVAUSCHEIDEL, D; WHITE, BE				SIETSEMA, JM; NELSON, DL; MULDER, RM; MERVAUSCHEIDEL, D; WHITE, BE			THE USE OF A GAME TO PROMOTE ARM REACH IN PERSONS WITH TRAUMATIC BRAIN INJURY	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						DEVELOPMENTAL TASKS; MOTOR CONTROL; MOVEMENT ANALYSIS; NEURODEVELOPMENTAL THERAPY	CEREBRAL-PALSY; ADDED-PURPOSE; PERFORMANCE; OCCUPATION	This study tested a principle of occupational therapy and motor learning theory in the context of neurodevelopmental treatment techniques. Ten trials of occupationally embedded intervention (playing Simon,(TM) a computer-controlled game) were compared with 10 trials of rote arm-reach exercise. A counterbalanced design was structured so that each subject experienced each condition one week apart Subjects were 17 men and 3 women with traumatic brain injury who exhibited mild to moderate spasticity in the upper extremity. Maximum distance from hip to wrist during active reach of the affected extremity was measured by digitization of videotape with the Motion Analysis(TM) EV-3D system. Results indicated that the use of the game elicited significantly more range of motion than the rote exercise (t (19) = 5 77, p < .001). These results support the use of an occupationally embedded intervention for persons with traumatic brain injury and add to the theoretical base of occupational therapy.	NETWORK BRAIN INJURY PROGRAM, GRAND RAPIDS, MI USA; WESTERN MICHIGAN ARTHRIT INST, GRAND RAPIDS, MI USA; WESTERN MICHIGAN UNIV, DEPT OCCUPAT THERAPY, KALAMAZOO, MI 49008 USA; NOVACARE, GRAND RAPIDS, MI USA; MARY FREE BED HOSP & REHABIL CTR, GRAND RAPIDS, MI USA; WESTERN MICHIGAN UNIV, DEPT IND ENGN, KALAMAZOO, MI 49008 USA								Bernstein NA., 1967, COORDINATION REGULAT; BLOCH MW, 1989, AM J OCCUP THER, V43, P25, DOI 10.5014/ajot.43.1.25; BOBATH B, 1971, ABNORMAL POSTURAL RE; BOBATH B, 1979, ADULT HEMIPLEGIA EVA; Carr JH, 1987, MOTOR RELEARNING PRO; Christiansen C., 1991, OCCUPATIONAL THERAPY; DAVIS PM, 1985, STEPS FOLLOW GUIDE T; DOW PW, 1989, OCCUPATIONAL THERAPY, P484; EGGERS O, 1983, OCCUPATIONALO THERAP; FIDLER GS, 1978, AM J OCCUP THER, V32, P305; HECK SA, 1988, AM J OCCUP THER, V42, P577, DOI 10.5014/ajot.42.9.577; KIELHOFNER G, 1980, AM J OCCUP THER, V34, P572, DOI 10.5014/ajot.34.9.572; KIRCHER MA, 1984, AM J OCCUP THER, V38, P165, DOI 10.5014/ajot.38.3.165; KLUZIK J, 1990, PHYS THER, V70, P65, DOI 10.1093/ptj/70.2.65; MALKMUS D, 1980, REHABILITATION HEAD; Marteniuk RG, 1979, PHYSIOTHER CAN, V31, P187; MATHIOWETZ VG, 1992, THESIS U MINNESOTA; MCPHERSON JJ, 1991, AM J OCCUP THER, V45, P123, DOI 10.5014/ajot.45.2.123; MILLER L, 1987, Occupational Therapy in Mental Health, V7, P55, DOI 10.1300/J004v07n01_04; Mosey AC., 1986, PSYCHOSOCIAL COMPONE; Mullins C., 1987, PHYSICAL OCCUPATIONA, V5, P29, DOI 10.1300/J148v05n03_04; NELSON DL, 1988, AM J OCCUP THER, V42, P633, DOI 10.5014/ajot.42.10.633; NELSON DL, 1989, TOP GERIATR REHABIL, V4, P12; Posner M. I., 1967, LEARNING SKILLED PER; SABARI JS, 1991, AM J OCCUP THER, V45, P523, DOI 10.5014/ajot.45.6.523; Schmidt R. A., 1988, MOTOR CONTROL LEARNI; STEINBECK TM, 1986, AM J OCCUP THER, V40, P529, DOI 10.5014/ajot.40.8.529; WEST WL, 1984, AM J OCCUP THER, V38, P15, DOI 10.5014/ajot.38.1.15; YODER RM, 1989, AM J OCCUP THER, V43, P581, DOI 10.5014/ajot.43.9.581	29	51	52	0	11	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JAN	1993	47	1					19	24		10.5014/ajot.47.1.19			6	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	KC858	WOS:A1993KC85800003	8418672				2022-02-06	
J	COLLINS, JC; LEVINE, G; WAXMAN, K				COLLINS, JC; LEVINE, G; WAXMAN, K			OCCULT TRAUMATIC PNEUMOTHORAX - IMMEDIATE TUBE THORACOSTOMY VERSUS EXPECTANT MANAGEMENT	AMERICAN SURGEON			English	Article; Proceedings Paper	1992 ANNUAL MEETING OF THE SOUTHERN CALIFORNIA CHAPTER OF THE AMERICAN COLLEGE OF SURGEONS	JAN 17-19, 1992	INDIAN WELLS, CA	AMER COLL SURGEONS, SO CALIF CHAPTER			DIAGNOSIS	Occult pneumothorax is pneumothorax identified by computed tomography but not seen on conventional chest radiographs. Twenty-seven occult traumatic pneumothoraces in 26 patients were identified retrospectively at the authors' level I trauma center. Of these, 24 patients survived to discharge or transfer, 2 died of brain injury. Eleven patients were treated immediately with tube thoracostomy (TT) and 13 were observed with interval chest radiography. The authors' data support the conclusion that it is safe to withhold immediate TT in patients who are hemodynamically stable. Close clinical observation and interval chest radiography can identify those patients who require subsequent TT. Prospective study of larger numbers of patients is needed to confirm the safety and cost efficacy of this approach.	UNIV CALIF IRVINE,DEPT SURG,ORANGE,CA 92668; UNIV CALIF IRVINE,DEPT RADIOL,ORANGE,CA 92668		WAXMAN, K (corresponding author), UNIV CALIF IRVINE,MED CTR,101 CITY DR,ORANGE,CA 92668, USA.						BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BLAIR E, 1971, J TRAUM, V11, P129, DOI 10.1097/00005373-197102000-00005; GARRAMONE RR, 1991, SURG GYNECOL OBSTET, V173, P257; HEHIR MD, 1990, AUST NZ J SURG, V60, P529, DOI 10.1111/j.1445-2197.1990.tb07420.x; SHORR RM, 1987, ANN SURG, V206, P200, DOI 10.1097/00000658-198708000-00013; TOCINO IM, 1984, AM J ROENTGENOL, V143, P987, DOI 10.2214/ajr.143.5.987; WALL SD, 1983, AM J ROENTGENOL, V141, P919, DOI 10.2214/ajr.141.5.919; 1989, ADV TRAUMA LIFE SUPP	8	51	51	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352	0003-1348			AM SURGEON	Am. Surg.	DEC	1992	58	12					743	746					4	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	KC519	WOS:A1992KC51900007	1456598				2022-02-06	
J	SCHMOKER, JD; ZHUANG, J; SHACKFORD, SR; ROSNER, MJ; POOLE, GV; SIEGEL, JH; TRASK, AL; SCHMOKER, J				SCHMOKER, JD; ZHUANG, J; SHACKFORD, SR; ROSNER, MJ; POOLE, GV; SIEGEL, JH; TRASK, AL; SCHMOKER, J			HEMORRHAGIC HYPOTENSION AFTER BRAIN INJURY CAUSES AN EARLY AND SUSTAINED REDUCTION IN CEREBRAL OXYGEN DELIVERY DESPITE NORMALIZATION OF SYSTEMIC OXYGEN DELIVERY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	51ST ANNUAL SESSION OF THE AMERICAN ASSOC FOR THE SURGERY OF TRAUMA	SEP 11-14, 1991	PHILADELPHIA, PA	AMER ASSOC SURG TRAUMA			6-PERCENT DEXTRAN-70; HYPERTONIC SALINE; 7.5-PERCENT NACL; SHOCK; RESUSCITATION; SWINE	Morbidity and mortality are doubled when hemorrhagic hypotension (HEM) accompanies a traumatic brain injury (TBI). Hemorrhagic hypotension initiates a "secondary" injury (SI) that has been attributed to ischemia, but this has not been confirmed in the laboratory. All previous studies have been of relatively short duration (<6 hours), allowing insufficient time to study the pathophysiology of SI, since maximal intracranial pressure (ICP) elevations may occur 16 to 20 hours after injury. We hypothesized that HEM combined with TBI would reduce cerebral oxygen delivery (cO2del) and cerebral metabolic rate for oxygen (cMR(o2)) to a greater degree than would occur with TBI alone. In a porcine model of TBI and HEM we recorded systemic oxygen delivery (sO2del), ICP, cerebral blood flow (CBF), cO2del, cMRO2, brain oxygen extraction ratio (cO2ER), and cortical water content (CWC) over a 24-hour study period. Controls (n = 7) were instrumented only, group 1 (n = 14) received a focal cryogenic lesion only, group 2 (n = 21) received a cryogenic lesion plus hemorrhage to 50 mm Hg for 45 minutes. Animals were resuscitated with crystalloid solutions; shed blood in group 2 animals was returned after one hour. Hemorrhagic hypotension following TBI produced a significant and sustained reduction in cO2del associated with a lower cMR(O)2 and CO2ER, and higher ICP and CWC, than seen with lesion alone. This occurred despite adequate early restoration of sO2del. This confirms that cerebral ischemia is ongoing despite restoration of systemic hemodynamics.	UNIV VERMONT,COLL MED,DEPT SURG,BURLINGTON,VT 05405						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1-R01-NS 28637-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028637] Funding Source: NIH RePORTER		CHESNUT RM, 1991, JAMA; CLASEN RA, 1953, SURG GYNECOL OBSTET, V96, P605; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; GAZITUA S, 1969, AM J PHYSIOL, V217, P1216, DOI 10.1152/ajplegacy.1969.217.4.1216; GAZITUA S, 1971, AM J PHYSIOL, V220, P384, DOI 10.1152/ajplegacy.1971.220.2.384; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; MANINGAS PA, 1987, CRIT CARE MED, V15, P1121, DOI 10.1097/00003246-198712000-00009; MANINGAS PA, 1986, ANN EMERG MED, V15, P1131, DOI 10.1016/S0196-0644(86)80852-6; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; NERLICH M, 1983, CIRC SHOCK, V10, P179; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; Pasztor E, 1973, STROKE, V4, P556, DOI 10.1161/01.STR.4.4.556; READ RC, 1960, CIRC RES, V8, P538, DOI 10.1161/01.RES.8.3.538; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; WALD S, 1991, Journal of Trauma, V31, P1041, DOI 10.1097/00005373-199107000-00102; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; ZHUANG J, 1992, IN PRESS J TRAUMA; [No title captured]	24	51	53	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1992	32	6					714	722		10.1097/00005373-199206000-00007			9	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	JB335	WOS:A1992JB33500008	1613830				2022-02-06	
J	DEUTSCHMAN, CS; KONSTANTINIDES, FN; RAUP, S; THIENPRASIT, P; CERRA, FB				DEUTSCHMAN, CS; KONSTANTINIDES, FN; RAUP, S; THIENPRASIT, P; CERRA, FB			PHYSIOLOGICAL AND METABOLIC RESPONSE TO ISOLATED CLOSED-HEAD INJURY .1. BASAL METABOLIC STATE - CORRELATIONS OF METABOLIC AND PHYSIOLOGICAL-PARAMETERS WITH FASTING AND STRESSED CONTROLS	JOURNAL OF NEUROSURGERY			English	Article									UNIV MINNESOTA, SCH MED, DEPT SURG, MINNEAPOLIS, MN 55455 USA; ST PAUL RAMSEY MED CTR, DEPT SURG, DIV NEUROSURG, ST PAUL, MN 55101 USA; ST PAUL RAMSEY MED CTR, SURG METAB RES FACIL, ST PAUL, MN 55101 USA				Deutschman, Clifford/AAN-2742-2021				ALEXANDER JW, 1980, ANN SURG, V192, P505, DOI 10.1097/00000658-198010000-00009; ASKANAZI J, 1980, ANN SURG, V191, P40, DOI 10.1097/00000658-198001000-00008; ASKANAZI J, 1980, JAMA-J AM MED ASSOC, V243, P1444, DOI 10.1001/jama.243.14.1444; BEISEL WR, 1980, JPEN-PARENTER ENTER, V4, P277, DOI 10.1177/0148607180004003277; BESSEY PQ, 1982, P METABOLIC NUTRITIO, P9; BIRGE SJ, 1984, ADV EXP MED BIOL, V171, P53; BISTRIAN BR, 1975, AM J CLIN NUTR, V28, P1148, DOI 10.1093/ajcn/28.10.1148; BORDER JR, 1976, SURG CLIN N AM, V56, P1147; CERRA FB, 1979, J TRAUMA, V19, P621, DOI 10.1097/00005373-197908000-00010; CERRA FB, 1980, ANN SURG, V192, P570, DOI 10.1097/00000658-198010000-00015; CERRA FB, 1980, CRIT CARE MED, V8, P230, DOI 10.1097/00003246-198004000-00027; CERRA FB, 1982, CRITICAL CARE STATE, pL1; CERRA FB, 1982, PROFILES NUTRITION M; CERRA FB, 1982, PATHOPHYSIOLOGY SHOC, P254; CLIFTON GL, 1983, SURG FORUM, V34, P538; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLOWES GHA, 1980, SURGERY, V88, P531; CLOWES GHA, 1976, SURG CLIN N AM, V56, P1169; CUTHBERTSON DP, 1979, JPEN-PARENTER ENTER, V3, P108, DOI 10.1177/0148607179003003108; DALE G, 1977, SURGERY, V81, P295; DEITRICK JE, 1948, AM J MED, V4, P3, DOI 10.1016/0002-9343(48)90370-2; FELIG P, 1969, J CLIN INVEST, V48, P584, DOI 10.1172/JCI106017; FELIG P, 1970, NEW ENGL J MED, V282, P166; FELL D, 1984, CRIT CARE MED, V12, P649, DOI 10.1097/00003246-198408000-00009; FISCHER JE, 1976, SURGERY, V80, P77; FREUND HR, 1978, ANN SURG, V188, P423, DOI 10.1097/00000658-197809000-00017; GUMP FE, 1975, J TRAUMA, V15, P704, DOI 10.1097/00005373-197508000-00013; GUYTON AC, 1981, TXB MED PHYSL, P720; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; HASSETT J, 1983, WORLD J SURG, V7, P125, DOI 10.1007/BF01655920; KAMINSKI MV, 1977, JPEN, V1, P22; LAW DK, 1973, ANN INTERN MED, V79, P545, DOI 10.7326/0003-4819-79-4-545; LEVENSON SM, 1983, SURGICAL NUTRITION, P423; LINDSAY DB, 1980, P NUTR SOC, V39, P53, DOI 10.1079/PNS19800008; LONG CL, 1979, JPEN-PARENTER ENTER, V3, P69, DOI 10.1177/014860717900300269; LONG CL, 1981, METABOLISM, V30, P765, DOI 10.1016/0026-0495(81)90022-6; LONG CL, 1977, AM J CLIN NUTR, V30, P1349, DOI 10.1093/ajcn/30.8.1349; LONG CL, 1971, J APPL PHYSIOL, V31, P110, DOI 10.1152/jappl.1971.31.1.110; LONG CL, 1983, NUTRITIONAL MANAGEME, P5; MCMENAMY RH, 1981, J TRAUMA, V21, P228, DOI 10.1097/00005373-198103000-00006; MEGUID MM, 1974, ARCH SURG-CHICAGO, V109, P776; MILLER SL, 1984, S AFR MED J, V65, P90; MULLEN JL, 1980, ANN SURG, V192, P604, DOI 10.1097/00000658-198019250-00004; MULLIN TJ, 1981, SURGERY, V90, P610; OWEN OE, 1973, J CLIN INVEST, V52, P2596, DOI 10.1172/JCI107452; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; POPP AJ, 1982, J SURG RES, V32, P416, DOI 10.1016/0022-4804(82)90121-4; POPP MB, 1983, SURGICAL NUTRITION, P479; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; SCHONHEYDER F, 1954, SCAND J CLIN LAB INV, V6, P178, DOI 10.3109/00365515409136355; Siegel J H, 1979, Adv Shock Res, V2, P177; SIEGEL JH, 1979, SURGERY, V86, P163; SPANIER AH, 1977, AM J SURG, V133, P99, DOI 10.1016/0002-9610(77)90201-X; SPANIER AH, 1976, SURG FORUM, V27, P332; STONER HB, 1979, CLIN SCI, V56, P563, DOI 10.1042/cs0560563; VINNARS E, 1979, ACTA CHIR SCAND    S, V494, P133; WATERS DC, 1984, SURG FORUM, V35, P482; WILMORE DW, 1980, ANN SURG, V192, P491, DOI 10.1097/00000658-198010000-00008; WILMORE DW, 1976, SURG CLIN N AM, V56, P999; WISE BL, 1984, J NEUROSURG, V61, P620	62	51	52	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	1986	64	1					89	98		10.3171/jns.1986.64.1.0089			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AWW31	WOS:A1986AWW3100014	3079825				2022-02-06	
J	LEVIN, HS; GROSSMAN, RG; SARWAR, M; MEYERS, CA				LEVIN, HS; GROSSMAN, RG; SARWAR, M; MEYERS, CA			LINGUISTIC RECOVERY AFTER CLOSED HEAD-INJURY	BRAIN AND LANGUAGE			English	Article											LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BARR AN, 1978, NEUROLOGY, V28, P1196, DOI 10.1212/WNL.28.11.1196; BARRON SA, 1976, NEUROLOGY, V26, P1011, DOI 10.1212/WNL.26.11.1011; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Benton A.L., 1967, CORTEX, V3, P32, DOI [10.1016/s0010-9452(67)80005-4, DOI 10.1016/S0010-9452(67)80005-4]; Goodglass H., 1972, ASSESSMENT APHASIA R; Hecaen H., 1978, HUMAN NEUROPSYCHOLOG; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Heilman KM, 1979, CLIN NEUROPSYCHOLOGY, P159; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; SPREEN O, 1969, MANUAL NEUROSENSORY; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SYNEK V, 1976, BRIT J RADIOL, V49, P233, DOI 10.1259/0007-1285-49-579-233; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713	22	51	51	0	3	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0093-934X			BRAIN LANG	Brain Lang.		1981	12	2					360	374		10.1016/0093-934X(81)90025-0			15	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	LG902	WOS:A1981LG90200012	6163504				2022-02-06	
J	Yuen, KCJ; Biller, BMK; Radovick, S; Carmichael, JD; Jasim, S; Pantalone, KM; Hoffman, AR				Yuen, Kevin C. J.; Biller, Beverly M. K.; Radovick, Sally; Carmichael, John D.; Jasim, Sina; Pantalone, Kevin M.; Hoffman, Andrew R.			AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE 2019 AACE GROWTH HORMONE TASK FORCE	ENDOCRINE PRACTICE			English	Article							GH-REPLACEMENT THERAPY; GLUCAGON STIMULATION TEST; QUALITY-OF-LIFE; BONE-MINERAL DENSITY; TRAUMATIC BRAIN-INJURY; RECOMBINANT HUMAN GH; CARDIOVASCULAR RISK MARKERS; RESEARCH SOCIETY PERSPECTIVE; ANTERIOR-PITUITARY FUNCTION; LEUKEMIA INHIBITORY FACTOR	Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPG). Methods: Recommendations are based on diligent reviews of clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols. Results: The Executive Summary of this 2019 updated guideline contains 58 numbered recommendations: 12 are Grade A (21%), 19 are Grade B (33%), 21 are Grade C (36%), and 6 are Grade D (10%). These detailed, evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world care of patients. The evidence base presented in the subsequent Appendix provides relevant supporting information for the Executive Summary recommendations. This update contains 357 citations of which 51 (14%) are evidence level (EL) 1 (strong), 168 (47%) are EL 2 (intermediate), 61 (17%) are EL 3 (weak), and 77 (22%) are EL 4 (no clinical evidence). Conclusion: This CPG is a practical tool that practicing endocrinologists and regulatory bodies can refer to regarding the identification, diagnosis, and treatment of adults and patients transitioning from pediatric to adultcare services with growth hormone deficiency (GHD). It provides guidelines on assessment, screening, diagnostic testing, and treatment recommendations for a range of individuals with various causes of adult GHD. The recommendations emphasize the importance of considering testing patients with a reasonable level of clinical suspicion of GHD using appropriate growth hormone (GH) cut-points for various GH-stimulation tests to accurately diagnose adult GHD, and to exercise caution interpreting serum GH and insulin-like growth factor-1 (IGF-1) levels, as various GH and IGF-1 assays are used to support treatment decisions. The intention to treat often requires sound clinical judgment and careful assessment of the benefits and risks specific to each individual patient. Unapproved uses of GH, long-term safety, and the current status of long-acting GH preparations are also discussed in this document.	[Yuen, Kevin C. J.] Univ Arizona, Barrow Pituitary Ctr, Barrow Neurol Inst, Coll Med, Phoenix, AZ 85013 USA; [Yuen, Kevin C. J.] Univ Arizona, St Josephs Hosp & Med Ctr, Coll Med, Phoenix, AZ 85013 USA; [Yuen, Kevin C. J.] Creighton Sch Med, Phoenix, AZ USA; [Biller, Beverly M. K.] Harvard Med Sch, Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02115 USA; [Radovick, Sally] Rutgers Robert Wood Johnson Sch Med, Div Endocrinol, Dept Pediat, New Brunswick, NJ USA; [Carmichael, John D.] Univ Southern Calif, Div Endocrinol, Dept Med, Keck Sch Med, Los Angeles, CA 90007 USA; [Jasim, Sina] Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO USA; [Pantalone, Kevin M.] Cleveland Clin, Dept Endocrinol Diabet & Metab, Cleveland, OH 44106 USA; [Hoffman, Andrew R.] VA Palo Alto Hlth Care Syst, Dept Med, Palo Alto, CA USA; [Hoffman, Andrew R.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA		Yuen, KCJ (corresponding author), Barrow Neurol Inst, Barrow Pituitary Ctr, Dept Neuroendocrinol, 124 West Thomas Rd,Suite 300, Phoenix, AZ 85013 USA.; Yuen, KCJ (corresponding author), Barrow Neurol Inst, Barrow Pituitary Ctr, Dept Neurosurg, 124 West Thomas Rd,Suite 300, Phoenix, AZ 85013 USA.	kevin.yuen@dignityhealth.org	Jasim, Sina/ABB-5030-2020	Jasim, Sina/0000-0001-8984-3079			Abbud RA, 2004, ENDOCRINOLOGY, V145, P867, DOI 10.1210/en.2003-0897; Agha A, 2007, CLIN ENDOCRINOL, V66, P72, DOI 10.1111/j.1365-2265.2006.02688.x; Ahmid M, 2016, ENDOCR CONNECT, V5, pR1, DOI 10.1530/EC-16-0024; Aimaretti G, 2015, J ENDOCRINOL INVEST, V38, P377, DOI 10.1007/s40618-014-0201-7; Aimaretti G, 2000, EUR J ENDOCRINOL, V142, P347, DOI 10.1530/eje.0.1420347; ALBINI CH, 1988, PEDIATR RES, V23, P89, DOI 10.1203/00006450-198801000-00020; Allen DB, 2016, EUR J ENDOCRINOL, V174, pP1, DOI 10.1530/EJE-15-0873; Miguel GA, 2016, THER ADV ENDOCRINOL, V7, P93, DOI 10.1177/2042018816643908; Altinova AE, 2016, ENDOCRINE, V52, P374, DOI 10.1007/s12020-015-0789-1; Amato G, 2000, J CLIN ENDOCR METAB, V85, P3720, DOI 10.1210/jc.85.10.3720; Anderson LJ, 2018, MOL CELL ENDOCRINOL, V464, P65, DOI 10.1016/j.mce.2017.06.010; Andiran N, 2007, GROWTH HORM IGF RES, V17, P149, DOI 10.1016/j.ghir.2007.01.002; Anisimov Vladimir N, 2007, Cancer Control, V14, P23; Appelman-Dijkstra NM, 2014, CLIN ENDOCRINOL, V81, P727, DOI 10.1111/cen.12493; Arafat AM, 2010, DIABETOLOGIA, V53, P1304, DOI 10.1007/s00125-010-1738-4; Arwert LI, 2005, CLIN ENDOCRINOL, V63, P310, DOI 10.1111/j.1365-2265.2005.02343.x; Attanasio AF, 2004, J CLIN ENDOCR METAB, V89, P4857, DOI 10.1210/jc.2004-0551; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; Attanasio AF, 2011, J CLIN ENDOCR METAB, V96, P2255, DOI 10.1210/jc.2011-0448; Attanasio AF, 2010, J CLIN ENDOCR METAB, V95, P74, DOI 10.1210/jc.2009-1326; Auer MK, 2016, CLIN ENDOCRINOL, V84, P862, DOI 10.1111/cen.13030; Bansch D, 1997, METABOLISM, V46, P1039, DOI 10.1016/S0026-0495(97)90275-4; Barake M, 2014, J CLIN ENDOCR METAB, V99, P852, DOI 10.1210/jc.2013-3921; Baroncelli GI, 2004, CLIN ENDOCRINOL, V60, P175, DOI 10.1046/j.1365-2265.2003.01949.x; Bartke A, 2019, WORLD J MENS HEALTH, V37, P19, DOI 10.5534/wjmh.180018; Bartke A, 2017, BEST PRACT RES CL EN, V31, P113, DOI 10.1016/j.beem.2017.02.005; Bassiouny YA, 2016, FERTIL STERIL, V105, P697, DOI 10.1016/j.fertnstert.2015.11.026; Battelino T, 2017, CLIN ENDOCRINOL, V87, P350, DOI 10.1111/cen.13409; Baum HBA, 1996, J CLIN ENDOCR METAB, V81, P84, DOI 10.1210/jc.81.1.84; BAUMANN G, 1991, ENDOCR REV, V12, P424, DOI 10.1210/edrv-12-4-424; Baumann GP, 2012, ENDOCR REV, V33, P155, DOI 10.1210/er.2011-1035; Beauregard C, 2008, J CLIN ENDOCR METAB, V93, P2063, DOI 10.1210/jc.2007-2371; Behan LA, 2011, CLIN ENDOCRINOL, V74, P281, DOI 10.1111/j.1365-2265.2010.03815.x; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Berberoglu M, 2008, J CLIN RES PEDIATR E, V1, P30, DOI [10.4008/jcrpe.v1i1.721318062, DOI 10.4008/JCRPE.V1I1.721318062]; Berg C, 2010, EUR J ENDOCRINOL, V162, P477, DOI 10.1530/EJE-09-0824; Berglund A, 2015, CLIN ENDOCRINOL, V83, P677, DOI 10.1111/cen.12848; Bidlingmaier M, 2007, NAT CLIN PRACT ENDOC, V3, P769, DOI 10.1038/ncpendmet0644; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bollerslev J, 2006, EUR J ENDOCRINOL, V154, P537, DOI 10.1530/eje.1.02125; Bonfig W, 2008, J PEDIATR ENDOCR MET, V21, P1049; Booij HA, 2018, ENDOCR CONNECT, V7, pR223, DOI 10.1530/EC-18-0147; Boot AM, 2009, HORM RES, V71, P364, DOI 10.1159/000223422; Boschetti M, 2017, ENDOCRINE, V55, P573, DOI 10.1007/s12020-016-0951-4; Brabant G, 2009, EUR J ENDOCRINOL, V161, pS25, DOI 10.1530/EJE-09-0273; Bredella MA, 2009, J CLIN ENDOCR METAB, V94, P3995, DOI 10.1210/jc.2009-0438; Brignardello E, 2015, J ENDOCRINOL INVEST, V38, P171, DOI 10.1007/s40618-014-0179-1; BRIXEN K, 1992, ACTA ENDOCRINOL-COP, V127, P331, DOI 10.1530/acta.0.1270331; Bryden KS, 2003, DIABETES CARE, V26, P1052, DOI 10.2337/diacare.26.4.1052; Bulow B, 1997, CLIN ENDOCRINOL, V46, P75, DOI 10.1046/j.1365-2265.1997.d01-1749.x; BUNT JC, 1986, J APPL PHYSIOL, V61, P1796, DOI 10.1152/jappl.1986.61.5.1796; Burman P, 1997, J CLIN ENDOCR METAB, V82, P550, DOI 10.1210/jc.82.2.550; Burman P, 2013, J CLIN ENDOCR METAB, V98, P1466, DOI 10.1210/jc.2012-4059; Cakir I, 2012, GROWTH HORM IGF RES, V22, P17, DOI 10.1016/j.ghir.2011.12.001; Capalbo D, 2009, J CLIN ENDOCR METAB, V94, P3347, DOI 10.1210/jc.2008-2639; Carroll PV, 2004, J CLIN ENDOCR METAB, V89, P3890, DOI 10.1210/jc.2003-031588; Castillo AR, 2018, HORM METAB RES, P50; Chandrashekar V, 2004, BIOL REPROD, V71, P17, DOI 10.1095/biolreprod.103.027060; Chikani V, 2016, CLIN ENDOCRINOL, V85, P660, DOI 10.1111/cen.13147; Child CJ, 2019, J CLIN ENDOCR METAB, V104, P379, DOI 10.1210/jc.2018-01189; Child CJ, 2011, EUR J ENDOCRINOL, V165, P217, DOI 10.1530/EJE-11-0286; Choe SA, 2018, ARCH GYNECOL OBSTET, V297, P791, DOI 10.1007/s00404-017-4613-4; Chrisoulidou A, 2000, J CLIN ENDOCR METAB, V85, P3762, DOI 10.1210/jc.85.10.3762; Christ ER, 2016, SCI REP-UK, V6, DOI 10.1038/srep19310; Christiansen JS, 2016, EUR J ENDOCRINOL, V174, pC1, DOI 10.1530/EJE-16-0111; Cittadini A, 2013, JACC-HEART FAIL, V1, P325, DOI 10.1016/j.jchf.2013.04.003; Claessen KMJA, 2014, EUR J ENDOCRINOL, V170, P263, DOI 10.1530/EJE-13-0764; Claessen KMJA, 2013, J CLIN ENDOCR METAB, V98, P352, DOI 10.1210/jc.2012-2940; Clayton P, 2007, GROWTH HORM IGF RES, V17, P369, DOI 10.1016/j.ghir.2007.04.010; Clemmons DR, 2011, CLIN CHEM, V57, P555, DOI 10.1373/clinchem.2010.150631; Colao A, 2002, J CLIN ENDOCR METAB, V87, P3650, DOI 10.1210/jc.87.8.3650; Colao A, 2008, J CLIN ENDOCR METAB, V93, P3416, DOI 10.1210/jc.2007-2810; Colson A, 2006, HORM RES, V66, P257, DOI 10.1159/000095168; Conceicao FL, 2003, J ENDOCRINOL INVEST, V26, P1065, DOI 10.1007/BF03345251; Conway GS, 2009, EUR J ENDOCRINOL, V160, P899, DOI 10.1530/EJE-08-0436; COOK D, 2004, AM J MANAG CARE S, V10, pS41; Cook DM, 2009, ENDOCR PRACT, V15, P580, DOI 10.4158/EP.15.6.580; Cook DM, 1999, J CLIN ENDOCR METAB, V84, P3956, DOI 10.1210/jc.84.11.3956; Correa FA, 2017, J ENDOCR SOC, V1, P1322, DOI 10.1210/js.2017-00005; Courtillot C, 2013, EUR J ENDOCRINOL, V169, P587, DOI 10.1530/EJE-13-0572; Curran AJ, 1998, EUR J ENDOCRINOL, V139, P54, DOI 10.1530/eje.0.1390054; Cutfield WS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016223; Cutfield WS, 2000, LANCET, V355, P610, DOI 10.1016/S0140-6736(99)04055-6; Darzy KH, 2009, CLIN ENDOCRINOL, V70, P287, DOI 10.1111/j.1365-2265.2008.03359.x; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; Deepak D, 2010, GROWTH HORM IGF RES, V20, P220, DOI 10.1016/j.ghir.2010.02.002; di Iorgi N, 2007, J CLIN ENDOCR METAB, V92, P3875, DOI 10.1210/jc.2007-1081; Di Somma C, 2010, J ENDOCRINOL INVEST, V33, P171, DOI [10.1007/BF03346577, 10.3275/6519]; Dichtel LE, 2014, J CLIN ENDOCR METAB, V99, P4712, DOI 10.1210/jc.2014-2830; Diri H, 2015, PITUITARY, V18, P884, DOI 10.1007/s11102-015-0666-1; Drake WM, 2003, J CLIN ENDOCR METAB, V88, P1658, DOI 10.1210/jc.2002-021541; Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576; Elbornsson M, 2017, EUR J ENDOCRINOL, V176, P99, DOI 10.1530/EJE-16-0875; Elbornsson M, 2013, EUR J ENDOCRINOL, V168, P745, DOI 10.1530/EJE-12-1083; Ferro P, 2016, J PHARMACEUT BIOMED, V128, P111, DOI 10.1016/j.jpba.2016.05.022; Feuillan P, 2001, J PEDIATR ENDOCR MET, V14, P141; Fisker S, 1997, METABOLISM, V46, P812, DOI 10.1016/S0026-0495(97)90128-1; Florakis D, 2000, CLIN ENDOCRINOL, V53, P453, DOI 10.1046/j.1365-2265.2000.01108.x; Franks S, 1998, BAILLIERE CLIN ENDOC, V12, P331, DOI 10.1016/S0950-351X(98)80026-8; Freemark M, 2010, J CLIN ENDOCR METAB, V95, P2054, DOI 10.1210/jc.2010-0517; Gaillard RC, 2012, EUR J ENDOCRINOL, V166, P1069, DOI 10.1530/EJE-11-1028; Garcia JM, 2013, J CLIN ENDOCR METAB, V98, P2422, DOI 10.1210/jc.2013-1157; Garcia JM, 2018, J CLIN ENDOCR METAB, V103, P3083, DOI 10.1210/jc.2018-00665; Gardner CJ, 2015, EUR J ENDOCRINOL, V172, P371, DOI 10.1530/EJE-14-0654; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P780, DOI 10.1210/jc.79.3.780; Gazzaruso C, 2014, J CLIN ENDOCR METAB, V99, P18, DOI 10.1210/jc.2013-2394; GELATO MC, 1986, J CLIN ENDOCR METAB, V63, P174, DOI 10.1210/jcem-63-1-174; GHIGO E, 1994, J ENDOCRINOL INVEST, V17, P849, DOI 10.1007/BF03347790; Giagulli VA, 2017, ENDOCR METAB IMMUNE, V17, P285, DOI 10.2174/1871530317666170919121729; Giampietro A, 2009, FERTIL STERIL, V91, DOI 10.1016/j.fertnstert.2008.09.065; Giannoulis MG, 2006, J CLIN ENDOCR METAB, V91, P477, DOI 10.1210/jc.2005-0957; Giavoli C, 2004, J CLIN ENDOCR METAB, V89, P5397, DOI 10.1210/jc.2004-1114; Gibney J, 1999, J CLIN ENDOCR METAB, V84, P2596, DOI 10.1210/jc.84.8.2596; Gilchrist FJ, 2002, CLIN ENDOCRINOL, V57, P363, DOI 10.1046/j.1365-2265.2002.01608.x; Giritharan S, 2017, PITUITARY, V20, P624, DOI 10.1007/s11102-017-0825-7; Giuliano S, 2017, ENDOCRINE, V58, P115, DOI 10.1007/s12020-016-1183-3; Gleeson HK, 2005, J CLIN ENDOCR METAB, V90, P1061, DOI 10.1210/jc.2004-0501; Gleeson HK, 2004, J CLIN ENDOCR METAB, V89, P662, DOI 10.1210/jc.2003-031224; Glynn N, 2018, ENDOCR PRACT, V24, P342, DOI 10.4158/EP-2017-0223; Glynn N, 2017, CLIN ENDOCRINOL, V86, P747, DOI 10.1111/cen.13272; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; Gonzalez S, 2017, J INT MED RES, V45, P1708, DOI 10.1177/0300060517723798; Gonzalez S, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00056; Gonzalez-Duarte D, 2012, PITUITARY, V15, P589, DOI 10.1007/s11102-011-0374-4; Gordon MB, 2016, ENDOCR PRACT, V22, P396, DOI 10.4158/EP14603.OR; Gotherstrom G, 2007, J CLIN ENDOCR METAB, V92, P1442, DOI 10.1210/jc.2006-1487; Gotherstrom G, 2001, J CLIN ENDOCR METAB, V86, P4657, DOI 10.1210/jc.86.10.4657; Gotherstrom G, 2010, EUR J ENDOCRINOL, V163, P207, DOI 10.1530/EJE-10-0009; Hall R, 2006, CLIN ENDOCRINOL, V65, P71, DOI 10.1111/j.1365-2265.2006.02550.x; Hammarstrand C, 2017, EUR J ENDOCRINOL, V177, P251, DOI 10.1530/EJE-17-0340; Hamrahian AH, 2016, PITUITARY, V19, P332, DOI 10.1007/s11102-016-0712-7; Harden PN, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3718; Hartman ML, 2013, J CLIN ENDOCR METAB, V98, P980, DOI 10.1210/jc.2012-2684; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; Hazem A, 2012, EUR J ENDOCRINOL, V166, P13, DOI 10.1530/EJE-11-0558; Healy ML, 2003, J CLIN ENDOCR METAB, V88, P5221, DOI 10.1210/jc.2002-021872; Hermansen K, 2017, GROWTH HORM IGF RES, V34, P38, DOI 10.1016/j.ghir.2017.05.005; Hjartaker A, 2008, ADV EXP MED BIOL, V630, P72; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Ho KKY, 2006, FRONT HORM RES, V35, P115, DOI 10.1159/000094314; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; HOECK HC, 1995, EUR J ENDOCRINOL, V133, P305, DOI 10.1530/eje.0.1330305; Hoffman AR, 2004, J CLIN ENDOCR METAB, V89, P3224, DOI 10.1210/jc.2003-032082; Hoffman AR, 2004, J CLIN ENDOCR METAB, V89, P2048, DOI 10.1210/jc.2003-030346; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; Hokken-Koelega A, 2016, ENDOCR CONNECT, V5, pR44, DOI 10.1530/EC-16-0028; Hoybye C, 2006, J ENDOCRINOL INVEST, V29, P950; Hoybye C, 2017, CLIN ENDOCRINOL, V86, P798, DOI 10.1111/cen.13330; Hoybye C, 2015, GROWTH HORM IGF RES, V25, P201, DOI 10.1016/j.ghir.2015.07.004; Hubina Erika, 2004, Horm Res, V61, P211, DOI 10.1159/000076538; Hulthen L, 2001, J CLIN ENDOCR METAB, V86, P4765, DOI 10.1210/jc.86.10.4765; Hwu CM, 1997, J CLIN ENDOCR METAB, V82, P3285, DOI 10.1210/jc.82.10.3285; Ioachimescu AG, 2015, PITUITARY, V18, P535, DOI 10.1007/s11102-014-0606-5; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; Janssen YJ, 2000, J CLIN ENDOCR METAB, P85; Jasim S, 2017, ENDOCRINE, V56, P33, DOI 10.1007/s12020-016-1159-3; Joaquin C, 2008, EUR J ENDOCRINOL, V158, P483, DOI 10.1530/EJE-07-0554; Johannsson G., 1999, Journal of Endocrinological Investigation, V22, P41; Johannsson G, 1999, J CLIN ENDOCR METAB, V84, P4516, DOI 10.1210/jc.84.12.4516; Johannsson G, 2019, J ENDOCR SOC S1, V3; Johannsson G, 2018, EUR J ENDOCRINOL, V178, P491, DOI 10.1530/EJE-17-1073; Johannsson G, 2018, ENDOCR CONNECT, V7, pR126, DOI 10.1530/EC-18-0047; JOHANSSON JO, 1995, METABOLISM, V44, P1126, DOI 10.1016/0026-0495(95)90004-7; Jorgensen AP, 2011, GROWTH HORM IGF RES, V21, P69, DOI 10.1016/j.ghir.2011.01.001; JORGENSEN JOL, 1989, LANCET, V1, P1221; Joustra SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090602; Junnila RK, 2015, ENDOCRIN METAB CLIN, V44, P27, DOI 10.1016/j.ecl.2014.10.003; Kanaley JA, 1997, J APPL PHYSIOL, V83, P1756, DOI 10.1152/jappl.1997.83.5.1756; Karamouzis I, 2016, ENDOCRINE, V52, P441, DOI 10.1007/s12020-015-0796-2; KELLY JJ, 1993, CLIN ENDOCRINOL, V39, P561, DOI 10.1111/j.1365-2265.1993.tb02410.x; Kipps S, 2002, DIABETIC MED, V19, P649, DOI 10.1046/j.1464-5491.2002.00757.x; Kniess A, 2003, ANAL BIOANAL CHEM, V376, P696, DOI 10.1007/s00216-003-1926-x; Kokshoorn NE, 2011, EUR J ENDOCRINOL, V164, P657, DOI 10.1530/EJE-10-1170; Koltowska-Haggstrom M, 2005, HORM RES, V64, P46, DOI 10.1159/000087444; Kotzmann H, 1998, CALCIFIED TISSUE INT, V62, P40, DOI 10.1007/s002239900392; Krzyzanowska-Mittermayer K, 2018, J CLIN ENDOCR METAB, V103, P523, DOI 10.1210/jc.2017-01899; Kuzma M, 2014, GROWTH HORM IGF RES, V24, P22, DOI 10.1016/j.ghir.2013.12.001; Laursen T, 2001, J CLIN ENDOCR METAB, V86, P1222, DOI 10.1210/jc.86.3.1222; Lee P, 2009, CLIN ENDOCRINOL, V71, P82, DOI 10.1111/j.1365-2265.2008.03466.x; Leger J, 2005, J CLIN ENDOCR METAB, V90, P650, DOI 10.1210/jc.2004-1274; Leong KS, 2001, CLIN ENDOCRINOL, V54, P463, DOI 10.1046/j.1365-2265.2001.01169.x; Leung KC, 2002, AM J PHYSIOL-ENDOC M, V283, pE836, DOI 10.1152/ajpendo.00122.2002; Leung KC, 2004, ENDOCR REV, V25, P693, DOI 10.1210/er.2003-0035; Li LM, 2012, ENDOCRINE, V42, P375, DOI 10.1007/s12020-012-9697-9; Li ZZ, 2016, ONCOTARGET, V7, P81862, DOI 10.18632/oncotarget.13251; Lillicrap T, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00713; Lindholm J, 2006, CLIN ENDOCRINOL, V65, P51, DOI 10.1111/j.1365-2265.2006.02545.x; LITTLEY MD, 1989, CLIN ENDOCRINOL, V31, P527, DOI 10.1111/j.1365-2265.1989.tb01276.x; Liu H, 2008, ANN INTERN MED, V148, P747, DOI 10.7326/0003-4819-148-10-200805200-00215; Liu H, 2007, ANN INTERN MED, V146, P104, DOI 10.7326/0003-4819-146-2-200701160-00005; Longobardi S, 1996, J CLIN ENDOCR METAB, V81, P1244, DOI 10.1210/jc.81.3.1244; Longobardi S, 1998, CLIN ENDOCRINOL, V48, P137, DOI 10.1046/j.1365-2265.1998.00281.x; Lopez-Siguero JP, 2011, J ENDOCRINOL INVEST, V34, P300, DOI [10.1007/BF03347090, 10.3275/7169]; Loukianou E, 2016, CASE REP OPHTHALMOL, V2016, DOI 10.1155/2016/4756894; Luger A, 2012, DIABETES CARE, V35, P57, DOI 10.2337/dc11-0449; Lyle WG, 2002, PLAST RECONSTR SURG, V110, P1585, DOI 10.1097/00006534-200211000-00032; Macklon NS, 2006, ENDOCR REV, V27, P170, DOI 10.1210/er.2005-0015; Maghnie M, 1999, J CLIN ENDOCR METAB, V84, P1324, DOI 10.1210/jc.84.4.1324; MAGHNIE M, 1991, J CLIN ENDOCR METAB, V73, P79, DOI 10.1210/jcem-73-1-79; Maghnie M, 2001, J CLIN ENDOCR METAB, V86, P1574, DOI 10.1210/jc.86.4.1574; Maison P, 2003, CIRCULATION, V108, P2648, DOI 10.1161/01.CIR.0000100720.01867.1D; Makimura H, 2008, J CLIN ENDOCR METAB, V93, P4254, DOI 10.1210/jc.2008-1333; MALOZOWSKI S, 1995, J PEDIATR-US, V126, P996, DOI 10.1016/S0022-3476(95)70232-6; Gomez JM, 2006, CURR PHARM BIOTECHNO, V7, P125; MASON HD, 1990, J ENDOCRINOL, V126, pR1, DOI 10.1677/joe.0.126R001; Mathus-Vliegen EMH, 2012, OBESITY FACTS, V5, P460, DOI 10.1159/000341193; Mauras N, 2005, J CLIN ENDOCR METAB, V90, P3946, DOI 10.1210/jc.2005-0208; McHugh CM, 2005, CLIN CHEM, V51, P1587, DOI 10.1373/clinchem.2005.047845; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Meazza C, 2017, MINERVA ENDOCRINOL, V42, P325, DOI 10.23736/S0391-1977.16.02510-4; Mechanick JI, 2017, ENDOCR PRACT, V23, P1006, DOI 10.4158/EP171866.GL; Meienberg F, 2016, CLIN ENDOCRINOL, V85, P76, DOI 10.1111/cen.13042; Meinhardt U, 2010, ANN INTERN MED, V152, P568, DOI 10.7326/0003-4819-152-9-201005040-00007; Mitra MT, 2017, CLIN ENDOCRINOL, V86, P526, DOI 10.1111/cen.13291; Mo DJ, 2014, J CLIN ENDOCR METAB, V99, P4581, DOI 10.1210/jc.2014-2892; Mo DJ, 2014, PITUITARY, V17, P477, DOI 10.1007/s11102-013-0529-6; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Monson JP, 2007, CLIN ENDOCRINOL, V67, P623, DOI 10.1111/j.1365-2265.2007.02935.x; Mulder RL, 2009, CANCER TREAT REV, V35, P616, DOI 10.1016/j.ctrv.2009.06.004; MULLER J, 1995, EUR J ENDOCRINOL, V132, P727, DOI 10.1530/eje.0.1320727; Nagra A, 2015, ARCH DIS CHILDHOOD-E, V100, P313, DOI 10.1136/archdischild-2014-307423; Nelson AE, 2008, J CLIN ENDOCR METAB, V93, P2213, DOI 10.1210/jc.2008-0402; Nelson AE, 2008, ASIAN J ANDROL, V10, P416, DOI 10.1111/j.1745-7262.2008.00395.x; Newman CB, 2015, PITUITARY, V18, P297, DOI 10.1007/s11102-014-0571-z; Nicolson A, 1996, CLIN ENDOCRINOL, V44, P311, DOI 10.1046/j.1365-2265.1996.671492.x; Nielsen EH, 2007, CLIN ENDOCRINOL, V67, P693, DOI 10.1111/j.1365-2265.2007.02947.x; Nishizawa H, 2012, EUR J ENDOCRINOL, V167, P67, DOI 10.1530/EJE-12-0252; Norrelund H, 2000, J CLIN ENDOCR METAB, V85, P1912, DOI 10.1210/jc.85.5.1912; O'Sullivan AJ, 2000, J PEDIATR ENDOCR MET, V13, P1457; OGLE GD, 1994, ACTA PAEDIATR, V83, P3, DOI 10.1111/j.1651-2227.1994.tb13274.x; Olsson DS, 2017, EUR J ENDOCRINOL, V176, P67, DOI 10.1530/EJE-16-0450; Olsson DS, 2015, J CLIN ENDOCR METAB, V100, P2651, DOI 10.1210/jc.2015-1475; Orme SM, 1998, CLIN ENDOCRINOL, V49, P773, DOI 10.1046/j.1365-2265.1998.00610.x; Osawa M, 1997, GENE, V196, P121, DOI 10.1016/S0378-1119(97)00216-3; Pappachan JM, 2015, J CLIN ENDOCR METAB, V100, P1405, DOI 10.1210/jc.2014-3787; Patterson BC, 2014, J CLIN ENDOCR METAB, V99, P2030, DOI 10.1210/jc.2013-4159; Pekic S, 2017, EUR J ENDOCRINOL, V176, pR269, DOI 10.1530/EJE-16-1065; Penta L, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16030307; Perls TT, 2004, J GERONTOL A-BIOL, V59, P682; Pfeifer M, 2001, CLIN ENDOCRINOL, V54, P17, DOI 10.1046/j.1365-2265.2001.01179.x; Piccoli F, 2007, J CLIN ENDOCR METAB, V92, P1814, DOI 10.1210/jc.2006-2160; Pijl H, 2001, J CLIN ENDOCR METAB, V86, P5509, DOI 10.1210/jc.86.11.5509; Pokrajac A, 2007, CLIN ENDOCRINOL, V67, P65, DOI 10.1111/j.1365-2265.2007.02836.x; Powrie JK, 2007, GROWTH HORM IGF RES, V17, P220, DOI 10.1016/j.ghir.2007.01.011; Prestidge C, 2012, PEDIATR NEPHROL, V27, P295, DOI 10.1007/s00467-011-1980-0; Profka E, 2015, J ENDOCRINOL INVEST, V38, P413, DOI 10.1007/s40618-014-0196-0; Puche JE, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-224; Rahim A, 1996, CLIN ENDOCRINOL, V45, P557; Regal M, 2001, CLIN ENDOCRINOL, V55, P735, DOI 10.1046/j.1365-2265.2001.01406.x; Riasi HR, 2017, IRAN J MED SCI, V42, P611; Ribeiro de Oliveira Longo Schweizer Junia, 2018, Clin Diabetes Endocrinol, V4, P18, DOI 10.1186/s40842-018-0068-1; Rochira V, 2018, J ENDOCRINOL INVEST, V41, P1259, DOI 10.1007/s40618-018-0860-x; Roelfsema F, 2012, PITUITARY, V15, P71, DOI 10.1007/s11102-011-0347-7; Rogers AH, 1999, OPHTHALMOLOGY, V106, P1186, DOI 10.1016/S0161-6420(99)90266-X; Rosenfeld RG, 2003, HORM RES, V60, P74, DOI 10.1159/000071230; Rosenfeld Ron G, 2008, Endocr Pract, V14, P143; Rufinatscha K, 2018, HEPATOL INT, V12, P474, DOI 10.1007/s12072-018-9893-7; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Sattler FR, 2009, J CLIN ENDOCR METAB, V94, P1991, DOI 10.1210/jc.2008-2338; Savendahl L, 2019, J CLIN ENDOCR METAB, V104, P4730, DOI 10.1210/jc.2019-00775; Savendal L, 2019, J ENDOCR SOC S1, V3; Scacchi M, 2006, J ENDOCRINOL INVEST, V29, P899, DOI 10.1007/BF03349194; Schaefer S, 2008, EUR J ENDOCRINOL, V158, P3, DOI 10.1530/EJE-07-0484; Schiffman JD, 2013, PEDIATR BLOOD CANCER, V60, P1247, DOI 10.1002/pbc.24555; Schneider HJ, 2011, CLIN ENDOCRINOL, V75, P825, DOI 10.1111/j.1365-2265.2011.04137.x; Secco A, 2009, J CLIN ENDOCR METAB, V94, P4195, DOI 10.1210/jc.2009-0602; Serri O, 1999, J CLIN ENDOCR METAB, V84, P58, DOI 10.1210/jc.84.1.58; Sesmilo G, 2000, ANN INTERN MED, V133, P111, DOI 10.7326/0003-4819-133-2-200007180-00010; Setola E, 2008, METABOLISM, V57, P1685, DOI 10.1016/j.metabol.2008.07.024; Sfeir JG, 2018, J CLIN ENDOCR METAB, V103, P2785, DOI 10.1210/jc.2018-01204; Shaw KL, 2007, CHILD CARE HLTH DEV, V33, P368, DOI 10.1111/j.1365-2214.2006.00698.x; Shaw KL, 2014, CHILD CARE HLTH DEV, V40, P663, DOI 10.1111/cch.12110; Siebert DM, 2018, SPORTS HEALTH; Silva PPB, 2017, EUR J ENDOCRINOL, V177, P409, DOI 10.1530/EJE-17-0468; Sklar CA, 2002, J CLIN ENDOCR METAB, V87, P3136, DOI 10.1210/jc.87.7.3136; Sklar CA, 2018, J CLIN ENDOCR METAB, V103, P2761, DOI 10.1210/jc.2018-01175; Sonksen P, 2018, BRIT J SPORT MED, V52, P219, DOI 10.1136/bjsports-2016-096742; Sonksen PH, 2018, CLIN DIABETES ENDOCR, V4, P3; Spielhagen C, 2011, GROWTH HORM IGF RES, V21, P1, DOI 10.1016/j.ghir.2010.10.005; Stochholm K, 2007, EUR J ENDOCRINOL, V157, P9, DOI 10.1530/EJE-07-0013; Stochholm K, 2008, EUR J ENDOCRINOL, V158, P447, DOI 10.1530/EJE-07-0523; Stochholm K, 2006, EUR J ENDOCRINOL, V155, P61, DOI 10.1530/eje.1.02191; Stochholm K, 2018, CLIN ENDOCRINOL, V88, P515, DOI 10.1111/cen.13502; Stochholm K, 2015, GROWTH HORM IGF RES, V25, P149, DOI 10.1016/j.ghir.2015.06.006; Stochholm K, 2014, J CLIN ENDOCR METAB, V99, P4141, DOI 10.1210/jc.2014-1814; Strahm B, 2006, INT J CANCER, V119, P2001, DOI 10.1002/ijc.21962; Sumida Y, 2015, HEPATOL RES, V45, P771, DOI 10.1111/hepr.12408; Svensson J, 2004, J CLIN ENDOCR METAB, V89, P3306, DOI 10.1210/jc.2003-031601; Svensson J, 2002, J CLIN ENDOCR METAB, V87, P2121, DOI 10.1210/jc.87.5.2121; Tamhane S, 2018, J CLIN ENDOCRINOL ME; Tan SH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09968-7; Tanriverdi F, 2017, BEST PRACT RES CL EN, V31, P3, DOI 10.1016/j.beem.2017.02.001; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; The World Anti-Doping Agency, 2019, PROH LIST INT STAND; Thevis M, 2016, J PHARMACEUT BIOMED, V130, P220, DOI 10.1016/j.jpba.2016.03.055; Thornton P, 2019, J ENDOCR SOC S1, V3; Tolli A, 2017, J ENDOCRINOL INVEST, V40, P193, DOI 10.1007/s40618-016-0546-1; Tomida M, 2001, CYTOKINE, V14, P202, DOI 10.1006/cyto.2001.0874; Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X; Toogood AA, 2000, J CLIN ENDOCR METAB, V85, P1727, DOI 10.1210/jc.85.4.1727; Tritos NA, 2012, EUR J ENDOCRINOL, V167, P343, DOI 10.1530/EJE-12-0070; Tsiakalos A, 2010, J CLIN ENDOCR METAB, V95, P3277, DOI 10.1210/jc.2010-0144; Ukropec J, 2008, J CLIN ENDOCR METAB, V93, P2255, DOI 10.1210/jc.2007-2188; Underwood LE, 2003, J CLIN ENDOCR METAB, V88, P5273, DOI 10.1210/jc.2003-030204; Undurti A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00072; US Food and Drug Administration, DRUG TRIALS SNAPSH M; Utz AL, 2008, J CLIN ENDOCR METAB, V93, P4033, DOI 10.1210/jc.2008-0930; van Bunderen CC, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0963-2; van Bunderen CC, 2016, EUR J INTERN MED, V31, P88, DOI 10.1016/j.ejim.2016.03.026; van Bunderen CC, 2014, CLIN ENDOCRINOL, V81, P1, DOI 10.1111/cen.12477; van Bunderen CC, 2011, J CLIN ENDOCR METAB, V96, P3151, DOI 10.1210/jc.2011-1215; van Dam EWCM, 2002, J CLIN ENDOCR METAB, V87, P4225, DOI 10.1210/jc.2002-012006; van der Klaauw AA, 2006, EUR J ENDOCRINOL, V155, P701, DOI 10.1530/eje.1.02283; van der Klaauw AA, 2007, EUR J ENDOCRINOL, V157, P709, DOI 10.1530/EJE-07-0412; Vance ML, 2003, NEW ENGL J MED, V348, P779, DOI 10.1056/NEJMp020186; VELDHUIS JD, 1991, J CLIN ENDOCR METAB, V72, P51, DOI 10.1210/jcem-72-1-51; Verboven C, 2002, NAT STRUCT BIOL, V9, P131, DOI 10.1038/nsb754; Verhelst J, 2018, ENDOCR CONNECT, V7, P653, DOI 10.1530/EC-18-0096; Vila G, 2018, MINERVA ENDOCRINOL, V43, P451, DOI 10.23736/S0391-1977.18.02834-1; Vila G, 2015, FERTIL STERIL, V104, P1210, DOI 10.1016/j.fertnstert.2015.07.1132; Vischi A, 2006, EUR J OPHTHALMOL, V16, P178, DOI 10.1177/112067210601600131; VONBULOW FA, 1993, HISTOCHEMISTRY, V99, P13, DOI 10.1007/BF00268015; Wallace JD, 1999, J CLIN ENDOCR METAB, V84, P3591, DOI 10.1210/jc.84.10.3591; Wallace JD, 2000, J CLIN ENDOCR METAB, V85, P124, DOI 10.1210/jc.85.1.124; Wang YT, 2019, ENDOCR PRACT, V25, P446, DOI 10.4158/EP-2018-0541; Watson AR, 2000, PEDIATR NEPHROL, V14, P469, DOI 10.1007/s004670050794; Webb SM, 2010, J CLIN ENDOCR METAB, V95, P630, DOI 10.1210/jc.2009-0806; Weber MM, 2017, CLIN ENDOCRINOL, V86, P192, DOI 10.1111/cen.13256; Wilson JR, 2016, GROWTH HORM IGF RES, V26, P24, DOI 10.1016/j.ghir.2015.12.005; Wilson PWF, 2005, CIRCULATION, V112, P3066, DOI 10.1161/CIRCULATIONAHA.105.539528; Wilson TA, 2003, J PEDIATR-US, V143, P415, DOI 10.1067/S0022-3476(03)00246-4; Tavares ABW, 2017, ENDOCRINE, V56, P317, DOI 10.1007/s12020-017-1275-8; Tavares ABW, 2015, GROWTH HORM IGF RES, V25, P53, DOI 10.1016/j.ghir.2014.11.002; Wiren L, 2002, CLIN ENDOCRINOL, V57, P235, DOI 10.1046/j.1365-2265.2002.01572.x; Woodmansee WW, 2013, EUR J ENDOCRINOL, V168, P565, DOI 10.1530/EJE-12-0967; World Anti-Doping Agency, TD2015GH WADA; World Anti-Doping Agency, 2016, GUID HUM GROWTH HORM; Wu Z, 1999, LANCET, V353, P895, DOI 10.1016/S0140-6736(99)00775-8; Yamauchi I, 2018, ENDOCRINE, V59, P353, DOI 10.1007/s12020-017-1495-y; Yang HB, 2019, EUR J ENDOCRINOL, V180, P147, DOI 10.1530/EJE-18-0711; Yang HB, 2018, J PEDIATR ENDOCR MET, V31, P533, DOI 10.1515/jpem-2018-0019; Yuen KCJ, 2006, HORM RES, V65, P6, DOI 10.1159/000090121; Yuen KCJ, 2005, CLIN ENDOCRINOL, V63, P428, DOI 10.1111/j.1365-2265.2005.02359.x; Yuen KCJ, 2018, CURR OPIN ENDOCRINOL, V25, P267, DOI 10.1097/MED.0000000000000416; Yuen KCJ, 2018, J CLIN ENDOCR METAB, V103, P768, DOI 10.1210/jc.2017-01542; Yuen KCJ, 2016, ENDOCR PRACT, V22, P1235, DOI 10.4158/EP161407.DSCR; Yuen KCJ, 2016, ENDOCRINE, V52, P194, DOI 10.1007/s12020-015-0840-2; Yuen KCJ, 2014, J CLIN ENDOCR METAB, V99, pE1862, DOI 10.1210/jc.2014-1532; Yuen KCJ, 2013, EUR J ENDOCRINOL, V169, P511, DOI 10.1530/EJE-13-0280; Yuen KCJ, 2013, PITUITARY, V16, P220, DOI 10.1007/s11102-012-0407-7; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299; ZADIK Z, 1985, J CLIN ENDOCR METAB, V60, P513, DOI 10.1210/jcem-60-3-513; Zheng XY, 2019, CLIN ENDOCRINOL, V90, P834, DOI 10.1111/cen.13958; Ziagaki A, 2019, EUR J ENDOCRINOL; Zueger T, 2012, J CLIN ENDOCR METAB, V97, pE1938, DOI 10.1210/jc.2012-2432	355	50	53	0	4	AMER ASSOC CLINICAL ENDOCRINOLOGISTS	JACKSONVILLE	245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA	1530-891X	1934-2403		ENDOCR PRACT	Endocr. Pract.	NOV	2019	25	11					1191	1232		10.4158/GL-2019-0405			42	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Endocrinology & Metabolism	JP0HS	WOS:000497953400012	31760824				2022-02-06	
J	Bhowmick, S; D'Mello, V; Caruso, D; Wallerstein, A; Abdul-Muneer, PM				Bhowmick, Saurav; D'Mello, Veera; Caruso, Danielle; Wallerstein, Alex; Abdul-Muneer, P. M.			Impairment of pericyte-endothelium crosstalk leads to blood-brain barrier dysfunction following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Blood-brain barrier; Pericytes; Endothelial cells; PDGF-B/PDGFR-beta signaling; Vasogenic edema	VESSEL FORMATION; ANIMAL-MODEL; N-CADHERIN; PDGF-B; BETA; NEUROINFLAMMATION; ADHESION; ANGIOGENESIS; RECRUITMENT; DISRUPTION	The blood-brain barrier (BBB) constitutes a neurovascular unit formed by microvascular endothelial cells, pericytes, and astrocytes. Brain pericytes are important regulators of BBB integrity, permeability, and blood flow. Pericyte loss has been implicated in injury; however, how the crosstalk among pericytes, endothelial cells, and astrocytes ultimately leads to BBB dysfunction in traumatic brain injury (TBI) remains elusive. In this study, we demonstrate the importance of pericyte-endothelium interaction in maintaining the BBB function. TBI causes the platelet-derived growth factor-B (PDGF-B)/PDGF receptor-beta signaling impairment that results in loss of interaction with endothelium and leads to neurovascular dysfunction. Using in vivo mild (7 psi) and moderate (15 psi) fluid percussion injury (FPI) in mice, we demonstrate the expression of various pericyte markers including PDGFR-beta, NG2 and CD13 that were significantly reduced with a subsequent reduction in the expression of various integrins; adherent junction protein, N-cadherin; gap junction protein, connexin-43; and tight junction proteins such as occludin, claudin-5, ZO-1, and JAM-a. Impairment of pericyte-endothelium interaction increases the BBB permeability to water that is marked by a significant increase in aquaporin4 expression in injured animals. Similarly, pericyte-endothelium integrity impairment in FPI animals greatly increases the permeability of small-molecular-weight sodium fluorescein and high-molecular-weight-tracer Evans blue across the BBB. In addition, the injury-inflicted animals show significantly higher levels of S100 beta and NSE in the blood samples compared with controls. In conclusion, our data provide an insight that brain trauma causes an early impairment of pericyte-endothelium integrity and results in BBB dysregulation that initiates pathological consequences associated with TBI.	[Bhowmick, Saurav; D'Mello, Veera; Caruso, Danielle; Wallerstein, Alex; Abdul-Muneer, P. M.] Hackensack Meridian Hlth JFK Med Ctr, JFK Neurosci Inst, Lab CNS Injury & Mol Therapy, 65 James St, Edison, NJ 08820 USA		Abdul-Muneer, PM (corresponding author), Hackensack Meridian Hlth JFK Med Ctr, JFK Neurosci Inst, Lab CNS Injury & Mol Therapy, 65 James St, Edison, NJ 08820 USA.	Mohammed.Muneer@hackensackmeridian.org	Bhowmick, Saurav/Y-6011-2019	Abdul-Muneer, P. M/0000-0001-8231-4385	Neuroscience Institute at Hackensack Meridian Health JFK Medical Center, Edison, NJ	This work was supported by the Neuroscience Institute at Hackensack Meridian Health JFK Medical Center, Edison, NJ to P.M. Abdul-Muneer.	Abdul-Muneer PM, 2018, MOL NEUROBIOL, V55, P5901, DOI 10.1007/s12035-017-0812-z; Abdul-Muneer PM, 2017, MOL NEUROBIOL, V54, P3964, DOI 10.1007/s12035-016-9949-4; Abdul-Muneer PM, 2017, BRAIN BEHAV IMMUN, V62, P291, DOI 10.1016/j.bbi.2017.02.014; Abdul-Muneer PM, 2017, BRAIN BEHAV IMMUN, V59, P190, DOI 10.1016/j.bbi.2016.09.002; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; Alikunju S, 2011, BRAIN BEHAV IMMUN, V25, pS129, DOI 10.1016/j.bbi.2011.01.007; Arimura K, 2012, CURR NEUROVASC RES, V9, P1; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Bankhead P., 2014, AN FLUOR MICR IM IMA; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; Bhowmick S, 2019, MOL NEUROBIOL, V56, P1124, DOI 10.1007/s12035-018-1132-7; Bhowmick S, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8010011; Bjarnegard M, 2004, DEVELOPMENT, V131, P1847, DOI 10.1242/dev.01080; Chew SSL, 2010, EXP NEUROL, V225, P250, DOI 10.1016/j.expneurol.2010.07.014; Daneman R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020412; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; Diaz-Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH-24.909; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Fisher M, 2009, STROKE, V40, pS13, DOI 10.1161/STROKEAHA.108.533117; Francesca B, 2010, CURR NEUROPHARMACOL, V8, P92, DOI 10.2174/157015910791233132; Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052; Gerhardt H, 2000, DEV DYNAM, V218, P472, DOI 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Harris AL, 2007, PROG BIOPHYS MOL BIO, V94, P120, DOI 10.1016/j.pbiomolbio.2007.03.011; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Huang FJ, 2010, DEV BIOL, V344, P1035, DOI 10.1016/j.ydbio.2010.06.023; Krueger M, 2010, GLIA, V58, P1, DOI 10.1002/glia.20898; KUNZ J, 1994, J NEUROCHEM, V62, P2375; Lebrin F, 2010, NAT MED, V16, P420, DOI 10.1038/nm.2131; Li FF, 2011, DEV CELL, V20, P291, DOI 10.1016/j.devcel.2011.01.011; Lindahl P, 1999, CURR TOPICS PATHOL, V93, P27; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23; Muneer PMA, 2012, ARTERIOSCL THROM VAS, V32, P1167, DOI 10.1161/ATVBAHA.112.247668; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Osada T, 2011, J CEREBR BLOOD F MET, V31, P1972, DOI 10.1038/jcbfm.2011.99; Patel RK, 2017, BRAIN BEHAV IMMUN, V64, P244, DOI 10.1016/j.bbi.2017.04.012; Sengillo JD, 2013, BRAIN PATHOL, V23, P303, DOI 10.1111/bpa.12004; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Simard M, 2003, J NEUROSCI, V23, P9254; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Stratman AN, 2009, BLOOD, V114, P5091, DOI 10.1182/blood-2009-05-222364; Sweeney MD, 2016, NAT NEUROSCI, V19, P771, DOI 10.1038/nn.4288; Takata F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-106; Tallquist MD, 2003, PLOS BIOL, V1, P288, DOI 10.1371/journal.pbio.0000052; Tallquist MD, 2003, DEVELOPMENT, V130, P507, DOI 10.1242/dev.00241; Thanabalasundaram G, 2011, INT J BIOCHEM CELL B, V43, P1284, DOI 10.1016/j.biocel.2011.05.002; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Winkler EA, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-32; Zehendner CM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13497; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	59	50	52	2	24	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2019	317						260	270		10.1016/j.expneurol.2019.03.014			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IC2PY	WOS:000470803400024	30926390				2022-02-06	
J	Ritzel, RM; Doran, SJ; Barrett, JP; Henry, RJ; Ma, EL; Faden, AI; Loane, DJ				Ritzel, Rodney M.; Doran, Sarah J.; Barrett, James P.; Henry, Rebecca J.; Ma, Elise L.; Faden, Alan I.; Loane, David J.			Chronic Alterations in Systemic Immune Function after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						chronic inflammation; immunosuppression; systemic immunity; traumatic brain injury	PROGRESSIVE NEURODEGENERATION; EXPERIMENTAL STROKE; INTERFERON-GAMMA; T-LYMPHOCYTES; ACTIVATION; INFECTION; IMMUNODEPRESSION; INFLAMMATION; CONSEQUENCES; MONOCYTES	There is a compelling link between severe brain trauma and immunosuppression in patients with traumatic brain injury (TBI). Although acute changes in the systemic immune compartment have been linked to outcome severity, the long-term consequences of TBI on systemic immune function are unknown. Here, adult male C57Bl/6 mice underwent moderate-level controlled cortical impact (CCI) or sham surgery, and systemic immune function was evaluated at 1, 3, 7, 14, and 60 days post-injury. Bone marrow, blood, thymus, and spleen were examined by flow cytometry to assess changes in immune composition, reactive oxygen species (ROS) production, phagocytic activity, and cytokine production. Bone marrow derived macrophages (BMDMs) from sham and 60-day CCI mice were cultured for immune challenge studies using lipopolysaccharide (LPS) and interleukin-4 (IL-4) models. Acutely, TBI caused robust bone marrow activation and neutrophilia. Neutrophils and monocytes exhibited impairments in respiratory burst, cytokine production, and phagocytosis; in contrast, ROS levels and pro-inflammatory cytokine production were chronically elevated at 60 days post-injury. Cultures of BMDMs from chronic CCI mice demonstrated defects in LPS- and IL-4-induced polarization when compared with stimulated BMDMs from sham mice. TBI also caused thymic involution, inverted CD4:CD8 ratios, chronic T lymphopenia, greater memory conversion, increased T cell activation, impaired interferon induction, and chronically elevated Th1 cytokine and ROS production. Collectively, our in-depth phenotypic and functional analyses demonstrate that TBI induces widespread suppression of innate and adaptive immune responses after TBI. Moreover, at chronic time points, TBI mice exhibit hallmarks of accelerated immune aging, displaying chronic deficits in systemic immune function.	[Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA		Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.	dloane@som.umaryland.edu	Loane, David/ABD-5177-2021	Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348; Henry, Rebecca/0000-0001-8548-1170; Ritzel, Rodney/0000-0002-0160-2930; Barrett, James/0000-0002-0924-9449	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082308, R01NS037313, F32NS105355]; National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center [P30-AG028747]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32AI095190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	We would like to acknowledge Ethan Glaser, B.Sc., for his technical assistance, and Dr. Xiaoxuan Fan, Ph.D., and Karen Underwood, B.Sc., of the University of Maryland Greenebaum Comprehensive Cancer Center Flow Cytometry Facility for support with flow cytometry studies. We would also like to thank Dr. Nevil Singh, Ph.D., for helpful discussion. This work was supported by National Institutes of Health grants R01NS082308 (D.J. Loane), R01NS037313 (A.I. Faden), and F32NS105355 (R.M. Ritzel), and The National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center P30-AG028747 (D.J. Loane).	Alharfi IM, 2014, J NEUROTRAUM, V31, P452, DOI [10.1089/neu.2013.2904, 10.1089/NEU.2013.2904]; Amit I, 2016, NAT IMMUNOL, V17, P18, DOI 10.1038/ni.3325; Bai RJ, 2017, MED SCI MONITOR, V23, P1707, DOI 10.12659/MSM.901124; Barrett JP, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0843-4; Bosmann M, 2013, TRENDS IMMUNOL, V34, P129, DOI 10.1016/j.it.2012.09.004; Brubaker AL, 2011, AGING DIS, V2, P346; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; CHEADLE WG, 1991, AM J SURG, V161, P639, DOI 10.1016/0002-9610(91)91247-G; Chen Y, 2012, METHODS MOL BIOL, V844, P115, DOI 10.1007/978-1-61779-527-5_8; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Correa BL, 2014, NEUROIMMUNOMODULAT, V21, P206, DOI 10.1159/000356827; Courties G, 2015, CIRC RES, V116, P407, DOI 10.1161/CIRCRESAHA.116.305207; Denes A, 2011, J CEREBR BLOOD F MET, V31, P1036, DOI 10.1038/jcbfm.2010.198; El-Benna J, 2016, IMMUNOL REV, V273, P180, DOI 10.1111/imr.12447; Emsley Hedley C. A., 2010, Infectious Disorders - Drug Targets, V10, P91; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Gennery Andrew, 2017, F1000Res, V6, P1427, DOI 10.12688/f1000research.11789.1; Hazeldine J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00235; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Junger WG, 2013, SHOCK, V40, P366, DOI 10.1097/SHK.0000000000000038; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Liesz A, 2009, STROKE, V40, P2849, DOI 10.1161/STROKEAHA.109.549618; Linehan E, 2015, EUR J MICROBIOL IMMU, V5, P14, DOI [10.1556/EuJMI-D-14-00035, 10.1556/EUJMI-D-14-00035]; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Ma EL, 2017, BRAIN BEHAV IMMUN, V66, P56, DOI 10.1016/j.bbi.2017.06.018; Marks W, 2013, CENT EUR J IMMUNOL, V38, P494, DOI 10.5114/ceji.2013.39767; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meisel C, 2004, STROKE, V35, P2, DOI 10.1161/01.STR.0000109041.89959.4C; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nikolich-Zugich J, 2014, J IMMUNOL, V193, P2622, DOI 10.4049/jimmunol.1401174; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Perkins DJ, 2016, J INTERF CYTOK RES, V36, P454, DOI 10.1089/jir.2016.0003; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Ritzel RM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0329-1; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Scott BNV, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-68; Seifert HA, 2012, METAB BRAIN DIS, V27, P131, DOI 10.1007/s11011-012-9283-0; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smrcka M, 2005, Bratisl Lek Listy, V106, P144; Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537; Suz P, 2006, J NEUROSURG ANESTH, V18, P5, DOI 10.1097/01.ana.0000189079.26212.37; Vernon PJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146105; Winkler MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182427; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; Wood RL, 2017, BRAIN INJURY, V31, P1270, DOI 10.1080/02699052.2017.1332387; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yang YH, 2013, INT REV IMMUNOL, V32, P249, DOI 10.3109/08830185.2012.755176; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046	59	50	50	2	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	13					1419	1436		10.1089/neu.2017.5399		MAY 2018	18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GJ4CQ	WOS:000431466600001	29421977	Green Published			2022-02-06	
J	Dong, WW; Yang, B; Wang, LL; Li, BX; Guo, XS; Zhang, M; Jiang, ZF; Fu, JQ; Pi, JB; Guan, DW; Zhao, R				Dong, Wenwen; Yang, Bei; Wang, Linlin; Li, Bingxuan; Guo, Xiangshen; Zhang, Miao; Jiang, Zhenfei; Fu, Jingqi; Pi, Jingbo; Guan, Dawei; Zhao, Rui			Curcumin plays neuroprotective roles against traumatic brain injury partly via Nrf2 signaling	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Traumatic brain injury (TBI); Curcumin; NF-E2-related factor (Nrf2); Antioxidant response; Inflammation; Apoptosis	TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; PROVIDES NEUROPROTECTION; ANTIOXIDANT RESPONSE; COUNTERACTS; MODULATION; EXPRESSION; INDUCTION; GENES; EDEMA	Traumatic brain injury (TBI), which leads to high mortality and morbidity, is a prominent public health problem worldwide with no effective treatment. Curcumin has been shown to be beneficial for neuroprotection in vivo and in vitro, but the underlying mechanism remains unclear. This study determined whether the neuroprotective role of curcumin in mouse TBI is dependent on the NF-E2-related factor (Nrf2) pathway. The Feeney weight-drop contusion model was used to mimic TBI. Curcumin was administered intraperitoneally 15 min after TBI induction, and brains were collected at 24 h after TBI. The levels of Nrf2 and its downstream genes (Hmox-1, Nqo1, Gclm, and Gclc) were detected by Western blot and qRT-PCR at 24 h after TBI. In addition, edema, oxidative damage, cell apoptosis and inflammatory reactions were evaluated in wild type (W7) and Nrf2-knockout (Nrf2-KO) mice to explore the role of Nrf2 signaling after curcumin treatment. In wild type mice, curcumin treatment resulted in reduced ipsilateral cortex injury, neutrophil infiltration, and microglia activation, improving neuron survival against TBI-induced apoptosis and degeneration. These effects were accompanied by increased expression and nuclear translocation of Nrf2, and enhanced expression of antioxidant enzymes. However, Nrf2 deletion attenuated the neuroprotective effects of curcumin in Nrf2-KO mice after TBI. These findings demonstrated that curcumin effects on TBI are associated with the activation the Nrf2 pathway, providing novel insights into the neuroprotective role of Nrf2 and the potential therapeutic use of curcumin for TBI.	[Dong, Wenwen; Wang, Linlin; Li, Bingxuan; Guo, Xiangshen; Zhang, Miao; Jiang, Zhenfei; Guan, Dawei; Zhao, Rui] China Med Univ, Sch Forens Med, Dept Forens Pathol, Shenyang 110122, Liaoning, Peoples R China; [Yang, Bei] China Med Univ, Coll Basic Med Sci, Dept Histol & Embryol, Shenyang 110122, Liaoning, Peoples R China; [Fu, Jingqi; Pi, Jingbo] China Med Univ, Sch Publ Hlth, Program Environm Toxicol, Shenyang 110122, Liaoning, Peoples R China		Guan, DW; Zhao, R (corresponding author), China Med Univ, Sch Forens Med, Dept Forens Pathol, Shenyang 110122, Liaoning, Peoples R China.	dwguan@cmu.edu.cn; rzhao@cmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81372943, 81772023, 81671862, 81602825]; Liaoning Provincial Department of Education Science Research Project [LJQ2015119]; Liaoning Natural science Foundation of China [201602882]; Science and Technology Research Program from Education Department of Liaoning Province, China [LK201658]	This work was partly supported by grants from the National Natural Science Foundation of China (81372943, 81772023, 81671862 and 81602825), the Liaoning Provincial Department of Education Science Research Project for outstanding young investigator (LJQ2015119), the Liaoning Natural science Foundation of China (201602882) and the Science and Technology Research Program from Education Department of Liaoning Province, China (LK201658).	Agarwal NB, 2011, PHYTOMEDICINE, V18, P756, DOI 10.1016/j.phymed.2010.11.007; Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cui XL, 2017, EXP THER MED, V14, P1512, DOI 10.3892/etm.2017.4683; Ding H, 2017, NEUROCHEM INT, V111, P32, DOI 10.1016/j.neuint.2017.04.016; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dressler Jan, 2009, Leg Med (Tokyo), V11 Suppl 1, pS54, DOI 10.1016/j.legalmed.2009.02.024; Gold R, 2012, CLIN IMMUNOL, V142, P44, DOI 10.1016/j.clim.2011.02.017; Gonzalez-Reyes S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/801418; Guo Y, 2015, FREE RADICAL BIO MED, V88, P337, DOI 10.1016/j.freeradbiomed.2015.06.013; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Innamorato NG, 2008, J IMMUNOL, V181, P680, DOI 10.4049/jimmunol.181.1.680; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Kaidery NA, 2013, ANTIOXID REDOX SIGN, V18, P139, DOI 10.1089/ars.2011.4491; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Li W, 2016, MICROVASC RES, V106, P117, DOI 10.1016/j.mvr.2015.12.008; Lu XY, 2015, CELL MOL NEUROBIOL, V35, P713, DOI 10.1007/s10571-015-0167-9; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008; Nair S, 2008, BRIT J CANCER, V99, P2070, DOI 10.1038/sj.bjc.6604703; Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; Piantadosi CA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207738; RAVINDRANATH V, 1980, TOXICOLOGY, V16, P259, DOI 10.1016/0300-483X(80)90122-5; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Sakata H, 2012, J NEUROSCI, V32, P3462, DOI 10.1523/JNEUROSCI.5686-11.2012; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Scannevin RH, 2012, J PHARMACOL EXP THER, V341, P274, DOI 10.1124/jpet.111.190132; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450; Shu LF, 2016, NEUROSCI LETT, V611, P74, DOI 10.1016/j.neulet.2015.11.012; Tu ZS, 2017, EUR J MED CHEM, V134, P72, DOI 10.1016/j.ejmech.2017.04.008; Tumer N, 2013, NEUROSCI LETT, V544, P62, DOI 10.1016/j.neulet.2013.03.042; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2011, NEUROREHAB NEURAL RE, V25, P332, DOI 10.1177/1545968310397706; Wu G, 2016, MED SCI MONITOR, V22, P2161, DOI 10.12659/MSM.896568; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46763; Zhao J, 2008, BRAIN RES, V1229, P224, DOI 10.1016/j.brainres.2008.06.117; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao R, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/412576; Zhao R, 2011, ENVIRON HEALTH PERSP, V119, P56, DOI 10.1289/ehp.1002304; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	52	50	53	2	32	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X	1096-0333		TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	MAY 1	2018	346						28	36		10.1016/j.taap.2018.03.020			9	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Toxicology	GC9XR	WOS:000430152600004	29571711				2022-02-06	
J	Frik, J; Merl-Pham, J; Plesnila, N; Mattugini, N; Kjell, J; Kraska, J; Gomez, RM; Hauck, SM; Sirko, S; Gotz, M				Frik, Jesica; Merl-Pham, Juliane; Plesnila, Nikolaus; Mattugini, Nicola; Kjell, Jacob; Kraska, Jonas; Gomez, Ricardo M.; Hauck, Stefanie M.; Sirko, Swetlana; Goetz, Magdalena			Cross-talk between monocyte invasion and astrocyte proliferation regulates scarring in brain injury	EMBO REPORTS			English	Article						aryl hydrocarbon receptor; astrogliosis; monocytes; scar formation; sonic hedgehog pathway; traumatic brain injury	ARYL-HYDROCARBON RECEPTOR; SPINAL-CORD-INJURY; REACTIVE ASTROCYTES; COGNITIVE DYSFUNCTION; RADIAL GLIA; CELLS; CCR2; MICROGLIA; SYSTEM; DELETION	Scar formation after brain injury is still poorly understood. To further elucidate such processes, here, we examine the interplay between astrocyte proliferation taking place predominantly at the vascular interface and monocyte invasion. Using genetic mouse models that decrease or increase reactive astrocyte proliferation, we demonstrate inverse effects on monocyte numbers in the injury site. Conversely, reducing monocyte invasion using CCR2(-/-) mice causes a strong increase in astrocyte proliferation, demonstrating an intriguing negative cross-regulation between these cell types at the vascular interface. CCR2(-/-) mice show reduced scar formation with less extracellular matrix deposition, smaller lesion site and increased neuronal coverage. Surprisingly, the GFAP(+) scar area in these mice is also significantly decreased despite increased astrocyte proliferation. Proteomic analysis at the peak of increased astrocyte proliferation reveals a decrease in extracellular matrix synthesizing enzymes in the injury sites of CCR2(-/-) mice, highlighting how early key aspects of scar formation are initiated. Taken together, we provide novel insights into the cross-regulation of juxtavascular proliferating astrocytes and invading monocytes as a crucial mechanism of scar formation upon brain injury.	[Frik, Jesica; Mattugini, Nicola; Kjell, Jacob; Kraska, Jonas; Sirko, Swetlana; Goetz, Magdalena] Ludwig Maximilians Univ Munchen, Biomed Ctr, Physiol Genom, Munich, Germany; [Frik, Jesica; Mattugini, Nicola; Kjell, Jacob; Sirko, Swetlana; Goetz, Magdalena] Helmholtz Ctr Munich, Inst Stem Cell Res, Munich, Germany; [Frik, Jesica; Gomez, Ricardo M.] UNLP, CONICET, Inst Biotecnol & Biol Mol, La Plata, Buenos Aires, Argentina; [Merl-Pham, Juliane; Hauck, Stefanie M.] Helmholtz Ctr Munich, Res Unit Prot Sci, Munich, Germany; [Plesnila, Nikolaus] Univ Munich, Med Sch, Expt Stroke Res, Inst Stroke & Dementia Res, Munich, Germany; [Plesnila, Nikolaus; Goetz, Magdalena] Univ Munich, Excellence Cluster Syst Neurol, SYNERGY, Munich, Germany; [Mattugini, Nicola] Ludwig Maximilians Univ Munchen, Bioctr, Grad Sch System Neurosci, Munich, Germany		Sirko, S; Gotz, M (corresponding author), Ludwig Maximilians Univ Munchen, Biomed Ctr, Physiol Genom, Munich, Germany.; Sirko, S; Gotz, M (corresponding author), Helmholtz Ctr Munich, Inst Stem Cell Res, Munich, Germany.; Gotz, M (corresponding author), Univ Munich, Excellence Cluster Syst Neurol, SYNERGY, Munich, Germany.	swetlana.sirko@med.uni-muenchen.de; magdalena.goetz@helmholtz-muenchen.de	Gomez, Ricardo M/AAG-9555-2019; Merl-Pham, Juliane/N-7258-2014; Plesnila, Nikolaus/T-7522-2019; Sirko, Swetlana/O-5725-2019; Frik, Jesica/AAI-3992-2021; Hauck, Stefanie/B-3300-2013	Gomez, Ricardo M/0000-0002-4001-519X; Merl-Pham, Juliane/0000-0002-3422-4083; Sirko, Swetlana/0000-0001-5950-616X; Mattugini, Nicola/0000-0003-4489-1661; Frik, Jesica/0000-0002-8750-2112; Kjell, Jacob/0000-0002-8335-0780; Hauck, Stefanie/0000-0002-1630-6827	German Research FoundationGerman Research Foundation (DFG) [SFB870]; Synergy Excellence Cluster; ALEARG Program [1757]; Ministry of Education, Science and Technology of Argentina; German Academic Exchange Service (DAAD)Deutscher Akademischer Austausch Dienst (DAAD); Swedish Society for Medical Research (SSMF)	We are particularly grateful to Gabi Jager and Manja Thorwirth for excellent technical assistance. We thank Giacomo Masserdotti for help with statistics and Adam O'Neill for excellent suggestions on the manuscript. We are also thankful to Prof. Dr. Andreas Faissner (Ruhr-University Bochum, Germany) for generously providing the KAF14 antibody and to Elisabetta Petroziello for help with identification of invading immune cells by MACS and FACS. This work was supported by the German Research Foundation to MG via the SFB870, Synergy Excellence Cluster, and the Priority Program 1757, a Scholarship to JF from the ALEARG Program co-funded by the Ministry of Education, Science and Technology of Argentina and the German Academic Exchange Service (DAAD) and to JKj by Swedish Society for Medical Research (SSMF).	Adams KL, 2018, NAT NEUROSCI, V21, P9, DOI 10.1038/s41593-017-0033-9; Alunni A, 2016, DEVELOPMENT, V143, P741, DOI 10.1242/dev.122796; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Barbosa JS, 2015, SCIENCE, V348, P789, DOI 10.1126/science.aaa2729; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Barrow LL, 2002, TERATOLOGY, V66, P85, DOI 10.1002/tera.10062; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179; Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Chu HX, 2014, J CEREBR BLOOD F MET, V34, P1425, DOI 10.1038/jcbfm.2014.120; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Filous AR, 2016, PROG NEUROBIOL, V144, P173, DOI 10.1016/j.pneurobio.2016.03.009; Frisen J, 2016, ANNU REV CELL DEV BI, V32, P127, DOI 10.1146/annurev-cellbio-111315-124953; Fujimoto M, 2016, J NEUROSURG, V124, P1693, DOI 10.3171/2015.4.JNS15484; Grosche A, 2016, MOL CELL PROTEOMICS, V15, P462, DOI 10.1074/mcp.M115.052183; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Haan N, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0327-3; Hara M, 2017, NAT MED, V23, P818, DOI 10.1038/nm.4354; Hayakawa K, 2016, NEURAL REGEN RES, V11, P529, DOI 10.4103/1673-5374.180725; Heimann G, 2017, CEREB CORTEX, V27, P4213, DOI 10.1093/cercor/bhx112; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Horng S, 2017, J CLIN INVEST, V127, P3136, DOI 10.1172/JCI91301; Howitt J, 2015, J MOL CELL BIOL, V7, P119, DOI 10.1093/jmcb/mjv020; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Jiang P., 2016, NEUROGENESIS AUSTIN, V3, DOI [10.1080/23262133.2016.1224453, DOI 10.1080/23262133.2016.122445]; Kamphuis W, 2015, GLIA, V63, P1036, DOI 10.1002/glia.22800; Katsumoto A, 2014, J IMMUNOL, V193, P2615, DOI 10.4049/jimmunol.1400716; Kim SK, 2017, GLIA, V65, P1719, DOI 10.1002/glia.23169; Kroehne V, 2011, DEVELOPMENT, V138, P4831, DOI 10.1242/dev.072587; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Long FX, 2001, DEVELOPMENT, V128, P5099; Ly A, 2016, J PROTEOME RES, V15, P1350, DOI 10.1021/acs.jproteome.6b00111; Martin-Lopez E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074039; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mori T, 2006, GLIA, V54, P21, DOI 10.1002/glia.20350; Nakamura T, 2006, CIRC RES, V98, P1547, DOI 10.1161/01.RES.0000227505.19472.69; Nebert DW, 2017, PROG LIPID RES, V67, P38, DOI 10.1016/j.plipres.2017.06.001; O'Callaghan JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102003; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Reaux-Le Goazigo A, 2013, PROG NEUROBIOL, V104, P67, DOI 10.1016/j.pneurobio.2013.02.001; Ren YL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41122; Robel S, 2016, NAT NEUROSCI, V19, P28, DOI 10.1038/nn.4184; Robel S, 2011, J NEUROSCI, V31, P12471, DOI 10.1523/JNEUROSCI.2696-11.2011; Rothhammer V, 2016, NAT MED, V22, P586, DOI 10.1038/nm.4106; Sabelstrom H, 2013, SCIENCE, V342, P637, DOI 10.1126/science.1242576; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Sang Q, 2006, J NEUROSCI, V26, P7234, DOI 10.1523/JNEUROSCI.1398-06.2006; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; Sirko S, 2015, GLIA, V63, P2340, DOI 10.1002/glia.22898; Sirko S, 2013, CELL STEM CELL, V12, P426, DOI 10.1016/j.stem.2013.01.019; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tanaka EM, 2009, NAT REV NEUROSCI, V10, P713, DOI 10.1038/nrn2707; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Tomita S, 2003, J IMMUNOL, V171, P4113, DOI 10.4049/jimmunol.171.8.4113; Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Watkins S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5196; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Wu XW, 2006, GENE DEV, V20, P571, DOI 10.1101/gad.361406; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Xu JW, 2017, BEHAV BRAIN RES, V332, P145, DOI 10.1016/j.bbr.2017.05.066; Xu K, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0522-2; Yanagida K, 2017, P NATL ACAD SCI USA, V114, P4531, DOI 10.1073/pnas.1618659114; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	80	50	51	2	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-221X	1469-3178		EMBO REP	EMBO Rep.	MAY	2018	19	5							e45294	10.15252/embr.201745294			20	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GF0PS	WOS:000431633800009	29632244	Green Published, hybrid			2022-02-06	
J	Gollihue, JL; Patel, SP; Eldahan, KC; Cox, DH; Donahue, RR; Taylor, BK; Sullivan, PG; Rabchevsky, AG				Gollihue, Jenna L.; Patel, Samir P.; Eldahan, Khalid C.; Cox, David H.; Donahue, Renee R.; Taylor, Bradley K.; Sullivan, Patrick G.; Rabchevsky, Alexander G.			Effects of Mitochondrial Transplantation on Bioenergetics, Cellular Incorporation, and Functional Recovery after Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						Basso; Beattie; Bresnahan locomotor rating scale; mitochondrial respiration; transgenic labeling; Von Frey hair test	ACETYL-L-CARNITINE; TRAUMATIC BRAIN; OXIDATIVE STRESS; NONSYNAPTIC MITOCHONDRIA; ANTIOXIDANT THERAPIES; UNCOUPLING AGENT; DYSFUNCTION; NEURONS; 2,4-DINITROPHENOL; PROTECTS	Our previous studies reported that pharmacological maintenance of mitochondrial bioenergetics after experimental spinal cord injury (SCI) provided functional neuroprotection. Recent evidence indicates that endogenous mitochondrial transfer is neuroprotective as well, and, therefore, we extended these studies with a novel approach to transplanting exogenous mitochondria into the injured rat spinal cord. Using a rat model of L1/L2 contusion SCI, we herein report that transplantation of exogenous mitochondria derived from either cell culture or syngeneic leg muscle maintained acute bioenergetics of the injured spinal cord in a concentration-dependent manner. Moreover, transplanting transgenically labeled turbo green fluorescent (tGFP) PC12-derived mitochondria allowed for visualization of their incorporation in both a time-dependent and cell-specific manner at 24h, 48h, and 7 days post-injection. tGFP mitochondria co-localized with multiple resident cell types, although they were absent in neurons. Despite their contribution to the maintenance of normal bioenergetics, mitochondrial transplantation did not yield long-term functional neuroprotection as assessed by overall tissue sparing or recovery of motor and sensory functions. These experiments are the first to investigate mitochondrial transplantation as a therapeutic approach to treating spinal cord injury. Our initial bioenergetic results are encouraging, and although they did not translate into improved long-term outcome measures, caveats and technical hurdles are discussed that can be addressed in future studies to potentially increase long-term efficacy of transplantation strategies.	[Gollihue, Jenna L.; Patel, Samir P.; Eldahan, Khalid C.; Donahue, Renee R.; Taylor, Bradley K.; Rabchevsky, Alexander G.] Univ Kentucky, Dept Physiol, Lexington, KY USA; [Sullivan, Patrick G.] Univ Kentucky, Dept Neurosci, Lexington, KY USA; [Gollihue, Jenna L.; Patel, Samir P.; Eldahan, Khalid C.; Cox, David H.; Taylor, Bradley K.; Sullivan, Patrick G.; Rabchevsky, Alexander G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B471,BBSRB 741 S Limestone, Lexington, KY 40536 USA		Rabchevsky, AG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B471,BBSRB 741 S Limestone, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021; Donahue, Renee/AAI-3512-2020	Rabchevsky, Alexander/0000-0002-1991-0915; Cox, David/0000-0002-9483-5900; Donahue, Renee/0000-0002-3344-5650	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F31 NS093904-01A1]; Conquer Paralysis Now; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS096670]; Spinal Cord and Brain Injury Research Center (SCoBIRC) Chair Endowment; NIH/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P30NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045954, R01NS062306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG057461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA037621] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health (NIH) F31 NS093904-01A1 (J.L.G.), Conquer Paralysis Now (A.G.R.), NIH R21 NS096670 (A.G.R.), Spinal Cord and Brain Injury Research Center (SCoBIRC) Chair Endowment (A.G.R.), and NIH/National Institute of Neurological Disorders and Stroke (NINDS) 2P30NS051220.	Ahmed LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108889; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Aygok GA, 2008, ACTA NEUROCHIR SUPPL, V102, P57, DOI 10.1007/978-3-211-85578-2_12; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Bolanos JP, 2009, ADV DRUG DELIVER REV, V61, P1299, DOI 10.1016/j.addr.2009.05.009; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Brightwell JJ, 2009, NEUROSCIENCE, V160, P174, DOI 10.1016/j.neuroscience.2009.02.023; CARTA A, 1991, ANN NY ACAD SCI, V640, P228; Chang J., 2013, CHANGHUA J MED, V11, P8; Chang JC, 2016, TRANSL RES, V170, P40, DOI 10.1016/j.trsl.2015.12.003; Chang JC, 2013, NEUROSIGNALS, V21, P160, DOI 10.1159/000341981; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; CLARK MA, 1982, NATURE, V295, P605, DOI 10.1038/295605a0; Cowan DB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160889; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Fernandez-Vizarra E, 2011, MITOCHONDRION, V11, P207, DOI 10.1016/j.mito.2010.09.011; Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003; Gollihue JL, 2017, MITOCHONDRION, V35, P70, DOI 10.1016/j.mito.2017.05.007; Gollihue JL, 2017, J NEUROSCI METH, V287, P1, DOI 10.1016/j.jneumeth.2017.05.023; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hamilton Nicola B, 2010, Front Neuroenergetics, V2, DOI 10.3389/fnene.2010.00005; Hayakawa K, 2016, NATURE, V535, P551, DOI 10.1038/nature18928; Hou SP, 2008, J COMP NEUROL, V509, P382, DOI 10.1002/cne.21771; Ide T, 2001, CIRC RES, V88, P529, DOI 10.1161/01.RES.88.5.529; Intondi AB, 2008, PAIN, V137, P352, DOI 10.1016/j.pain.2007.09.016; Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736; Rodriguez-Jimenez FJ, 2012, STEM CELLS, V30, P2221, DOI 10.1002/stem.1189; Jin H, 2014, BBA-MOL BASIS DIS, V1842, P1282, DOI 10.1016/j.bbadis.2013.09.007; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Katrangi E, 2007, REJUV RES, V10, P561, DOI 10.1089/rej.2007.0575; Kaza AK, 2017, J THORAC CARDIOV SUR, V153, P934, DOI 10.1016/j.jtcvs.2016.10.077; Koyanagi M, 2005, CIRC RES, V96, P1039, DOI 10.1161/01.RES.0000168650.23479.0c; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Laird MD, 2013, TRANSL STROKE RES, V4, P643, DOI 10.1007/s12975-013-0275-0; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; Magnuson DSK, 2005, J NEUROTRAUM, V22, P529, DOI 10.1089/neu.2005.22.529; Maragos WF, 2003, BRAIN RES, V966, P312, DOI 10.1016/S0006-8993(02)04225-7; Markiewicz I, 2006, ACTA NEUROBIOL EXP, V66, P343; Masuzawa A, 2013, AM J PHYSIOL-HEART C, V304, pH966, DOI 10.1152/ajpheart.00883.2012; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCully JD, 2017, MITOCHONDRION, V34, P127, DOI 10.1016/j.mito.2017.03.004; McCully JD, 2009, AM J PHYSIOL-HEART C, V296, pH94, DOI 10.1152/ajpheart.00567.2008; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Muramatsu R, 2014, NEUROSCI RES, V81-82, P38, DOI 10.1016/j.neures.2014.01.007; Pacak CA, 2015, BIOL OPEN, V4, P622, DOI 10.1242/bio.201511478; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Patel SP, 2012, NEUROSCIENCE, V210, P296, DOI 10.1016/j.neuroscience.2012.03.006; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; PETRUZZELLA V, 1992, ARCH GERONTOL GERIAT, V14, P131, DOI 10.1016/0167-4943(92)90048-9; PUCA FM, 1990, INT J CLIN PHARM RES, V10, P139; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Robb EL, 2008, BIOCHEM BIOPH RES CO, V372, P254, DOI 10.1016/j.bbrc.2008.05.028; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schwartz M, 2003, J CEREBR BLOOD F MET, V23, P385, DOI 10.1097/01.WCB.0000061881.75234.5E; Sheu SS, 2006, BBA-MOL BASIS DIS, V1762, P256, DOI 10.1016/j.bbadis.2005.10.007; Shi XX, 2017, MITOCHONDRION, V34, P91, DOI 10.1016/j.mito.2017.02.005; Smith RAJ, 2008, ANN NY ACAD SCI, V1147, P105, DOI 10.1196/annals.1427.003; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Swerdlow RH, 2004, MED HYPOTHESES, V63, P8, DOI 10.1016/j.mehy.2003.12.045; Tata M, 2015, MECH DEVELOP, V138, P26, DOI 10.1016/j.mod.2015.07.001; Ungvari Z, 2009, AM J PHYSIOL-HEART C, V297, pH1876, DOI 10.1152/ajpheart.00375.2009; Wang X, 2015, CELL DEATH DIFFER, V22, P1181, DOI 10.1038/cdd.2014.211; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Winklhofer KF, 2010, BBA-MOL BASIS DIS, V1802, P29, DOI 10.1016/j.bbadis.2009.08.013; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025	76	50	52	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2018	35	15					1800	1818		10.1089/neu.2017.5605		APR 2018	19	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GL8IW	WOS:000431110300001	29648982	Green Published, Green Submitted			2022-02-06	
J	Braun, M; Khan, ZT; Khan, MB; Kumar, M; Ward, A; Achyut, BR; Arbab, AS; Hess, DC; Hoda, MN; Baban, B; Dhandapani, KM; Vaibhav, K				Braun, Molly; Khan, Zenab T.; Khan, Mohammad B.; Kumar, Manish; Ward, Ayobami; Achyut, Bhagelu R.; Arbab, Ali S.; Hess, David C.; Hoda, Md. Nasrul; Baban, Babak; Dhandapani, Krishnan M.; Vaibhav, Kumar			Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Cannabinoid receptor 2; Macrophage; Controlled cortical impact; Inflammation; Marijuana	IN-VITRO MODEL; CB2 RECEPTOR; CEREBRAL EDEMA; CANNABIDIOL; INFLAMMATION; CELL; AGONIST; MODERATE; MICE; NEUROPROTECTION	Inflammation is an important mediator of secondary neurological injury after traumatic brain injury (TBI). Endocannabinoids, endogenously produced arachidonate based lipids, have recently emerged as powerful anti-inflammatory compounds, yet the molecular and cellular mechanisms underlying these effects are poorly defined. Endocannabinoids are physiological ligands for two known cannabinoid receptors, CB1R and CB2R. In the present study, we hypothesized that selective activation of CB2R attenuates neuroinflammation and reduces neurovascular injury after TBI. Using a murine controlled cortical impact (CCI) model of TBI, we observed a dramatic upregulation of CB2R within infiltrating myeloid cells beginning at 72 h. Administration of the selective CB2R agonist, GP1a (1-5 mg/kg), attenuated pro-inflammatory M1 macrophage polarization, increased anti-inflammatory M2 polarization, reduced edema development, enhanced cerebral blood flow, and improved neurobehavioral outcomes after TBI. In contrast, the CB2R antagonist, AM630, worsened outcomes. Taken together, our findings support the development of selective CB2R agonists as a therapeutic strategy to improve TBI outcomes while avoiding the psychoactive effects of CB1R activation. Published by Elsevier Inc.	[Braun, Molly; Khan, Zenab T.; Ward, Ayobami; Dhandapani, Krishnan M.; Vaibhav, Kumar] Augusta Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA USA; [Khan, Zenab T.] Augusta Univ, Ctr Nursing Res, Augusta, GA USA; [Khan, Mohammad B.; Hess, David C.; Hoda, Md. Nasrul; Baban, Babak] Augusta Univ, Med Coll Georgia, Dept Neurol, Augusta, GA USA; [Kumar, Manish] EMBL, Monterotondo, Italy; [Baban, Babak] Augusta Univ, Dent Coll Georgia, Dept Oral Biol, Augusta, GA USA; [Achyut, Bhagelu R.; Arbab, Ali S.] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA; [Hoda, Md. Nasrul; Vaibhav, Kumar] Augusta Univ, Coll Allied Hlth Sci, Dept Med Lab Imaging & Radiol Sci, Augusta, GA USA; [Baban, Babak] Augusta Univ, Med Coll Georgia, Dept Surg, Augusta, GA USA		Vaibhav, K (corresponding author), Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA.	kvaibhav@augusta.edu	Vaibhav, Kumar/H-4120-2019; Arbab, Ali/AAS-1933-2020; Kumar, Manish/AAC-2278-2019	Kumar, Manish/0000-0002-0855-3406; Vaibhav, Kumar/0000-0002-4206-3830; Dhandapani, Krishnan/0000-0001-7044-1117	Augusta University Research Institute [PSRP00095]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R03HD094606, R01NS065172, R21NS075774, R03NS084228]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD094606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075774, R03NS084228, R01NS065172] Funding Source: NIH RePORTER	Financial support for this project was provided by a Grant from the Augusta University Research Institute (PSRP00095) and by Grants from the National Institutes of Health (R03HD094606, R01NS065172, R21NS075774 and R03NS084228).	Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Allen S, 2016, SUBST USE MISUSE, V51, P1577, DOI 10.1080/10826084.2016.1188955; Anday JK, 2005, PHARMACOL RES, V52, P463, DOI 10.1016/j.phrs.2005.07.005; Ashton CH, 2011, ACTA PSYCHIAT SCAND, V124, P250, DOI 10.1111/j.1600-0447.2011.01687.x; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Baban B, 2005, INT IMMUNOL, V17, P909, DOI 10.1093/intimm/dxh271; Baban B, 2013, EXP MOL PATHOL, V95, P288, DOI 10.1016/j.yexmp.2013.09.002; Bahi A, 2014, PHYSIOL BEHAV, V135, P119, DOI 10.1016/j.physbeh.2014.06.003; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Braun M, 2017, J IMMUNOL, V198, P3615, DOI 10.4049/jimmunol.1601948; Bravo-Ferrer I, 2017, STROKE, V48, P204, DOI 10.1161/STROKEAHA.116.014793; Buch SJ, 2013, AM J PATHOL, V183, P1375, DOI 10.1016/j.ajpath.2013.08.003; Campos AC, 2012, PHILOS T R SOC B, V367, P3364, DOI 10.1098/rstb.2011.0389; Castillo A, 2010, NEUROBIOL DIS, V37, P434, DOI 10.1016/j.nbd.2009.10.023; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00209; Chen H, 2016, CLIN EXP PHARMACOL P, V43, P1107, DOI 10.1111/1440-1681.12650; Chuchawankul S, 2004, INT IMMUNOPHARMACOL, V4, P265, DOI 10.1016/j.intimp.2003.12.011; Conti S, 2002, BRIT J PHARMACOL, V135, P181, DOI 10.1038/sj.bjp.0704466; Croxford JL, 2005, J NEUROIMMUNOL, V166, P3, DOI 10.1016/j.jneuroim.2005.04.023; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Schier ARD, 2014, CNS NEUROL DISORD-DR, V13, P953, DOI 10.2174/1871527313666140612114838; Di Marzo V, 2006, ANNU REV MED, V57, P553, DOI 10.1146/annurev.med.57.011205.135648; Donat CK, 2014, ACTA NEUROBIOL EXP, V74, P197; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hind WH, 2016, BRIT J PHARMACOL, V173, P815, DOI 10.1111/bph.13368; Hou JM, 2017, J NEUROTRAUM, V34, P2456, DOI 10.1089/neu.2016.4851; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Ignatowska-Jankowska BM, 2013, PSYCHOPHARMACOLOGY, V229, P591, DOI 10.1007/s00213-013-3117-6; Jin X, 2012, J SOFTWARE, V7, P6, DOI DOI 10.1371/J0URNAL.P0NE.0041892; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; Kawamata T, 2006, ACTA NEUROCHIR SUPPL, V96, P3; Khan MB, 2015, TRANSL STROKE RES, V6, P69, DOI 10.1007/s12975-014-0374-6; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kishimoto S, 2005, J BIOCHEM, V137, P217, DOI 10.1093/jb/mvi021; Kozela E, 2013, J NEUROIMMUNE PHARM, V8, P1265, DOI 10.1007/s11481-013-9493-1; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Lopez-Rodriguez AB, 2015, CEREB CORTEX, V25, P35, DOI 10.1093/cercor/bht202; Luong TN, 2011, JOVE-J VIS EXP, DOI 10.3791/2376; Massa F, 2006, J Endocrinol Invest, V29, P47; McKallip RJ, 2002, J PHARMACOL EXP THER, V302, P451, DOI 10.1124/jpet.102.033506; McKallip RJ, 2002, BLOOD, V100, P627, DOI 10.1182/blood-2002-01-0098; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nilsson O, 2006, EUR J PHARMACOL, V547, P165, DOI 10.1016/j.ejphar.2006.07.016; Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442; Peterson TC, 2015, BEHAV BRAIN RES, V294, P254, DOI 10.1016/j.bbr.2015.08.007; Plomgaard AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173440; Pottker B., 2017, BRAIN STRUCT FUNCT; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Rom S, 2013, AM J PATHOL, V183, P1548, DOI 10.1016/j.ajpath.2013.07.033; Pazos MR, 2013, NEUROPHARMACOLOGY, V71, P282, DOI 10.1016/j.neuropharm.2013.03.027; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Salehi A., 2017, J CEREB BLOOD FLOW M; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Sharma MD, 2010, IMMUNITY, V33, P942, DOI 10.1016/j.immuni.2010.11.022; Shi H, 2015, EXP NEUROL, V272, P17, DOI 10.1016/j.expneurol.2015.03.017; Steffens S, 2012, BRIT J PHARMACOL, V167, P313, DOI 10.1111/j.1476-5381.2012.02042.x; Su E, 2016, TRANSLATIONAL RES TR; Syed YY, 2014, DRUGS, V74, P563, DOI 10.1007/s40265-014-0197-5; Tchantchou F, 2014, NEUROPHARMACOLOGY, V85, P427, DOI 10.1016/j.neuropharm.2014.06.006; Tomar S, 2015, J PHARMACOL EXP THER, V353, P369, DOI 10.1124/jpet.114.220368; Valenzano KJ, 2005, NEUROPHARMACOLOGY, V48, P658, DOI 10.1016/j.neuropharm.2004.12.008; Vos B.C., 2017, CLIN J SPORT MED; Zhang DD, 2014, NEUROCHEM INT, V75, P11, DOI 10.1016/j.neuint.2014.05.003; Zhang M, 2008, NEUROSCIENCE, V152, P753, DOI 10.1016/j.neuroscience.2008.01.022; Zhang Melvyn Weibin, 2015, J Addict, V2015, P707596, DOI 10.1155/2015/707596; Ziring D, 2006, IMMUNOGENETICS, V58, P714, DOI 10.1007/s00251-006-0138-x	81	50	51	1	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	FEB	2018	68						224	237		10.1016/j.bbi.2017.10.021			14	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	FU7YL	WOS:000424068600021	29079445	Green Accepted, Bronze			2022-02-06	
J	Lamond, LC; Caccese, JB; Buckley, TA; Glutting, J; Kaminski, TW				Lamond, Lindsey C.; Caccese, Jaclyn B.; Buckley, Thomas A.; Glutting, Joseph; Kaminski, Thomas W.			Linear Acceleration in Direct Head Contact Across Impact Type, Player Position, and Playing Scenario in Collegiate Women's Soccer Players	JOURNAL OF ATHLETIC TRAINING			English	Article						repetitive head impacts; subconcussive head impacts; impact exposure; concussions	AMERICAN FOOTBALL; YOUTH SOCCER; EXPOSURE; SEASON	Context: Heading, an integral component of soccer, exposes athletes to a large number of head impacts over a career. The literature has begun to indicate that cumulative exposure may lead to long-term functional and psychological deficits. Quantifying an athlete's exposure over a season is a first step in understanding cumulative exposure. Objective: To measure the frequency and magnitude of direct head impacts in collegiate women's soccer players across impact type, player position, and game or practice scenario. Design: Cross-sectional study. Setting: National Collegiate Athletic Association Division I institution. Patients or Other Participants: Twenty-three collegiate women's soccer athletes. Main Outcome Measure(s): Athletes wore Smart Impact Monitor accelerometers during all games and practices. Impacts were classified during visual, on-field monitoring of athletic events. All direct head impacts that exceeded the 10g threshold were included in the final data analysis. The dependent variable was linear acceleration, and the fixed effects were (1) type of impact: clear, pass, shot, unintentional deflection, or head-to-head contact; (2) field position: goalkeeper, defense, forward, or midfielder; (3) playing scenario: game or practice. Results: Shots (32.94g +/- 12.91g, n = 38; P = .02) and clears (31.09g +/- 13.43g, n = 101; P = .008) resulted in higher mean linear accelerations than passes (26.11g +/- 15.48g, n = 451). Head-to-head impacts (51.26g +/- 36.61g, n = 13; P <. 001) and unintentional deflections (37.40g +/- 34.41g, n = 24; P = .002) resulted in higher mean linear accelerations than purposeful headers (ie, shots, clears, and passes). No differences were seen in linear acceleration across player position or playing scenario. Conclusions: Nonheader impacts, including head-to-head impacts and unintentional deflections, resulted in higher mean linear accelerations than purposeful headers, including shots, clears, and passes, but occurred infrequently on the field. Therefore, these unanticipated impacts may not add substantially to an athlete's cumulative exposure, which is a function of both frequency and magnitude of impact.	[Lamond, Lindsey C.; Caccese, Jaclyn B.; Buckley, Thomas A.; Kaminski, Thomas W.] Univ Delaware, Dept Kinesiol & Appl Physiol, 540 South Coll Ave, Newark, DE 19716 USA; [Glutting, Joseph] Univ Delaware, Sch Educ, Newark, DE USA		Caccese, JB (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, 540 South Coll Ave, Newark, DE 19716 USA.	jcaccese@udel.edu	Caccese, Jaclyn B./AAH-4571-2020; Buckley, Thomas A/B-7525-2016	Caccese, Jaclyn B./0000-0003-2329-3603; Buckley, Thomas A/0000-0002-0515-0150			Ahmadisoleymani SS, 2015, PROCEDIA MANUF, V3, P3796, DOI 10.1016/j.promfg.2015.07.882; Caccese JB, 2016, RES SPORTS MED, V24, P407, DOI 10.1080/15438627.2016.1230549; Caccese JB, 2016, SPORTS MED, V46, P1591, DOI 10.1007/s40279-016-0544-7; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Cummiskey B, 2017, P I MECH ENG P-J SPO, V231, P144, DOI 10.1177/1754337116658395; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Hox J.J., 2002, MULTILEVEL ANAL TECH; Hwang S, 2017, J NEUROTRAUM, V34, P8, DOI 10.1089/neu.2015.4238; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Karton C, 2016, 34 INT C BIOM SPORTS; Kawata K, 2016, INT J SPORTS MED, V37, P405, DOI 10.1055/s-0035-1569290; Kawata K, 2016, JAMA OPHTHALMOL, V134, P763, DOI 10.1001/jamaophthalmol.2016.1085; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lynall RC, 2016, MED SCI SPORT EXER, V48, P1772, DOI 10.1249/MSS.0000000000000951; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Oeur RA, 2016, 34 INT C BIOM SPORTS, P79; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V1; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; Tarnutzer AA, 2017, BRIT J SPORT MED, V51, P1592, DOI 10.1136/bjsports-2016-096593; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3	26	50	49	0	4	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	FEB	2018	53	2					115	121		10.4085/1062-6050-90-17			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	FY8CL	WOS:000427090400002	29373056	Green Published, gold			2022-02-06	
J	Grima, NA; Rajaratnam, SMW; Mansfield, D; Sletten, TL; Spitz, G; Ponsford, JL				Grima, Natalie A.; Rajaratnam, Shantha M. W.; Mansfield, Darren; Sletten, Tracey L.; Spitz, Gershon; Ponsford, Jennie L.			Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial	BMC MEDICINE			English	Article						Sleep; Insomnia; Traumatic brain injury; Acquired brain injury	PROLONGED-RELEASE MELATONIN; RUNNING CIRCADIAN-RHYTHMS; BLIND SUBJECTS; INSOMNIA; DISORDERS; ASSOCIATION; TETRAPLEGIA; PREVALENCE; ALERTNESS; THERAPY	Background: The study aimed to determine the efficacy of melatonin supplementation for sleep disturbances in patients with traumatic brain injury (TBI). Methods: This is a randomised double-blind placebo-controlled two-period two-treatment (melatonin and placebo) crossover study. Outpatients were recruited from Epworth and Austin Hospitals Melbourne, Australia. They had mild to severe TBI (n = 33) reporting sleep disturbances post-injury (mean age 37 years, standard deviation 11 years; 67% men). They were given prolonged-release melatonin formulation (2 mg; Circadin (R)) and placebo capsules for 4 weeks each in a counterbalanced fashion separated by a 48-hour washout period. Treatment was taken nightly 2 hours before bedtime. Serious adverse events and side-effects were monitored. Results: Melatonin supplementation significantly reduced global Pittsburgh Sleep Quality Index scores relative to placebo, indicating improved sleep quality [melatonin 7.68 vs. placebo 9.47, original score units; difference -1.79; 95% confidence interval (CI), -2.70 to -0.88; p <= 0.0001]. Melatonin had no effect on sleep onset latency (melatonin 1.37 vs. placebo 1.42, log units; difference -0.05; 95% CI, -0.14 to 0.03; p = 0.23). With respect to the secondary outcomes, melatonin supplementation increased sleep efficiency on actigraphy, and vitality and mental health on the SF-36 v1 questionnaire (p <= 0.05 for each). Melatonin decreased anxiety on the Hospital Anxiety Depression Scale and fatigue on the Fatigue Severity Scale (p <= 0.05 for both), but had no significant effect on daytime sleepiness on the Epworth Sleepiness Scale (p = 0.15). No serious adverse events were reported. Conclusions: Melatonin supplementation over a 4-week period is effective and safe in improving subjective sleep quality as well as some aspects of objective sleep quality in patients with TBI.	[Grima, Natalie A.] Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA; [Rajaratnam, Shantha M. W.; Sletten, Tracey L.; Spitz, Gershon; Ponsford, Jennie L.] Monash Univ, Sch Psychol Sci, 18 Innovat Walk,Clayton Campus,Wellington Rd, Melbourne, Vic 3800, Australia; [Mansfield, Darren] Monash Hlth, Monash Lung & Sleep, 246 Clayton Rd, Clayton, Vic 3800, Australia; [Ponsford, Jennie L.] Epworth Healthcare, Monash Epworth Rehabil Res Ctr, 89 Bridge Rd, Richmond, Vic 3121, Australia		Ponsford, JL (corresponding author), Monash Univ, Sch Psychol Sci, 18 Innovat Walk,Clayton Campus,Wellington Rd, Melbourne, Vic 3800, Australia.; Ponsford, JL (corresponding author), Epworth Healthcare, Monash Epworth Rehabil Res Ctr, 89 Bridge Rd, Richmond, Vic 3121, Australia.	jennie.ponsford@monash.edu	; Spitz, Gershon/H-7755-2014	Rajaratnam, Shantha/0000-0001-7527-8558; Sletten, Tracey/0000-0002-0005-7838; Spitz, Gershon/0000-0002-7810-1480	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [1028733]	Funding of the study was supported by an Australian National Health and Medical Research Council project grant (1028733). The funder provided input into study design, but it was not involved in the collection, analysis or interpretation of the data. The funder played no role in the preparation, review, writing or approval of the manuscript.	*AM AC SLEEP MED, 2001, INT CLASS SLEEP DIS; American Academy of Sleep Medicine, 2014, INT CLASSIFICATION S; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Bruni O, 2017, EUR J PAEDIATR NEURO, V21, P420, DOI 10.1016/j.ejpn.2017.01.009; CAGNACCI A, 1992, J CLIN ENDOCR METAB, V75, P447, DOI 10.1210/jc.75.2.447; Cunnington D, 2013, MED J AUSTRALIA, V199, pS36, DOI 10.5694/mja13.10718; Department of Health and Ageing, 2009, ANN REP, P42; Department of Health and Ageing Therapeutic Goods Administration, 2011, AUSTR PUBL ASS REP M; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; GOLOMBEK DA, 1993, EUR J PHARMACOL, V237, P231, DOI 10.1016/0014-2999(93)90273-K; Grima NA, 2016, NEUROREHAB NEURAL RE, V30, P972, DOI 10.1177/1545968316650279; Hack LM, 2003, J BIOL RHYTHM, V18, P420, DOI 10.1177/0748730403256796; HAIMOV I, 1995, SLEEP, V18, P598, DOI 10.1093/sleep/18.7.598; Imbach LL, 2016, NEUROLOGY, V86, P1945, DOI 10.1212/WNL.0000000000002697; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; Lavie P, 1997, J BIOL RHYTHM, V12, P657, DOI 10.1177/074873049701200622; Lavigne G, 2015, PAIN, V156, pS75, DOI 10.1097/j.pain.0000000000000111; Lemoine P, 2007, J SLEEP RES, V16, P372, DOI 10.1111/j.1365-2869.2007.00613.x; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; Lockley SW, 2000, J ENDOCRINOL, V164, pR1, DOI 10.1677/joe.0.164R001; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Marseglia L, 2015, INT J MOL SCI, V16, P1209, DOI 10.3390/ijms16011209; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Nguyen S, 2017, ARCH PHYS MED REHAB, V98, P1508, DOI 10.1016/j.apmr.2017.02.031; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; PIERREFICHE G, 1993, RES COMMUN CHEM PATH, V82, P131; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Rajaratnam SMW, 2009, SLEEP MED CLIN, V4, P179, DOI 10.1016/j.jsmc.2009.02.007; Rajaratnam SMW, 2004, J PHYSIOL-LONDON, V561, P339, DOI 10.1113/jphysiol.2004.073742; Rogers NL, 2003, SLEEP, V26, P1058; Sack RL, 2000, NEW ENGL J MED, V343, P1070, DOI 10.1056/NEJM200010123431503; Scheer FAJL, 2006, SPINAL CORD, V44, P78, DOI 10.1038/sj.sc.3101784; Shan RSLP, 2004, AM J PHYS MED REHAB, V83, P421, DOI 10.1097/00002060-200406000-00003; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shochat T, 1997, AM J PHYSIOL-REG I, V273, pR364, DOI 10.1152/ajpregu.1997.273.1.R364; Sinclair KL, 2012, BEHAV SLEEP MED; Spong J, 2014, SPINAL CORD, V52, P629, DOI 10.1038/sc.2014.84; Spong J., 2013, SLEEP DISORD, V2013, P1, DOI [10.1155/2013/128197, DOI 10.1155/2013/128197]; Valko PO, 2016, SLEEP, V39, P1249, DOI 10.5665/sleep.5844; Valko PO, 2015, ANN NEUROL, V77, P177, DOI 10.1002/ana.24298; Wade AG, 2010, BIOMED CENTRAL MED, V8; Wade AG, 2007, CURR MED RES OPIN, V23, P2597, DOI 10.1185/030079907X233098; Wade AG, 2011, CURR MED RES OPIN, V27, P87, DOI 10.1185/03007995.2010.537317; Zeitzer JM, 2000, J CLIN ENDOCR METAB, V85, P2189, DOI 10.1210/jc.85.6.2189	51	50	52	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1741-7015			BMC MED	BMC Med.	JAN 19	2018	16								8	10.1186/s12916-017-0995-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT4JN	WOS:000423121400001	29347988	Green Published, gold			2022-02-06	
J	Kovacs, GG; Andreasson, U; Liman, V; Regelsberger, G; Lutz, MI; Danics, K; Keller, E; Zetterberg, H; Blennow, K				Kovacs, G. G.; Andreasson, U.; Liman, V.; Regelsberger, G.; Lutz, M. I.; Danics, K.; Keller, E.; Zetterberg, H.; Blennow, K.			Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						Alzheimer disease; Creutzfeldt-Jakob disease; neurodegeneration; neurofilament light chain; rapidly progressive neurological syndrome; tau	CREUTZFELDT-JAKOB-DISEASE; PROTEASE-SENSITIVE PRIONOPATHY; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY PATHOLOGY; FRONTOTEMPORAL DEMENTIA; CSF BIOMARKERS; PRION PROTEIN; LIGHT PROTEIN	Background and purposeCerebrospinal fluid (CSF) tau and neurofilament light chain (NF-L) proteins have proved to be reliable biomarkers for neuronal damage; however, there is a strong need for blood-based tests. MethodsThe present study included 132 autopsy cases with rapidly progressive neurological syndromes, including Alzheimer disease (AD) (21), sporadic (65) and genetic (21) Creutzfeldt-Jakob disease (CJD), 25 cases with vascular, neoplastic and inflammatory alterations, and additionally 18 healthy control individuals. CSF tau and NF-L concentrations were measured by enzyme-linked immunosorbent assay. Plasma tau and NF-L concentrations were measured using ultra-sensitive single molecule array technology. ResultsPlasma and CSF tau (R = 0.59, P < 0.001) and NF-L (R = 0.69, P < 0.001) levels correlated significantly (Spearman test). Plasma tau and NF-L levels were significantly higher in all disease groups compared to healthy controls (P < 0.001). Receiver operating characteristic curves were used and area under the curve values for comparisons with controls were 0.82 (AD), 0.94 (sporadic CJD), 0.92 (genetic CJD) and 0.83 (other neurological disorders) for plasma tau and 0.99, 0.99, 1.00 and 0.96 for plasma NF-L, respectively. Molecular subtyping of sporadic CJD showed a strong effect (linear logistic regression) on plasma tau (P < 0.001) but not NF-L levels (P = 0.19). ConclusionPlasma tau and NF-L concentrations are strongly increased in CJD and show similar diagnostic performance to the corresponding CSF measure. Molecular subtypes of sporadic CJD show different levels of plasma tau. Although not disease-specific, these findings support the use of plasma tau and NF-L as tools to identify, or to rule out, neurodegeneration.	[Kovacs, G. G.; Regelsberger, G.; Lutz, M. I.] Med Univ Vienna, Inst Neurol, r, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria; [Kovacs, G. G.; Danics, K.; Keller, E.] Semmelweis Univ, Prion Dis & Neuropathol Reference Ctr, Budapest, Hungary; [Andreasson, U.; Liman, V.; Zetterberg, H.; Blennow, K.] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Andreasson, U.; Zetterberg, H.; Blennow, K.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Danics, K.; Keller, E.] Semmelweis Univ, Dept Forens & Insurance Med, Budapest, Hungary; [Zetterberg, H.] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England		Kovacs, GG (corresponding author), Med Univ Vienna, Inst Neurol, r, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria.; Blennow, K (corresponding author), Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden.	gabor.kovacs@meduniwien.ac.at; kaj.blennow@neuro.gu.se	Kovacs, Gabor G/A-7468-2013	Kovacs, Gabor G/0000-0003-3841-5511; Regelsberger, Gunther/0000-0002-3233-1491	VINNOVAVinnova; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Torsten Soderberg Foundation; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; European Research CouncilEuropean Research Council (ERC)European Commission; Swedish Brain Foundation; Alzheimerfonden; Frimurarestiftelsen	The study was supported by grants from VINNOVA, the Swedish Research Council, the Torsten Soderberg Foundation, the Knut and Alice Wallenberg Foundation, the European Research Council, the Swedish Brain Foundation, Alzheimerfonden and Frimurarestiftelsen.	Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x; Assar H, 2015, J NEUROL NEUROSUR PS, V86, P816, DOI 10.1136/jnnp-2014-309871; Bergman J, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000271; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Buchhave P, 2012, ARCH GEN PSYCHIAT, V69, P98, DOI 10.1001/archgenpsychiatry.2011.155; Dorey A, 2015, JAMA NEUROL, V72, P267, DOI 10.1001/jamaneurol.2014.4068; Dubois B, 2016, ALZHEIMERS DEMENT, V12, P292, DOI 10.1016/j.jalz.2016.02.002; Foutz A, 2017, ANN NEUROL, V81, P79, DOI 10.1002/ana.24833; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Gmitterova K, 2016, EUR J NEUROL, V23, P1126, DOI 10.1111/ene.12991; Jack CR, 2013, NEURON, V80, P1347, DOI 10.1016/j.neuron.2013.12.003; Jackson GS, 2014, JAMA NEUROL, V71, P421, DOI 10.1001/jamaneurol.2013.6001; Kovacs GG, 2015, NEUROPATH APPL NEURO, V41, P3, DOI 10.1111/nan.12208; Kovacs GG, 2010, CLIN NEUROPATHOL, V29, P271; Kovacs GG, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020189; Kovacs GG, 2010, BRAIN RES, V1323, P192, DOI 10.1016/j.brainres.2010.01.089; Kovacs GG, 2010, ACTA NEUROPATHOL, V119, P389, DOI 10.1007/s00401-010-0658-1; Ladogana A, 2009, J NEUROL, V256, P1620, DOI 10.1007/s00415-009-5163-x; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Llorens F, 2017, ALZHEIMERS DEMENT, V13, P710, DOI 10.1016/j.jalz.2016.09.013; Llorens F, 2016, PROG NEUROBIOL, V138, P36, DOI 10.1016/j.pneurobio.2016.03.003; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; McGuire LI, 2016, ANN NEUROL, V80, P160, DOI 10.1002/ana.24679; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Nielsen MS, 2016, DEMENT GER COGN D EX, V6, P465, DOI 10.1159/000449410; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/s1474-4422(16)00070-3, 10.1016/S1474-4422(16)00070-3]; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 2012, ACTA NEUROPATHOL, V124, P517, DOI 10.1007/s00401-012-1002-8; Rahimi J, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0082-1; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Rohrer JD, 2016, NEUROLOGY, V87, P1329, DOI 10.1212/WNL.0000000000003154; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Scheltens P, 2016, LANCET, V388, P505, DOI 10.1016/S0140-6736(15)01124-1; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Simonsen AH, 2016, BIOMARK MED, V10, P19, DOI 10.2217/BMM.14.105; Skillback T, 2014, JAMA NEUROL, V71, P476, DOI 10.1001/jamaneurol.2013.6455; Steinacker P, 2016, SCI REP-UK, V6, DOI 10.1038/srep38737; Stoeck K, 2012, BRAIN, V135, P3051, DOI 10.1093/brain/aws238; Suarez-Calvet M, 2014, J NEUROL NEUROSUR PS, V85, P684, DOI 10.1136/jnnp-2013-305972; Teunissen CE, 2012, MULT SCLER J, V18, P552, DOI 10.1177/1352458512443092; van Rossum IA, 2012, NEUROLOGY, V79, P1809, DOI 10.1212/WNL.0b013e3182704056; Zetterberg H, 2017, NEUROPATH APPL NEURO, V43, P194, DOI 10.1111/nan.12378; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163; Zou WQ, 2010, ANN NEUROL, V68, P162, DOI 10.1002/ana.22094	47	50	50	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	NOV	2017	24	11					1326	+		10.1111/ene.13389			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FJ4AA	WOS:000412673700006	28816001	Green Submitted			2022-02-06	
J	Zhong, JJ; Jiang, L; Huang, ZJ; Zhang, HR; Cheng, CJ; Liu, H; He, JC; Wu, JC; Darwazeh, R; Wu, Y; Sun, XC				Zhong, Jianjun; Jiang, Li; Huang, Zhijian; Zhang, Hongrong; Cheng, Chongjie; Liu, Han; He, Junchi; Wu, Jingchuan; Darwazeh, Rami; Wu, Yue; Sun, Xiaochuan			The long non-coding RNA Neat1 is an important mediator of the therapeutic effect of bexarotene on traumatic brain injury in mice	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Bexarotene; RXR; IncRNA; Neat1; Pidd1; TBI	NF-KAPPA-B; P53-INDUCED PROTEIN; EXPRESSION; DISEASE; PIDD; RXR; IDENTIFICATION; ACTIVATION; PLASTICITY; RECEPTORS	Objective: Bexarotene treatments exert neuroprotective effects on mice following traumatic brain injury (TBI). The present study aims to investigate the potential roles of the long noncoding RNA Neat1 in the neuroprotective effects of bexarotene. Materials and methods: Adult male C57BL/8J mice (n = 80) and newborn mice (within 24 h after birth) (n = 20) were used to generate a "controlled cortical impact" (CCI) model and harvest primary cortex neurons, respectively. The HT22 cell line and the BV2 cell line were cultured under "normal" or "oxygen/glucose-deprived" (OGD) conditions. The relationship between RXR-alpha and the Neat1 promoter was clarified using ChIP-qPCR and dual-luciferase reporter gene assays. The mRNA alterations induced by Neat1 knockdown were measured using next-generation RNA sequencing. Proteins were captured by Neat1, pulled down and subjected to mass spectrometry. The neurological severity score, rotarod test and water maze test were employed to measure the animals' motor and cognitive functions. Results: Bexarotene prominently up-regulated the Neat1 level in an RXR-alpha-dependent manner. Neat1 knockdown induced significant changes in mRNA expression, and the altered mRNAs were involved in many biological processes, including synapse formation and axon guidance. In primary neurons, Neat1 knockdown inhibited and Neat1 over-expression prompted axon elongation. Multiple proteins, including Pidd1, were captured by Neat1. Neat1 inhibited cell apoptosis and restricted inflammation by capturing Pidd1. The in vitro anti-apoptotic and anti-inflammatory effects of Neat1 were further confirmed in C57BL/6 mice, which resulted in better motor and cognitive function after TBI. Conclusion: Bexarotene up-regulates the IncRNA Neat1, which inhibits apoptosis and inflammation, thereby resulting in better functional recovery in mice after TBI. (C) 2017 Elsevier Inc. All rights reserved.	[Zhong, Jianjun; Jiang, Li; Huang, Zhijian; Zhang, Hongrong; Cheng, Chongjie; Liu, Han; He, Junchi; Wu, Jingchuan; Darwazeh, Rami; Wu, Yue; Sun, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China		Jiang, L; Sun, XC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	156313147@qq.com; sunxch1445@qq.com	He, Junchi/AAD-8482-2019; Wu, Jingchuan/AAV-7799-2020; Darwazeh, Rami/AAT-7891-2020	Wu, Jingchuan/0000-0002-1213-4888; Darwazeh, Rami/0000-0003-3099-8257; Huang, Zhijian/0000-0002-8241-0761; sun, xiao chuan/0000-0001-6992-332X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571159, 81371319]; National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81601072]; Chongqing Graduate Innovation Project [40010200100417]	This work was supported by grants from the National Natural Science Foundation of China (grant nos. 81571159 and 81371319), National Natural Science Foundation for Youth of China (No. 81601072) and the Chongqing Graduate Innovation Project (grant no. 40010200100417). We express special gratitude to the "Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology" for providing the experimental platform.	Bali KK, 2014, TRENDS MOL MED, V20, P437, DOI 10.1016/j.molmed.2014.05.006; Barry G, 2014, MOL PSYCHIATR, V19, P410, DOI 10.1038/mp.2013.196; Barry G, 2017, SCI REP-UK, V7, DOI 10.1038/srep40127; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bernard D, 2010, EMBO J, V29, P3082, DOI 10.1038/emboj.2010.199; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Bhat SA, 2016, MOL NEUROBIOL, V53, P6950, DOI 10.1007/s12035-015-9584-5; Bock FJ, 2012, ONCOGENE, V31, P4733, DOI 10.1038/onc.2011.639; Briggs JA, 2015, NEURON, V88, P861, DOI 10.1016/j.neuron.2015.09.045; Campos-Pires R, 2015, CRIT CARE MED, V43, P149, DOI 10.1097/CCM.0000000000000624; Choudhry H, 2015, ONCOGENE, V34, P4546, DOI 10.1038/onc.2014.431; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Das D, 2013, WORLD J GASTROENTERO, V19, P7374, DOI 10.3748/wjg.v19.i42.7374; Donofrio G, 2006, MICROBES INFECT, V8, P898, DOI 10.1016/j.micinf.2005.10.016; Dubovicky Michal, 2014, Interdiscip Toxicol, V7, P201, DOI 10.2478/intox-2014-0029; Evans RM, 2014, CELL, V157, P255, DOI 10.1016/j.cell.2014.03.012; Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784; Guo J, 2016, MOL NEUROBIOL, V53, P3154, DOI 10.1007/s12035-015-9222-2; Hirose T, 2014, MOL BIOL CELL, V25, P169, DOI 10.1091/mbc.E13-09-0558; Hung YH, 2016, MOL NEUROBIOL, V53, P793, DOI 10.1007/s12035-014-9046-5; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Jalali S, 2015, BIOINFORMATICS, V31, P2241, DOI 10.1093/bioinformatics/btv148; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Joshi S, 2011, MOL CELL BIOL, V31, P3653, DOI 10.1128/MCB.05020-11; Kerin T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003479; Kim IR, 2009, APOPTOSIS, V14, P1039, DOI 10.1007/s10495-009-0375-1; Kour S, 2017, MOL NEUROBIOL, V54, P639, DOI 10.1007/s12035-015-9634-z; Kraus TFJ, 2017, MOL NEUROBIOL, V54, P2869, DOI 10.1007/s12035-016-9854-x; le Maire A, 2009, EMBO REP, V10, P367, DOI 10.1038/embor.2009.8; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Maden M, 2007, NAT REV NEUROSCI, V8, P755, DOI 10.1038/nrn2212; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Marin-Bejar O, 2015, METHODS MOL BIOL, V1206, P87, DOI 10.1007/978-1-4939-1369-5_8; Mercer TR, 2008, P NATL ACAD SCI USA, V105, P716, DOI 10.1073/pnas.0706729105; Miyamoto S, 2011, CELL RES, V21, P116, DOI 10.1038/cr.2010.179; Modarresi F, 2012, NAT BIOTECHNOL, V30, P453, DOI 10.1038/nbt.2158; Mounier A, 2015, J NEUROSCI, V35, P11862, DOI 10.1523/JNEUROSCI.1001-15.2015; Nakagawa S, 2011, J CELL BIOL, V193, P31, DOI 10.1083/jcb.201011110; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Pajeau AK, 2001, CRIT CARE MED, V29, P675, DOI 10.1097/00003246-200103000-00043; Qureshi IA, 2012, NAT REV NEUROSCI, V13, P528, DOI 10.1038/nrn3234; Ramos AD, 2013, CELL STEM CELL, V12, P616, DOI 10.1016/j.stem.2013.03.003; Salvi A, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5059043; Shen Q, 2005, J BIOL CHEM, V280, P40589, DOI 10.1074/jbc.M504166200; Teng YC, 2013, MOL NEUROBIOL, V48, P281, DOI 10.1007/s12035-013-8492-9; Teng ZP, 2016, STROKE, V47, P196, DOI 10.1161/STROKEAHA.115.011701; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Zhang FF, 2016, J AUTOIMMUN, V75, P96, DOI 10.1016/j.jaut.2016.07.012; Zhang Q, 2016, MOL NEUROBIOL, V53, P662, DOI 10.1007/s12035-014-9035-8; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4; Zhao XL, 2013, NAT NEUROSCI, V16, P1024, DOI 10.1038/nn.3438; Zhong JJ, 2017, NEUROSCIENCE, V343, P434, DOI 10.1016/j.neuroscience.2016.05.033; Zhong JJ, 2016, BRAIN RES, V1646, P589, DOI 10.1016/j.brainres.2016.07.002	53	50	53	1	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	OCT	2017	65						183	194		10.1016/j.bbi.2017.05.001			12	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	FC6YD	WOS:000406986700018	28483659				2022-02-06	
J	Cnossen, MC; Huijben, JA; van der Jagt, M; Volovici, V; van Essen, T; Polinder, S; Nelson, D; Ercole, A; Stocchetti, N; Citerio, G; Peul, WC; Maas, AIR; Menon, D; Steyerberg, EW; Lingsma, HF				Cnossen, Maryse C.; Huijben, Jilske A.; van der Jagt, Mathieu; Volovici, Victor; van Essen, Thomas; Polinder, Suzanne; Nelson, David; Ercole, Ari; Stocchetti, Nino; Citerio, Giuseppe; Peul, Wilco C.; Maas, Andrew I. R.; Menon, David; Steyerberg, Ewout W.; Lingsma, Hester F.		CENTER-TBI Investigators	Variation in monitoring and treatment policies for intracranial hypertension in traumatic brain injury: a survey in 66 neurotrauma centers participating in the CENTER-TBI study	CRITICAL CARE			English	Article						Traumatic brain injury; Intracranial hypertension; ICP; ICU; Comparative effectiveness research; Survey	EUROPEAN-BRAIN; MANAGEMENT; CARE; PRESSURE; MODERATE; IMPACT	Background: No definitive evidence exists on how intracranial hypertension should be treated in patients with traumatic brain injury (TBI). It is therefore likely that centers and practitioners individually balance potential benefits and risks of different intracranial pressure (ICP) management strategies, resulting in practice variation. The aim of this study was to examine variation in monitoring and treatment policies for intracranial hypertension in patients with TBI. Methods: A 29-item survey on ICP monitoring and treatment was developed on the basis of literature and expert opinion, and it was pilot-tested in 16 centers. The questionnaire was sent to 68 neurotrauma centers participating in the Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. Results: The survey was completed by 66 centers (97% response rate). Centers were mainly academic hospitals (n = 60, 91%) and designated level I trauma centers (n = 44, 67%). The Brain Trauma Foundation guidelines were used in 49 (74%) centers. Approximately 90% of the participants (n = 58) indicated placing an ICP monitor in patients with severe TBI and computed tomographic abnormalities. There was no consensus on other indications or on peri-insertion precautions. We found wide variation in the use of first-and second-tier treatments for elevated ICP. Approximately half of the centers were classified as using a relatively aggressive approach to ICP monitoring and treatment (n = 32, 48%), whereas the others were considered more conservative (n = 34, 52%). Conclusions: Substantial variation was found regarding monitoring and treatment policies in patients with TBI and intracranial hypertension. The results of this survey indicate a lack of consensus between European neurotrauma centers and provide an opportunity and necessity for comparative effectiveness research.	[Cnossen, Maryse C.; Huijben, Jilske A.; Volovici, Victor; Polinder, Suzanne; Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [van der Jagt, Mathieu] Erasmus MC, Dept Intens Care, Rotterdam, Netherlands; [Volovici, Victor] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; [van Essen, Thomas; Peul, Wilco C.] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands; [Nelson, David] Karolinska Inst, Sect Perioperat Med & Intens Care, Dept Physiol & Pharmacol, Stockholm, Sweden; [Ercole, Ari; Menon, David] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge, England; [Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplants, Milan, Italy; [Stocchetti, Nino] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Dept Anesthesia & Crit Care, Neurosci Intens Care Unit, Milan, Italy; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] ASST Monza, San Gerardo Hosp, Neurointens Care Unit, Monza, Italy; [Peul, Wilco C.] Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands		Cnossen, MC (corresponding author), Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands.	m.c.cnossen@erasmusmc.nl	Gomez, Pedro/N-5051-2019; Sahakian, Barbara/AAW-1198-2020; Citerio, Giuseppe/B-1839-2015; Maas, Andrew IR/C-5584-2013; Santos, Edgar/AAV-2506-2021; Bartels, Ronald HMA/L-4184-2015; Sahuquillo, Juan/B-3577-2008; Volovici, Victor/AAZ-8901-2020; Hoedemaekers, C.W.E./L-4375-2015; Boogert, Hugo F den/B-2782-2016; Castano-Leon, Ana M/ABF-6322-2020; Gomez, Pedro A/E-2411-2014; Cooper, D. James/G-7961-2013; Ercole, Ari/B-6288-2009; Oresic, Matej/K-7673-2016; Raj, Rahul/K-7693-2012; Lagares, Alfonso/B-2969-2011; Vande Vyvere, Thijs/AAB-5180-2022; Lanyon, Linda/L-9238-2019; Badenes, Rafael/K-6628-2019; Freo, Ulderico/V-8249-2017; Laureys, Steven/AAN-2097-2021; Belli, Antonio/I-3799-2015; van der Jagt, Mathieu/G-1905-2017	Gomez, Pedro/0000-0002-4185-5238; Sahakian, Barbara/0000-0001-7352-1745; Citerio, Giuseppe/0000-0002-5374-3161; Maas, Andrew IR/0000-0003-1612-1264; Santos, Edgar/0000-0002-8976-5549; Bartels, Ronald HMA/0000-0002-8638-4660; Sahuquillo, Juan/0000-0003-0713-5875; Volovici, Victor/0000-0002-5798-5360; Castano-Leon, Ana M/0000-0002-7918-5049; Gomez, Pedro A/0000-0002-4185-5238; Cooper, D. James/0000-0002-5872-9051; Ercole, Ari/0000-0001-8350-8093; Oresic, Matej/0000-0002-2856-9165; Raj, Rahul/0000-0003-4243-9591; Lagares, Alfonso/0000-0003-3996-0554; Vande Vyvere, Thijs/0000-0003-4032-5443; Lanyon, Linda/0000-0002-0885-1825; Badenes, Rafael/0000-0001-7017-0150; Freo, Ulderico/0000-0001-6183-2909; Laureys, Steven/0000-0002-3096-3807; Hartings, Jed/0000-0001-8583-3471; Sakowitz, Oliver/0000-0003-3248-6335; Pomposo Gaztelu, Inigo/0000-0002-3095-2649; Rossi, Sandra/0000-0002-9963-8121; Palotie, Aarno/0000-0002-2527-5874; MARTIN, Didier/0000-0001-7325-4958; Sanchez-Porras, Renan/0000-0002-9084-8114; Wade, Derick/0000-0002-1188-8442; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601; Pullens, Pim/0000-0003-2014-7248; Belli, Antonio/0000-0002-3211-9933; Newcombe, Virginia/0000-0001-6044-9035; Te Ao, Braden/0000-0002-1050-200X; Kondziella, Daniel/0000-0001-5562-9808; Pirinen, Matti/0000-0002-1664-1350; Parizel, Paul M./0000-0002-0221-2854; Dawes, Helen/0000-0002-2933-5213; Huijben, Jilske (Antonia)/0000-0002-2892-5406; Della Corte, Francesco/0000-0003-1736-2318; Feigin, Valery L./0000-0002-6372-1740; van der Naalt, Joukje/0000-0001-9873-2418; Kolias, Angelos/0000-0003-3992-0587; Coles, Jonathan/0000-0003-4013-679X; van der Jagt, Mathieu/0000-0003-2566-8325; Lozano Roig, Angels/0000-0001-9761-4938; Blaabjerg, Morten/0000-0001-6007-1861; Van Essen, Thomas/0000-0003-4657-5283; Bragge, Peter/0000-0003-0745-5131; Cameron, Peter/0000-0002-1443-557X; Morganti-Kossmann, Cristina/0000-0002-0807-2063; Bullinger, Monika/0000-0001-8876-0159; Andelic, Nada/0000-0002-3719-4406; Nelson, David/0000-0003-2530-8207; Dippel, Diederik/0000-0002-9234-3515; Wang, Kevin/0000-0002-9343-6473; Ledig, Christian/0000-0003-4862-3138	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [602150]; Dutch Brain Foundation (Hersenstichting Nederland); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986] Funding Source: UKRI; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, ACF-2009-14-007] Funding Source: researchfish	Data used in the preparation of this article were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Commission Seventh Framework program (602150). In addition, TvE and WCP were supported by a grant from the Dutch Brain Foundation (Hersenstichting Nederland) for the Neurotraumatology Quality Registry (Net-QuRe) study.	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bosco JLF, 2010, J CLIN EPIDEMIOL, V63, P64, DOI 10.1016/j.jclinepi.2009.03.001; Bragge P, 2016, J NEUROTRAUM, V33, P1461, DOI 10.1089/neu.2015.4233; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cnossen MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161367; Cnossen MC, 2017, CRIT CARE MED, V45, P660, DOI 10.1097/CCM.0000000000002263; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; European Defence Agency, 2007, SOC SIT EUR UN 2007, p[1, 3]; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; IBM Corp. Released, 2012, IBM SPSS STAT WIND V; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Nathens AB, 2006, ANN SURG, V244, P545, DOI 10.1097/01.sla.0000239005.26353.49; Sharma S, 2014, J AM COLL SURGEONS, V218, P51, DOI 10.1016/j.jamcollsurg.2013.10.005; Signorello Lisa B, 2002, Am J Ther, V9, P199, DOI 10.1097/00045391-200205000-00005; Skoglund K, 2013, J NEUROSCI NURS, V45, P360, DOI 10.1097/JNN.0b013e3182a3cf4f; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Thomas LH, 1999, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000349; Timmons SD, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS1296; van Essen TA, 2017, J NEUROTRAUM, V34, P881, DOI 10.1089/neu.2016.4495; Zuercher P, 2016, J NEUROTRAUM, V33, P1768, DOI 10.1089/neu.2015.4266	21	50	50	0	15	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	SEP 6	2017	21								233	10.1186/s13054-017-1816-9			12	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF8KB	WOS:000409265900001	28874206	Green Published, Green Submitted, Green Accepted, gold			2022-02-06	
J	King, LA; Mancini, M; Fino, PC; Chesnutt, J; Swanson, CW; Markwardt, S; Chapman, JC				King, Laurie A.; Mancini, Martina; Fino, Peter C.; Chesnutt, James; Swanson, Clayton W.; Markwardt, Sheila; Chapman, Julie C.			Sensor-Based Balance Measures Outperform Modified Balance Error Scoring System in Identifying Acute Concussion	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; mTBI; Balance; BESS; Postural sway; Brain injury; Inertial sensors	POSTURAL CONTROL; INTERNATIONAL-CONFERENCE; CEREBRAL CONCUSSION; CONSENSUS STATEMENT; PARKINSONS-DISEASE; FOOTBALL PLAYERS; BRAIN-INJURY; HIGH-SCHOOL; SPORT HELD; GAIT	Balance assessment is an integral component of concussion evaluation and management. Although the modified balance error scoring system (mBESS) is the conventional clinical tool, objective metrics derived from wearable inertial sensors during the mBESS may increase sensitivity in detecting subtle balance deficits post-concussion. The aim of this study was to identify which stance condition and postural sway metrics obtained from an inertial sensor placed on the lumbar spine during the mBESS best discriminate athletes with acute concussion. Fifty-two college athletes in the acute phase of concussion and seventy-six controls participated in this study. Inertial sensor-based measures objectively detected group differences in the acutely concussed group of athletes while the clinical mBESS did not (p < 0.001 and p = 0.06, respectively). Mediolateral postural sway during the simplest condition of the mBESS (double stance) best classified those with acute concussion. Inertial sensors provided a sensitive and objective measure of balance in acute concussion. These results may be developed into practical guidelines to improve and simplify postural sway analysis post-concussion.	[King, Laurie A.; Mancini, Martina; Fino, Peter C.; Swanson, Clayton W.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Parkinson Ctr Oregon, OP32,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA; [Chesnutt, James] Oregon Hlth & Sci Univ, Sch Med, Dept Orthoped & Rehabil, Portland, OR 97201 USA; [Markwardt, Sheila] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA; [Chapman, Julie C.] Vet Affairs Med Ctr, Dept Neurol, 50 Irving St NW, Washington, DC 20422 USA; [Chapman, Julie C.] Georgetown Univ, Sch Med, Dept Neurol, Washington, DC USA		King, LA (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Parkinson Ctr Oregon, OP32,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	kingla@ohsu.edu	Swanson, Clayton W./AAU-1280-2020	Swanson, Clayton/0000-0002-2163-610X; Fino, Peter/0000-0002-8621-3706; Mancini, Martina/0000-0002-4532-3984	Oregon Clinical and Translational Research Institute from the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH) [KL2TR000152]; Eunice Kennedy Shriver National Institute of Child Health & Human Development of the NIH [R21HD080398];  [UL1TR000128]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD080398] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000128, KL2TR000152] Funding Source: NIH RePORTER	This project was supported by the Oregon Clinical and Translational Research Institute (KL2TR000152) from the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH); (UL1TR000128) and Eunice Kennedy Shriver National Institute of Child Health & Human Development of the NIH under Award Number (R21HD080398). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors would like to thank all of the participating universities and athletic trainers who contributed to recruitment of subjects and athletes for their participation. All inertial sensor data presented in this paper was obtained using APDM wearable technologies. The results of this study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.	Bauer CM, 2016, Z GERONTOL GERIATR, V49, P232, DOI 10.1007/s00391-015-0885-0; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Brown HJ, 2014, MED SCI SPORT EXER, V46, P1610, DOI 10.1249/MSS.0000000000000263; CARROLL JP, 1993, J BIOMECH, V26, P409, DOI 10.1016/0021-9290(93)90004-X; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Doherty C, 2017, HUM MOVEMENT SCI, V52, P160, DOI 10.1016/j.humov.2017.02.005; Doherty C, 2017, CLIN BIOMECH, V42, P79, DOI 10.1016/j.clinbiomech.2017.01.007; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fino PC, 2016, GAIT POSTURE, V50, P69, DOI 10.1016/j.gaitpost.2016.08.026; Fino PC, 2016, J BIOMECH, V49, P1983, DOI 10.1016/j.jbiomech.2016.05.004; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Haran FJ, 2016, J NEUROTRAUM, V33, P705, DOI 10.1089/neu.2015.4060; Horak F, 2015, PHYS THER, V95, P461, DOI 10.2522/ptj.20140253; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Hufschmidt A., 1970, ARCH PSYCHIAT NERVEN, V228, P135; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Liaw A., 2002, R NEWS, V2, P18, DOI DOI 10.1177/154405910408300516; Mak MK, 2003, ARCH PHYS MED REHAB, V84, P683, DOI 10.1016/S0003-9993(03)04810-4; MAKI BE, 1991, J GERONTOL, V46, pM123, DOI 10.1093/geronj/46.4.M123; Mancini M., 2011, J BIOENG BIOMED S S1, V1, P7, DOI DOI 10.4172/2155-9538.S1-007; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Mancini M, 2011, PARKINSONISM RELAT D, V17, P557, DOI 10.1016/j.parkreldis.2011.05.010; Maurer C, 2005, J NEUROPHYSIOL, V93, P189, DOI 10.1152/jn.00221.2004; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Melzer I, 2010, CLIN BIOMECH, V25, P984, DOI 10.1016/j.clinbiomech.2010.07.007; Miyashita T. L., 2017, SPORTS HEALTH; Mulligan IJ, 2013, SPORTS HEALTH, V5, P22, DOI 10.1177/1941738112467755; O'Connor SM, 2009, J NEUROPHYSIOL, V102, P1411, DOI 10.1152/jn.00131.2009; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Prieto TE, 1996, IEEE T BIO-MED ENG, V43, P956, DOI 10.1109/10.532130; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rocchi L, 2004, MED BIOL ENG COMPUT, V42, P71, DOI 10.1007/BF02351013; Rocchi L, 2002, J NEUROL NEUROSUR PS, V73, P267, DOI 10.1136/jnnp.73.3.267; Runkle D., 2010, COMMUNICATION, V29; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Stel VS, 2003, J CLIN EPIDEMIOL, V56, P659, DOI 10.1016/S0895-4356(03)00082-9; Whitney SL, 2011, GAIT POSTURE, V33, P594, DOI 10.1016/j.gaitpost.2011.01.015; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Winter DA, 1996, J NEUROPHYSIOL, V75, P2334, DOI 10.1152/jn.1996.75.6.2334; Zatsiorsky VM, 1999, MOTOR CONTROL, V3, P28, DOI 10.1123/mcj.3.1.28	57	50	50	1	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	SEP	2017	45	9					2135	2145		10.1007/s10439-017-1856-y			11	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	FE4QF	WOS:000408197700008	28540448	Green Accepted			2022-02-06	
J	Kovacs, GG; Lee, VM; Trojanowski, JQ				Kovacs, Gabor G.; Lee, Virginia M.; Trojanowski, John Q.			Protein astrogliopathies in human neurodegenerative diseases and aging	BRAIN PATHOLOGY			English	Article						A-beta; alpha-synuclein; ARTAG; astrocyte; neurodegeneration; PAG; prion; prion protein; protein astrogliopathy; tau; TDP-43	PROGRESSIVE SUPRANUCLEAR PALSY; CHRONIC TRAUMATIC ENCEPHALOPATHY; FRONTOTEMPORAL LOBAR DEGENERATION; GLIAL FIBRILLARY TANGLES; MULTIPLE SYSTEM ATROPHY; AMYOTROPHIC-LATERAL-SCLEROSIS; ARGYROPHILIC GRAIN DISEASE; THORN-SHAPED ASTROCYTES; INCIDENTAL CORTICOBASAL DEGENERATION; SPORADIC PARKINSONS-DISEASE	Neurodegenerative diseases are characterized by progressive dysfunction and loss of neurons associated with depositions of pathologically altered proteins showing hierarchical involvement of brain regions. The role of astrocytes in the pathogenesis of neurodegenerative diseases is explored as contributors to neuronal degeneration or neuroprotection pathways, and also as potential mediators of the transcellular spreading of disease-associated proteins. Protein astrogliopathy (PAG), including deposition of amyloid-, prion protein, tau, -synuclein, and very rarely transactive response DNA-binding protein 43 (TDP-43) is not unprecedented or unusual in neurodegenerative diseases. Morphological characterization of PAG is considered, however, only for the neuropathological diagnosis and classification of tauopathies. Astrocytic tau pathology is seen in primary frontotemporal lobar degeneration (FTLD) associated with tau pathologies (FTLD-Tau), and also in the form of aging-related tau astrogliopathy (ARTAG). Importantly, ARTAG shares common features with primary FTLD-Tau as well as with the astroglial tau pathologies that are thought to be hallmarks of a brain injury-related tauopathy known as chronic traumatic encephalopathy (CTE). Supported by experimental observations, the morphological variability of PAG might reflect distinct pathogenic involvement of different astrocytic populations. PAG might indicate astrocytic contribution to spreading or clearance of disease-associated proteins, however, this might lead to astrocytic dysfunction and eventually contribute to the degeneration of neurons. Here, we review recent advances in understanding ARTAG and other related forms of PAG.	[Kovacs, Gabor G.] Med Univ Vienna, Inst Neurol, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria; [Lee, Virginia M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Inst Aging, Philadelphia, PA 19104 USA; [Lee, Virginia M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19103 USA		Kovacs, GG (corresponding author), Med Univ Vienna, Inst Neurol, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria.	gabor.kovacs@meduniwien.ac.at	Kovacs, Gabor G/A-7468-2013	Kovacs, Gabor G/0000-0003-3841-5511	National Institute on Aging of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30-AG10124, PO1-AG17586, NS088341, NS094003]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS088341, R01NS094003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG017586, P30AG010124] Funding Source: NIH RePORTER	Support for this work was provided by grants from the National Institute on Aging of the National Institutes of Health (P30-AG10124, PO1-AG17586, NS088341, and NS094003).	Ahmed Z, 2013, ACTA NEUROPATHOL, V126, P537, DOI 10.1007/s00401-013-1171-0; Aho L, 2010, J ALZHEIMERS DIS, V20, P1015, DOI 10.3233/JAD-2010-091681; Alexander J, 2016, NEUROBIOL AGING, V42, P199, DOI 10.1016/j.neurobiolaging.2016.03.012; Alzheimer A, 1911, Z GESAMTE NEUROL PSY, V1911, P365; Arai N, 1996, NEUROPATHOLOGY, V16, P133, DOI 10.1111/j.1440-1789.1996.tb00168.x; Arai T, 1999, NEUROSCI LETT, V259, P83, DOI 10.1016/S0304-3940(98)00890-8; Arima K, 2006, NEUROPATHOLOGY, V26, P475, DOI 10.1111/j.1440-1789.2006.00669.x; Armstrong RA, 2013, NEUROL SCI, V34, P337, DOI 10.1007/s10072-012-1006-0; Armstrong RA, 2011, ACTA NEUROPATHOL, V121, P219, DOI 10.1007/s00401-010-0753-3; Ash PEA, 2013, NEURON, V77, P639, DOI 10.1016/j.neuron.2013.02.004; Beach TG, 2009, ACTA NEUROPATHOL, V117, P169, DOI 10.1007/s00401-008-0450-7; Boluda S, 2015, ACTA NEUROPATHOL, V129, P221, DOI 10.1007/s00401-014-1373-0; Botez G, 1999, ACTA NEUROPATHOL, V98, P251, DOI 10.1007/s004010051077; BRAAK H, 1987, NEUROSCI LETT, V76, P124, DOI 10.1016/0304-3940(87)90204-7; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Braak H, 2007, ACTA NEUROPATHOL, V114, P231, DOI 10.1007/s00401-007-0244-3; Brettschneider J, 2015, NAT REV NEUROSCI, V16, P109, DOI 10.1038/nrn3887; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Cavaliere F, 2017, NEUROBIOL DIS, V103, P101, DOI 10.1016/j.nbd.2017.04.011; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Davis CHO, 2014, P NATL ACAD SCI USA, V111, P9633, DOI 10.1073/pnas.1404651111; Delisle MB, 1999, ACTA NEUROPATHOL, V98, P62, DOI 10.1007/s004010051052; Dickson DW, 2010, CURR OPIN NEUROL, V23, P394, DOI 10.1097/WCO.0b013e32833be924; Dickson DW, 1998, BRAIN PATHOL, V8, P339; DIEDRICH JF, 1991, P NATL ACAD SCI USA, V88, P375, DOI 10.1073/pnas.88.2.375; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Evidente VGH, 2011, PARKINSONISM RELAT D, V17, P365, DOI 10.1016/j.parkreldis.2011.02.017; Feany MB, 1996, J NEUROPATH EXP NEUR, V55, P53, DOI 10.1097/00005072-199601000-00006; FEANY MB, 1995, AM J PATHOL, V146, P1388; Ferrer I, 2003, NEUROPATH APPL NEURO, V29, P23, DOI 10.1046/j.1365-2990.2003.00435.x; Ferrer I, 2015, J NEUROPATH EXP NEUR, V74, P370, DOI 10.1097/NEN.0000000000000180; Ferrer I, 2014, J NEUROPATH EXP NEUR, V73, P81, DOI 10.1097/NEN.0000000000000030; Ferrer I, 2008, BRAIN, V131, P1416, DOI 10.1093/brain/awm305; Ferrer I, 2017, BRAIN PATHOL, V27, P645, DOI 10.1111/bpa.12538; Forman MS, 2005, J NEUROSCI, V25, P3539, DOI 10.1523/JNEUROSCI.0081-05.2005; Fu YJ, 2010, ACTA NEUROPATHOL, V120, P21, DOI 10.1007/s00401-010-0649-2; Funato H, 1998, AM J PATHOL, V152, P983; Ghetti B, 2015, NEUROPATH APPL NEURO, V41, P24, DOI 10.1111/nan.12213; Ghetti B, 2011, NEURODEGENERATION MO, P110, DOI [10.1002/9781444341256.ch14, DOI 10.1002/9781444341256.CH14]; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Guo JL, 2014, NAT MED, V20, P130, DOI 10.1038/nm.3457; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; Halliday GM, 2006, BRAIN, V129, DOI 10.1093/brain/awh720; HAUW JJ, 1990, NEUROSCI LETT, V119, P182, DOI 10.1016/0304-3940(90)90829-X; Hayashi S, 2002, ANN NEUROL, V51, P525, DOI 10.1002/ana.10163; Hedley-Whyte ET, 2009, J NEUROPATH EXP NEUR, V68, P136, DOI 10.1097/NEN.0b013e318195203; Higuchi M, 2002, NEURON, V35, P433, DOI 10.1016/S0896-6273(02)00789-4; Hogg M, 2003, ACTA NEUROPATHOL, V106, P323, DOI 10.1007/s00401-003-0734-x; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Iijima M, 1999, NEUROREPORT, V10, P497, DOI 10.1097/00001756-199902250-00010; Ikeda C, 2016, BRAIN PATHOL, V26, P488, DOI 10.1111/bpa.12319; Ikeda K, 1998, NEUROBIOL AGING, V19, pS85, DOI 10.1016/S0197-4580(98)00034-7; Ikeda K, 1996, NEUROPATHOLOGY, V16, P71, DOI 10.1111/j.1440-1789.1996.tb00158.x; IKEDA K, 1995, ACTA NEUROPATHOL, V90, P620; Irwin DJ, 2016, ANN NEUROL, V79, P272, DOI 10.1002/ana.24559; Iseki E, 2001, ACTA NEUROPATHOL, V102, P285; Jucker M, 2013, NATURE, V501, P45, DOI 10.1038/nature12481; Kobayashi K, 2003, J NEUROL, V250, P990, DOI 10.1007/s00415-003-1137-6; Kobayashi T, 2003, ANN NEUROL, V53, P133, DOI 10.1002/ana.10447; Koga S, 2016, J NEUROPATH EXP NEUR, V75, P963, DOI 10.1093/jnen/nlw073; Komori T, 1999, BRAIN PATHOL, V9, P663; Komori T, 1998, ACTA NEUROPATHOL, V96, P401, DOI 10.1007/s004010050911; Kovacs GG, 2017, NEUROPATH APPL NEURO, V43, P191, DOI 10.1111/nan.12372; Kovacs GG, 2015, NEUROPATH APPL NEURO, V41, P3, DOI 10.1111/nan.12208; Kovacs GG, 2013, NEUROPATH APPL NEURO, V39, P166, DOI 10.1111/j.1365-2990.2012.01272.x; Kovacs GG, 2008, J NEUROPATH EXP NEUR, V67, P963, DOI 10.1097/NEN.0b013e318187a80f; Kovacs GG, 2018, BRAIN PATHOL, V28, P274, DOI 10.1111/bpa.12482; Kovacs GG, 2017, J NEUROPATH EXP NEUR, V76, P605, DOI 10.1093/jnen/nlx041; Kovacs GG, 2017, J NEUROPATH EXP NEUR, V76, P270, DOI 10.1093/jnen/nlx007; Kovacs GG, 2017, BRAIN PATHOL, V27, P332, DOI 10.1111/bpa.12411; Kovacs GG, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020189; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Kovacs GG, 2014, NEUROBIOL DIS, V69, P76, DOI 10.1016/j.nbd.2014.05.020; Kovacs GG, 2013, ACTA NEUROPATHOL, V126, P365, DOI 10.1007/s00401-013-1157-y; Kovacs GG, 2012, ACTA NEUROPATHOL, V124, P37, DOI 10.1007/s00401-012-0964-x; Kovacs GG, 2011, ACTA NEUROPATHOL, V122, P205, DOI 10.1007/s00401-011-0819-x; Kovacs GG, 2009, INT J MOL SCI, V10, P976, DOI 10.3390/ijms10030976; Kovacs GG, 2005, AM J PATHOL, V166, P287, DOI 10.1016/S0002-9440(10)62252-3; KSIEZAKREDING H, 1994, AM J PATHOL, V145, P1496; Kurt MA, 1999, EXP NEUROL, V158, P221, DOI 10.1006/exnr.1999.7096; Kwong LK, 2008, NEUROSIGNALS, V16, P41, DOI 10.1159/000109758; Lace G, 2012, DEMENT GERIATR COGN, V34, P15, DOI 10.1159/000341581; Le Guennec K, 2017, MOL PSYCHIATR, V22, P1119, DOI 10.1038/mp.2016.226; Lee EB, 2008, ACTA NEUROPATHOL, V115, P305, DOI 10.1007/s00401-007-0331-5; Lee HJ, 2010, J BIOL CHEM, V285, P9262, DOI 10.1074/jbc.M109.081125; Lee SJ, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0173-3; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Liberski PP, 2005, NEUROPATH APPL NEURO, V31, P88, DOI 10.1111/j.1365-2990.2004.00595.x; Lin WL, 2009, J NEUROPATH EXP NEUR, V68, P1167, DOI 10.1097/NEN.0b013e3181baacec; Lindstrom V, 2017, MOL CELL NEUROSCI, V82, P143, DOI 10.1016/j.mcn.2017.04.009; Ling H, 2016, BRAIN, V139, P3237, DOI 10.1093/brain/aww256; Lippa CF, 2000, ANN NEUROL, V48, P850, DOI 10.1002/1531-8249(200012)48:6<850::AID-ANA5>3.3.CO;2-M; Liu AKL, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0330-7; Lopez-Gonzalez I, 2013, BRAIN PATHOL, V23, P144, DOI 10.1111/j.1750-3639.2012.00627.x; MacDonald ST, 1996, NEURODEGENERATION, V5, P87; Mackenzie IR, 2017, ACTA NEUROPATHOL, V134, P79, DOI 10.1007/s00401-017-1716-8; Mackenzie IRA, 2011, ACTA NEUROPATHOL, V122, P111, DOI 10.1007/s00401-011-0845-8; Mackenzie IRA, 2011, ACTA NEUROPATHOL, V122, P87, DOI 10.1007/s00401-011-0838-7; Malkani R, 2006, NEUROBIOL DIS, V22, P401, DOI 10.1016/j.nbd.2005.12.001; Martinez-Maldonado A, 2016, NEUROPATH APPL NEURO, V42, P659, DOI 10.1111/nan.12339; MATTIACE LA, 1991, J NEUROPATH EXP NEUR, V50, P310; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Milenkovic I, 2013, CLIN NEUROPATHOL, V32, P69, DOI 10.5414/NP300515; Mori F, 2012, NEUROPATH APPL NEURO, V38, P322, DOI 10.1111/j.1365-2990.2011.01217.x; Mori F, 2002, EXP NEUROL, V176, P98, DOI 10.1006/exnr.2002.7929; Mori F, 2008, ACTA NEUROPATHOL, V115, P453, DOI 10.1007/s00401-007-0316-4; Munoz DG, 2007, ACTA NEUROPATHOL, V114, P347, DOI 10.1007/s00401-007-0266-x; Munoz DG, 2009, ACTA NEUROPATHOL, V118, P617, DOI 10.1007/s00401-009-0598-9; Nagele RG, 2003, BRAIN RES, V971, P197, DOI 10.1016/S0006-8993(03)02361-8; Nakamura K, 2016, NEUROPATHOLOGY, V36, P157, DOI 10.1111/neup.12243; Neumann M, 2001, ANN NEUROL, V50, P503, DOI 10.1002/ana.1223; Neumann M, 2007, J NEUROPATH EXP NEUR, V66, P177, DOI 10.1097/01.jnen.0000248554.45456.58; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Neumann M, 2011, BRAIN, V134, P2595, DOI 10.1093/brain/awr201; Neumann M, 2009, ACTA NEUROPATHOL, V118, P605, DOI 10.1007/s00401-009-0581-5; Neumann M, 2009, BRAIN, V132, P2922, DOI 10.1093/brain/awp214; NISHIMURA M, 1992, NEUROSCI LETT, V143, P35, DOI 10.1016/0304-3940(92)90227-X; Noy S, 2016, J NEUROPATH EXP NEUR, V75, P1145, DOI 10.1093/jnen/nlw092; Oide T, 2006, NEUROPATH APPL NEURO, V32, P539, DOI 10.1111/j.1365-2990.2006.00767.x; PAPP MI, 1989, J NEUROL SCI, V94, P79, DOI 10.1016/0022-510X(89)90219-0; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Piao YS, 2003, ACTA NEUROPATHOL, V105, P403, DOI 10.1007/s00401-002-0655-0; Pickering-Brown SM, 2004, BRAIN, V127, P1415, DOI 10.1093/brain/awh147; Plowey ED, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0388-2; Poorkaj P, 2002, ANN NEUROL, V52, P511, DOI 10.1002/ana.10340; PROBST A, 1988, ACTA NEUROPATHOL, V77, P61, DOI 10.1007/BF00688244; Reed LA, 1998, J NEUROPATH EXP NEUR, V57, P588, DOI 10.1097/00005072-199806000-00006; Ries M, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00160; Rohan Z, 2016, J NEUROPATH EXP NEUR, V75, P1100, DOI 10.1093/jnen/nlw087; Rohan Z, 2014, NEURODEGENER DIS, V14, P117, DOI 10.1159/000362929; Ros R, 2005, ARCH NEUROL-CHICAGO, V62, P1444, DOI 10.1001/archneur.62.9.1444; Saito Y, 2004, J NEUROPATH EXP NEUR, V63, P911, DOI 10.1093/jnen/63.9.911; Sakai K, 2006, ACTA NEUROPATHOL, V112, P341, DOI 10.1007/s00401-006-0093-5; Sakurai A, 2013, NEUROPATHOLOGY, V33, P673, DOI 10.1111/neup.12038; Santpere G, 2009, BRAIN PATHOL, V19, P177, DOI 10.1111/j.1750-3639.2008.00173.x; Schultz C, 2004, NEUROBIOL AGING, V25, P397, DOI 10.1016/S0197-4580(03)00113-1; Schultz C, 2000, J NEUROPATH EXP NEUR, V59, P39, DOI 10.1093/jnen/59.1.39; Schultz C, 1996, NEUROSCI LETT, V212, P103, DOI 10.1016/0304-3940(96)12787-7; Schultz C, 1999, EXP NEUROL, V160, P186, DOI 10.1006/exnr.1999.7185; Shibuya K, 2011, BRAIN RES, V1404, P50, DOI 10.1016/j.brainres.2011.06.014; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song YJC, 2009, J NEUROPATH EXP NEUR, V68, P1073, DOI 10.1097/NEN.0b013e3181b66f1b; Spillantini MG, 2000, ANN NEUROL, V48, P939; Spina S, 2007, ACTA NEUROPATHOL, V113, P461, DOI 10.1007/s00401-006-0182-5; Stanford PM, 2000, BRAIN, V123, P880, DOI 10.1093/brain/123.5.880; Surgucheva I, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0132-8; Tacik P, 2017, NEUROPATH APPL NEURO, V43, P200, DOI 10.1111/nan.12367; Tacik P, 2015, ACTA NEUROPATHOL, V130, P199, DOI 10.1007/s00401-015-1425-0; Terada S, 2000, ACTA NEUROPATHOL, V100, P464, DOI 10.1007/s004010000213; Thal DR, 2000, ACTA NEUROPATHOL, V100, P608, DOI 10.1007/s004010000242; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Togo T, 2002, ACTA NEUROPATHOL, V104, P398, DOI 10.1007/s00401-002-0569-x; Trojanowski JQ, 2007, NEUROPATH APPL NEURO, V33, P615, DOI 10.1111/j.1365-2990.2007.00907.x; Uryu K, 2008, J NEUROPATH EXP NEUR, V67, P555, DOI 10.1097/NEN.0b013e31817713b5; van Herpen E, 2003, ANN NEUROL, V54, P573, DOI 10.1002/ana.10721; Verkhratsky A, 2017, BRAIN PATHOL, V27, P629, DOI 10.1111/bpa.12537; Wakabayashi K, 2000, NEUROPATH APPL NEURO, V26, P477, DOI 10.1046/j.1365-2990.2000.00266-2.x; WAKABAYASHI K, 1994, ACTA NEUROPATHOL, V87, P545; Wakabayashi K, 2000, ACTA NEUROPATHOL, V99, P14, DOI 10.1007/PL00007400; Walker AK, 2014, J NEUROSCI, V34, P6448, DOI 10.1523/JNEUROSCI.0248-14.2014; YAMADA T, 1990, NEUROSCI LETT, V120, P163, DOI 10.1016/0304-3940(90)90028-8; YAMADA T, 1992, NEUROSCI LETT, V135, P99, DOI 10.1016/0304-3940(92)90145-W; YAMADA T, 1993, ACTA NEUROPATHOL, V85, P308; YAMAZAKI M, 1994, ACTA NEUROPATHOL, V88, P587; Yoshida K, 2017, ACTA NEUROPATHOL, V133, P809, DOI 10.1007/s00401-016-1665-7; Yoshida M, 2014, NEUROPATHOLOGY, V34, P555, DOI 10.1111/neup.12143; Zarranz JJ, 2005, NEUROLOGY, V64, P1578, DOI 10.1212/01.WNL.0000160116.65034.12	174	50	50	1	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	SEP	2017	27	5					675	690		10.1111/bpa.12536			16	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	FD6MN	WOS:000407642700009	28805003	Green Published, Green Accepted			2022-02-06	
J	Yoo, D; Magsam, AW; Kelly, AM; Stayton, PS; Kievit, FM; Convertine, AJ				Yoo, Dasom; Magsam, Alexander W.; Kelly, Abby M.; Stayton, Patrick S.; Kievit, Forrest M.; Convertine, Anthony J.			Core-Cross-Linked Nanoparticles Reduce Neuroinflammation and Improve Outcome in a Mouse Model of Traumatic Brain Injury	ACS NANO			English	Article						polysorbate 80; antioxidant; controlled cortical impact; gliosis; hippocampus; startle habituation	CONTROLLED CORTICAL IMPACT; SUPEROXIDE-DISMUTASE; PATTERN SEPARATION; DENTATE GYRUS; THIOL; DELIVERY; MEMORY; MICE; NEURODEGENERATION; INHIBITION	Traumatic brain injury (TBI) is the leading cause of death and disability in children and young adults, yet there are currently no treatments available that prevent the secondary spread of damage beyond the initial insult. The chronic progression of this secondary injury is in part caused by the release of reactive oxygen species (ROS) into surrounding normal brain. Thus, treatments that can enter the brain and reduce the spread of ROS should improve outcome from TBI. Here a highly versatile, reproducible, and scalable method to synthesize core-cross-linked nanoparticles (NPs) from polysorbate 80 (PS80) using a combination of thiol-ene and thiol-Michael chemistry is described. The resultant NPs consist of a ROS-reactive thioether cross-linked core stabilized in aqueous solution by hydroxy-functional oligoethylene oxide segments. These NPs show narrow molecular weight distributions and have a high proportion of thioether units that reduce local levels of ROS. In a controlled cortical impact mouse model of TBI, the NPs are able to rapidly accumulate and be retained in damaged brain as visualized through fluorescence imaging, reduce neuroinflammation and the secondary spread of injury as determined through magnetic resonance imaging and histopathology, and improve functional outcome as determined through behavioral analyses. Our findings provide strong evidence that these NPs may, upon further development and testing, provide a useful strategy to help improve the outcome of patients following a TBI.	[Yoo, Dasom; Kelly, Abby M.; Stayton, Patrick S.; Convertine, Anthony J.] Mol Engn & Sci Inst, Dept Bioengn, Box 355061, Seattle, WA 98195 USA; [Magsam, Alexander W.; Kievit, Forrest M.] Univ Nebraska, Dept Biol Syst Engn, Lincoln, NE 68583 USA		Convertine, AJ (corresponding author), Mol Engn & Sci Inst, Dept Bioengn, Box 355061, Seattle, WA 98195 USA.; Kievit, FM (corresponding author), Univ Nebraska, Dept Biol Syst Engn, Lincoln, NE 68583 USA.	fkievit2@unl.edu; aconv@uw.edu	Stayton, Patrick/C-1975-2018; Kelly, Abby/E-5986-2016	Stayton, Patrick/0000-0001-6939-6371; Kievit, Forrest/0000-0002-9847-783X; Kelly, Abby/0000-0001-7202-3701	National Institute of General Medical Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM104320]; Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM103480]; Nebraska Settlement Biomedical Research Development Funds	We acknowledge the Biomedical and Obesity Research Core facility supported by a grant (P20GM104320) from the National Institute of General Medical Sciences, National Institutes of Health, for use of the iBox small-animal imaging system, startle response system, and Rotor-Rod. We also thank D. Yates for use of his microscope. We thank A. Manske, B. Murphy, and C. Gee for assistance with animal procedures. F.K. acknowledges support from an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (P20GM103480) and the Nebraska Settlement Biomedical Research Development Funds.	Astete CE, 2011, ACS NANO, V5, P9313, DOI 10.1021/nn102845t; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bast T, 2003, PROG NEUROBIOL, V70, P319, DOI 10.1016/S0301-0082(03)00112-6; Bharadwaj VN, 2016, SCI REP-UK, V6, DOI 10.1038/srep29988; Bird CM, 2008, NAT REV NEUROSCI, V9, P182, DOI 10.1038/nrn2335; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; BORCHARD G, 1994, INT J PHARMACEUT, V110, P29, DOI 10.1016/0378-5173(94)90372-7; Boyd BJ, 2015, J DRUG TARGET, V23, P847, DOI 10.3109/1061186X.2015.1034280; Carlson S, 1998, J NEUROPHYSIOL, V79, P2603, DOI 10.1152/jn.1998.79.5.2603; Chan JW, 2010, MACROMOLECULES, V43, P6381, DOI 10.1021/ma101069c; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clond MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061819; Cruz LJ, 2016, J CONTROL RELEASE, V223, P31, DOI 10.1016/j.jconrel.2015.12.029; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Girgis F, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00008; Goff HD, 1997, INT DAIRY J, V7, P363, DOI 10.1016/S0958-6946(97)00040-X; Gulyaev AE, 1999, PHARM RES-DORDR, V16, P1564, DOI 10.1023/A:1018983904537; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hayashi K, 2010, CHEM MATER, V22, P3768, DOI 10.1021/cm100810g; Hiemstra C, 2007, BIOMACROMOLECULES, V8, P1548, DOI 10.1021/bm061191m; Hoyle CE, 2004, J POLYM SCI POL CHEM, V42, P5301, DOI 10.1002/pola.20366; Hoyle CE, 2010, CHEM SOC REV, V39, P1355, DOI 10.1039/b901979k; Hoyle CE, 2010, ANGEW CHEM INT EDIT, V49, P1540, DOI 10.1002/anie.200903924; Huynh VT, 2011, BIOMACROMOLECULES, V12, P1738, DOI 10.1021/bm200135e; Impellizzeri D, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00458; KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J; Kwon EJ, 2016, ACS NANO, V10, P7926, DOI 10.1021/acsnano.6b03858; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Lowe AB, 2010, POLYM CHEM-UK, V1, P17, DOI 10.1039/b9py00216b; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; Nair DP, 2014, CHEM MATER, V26, P724, DOI 10.1021/cm402180t; Napoli A, 2004, NAT MATER, V3, P183, DOI 10.1038/nmat1081; OSWALD AA, 1966, J ORG CHEM, V31, P830, DOI 10.1021/jo01341a044; Pang KCH, 2015, J NEUROTRAUM, V32, P801, DOI 10.1089/neu.2014.3451; Qiu B, 2003, BIOMATERIALS, V24, P11, DOI 10.1016/S0142-9612(02)00227-2; Rebola N, 2017, NAT REV NEUROSCI, V18, P209, DOI 10.1038/nrn.2017.10; Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1; Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947; Sajja VSSS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15075; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Singer P, 2013, BEHAV BRAIN RES, V242, P166, DOI 10.1016/j.bbr.2012.12.011; Singhal A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.362; Spizzirri UG, 2009, BIOMACROMOLECULES, V10, P1923, DOI 10.1021/bm900325t; Syrett JA, 2011, CHEM COMMUN, V47, P1449, DOI 10.1039/c0cc04532b; Wan AJ, 2013, J AGR FOOD CHEM, V61, P6921, DOI 10.1021/jf402242e; Xu JL, 2016, ADV FUNCT MATER, V26, P4124, DOI 10.1002/adfm.201504416	50	50	50	8	41	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	SEP	2017	11	9					8600	8611		10.1021/acsnano.7b03426			12	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science	FI4CV	WOS:000411918200007	28783305				2022-02-06	
J	Churchill, NW; Hutchison, MG; Richards, D; Leung, G; Graham, SJ; Schweizer, TA				Churchill, Nathan W.; Hutchison, Michael G.; Richards, Doug; Leung, General; Graham, Simon J.; Schweizer, Tom A.			Neuroimaging of sport concussion: persistent alterations in brain structure and function at medical clearance	SCIENTIFIC REPORTS			English	Article							PARTIAL LEAST-SQUARES; DEFAULT-MODE NETWORK; RESTING-STATE FMRI; RECURRENT CONCUSSION; FOOTBALL PLAYERS; INJURY; METAANALYSIS; INDIVIDUALS; RECOVERY; GENDER	The medical decision of return to play (RTP) after a sport concussion is largely based on symptom status following a graded exercise protocol. However, it is currently unknown how objective markers of brain structure and function relate to clinical recovery. The goal of this study was to determine whether differences in brain structure and function at acute injury remain present at RTP. In this longitudinal study, 54 active varsity athletes were scanned using magnetic resonance imaging (MRI), including 27 with recent concussion, imaged at both acute injury and medical clearance, along with 27 matched controls. Diffusion tensor imaging was used to measure fractional anisotropy (FA) and mean diffusivity (MD) of white matter and resting-state functional MRI was used to measure global functional connectivity (Gconn). At acute injury, concussed athletes had reduced FA and increased MD, along with elevated Gconn; these effects remained present at RTP. Athletes who took longer to reach RTP also showed elevated Gconn in dorsal brain regions, but no significant white matter effects. This study presents the first evidence of altered brain structure and function at the time of medical clearance to RTP, with greater changes in brain function for athletes with a longer recovery time.	[Churchill, Nathan W.; Schweizer, Tom A.] St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada; [Churchill, Nathan W.; Hutchison, Michael G.; Leung, General; Schweizer, Tom A.] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Hutchison, Michael G.; Richards, Doug] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Leung, General] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada; [Graham, Simon J.] Univ Toronto, Sunnybrook Hosp, Dept Med Biophys, Toronto, ON, Canada; [Graham, Simon J.] Sunnybrook Res Inst, Sunnybrook Hlth Sci Ctr, Phys Sci Platform, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada		Churchill, NW (corresponding author), St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada.; Churchill, NW (corresponding author), St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada.	nchurchill.research@gmail.com			Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [RN294001-367456]; Defence Research and Development Canada (DRDC); Canadian Institutes of Military and Veterans Health (CIMVHR) [W7714-145967]; Siemens Canada, Ltd.	This work was supported by the Canadian Institutes of Health Research (CIHR) [grant number RN294001-367456]; the Defence Research and Development Canada (DRDC) and the Canadian Institutes of Military and Veterans Health (CIMVHR) [grant number W7714-145967]; and pilot funding from Siemens Canada, Ltd.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Binder JR, 2009, CEREB CORTEX, V19, P2767, DOI 10.1093/cercor/bhp055; Churchill N., 2016, J NEUROTRAU IN PRESS; Churchill N., 2016, BRAIN INJUR IN PRESS; Churchill NW, 2017, NEUROIMAGE-CLIN, V14, P480, DOI 10.1016/j.nicl.2017.02.015; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Derrfuss J, 2005, HUM BRAIN MAPP, V25, P22, DOI 10.1002/hbm.20127; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grefkes C, 2014, LANCET NEUROL, V13, P206, DOI 10.1016/S1474-4422(13)70264-3; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hillary FG, 2015, NEUROPSYCHOLOGY, V29, P59, DOI 10.1037/neu0000110; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krishnan A, 2011, NEUROIMAGE, V56, P455, DOI 10.1016/j.neuroimage.2010.07.034; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Marmarou A., 2007, NEUROSURG FOCUS, V22, P1; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AR, 2004, NEUROIMAGE, V23, P764, DOI 10.1016/j.neuroimage.2004.05.018; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rosipal R, 2006, LECT NOTES COMPUT SC, V3940, P34, DOI 10.1007/11752790_2; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	39	50	50	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 24	2017	7								8297	10.1038/s41598-017-07742-3			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE8FC	WOS:000408440000001	28839132	Green Published, gold			2022-02-06	
J	Churchill, N; Hutchison, M; Richards, D; Leung, G; Graham, S; Schweizer, TA				Churchill, Nathan; Hutchison, Michael; Richards, Doug; Leung, General; Graham, Simon; Schweizer, Tom A.			Brain Structure and Function Associated with a History of Sport Concussion: A Multi-Modal Magnetic Resonance Imaging Study	JOURNAL OF NEUROTRAUMA			English	Article						blood flow; concussion; diffusion tensor imaging; MRI; traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; RESTING-STATE FMRI; RECURRENT CONCUSSION; NCAA CONCUSSION; HEAD TRAUMA; INJURY; RECOVERY; MRI; TRACTOGRAPHY; DEPRESSION	There is growing concern about the potential long-term consequences of sport concussion for young, currently active athletes. However, there remains limited information about brain abnormalities associated with a history of concussion and how they relate to clinical factors. In this study, advanced MRI was used to comprehensively describe abnormalities in brain structure and function associated with a history of sport concussion. Forty-three athletes (21 male, 22 female) were recruited from interuniversity teams at the beginning of the season, including 21 with a history of concussion and 22 without prior concussion; both groups also contained a balanced sample of contact and noncontact sports. Multi-modal MRI was used to evaluate abnormalities in brain structure and function. Athletes with a history of concussion showed frontal decreases in brain volume and blood flow. However, they also demonstrated increased posterior cortical volume and elevated markers of white matter microstructure. A greater number of prior concussions was associated with more extensive decreases in cerebral blood flow and insular volume, whereas recovery time from most recent concussion was correlated with reduced frontotemporal volume. White matter showed limited correlations with clinical factors, predominantly in the anterior corona radiata. This study provides the first evidence of the long-term effects of concussion on gray matter volume, blood flow, and white matter microstructure within a single athlete cohort. This was examined for a mixture of male and female athletes in both contact and noncontact sports, demonstrating the relevance of these findings for the overall sporting community.	[Churchill, Nathan; Leung, General; Schweizer, Tom A.] St Michaels Hosp, Keenan Res Ctr, Toronto, ON, Canada; [Hutchison, Michael; Richards, Doug] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Leung, General] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada; [Graham, Simon] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada; [Graham, Simon] Sunnybrook Res Inst, Phys Sci, Toronto, ON, Canada		Churchill, N (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, 209 Victoria St, Toronto, ON M5B 1M8, Canada.	nchurchill.research@gmail.com			Siemens Canada Ltd.; Defence Research & Development Canada (DRDC); Canadian Institutes of Military and Veterans Health (CIMVHR)	This study was conducted with partial support from Siemens Canada Ltd.; This research received funding from the Defence Research & Development Canada (DRDC) and the Canadian Institutes of Military and Veterans Health (CIMVHR). This study was approved by the Canadian Forces Surgeon General's Health Research Program.	Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Conti AC, 1998, J NEUROSCI, V18, P5663; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Efron B., 1994, INTRO BOOTSTRAP; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2016, J NEUROTRAUM, V33, P330, DOI 10.1089/neu.2015.3919; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Terry DP, 2012, BRAIN INJURY, V26, P1684, DOI 10.3109/02699052.2012.722259; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413; [No title captured]	48	50	50	2	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					765	771		10.1089/neu.2016.4531			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200002	27246317				2022-02-06	
J	Roy, S; Butman, JA; Pham, DL				Roy, Snehashis; Butman, John A.; Pham, Dzung L.		Alzheimers Dis Neuroimaging Initia	Robust skull stripping using multiple MR image contrasts insensitive to pathology	NEUROIMAGE			English	Article						Skull stripping; Brain extraction; Patches; Atlas; Segmentation; Non-local; Sparsity	BRAIN EXTRACTION; AUTOMATIC SEGMENTATION; ALGORITHM; REGISTRATION; ACCURATE; VOLUME; REGULARIZATION; PERFORMANCE; MESHES	Automatic skull-stripping or brain extraction of magnetic resonance (MR) images is often a fundamental step in many neuroimage processing pipelines. The accuracy of subsequent image processing relies on the accuracy of the skull-stripping. Although many automated stripping methods have been proposed in the past, it is still an active area of research particularly in the context of brain pathology. Most stripping methods are validated on T-1-w MR images of normal brains, especially because high resolution T-1-w sequences are widely acquired and ground truth manual brain mask segmentations are publicly available for normal brains. However, different MR acquisition protocols can provide complementary information about the brain tissues, which can be exploited for better distinction between brain, cerebrospinal fluid, and unwanted tissues such as skull, dura, marrow, or fat. This is especially true in the presence of pathology, where hemorrhages or other types of lesions can have similar intensities as skull in a T-1-w image. In this paper, we propose a sparse patch based Multi-cONtrast brain STRipping method (MONSTR),(2) where non-local patch information from one or more atlases, which contain multiple MR sequences and reference delineations of brain masks, are combined to generate a target brain mask. We compared MONSTR with four state-of-the-art, publicly available methods: BEaST, SPECTRE, ROBEX, and OptiBET. We evaluated the performance of these methods on 6 datasets consisting of both healthy subjects and patients with various pathologies. Three datasets (ADNI, MRBrainS, NAMIC) are publicly available, consisting of 44 healthy volunteers and 10 patients with schizophrenia. Other three in-house datasets, comprising 87 subjects in total, consisted of patients with mild to severe traumatic brain injury, brain tumors, and various movement disorders. A combination of T-1-w, T-2-w were used to skull-strip these datasets. We show significant improvement in stripping over the competing methods on both healthy and pathological brains. We also show that our multi-contrast framework is robust and maintains accurate performance across different types of acquisitions and scanners, even when using normal brains as atlases to strip pathological brains, demonstrating that our algorithm is applicable even when reference segmentations of pathological brains are not available to be used as atlases.	[Roy, Snehashis; Butman, John A.; Pham, Dzung L.] Henry M Jackson Fdn, Ctr Neurosci & Regenerat Med, Bethesda, MD 20817 USA; [Butman, John A.] NIH, Dept Diagnost Radiol, Bethesda, MD USA		Roy, S (corresponding author), Henry M Jackson Fdn, Ctr Neurosci & Regenerat Med, Bethesda, MD 20817 USA.	snehashis.roy@nih.gov	Butman, John/J-2780-2013; Pham, Dzung/AAR-8263-2020; Butman, John A/A-2694-2008	Butman, John/0000-0002-1547-9195; Roy, Snehashis/0000-0002-7997-3993	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; intramural research program at NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS070906]; National MS SocietyNational Multiple Sclerosis Society [RG-1507-05243]; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging, the National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); AbbVieAbbVie; Alzheimer's AssociationAlzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; BiogenBiogen; Bristol-Myers Squibb CompanyBristol-Myers Squibb; CereSpir, Inc.; Eisai Inc.Eisai Co Ltd; Elan Pharmaceuticals, Inc.; Eli Lilly and CompanyEli Lilly; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE HealthcareGeneral ElectricGE Healthcare; IXICO Ltd.; Janssen Alzheimer Immuno therapy Research AMP; Development, LLC.; Johnson AMP; Johnson Pharmaceutical Research AMP; Development LLC.; Lumosity; LundbeckLundbeck Corporation; Merck Co., Inc.Merck & Company; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals CorporationNovartis; Pfizer Inc.Pfizer; Piramal Imaging; ServierServier; Takeda Pharmaceutical CompanyTakeda Pharmaceutical Company Ltd; Transition Therapeutics; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Northern California Institute for Research and Education; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS070906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG024904] Funding Source: NIH RePORTER	Support for this work included funding from the Department of Defense in the Center for Neuroscience and Regenerative Medicine and intramural research program at NIH. This work was also partially supported by grants NIH/NINDS R01NS070906 and National MS Society RG-1507-05243. This work utilized the computational resources of the NIH HPC Biowulf cluster. (http://hpc.nih.gov).r For the ADNI-29 dataset, data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immuno therapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.	Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Boesen K, 2004, NEUROIMAGE, V22, P1255, DOI 10.1016/j.neuroimage.2004.03.010; Buades A, 2005, PROC CVPR IEEE, P60, DOI 10.1109/cvpr.2005.38; Burgos N, 2014, IEEE T MED IMAGING, V33, P2332, DOI 10.1109/TMI.2014.2340135; Carass A, 2011, NEUROIMAGE, V56, P1982, DOI 10.1016/j.neuroimage.2011.03.045; Carass A, 2007, I S BIOMED IMAGING, P656, DOI 10.1109/ISBI.2007.356937; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Coupe P, 2012, NEUROIMAGE, V59, P3736, DOI 10.1016/j.neuroimage.2011.10.080; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Desbrun M, 1999, COMP GRAPH, P317; Donoho DL, 2006, COMMUN PUR APPL MATH, V59, P907, DOI 10.1002/cpa.20131; Doshi J, 2013, ACAD RADIOL, V20, P1566, DOI 10.1016/j.acra.2013.09.010; Eskildsen SF, 2012, NEUROIMAGE, V59, P2362, DOI 10.1016/j.neuroimage.2011.09.012; Galdames FJ, 2012, J NEUROSCI METH, V206, P103, DOI 10.1016/j.jneumeth.2012.02.017; Geremia E, 2011, NEUROIMAGE, V57, P378, DOI 10.1016/j.neuroimage.2011.03.080; Guizard N, 2015, NEUROIMAGE-CLIN, V8, P376, DOI 10.1016/j.nicl.2015.05.001; Hahn HK, 2000, LECT NOTES COMPUT SC, V1935, P134; Heckemann RA, 2006, NEUROIMAGE, V33, P115, DOI 10.1016/j.neuroimage.2006.05.061; Heckemann RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129211; Hu SY, 2014, HUM BRAIN MAPP, V35, P377, DOI 10.1002/hbm.22183; Iglesias JE, 2013, LECT NOTES COMPUT SC, V8149, P631, DOI 10.1007/978-3-642-40811-3_79; Iglesias JE, 2011, IEEE T MED IMAGING, V30, P1617, DOI 10.1109/TMI.2011.2138152; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jog A, 2015, MED IMAGE ANAL, V24, P63, DOI 10.1016/j.media.2015.05.002; Jog A, 2013, PROC SPIE, V8669, DOI 10.1117/12.2007062; Kleesiek J, 2016, NEUROIMAGE, V129, P460, DOI 10.1016/j.neuroimage.2016.01.024; Ledig C, 2015, MED IMAGE ANAL, V21, P40, DOI 10.1016/j.media.2014.12.003; Lemieux L, 1999, MAGN RESON MED, V42, P127; Leung KK, 2011, NEUROIMAGE, V55, P1091, DOI 10.1016/j.neuroimage.2010.12.067; Lutkenhoff ES, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115551; Mairal J, 2012, FOUND TRENDS COMPUT, V8, DOI 10.1561/0600000058; Malone IB, 2015, NEUROIMAGE, V104, P366, DOI 10.1016/j.neuroimage.2014.09.034; Manjon JV, 2010, INT J BIOMED IMAGING, V2010, DOI 10.1155/2010/425891; Mendrik AM, 2015, COMPUT INTEL NEUROSC, V2015, DOI 10.1155/2015/813696; Mikheev A, 2008, J MAGN RESON IMAGING, V27, P1235, DOI 10.1002/jmri.21372; Mueller SG, 2005, NEUROIMAG CLIN N AM, V15, P869, DOI 10.1016/j.nic.2005.09.008; Park JG, 2009, NEUROIMAGE, V47, P1394, DOI 10.1016/j.neuroimage.2009.04.047; Pham DL, 1999, IEEE T MED IMAGING, V18, P737, DOI 10.1109/42.802752; Rehm K, 2004, NEUROIMAGE, V22, P1262, DOI 10.1016/j.neuroimage.2004.03.011; Rex DE, 2004, NEUROIMAGE, V23, P625, DOI 10.1016/j.neuroimage.2004.06.019; Roura E, 2014, COMPUT METH PROG BIO, V113, P655, DOI 10.1016/j.cmpb.2013.11.015; Rousseau F, 2011, IEEE T MED IMAGING, V30, P1852, DOI 10.1109/TMI.2011.2156806; Rousseau F, 2008, LECT NOTES COMPUT SC, V5302, P497, DOI 10.1007/978-3-540-88682-2_38; Roy Snehashis, 2015, Mach Learn Med Imaging, V9352, P194, DOI 10.1007/978-3-319-24888-2_24; Roy S, 2015, IEEE J BIOMED HEALTH, V19, P1598, DOI 10.1109/JBHI.2015.2439242; Roy S, 2014, J NUCL MED, V55, P2071, DOI 10.2967/jnumed.114.143958; Roy S, 2014, PROC SPIE, V9034, DOI 10.1117/12.2043917; Roy S, 2014, PROC SPIE, V9034, DOI 10.1117/12.2043954; Roy S, 2013, I S BIOMED IMAGING, P1384; Roy S, 2013, IEEE T MED IMAGING, V32, P2348, DOI 10.1109/TMI.2013.2282126; Roy S, 2010, I S BIOMED IMAGING, P932, DOI 10.1109/ISBI.2010.5490140; Roy S, 2010, PROC SPIE, V7623, DOI 10.1117/12.844575; Sadananthan SA, 2010, NEUROIMAGE, V49, P225, DOI 10.1016/j.neuroimage.2009.08.050; Serag A, 2016, SCI REP-UK, V6, DOI 10.1038/srep23470; Shan ZY, 2002, NEUROIMAGE, V17, P1587, DOI 10.1006/nimg.2002.1287; Shattuck DW, 2001, NEUROIMAGE, V13, P856, DOI 10.1006/nimg.2000.0730; Shi F, 2012, NEUROIMAGE, V62, P1975, DOI 10.1016/j.neuroimage.2012.05.042; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; van der Kouwe AJW, 2008, NEUROIMAGE, V40, P559, DOI 10.1016/j.neuroimage.2007.12.025; van Tulder G, 2015, LECT NOTES COMPUT SC, V9349, P531, DOI 10.1007/978-3-319-24553-9_65; Wang HZ, 2013, IEEE T PATTERN ANAL, V35, P611, DOI 10.1109/TPAMI.2012.143; Wang L, 2014, NEUROIMAGE, V89, P152, DOI 10.1016/j.neuroimage.2013.11.040; Wang YP, 2011, LECT NOTES COMPUT SC, V6893, P635, DOI 10.1007/978-3-642-23626-6_78; Warfield SK, 2004, IEEE T MED IMAGING, V23, P903, DOI 10.1109/TMI.2004.828354; Zhao C., 2016, P SPIE MED IM SPIE, P97840; Zhuang AH, 2006, NEUROIMAGE, V32, P79, DOI 10.1016/j.neuroimage.2006.03.019; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	69	50	50	2	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	FEB 1	2017	146						132	147		10.1016/j.neuroimage.2016.11.017			16	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EL3ZX	WOS:000394560700013	27864083	Bronze, Green Accepted			2022-02-06	
J	Erdodi, LA; Jongsma, KA; Issa, M				Erdodi, Laszlo A.; Jongsma, Katherine A.; Issa, Meriam			The 15-item version of the Boston Naming Test as an index of English proficiency	CLINICAL NEUROPSYCHOLOGIST			English	Article						Boston Naming Test; limited English proficiency; neuropsychological testing; bilingualism; cross-cultural competence	TRAUMATIC BRAIN-INJURY; TEST-PERFORMANCE; LANGUAGE; BILINGUALS; VALIDITY; ACCULTURATION; INDIVIDUALS; RECOGNITION; NORMS	Objective: The present study was designed to examine the potential of the Boston Naming Test - Short Form (BNT-15) to provide an objective estimate of English proficiency. A secondary goal was to examine the effect of limited English proficiency (LEP) on neuropsychological test performance. Method: A brief battery of neuropsychological tests was administered to 79 bilingual participants (40.5% male, M-Age=26.9, M-Education=14.2). The majority (n=56) were English dominant (EN), and the rest were Arabic dominant (AR). The BNT-15 was further reduced to 10 items that best discriminated between EN and AR (BNT-10). Participants were divided into low, intermediate, and high English proficiency subsamples based on BNT-10 scores (6, 7-8, and 9). Performance across groups was compared on neuropsychological tests with high and low verbal mediation. Results: The BNT-15 and BNT-10 respectively correctly identified 89 and 90% of EN and AR participants. Level of English proficiency had a large effect (partial (2)=.12-.34; Cohen's d=.67-1.59) on tests with high verbal mediation (animal fluency, sentence comprehension, word reading), but no effect on tests with low verbal mediation (auditory consonant trigrams, clock drawing, digit-symbol substitution). Conclusions: The BNT-15 and BNT-10 can function as indices of English proficiency and predict the deleterious effect of LEP on neuropsychological tests with high verbal mediation. Interpreting low scores on such measures as evidence of impairment in examinees with LEP would likely overestimate deficits.	[Erdodi, Laszlo A.; Jongsma, Katherine A.; Issa, Meriam] Univ Windsor, Dept Psychol, Windsor, ON, Canada		Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, Windsor, ON, Canada.	lerdodi@gmail.com			Faculty of Arts, Humanities and Social Sciences at the University of Windsor	This research was supported by the Dean of the Faculty of Arts, Humanities and Social Sciences at the University of Windsor.	Akamatsu N, 1999, READ WRIT, V11, P381, DOI 10.1023/A:1008053520326; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Boone K.B., 2013, CLIN PRACTICE FORENS; Boone KB, 2007, ARCH CLIN NEUROPSYCH, V22, P355, DOI 10.1016/j.acn.2007.01.010; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Erdodi L, 2012, HUMOR, V25, P459, DOI 10.1515/humor-2012-0024; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Fastenau PS, 1998, J CLIN EXP NEUROPSYC, V20, P828, DOI 10.1076/jcen.20.6.828.1105; Frederick RI, 2000, ARCH CLIN NEUROPSYCH, V15, P281, DOI 10.1016/S0887-6177(99)00002-5; Gollan TH, 2007, J INT NEUROPSYCH SOC, V13, P197, DOI 10.1017/S1355617707070038; Gollan TH, 2012, BILING-LANG COGN, V15, P594, DOI 10.1017/S1366728911000332; Gollan TH, 2002, NEUROPSYCHOLOGY, V16, P562, DOI 10.1037//0894-4105.16.4.562; Harris J. G., 2003, CLIN INTERPRETATION, P343, DOI DOI 10.1016/B978-012703570-3/50015-8; Heaton R. K., 2004, REVISED COMPREHENSIV; Heaton RK, 2009, NEUROPSYCHOLOGICAL A, P127; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kaplan E., 2001, BOSTON NAMING TEST; Leon-~Carrion J, 2001, NEUROPSYCHOLOGY HISP, P39; Li P, 2006, BEHAV RES METHODS, V38, P202, DOI 10.3758/BF03192770; MACK WJ, 1992, J GERONTOL, V47, pP154, DOI 10.1093/geronj/47.3.P154; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Mindt MR, 2008, NEUROPSYCHOL REV, V18, P255, DOI 10.1007/s11065-008-9069-7; Pearson, 2009, ADV CLIN SOLUTIONS W; Razani J, 2007, CLIN NEUROPSYCHOL, V21, P776, DOI 10.1080/13854040701437481; Razani J, 2007, ARCH CLIN NEUROPSYCH, V22, P333, DOI 10.1016/j.acn.2007.01.008; Rey A., 1964, EXAMEN CLIN PSYCHOL; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Roberts PM, 2002, APHASIOLOGY, V16, P635, DOI [DOI 10.1080/02687030244000220, 10.1080/02687030244000220]; Robles L, 2015, J CLIN EXP NEUROPSYC, V37, P614, DOI 10.1080/13803395.2015.1039961; ROULEAU I, 1992, BRAIN COGNITION, V18, P70, DOI 10.1016/0278-2626(92)90112-Y; Salazar X.F., 2007, ASSESSMENT FEIGNED C, P405; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Shin H.B., 2011, FED FOR C WASH DC; Sotelo-Dynega M, 2013, PSYCHOL SCHOOLS, V50, P781, DOI 10.1002/pits.21706; Statistics Canada, 2011, 2011 CEN HDB; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1988, CLIN NEUROPSYCHOL, V2, P246, DOI [DOI 10.1080/13854048808520107, 10.1080/13854048808520107]; United States Census Bureau, 2013, 2009 2013 AM COMM SU; Walker AJ, 2010, AUST PSYCHOL, V45, P112, DOI 10.1080/00050060903428210; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilde MC, 2006, CLIN NEUROPSYCHOL, V20, P702, DOI 10.1080/13854040500246901; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME	44	50	50	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	1					168	178		10.1080/13854046.2016.1224392			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	EK2VR	WOS:000393785300010	27556291				2022-02-06	
J	Chapple, LAS; Deane, AM; Heyland, DK; Lange, K; Kranz, AJ; Williams, LT; Chapman, MJ				Chapple, Lee-anne S.; Deane, Adam M.; Heyland, Daren K.; Lange, Kylie; Kranz, Amelia J.; Williams, Lauren T.; Chapman, Marianne J.			Energy and protein deficits throughout hospitalization in patients admitted with a traumatic brain injury	CLINICAL NUTRITION			English	Article						Nutrition; Oral intake; Critical care; Head injury; Traumatic brain injury	CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; SEVERE HEAD-INJURY; ENTERAL NUTRITION; SUPPORT PRACTICES; ORAL INTAKE; SEDATION; TRIAL; MANAGEMENT; ADEQUACY	Background and aims: Patients with traumatic brain injury (TBI) experience considerable energy and protein deficits in the intensive care unit (ICU) and these are associated with adverse outcomes. However, nutrition delivery after ICU discharge during ward-based care, particularly from oral diet, has not been measured. This study aimed to quantify energy and protein delivery and deficits over the entire hospitalization for critically ill TBI patients. Methods: Consecutively admitted adult patients with a moderate-severe TBI (Glasgow Coma Scale 3-12) over 12 months were eligible. Observational data on energy and protein delivered from all routes were collected until hospital discharge or day 90 and compared to dietician prescriptions. Oral intake was quantified using weighed food records on three pre-specified days each week. Data are mean (SD) unless indicated. Cumulative deficit is the mean absolute difference between intake and estimated requirements. Results: Thirty-seven patients [45.3 (15.8) years; 87% male; median APACHE II 18 (IQR: 14-22)] were studied for 1512 days. Median duration of ICU and ward-based stay was 13.4 (IQR: 6.4-17.9) and 19.9 (9.6-32.0) days, respectively. Over the entire hospitalization patients had a cumulative deficit of 18,242 (16,642) kcal and 1315 (1028) g protein. Energy and protein intakes were less in ICU than the ward (1798 (800) vs 1980 (915) kcal/day, p = 0.015; 79 (47) vs 89 (41) g/day protein, p = 0.001). Energy deficits were almost two-fold greater in patients exclusively receiving nutrition orally than tube-fed (806 (616) vs 445 (567) kcal/day, p = 0.016) while protein deficits were similar (40 (5) vs 37 (6) g/day, p = 0.616). Primary reasons for interruptions to enteral and oral nutrition were fasting for surgery/procedures and patient related reasons, respectively. Conclusions: Patients admitted to ICU with a TBI have energy and protein deficits that persist after ICU discharge, leading to considerable shortfalls over the entire hospitalization. Patients ingesting nutrition orally are at particular risk of energy deficit. (C) 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.	[Chapple, Lee-anne S.; Deane, Adam M.; Kranz, Amelia J.; Chapman, Marianne J.] Univ Adelaide, Discipline Acute Care Med, N Terrace, Adelaide, SA, Australia; [Chapple, Lee-anne S.; Deane, Adam M.; Chapman, Marianne J.] Australia Ctr Clin Res Excellence Nutr Physiol, Natl Hlth & Med Res Council, Level 6,Eleanor Harrald Bldg,North Terrace, Adelaide, SA, Australia; [Deane, Adam M.; Chapman, Marianne J.] Royal Adelaide Hosp, Intens Care Unit, Level 4,Emergency Serv Bldg,North Terrace, Adelaide, SA, Australia; [Heyland, Daren K.] Kingston Gen Hosp, Clin Evaluat Res Unit, Kingston, ON, Canada; [Lange, Kylie] Univ Adelaide, Discipline Med, N Terrace, Adelaide, SA, Australia; [Williams, Lauren T.] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld 4111, Australia		Chapple, LAS (corresponding author), Univ Adelaide, Discipline Acute Care Med, N Terrace, Adelaide, SA, Australia.	lee-anne.costello@adelaide.edu.au; adam.m.deane@gmail.com; dkh2@queensu.ca; kylie.lange@adelaide.edu.au; amelia-jk@hotmail.com; lauren.williams@griffith.edu.au; Marianne.chapman@health.sa.gov.au	Chapple, Lee-anne/AAN-7751-2021; Deane, Adam/AAF-7370-2020; Williams, Lauren T./G-6301-2013	Deane, Adam/0000-0002-7620-5577; Williams, Lauren T./0000-0002-7860-0319; chapman, marianne/0000-0003-0710-3283; Chapple, Lee-anne S/0000-0002-9818-2484	Australasian Society of Parenteral and Enteral Nutrition (AuSPEN); Neurosurgical Research Foundation; Australian Post-Graduate AwardAustralian Government; Royal Adelaide Hospital Dawes Top-Up Scholarship	This research was funded by an Australasian Society of Parenteral and Enteral Nutrition (AuSPEN) small project grant and a Neurosurgical Research Foundation grant. LSC was supported by an Australian Post-Graduate Award and Royal Adelaide Hospital Dawes Top-Up Scholarship.	Alberda C, 2009, INTENS CARE MED, V35, P1728, DOI 10.1007/s00134-009-1567-4; Alhashemi HH, 2010, NEUROSCIENCES, V15, P231; Chapple LAS, 2016, CRIT CARE, V20, DOI 10.1186/s13054-015-1177-1; Costello LAS, 2014, INJURY, V45, P1834, DOI 10.1016/j.injury.2014.06.004; De Beaux I, 2001, ANAESTH INTENS CARE, V29, P619, DOI 10.1177/0310057X0102900611; De Jonghe B, 2001, CRIT CARE MED, V29, P8, DOI 10.1097/00003246-200101000-00002; DeChicco R., 1995, J AM DIET ASSOC, V95, pA25, DOI [10.1016/S0002-8223(95)00438-6, DOI 10.1016/S0002-8223(95)00438-6]; Denes Z, 2004, DISABIL REHABIL, V26, P1163, DOI 10.1080/09638280412331270380; DETSKY AS, 1984, JPEN-PARENTER ENTER, V8, P153, DOI 10.1177/0148607184008002153; Dhandapani SS, 2007, INDIAN J NEUROTRAUM, V4, P35, DOI 10.1016/S0973-0508(07)80009-8; Foley N, 2006, J NUTR HEALTH AGING, V10, P171; Foley N, 2008, J NEUROTRAUM, V25, P1415, DOI 10.1089/neu.2008.0628; GARREL DR, 1995, JPEN-PARENTER ENTER, V19, P482, DOI 10.1177/0148607195019006482; Hansen TS, 2008, ARCH PHYS MED REHAB, V89, P1556, DOI 10.1016/j.apmr.2007.11.063; Hart DW, 2001, CRIT CARE MED, V29, P1318, DOI 10.1097/00003246-200107000-00004; Heyland DK, 2011, CRIT CARE, V15, DOI 10.1186/cc10546; Heyland DK, 2010, CRIT CARE, V14, DOI 10.1186/cc8991; Hiesmayr M, 2009, CLIN NUTR, V28, P484, DOI 10.1016/j.clnu.2009.05.013; Lewis Frank D, 2013, J Spec Oper Med, V13, P56; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; Mistraletti G, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-92; Morgan Laurie M, 2004, Nutr Clin Pract, V19, P511, DOI 10.1177/0115426504019005511; Nicolo M, 2016, JPEN-PARENTER ENTER, V40, P45, DOI 10.1177/0148607115583675; Peake SL, 2014, AM J CLIN NUTR, V100, P616, DOI 10.3945/ajcn.114.086322; Pendyala S, 2012, GASTROENTEROLOGY, V142, P1100, DOI 10.1053/j.gastro.2012.01.034; Peterson SJ, 2011, CURR OPIN CLIN NUTR, V14, P182, DOI 10.1097/MCO.0b013e3283428e65; Peterson SJ, 2010, J AM DIET ASSOC, V110, P427, DOI 10.1016/j.jada.2009.11.020; Reade MC, 2014, NEW ENGL J MED, V370, P444, DOI 10.1056/NEJMra1208705; Shehabi Y, 2013, CRIT CARE MED, V41, P1983, DOI 10.1097/CCM.0b013e31828a437d; Singer P, 2011, INTENS CARE MED, V37, P601, DOI 10.1007/s00134-011-2146-z; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; Tan M, 2011, BRIT J NEUROSURG, V25, P2, DOI 10.3109/02688697.2010.522745; Wang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058838; Wei XJ, 2015, CRIT CARE MED, V43, P1569, DOI 10.1097/CCM.0000000000001000; Wrieden W, 2003, MON SCOTT DIET TARG; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668	36	50	58	0	13	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0261-5614	1532-1983		CLIN NUTR	Clin. Nutr.	DEC	2016	35	6					1315	1322		10.1016/j.clnu.2016.02.009			8	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	EC3UI	WOS:000388051900013	26949198				2022-02-06	
J	McCarty, CA; Zatzick, D; Stein, E; Wang, J; Hilt, R; Rivara, FP				McCarty, Carolyn A.; Zatzick, Douglas; Stein, Elizabeth; Wang, Jin; Hilt, Robert; Rivara, Frederick P.		Seattle Sports Concussion Res	Collaborative Care for Adolescents With Persistent Postconcussive Symptoms: A Randomized Trial	PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS; PEDIATRIC POPULATION; DEPRESSIVE SYMPTOMS; CHILDREN; HEALTH; INTERVENTION; VALIDITY; OUTCOMES	BACKGROUND AND OBJECTIVES: Postconcussive and co-occurring psychological symptoms are not uncommon after sports-related concussion and are associated with functional impairment and societal costs. There is no evidence-based treatment targeting postconcussive symptoms in children and adolescents. The goal of this study was to test a collaborative care intervention model with embedded cognitive-behavioral therapy, care management, and psychopharmacological consultation. We hypothesized that patients in collaborative care would demonstrate greater reductions in postconcussive, depressive, and anxiety symptoms and improvement in functioning over the course of 6 months, compared with usual care control. METHODS: Patients aged 11 to 17 years with persistent symptoms >= 1 month after sportsrelated concussion were randomly assigned to receive collaborative care (n = 25) or care as usual (n = 24). Patients were assessed before randomization and after 1, 3, and 6 months. Groups were compared over time via linear mixed effects regression models. RESULTS: Adolescents assigned to collaborative care experienced clinically and statistically significant improvements in postconcussive symptoms in addition to functional gains at 6 months compared with controls. Six months after the baseline assessment, 13.0% of intervention patients and 41.7% of control patients reported high levels of postconcussive symptoms (P = .03), and 78% of intervention patients and 45.8% of control patients reported >= 50% reduction in depression symptoms (P = .02). No changes between groups were demonstrated in anxiety symptoms. CONCLUSIONS: Orchestrated efforts to systematically implement collaborative care treatment approaches for slow-to-recover adolescents may be useful given the reductions in postconcussive and co-occurring psychological symptoms in addition to improved quality of life.	[McCarty, Carolyn A.; Stein, Elizabeth; Rivara, Frederick P.] Seattle Childrens Hosp, Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [Hilt, Robert] Seattle Childrens Hosp, Dept Psychiat & Behav Med, Seattle, WA USA; [McCarty, Carolyn A.; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Zatzick, Douglas; Hilt, Robert] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Zatzick, Douglas; Wang, Jin; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA		McCarty, CA (corresponding author), POB 5371,Suite 400,Mailstop CW8-5A, Seattle, WA 98145 USA.	cari.mccarty@seattlechildrens.org	Hilt, Robert/AAJ-3792-2020	Hilt, Robert/0000-0001-8153-6461; Stein, Elizabeth/0000-0002-1820-3821	Seattle Sports Concussion Research Collaborative; National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA grant [UL1TR000423]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Supported by the Seattle Sports Concussion Research Collaborative and by the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA grant UL1TR000423. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funded by the National Institutes of Health (NIH).	Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Asarnow JR, 2015, JAMA PEDIATR, V169, P929, DOI 10.1001/jamapediatrics.2015.1141; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; Cohen J., 2013, STAT POWER ANAL BEHA; Conder R, 2015, BRAIN INJURY, V29, P249, DOI 10.3109/02699052.2014.965209; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fisher E, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011118.pub2; Freed LH, 1998, J ADOLESCENT HEALTH, V22, P475, DOI 10.1016/S1054-139X(98)00002-0; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Hajek CA, 2010, BRAIN INJURY, V24, P100, DOI 10.3109/02699050903508226; Hopkins K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h824; Institute of Medicine (IOM) and National Research Council (NRC), 2013, SPORTS RELATED CONCU; Irwin DE, 2010, QUAL LIFE RES, V19, P595, DOI 10.1007/s11136-010-9619-3; Katon WJ, 2010, NEW ENGL J MED, V363, P2611, DOI 10.1056/NEJMoa1003955; Kaye AJ, 2010, J TRAUMA, V68, P1396, DOI 10.1097/TA.0b013e3181cf7d1b; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Max JE, 2014, PSYCHIAT CLIN N AM, V37, P125, DOI 10.1016/j.psc.2013.11.003; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Pangilinan PH, 2010, PM&R, V2, P1127, DOI 10.1016/j.pmrj.2010.07.007; Peterson RL, 2013, J HEAD TRAUMA REHAB, V28, pE1, DOI 10.1097/HTR.0b013e318263f5ba; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Richardson LP, 2014, JAMA-J AM MED ASSOC, V312, P809, DOI 10.1001/jama.2014.9259; Richardson LP, 2012, PEDIATRICS, V130, pE1541, DOI 10.1542/peds.2012-0450; Riley WT, 2010, QUAL LIFE RES, V19, P1311, DOI 10.1007/s11136-010-9694-5; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P313, DOI 10.1097/HTR.0b013e3182915cb5; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Vargas G, 2015, J ATHL TRAINING, V50, P250, DOI 10.4085/1062-6050-50.3.02; Varni James W, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P705, DOI 10.1586/14737167.5.6.705; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick D, 2014, JAMA PEDIATR, V168, P532, DOI 10.1001/jamapediatrics.2013.4784; Zatzick D, 2013, ANN SURG, V257, P390, DOI 10.1097/SLA.0b013e31826bc313; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	49	50	50	0	18	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2016	138	4							e20160459	10.1542/peds.2016-0459			11	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	DX3ZT	WOS:000384317700022		Green Published			2022-02-06	
J	Erturk, A; Mentz, S; Stout, EE; Hedehus, M; Dominguez, SL; Neumaier, L; Krammer, F; Llovera, G; Srinivasan, K; Hansen, DV; Liesz, A; Scearce-Levie, KA; Sheng, M				Ertuerk, Ali; Mentz, Susanne; Stout, Erik E.; Hedehus, Maj; Dominguez, Sara L.; Neumaier, Lisa; Krammer, Franziska; Llovera, Gemma; Srinivasan, Karpagam; Hansen, David V.; Liesz, Arthur; Scearce-Levie, Kimberly A.; Sheng, Morgan			Interfering with the Chronic Immune Response Rescues Chronic Degeneration After Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						3D imaging; axon; degeneration; inflammation; spine; trauma	FRACTALKINE RECEPTOR CX(3)CR1; SPINAL-CORD-INJURY; DENDRITIC SPINES; UNITED-STATES; NITRIC-OXIDE; CELL-DEATH; MICROGLIA; INFLAMMATION; COMPLEMENT; DAMAGE	After traumatic brain injury (TBI), neurons surviving the initial insult can undergo chronic (secondary) degeneration via poorly understood mechanisms, resulting in long-term cognitive impairment. Although a neuroinflammatory response is promptly activated after TBI, it is unknown whether it has a significant role in chronic phases of TBI (> 1 year after injury). Using a closed-head injury model of TBI in mice, we showed by MRI scans that TBI caused substantial degeneration at the lesion site within a few weeks and these did not expand significantly thereafter. However, chronic alterations in neurons were observed, with reduced dendritic spine density lasting > 1 year after injury. In parallel, we found a long-lasting inflammatory response throughout the entire brain. Deletion of one allele of CX(3)CR1, a chemokine receptor, limited infiltration of peripheral immune cells and largely prevented the chronic degeneration of the injured brain and provided a better functional recovery in female, but not male, mice. Therefore, targeting persistent neuroinflammation presents a new therapeutic option to reduce chronic neurodegeneration.	[Ertuerk, Ali; Mentz, Susanne; Neumaier, Lisa; Krammer, Franziska; Llovera, Gemma; Liesz, Arthur] Ludwig Maximilian Univ Munich, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany; [Ertuerk, Ali; Liesz, Arthur] Munich Cluster Syst Neurol SyNergy, D-81377 Munich, Germany; [Ertuerk, Ali; Liesz, Arthur] Grad Sch Neurosci Munich, D-82152 Planegg Martinsried, Germany; [Ertuerk, Ali; Stout, Erik E.; Hedehus, Maj; Dominguez, Sara L.; Srinivasan, Karpagam; Hansen, David V.; Scearce-Levie, Kimberly A.; Sheng, Morgan] Genentech Inc, Dept Neurosci, San Francisco, CA 94080 USA		Erturk, A (corresponding author), Ludwig Maximilian Univ Munich, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany.	Ali.Ertuerk@med.uni-muenchen.de	Liesz, Arthur/AAT-7147-2021	Liesz, Arthur/0000-0002-9069-2594; Sheng, Morgan/0000-0002-8703-5366; Hansen, David/0000-0001-9679-7189; Llovera, Gemma/0000-0002-7509-7500			Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Denes A, 2008, J CEREBR BLOOD F MET, V28, P1707, DOI 10.1038/jcbfm.2008.64; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; Erturk A, 2014, JOVE-J VIS EXP, DOI 10.3791/51382; Erturk A, 2014, J NEUROSCI, V34, P1672, DOI 10.1523/JNEUROSCI.3121-13.2014; Erturk A, 2012, NAT PROTOC, V7, P1983, DOI 10.1038/nprot.2012.119; Erturk A, 2012, NAT MED, V18, P166, DOI 10.1038/nm.2600; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Jeong Hey-Kyeong, 2013, Exp Neurobiol, V22, P59, DOI 10.5607/en.2013.22.2.59; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Liesz A, 2011, BRAIN, V134, P704, DOI 10.1093/brain/awr008; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lourbopoulos A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00054; Luong TN, 2011, JOVE-J VIS EXP, DOI 10.3791/2376; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Masel BE, 2012, J NEUROTRAUM, V29, P2143, DOI 10.1089/neu.2011.2258; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mionnet C, 2010, NAT MED, V16, P1305, DOI 10.1038/nm.2253; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; RINK A, 1995, AM J PATHOL, V147, P1575; Rogers JT, 2011, J NEUROSCI, V31, P16241, DOI 10.1523/JNEUROSCI.3667-11.2011; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Sheridan GK, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.130181; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078	80	50	50	0	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 21	2016	36	38					9962	9975		10.1523/JNEUROSCI.1898-15.2016			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EC3AC	WOS:000387995300020	27656033	Bronze, Green Published			2022-02-06	
J	Buckley, TA; Munkasy, BA; Clouse, BP				Buckley, Thomas A.; Munkasy, Barry A.; Clouse, Brandy P.			Acute Cognitive and Physical Rest May Not Improve Concussion Recovery Time	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rest; concussion; mild traumatic brain injury; physical rest; recovery	SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; ERROR SCORING SYSTEM; HIGH-SCHOOL; NCAA CONCUSSION; HEAD-INJURY; BED REST; SYMPTOMS; PERFORMANCE; MANAGEMENT	Objective: To evaluate the effectiveness of an acute period of cognitive and physical rest on concussion. Participants: Fifty consecutive patients with a diagnosis of concussions. Design: Participants were evaluated before (n = 25) and after (n = 25) a policy change that incorporated cognitive and physical rest. Patients in the rest group were withheld from activities, including classes, for the remainder of the injury day and the following day, whereas patients in the no-rest group were not provided any postinjury accommodations. Main Measures: Patients were evaluated on a graded symptom checklist, Balance Error Scoring System, Standard Assessment of Concussion, and computerized neuropsychological tests. The number of days until each test achieved baseline values was compared between groups with independent-samples t test. Results: The no-rest group achieved asymptomatic status sooner than the rest group (5.2 +/- 2.9 days and 3.9 +/- 1.9 days, respectively; P = .047). There were no differences between groups for time to baseline values on the Balance Error Scoring System, Standard Assessment of Concussion, computerized neuropsychological tests, or time to clinical recovery. Conclusion: A prescribed day of cognitive and physical rest was not effective in reducing postconcussion recovery time. These results agree with a previous study and suggest that light activity postconcussion may not be deleterious to the concussion recovery process.	[Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, 541 South Coll Ave, Newark, DE 19716 USA; [Munkasy, Barry A.] Georgia Southern Univ, Sch Hlth & Kinesiol, Statesboro, GA USA; [Clouse, Brandy P.] Georgia Southern Univ, Dept Intercollegiate Athlet, Statesboro, GA USA		Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, Human Performance Lab 144, 541 South Coll Ave, Newark, DE 19716 USA.	TBuckley@UDel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS070744]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS070744] Funding Source: NIH RePORTER	This project was funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (1R15NS070744). The funding agency had no role in the development of the manuscript or the decision to submit to the Journal of Head Trauma Rehabilitation.	Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; Berlin AA, 2006, PSYCHOSOM MED, V68, P224, DOI 10.1097/01.psy.0000204628.73273.23; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Crane AT, 2012, RESTOR NEUROL NEUROS, V30, P325, DOI 10.3233/RNN-2012-120232; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grady MF, 2012, PEDIATR ANN, V41, P377, DOI 10.3928/00904481-20120827-12; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Herring SA, 2011, MED SCI SPORTS EXERC, V43, P2412; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; LOGAN K, 2009, ATHLETIC TRAINING SP, V1, P251; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Ouyang L, 2011, NEURAL REGEN RES, V6, P2617, DOI 10.3969/j.issn.1673-5374.2011.33.010; Rahn C, 2015, CLIN J SPORT MED, V25, P248, DOI 10.1097/JSM.0000000000000141; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Reynolds Erin, 2014, Neurosurgery, V75 Suppl 4, pS71, DOI 10.1227/NEU.0000000000000471; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Smorawinski J, 2001, J APPL PHYSIOL, V91, P249, DOI 10.1152/jappl.2001.91.1.249; Solomon GS, 2007, J NEUROPSYCH CLIN N, V19, P195, DOI 10.1176/appi.neuropsych.19.2.195; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Wood RL, 2011, BRAIN INJURY, V25, P1296, DOI 10.3109/02699052.2011.624569	46	50	50	1	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2016	31	4					233	241		10.1097/HTR.0000000000000165			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DR3FW	WOS:000379789000008	26394292	Green Accepted			2022-02-06	
J	Fino, PC				Fino, Peter C.			A preliminary study of longitudinal differences in local dynamic stability between recently concussed and healthy athletes during single and dual-task gait	JOURNAL OF BIOMECHANICS			English	Article						Concussion; Brain injury; Gait; Local dynamic stability; Lyapunov exponents; MTBI	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; BALANCE CONTROL; LYAPUNOV EXPONENTS; NONLINEAR DYNAMICS; DIVIDED ATTENTION; VARIABILITY; WALKING; LOCOMOTOR; ABNORMALITIES	Concussed individuals commonly exhibit locomotor deficits during dual-task gait that can last substantially longer than clinical signs and symptoms. Previous studies have examined traditional stability measures, but nonlinear stability may offer further information about the health of the motor control system post-concussion. For up to one year post-concussion, this study longitudinally examined the local dynamic stability of five concussed athletes and four matched healthy controls during single- and dual-task gait. Local dynamic stability (LDS) was estimated using short-term, finite-time maximum Lyapunov exponents calculated from tri-axial accelerometers placed on the trunk and head. No main effects of group or task were found for LDS or stride time variability, but significant group*task interactions were apparent for trunk stability and stride time variability. Concussed individuals exhibited decreased trunk LDS and increased stride time variability during dual-task walking compared to matched controls despite similar single-task stability and variability. These preliminary results reinforce previous reports that concussions persistently affect dual-task processes even when single-tasks may be unaffected. Furthermore, the decreased local dynamic stability during dual-task gait indicates the concussed group attenuated local disturbances less than their healthy teammates. The decreased dynamic stability during dual-task activities was present after the athletes were cleared for competition and may be a contributing factor in the higher rates of musculoskeletal injuries in athletes post-concussion. (C) 2016 Elsevier Ltd. All rights reserved.	[Fino, Peter C.] Virginia Polytech Inst & State Univ, Dept Mech Engn, Blacksburg, VA 24061 USA		Fino, PC (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97201 USA.	fino@ohsu.edu		Fino, Peter/0000-0002-8621-3706	National Science FoundationNational Science Foundation (NSF) [DGE0822220]	The authors would like to thank Dr. Thurmon Lockhart, Dr. Maury Nussbaum, and Dr. Gunnar Brolinson for general guidance throughout the study, and Lauren Becker and Brett Griesemer for contributing to data collection. This research was funded by a National Science Foundation Graduate Research Fellowship (Grant No. DGE0822220). Opinions, findings, and conclusions do not reflect the views of the NSF.	Barth A.T., 2009, P 6 INT WORKSH WEAR; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Bruijn SM, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0999; Bruijn SM, 2012, MED ENG PHYS, V34, P428, DOI 10.1016/j.medengphy.2011.07.024; Bruijn SM, 2009, J BIOMECH, V42, P1506, DOI 10.1016/j.jbiomech.2009.03.047; Bruijn SM, 2009, J NEUROSCI METH, V178, P327, DOI 10.1016/j.jneumeth.2008.12.015; Buckley T.A., 2016, J SPORT HLT IN PRESS; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Buzzi UH, 2003, CLIN BIOMECH, V18, P435, DOI 10.1016/S0268-0033(03)00029-9; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Chiu SL, 2013, GAIT POSTURE, V38, P717, DOI 10.1016/j.gaitpost.2013.03.010; Cossette I, 2014, ARCH PHYS MED REHAB, V95, P1594, DOI 10.1016/j.apmr.2014.03.019; Cross M, 2015, BR J SPORTS MED; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Dingwell JB, 2006, J BIOMECH, V39, P444, DOI 10.1016/j.jbiomech.2004.12.014; Dingwell JB, 2000, CHAOS, V10, P848, DOI 10.1063/1.1324008; Dingwell JB, 2008, J NEUROENG REHABIL, V5, DOI 10.1186/1743-0003-5-12; England SA, 2007, GAIT POSTURE, V25, P172, DOI 10.1016/j.gaitpost.2006.03.003; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lockhart T, 2008, ERGONOMICS, V51, P1860, DOI 10.1080/00140130802567079; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Powers KC, 2014, GAIT POSTURE, V39, P728, DOI 10.1016/j.gaitpost.2013.10.005; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; ROSENSTEIN MT, 1993, PHYSICA D, V65, P117, DOI 10.1016/0167-2789(93)90009-P; Sinopoli KJ, 2014, J NEUROTRAUM, V31, P1843, DOI 10.1089/neu.2014.3326; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Sloot LH, 2011, ANN BIOMED ENG, V39, P1563, DOI 10.1007/s10439-010-0240-y; Soangra R, 2013, ANN BIOMED ENG, V41, P795, DOI 10.1007/s10439-012-0701-6; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Stergiou N, 2011, HUM MOVEMENT SCI, V30, P869, DOI 10.1016/j.humov.2011.06.002; TENENBAUM G, 1993, HDB RES SPORT PSYCHO, P171; Toebes MJP, 2012, GAIT POSTURE, V36, P527, DOI 10.1016/j.gaitpost.2012.05.016; van Schooten KS, 2014, GAIT POSTURE, V39, P695, DOI 10.1016/j.gaitpost.2013.09.020; van Schooten KS, 2013, J BIOMECH, V46, P137, DOI 10.1016/j.jbiomech.2012.10.032; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720	49	50	50	0	31	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUN 14	2016	49	9					1983	1988		10.1016/j.jbiomech.2016.05.004			6	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	DO4DE	WOS:000377731200079	27207386	Bronze			2022-02-06	
J	Pham, PV; Truong, NC; Le, PTB; Tran, TDX; Vu, NB; Bui, KHT; Phan, NK				Phuc Van Pham; Nhat Chau Truong; Phuong Thi-Bich Le; Tung Dang-Xuan Tran; Ngoc Bich Vu; Khanh Hong-Thien Bui; Ngoc Kim Phan			Isolation and proliferation of umbilical cord tissue derived mesenchymal stem cells for clinical applications	CELL AND TISSUE BANKING			English	Article						Activated platelet rich plasma; Clinical application of mesenchymal stem cells; Umbilical cord; Umbilical cord derived mesenchymal stem cells; Good manufacturing practice; UC-MSCs	SYSTEMIC-LUPUS-ERYTHEMATOSUS; PLATELET-RICH PLASMA; FETAL BOVINE SERUM; TRAUMATIC BRAIN-INJURY; STROMAL CELLS; LIVER-FUNCTION; BONE-MARROW; BLOOD-SERUM; TRANSPLANTATION; EXPANSION	Umbilical cord (UC) is a rich source of rapidly proliferating mesenchymal stem cells (MSCs) that are easily cultured on a large-scale. Clinical applications of UC-MSCs include graft-versus-host disease, and diabetes mellitus types 1 and 2. UC-MSCs should be isolated and proliferated according to good manufacturing practice (GMP) with animal component-free medium, quality assurance, and quality control for their use in clinical applications. This study developed a GMP standard protocol for UC-MSC isolation and culture. UC blood and UC were collected from the same donors. Blood vasculature was removed from UC. UC blood was used as a source of activated platelet rich plasma (aPRP). Small fragments (1-2 mm(2)) of UC membrane and Wharton's jelly were cut and cultured in DMEM/F12 medium containing 1 % antibiotic-antimycotic, aPRP (2.5, 5, 7.5 and 10 %) at 37 A degrees C in 5 % CO2. The MSC properties of UC-MSCs at passage 5 such as osteoblast, chondroblast and adipocyte differentiation, and markers including CD13, CD14, CD29, CD34, CD44, CD45, CD73, CD90, CD105, and HLA-DR were confirmed. UC-MSCs also were analyzed for karyotype, expression of tumorigenesis related genes, cell cycle, doubling time as well as in vivo tumor formation in NOD/SCID mice. Control cells consisted of UC-MSCs cultured in DMEM/F12 plus 1 % antibiotic-antimycotic, and 10 % fetal bovine serum (FBS). All UC-MSC (n = 30) samples were successfully cultured in medium containing 7.5 and 10 % aPRP, 92 % of samples grew in 5.0 % aPRP, 86 % of samples in 2.5 % aPRP, and 72 % grew in 10 % FBS. UC-MSCs in these four groups exhibited similar marker profiles. Moreover, the proliferation rates in medium with PRP, especially 7.5 and 10 %, were significantly quicker compared with 2.5 and 5 % aPRP or 10 % FBS. These cells maintained a normal karyotype for 15 sub-cultures, and differentiated into osteoblasts, chondroblasts, and adipocytes. The analysis of pluripotent cell markers showed UC-MSCs maintained the expression of the oncogenes Nanog and Oct4 after long term culture but failed to transfer tumors in NOD/SCID mice. Replacing FBS with aPRP in the culture medium for UC tissues allowed the successful isolation of UC-MSCs that satisfy the minimum standards for clinical applications.	[Phuc Van Pham; Nhat Chau Truong; Ngoc Bich Vu; Ngoc Kim Phan] Vietnam Natl Univ, Univ Sci, Lab Stem Cell Res & Applicat, Ho Chi Minh City, Vietnam; [Phuong Thi-Bich Le; Tung Dang-Xuan Tran] Van Hanh Hosp, Van Hanh Stem Cell Unit, Ho Chi Minh City, Vietnam; [Khanh Hong-Thien Bui] Univ Med & Pharm, Univ Med Ctr, Ho Chi Minh City, Vietnam		Pham, PV (corresponding author), Vietnam Natl Univ, Univ Sci, Lab Stem Cell Res & Applicat, Ho Chi Minh City, Vietnam.	pvphuc@hcmuns.edu.vn; tcnhat@hcmus.edu.vn; drbphuong@gmail.com; drxuantung@gmail.com; vbngoc@hcmus.edu.vn; khanhbui1969@yahoo.com; pvphuc@hcmus.edu.vn	Van Pham, Phuc/L-6131-2013; tdx, tung/T-8246-2019; Truong, Nhat/AAH-4931-2021	Van Pham, Phuc/0000-0001-7254-0717; Truong, Nhat/0000-0001-5866-9506; DANG XUAN TRAN, TUNG/0000-0001-5723-2505	Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [DTDL.2012-G/23]	This research was funded by Ministry of Science and Technology via project Grant No. DTDL.2012-G/23.	Baba K, 2013, J CRANIO MAXILL SURG, V41, P775, DOI 10.1016/j.jcms.2013.01.025; Badraiq Heba, 2015, Methods Mol Biol, V1283, P65, DOI 10.1007/7651_2014_116; Bieback K, 2009, STEM CELLS, V27, P2331, DOI 10.1002/stem.139; Blande IS, 2009, TRANSFUSION, V49, P2680, DOI 10.1111/j.1537-2995.2009.02346.x; Buyl K, 2015, TOXICOL IN VITRO, V29, P1254, DOI 10.1016/j.tiv.2014.12.008; Chen Guang-hua, 2012, Zhonghua Xue Ye Xue Za Zhi, V33, P303; Cheng HB, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0253-7; Ding DC, 2015, CELL TRANSPLANT, V24, P339, DOI 10.3727/096368915X686841; Ding Y, 2013, IN VITRO CELL DEV-AN, V49, P771, DOI 10.1007/s11626-013-9663-8; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Escobedo-Lucea C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067870; Fekete N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043255; Gu F, 2014, CLIN RHEUMATOL, V33, P1611, DOI 10.1007/s10067-014-2754-4; Han DM, 2011, CYTOTHERAPY, V13, P913, DOI 10.3109/14653249.2011.579958; Iftimia-Mander A, 2013, BIOPRESERV BIOBANK, V11, P291, DOI 10.1089/bio.2013.0027; Jiang YJ, 2013, CELL TRANSPLANT, V22, P2291, DOI 10.3727/096368912X658818; Jin JL, 2013, CURR NEUROVASC RES, V10, P11, DOI 10.2174/156720213804805936; Jonsdottir-Buch SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068984; Kim JW, 2004, ANN HEMATOL, V83, P733, DOI 10.1007/s00277-004-0918-z; Kocaoemer A, 2007, STEM CELLS, V25, P1270, DOI 10.1634/stemcells.2006-0627; Kong DX, 2014, CLIN LAB, V60, P1969, DOI 10.7754/Clin.Lab.2014.140305; Lee JY, 2011, IN VITRO CELL DEV-AN, V47, P157, DOI 10.1007/s11626-010-9364-5; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Liu J, 2013, CYTOTHERAPY, V15, P185, DOI 10.1016/j.jcyt.2012.09.005; Lv YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-196; Ma HY, 2012, CELL TRANSPLANT, V21, P857, DOI 10.3727/096368911X612486; Mareschi K, 2001, HAEMATOLOGICA, V86, P1099; Marx RE, 2004, J ORAL MAXIL SURG, V62, P489, DOI 10.1016/j.joms.2003.12.003; Mori Y, 2015, TISSUE ENG PART C-ME, V21, P367, DOI [10.1089/ten.tec.2014.0385, 10.1089/ten.TEC.2014.0385]; Murphy MB, 2012, BIOMATERIALS, V33, P5308, DOI 10.1016/j.biomaterials.2012.04.007; Nascimento DS, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt394; Otte A, 2013, TISSUE ENG PART C-ME, V19, P937, DOI [10.1089/ten.tec.2013.0007, 10.1089/ten.TEC.2013.0007]; Peng WJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0034-0; Phuc PV, 2012, CELL TISSUE BANK, V13, P341, DOI 10.1007/s10561-011-9262-4; Pham PV, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-56; Pineault N, 2015, EXP HEMATOL, V43, P498, DOI 10.1016/j.exphem.2015.04.011; Rauch C, 2011, ALTEX-ALTERN ANIM EX, V28, P305, DOI 10.14573/altex.2011.4.305; Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21-1-105; Shetty P, 2007, CELL BIOL INT, V31, P293, DOI 10.1016/j.cellbi.2006.11.010; Shi DY, 2012, CLIN RHEUMATOL, V31, P841, DOI 10.1007/s10067-012-1943-2; Shi M, 2012, STEM CELL TRANSL MED, V1, P725, DOI 10.5966/sctm.2012-0034; Sun LY, 2010, ARTHRITIS RHEUM-US, V62, P2467, DOI 10.1002/art.27548; Van Pham Phuc, 2015, Methods Mol Biol, V1283, P73, DOI 10.1007/7651_2014_125; Wang DD, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4520; Wang DD, 2013, CELL TRANSPLANT, V22, P2267, DOI [10.3727/096368911X582769c, 10.3727/096368911X582769]; Wang LF, 2013, J GASTROEN HEPATOL, V28, P85, DOI 10.1111/jgh.12029; Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001; Woodworth TG, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4677; Wu KH, 2013, CELL TRANSPLANT, V22, P2041, DOI 10.3727/096368912X663533; Wu KH, 2013, TRANSPLANTATION, V95, P773, DOI 10.1097/TP.0b013e31827a93dd; Zhang H, 2012, CELL BIOCHEM FUNCT, V30, P643, DOI 10.1002/cbf.2843; Zhang Z, 2012, J GASTROEN HEPATOL, V27, P112, DOI 10.1111/j.1440-1746.2011.07024.x	52	50	52	0	27	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1389-9333	1573-6814		CELL TISSUE BANK	Cell Tissue Banking	JUN	2016	17	2					289	302		10.1007/s10561-015-9541-6			14	Cell Biology; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Engineering	DN3UD	WOS:000376988400014	26679929				2022-02-06	
J	Zanier, ER; Marchesi, F; Ortolano, F; Perego, C; Arabian, M; Zoerle, T; Sammali, E; Pischiutta, F; De Simoni, MG				Zanier, Elisa R.; Marchesi, Federica; Ortolano, Fabrizio; Perego, Carlo; Arabian, Maedeh; Zoerle, Tommaso; Sammali, Eliana; Pischiutta, Francesca; De Simoni, Maria-Grazia			Fractalkine Receptor Deficiency Is Associated with Early Protection but Late Worsening of Outcome following Brain Trauma in Mice	JOURNAL OF NEUROTRAUMA			English	Article						fractalkine receptor; inflammation; macrophages; microglia; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; ANTIINFLAMMATORY CYTOKINES; MICROGLIAL ACTIVATION; WHITE-MATTER; MOUSE MODEL; CX(3)CR1; INFLAMMATION; DISEASE	An impaired ability to regulate microglia activation by fractalkine (CX3CL1) leads to microglia chronic sub-activation. How this condition affects outcome after acute brain injury is still debated, with studies showing contrasting results depending on the timing and the brain pathology. Here, we investigated the early and delayed consequences of fractalkine receptor (CX3CR1) deletion on neurological outcome and on the phenotypical features of the myeloid cells present in the lesions of mice with traumatic brain injury (TBI). Wild type (WT) and CX3CR1(-/-) C57Bl/6 mice were subjected to sham or controlled cortical impact brain injury. Outcome was assessed at 4 days and 5 weeks after TBI by neuroscore, neuronal count, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Compared with WT mice, CX3CR1(-/-) TBI mice showed a significant reduction of sensorimotor deficits and lower cellular damage in the injured cortex 4 days post-TBI. Conversely, at 5 weeks, they showed a worsening of sensorimotor deficits and pericontusional cell death. Microglia (M) and macrophage () activation and polarization were assessed by quantitative immunohistochemistry for CD11b, CD68, Ym1, and inducible nitric oxide synthase (iNOS)markers of M/ activation, phagocytosis, M2, and M1 phenotypes, respectively. Morphological analysis revealed a decreased area and perimeter of CD11b(+) cells in CX3CR1(-/-) mice at 4 days post-TBI, whereas, at 5 weeks, both parameters were significantly higher, compared with WT mice. At 4 days, CX3CR1(-/-) mice showed significantly decreased CD68 and iNOS immunoreactivity, while at 5 weeks post-injury, they showed a selective increase of iNOS. Gene expression on CD11b(+) sorted cells revealed an increase of interleukin 10 and insulin-like growth factor 1 (IGF1) at 1 day and a decrease of IGF1 4 days and 5 weeks post-TBI in CX3CR1(-/-), compared with WT mice. These data show an early protection followed by a chronic exacerbation of TBI outcome in the absence of CX3CR1. Thus, longitudinal effects of myeloid cell manipulation at different stages of pathology should be investigated to understand how and when their modulation may offer therapeutic chances.	[Zanier, Elisa R.; Marchesi, Federica; Perego, Carlo; Arabian, Maedeh; Sammali, Eliana; Pischiutta, Francesca; De Simoni, Maria-Grazia] IRCCS Ist Recerche Farmacol Mario Negri, Dept Neurosci, Milan, Italy; [Ortolano, Fabrizio; Zoerle, Tommaso] Osped Maggiore Policlin, Neurosci ICU, Fdn IRCCS Ca Granda, Milan, Italy; [Arabian, Maedeh] Univ Tehran Med Sci, Dept Physiol, Fac Med, Tehran, Iran; [Sammali, Eliana] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy; [Marchesi, Federica] Univ Milan, Div Med 3, Osped San Paolo, Dipartimiento Szienze Salute, Milan, Italy		Zanier, ER (corresponding author), IRCCS Mario Negri Inst, Dept Neurosci, I-20154 Milan, Italy.	elisa.zanier@marionegri.it	De Simoni, Maria Grazia/I-6021-2012; Pischiutta, Francesca/AAA-7927-2020; Perego, Carlo/AAA-6513-2020; Sammali, Eliana/AAA-2464-2019; Zanier, Elisa/AAA-8095-2020; arabian, maedeh/AAZ-2614-2020	De Simoni, Maria Grazia/0000-0001-6695-5297; Pischiutta, Francesca/0000-0002-7151-0812; Perego, Carlo/0000-0002-0259-0003; Zanier, Elisa/0000-0002-3011-8718; Zoerle, Tommaso/0000-0001-8713-8085; Ortolano, Fabrizio/0000-0003-1996-948X			Amantea D, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00147; Amantea D, 2010, BRAIN RES, V1313, P259, DOI 10.1016/j.brainres.2009.12.017; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Blomster LV, 2013, EXP NEUROL, V247, P226, DOI 10.1016/j.expneurol.2013.05.002; Briones TL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-13; Cardona AE, 2008, BLOOD, V112, P256, DOI 10.1182/blood-2007-10-118497; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Cho SH, 2011, J BIOL CHEM, V286, P32713, DOI 10.1074/jbc.M111.254268; Cipriani R, 2011, J NEUROSCI, V31, P16327, DOI 10.1523/JNEUROSCI.3611-11.2011; Cohen M, 2014, EMBO J, V33, P2906, DOI 10.15252/embj.201489293; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Cunningham CL, 2013, J NEUROSCI, V33, P4216, DOI 10.1523/JNEUROSCI.3441-12.2013; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Denes A, 2008, J CEREBR BLOOD F MET, V28, P1707, DOI 10.1038/jcbfm.2008.64; Denes A, 2007, J CEREBR BLOOD F MET, V27, P1941, DOI 10.1038/sj.jcbfm.9600495; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Fuhrmann M, 2010, NAT NEUROSCI, V13, P411, DOI 10.1038/nn.2511; Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Garcia JA, 2013, J IMMUNOL, V191, P1063, DOI 10.4049/jimmunol.1300040; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Gosselin D, 2014, CELL, V159, P1327, DOI 10.1016/j.cell.2014.11.023; Grizenkova J, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-44; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Karlstrom S, 2013, J MED CHEM, V56, P3177, DOI 10.1021/jm3012273; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; Lastres-Becker I, 2014, BRAIN, V137, P78, DOI 10.1093/brain/awt323; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longhi L, 2014, CRIT CARE MED, V42, P1910, DOI 10.1097/CCM.0000000000000399; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; McWhorter FY, 2013, P NATL ACAD SCI USA, V110, P17253, DOI 10.1073/pnas.1308887110; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Prinz M, 2010, J NEUROIMMUNOL, V224, P80, DOI 10.1016/j.jneuroim.2010.05.015; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rogers JT, 2011, J NEUROSCI, V31, P16241, DOI 10.1523/JNEUROSCI.3667-11.2011; Rojo AI, 2014, ANTIOXID REDOX SIGN, V21, P1766, DOI 10.1089/ars.2013.5745; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Soriano SG, 2002, J NEUROIMMUNOL, V125, P59, DOI 10.1016/S0165-5728(02)00033-4; Tang ZW, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-26; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; Taylor SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097096; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Ueno M, 2013, NAT NEUROSCI, V16, P543, DOI 10.1038/nn.3358; Vitkovic L, 2001, NEUROIMMUNOMODULAT, V9, P295, DOI 10.1159/000059387; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wolf Y, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00026; Wollberg AR, 2014, P NATL ACAD SCI USA, V111, P5409, DOI 10.1073/pnas.1316510111; Zanier Elisa R, 2015, Intensive Care Med Exp, V3, P39, DOI 10.1186/s40635-015-0039-0; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	64	50	52	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2016	33	11					1060	1072		10.1089/neu.2015.4041			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DN3SU	WOS:000376984600010	26180940	Green Published			2022-02-06	
J	Terwilliger, VK; Pratson, L; Vaughan, CG; Gioia, GA				Terwilliger, Virginia K.; Pratson, Lincoln; Vaughan, Christopher G.; Gioia, Gerard A.			Additional Post-Concussion Impact Exposure May Affect Recovery in Adolescent Athletes	JOURNAL OF NEUROTRAUMA			English	Article						concussion; athletes; mTBI; brain injury	HEAD-INJURY; VULNERABILITY; WINDOW	Repeat concussion has been associated with risk for prolonged and pronounced clinical recovery in athletes. In this study of adolescent athletes, we examined whether an additional head impact within 24 h of a sports-related concussion (SRC) is associated with higher symptom burden and prolonged clinical recovery compared with a single-injury group. Forty-two student-athletes (52% male, mean age = 14.9 years) diagnosed with an SRC in a concussion clinic were selected for this study: (1) 21 athletes who sustained an additional significant head impact within 24 h of the initial injury (additional-impact group); (2) 21 single-injury athletes, age and gender matched, who sustained only one discrete concussive blow to the head (single-injury group). Groups did not differ on initial injury characteristics or pre-injury risk factors. The effect of injury status (single- vs. additional-impact) was examined on athlete- and parent-reported symptom burden (at first clinic visit) and length of recovery (LOR). Higher symptom burden was reported by the athletes and parents in the additional-impact group at the time of first visit. The additional-impact group also had a significantly longer LOR compared with the single-injury group. These findings provide preliminary, hypothesis-generating evidence for the importance of immediate removal from play following an SRC to protect athletes from re-injury, which may worsen symptoms and prolong recovery. The retrospective study design from a specialized clinical sample points to the need for future prospective studies of the relationship between single- and additional-impact injuries on symptom burden and LOR.	[Terwilliger, Virginia K.; Vaughan, Christopher G.; Gioia, Gerard A.] Childrens Natl Hlth Syst, Div Pediat Neuropsychol, Washington, DC USA; [Pratson, Lincoln] E Carolina Univ, Brody Sch Med, Greenville, NC USA; [Vaughan, Christopher G.; Gioia, Gerard A.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA; [Terwilliger, Virginia K.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, 446 East Ontario,7-200, Chicago, IL 60611 USA		Terwilliger, VK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, 446 East Ontario,7-200, Chicago, IL 60611 USA.	virginia.k.terwilliger@gmail.com			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P30/HDO40677-07, U17/CCU323352] Funding Source: Medline; NCIPC CDC HHS [U49CE001385] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE001385] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER		Bompadre V, 2014, J ATHL TRAINING, V49, P486, DOI 10.4085/1062-6050-49.3.30; Cohen J., 2013, STAT POWER ANAL BEHA; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Gioia G, 2006, ACUTE CONCUSSION EVA; Gioia G, 2012, POSTCONCUSSION SYMPT; Gioia GA, 2015, BRAIN INJURY, V29, P195, DOI 10.3109/02699052.2014.965210; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Spicer M.A.C.M., 2014, SPORTS RELATED CONCU; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	14	50	50	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2016	33	8					761	765		10.1089/neu.2015.4082			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DJ0ZM	WOS:000373932900006	26421452	Green Published			2022-02-06	
J	Campbell, KR; Warnica, MJ; Levine, IC; Brooks, JS; Laing, AC; Burkhart, TA; Dickey, JP				Campbell, Kody R.; Warnica, Meagan J.; Levine, Iris C.; Brooks, Jeffrey S.; Laing, Andrew C.; Burkhart, Timothy A.; Dickey, James P.			Laboratory Evaluation of the gForce Tracker (TM), a Head Impact Kinematic Measuring Device for Use in Football Helmets	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; mTBI; Head acceleration; Head impact biomechanics; Impact monitoring; Helmet sensors	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; ACCELERATION; EPIDEMIOLOGY; DIRECTION; SYSTEM; RISK	This study sought to compare a new head impact-monitoring device, which is not limited to specific helmet styles, against reference accelerometer measurements. Laboratory controlled impacts were delivered using a linear pneumatic impactor to a Hybrid III headform (HIII) fitted with a football helmet and the impact monitoring device (gForce Tracker-GFT) affixed to the inside of the helmet. Linear regression analyses and absolute mean percent error (MAPE) were used to compare the head impact kinematics measured by the GFT to a reference accelerometer located at the HIII's center of mass. The coefficients of determination were strong for the peak linear acceleration, peak rotational velocity, and HIC15 across all impact testing locations (r (2) = 0.82, 0.94, and 0.70, respectively), but there were large MAPE for the peak linear acceleration and HIC15 (MAPE = 49 +/- A 21% and 108 +/- A 58%). The raw GFT was accurate at measuring the peak rotational velocity at the center of mass of the HIII (MAPE = 9%). Results from the impact testing were used to develop a correction algorithm. The coefficients of determination for all impact parameters improved using the correction algorithm for the GFT (r (2) > 0.97), and the MAPE were less than 14%. The GFT appears to be a suitable impact-monitoring device that is not limited to specific styles of football helmets, however, correction algorithms will need to be developed for each helmet style.	[Campbell, Kody R.; Brooks, Jeffrey S.; Dickey, James P.] Western Univ, Sch Kinesiol, Joint Biomech Lab, Thames Hall,1151 Richmond St, London, ON N6A 3K7, Canada; [Warnica, Meagan J.; Levine, Iris C.; Laing, Andrew C.] Univ Waterloo, Dept Kinesiol, Injury Biomech & Aging Lab, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada; [Burkhart, Timothy A.] Western Univ, Mech & Mat Engn, Thompson Engn Bldg,1151 Richmond St, London, ON N6A 5B9, Canada; [Campbell, Kody R.] Univ N Carolina, Dept Allied Hlth Sci, Stallings Evans Sports Med Ctr 2207, Campus Box 8700, Chapel Hill, NC 27599 USA		Campbell, KR (corresponding author), Univ N Carolina, Dept Allied Hlth Sci, Stallings Evans Sports Med Ctr 2207, Campus Box 8700, Chapel Hill, NC 27599 USA.	kcampb@live.unc.edu	Burkhart, Timothy/N-8261-2015; Dickey, James P/K-6776-2013	Burkhart, Timothy/0000-0001-6185-2395; Dickey, James P/0000-0002-4101-835X; Campbell, Kody/0000-0002-4534-5497	NSERC Engage Grant	The authors would like to thank Artaflex Inc. for providing the gForce Tracker equipment used in this study. The authors would also like to thank the efforts of Chris Withnall and Michael Wonnacott at Biokinetics & Associates, Ltd., Ottawa, Ontario, Canada, for their assistance and expertise during data collection. A NSERC Engage Grant supported this study. None of the authors have any financial interest in any of the systems used in this study.	Allison MA, 2014, ANN BIOMED ENG; [Anonymous], 2007, J2111 SAE; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cichos D., 2006, WORKGROUP DATA PROCE; Cobb B. R., 2014, P I MECH ENG P-J SPO; DiMasi F, 1995, TECHNICAL REPORT; GURDJIAN ES, 1961, SURG GYNECOL OBSTET, V113, P185; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; National Research Council, 2006, 08104M04 NAT COMM ST, P1; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Takhounts EG, 2008, STAPP CAR C, V52, P1; UNTERHARNSCHEIDT F, 1969, TEX REP BIOL MED, V27, P127; Versace J., 1971, REV SEVERITY INDEX, P771; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0	30	50	50	1	15	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	APR	2016	44	4					1246	1256		10.1007/s10439-015-1391-7			11	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	DI8HJ	WOS:000373741800035	26198174				2022-02-06	
J	Mondello, S; Shear, DA; Bramlett, HM; Dixon, CE; Schmid, KE; Dietrich, WD; Wang, KKW; Hayes, RL; Glushakova, O; Catania, M; Richieri, SP; Povlishock, JT; Tortella, FC; Kochanek, PM				Mondello, Stefania; Shear, Deborah A.; Bramlett, Helen M.; Dixon, C. Edward; Schmid, Kara E.; Dietrich, W. Dalton; Wang, Kevin K. W.; Hayes, Ronald L.; Glushakova, Olena; Catania, Michael; Richieri, Steven P.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.			Insight into Pre-Clinical Models of Traumatic Brain Injury Using Circulating Brain Damage Biomarkers: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						theranostic; fluid percussion injury; rat; ubiquitin carboxyl-terminal hydrolase-L1; penetrating ballistic-like brain injury; biomarkers; glial fibrillary acidic protein; Morris water maze; controlled cortical impact	BARRIER PERMEABILITY; BLOOD; FLUID; RAT; ERYTHROPOIETIN; BREAKDOWN; SEVERITY; MARKERS	Operation Brain Trauma Therapy (OBTT) is a multicenter pre-clinical drug screening consortium testing promising therapies for traumatic brain injury (TBI) in three well-established models of TBI in rats-namely, parasagittal fluid percussion injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI). This article presents unique characterization of these models using histological and behavioral outcomes and novel candidate biomarkers from the first three treatment trials of OBTT. Adult rats underwent CCI, FPI, or PBBI and were treated with vehicle (VEH). Shams underwent all manipulations except trauma. The glial marker glial fibrillary acidic protein (GFAP) and the neuronal marker ubiquitin C-terminal hydrolase (UCH-L1) were measured by enzyme-linked immunosorbent assay in blood at 4 and 24 h, and their delta 24-4 h was calculated for each marker. Comparing sham groups across experiments, no differences were found in the same model. Similarly, comparing TBI + VEH groups across experiments, no differences were found in the same model. GFAP was acutely increased in injured rats in each model, with significant differences in levels and temporal patterns mirrored by significant differences in delta 24-4 h GFAP levels and neuropathological and behavioral outcomes. Circulating GFAP levels at 4 and 24 h were powerful predictors of 21 day contusion volume and tissue loss. UCH-L1 showed similar tendencies, albeit with less robust differences between sham and injury groups. Significant differences were also found comparing shams across the models. Our findings (1) demonstrate that TBI models display specific biomarker profiles, functional deficits, and pathological consequence; (2) support the concept that there are different cellular, molecular, and pathophysiological responses to TBI in each model; and (3) advance our understanding of TBI, providing opportunities for a successful translation and holding promise for theranostic applications. Based on our findings, additional studies in pre-clinical models should pursue assessment of GFAP as a surrogate histological and/or theranostic end-point.	[Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Shear, Deborah A.; Schmid, Kara E.; Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Glushakova, Olena; Catania, Michael; Richieri, Steven P.] Banyan Biomarkers, Alachua, FL USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 Fifth Ave, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Mondello, Stefania/A-1813-2012; Glushakova, Olena/AAY-1130-2021	Mondello, Stefania/0000-0002-8587-3614; Glushakova, Olena/0000-0002-2109-3651; Wang, Kevin/0000-0002-9343-6473			Boutte AM, 2016, J NEUROTRAUM, V33, P147, DOI 10.1089/neu.2014.3672; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brouns R, 2010, CLIN CHEM, V56, P451, DOI 10.1373/clinchem.2009.134122; Browning M, 2016, J NEUROTRAUM, V33, P581, DOI 10.1089/neu.2015.4131; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; Lieutaud T, 2008, J NEUROTRAUM, V25, P1179, DOI 10.1089/neu.2008.0591; Luepker RV, 2003, CIRCULATION, V108, P2543, DOI 10.1161/01.CIR.0000100560.46946.EA; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mountney A, 2016, J NEUROTRAUM, V33, P567, DOI 10.1089/neu.2015.4130; PAKKENBERG B, 1988, J MICROSC-OXFORD, V150, P1, DOI 10.1111/j.1365-2818.1988.tb04582.x; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2011, J NEUROTRAUM, V28, P2185, DOI 10.1089/neu.2011.1916; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yokobori S, 2013, J NEUROSURG, V118, P370, DOI 10.3171/2012.10.JNS12725; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	31	50	50	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					595	605		10.1089/neu.2015.4132			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800008	26671651				2022-02-06	
J	Plesnila, N				Plesnila, Nikolaus			The immune system in traumatic brain injury	CURRENT OPINION IN PHARMACOLOGY			English	Article							BRADYKININ B-2 RECEPTOR; MICROGLIAL ACTIVATION; HEAD-INJURY; INFLAMMATORY RESPONSE; ADHESION MOLECULES; LEUKOCYTE ADHESION; TEMPORAL PROFILE; B1 PROTECTS; EDEMA; DAMAGE	Traumatic brain injury (TBI) is the major cause of death in children and young adults and one of the major reasons for long-term disability worldwide, however, no specific clinical treatment option could be established so far. This is surprising since it is well known that following the initial mechanical damage to the brain a plethora of delayed processes are activated which ultimately result in additional brain damage. Among these secondary mechanisms, acute and chronic activation of the innate and adaptive immune system is increasingly believed to play an important role for the pathogenesis of TBI. Understanding these processes may results in new, clinically applicable therapeutic options for TBI patients.	[Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Munich, Germany; [Plesnila, Nikolaus] Univ Munich, Med Ctr, Munich Cluster Syst Neurol Synergy, Munich, Germany		Plesnila, N (corresponding author), Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Munich, Germany.; Plesnila, N (corresponding author), Univ Munich, Med Ctr, Munich Cluster Syst Neurol Synergy, Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019	Plesnila, Nikolaus/0000-0001-8832-228X			Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Albert-Weissenberger C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00345; Albert-Weissenberger C, 2012, J CEREBR BLOOD F MET, V32, P1747, DOI 10.1038/jcbfm.2012.62; Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; AUER LM, 1979, ACTA NEUROCHIR, V49, P207, DOI 10.1007/BF01808960; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; Balk RA, 2014, VIRULENCE, V5, P20, DOI 10.4161/viru.27135; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Caielli S, 2012, CURR OPIN IMMUNOL, V24, P671, DOI 10.1016/j.coi.2012.09.008; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Estes ML, 2014, BRAIN PATHOL, V24, P623, DOI 10.1111/bpa.12198; Evans TA, 2014, EXP NEUROL, V254, P109, DOI 10.1016/j.expneurol.2014.01.013; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harris MG, 2014, SCI REP-UK, V4, DOI 10.1038/srep04422; Hartl R, 1997, ACT NEUR S, V70, P240; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Isaksson J, 2001, ACTA NEUROPATHOL, V102, P246; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Izzy S, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-013-0278-x; Jin Q, 2014, BRAIN BEHAV IMMUN, V40, P131, DOI 10.1016/j.bbi.2014.03.003; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Karve I.P., 2015, BR J PHARM; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kunz M, 2013, J NEUROTRAUM, V30, P1638, DOI 10.1089/neu.2012.2774; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Loane D.J., 2015, EXP NEUROL; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Lourbopoulos A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00054; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; McKeating EG, 1998, ACT NEUR S, V71, P200; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nourshargh S, 2014, IMMUNITY, V41, P694, DOI 10.1016/j.immuni.2014.10.008; Perdiguero EG, 2013, GLIA, V61, P112, DOI 10.1002/glia.22393; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Raslan F, 2010, J CEREBR BLOOD F MET, V30, P1477, DOI 10.1038/jcbfm.2010.28; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; REILLY PL, 1975, LANCET, V2, P375; Schulz J, 2000, ACT NEUR S, V76, P137; Schwarzmaier SM, 2015, J NEUROTRAUM, V32, P731, DOI 10.1089/neu.2014.3650; Schwarzmaier SM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-32; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; Villalba N, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001474; Warner DS, 2014, JAMA NEUROL, V71, P1311, DOI 10.1001/jamaneurol.2014.1238; Weaver KD, 2000, J TRAUMA, V48, P1081, DOI 10.1097/00005373-200006000-00014; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160; Wu Y, 2015, THROMB J, V13, DOI 10.1186/s12959-015-0048-y; Young LA, 2015, SEMIN NEUROL, V35, P5, DOI 10.1055/s-0035-1544242; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; Zweckberger K, 2009, NEUROSCI LETT, V454, P115, DOI 10.1016/j.neulet.2009.02.014	84	50	50	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4892	1471-4973		CURR OPIN PHARMACOL	Curr. Opin. Pharmacol.	FEB	2016	26						110	117		10.1016/j.coph.2015.10.008			8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	DC4RP	WOS:000369208300017	26613129				2022-02-06	
J	Kanaan, NM; Cox, K; Alvarez, VE; Stein, TD; Poncil, S; Mckee, AC				Kanaan, Nicholas M.; Cox, Kristine; Alvarez, Victor E.; Stein, Thor D.; Poncil, Sharra; Mckee, Ann C.			Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Alzheimer disease; Chronic traumatic encephalopathy; Dementia; Oligomers; Phosphatase-activating domain; Tauopathy; Traumatic brain injury	PROGRESSIVE SUPRANUCLEAR PALSY; DEPENDENT AXONAL-TRANSPORT; MILD COGNITIVE IMPAIRMENT; REPETITIVE HEAD-INJURY; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; BRAIN-INJURY; POTENTIAL TARGETS; CASPASE-CLEAVAGE; NEURODEGENERATIVE DISORDERS	Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy that develops after repetitive head injury. Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD). Additionally, phosphorylation at serine 422 in tau occurs early and correlates with cognitive decline in patients with Alzheimer disease (AD). We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of 9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each). All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE. Notably, the TauC3 epitope, which is abundant in AD, was relatively sparse in CTE. Together, these results provide the first description of PAD exposure, TOC1 reactive oligomers, phosphorylation of S422, and TauC3 truncation in the tau pathology of CTE.	[Kanaan, Nicholas M.; Cox, Kristine; Poncil, Sharra] Michigan State Univ, Coll Human Med, Dept Translat Sci & Mol Med, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA; [Kanaan, Nicholas M.] Mercy Hlth St Marys, Hauenstein Neurosci Ctr, Grand Rapids, MI USA; [Alvarez, Victor E.; Stein, Thor D.; Mckee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA; [Alvarez, Victor E.; Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, CTE Program, Alzheimers Dis Ctr, Boston, MA 02215 USA; [Stein, Thor D.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02215 USA		Kanaan, NM (corresponding author), Michigan State Univ, Coll Human Med, Dept Translat Sci & Mol Med, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	Nicholas.kanaan@hc.msu.edu	Kanaan, Nicholas M./J-3428-2016	Kanaan, Nicholas M./0000-0002-4362-2593; Stein, Thor/0000-0001-6954-4477	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AG044372, R01 NS082730]; BrightFocus FoundationBrightFocus Foundation [A2013364S]; Department of Veterans AffairsUS Department of Veterans Affairs; National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1U01NS086659-01]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; National Institute of Aging Boston University Framingham Heart Study [AG1649]; Alzheimer's AssociationAlzheimer's Association [NIRG-305779]; Sports Legacy Institute; National Operating Committee on Standards for Athletic Equipment; Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute of Neurological Disorders and Stroke (National Brain and Tissue Resource for Parkinson's Disease and Related Disorders) [U24 NS072026]; National Institute on Aging (Arizona Alzheimer's Disease Core Center)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG19610]; Arizona Department of Health Services (Arizona Alzheimer's Research Center) [211002]; Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]; Michael J. Fox Foundation for Parkinson's Research; Alzheimer's Disease Core Center grant from the National Institute on Aging [P30 AG013854]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659, R01NS082730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, R01AG044372, P30AG019610] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	This work was supported by NIH grants R01 AG044372 and R01 NS082730 (NMK), the BrightFocus Foundation (A2013364S, NMK), the Department of Veterans Affairs (ACM); National Institute of Neurological Diseases and Stroke 1U01NS086659-01 (ACM), National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846; supplement 0572063345-5, ACM]; National Institute of Aging Boston University Framingham Heart Study R01 [AG1649, ACM]; Alzheimer's Association (NIRG-305779, TDS); Sports Legacy Institute (ACM); National Operating Committee on Standards for Athletic Equipment (ACM); the Veterans Affairs Biorepository (CSP 501, ACM); Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C, ACM), unrestricted gifts from the National Football League, the Andlinger Foundation and the World Wrestling Entertainment, Inc. (WWE) (ACM), the Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901, and 1001 to the Arizona Parkinson's Disease Consortium), the Michael J. Fox Foundation for Parkinson's Research, and the Alzheimer's Disease Core Center grant (P30 AG013854) from the National Institute on Aging to Northwestern University, Chicago Illinois.	Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Bancher C, 1989, Prog Clin Biol Res, V317, P837; Beach TG, 2015, NEUROPATHOLOGY, V35, P354, DOI 10.1111/neup.12189; Berry RW, 2004, J NEUROCYTOL, V33, P287, DOI 10.1023/B:NEUR.0000044190.96426.b9; Berry RW, 2001, NEUROCHEM INT, V39, P469, DOI 10.1016/S0197-0186(01)00054-7; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Castillo-Carranza DL, 2014, J ALZHEIMERS DIS, V40, pS97, DOI 10.3233/JAD-132477; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Cardenas-Aguayo MD, 2014, ACS CHEM NEUROSCI, V5, P1178, DOI 10.1021/cn500148z; Dickson DW, 1999, J NEUROL, V246, P6; DUONG T, 1993, BRAIN RES, V603, P74, DOI 10.1016/0006-8993(93)91301-8; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Flores-Rodriguez P, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00033; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Garcia-Sierra F, 2000, ACTA NEUROPATHOL, V100, P29, DOI 10.1007/s004010051189; Garcia-Sierra F, 2003, J ALZHEIMERS DIS, V5, P65, DOI 10.3233/JAD-2003-5201; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guillozet-Bongaarts AL, 2006, J NEUROCHEM, V97, P1005, DOI 10.1111/j.1471-4159.2006.03784.x; Guillozet-Bongaarts AL, 2005, NEUROBIOL AGING, V26, P1015, DOI 10.1016/j.neurobiolaging.2004.09.019; Guillozet-Bongaarts AL, 2007, ACTA NEUROPATHOL, V113, P513, DOI 10.1007/s00401-007-0209-6; Guzman-Martinez L, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00167; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jeganathan S, 2008, J BIOL CHEM, V283, P32066, DOI 10.1074/jbc.M805300200; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kanaan NM, 2008, GLIA, V56, P1199, DOI 10.1002/glia.20690; Kanaan NM, 2007, J COMP NEUROL, V502, P683, DOI 10.1002/cne.21333; Kanaan NM, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.06.006; Kanaan NM, 2011, J NEUROSCI, V31, P9858, DOI 10.1523/JNEUROSCI.0560-11.2011; Kanaan NM, 2010, NEUROBIOL AGING, V31, P937, DOI 10.1016/j.neurobiolaging.2008.07.006; Kandan NM, 2013, EXP NEUROL, V246, P44, DOI 10.1016/j.expneurol.2012.06.003; Kiernan PT, 2015, SEMIN NEUROL, V35, P20, DOI 10.1055/s-0035-1545080; Kokjohn TA, 2013, J NEUROTRAUM, V30, P981, DOI 10.1089/neu.2012.2699; Kuchibhotla KV, 2014, P NATL ACAD SCI USA, V111, P510, DOI 10.1073/pnas.1318807111; LaPointe NE, 2009, J NEUROSCI RES, V87, P440, DOI 10.1002/jnr.21850; Lasagna-Reeves CA, 2011, CURR ALZHEIMER RES, V8, P659; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Ling H, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-24; Luna-Munoz J, 2005, J ALZHEIMERS DIS, V8, P29; Luna-Munoz J, 2007, J ALZHEIMERS DIS, V12, P365; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Mondragon-Rodriguez S, 2014, NEUROPATH APPL NEURO, V40, P121, DOI 10.1111/nan.12084; Mondragon-Rodriguez S, 2008, INT J EXP PATHOL, V89, P81, DOI 10.1111/j.1365-2613.2007.00568.x; Morfini GA, 2009, J NEUROSCI, V29, P12776, DOI 10.1523/JNEUROSCI.3463-09.2009; Morsch R, 1999, J NEUROPATH EXP NEUR, V58, P188, DOI 10.1097/00005072-199902000-00008; Mufson EJ, 2014, NEURODEGENER DIS, V13, P151, DOI 10.1159/000353687; Patterson KR, 2011, BIOCHEMISTRY-US, V50, P10300, DOI 10.1021/bi2009147; Patterson KR, 2011, J BIOL CHEM, V286, P23063, DOI 10.1074/jbc.M111.237974; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Sahara N, 2008, CURR ALZHEIMER RES, V5, P591, DOI 10.2174/156720508786898442; Sahara N, 2014, J ALZHEIMERS DIS, V40, pS91, DOI 10.3233/JAD-132429; Gadad BS, 2011, J ALZHEIMERS DIS, V24, P223, DOI 10.3233/JAD-2011-110182; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Tian H., 2013, Int. J. Cell Biol., V2013, DOI DOI 10.1155/2013/260787; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Vana L, 2011, AM J PATHOL, V179, P2533, DOI 10.1016/j.ajpath.2011.07.044; Ward SM, 2014, NEUROBIOL DIS, V67, P37, DOI 10.1016/j.nbd.2014.03.002; Ward SM, 2013, J ALZHEIMERS DIS, V37, P593, DOI 10.3233/JAD-131235; Ward SM, 2012, BIOCHEM SOC T, V40, P667, DOI 10.1042/BST20120134; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	72	50	50	2	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JAN	2016	75	1					19	34		10.1093/jnen/nlv001			16	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	DK9DJ	WOS:000375230400003	26671985	Green Published, Bronze, Green Accepted			2022-02-06	
J	Escudero, D; Valentin, MO; Escalante, JL; Sanmartin, A; Perez-Basterrechea, M; de Gea, J; Martin, M; Velasco, J; Pont, T; Masnou, N; de la Calle, B; Marcelo, B; Lebron, M; Perez, JM; Burgos, M; Gimeno, R; Kot, P; Yus, S; Sancho, I; Zabalegui, A; Arroyo, M; Minambres, E; Elizalde, J; Montejo, JC; Dominguez-Gil, B; Matesanz, R				Escudero, D.; Valentin, M. O.; Escalante, J. L.; Sanmartin, A.; Perez-Basterrechea, M.; de Gea, J.; Martin, M.; Velasco, J.; Pont, T.; Masnou, N.; de la Calle, B.; Marcelo, B.; Lebron, M.; Perez, J. M.; Burgos, M.; Gimeno, R.; Kot, P.; Yus, S.; Sancho, I.; Zabalegui, A.; Arroyo, M.; Minambres, E.; Elizalde, J.; Montejo, J. C.; Dominguez-Gil, B.; Matesanz, R.			Intensive care practices in brain death diagnosis and organ donation	ANAESTHESIA			English	Article							DONORS; VARIABILITY; PERFORMANCE; HEMORRHAGE; MANAGEMENT; STROKE; SCALE; SCORE; TIME	We conducted a multicentre study of 1844 patients from 42 Spanish intensive care units, and analysed the clinical characteristics of brain death, the use of ancillary testing, and the clinical decisions taken after the diagnosis of brain death. The main cause of brain death was intracerebral haemorrhage (769/1844, 42%), followed by traumatic brain injury (343/1844, 19%) and subarachnoid haemorrhage (257/1844, 14%). The diagnosis of brain death was made rapidly (50% in the first 24 h). Of those patients who went on to die, the Glasgow Coma Scale on admission was >= 8/15 in 1146/1261 (91%) of patients with intracerebral haemorrhage, traumatic brain injury or anoxic encephalopathy; the Hunt and Hess Scale was 4-5 in 207/251 (83%) of patients following subarachnoid haemorrhage; and the National Institutes of Health Stroke Scale was >= 15 in 114/129 (89%) of patients with strokes. Brain death was diagnosed exclusively by clinical examination in 92/1844 (5%) of cases. Electroencephalography was the most frequently used ancillary test (1303/1752, 70.7%), followed by transcranial Doppler (652/1752, 37%). Organ donation took place in 70% of patients (1291/1844), with medical unsuitability (267/553, 48%) and family refusal (244/553, 13%) the main reasons for loss of potential donors. All life-sustaining measures were withdrawn in 413/553 of non-donors (75%).	[Escudero, D.] Cent Univ Hosp Asturias, Dept, Oviedo, Spain; [Martin, M.] Cent Univ Hosp Asturias, Intens Care Unit, Oviedo, Spain; [Perez-Basterrechea, M.] Cent Univ Hosp Asturias, Unit Transplants Cell Therapy & Regenerat Med, Oviedo, Spain; [Valentin, M. O.; Dominguez-Gil, B.; Matesanz, R.] Spanish Natl Transplant Org ONT, Madrid, Spain; [Escalante, J. L.] Gregorio Maran Univ Hosp, Hosp Transplant Program, Madrid, Spain; [de la Calle, B.] Gregorio Maran Univ Hosp, Intens Care Unit, Madrid, Spain; [Sanmartin, A.; de Gea, J.] Virgen Arrixaca Hosp, Intens Care Unit, Murcia, Spain; [Velasco, J.] Son Espases Univ Hosp, Intens Care Unit, Palma de Mallorca, Spain; [Pont, T.; Masnou, N.] Vall Hebron Hosp, Intens Care Unit, Barcelona, Spain; [Marcelo, B.] Infanta Cristina Univ Hosp, Intens Care Unit, Badajoz, Spain; [Lebron, M.] Carlos Haya Hosp, Intens Care Unit, Malaga, Spain; [Perez, J. M.; Burgos, M.] Virgen Nieves Univ Hosp, Intens Care Unit, Granada, Spain; [Gimeno, R.] La Fe Univ Hosp, Intens Care Unit, Valencia, Spain; [Kot, P.; Yus, S.] La Paz Univ Hosp, Intens Care Unit, Madrid, Spain; [Sancho, I.] Miguel Servet Univ Hosp, Intens Care Unit, Zaragoza, Spain; [Zabalegui, A.; Arroyo, M.] Gen Yague Hosp, Intens Care Unit, Burgos, Spain; [Minambres, E.] Marques Valdecilla Univ Hosp, Intens Care Unit, Santander, Spain; [Elizalde, J.] Asistential Complex Navarra, Intens Care Unit, Pamplona, Spain; [Montejo, J. C.] 12 Octubre Univ Hosp, Intens Care Unit, Dept, Madrid, Spain		Escudero, D (corresponding author), Cent Univ Hosp Asturias, Dept, Oviedo, Spain.	lolaescudero@telefonica.net	Basterrechea, Marcos Perez/L-9052-2014; VALENTIN, MARIA O/AAW-1865-2020; Minambres, Eduardo/H-7761-2019; de Gea Garcia, Jose Higinio/H-8451-2016	Basterrechea, Marcos Perez/0000-0002-8242-5365; VALENTIN, MARIA O/0000-0003-4381-1332; Martinez Perez, Adolfo/0000-0002-7441-4092; Escudero, Dolores/0000-0002-9037-3411; Pont, Teresa/0000-0003-4409-1189; Dominguez-Gil, Beatriz/0000-0002-5695-8993; de Gea Garcia, Jose Higinio/0000-0003-2460-5074	SEMICYUC	We acknowledge ONT, with special thanks to Mr. L. Gallardo, for providing all the informatics support needed for the development of the study, as well as SEMICYUC for its dedicated support. We also thank Dr. J. Escudero (Department of English Philology, University of Oviedo) for her review of the manuscript, as well as all those investigators who have participated in case collection (Appendix 1).	Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; [Anonymous], PEOPL KILL ROAD ACC; [Anonymous], 1968, JAMA-J AM MED ASSOC, V205, P85; [Anonymous], 1995, NEUROLOGY, V45, P1012, DOI DOI 10.1212/WNL.45.5.1012; Barber K, 2006, BMJ-BRIT MED J, V332, P1124, DOI 10.1136/bmj.38804.658183.55; Bell MDD, 2004, BRIT J ANAESTH, V92, P633, DOI 10.1093/bja/aeh108; Bernat JL, 2008, NEUROLOGY, V70, P252, DOI 10.1212/01.wnl.0000298089.91799.b5; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; de Groot YJ, 2010, INTENS CARE MED, V36, P1488, DOI 10.1007/s00134-010-1848-y; de la Rosa G, 2012, AM J TRANSPLANT, V12, P2507, DOI 10.1111/j.1600-6143.2012.04138.x; Escalante JL, 1998, REV PORTUGUESA MED I, V7, P127; Escalante JL., 1998, REV PORTUGUESA MED I, V7, P107; Escudero D, 2009, MED INTENSIVA, V33, P450, DOI 10.1016/j.medin.2009.06.004; Escudero D, 2009, MED INTENSIVA, V33, P415, DOI 10.1016/j.medin.2009.07.011; Escudero D, 2007, Med. Intensiva, V31, P335; Escudero D, 2009, MED INTENSIVA, V33, P185, DOI 10.1016/S0210-5691(09)71215-X; Escudero D, 2009, NEUROCRIT CARE, V11, P261, DOI 10.1007/s12028-009-9243-7; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Greer DM, 2008, NEUROLOGY, V70, P284, DOI 10.1212/01.wnl.0000296278.59487.c2; Haupt WF, 1999, J NEUROL, V246, P432, DOI 10.1007/s004150050378; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Jaffe J, 2009, NEUROSURGERY, V64, P436, DOI 10.1227/01.NEU.0000330402.20883.1B; Jansen NE, 2012, TRANSPL INT, V25, P830, DOI 10.1111/j.1432-2277.2012.01505.x; Jansen NE, 2010, NEPHROL DIAL TRANSPL, V25, P1992, DOI 10.1093/ndt/gfp705; JENNETT B, 1975, LANCET, V1, P480; Kompanje EJO, 2011, TRANSPLANTATION, V91, P1177, DOI 10.1097/TP.0b013e3182180567; Laureys S, 2008, NEUROLOGY, V70, P14; Martin-Lefevre L, 2011, REV NEUROL-FRANCE, V167, P463, DOI 10.1016/j.neurol.2011.01.004; Matesanz R, 2011, TRANSPL INT, V24, P333, DOI 10.1111/j.1432-2277.2010.01204.x; Moller C, 2009, TRANSPL P, V41, P729, DOI 10.1016/j.transproceed.2009.01.076; Munari M, 2005, CRIT CARE MED, V33, P2068, DOI 10.1097/01.CCM.0000179143.19233.6A; NOVOA S FERNANDO, 2007, Rev. chil. pediatr., V78, P355; Palacios JM, 2003, REV CHIL CIR, V55, P244; Powner DJ, 2004, CRIT CARE MED, V32, P1284, DOI 10.1097/01.ccm.0000127265.62431.0d; Schnitzler MA, 2005, AM J TRANSPLANT, V5, P2289, DOI 10.1111/j.1600-6143.2005.01021.x; Sharma D, 2011, NEUROCRIT CARE, V14, P370, DOI 10.1007/s12028-010-9415-5; Sheehy E, 2003, NEW ENGL J MED, V349, P667, DOI 10.1056/NEJMsa021271; Sheerani Mughis, 2008, J Pak Med Assoc, V58, P352; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; Swinburn JMA, 1999, BRIT MED J, V318, P1753; Vincent A, 2012, BRIT J ANAESTH, V108, pI80, DOI 10.1093/bja/aer353; Wijdicks EFM, 2010, NEUROLOGY, V74, P1911, DOI 10.1212/WNL.0b013e3181e242a8; Wijdicks EFM, 2005, MAYO CLIN PROC, V80, P550, DOI 10.4065/80.4.550; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20	45	50	54	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	OCT	2015	70	10					1130	1139		10.1111/anae.13065			10	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	CT2WY	WOS:000362667400005	26040194	Bronze			2022-02-06	
J	Kerr, ZY; Yeargin, SW; McLeod, TCV; Mensch, J; Hayden, R; Dompier, TP				Kerr, Zachary Y.; Yeargin, Susan W.; McLeod, Tamara C. Valovich; Mensch, James; Hayden, Ross; Dompier, Thomas P.			Comprehensive Coach Education Reduces Head Impact Exposure in American Youth Football	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						epidemiology; injury; concussion; pediatric; youth sports	CERVICAL-SPINE INJURIES; HIGH-SCHOOL; PLAYERS; CONCUSSION; BIOMECHANICS; ASSOCIATION; SPORTS	Background: Despite little evidence that defines a threshold of head impact exposure or that participation in youth sports leads to long-term cognitive impairments, it is prudent to identify methods of reducing the frequency of head impacts. Purpose: To compare the mean number of head impacts between youth football players in practice and games between leagues that implemented the Heads Up Football (HUF) educational program and those that did not (NHUF). Study Design: Cohort study; Level of evidence, 2. Methods: During the 2014 season, head impact exposure was measured using xPatch accelerometers from 70 youth football players aged 8 to 15 years from 5 leagues. Data were collected during both games and practices. The NHUF group comprised 32 players from 8 teams within 3 leagues. The HUF group comprised 38 players from 7 teams within 2 leagues. Independent-sample t tests evaluated differences in head impact exposure across groups (ie, HUF and NHUF). Results: Players (mean +/- SD: age, 11.7 +/- 1.4 years; height, 152.2 +/- 10.5 cm; weight, 51.6 +/- 9.6 kg) experienced a total of 7478 impacts over 10g, of which 4250 (56.8%) and 3228 (43.2%) occurred in practices and games, respectively. The majority of impacts occurred within the NHUF group (62.0%), followed by the HUF group (38.0%). With a 10g impact threshold, the mean number of impacts during practice per individual event was lower in the HUF group (mean +/- SD, 5.6 +/- 2.9) than in the NHUF group (mean +/- SD, 8.9 +/- 3.1; difference, 3.4; 95% CI, 2.9-3.9). This difference was attenuated when the threshold was changed to 20g but remained significant (difference, 1.0; 95% CI, 0.7-1.3). At both the 10g and 20g impact thresholds, no differences were found in games. Conclusion: Players who participated in HUF leagues accumulated fewer head impacts per practice at both the 10g and 20g thresholds. Youth football leagues should consider the HUF educational program, while exploring additional interventions, to help reduce the number of head impacts in players.	[Kerr, Zachary Y.; Yeargin, Susan W.; McLeod, Tamara C. Valovich; Mensch, James; Hayden, Ross; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent Inc, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA		Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Kerr, Zachary/0000-0003-1423-1259			Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Boden BP, 2006, AM J SPORT MED, V34, P1223, DOI 10.1177/0363546506288306; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Dick R, 2007, J ATHL TRAINING, V42, P221; Dompier TP, 2007, J ATHL TRAINING, V42, P395; Fainaru S, YOUTH FOOTBALL PARTI; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, AM J SPORT MED, V43, P1134, DOI 10.1177/0363546515570622; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; Mueller FO, 2001, J ATHL TRAINING, V36, P312; Mueller FO, 2011, PREVENTING SUDDEN DE, P1; Munce TA, 2015, MED SCI SPORT EXER, V47, P1567, DOI 10.1249/MSS.0000000000000591; National Council of Youth Sports, REP TRENDS PART ORG; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; Pop Warner Football, RUL CHANG REG PRACT; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; USA Football, FOOTB SPONS; Wallerson R, YOUTH PARTICIPATION; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055	26	50	50	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	OCT	2015	3	10							2325967115610545	10.1177/2325967115610545			6	Orthopedics; Sport Sciences	Emerging Sources Citation Index (ESCI)	Orthopedics; Sport Sciences	DE1ZW	WOS:000370426700003	26779546	gold, Green Submitted, Green Published			2022-02-06	
J	Folkerson, LE; Sloan, D; Cotton, BA; Holcomb, JB; Tomasek, JS; Wade, CE				Folkerson, Lindley E.; Sloan, Duncan; Cotton, Bryan A.; Holcomb, John B.; Tomasek, Jeffrey S.; Wade, Charles E.			Predicting progressive hemorrhagic injury from isolated traumatic brain injury and coagulation	SURGERY			English	Article							RECOMBINANT FACTOR VIIA; CLINICAL-TRIAL; COAGULOPATHY; PROGESTERONE; THROMBELASTOGRAPHY; METAANALYSIS; TESTS	Background. Progressive hemorrhagic injury (PHI) in traumatic brain injury (TBI) patients is associated with poor outcomes. Early prediction of PHI is difficult yet vital. We hypothesize that TBI subtype and coagulation would be predictors of PHI. Methods. This was a retrospective analysis of highest level activation adult trauma patients with evidence of TBI (head Abbreviated Injury Scale >= 3). Coagulopathy was determined using rapid thrombelastography (r-TEG), complete blood counts, and conventional coagulation tests obtained on arrival. Patients were dichotomized into PHI and stable groups based on head computerized CT Subtypes of TBI included subdural hematoma, intraparenchymal contusions (IPC), subarachnoid hemorrhage, epidural hematoma, and combined. Data are reported as median values with interquartile range (IQR). Multivariate logistic regression was used to assess the effect of subtype and coagulation on PHI. Results. We included 279 isolated TBI patients who met study criteria. There were 157 patients (56%) who experienced PHI; 122 (44%) were stable on repeat CT Patients with PHI were older, had fewer hospital-free days, and higher mortality (all P < .001). No differences were noted in r-TEG parameters between groups; however, coagulopathy and age were independent predictors of progression in all subtypes (odds ratio [OR], 1.81; 95% CI, 1.09-3.01 [P = .021]; OR, 1.02, 95% CI, 1.01-1.04 [P = .006]). Controlling for age, Glasgow Coma Scale score, and coagulopathy, patients with IPC were more likely to experience PHI (OA 4.49; 95% CI, 2.24-8.98; P < .0001). Conclusion. This study demonstrates that older patients with coagulation abnormalities and IPC on admission are more likely to experience PHI, identifying a target population for earlier therapies.	[Folkerson, Lindley E.; Sloan, Duncan; Cotton, Bryan A.; Holcomb, John B.; Tomasek, Jeffrey S.; Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX 77030 USA; [Folkerson, Lindley E.; Sloan, Duncan; Cotton, Bryan A.; Holcomb, John B.; Tomasek, Jeffrey S.; Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA		Folkerson, LE (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Surg, Ctr Translat Injury Res, 6431 Fannin St,MSB 5-212, Houston, TX 77030 USA.	Lindley.E.Folkerson@uth.tmc.edu		holcomb, john/0000-0001-8312-9157	State of Texas Emerging Technology Fund; University of Texas Health Science Center's Center for Translational Injury Research	Support for this work was provided by The State of Texas Emerging Technology Fund and The University of Texas Health Science Center's Center for Translational Injury Research.	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Brohi K, 2007, CURR OPIN CRIT CARE, V13, P680, DOI 10.1097/MCC.0b013e3282f1e78f; Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; ClinicalTrials.gov, 2013, NCT01990768 CLINICAL; ClinicalTrials.gov, 2011, NCT01402882 CLINICAL; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Manoel ALD, 2015, NEUROCRIT CARE, V22, P34, DOI 10.1007/s12028-014-0026-4; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Imam A, 2015, J NEUROTRAUM, V32, P307, DOI 10.1089/neu.2014.3535; Joseph B, 2014, AM SURGEON, V80, P335; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Lee TH, 2014, J TRAUMA ACUTE CARE, V77, P67, DOI 10.1097/TA.0000000000000255; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Post A, 2015, NEUROSURGERY, V76, P81, DOI 10.1227/NEU.0000000000000554; Sixta SL, 2012, INT J BURNS TRAUMA, V2, P158; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tong WS, 2011, NEURORADIOLOGY, V53, P305, DOI 10.1007/s00234-010-0659-8; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Yuan Q, 2015, J CRIT CARE, V30, P116, DOI 10.1016/j.jcrc.2014.07.009; Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20; Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023	32	50	57	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	SEP	2015	158	3					655	661		10.1016/j.surg.2015.02.029			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	CP3CS	WOS:000359755000010	26067457				2022-02-06	
J	Potter, DR; Baimukanova, G; Keating, SM; Deng, XT; Chu, JA; Gibb, SL; Peng, ZL; Muench, MO; Fomin, ME; Spinella, PC; Kozar, R; Pati, S				Potter, Daniel R.; Baimukanova, Gail; Keating, Sheila M.; Deng, Xutao; Chu, Jeffrey A.; Gibb, Stuart L.; Peng, Zhanglong; Muench, Marcus O.; Fomin, Marina E.; Spinella, Philip C.; Kozar, Rosemary; Pati, Shibani			Fresh frozen plasma and spray-dried plasma mitigate pulmonary vascular permeability and inflammation in hemorrhagic shock	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	4th Annual Conference on Remote Damage Control Resuscitation (RDCR)	JUN 09-11, 2014	Bergen, NORWAY			Hemorrhagic shock; lung injury; vascular permeability; spray-dried plasma; mice	TRAUMATIC BRAIN-INJURY; DAMAGE CONTROL RESUSCITATION; RED-BLOOD-CELL; LYOPHILIZED PLASMA; BETA-CATENIN; JUNCTIONS; MORTALITY; RATIOS; MODEL; COAGULOPATHY	BACKGROUND: In retrospective and prospective observational studies, fresh frozen plasma (FFP) has been associated with a survival benefit in massively transfused trauma patients. A dry plasma product, such as spray-dried plasma (SDP), offers logistical advantages over FFP. Recent studies on FFP have demonstrated that FFP modulates systemic vascular stability and inflammation. The effect of SDP on these measures has not been previously examined. This study compares SDP with FFP using in vitro assays of endothelial function and in vivo assays of lung injury using a mouse model of hemorrhagic shock (HS) and trauma. METHODS: FFP, SDP, and lactated Ringer's (LR) solution were compared in vitro using assays of endothelial cell (EC) permeability, cytokine production and content, gene expression, as well as tight and adherens junction stability. All resuscitation products were also compared in a murine model of HS. Mean arterial pressures and physiologic measures were assessed. Pulmonary vascular permeability was measured using tagged dextran. Lung tissues were stained for CD68, VE-cadherin, and occludin. RESULTS: Treatment of ECs with FFP and SDP, but not LR, preserved the integrity of EC monolayers in vitro and resulted in similar EC gene expression patterns and cytokine/growth factor production. FFP and SDP also reduced HS-induced pulmonary vascular permeability in vivo to the same extent. In mice with HS, mean arterial pressures and base excess were corrected by both FFP and SDP to levels observed in sham-treated mice. Treatment after HS with FFP and SDP but not LR solution reduce alveolar wall thickening, leukocyte infiltration, and the breakdown of EC junctions, as measured by staining for VE-cadherin, and occludin. CONCLUSION: Both FFP and SDP similarly modulate pulmonary vascular integrity, permeability, and inflammation in vitro and in vivo in a murine model of HS and trauma. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.	[Potter, Daniel R.; Baimukanova, Gail; Keating, Sheila M.; Deng, Xutao; Chu, Jeffrey A.; Gibb, Stuart L.; Muench, Marcus O.; Fomin, Marina E.; Pati, Shibani] Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94143 USA; [Muench, Marcus O.; Pati, Shibani] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Peng, Zhanglong] Univ Texas Houston, Sch Med, Dept Surg, Houston, TX USA; [Spinella, Philip C.] Washington Sch Med, Dept Pediat, Div Crit Care Med, St Louis, MO USA; [Kozar, Rosemary] Univ Maryland, Ctr Shock Trauma, Baltimore, MD 21201 USA		Pati, S (corresponding author), Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.	spati@bloodsystems.org	Muench, Marcus O./C-5025-2009	Muench, Marcus O./0000-0001-8946-6605; Keating, Sheila/0000-0002-8324-3694			Alam HB, 2011, J TRAUMA, V70, P636, DOI 10.1097/TA.0b013e31820d0dcc; [Anonymous], 2002, BIOTECHNIQUES; Benest AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070459; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004; del Junco DJ, 2013, J TRAUMA ACUTE CARE, V75, pS24, DOI 10.1097/TA.0b013e31828fa3b9; Derouette JP, 2009, ATHEROSCLEROSIS, V206, P69, DOI 10.1016/j.atherosclerosis.2009.02.020; Duan CJ, 2011, SHOCK, V36, P54, DOI 10.1097/SHK.0b013e318214475e; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616; GIAEVER I, 1986, IEEE T BIO-MED ENG, V33, P242, DOI 10.1109/TBME.1986.325896; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Haywood-Watson RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023530; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2013, HEMATOL-AM SOC HEMAT, P656, DOI 10.1182/asheducation-2013.1.656; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Imam AM, 2013, J TRAUMA ACUTE CARE, V75, P976, DOI 10.1097/TA.0b013e31829e2186; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jenkins DH, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000140; Kashuk JL, 2008, J TRAUMA, V65, P261, DOI 10.1097/TA.0b013e31817de3e1; Keese CR, 2002, BIOTECHNIQUES, V33, P842, DOI 10.2144/02334rr01; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Li XR, 2001, INT J BIOCHEM CELL B, V33, P421, DOI 10.1016/S1357-2725(01)00027-9; London NR, 2009, ANGIOGENESIS, V12, P149, DOI 10.1007/s10456-009-9130-z; Maegele M, 2008, VOX SANG, V95, P112, DOI 10.1111/j.1423-0410.2008.01074.x; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Martinaud C, 2011, J TRAUMA, V71, P4; Martinaud C, 2011, J TRAUMA, V71, P1761, DOI 10.1097/TA.0b013e31822f1285; Martinaud C, 2011, J TRAUMA, V71, P1091, DOI 10.1097/TA.0b013e31822a8fd5; Moore FA, 2004, LANCET, V363, P1988, DOI 10.1016/S0140-6736(04)16415-5; Norton R, 2013, NEW ENGL J MED, V368, P1723, DOI 10.1056/NEJMra1109343; Pacurari M, 2014, INT J INFLAMM, V2014, DOI 10.1155/2014/689360; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc; Peng ZL, 2012, SHOCK, V38, P57, DOI 10.1097/SHK.0b013e31825a188a; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; Sailliol A, 2013, TRANSFUSION, V53, p65S, DOI 10.1111/trf.12038; Sauaia A, 2014, J TRAUMA ACUTE CARE, V76, P582, DOI 10.1097/TA.0000000000000147; Sawant DA, 2011, J TRAUMA, V70, P481, DOI 10.1097/TA.0b013e31820b3ed7; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Simon TL, 2011, ROSSIS PRINCIPLES TR; Tharakan B, 2012, SHOCK, V37, P306, DOI 10.1097/SHK.0b013e318240b564; Tollofsrud S, 2001, ANESTH ANALG, V93, P823, DOI 10.1097/00000539-200110000-00005; Wataha K, 2013, TRANSFUSION, V53, p80S, DOI 10.1111/trf.12040	49	50	51	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUN	2015	78			1			S7	S17		10.1097/TA.0000000000000630			11	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	DJ7QU	WOS:000374406700003	26002267				2022-02-06	
J	Rosenfeld, JV; Bell, RS; Armonda, R				Rosenfeld, Jeffrey V.; Bell, Randy S.; Armonda, Rocco			Current Concepts in Penetrating and Blast Injury to the Central Nervous System	WORLD JOURNAL OF SURGERY			English	Article							TRAUMATIC BRAIN-INJURY; CIVILIAN GUNSHOT WOUNDS; SPINAL-INJURIES; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; WARTIME; MILITARY; COAGULOPATHY; PREDICTORS; FRACTURES	To review the current management, prognostic factors and outcomes of penetrating and blast injuries to the central nervous system and highlight the differences between gunshot wound, blast injury and stabbing. A review of the current literature was performed. Of patients with craniocerebral GSW, 66-90 % die before reaching hospital. Of those who are admitted to hospital, up to 51 % survive. The patient age, GCS, pupil size and reaction, ballistics and CT features are important factors in the decision to operate and in prognostication. Blast injury to the brain is a component of multisystem polytrauma and has become a common injury encountered in war zones and following urban terrorist events. GSW to the spine account for 13-17 % of all gunshot injuries. Urgent resuscitation, correction of coagulopathy and early surgery with wide cranial decompression may improve the outcome in selected patients with severe craniocerebral GSW. More limited surgery is undertaken for focal brain injury due to GSW. A non-operative approach may be taken if the clinical status is very poor (GCS 3, fixed dilated pupils) or GCS 4-5 with adverse CT findings or where there is a high likelihood of death or poor outcome. Civilian spinal GSWs are usually stable neurologically and biomechanically and do not require exploration. The indications for exploration are as follows: (1) compressive lesions with partial spinal cord or cauda equina injury, (2) mechanical instability and (3) complications. The principles of management of blast injury to the head and spine are the same as for GSW. Multidisciplinary specialist management is required for these complex injuries.	[Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Alfred Ctr, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.; Bell, Randy S.; Armonda, Rocco] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Surg, Bethesda, MD 20814 USA; [Bell, Randy S.; Armonda, Rocco] MedStar Georgetown Univ Hosp, Dept Neurosurg, Washington, DC USA; [Bell, Randy S.; Armonda, Rocco] Washington Hosp Ctr, Washington, DC 20010 USA		Rosenfeld, JV (corresponding author), Monash Univ, Dept Surg, Alfred Ctr, 6th Floor,99 Commercial Rd, Melbourne, Vic 3004, Australia.	j.rosenfeld@alfred.org.au					Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; Aarabi B, 2014, J NEUROSURG, V120, P1138, DOI 10.3171/2014.1.JNS131869; [Anonymous], 2001, J TRAUMA, V51, pS34; [Anonymous], 2001, J TRAUMA, V51, pS29; [Anonymous], 2001, J Trauma, V51, pS3; [Anonymous], 2012, JOINT THEAT TRAUM SY; [Anonymous], 2012, JOINT THEAT TRAUM SY; Armonda R, 2011, J NEUROTRAUM, V28, pA5; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Aryan HE, 2005, NEUROSURGERY, V57, P748, DOI 10.1227/01.NEU.0000175728.93653.b1; Baraniuk S, 2014, INJURY, V45, P1287, DOI 10.1016/j.injury.2014.06.001; Bayston R, 2000, LANCET, V355, P1813, DOI 10.1016/S0140-6736(00)02275-3; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022; Bell RS, 2010, NEUROSURGERY, V66, P66, DOI 10.1227/01.NEU.0000361285.50218.A8; Blair JA, 2012, SPINE J, V12, P762, DOI 10.1016/j.spinee.2011.10.009; Bono Christopher M, 2004, Spine J, V4, P230, DOI 10.1016/S1529-9430(03)00178-5; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Ecker RD, 2011, J NEUROSURG, V115, P124, DOI 10.3171/2011.2.JNS101490; Elserry Tarek, 2013, Surg Neurol Int, V4, pS448, DOI 10.4103/2152-7806.121642; Enicker B, 2014, INJURY, V45, P1355, DOI 10.1016/j.injury.2014.04.036; Epstein DS, 2015, BRIT J NEUROSURG, V29, P118, DOI 10.3109/02688697.2014.950632; Glapa M, 2009, AM SURGEON, V75, P223; Gressot LV, 2014, J NEUROSURG, V121, P645, DOI 10.3171/2014.5.JNS131872; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Heary RFMA, 2010, SEMIN SPINE SURG, V22, P73; Jaiswal M, 2013, ASIAN SPINE J, V7, P359, DOI 10.4184/asj.2013.7.4.359; Jandial R, 2008, NEUROSURGERY, V62, P472, DOI 10.1227/01.neu.0000316015.05550.7a; Joseph B, 2014, J AM COLL SURGEONS, V218, P58, DOI 10.1016/j.jamcollsurg.2013.08.018; KAUFMAN HH, 1995, NEUROSURG CLIN N AM, V6, P701, DOI 10.1016/s1042-3680(18)30426-1; Kazim Syed Faraz, 2011, J Emerg Trauma Shock, V4, P395, DOI 10.4103/0974-2700.83871; Kim KA, 2005, NEUROSURGERY, V57, P737, DOI [10.1227/01.NEU.0000175727.76530.94, 10.1227/01.NEU.0000164174.07281.F9]; Klimo P, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1036; Levy M L, 2000, Neurosurg Focus, V8, pe2, DOI 10.3171/foc.2000.8.1.153; Lin DJ., 2012, SURG NEUROL INT, V3, P98, DOI [DOI 10.4103/2152-7806, 10.4103/2152-7806.100187, DOI 10.4103/2152-7806.100187]; McCully SP, 2013, SEMIN THROMB HEMOST, V39, P896, DOI 10.1055/s-0033-1357484; Medzon R, 2005, SPINE, V30, P2274, DOI 10.1097/01. brs.0000182083.43553.fa; Mitra B, 2013, ANZ J SURG, V83, P918, DOI 10.1111/ans.12417; Parks SE, 2014, MMWR SURVEILL SUMM, V63, P1; Patzkowski JC, 2012, SPINE J, V12, P791, DOI 10.1016/j.spinee.2011.10.001; POLIN RS, 1995, NEUROSURG CLIN N AM, V6, P689; Powers David B, 2013, Atlas Oral Maxillofac Surg Clin North Am, V21, P15, DOI 10.1016/j.cxom.2012.12.001; Ragel BT, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.3.FOCUS1028; Ramasamy A, 2009, INJURY, V40, P1342, DOI 10.1016/j.injury.2009.06.168; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rosenfeld JV, 2002, J CLIN NEUROSCI, V9, P9, DOI 10.1054/jocn.2001.0949; Schoenfeld AJ, 2013, INJURY, V44, P1866, DOI 10.1016/j.injury.2013.08.001; Schoenfeld AJ, 2013, SPINE, V38, P1770, DOI 10.1097/BRS.0b013e31829ef226; Schoenfeld AJ, 2012, SPINE J, V12, P817, DOI 10.1016/j.spinee.2011.04.028; Schoenfeld AJ, 2012, SPINE J, V12, P771, DOI 10.1016/j.spinee.2010.05.004; Shahlaie K, 2006, J NEUROSURG-SPINE, V4, P400, DOI 10.3171/spi.2006.4.5.400; Shen FHT, 2013, ASIAN SPINE J, V7, P44, DOI 10.4184/asj.2013.7.1.44; Sidhu GS, 2013, CLIN ORTHOP RELAT R, V471, P3945, DOI 10.1007/s11999-013-2901-2; Smith CE BA, 2014, MASSIVE TRANSFUSION; Syre P, 2013, J NEUROSURG-SPINE, V19, P759, DOI 10.3171/2013.8.SPINE12907; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Trahan J, 2013, INJURY, V44, P1601, DOI 10.1016/j.injury.2013.06.021; Weisbrod AB, 2012, J TRAUMA ACUTE CARE, V73, P1525, DOI 10.1097/TA.0b013e318270e179	57	50	55	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	JUN	2015	39	6					1352	1362		10.1007/s00268-014-2874-7			11	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	CH6FI	WOS:000354131400004	25446474	Green Published, hybrid			2022-02-06	
J	Failla, MD; Kumar, RG; Peitzman, AB; Conley, YP; Ferrell, RE; Wagner, AK				Failla, Michelle D.; Kumar, Raj G.; Peitzman, Andrew B.; Conley, Yvette P.; Ferrell, Robert E.; Wagner, Amy K.			Variation in the BDNF Gene Interacts With Age to Predict Mortality in a Prospective, Longitudinal Cohort with Severe TBI	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						brain injury; BDNF; TrkB; mortality; age; genetic association study	TRAUMATIC BRAIN-INJURY; RESPIRATORY-DISTRESS-SYNDROME; ACTIVITY-DEPENDENT SECRETION; HPA-AXIS REACTIVITY; TRKB MESSENGER-RNA; NEUROTROPHIC FACTOR; VAL66MET POLYMORPHISM; TRUNCATED TRKB; HEAD-INJURY; LIFE-SPAN	Background. Mortality predictions following traumatic brain injury (TBI), and our understanding of TBI pathology, may be improved by including genetic risk in addition to traditional prognostic variables. One promising target is the gene coding for brain-derived neurotrophic factor (BDNF), a ubiquitous neurotrophin important for neuronal survival and neurogenesis. Objective. We hypothesized the addition of BDNF genetic variation would improve mortality prediction models and that BDNF Met-carriers (rs6265) and C-carriers (rs7124442) would have the highest mortality rates post-TBI. Methods. This study examined BDNF functional single nucleotide polymorphisms rs6265 (val66met) and rs7124442 (T>C) in relation to mortality in a prospective, longitudinal cohort with severe TBI. We examined 315 individuals receiving care for a closed head injury within the University of Pittsburgh Medical Center, aged 16 to 74 years. Mortality was examined acutely (0-7 days postinjury) and postacutely (8-365 days postinjury). A gene risk score (GRS) was developed to examine both BDNF loci. Cox proportional hazards models were used to calculate hazard ratios for survivability post-TBI while controlling for covariates. Results. BDNF GRS was significantly associated with acute mortality, regardless of age. Interestingly, subjects in the hypothesized no-risk allele group had the lowest survival probability. Postacutely, BDNF-GRS interacted with age such that younger participants in the no-risk group had the highest survival probability, while older participants in the hypothesized no-risk group had the lowest probability of survival. Conclusions. These data suggest complex relationships between BDNF and TBI mortality that interact with age to influence survival predictions beyond clinical variables alone. Evidence supporting dynamic, temporal balances of pro-survival/pro-apoptotic target receptors may explain injury and age-related gene associations.	[Failla, Michelle D.; Kumar, Raj G.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Peitzman, Andrew B.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA; [Ferrell, Robert E.] Univ Pittsburgh, Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Wagner, AK (corresponding author), Safar Ctr Resuscitat Res, Dept Phys Med & Rehabil, 3471 Fifth Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067	Department of DefenseUnited States Department of Defense [W81XWH-07-1-0701]; National Institute on Disability and Rehabilitation Research [NIDRR H133A120087]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048162, R01NR008424, R01NR013342]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013342, R01NR008424] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Department of Defense (W81XWH-07-1-0701, Wagner), National Institute on Disability and Rehabilitation Research (NIDRR H133A120087, Wagner), and National Institute of Health (R01HD048162, Wagner; R01NR008424 and R01NR013342, Conley).	Alexander N, 2010, PSYCHONEUROENDOCRINO, V35, P949, DOI 10.1016/j.psyneuen.2009.12.008; Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; An JJ, 2008, CELL, V134, P175, DOI 10.1016/j.cell.2008.05.045; Barker PA, 2009, NAT NEUROSCI, V12, P105, DOI 10.1038/nn0209-105; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Brady R, 1999, J NEUROSCI, V19, P2131; Caporali A, 2009, PHYSIOL REV, V89, P279, DOI 10.1152/physrev.00007.2008; Centers for Disease Control and Prevention, 2010, TRAUMATIC BRAIN INJU; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; COX DR, 1972, J R STAT SOC B, V34, P187; Croll SD, 1998, BRAIN RES, V812, P200, DOI 10.1016/S0006-8993(98)00993-7; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Erickson KI, 2012, NEUROSCIENTIST, V18, P82, DOI 10.1177/1073858410397054; Failla MD, 2013, BRAIN INJURY, V27, P696, DOI 10.3109/02699052.2013.775481; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; GenealogyBank. com, 2013, SOC SEC DEATH IND; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Gomes JR, 2012, J NEUROSCI, V32, P4610, DOI 10.1523/JNEUROSCI.0374-12.2012; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; Hallden S, 2013, HEART, V99, P949, DOI 10.1136/heartjnl-2013-303634; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Kalish H, 2010, J CHROMATOGR B, V878, P194, DOI 10.1016/j.jchromb.2009.10.022; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kasselman LJ, 2006, J NEUROIMMUNOL, V175, P118, DOI 10.1016/j.jneuroim.2006.03.008; Kernie SG, 2000, EMBO J, V19, P1290, DOI 10.1093/emboj/19.6.1290; Krabbe KS, 2009, J AM GERIATR SOC, V57, P1447, DOI 10.1111/j.1532-5415.2009.02345.x; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Matsumoto T, 2008, NAT NEUROSCI, V11, P131, DOI 10.1038/nn2038; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Orefice LL, 2013, J NEUROSCI, V33, P11618, DOI 10.1523/JNEUROSCI.0012-13.2013; Pruunsild P, 2007, GENOMICS, V90, P397, DOI 10.1016/j.ygeno.2007.05.004; Qin LY, 2014, J NEUROSCI, V34, P2493, DOI 10.1523/JNEUROSCI.4140-13.2014; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Ritter C, 2012, CRIT CARE, V16, DOI 10.1186/cc11902; Romanczyk TB, 2002, EUR J NEUROSCI, V15, P269, DOI 10.1046/j.0953-816x.2001.01858.x; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Rothman SM, 2012, ANN NY ACAD SCI, V1264, P49, DOI 10.1111/j.1749-6632.2012.06525.x; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Shalev I, 2009, PSYCHONEUROENDOCRINO, V34, P382, DOI 10.1016/j.psyneuen.2008.09.017; Siironen J, 2007, STROKE, V38, P2858, DOI 10.1161/STROKEAHA.107.485441; Silhol M, 2005, NEUROSCIENCE, V132, P613, DOI 10.1016/j.neuroscience.2005.01.008; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Vidaurre OG, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.143; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2012, BRAIN INJURY, V26, P1658, DOI 10.3109/02699052.2012.700089; Wan RQ, 2014, J NEUROCHEM, V129, P573, DOI 10.1111/jnc.12656; Wang H, 2002, NEUROSCIENCE, V112, P967, DOI 10.1016/S0306-4522(02)00085-4; Webster MJ, 2006, GENE EXPR PATTERNS, V6, P941, DOI 10.1016/j.modgep.2006.03.009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yang AC, 2010, AM J MED GENET B, V153B, P1024, DOI 10.1002/ajmg.b.31069; Yang B, 2002, NAT NEUROSCI, V5, P539, DOI 10.1038/nn853; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868	65	50	51	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAR-APR	2015	29	3					234	246		10.1177/1545968314542617			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	CB2PD	WOS:000349469000004	25063686	Green Accepted			2022-02-06	
J	Iverson, GL; Schatz, P				Iverson, Grant L.; Schatz, Philip			Advanced topics in neuropsychological assessment following sport-related concussion	BRAIN INJURY			English	Article						Cognitive functioning; concussion; mild traumatic brain injury; neuropsychological assessment; psychometrics; reliable change	TEST-RETEST RELIABILITY; SCHOOL FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; TEST-PERFORMANCE; PROFESSIONAL FOOTBALL; BASE RATES; INTERNATIONAL-CONFERENCE; CLINICAL-SIGNIFICANCE; COGNITIVE IMPAIRMENT; INTERPRETING CHANGE	Objective: This study examined seven topics relating to neuropsychological assessment following sport-related concussion: (i) traditional vs. computerized tests; (ii) the value of baseline, pre-season testing; (iii) invalid baseline scores and poor effort; (iv) when to assess following injury; (v) the reliability of neuropsychological tests; (vi) reliable change methodology; and (vii) new methods for identifying cognitive impairment. Main results: Baseline testing can be helpful for quantifying cognitive deficits following injury and for assessing recovery. At present, however, there is insufficient evidence to conclude that having baseline test results is clearly superior to not having baseline test results. Although invalid baseline test performance can be detected in some athletes, validity indicators cannot determine the extent to which the results were due to deliberately poor performance, confusion or misunderstanding regarding some aspect of the test, distractions in group testing environments or some combination of factors. When interpreting baseline and post-injury data, sophisticated psychometric methods (e.g. reliable change, multivariate base rates) are available to assist with more accurate identification of cognitive impairment and the serial monitoring of recovery. Conclusions: The value of neuropsychological assessment in the management of sport-related concussion has a strong empirical foundation. Additional research is needed, however, to refine its use.	[Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Charlestown, MA 02129 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Charlestown, MA USA; [Iverson, Grant L.] MassGeneral Hosp Children Sport Concuss Program, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.; Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA		Iverson, GL (corresponding author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Neuropsychol Outcome Assessment Lab, 79-96 Thirteenth St, Charlestown, MA 02129 USA.	giverson@mgh.harvard.edu		Iverson, Grant/0000-0001-7348-9570	ImPACT Applications, Inc.; CNS Vital Signs; Psychological Assessment Resources (PAR, Inc.)	Grant Iverson, PhD, has been reimbursed by the government, professional scientific bodies and commercial organizations for discussing or presenting research relating to mild TBI and sport-related concussion at meetings, scientific conferences and symposiums. He has a clinical and consulting practice in forensic neuropsychology involving individuals who have sustained mild TBIs (including professional athletes). He has received research funding from several test publishing companies, including ImPACT Applications, Inc., CNS Vital Signs and Psychological Assessment Resources (PAR, Inc.). He has not received research support from ImPACT Applications, Inc. in the past 3 years. He receives royalties from two books relating to neuropsychology and one test (WCST-64). Philip Schatz, PhD, has served as a consultant to the International Brain Research Foundation, the Sports Concussion Center of New Jersey and ImPACT Applications, Inc., to study the effects of concussion in high school and collegiate athletes. However, these entities had no role in the conceptualization or content of the current manuscript or the decision to submit for publication.	[Anonymous], SPORTINGNEWS, V2012; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Axelrod BN, 2007, INT J NEUROSCI, V117, P1591, DOI 10.1080/00207450600941189; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT, 1989, MILD HEAD INJURY, P257; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brooks BL, 2008, J INT NEUROPSYCH SOC, V14, P463, DOI 10.1017/S1355617708080521; Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Brooks BL, 2013, PRACT RESOUR MENT, P75, DOI 10.1016/B978-0-12-386934-0.00002-X; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Chelune GJ, 2003, PREDICTION IN FORENSIC AND NEUROPSYCHOLOGY, P123; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P498; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comper P, 2010, BRAIN INJURY, V24, P1257, DOI 10.3109/02699052.2010.506854; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Delis DC., 2001, DELIS KAPLAN EXECUTI; Delis DC., 1994, CALIFORNIA VERBAL LE; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Franzen M. D., 1989, RELIABILITY VALIDITY; Franzen M. D., 2000, RELIABILITY VALIDITY; Gardner A, 2012, APPL NEUROPSYCH-ADUL, V19, P90, DOI 10.1080/09084282.2011.643945; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Heaton R. K., 2004, REVISED COMPREHENSIV; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Heaton RK, 1991, COMPREHENSIVE NORMS; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Iverson G. L., 2011, HDB SPORT NEUROPSYCH, P131; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 1998, INT J GERIATR PSYCH, V13, P661, DOI 10.1002/(SICI)1099-1166(1998100)13:10<661::AID-GPS838>3.0.CO;2-0; Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3; Iverson GL, 2012, NEUROPSYCHOLOGICAL A, P360; Iverson GL, 2008, NEUROPSYCHOLOGY COUR, P243; Iverson GL, 2009, BRIT J SPORT MED, V43, pi100; Iverson GL, 2007, J INT NEUROPSYCH SOC, V13, P65; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P923, DOI 10.1007/978-0-387-76978-3_32; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; JACOBSON NS, 1988, BEHAV ASSESS, V10, P133; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Lovell M. R., 2002, Medicine & Science in Sports & Exercise, V34, pS298, DOI 10.1097/00005768-200205001-01680; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Palmer BW, 1998, ARCH CLIN NEUROPSYCH, V13, P503, DOI 10.1016/S0887-6177(97)00037-1; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Putukian M, 2012, ANN C 4 INT CONS C C; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Resch JE, 2013, CLIN NEUROPSYCHOL, V27, P1265, DOI 10.1080/13854046.2013.845247; Resch JE, 2012, EQUIVALENCE ALTERNAT; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wechsler D, 2003, WECHSLER INTELLIGENC	99	50	50	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	2					263	275		10.3109/02699052.2014.965214			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AZ4OI	WOS:000348201500015	25313596				2022-02-06	
J	Theodoroff, SM; Lewis, MS; Folmer, RL; Henry, JA; Carlson, KF				Theodoroff, Sarah M.; Lewis, M. Samantha; Folmer, Robert L.; Henry, James A.; Carlson, Kathleen F.			Hearing Impairment and Tinnitus: Prevalence, Risk Factors, and Outcomes in US Service Members and Veterans Deployed to the Iraq and Afghanistan Wars	EPIDEMIOLOGIC REVIEWS			English	Article						hearing loss; prevalence; risk factors; tinnitus; veterans' health	TRAUMATIC BRAIN-INJURY; OPERATION ENDURING FREEDOM; COMBAT WOUNDS; BLAST INJURY; GLOBAL WAR; MECHANISM; TERROR; AIDS	Hearing loss and tinnitus are the 2 most prevalent service-connected disabilities among veterans in the United States. Veterans of Operations Enduring Freedom, Iraqi Freedom, and New Dawn have been exposed to multiple hazards associated with these conditions, such as blasts/explosions, ototoxic chemicals, and most notably high levels of noise. We conducted a systematic literature review of evidence on 1) prevalence of, 2) risk and protective factors for, and 3) functional and quality-of-life outcomes of hearing impairment and tinnitus in US Operations Enduring Freedom, Iraqi Freedom, and New Dawn veterans and military personnel. We identified studies published from 2001 through 2013 using PubMed, PsycINFO, REHABDATA, Cochrane Library, pearling, and expert recommendation. Peer-reviewed English language articles describing studies of 30 or more adults were included if they informed one or more key questions. A total of 839 titles/abstracts were reviewed for relevance by investigators trained in critical analysis of literature; 14 studies met inclusion criteria. Of these, 13 studies presented data on prevalence and 4 on risk/protective factors, respectively. There were no included studies reporting on outcomes. Findings from this systematic review will help inform clinicians, researchers, and policy makers on future resource and research needs pertaining to hearing impairment and tinnitus in this newest generation of veterans.	[Theodoroff, Sarah M.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA		Theodoroff, SM (corresponding author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA.	sarah.theodoroff@va.gov	Folmer, Robert L/E-3105-2010		Department of Defense Congressionally Directed Medical Research ProgramsUnited States Department of Defense [PR121146]; Veterans Health Administration Health Services Research and Development ServiceUS Department of Veterans Affairs [CDA 08-025]; National Center for Rehabilitative Auditory Research - VA RR&D at the Portland VA Medical Center [C9230C]	This work was supported, in part, by the Department of Defense Congressionally Directed Medical Research Programs (PR121146 to J. A. H.) and a career development grant from the Veterans Health Administration Health Services Research and Development Service (CDA 08-025 to K. F. C.). Additional support was provided by the National Center for Rehabilitative Auditory Research (funded by VA RR&D grant C9230C) at the Portland VA Medical Center.	[Anonymous], 2012, RS21405 CRS; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belmont Philip J, 2010, J Surg Orthop Adv, V19, P2; Belmont PJ, 2012, J TRAUMA ACUTE CARE, V73, P3, DOI 10.1097/TA.0b013e318250bfb4; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Defense Casualty Analysis System US Department of Defense, 2014, US MIL CAS GWOT CAS; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Defense, 2014, PRINC WARS WHICH US; Department of Veterans Affairs Office of Research and Development, 2013, TRAUM BRAIN INJ SPOT; Dobie R. A. J. B., 2004, TINNITUS THEORY MANA, p1 7; Donnelly K, 2008, DEP VET AFF QUERI NA; Dougherty AL, 2013, J REHABIL RES DEV, V50, P893, DOI 10.1682/JRRD.2012.02.0024; Epidemiology Program Post-Deployment Health Group Office of Public Health Veterans Health Administration Department of Veterans Affairs, 2014, AN VA HLTH CAR UT OP; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Folmer RL, 2011, J REHABIL RES DEV, V48, P503, DOI 10.1682/JRRD.2010.07.0138; Frayne SM, 2011, J GEN INTERN MED, V26, P33, DOI 10.1007/s11606-010-1497-4; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Geiling J, 2012, MIL MED, V177, P1235, DOI 10.7205/MILMED-D-12-00031; Helfer Thomas M, 2005, Am J Audiol, V14, P161, DOI 10.1044/1059-0889(2005/018); Helfer TM, 2011, AM J AUDIOL, V20, P33, DOI 10.1044/1059-0889(2011/10-0033); Henry James A, 2008, Trends Amplif, V12, P170, DOI 10.1177/1084713808319941; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2014, GULF WAR HLTH, V9; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Mrena R, 2004, ACTA OTO-LARYNGOL, V124, P946, DOI 10.1080/00016480310017045; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Nagorski T, 2010, ABC NEWS; National Research Council, 2006, NOIS MIL SERV IMPL H; Oleksiak M, 2012, J REHABIL RES DEV, V49, P995, DOI 10.1682/JRRD.2011.01.0001; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Papesh MA, 2014, 37 ANN MIDWINTER M A; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Searchfield GD, 2010, INT J AUDIOL, V49, P574, DOI 10.3109/14992021003777267; Shekhawat GS, 2013, J AM ACAD AUDIOL, V24, P747, DOI 10.3766/jaaa.24.8.11; Surjan G, 1999, INT J MED INFORM, V54, P77, DOI 10.1016/S1386-5056(98)00171-3; U.S. Department of Defense, 1997, MILSTD1474D US DEP D; *US DEP HHS, 2003, DHHS PUBL; van Walraven C, 2012, J CLIN EPIDEMIOL, V65, P126, DOI 10.1016/j.jclinepi.2011.08.002; Veterans Benefits Administration US Department of Veterans Affairs, 2014, ANN BEN REPO FISC YE; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Williamson V., 2009, INVISIBLE WOUNDS PSY; Zaugg T. L., 2002, P 7 INT TINN SEM, P226	46	50	51	0	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0193-936X	1478-6729		EPIDEMIOL REV	Epidemiol. Rev.		2015	37	1					71	85		10.1093/epirev/mxu005			15	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	CL3ZX	WOS:000356892800006	25600417	Green Submitted, Bronze			2022-02-06	
J	Chevignard, MP; Lind, K				Chevignard, Mathilde P.; Lind, Katia			Long-term outcome of abusive head trauma	PEDIATRIC RADIOLOGY			English	Article						Abusive head trauma; Shaken baby syndrome; Traumatic brain injury; Long-term outcome; Cognitive impairment; Children	SHAKEN-BABY-SYNDROME; BRAIN-INJURY; YOUNG-CHILDREN; IMPACT SYNDROME; FOLLOW-UP; RADIOLOGICAL FINDINGS; SYNDROME GUIDELINES; COGNITIVE SEQUELAE; ROBUST DIAGNOSIS; PREDICTIVE-VALUE	Abusive head trauma is a severe inflicted traumatic brain injury, occurring under the age of 2 years, defined by an acute brain injury (mostly subdural or subarachnoidal haemorrhage), where no history or no compatible history with the clinical presentation is given. The mortality rate is estimated at 20-25% and outcome is extremely poor. High rates of impairments are reported in a number of domains, such as delayed psychomotor development; motor deficits (spastic hemiplegia or quadriplegia in 15-64%); epilepsy, often intractable (11-32%); microcephaly with corticosubcortical atrophy (61-100%); visual impairment (18-48%); language disorders (37-64%), and cognitive, behavioral and sleep disorders, including intellectual deficits, agitation, aggression, tantrums, attention deficits, memory, inhibition or initiation deficits (23-59%). Those combined deficits have obvious consequences on academic achievement, with high rates of special education in the long term. Factors associated with worse outcome include demographic factors (lower parental socioeconomic status), initial severe presentation (e.g., presence of a coma, seizures, extent of retinal hemorrhages, presence of an associated cranial fracture, extent of brain lesions, cerebral oedema and atrophy). Given the high risk of severe outcome, long-term comprehensive follow-up should be systematically performed to monitor development, detect any problem and implement timely adequate rehabilitation interventions, special education and/or support when necessary. Interventions should focus on children as well as families, providing help in dealing with the child's impairment and support with psychosocial issues. Unfortunately, follow-up of children with abusive head trauma has repeatedly been reported to be challenging, with very high attrition rates.	[Chevignard, Mathilde P.] St Maurice Hosp, Rehabil Dept Children Acquired Neurol Injury, F-94410 St Maurice, France; [Chevignard, Mathilde P.] Univ Paris 06, Sorbonne Univ, UMR 7371, UMRS 1146,LIB, Paris, France; [Chevignard, Mathilde P.] CNRS, UMR 7371, LIB, Paris, France; [Chevignard, Mathilde P.] INSERM, UMRS 1146, LIB, Paris, France; [Lind, Katia] Necker Enfants Malades Hosp, Paris, France; [Lind, Katia] Paris Descartes Univ, Paris, France		Chevignard, MP (corresponding author), St Maurice Hosp, Rehabil Dept Children Acquired Neurol Injury, 14 Rue Val Osne, F-94410 St Maurice, France.	m.chevignard@hopitaux-st-maurice.fr					Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Ashton R, 2010, J CHILD PSYCHOL PSYC, V51, P967, DOI 10.1111/j.1469-7610.2010.02272.x; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Benayer B, 2000, APRES DEVENIR POPULA, P159; Bonnier C, 2006, ARCH PEDIATRIE, V13, P531, DOI 10.1016/j.arcped.2006.03.113; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Bonnier C, 2003, PEDIATRICS, V112, P808, DOI 10.1542/peds.112.4.808; Bourgeois M, 2008, CHILD NERV SYST, V24, P169, DOI 10.1007/s00381-007-0493-4; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Chevignard M, 2010, CHILD CARE HLTH DEV, V36, P31, DOI 10.1111/j.1365-2214.2009.00949.x; Chevignard MP, 2010, CURR OPIN NEUROL, V23, P695, DOI 10.1097/WCO.0b013e328340296f; David TJ, 1999, J ROY SOC MED, V92, P556, DOI 10.1177/014107689909201105; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Fanconi M, 2010, EUR J PEDIATR, V169, P1023, DOI 10.1007/s00431-010-1175-x; FISCHER H, 1994, CLIN PEDIATR, V33, P696, DOI 10.1177/000992289403301113; Friedman J, 2012, CHILD ABUSE NEGLECT, V36, P760, DOI 10.1016/j.chiabu.2012.07.008; Greiner MV, 2012, CHILD NERV SYST, V28, P889, DOI 10.1007/s00381-012-1714-z; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Ilves P, 2010, ACTA PAEDIATR, V99, P1329, DOI 10.1111/j.1651-2227.2010.01820.x; Jayawant S, 2007, ARCH DIS CHILD, V92, P343, DOI 10.1136/adc.2005.084988; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson AR, 2009, DEV DISABIL RES REV, V15, P124, DOI 10.1002/ddrr.63; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Kairys SW, 2001, PEDIATRICS, V108, P206; Kapapa T, 2010, J CHILD NEUROL, V25, P409, DOI 10.1177/0883073809340697; Karandikar S., 2004, CHILD ABUSE REV, V13, P178, DOI DOI 10.1002/CAR.850; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Laurent-Vannier A., 2011, Annals of Physical and Rehabilitation Medicine, V54, P533, DOI 10.1016/j.rehab.2011.10.003; Laurent-Vannier A., 2011, Annals of Physical and Rehabilitation Medicine, V54, P600, DOI 10.1016/j.rehab.2011.10.002; Laurent-Vannier A, 2009, Ann Phys Rehabil Med, V52, P436, DOI 10.1016/j.rehab.2009.03.001; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Libby AM, 2003, PEDIATRICS, V112, P58, DOI 10.1542/peds.112.1.58; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Lind K, 2012, BRAIN INJURY, V26, P532; Lo T Y M, 2003, Pediatr Rehabil, V6, P47, DOI 10.1080/1363849031000109516; Minns RA, 2005, CLIN DEV MED, P364; OLIVER JE, 1975, BRIT MED J, V2, P262, DOI 10.1136/bmj.2.5965.262; Rhine T, 2012, J TRAUMA ACUTE CARE, V73, pS248, DOI 10.1097/TA.0b013e31826b0062; Stipanicic A, 2008, CHILD ABUSE NEGLECT, V32, P415, DOI 10.1016/j.chiabu.2007.07.008; Talvik I, 2007, ACTA PAEDIATR, V96, P1164, DOI 10.1111/j.1651-2227.2007.00362.x; Talvik I, 2006, ACTA PAEDIATR, V95, P799, DOI 10.1080/08035250500464923; Tanoue K, 2013, ACTA PAEDIATR, V102, P805, DOI 10.1111/apa.12281; Tanoue K, 2012, ACTA PAEDIATR, V101, P614, DOI 10.1111/j.1651-2227.2012.02635.x; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Toure H, 2007, DEV NEUROREHABIL, P275; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Vinchon M, 2003, PEDIATR NEUROSURG, V39, P122, DOI 10.1159/000071648	65	50	51	1	42	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	DEC	2014	44			4	SI		548	558		10.1007/s00247-014-3169-8			11	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	AW4KG	WOS:000346249400004	25501726				2022-02-06	
J	Le Roux, P; Menon, DK; Citerio, G; Vespa, P; Bader, MK; Brophy, G; Diringer, MN; Stocchetti, N; Videtta, W; Armonda, R; Badjatia, N; Bosel, J; Chesnut, R; Chou, S; Claassen, J; Czosnyka, M; De Georgia, M; Figaji, A; Fugate, J; Helbok, R; Horowitz, D; Hutchinson, P; Kumar, M; McNett, M; Miller, C; Naidech, A; Oddo, M; Olson, D; O'Phelan, K; Provencio, JJ; Puppo, C; Riker, R; Roberson, C; Schmidt, M; Taccone, F				Le Roux, Peter; Menon, David K.; Citerio, Giuseppe; Vespa, Paul; Bader, Mary Kay; Brophy, Gretchen; Diringer, Michael N.; Stocchetti, Nino; Videtta, Walter; Armonda, Rocco; Badjatia, Neeraj; Boesel, Julian; Chesnut, Randall; Chou, Sherry; Claassen, Jan; Czosnyka, Marek; De Georgia, Michael; Figaji, Anthony; Fugate, Jennifer; Helbok, Raimund; Horowitz, David; Hutchinson, Peter; Kumar, Monisha; McNett, Molly; Miller, Chad; Naidech, Andrew; Oddo, Mauro; Olson, DaiWai; O'Phelan, Kristine; Provencio, J. Javier; Puppo, Corinna; Riker, Richard; Roberson, Claudia; Schmidt, Michael; Taccone, Fabio			The International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: A List of Recommendations and Additional Conclusions A Statement for Healthcare Professionals From the Neurocritical Care Society and the European Society of Intensive Care Medicine	NEUROCRITICAL CARE			English	Article						Consensus development conference; Grading of recommendations assessment development and evaluation (GRADE); Brain metabolism; Brain oxygen; Clinical trials; Intracranial pressure; Microdialysis; Multimodal monitoring; Neuromonitoring; Traumatic brain injury; Brain physiology; Bio-informatics; Biomarkers; Neurocritical care; Clinical guidelines		Careful patient monitoring using a variety of techniques including clinical and laboratory evaluation, bedside physiological monitoring with continuous or non-continuous techniques and imaging is fundamental to the care of patients who require neurocritical care. How best to perform and use bedside monitoring is still being elucidated. To create a basic platform for care and a foundation for further research the Neurocritical Care Society in collaboration with the European Society of Intensive Care Medicine, the Society for Critical Care Medicine and the Latin America Brain Injury Consortium organized an international, multidisciplinary consensus conference to develop recommendations about physiologic bedside monitoring. This supplement contains a Consensus Summary Statement with recommendations and individual topic reviews as a background to the recommendations. In this article, we highlight the recommendations and provide additional conclusions as an aid to the reader and to facilitate bedside care.	[Le Roux, Peter] Lankenau Med Ctr, Brain & Spine Ctr, Wynnewood, PA 19096 USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Neurosci Crit Care Unit, Cambridge CB2 2QQ, England; [Citerio, Giuseppe] Osped San Gerardo, Dept Anesthesia & Crit Care, I-20900 Monza, Italy; [Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Bader, Mary Kay] Neuro Crit Care CNS Mission Hosp, Mission Viejo, CA 92691 USA; [Brophy, Gretchen] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA 23298 USA; [Brophy, Gretchen] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Diringer, Michael N.] Washington Univ, Neurocrit Care Sect, Dept Neurol, St Louis, MO 63110 USA; [Stocchetti, Nino] Univ Milan, Dept Physiopathol & Transplant, Maggiore Policlin, Fdn IRCCS Ca Granda Osped, I-20122 Milan, Italy; [Videtta, Walter] Hosp Nacl Prof A Posadas, ICU Neurocrit Care, El Palomar, Buenos Aires, Argentina; [Armonda, Rocco] MedStar Georgetown Univ Hosp, Dept Neurosurg, Medstar Hlth, Washington, DC 20007 USA; [Badjatia, Neeraj] Univ Maryland, Dept Neurol, Med Ctr, Baltimore, MD 21201 USA; [Boesel, Julian] Univ Heidelberg Hosp, Dept Neurol Ruprect Karls, D-69120 Heidelberg, Germany; [Chesnut, Randall] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Chou, Sherry] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; [Claassen, Jan] Columbia Univ Coll Phys & Surg, Dept Neurol & Neurosurg, New York, NY 10017 USA; [Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 0QQ, England; [De Georgia, Michael] Case Western Reserve Univ, Sch Med, Dept Neurol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Figaji, Anthony] Univ Cape Town, Inst Child Hlth Red Cross Childrens Hosp Rondebos, Dept Pediat Neurosurg, ZA-7700 Cape Town, South Africa; [Fugate, Jennifer] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Helbok, Raimund] Med Univ Innsbruck, Dept Neurol, Neurocrit Care Unit, A-6020 Innsbruck, Austria; [Horowitz, David] Univ Penn Hlth Syst, Philadelphia, PA 19104 USA; [Hutchinson, Peter] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Kumar, Monisha] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [McNett, Molly] MetroHlth Syst, Cleveland, OH 44109 USA; [Miller, Chad] Ohio State Univ, Div Cerebrovasc Dis & Neurocrit Care, Columbus, OH 43210 USA; [Naidech, Andrew] Univ Feinberg SOM, Dept Neurol Northwestern, Chicago, IL 60611 USA; [Oddo, Mauro] Med Univ Lausanne, CHUV Univ Hosp, Dept Intens Care Med, Fac Biol, CH-1011 Lausanne, Switzerland; [Olson, DaiWai] Univ Texas Southwestern, Dept Neurol Neurotherapeut & Neurosurg, Dallas, TX 75390 USA; [O'Phelan, Kristine] Univ Miami, Miller Sch Med JMH, Dept Neurol, Miami, FL 33136 USA; [Provencio, J. Javier] Cleveland Clin, Lerner Coll Med, Cerebrovasc Ctr, Cleveland, OH 44195 USA; [Provencio, J. Javier] Cleveland Clin, Lerner Coll Med, Neuroinflammat Res Ctr, Cleveland, OH 44195 USA; [Puppo, Corinna] Univ Republica, Hosp Clin, Intens Care Unit, Montevideo, Uruguay; [Riker, Richard] Maine Med Ctr, Crit Care Med, Portland, ME 04102 USA; [Roberson, Claudia] Baylor Coll Med, Ben Taub Hosp, Dept Neurosurg, Houston, TX 77030 USA; [Schmidt, Michael] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Taccone, Fabio] Free Univ Brussels, Erasme Hosp, Dept Intens Care, Lab Rech Expt, B-1050 Brussels, Belgium		Le Roux, P (corresponding author), Lankenau Med Ctr, Brain & Spine Ctr, Suite 370,Med Sci Bldg,100 East Lancaster Ave, Wynnewood, PA 19096 USA.	lerouxp@mlhs.org; dkm13@wbic.cam.ac.uk; g.citerio@hsgerardo.org; PVespa@mednet.ucla.edu; Marykay.Bader@stjoe.org; gbrophy@vcu.edu; diringerm@neuro.wustl.edu; stocchet@policlinico.mi.it; wvidetta@ar.inter.net; Rocco.Armonda@gmail.com; nbadjatia@umm.edu; Julian.Boesel@med.uni-heidelberg.de; chesnutr@u.washington.edu; schou1@partners.org; jc1439@cumc.columbia.edu; mc141@medschl.cam.ac.uk; michael.degeorgia@uhhospitals.org; anthony.figaji@uct.ac.za; Jennifer@mayo.edu; raimund.helbok@uki.at; david.horowitz@uphs.upenn.edu; pjah2@cam.ac.uk; monisha.kumar@uphs.upenn.edu; mmcnett@metrohealth.org; ChadM.Miller@osumc.edu; ANaidech@nmff.org; Mauro.Oddo@chuv.ch; daiwai.olson@utsouthwestern.edu; kophelan@med.miami.edu; provenj@ccf.org; coripuppo@gmail.com; RRiker@cmamaine.com; claudiar@bcm.tmc.edu; mjs2134@columbia.edu; ftaccone@ulb.ac.be	Olson, DaiWai/I-5932-2019; Badjatia, Neeraj/AAS-4855-2021; Claassen, Jan/AAA-5451-2020; Chou, Sherry/G-5779-2015; Diringer, Michael N/C-1165-2008; Provencio, Jose Javier/AAG-5114-2021; Oddo, Mauro/R-3370-2016; Helbok, Raimund/AAA-8361-2021; Citerio, Giuseppe/B-1839-2015; Stocchetti, Nino/O-7444-2017	Olson, DaiWai/0000-0002-9280-078X; Chou, Sherry/0000-0002-5483-2908; Diringer, Michael N/0000-0003-2337-5537; Provencio, Jose Javier/0000-0003-1298-1806; Oddo, Mauro/0000-0002-6155-2525; Citerio, Giuseppe/0000-0002-5374-3161; Stocchetti, Nino/0000-0003-3250-6834; Chesnut, Randall/0000-0001-6377-3666; Hutchinson, Peter/0000-0002-2796-1835; Brophy, Gretchen/0000-0002-4749-2693; Badjatia, Neeraj/0000-0003-1509-9034; Figaji, Anthony/0000-0002-3357-6490; czosnyka, marek/0000-0003-2446-8006	Department of HealthEuropean Commission [12/35/57, NIHR-RP-R3-12-013] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G9439390, G0601025, G0001237, G0600986] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS073806] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601025, G9439390, G0600986, G1002277, G0001237] Funding Source: UKRI; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, 12/35/57, NF-SI-0512-10090] Funding Source: researchfish		Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Jaeschke R, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a744; Le Roux P, 2014, NEUROCRIT CARE, V21, P1, DOI 10.1007/s12028-014-0041-5; Rochwerg B, 2014, INTENS CARE MED, V40, P877, DOI 10.1007/s00134-014-3273-0; Stubbs B., 2017, BMJ, V7, P1, DOI [10.1038/s41467-019-10003-8, 10.1038/s41598-017-07579-w, DOI 10.1136/BMJ.B2535]	5	50	50	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2014	21			2			282	296		10.1007/s12028-014-0077-6			15	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CD7AM	WOS:000351242600019	25501689	Green Accepted			2022-02-06	
J	Stepniak, B; Papiol, S; Hammer, C; Ramin, A; Everts, S; Hennig, L; Begemann, M; Ehrenreich, H				Stepniak, Beata; Papiol, Sergi; Hammer, Christian; Ramin, Anna; Everts, Sarah; Hennig, Lena; Begemann, Martin; Ehrenreich, Hannelore			Accumulated environmental risk determining age at schizophrenia onset: a deep phenotyping-based study	LANCET PSYCHIATRY			English	Article							GENOME-WIDE ASSOCIATION; WHITE-MATTER VOLUME; CANNABIS USE; CHILDHOOD TRAUMA; LIFE STRESS; PSYCHOSIS; METAANALYSIS; SAMPLE; BRAIN; BIRTH	Background Schizophrenia is caused by a combination of genetic and environmental factors, as first evidenced by twin studies. Extensive efforts have been made to identify the genetic roots of schizophrenia, including large genome-wide association studies, but these yielded very small effect sizes for individual markers. In this study, we aimed to assess the relative contribution of genome-wide association study-derived genetic versus environmental risk factors to crucial determinants of schizophrenia severity: disease onset, disease severity, and socioeconomic measures. Methods In this parallel analysis, we studied 750 male patients from the Gottingen Research Association for Schizophrenia (GRAS) dataset (Germany) with schizophrenia for whom both genome-wide coverage of single-nucleotide polymorphisms and deep clinical phenotyping data were available. Specifically, we investigated the potential effect of schizophrenia risk alleles as identified in the most recent large genome-wide association study versus the effects of environmental hazards (ie, perinatal brain insults, cannabis use, neurotrauma, psychotrauma, urbanicity, and migration), alone and upon accumulation, on age at disease onset, age at prodrome, symptom expression, and socioeconomic parameters. Findings In this study, we could show that frequent environmental factors become a major risk for early schizophrenia onset when accumulated (prodrome begins up to 9 years earlier; p=2.9x10(-10)). In particular, cannabis use-an avoidable environmental risk factor-is highly significantly associated with earlier age at prodrome (p=3.8x10(-2)0). By contrast, polygenic genome-wide association study risk scores did not have any detectable effects on schizophrenia phenotypes. Interpretation These findings should be translated to preventive measures to reduce environmental risk factors, since age at onset of schizophrenia is a crucial determinant of an affected individual's fate and the total socioeconomic cost of the illness.	[Stepniak, Beata; Papiol, Sergi; Hammer, Christian; Ramin, Anna; Everts, Sarah; Hennig, Lena; Begemann, Martin; Ehrenreich, Hannelore] Max Planck Inst Expt Med, D-37075 Gottingen, Germany; [Papiol, Sergi; Ehrenreich, Hannelore] DFG Res Ctr Nanoscale Microscopy & Mol Physiol Br, Gottingen, Germany		Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Hammer, Christian/C-5827-2014	Hammer, Christian/0000-0003-4548-7548; Papiol, Sergi/0000-0001-9366-8728; Ehrenreich, Hannelore/0000-0001-8371-5711	Max Planck SocietyMax Planck Society; Max Planck ForderstiftungMax Planck Society; German Research Foundation (Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain); EXTRABRAIN EU-FP7; ERA-Net NEURON [01EW1106]	This work was supported by the Max Planck Society, Max Planck Forderstiftung, the German Research Foundation (Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain), EXTRABRAIN EU-FP7, and ERA-Net NEURON (grant no. 01EW1106). We thank all Gottingen Research Association for Schizophrenia (GRAS) patients for participating in the study, and all the many colleagues who have contributed to the GRAS data collection during the past 10 years.	Abel KM, 2010, INT REV PSYCHIATR, V22, P417, DOI 10.3109/09540261.2010.515205; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; ANDREASSON S, 1987, LANCET, V2, P1483, DOI 10.1016/s0140-6736(87)92620-1; Beards S, 2013, SCHIZOPHRENIA BULL, V39, P740, DOI 10.1093/schbul/sbt065; Begemann M, 2010, ARCH GEN PSYCHIAT, V67, P879, DOI 10.1001/archgenpsychiatry.2010.107; Brown AS, 2011, PROG NEUROBIOL, V93, P23, DOI 10.1016/j.pneurobio.2010.09.003; Cardno AG, 2000, AM J MED GENET, V97, P12, DOI 10.1002/(SICI)1096-8628(200021)97:1<12::AID-AJMG3>3.3.CO;2-L; Delaneau O, 2013, NAT METHODS, V10, P5, DOI 10.1038/nmeth.2307; Di Forti M, 2007, CURR OPIN PSYCHIATR, V20, P228; Ehrenreich H, 1999, PSYCHOPHARMACOLOGY, V142, P295, DOI 10.1007/s002130050892; Ehrenreich H, 2014, GENES-BASEL, V5, P97, DOI 10.3390/genes5010097; Fanous AH, 2012, AM J PSYCHIAT, V169, P1309, DOI 10.1176/appi.ajp.2012.12020218; Giusti-Rodriguez P, 2013, J CLIN INVEST, V123, P4557, DOI 10.1172/JCI66031; Glaser JP, 2006, J PSYCHOSOM RES, V61, P229, DOI 10.1016/j.jpsychores.2006.04.014; Hafner H, 2003, SCHIZOPHRENIA, P101; Hammer C, 2014, MOL PSYCHIATR, V19, P1143, DOI 10.1038/mp.2013.110; Hare E, 2010, AM J MED GENET B, V153B, P298, DOI 10.1002/ajmg.b.30959; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Korosi A, 2012, BEHAV BRAIN RES, V227, P400, DOI 10.1016/j.bbr.2011.07.037; Large M, 2011, ARCH GEN PSYCHIAT, V68, P555, DOI 10.1001/archgenpsychiatry.2011.5; Lederbogen F, 2011, NATURE, V474, P498, DOI 10.1038/nature10190; Malone DT, 2010, BRIT J PHARMACOL, V160, P511, DOI 10.1111/j.1476-5381.2010.00721.x; McDonald C, 2000, BRAIN RES REV, V31, P130, DOI 10.1016/S0165-0173(99)00030-2; Messias E, 2004, ARCH GEN PSYCHIAT, V61, P985, DOI 10.1001/archpsyc.61.10.985; Miller B, 2011, SCHIZOPHRENIA BULL, V37, P1039, DOI 10.1093/schbul/sbq011; Monshouwer K, 2005, ADDICTION, V100, P963, DOI 10.1111/j.1360-0443.2005.01088.x; Mortensen PB, 1999, NEW ENGL J MED, V340, P603, DOI 10.1056/NEJM199902253400803; Papiol S, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.126; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Read J, 2005, ACTA PSYCHIAT SCAND, V112, P330, DOI 10.1111/j.1600-0447.2005.00634.x; Ribbe K, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-91; Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Romeo RD, 2010, DEV PSYCHOBIOL, V52, P244, DOI 10.1002/dev.20437; Schneider M, 2008, ADDICT BIOL, V13, P253, DOI 10.1111/j.1369-1600.2008.00110.x; Semple DM, 2005, J PSYCHOPHARMACOL, V19, P187, DOI 10.1177/0269881105049040; Sturman DA, 2011, NEUROSCI BIOBEHAV R, V35, P1704, DOI 10.1016/j.neubiorev.2011.04.003; van Os J, 2010, NATURE, V468, P203, DOI 10.1038/nature09563; van Scheltinga AFT, 2013, BIOL PSYCHIAT, V73, P525, DOI 10.1016/j.biopsych.2012.08.017; Verdoux H, 1997, AM J PSYCHIAT, V154, P1220	40	50	50	1	25	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2215-0374			LANCET PSYCHIAT	Lancet Psychiatry	NOV	2014	1	6					444	453		10.1016/S2215-0366(14)70379-7			10	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	AU5GP	WOS:000345635400025	26361199				2022-02-06	
J	Fakhran, S; Yaeger, K; Collins, M; Alhilali, L				Fakhran, Saeed; Yaeger, Karl; Collins, Michael; Alhilali, Lea			Sex Differences in White Matter Abnormalities after Mild Traumatic Brain Injury: Localization and Correlation with Outcome	RADIOLOGY			English	Article							TENSOR IMAGING FINDINGS; CONCUSSION SYMPTOMS; NEUROPSYCHOLOGICAL FUNCTION; UNCINATE FASCICULUS; GENDER; AGE; ADOLESCENCE; MODERATE	Purpose: To evaluate sex differences in diffusion-tensor imaging (DTI) white matter abnormalities after mild traumatic brain injury (mTBI) using tract-based spatial statistics (TBSS) and to compare associated clinical outcomes. Materials and Methods: The institutional review board approved this study, with waiver of informed consent. DTI in 69 patients with mTBI (47 male and 22 female patients) and 21 control subjects (10 male and 11 female subjects) with normal conventional magnetic resonance (MR) images were retrospectively reviewed. Fractional anisotropy (FA) maps were generated as a measure of white matter integrity. Patients with mTBI underwent serial neurocognitive testing with Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT). Correlation between sex, white matter FA values, ImPACT scores, and time to symptom resolution (TSR) were analyzed with multivariate analysis and TBSS. Results: No significant difference in age was seen between males and females (control subjects, P = .3; patients with mTBI, P = .34). No significant difference was seen in initial ImPACT symptom scores (P = .33) between male and female patients with mTBI. Male patients with mTBI had significantly decreased FA values in the uncinate fasciculus (UF) bilaterally (mean FA, 0.425; 95% confidence interval: 0.375, 0.476) compared with female patients with mTBI and control subjects (P < .05), with a significantly longer TSR (P = .04). Multivariate analysis showed sex and UF FA values independently correlated with TSR longer than 3 months (adjusted odds ratios, 2.27 and 2.38; P = .04 and P < .001, respectively), but initial symptom severity did not (adjusted odds ratio, 1.15; P = .35). Conclusion: Relative sparing of the UF is seen in female compared with male patients after mTBI, with sex and UF FA values as stronger predictors of TSR than initial symptom severity. (C) RSNA, 2014	[Fakhran, Saeed; Yaeger, Karl; Alhilali, Lea] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA 15213 USA; [Collins, Michael] Univ Pittsburgh, Sch Med, Sports Med Concuss Program, Pittsburgh, PA 15213 USA		Fakhran, S (corresponding author), Univ Pittsburgh, Sch Med, Dept Radiol, 200 Lothrop St,Presby South Tower,8th Floor, Pittsburgh, PA 15213 USA.	fakhrans@upmc.edu					Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Centers for Disease Control and Prevention (CDC), 2003, NATL CTR INJ PREV CO; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Farace E, 2000, Neurosurg Focus, V8, pe6; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Giorgio A, 2008, NEUROIMAGE, V39, P52, DOI 10.1016/j.neuroimage.2007.07.043; Giorgio A, 2010, NEUROIMAGE, V49, P94, DOI 10.1016/j.neuroimage.2009.08.003; Hasan KM, 2009, BRAIN RES, V1276, P67, DOI 10.1016/j.brainres.2009.04.025; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Inano S, 2011, AM J NEURORADIOL, V32, P2103, DOI 10.3174/ajnr.A2785; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lee AJY, 2007, J APPL BIOMECH, V23, P173, DOI 10.1123/jab.23.3.173; Ma JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub3; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Peters BD, 2012, SCHIZOPHRENIA BULL, V38, P1308, DOI 10.1093/schbul/sbs054; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Salimi-Khorshidi G, 2011, NEUROIMAGE, V54, P2006, DOI 10.1016/j.neuroimage.2010.09.088; Sato T, 2012, IEEE ENG MED BIO, P424, DOI 10.1109/EMBC.2012.6345958; Schumacher M, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00010; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Von Der Heide RJ, 2013, BRAIN, V136, P1692, DOI 10.1093/brain/awt094; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wang YY, 2012, BRAIN RES, V1478, P1, DOI 10.1016/j.brainres.2012.08.038; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y	36	50	50	0	16	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	SEP	2014	272	3					815	823		10.1148/radiol.14132512			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	AO2WX	WOS:000341188900022	24802388	Bronze			2022-02-06	
J	Grubenhoff, JA; Deakyne, SJ; Brou, L; Bajaj, L; Comstock, RD; Kirkwood, MW				Grubenhoff, Joseph A.; Deakyne, Sara J.; Brou, Lina; Bajaj, Lalit; Comstock, R. Dawn; Kirkwood, Michael W.			Acute Concussion Symptom Severity and Delayed Symptom Resolution	PEDIATRICS			English	Article						brain concussion; brain injury; acute; brain injury; traumatic; post-concussion symptoms; post-concussion syndrome; emergency medicine	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; SPORTS-RELATED CONCUSSION; POSTCONCUSSION SYNDROME; EMERGENCY-DEPARTMENT; CHILDREN; PREDICTION; ADOLESCENTS; RECOVERY; CRITERIA	BACKGROUND AND OBJECTIVES: Up to 30% of children who have concussion initially evaluated in the emergency department (ED) display delayed symptom resolution (DSR). Greater initial symptom severity may be an easily quantifiable predictor of DSR. We hypothesized that greater symptom severity immediately after injury increases the risk for DSR. METHODS: We conducted a prospective longitudinal cohort study of children 8 to 18 years old presenting to the ED with concussion. Acute symptom severity was assessed using a graded symptom inventory. Presence of DSR was assessed 1 month later. Graded symptom inventory scores were tested for association with DSR by sensitivity analysis. We conducted a similar analysis for post-concussion syndrome (PCS) as defined by the International Statistical Classification of Diseases and Related Health Problems, 10th revision. Potential symptoms characteristic of DSR were explored by using hierarchical cluster analysis. RESULTS: We enrolled 234 subjects; 179 (76%) completed follow-up. Thirty-eight subjects (21%) experienced DSR. Initial symptom severity was not significantly associated with DSR 1 month after concussion. A total of 22 subjects (12%) had PCS. Scores >10 (possible range, 0-28) were associated with an increased risk for PCS (RR, 3.1; 95% confidence interval 1.2-8.0). Three of 6 of the most characteristic symptoms of DSR were also most characteristic of early symptom resolution. However, cognitive symptoms were more characteristic of subjects reporting DSR. CONCLUSIONS: Greater symptom severity measured at ED presentation does not predict DSR but is associated with PCS. Risk stratification therefore depends on how the persistent symptoms are defined. Cognitive symptoms may warrant particular attention in future study. Follow-up is recommended for all patients after ED evaluation of concussion to monitor for DSR.	[Grubenhoff, Joseph A.; Brou, Lina; Bajaj, Lalit; Comstock, R. Dawn] Univ Colorado, Dept Pediat, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Grubenhoff, Joseph A.; Brou, Lina; Bajaj, Lalit] Childrens Hosp Colorado, Emergency Dept, Aurora, CO USA; [Deakyne, Sara J.] Childrens Hosp Colorado, Dept Res Informat, Aurora, CO USA; [Comstock, R. Dawn] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA		Grubenhoff, JA (corresponding author), 13123 East 16th Ave,B-251, Aurora, CO 80045 USA.	joe.grubenhoff@childrenscolorado.org	Grubenhoff, Joseph A/H-9994-2019; Meijer, Anna/K-5118-2016	Grubenhoff, Joseph A/0000-0001-5072-4064; 	Thrasher Research Fund Early Career Award; NIH/NCATS Colorado CTSIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000154]	Funding for the conduct of this study was provided by a Thrasher Research Fund Early Career Award to Dr Grubenhoff. Use of REDCap Database was supported by NIH/NCATS Colorado CTSI grant UL1 TR000154. Contents are the authors' sole responsibility and do not necessarily represent official NIH or Thrasher Research Fund views.	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Beckstead JW, 2002, WESTERN J NURS RES, V24, P307, DOI 10.1177/01939450222045923; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Drake AI, 2006, BRAIN INJURY, V20, P469, DOI 10.1080/02699050600676370; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faul M, 2010, TRAUMATIC BRAIN INJU; Frances A, 2013, ANN INTERN MED, V159, P221, DOI 10.7326/0003-4819-159-3-201308060-00655; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kendell R, 2003, AM J PSYCHIAT, V160, P4, DOI 10.1176/appi.ajp.160.1.4; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Moran LM, 2011, J HEAD TRAUMA REHAB, V26, P348, DOI 10.1097/HTR.0b013e3181f8d32e; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; *WHO, 1992, ICD 10 CLASS MEN BEH; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	51	50	50	0	17	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2014	134	1					54	62		10.1542/peds.2013-2988			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	AK9UZ	WOS:000338774800050	24958583				2022-02-06	
J	Babl, FE; Lyttle, MD; Bressan, S; Borland, M; Phillips, N; Kochar, A; Dalziel, SR; Dalton, S; Cheek, JA; Furyk, J; Gilhotra, Y; Neutze, J; Ward, B; Donath, S; Jachno, K; Crowe, L; Williams, A; Oakley, E				Babl, Franz E.; Lyttle, Mark D.; Bressan, Silvia; Borland, Meredith; Phillips, Natalie; Kochar, Amit; Dalziel, Stuart R.; Dalton, Sarah; Cheek, John A.; Furyk, Jeremy; Gilhotra, Yuri; Neutze, Jocelyn; Ward, Brenton; Donath, Susan; Jachno, Kim; Crowe, Louise; Williams, Amanda; Oakley, Ed		PREDICT Res Network	A prospective observational study to assess the diagnostic accuracy of clinical decision rules for children presenting to emergency departments after head injuries (protocol): the Australasian Paediatric Head Injury Rules Study (APHIRST)	BMC PEDIATRICS			English	Article						Head injury; Clinical decision rule; Computed tomography; Validation	COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; PREDICTION; CHALICE; CHILDHOOD; SCANS; CATCH; RISK	Background: Head injuries in children are responsible for a large number of emergency department visits. Failure to identify a clinically significant intracranial injury in a timely fashion may result in long term neurodisability and death. Whilst cranial computed tomography (CT) provides rapid and definitive identification of intracranial injuries, it is resource intensive and associated with radiation induced cancer. Evidence based head injury clinical decision rules have been derived to aid physicians in identifying patients at risk of having a clinically significant intracranial injury. Three rules have been identified as being of high quality and accuracy: the Canadian Assessment of Tomography for Childhood Head Injury (CATCH) from Canada, the Children's Head Injury Algorithm for the Prediction of Important Clinical Events (CHALICE) from the UK, and the prediction rule for the identification of children at very low risk of clinically important traumatic brain injury developed by the Pediatric Emergency Care Applied Research Network (PECARN) from the USA. This study aims to prospectively validate and compare the performance accuracy of these three clinical decision rules when applied outside the derivation setting. Methods/design: This study is a prospective observational study of children aged 0 to less than 18 years presenting to 10 emergency departments within the Paediatric Research in Emergency Departments International Collaborative (PREDICT) research network in Australia and New Zealand after head injuries of any severity. Predictor variables identified in CATCH, CHALICE and PECARN clinical decision rules will be collected. Patients will be managed as per the treating clinicians at the participating hospitals. All patients not undergoing cranial CT will receive a follow up call 14 to 90 days after the injury. Outcome data collected will include results of cranial CTs (if performed) and details of admission, intubation, neurosurgery and death. The performance accuracy of each of the rules will be assessed using rule specific outcomes and inclusion and exclusion criteria. Discussion: This study will allow the simultaneous comparative application and validation of three major paediatric head injury clinical decision rules outside their derivation setting.	[Babl, Franz E.; Lyttle, Mark D.; Bressan, Silvia; Cheek, John A.; Oakley, Ed] Royal Childrens Hosp, Dept Emergency Med, Parkville, Vic 3052, Australia; [Babl, Franz E.; Bressan, Silvia; Cheek, John A.; Ward, Brenton; Donath, Susan; Jachno, Kim; Crowe, Louise; Williams, Amanda; Oakley, Ed] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Babl, Franz E.; Donath, Susan; Jachno, Kim; Crowe, Louise; Williams, Amanda; Oakley, Ed] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Paediat, Melbourne, Vic 3010, Australia; [Babl, Franz E.] Natl Trauma Res Inst, Prahran, Vic, Australia; [Lyttle, Mark D.] Bristol Royal Hosp Children, Bristol, Avon, England; [Lyttle, Mark D.] Univ W England, Acad Dept Emergency Care, Bristol BS16 1QY, Avon, England; [Bressan, Silvia] Univ Padua, Padua, Italy; [Borland, Meredith] Princess Margaret Hosp Children, Perth, WA, Australia; [Phillips, Natalie] Univ Queensland, Royal Childrens Hosp, Brisbane, Qld, Australia; [Phillips, Natalie] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Kochar, Amit] Womens & Childrens Hosp, Adelaide, SA, Australia; [Dalziel, Stuart R.] Starship Hosp, Auckland, New Zealand; [Dalziel, Stuart R.] Univ Auckland, Liggins Inst, Auckland 1, New Zealand; [Dalton, Sarah] Childrens Hosp Westmead, Sydney, NSW, Australia; [Cheek, John A.] Monash Med Ctr, Clayton, Vic 3168, Australia; [Furyk, Jeremy] Townsville Hosp, Townsville, Qld, Australia; [Gilhotra, Yuri] Univ Queensland, Mater Childrens Hosp, Brisbane, Qld 4101, Australia; [Neutze, Jocelyn] Kidzfirst Middlemore Hosp, Auckland, New Zealand		Babl, FE (corresponding author), Royal Childrens Hosp, Dept Emergency Med, Flemington Rd, Parkville, Vic 3052, Australia.	franz.babl@rch.org.au		Furyk, Jeremy/0000-0002-9503-0928; Jachno, Kim/0000-0003-2550-9674; Donath, Susan/0000-0003-2489-3977; Crowe, Louise/0000-0003-4619-9708; Lyttle, Mark/0000-0002-8634-7210	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [GNT1046727]; Centre of Research Excellence for Paediatric Emergency Medicine, Canberra, Australia [GNT1058560]; Murdoch Childrens Research Institute, Melbourne, Australia; Queensland Emergency Medicine Research Foundation, Brisbane, Australia [EMPJ-11162]; Perpetual Philanthropic Services, Australia [2012/1140]; Auckland Medical Research Foundation [3112011]; A + Trust (Auckland District Health Board), Auckland, New Zealand; WA Health Targeted Research Funds , Perth, Australia; Townsville Hospital and Health Service Private Practice Research and Education Trust Fund, Townsville, Australia; Victorian Government's Infrastructure Support Program, Melbourne, Australia; Murdoch Children's Research Institute; Health Research Council of New ZealandHealth Research Council of New Zealand [HRC13/556]	We would like to thank participating families, emergency department staff and the site research assistants. The study is funded by grants from the National Health and Medical Research Council (project grant GNT1046727, Centre of Research Excellence for Paediatric Emergency Medicine GNT1058560), Canberra, Australia; the Murdoch Childrens Research Institute, Melbourne, Australia; the Queensland Emergency Medicine Research Foundation (EMPJ-11162), Brisbane, Australia; Perpetual Philanthropic Services (2012/1140), Australia; Auckland Medical Research Foundation (No. 3112011) and the A + Trust (Auckland District Health Board), Auckland, New Zealand; WA Health Targeted Research Funds 2013, Perth, Australia; the Townsville Hospital and Health Service Private Practice Research and Education Trust Fund, Townsville, Australia; and the Victorian Government's Infrastructure Support Program, Melbourne, Australia. FEB's time was part funded by a grant from the Murdoch Children's Research Institute. SRDs time was part funded by the Health Research Council of New Zealand (HRC13/556).	Bossuyt PM, 2003, BRIT MED J, V326, P41, DOI 10.1136/bmj.326.7379.41; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Conners GP, 1999, PEDIATR EMERG CARE, V15, P241; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Gazelle GS, 2005, RADIOLOGY, V235, P361, DOI 10.1148/radiol.2352040330; Hoyle JD, 2014, PEDIATR EMERG CARE, V30, P1, DOI 10.1097/PEC.0000000000000059; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lockie FD, 2013, EMERG MED AUSTRALAS, V25, P75, DOI 10.1111/1742-6723.12019; Lyttle MD, 2013, EMERG MED J, V30, P790, DOI 10.1136/emermed-2012-201887; Lyttle MD, 2012, EMERG MED J, V29, P785, DOI 10.1136/emermed-2011-200225; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; National Center for Health Statistics Centers for Disease Control and Prevention, 2005, PUBL US DAT FIL EM D; National Center for Health Statistics Centers for Disease Control and Prevention, 1995, PUBL US DAT FIL EM D; OSMOND M, 2012, CJEM S1, V14; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4	25	50	53	0	17	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2431			BMC PEDIATR	BMC Pediatr.	JUN 13	2014	14								148	10.1186/1471-2431-14-148			10	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	AK3WJ	WOS:000338355600002	24927811	Green Published, gold			2022-02-06	
J	Thelin, EP; Nelson, DW; Bellander, BM				Thelin, Eric P.; Nelson, David W.; Bellander, Bo-Michael			Secondary Peaks of S100B in Serum Relate to Subsequent Radiological Pathology in Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						S100B; Biomarkers; Neuro-intensive care; Traumatic brain injury; Secondary injury; Outcome	CRITICALLY-ILL PATIENTS; PROGNOSTIC VALUE; INTRAHOSPITAL TRANSPORT; COMPUTED-TOMOGRAPHY; CEREBRAL INFARCTION; S-100B PROTEIN; RISK-FACTORS; HEAD-INJURY; DAMAGE; INSULTS	Patients suffering from severe traumatic brain injury (TBI) often develop secondary brain lesions that may worsen outcome. S100B, a biomarker of brain damage, has been shown to increase in response to secondary cerebral deterioration. The aim of this study was to analyze the occurrence of secondary increases in serum levels of S100B and their relation to potential subsequent radiological pathology present on CT/MRI-scans. Retrospective study from a trauma level 1 hospital, neuro-intensive care unit. 250 patients suffering from TBI were included. Inclusion required a minimum of two radiological examinations and at least three serum samples of S100B, with at least one > 48 h after trauma. Secondary pathological findings on CT/MRI, present in 39 % (n = 98) of the patients, were highly correlated to secondary increases of a parts per thousand yen0.05 mu g/L S100B (P < 0.0001, pseudo-R (2) 0.532). Significance remained also after adjusting for known important TBI predictors. In addition, secondary radiological findings were significantly correlated to outcome (Glasgow Outcome Score, GOS) in uni-(P < 0.0001, pseudo-R (2) 0.111) and multivariate analysis. The sensitivity and specificity of detecting later secondary radiological findings was investigated at three S100B cut-off levels: 0.05, 0.1, and 0.5 mu g/L. A secondary increase of a parts per thousand yen0.05 mu g/L had higher sensitivity (80 %) but lower specificity (89 %), compared with a secondary increase of a parts per thousand yen0.5 mu g/L (16 % sensitivity, 98 % specificity), to detect secondary radiological findings. Secondary increases in serum levels of S100B, even as low as a parts per thousand yen0.05 mu g/L, beyond 48 h after TBI are strongly correlated to the development of clinically significant secondary radiological findings.	[Thelin, Eric P.; Bellander, Bo-Michael] Karolinska Inst, Karolinska Univ Hosp Solna, Sect Neurosurg, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Nelson, David W.] Karolinska Inst, Sect Anesthesiol & Intens Care, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden		Thelin, EP (corresponding author), Karolinska Inst, Karolinska Univ Hosp Solna, Sect Neurosurg, Dept Clin Neurosci, R2 02, S-17176 Stockholm, Sweden.	eric.thelin@ki.se; david.nelson@karolinska.se; bo-michael.bellander@karolinska.se	Viani, Rafael/V-1196-2018; Thelin, Eric Peter/K-2144-2012	Thelin, Eric Peter/0000-0002-2338-4364; Nelson, David/0000-0003-2530-8207			Acker JE, 2004, ADV TRAUMA LIFE SUPP; Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bouvier D, 2012, ANN BIOL CLIN-PARIS, V70, P269, DOI 10.1684/abc.2012.0701; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Einav S, 2008, BMC CLIN PATHOL, V8, DOI 10.1186/1472-6890-8-9; Fazio V, 2004, ANN THORAC SURG, V78, P46, DOI 10.1016/j.athoracsur.2003.11.042; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gunnarsson T, 2000, Neurosurg Focus, V9, pe5; HAIMOTO H, 1987, LAB INVEST, V57, P489; James ML, 2009, BIOMARKERS, V14, P388, DOI 10.1080/13547500903015784; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Lovell MA, 2001, ANAESTH INTENS CARE, V29, P400, DOI 10.1177/0310057X0102900412; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARSHALL LF, 1990, ACT NEUR S, V51, P300; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Moritz S, 2010, J NEUROSURG ANESTH, V22, P21, DOI 10.1097/ANA.0b013e3181bdf50d; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mussack T, 2006, CLIN BIOCHEM, V39, P349, DOI 10.1016/j.clinbiochem.2005.12.007; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Persson Malin Elisabet, 2012, Front Neurol, V3, P170, DOI 10.3389/fneur.2012.00170; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Smit LHM, 2005, INT J BIOL MARKER, V20, P34, DOI 10.1177/172460080502000106; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; TEASDALE G, 1974, LANCET, V2, P81; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Tian HL, 2008, NEUROSURG REV, V31, P431, DOI 10.1007/s10143-008-0153-5; Tong WS, 2012, BRAIN INJURY, V26, P1136, DOI 10.3109/02699052.2012.666437; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2004, SCAND J INFECT DIS, V36, P10, DOI 10.1080/00365540310017294; Unden J, 2007, NEUROCRIT CARE, V6, P94, DOI 10.1007/s12028-007-0005-0; USUI A, 1989, CLIN CHEM, V35, P1942; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	64	50	52	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2014	20	2					217	229		10.1007/s12028-013-9916-0			13	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AD0XA	WOS:000332956400007	24146416				2022-02-06	
J	Fan, WY; Dai, YQ; Xu, HC; Zhu, XM; Cai, P; Wang, LX; Sun, CG; Hu, CL; Zheng, P; Zhao, BQ				Fan, Wenying; Dai, Yiqin; Xu, Haochen; Zhu, Ximin; Cai, Ping; Wang, Lixiang; Sun, Chungang; Hu, Changlong; Zheng, Ping; Zhao, Bing-Qiao			Caspase-3 Modulates Regenerative Response After Stroke	STEM CELLS			English	Article						Stroke; Neurogenesis; Stroke recovery; Caspase-3; Neuronal precursor cells	FOCAL CEREBRAL-ISCHEMIA; PROGENITOR-CELL PROLIFERATION; TISSUE-PLASMINOGEN-ACTIVATOR; TRAUMATIC BRAIN-INJURY; MOUSE MODEL; SYNAPTIC PLASTICITY; STEM-CELLS; ENHANCES NEUROGENESIS; CLINICAL TRANSLATION; FUNCTIONAL RECOVERY	Stroke is a leading cause of long-lasting disability in humans. However, currently there are still no effective therapies available for promoting stroke recovery. Recent studies have shown that the adult brain has the capacity to regenerate neurons after stroke. Although this neurogenic response may be functionally important for brain repair after injury, the mechanisms underlying stroke-induced neurogenesis are not known. Caspase-3 is a major executioner and has been identified as a key mediator of neuronal death in the acute stage of stroke. Recently, however, accumulating data indicate that caspase-3 also participates in various biological processes that do not cause cell death. Here, we show that cleaved caspase-3 was increased in newborn neuronal precursor cells (NPCs) in the subventricular zone (SVZ) and the dentate gyrus during the period of stroke recovery, with no evidence of apoptosis. We observed that cleaved caspase-3 was expressed by NPCs and limited its self-renewal without triggering apoptosis in cultured NPCs from the SVZ of ischemic mice. Moreover, we revealed that caspase-3 negatively regulated the proliferation of NPCs through reducing the phosphorylation of Akt. Importantly, we demonstrated that peptide inhibition of caspase-3 activity significantly promoted the proliferation and migration of SVZ NPCs and resulted in a significant increase in subsequent neuronal regeneration and functional recovery after stroke. Together, our data identify a previously unknown caspase-3-dependent mechanism that constrains stroke-induced endogenous neurogenesis and should revitalize interest in targeting caspase-3 for treatment of stroke. Stem Cells2014;32:473-486	[Fan, Wenying; Dai, Yiqin; Xu, Haochen; Zhu, Ximin; Cai, Ping; Wang, Lixiang; Sun, Chungang; Hu, Changlong; Zheng, Ping; Zhao, Bing-Qiao] Fudan Univ, State Key Lab Med Neurobiol, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Fan, Wenying; Dai, Yiqin; Xu, Haochen; Zhu, Ximin; Cai, Ping; Wang, Lixiang; Sun, Chungang; Hu, Changlong; Zheng, Ping; Zhao, Bing-Qiao] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China; [Hu, Changlong] Fudan Univ, Sch Life Sci, Shanghai 200032, Peoples R China		Zhao, BQ (corresponding author), Fudan Univ, State Key Lab Med Neurobiol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	wenyingf@fudan.edu.cn; bingqiaoz@fudan.edu.cn	Hu, Changlong/AAQ-8348-2020	Hu, Changlong/0000-0002-8609-8947; Cai, Ping/0000-0003-2819-2940	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30971014, 81071062, 81271457]; National Program of Basic ResearchNational Basic Research Program of China; Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2011CB503700-G]	We thank Dr. Eng H Lo (Department of Radiology, MA General Hospital, Harvard Medical School) and Dr. Mingming Ning (Cardio-Neurology Clinic, Clinical Proteomics Research Center and Department of Neurology, MA General Hospital, Harvard Medical School) for carefully reading the manuscript and many helpful discussions. This work was supported by grants from the National Natural Science Foundation of China (30971014, 81071062, and 81271457) and National Program of Basic Research, sponsored by the Ministry of Science and Technology of China (2011CB503700-G).	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Braeuninger Stefan, 2009, Exp Transl Stroke Med, V1, P8, DOI 10.1186/2040-7378-1-8; Bravarenko NI, 2006, EUR J NEUROSCI, V23, P129, DOI 10.1111/j.1460-9568.2005.04549.x; BRINT S, 1988, J CEREBR BLOOD F MET, V8, P474, DOI 10.1038/jcbfm.1988.88; Campbell PA, 2013, STEM CELLS, V31, P1107, DOI 10.1002/stem.1365; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Chen J, 1998, J NEUROSCI, V18, P4914; Chen J, 2008, STROKE, V39, P220, DOI 10.1161/STROKEAHA.107.490946; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180; D'Amelio M, 2011, NAT NEUROSCI, V14, P69, DOI 10.1038/nn.2709; Dempsey RJ, 2003, J NEUROCHEM, V87, P586, DOI 10.1046/j.1471-4159.2003.02022.x; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; Dobkin BH, 2008, NAT CLIN PRACT NEURO, V4, P76, DOI 10.1038/ncpneuro0709; Gilman CP, 2002, NEUROMOL MED, V2, P197, DOI 10.1385/NMM:2:2:197; Gregorian C, 2009, J NEUROSCI, V29, P1874, DOI 10.1523/JNEUROSCI.3095-08.2009; Hermann DM, 2012, LANCET NEUROL, V11, P369, DOI 10.1016/S1474-4422(12)70039-X; Hyman BT, 2012, NAT REV NEUROSCI, V13, P395, DOI 10.1038/nrn3228; Israels LG, 1999, STEM CELLS, V17, P306, DOI 10.1002/stem.170306; Janzen V, 2008, CELL STEM CELL, V2, P584, DOI 10.1016/j.stem.2008.03.012; Jin KL, 2011, BRAIN RES, V1374, P56, DOI 10.1016/j.brainres.2010.12.037; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; Lee SR, 2006, J NEUROSCI, V26, P3491, DOI 10.1523/JNEUROSCI.4085-05.2006; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li Z, 2010, CELL, V141, P859, DOI 10.1016/j.cell.2010.03.053; Liauw J, 2008, J CEREBR BLOOD F MET, V28, P1722, DOI 10.1038/jcbfm.2008.65; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Lo EH, 2010, NAT MED, V16, P1205, DOI 10.1038/nm.2226; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; Mackey ME, 1997, STROKE, V28, P2012, DOI 10.1161/01.STR.28.10.2012; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; McLaughlin B, 2004, APOPTOSIS, V9, P111, DOI 10.1023/B:APPT.0000018793.10779.dc; Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Pinan-Lucarre B, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001331; Rosell A, 2013, TRANSL STROKE RES, V4, P297, DOI 10.1007/s12975-012-0234-1; Shen J, 2012, J CEREBR BLOOD F MET, V32, P353, DOI 10.1038/jcbfm.2011.136; Shioda N, 2008, NEUROSCIENCE, V155, P876, DOI 10.1016/j.neuroscience.2008.05.056; SUN FJ, 2012, PLOS ONE, V7; Sun H, 2011, NEUROBIOL DIS, V44, P73, DOI 10.1016/j.nbd.2011.06.006; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Wagner DC, 2011, BRAIN RES, V1381, P237, DOI 10.1016/j.brainres.2011.01.041; Wang LX, 2013, ANN NEUROL, V73, P189, DOI 10.1002/ana.23762; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yan XX, 2001, J COMP NEUROL, V433, P4, DOI 10.1002/cne.1121; Yuan JY, 2006, MOL CELL, V23, P1, DOI 10.1016/j.molcel.2006.06.008; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhao BQ, 2009, BLOOD, V114, P3329, DOI 10.1182/blood-2009-03-213264; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; Zhao BQ, 2004, BLOOD, V103, P2610, DOI 10.1182/blood-2003-03-0835; Zhou CM, 2004, J CEREBR BLOOD F MET, V24, P419, DOI 10.1097/00004647-200404000-00007	61	50	57	4	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	FEB	2014	32	2					473	486		10.1002/stem.1503			14	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	304JE	WOS:000330742100013	23939807	Bronze			2022-02-06	
J	Ferrada, P; Evans, D; Wolfe, L; Anand, RJ; Vanguri, P; Mayglothling, J; Whelan, J; Malhotra, A; Goldberg, S; Duane, T; Aboutanos, M; Ivatury, RR				Ferrada, Paula; Evans, David; Wolfe, Luke; Anand, Rahul J.; Vanguri, Poornima; Mayglothling, Julie; Whelan, James; Malhotra, Ajai; Goldberg, Stephanie; Duane, Therese; Aboutanos, Michel; Ivatury, Rao R.			Findings of a randomized controlled trial using limited transthoracic echocardiogram (LTTE) as a hemodynamic monitoring tool in the trauma bay	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	72nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 18-23, 2013	San Francisco, CA	Amer Assoc Surg Trauma		Hemodynamic monitoring in the trauma bay; echocardiogram in the trauma bay; inferior vena cava as a hemodynamic parameter in trauma patients; echocardiogram in trauma; echocardiogram for fluid status management	INFERIOR VENA-CAVA; SURGEON-PERFORMED ULTRASOUND; GOAL-DIRECTED RESUSCITATION; EARLY FLUID RESUSCITATION; HEMORRHAGIC-SHOCK; SONOGRAPHIC MEASUREMENT; HYPOVOLEMIC SHOCK; VOLUME STATUS; BRAIN-INJURY; HEART-RATE	BACKGROUND: We hypothesize that limited transthoracic echocardiogram (LTTE) is a useful tool to guide therapy during the initial phase of resuscitation in trauma patients. METHODS: All highest-level alert patients with at least one measurement of systolic blood pressure less than 100 mm Hg, a mean arterial pressure less than 60 mm Hg, and/or a heart rate greater than 120 beats per minute who arrived to the trauma bay (TB) were randomized to have either LTTE performed (LTTEp) or not performed (non-LTTE) as part of their initial evaluation. Images were stored, and results were reported regarding contractility (good vs. poor), fluid status (empty inferior vena cava [hypovolemic] vs. full inferior vena cava [not hypovolemic]), and pericardial effusion (present vs. absent). Time from TB to operating room, intravenous fluid administration, blood product requirement, intensive care unit admission, and mortality were examined in both groups. RESULTS: A total of 240 patients were randomized. Twenty-five patients were excluded since they died upon arrival to the TB, leaving 215 patients in the study. Ninety-two patients were in the LTTEp group with 123 patients in the non-LTTE group. The LTTEp and non-LTTE groups were similar in age (38 years vs. 38.8 years, p = 0.75), Injury Severity Score (ISS) (19.2 vs. 19.0, p = 0.94), Revised Trauma Score (RTS) (5.5 vs. 6.0, p = 0.09), lactate (4.2 vs. 3.6, p = 0.14), and mechanism of injury (p = 0.44). Strikingly, LTTEp had significantly less intravenous fluid than non-LTTE patients (1.5 L vs. 2.5 L, p < 0.0001), less time from TB to operating room (35.6 minutes vs. 79.1 min, p = 0.0006), higher rate of intensive care unit admission (80.4% vs. 67.2%, p = 0.04), and a lower mortality rate (11% vs. 19.5%, p = 0.09). Mortality differences were particularly evident in the traumatic brain injury patients (14.7% in LTTEp vs. 39.5% in non-LTTE, p = 0.03). CONCLUSION: LTTE is a useful guide for therapy in hypotensive trauma patients during the early phase of resuscitation. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Ferrada, Paula; Evans, David; Wolfe, Luke; Anand, Rahul J.; Vanguri, Poornima; Mayglothling, Julie; Whelan, James; Malhotra, Ajai; Goldberg, Stephanie; Duane, Therese; Aboutanos, Michel; Ivatury, Rao R.] Virginia Commonwealth Univ, Richmond, VA 23298 USA		Ferrada, P (corresponding author), Virginia Commonwealth Univ, West Hosp, 15th Floor East,1200 E Broad St,POB 980454, Richmond, VA 23298 USA.	pferrada@mcvh-vcu.edu	Ivatury, Rao R./H-2922-2019				Abbasi S, 2012, EUR J EMERG MED; Akilli B, 2010, ULUS TRAVMA ACIL CER, V16, P113; Alam HB, 2005, MIL MED, V170, P63, DOI 10.7205/MILMED.170.1.63; Bahner DP, 2012, ACAD MED; Balogh Z, 2002, AM J SURG, V184, P538, DOI 10.1016/S0002-9610(02)01050-4; BICKELL WH, 1991, SURGERY, V110, P529; Bruttig SP, 2005, SHOCK, V24, P92, DOI 10.1097/01.shk.0000168872.37660.d2; Cotton BA, 2008, J TRAUMA, V64, P1177, DOI 10.1097/TA.0b013e31816c5c80; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Dipti A, 2012, AM J EMERG MED, V30, P1414, DOI 10.1016/j.ajem.2011.10.017; Duchesne JC, 2012, AM SURGEON, V78, P962; Duke MD, 2012, J TRAUMA ACUTE CARE, V73, P674, DOI 10.1097/TA.0b013e318265ce1f; Ferrada P, 2013, J TRAUMA ACUTE CARE, V74, P220, DOI 10.1097/TA.0b013e318278918a; Ferrada P, 2012, AM SURGEON, V78, P1396; Ferrada P, 2012, AM SURGEON, V78, P468; Ferrada P, 2011, J TRAUMA, V71, P1327, DOI 10.1097/TA.0b013e3182318574; Ferrada P, 2011, J TRAUMA, V70, P56, DOI 10.1097/TA.0b013e318207e6ee; Gunst M, 2008, J TRAUMA, V65, P509, DOI 10.1097/TA.0b013e3181825bc5; Harris T, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5752; Holley A, 2012, EMERG MED AUSTRALAS, V24, P127, DOI 10.1111/j.1742-6723.2011.01515.x; Holley A, 2012, EMERG MED AUSTRALAS, V24, P14, DOI 10.1111/j.1742-6723.2011.01516.x; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Kasotakis G, 2013, J TRAUMA ACUTE CARE, V74, P1215, DOI 10.1097/TA.0b013e3182826e13; King DR, 2009, J TRAUMA, V67, P436, DOI 10.1097/TA.0b013e3181ad67de; Maitland K, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-68; McNeer Richard R, 2013, Anesthesiol Clin, V31, P179, DOI 10.1016/j.anclin.2012.11.005; Nucifora G, 2011, MINERVA CARDIOANGIOL, V59, P519; Opreanu RC, 2010, AM SURGEON, V76, P296; ROZYCKI GS, 1995, J TRAUMA, V39, P492; Rozycki GS, 1998, ANN SURG, V228, P557, DOI 10.1097/00000658-199810000-00012; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Sisley AC, 1998, J TRAUMA, V44, P291, DOI 10.1097/00005373-199802000-00009; Soller BR, 2012, J TRAUMA ACUTE CARE, V73, pS106, DOI 10.1097/TA.0b013e318260a928; Stern SA, 2000, J NEUROSURG, V93, P305, DOI 10.3171/jns.2000.93.2.0305; Teixeira PGR, 2007, J TRAUMA, V63, P1338, DOI 10.1097/TA.0b013e31815078ae; Yanagawa Y, 2005, J TRAUMA, V58, P825, DOI 10.1097/01.TA.0000145085.42116.A7; Yanagawa Y, 2007, J TRAUMA, V63, P1245, DOI 10.1097/TA.0b013e318068d72b; Zengin S, 2013, AM J EMERG MED	38	50	52	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2014	76	1					31	37		10.1097/TA.0b013e3182a74ad9			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	AH8JN	WOS:000336384200008	24368354				2022-02-06	
J	Tillou, A; Kelley-Quon, L; Burruss, S; Morley, E; Cryer, H; Cohen, M; Min, L				Tillou, Areti; Kelley-Quon, Lorraine; Burruss, Sigrid; Morley, Eric; Cryer, Henry; Cohen, Marilyn; Min, Lillian			Long-term Postinjury Functional Recovery Outcomes of Geriatric Consultation	JAMA SURGERY			English	Article							VULNERABLE ELDERS SURVEY; TRAUMATIC BRAIN-INJURY; ACUTE MEDICAL ILLNESS; HIP FRACTURE; RESOURCE USE; CARE; MORTALITY; DECLINE; HOSPITALIZATION; MANAGEMENT	IMPORTANCE Functional recovery is an important outcome following injury. Functional impairment is persistent in the year following injury for older trauma patients. OBJECTIVE To measure the impact of routine geriatric consultation on functional outcomes in older trauma patients. DESIGN, SETTING, AND PARTICIPANTS In this pretest-posttest study, the pretest control group (n = 37) was retrospectively identified (December 2006-November 2007). The posttest geriatric consultation (GC) group (n = 85) was prospectively enrolled (December 2007-June 2010). We then followed up both groups for 1 year after enrollment. This study was conducted at an academic level 1 trauma center with adults 65 years of age and older admitted as an activated code trauma. INTERVENTION Routine GC. MAIN OUTCOMES AND MEASURES The Short Functional Status survey of 5 activities of daily living (ADLs) at hospital admission and 3, 6, and 12 months postinjury. RESULTS The unadjusted Short Functional Status score (GC group only) declined from 4.6 preinjury to 3.7 at 12 months postinjury, a decline of nearly 1 full ADL (P < .05). The ability to shop for personal items was the specific ADL more commonly retained by the GC group compared with the control group. The GC group had a better recovery of function in the year following injury than the GC group, controlling for age, sex, race/ethnicity, length of stay, comorbidity, injury severity, postdischarge rehabilitation, complication, and whether surgery was performed (P < .01), a difference of 0.67 ADL abilities retained by the GC group compared with the control group (95% CI, 0.06-1.4). CONCLUSIONS AND RELEVANCE Functional recovery for older adults following injury may be improved by GC. Early introduction of multidisciplinary care in geriatric trauma patients warrants further investigation.	[Tillou, Areti; Kelley-Quon, Lorraine; Burruss, Sigrid; Cryer, Henry; Cohen, Marilyn] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA; [Morley, Eric] Boston Univ, Sch Med, Boston, MA 02118 USA; [Min, Lillian] Univ Michigan, Sch Med, Div Geriatr, Ann Arbor, MI 48109 USA		Min, L (corresponding author), Univ Michigan, Sch Med, Div Geriatr, 300 N Ingalls, Ann Arbor, MI 48109 USA.	lmin@med.umich.edu			American Geriatrics Society Jahnigen Award; K12 University of California, Los Angeles Mentored Clinical Scientist Development Program in Geriatrics (National Institute on Aging); Research Career Development Core grant from the University of Michigan Pepper Center (National Institute on Aging); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024824] Funding Source: NIH RePORTER	Dr Tillou was supported by an American Geriatrics Society Jahnigen Award (2009-11). Drs Tillou and Min were supported by the K12 University of California, Los Angeles Mentored Clinical Scientist Development Program in Geriatrics (National Institute on Aging). Dr Min is supported by a Research Career Development Core grant from the University of Michigan Pepper Center (National Institute on Aging).	Agostini JV, 2001, AHRQ PUBLICATION, V01-E058; American College of Surgeons, 2007, NAT TRAUM DAT BANK R; Bachmann S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1718; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Campbell P.R., 1996, POPULATION PROJECTIO; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; COVINGTON DL, 1993, J AM GERIATR SOC, V41, P847, DOI 10.1111/j.1532-5415.1993.tb06182.x; DEMARIA EJ, 1988, J TRAUMA, V28, P1244, DOI 10.1097/00005373-198808000-00018; Demetriades D, 2002, BRIT J SURG, V89, P1319, DOI 10.1046/j.1365-2168.2002.02210.x; Deschodt M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-48; Dudgeon BJ, 2008, ARCH PHYS MED REHAB, V89, P1256, DOI 10.1016/j.apmr.2007.11.038; Fallon WF, 2006, J TRAUMA, V61, P1040, DOI 10.1097/01.ta.0000238652.48008.59; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; Givens JL, 2008, J AM GERIATR SOC, V56, P1075, DOI 10.1111/j.1532-5415.2008.01711.x; Glance LG, 2004, J TRAUMA, V56, P682, DOI 10.1097/01.TA.0000053469.92142.40; Glance LG, 2004, J TRAUMA, V56, P165, DOI 10.1097/01.TA.0000047808.77902.83; Jacobs DG, 2003, J TRAUMA, V54, P391, DOI 10.1097/01.TA.0000042015.54022.BE; Kelley-Quon L, 2010, AM SURGEON, V76, P1055; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; KENNIE DC, 1988, BRIT MED J, V297, P1083, DOI 10.1136/bmj.297.6656.1083; KNUDSON MM, 1994, ARCH SURG-CHICAGO, V129, P448; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Malani PN, 2009, JAMA-J AM MED ASSOC, V302, P1582, DOI 10.1001/jama.2009.1453; Marcantonio ER, 2001, J AM GERIATR SOC, V49, P516, DOI 10.1046/j.1532-5415.2001.49108.x; Marcantonio ER, 2000, J AM GERIATR SOC, V48, P618, DOI 10.1111/j.1532-5415.2000.tb04718.x; McCusker J, 2002, J GERONTOL A-BIOL, V57, pM569, DOI 10.1093/gerona/57.9.M569; McGwin G, 2004, J TRAUMA, V56, P1291, DOI 10.1097/01.TA.0000089354.02065.D0; McGwin G, 2000, J TRAUMA, V49, P470, DOI 10.1097/00005373-200009000-00014; McKevitt EC, 2003, CAN J SURG, V46, P211; Min LC, 2006, J AM GERIATR SOC, V54, P507, DOI 10.1111/j.1532-5415.2005.00615.x; Min L, 2009, J AM GERIATR SOC, V57, P2070, DOI 10.1111/j.1532-5415.2009.02497.x; Min LC, 2008, J AM GERIATR SOC, V56, P1932, DOI 10.1111/j.1532-5415.2008.01921.x; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; ROSS N, 1989, SOUTHERN MED J, V82, P857, DOI 10.1097/00007611-198907000-00016; Rudolph JL, 2010, ACTA ANAESTH SCAND, V54, P663, DOI 10.1111/j.1399-6576.2010.02236.x; Ruhm CJ, 2005, INT J EPIDEMIOL, V34, P1206, DOI 10.1093/ije/dyi143; Rzepka SG, 2001, J CLIN EPIDEMIOL, V54, P627, DOI 10.1016/S0895-4356(00)00337-1; Sager MA, 1996, ARCH INTERN MED, V156, P645, DOI 10.1001/archinte.156.6.645; Sager MA, 1996, J AM GERIATR SOC, V44, P251, DOI 10.1111/j.1532-5415.1996.tb00910.x; Saliba D, 2000, J GERONTOL A-BIOL, V55, pM750, DOI 10.1093/gerona/55.12.M750; Saliba D, 2001, J AM GERIATR SOC, V49, P1691, DOI 10.1046/j.1532-5415.2001.49281.x; SCHWAB CW, 1992, ARCH SURG-CHICAGO, V127, P701; SHABOT MM, 1995, J TRAUMA, V39, P254, DOI 10.1097/00005373-199508000-00011; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; VANAALST JA, 1991, J TRAUMA, V31, P1096; vanderSluis CK, 1996, J TRAUMA, V40, P78, DOI 10.1097/00005373-199601000-00015; Wu HY, 2006, ANN ACAD MED SINGAP, V35, P17	52	50	50	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	JAN	2014	149	1					83	89		10.1001/jamasurg.2013.4244			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Surgery	295LJ	WOS:000330117300016	24284836	Bronze, Green Accepted			2022-02-06	
J	Bedi, SS; Hetz, R; Thomas, C; Smith, P; Olsen, AB; Williams, S; Xue, HS; Aroom, K; Uray, K; Hamilton, J; Mays, RW; Cox, CS				Bedi, Supinder S.; Hetz, Robert; Thomas, Chelsea; Smith, Philippa; Olsen, Alex B.; Williams, Stephen; Xue, Hasen; Aroom, Kevin; Uray, Karen; Hamilton, Jason; Mays, Robert W.; Cox, Charles S., Jr.			Intravenous Multipotent Adult Progenitor Cell Therapy Attenuates Activated Microglial/Macrophage Response and Improves Spatial Learning After Traumatic Brain Injury	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Adult stem cells; Neuroimmune; Rat model; Stem/progenitor cell	MARROW MONONUCLEAR-CELLS; MOUSE SPINAL-CORD; INFLAMMATORY RESPONSE; TNF-ALPHA; MICROGLIA; NEUROINFLAMMATION; ASTROCYTES; EXPRESSION; DAMAGE; RATS	We previously demonstrated that the intravenous delivery of multipotent adult progenitor cells (MAPCs) after traumatic brain injury (TBI) in rodents provides neuroprotection by preserving the blood-brain barrier and systemically attenuating inflammation in the acute time frame following cell treatment; however, the long-term behavioral and anti-inflammatory effects of MAPC administration after TBI have yet to be explored. We hypothesized that the intravenous injection of MAPCs after TBI attenuates the inflammatory response (as measured by microglial morphology) and improves performance at motor tasks and spatial learning (Morris water maze [MWM]). MAPCs were administered intravenously 2 and 24 hours after a cortical contusion injury (CCI). We tested four groups at 120 days after TBI: sham (uninjured), injured but not treated (CCI), and injured and treated with one of two concentrations of MAPCs, either 2 million cells per kilogram (CCI-2) or 10 million cells per kilogram (CCI-10). CCI-10 rats showed significant improvement in left hind limb deficit on the balance beam. On the fifth day of MWM trials, CCI-10 animals showed a significant decrease in both latency to platform and distance traveled compared with CCI. Probe trials revealed a significant decrease in proximity measure in CCI-10 compared with CCI, suggesting improved memory retrieval. Neuroinflammation was quantified by enumerating activated microglia in the ipsilateral hippocampus. We observed a significant decrease in the number of activated microglia in the dentate gyrus in CCI-10 compared with CCI. Our results demonstrate that intravenous MAPC treatment after TBI in a rodent model offers long-term improvements in spatial learning as well as attenuation of neuroinflammation.	[Bedi, Supinder S.; Hetz, Robert; Thomas, Chelsea; Smith, Philippa; Olsen, Alex B.; Williams, Stephen; Xue, Hasen; Aroom, Kevin; Uray, Karen; Cox, Charles S., Jr.] Univ Texas Houston, Dept Pediat Surg, Hlth Sci Ctr Houston, Houston, TX USA; [Hetz, Robert; Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Houston, Dept Surg, Hlth Sci Ctr Houston5, Houston, TX USA; [Hamilton, Jason; Mays, Robert W.] Athersys Inc, Cleveland, OH USA; [Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA		Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu		Aroom, Kevin/0000-0003-1504-0585; Uray, Karen/0000-0001-6997-459X	Small Business Innovation Research (SBIR)United States Department of Agriculture (USDA); Athersys [NIH SBIR 1U44-NS077511-01]; Brown Foundation, Inc.; Children's Memorial Hermann Hospital Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U44NS077511] Funding Source: NIH RePORTER	We thank Dr. Pramod Dash for advice on the spatial learning experiments. This project was funded by a Small Business Innovation Research (SBIR) agreement with Athersys (NIH SBIR 1U44-NS077511-01) and by grants from the Brown Foundation, Inc., and the Children's Memorial Hermann Hospital Foundation.	Bannerman DM, 2012, NAT NEUROSCI, V15, P1153, DOI 10.1038/nn.3166; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Belarbi K, 2012, BRAIN BEHAV IMMUN, V26, P18, DOI 10.1016/j.bbi.2011.07.225; Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cusimano M, 2012, BRAIN, V135, P447, DOI 10.1093/brain/awr339; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; GAYTAN F, 1994, J ANDROL, V15, P558; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu N, 2009, CELL MOL IMMUNOL, V6, P207, DOI 10.1038/cmi.2009.28; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Savitz SI, 2011, ANN NEUROL, V70, P59, DOI 10.1002/ana.22458; Smith HS, 2010, PAIN PHYSICIAN, V13, P295; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; Terry AV, 2009, FRONT NEUROSCI, P267; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Xuan AG, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-202	36	50	51	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	DEC	2013	2	12					953	960		10.5966/sctm.2013-0100			8	Cell & Tissue Engineering	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263JH	WOS:000327804400009	24191266	gold, Green Published			2022-02-06	
J	Wiseman-Hakes, C; Murray, B; Moineddin, R; Rochon, E; Cullen, N; Gargaro, J; Colantonio, A				Wiseman-Hakes, Catherine; Murray, Brian; Moineddin, Rahim; Rochon, Elizabeth; Cullen, Nora; Gargaro, Judith; Colantonio, Angela			Evaluating the impact of treatment for sleep/wake disorders on recovery of cognition and communication in adults with chronic TBI	BRAIN INJURY			English	Article						Cognition; communication; mood; outcomes; sleep disorders; traumatic brain injury	TRAUMATIC BRAIN-INJURY; INSOMNIA; RELIABILITY; DISTURBANCE; NEUROGENESIS; CONSEQUENCES; HIPPOCAMPUS; SLEEPINESS; INVENTORY; VALIDITY	Objective: To longitudinally examine objective and self-reported outcomes for recovery of cognition, communication, mood and participation in adults with traumatic brain injury (TBI) and co-morbid post-traumatic sleep/wake disorders. Design: Prospective, longitudinal, single blind outcome study. Setting: Community-based. Participants: Ten adults with moderate-severe TBI and two adults with mild TBI and persistent symptoms aged 18-58 years. Six males and six females, who were 1-22 years post-injury and presented with self-reported sleep/wake disturbances with onset post-injury. Interventions: Individualized treatments for sleep/wake disorders that included sleep hygiene recommendations, pharmacological interventions and/or treatments for sleep apnea with follow-up. Main outcome measures: Insomnia Severity Index, Beck Depression and Anxiety Inventories, Latrobe Communication Questionnaire, Speed and Capacity of Language Processing, Test of Everyday Attention, Repeatable Battery for the Assessment of Neuropsychological Status, Daily Cognitive-Communication and Sleep Profile. Results: Group analysis revealed positive trends in change for each measure and across sub-tests of all measures. Statistically significant changes were noted in insomnia severity, p = 0.0003; depression severity, p = 0.03; language, p = 0.01; speed of language processing, p = 0.007. Conclusions: These results add to a small but growing body of evidence that sleep/wake disorders associated with TBI exacerbate trauma-related cognitive, communication and mood impairments. Treatment for sleep/wake disorders may optimize recovery and outcomes.	[Wiseman-Hakes, Catherine] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; [Wiseman-Hakes, Catherine; Rochon, Elizabeth; Cullen, Nora; Colantonio, Angela] Toronto Rehabil Inst, Toronto, ON, Canada; [Murray, Brian] Univ Toronto, Dept Med, Sunnybrook Hlth Sci Ctr, Div Neurol, Toronto, ON, Canada; [Moineddin, Rahim] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada; [Rochon, Elizabeth] Univ Toronto, Dept Speech Language Pathol, Toronto, ON, Canada; [Cullen, Nora; Gargaro, Judith] West Pk Hlth Care Ctr, Toronto, ON, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Therapy & Occupat Sci, Toronto, ON, Canada		Wiseman-Hakes, C (corresponding author), 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	catherinewh@utoronto.ca	Murray, Brian/E-6786-2016; Lang, Steven/AAE-8102-2021; Wiseman-Hakes, Catherine/AAC-8303-2021	Murray, Brian/0000-0001-5085-0909; Lang, Steven/0000-0003-1669-9146; Wiseman-Hakes, Catherine/0000-0001-8441-884X; Rochon, Elizabeth/0000-0001-5521-0513; Cullen, Nora/0000-0001-6359-9418; Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); University of Toronto Open FellowshipUniversity of Toronto; Ontario Ministry of Long Term Care; Ontario Work Study Program	The authors report no conflicts of interest. The study was funded through a fellowship in Clinical Research from the Canadian Institutes for Health Research and a University of Toronto Open Fellowship. Other support came from the Toronto Rehabilitation Institute who receives funding through the Ontario Ministry of Long Term Care. Support was also provided through the Ontario Work Study Program.	*AASM, 2005, INT 57 CLASS SLEEP D; [Anonymous], 2007, MAN SCOR SLEEP ASS E; Backhaus J, 2006, BIOL PSYCHIAT, V60, P1324, DOI 10.1016/j.biopsych.2006.03.051; Baddeley A., 1992, SPEED CAPACITY LANGU; Banks S, 2007, J CLIN SLEEP MED, V3, P519; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Coelho FMS, 2011, CURR OPIN PULM MED, V17, P406, DOI 10.1097/MCP.0b013e32834b7e04; Doghramji K, 1997, ELECTROEN CLIN NEURO, V103, P554, DOI 10.1016/S0013-4694(97)00010-2; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Fung C., 2011, SLEEP MED S1, V12, pS127; Gosselin N, 2010, J NEUROL NEUROSUR PS, V81, P1297, DOI 10.1136/jnnp.2010.222471; Guzman-Marin R, 2005, EUR J NEUROSCI, V22, P2111, DOI 10.1111/j.1460-9568.2005.04376.x; Guzman-Marin R, 2008, SLEEP, V31, P167, DOI 10.1093/sleep/31.2.167; Hagen C, 1973, RANCHO LEVELS COGNIT; Iber C., 2007, AASM MANUAL SCORING, P7; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MacDonald S, 2010, BRAIN INJURY, V24, P486, DOI 10.3109/02699050903518118; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004; Mirescu C, 2006, P NATL ACAD SCI USA, V103, P19170, DOI 10.1073/pnas.0608644103; Morin CM, 1993, INSOMNIA PSYCHOL ASS; Morrell MJ, 2003, SLEEP MED, V4, P451, DOI 10.1016/S1389-9457(03)00159-X; Novati A, 2011, NEUROSCIENCE, V190, P145, DOI 10.1016/j.neuroscience.2011.06.027; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Orban P, 2006, P NATL ACAD SCI USA, V103, P7124, DOI 10.1073/pnas.0510198103; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, ARCH PHYS MED REHAB, V85, P1298, DOI 10.1016/j.apmr.2003.11.036; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Peigneux P, 2004, NEURON, V44, P535, DOI 10.1016/j.neuron.2004.10.007; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Randolph C., 1998, REPEATABLE BATTERY A; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Riemann D, 2007, SLEEP, V30, P955, DOI 10.1093/sleep/30.8.955; ROBERTSON H, 1994, TEST EVERYDAY ATTENT; SAS Institute Inc, 2008, SAS SYST WIND V9 2; Shan RSLP, 2004, AM J PHYS MED REHAB, V83, P421, DOI 10.1097/00002060-200406000-00003; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; TEASDALE G, 1974, LANCET, V2, P81; Walker MP, 2005, NEUROSCIENCE, V133, P911, DOI 10.1016/j.neuroscience.2005.04.007; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Wiseman-Hakes C., 2009, CRIT REV PHYS REHABI, V21, P317, DOI [10.1615/CritRevPhysRehabilMed.v21.i3-4.70, DOI 10.1615/CRITREVPHYSREHABILMED.V21.I3-4.70]; Wiseman-Hakes C, 2011, BRAIN INJURY, V25, P1256, DOI 10.3109/02699052.2011.608215; World Health Organization, 2001, INT CLASS FUNCT DIS, P299; Zollman FS, 2012, J HEAD TRAUMA REHAB, V27, P135, DOI 10.1097/HTR.0b013e3182051397	60	50	51	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2013	27	12					1364	1376		10.3109/02699052.2013.823663			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	235UF	WOS:000325745500005	24070180	Green Published, Bronze			2022-02-06	
J	Seel, RT; Douglas, J; Dennison, AC; Heaner, S; Farris, K; Rogers, C				Seel, Ronald T.; Douglas, Jennifer; Dennison, Andrew C.; Heaner, Sarah; Farris, Kathryn; Rogers, Catherine			Specialized Early Treatment for Persons With Disorders of Consciousness: Program Components and Outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Diagnosis; Prognosis; Rehabilitation; Vegetative state	COMA RECOVERY SCALE; TRAUMATIC BRAIN-INJURY; UPPER-LIMB SPASTICITY; TOXIN TYPE-A; VEGETATIVE STATE; BOTULINUM TOXIN; CONTROLLED-TRIAL; REHABILITATION; MANAGEMENT; CAREGIVERS	Objectives: To describe a specialized early treatment program for persons with disorders of consciousness (DOC) that includes family education; to identify rates of secondary conditions, imaging used, and selected interventions; and to evaluate outcomes. Design: A single-center, retrospective, pre-post design using electronic medical record data. Setting: A Commission on Accreditation of Rehabilitation Facilities accredited, long-term acute care hospital that provides acute medical and inpatient rehabilitation levels of care for people with catastrophic injuries. Participants: Persons (N=210) aged 14 to 69 years with DOC of primarily traumatic etiology admitted at a mean +/- SD of 41.0 +/- 27.2 days postinjury; 2% were in coma, 41% were in the vegetative state, and 57% were in the minimally conscious state. Interventions: An acute medical level of care with >= 90 minutes of daily interdisciplinary rehabilitation and didactic and hands-on caretaking education for families. Main Outcome Measures: Coma Recovery Scale Revised, Modified Ashworth Scale, and discharge disposition. Results: Program admission medical acuity included dysautonomia (15%), airway modifications (79%), infections (eg, pneumonia, 16%; urinary tract infection, 14%; blood, 11%), deep vein thrombosis (17%), pressure ulcers (14%), and marked hypertonia (30% in each limb). There were 168 program interruptions (ie, 139 surgeries, 29 nonsurgical intensive care unit transfers). Mean length of stay +/- SD was 39.1 +/- 29.4 days (range, 6-204d). Patients showed improved consciousness and respiratory function and reduced presence or severity of pressure ulcers and upper extremity hypertonia. At discharge, 54% showed sufficient emergence from a minimally conscious state to transition to mainstream inpatient rehabilitation, and 29% did not emerge but were discharged home to family with ongoing programmatic support; only 13% did not emerge and were institutionalized. Conclusions: Persons with DOC resulting primarily from a traumatic etiology who receive specialized early treatment that includes acute medical care and >= 90 minutes of daily rehabilitation are likely to show improved consciousness and body function; more than half may transition to mainstream inpatient rehabilitation. Families who receive comprehensive education and hands-on training with ongoing follow-up support may be twice as likely to provide care for medically stable persons with DOC in their homes versus nursing facility placement. (c) 2013 by the American Congress of Rehabilitation Medicine	[Seel, Ronald T.; Douglas, Jennifer; Dennison, Andrew C.; Heaner, Sarah; Farris, Kathryn; Rogers, Catherine] Shepherd Ctr, Crawford Res Inst, Brain Injury Program, Atlanta, GA 30309 USA		Seel, RT (corresponding author), Shepherd Ctr, Crawford Res Inst, 2020 Peachtree Rd, Atlanta, GA 30309 USA.	ron_seel@shepherd.org					Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Andrews K, 2005, NEUROPSYCHOL REHABIL, V15, P461, DOI 10.1080/09602010443000326; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bernat JL, 2009, ANNU REV MED, V60, P381, DOI 10.1146/annurev.med.60.060107.091250; Berube J, MOHONK REPORT DISORD; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Childers MK, 2004, ARCH PHYS MED REHAB, V85, P1063, DOI 10.1016/j.apmr.2003.10.015; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Choi JH, 2008, J TRAUMA, V65, P1028, DOI 10.1097/TA.0b013e31815eba9b; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; Dumas HM, 2004, PHYS THER, V84, P232, DOI 10.1093/ptj/84.3.232; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Elliott L, 2005, NEUROPSYCHOL REHABIL, V15, P480, DOI 10.1080/09602010443000506; Elovic EP, 2008, ARCH PHYS MED REHAB, V89, P799, DOI 10.1016/j.apmr.2008.01.007; Elovic EP, 2004, J HEAD TRAUMA REHAB, V19, P155, DOI 10.1097/00001199-200403000-00007; Esquenazi A, 2012, AM J PHYS MED REHAB, V91, P729, DOI 10.1097/PHM.0b013e31824fa9ca; European Pressure Ulcer Advisory Panel and the American National Pressure Ulcer Advisory Panel, 2009, PREV TREATM PRESS UL; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2005, NEUROPSYCHOL REHABIL, V15, P166, DOI 10.1080/09602010443000498; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Puggina ACG, 2012, J NEUROSCI NURS, V44, P260, DOI 10.1097/JNN.0b013e3182666407; Giovannetti AM, 2013, ACTA NEUROL SCAND, V127, P10, DOI 10.1111/j.1600-0404.2012.01666.x; Gormley ME, 1997, MUSCLE NERVE, pS14; Hinderer SR, 1996, ARCH PHYS MED REHAB, V77, P1083, DOI 10.1016/S0003-9993(96)90073-8; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Laureys S, 2005, CURR OPIN NEUROL, V18, P726, DOI 10.1097/01.wco.0000189874.92362.12; Legner VJ, 2009, ANN SURG, V249, P250, DOI 10.1097/SLA.0b013e318195e12f; Leonardi M, 2012, BRAIN INJURY, V26, P1201, DOI 10.3109/02699052.2012.667589; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; McNamee S, 2012, J HEAD TRAUMA REHAB, V27, P244, DOI 10.1097/HTR.0b013e31825e12c8; Mortenson PA, 2003, PHYS THER, V83, P648, DOI 10.1093/ptj/83.7.648; Moseley AM, 1997, PHYS THER, V77, P240, DOI 10.1093/ptj/77.3.240; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Ng YS, 2005, NEUROREHABILITATION, V20, P97; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, pS10, DOI 10.1016/S0003-9993(98)90114-9; Plum F., 1982, DIAGNOSIS STUPOR COM, V3rd; Reimer M, 2005, NEUROPSYCHOL REHABIL, V15, P473, DOI 10.1080/09602010443000362; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2010, EXPERT REV NEUROTHER, V10, P1725, DOI 10.1586/ERN.10.148; Schnakers C, 2010, PAIN, V148, P215, DOI 10.1016/j.pain.2009.09.028; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Simpson DM, 2009, J NEUROL NEUROSUR PS, V80, P380, DOI 10.1136/jnnp.2008.159657; Singer BJ, 2003, BRAIN INJURY, V17, P309, DOI 10.1080/0269905021000013237; Singer BJ, 2003, ARCH PHYS MED REHAB, V84, P483, DOI 10.1053/apmr.2003.50041; Sorbo A, 2005, BRAIN INJURY, V19, P493, DOI 10.1080/02699050400013709; Verplancke D, 2005, CLIN REHABIL, V19, P117, DOI 10.1191/0269215505cr827oa; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Winzelberg GS, 2003, ARCH INTERN MED, V163, P2552, DOI 10.1001/archinte.163.21.2552; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216; Zafonte R, 2004, J HEAD TRAUMA REHAB, V19, P89, DOI 10.1097/00001199-200403000-00002	63	50	51	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1908	1923		10.1016/j.apmr.2012.11.052			16	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	231TU	WOS:000325442100009	23732166				2022-02-06	
J	Tung, KC; Uh, J; Mao, D; Xu, F; Xiao, GH; Lu, HZ				Tung, Kuang-Chi; Uh, Jinsoo; Mao, Deng; Xu, Feng; Xiao, Guanghua; Lu, Hanzhang			Alterations in resting functional connectivity due to recent motor task	NEUROIMAGE			English	Article						Resting state; Functional connectivity MRI; Motor cortex; Blood oxygenation	POSITRON-EMISSION-TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; STATE FMRI; DEFAULT-MODE; ALZHEIMERS-DISEASE; HEALTHY-SUBJECTS; MENTAL-IMAGERY; BOLD SIGNAL; NETWORK; CORTEX	The impact of recent experiences of task performance on resting functional connectivity MRI (fcMRI) has important implications for the design of many neuroimaging studies, because, if an effect is present, the fcMRI scan then must be performed before any evoked fMRI or after a time gap to allow it to dissipate. The present study aims to determine the effect of simple button presses, which are used in many cognitive fMRI tasks as a response recording method, on later acquired fcMRI data. Human volunteers were subject to a 23-minute button press motor task. Their resting-state brain activity before and after the task was assessed with fcMRI. It was found that, compared to the pre-task resting period, the post-task resting fcMRI revealed a significantly higher (p = 0.002, N = 24) cross correlation coefficient (CC) between left and right motor cortices. These changes were not present in sham control studies that matched the paradigm timing but had no actual task. The amplitude of fcMRI signal fluctuation (AF) also demonstrated an increase in the post-task period compared to pre-task. These changes were observed using both the right-hand-only task and the two-hand task. Study of the recovery time course of these effects revealed that the CC changes lasted for about 5 min while the AF change lasted for at least 15 min. Finally, voxelwise analysis revealed that the pre/post-task differences were also observed in several other brain regions, including the auditory cortex, visual areas, and the thalamus. Our data suggest that the recent performance of the simple button press task can result in elevated fcMRI CC and AF in relevant brain networks and that fcMRI scan should be performed either before evoked fMRI or after a sufficient time gap following fMRI. (C) 2013 Elsevier Inc. All rights reserved.	[Tung, Kuang-Chi; Uh, Jinsoo; Mao, Deng; Xu, Feng; Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Tung, Kuang-Chi; Mao, Deng; Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Mol Biophys Grad Program, Dallas, TX 75390 USA; [Uh, Jinsoo; Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Xiao, Guanghua] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Div Biostat, Dallas, TX 75390 USA; [Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA		Lu, HZ (corresponding author), Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	hanzhang.lu@utsouthwestern.edu	Xu, Feng/K-7760-2015	Xu, Feng/0000-0001-7958-3787	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH084021, R01 NS067015, R01 AG042753, R21 NS078656, R21 AG034318]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH084021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078656, R01NS067015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG034318, R01AG042753] Funding Source: NIH RePORTER	This study was supported in part by NIH grants R01 MH084021 (to HL), R01 NS067015 (to HL), R01 AG042753 (to HL), R21 NS078656 (to HL), and R21 AG034318 (to HL). The authors are grateful to Dr. Janet Jerrow for scientific editing of the manuscript.	Albert NB, 2009, CURR BIOL, V19, P1023, DOI 10.1016/j.cub.2009.04.028; Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Baria AT, 2011, J NEUROSCI, V31, P7910, DOI 10.1523/JNEUROSCI.1296-11.2011; Barnes A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006626; Baumann S, 2005, ANN NY ACAD SCI, V1060, P186, DOI 10.1196/annals.1360.038; Binkofski F, 2000, HUM BRAIN MAPP, V11, P273, DOI 10.1002/1097-0193(200012)11:4<273::AID-HBM40>3.0.CO;2-0; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bluhm RL, 2007, SCHIZOPHRENIA BULL, V33, P1004, DOI 10.1093/schbul/sbm052; Boecker H, 2002, NEUROIMAGE, V17, P999, DOI 10.1006/nimg.2002.1139; Chang C, 2009, NEUROIMAGE, V47, P1448, DOI 10.1016/j.neuroimage.2009.05.012; CHAVIS DA, 1976, BRAIN RES, V117, P369, DOI 10.1016/0006-8993(76)90089-5; Chen HF, 2009, NEUROIMAGE, V47, P1844, DOI 10.1016/j.neuroimage.2009.06.026; Cingolani LA, 2008, NEURON, V58, P749, DOI 10.1016/j.neuron.2008.04.011; Cordes D, 2000, AM J NEURORADIOL, V21, P1636; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Luca M, 2005, EXP BRAIN RES, V167, P587, DOI 10.1007/s00221-005-0059-1; Dechent P, 2004, COGNITIVE BRAIN RES, V19, P138, DOI 10.1016/j.cogbrainres.2003.11.012; Deiber MP, 1998, NEUROIMAGE, V7, P73, DOI 10.1006/nimg.1997.0314; Fukunaga M, 2008, J CEREBR BLOOD F MET, V28, P1377, DOI 10.1038/jcbfm.2008.25; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Hanakawa T, 2002, CEREB CORTEX, V12, P1157, DOI 10.1093/cercor/12.11.1157; Hasson U, 2009, P NATL ACAD SCI USA, V106, P10841, DOI 10.1073/pnas.0903253106; He HJ, 2012, NEUROIMAGE, V59, P2339, DOI 10.1016/j.neuroimage.2011.09.018; He Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005226; Hoffman KL, 2002, SCIENCE, V297, P2070, DOI 10.1126/science.1073538; Hong LE, 2009, ARCH GEN PSYCHIAT, V66, P431, DOI 10.1001/archgenpsychiatry.2009.2; Iseki K, 2008, NEUROIMAGE, V41, P1021, DOI 10.1016/j.neuroimage.2008.03.010; Kasess CH, 2008, NEUROIMAGE, V40, P828, DOI 10.1016/j.neuroimage.2007.11.040; Klingner CM, 2013, HUM BRAIN MAPP, V34, P2343, DOI 10.1002/hbm.22074; la Fougere C, 2010, NEUROIMAGE, V50, P1589, DOI 10.1016/j.neuroimage.2009.12.060; Leonardo M, 1995, HUM BRAIN MAPP, V3, P83, DOI 10.1002/hbm.460030205; Lewisa CM, 2009, P NATL ACAD SCI USA, V106, P17558, DOI 10.1073/pnas.0902455106; Liang M, 2006, NEUROREPORT, V17, P209, DOI 10.1097/01.wnr.0000198434.06518.b8; Liu HH, 2006, NEUROREPORT, V17, P19, DOI 10.1097/01.wnr.0000195666.22714.35; Lowe MJ, 2002, RADIOLOGY, V224, P184, DOI 10.1148/radiol.2241011005; Luchinger R, 2012, NEUROIMAGE, V60, P1426, DOI 10.1016/j.neuroimage.2012.01.031; Lushnikova I, 2009, HIPPOCAMPUS, V19, P753, DOI 10.1002/hipo.20551; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Munzert J, 2009, PROG BRAIN RES, V174, P219, DOI 10.1016/S0079-6123(09)01318-1; Nair DG, 2003, COGNITIVE BRAIN RES, V15, P250, DOI 10.1016/S0926-6410(02)00197-0; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Peltier SJ, 2005, BRAIN RES, V1057, P10, DOI 10.1016/j.brainres.2005.06.078; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; RAO SM, 1993, NEUROLOGY, V43, P2311, DOI 10.1212/WNL.43.11.2311; Salvador R, 2007, NEUROIMAGE, V35, P83, DOI 10.1016/j.neuroimage.2006.12.001; Sharma N, 2006, STROKE, V37, P1941, DOI 10.1161/01.STR.0000226902.43357.fc; STEPHAN KM, 1995, J NEUROPHYSIOL, V73, P373, DOI 10.1152/jn.1995.73.1.373; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Stevens WD, 2010, CEREB CORTEX, V20, P1997, DOI 10.1093/cercor/bhp270; Stinear CM, 2006, BRAIN RES, V1095, P139, DOI 10.1016/j.brainres.2006.04.008; Tambini A, 2010, NEURON, V65, P280, DOI 10.1016/j.neuron.2010.01.001; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tomasi D, 2012, MOL PSYCHIATR, V17, P549, DOI 10.1038/mp.2011.81; van den Heuvel M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002001; Waites AB, 2005, HUM BRAIN MAPP, V24, P59, DOI 10.1002/hbm.20069; Wang K, 2007, HUM BRAIN MAPP, V28, P967, DOI 10.1002/hbm.20324; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Wig GS, 2011, ANN NY ACAD SCI, V1224, P126, DOI 10.1111/j.1749-6632.2010.05947.x; Xu F, 2011, J CEREBR BLOOD F MET, V31, P58, DOI 10.1038/jcbfm.2010.153; Xu G, 2007, NEUROLOGY, V69, P1650, DOI 10.1212/01.wnl.0000296941.06685.22; Yang H, 2007, NEUROIMAGE, V36, P144, DOI 10.1016/j.neuroimage.2007.01.054; Yoshida M, 2009, NEUROSCI RES, V64, P118, DOI 10.1016/j.neures.2009.02.002; Zhang S, 2012, CEREB CORTEX, V22, P99, DOI 10.1093/cercor/bhr088; Zhou Y, 2007, NEUROSCI LETT, V417, P297, DOI 10.1016/j.neulet.2007.02.081	65	50	50	0	26	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	SEP	2013	78						316	324		10.1016/j.neuroimage.2013.04.006			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	165MV	WOS:000320488900031	23583747	Green Accepted			2022-02-06	
J	Patz, S; Trattnig, C; Grunbacher, G; Ebner, B; Gully, C; Novak, A; Rinner, B; Leitinger, G; Absenger, M; Tomescu, OA; Thallinger, GG; Fasching, U; Wissa, S; Archelos-Garcia, J; Schafer, U				Patz, Silke; Trattnig, Christa; Gruenbacher, Gerda; Ebner, Birgit; Guelly, Christian; Novak, Alexandra; Rinner, Beate; Leitinger, Gerd; Absenger, Markus; Tomescu, Oana A.; Thallinger, Gerhard G.; Fasching, Ulrike; Wissa, Sonja; Archelos-Garcia, Juan; Schaefer, Ute			More than Cell Dust: Microparticles Isolated from Cerebrospinal Fluid of Brain Injured Patients Are Messengers Carrying mRNAs, miRNAs, and Proteins	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; microparticles; microRNA; traumatic brain injury	MICROMETER-SIZED PARTICLES; PERIPHERAL-BLOOD; MICRORNA EXPRESSION; NEURAL PROGENITORS; BETA-ENDORPHIN; NERVOUS-SYSTEM; TUMOR-GROWTH; MICROVESICLES; COMMUNICATION; LUMBAR	Microparticles are cell-derived, membrane-sheathed structures that are believed to shuttle proteins, mRNA, and miRNA to specific local or remote target cells. To date best described in blood, we now show that cerebrospinal fluid (CSF) contains similar structures that can deliver RNAs and proteins to target cells. These are, in particular, molecules associated with neuronal RNA granules and miRNAs known to regulate neuronal processes. Small RNA molecules constituted 50% of the shuttled ribonucleic acid. Using microarray analysis, we identified 81 mature miRNA molecules in CSF microparticles. Microparticles from brain injured patients were more abundant than in non-injured subjects and contained distinct genetic information suggesting that they play a role in the adaptive response to injury. Notably, miR-9 and miR-451 were differentially packed into CSF microparticles derived from patients versus non-injured subjects. We confirmed the transfer of genetic material from CSF microparticles to adult neuronal stem cells in vitro and a subsequent microRNA-specific repression of distinct genes. This first indication of a regulated transport of functional genetic material in human CSF may facilitate the diagnosis and analysis of cerebral modulation in an otherwise inaccessible organ.	[Patz, Silke; Trattnig, Christa; Gruenbacher, Gerda; Fasching, Ulrike; Schaefer, Ute] Med Univ Graz, Res Unit Expt Neurotraumatol, Dept Neurosurg, A-8036 Graz, Austria; [Ebner, Birgit; Guelly, Christian; Novak, Alexandra; Rinner, Beate; Absenger, Markus] Med Univ Graz, Med Res Ctr, A-8036 Graz, Austria; [Leitinger, Gerd] Med Univ Graz, Inst Cell Biol Histol & Embryol, A-8036 Graz, Austria; [Tomescu, Oana A.; Thallinger, Gerhard G.] Med Univ Graz, Inst Genom & Bioinformat, ACIB, A-8036 Graz, Austria; [Wissa, Sonja] Med Univ Graz, Dept Neurosurg, A-8036 Graz, Austria; [Archelos-Garcia, Juan] Med Univ Graz, Dept Neurol, Clin Div Gen Neurol, A-8036 Graz, Austria		Schafer, U (corresponding author), Med Univ Graz, Res Unit Expt Neurotraumatol, Auenbruggerpl 2, A-8036 Graz, Austria.	ute.schaefer@medunigraz.at	Zeleznik, Oana Alina/S-6015-2019	Zeleznik, Oana Alina/0000-0002-8705-1163; Leitinger, Gerd/0000-0002-5281-9830; Thallinger, Gerhard G./0000-0002-2864-5404	Styria government	We thank Chris Wrighton for editing the article and helpful comments. This work was supported by a grant from the Styria government.	Aliotta JM, 2010, EXP HEMATOL, V38, P233, DOI 10.1016/j.exphem.2010.01.002; ATACK JR, 1990, NEUROCHEM INT, V16, P533, DOI 10.1016/0197-0186(90)90013-J; BACH FW, 1992, CLIN CHEM, V38, P847; Bonev B, 2011, DEV CELL, V20, P19, DOI 10.1016/j.devcel.2010.11.018; Bruno S, 2013, STEM CELLS DEV, V22, DOI 10.1089/scd.2012.0304; Burnier L, 2009, THROMB HAEMOSTASIS, V101, P439, DOI 10.1160/TH08-08-0521; Cantaluppi V, 2012, KIDNEY INT, V82, P412, DOI 10.1038/ki.2012.105; Collino F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011803; De Maio A, 2011, CELL STRESS CHAPERON, V16, P235, DOI 10.1007/s12192-010-0236-4; Diehl P, 2012, CARDIOVASC RES, V93, P633, DOI 10.1093/cvr/cvs007; Ekelund J, 2003, NEUROSCI LETT, V349, P68, DOI 10.1016/S0304-3940(03)00654-2; FACCHINETTI F, 1987, NEUROSCI LETT, V77, P349, DOI 10.1016/0304-3940(87)90526-X; Faull KF, 1999, NEUROCHEM RES, V24, P1249, DOI 10.1023/A:1020973023059; Garcia BA, 2005, J PROTEOME RES, V4, P1516, DOI 10.1021/pr0500760; Gibbings DJ, 2009, NAT CELL BIOL, V11, P1143, DOI 10.1038/ncb1929; Harrington MG, 2009, FLUIDS BARRIERS CNS, V6, DOI 10.1186/1743-8454-6-10; Huang M, 2009, SURG NEUROL, V72, P481, DOI 10.1016/j.surneu.2008.12.016; Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694; Kiebler MA, 2006, NEURON, V51, P685, DOI 10.1016/j.neuron.2006.08.021; Langlois Agnes, 1997, Methods in Cell Science, V19, P213, DOI 10.1023/A:1009731707443; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046957; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Marzesco AM, 2005, J CELL SCI, V118, P2849, DOI 10.1242/jcs.02439; Mause SF, 2010, CIRC RES, V107, P1047, DOI 10.1161/CIRCRESAHA.110.226456; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Mrvar-Brecko A, 2010, BLOOD CELL MOL DIS, V44, P307, DOI 10.1016/j.bcmd.2010.02.003; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Pluskota E, 2008, BLOOD, V112, P2327, DOI 10.1182/blood-2007-12-127183; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Sadallah S, 2008, J LEUKOCYTE BIOL, V84, P1316, DOI 10.1189/jlb.0108013; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shet AS, 2003, BLOOD, V102, P2678, DOI 10.1182/blood-2003-03-0693; Shibata M, 2011, J NEUROSCI, V31, P3407, DOI 10.1523/JNEUROSCI.5085-10.2011; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Sinauridze EI, 2007, THROMB HAEMOSTASIS, V97, P425, DOI 10.1160/TH06-06-0313; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Smalheiser Neil R, 2009, Cardiovasc Psychiatry Neurol, V2009, P383086, DOI 10.1155/2009/383086; Smalheiser NR, 2007, BIOL DIRECT, V2, DOI 10.1186/1745-6150-2-35; Sommer JB, 2002, EUR NEUROL, V47, P224, DOI 10.1159/000057904; Tarnaris A, 2011, NEUROCHEM RES, V36, P528, DOI 10.1007/s11064-010-0374-1; van der Vos KE, 2011, CELL MOL NEUROBIOL, V31, P949, DOI 10.1007/s10571-011-9697-y; VanWijk MJ, 2003, CARDIOVASC RES, V59, P277, DOI 10.1016/S0008-6363(03)00367-5; Waldenstrom A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034653; Wetterberg L, 2002, NEUROSCI LETT, V329, P91, DOI 10.1016/S0304-3940(02)00580-3; WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x; Yuan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004722	50	50	55	0	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1232	1242		10.1089/neu.2012.2596			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100003	23360174				2022-02-06	
J	Radford, K; Phillips, J; Drummond, A; Sach, T; Walker, M; Tyerman, A; Haboubi, N; Jones, T				Radford, Kate; Phillips, Julie; Drummond, Avril; Sach, Tracey; Walker, Marion; Tyerman, Andy; Haboubi, Naseer; Jones, Trevor			Return to work after traumatic brain injury: Cohort comparison and economic evaluation	BRAIN INJURY			English	Article						Work; vocational rehabilitation; traumatic brain injury; job retention; community-based rehabilitation; occupational therapy; employment; activities of daily living	VOCATIONAL-REHABILITATION CLIENTS; QUALITY-OF-LIFE; SUPPORTED EMPLOYMENT; HOSPITAL ANXIETY; HEAD-INJURY; FOLLOW-UP; OUTCOMES; MODEL; DISABILITY; PROGRAM	Background: Returning to work (RTW) in the UK is problematic following TBI. Vocational rehabilitation (VR) is limited and efficacy or costs seldom reported. This study aimed to determine whether a TBI specialist VR intervention (TBI VR) was more effective at work return and retention 12 months after injury than usual care (UC). Secondary aims were to explore the feasibility of collecting economic data to inform a definitive trial. Method: Work outcomes of TBI-VR were compared to UC. Ninety-four participants (40 TBI-VR) with TBI resulting in hospitalization >= 48 hours, who were working at injury were followed up by postal questionnaire at 3, 6 and 12 months posthospital discharge. Primary outcome was RTW. Secondary outcomes were functional ability, mood and quality-of-life. Health resource use was measured by self-report. Results: At 12 months, 15% more TBI-VR participants (27% more with moderate/severe TBI) were working than UC (27/36, 75% vs. 27/45, 60%). Mean TBI-VR health costs per person (consultant, GP, therapy, medication) were only 75 pound greater at 1 year. Secondary outcomes showed no significant baseline differences between groups. Discussion: More TBI-VR participants returned to work than UC. People with moderate/severe TBI benefitted most. This positive trend was achieved without greatly increased health costs, suggesting cost-effectiveness. This study justifies the need for and can inform a definitive Randomized Controlled Trial (RCT).	[Radford, Kate; Drummond, Avril; Walker, Marion] Univ Nottingham, Nottingham NG7 2RD, England; [Phillips, Julie] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Sach, Tracey] Univ E Anglia, Norwich NR4 7TJ, Norfolk, England; [Tyerman, Andy] Cambourne Ctr, Aylesbury, Bucks, England; [Haboubi, Naseer] Univ Hosp NHS Trust, Nottingham, England; [Jones, Trevor] Serv User Representat, Nottingham, England		Radford, K (corresponding author), Queens Med Ctr, Div Rehabil & Ageing, Sch Med, B102, Nottingham NG7 2UH, England.	kate.radford@nottingham.ac.uk	Radford, Kate A/F-8571-2013	Radford, Kate A/0000-0001-6246-3180; Walker, Marion/0000-0002-3534-591X; Sach, Tracey/0000-0002-8098-9220; Drummond, Avril/0000-0003-1220-8354	College of Occupational Therapists; Nottingham Traumatic Brain Injury Service; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10092] Funding Source: researchfish	This project was funded by the College of Occupational Therapists. The authors wish to acknowledge the support of the Nottingham Traumatic Brain Injury Service, Professor Nadina Lincoln, Professor of Clinical Psychology and Dr Graham Warren, Medical Statistician for their advice, members of the steering group and principally the participants.	Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; [Anonymous], 2007, BRIT NAT FORM V54; Association of Personal Injury Lawyers, 2008, THINK REH BEST PRACT; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Black CM., 2008, WORKING HLTH TOMORRO; Brazier J, 2004, HEALTH ECON, V13, P873, DOI 10.1002/hec.866; British Society of Rehabilitation Medicine, 2003, REH FOLL ACQ BRAIN I; Catalano D, 2006, NEUROREHABILITATION, V21, P279; Chamberlain MA, 2007, CLIN MED, V7, P603, DOI 10.7861/clinmedicine.7-6-603; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cullen N, 2007, BRAIN INJURY, V21, P113, DOI 10.1080/02699050701201540; Department of Health, 2009, NHS REF COSTS 2007 0; Department of Health, 2010, NHS OUTC FRAM 2011 1; Deshpande P, 2004, VOCATIONAL ASSESSMEN; Deutsch PM, 2006, NEUROREHABILITATION, V21, P305; Dolan P, 1995, SOCIAL TARIFF EUROQO; Drummond M., 2005, METHODS EC EVALUATIO; Drummond MF, 2015, METHODS EC EVALUATIO; Fadyl JK, 2009, J HEAD TRAUMA REHAB, V24, P195, DOI 10.1097/HTR.0b013e3181a0d458; Frank AO, 2006, INT J THER REHABIL, V13, P126, DOI 10.12968/ijtr.2006.13.3.21364; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gibson AM, 2011, CLIN REHABIL, V25, P956; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gray AM., 1999, HLTH TECHNOLOGY ASSE, V3, P1, DOI DOI 10.3310/hta3020; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Johnstone B, 2006, NEUROREHABILITATION, V21, P335; Kendall E, 2006, J VOCAT REHABIL, V25, P149; KIND P, 1999, 172 U YORK CTR HLTH; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; Malec JF, 2006, BRAIN INJURY, V20, P227, DOI 10.1080/02699050500488124; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Marsh JM, 2010, CLIN REHABIL, V24, P281; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; Muirhead L., 2008, COMMUNICATION; Murphy L, 2006, BRAIN INJURY, V20, P1119, DOI 10.1080/02699050600664335; National Institute for Health and Clinical Excellence, 2009, GUID MAN; O'Brien L, 2007, BRAIN INJURY, V21, P465, DOI 10.1080/02699050701315134; Office for National Statistics, 2007, ANN SURV HOURS EARN; Office for National Statistics, 2008, STAND OCC CLASS 2000; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Paniak C, 2000, BRAIN INJURY, V14, P219; Personal Social Services Research Unit, 2007, UNIT COSTS HLTH SOCI; Phillips J, 2010, BRIT J OCCUP THER, V73, P422, DOI 10.4276/030802210X12839367526138; Playford ED, 2011, MAPPING VOCATIONAL R; Possl O, 2001, BRAIN INJURY, V15, P15; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1295, DOI 10.1080/02699050701721802; Relyea-Chew A, 2009, ARCH PHYS MED REHAB, V90, P413, DOI 10.1016/j.apmr.2008.07.031; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; Thompson S, 2001, ANNOTATED COST QUEST; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Turner-Stokes L, 2005, COCHRANE DB SYST REV, V20; Tyerman A, 2004, VOCATIONAL ASSESSMEN; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; van Velzen JM, 2011, DISABIL REHABIL, V33, P2237, DOI 10.3109/09638288.2011.563821; Waddell G, 2008, VOCATIONAL REHABILIT; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	71	50	51	0	41	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2013	27	5					507	520		10.3109/02699052.2013.766929			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	124UK	WOS:000317493000001	23473058				2022-02-06	
J	Singh, IN; Gilmer, LK; Miller, DM; Cebak, JE; Wang, JA; Hall, ED				Singh, Indrapal N.; Gilmer, Lesley K.; Miller, Darren M.; Cebak, John E.; Wang, Juan A.; Hall, Edward D.			Phenelzine mitochondrial functional preservation and neuroprotection after traumatic brain injury related to scavenging of the lipid peroxidation-derived aldehyde 4-hydroxy-2-nonenal	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						lipid peroxidation; mitochondria; phenelzine; traumatic brain injury; 4-hydroxy-2-nonenal	CYCLOSPORINE-A ANALOG; SPINAL-CORD; REACTIVE ALDEHYDES; OXIDATIVE STRESS; FREE-RADICALS; CELL-DEATH; DAMAGE; PEROXYNITRITE; DYSFUNCTION; INHIBITION	Phenelzine (PZ) is a scavenger of the lipid peroxidation (LP)-derived reactive aldehyde 4-hydroxynonenal (4-HNE) due to its hydrazine functional group, which can covalently react with 4-HNE. In this study, we first examined the ability of PZ to prevent the respiratory depressant effects of 4-HNE on normal isolated brain cortical mitochondria. Second, in rats subjected to controlled cortical impact traumatic brain injury (CCI-TBI), we evaluated PZ (10 mg/kg subcutaneously at 15 minutes after CCI-TBI) to attenuate 3-hour post-TBI mitochondrial respiratory dysfunction, and in separate animals, to improve cortical tissue sparing at 14 days. While 4-HNE exposure inhibited mitochondrial complex I and II respiration in a concentration-dependent manner, pretreatment with equimolar concentrations of PZ antagonized these effects. Western blot analysis demonstrated a PZ decrease in 4-HNE in mitochondrial proteins. Mitochondria isolated from peri-contusional brain tissue of CCI-TBI rats treated with vehicle at 15 minutes after injury showed a 37% decrease in the respiratory control ratio (RCR) relative to noninjured mitochondria. In PZ-treated rats, RCR suppression was prevented (P<0.05 versus vehicle). In another cohort, PZ administration increased spared cortical tissue from 86% to 97% (P<0.03). These results suggest that PZ's neuroprotective effect is due to mitochondrial protection by scavenging of LP-derived 4-HNE. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 593-599; doi:10.1038/jcbfm.2012.211; published online 16 January 2013	[Singh, Indrapal N.; Gilmer, Lesley K.; Miller, Darren M.; Cebak, John E.; Wang, Juan A.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,BBRSB Room 477, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2P30 NS051220, 2P01 NS058484, 1T32 DA022378, 1T32 077889]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, P01NS058484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K01DA022378] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health Grants 2P30 NS051220, 2P01 NS058484, 1T32 DA022378, 1T32 077889 and funding from the Kentucky Spinal Cord and Head Injury Research Trust.	Bayir H, 2006, BBA-BIOENERGETICS, V1757, P648, DOI 10.1016/j.bbabio.2006.03.002; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Dranka BP, 2011, FREE RADICAL BIO MED, V51, P1621, DOI 10.1016/j.freeradbiomed.2011.08.005; Eisenberg T, 2007, APOPTOSIS, V12, P1011, DOI 10.1007/s10495-007-0758-0; Ferrick DA, 2008, DRUG DISCOV TODAY, V13, P268, DOI 10.1016/j.drudis.2007.12.008; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Galvani S, 2008, FREE RADICAL BIO MED, V45, P1457, DOI 10.1016/j.freeradbiomed.2008.08.026; Gerencser AA, 2009, ANAL CHEM, V81, P6868, DOI 10.1021/ac900881z; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Halliwell B, 2012, NUTR REV, V70, P257, DOI 10.1111/j.1753-4887.2012.00476.x; Hamann K, 2008, J NEUROCHEM, V104, P708, DOI 10.1111/j.1471-4159.2007.05002.x; MacKenzie EM, 2008, NEUROCHEM RES, V33, P430, DOI 10.1007/s11064-007-9448-0; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nakai D, 2004, AGING CELL, V3, P273, DOI 10.1111/j.1474-9728.2004.00116.x; Raza H, 2006, TOXICOL APPL PHARM, V216, P309, DOI 10.1016/j.taap.2006.06.001; Rogers GW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021746; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Song MS, 2010, J NEUROCHEM, V114, P1405, DOI 10.1111/j.1471-4159.2010.06857.x; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Wood PL, 2006, BRAIN RES, V1095, P190, DOI 10.1016/j.brainres.2006.04.038; Wood PL, 2006, BRAIN RES, V1122, P184, DOI 10.1016/j.brainres.2006.09.003; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x	35	50	51	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2013	33	4					593	599		10.1038/jcbfm.2012.211			7	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	117CR	WOS:000316930200016	23321786	Bronze, Green Published			2022-02-06	
J	Feng, Y; Clayton, EH; Chang, Y; Okamoto, RJ; Bayly, PV				Feng, Y.; Clayton, E. H.; Chang, Y.; Okamoto, R. J.; Bayly, P. V.			Viscoelastic properties of the ferret brain measured in vivo at multiple frequencies by magnetic resonance elastography	JOURNAL OF BIOMECHANICS			English	Article						Magnetic resonance elastography; MRE; Viscoelasticity; Brain; Shear modulus	MULTIFREQUENCY MR ELASTOGRAPHY; LIVER VISCOELASTICITY; TISSUE; SHEAR; RHEOMETRY; BEHAVIOR; INJURY; MODEL; VITRO	Characterization of the dynamic mechanical behavior of brain tissue is essential for understanding and simulating the mechanisms of traumatic brain injury (TBI). Changes in mechanical properties may also reflect changes in the brain due to aging or disease. In this study, we used magnetic resonance elastography (MRE) to measure the viscoelastic properties of ferret brain tissue in vivo. Three-dimensional (3D) displacement fields were acquired during wave propagation in the brain induced by harmonic excitation of the skull at 400 Hz, 600 Hz and 800 Hz. Shear waves with wavelengths in the order of millimeters were clearly visible in the displacement field, in strain fields, and in the curl of displacement field (which contains no contributions from longitudinal waves). Viscoelastic parameters (storage and loss moduli) governing dynamic shear deformation were estimated in gray and white matter for these excitation frequencies. To characterize the reproducibility of measurements, two ferrets were studied on three different dates each. Estimated viscoelastic properties of white matter in the ferret brain were generally similar to those of gray matter and consistent between animals and scan dates. In both tissue types G' increased from approximately 3 kPa at 400 Hz to 7 kPa at 800 Hz and G '' increased from approximately 1 kPa at 400 Hz to 2 kPa at 800 Hz. These measurements of shear wave propagation in the ferret brain can be used to both parameterize and validate finite element models of brain biomechanics. (C) 2013 Elsevier Ltd. All rights reserved.	[Feng, Y.; Clayton, E. H.; Okamoto, R. J.; Bayly, P. V.] Washington Univ, Dept Mech Engn & Mat Sci, St Louis, MO 63130 USA; [Chang, Y.] Washington Univ, Dept Radiol, St Louis, MO 63130 USA; [Bayly, P. V.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA		Bayly, PV (corresponding author), Washington Univ, Dept Mech Engn & Mat Sci, 305 Jolley Hall,Campus Box 1185,1 Brookings Dr, St Louis, MO 63130 USA.	pvb@wustl.edu	Feng, Yuan/C-7417-2011	Feng, Yuan/0000-0003-1902-3408; Okamoto, Ruth/0000-0002-3085-3878; Bayly, Philip/0000-0003-4303-0704	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055951]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	Financial support for this study was provided by the NIH grant NS055951. We gratefully acknowledge the technical assistance of Chad Faulkner, Amy Grater, and Summer Thompson from DCM for animal handling, and Bill Spees and John Engelbach from the Washington University Biomedical Magnetic Resonance Lab (BMRL) for imaging assistance.	Asbach P, 2008, MAGN RESON MED, V60, P373, DOI 10.1002/mrm.21636; Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Auld B. A., 1990, ACOUSTIC FIELDS WAVE; Barnette AR, 2009, PEDIATR RES, V66, P80, DOI 10.1203/PDR.0b013e3181a291d9; Boulet T, 2011, J NEUROSCI METH, V201, P296, DOI 10.1016/j.jneumeth.2011.08.019; Chang Y. V., 2011, P 19 ANN ISMRM SCI M, P3474; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Clayton EH, 2011, PHYS MED BIOL, V56, P2391, DOI 10.1088/0031-9155/56/8/005; Clayton E. H., 2012, TRANSMISSION ATTENUA; Di Ieva A, 2010, NEUROSURG REV, V33, P137, DOI 10.1007/s10143-010-0249-6; Feng Y., 2012, ASME INT MECH ENG C; Feng Y., 2012, P SEM ANN C EXP EXP; Flugge W., 1975, VISCOELASTICITY; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Hamhaber U, 2010, J MAGN RESON IMAGING, V32, P577, DOI 10.1002/jmri.22294; Hrapko M, 2008, BIORHEOLOGY, V45, P663, DOI 10.3233/BIR-2008-0512; Kaster T, 2011, J BIOMECH, V44, P1158, DOI 10.1016/j.jbiomech.2011.01.019; Klatt D, 2007, PHYS MED BIOL, V52, P7281, DOI 10.1088/0031-9155/52/24/006; Klatt D, 2010, BIORHEOLOGY, V47, P133, DOI 10.3233/BIR-2010-0565; KLEIVEN S, 2002, THESIS ROYAL I TECHN; Knutsen AK, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4002430; Kolsky H., 1963, STRESS WAVES SOLIDS; Kruse SA, 2003, P 11 ISMRM SCI M EXH, P1084; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Margulies S, 2006, FORENSIC SCI INT, V164, P278, DOI 10.1016/j.forsciint.2005.12.018; McCracken PJ, 2005, MAGN RESON MED, V53, P628, DOI 10.1002/mrm.20388; McGarry MDJ, 2011, PHYS MED BIOL, V56, pN153, DOI 10.1088/0031-9155/56/13/N02; Murphy MC, 2012, MAGN RESON IMAGING, V30, P535, DOI 10.1016/j.mri.2011.12.019; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Muthupillai R, 1996, NAT MED, V2, P601, DOI 10.1038/nm0596-601; Neal J, 2007, J ANAT, V210, P66, DOI 10.1111/j.1469-7580.2006.00674.x; Okamoto RJ, 2011, PHYS MED BIOL, V56, P6379, DOI 10.1088/0031-9155/56/19/014; Pattison AJ, 2010, J BIOMECH, V43, P2747, DOI 10.1016/j.jbiomech.2010.06.008; Qin E. G., 2012, J MAGNETIC RESONANCE; Raul JS, 2008, INT J LEGAL MED, V122, P359, DOI 10.1007/s00414-008-0248-0; Riek K, 2011, J BIOMECH, V44, P1380, DOI 10.1016/j.jbiomech.2010.12.031; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Romano AJ, 2005, MAGN RESON MED, V54, P893, DOI 10.1002/mrm.20607; Romano A, 2012, MAGN RESON MED, V68, P1410, DOI 10.1002/mrm.24141; Sack I, 2008, NMR BIOMED, V21, P265, DOI 10.1002/nbm.1189; Schregel K, 2012, P NATL ACAD SCI USA, V109, P6650, DOI 10.1073/pnas.1200151109; Sinkus R, 2005, MAGN RESON IMAGING, V23, P159, DOI 10.1016/j.mri.2004.11.060; Sinkus R, 2005, MAGNET RESON MED, V53, P372, DOI 10.1002/mrm.20355; Soutas-Little R. W, 1973, ELASTICITY; Spottiswoode BS, 2007, IEEE T MED IMAGING, V26, P15, DOI 10.1109/TMI.2006.884215; Tong YY, 2003, ACM T GRAPHIC, V22, P445, DOI 10.1145/882262.882290; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Vappou J, 2007, MAGN RESON MATER PHY, V20, P273, DOI 10.1007/s10334-007-0098-7; Xu G, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4001683; Zhang J, 2011, J BIOMECH, V44, P1909, DOI 10.1016/j.jbiomech.2011.04.034; Zhang L, 2001, Stapp Car Crash J, V45, P369	52	50	51	0	37	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	MAR 15	2013	46	5					863	870		10.1016/j.jbiomech.2012.12.024			8	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	115RN	WOS:000316829700003	23352648	Green Accepted			2022-02-06	
J	Anglin, CO; Spence, JS; Warner, MA; Paliotta, C; Harper, C; Moore, C; Sarode, R; Madden, C; Diaz-Arrastia, R				Anglin, Catherine O.; Spence, Jeffrey S.; Warner, Matthew A.; Paliotta, Christopher; Harper, Caryn; Moore, Carol; Sarode, Ravi; Madden, Christopher; Diaz-Arrastia, Ramon			Effects of platelet and plasma transfusion on outcome in traumatic brain injury patients with moderate bleeding diatheses	JOURNAL OF NEUROSURGERY			English	Article						transfusion; traumatic brain injury; platelet; fresh frozen plasma; Glasgow Outcome Scale-Extended	FRESH-FROZEN PLASMA; FUNCTIONAL STATUS EXAMINATION; CLOSED-HEAD INJURY; INTRAVASCULAR COAGULATION; COAGULOPATHY; ANEMIA; MORTALITY; SCALE	Object. Coagulopathy and thrombocytopenia are common after traumatic brain injury (TBI), yet transfusion thresholds for mildly to moderately abnormal ranges of international normalized ratio and platelet count remain controversial. This study evaluates associations between fresh frozen plasma (FFP) and platelet transfusions with long-term functional outcome and survival in TBI patients with moderate hemostatic laboratory abnormalities. Methods. This study is a retrospective review of prospectively collected data of patients with mild to severe TBI. Data include patient demographics, several initial injury severity metrics, daily laboratory values, Glasgow Outcome Score-Extended (GOSE) scores, Functional Status Examination (FSE) scores, and survival to 6 months. Correlations were evaluated between these variables and transfusion of FIT, platelets, packed red blood cells (RBCs), cryoprecipitate, recombinant factor VIIa, and albumin. Ordinal regression was performed to account for potential confounding variables to further define relationships between transfusion status and long-term outcome. By analyzing collected data, mild to moderate coagulopathy was defined as an international normalized ratio 1.4-2.0, moderate thrombocytopenia as platelet count 50 x 10(9)/L to 107 x 10(9)/L, and moderate anemia as 21%-30% hematocrit. Results. In patients with mild to moderate laboratory hematological abnormalities, univariate analysis shows significant correlations between poor outcome scores and FFP, platelet, or packed RBC transfusion; the volume of FFP or packed RBCs transfused also correlated with poor outcome. Several measures of initial injury and laboratory abnormalities also correlated with poor outcome. Patient age, initial Glasgow Coma Scale score, and highest recorded serum sodium were included in the ordinal regression model using backward variable selection. In the moderate coagulopathy subgroup, patients transfused with FIT were more likely to have a lower GOSE score relative to those who did not receive a transfusion (OR 5.20 [95% CI 1.72-15.73]). Patients with moderate coagulopathy who received FFP and packed RBCs were even more likely to be have a lower GOSE score (OR 7.17 [95% CI 2.12-24.12]). Moderately anemic patients who received packed RBCs alone were more likely to have a worse long-term functional outcome as determined by GOSE and FSE scores (GOSE: OR 2.41 [95% CI 1.51-3.85]; and FSE: OR 3.27 [95% CI 2.00-5.35]). No transfusion types or combinations were noted to significantly correlate with the 6-month mortality in ordinal regression. Conclusions. In TBI patients with moderate coagulopathy, FFP transfusions alone or a combination of FFP and packed RBCs were associated with poorer long-term functional outcomes as measured by the GOSE. Red blood cell transfusions were associated with poor long-term functional outcome in TBI patients with moderate anemia. Platelet transfusion in patients with moderate thrombocytopenia was not significantly associated with outcome. Although transfusion is beneficial to many patients with severe hematological abnormalities, it is not without risk, and the indications for transfusion should be carefully considered in patients with moderate hematological abnormalities. (http://thejns.org/doi/abs/10.3171/2012.11.JNS12622)	[Anglin, Catherine O.; Warner, Matthew A.; Paliotta, Christopher; Harper, Caryn; Moore, Carol; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Neurol, Dallas, TX 75390 USA; [Spence, Jeffrey S.] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Clin Sci & Internal Med, Dallas, TX 75390 USA; [Madden, Christopher] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Neurol Surg, Dallas, TX 75390 USA; [Sarode, Ravi] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Pathol, Dallas, TX 75390 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA		Diaz-Arrastia, R (corresponding author), Uniformed Serv Univ Hlth Sci, 12725 Twinbrook Pkwy, Rockville, MD 20851 USA.	Ramon.Diaz-Arrastia@USUHS.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	Clinical Research Fellowship through the Doris Duke Charitable Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD48179, U01 HD42652]; National Institute on Disability and Rehabilitation Research (NIDRR) [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	This study was supported by a Clinical Research Fellowship through the Doris Duke Charitable Foundation to Ms Anglin and Dr. Warner, and by support from the NIH (Grant Nos. R01 HD48179, U01 HD42652) and the National Institute on Disability and Rehabilitation Research (NIDRR) (Grant No. H133 A020526) to Dr. Diaz-Arrastia.	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Bostrom K, 1986, Acta Neurochir Suppl (Wien), V36, P51; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Duane TM, 2008, J SURG RES, V147, P163, DOI 10.1016/j.jss.2008.02.044; Etemadrezaie H, 2007, CLIN NEUROL NEUROSUR, V109, P166, DOI 10.1016/j.clineuro.2006.09.001; George ME, 2008, NEUROCRIT CARE, V8, P337, DOI 10.1007/s12028-008-9066-y; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Ozier Y, 2008, TRANSFUS CLIN BIOL, V15, P240, DOI 10.1016/j.tracli.2008.09.010; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Shariff MM, 2007, JCPSP-J COLL PHYSICI, V17, P207; Stainsby D, 2006, TRANSFUS MED REV, V20, P273, DOI 10.1016/j.tmrv.2006.05.002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Triulzi DJ, 2009, ANESTH ANALG, V108, P770, DOI 10.1213/ane.0b013e31819029b2; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	26	50	52	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2013	118	3					676	686		10.3171/2012.11.JNS12622			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	094DW	WOS:000315244200032	23259827				2022-02-06	
J	Rodriguez-Rodriguez, A; Egea-Guerrero, JJ; Leon-Justel, A; Gordillo-Escobar, E; Revuelto-Rey, J; Vilches-Arenas, A; Carrillo-Vico, A; Dominguez-Roldan, JM; Murillo-Cabezas, F; Guerrero, JM				Rodriguez-Rodriguez, Ana; Jose Egea-Guerrero, Juan; Leon-Justel, Antonio; Gordillo-Escobar, Elena; Revuelto-Rey, Jaume; Vilches-Arenas, Angel; Carrillo-Vico, Antonio; Maria Dominguez-Roldan, Jose; Murillo-Cabezas, Francisco; Miguel Guerrero, Juan			Role of S100B protein in urine and serum as an early predictor of mortality after severe traumatic brain injury in adults	CLINICA CHIMICA ACTA			English	Article						Traumatic brain injury; S100B; Urine; Mortality; Biomarkers	NEURON-SPECIFIC ENOLASE; S100-BETA PROTEIN; S-100B; DAMAGE; BIOMARKERS; CHILDREN; INFANTS; MARKERS; LEVEL	S100B is a calcium-binding protein released into the blood from astroglial cells due to brain injury. Some authors have described a correlation between S100B serum concentration and severity of brain damage. There is not much information about the accuracy of urinary S100B for predicting outcome after severe traumatic brain injury (TBI). 55 patients with severe TBI were included in the study. Blood and urine samples were drawn to determine S100B levels on admission and on the subsequent 24, 48, 72 and 96 h. S100B concentrations (serum and urine) were significantly higher in patients who were dead a month after the accident compared to survivors. ROC-analysis showed that S100B at 24 h post-severe TBI is a useful tool for predicting mortality (serum: AUC 0.958, urine: AUC 0.778). The best cut-offs for S100B were 0.461 mu g/L and 0.025 mu g/L (serum and urine respectively), with a sensitivity of 90% for both measurements and a specificity of 88.4% (serum) and 62.8% (urine). We can state that the determination of S100B levels both in urine and serum acts as a sensitive and an effective biomarker for the early prediction of mortality after severe TBI. (C) 2012 Elsevier B.V. All rights reserved.	[Rodriguez-Rodriguez, Ana; Leon-Justel, Antonio; Miguel Guerrero, Juan] Univ Seville, CSIC, IBIS, Virgen del Rocio Univ Hosp,Dept Clin Biochem, Seville 41013, Spain; [Jose Egea-Guerrero, Juan; Gordillo-Escobar, Elena; Revuelto-Rey, Jaume; Carrillo-Vico, Antonio; Maria Dominguez-Roldan, Jose; Murillo-Cabezas, Francisco] Univ Seville, CSIC, IBIS, Virgen del Rocio Univ Hosp,NeuroCrit Care Unit, Seville 41013, Spain; [Vilches-Arenas, Angel] Univ Seville, Dept Prevent Med & Publ Hlth, Seville 41013, Spain		Guerrero, JM (corresponding author), Univ Seville, CSIC, IBIS, Virgen del Rocio Univ Hosp,Dept Clin Biochem, Avda Manuel Siurot S-N, Seville 41013, Spain.	guerrero@us.es	Dominguez-Roldan, Jose-Maria/M-1728-2016; Egea-Guerrero, Juan Jose JJ/P-5080-2014; Guerrero, Josep M./Y-2929-2019; Carrillo-Vico, Antonio/K-5265-2014; Murillo-Cabezas, Francisco/AAO-3348-2021; Rodriguez-Rodriguez, Ana/F-4718-2016; IBIS, NEUROINMUNO/O-9306-2015; Vilches-Arenas, Angel/C-1167-2015; IBIS, NEUROCRITICOS/C-1805-2016	Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478; Egea-Guerrero, Juan Jose JJ/0000-0002-4166-313X; Guerrero, Josep M./0000-0001-5236-4592; Carrillo-Vico, Antonio/0000-0002-8516-0999; Rodriguez-Rodriguez, Ana/0000-0002-6854-9695; Vilches-Arenas, Angel/0000-0003-2197-3760; Guerrero, Juan Miguel/0000-0001-7553-0119; Revuelto-Rey, Jaume/0000-0001-8350-9555			Anderson JL, 2007, CIRCULATION, V116, pE148, DOI 10.1161/CIRCULATIONAHA.107.181940; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Beaudeux JL, 1999, ANN BIOL CLIN-PARIS, V57, P261; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Copes W. S, P 33 ANN M ASS ADV A, P205; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Ferguson MA, 2008, TOXICOLOGY, V245, P182, DOI 10.1016/j.tox.2007.12.024; Gazzolo D, 2002, CRIT CARE MED, V30, P1356, DOI 10.1097/00003246-200206000-00037; Gazzolo D, 1999, J NEUROL SCI, V170, P32, DOI 10.1016/S0022-510X(99)00194-X; Hallen M, 2008, CLIN CHEM LAB MED, V46, P1025, DOI 10.1515/CCLM.2008.190; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hu JR, 1997, J NEUROCHEM, V69, P2294; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Koppal T, 2001, NEUROCHEM INT, V39, P401, DOI 10.1016/S0197-0186(01)00047-X; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Lee CC, 2010, J CHIN MED ASSOC, V73, P8, DOI 10.1016/S1726-4901(10)70015-0; Macher H, 2012, CLIN CHIM ACTA, V414, P12, DOI 10.1016/j.cca.2012.08.001; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nagdyman N, 2001, PEDIATR RES, V49, P502, DOI 10.1203/00006450-200104000-00011; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pickering A, 2008, EMERG MED J, V25, P88, DOI 10.1136/emj.2007.046631; Portela LVC, 2002, CLIN CHEM, V48, P950; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Risso FM, 2012, CLIN CHIM ACTA, V413, P150, DOI 10.1016/j.cca.2011.09.011; Schultke E, 2009, CAN J NEUROL SCI, V36, P612, DOI 10.1017/S031716710000812X; Steiner J, 2011, CLIN CHEM LAB MED, V49, P409, DOI 10.1515/CCLM.2011.083; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Vassalotti JA, 2007, AM J KIDNEY DIS, V50, P169, DOI 10.1053/j.ajkd.2007.06.013; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	39	50	51	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	DEC 24	2012	414						228	233		10.1016/j.cca.2012.09.025			6	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	059DU	WOS:000312685400048	23031665				2022-02-06	
J	Wang, KY; Yu, GF; Zhang, ZY; Huang, Q; Dong, XQ				Wang, Ke-Yi; Yu, Guo-Feng; Zhang, Zu-Yong; Huang, Qiang; Dong, Xiao-Qiao			Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury	CLINICA CHIMICA ACTA			English	Article						High-mobility group box 1; Traumatic brain injury; Functional outcome; Mortality	DNA-BINDING PROTEINS; SUBARACHNOID HEMORRHAGE; CHROMATIN PROTEIN; HEAD-INJURY; HMGB1; ISCHEMIA; RELEASE; HMG-1; INFLAMMATION; ARTHRITIS	Background: High-mobility group box 1 (HMGB1), a marker of inflammation, has been associated with poor outcome of critical illness. The present study was undertaken to investigate the plasma HMGB1 concentrations in patients with traumatic brain injury (TBI) and to analyze the correlation of HMGB1 with TBI outcome. Methods: We performed an observational, clinical study. Plasma HMGB1 concentration of 106 healthy subjects and 106 patients with severe TBI was measured by ELISA. The correlation with 1-y mortality and unfavorable outcome (Glasgow Outcome Scale score of 1-3) was analyzed. Results: Thirty-one patients (29.2%) died and 48 patients (45.3%) had an unfavorable outcome at 1 y after TBI. Plasma HMGB1 level was substantially higher in patients than in healthy controls. A multivariate analysis selected plasma HMGB1 level as an independent predictor for 1-y mortality and unfavorable outcome of patients. A receiver operating characteristic curve analysis showed plasma HMGB1 level statistically significantly predicted 1-y mortality and unfavorable outcome. The prognostic value of HMGB1 was similar to that of Glasgow Coma Scale score for 1-y clinical outcomes. Conclusions: Plasma HMGB1 concentration emerges as a novel biomarker for predicting 1-y clinical outcomes of TBI. (c) 2012 Elsevier B.V. All rights reserved.	[Zhang, Zu-Yong; Dong, Xiao-Qiao] Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China; [Yu, Guo-Feng; Huang, Qiang] Quzhou Peoples Hosp, Dept Neurosurg, Quzhou 324100, Peoples R China; [Wang, Ke-Yi] Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Cent Lab, Hangzhou 310006, Zhejiang, Peoples R China		Dong, XQ (corresponding author), Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China.	dxqhyy@163.com			Zhejiang Provincial Program [2012KYB148]	This work was financially supported by the Zhejiang Provincial Program (No. 2012KYB148).	Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Agnello D, 2002, CYTOKINE, V18, P231, DOI 10.1006/cyto.2002.0890; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; Goldstein RS, 2006, SHOCK, V25, P571, DOI 10.1097/01.shk.0000209540.99176.72; Guazzi S, 2003, GENE EXPR PATTERNS, V3, P29, DOI 10.1016/S1567-133X(02)00093-5; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; King MD, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09223; Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008-00034.Klune; Kokkola R, 2003, ARTHRITIS RHEUM, V48, P2052, DOI 10.1002/art.11161; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Murakami K, 2011, TRANSL STROKE RES, V2, P72, DOI 10.1007/s12975-010-0052-2; Nakahara T, 2009, NEUROCRIT CARE, V11, P362, DOI 10.1007/s12028-009-9276-y; Ombrellino M, 1999, LANCET, V354, P1446, DOI 10.1016/S0140-6736(99)02658-6; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Tang DL, 2008, CRIT CARE MED, V36, P291, DOI 10.1097/01.CCM.0000295316.86942.CE; Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-188OC; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Vogelgesang A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008718; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang HC, 1999, SURGERY, V126, P389, DOI 10.1067/msy.1999.99167; Watanabe M, 2012, ACTA NEUROCHIR SUPPL, V113, P91, DOI 10.1007/978-3-7091-0923-6_19; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Zhou Y, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/142458	36	50	54	0	94	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981			CLIN CHIM ACTA	Clin. Chim. Acta	NOV 12	2012	413	21-22					1737	1741		10.1016/j.cca.2012.07.002			5	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	003PB	WOS:000308622700004	22789964				2022-02-06	
J	Benedict, AL; Mountney, A; Hurtado, A; Bryan, KE; Schnaar, RL; Dinkova-Kostova, AT; Talalay, P				Benedict, Andrea L.; Mountney, Andrea; Hurtado, Andres; Bryan, Kelley E.; Schnaar, Ronald L.; Dinkova-Kostova, Albena T.; Talalay, Paul			Neuroprotective Effects of Sulforaphane after Contusive Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						neuroprotection; spinal cord injury; sulforaphane	MIGRATION INHIBITORY FACTOR; TRAUMATIC BRAIN-INJURY; MURINE HEPATOMA-CELLS; KAPPA-B; QUANTITATIVE-DETERMINATION; THERAPEUTIC INTERVENTION; CHEMOPREVENTIVE AGENTS; GLUTATHIONE SYNTHESIS; NEURONAL GLUTATHIONE; FUNCTIONAL RECOVERY	Traumatic spinal cord injury (SCI) leads to oxidative stress, calcium mobilization, glutamate toxicity, the release of proinflammatory factors, and depletion of reduced glutathione (GSH) at the site of injury. Induction of the Keap1/Nrf2/ARE pathway can alleviate neurotoxicity by protecting against GSH depletion, oxidation, intracellular calcium overload, mitochondrial dysfunction, and excitotoxicity. Sulforaphane (SF), an isothiocyanate derived from broccoli, is a potent naturally-occurring inducer of the Keap1/Nrf2/ARE pathway, leading to upregulation of genes encoding cytoprotective proteins such as NAD(P)H: quinone oxidoreductase 1, and GSH-regulatory enzymes. Additionally, SF can attenuate inflammation by inhibiting the nuclear factor-kappa B (NF-kappa B) pathway, and the enzymatic activity of the proinflammatory cytokine macrophage inhibitory factor (MIF). Our study examined systemic administration of SF in a rat model of contusion SCI, in an effort to utilize its indirect antioxidant and anti-inflammatory properties to decrease secondary injury. Two doses of SF (10 or 50 mg/kg) were administered at 10 min and 72 h after contusion SCI. SF (50 mg/kg) treatment resulted in both acute and long-term beneficial effects, including upregulation of the phase 2 antioxidant response at the injury site, decreased mRNA levels of inflammatory cytokines (i.e., MMP-9) in the injured spinal cord, inactivation of urinary MIF tautomerase activity, enhanced hindlimb locomotor function, and an increased number of serotonergic axons caudal to the lesion site. These findings demonstrate that SF provides neuroprotective effects in the spinal cord after injury, and could be a candidate for therapy of SCI.	[Benedict, Andrea L.; Bryan, Kelley E.; Dinkova-Kostova, Albena T.; Talalay, Paul] Johns Hopkins Univ, Sch Med, Lewis B & Dorothy Cullman Chemoprotect Ctr, Baltimore, MD USA; [Benedict, Andrea L.; Mountney, Andrea; Bryan, Kelley E.; Schnaar, Ronald L.; Dinkova-Kostova, Albena T.; Talalay, Paul] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Hurtado, Andres] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Schnaar, Ronald L.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Dinkova-Kostova, Albena T.] Univ Dundee, Med Res Inst, Dundee, Scotland; [Hurtado, Andres] Hugo W Moser Res Inst Kennedy Krieger, Int Ctr Spinal Cord Injury, Baltimore, MD USA		Talalay, P (corresponding author), Johns Hopkins Med Sch, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	ptalalay@jhmi.edu	Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484; Dinkova-Kostova, Albena/0000-0003-0316-9859	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057338]; Lewis B. and Dorothy Cullman Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057338] Funding Source: NIH RePORTER	We are grateful to Dr. W. D. Holtzclaw, Jr., K. L. Wade, and K. K. Stephenson (Johns Hopkins University) for technical assistance. We would like to thank D. Wendell (Hugo W. Moser Research Institute at Kennedy Krieger) for help with surgical procedures and behavioral testing. This work was supported in part by NIH grant NS057338 and the Lewis B. and Dorothy Cullman Foundation.	Al-Abed Y, 2005, J BIOL CHEM, V280, P36541, DOI 10.1074/jbc.C500243200; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Basso DM, 2004, J NEUROTRAUM, V21, P395, DOI 10.1089/089771504323004548; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brambilla R, 2009, J NEUROCHEM, V110, P765, DOI 10.1111/j.1471-4159.2009.06190.x; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brown KK, 2009, J BIOL CHEM, V284, P32425, DOI 10.1074/jbc.M109.047092; Calabrese V, 2010, ANTIOXID REDOX SIGN, V13, P1763, DOI 10.1089/ars.2009.3074; Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8; Cornblatt BS, 2007, CARCINOGENESIS, V28, P1485, DOI 10.1093/carcin/bgm049; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Dringen R, 1999, J NEUROCHEM, V72, P2523, DOI 10.1046/j.1471-4159.1999.0722523.x; Dringen R, 2003, BIOL CHEM, V384, P505, DOI 10.1515/BC.2003.059; Dringen R, 1999, J NEUROSCI, V19, P562, DOI 10.1523/jneurosci.19-02-00562.1999; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Elbarbry F, 2011, J MED PLANTS RES, V5, P473; Guerrero-Beltran CE, 2012, EXP TOXICOL PATHOL, V64, P503, DOI 10.1016/j.etp.2010.11.005; Escartin C, 2011, J NEUROSCI, V31, P7392, DOI 10.1523/JNEUROSCI.6577-10.2011; Garai J, 2009, CURR MED CHEM, V16, P1091, DOI 10.2174/092986709787581842; Ghosh N, 2011, FREE RADICAL RES, V45, P888, DOI 10.3109/10715762.2011.574290; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Healy ZR, 2011, CANCER EPIDEM BIOMAR, V20, P1516, DOI 10.1158/1055-9965.EPI-11-0279; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Hu CQ, 2011, CHEM RES TOXICOL, V24, P515, DOI 10.1021/tx100389r; Hwang ES, 2005, J MED FOOD, V8, P198, DOI 10.1089/jmf.2005.8.198; Jeong WS, 2004, PHARM RES-DORDR, V21, P661, DOI 10.1023/B:PHAM.0000022413.43212.cf; Johnson JA, 2008, ANN NY ACAD SCI, V1147, P61, DOI 10.1196/annals.1427.036; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Mao L, 2011, J SURG RES, V170, pE105, DOI 10.1016/j.jss.2011.05.049; Mao L, 2010, ANN CLIN LAB SCI, V40, P354; Mountney A, 2010, P NATL ACAD SCI USA, V107, P11561, DOI 10.1073/pnas.1006683107; Nishio Y, 2009, ACTA NEUROPATHOL, V117, P321, DOI 10.1007/s00401-008-0476-x; Ping Z, 2010, BRAIN RES, V1343, P178, DOI 10.1016/j.brainres.2010.04.036; Schmidt BJ, 2000, BRAIN RES BULL, V53, P689, DOI 10.1016/S0361-9230(00)00402-0; Wang FZ, 2011, NEUROSCI RES, V71, P210, DOI 10.1016/j.neures.2011.07.1821; Wang XL, 2012, J NEUROTRAUM, V29, P936, DOI 10.1089/neu.2011.1922; Xu CJ, 2006, CANCER RES, V66, P8293, DOI 10.1158/0008-5472.CAN-06-0300; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Ye LX, 2002, CLIN CHIM ACTA, V316, P43, DOI 10.1016/S0009-8981(01)00727-6; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; ZHANG YS, 1995, BIOCHEM BIOPH RES CO, V206, P748, DOI 10.1006/bbrc.1995.1106; Zhang YS, 1996, ANAL BIOCHEM, V239, P160, DOI 10.1006/abio.1996.0311; Zhang YS, 2000, CARCINOGENESIS, V21, P1175, DOI 10.1093/carcin/21.6.1175; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007	57	50	58	0	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	16					2576	2586		10.1089/neu.2012.2474			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	035CS	WOS:000310920900006	22853439	Green Published			2022-02-06	
J	Halpern, AE; Ramig, LO; Matos, CEC; Petska-Cable, JA; Spielman, JL; Pogoda, JM; Gilley, PM; Sapir, S; Bennett, JK; McFarland, DH				Halpern, Angela E.; Ramig, Lorraine O.; Matos, Carlos E. C.; Petska-Cable, Jill A.; Spielman, Jennifer L.; Pogoda, Janice M.; Gilley, Phillip M.; Sapir, Shimon; Bennett, John K.; McFarland, David H.			Innovative Technology for the Assisted Delivery of Intensive Voice Treatment (LSVT (R) LOUD) for Parkinson Disease	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						Parkinson; speech treatment; technology	TRAUMATIC BRAIN-INJURY; TREATMENT LSVT LOUD; SPEECH TREATMENT; NEURAL PLASTICITY; DISORDERED SPEECH; INDIVIDUALS; DYSARTHRIA; THERAPY; REHABILITATION; PERCEPTION	Purpose: To assess the feasibility and effectiveness of a newly developed assistive technology system, Lee Silverman Voice Treatment Companion (LSVT (R) Companion (TM), hereafter referred to as "Companion"), to support the delivery of LSVT (R) LOUD, an efficacious speech intervention for individuals with Parkinson disease (PD). Method: Sixteen individuals with PD were randomized to an immediate (n = 8) or a delayed (n = 8) treatment group. They participated in 9 LSVT LOUD sessions and 7 Companion sessions, independently administered at home. Acoustic, listener perception, and voice and speech rating data were obtained immediately before (pre), immediately after (post), and at 6 months post treatment (follow-up). System usability ratings were collected immediately post treatment. Changes in vocal sound pressure level were compared to data from a historical treatment group of individuals with PD treated with standard, in-person LSVT LOUD. Results: All 16 participants were able to independently use the Companion. These individuals had therapeutic gains in sound pressure level, pre to post and pre to follow-up, similar to those of the historical treatment group. Conclusions: This study supports the use of the Companion as an aid in treatment of hypokinetic dysarthria in individuals with PD. Advantages and disadvantages of the Companion, as well as limitations of the present study and directions for future studies, are discussed.	[Halpern, Angela E.; Ramig, Lorraine O.; Spielman, Jennifer L.; Gilley, Phillip M.; Bennett, John K.] Univ Colorado, Boulder, CO 80309 USA; [Halpern, Angela E.; Ramig, Lorraine O.; Petska-Cable, Jill A.; Spielman, Jennifer L.] Natl Ctr Voice & Speech, Denver, CO USA; [Matos, Carlos E. C.] Fac Ruy Barbosa, Salvador, BA, Brazil; [Pogoda, Janice M.] Univ So Calif, Los Angeles, CA USA; [Sapir, Shimon] Univ Haifa, IL-31999 Haifa, Israel; [McFarland, David H.] Univ Montreal, Quebec City, PQ, Canada; [McFarland, David H.] McGill Univ, Montreal, PQ, Canada		Halpern, AE (corresponding author), Univ Colorado, Boulder, CO 80309 USA.	angela.halpern@lsvtglobal.com			National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21-DC05583]; The Michael J. Fox Foundation; The Coleman Institute for Cognitive Disabilities; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R21DC005583] Funding Source: NIH RePORTER	This research was funded by National Institute on Deafness and Other Communication Disorders and National Institute of Neurological Disorders and Stroke Grant R21-DC05583, The Michael J. Fox Foundation, and The Coleman Institute for Cognitive Disabilities. We thank our research assistants Heather Gustafson and Leslie Mahler. We also express our gratitude to the individuals who volunteered their time to participate in this study.	Adams S, 2006, J MED SPEECH-LANG PA, V14, P221; ADAMS SG, 1992, EUR J DISORDER COMM, V27, P121; Ball LJ, 2004, J COMMUN DISORD, V37, P197, DOI 10.1016/j.jcomdis.2003.09.002; Baumgartner CA, 2001, J VOICE, V15, P105, DOI 10.1016/S0892-1997(01)00010-8; BAYLES KA, 1993, J CLIN EXP NEUROPSYC, V15, P547, DOI 10.1080/01688639308402578; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Benton AL, 1994, MULTILINGUAL APHASIA; Boliek C, 2009, MOVEMENT DISORD, V24, pS450; Cariski D, 1999, J MED SPEECH-LANG PA, V7, P315; Cole E., 2006, PAT CTR DESIGN RES S; Constantinescu G, 2011, INT J LANG COMM DIS, V46, P1, DOI 10.3109/13682822.2010.484848; Constantinescu G, 2010, INT J LANG COMM DIS, V45, P630, DOI 10.3109/13682820903470569; Constantinescu GA, 2010, J TELEMED TELECARE, V16, P100, DOI 10.1258/jtt.2009.090306; Countryman S., 1997, AM J SPEECH-LANG PAT, V6, P74; DOWNIE AW, 1981, BRIT J DISORD COMMUN, V16, P135; DROMEY C, 1995, J SPEECH HEAR RES, V38, P751, DOI 10.1044/jshr.3804.751; Dykstra A., 2010, ANN CONV AM SPEECH L; Efron B., 1986, STAT SCI, V1, P54, DOI 10.1214/ss/1177013815; El Sharkawi A, 2002, J NEUROL NEUROSUR PS, V72, P31; Fairbanks G., 1960, VOICE ARTICULATION D; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox Cynthia M., 2006, Seminars in Speech and Language, V27, P283, DOI 10.1055/s-2006-955118; Fox CM, 2012, J SPEECH LANG HEAR R, V55, P930, DOI 10.1044/1092-4388(2011/10-0235); Greene M C, 1972, J Laryngol Otol, V86, P595, DOI 10.1017/S0022215100075629; Guadagnoli MA, 2002, PARKINSONISM RELAT D, V9, P89, DOI 10.1016/S1353-8020(02)00007-X; HANSON WR, 1980, J SPEECH HEAR DISORD, V45, P268, DOI 10.1044/jshd.4502.268; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; HARTELIUS L, 1994, FOLIA PHONIATR LOGO, V46, P9, DOI 10.1159/000266286; Hill AJ, 2006, AM J SPEECH-LANG PAT, V15, P45, DOI 10.1044/1058-0360(2006/006); Hillman RE, 2006, ANN OTO RHINOL LARYN, V115, P795, DOI 10.1177/000348940611501101; Ho AK, 2000, MOVEMENT DISORD, V15, P1125, DOI 10.1002/1531-8257(200011)15:6<1125::AID-MDS1010>3.0.CO;2-R; Ho AK, 1998, BEHAV NEUROL, V11, P131, DOI 10.1155/1999/327643; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Howell S, 2009, INT J LANG COMM DIS, V44, P287, DOI 10.1080/13682820802033968; *ISO, 1999, 134071999E ISO; Jacobson BH., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI DOI 10.1044/1058-0360.0603.66; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Krause M, 2004, J NEUROL SCI, V219, P119, DOI 10.1016/j.jns.2004.01.004; Liotti M, 2003, NEUROLOGY, V60, P432, DOI 10.1212/WNL.60.3.432; LOGEMANN JA, 1978, J SPEECH HEAR DISORD, V43, P47, DOI 10.1044/jshd.4301.47; Mahler LA, 2009, J MED SPEECH-LANG PA, V17, P165; Mashima PA, 2003, AM J SPEECH-LANG PAT, V12, P432, DOI 10.1044/1058-0360(2003/089); Mashima Pauline A, 2008, Telemed J E Health, V14, P1101, DOI 10.1089/tmj.2008.0080; Massaro DW, 2004, J SPEECH LANG HEAR R, V47, P304, DOI 10.1044/1092-4388(2004/025); Matos C., 2001, THESIS U COLORADO BO; Matos C., 2002, F0 AUTOCORRELA UNPUB; Matos C., 2003, SPL EXTRACTOR UNPUB; McFarland David H., 2006, Seminars in Speech and Language, V27, P300, DOI 10.1055/s-2006-955119; Narayana S, 2010, HUM BRAIN MAPP, V31, P222, DOI 10.1002/hbm.20859; Petska J., 2006, 13 BIENN C MOT SPEEC; Pinto S, 2004, LANCET NEUROL, V3, P547, DOI 10.1016/S1474-4422(04)00854-3; Ramig L., 1988, CLIN DYS C SAN DIEG; Ramig LO, 2001, MOVEMENT DISORD, V16, P79, DOI 10.1002/1531-8257(200101)16:1<79::AID-MDS1013>3.0.CO;2-H; Ramig LO, 2001, J NEUROL NEUROSUR PS, V71, P493, DOI 10.1136/jnnp.71.4.493; RAMIG LO, 1995, J SPEECH HEAR RES, V38, P1232, DOI 10.1044/jshr.3806.1232; Ramig Lorraine Olson, 2004, Seminars in Speech and Language, V25, P169; RASKIN SA, 1992, NEUROPSYCHOLOGIA, V30, P95, DOI 10.1016/0028-3932(92)90018-H; Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571; RUBOW R, 1985, J SPEECH HEAR DISORD, V50, P178, DOI 10.1044/jshd.5002.178; Sapir S, 2003, AM J SPEECH-LANG PAT, V12, P387, DOI 10.1044/1058-0360(2003/085); Sapir S., 2001, J MED SPEECH-LANG PA, V9, P35; Sapir S, 2007, J SPEECH LANG HEAR R, V50, P899, DOI 10.1044/1092-4388(2007/064); SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SMITH ME, 1995, J VOICE, V9, P453, DOI 10.1016/S0892-1997(05)80210-3; Spielman J., 2010, 15 BIENN C MOT SPEEC; Spielman Jennifer L, 2003, Cogn Behav Neurol, V16, P177, DOI 10.1097/00146965-200309000-00005; Svec Jan G, 2003, Logoped Phoniatr Vocol, V28, P181; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; The RAND Corporation, 2001, PREP AG WORLD POL BR; Theodoros DG, 2006, J TELEMED TELECARE, V12, P88, DOI 10.1258/135763306779380101; ThinkQuest, WORLD AG; Tindall LR, 2008, TELEMED J E-HEALTH, V14, P1070, DOI 10.1089/tmj.2008.0040; Trail M, 2005, NEUROREHABILITATION, V20, P205; Usability First, US METH; Ward EC, 2000, J MED SPEECH-LANG PA, V8, P331; Yorkston KM, 2003, J MED SPEECH-LANG PA, V11, P73	79	50	50	0	50	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	NOV 1	2012	21	4					354	367		10.1044/1058-0360(2012/11-0125)			14	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	083JY	WOS:000314460700007	23071195				2022-02-06	
J	Johnson, B; Gay, M; Zhang, K; Neuberger, T; Horovitz, SG; Hallett, M; Sebastianelli, W; Slobounov, S				Johnson, Brian; Gay, Michael; Zhang, Kai; Neuberger, Thomas; Horovitz, Silvina G.; Hallett, Mark; Sebastianelli, Wayne; Slobounov, Semyon			The Use of Magnetic Resonance Spectroscopy in the Subacute Evaluation of Athletes Recovering from Single and Multiple Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						concussion; H-1-MRS; MTBI; multiple MTBI	ACETYL-L-ASPARTATE; CORPUS-CALLOSUM; MR SPECTROSCOPY; MITOCHONDRIAL BIOGENESIS; N-ACETYLASPARTATE; TEMPORAL WINDOW; CONCUSSION; GRAY; ABNORMALITIES; VULNERABILITY	Advanced neuroimaging techniques have shown promise in highlighting the subtle changes and nuances in mild traumatic brain injury (MTBI) even though clinical assessment has shown a return to pre-injury levels. Here we use H-1-magnetic resonance spectroscopy (H-1-MRS) to evaluate the brain metabolites N-acetyl aspartate (NAA), choline (Cho), and creatine (Cr) in the corpus callosum in MTBI. Specifically, we looked at the NAA/Cho, NAA/Cr, and Cho/Cr ratios in the genu and splenium. We recruited 20 normal volunteers (NV) and 28 student athletes recovering from the subacute phase of MTBI. The MTBI group was categorized based upon the number of MTBIs and time from injury to H-1-MRS evaluation. Significant reductions in NAA/Cho and NAA/Cr ratios were seen in the genu of the corpus callosum, but not in the splenium, for MTBI subjects, regardless of the number of MTBIs. MTBI subjects recovering from their first MTBI showed the greatest alteration in NAA/Cho and NAA/Cr ratios. Time since injury to H-1-MRS acquisition was based upon symptom resolution and did not turn out to be a significant factor. We observed that as the number of MTBIs increased, so did the length of time for symptom resolution. Unexpected findings from this study are that MTBI subjects showed a trend of increasing NAA/Cho and NAA/Cr ratios that coincided with increasing number of MTBIs.	[Johnson, Brian; Gay, Michael; Zhang, Kai; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Johnson, Brian; Neuberger, Thomas] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; [Sebastianelli, Wayne; Slobounov, Semyon] Penn State Univ, Dept Orthopaed Surg & Rehabil, University Pk, PA 16802 USA; [Horovitz, Silvina G.; Hallett, Mark; Slobounov, Semyon] NINDS, NIH, Bethesda, MD 20892 USA		Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	Neuberger, Thomas/ABE-3055-2021; Zhang, Kai/F-3261-2015	Horovitz, Silvina G./0000-0002-5501-5918; Zhang, Kai/0000-0002-5460-6150	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227, ZIANS002667] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury."	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Arun P, 2009, NEUROCHEM INT, V55, P219, DOI 10.1016/j.neuint.2009.03.003; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Covaciu L, 2010, J MAGN RESON IMAGING, V31, P807, DOI 10.1002/jmri.22107; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Degaonkar MN, 2005, J MAGN RESON IMAGING, V22, P175, DOI 10.1002/jmri.20353; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Giza CC, 2001, J ATHL TRAINING, V36, P228; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gutsaeva DR, 2008, J NEUROSCI, V28, P2015, DOI 10.1523/JNEUROSCI.5654-07.2008; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Maniega SM, 2008, STROKE, V39, P2467, DOI 10.1161/STROKEAHA.107.507020; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McLean MA, 2000, MAGNET RESON MED, V44, P401, DOI 10.1002/1522-2594(200009)44:3<401::AID-MRM10>3.0.CO;2-W; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; Park HJ, 2008, HUM BRAIN MAPP, V29, P503, DOI 10.1002/hbm.20314; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stefan D, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/10/104035; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yin W, 2008, STROKE, V39, P3057, DOI 10.1161/STROKEAHA.108.520114; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	60	50	51	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	13					2297	2304		10.1089/neu.2011.2294			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	000PU	WOS:000308399900005	22780855	Green Published			2022-02-06	
J	Beaulieu-Bonneau, S; Morin, CM				Beaulieu-Bonneau, Simon; Morin, Charles M.			Sleepiness and fatigue following traumatic brain injury	SLEEP MEDICINE			English	Article						Brain injury; Sleepiness; Fatigue; Sleep; Neurological disorders; Case-control study	DAYTIME SLEEPINESS; UNITED-STATES; RISK-FACTORS; CLINICAL-USE; POPULATION; PREVALENCE; INSTRUMENT; DISORDERS; FREQUENCY; INSOMNIA	Objectives: To compare individuals with traumatic brain injury (TBI) to healthy controls (CTLs) on measures of sleepiness, fatigue, and sleep, and explore correlates of sleepiness and fatigue separately for each group. Methods: Participants were 22 adults with moderate/severe TBI (time since injury >= 1 year; mean = 53.0 +/- 37.1 months) and 22 matched healthy CTLs. They underwent one night of polysomnographic (PSG) recording of their sleep followed the next day by the Maintenance of Wakefulness Test (MWT). They also completed a 14-day sleep diary, the Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire (FOSQ), and the Multidimensional Fatigue Inventory (MFI). Results: There were no significant group differences on measures of objective (MWT) or subjective (ESS) sleepiness, both groups being quite alert. However, TBI participants reported greater consequences of sleepiness on their general productivity (FOSQ), spent more time in bed at night, and napped more frequently and for a longer time during the day. Subjective fatigue was significantly higher in TBI participants on the general, physical, and mental fatigue MFI subscales. There were no between-group differences on any sleep parameters derived either from PSG or sleep diary. Conclusions: Fatigue appeared to be a more prominent symptom than sleepiness when assessed between 1 and 11 years after TBI. Participants with TBI used compensatory strategies such as increasing time spent in bed and daytime napping in this sample. Future research should document the time course of sleepiness and fatigue after TBI and investigate treatment options. (C) 2012 Elsevier B.V. All rights reserved.	[Beaulieu-Bonneau, Simon; Morin, Charles M.] Univ Laval, Ecole Psychol, Quebec City, PQ G1V 0A6, Canada		Beaulieu-Bonneau, S (corresponding author), Univ Laval, Ecole Psychol, Pavillon Felix Antoine Savard 2325,Rue Bibliotheq, Quebec City, PQ G1V 0A6, Canada.	Simon.Beaulieu-Bonneau.1@ulaval.ca	Morin, Charles M./A-4700-2008	Morin, Charles M./0000-0002-8649-8895; Beaulieu-Bonneau, Simon/0000-0002-9544-5023	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	This study was supported by a doctoral fellowship awarded to Simon Beaulieu-Bonneau, M.Ps., by the Canadian Institutes of Health Research. We are grateful to Hans Ivers, Ph.D., for statistical support, and to Marie-Christine Ouellet, Ph.D., for comments on the manuscript.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Arand D, 2005, SLEEP, V28, P123, DOI 10.1093/sleep/28.1.123; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Dauvilliers Y, 2003, J NEUROL NEUROSUR PS, V74, P1667, DOI 10.1136/jnnp.74.12.1667; Duntley SP, 2005, ISS CLIN COGN NEUROP, P209; Edinger J. D., 2004, DUKE STRUCTURED INTE; First M., 1997, STRUCTURED CLIN INTE; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 1994, SLEEP, V17, P701; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Lin Jin-Mann S, 2009, Popul Health Metr, V7, P18, DOI 10.1186/1478-7954-7-18; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Ministere de la sante et des services sociaux du Quebec & Societe d'assurance automobile du Quebec, 2005, OR MIN TRAUM CRAN LE; MONK TH, 1987, SLEEP, V10, P343, DOI 10.1093/sleep/10.4.343; Morin CM, 1993, INSOMNIA PSYCHOL ASS; Neu D, 2010, ACTA NEUROL BELG, V110, P15; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Pallesen S, 2007, SLEEP, V30, P619, DOI 10.1093/sleep/30.5.619; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schwarz R, 2003, ONKOLOGIE, V26, P140, DOI 10.1159/000069834; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Singer S, 2011, BRIT J CANCER, V105, P445, DOI 10.1038/bjc.2011.251; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; Tabachnik BG, 2007, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Weaver TE, 1997, SLEEP, V20, P835; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; [No title captured]	49	50	52	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457			SLEEP MED	Sleep Med.	JUN	2012	13	6					598	605		10.1016/j.sleep.2012.02.010			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	972TZ	WOS:000306304700008	22425680	Green Accepted			2022-02-06	
J	Yan, XX; Jeromin, AR				Yan, Xiao-Xin; Jeromin, Andreas			Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases	CURRENT GERIATRICS REPORTS			English	Article						Aging; Alzheimer's disease; Apoptosis; Autophagy; Calcium; Calpain; Caspases; Membrane skeleton; Neuroplasticity; Neurodegeneration; Proteolysis; Biomarkers; Spectrin breakdown products		The expected lifespan of the world's human population grows rapidly thanks to the great advance in modern medicine. While more and more body system diseases become treatable and curable, age-related neurodegenerative diseases remain poorly understood mechanistically, and are desperately in need of preventive and therapeutic interventions. Biomarker development consists of a key part of concerted efforts in combating neurodegenerative diseases. In many chronic neurodegenerative conditions, neuronal damage/death occurs long before the onset of disease symptoms, and abnormal proteolysis may either play an active role or be an accompanying event of neuronal injury. Increased spectrin cleavage yielding elevated spectrin breakdown products (SBDPs) by calcium-sensitive proteases such as calpain and caspases has been established in conditions associated with acute neuronal damage such as traumatic brain injury (TBI). In this article, we review literature regarding spectrin expression and metabolism in the brain, and propose a potential use of SBDPs as biomarkers for neurodegenerative diseases such as Alzheimer's disease.	[Yan, Xiao-Xin] Cent S Univ, Xiangya Med Sch, Dept Anat & Neurobiol, 172 Tongzi Po Rd, Changsha 410013, Hunan, Peoples R China; [Jeromin, Andreas] Banyan Biomarkers, Alachua, FL 32615 USA		Yan, XX (corresponding author), Cent S Univ, Xiangya Med Sch, Dept Anat & Neurobiol, 172 Tongzi Po Rd, Changsha 410013, Hunan, Peoples R China.	yanxiaoxin@csu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171091]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS056371] Funding Source: NIH RePORTER	The authors thank Drs. Yan Cai and Xie-Mei Zhang for excellent technical assistance, and the National Natural Science Foundation of China (grant #81171091) for supporting Alzheimer's disease research in our laboratory.	Alvira D, 2008, PARKINSONISM RELAT D, V14, P309, DOI 10.1016/j.parkreldis.2007.09.005; Ayala-Grosso C, 2006, NEUROSCIENCE, V141, P863, DOI 10.1016/j.neuroscience.2006.04.041; BAHR BA, 1995, J PHARMACOL EXP THER, V273, P902; BAHR BA, 1991, NEUROSCI LETT, V131, P237, DOI 10.1016/0304-3940(91)90622-Z; Baines AJ, 2009, BIOCHEM SOC T, V37, P796, DOI 10.1042/BST0370796; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; Bennett V, 2008, TRENDS MOL MED, V14, P28, DOI 10.1016/j.molmed.2007.11.005; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; Bernath E, 2006, NEUROBIOL AGING, V27, P624, DOI 10.1016/j.neurobiolaging.2005.02.013; Bi XN, 1996, BRAIN RES, V726, P98, DOI 10.1016/0006-8993(95)01360-1; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; COLEMAN TR, 1987, J CELL BIOL, V104, P519, DOI 10.1083/jcb.104.3.519; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; DAVIS JQ, 1984, J BIOL CHEM, V259, P1874; Delaunay J, 2007, BLOOD REV, V21, P1, DOI 10.1016/j.blre.2006.03.005; Dhermy D, 1998, BLOOD CELL MOL DIS, V24, P251, DOI 10.1006/bcmd.1998.0190; Dufty BM, 2007, AM J PATHOL, V170, P1725, DOI 10.2353/ajpath.2007.061232; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; FOWLER V, 1980, J CELL BIOL, V85, P361, DOI 10.1083/jcb.85.2.361; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; FUKUSHIMA Y, 1990, CYTOGENET CELL GENET, V53, P232, DOI 10.1159/000132939; Gaczynska M., 1992, Cytobios, V72, P197; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Gallagher Patrick G, 2004, Curr Hematol Rep, V3, P85; Gallagher PG, 1997, J CLIN INVEST, V99, P267, DOI 10.1172/JCI119155; Gao YZ, 2011, J NEUROSCI, V31, P16581, DOI 10.1523/JNEUROSCI.3332-11.2011; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; Garg S, 2011, NEUROBIOL AGING, V32, P1, DOI 10.1016/j.neurobiolaging.2010.09.008; Gold MS, 2009, BIOL PSYCHIAT, V66, P118, DOI 10.1016/j.biopsych.2009.02.021; GOODMAN SR, 1983, CELL MOTIL CYTOSKEL, V3, P635, DOI 10.1002/cm.970030528; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Higuchi M, 2012, FASEB J, V26, P1204, DOI 10.1096/fj.11-187740; Hsu YJ, 2005, CELL MOL BIOL, V51, P187, DOI 10.1170/T618; Huang W, 2010, INVEST OPHTH VIS SCI, V51, P3049, DOI 10.1167/iovs.09-4364; Hulsmeier J, 2007, DEVELOPMENT, V134, P713, DOI 10.1242/dev.02758; Hwang IK, 2008, NEUROSCI LETT, V435, P251, DOI 10.1016/j.neulet.2008.02.050; Ikeda Y, 2006, NAT GENET, V38, P184, DOI 10.1038/ng1728; Jiang XH, 2010, HISTOL HISTOPATHOL, V25, P1497, DOI 10.14670/HH-25.1497; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; KOENIG E, 1985, J NEUROSCI, V5, P715; Lacas-Gervais S, 2004, J CELL BIOL, V166, P983, DOI 10.1083/jcb.200408007; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; Levy OA, 2009, APOPTOSIS, V14, P478, DOI 10.1007/s10495-008-0309-3; Liang B, 2010, J BIOL CHEM, V285, P27737, DOI 10.1074/jbc.M110.117960; Lorenzo DN, 2010, J CELL BIOL, V189, P143, DOI 10.1083/jcb.200905158; MANGEAT PH, 1988, BIOL CELL, V64, P261, DOI 10.1016/0248-4900(88)90001-9; MARCHESI V. T., 1968, SCIENCE, V159, P203, DOI 10.1126/science.159.3811.203; MASLIAH E, 1990, BRAIN RES, V531, P36, DOI 10.1016/0006-8993(90)90755-Z; Mastrangelo M, 2012, PEDIATR NEUROL, V46, P24, DOI 10.1016/j.pediatrneurol.2011.11.003; Mattson MP, 2006, ANTIOXID REDOX SIGN, V8, P1997, DOI 10.1089/ars.2006.8.1997; Vicencio JM, 2010, CELL CALCIUM, V47, P112, DOI 10.1016/j.ceca.2009.12.013; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Morris CE, 2001, CELL MOL BIOL LETT, V6, P703; MouattPrigent A, 1996, NEUROSCIENCE, V73, P979, DOI 10.1016/0306-4522(96)00100-5; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nestor MW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016197; Newcomb-Fernandez JK, 2001, J CEREBR BLOOD F MET, V21, P1281, DOI 10.1097/00004647-200111000-00004; NILSSON E, 1990, NEUROBIOL AGING, V11, P425, DOI 10.1016/0197-4580(90)90009-O; PALEK J, 1990, SEMIN HEMATOL, V27, P290; Perkins EM, 2010, J NEUROSCI, V30, P4857, DOI 10.1523/JNEUROSCI.6065-09.2010; PETERSON C, 1991, NEUROSCI LETT, V121, P239, DOI 10.1016/0304-3940(91)90694-O; Pielage J, 2006, J CELL BIOL, V175, P491, DOI 10.1083/jcb.200607036; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Puchkov D, 2011, CEREB CORTEX, V21, P2217, DOI 10.1093/cercor/bhq283; Ramser EM, 2010, MOL CELL NEUROSCI, V45, P66, DOI 10.1016/j.mcn.2010.05.013; Raynaud F, 2006, FEBS J, V273, P3437, DOI 10.1111/j.1742-4658.2006.05352.x; Rohn TT, 2008, REV NEUROSCIENCE, V19, P383; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SEUBERT P, 1988, BRAIN RES, V460, P189, DOI 10.1016/0006-8993(88)91222-X; SIMAN R, 1989, J NEUROSCI, V9, P1579; Stabach PR, 2000, J BIOL CHEM, V275, P21385, DOI 10.1074/jbc.C000159200; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; Stankewich MC, 2010, P NATL ACAD SCI USA, V107, P6022, DOI 10.1073/pnas.1001522107; Sunderland WJ, 2000, J NEUROSCI, V20, P1009, DOI 10.1523/JNEUROSCI.20-03-01009.2000; Susuki K, 2011, P NATL ACAD SCI USA, V108, P8009, DOI 10.1073/pnas.1019600108; Tamada Y, 2005, BRAIN RES, V1050, P148, DOI 10.1016/j.brainres.2005.05.048; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1111/j.1365-2613.2000.00169.x; Voas MG, 2007, CURR BIOL, V17, P562, DOI 10.1016/j.cub.2007.01.071; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Weiss ES, 2009, ANN THORAC SURG, V88, P543, DOI 10.1016/j.athoracsur.2009.04.016; Wellington CL, 2002, J NEUROSCI, V22, P7862; Westphal D, 2010, J BIOL CHEM, V285, P42046, DOI 10.1074/jbc.M110.177147; WINKELMANN JC, 1993, BLOOD, V81, P3173; Yang Y, 2007, J CELL BIOL, V176, P509, DOI 10.1083/jcb.200610128; ZAGON IS, 1986, J NEUROSCI, V6, P2977; Zhang XM, 2009, EUR J NEUROSCI, V30, P2271, DOI 10.1111/j.1460-9568.2009.07017.x; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	94	50	50	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	2196-7865			CURR GERIATR REP	Curr. Geriatr. Rep.	JUN	2012	1	2					85	93		10.1007/s13670-012-0009-2			9	Geriatrics & Gerontology	Emerging Sources Citation Index (ESCI)	Geriatrics & Gerontology	V3S8C	WOS:000218554500005	23710421	Green Accepted, Bronze			2022-02-06	
J	Whitmore, RG; Thawani, JP; Grady, MS; Levine, JM; Sanborn, MR; Stein, SC				Whitmore, Robert G.; Thawani, Jayesh P.; Grady, M. Sean; Levine, Joshua M.; Sanborn, Matthew R.; Stein, Sherman C.			Is aggressive treatment of traumatic brain injury cost-effective?	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; decompressive hemicraniectomy; intracranial pressure monitoring; cost analysis; quality-adjusted life year	SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; CLINICAL-TRIALS; UNITED-STATES; OUTCOMES; MANAGEMENT; GUIDELINES; SURVIVAL; BENEFIT; DEATH	Object. The object of this study was to determine whether aggressive treatment of severe traumatic brain injury (TBI), including invasive intracranial monitoring and decompressive craniectomy, is cost-effective. Methods. A decision-analytical model was created to compare costs, outcomes, and cost-effectiveness of 3 strategies for treating a patient with severe TBI. The aggressive-care approach is compared with "routine care," in which Brain Trauma Foundation guidelines are not followed. A "comfort care" category, in which a single day in the ICU is followed by routine floor care, is included for comparison only. Probabilities of each treatment resulting in various Glasgow Outcome Scale (GOS) scores were obtained from the literature The GOS scores were converted to quality-adjusted life years (QALYs), based on expected longevity and calculated quality of life associated with each GOS category. Estimated direct (acute and long-term medical care) and indirect (loss of productivity) costs were calculated from the perspective of society. Sensitivity analyses employed a 2D Monte Carlo simulation of 1000 trials, each with 1000 patients. The model was also used to estimate these values for patients 40, 60, and 80 years of age. Results. For the average 20-year-old, aggressive care yields 11.7 ( +/- 1.6 [SD]) QALYs, compared with routine care (10.0 +/- 1.5 QALYs). This difference is highly significant (p < 0.0001). Although the differences in effectiveness between the 2 strategies diminish with advancing age, aggressive care remains significantly better at all ages. When all costs are considered, aggressive care is also significantly less costly than routine care ($1,264,000 +/- $118,000 vs $1,361,000 +/- $107,000) for the average 20-year-old. Aggressive care remains significantly less costly until age 80, at which age it costs more than routine care. However, even in the 80-year-old, aggressive care is likely the more cost-effective approach. Comfort care is associated with poorer outcomes at all ages and with higher costs for all groups except 80-year-olds. Conclusions. When all the costs of severe TBI are considered, aggressive treatment is a cost-effective option, even for older patients. Comfort care for severe TBI is associated with poor outcomes and high costs, and should be reserved for situations in which aggressive approaches have failed or testing suggests such treatment is futile. (http://thejns.org/doi/abs/10.317/2012.1.JNS11962)	[Whitmore, Robert G.; Thawani, Jayesh P.; Grady, M. Sean; Levine, Joshua M.; Sanborn, Matthew R.; Stein, Sherman C.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.] Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Levine, Joshua M.] Hosp Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA		Whitmore, RG (corresponding author), Hosp Univ Penn, Dept Neurosurg, 3rd Floor Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	robert.whitmore@uphs.upenn.edu			National Institutes of Health's National Institute of Neurological Disorders and Stroke [5T32NS43126-08]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health's National Institute of Neurological Disorders and Stroke (5T32NS43126-08). The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Akopian G, 2007, AM SURGEON, V73, P447; Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; Arias Elizabeth, 2004, Natl Vital Stat Rep, V53, P1; Braithwaite RS, 2008, MED CARE, V46, P349, DOI 10.1097/MLR.0b013e31815c31a7; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Centers for Medicare and Medicaid Services, 2010, AC INP PROSP PAYM SY; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Finkelstein E., 2006, INCIDENCE EC BURDEN; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gold M., 1996, COST EFFECTIVENESS H; Harris OA, 2008, J NEUROSURG, V109, P433, DOI 10.3171/JNS/2008/109/9/0433; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Ibrahim MI, 2007, ASIAN J SURG, V30, P261, DOI 10.1016/S1015-9584(08)60036-6; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KUMAR R, 1991, CHILD NERV SYST, V7, P299, DOI 10.1007/BF00304824; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; Le QA, 2009, CANCER-AM CANCER SOC, V115, P489, DOI 10.1002/cncr.24033; Lipscomb J, 2009, MED CARE, V47, pS1, DOI 10.1097/MLR.0b013e3181a7e401; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Malmivaara K, 2011, EUR J NEUROL, V18, P656, DOI 10.1111/j.1468-1331.2010.03294.x; Marion D. W., 1998, TRAUMATIC BRAIN INJU; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Murray CJL., 1996, GLOBAL BURDEN DIS CO; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shiroiwa T, 2010, MOL DIAGN THER, V14, P375, DOI 10.2165/11587610-000000000-00000; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Tilford JM, 2007, J TRAUMA, V63, pS113, DOI 10.1097/TA.0b013e31815acc8b; Tosteson ANA, 2008, ANN INTERN MED, V149, P845, DOI 10.7326/0003-4819-149-12-200812160-00003; US Bureau of Labor Statistics, CPI INFL CALC; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E	49	50	50	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2012	116	5					1106	1113		10.3171/2012.1.JNS11962			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	929TO	WOS:000303088800027	22394292				2022-02-06	
J	Xiong, Y; Zhang, YL; Mahmood, A; Meng, YL; Zhang, ZG; Morris, DC; Chopp, M				Xiong, Ye; Zhang, Yanlu; Mahmood, Asim; Meng, Yuling; Zhang, Zheng Gang; Morris, Daniel C.; Chopp, Michael			Neuroprotective and neurorestorative effects of thymosin beta 4 treatment initiated 6 hours after traumatic brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						neuroprotection; neurogenesis; rat; thymosin beta 4; traumatic brain injury	MARROW STROMAL CELLS; HIPPOCAMPAL CA3 REGION; NITRIC-OXIDE DONOR; COGNITIVE RECOVERY; CORTICAL IMPACT; DENTATE GYRUS; FUNCTIONAL RECOVERY; ADULT NEUROGENESIS; EPITHELIAL-CELLS; NERVOUS-SYSTEM	Object. Thymosin beta 4 (T beta 4) is a regenerative multifunctional peptide. The aim of this study was to test the hypothesis that T beta 4 treatment initiated 6 hours postinjury reduces brain damage and improves functional recovery in rats subjected to traumatic brain injury (TBI). Methods. Traumatic brain injury was induced by controlled cortical impact over the left parietal cortex in young adult male Wistar rats. The rats were randomly divided into the following groups: 1) saline group (n = 7); 2) 6 mg/kg T beta 4 group (n = 8); and 3) 30 mg/kg T beta 4 group (n = 8). Thymosin beta 4 or saline was administered intraperitoneally starting at 6 hours postinjury and again at 24 and 48 hours. An additional group of 6 animals underwent surgery without TBI (sham-injury group). Sensorimotor function and spatial learning were assessed using the modified Neurological Severity Score and the Morris water maze test, respectively. Animals were euthanized 35 days after injury, and brain sections were processed to assess lesion volume, hippocampal cell loss, cell proliferation, and neurogenesis after T beta 4 treatment. Results. Compared with saline administration, T beta 4 treatment initiated 6 hours postinjury significantly improved sensorimotor functional recovery and spatial learning, reduced cortical lesion volume and hippocampal cell lass, and enhanced cell proliferation and neurogenesis in the injured hippocampus. The high dose of T beta 4 showed better beneficial effects compared with the low-dose treatment. Conclusions. Thymosin beta 4 treatment initiated 6 hours postinjury provides both neuroprotection and neurorestoration after TBI, indicating that T beta 4 has promising therapeutic potential in patients with TBI. These data warrant further investigation of the optimal dose and therapeutic window of T beta 4 treatment for TBI and the associated underlying mechanisms. (http://thejns.org/doi/abs/10.3171/2012.1.JNS111729)	[Xiong, Ye; Zhang, Yanlu; Mahmood, Asim; Meng, Yuling] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Morris, Daniel C.] Henry Ford Hlth Syst, Dept Emergency Med, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA		Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS62002, P01 NS023393]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS023393, P50NS023393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG038648] Funding Source: NIH RePORTER	This work was supported by NIH grants No. R01 NS62002 (to Dr. Xiong) and No. P01 NS023393 (to Dr. Chopp). Drs. Z. G. Zhang, Morris, and Chopp have applied for a patent for the use of T beta 4 as a treatment for stroke, neurological disease, and injury.	Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bednarek R, 2008, J BIOL CHEM, V283, P1534, DOI 10.1074/jbc.M707539200; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Bubb MR, 2003, VITAM HORM, V66, P297, DOI 10.1016/S0083-6729(03)01008-2; Cavasin Maria A, 2006, Am J Cardiovasc Drugs, V6, P305, DOI 10.2165/00129784-200606050-00003; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Choi SY, 2007, BIOCHEM BIOPH RES CO, V362, P587, DOI 10.1016/j.bbrc.2007.08.031; Crockford D, 2007, ANN NY ACAD SCI, V1112, P385, DOI 10.1196/annals.1415.051; Crockford D, 2010, ANN NY ACAD SCI, V1194, P179, DOI 10.1111/j.1749-6632.2010.05492.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dong JH, 2005, NEUROREPORT, V16, P1629, DOI 10.1097/01.wnr.0000183326.21241.48; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fine JD, 2007, ANN NY ACAD SCI, V1112, P396, DOI 10.1196/annals.1415.017; Freeman KW, 2011, FASEB J, V25, P907, DOI 10.1096/fj.10-169417; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Gullo C, 2006, BBA-REV CANCER, V1765, P223, DOI 10.1016/j.bbcan.2006.01.001; Hinkel R, 2008, CIRCULATION, V117, P2232, DOI 10.1161/CIRCULATIONAHA.107.758904; Ho JHC, 2008, BRIT J OPHTHALMOL, V92, P992, DOI 10.1136/bjo.2007.136747; Ho JHC, 2007, INVEST OPHTH VIS SCI, V48, P27, DOI 10.1167/iovs.06-0826; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kohler SJ, 2011, P NATL ACAD SCI USA, V108, P10326, DOI 10.1073/pnas.1017099108; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mora CA, 1997, INT J IMMUNOPHARMACO, V19, P1, DOI 10.1016/S0192-0561(97)00005-2; Morris DC, 2010, NEUROSCIENCE, V169, P674, DOI 10.1016/j.neuroscience.2010.05.017; Morris DC, 2010, ANN NY ACAD SCI, V1194, P112, DOI 10.1111/j.1749-6632.2010.05469.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Paulussen M, 2009, PEPTIDES, V30, P1822, DOI 10.1016/j.peptides.2009.07.010; Philp D, 2004, MECH AGEING DEV, V125, P113, DOI 10.1016/j.mad.2003.11.005; Philp D, 2007, ANN NY ACAD SCI, V1112, P95, DOI 10.1196/annals.1415.009; Popoli P, 2007, ANN NY ACAD SCI, V1112, P219, DOI 10.1196/annals.1415.033; Qiu FY, 2009, J CARDIOVASC PHARM, V53, P209, DOI 10.1097/FJC.0b013e318199f326; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reti R, 2008, EUR J ORAL SCI, V116, P424, DOI 10.1111/j.1600-0722.2008.00569.x; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Riley PR, 2009, BIOCHEM SOC T, V37, P1218, DOI 10.1042/BST0371218; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Ruff D, 2010, ANN NY ACAD SCI, V1194, P223, DOI 10.1111/j.1749-6632.2010.05474.x; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Sierra A, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00047; Smart Nicola, 2007, Angiogenesis, V10, P229, DOI 10.1007/s10456-007-9077-x; Smart N, 2007, ANN NY ACAD SCI, V1112, P171, DOI 10.1196/annals.1415.000; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Sosne G, 2007, ANN NY ACAD SCI, V1112, P114, DOI 10.1196/annals.1415.004; Sosne G, 2010, FASEB J, V24, P2144, DOI 10.1096/fj.09-142307; Srivastava D, 2007, ANN NY ACAD SCI, V1112, P161, DOI 10.1196/annals.1415.048; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sun W, 2007, ANN NY ACAD SCI, V1112, P210, DOI 10.1196/annals.1415.013; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Yang H, 2008, NEUROCHEM RES, V33, P2269, DOI 10.1007/s11064-008-9712-y; Yang H, 2010, CELL MOL NEUROBIOL, V30, P149, DOI 10.1007/s10571-009-9439-6; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	86	50	53	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2012	116	5					1081	1092		10.3171/2012.1.JNS111729			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	929TO	WOS:000303088800024	22324420	Green Accepted			2022-02-06	
J	Kashif, FM; Verghese, GC; Novak, V; Czosnyka, M; Heldt, T				Kashif, Faisal M.; Verghese, George C.; Novak, Vera; Czosnyka, Marek; Heldt, Thomas			Model-Based Noninvasive Estimation of Intracranial Pressure from Cerebral Blood Flow Velocity and Arterial Pressure	SCIENCE TRANSLATIONAL MEDICINE			English	Article							CLINICAL-EXPERIENCE; BRAIN-INJURY; ICP; HYPERTENSION; DYNAMICS	Intracranial pressure (ICP) is affected in many neurological conditions. Clinical measurement of pressure on the brain currently requires placing a probe in the cerebrospinal fluid compartment, the brain tissue, or other intracranial space. This invasiveness limits the measurement to critically ill patients. Because ICP is also clinically important in conditions ranging from brain tumors and hydrocephalus to concussions, noninvasive determination of ICP would be desirable. Our model-based approach to continuous estimation and tracking of ICP uses routinely obtainable time-synchronized, noninvasive (or minimally invasive) measurements of peripheral arterial blood pressure and blood flow velocity in the middle cerebral artery (MCA), both at intra-heartbeat resolution. A physiological model of cerebrovascular dynamics provides mathematical constraints that relate the measured waveforms to ICP. Our algorithm produces patient-specific ICP estimates with no calibration or training. Using 35 hours of data from 37 patients with traumatic brain injury, we generated ICP estimates on 2665 nonoverlapping 60-beat data windows. Referenced against concurrently recorded invasive parenchymal ICP that varied over 100 millimeters of mercury (mmHg) across all records, our estimates achieved a mean error (bias) of 1.6 mmHg and SD of error (SDE) of 7.6 mmHg. For the 1673 data windows over 22 hours in which blood flow velocity recordings were available from both the left and the right MCA, averaging the resulting bilateral ICP estimates reduced the bias to 1.5 mmHg and SDE to 5.9 mmHg. This accuracy is already comparable to that of some invasive ICP measurement methods in current clinical use.	[Kashif, Faisal M.; Verghese, George C.; Heldt, Thomas] MIT, Elect Res Lab, Cambridge, MA 02139 USA; [Novak, Vera] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA; [Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 0SP, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, PL-00665 Warsaw, Poland		Heldt, T (corresponding author), MIT, Elect Res Lab, Cambridge, MA 02139 USA.	thomas@mit.edu		/0000-0002-5930-7694	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 EB001659, 4R37 AG2537-05, 4P30 AG02871702]; Center for Integration of Medicine and Innovative Technology, Boston; National Institute of Health Research Biomedical Research Centre, Cambridge University Hospital Foundation Trust-Neurosciences ThemeNational Institute for Health Research (NIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0001237, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G9439390] Funding Source: researchfish; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028717, R37AG025037] Funding Source: NIH RePORTER	F.M.K., G.C.V., and T.H. were supported in part by NIH R01 EB001659 and by the Center for Integration of Medicine and Innovative Technology, Boston. M. C. was supported by the National Institute of Health Research Biomedical Research Centre, Cambridge University Hospital Foundation Trust-Neurosciences Theme. V.N. was supported in part by NIH grants 4R37 AG2537-05 and 4P30 AG02871702.	Alperin NJ, 2000, RADIOLOGY, V217, P877, DOI 10.1148/radiology.217.3.r00dc42877; Banister K, 2000, PHYSIOL MEAS, V21, P473, DOI 10.1088/0967-3334/21/4/304; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Borchert M., 1998, U.S. Patent, Patent No. [09/021 966, 09021966]; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Eide PK, 2010, J NEUROSURG, V113, P1317, DOI 10.3171/2010.7.JNS10483; Frank AM, 2000, ZBL NEUROCHIR, V61, P177, DOI 10.1055/s-2000-15597; HANLO PW, 1995, ULTRASOUND MED BIOL, V21, P613, DOI 10.1016/0301-5629(94)00147-6; HAYASHI M, 1991, BRAIN, V114, P2681, DOI 10.1093/brain/114.6.2681; Hlatky Roman, 2003, Neurosurg Focus, V14, pe2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Kashif F., 2011, THESIS MIT; Kashif FM, 2008, COMPUTERS IN CARDIOLOGY 2008, VOLS 1 AND 2, P369, DOI 10.1109/CIC.2008.4749055; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Marmarou A., 2007, NEUROSURG FOCUS, V22, P1; MENDELOW AD, 1983, J NEUROSURG, V58, P45, DOI 10.3171/jns.1983.58.1.0045; Michaeli D, 2002, J NEUROSURG, V96, P1132, DOI 10.3171/jns.2002.96.6.1132; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Morgalla MH, 2001, J NEUROSURG, V95, P529, DOI 10.3171/jns.2001.95.3.0529; Mourad PD, 2004, US Patent, Patent No. [7,547,283, 7547283]; Novak V, 2004, BIOMED ENG ONLINE, V3, DOI 10.1186/1475-925X-3-39; Olufsen MS, 2002, AM J PHYSIOL-REG I, V282, pR611, DOI 10.1152/ajpregu.00285.2001; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; Piper I, 2001, NEUROSURGERY, V49, P1158, DOI 10.1097/00006123-200111000-00026; Popovic Djordje, 2009, Recent Patents on Biomedical Engineering, V2, P165, DOI 10.2174/1874764710902030165; Querfurth HW, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-106; Ragauskas A, 2005, ACT NEUR S, V95, P357; Ragauskas A, 2003, MED ENG PHYS, V25, P667, DOI 10.1016/S1350-4533(03)00082-1; REID A, 1989, J NEUROL NEUROSUR PS, V52, P610, DOI 10.1136/jnnp.52.5.610; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Ueno T, 1998, ACT NEUR S, V71, P66; Ursino M, 1997, J APPL PHYSIOL, V82, P1256, DOI 10.1152/jappl.1997.82.4.1256; Wakeland W, 2008, COMPUT BIOL MED, V38, P1024, DOI 10.1016/j.compbiomed.2008.07.004; Westerhof N, 2009, MED BIOL ENG COMPUT, V47, P131, DOI 10.1007/s11517-008-0359-2; Xu P, 2010, IEEE T INF TECHNOL B, V14, P971, DOI 10.1109/TITB.2009.2027317; Zhao YL, 2005, ACTA NEUROCHIR SUPPL, V95, P351; Zhu YS, 2011, J APPL PHYSIOL, V111, P376, DOI 10.1152/japplphysiol.01418.2010; Zong W, 2003, COMPUT CARDIOL, V30, P259, DOI 10.1109/CIC.2003.1291140	46	50	50	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	APR 11	2012	4	129							129ra44	10.1126/scitranslmed.3003249			9	Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	925QY	WOS:000302777300004	22496546	Green Accepted, Green Submitted			2022-02-06	
J	Verdejo-Garcia, A; Betanzos-Espinosa, P; Lozano, OM; Vergara-Moragues, E; Gonzalez-Saiz, F; Fernandez-Calderon, F; Bilbao-Acedos, I; Perez-Garcia, M				Verdejo-Garcia, A.; Betanzos-Espinosa, P.; Lozano, O. M.; Vergara-Moragues, E.; Gonzalez-Saiz, F.; Fernandez-Calderon, F.; Bilbao-Acedos, I.; Perez-Garcia, M.			Self-regulation and treatment retention in cocaine dependent individuals: A longitudinal study	DRUG AND ALCOHOL DEPENDENCE			English	Article						Cocaine; Executive functions; Orbitofrontal cortex; Self-regulation; Retention; Therapeutic community	TRAUMATIC BRAIN-INJURY; IOWA GAMBLING TASK; DECISION-MAKING; GRAY-MATTER; ORBITOFRONTAL CORTEX; SUBSTANCE-ABUSERS; DAMAGE; VALIDITY; BEHAVIOR; EMOTION	Background: We aimed to explore the association between baseline executive functioning and treatment outcome in Therapeutic Communities (TCs). Methods: We used a longitudinal descriptive design: a baseline neuropsychological assessment was performed within the first 30 days of treatment in TCs. Once participants finished or abandoned treatment, the information about time of stay in treatment was computed for each individual. The study was conducted across six TCs located in the region of Andalusia (Spain): Cartaya, Almonte, Mijas, Los Palacios, La Linea, and Tarifa. Participants were 131 patients with cocaine dependence who initiated and finished treatment in TCs between January 2009 and December 2010 (2 years). Cognitive assessment was composed of general measures of executive functioning: Letter Number Sequencing (working memory) and Similarities (reasoning), and executive tasks sensitive to ventromedial prefrontal cortex dysfunction, including the Delis-Kaplan Stroop test (inhibition/cognitive switching), the Revised-Strategy Application Test (strategy application/multitasking), and the Iowa Gambling Task (decision-making). The outcome measure was retention, defined as time in TC treatment (number of days). Results: Poor executive functioning significantly predicted shorter treatment retention in cocaine dependent individuals on TC residential treatment (14% of explained variance). Reduced performance on the R-SAT, a multitasking test taxing the ability to develop and apply the best strategy to organize multiple sub-routine tasks in order to achieve a long-term goal, was the most powerful predictor of treatment retention. Conclusions: Self-regulation deficits predict the capacity to remain in residential treatment among cocaine dependents. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Verdejo-Garcia, A.; Betanzos-Espinosa, P.; Perez-Garcia, M.] Univ Granada, Dept Clin Psychol, E-18071 Granada, Spain; [Verdejo-Garcia, A.; Perez-Garcia, M.] Univ Granada, Inst Neurosci F Oloriz, E-18071 Granada, Spain; [Lozano, O. M.; Fernandez-Calderon, F.] Univ Huelva, Dept Psychol, Huelva, Spain; [Vergara-Moragues, E.; Gonzalez-Saiz, F.; Fernandez-Calderon, F.; Bilbao-Acedos, I.] Fdn Andaluza Atenc Drogodependencias & Incorp Soc, Seville, Spain; [Gonzalez-Saiz, F.] Unidad Gest Clin Hosp Jerez, Unidad Salud Mental Comunitaria Villamartin, Cadiz, Spain		Verdejo-Garcia, A (corresponding author), Univ Granada, Fac Psicol, Campus Cartuja S-N, E-18071 Granada, Spain.	averdejo@ugr.es	Garcia, Miguel Perez/F-9630-2010; Lozano, Oscar M./C-6070-2011; Verdejo-Garcia, Antonio/AAV-1147-2021; Vergara-Moragues, Esperanza/H-9787-2015; Calderon, Fermin Fernandez/Y-5665-2019	Garcia, Miguel Perez/0000-0003-4775-7556; Lozano, Oscar M./0000-0003-2722-6563; Verdejo-Garcia, Antonio/0000-0001-8874-9339; Vergara-Moragues, Esperanza/0000-0003-2669-631X; Calderon, Fermin Fernandez/0000-0002-2981-1670	Junta de AndaluciaJunta de Andalucia [P07.HUM 03089]; COPER-NICO from the Plan Nacional sobre Drogas-Ministerio de Sanidad y Consumo	This work has been funded by grants: P07.HUM 03089 from the Junta de Andalucia (Proyectos de Excelencia 2007) and COPER-NICO from the Plan Nacional sobre Drogas-Ministerio de Sanidad y Consumo (Convocatoria 2009).	Aharonovich E, 2006, DRUG ALCOHOL DEPEN, V81, P313, DOI 10.1016/j.drugalcdep.2005.08.003; Aharonovich E, 2003, DRUG ALCOHOL DEPEN, V71, P207, DOI 10.1016/S0376-8716(03)00092-9; Aklin WM, 2009, PERS INDIV DIFFER, V46, P454, DOI 10.1016/j.paid.2008.11.018; Alfonso JP, 2011, DRUG ALCOHOL DEPEN, V117, P78, DOI 10.1016/j.drugalcdep.2010.12.025; Alia-Klein N, 2011, ARCH GEN PSYCHIAT, V68, P283, DOI 10.1001/archgenpsychiatry.2011.10; Arenas F., 2003, PROGRAMA INTERVENCIO; Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584; Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Belsey D.A., 1991, CONDITIONING DIAGNOS; Bickel WK, 2011, BIOL PSYCHIAT, V69, P260, DOI 10.1016/j.biopsych.2010.08.017; Birnboim S., 2011, CAN J OCCUP THER, V71, P47; Blume AW, 2009, ANN BEHAV MED, V37, P117, DOI 10.1007/s12160-009-9093-8; Bowden-Jones H, 2005, J NEUROPSYCH CLIN N, V17, P417, DOI 10.1176/appi.neuropsych.17.3.417; Buckley MJ, 2009, SCIENCE, V325, P52, DOI 10.1126/science.1172377; Burgess P.W., 2010, PSYCHOL RES, V63, P279; Cato MA, 2004, J INT NEUROPSYCH SOC, V10, P453, DOI 10.1017/S1355617704103123; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dreher JC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003227; Ersche KD, 2008, PSYCHOPHARMACOLOGY, V197, P421, DOI 10.1007/s00213-007-1051-1; European Monitoring Centre for Drugs and Drugs Addiction, 2010, EUR MON CTR DRUGS DR; Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0; Knapp WP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003023.pub2; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; Langleben DD, 2008, AM J PSYCHIAT, V165, P390, DOI 10.1176/appi.ajp.2007.07010070; Lemma, 2008, COCHRANE DB SYST REV, V3, DOI [https://doi.org/10.1002/14651858.CD002208, DOI 10.1002/14651858.CD002208]; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Li XR, 2010, HUM BRAIN MAPP, V31, P410, DOI 10.1002/hbm.20875; National Institute on Drug Abuse, 2011, UND DRUG AB ADD; Passetti F, 2008, DRUG ALCOHOL DEPEN, V94, P82, DOI 10.1016/j.drugalcdep.2007.10.008; Passetti F, 2011, DRUG ALCOHOL DEPEN, V118, P12, DOI 10.1016/j.drugalcdep.2011.02.015; Paulus MP, 2005, ARCH GEN PSYCHIAT, V62, P761, DOI 10.1001/archpsyc.62.7.761; Peirce JM, 2009, AM J DRUG ALCOHOL AB, V35, P48, DOI 10.1080/00952990802455444; Reske M, 2008, ANN NY ACAD SCI, V1141, P270, DOI 10.1196/annals.1441.011; Sellitto M, 2010, J NEUROSCI, V30, P16429, DOI 10.1523/JNEUROSCI.2516-10.2010; Simpson DD, 1999, ARCH GEN PSYCHIAT, V56, P507, DOI 10.1001/archpsyc.56.6.507; Sinha R, 2006, ARCH GEN PSYCHIAT, V63, P324, DOI 10.1001/archpsyc.63.3.324; Smith LA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005338.pub2; Streeter CC, 2008, NEUROPSYCHOPHARMACOL, V33, P827, DOI 10.1038/sj.npp.1301465; Substance Abuse and Mental Health Services Administration & Office of Applied Studies, 2009, DASIS SER S, V(SMA) 09-4360; Tanabe J, 2009, BIOL PSYCHIAT, V65, P160, DOI 10.1016/j.biopsych.2008.07.030; Torrens M, 2004, AM J PSYCHIAT, V161, P1231, DOI 10.1176/appi.ajp.161.7.1231; Tranel D, 2007, J CLIN EXP NEUROPSYC, V29, P319, DOI 10.1080/13803390600701376; Turner TH, 2009, J SUBST ABUSE TREAT, V37, P328, DOI 10.1016/j.jsat.2009.03.009; Verdejo-Garcia A, 2007, DRUG ALCOHOL DEPEN, V90, P48, DOI 10.1016/j.drugalcdep.2007.02.010; Verdejo-Garcia A, 2007, DRUG ALCOHOL DEPEN, V86, P139, DOI 10.1016/j.drugalcdep.2006.05.024; Verdejo-Garcia A, 2006, PSYCHOL BELG, V46, P55, DOI 10.5334/pb-46-1-2-55; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Woicik PA, 2011, NEUROPSYCHOLOGIA, V49, P1660, DOI 10.1016/j.neuropsychologia.2011.02.037; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012	52	50	50	0	21	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	APR 1	2012	122	1-2					142	148		10.1016/j.drugalcdep.2011.09.025			7	Substance Abuse; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Substance Abuse; Psychiatry	925CW	WOS:000302739300020	22018602				2022-02-06	
J	Kirkwood, MW; Yeates, KO; Randolph, C; Kirk, JW				Kirkwood, Michael W.; Yeates, Keith Owen; Randolph, Christopher; Kirk, John W.			The Implications of Symptom Validity Test Failure for Ability-Based Test Performance in a Pediatric Sample	PSYCHOLOGICAL ASSESSMENT			English	Article						symptom validity testing; response bias; mild traumatic brain injury; postconcussion syndrome; children	TRAUMATIC BRAIN-INJURY; WORD MEMORY TEST; CLINICAL NEUROPSYCHOLOGY; RESPONSE BIAS; CHILDREN; TOMM; ADOLESCENTS; CAPACITY; RECOVERY; ADULTS	If an examinee exerts inadequate effort to perform well during a psychological or neuropsychological exam, the resulting data will represent an inaccurate representation of the individual's true abilities and difficulties. In adult populations, methodologies to identify noncredible effort have grown exponentially in the last 2 decades. Though a comparatively modest amount of work has focused on tools to identify noncredible effort in pediatric populations, recent research has demonstrated that children can consistently pass several stand-alone symptom validity tests (SVTs) using cutoffs established with adults. However, no identified studies have examined the implications of pediatric SVT failure for ability-based test performance. The current sample consisted of 276 children aged 8-16 years referred consecutively for outpatient clinical neuropsychological consultation following mild traumatic brain injury (TB!). An earlier subgroup of this same case series that also included 17-year-olds was presented in Kirkwood and Kirk (2010). Nineteen percent of the current sample performed below the actuarial cutoff on the Medical Symptom Validity Test (MSVT). No background or injury-related variable differentiated those who passed from those who failed the MSVT. Performance on the MSVT was correlated significantly with performance on all ability-based tests and explained 38% of the total ability-based test variance. Participants failing the MSVT performed significantly worse on nearly all neuropsychological tests, with large effect sizes apparent across most tests. The results provide compelling evidence that practitioners should add objective SVTs to the evaluation of school-aged youth, even when secondary gain issues might not be readily apparent and particularly following mild TBI.	[Kirkwood, Michael W.; Kirk, John W.] Childrens Hosp Colorado, Concuss Program, Aurora, CO 80045 USA; [Kirkwood, Michael W.; Kirk, John W.] Univ Colorado Denver Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA		Kirkwood, MW (corresponding author), Childrens Hosp Colorado, Concuss Program, B285,13123 E 16th Ave, Aurora, CO 80045 USA.	michael.kirkwood@childrenscolorado.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892			Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baron I. S., 2004, NEUROPSYCHOLOGICAL E; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Boone K.B., 2007, ASSESSMENT FEIGNED C; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Cohen J., 2013, STAT POWER ANAL BEHA; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Delis DC., 1994, CALIFORNIA VERBAL LE; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Flaro L., 2009, NEUROPSYCHOLOGY MALI, P369; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2004, MANUAL MED SYMPTOM V; Green P., DETECTION M IN PRESS; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry G. K., 2005, FORENSIC NEUROPSYCHO, P205; Kirk JW, 2011, CHILD NEUROPSYCHOL, V17, P242, DOI 10.1080/09297049.2010.533166; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; McCaffrey R. J., 2009, NEUROPSYCHOLOGY MALI, P377; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Newton P, 2000, BRIT J DEV PSYCHOL, V18, P297, DOI 10.1348/026151000165706; Reitan R, 1969, MANUAL ADM NEUROPSYC; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; STOUTHAMERLOEBER M, 1986, J ABNORM CHILD PSYCH, V14, P551, DOI 10.1007/BF01260523; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Wechsler D, 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHSLER ABBREVIATED; Wilson AE, 2003, SOC DEV, V12, P21, DOI 10.1111/1467-9507.00220; Woodcock R. W., 2001, WOODCOCKJOHNSON 3 TE	50	50	50	0	10	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	MAR	2012	24	1					36	45		10.1037/a0024628			10	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	905XT	WOS:000301310200004	21767023				2022-02-06	
J	He, YL; Qu, SY; Wang, J; He, XS; Lin, W; Zhen, HN; Zhang, X				He, Yalong; Qu, Shuoyao; Wang, Jiang; He, Xiaosheng; Lin, Wei; Zhen, Haining; Zhang, Xiang			Neuroprotective effects of osthole pretreatment against traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Apoptosis; Neuroprotective effect; Osthole; Oxidative stress; Secondary brain damage; Traumatic brain injury	EXPERIMENTAL ANIMAL-MODELS; CENTRAL-NERVOUS-SYSTEM; INDUCED FATTY LIVER; CNIDIUM-MONNIERI; ALZHEIMERS-DISEASE; HEAD-INJURY; LIPID-PEROXIDATION; OXIDATIVE STRESS; CELL-DEATH; OXYGEN	Osthole, a coumarin compound isolated from the plant-derived herb Cnidium monnieri, has been the subject of considerable interest because of its broad spectrum of pharmacological properties. The aim of this study was to investigate the potential protective effects of osthole in adult rats in the setting of traumatic brain injury (TBI). We employed Feeney's weight-drop model to ascertain whether intraperitoneal administration of osthole (10 mg/kg, 20 mg/kg and 40 mg/kg) 30 mm before TBI could reduce the severity of neurological deficits, cerebral edema, and hippocampal neuron loss. The levels of malondialdehyde (MDA) and glutathione (GSH), the activity of superoxide dismutase (SOD), the expressions of Bcl-2, Bax, and active caspase-3, and the number of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive apoptotic cells were also measured to characterize the antioxidative and antiapoptotic properties. A significant reduction of neurological deficits, cerebral edema and hippocampal neuron loss was observed in the osthole pretreatment groups (20 mg/kg and 40 mg/kg, but not 10 mg/kg) by 24 h after TBI compared with the TB! group. Furthermore, pretreatment with osthole (40 mg/kg) significantly increased the activity of SOD, the level of GSH, and the ratio of Bcl-2/Bax, and also reduced the level of MDA, the expression of active caspase-3, and the number of apoptotic cells at 24 h after TBI. In summary, these results suggested that osthole had a neuroprotective effect against TBI, and the protection may be associated with its antioxidative and antiapoptotic functions. (C) 2011 Elsevier BM. All rights reserved.	[He, Yalong; Wang, Jiang; He, Xiaosheng; Lin, Wei; Zhen, Haining; Zhang, Xiang] Fourth Mil Med Univ, Xijing Inst Clin Neurosci, Xijing Hosp, Dept Neurosurg, Xian 710032, Shanxi, Peoples R China		Zhang, X (corresponding author), Fourth Mil Med Univ, Xijing Inst Clin Neurosci, Xijing Hosp, Dept Neurosurg, 127 Changle Western Rd, Xian 710032, Shanxi, Peoples R China.	xzhang@fmmu.edu.cn		He, yalong/0000-0002-4669-5384			Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butterfield DA, 1997, J NEUROCHEM, V68, P2451; Chao XD, 2010, BRAIN RES, V1363, P206, DOI 10.1016/j.brainres.2010.09.052; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen XH, 2010, EUR J PHARMACOL, V629, P40, DOI 10.1016/j.ejphar.2009.12.008; Chou SY, 2007, PHYTOTHER RES, V21, P226, DOI 10.1002/ptr.2044; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Ji HJ, 2010, EUR J PHARMACOL, V636, P96, DOI 10.1016/j.ejphar.2010.03.038; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092; Li XX, 2002, BIOL PHARM BULL, V25, P738, DOI 10.1248/bpb.25.738; Liang HJ, 2009, CHEM-BIOL INTERACT, V181, P309, DOI 10.1016/j.cbi.2009.08.003; Liu WB, 2010, NEUROCHEM INT, V57, P206, DOI 10.1016/j.neuint.2010.05.011; Luszczki JJ, 2009, EUR J PHARMACOL, V607, P107, DOI 10.1016/j.ejphar.2009.02.022; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matsuda H, 2002, BIOL PHARM BULL, V25, P809, DOI 10.1248/bpb.25.809; McDonnell TJ, 1996, EXPERIENTIA, V52, P1008, DOI 10.1007/BF01920110; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakamura T, 2009, J NAT MED-TOKYO, V63, P21, DOI 10.1007/s11418-008-0277-5; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nishio S, 1997, ACT NEUR S, V70, P84; Nunomura A, 1999, J NEUROSCI, V19, P1959; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Song F, 2006, WORLD J GASTROENTERO, V12, P4359, DOI 10.3748/wjg.v12.i27.4359; Sun F, 2009, DIGEST LIVER DIS, V41, P127, DOI 10.1016/j.dld.2008.01.011; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wang SJ, 2008, NEUROCHEM INT, V53, P416, DOI 10.1016/j.neuint.2008.09.013; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; Wu SN, 2002, BIOCHEM PHARMACOL, V63, P199, DOI 10.1016/S0006-2952(01)00873-5; Zhang JJ, 2011, PHYTOTHER RES, V25, P638, DOI 10.1002/ptr.3315; Zhang QY, 2007, PLANTA MED, V73, P13, DOI 10.1055/s-2006-951724	48	50	52	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JAN 18	2012	1433						127	136		10.1016/j.brainres.2011.11.027			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	895ZB	WOS:000300534100015	22153917				2022-02-06	
J	Benson, RR; Gattu, R; Sewick, B; Kou, ZF; Zakariah, N; Cavanaugh, JM; Haacke, EM				Benson, Randall R.; Gattu, Ramtilak; Sewick, Bradley; Kou, Zhifeng; Zakariah, Nisrine; Cavanaugh, John M.; Haacke, E. Mark			Detection of hemorrhagic and axonal pathology in mild traumatic brain injury using advanced MRI: Implications for neurorehabilitation	NEUROREHABILITATION			English	Article						Diffusion tensor imaging; susceptibility-weighted imaging; hemorrhagic pathology; axonal pathology and mild traumatic brain injury	WORKING-MEMORY CAPACITY; GLASGOW COMA SCALE; LEARNING-DISABILITIES; IMAGING FINDINGS; CORPUS-CALLOSUM; STRETCH-INJURY; HEAD-INJURY; DIFFUSION; CHILDREN; IMPACT	Introduction: There is a need to more accurately diagnose milder traumatic brain injuries with increasing awareness of the high prevalence in both military and civilian populations. Magnetic resonance imaging methods may be capable of detecting a number of the pathoanatomical and pathophysiological consequences of focal and diffuse traumatic brain injury. Susceptibility-weighted imaging (SWI) detects heme iron and reveals even small venous microhemorrhages occurring in diffuse vascular injury. Diffusion tensor imaging (DTI) reveals axonal injury by detecting alterations in water flow in and around injured axons. The overarching hypothesis of this paper is that newer, advanced MR imaging generates sensitive biomarkers of regional brain injury which allows for correlation with clinical signs and symptoms. Methods: Studies involving subjects with a history of traumatic brain injury as well as healthy, non-trauma controls were used. Analysis involved comparison of TBI patients' imaging results with healthy controls as well as correlation of imaging findings with clinical measures of injury severity. An additional animal study of Sprague-Dawley albino rats compared imaging results with histopathological findings after the animals were sacrificed and stained for b-APP. Results: SWI revealed small foci of hemosiderin for some patients while aggregate lesion volume on SWI correlated with clinical injury severity indices. Similarly, DTI showed striking group differences for fractional anisotropy over the white matter globally, while tract and voxel-based regional results colocalized with SWI and FLAIR lesions in some cases and correlated with clinical deficits. For the rats, correlations were seen between imaging findings and staining of axonal injury. Discussion: Animal data gave important tissue correlations with imaging results. SWI and DTI are commercially available sequences that can improve the diagnostic and prognostic ability of the trauma clinician. These biomarkers of regional brain injury which are present in imaging shortly after acute injury and persist indefinitely can inform clinicians and researchers about not only injury severity but also which neurobehavioral systems were injured. Analogous to stroke rehabilitation, having an understanding of the distribution of brain injury should ultimately allow for development ofmore effective rehabilitation strategies and more efficient clinical interventional trials.	[Benson, Randall R.] Ctr Neurol Studies, Novi, MI 48375 USA; [Gattu, Ramtilak; Kou, Zhifeng; Haacke, E. Mark] Wayne State Univ, Sch Med, Dept Diagnost Radiol, Detroit, MI USA; [Sewick, Bradley] Spectrum Rehabil, Southfield, MI USA; [Zakariah, Nisrine; Cavanaugh, John M.] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA		Benson, RR (corresponding author), Ctr Neurol Studies, 43000 W 9 Mile Rd,Suite 116, Novi, MI 48375 USA.	drbenson@neurologicstudies.com					Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Bain AC, 2003, J BIOMECH ENG-T ASME, V125, P798, DOI 10.1115/1.1632627; Benson R. R., 2009, VARIATION DTI FA FUN; Benson R. R., 2009, AM AC NEUR ANN M; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Binder DK, 2000, NEUROSURGERY, V47, P9, DOI 10.1097/00006123-200007000-00003; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Brambilla P, 2011, PSYCHOL MED, V25, P1; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CERVOSNAVARRO J, 1991, CRIT REV NEUROBIOL, V6, P149; Chalela JA, 2000, STROKE, V31, P680, DOI 10.1161/01.STR.31.3.680; CHOPP M, 1984, Magnetic Resonance Imaging, V2, P329, DOI 10.1016/0730-725X(84)90199-1; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319; Dodson MB, 2010, WORK, V36, P449, DOI 10.3233/WOR-2010-1044; Doelken M, 2007, DIAGN INTERV RADIOL, V13, P125; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; EHRLICH MF, 1994, PSYCHOL RES-PSYCH FO, V56, P110, DOI 10.1007/BF00419718; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Gattu R., 2009, EFFECT VOXEL SIZE DT; Gattu R., 2008, AGEING FRACTIONAL AN; Gattu R., 2012, P INT SOC MAGN RES M; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grossman RI, 2003, NEURORADIOLOGY REQUI, P243; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Hattori N, 2003, J NUCL MED, V44, P1709; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; HOSSMANN KA, 1994, J CEREBR BLOOD F MET, V14, P723, DOI 10.1038/jcbfm.1994.93; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Hyndman OR, 1939, ARCH NEURO PSYCHIATR, V42, P735, DOI 10.1001/archneurpsyc.1939.02270220151009; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Johnson J, 2003, CHILD DEV, V74, P1594, DOI 10.1046/j.1467-8624.2003.00626.x; Just MA, 1996, PSYCHOL REV, V103, P773, DOI 10.1037/0033-295X.103.4.773; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kou Z., 2007, ISMRM ESMRMB; Kou Z., 2008, CLIN MR NEUROIMAGING; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Krave U, 2011, J NEUROTRAUM, V28, P57, DOI 10.1089/neu.2010.1431; KWONG KK, 1995, MAGNET RESON MED, V34, P878, DOI 10.1002/mrm.1910340613; Leon-Carrion J, 2008, BRAIN INJURY, V22, P61, DOI 10.1080/02699050701824143; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marton K, 2003, J SPEECH LANG HEAR R, V46, P1138, DOI 10.1044/1092-4388(2003/089); Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; McCrea M., 2008, OXFORD WORKSHOP SERI, Vxv, P205; Miller L, 2001, NEUROREHABILITATION, V16, P109; Nakai T, 1996, JMRI-J MAGN RESON IM, V6, P445, DOI 10.1002/jmri.1880060306; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Passolunghi MC, 2012, J LEARN DISABIL-US, V45, P341, DOI 10.1177/0022219411400746; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Scheel M. E., 2009, J VISION, V9, DOI [10.1167/9.8.772, DOI 10.1167/9.8.772]; Shimony JS, 2009, BIOL PSYCHIAT, V66, P245, DOI 10.1016/j.biopsych.2009.02.032; Singer M, 1996, MEM COGNITION, V24, P733, DOI 10.3758/BF03201098; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100107-01, 10.3928/02793695-20100108-02]; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Swanson HL, 2001, J EXP CHILD PSYCHOL, V79, P294, DOI 10.1006/jecp.2000.2587; Talavage TM, 2010, J NEUROTRAUMA; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Vanderploeg RD, 2001, NEUROREHABILITATION, V16, P245; Varkuti B., 2012, NEUROREHABIL NEURAL; Wallace BE, 2001, J HEAD TRAUMA REHAB, V16, P165, DOI 10.1097/00001199-200104000-00006; Wasserman T, 2012, APPL NEUROPSYCH-ADUL, V19, P42, DOI 10.1080/09084282.2011.643940; WEINER MW, 1987, ANN NY ACAD SCI, V508, P287, DOI 10.1111/j.1749-6632.1987.tb32911.x; WEINTRAUB S, 1983, ARCH NEUROL-CHICAGO, V40, P463, DOI 10.1001/archneur.1983.04210070003003; Williams RF, 2008, J AM COLL SURGEONS, V206, P962, DOI 10.1016/j.jamcollsurg.2007.12.016; Work SS, 2011, ADV THER, V28, P586, DOI 10.1007/s12325-011-0031-3; Wortzel HS, 2008, J AM ACAD PSYCHIATRY, V36, P310	90	50	50	1	29	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2012	31	3					261	279		10.3233/NRE-2012-0795			19	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	028QC	WOS:000310436200004	23093454				2022-02-06	
J	Wolf, GK; Strom, TQ; Kehle, SM; Eftekhari, A				Wolf, Gregory K.; Strom, Thad Q.; Kehle, Shannon M.; Eftekhari, Afsoon			A Preliminary Examination of Prolonged Exposure Therapy With Iraq and Afghanistan Veterans With a Diagnosis of Posttraumatic Stress Disorder and Mild to Moderate Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						evidence-based treatments; posttraumatic stress disorder; prolonged exposure therapy; psychotherapy; traumatic brain injury; Veterans	SERVICE MEMBERS; COMBAT VETERANS; WAR VETERANS; PTSD; SUICIDALITY; SYMPTOMS; OUTCOMES	Objective: Preliminary examination of the effectiveness of prolonged exposure (PE) therapy for the treatment of posttraumatic stress disorder (PTSD) with Operation Enduring Freedom and Operation Iraqi Freedom Veterans who have experienced traumatic brain injury (TBI). Participants: Ten Veterans with a history of mild to moderate TBI and chronic PTSD. Setting: Outpatient Mental Health/PTSD clinics and polytrauma centers at 2 VA medical centers. Measures: Comprehensive evaluation that included clinical interview, neuropsychologic evaluation, and/or neuroimaging; Posttraumatic Stress Disorder Checklist and Beck Depression Inventory-Second Edition. Procedures: Standard implementation of the PE manual was used in all cases with slight adjustments to account for Veterans' residual cognitive deficits. Veterans completed between 8 and 18 sessions. Results: Veterans demonstrated significant reductions in total PTSD and depression symptoms from pre- to posttreatment. Within-group effect sizes were large. Conclusions: These findings suggest that PE can be safely and effectively implemented with Veterans with PTSD, a history of mild to moderate TBI, and current cognitive impairment.	[Wolf, Gregory K.] James A Haley Vet Affairs Med Ctr, Tampa, FL USA; [Strom, Thad Q.; Kehle, Shannon M.] Univ Minnesota, Dept Vet Affairs Med Ctr, Minneapolis, MN USA; [Strom, Thad Q.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Eftekhari, Afsoon] Natl Ctr PTSD, Disseminat & Training Div, Menlo Pk, CA USA		Wolf, GK (corresponding author), James A Haley VA Med Ctr MHBS, 13000 Bruce B Downs, Tampa, FL 33612 USA.	Gregory.Wolf2@va.gov		Strom, Thad/0000-0001-6743-9999			Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Blake D. D., 1990, BEHAV THER, V13, P187, DOI DOI 10.1007/BF02105408; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2006, COGN BEHAV PRACT, V13, P17, DOI 10.1016/j.cbpra.2005.03.002; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Cohen J, 1969, STAT POWER ANAL BEHA; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Department of Veterans Affairs, 2010, VA CONS C PRACT REC; Department of Veterans Affairs/Department of Defense, 2009, VA DOD CLIN PRACT GU; Erbes C, 2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; Feeny NC, 2003, COGN BEHAV PRACT, V10, P85, DOI 10.1016/S1077-7229(03)80011-1; Foa E.B., 2007, PROLONGED EXPOSURE T; Foa EB, 1999, PSYCHOL ASSESSMENT, V11, P303, DOI 10.1037/1040-3590.11.3.303; Foa EB, 2005, J CONSULT CLIN PSYCH, V73, P953, DOI 10.1037/0022-006X.73.5.953; Foa EB, 2002, J CONSULT CLIN PSYCH, V70, P1022, DOI 10.1037//0022-006X.70.4.1022; Gawande A, 2005, NEW ENGL J MED, V352, P1497; Gutierrez PM, 2008, ARCH SUICIDE RES, V12, P336, DOI 10.1080/13811110802324961; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2007, TREATM PTSD ASS EV; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; KEANE TM, 1989, BEHAV THER, V20, P245, DOI 10.1016/S0005-7894(89)80072-3; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Mills KL, 2006, AM J PSYCHIAT, V163, P652, DOI 10.1176/appi.ajp.163.4.652; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rauch SAM, 2009, J TRAUMA STRESS, V22, P60, DOI 10.1002/jts.20380; Rosen CS, 2004, J TRAUMA STRESS, V17, P213, DOI 10.1023/B:JOTS.0000029264.23878.53; Rothbaum BO, 2005, J TRAUMA STRESS, V18, P607, DOI 10.1002/jts.20069; Rothbaum BO, 2000, EFFECTIVE TREATMENTS FOR PTSD, P60; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tuerk PW, 2011, J ANXIETY DISORD, V25, P397, DOI 10.1016/j.janxdis.2010.11.002; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Weathers F.W., 1993, ANN CONV INT SOC TRA; YEHUDA R, 1995, AM J PSYCHIAT, V152, P137	43	50	50	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					26	32		10.1097/HTR.0b013e31823cd01f			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400003	22218201				2022-02-06	
J	Wilde, EA; Newsome, MR; Bigler, ED; Pertab, J; Merkley, TL; Hanten, G; Scheibel, RS; Li, XQ; Chu, ZL; Yallampalli, R; Hunter, JV; Levin, HS				Wilde, Elisabeth A.; Newsome, Mary R.; Bigler, Erin D.; Pertab, Jon; Merkley, Tricia L.; Hanten, Gerri; Scheibel, Randall S.; Li, Xiaoqi; Chu, Zili; Yallampalli, Ragini; Hunter, Jill V.; Levin, Harvey S.			Brain imaging correlates of verbal working memory in children following traumatic brain injury	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Working memory; Sternberg Item Recognition; Functional magnetic resonance imaging (fMRI); Diffusion tensor imaging (DTI); Volumetric; Cortical thickness; Traumatic brain injury; Children	DIFFUSE AXONAL INJURY; EVENT-RELATED FMRI; PREFRONTAL CORTEX; CEREBRAL-CORTEX; ACTIVATION; MODERATE; MRI; TASK; IMPAIRMENTS; REGIONS	Neural correlates of working memory (WM) based on the Sternberg Item Recognition Task (SIRT) were assessed in 40 children with moderate-to-severe traumatic brain injury (TBI) compared to 41 demographically-comparable children with orthopedic injury (OI). Multiple magnetic resonance imaging (MRI) methods assessed structural and functional brain correlates of WM, including volumetric and cortical thickness measures on all children: functional MRI (fMRI) and diffusion tensor imaging (DTI) were performed on a subset of children. Confirming previous findings, children with TBI had decreased cortical thickness and volume as compared to the OI group. Although the findings did not confirm the predicted relation of decreased frontal lobe cortical thickness and volume to SIRT performance, left parietal volume was negatively related to reaction time (RI). In contrast, cortical thickness was positively related to SIRT accuracy and RT in the OI group, particularly in aspects of the frontal and parietal lobes, but these relationships were less robust in the TBI group. We attribute these findings to disrupted fronto-parietal functioning in attention and WM. fMRI results from a subsample demonstrated fronto-temporal activation in the OI group, and parietal activation in the TBI group, and DTI findings reflected multiple differences in white matter tracts that engage fronto-parietal networks. Diminished white matter integrity of the frontal lobes and cingulum bundle as measured by DTI was associated with longer RI on the SIRT. Across modalities, the cingulate emerged as a common structure related to performance after TBI. These results are discussed in terms of how different imaging modalities tap different types of pathologic correlates of brain injury and their relationship with WM. (C) 2011 Elsevier B.V. All rights reserved.	[Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Newsome, Mary R.; Merkley, Tricia L.; Hanten, Gerri; Scheibel, Randall S.; Li, Xiaoqi; Yallampalli, Ragini; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [Wilde, Elisabeth A.; Chu, Zili; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Newsome, Mary R.; Scheibel, Randall S.; Yallampalli, Ragini; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Bigler, Erin D.; Pertab, Jon; Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, DC USA; [Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Newsome, Mary R.; Merkley, Tricia L.; Hanten, Gerri; Scheibel, Randall S.; Li, Xiaoqi; Yallampalli, Ragini; Levin, Harvey S.] Phys Med & Rehabil Alliance Baylor Coll Med, Houston, TX USA		Wilde, EA (corresponding author), Baylor Coll Med, Dept Neurol, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu	Merkley, Tricia L./AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-21889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by NIH grant NS-21889, Neurobehavioral Outcome of Head Injury in Children. The South Central Mental Illness Research, Education, and Clinical Center (MIRECC) provided equipment and laboratory space for the analysis of the fMRI data. We gratefully acknowledge the assistance of Alyssa P. Ibarra and Philip C. Burton.	Baddeley A.D., 1986, WORKING MEMORY; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bijur P., 1995, TRAUMATIC HEAD INJUR; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Casey B., 2002, ENCY HUMAN BRAIN, V1, P145; Cazalis Fabienne, 2011, Front Neurol, V1, P158, DOI 10.3389/fneur.2010.00158; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; *COMM INJ SCAL, 1990, ABBR INJ SCAL; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Gazzaley Adam, 2004, Cognitive Affective & Behavioral Neuroscience, V4, P580, DOI 10.3758/CABN.4.4.580; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Klingberg T, 2006, NEUROPSYCHOLOGIA, V44, P2171, DOI 10.1016/j.neuropsychologia.2005.11.019; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Narayanan NS, 2005, NEUROPSYCHOLOGY, V19, P223, DOI 10.1037/0894-4105.19.2.223; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; TEASDALE G, 1974, LANCET, V2, P81; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	55	50	50	0	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		86	96		10.1016/j.ijpsycho.2011.04.006			11	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600010	21565227	Green Accepted			2022-02-06	
J	Gacar, N; Mutlu, O; Utkan, T; Celikyurt, IK; Gocmez, SS; Ulak, G				Gacar, Nejat; Mutlu, Oguz; Utkan, Tijen; Celikyurt, Ipek Komsuoglu; Gocmez, Semil Selcen; Ulak, Guner			Beneficial effects of resveratrol on scopolamine but not mecamylamine induced memory impairment in the passive avoidance and Morris water maze tests in rats	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Resveratrol; Cognition; Morris water maze; Passive avoidance; Rat	LONG-TERM POTENTIATION; ASPARTATE RECEPTOR ANTAGONIST; INDUCED COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; SELECTIVE IMPAIRMENT; RECOGNITION MEMORY; IN-VIVO; ACETYLCHOLINESTERASE; WORKING	Resveratrol (3,5,4-trihydroxy-trans-stilbene), which is found in grapes and red wine has been shown to protect neuronal cells with its antioxidant activity, improve memory function in dementia and reverse acetylcholine esterase (AChE) activity. The aim of this study was to investigate the effect of resveratrol on emotional and spatial memory in naive rats, as well as on scopolamine- and mecamylamine-induced memory impairment in the passive avoidance and Morris water maze (MWM) tests. Resveratrol (12.5, 25 and 50 mg/kg), scopolamine (0.6 mg/kg) and mecamylamine (10 mg/kg) were administered to male Wistar rats. In the passive avoidance test, there was no significant difference in the first day latency between all groups, whereas scopolamine and mecamylamine significantly shortened the second day latency compared to the control group. Resveratrol reversed the effect of scopolamine at all doses used, but it had no effect on mecamylamine-induced memory impairment in the passive avoidance test. Both scopolamine and mecamylamine significantly decreased the time spent in the escape platform quadrant during the probe trial of the MWM test compared to the control group. Resveratrol reversed the effect of scopolamine at all doses, but did not change the effect of mecamylamine in the MWM test. There were no significant differences in the locomotor activities of any of the groups. In conclusion, we suggested that resveratrol had improving effects on learning and memory by acting on muscarinic cholinergic receptors and at least in part, may reverse AChE activity. (C) 2011 Elsevier Inc. All rights reserved.	[Gacar, Nejat; Mutlu, Oguz; Utkan, Tijen; Celikyurt, Ipek Komsuoglu; Ulak, Guner] Kocaeli Univ, Fac Med, Dept Pharmacol, TR-41380 Kocaeli, Turkey; [Gocmez, Semil Selcen] Namik Kemal Univ, Fac Med, Dept Pharmacol, TR-59100 Tekirdag, Turkey		Mutlu, O (corresponding author), Kocaeli Univ, Fac Med, Dept Pharmacol, TR-41380 Kocaeli, Turkey.	mngacar@hotmail.com; oguzmutlu80@hotmail.com; tijenutkan@hotmail.com; ikomsu@hotmail.com; selcengmez@yahoo.com; gunerulak@yahoo.com	Utkan, Tijen/G-2398-2018; ulak, guner/F-5624-2018; gocmez, semil selcen/G-2401-2018; Celikyurt, Ipek Komsuoglu/F-7363-2018; MUTLU, OGUZ/F-5952-2018	gocmez, semil selcen/0000-0001-7341-4907; Celikyurt, Ipek Komsuoglu/0000-0003-0895-3490; MUTLU, OGUZ/0000-0003-0952-0742; utkan, tijen/0000-0001-5848-3680			Anekonda TS, 2006, BRAIN RES REV, V52, P316, DOI 10.1016/j.brainresrev.2006.04.004; APPLEYARD ME, 1992, TRENDS NEUROSCI, V15, P485, DOI 10.1016/0166-2236(92)90100-M; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blokland A, 1995, BRAIN RES REV, V21, P285, DOI 10.1016/0165-0173(95)00016-X; Brioni J D, 1997, Adv Pharmacol, V37, P153; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Cachard-Chastel M, 2008, BEHAV BRAIN RES, V187, P455, DOI 10.1016/j.bbr.2007.10.008; Chander V, 2005, J VASC SURG, V42, P1198, DOI 10.1016/j.jvs.2005.08.032; Chauhan Ved, 2006, Pathophysiology, V13, P195, DOI 10.1016/j.pathophys.2006.05.004; Chen RS, 2002, J AGR FOOD CHEM, V50, P1665, DOI 10.1021/jf011134e; DARTIGUES JF, 1993, THERAPIE, V48, P185; DECKER MW, 1995, LIFE SCI, V56, P545, DOI 10.1016/0024-3205(94)00488-E; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Duva CA, 1997, BEHAV NEUROSCI, V111, P1184, DOI 10.1037/0735-7044.111.6.1184; Hiramatsu M, 1998, J PHARMACOL EXP THER, V284, P858; HUNTER B, 1988, HDB PSYCHOPHARMACOLO, V19, P531; IZQUIERDO I, 1992, BEHAV NEURAL BIOL, V58, P16, DOI 10.1016/0163-1047(92)90847-W; Kuhad A, 2008, LIFE SCI, V83, P128, DOI 10.1016/j.lfs.2008.05.013; Kumar A, 2007, PHARMACOLOGY, V79, P17, DOI 10.1159/000097511; Levin ED, 1996, PSYCHOPHARMACOLOGY, V127, P25, DOI 10.1007/BF02805971; Levin ED, 1997, BEHAV PHARMACOL, V8, P236; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Mesulam MM, 2002, NEUROSCIENCE, V110, P627, DOI 10.1016/S0306-4522(01)00613-3; Mokni M, 2007, NEUROCHEM RES, V32, P981, DOI 10.1007/s11064-006-9255-z; Monleon S, 2002, BEHAV BRAIN RES, V136, P483, DOI 10.1016/S0166-4328(02)00194-8; MORAN PM, 1993, PHARMACOL BIOCHEM BE, V45, P533, DOI 10.1016/0091-3057(93)90502-K; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Ogren SO, 1985, SOC NEUR ABSTR, V256, P11; OHNO M, 1993, PHARMACOL BIOCHEM BE, V45, P89, DOI 10.1016/0091-3057(93)90091-7; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Ozkul A, 2007, J CLIN NEUROSCI, V14, P1062, DOI 10.1016/j.jocn.2006.11.008; Pothion S, 2004, BEHAV BRAIN RES, V155, P135, DOI 10.1016/j.bbr.2004.04.008; Quincozes-Santos A, 2007, NEUROTOXICOLOGY, V28, P886, DOI 10.1016/j.neuro.2007.03.008; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Schmatz R, 2009, BRAIN RES BULL, V80, P371, DOI 10.1016/j.brainresbull.2009.08.019; Schmatz R, 2009, EUR J PHARMACOL, V610, P42, DOI 10.1016/j.ejphar.2009.03.032; Sharma M, 2002, LIFE SCI, V71, P2489, DOI 10.1016/S0024-3205(02)02083-0; SHARMA M, 2005, J PHYSIOL PHARMACOL, V49, P395; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Truelsen T, 2002, ANN NEUROL, V52, pS31; Tsuji M, 2003, NEUROPSYCHOPHARMACOL, V28, P664, DOI 10.1038/sj.npp.1300080; Uguralp S, 2005, EUR J PEDIATR SURG, V15, P114, DOI 10.1055/s-2004-830359; Wang Q, 2004, NEUROCHEM RES, V29, P2105, DOI 10.1007/s11064-004-6883-z; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Zamin LL, 2006, NEUROBIOL DIS, V24, P170, DOI 10.1016/j.nbd.2006.06.002	50	50	51	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	SEP	2011	99	3					316	323		10.1016/j.pbb.2011.05.017			8	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	800OL	WOS:000293371100005	21624386				2022-02-06	
J	Cao, C; Slobounov, S				Cao, Cheng; Slobounov, Semyon			Application of a novel measure of EEG non-stationarity as 'Shannon-entropy of the peak frequency shifting' for detecting residual abnormalities in concussed individuals	CLINICAL NEUROPHYSIOLOGY			English	Article						EEG; Non-stationarity; Mild traumatic brain injury (mTBI)	POSTURAL CONTROL; CEREBRAL CONCUSSION; SPECTRAL-ANALYSIS; BRAIN-INJURY; COLLEGIATE; DEFICITS	Objective: The aim of this report was to propose a novel measure of non-stationarity of EEG signals, named Shannon-entropy of the peak frequency shifting (SEPFS). The feasibility of this method was documented comparing this measure with traditional time domain assessment of non-stationarity and its application to EEG data sets obtained from student-athletes before and after suffering a single episode of mild traumatic brain injury (mTBI) with age-matched normal controls. Methods: Instead of assessing the power density distribution on the time-frequency plane, like previously proposed measures of signal non-stationarity, this new measure is based on the shift of the dominant frequency of the EEG signal over time. We applied SEPFS measure to assess the properties of EEG non-stationarity in subjects before and shortly after they suffered mTBI. Student-athletes at high risk for mTBI (n = 265) were tested prior to concussive episodes as a baseline. From this subject pool, 30 athletes who suffered from mTBI were retested on day 30 post-injury. Additional subjects pool (student-athletes without history of concussion, n = 30) were recruited and test-re-tested within the same 30 day interval. Thirty-two channels EEG signals were acquired in sitting eyes closed condition. Results: The results showed that the SEPFS values significantly decreased in subjects suffering from mTBI. Specifically, reduced EEG non-stationarity was observed in occipital, temporal and central brain areas, indicating the possibility of residual brain dysfunctions in concussed individuals. A similar but less statistically significant trend was observed using traditional time domain analysis of EEG non-stationarity. Conclusions: The proposed measure has at least two merits of interest: (1) it is less affected by the limited resolution of time-frequency representation of the EEG signal; (2) it takes into account the neural characteristics of the EEG signal that have not been considered in previously proposed measures of non-stationarity. Significance: This new method may potentially be used as a complementary tool to assess the alteration of brain functions as a result of mTBI. Published by Elsevier Ltd. on behalf of International Federation of Clinical Neurophysiology.	[Cao, Cheng; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA		Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	This study was supported by NIH Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury".	BERGER H, 1969, ELECTROENCEPHALOGR S, V28; BIGLER E, 2010, DIFFUSION TENSOR IMA; Bluml S, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P197, DOI 10.1007/0-387-32565-4_9; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Gabor D., 1946, Journal of the Institution of Electrical Engineers. III. Radio and Communication Engineering, V93, P429; Goryunova A V, 2007, Neurosci Behav Physiol, V37, P761, DOI 10.1007/s11055-007-0079-3; GROSSMANN A, 1984, SIAM J MATH ANAL, V15, P723, DOI 10.1137/0515056; Holschneider Daniel P., 1995, Brain Topography, V8, P169, DOI 10.1007/BF01199780; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Li XL, 2005, J NEURAL ENG, V2, P11, DOI 10.1088/1741-2560/2/2/002; Mantini D, 2007, P NATL ACAD SCI USA, V104, P13170, DOI 10.1073/pnas.0700668104; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Meyer Y., 1993, SIAM; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Randolph C, 2001, J ATHL TRAINING, V36, P288; RANDOLPH C, 1988, NEUROPSYCHOBIOLOGY, V20, P43, DOI 10.1159/000118471; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; SLOBOUNOV S, 2006, FDN SPORT RELATED BR; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Tong S, 2003, P ANN INT IEEE EMBS, V25, P2570; TONG S, 2007, IEEE T BIOMED ENG, V54, P129; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6	42	50	51	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JUL	2011	122	7					1314	1321		10.1016/j.clinph.2010.12.042			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	770PZ	WOS:000291102300009	21216191	Green Accepted			2022-02-06	
J	Grote, S; Bocker, W; Mutschler, W; Bouillon, B; Lefering, R				Grote, Stefan; Boecker, Wolfgang; Mutschler, Wolf; Bouillon, Bertil; Lefering, Rolf			Diagnostic Value of the Glasgow Coma Scale for Traumatic Brain Injury in 18,002 Patients with Severe Multiple Injuries	JOURNAL OF NEUROTRAUMA			English	Article						Abbreviated Injury Scale; Glasgow Coma Scale; Injury Severity Score; multiple trauma; traumatic brain injury; unconsciousness	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; DATA-BANK; SCORE; TALK; SERUM; DETERIORATE; PREDICTION; PROGNOSIS; MORTALITY	Although patients with severe multiple injuries may have other reasons for unconsciousness, traumatic brain injury (TBI) in these patients is frequently defined by the Glasgow Coma Scale (GCS). Nevertheless, the diagnostic value of GCS for severe TBI in the multiple-injured patient is unknown. Therefore, we investigated the diagnostic value of GCS to identify severe TBI in multiple-injured patients. The records of 18,002 severely injured adult (ISS > 16) patients from the Trauma Register of the German Society for Trauma Surgery were analyzed and initial GCS and Abbreviated Injury Scale head (AIS(head)) were recorded. A severe TBI was defined by an AIS(head) >= 3. On the other hand, unconsciousness was defined by an initial GCS <= 8. By these criteria, 6546 patients (36.3%) were unconscious, and 8746 patients (48.6%) had severe TBI. Nine percent of all cases (n = 1643) had a GCS <= 8 without severe TBI. Only 56.1% of patients with severe TBI (n = 4903) had been unconscious. Decreasing levels of unconsciousness (as defined by GCS) showed consistent rising prevalence of severe TBI (correlation coefficient r= -0.52). Approximately 20% of all multiple-injured patients arriving in the emergency department with an initial GCS of 15 had severe TBI (AIS(head) >= 3). The diagnostic value of GCS <= 8 for severe TBI in patients with multiple injuries has low sensitivity (56.1%) but higher specificity (82.2%). Our study indicates that the GCS (as defined <= 8) in unconsciousness patients with multiple injuries shows only a moderate correlation with the diagnosis of severe TBI. Nevertheless, the main reason for unconsciousness in patients with multiple injuries is TBI, since only 9% of these patients had another reason for unconsciousness. However, due to the poor sensitivity of GCS, we suggest the use of the anatomical scoring system with AIS(head) >= 3 to define severe TBI in patients with multiple injuries.	[Grote, Stefan; Boecker, Wolfgang; Mutschler, Wolf] Univ Munich, Dept Trauma Surg, D-80336 Munich, Germany; [Bouillon, Bertil] Univ Witten Herdecke, Cologne Med Ctr, Dept Orthopaed & Trauma Surg, Cologne, Germany; [Lefering, Rolf] Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany		Grote, S (corresponding author), Univ Munich, Dept Trauma Surg, Nussbaumstr, D-80336 Munich, Germany.	stefan.grote@med.uni-muenchen.de			Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [Ne 385/5]; Novo Nordisk A/S (Bagsvaerd, Denmark)Novo Nordisk	The authors are participants in the Committee on Emergency Medicine, Intensive and Trauma Care (NIS) of the German Society of Trauma Surgery (DGU). The German Trauma Registry of the DGU (German Society of Trauma Surgery) was partly funded by the Deutsche Forschungsgemeinschaft (Ne 385/5) and by a grant from Novo Nordisk A/S (Bagsvaerd, Denmark).	*ASS ADV AUT MED, 1990, ABBR INJ SCAL AIS; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; CAYARD C, 1983, J NEUROSURG, V59, P276; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; COOKE RS, 1995, INJURY, V26, P399, DOI 10.1016/0020-1383(95)00064-G; COPES WS, 1988, J TRAUMA, V28, P78, DOI 10.1097/00005373-198801000-00011; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Goldschlager T, 2007, J CLIN NEUROSCI, V14, P618, DOI 10.1016/j.jocn.2006.02.018; Huber-Wagner S, 2009, LANCET, V373, P1455, DOI 10.1016/S0140-6736(09)60232-4; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1981, NEUROSURGERY, V9, P201; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; REILLY PL, 1975, LANCET, V2, P375; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1979, JACEP-J AM COLL EMER, V8, P64, DOI 10.1016/S0361-1124(79)80039-8; Ruchholtz S, 2000, UNFALLCHIRURG, V103, P30, DOI 10.1007/s001130050005; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	40	50	52	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2011	28	4					527	534		10.1089/neu.2010.1433			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	746IW	WOS:000289240200004	21265592				2022-02-06	
J	Catena, RD; van Donkelaar, P; Chou, LS				Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan			The effects of attention capacity on dynamic balance control following concussion	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; STABILITY FOLLOWING CONCUSSION; DUAL-TASK INTERFERENCE; PERFORMANCE TRADE-OFFS; OBSTACLE AVOIDANCE; OLDER-ADULTS; GAIT; INSTABILITY; HEALTHY; LIFE	The purpose of this study was to examine how individuals modulate attention in a gait/cognition dual task during a 4-week period following a concussion. Ten individuals suffering from a grade 2 concussion and 10 matched controls performed a single task of level walking, a seated auditory Stroop task and a simultaneous auditory Stroop and walking task. Reaction time and accuracy were measured from the Stroop task. Dynamic balance control during gait was measured by the interaction (displacement and velocity) between the center of mass (CoM) and center of pressure (CoP) in the coronal and sagittal planes. Concussed individuals shifted from conservative control of balance (shorter separation between CoM and CoP) immediately after injury to normal balance control over 28 days post-injury. Immediately after injury, correlations analyses using each subject on each testing day as a data point showed that there was a spectrum of deficient performance among concussed individuals on the first testing day. Within a testing session, deficiencies in reaction time of processing involved in the Stroop task were commonly seen with reduce dynamic balance control. However, the prioritization was not always towards the same task between trials. There were no correlations in the control group. Information provided in this study would enhance our understanding of the interaction between attention and gait following concussion.	[Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA		Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu	Catena, Robert/AAT-1510-2021	Catena, Robert/0000-0001-9128-1343	Center for Disease Control and Prevention [R49/CCR021735, CCR023203]	This study was supported by the Center for Disease Control and Prevention (R49/CCR021735 and CCR023203). The authors gratefully acknowledge the assistance of Louis R. Osternig, Jacqueline Poston and Erik Noren.	Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Kaya BK, 1998, J GERONTOL A-BIOL, V53, pM126, DOI 10.1093/gerona/53A.2.M126; Kelly JP, 1997, NEUROLOGY, V48, P581; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Lee HJ, 2006, ARCH PHYS MED REHAB, V87, P569, DOI 10.1016/j.apmr.2005.11.033; Matthews A, 2006, NEUROSCI LETT, V400, P172, DOI 10.1016/j.neulet.2006.02.043; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Montero-Odasso M, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-35; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; ShumwayCook A, 1997, J GERONTOL A-BIOL, V52, pM232, DOI 10.1093/gerona/52A.4.M232; Siu KC, 2008, AGING CLIN EXP RES, V20, P349, DOI 10.1007/BF03324867; Siu KC, 2008, EXP BRAIN RES, V184, P115, DOI 10.1007/s00221-007-1087-9; SOLOMON GS, 2006, HEADS UP SPORT CONCU; Temprado JJ, 2001, J EXP PSYCHOL HUMAN, V27, P1303, DOI 10.1037//0096-1523.27.6.1303; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; WINTER DA, 1990, BIOMECHANICS MOTOR C, P2; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	26	50	50	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	FEB 3	2011	8								8	10.1186/1743-0003-8-8			8	Engineering, Biomedical; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Engineering; Neurosciences & Neurology; Rehabilitation	721LC	WOS:000287354800001	21291548	gold, Green Published			2022-02-06	
J	Rattka, M; Brandt, C; Bankstahl, M; Broer, S; Loscher, W				Rattka, Marta; Brandt, Claudia; Bankstahl, Marion; Broeer, Sonja; Loescher, Wolfgang			Enhanced susceptibility to the GABA antagonist pentylenetetrazole during the latent period following a pilocarpine-induced status epilepticus in rats	NEUROPHARMACOLOGY			English	Article						Epilepsy; Epileptogenesis; Seizure threshold; Neuronal hyperexcitability; Antiepileptogenesis; Disease modification	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; SPONTANEOUS RECURRENT SEIZURES; ANTIEPILEPTIC DRUGS; GABAERGIC INHIBITION; LITHIUM-PILOCARPINE; VALPROIC ACID; IN-VIVO; MODEL; EPILEPTOGENESIS	A variety of acute brain insults bear the risk of subsequent development of chronic epilepsy. Enhanced understanding of the brain alterations underlying this process may ultimately lead to interventions that prevent, interrupt or reverse epileptogenesis in people at risk. Various interventions have been evaluated in rat models of symptomatic epilepsy, in which epileptogenesis was induced by status epilepticus (SE) or traumatic brain injury (TBI). Paradoxically, recent data indicated that administration of proconvulsant drugs after TBI or SE exerts antiepileptogenic or disease-modifying effects, although epilepsy is often considered to represent a decrease in seizure threshold. Surprisingly, to our knowledge, it is not known whether alterations in seizure threshold occur during the latent period following SE. This prompted us to study seizure threshold during and after the latent period following SE induced by lithium/pilocarpine in rats. Timed intravenous infusion of the GABA(A) receptor antagonist pentylenetetrazole (PTZ) was used for this purpose. The duration of the latent period was determined by continuous video/EEG monitoring. Compared to control seizure threshold determined before SE, threshold significantly decreased two days after SE, but returned to pre-SE control thereafter. Moreover, the duration of PTZ-induced seizures was significantly increased throughout the latent period, which ranged from 6 to 10 days after SE. This increased susceptibility to PTZ likely reflects the complex alterations in GABA-mediated transmission that occur during the latent period following SE. The data will allow developing dosing regimens for evaluation of whether treatment with subconvulsant doses of PTZ during the latent period affects the development of epilepsy. (C) 2010 Elsevier Ltd. All rights reserved.	[Rattka, Marta; Brandt, Claudia; Bankstahl, Marion; Broeer, Sonja; Loescher, Wolfgang] Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; [Rattka, Marta; Brandt, Claudia; Bankstahl, Marion; Broeer, Sonja; Loescher, Wolfgang] Ctr Syst Neurosci, Hannover, Germany		Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Loscher, Wolfgang/G-9824-2016	Loscher, Wolfgang/0000-0002-9648-8973; Broer, Sonja/0000-0002-7969-6586; Bankstahl, Marion/0000-0002-5775-188X	Deutsche Forschungsgemeinschaft (Bonn, Germany)German Research Foundation (DFG) [Lo 274/11-1]	We thank P. Demmer, N. Ernst, M. Kruger, and M. Topfer for skilful technical assistance. The study was supported by a grant (Lo 274/11-1) from the Deutsche Forschungsgemeinschaft (Bonn, Germany).	Amado D, 1998, EPILEPSY RES, V32, P266, DOI 10.1016/S0920-1211(98)00057-6; Armstrong C, 2009, EPILEPSIA, V50, P1657, DOI 10.1111/j.1528-1167.2009.02173.x; Bankstahl JP, 2008, EPILEPSY RES, V82, P70, DOI 10.1016/j.eplepsyres.2008.07.007; Ben-Ari Yehezkel, 2006, Critical Reviews in Neurobiology, V18, P135; Blaesse P, 2009, NEURON, V61, P820, DOI 10.1016/j.neuron.2009.03.003; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Brandt C, 2010, J NEUROSCI, V30, P8602, DOI 10.1523/JNEUROSCI.0633-10.2010; BROWNING RA, 1990, EPILEPSY RES, V6, P1, DOI 10.1016/0920-1211(90)90002-D; Chen K, 2007, J NEUROSCI, V27, P46, DOI 10.1523/JNEUROSCI.3966-06.2007; Cossart R, 2005, TRENDS NEUROSCI, V28, P108, DOI 10.1016/j.tins.2004.11.011; Coulter DA, 2001, INT REV NEUROBIOL, V45, P237; Dichter MA, 2009, ARCH NEUROL-CHICAGO, V66, P443, DOI 10.1001/archneurol.2009.10; Dudek FE, 2009, NEUROTHERAPEUTICS, V6, P319, DOI 10.1016/j.nurt.2009.01.020; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; FINN DA, 1994, J PHARMACOL EXP THER, V271, P164; Freichel C, 2006, NEUROSCIENCE, V141, P2177, DOI 10.1016/j.neuroscience.2006.05.040; Glien M, 2002, EPILEPSIA, V43, P350, DOI 10.1046/j.1528-1157.2002.18101.x; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; Goffin K, 2007, EXP NEUROL, V205, P501, DOI 10.1016/j.expneurol.2007.03.008; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Jacobs MP, 2009, EPILEPSY BEHAV, V14, P438, DOI 10.1016/j.yebeh.2009.02.036; Khazipov R, 2003, J NEUROSCI, V23, P5337; Kohling R, 2002, SCIENCE, V298, P1350; Kucker S, 2010, NEUROBIOL DIS, V37, P661, DOI 10.1016/j.nbd.2009.12.002; Kuteykin-Teplyakov K, 2009, EPILEPSIA, V50, P887, DOI 10.1111/j.1528-1167.2008.01916.x; Loscher W, 2007, EPILEPSIA, V48, P1245, DOI 10.1111/j.1528-1167.2007.01093.x; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Loscher W, 2010, EPILEPSY BEHAV, V19, P105, DOI 10.1016/j.yebeh.2010.06.035; Loscher W, 2009, EUR J PHARMACOL, V610, P1, DOI 10.1016/j.ejphar.2009.03.025; LOSCHER W, 1983, NEUROCHEM INT, V5, P405, DOI 10.1016/0197-0186(83)90069-4; MACDONALD RL, 1977, NATURE, V267, P720, DOI 10.1038/267720a0; Mann EO, 2008, CURR OPIN NEUROL, V21, P155, DOI 10.1097/WCO.0b013e3282f52f5f; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; Nehlig A, 2002, EPILEPSY RES, V51, P189, DOI 10.1016/S0920-1211(02)00125-0; PACHECO MF, 1981, COMP BIOCHEM PHYS C, V68, P99, DOI 10.1016/0306-4492(81)90044-7; Pathak HR, 2007, J NEUROSCI, V27, P14012, DOI 10.1523/JNEUROSCI.4390-07.2007; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2004, EPILEPSY RES, V61, P119, DOI 10.1016/j.eplepsyres.2004.07.005; Pitkanen A, 2004, EXPERT OPIN PHARMACO, V5, P777, DOI 10.1517/eoph.5.4.777.30162; Pitkanen A, 2007, EPILEPSIA, V48, P13, DOI 10.1111/j.1528-1167.2007.01063.x; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; POLLACK GM, 1985, J PHARMACOL METHOD, V13, P135, DOI 10.1016/0160-5402(85)90057-9; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RAMANJANEYULU R, 1984, EUR J PHARMACOL, V98, P337, DOI 10.1016/0014-2999(84)90282-6; Rigoulot MA, 2003, EPILEPSIA, V44, P529, DOI 10.1046/j.1528-1157.2003.50502.x; Scharfman HE, 2006, EPILEPSIA, V47, P1423, DOI 10.1111/j.1528-1167.2006.00672.x; Sirven JI, 2009, EPILEPSY CURR, V9, P164, DOI 10.1111/j.1535-7511.2009.01330.x; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; WAHNSCHAFFE U, 1992, EPILEPSY RES, V13, P199, DOI 10.1016/0920-1211(92)90053-V; Walker MC, 2002, BRAIN, V125, P1937, DOI 10.1093/brain/awf203; Woolley CS, 1998, EPILEPSIA, V39, pS2, DOI 10.1111/j.1528-1157.1998.tb02601.x; Wu K, 2001, NEUROSCIENCE, V104, P379, DOI 10.1016/S0306-4522(01)00043-4; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; Zhang GJ, 2004, J NEUROCHEM, V88, P91, DOI 10.1046/j.1471-4159.2003.02124.x	57	50	52	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB-MAR	2011	60	2-3					505	512		10.1016/j.neuropharm.2010.11.005			8	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	717NL	WOS:000287054600039	21075125				2022-02-06	
J	Toman, J; Fiskum, G				Toman, Julia; Fiskum, Gary			Influence of aging on membrane permeability transition in brain mitochondria	JOURNAL OF BIOENERGETICS AND BIOMEMBRANES			English	Article						Neurodegeneration; Neuron; Calcium; Oxidative stress; Apoptosis	ADENINE-NUCLEOTIDE TRANSLOCASE; CYTOCHROME-C RELEASE; OXIDATIVE STRESS; RAT-BRAIN; PORE; ACTIVATION; MECHANISMS; CALCIUM; INJURY; NEUROPROTECTION	The mitochondrial inner membrane permeability transition (MPT) plays an important role in the pathophysiology of acute disorders of the central nervous systems, including ischemic and traumatic brain injury, and possibly in neurodegenerative diseases. Opening of the permeability transition pore (PTP) by a combination of abnormally elevated intramitochondrial Ca2+ and oxidative stress induces the collapse of transmembrane ion gradients, resulting in membrane depolarization and uncoupling of oxidative phosphorylation. This loss of ATP synthesis eventually results in cellular metabolic failure and necrotic cell death. Drugs, e.g., cyclosporin A, can inhibit the permeability transition through their interaction with the mitochondria-specific protein, cyclophilin D, and demonstrate neuroprotection in several animal models. These characteristics of the MPT were developed almost exclusively from experiments performed with young, mature rodents whereas the neuropathologies associated with the MPT are most prevalent in the elderly population. Some evidence indicates that the sensitivity of mitochondria to Ca2+-induced PTP opening is greater in the aged compared to the young mature brain; however, the basis for this difference is unknown. Based on knowledge of factors that regulate the MPT and on other comparisons between cells and mitochondria from young and old animals, several features may be important. These aging-related features include impaired neuronal Ca2+ homeostasis, increased oxidative stress, increased cyclophilin D protein levels, oxidative modification of the adenine nucleotide translocase and of cardiolipin, and changes in the levels of anti-death mitochondrial proteins, e.g., Bcl-2. The influence of aging on both the contribution of the MPT to neuropathology and the neuroprotective efficacy of MPT inhibitors is a substantial knowledge gap that requires extensive research at the subcellular, cellular, and animal model levels.	[Toman, Julia; Fiskum, Gary] Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA; [Toman, Julia; Fiskum, Gary] Univ Maryland, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Baltimore, MD 21201 USA		Fiskum, G (corresponding author), Univ Maryland, Dept Anesthesiol, Sch Med, 685 W Baltimore St, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T35 AG036679] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD016596] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS034152] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T35AG036679] Funding Source: NIH RePORTER		BAZIL JN, 2010, J THEORETIC IN PRESS; Brown MR, 2004, J BIOENERG BIOMEMBR, V36, P401, DOI 10.1023/B:JOBB.0000041775.10388.23; CHEN JJ, 1995, FREE RADICAL BIO MED, V19, P583, DOI 10.1016/0891-5849(95)00066-7; Crompton M, 2004, AGING CELL, V3, P3, DOI 10.1046/j.1474-9728.2003.00073.x; DI LF, 2005, CARDIOVASC RES, V66, P222; ELISEEV RA, 2006, NEUROBIOL AGING, P1532; Eliseev RA, 2009, J BIOL CHEM, V284, P9692, DOI 10.1074/jbc.M808750200; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Fiskum G, 2008, ANN NY ACAD SCI, V1147, P129, DOI 10.1196/annals.1427.026; Garcia N, 2009, COMP BIOCHEM PHYS C, V149, P374, DOI 10.1016/j.cbpc.2008.09.006; GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j; Gouspillou G, 2010, BBA-BIOENERGETICS, V1797, P143, DOI 10.1016/j.bbabio.2009.09.004; Greco T, 2010, J BIOENERG BIOMEMBR, V42, P491, DOI 10.1007/s10863-010-9312-9; Greco T, 2010, J ALZHEIMERS DIS, V20, pS427, DOI 10.3233/JAD-2010-100519; Groeger AL, 2010, MOL INTERV, V10, P39, DOI 10.1124/mi.10.1.7; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Halestrap AP, 2010, BIOCHEM SOC T, V38, P841, DOI 10.1042/BST0380841; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Hofer T, 2009, MECH AGEING DEV, V130, P297, DOI 10.1016/j.mad.2009.01.004; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Kowaltowski AJ, 2004, FREE RADICAL BIO MED, V37, P1845, DOI 10.1016/j.freeradbiomed.2004.09.005; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LaFrance R, 2005, AGING CELL, V4, P139, DOI 10.1111/j.1474-9726.2005.00156.x; Leite ACR, 2010, BBA-BIOENERGETICS, V1797, P1210, DOI 10.1016/j.bbabio.2010.01.034; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Linard D, 2009, ARCH BIOCHEM BIOPHYS, V491, P39, DOI 10.1016/j.abb.2009.09.002; Macho A, 1997, J IMMUNOL, V158, P4612; Marzetti E, 2008, MECH AGEING DEV, V129, P542, DOI 10.1016/j.mad.2008.05.005; Mather M, 2000, BIOCHEM BIOPH RES CO, V273, P603, DOI 10.1006/bbrc.2000.2994; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Morrison CD, 2010, J NEUROCHEM, V114, P1581, DOI 10.1111/j.1471-4159.2010.06865.x; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicholls DG, 2009, BBA-BIOENERGETICS, V1787, P1416, DOI 10.1016/j.bbabio.2009.03.010; Pallardo FV, 1998, FREE RADICAL RES, V29, P617, DOI 10.1080/10715769800300671; Parihar MS, 2008, J NEUROSCI RES, V86, P2339, DOI 10.1002/jnr.21679; Petrosillo G, 2008, NEUROCHEM INT, V53, P126, DOI 10.1016/j.neuint.2008.07.001; Petrosillo G, 2010, J PINEAL RES, V48, P340, DOI 10.1111/j.1600-079X.2010.00758.x; Rasola A, 2010, FEBS LETT, V584, P1989, DOI 10.1016/j.febslet.2010.02.022; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; SAWADA M, 1987, MECH AGEING DEV, V41, P125, DOI 10.1016/0047-6374(87)90057-1; Sen T, 2007, NEUROCHEM INT, V50, P719, DOI 10.1016/j.neuint.2007.01.007; Soane L, 2007, J NEUROSCI RES, V85, P3407, DOI 10.1002/jnr.21498; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Toescu EC, 2004, TRENDS NEUROSCI, V27, P614, DOI 10.1016/j.tins.2004.07.010; Toescu EC, 2010, CELL CALCIUM, V47, P158, DOI 10.1016/j.ceca.2009.11.013; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Jacob MHVM, 2010, EXP GERONTOL, V45, P957, DOI 10.1016/j.exger.2010.08.017; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Xiong J, 2002, J NEUROSCI, V22, P10761; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896; Zorov DB, 2009, CARDIOVASC RES, V83, P213, DOI 10.1093/cvr/cvp151	57	50	51	0	7	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0145-479X	1573-6881		J BIOENERG BIOMEMBR	J. Bioenerg. Biomembr.	FEB	2011	43	1					3	10		10.1007/s10863-011-9337-8			8	Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Cell Biology	729SI	WOS:000287970700002	21311961	Green Accepted			2022-02-06	
J	Xiong, Y; Mahmood, A; Zhang, YL; Meng, YL; Zhang, ZG; Qu, CS; Sager, TN; Chopp, M				Xiong, Ye; Mahmood, Asim; Zhang, Yanlu; Meng, Yuling; Zhang, Zheng Gang; Qu, Changsheng; Sager, Thomas N.; Chopp, Michael			Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						angiogenesis; carbamylated erythropoietin; functional recovery; neurogenesis; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; MARROW STROMAL CELLS; SPATIAL MEMORY; HEAD-INJURY; IN-VIVO; STROKE; MICE; DERIVATIVES; RECOVERY; NEURONS	Object. Carbamylated erythropoietin (CEPO) is a modified erythropoietin molecule that does not affect hematocrit. In this study, the authors compared the efficacy of a single dose with a triple dose of CEPO treatment for traumatic brain injury (TBI) in rats. Methods. Traumatic brain injury was induced by controlled cortical impact over the left parietal cortex. Carbamylated erythropoietin (50 mu g/kg) was administered intraperitoneally in rats with TBI at 6 hours (CEPO x 1) or at 6,24, and 48 hours (CEPO x 3) postinjury. Neurological function was assessed using a modified neurological severity score and foot fault and Morris water maze tests. Animals were killed 35 days after injury, and brain sections were stained for immunohistochemical analysis to assess lesion volume, cell loss, cell proliferation, angiogenesis, and neurogenesis after CEPO treatment. Results. Compared with the vehicle treatment, single treatment of CEPO (6 hours) significantly reduced lesion volume and hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, and significantly improved sensorimotor functional recovery and spatial learning in rats after TBI. Importantly, triple dosing of CEPO (6,24, and 48 hours) further reduced lesion volume and improved functional recovery and neurogenesis compared with the CEPO x 1 group. Conclusions. The authors' results indicate that CEPO has considerable therapeutic potential in TBI and related pathologies and furthermore that repeated dosing in the subacute phase might have important pharmacological relevance. (DOI: 10.3171/2010.10.JNS10925)	[Xiong, Ye; Mahmood, Asim; Zhang, Yanlu; Meng, Yuling; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Sager, Thomas N.] H Lundbeck & Co AS, Neurodegenerat Sect, Div Discovery Pharmacol Res, Copenhagen, Denmark		Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS62002, P01 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS062002] Funding Source: NIH RePORTER	This work was supported by NIH Grant Nos. R01 NS62002 (to Dr. Xiong) and P01 NS42345 (to Drs. Mahmood and Chopp). Dr. Thomas N. Sager is a full-time employee of H. Lundbeck A/S.	Adembri C, 2008, CRIT CARE MED, V36, P975, DOI 10.1097/CCM.0B013E3181644343; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cerami A, 2001, SEMIN ONCOL, V28, P66, DOI 10.1053/sonc.2001.25401; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Doggrell SA, 2004, EXPERT OPIN INV DRUG, V13, P1517, DOI 10.1517/13543784.13.11.1517; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; King VR, 2007, EUR J NEUROSCI, V26, P90, DOI 10.1111/j.1460-9568.2007.05635.x; Lapchak PA, 2008, EXPERT OPIN INV DRUG, V17, P1175, DOI 10.1517/13543784.17.8.1175 ; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Mennini T, 2006, MOL MED, V12, P153, DOI 10.2119/2006-00045.Mennini; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Savino C, 2006, J NEUROIMMUNOL, V172, P27, DOI 10.1016/j.jneuroim.2005.10.016; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2007, J BIOL CHEM, V282, P32462, DOI 10.1074/jbc.M706880200; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xu X, 2009, SURGERY, V146, P506, DOI 10.1016/j.surg.2009.03.022; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	42	50	57	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2011	114	2					549	559		10.3171/2010.10.JNS10925			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	710WU	WOS:000286548500044	21073254	Green Accepted			2022-02-06	
J	Denic, A; Macura, SI; Mishra, P; Gamez, JD; Rodriguez, M; Pirko, I				Denic, Aleksandar; Macura, Slobodan I.; Mishra, Prasanna; Gamez, Jeffrey D.; Rodriguez, Moses; Pirko, Istvan			MRI in Rodent Models of Brain Disorders	NEUROTHERAPEUTICS			English	Article						Small animal MRI; mouse model; rodent model; brain disorders; MRI	RAT SPINAL-CORD; MANGANESE-ENHANCED MRI; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MAGNETIC-RESONANCE-SPECTROSCOPY; SUPERPARAMAGNETIC IRON-OXIDE; CEREBRAL ARTERIOVENOUS-MALFORMATIONS; APPARENT DIFFUSION-COEFFICIENT; ALZHEIMERS AMYLOID PLAQUES; MOTOR-NEURON DEGENERATION	Magnetic resonance imaging (MRI) is a well-established tool in clinical practice and research on human neurological disorders. Translational MRI research utilizing rodent models of central nervous system (CNS) diseases is becoming popular with the increased availability of dedicated small animal MRI systems. Projects utilizing this technology typically fall into one of two categories: 1) true "pre-clinical" studies involving the use of MRI as a noninvasive disease monitoring tool which serves as a biomarker for selected aspects of the disease and 2) studies investigating the pathomechanism of known human MRI findings in CNS disease models. Most small animal MRI systems operate at 4.7-11.7 Tesla field strengths. Although the higher field strength clearly results in a higher signal-to-noise ratio, which enables higher resolution acquisition, a variety of artifacts and limitations related to the specific absorption rate represent significant challenges in these experiments. In addition to standard T1-, T2-, and T2*-weighted MRI methods, all of the currently available advanced MRI techniques have been utilized in experimental animals, including diffusion, perfusion, and susceptibility weighted imaging, functional magnetic resonance imaging, chemical shift imaging, heteronuclear imaging, and H-1 or P-31 MR spectroscopy. Selected MRI techniques are also exclusively utilized in experimental research, including manganese-enhanced MRI, and cell-specific/molecular imaging techniques utilizing negative contrast materials. In this review, we describe technical and practical aspects of small animal MRI and provide examples of different MRI techniques in anatomical imaging and tract tracing as well as several models of neurological disorders, including inflammatory, neurodegenerative, vascular, and traumatic brain and spinal cord injury models, and neoplastic diseases.	[Gamez, Jeffrey D.; Rodriguez, Moses; Pirko, Istvan] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Denic, Aleksandar] Mayo Clin, Dept Neurosci, Rochester, MN 55905 USA; [Macura, Slobodan I.; Mishra, Prasanna] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA		Pirko, I (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	pirko@mayo.edu		Denic, Aleksandar/0000-0001-9157-5405; Rodriguez, Moses/0000-0001-6328-6497			Ahrens ET, 1998, MAGN RESON MED, V40, P119, DOI 10.1002/mrm.1910400117; Anderson SA, 2004, ANN NEUROL, V55, P654, DOI 10.1002/ana.20066; Andjus RK, 2005, ANN NY ACAD SCI, V1048, P10, DOI 10.1196/annals.1342.003; Angenstein F, 2004, NEUROREPORT, V15, P2271, DOI 10.1097/00001756-200410050-00026; Bakshi R, 2001, J NEUROL SCI, V185, P19, DOI 10.1016/S0022-510X(01)00477-4; Barber PA, 2005, NEUROSCI LETT, V388, P54, DOI 10.1016/j.neulet.2005.06.067; Barth M, 2003, INVEST RADIOL, V38, P409, DOI 10.1097/00004424-200307000-00005; Beckmann N, 2000, MAGNET RESON MED, V44, P252, DOI 10.1002/1522-2594(200008)44:2<252::AID-MRM12>3.0.CO;2-G; Bernstein MA, 2006, J MAGN RESON IMAGING, V24, P735, DOI 10.1002/jmri.20698; Bilgen M, 2005, MAGN RESON IMAGING, V23, P829, DOI 10.1016/j.mri.2005.06.004; Bilgen Mehmet, 2006, BMC Med Imaging, V6, P15, DOI 10.1186/1471-2342-6-15; Bock C, 1998, MAGNET RESON MED, V39, P457, DOI 10.1002/mrm.1910390316; Brinker G, 1999, MAGNET RESON MED, V41, P469, DOI 10.1002/(SICI)1522-2594(199903)41:3<469::AID-MRM7>3.0.CO;2-9; Bucher S, 2007, EUR J NEUROSCI, V26, P1895, DOI 10.1111/j.1460-9568.2007.05831.x; Bulte JWM, 2003, MAGN RESON MED, V50, P201, DOI 10.1002/mrm.10511; Bulte JWM, 2004, METHOD ENZYMOL, V386, P275; Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924; Chamberlain R, 2009, MAGN RESON MED, V61, P1158, DOI 10.1002/mrm.21951; Chen JW, 2006, RADIOLOGY, V240, P473, DOI 10.1148/radiol.2402050994; Choi IY, 2003, NEUROCHEM RES, V28, P987, DOI 10.1023/A:1023370104289; Dalton CM, 2002, J NEUROL NEUROSUR PS, V73, P141, DOI 10.1136/jnnp.73.2.141; Dedeoglu A, 2004, BRAIN RES, V1012, P60, DOI 10.1016/j.brainres.2004.02.079; Dhenain M, 2001, DEV BIOL, V232, P458, DOI 10.1006/dbio.2001.0189; Dousset V, 1999, AM J NEURORADIOL, V20, P223; DRAPEAU P, 1984, J PHYSIOL-LONDON, V348, P493, DOI 10.1113/jphysiol.1984.sp015121; Dreher W, 1998, MAGNET RESON MED, V39, P878, DOI 10.1002/mrm.1910390605; Engberink RDO, 2007, RADIOLOGY, V243, P467, DOI 10.1148/radiol.2432060120; Essig M, 2001, RADIOLOGE, V41, P288, DOI 10.1007/s001170050989; Essig M, 1999, MAGN RESON IMAGING, V17, P1417, DOI 10.1016/S0730-725X(99)00084-3; FRAHM J, 1988, MAGNET RESON MED, V6, P474, DOI 10.1002/mrm.1910060412; Fricke ST, 2004, J NEUROSCI METH, V136, P99, DOI 10.1016/j.jneumeth.2004.01.003; Ge YL, 2001, RADIOLOGY, V220, P606, DOI 10.1148/radiol.2203001776; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Gilissen EP, 1998, AM J PRIMATOL, V45, P291, DOI 10.1002/(SICI)1098-2345(1998)45:3<291::AID-AJP5>3.0.CO;2-R; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; GYNGELL ML, 1994, ACTA NEUROCHIR, P350; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2006, Z MED PHYS, V16, P237, DOI 10.1078/0939-3889-00321; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hamans BC, 2006, Z MED PHYS, V16, P269, DOI 10.1078/0939-3889-00325; HANSEN G, 1980, RADIOLOGY, V136, P695, DOI 10.1148/radiology.136.3.7403549; Hata R, 1998, J CEREBR BLOOD F MET, V18, P367, DOI 10.1097/00004647-199804000-00004; HEIDE AC, 1993, MAGNET RESON MED, V29, P478, DOI 10.1002/mrm.1910290409; HENNIG J, 1988, MAGN RESON IMAGING, V6, P391, DOI 10.1016/0730-725X(88)90475-4; Hesselbarth D, 1998, NMR BIOMED, V11, P423, DOI 10.1002/(SICI)1099-1492(199812)11:8<423::AID-NBM538>3.0.CO;2-V; Hirakawa K, 1988, Acta Neurochir Suppl (Wien), V43, P140; Hoehn M, 2001, J MAGN RESON IMAGING, V14, P491, DOI 10.1002/jmri.1213; Howe FA, 2001, NMR BIOMED, V14, P497, DOI 10.1002/nbm.716; Hsu EW, 1998, MAGN RESON MED, V40, P421, DOI 10.1002/mrm.1910400312; Hu TCC, 2001, MAGNET RESON MED, V46, P884, DOI 10.1002/mrm.1273; Illanes S, 2010, BRAIN RES, V1320, P135, DOI 10.1016/j.brainres.2010.01.015; Jack CR, 2007, NEUROSCIENTIST, V13, P38, DOI 10.1177/1073858406295610; Jack CR, 2004, MAGN RESON MED, V52, P1263, DOI 10.1002/mrm.20266; Jacobs RE, 1999, COMPUT MED IMAG GRAP, V23, P15, DOI 10.1016/S0895-6111(98)00059-7; Jacobs RE, 2003, NAT CELL BIOL, pSS10, DOI 10.1038/nrm1195; Jost SC, 2009, INT J RADIAT ONCOL, V75, P527, DOI 10.1016/j.ijrobp.2009.06.007; Kannurpatti SS, 2004, BRAIN RES, V1011, P141, DOI 10.1016/j.brainres.2004.02.076; Kato Y, 2006, MAGN RESON MED, V55, P755, DOI 10.1002/mrm.20831; Kato Y, 2010, NEURO-ONCOLOGY, V12, P71, DOI 10.1093/neuonc/nop006; Keen CL, 2000, MET IONS BIOL SYST, V37, P89; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Knight RA, 2008, STROKE, V39, P2596, DOI 10.1161/STROKEAHA.107.506683; Kovacevic N, 2005, CEREB CORTEX, V15, P639, DOI 10.1093/cercor/bhh165; Ladewig G, 2009, EXP NEUROL, V220, P207, DOI 10.1016/j.expneurol.2009.08.027; Lawrence J, 2004, NEUROIMAGE, V22, P1802, DOI 10.1016/j.neuroimage.2004.04.001; Lawrence J, 2008, MAGN RESON IMAGING, V26, P1, DOI 10.1016/j.mri.2007.05.001; Lee BCP, 1999, AM J NEURORADIOL, V20, P1239; Lee WT, 2004, PROG NEUROBIOL, V72, P87, DOI 10.1016/j.pneurobio.2004.02.002; Lin WL, 1999, JMRI-J MAGN RESON IM, V10, P118, DOI 10.1002/(SICI)1522-2586(199908)10:2<118::AID-JMRI2>3.3.CO;2-M; Lin YJ, 1997, MAGN RESON MED, V38, P378, DOI 10.1002/mrm.1910380305; Lukasik VM, 2003, NMR BIOMED, V16, P459, DOI 10.1002/nbm.836; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MacKenzie-Graham A, 2004, J ANAT, V204, P93, DOI 10.1111/j.1469-7580.2004.00264.x; MacKenzie-Graham A, 2009, NEUROIMAGE, V48, P637, DOI 10.1016/j.neuroimage.2009.06.073; Majcher K, 2006, EXP NEUROL, V197, P458, DOI 10.1016/j.expneurol.2005.10.012; Malisza KL, 2003, J MAGN RESON IMAGING, V18, P152, DOI 10.1002/jmri.10339; Malisza KL, 2002, J MAGN RESON IMAGING, V16, P553, DOI 10.1002/jmri.10185; Malisza KL, 1999, NMR BIOMED, V12, P31, DOI 10.1002/(SICI)1099-1492(199902)12:1<31::AID-NBM544>3.0.CO;2-M; Mandeville JB, 2001, MAGNET RESON MED, V45, P443, DOI 10.1002/1522-2594(200103)45:3<443::AID-MRM1058>3.3.CO;2-V; Mandeville JB, 1998, MAGNET RESON MED, V39, P615, DOI 10.1002/mrm.1910390415; McAteer MA, 2007, NAT MED, V13, P1253, DOI 10.1038/nm1631; McDaniel B, 2001, NEUROIMAGE, V14, P1244, DOI 10.1006/nimg.2001.0934; Metz S, 2004, EUR RADIOL, V14, P1851, DOI 10.1007/s00330-004-2405-2; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; Niessen HG, 2006, EXP NEUROL, V201, P293, DOI 10.1016/j.expneurol.2006.04.007; ORDIDGE RJ, 1994, MAGNET RESON MED, V32, P335, DOI 10.1002/mrm.1910320309; Pautler RG, 2002, NEUROIMAGE, V16, P441, DOI 10.1006/nimg.2002.1075; Pautler RG, 2003, MAGNET RESON MED, V50, P33, DOI 10.1002/mrm.10498; Pautler RG, 1998, MAGNET RESON MED, V40, P740, DOI 10.1002/mrm.1910400515; Pedrono E, 2010, J NEUROPATH EXP NEUR, V69, P188, DOI 10.1097/NEN.0b013e3181cd331c; Phuong LK, 2003, CANCER RES, V63, P2462; Pirko I, 2004, NEUROIMAGE, V21, P576, DOI 10.1016/j.neuroimage.2003.09.037; Pirko I, 2004, FRONT BIOSCI-LANDMRK, V9, P1222, DOI 10.2741/1322; Pirko I, 2003, CROAT MED J, V44, P463; Pirko I, 2004, FASEB J, V18, P179, DOI 10.1096/fj.02-1124fje; Pirko I, 2004, FASEB J, V18, P1577, DOI 10.1096/fj.04-2026fje; Pirko I, 2008, RADIOLOGY, V246, P790, DOI 10.1148/radiol.2463070338; Pirko Istvan, 2005, NeuroRx, V2, P250, DOI 10.1602/neurorx.2.2.250; Pirko I, 2009, J NEUROL SCI, V282, P34, DOI 10.1016/j.jns.2008.12.013; Pirko I, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-31; Poduslo JF, 2004, BIOCHEMISTRY-US, V43, P6064, DOI 10.1021/bi0359574; Poduslo JF, 2002, NEUROBIOL DIS, V11, P315, DOI 10.1006/nbdi.2002.0550; Querol M, 2006, J MAGN RESON IMAGING, V24, P971, DOI 10.1002/jmri.20724; Raghunand Natarajan, 2006, Methods Mol Med, V124, P347; Raineteau O, 2002, EUR J NEUROSCI, V16, P1761, DOI 10.1046/j.1460-9568.2002.02243.x; Rausch M, 2003, MAGNET RESON MED, V50, P309, DOI 10.1002/mrm.10541; Reichenbach JR, 2001, NEURORADIOLOGY, V43, P364, DOI 10.1007/s002340000503; Reichenbach JR, 2000, J COMPUT ASSIST TOMO, V24, P949, DOI 10.1097/00004728-200011000-00023; Robb RA, 2002, ST HEAL T, V85, P1; Robb RA, 1999, ANNU REV BIOMED ENG, V1, P377, DOI 10.1146/annurev.bioeng.1.1.377; Robinson KM, 2010, MOL IMAGING BIOL, V12, P240, DOI 10.1007/s11307-009-0272-6; Rosenzweig ES, 2004, CURR OPIN NEUROL, V17, P121, DOI 10.1097/00019052-200404000-00007; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2002, ACT NEUR S, V81, P209; Schwarcz A, 2003, MAGNET RESON MED, V49, P822, DOI 10.1002/mrm.10445; Shapiro EM, 2005, MAGNET RESON MED, V53, P329, DOI 10.1002/mrm.20342; STARK DD, 1988, RADIOLOGY, V168, P297, DOI 10.1148/radiology.168.2.3393649; Stieltjes B, 2006, MAGN RESON MED, V55, P1124, DOI 10.1002/mrm.20888; Stoffel M, 2004, J NEUROTRAUM, V21, P733, DOI 10.1089/0897715041269678; Suidan GL, 2006, NEUROL RES, V28, P250, DOI 10.1179/016164106X98116; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Tan IL, 2000, AM J NEURORADIOL, V21, P1039; Tatlisumak Turgut, 2004, Current Vascular Pharmacology, V2, P343, DOI 10.2174/1570161043385493; Thorek DLJ, 2008, BIOMATERIALS, V29, P3583, DOI 10.1016/j.biomaterials.2008.05.015; Thu MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007218; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tsai EC, 2001, J HISTOCHEM CYTOCHEM, V49, P1111, DOI 10.1177/002215540104900905; Turner R, 1998, EXP BRAIN RES, V123, P5, DOI 10.1007/s002210050538; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; WEISSLEDER R, 1988, RADIOLOGY, V169, P399, DOI 10.1148/radiology.169.2.3174987; WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474; Wilson JMB, 2004, NEUROIMAGE, V23, P336, DOI 10.1016/j.neuroimage.2004.05.026; Wu EX, 2003, MAGNET RESON MED, V49, P765, DOI 10.1002/mrm.10425; Wu QZ, 2008, J MAGN RESON IMAGING, V27, P446, DOI 10.1002/jmri.21111; Wu QZ, 2007, NEUROIMAGE, V37, P1138, DOI 10.1016/j.neuroimage.2007.06.029; Xu JQ, 2008, NMR BIOMED, V21, P928, DOI 10.1002/nbm.1307; Xu S, 1998, J NEUROSCI RES, V52, P549, DOI 10.1002/(SICI)1097-4547(19980601)52:5<549::AID-JNR7>3.0.CO;2-C; Xue R, 1999, MAGNET RESON MED, V42, P1123, DOI 10.1002/(SICI)1522-2594(199912)42:6<1123::AID-MRM17>3.0.CO;2-H; Yang J, 2007, P ANN INT IEEE EMBS, P51, DOI 10.1109/IEMBS.2007.4352220; Yang QX, 1998, MAGNET RESON MED, V39, P402, DOI 10.1002/mrm.1910390310; Yang QX, 1999, MAGNET RESON MED, V41, P423, DOI 10.1002/(SICI)1522-2594(199902)41:2<423::AID-MRM30>3.0.CO;2-M; Zaaraoui W, 2008, MAGN RESON MATER PHY, V21, P357, DOI 10.1007/s10334-008-0141-3; Zang DW, 2004, EUR J NEUROSCI, V20, P1745, DOI 10.1111/j.1460-9568.2004.03648.x; Zhang J, 2004, MAGN RESON MED, V51, P452, DOI 10.1002/mrm.10730	147	50	51	0	18	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JAN	2011	8	1					3	18		10.1007/s13311-010-0002-4			16	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	750RU	WOS:000289566500003	21274681	Green Published, Bronze			2022-02-06	
S	Gosseries, O; Vanhaudenhuyse, A; Bruno, MA; Demertzi, A; Schnakers, C; Boly, MM; Maudoux, A; Moonen, G; Laureys, S		Cvetkovic, D; Cosic, I		Gosseries, Olivia; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Demertzi, Athena; Schnakers, Caroline; Boly, Melanie M.; Maudoux, Audrey; Moonen, Gustave; Laureys, Steven			Disorders of Consciousness: Coma, Vegetative and Minimally Conscious States	STATES OF CONSCIOUSNESS: EXPERIMENTAL INSIGHTS INTO MEDITATION, WAKING, SLEEP AND DREAMS	Frontiers Collection		English	Article; Book Chapter						Brain injury; Coma; Consciousness; Electrophysiology; Functional neuroimaging; Locked-in syndrome; Minimally conscious state; Prognosis; Treatment; Vegetative state	LOCKED-IN SYNDROME; EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; WESSEX HEAD-INJURY; PATIENTS OWN NAME; MISMATCH NEGATIVITY; BISPECTRAL INDEX; RECOVERY; SCALE; ZOLPIDEM	Consciousness can be defined by two components: arousal and awareness. Disorders of consciousness (DOC) are characterized by a disrupted relationship between these two components. Coma is described by the absence of arousal and, hence, of awareness whereas the vegetative state is defined by recovery of arousal in the absence of any sign of awareness. In the minimally conscious state, patients show preserved arousal level and exhibit discernible but fluctuating signs of awareness. The study of DOC offers unique insights to the neural correlates of consciousness. We here review the challenges posed by the clinical examination of DOC patients and discuss the contribution of functional neuroimaging and electrophysiological techniques to the bedside assessment of consciousness. These studies raise important issues not only from a clinical and ethical perspective (i.e. diagnosis, prognosis and management of DOC patients) but also from a neuroscientific standpoint, as they enrich our current understanding of the emergence and function of the conscious mind.	[Gosseries, Olivia; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Demertzi, Athena; Schnakers, Caroline; Boly, Melanie M.; Maudoux, Audrey; Laureys, Steven] Univ Liege, Coma Sci Grp, Dept Neurol, B-4000 Liege, Belgium; [Gosseries, Olivia; Vanhaudenhuyse, Audrey; Bruno, Marie-Aurelie; Demertzi, Athena; Schnakers, Caroline; Boly, Melanie M.; Maudoux, Audrey; Laureys, Steven] Univ Liege, Cyclotron Res Ctr, B-4000 Liege, Belgium		Laureys, S (corresponding author), Univ Liege, Coma Sci Grp, Dept Neurol, Sari Tilman B30, B-4000 Liege, Belgium.	steven.laureys@ulg.ac.be	Gosseries, Olivia/AAB-6469-2020; Laureys, Steven/AAN-2097-2021; Vanhaudenhuyse, Audrey/AAP-2455-2020; Laureys, Steven/A-3349-2011	Gosseries, Olivia/0000-0001-9011-7496; Laureys, Steven/0000-0002-3096-3807; Demertzi, Athena/0000-0001-8021-3759			Alkire MT, 1999, ANESTHESIOLOGY, V90, P701, DOI 10.1097/00000542-199903000-00011; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Baars BJ, 2003, TRENDS NEUROSCI, V26, P671, DOI 10.1016/j.tins.2003.09.015; BAUBY JD, 1997, DIVING BELL BUTTERFL; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; Boly M, 2005, NEUROPSYCHOL REHABIL, V15, P283, DOI 10.1080/09602010443000371; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Bruno M, 2008, J NEUROL NEUROSUR PS, V79, P2, DOI 10.1136/jnnp.2007.125294; Bruno MA, 2011, BRIT MED J OPEN; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Childs NL, 1996, BRIT MED J, V313, P944; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss R, 2004, NEW ENGL J MED, V351, P511, DOI 10.1056/NEJM200407293510522; Clauss RP, 2004, ARZNEIMITTELFORSCH, V54, P641; Clauss RP, 2000, S AFR MED J, V90, P68; Cochrane TI, 2006, ANN INTERN MED, V144, P305, DOI 10.7326/0003-4819-144-4-200602210-00021; Cohen SI, 2008, AM J PHYS MED REHAB, V87, P229, DOI 10.1097/PHM.0b013e318161971b; Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019; Damasio A., 1999, FEELING WHAT HAPPENS; Demertzi A, 2011, J NEUROL, V258, P1058, DOI 10.1007/s00415-010-5882-z; Demertzi A, YB INTENSIV IN PRESS; Demertzi Athena, 2008, Expert Rev Neurother, V8, P1719, DOI 10.1586/14737175.8.11.1719; Deuschl G., 1999, RECOMMENDATIONS PRAC; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Dundon Stanislaus J, 1978, J Value Inq, V12, P280; Fang SC, 2005, P ANN INT IEEE EMBS, P4604, DOI 10.1109/IEMBS.2005.1615495; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Fins JJ, 2008, AM J BIOETHICS, V8, P3, DOI 10.1080/15265160802318113; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Fridman EA, 2010, BRAIN INJURY, V24, P636, DOI 10.3109/02699051003610433; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; Gosseries O, 2009, NEUROLOGY OF CONSCIOUSNESS: COGNITIVE NEUROSCIENCE AND NEUROPATHOLOGY, P191, DOI 10.1016/B978-0-12-374168-4.00015-0; Guerit JM, 2002, GUIDE PRATIQUE NEURO; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2005, BOUNDARIES CONSCIOUS; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Kuebler A, 2007, CURR OPIN NEUROL, V20, P643, DOI 10.1097/WCO.0b013e3282f14782; Laureys S, 2005, NAT REV NEUROSCI, V6, P899, DOI 10.1038/nrn1789; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2005, CURR OPIN NEUROL, V18, P726, DOI 10.1097/01.wco.0000189874.92362.12; Laureys S, 2000, LANCET, V355, P1825, DOI 10.1016/S0140-6736(05)73084-1; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Laureys S, 2003, 9 ANN M ORG HUM B S1, V19; Laureys S, 2002, 2002 YB INTENSIVE CA; Laureys S, 2000, 2000 YB INTENSIVE CA; Laureys S, 2008, NAT CLIN PRACT NEURO, V4, P544, DOI 10.1038/ncpneuro0887; Laureys S, 2008, NEUROLOGY, V70, pE14, DOI 10.1212/01.wnl.0000303264.66049.c1; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Laureys S, 2006, CURR OPIN NEUROL, V19, P520, DOI 10.1097/WCO.0b013e3280106ba9; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Leon-Carrion J, 2002, BRAIN INJURY, V16, P571, DOI 10.1080/02699050110119781; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; Lin JS, 2000, SLEEP MED REV, V4, P471, DOI 10.1053/smrv.2000.0116; Majerus S, 2000, NEUROPSYCHOL REHABIL, V10, P167, DOI 10.1080/096020100389237; Maquet P, 1997, J NEUROSCI, V17, P2807; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Naatanen R, 1997, AUDIOL NEURO-OTOL, V2, P341; Naccache L, 2005, CLIN NEUROPHYSIOL, V116, P988, DOI 10.1016/j.clinph.2004.10.009; Nieuwenhuijs D, 2002, ANESTH ANALG, V94, P125, DOI 10.1097/00000539-200201000-00024; Oh H, 2003, J CLIN NURS, V12, P394, DOI 10.1046/j.1365-2702.2003.00750.x; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Plum F., 1983, DIAGNOSIS STUPOR COM; Qin PM, 2008, NEUROSCI LETT, V448, P24, DOI 10.1016/j.neulet.2008.10.029; Rappaport M., 2000, COMA NEAR COMA SCALE; ROSENBERG JH, 1995, NEUROLOGY, V45, P1012; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Schnakers C, 2005, NEUROPSYCHOL REHABIL, V15, P381, DOI 10.1080/09602010443000524; Schnakers C, 2008, BRAIN INJURY, V22, P926, DOI 10.1080/02699050802530565; Schnakers C, 2004, REANIMATION, V13, DOI 10.1016/j.reaurg.2004.03.019; Schnakers C, 2005, 8 C ASS SCI STUD CON, V11; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2006, ANN NEUROL, V60, P744, DOI 10.1002/ana.20919; Schnakers C, 2009, NEUROCASE, V15, P271, DOI 10.1080/13554790902724904; Sellers EW, 2006, IEEE T NEUR SYS REH, V14, P221, DOI 10.1109/TNSRE.2006.875580; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; Sorger B, 2009, PROG BRAIN RES, V177, P275, DOI 10.1016/S0079-6123(09)17719-1; Struys M, 1998, ACTA ANAESTH SCAND, V42, P628, DOI 10.1111/j.1399-6576.1998.tb05293.x; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; Taira T, 2007, ACTA NEUROCHIR SUPPL, V97, P227; TEASDALE G, 1974, LANCET, V2, P81; Tolle Patrizia, 2003, Axone, V25, P20; van der Stelt O, 2008, CLIN NEUROPHYSIOL, V119, P2172, DOI 10.1016/j.clinph.2008.07.224; Vanhaudenhuyse A, 2008, NEUROLOGY, V71, P1374, DOI 10.1212/01.wnl.0000320110.70134.60; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Vanhaudenhuyse A, 2009, SCHOLARPEDIA, V4, P4163; Vanhaudenhuyse A, 2007, BEHAV BRAIN SCI, V30, P529, DOI 10.1017/S0140525X0700310X; Vanhaudenhuyse A, 2008, NEUROCRIT CARE, V8, P262, DOI 10.1007/s12028-007-9016-0; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wade DT, 1996, BRIT MED J, V313, P943; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wijdicks EFM, 2006, MAYO CLIN PROC, V81, P1155, DOI 10.4065/81.9.1155; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wilhelm B, 2006, NEUROLOGY, V67, P534, DOI 10.1212/01.wnl.0000228226.86382.5f; Wood R L, 1992, Brain Inj, V6, P411, DOI 10.3109/02699059209008137; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006; Zafonte RD, 2000, J HEAD TRAUMA REHAB, V15, P1179, DOI 10.1097/00001199-200010000-00014; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	124	50	51	0	5	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES	1612-3018		978-3-642-18046-0	FRONT COLLECT			2011							29	55		10.1007/978-3-642-18047-7_2	10.1007/978-3-642-18047-7		27	Engineering, Electrical & Electronic; Neurosciences	Book Citation Index – Science (BKCI-S)	Engineering; Neurosciences & Neurology	BYN19	WOS:000299398300002		Green Submitted			2022-02-06	
J	Gottshall, K				Gottshall, Kim			Vestibular rehabilitation after mild traumatic brain injury with vestibular pathology	NEUROREHABILITATION			English	Article						Vestibular; physical therapy; mild traumatic brain injury	GAZE STABILIZATION TEST; DYNAMIC POSTUROGRAPHY; DISORDERS; DIZZINESS; DYSFUNCTION; DIAGNOSIS	Vestibular complaints are the most frequent sequelae of mTBI. Vestibular physical therapy has been established as the most important treatment modality for this group of patients. Nevertheless there is little work objectively documenting the impact of vestibular physical therapy on this group of patients. Studies have been completed in the past examining clinical measures like the GCS on overall recovery pattern after TBI. But outcomes measures specifically aimed at examining the adequacy of vestibular tests to track vestibular recoveryhave remained lacking. Scherer and Schubert reinforced the need for best practice vestibular assessment for formulation of appropriate vestibular physical therapy treatment strategies. Now the application of vestibular testing and rehabilitation in this patient population is needed to provide information on objective outcome measures. Vestibular physical therapy is most effective when applied in a customized fashion. While we and others have developed vestibular physical therapy procedures that are applied in best practices for mTBI vestibular patients, these therapies must be customized for the patient entry level of function and expectation level of recovery. Knowledge of the patient's disability and diagnosis is critical to build the foundation for return to activity, work, or sport.	Vestibular Assessment & Rehabil, San Diego, CA USA		Gottshall, K (corresponding author), Vestibular Assessment & Rehabil, 34520 Bob Wilson Dr, San Diego, CA USA.	Kim.gottshall@med.navy.mil					Badaracco C, 2007, OTOL NEUROTOL, V28, P809, DOI 10.1097/MAO.0b013e3180cab73f; Goebel JA, 2007, OTOL NEUROTOL, V28, P68, DOI 10.1097/01.mao.0000244351.42201.a7; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Gottshall Kim R, 2005, Int Tinnitus J, V11, P81; Gottshall KR, 2005, OTOLARYNG HEAD NECK, V133, P326, DOI 10.1016/j.otohns.2005.06.001; Gottshall KR, 2003, LARYGNOSCOPE, V113, P1736; Herdman SJ, 1998, OTOLARYNG HEAD NECK, V119, P49, DOI 10.1016/S0194-5998(98)70195-0; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Mishra A, 2009, AM J AUDIOL, V18, P53, DOI 10.1044/1059-0889(2009/06-0024); Morris AE, 2009, INT J AUDIOL, V48, P24, DOI 10.1080/14992020802314905; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; NORRE ME, 1994, CLIN OTOLARYNGOL, V19, P433, DOI 10.1111/j.1365-2273.1994.tb01264.x; PAIGE GD, 1989, ACTA OTO-LARYNGOL, V108, P1, DOI 10.3109/00016488909107385; Powell L. E., 1995, J GERONTOL A-BIOL, V50A, P28, DOI DOI 10.1093/GERONA/50A.1.M28; Pritcher MR, 2008, OTOL NEUROTOL, V29, P982, DOI 10.1097/MAO.0b013e31818457fb; SCHERER MR, 2009, PHYS THER, V89, P1; Whitney SL, 2009, GAIT POSTURE, V29, P194, DOI 10.1016/j.gaitpost.2008.08.002; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906	22	50	51	0	24	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2011	29	2					167	171		10.3233/NRE-2011-0691			5	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	842IB	WOS:000296589600007	22027078				2022-02-06	
J	Gould, KR; Ponsford, JL; Johnston, L; Schonberger, M				Gould, Kate Rachel; Ponsford, Jennie Louise; Johnston, Lisa; Schoenberger, Michael			Relationship Between Psychiatric Disorders and 1-Year Psychosocial Outcome Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety disorders; brain injuries; craniocerebral trauma; depression; mental disorders; neuropsychology; outcome; psychosocial; substance-related disorders	SEVERE HEAD-INJURY; MAJOR DEPRESSION; ACUTE PREDICTORS; CHRONIC PAIN; MODERATE; SEVERITY; RETURN; ASSOCIATION; IMPAIRMENT; DISABILITY	Objective: To investigate the relationship of psychiatric functioning with psychosocial functioning at 1 year following traumatic brain injury (TBI), after controlling for relevant demographic, injury-related, and concurrent factors. Design: Prospective 1-year longitudinal study. Participants: Participants were 122 individuals with TBI and 88 proxy informants. Setting: Rehabilitation hospital. MainMeasures: The Structured Clinical Interview for DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders [Fourth Edition, Text Revision]) Axis I Disorders, Hospital Anxiety and Depression Scale, Sydney Psychosocial Reintegration Scale, and Glasgow Outcome Scale-Extended. Results: At 1 year postinjury, occupational activities were the area of most change after TBI followed by interpersonal relationships and independent living skills, according to the Sydney Psychosocial Reintegration Scale. The majority of participants were rated as having moderate disability on the Glasgow Outcome Scale-Extended. After controlling for relevant background factors, preinjury, acute postinjury, and concurrent psychiatric disorders were significantly related to 1-year psychosocial outcome. Conclusion: Screening in the acute postinjury stage for presence of preinjury psychiatric history or current distress may help identify individuals who require more intensive rehabilitation and psychiatric support and more active postdischarge monitoring. Further research exploring potential causal mechanisms for these findings is required.	[Gould, Kate Rachel; Ponsford, Jennie Louise; Johnston, Lisa; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Gould, Kate Rachel; Ponsford, Jennie Louise; Schoenberger, Michael] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie Louise] Natl Trauma Res Inst, Melbourne, Vic, Australia		Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton Campus, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Gould, Kate Rachel/AAA-5511-2020	Gould, Kate Rachel/0000-0002-3564-7408	Victorian Neurotrauma Initiative	The authors thank the Victorian Neurotrauma Initiative for their support.	Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Army Individual Test Battery, 1944, MAN DIR SCOR; BABOR TF, 2001, WHOMSDMSB016A DEP ME; BARNETT PA, 1988, PSYCHOL BULL, V104, P97, DOI 10.1037/0033-2909.104.1.97; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; FREDENBERG E, 1997, COPING SCALE ADULTS; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Gould K, 2010, BRAIN INJURY, V24, P337; Gould K, NATURE FREQUEN UNPUB; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hillier SL, 1997, BRAIN INJURY, V11, P661; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kervick RB, 2005, BRAIN INJURY, V19, P881, DOI 10.1080/02699050400025273; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kim JA, 1997, OCCUPATIONAL THERAPY, V4, P180; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nelson H.E., 1982, NATL ADULT READING T; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Robinson RG, 2005, TXB TRAUMATIC BRAIN, P201; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schretlen DJ, 2000, REHABIL PSYCHOL, V45, P260, DOI 10.1037/0090-5550.45.3.260; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808; Snaith RP, 1994, HADS HOSP ANXIETY DE; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	80	50	51	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2011	26	1					79	89		10.1097/HTR.0b013e3182036799			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	703GA	WOS:000285965200008	21209565				2022-02-06	
J	Roquilly, A; Mahe, PJ; Latte, DDD; Loutrel, O; Champin, P; Di Falco, C; Courbe, A; Buffenoir, K; Hamel, O; Lejus, C; Sebille, V; Asehnoune, K				Roquilly, Antoine; Mahe, Pierre Joachim; Latte, Dominique Demeure Dit; Loutrel, Olivier; Champin, Philippe; Di Falco, Christelle; Courbe, Athanase; Buffenoir, Kevin; Hamel, Olivier; Lejus, Corinne; Sebille, Veronique; Asehnoune, Karim			Continuous controlled-infusion of hypertonic saline solution in traumatic brain-injured patients: a 9-year retrospective study	CRITICAL CARE			English	Article							ELEVATED INTRACRANIAL-PRESSURE; DECOMPRESSIVE CRANIECTOMY; CEREBRAL EDEMA; RENAL-FAILURE; PRIMARY-CARE; CELL-VOLUME; HEAD-INJURY; HYPONATREMIA; MANNITOL; RESUSCITATION	Introduction: Description of a continuous hypertonic saline solution (HSS) infusion using a dose-adaptation of natremia in traumatic brain injured (TBI) patients with refractory intracranial hypertension (ICH). Methods: We performed a single-center retrospective study in a surgical intensive care unit of a tertiary hospital. Fifty consecutive TBI patients with refractory ICH treated with continuous HSS infusion adapted to a target of natremia. In brief, a physician set a target of natremia adapted to the evolution of intracranial pressure (ICP). Flow of NaCl 20% was a priori calculated according to natriuresis, and the current and target natremia that were assessed every 4 hours. Results: The HSS infusion was initiated for a duration of 7 (5 to 10) (8 +/- 4) days. ICP decreased from 29 (26 to 34) (31 +/- 9) mm Hg at H0 to 20 (15 to 26) (21 +/- 8) mm Hg at H1 (P < 0.05). Cerebral perfusion pressure increased from 61 (50 to 70) (61 +/- 13) mm Hg at H0 up to 67 (60 to 79) (69 +/- 12) mm Hg at H1 (P < 0.05). No rebound of ICH was reported after stopping continuous HSS infusion. Natremia increased from 140 (138 to 143) (140 +/- 4) at H0 up to 144 (141 to 148) (144 +/- 4) mmol/L at H4 (P < 0.05). Plasma osmolarity increased from 275 (268 to 281) (279 +/- 17) mmol/L at H0 up to 290 (284 to 307) (297 +/- 17) mmol/L at H24 (P < 0.05). The main side effect observed was an increase in chloremia from 111 (107 to 119) (113 +/- 8) mmol/L at H0 up to 121 (117 to 124) (121 +/- 6) mmol/L at H24 (P < 0.05). Neither acute kidney injury nor pontine myelinolysis was recorded. Conclusions: Continuous HSS infusion adapted to close biologic monitoring enables long-lasting control of natremia in TBI patients along with a decreased ICP without any rebound on infusion discontinuation.	[Roquilly, Antoine; Mahe, Pierre Joachim; Latte, Dominique Demeure Dit; Loutrel, Olivier; Champin, Philippe; Di Falco, Christelle; Courbe, Athanase; Lejus, Corinne; Asehnoune, Karim] Nantes Univ Hosp, Hotel Dieu, Anesthesiol & Intens Care Unit, F-44093 Nantes, France; [Buffenoir, Kevin; Hamel, Olivier] Nantes Univ Hosp, Hotel Dieu, Neurosurg Unit, F-44093 Nantes, France; [Sebille, Veronique] Univ Nantes, UFR Pharm, EA 4275, F-44000 Nantes, France		Asehnoune, K (corresponding author), Nantes Univ Hosp, Hotel Dieu, Anesthesiol & Intens Care Unit, 1 Pl Alexis Ricordeau, F-44093 Nantes, France.	karim.asehnoune@chu-nantes.fr	Buffenoir, Kevin/ABD-9003-2020; Sebille, Veronique/I-3309-2015; Roquilly, Antoine/P-9826-2017; Sebille, Veronique/L-8761-2015	Sebille, Veronique/0000-0002-0780-7742			Adrogue HJ, 1997, INTENS CARE MED, V23, P309, DOI 10.1007/s001340050333; Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Barsoum NR, 2002, NEPHROL DIAL TRANSPL, V17, P1176, DOI 10.1093/ndt/17.7.1176; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; CSERR HF, 1991, J PHYSIOL-LONDON, V442, P277, DOI 10.1113/jphysiol.1991.sp018793; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Handy JM, 2008, BRIT J ANAESTH, V101, P141, DOI 10.1093/bja/aen148; Hauer EM, 2011, CRIT CARE MED, V39, P1766, DOI 10.1097/CCM.0b013e318218a390; HOCHWALD GM, 1974, LIFE SCI, V15, P1309, DOI 10.1016/0024-3205(74)90312-9; HUANG PP, 1995, ANN SURG, V221, P543, DOI 10.1097/00000658-199505000-00012; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; LIEN YHH, 1991, J CLIN INVEST, V88, P303, DOI 10.1172/JCI115292; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; RUDEHILL A, 1993, J NEUROSURG ANESTH, V5, P4; Schatzmann C, 1998, ACT NEUR S, V71, P31; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; Uchino S, 2006, CRIT CARE MED, V34, P1913, DOI 10.1097/01.CCM.0000224227.70642.4F; Upadhyay A, 2006, AM J MED, V119, pS30, DOI 10.1016/j.amjmed.2006.05.005; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4	35	50	51	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	5							R260	10.1186/cc10522			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929GB	WOS:000303048200056	22035596	Green Published, gold			2022-02-06	
J	Theriault, M; De Beaumont, L; Tremblay, S; Lassonde, M; Jolicoeur, P				Theriault, Martin; De Beaumont, Louis; Tremblay, Sebastien; Lassonde, Maryse; Jolicoeur, Pierre			Cumulative effects of concussions in athletes revealed by electrophysiological abnormalities on visual working memory	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Event-related potentials; Sustained posterior contralateral negativity; Concussion; Athletes	SHORT-TERM-MEMORY; TRAUMATIC BRAIN-INJURY; RECURRENT CONCUSSION; LONG-TERM; SPORTS CONCUSSION; NEURAL ACTIVITY; EPIDEMIOLOGY; PERFORMANCE; COLLEGIATE; ATTENTION	Event-related potentials (ERPs) have been useful to detect subtle, pervasive alterations of cognition-related waveforms in athletes with multiple concussions. This study used the sustained posterior contralateral negativity (SPCN) waveform component recorded while participants performed a visual short-term memory task to investigate how working memory (WM) storage capacity was affected among athletes who differed according to their history of sports concussions. Fifty-five university-level football players were assigned to three groups: 1-2 concussion athletes; 3+ concussion athletes; non-concussed athletes. The main finding of the present study was that athletes with a history of three concussions or more exhibited significantly attenuated SPCN amplitude relative to both concussed athletes with only one or two prior concussions and athletes without concussions. The latter finding adds to previous evidence of disproportionately worse outcome in athletes presenting with a history of three or more concussions relative to those with fewer concussions. In addition, SPCN amplitude was found to correlate significantly with a visual memory capacity estimate (K), but this K value did not significantly differ across groups. This suggests that attenuated SPCN amplitude after three or more concussions did not interfere with apparent WM function. Taken together, these findings suggest that the altered neurophysiological index of WM storage might be a more sensitive measure of a latent WM function abnormality which may well worsen with aging, or perhaps additional brain insults.	[Jolicoeur, Pierre] Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada		Jolicoeur, P (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	pierre.jolicoeur@umontreal.ca		Tremblay, Sebastien/0000-0001-6251-9797			American Clinical Neurophysiology Society, 2006, J Clin Neurophysiol, V23, P107; [Anonymous], 1994, J Clin Neurophysiol, V11, P111; [Anonymous], 1991, J CLIN NEUROPHYSIOL, V8, P200, DOI 10.1097/00004691-199104000-00007; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Awh E, 2007, PSYCHOL SCI, V18, P622, DOI 10.1111/j.1467-9280.2007.01949.x; BARTH J, 1989, J COGNITIVE NEUROREH, V26, P451; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cowan N, 2001, BEHAV BRAIN SCI, V24, P87, DOI 10.1017/S0140525X01003922; Craik FIM, 2006, TRENDS COGN SCI, V10, P131, DOI 10.1016/j.tics.2006.01.007; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Drew TW, 2006, CLIN EEG NEUROSCI, V37, P286, DOI 10.1177/155005940603700405; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Fales CL, 2008, COGN AFFECT BEHAV NE, V8, P239, DOI 10.3758/CABN.8.3.239; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hecht S, 2005, CLIN J SPORT MED, V15, P281, DOI DOI 10.1097/01.jsm.0000172669.85640.05; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jolicoeur P, 2008, BRAIN RES, V1215, P160, DOI 10.1016/j.brainres.2008.03.059; Jolicoeur P, 2006, PSYCHOL RES-PSYCH FO, V70, P414, DOI 10.1007/s00426-005-0008-4; Klaver P, 1999, NEUROREPORT, V10, P2001, DOI 10.1097/00001756-199907130-00002; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Luck S.J., 2005, INTRO EVENT RELATED, V1st ed.; Mazza V, 2007, EXP BRAIN RES, V181, P531, DOI 10.1007/s00221-007-1002-4; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCollough AW, 2007, CORTEX, V43, P77, DOI 10.1016/S0010-9452(08)70447-7; McCrory P, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.014860; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; PASHLER H, 1988, PERCEPT PSYCHOPHYS, V44, P369, DOI 10.3758/BF03210419; Perron R, 2009, PSYCHOL RES-PSYCH FO, V73, P222, DOI 10.1007/s00426-008-0214-y; Polich J, 1998, J CLIN NEUROPHYSIOL, V15, P14, DOI 10.1097/00004691-199801000-00004; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Todd JJ, 2004, NATURE, V428, P751, DOI 10.1038/nature02466; Vogel EK, 2004, NATURE, V428, P748, DOI 10.1038/nature02447; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	54	50	52	0	29	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	1					30	41	PII 922289540	10.1080/13803391003772873			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	714QK	WOS:000286823900004	20480425				2022-02-06	
J	Lindhagen-Persson, M; Brannstrom, K; Vestling, M; Steinitz, M; Olofsson, A				Lindhagen-Persson, Malin; Brannstrom, Kristoffer; Vestling, Monika; Steinitz, Michael; Olofsson, Anders			Amyloid-beta Oligomer Specificity Mediated by the IgM Isotype - Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; A-BETA; PROTEIN-PRECURSOR; MOUSE MODEL; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; MEMORY LOSS; PEPTIDE	Background: Alzheimers disease (AD) has been strongly linked to an anomalous self-assembly of the amyloid-beta peptide (A beta). The correlation between clinical symptoms of AD and A beta depositions is, however, weak. Instead small and soluble A beta oligomers are suggested to exert the major pathological effects. In strong support of this notion, immunological targeting of A beta oligomers in AD mice-models shows that memory impairments can be restored without affecting the total burden of A beta deposits. Consequently a specific immunological targeting of A beta oligomers is of high therapeutic interest. Methodology/Principal Findings: Previously the generation of conformational-dependent oligomer specific anti-A beta antibodies has been described. However, to avoid the difficult task of identifying a molecular architecture only present on oligomers, we have focused on a more general approach based on the hypothesis that all oligomers expose multiple identical epitopes and therefore would have an increased binding to a multivalent receptor. Using the polyvalent IgM immunoglobulin we have developed a monoclonal anti-A beta antibody (OMAB). OMAB only demonstrates a weak interaction with A beta monomers and dimers having fast on and off-rate kinetics. However, as an effect of avidity, its interaction with A beta-oligomers results in a strong complex with an exceptionally slow off-rate. Through this mechanism a selectivity towards A beta oligomers is acquired and OMAB fully inhibits the cytotoxic effect exerted by A beta(1-42) at highly substoichiometric ratios. Anti-A beta auto-antibodies of IgM isotype are frequently present in the sera of humans. Through a screen of endogenous anti-A beta IgM auto-antibodies from a group of healthy individuals we show that all displays a preference for oligomeric A beta. Conclusions/Significance: Taken together we provide a simple and general mechanism for targeting of oligomers without the requirement of conformational-dependent epitopes. In addition, our results suggest that IgM anti-A beta auto-antibodies may exert a more specific protective mechanism in vivo than previously anticipated.	[Lindhagen-Persson, Malin; Brannstrom, Kristoffer; Vestling, Monika; Olofsson, Anders] Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden; [Steinitz, Michael] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pathol, IL-91010 Jerusalem, Israel		Lindhagen-Persson, M (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	anders.olofsson@medchem.umu.se	Brannstrom, Kristoffer/D-3648-2009; Brannstrom, Kristoffer/AAC-1204-2020		Ernst and Lili Rosenhain fund, Bruxelles, Belgium; J. C. Kempe; Swedish research councilSwedish Research CouncilEuropean Commission; Socialstyrelsen; FAMY; Medical Faculty of Umea University	This work was supported by Ernst and Lili Rosenhain fund, Bruxelles, Belgium, J. C. Kempe, the Swedish research council, Socialstyrelsen, FAMY and the Medical Faculty of Umea University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asami-Odaka A, 2005, NEURODEGENER DIS, V2, P36, DOI 10.1159/000086429; Banks WA, 2007, EXP NEUROL, V206, P248, DOI 10.1016/j.expneurol.2007.05.005; Barghorn S, 2005, J NEUROCHEM, V95, P834, DOI 10.1111/j.1471-4159.2005.03407.x; Chauhan NB, 2003, J NEUROSCI RES, V74, P142, DOI 10.1002/jnr.10721; DaSilva KA, 2009, VACCINE, V27, P1365, DOI 10.1016/j.vaccine.2008.12.044; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Dodel RC, 2004, J NEUROL NEUROSUR PS, V75, P1472, DOI 10.1136/jnnp.2003.033399; Dodel R, 2010, DRUGS, V70, P513, DOI 10.2165/11533070-000000000-00000; Geylis V, 2005, NEUROBIOL AGING, V26, P597, DOI 10.1016/j.neurobiolaging.2004.06.008; Giuffrida ML, 2009, J NEUROSCI, V29, P10582, DOI 10.1523/JNEUROSCI.1736-09.2009; Hartley DM, 2008, J BIOL CHEM, V283, P16790, DOI 10.1074/jbc.M802215200; Hasegawa K, 2002, BIOCHEMISTRY-US, V41, P13489, DOI 10.1021/bi020369w; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Jacobsen JS, 2006, P NATL ACAD SCI USA, V103, P5161, DOI 10.1073/pnas.0600948103; KATZMAN R, 1986, NEUROL CLIN, V4, P329, DOI 10.1016/S0733-8619(18)30972-1; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Kotilinek LA, 2002, J NEUROSCI, V22, P6331; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 2007, J NEUROCHEM, V100, P23, DOI 10.1111/j.1471-4159.2006.04157.x; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; MARCELLO A, 2009, NEUROBIOL AGING; Marcello A, 2009, J NEURAL TRANSM, V116, P913, DOI 10.1007/s00702-009-0224-y; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Munch G, 2002, J NEURAL TRANSM, V109, P1081, DOI 10.1007/s007020200091; Myagkova MA, 2001, B EXP BIOL MED+, V131, P127, DOI 10.1023/A:1017527508878; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nath A, 2003, NEUROMOL MED, V3, P29, DOI 10.1385/NMM:3:1:29; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; O'Nuallain B, 2008, BIOCHEMISTRY-US, V47, P12254, DOI 10.1021/bi801767k; Olofsson A, 2007, BIOCHEM J, V404, P63, DOI 10.1042/BJ20061561; Olofsson A, 2009, ANAL BIOCHEM, V385, P374, DOI 10.1016/j.ab.2008.10.034; ONUALLAIN B, J CLIN IMMUNOL S1, V30, pS37; PAUL S, J CLIN IMMUNOL S1, V30, pS43; Raby CA, 1998, J NEUROCHEM, V71, P2505; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shankar GM, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-48; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Sudol KL, 2009, MOL THER, V17, P2031, DOI 10.1038/mt.2009.174; Szabo P, 2008, AUTOIMMUN REV, V7, P415, DOI 10.1016/j.autrev.2008.03.007; Taguchi H, 2008, J BIOL CHEM, V283, P4714, DOI 10.1074/jbc.M707983200; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; Younkin SG, 2001, NAT MED, V7, P18, DOI 10.1038/83292	55	50	52	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2010	5	11							e13928	10.1371/journal.pone.0013928			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	677ZN	WOS:000284036800019	21085663	Green Published, Green Submitted, gold			2022-02-06	
J	Echlin, PS; Johnson, AM; Riverin, S; Tator, CH; Cantu, RC; Cusimano, MD; Taunton, JE; Upshur, REG; Hall, CR; Forwell, LA; Skopelja, EN				Echlin, Paul Sean; Johnson, Andrew M.; Riverin, Suzanne; Tator, Charles H.; Cantu, Robert C.; Cusimano, Michael D.; Taunton, Jack E.; Upshur, Ross E. G.; Hall, Craig R.; Forwell, Lorie A.; Skopelja, Elaine N.			A prospective study of concussion education in 2 junior ice hockey teams: implications for sports concussion education	NEUROSURGICAL FOCUS			English	Article						concussion; ice hockey; education; Hockey Concussion Education Project; Canada	PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; INJURY PREVENTION; HEAD-INJURY; KNOWLEDGE; COACHES; RETURN; GUIDELINES; BRAIN; VIDEO	Object. The aim of this study was to evaluate the effectiveness of an educational intervention on concussion knowledge within a sample of junior fourth-tier ice hockey players. Methods. A prospective cohort study, called the Hockey Concussion Education Project, was conducted during 1 junior ice hockey regular season (2009-2010) with 67 male fourth-tier ice hockey players (mean age 18.2 +/- 1.2 years, range 16-21 years) from 2 teams. All participating players were randomized into 3 concussion education intervention groups (DVD group, interactive computer module [ICM] group, or control group) before the beginning of the season. Each individual received a preintervention knowledge test prior to the intervention. The DVD and ICM groups received a posttest after the completion of their intervention. All participants were offered the same knowledge test at 15 games (50 days) and 30 games (91 days) later. Results. In the concussion education intervention component no significant group differences were observed at baseline between individuals in the control group and between individuals within the interventional group. At the 15-game follow-up, however, the difference between groups approached significance (F [1,30] = 3.91, p = 0.057). This group difference remained consistent at the 30-game follow-up. Conclusions. This study demonstrates a positive trend concerning concussion education intervention and knowledge acquisition with either the ICMs or the educational DVD. Both forms of intervention produced a positive and sustainable improvement that approached statistical significance when compared with the control group. The control group demonstrated a negative longitudinal trend concerning concussion knowledge. (DOI: 10.3171/2010.9.FOCUS10187)	[Echlin, Paul Sean] AIM Hlth Grp Family Med, London, ON, Canada; [Johnson, Andrew M.] Univ Western Ontario, Fac Hlth Sci, London, ON, Canada; [Riverin, Suzanne] Nipissing Univ, Fac Educ, N Bay, ON, Canada; [Tator, Charles H.; Cusimano, Michael D.] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Taunton, Jack E.] Univ British Columbia, Fac Med, Div Sports Med, Vancouver, BC V5Z 1M9, Canada; [Taunton, Jack E.] Univ British Columbia, Sch Human Kinet, Vancouver, BC V5Z 1M9, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Family, Toronto, ON M5S 1A1, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Community Med, Toronto, ON M5S 1A1, Canada; [Hall, Craig R.] Univ Western Ontario, Sch Kinesiol, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Dept Physiotherapy, London, ON, Canada; [Skopelja, Elaine N.] Indiana Univ, Sch Med Lib, Indianapolis, IN 46204 USA		Echlin, PS (corresponding author), 320 Adelaide St, S London, ON N5Z 3L2, Canada.	p_echlinfp@hotmail.com	Johnson, Andrew M/B-2048-2012; Cusimano, Michael/X-4059-2019	Johnson, Andrew M./0000-0002-7269-3016; Cusimano, Michael/0000-0002-9989-0650; Upshur, Ross/0000-0003-1128-0557	Ontario Trillium Foundation; Dr. Tom Pashby Safety Fund; Dave Irwin Foundation for Brain Injury; Canadian Institutes of Health Strategic Teams in Applied Injury Research	This work was funded by the Ontario Trillium Foundation, the Dr. Tom Pashby Safety Fund, and the Dave Irwin Foundation for Brain Injury. The Ontario Neurotrauma Foundation made administrative and facilitative contributions. Dr. Cusimano is funded by the Canadian Institutes of Health Strategic Teams in Applied Injury Research.	Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; Bonk C. J., 2006, DISTANCE EDUC, V27, P249, DOI DOI 10.1080/01587910600789670; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; Ciavarro C, 2008, COMPUT HUM BEHAV, V24, P2862, DOI 10.1016/j.chb.2008.04.011; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Goodman D, 2006, J ADOLESCENCE, V29, P351, DOI 10.1016/j.adolescence.2005.07.004; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; SCHWARZ A, 2010, NY TIMES        0628; SCHWARZ A, 2010, NY TIMES        1217; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	27	50	50	1	21	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E6	10.3171/2010.9.FOCUS10187			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900007	21039140				2022-02-06	
J	de Sousa, A; McDonald, S; Rushby, J; Li, S; Dimoska, A; James, C				de Sousa, Arielle; McDonald, Skye; Rushby, Jacqueline; Li, Sophie; Dimoska, Aneta; James, Charlotte			Why don't you feel how I feel? Insight into the absence of empathy after severe Traumatic Brain Injury	NEUROPSYCHOLOGIA			English	Article						Emotional empathy; Cognitive empathy; Emotional responsivity; Facial electromyography (EMG); Skin conductance	ANXIETY STRESS SCALES; EMOTIONAL CONTAGION; FACIAL EXPRESSIONS; BEHAVIORAL-CHANGES; MIMICRY; RECOGNITION; DEPRESSION; STATES; MIND	Although the existence of empathy deficits in people with traumatic brain injury (TBI) is generally well accepted it has been a topic of limited investigation The current study examined the relationship between self-reported emotional and cognitive empathy and psychophysiological responding to emotionally evocative pictures in 20 patients with severe TBI and 22 control participants Eighteen pictures with alternating pleasant unpleasant and neutral content selected from the International Affective Picture System (IAPS) were presented whilst facial muscle responses skin conductance and valence and arousal ratings were measured Self-reported emotional and cognitive empathy questionnaires were also administered In comparison to control participants those in the TBI group displayed a reduction in the ability to empathize both emotionally and cognitively and evidence that these two aspects of empathy may be interconnected was established Further TBI participants showed reduced facial responding to unpleasant pictures while also rating them as less unpleasant and arousing than controls In addition they exhibited lowered autonomic arousal to all pictures regardless of affective valence Interestingly hypoarousal to pleasant pictures in particular was found to be related to the absence of empathy observed after TBI and is consistent with the view that impaired emotional responsivity is associated with impairment to the empathy network The results represent a further step towards understanding what processes shape empathy (C) 2010 Elsevier Ltd All rights reserved	[de Sousa, Arielle; McDonald, Skye; Rushby, Jacqueline; Li, Sophie; Dimoska, Aneta; James, Charlotte] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		de Sousa, A (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Rushby, Jacqueline/D-1820-2010; McDonald, Skye/G-4118-2014	Rushby, Jacqueline/0000-0002-5018-638X; McDonald, Skye/0000-0003-0723-6094; Li, Sophie/0000-0002-4762-6911			Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; [Anonymous], 1996, BRIT MED J, V313, P1448; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; BARON CS, 2004, J AUTISM DEV DISORD, V34, P163; Bernat E, 2006, PSYCHOPHYSIOLOGY, V43, P93, DOI 10.1111/j.1469-8986.2006.00380.x; Blair RJR, 2005, CONSCIOUS COGN, V14, P698, DOI 10.1016/j.concog.2005.06.004; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Bradley M.M., 2000, SER AFFECTIVE SCI, P242; Bradley MM, 2001, EMOTION, V1, P276, DOI 10.1037//1528-3542.1.3.276; Britton JC, 2006, NEUROIMAGE, V31, P906, DOI 10.1016/j.neuroimage.2005.12.050; Critchley HD, 2000, J NEUROSCI, V20, P3033; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; *CSEA NIMH, 1999, INT AFF PICT SYST DI; Darwin C., 1998, EXPRESSION EMOTIONS; Davis M.H., 1980, JSAS CATALOG SELECTE, V10, P85; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; DESOUSA A, CORTEX IN PRESS, DOI DOI 10.1016/J.CORTEX.2010.02.004; DIMBERG U, 1982, PSYCHOPHYSIOLOGY, V19, P643, DOI 10.1111/j.1469-8986.1982.tb02516.x; Forster KI, 2003, BEHAV RES METH INS C, V35, P116, DOI 10.3758/BF03195503; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Hariri AR, 2003, BIOL PSYCHIAT, V53, P494, DOI 10.1016/S0006-3223(02)01786-9; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hess U, 2001, INT J PSYCHOPHYSIOL, V40, P129, DOI 10.1016/S0167-8760(00)00161-6; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Lang P. J., 1980, TECHNOLOGY MENTAL HL, P119, DOI DOI 10.1016/J.LINDIF.2013.01.005; Lang P. J., 1999, A4 U FLOR CTR RES PS; Lawrence EJ, 2004, PSYCHOL MED, V34, P911, DOI 10.1017/S0033291703001624; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; MCDONALD S, J CLIN EXPT IN PRESS; Mehrabian A., 2000, MANUAL BALANCED EMOT; Moody EJ, 2007, EMOTION, V7, P447, DOI 10.1037/1528-3542.7.2.447; Muncer SJ, 2006, PERS INDIV DIFFER, V40, P1111, DOI 10.1016/j.paid.2005.09.020; Nummenmaa L, 2008, NEUROIMAGE, V43, P571, DOI 10.1016/j.neuroimage.2008.08.014; ODDY M, 2003, HDB NEUROLOGICAL REH; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; SANCHEZ NJP, 2005, BEHAV NEUROSCI, V119, P87; Saunders JC, 2006, NEUROPSYCHOLOGY, V20, P224, DOI 10.1037/0894-4105.20.2.224; SCHULTE R, 2007, J COGNITIVE NEUROSCI, V19, P1354; SHAMAY TSG, 2008, BRAIN, V132, P617; SHAMAY TSG, 2003, J COGNITIVE NEUROSCI, V15, P1; SHAMAY TSG, 2007, NEUROPSYCHOLOGIA, V45, P3054; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Siegel S., 1956, NONPARAMETRIC STAT B, pXVII, 312; SONNBY BM, 2003, J NONVERBAL BEHAV, V27, P3; Sonnby-Borgstrom M, 2002, SCAND J PSYCHOL, V43, P433, DOI 10.1111/1467-9450.00312; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326	56	50	51	1	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	OCT	2010	48	12					3585	3595		10.1016/j.neuropsychologia.2010.08.008			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	677UM	WOS:000284017300024	20713073				2022-02-06	
J	Wise, EK; Mathews-Dalton, C; Dikmen, S; Temkin, N; Machamer, J; Bell, K; Powell, JM				Wise, Elizabeth K.; Mathews-Dalton, Christine; Dikmen, Sureyya; Temkin, Nancy; Machamer, Joan; Bell, Kathleen; Powell, Janet M.			Impact of Traumatic Brain Injury on Participation in Leisure Activities	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference on American-Occupational-Therapy-Associatioin	APR 10-13, 2008	Long Beach, CA	Amer Occupat Therapy Assoc, Univ Washington Traumatic Brain Injury Model Syst		Brain injuries; Recreation; Rehabilitation; Treatment outcome	QUALITY-OF-LIFE; FUNCTIONAL STATUS EXAMINATION; PHYSICAL-DISABILITIES; OCCUPATIONAL GAPS; EVERYDAY LIFE; ADULTS; SATISFACTION; REHABILITATION; INDIVIDUALS; SYSTEMS	Wise EK, Mathews-Dalton C. Dikmen S, Temkin N, Machamer J, Bell K, Powell JM. Impact of traumatic brain injury on participation in leisure activities. Arch Phys Med Rehabil 2010;91:1357-62. Objective: To determine how participation in leisure activities for people with traumatic brain injury (TBI) changes from before injury to 1 year after injury. Design: Prospective evaluation of leisure participation at 1 year after TBI. Setting: Level I trauma center. Participants: Rehabilitation inpatients (mean age, 35.3 years; 77% male; 77% white) with moderate to severe TBI (N=160). Interventions: Not applicable. Main Outcome Measure: Functional Status Examination. Results: At 1 year after injury, 81% had not returned to preinjury levels of leisure participation. Activities most frequently discontinued included partying, drug and alcohol use, and various sports. The activity most often reported as new after injury was watching television. Of the small fraction who returned to preinjury levels, 70% did so within 4 months of injury. Sixty percent of those who did not return to preinjury levels were moderately to severely bothered by the changes. Conclusions: At 1 year after injury, many TBI survivors engage in a reduced number of leisure activities, which are more sedentary and less social, with a substantial fraction dissatisfied with these changes. While discontinuing some activities may be viewed as a positive change, there are few new ones to replace them.	[Wise, Elizabeth K.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Dikmen, Sureyya; Temkin, Nancy; Machamer, Joan; Bell, Kathleen; Powell, Janet M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Mathews-Dalton, Christine] Shoreline Sch Dist, Shoreline, WA USA		Wise, EK (corresponding author), Univ Washington, Harborview Med Ctr, Box 359819,325 9th Ave, Seattle, WA 98104 USA.	bwise@u.washington.edu		Bell, Kathleen/0000-0002-0928-2046			ALLEN LR, 1982, J LEISURE RES, V14, P307, DOI 10.1080/00222216.1982.11969528; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; *CDCP, 2004, INJ PREV CONTR TRAUM; Chevan J, 2008, J STRENGTH COND RES, V22, P553, DOI 10.1519/JSC.0b013e3181636bee; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Eriksson G, 2006, J REHABIL MED, V38, P159, DOI 10.1080/16501970500415322; Eriksson G, 2009, J REHABIL MED, V41, P187, DOI 10.2340/16501977-0307; Fleiss J.L., 1981, STAT METHODS RATES P; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; *I MED, 2009, GULF WAR HLTH, V7, P301; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Kleiber DA, 2008, NEUROREHABILITATION, V23, P321; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kruger J., 2006, Morbidity and Mortality Weekly Report, V55, P769; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Malley D, 2008, NEUROREHABILITATION, V23, P329; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NIEMI ML, 1988, STROKE, V19, P1101, DOI 10.1161/01.STR.19.9.1101; Reynolds, 1997, BRIT J OCCUPATIONAL, V60, DOI [10.1177/030802269706000806, DOI 10.1177/030802269706000806]; RIDDICK CC, 1986, J LEISURE RES, V18, P259, DOI 10.1080/00222216.1986.11969664; Specht J, 2002, AM J OCCUP THER, V56, P436, DOI 10.5014/ajot.56.4.436; SPREITZER E, 1987, J LEISURE RES, V19, P49; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Taylor LPS, 1996, AM J OCCUP THER, V50, P39, DOI 10.5014/ajot.50.1.39; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; TINSLEY HEA, 1984, J LEISURE RES, V16, P234; UDD E, 1990, LEISURE CHALLENGES B; Viemero V, 1998, PSYCHOTHER PSYCHOSOM, V67, P317, DOI 10.1159/000012297; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; 2003, DICT COMS 21 CENTURY	35	50	50	1	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2010	91	9					1357	1362		10.1016/j.apmr.2010.06.009			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	651IM	WOS:000281921400007	20801252				2022-02-06	
J	Sigurdardottir, S; Jerstad, T; Andelic, N; Roe, C; Schanke, AK				Sigurdardottir, Solrun; Jerstad, Tone; Andelic, Nada; Roe, Cecilie; Schanke, Anne-Kristine			Olfactory Dysfunction, Gambling Task Performance and Intracranial Lesions After Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						neuropsychology; frontal lesions; anosmia; Iowa Gambling Task; MRI	VENTROMEDIAL PREFRONTAL CORTEX; DECISION-MAKING; WORKING-MEMORY; DAMAGE; INDIVIDUALS; PREDICTORS; AMBIGUITY; ANOSMIA	Objective: To estimate the incidence of olfactory dysfunction across traumatic brain injury (TBI) severity and decision-making deficits with regard to intracranial lesions' location and laterality. Method: A 1-year prospective study including 115 participants (16-55 years) with mild, moderate, and severe TBI. The Brief Smell Identification Test was used 3 months postinjury with a follow-up testing of olfactory dysfunction at I year. The Iowa Gambling Task (IGT) and 3 tasks of the Delis-Kaplan Executive Function System were administered 3-months postinjury. MRI was performed 1-year postinjury and TBI severity groups were then divided with respect to frontal, fronto-temporal, diffuse, and no lesions. Results: The incidence of olfactory dysfunction was estimated to be 22.3% at 3 months and 13.5% at I year. No significant differences were found on olfactory dysfunction across TBI severity at either check. Anosmia was identified in 10% with severe TBI and 3% with mild TBI. Olfactory dysfunction was associated with verbal fluency tasks. Repeated-measures analysis of variance revealed no significant effect over blocks on IGT, and no main group or interaction effects regarding TBI severity, lesions' location, or laterality. IGT performance at 3-months postinjury was deficient in 83% of persons with intracranial lesions and 71% of those without lesions. Conclusions: Olfactory dysfunction is independent of TBI severity, showing improvements in one third of cases from 3- to 12-months postinjury. However. anosmia was related to TBI severity. There is evidence for marked decision-making deficits after TBI, all subgroups performed similarly and failed to develop an advantageous strategy over time.	[Sigurdardottir, Solrun; Schanke, Anne-Kristine] Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; [Sigurdardottir, Solrun; Andelic, Nada; Roe, Cecilie; Schanke, Anne-Kristine] Univ Oslo, N-0316 Oslo, Norway; [Jerstad, Tone] Oslo Univ Hosp, Dept Neuroradiol, Ulleval, Norway; [Andelic, Nada; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway		Sigurdardottir, S (corresponding author), Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway.	solrun.sigurdardottir@sunnaas.no		Andelic, Nada/0000-0002-3719-4406	South-Eastern Norway Regional Health Authority	This study was supported by grants from the South-Eastern Norway Regional Health Authority. Special thanks to all participants, to Antoine Bechara for providing the University of Oslo with a copy of the Iowa Gambling Task, and to Susan Schanche for the proofreading the English text. There were no competing interests.	Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI 10.1016/S0028-3932(02)00015-5; Bechara A, 2004, NEUROPSYCHOLOGY, V18, P152, DOI 10.1037/0894-4105.18.1.152; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Bechara A, 2005, TRENDS COGN SCI, V9, P159, DOI 10.1016/j.tics.2005.02.002; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1999, J NEUROSCI, V19, P5473; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bonatti E, 2008, COGN BEHAV NEUROL, V21, P164, DOI 10.1097/WNN.0b013e318184e688; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Brand M, 2007, J CLIN EXP NEUROPSYC, V29, P86, DOI 10.1080/13803390500507196; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Costanzo R. M., 1992, J HEAD TRAUMA REHAB, V7, P15, DOI DOI 10.1097/00001199-199203000-00005; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Doty R.L., 2001, BRIEF SMELL IDENTIFI; Doty RL, 2007, AM J RHINOL, V21, P460, DOI 10.2500/ajr.2007.21.3043; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Grant S, 2000, NEUROPSYCHOLOGIA, V38, P1180, DOI 10.1016/S0028-3932(99)00158-X; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Haxel BR, 2008, J HEAD TRAUMA REHAB, V23, P407, DOI 10.1097/01.HTR.0000341437.59627.ec; Jollant F, 2007, EUR PSYCHIAT, V22, P455, DOI 10.1016/j.eurpsy.2007.06.001; Krantz EM, 2009, CHEM SENSES, V34, P435, DOI 10.1093/chemse/bjp018; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Malloy-Diniz L, 2007, J INT NEUROPSYCH SOC, V13, P693, DOI 10.1017/S1355617707070889; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Haaland VO, 2007, J INT NEUROPSYCH SOC, V13, P699, DOI 10.1017/S1355617707070890; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Santos DV, 2004, ARCH OTOLARYNGOL, V130, P317, DOI 10.1001/archotol.130.3.317; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Smeding HMM, 2007, J NEUROL NEUROSUR PS, V78, P517, DOI 10.1136/jnnp.2006.102061; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; Zamarian L, 2008, NEUROPSYCHOLOGY, V22, P645, DOI 10.1037/0894-4105.22.5.645	46	50	52	0	11	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2010	24	4					504	513		10.1037/a0018934			10	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	619HN	WOS:000279420500009	20604624				2022-02-06	
J	Rubovitch, V; Edut, S; Sarfstein, R; Werner, H; Pick, CG				Rubovitch, Vardit; Edut, Shahaf; Sarfstein, Rive; Werner, Haim; Pick, Chaim G.			The intricate involvement of the Insulin-like growth factor receptor signaling in mild traumatic brain injury in mice	NEUROBIOLOGY OF DISEASE			English	Article						mTBI; IGF-1R; Akt; ERK1/2; Spatial memory; Y-maze test	MINOR HEAD-INJURY; CELL-SURVIVAL; AKT PHOSPHORYLATION; COGNITIVE DEFICITS; FACTOR-I; RATS; DEATH; IGF-1; APOPTOSIS; ACTIVATION	Insulin-like growth factor-1 (IGF-1) was suggested as a potential neuroprotective treatment for traumatic brain injury (TBI) induced damage (cognitive as well as cellular). The main goal of the present study was to evaluate the role of the IGF-1R activation in spatial memory outcome following mild traumatic brain injury. mTBI-induced phosphorylation of IGF-1R, AKT and ERK1/2, in mice hippocampus, which was inhibited when mice were pretreated with the selective IGF-1R inhibitor AG1024. IGF-1 administration prevented spatial memory deficits following mTBI. Surprisingly, blocking the IGF-1R signaling in mTBI mice did not augment the spatial memory deficit. In addition, this data imply an intriguing and complex role of the IGF-1 signaling axis in the cellular and behavioral events following mTBI. (C) 2010 Elsevier Inc. All rights reserved.	[Rubovitch, Vardit; Edut, Shahaf; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Sarfstein, Rive; Werner, Haim] Tel Aviv Univ, Sackler Fac Med, Dep Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel		Pick, CG (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il			Adams Super Center for Brain Studies, Sackler Faculty of Medicine, Tel Aviv University	This work was supported by the Adams Super Center for Brain Studies, Sackler Faculty of Medicine, Tel Aviv University.	Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; ALEMAN A, 2009, PROG NEUROBIOL; BARATZ RR, J NEUROTRAU IN PRESS; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Carter CS, 2002, TRENDS GENET, V18, P295, DOI 10.1016/S0168-9525(02)02696-3; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; EDUT SRV, 2008, ISR SOC NEUR 17 ANN; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; FRANK TF, 2008, J NEUROPATHOL EXP NE, V59, P641; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lin SY, 2009, EXP NEUROL, V217, P361, DOI 10.1016/j.expneurol.2009.03.021; MADATHIL KS, 2009, J NEUROTRAUMA; Margulies S, 2000, J CLIN NEUROSCI, V7, P495, DOI 10.1054/jocn.1999.0773; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sawatzky DA, 2006, AM J PATHOL, V168, P33, DOI 10.2353/ajpath.2006.050058; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Tang BL, 2006, NEUROBIOL AGING, V27, P501, DOI 10.1016/j.neurobiolaging.2005.02.001; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	37	50	52	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAY	2010	38	2			SI		299	303		10.1016/j.nbd.2010.01.021			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	590UN	WOS:000277253900019	20138993				2022-02-06	
J	Ciurli, P; Bivona, U; Barba, C; Onder, G; Silvestro, D; Azicnuda, E; Rigon, J; Formisano, R				Ciurli, Paola; Bivona, Umberto; Barba, Carmen; Onder, Graziano; Silvestro, Daniela; Azicnuda, Eva; Rigon, Jessica; Formisano, Rita			Metacognitive unawareness correlates with executive function impairment after severe traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Executive functions; Metacognitive self-awareness; Perseverative errors; Severe TBI; Neuropsychological rehabilitation; SA assessment	COMPETENCE RATING-SCALE; CLOSED-HEAD-INJURY; SELF-AWARENESS; BEHAVIORAL LIMITATIONS; PRACTICAL SCALE; REHABILITATION; DEFICITS; ADULTS; COMA; CONSCIOUSNESS	The aim of this study was to evaluate clinical, neuropsychological, and functional differences between severe traumatic brain injury (TBI) outpatients with good and/or heightened metacognitive self-awareness (SA) and those with impaired metacognitive SA, assessed by the Patient Competency Rating Scale (PCRS). Fifty-two outpatients were recruited from a neurorehabilitation hospital based on the following inclusion criteria: 1) age ? 15 years; 2) diagnosis of severe TBI: 3) availability of neuroimaging data; 4) post-traumatic amnesia resolution; 5) provision of informed consent. Measures: A neuropsychological battery was used to evaluate attention, memory and executive functions. SA was assessed by the PCRS. which was administered to patients and close family members. Patients were divided into two groups representing those with and without SA. Patients with poor SA had more problems than those with good SA in some components of the executive system. as indicated by the high percentage of perseverative errors and responses they made on the Wisconsin Card Sorting Test. Moreover. a decrease in metacognitive SA correlated significantly with time to follow commands (TFC). This study suggests the importance of integrating an overall assessment of cognitive functions with a specific evaluation of SA to treat self-awareness and executive functions together during, the rehabilitation process. (JINS, 2010, 16, 360-368.)	[Ciurli, Paola] Fdn Santa Lucia, Serv Diag & Riabilitaz Neuropsicol, Postcoma Unit, I-00179 Rome, Italy; [Barba, Carmen] Childrens Hosp Meyer, Pediat Neurol Unit, Florence, Italy; [Onder, Graziano] Catholic Univ, Dept Geriatr, Rome, Italy; [Rigon, Jessica] San Camillo Hosp, Dept Neuropsychol, Venice Lido, Italy		Ciurli, P (corresponding author), Fdn Santa Lucia, Serv Diag & Riabilitaz Neuropsicol, Postcoma Unit, Via Ardeatina 306, I-00179 Rome, Italy.	p.ciurli@hsantalucia.it	Azicnuda, Eva/K-9010-2016; barba, carmen/K-4942-2016; Barba, Carmen/AAB-7162-2022	barba, carmen/0000-0001-5445-5842; 			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; APOLLONIO I, 2005, J NEUROL SCI, V26, P108; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Basso A, 1987, Funct Neurol, V2, P189; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; CICERONE KD, 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; CROSSON C, 1989, J HEAD TRAUMA REHAB, V4, P46; DERENZI E, 1962, BRAIN, V85, P556, DOI DOI 10.1093/BRAIN/85.4.665; Dirette DK, 2007, BRAIN INJURY, V21, P1131, DOI 10.1080/02699050701687326; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Flashman, 1998, Semin Clin Neuropsychiatry, V3, P201; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Formisano R, 2005, ACT NEUR S, V93, P201; Hagen C., 1972, LEVELS COGNITIVE FUN; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P285, DOI 10.1097/00001199-200507000-00001; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HEATON RK, 2000, ORG SPECIALI; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Hoofien D, 2006, ISR J PSYCHIATR REL, V43, P296; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mukhopadhyay P, 2008, PROG BRAIN RES, V168, P95, DOI 10.1016/S0079-6123(07)68008-X; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Orsini A., 2003, B PSICOL APPL, V239, P73; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1991, BNI Q, V7, P27; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROUECHE JR, 1987, COGNITIVE REHABILITA, V1, P4; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; TEASDALE G, 1974, LANCET, V2, P81; Toglia J, 2000, NEUROREHABILITATION, V15, P57; TRUDEL TM, 1998, REHABIL PSYCHOL, V43, P276; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zimmerman P., 1992, TEST BATTERIE AUFMER	71	50	51	0	19	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2010	16	2					360	368		10.1017/S135561770999141X			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	562DZ	WOS:000275030900017	20109243				2022-02-06	
J	Filanovsky, Y; Miller, P; Kao, J				Filanovsky, Yevgeny; Miller, Philip; Kao, Jesse			Myth: Ketamine should not be used as an induction agent for intubation in patients with head injury	CANADIAN JOURNAL OF EMERGENCY MEDICINE			English	Article						ketamine; head injury; intracranial pressure; rapid sequence intubation	CEREBRAL-BLOOD-FLOW; CEREBROSPINAL-FLUID PRESSURE; TRAUMATIC BRAIN INJURY; PERFUSION-PRESSURE; ANESTHESIA; ISCHEMIA; VOLUME; CONTUSIONS; S(+)-KETAMINE; HEMODYNAMICS		[Filanovsky, Yevgeny] Nanaimo Gen Reg Hosp, Emergency Dept, Nanaimo, BC V9S 2B7, Canada; [Miller, Philip] Univ Toronto, Dept Emergency Med, Toronto, ON, Canada; [Kao, Jesse] Univ British Columbia, Dept Emergency Med, Vancouver, BC V5Z 1M9, Canada		Filanovsky, Y (corresponding author), Nanaimo Gen Reg Hosp, Emergency Dept, 1200 Dufferin Cres, Nanaimo, BC V9S 2B7, Canada.	yfilanov@mac.com					BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bourgoin A, 2005, CRIT CARE MED, V33, P1109, DOI 10.1097/01.CCM.0000162491.26292.98; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chieregato A, 2003, ACTA NEUROCHIR SUPPL, V86, P361; Chieregato A, 2007, NEUROSURGERY, V60, P115, DOI 10.1227/01.NEU.0000249194.76527.28; den Brinker M, 2005, J CLIN ENDOCR METAB, V90, P5110, DOI 10.1210/jc.2005-1107; GARDNER AE, 1971, ANESTHESIOLOGY, V35, P226, DOI 10.1097/00000542-197108000-00029; GARDNER AE, 1972, ANESTH ANAL CURR RES, V51, P741; GIBBS JM, 1972, BRIT J ANAESTH, V44, P1298, DOI 10.1093/bja/44.12.1298; Himmelseher S, 2005, ANESTH ANALG, V101, P524, DOI 10.1213/01.ANE.0000160585.43587.5B; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; HOFFMAN WE, 1992, ANESTHESIOLOGY, V76, P755, DOI 10.1097/00000542-199205000-00014; Jackson WL, 2005, CHEST, V127, P1031, DOI 10.1378/chest.127.3.1031; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; LIST WF, 1972, ANESTHESIOLOGY, V36, P98, DOI 10.1097/00000542-197201000-00023; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MILLER RD, 2005, MILLERS ANESTHESIA, P346; Nagels W, 2004, ANESTH ANALG, V98, P1595, DOI 10.1213/01.ANE.0000117227.00820.0C; Schmittner MD, 2007, J NEUROSURG ANESTH, V19, P257, DOI 10.1097/ANA.0b013e31811f3feb; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Schroder ML, 1998, ACT NEUR S, V71, P127; Sehdev Rajesh S, 2006, Emerg Med Australas, V18, P37; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; Sivilotti Marco L A, 2006, CJEM, V8, P351; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; TINTINALLI J, 2004, EMERGEN MED, P113; TINTINALLI J, 2004, EMERGEN MED, P114; TINTINALLI J, 2004, EMERGEN MED, P279; Walls RM, 2008, ANN EMERG MED, V52, P13, DOI 10.1016/j.annemergmed.2008.01.001; WYTE SR, 1972, ANESTHESIOLOGY, V36, P174, DOI 10.1097/00000542-197202000-00021	35	50	53	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1481-8035	1481-8043		CAN J EMERG MED	Can. J. Emerg. Med.	MAR	2010	12	2					154	157					4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	573UV	WOS:000275941600009	20219164				2022-02-06	
J	Sandler, SJI; Figaji, AA; Adelson, PD				Sandler, Simon J. I.; Figaji, Anthony A.; Adelson, P. David			Clinical applications of biomarkers in pediatric traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						Biomarkers; Traumatic brain injury; Children; S100B	NEURON-SPECIFIC-ENOLASE; SEVERE HEAD-INJURY; COMPUTED-TOMOGRAPHY FINDINGS; S-100 PROTEIN MEASUREMENTS; FIBRILLARY ACIDIC PROTEIN; BILATERAL FEMUR FRACTURE; URINARY S100B PROTEIN; GLASGOW-COMA-SCALE; CEREBROSPINAL-FLUID; SERUM S100B	The diagnosis, treatment, and prediction of outcome in pediatric traumatic brain injury (TBI) present significant challenges to the treating clinician. Clinical and radiological tools for assessing injury severity and predicting outcome, in particular, lack sensitivity and specificity. In patients with mild TBI, often there is uncertainty about which patients should undergo radiological imaging and who is at risk for long term neurological sequelae. In severe TBI, often there is uncertainty about which patients will experience secondary insults and what the outcome for individual patients will be. In several other clinical specialties, biomarkers are used to diagnose disease, direct treatment, and prognosticate. However, an ideal biomarker for brain injury has not been found. In this review, we examine the various factors that must be taken into account in the search for a reliable biomarker in brain injury. We review the important studies that have investigated common biomarkers of structural brain injury, in particular S100B, neuron-specific enolase, myelin basic protein, and glial fibrillary acid protein. The potential uses and limitations of these biomarkers in the context of TBI are discussed.	[Figaji, Anthony A.] Red Cross Childrens Hosp, ZA-7700 Rondebosch, Cape Town, South Africa; [Adelson, P. David] Phoenix Childrens Neurosci Inst, Phoenix, AZ USA; [Sandler, Simon J. I.; Figaji, Anthony A.] Univ Cape Town, Red Cross War Mem Childrens Hosp, Div Neurosurg, Sch Child & Adolescent Hlth, ZA-7925 Cape Town, South Africa		Figaji, AA (corresponding author), Red Cross Childrens Hosp, 617 ICH Bldg,Klipfontein Rd, ZA-7700 Rondebosch, Cape Town, South Africa.	Anthony.Figaji@uct.ac.za	Adelson, David/W-2083-2019	Sandler, Simon/0000-0002-1887-8677; Figaji, Anthony/0000-0002-3357-6490	South African-Swedish Links Program [GUN 2072790]	This work was supported in part by a grant from the South African-Swedish Links Program (GUN 2072790).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson PD, 1998, ACT NEUR S, V71, P250; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Castellani C, 2008, CLIN CHEM LAB MED, V46, P1296, DOI 10.1515/CCLM.2008.262; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Figaji AA, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E4; Gazzolo D, 2005, PEDIATR RES, V58, P1170, DOI 10.1203/01.pdr.0000185131.22985.30; Gazzolo D, 2004, CLIN CHEM, V50, P941, DOI 10.1373/clinchem.2003.021048; Gazzolo D, 2004, CRIT CARE MED, V32, P131, DOI 10.1097/01.CCM.0000104116.91462.CD; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Gazzolo Diego, 2009, Cardiovascular & Hematological Agents in Medicinal Chemistry, V7, P108; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hatpio R, 2004, CLIN BIOCHEM, V37, P512, DOI 10.1016/j.clinbiochem.2004.05.012; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; KIRINO T, 1983, J NEUROSCI, V3, P915; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lo TYM, 2009, J NEUROTRAUM, V26, P1479, DOI [10.1089/neu.2008.0753, 10.1089/neu.2008-0753]; Lomas JP, 2005, EMERG MED J, V22, P889, DOI 10.1136/emj.2005.031732; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Mazzini GS, 2009, RESUSCITATION, V80, P144, DOI 10.1016/j.resuscitation.2008.08.024; Meybohm P, 2008, RESUSCITATION, V76, P449, DOI 10.1016/j.resuscitation.2007.09.002; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Park ES, 2000, YONSEI MED J, V41, P328, DOI 10.3349/ymj.2000.41.3.328; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pickering A, 2008, EMERG MED J, V25, P88, DOI 10.1136/emj.2007.046631; Portela LVC, 2002, CLIN CHEM, V48, P950; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Spinella Philip C, 2004, Pediatr Crit Care Med, V5, P53, DOI 10.1097/01.PCC.0000102221.98378.7D; Steiner J, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-2; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Subbaswamy A, 2009, NEUROCRIT CARE, V10, P129, DOI 10.1007/s12028-008-9122-7; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2009, SCAND J CLIN LAB INV, V69, P13, DOI 10.1080/00365510802651833; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wright NT, 2008, J BIOMOL NMR, V42, P279, DOI 10.1007/s10858-008-9282-y	78	50	57	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	FEB	2010	26	2					205	213		10.1007/s00381-009-1009-1			9	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	539GK	WOS:000273241700011	19902222				2022-02-06	
J	Snell, FI; Halter, MJ				Snell, Frances I.; Halter, Margaret Jordan			A SIGNATURE WOUND OF WAR Mild Traumatic Brain Injury	JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES			English	Article								Improvised explosive devices are the weapons of choice for the insurgent enemy in Iraq and Afghanistan. More soldiers are surviving these blast injuries due to improved torso protection yet are sustaining head and neck wounds in numbers that exceed those from previous wars. Although moderate and severe traumatic head injuries are easily identified and aggressively treated, mild traumatic brain injuries (m-TBIs), or concussions, had previously been deemed inconsequential and often overlooked. Recently, however, the U.S. Department of Defense and Veterans Health Administration have placed emphasis on identifying service members at risk for m-TBI because a select number continue to have disabling symptoms that can negatively affect quality of life. Research regarding the effects and treatment of blast injury are gaining momentum, but further work needs to be accomplished. This article provides a three-question screening tool that can be used to identify these at-risk veterans.	[Snell, Frances I.] Akron Community Based Outpatient Clin, Louis Stokes Cleveland VA Med Ctr, Akron, OH USA; [Halter, Margaret Jordan] Univ Akron, Coll Nursing, Akron, OH 44325 USA; [Snell, Frances I.] USA Reserves, Combat Support Hosp 256, Twinsburg, OH USA		Snell, FI (corresponding author), Akron VA Outpatient Clin, 55 W Waterloo Rd, Akron, OH 44319 USA.	Frances.Snell@va.gov					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; *DEF VET BRAIN INJ, 2005, C PROGR SERV MEMB VE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kudler Harold, 2008, N C Med J, V69, P39; LAMANCE R, 2009, MULLEN ADDRESSES SUI; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; President's Commission on Care for America's Returning Wounded Warriors, 2007, SERV SUPP SIMPL REP; Schwab KA, 2006, NEUROLOGY, V66, pA235; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T., 2008, INVISIBLE WOUNDS WAR; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *US GOV ACC OFF, 2008, PUBL US GOV ACC OFF; 2007, PTSD M TBI CHAIN TEA	19	50	50	0	8	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0279-3695	1938-2413		J PSYCHOSOC NURS MEN	J. Psychosoc. Nurs. Ment. Health Serv.	FEB	2010	48	2					22	28		10.3928/02793695-20100108-02			7	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	556IG	WOS:000274583700007	20166653				2022-02-06	
J	Green, W; Ciuffreda, KJ; Thiagarajan, P; Szymano-wicz, D; Ludlam, DP; Kapoor, N				Green, Wesley; Ciuffreda, Kenneth J.; Thiagarajan, Preethi; Szymano-wicz, Dora; Ludlam, Diana P.; Kapoor, Neera			Accommodation in mild traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						accommodation; accommodative dysfunction; brain injury; head injury; rehabilitation; TBI; traumatic brain injury; vision; vision rehabilitation; visual dysfunction	HEAD TRAUMA; CONVERGENCE INSUFFICIENCY; SYSTEM; REHABILITATION; SPASM; VERGENCE; FACILITY; WHIPLASH; MODEL	Accommodative dysfunction in individuals with mild traumatic brain injury (mTBI) can have a negative impact on quality of life, functional abilities, and rehabilitative progress. In this study, we used a range of dynamic and static objective laboratory and clinical measurements of accommodation to assess 12 adult patients (ages 18-40 years) with mTBI. The results were compared with either 10 control subjects with no visual impairment or normative literature values where available. Regarding the dynamic parameters, responses in those with mTBI were slowed and exhibited fatigue effects. With respect to static parameters, reduced accommodative amplitude and abnormal accommodative interactions were found in those with mTBI. These results provide further evidence for the substantial impact of mTBI on accommodative function. These findings suggest that a range of accommodative tests should be included in the comprehensive vision examination of individuals with mTBI.	[Green, Wesley; Ciuffreda, Kenneth J.; Thiagarajan, Preethi; Szymano-wicz, Dora; Ludlam, Diana P.] SUNY, Dept Vis Sci, State Coll Optometry, New York, NY 10036 USA; [Kapoor, Neera] SUNY Coll Optometry, Dept Clin Sci, New York, NY 10036 USA		Ciuffreda, KJ (corresponding author), SUNY, Dept Vis Sci, State Coll Optometry, 33 W 42nd St, New York, NY 10036 USA.	kciuffreda@sunyopt.edu			SUNY/State College of Optometry	This material is the result of work supported with resources of the Graduate Studies Program at SUNY/State College of Optometry.	ALQURAINY IA, 1995, BRIT J ORAL MAX SURG, V33, P71, DOI 10.1016/0266-4356(95)90203-1; Benjamin WT.., 2006, BORISHS CLIN REFRACT; BOHLMANN BJ, 1987, J CLIN NEURO-OPHTHAL, V7, P129; Brown S, 2003, CLIN EXP OPHTHALMOL, V31, P424, DOI 10.1046/j.1442-9071.2003.00690.x; BURKE JP, 1992, GRAEF ARCH CLIN EXP, V230, P335, DOI 10.1007/BF00165941; Chan RVP, 2002, J NEURO-OPHTHALMOL, V22, P15, DOI 10.1097/00041327-200203000-00005; Ciuffreda K. J, 2006, BORISHS CLIN REFRACT, V2nd, P77, DOI DOI 10.1016/B978-0-7506-7524-6.50009-0; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda KJ, 2006, NEUROREHABILITATION, V21, P9; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; Ciuffreda KJ, 2001, VISUAL VESTIBULAR CO, P77; Ciufredda KJ, 2009, OPTOM VIS DEV, V40, P16; Duane A, 1922, Trans Am Ophthalmol Soc, V20, P132; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; GILMARTIN B, 1986, OPHTHAL PHYSL OPT, V6, P23, DOI 10.1016/0275-5408(86)90115-8; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Griffin JR., 2002, BINOCULAR ANOMALIES, V4th ed; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002; Harrison RJ., 1987, BINO VIS, V2, P93; HEATH G G, 1956, Am J Optom Arch Am Acad Optom, V33, P569; Hung GK, 1996, OPHTHAL PHYSL OPT, V16, P31, DOI 10.1016/0275-5408(95)00110-7; HUNG GK, 1986, IEEE T BIO-MED ENG, V33, P1021, DOI 10.1109/TBME.1986.325868; HUNG GK, 1988, OPHTHAL PHYSL OPT, V8, P327, DOI 10.1016/0275-5408(88)90183-4; KAWASAKI T, 1993, BRIT J OPHTHALMOL, V77, P678, DOI 10.1136/bjo.77.10.678; KOWAL L, 1992, AUST NZ J OPHTHALMOL, V20, P35, DOI 10.1111/j.1442-9071.1992.tb00701.x; Leslie S., 2001, VISUAL VESTIBULAR CO, P56; Levine S, 1985, J Am Optom Assoc, V56, P286; Monteiro MLR, 2003, BRIT J OPHTHALMOL, V87, P243, DOI 10.1136/bjo.87.2.243; Morgan M. W. J., 1944, OPTOMETRY VISION SCI, V21, P183; Ohtsuka K, 2002, AM J OPHTHALMOL, V133, P425, DOI 10.1016/S0002-9394(01)01356-3; Ohtsuka K, 1997, BRIT J OPHTHALMOL, V81, P476, DOI 10.1136/bjo.81.6.476; OHTSUKA K, 1988, AM J OPHTHALMOL, V106, P60, DOI 10.1016/S0002-9394(14)76389-5; Rabbetts RB, 2007, BENNETT RABBETTS CLI; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; Roca P D, 1972, Ann Ophthalmol, V4, P63; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Scheiman M, 2001, VISUAL VESTIBULAR CO, P89; SIDEROV J, 1990, OPTOMETRY VISION SCI, V67, P551, DOI 10.1097/00006324-199007000-00014; SIDEROV J, 1991, OPTOMETRY VISION SCI, V68, P49, DOI 10.1097/00006324-199101000-00008; STEPHENS KG, 1985, AM J OPTOM PHYS OPT, V62, P402; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Wick, 2002, CLIN MANAGEMENT BINO	44	50	50	0	17	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2010	47	3					183	199		10.1682/JRRD.2009.04.0041			17	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	609JL	WOS:000278652400004	20665345	Bronze			2022-02-06	
J	Kennedy, JE; Cullen, MA; Amador, RR; Huey, JC; Leal, FO				Kennedy, Jan E.; Cullen, Maren A.; Amador, Ricardo R.; Huey, Judith C.; Leal, Felix O.			Symptoms in military service members after blast mTBI with and without associated injuries	NEUROREHABILITATION			English	Article						Mild traumatic brain injury; blast injury; PTSD; associated injuries; PCS	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; PTSD CHECKLIST; PSYCHOMETRIC PROPERTIES; CIVILIAN VERSION; PREVALENCE; VETERANS; IRAQ; PCL	Traumatic combat events can lead to neurobehavioral and stress-related symptoms among military troops. Physical injuries received during combat are associated with increased symptom report [8]. The effect of a concurrent mild traumatic brain injury (mTBI) on this relationship is unknown and forms the basis for this report. Subjects included a cohort of 274 male service members who received a blast-related mTBI during deployment in Iraq. They completed symptom ratings on the Posttraumatic Stress Disorder Checklist-Civilian version (PCL-C) and Neurobehavioral Symptom Inventory (NSI). Service members with mTBI, but no other associated physical injuries had higher symptom ratings than those who received mTBI plus associated injuries. Results suggest that in the presence of an invisible injury, such as mTBI, associated bodily injuries may be at least partially protective against the development of stress and neurobehavioral symptoms. It is proposed that an invisible wound, such as mTBI, creates ambiguity regarding the etiology of symptoms and expected course of recovery and leads to increased emotional and somatic symptom report. However, the observable nature of an associated physical injury and the systematic rehabilitation involved in recovery from such an injury provide a focus for attention and measurable progress toward recovery that serve to reduce emotionally-based symptom reports.	[Kennedy, Jan E.; Cullen, Maren A.; Amador, Ricardo R.; Huey, Judith C.; Leal, Felix O.] San Antonio Mil Med Ctr, Def & Vet Brain Injury Ctr, San Antonio, TX USA		Kennedy, JE (corresponding author), Wilford Hall USAF Med Ctr, DVBIC, 59 MDOS SGO5N,2200 Berquist Dr Suite 1, Lackland AFB, TX 78236 USA.	jan.kennedy@lackland.af.mil					Andrykowski MA, 1998, J CONSULT CLIN PSYCH, V66, P586, DOI 10.1037/0022-006X.66.3.586; *ASS ADV AUT MED, 2007, ABBR INJ SCAL 2005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; PITMAN RK, 1989, AM J PSYCHIAT, V146, P667; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Steinmann M, 2009, ALTRUISM RECONSIDERE, P1; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; WEATHERS FW, 1993, PTSD CHECKLIST PCL D	19	50	50	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2010	26	3					191	197		10.3233/NRE-2010-0555			7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	603OQ	WOS:000278218300003	20448309				2022-02-06	
J	Molenberghs, P; Gillebert, CR; Schoofs, H; Dupont, P; Peeters, R; Vandenberghe, R				Molenberghs, Pascal; Gillebert, Celine R.; Schoofs, Hanne; Dupont, Patrick; Peeters, Ronald; Vandenberghe, Rik			Lesion neuroanatomy of the Sustained Attention to Response task	NEUROPSYCHOLOGIA			English	Article						Inferior frontal; Stroke; Cognitive control; Go no-go	ANTERIOR CINGULATE CORTEX; FRONTAL-LOBE; PREFRONTAL CORTEX; COGNITIVE CONTROL; CONFLICT; GO; DISSOCIATION; PERFORMANCE; INHIBITION; PARIETAL	The Sustained Attention to Response task is a classical neuro psychological test that has been used by many centres to characterize the attentional deficits in traumatic brain injury, ADHD, autism and other disorders. During the SART a random series of digits 1-9 is presented repeatedly and subjects have to respond to each digit (go trial) except the digit '3' (no-go trial). Using voxel-based lesion symptom mapping (VLSM) in a consecutive series of 44 ischemic unifocal non-lacunar hemispheric stroke patients we determined the neuroanatomy of 4 SART parameters: commission and omission error rate, reaction time variability and post-error slowing. Lesions of the right inferior frontal gyrus significantly increased commission error rate. Lesions of the middle third of the right inferior frontal sulcus (IFS) reduced post-error slowing, a measure of how well subjects can utilize errors to adjust cognitive resource allocation. Omissions and reaction time variability had less localising value in our sample. To conclude, commission errors and post-error slowing in the SART mainly probe right inferior frontal integrity. (C) 2009 Elsevier Ltd. All rights reserved.	[Schoofs, Hanne; Vandenberghe, Rik] Univ Hosp Leuven, Dept Neurol, B-3000 Louvain, Belgium; [Molenberghs, Pascal; Gillebert, Celine R.; Dupont, Patrick; Vandenberghe, Rik] Katholieke Univ Leuven, Expt Neurol Sect, Cognit Neurol Lab, Louvain, Belgium; [Peeters, Ronald] Univ Hosp Leuven, Dept Radiol, B-3000 Louvain, Belgium		Vandenberghe, R (corresponding author), Univ Hosp Leuven, Dept Neurol, Herestr 49, B-3000 Louvain, Belgium.	rik.vandenberghe@uz.kuleuven.ac.be	Molenberghs, Pascal/C-8176-2009; Vandenberghe, Rik/K-2145-2014; Gillebert, Celine/J-4177-2012; Dupont, Patrick/B-8044-2009; Vandenberghe, Rik/AAR-7485-2020	Molenberghs, Pascal/0000-0003-0350-6659; Vandenberghe, Rik/0000-0001-6237-2502; Dupont, Patrick/0000-0003-1980-2540; Vandenberghe, Rik/0000-0001-6237-2502; Gillebert, Celine/0000-0001-6686-7262	FWOFWO [G.0076.02, G0668.07]; KU Leuven ResearchKU Leuven [OT/04/41, EF/05/014]; Inter-University Attraction PoleBelgian Federal Science Policy Office [P6/29]; Flanders (Belgium)	Supported by FWO grants G.0076.02 and G0668.07 (EuroCores) (R.V.), KU Leuven Research grants OT/04/41 and EF/05/014 (R.V.), and Inter-University Attraction Pole P6/29. R.V. is a Clinical Investigator of the Fund for Scientific Research (FWO), Flanders (Belgium), and CRG an FWO research fellow.	Alexander MP, 2007, NEUROLOGY, V68, P1515, DOI 10.1212/01.wnl.0000261482.99569.fb; Alexander MP, 2005, NEUROLOGY, V65, P572, DOI 10.1212/01.wnl.0000172912.07640.92; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; Bellgrove MA, 2006, CORTEX, V42, P838, DOI 10.1016/S0010-9452(08)70426-X; Bender M.B, 1952, DISORDERS PERCEPTION; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; Brunner E, 2000, BIOMETRICAL J, V42, P17, DOI 10.1002/(SICI)1521-4036(200001)42:1<17::AID-BIMJ17>3.0.CO;2-U; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Chambers CD, 2006, J COGNITIVE NEUROSCI, V18, P444, DOI 10.1162/jocn.2006.18.3.444; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050110034325; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Crawford JR, 1998, CLIN NEUROPSYCHOL, V12, P482, DOI 10.1076/clin.12.4.482.7241; Derrfuss J, 2005, HUM BRAIN MAPP, V25, P22, DOI 10.1002/hbm.20127; DREWE EA, 1975, NEUROPSYCHOLOGIA, V13, P421, DOI 10.1016/0028-3932(75)90065-2; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Fellows LK, 2005, BRAIN, V128, P788, DOI 10.1093/brain/awh405; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Garavan H, 2003, NEUROIMAGE, V20, P1132, DOI 10.1016/S1053-8119(03)00334-3; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Hjaltason H, 1996, NEUROPSYCHOLOGIA, V34, P1229, DOI 10.1016/0028-3932(96)00044-9; Hon N, 2006, J NEUROSCI, V26, P9805, DOI 10.1523/JNEUROSCI.3165-06.2006; Husain M, 1997, NATURE, V385, P154, DOI 10.1038/385154a0; Husain M, 2003, NAT REV NEUROSCI, V4, P26, DOI 10.1038/nrn1005; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Konishi S, 1999, BRAIN, V122, P981, DOI 10.1093/brain/122.5.981; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; KONOW A, 1970, NEUROPSYCHOLOGIA, V8, P489, DOI 10.1016/0028-3932(70)90044-8; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Lutcke H, 2008, CEREB CORTEX, V18, P508, DOI 10.1093/cercor/bhm090; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Malhotra P, 2009, BRAIN, V132, P645, DOI 10.1093/brain/awn350; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; MENNEMEIER MS, 1994, NEUROPSYCHOLOGIA, V32, P703, DOI 10.1016/0028-3932(94)90030-2; Molenberghs P, 2008, J NEUROSCI, V28, P3359, DOI 10.1523/JNEUROSCI.5247-07.2008; Mort DJ, 2003, BRAIN, V126, P1986, DOI 10.1093/brain/awg200; Nakahara K, 2002, SCIENCE, V295, P1532, DOI 10.1126/science.1067653; O'Connell RG, 2008, NEUROPSYCHOLOGIA, V46, P1379, DOI 10.1016/j.neuropsychologia.2007.12.018; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Raven JC., 1995, COLOURED PROGR MATRI; Richer F, 1996, NEUROPSYCHOLOGIA, V34, P509, DOI 10.1016/0028-3932(95)00132-8; Riddoch M. J., 1993, BIRMINGHAM OBJECT RE; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P1527, DOI 10.1016/S0028-3932(97)00084-5; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rorden C, 2007, J COGNITIVE NEUROSCI, V19, P1081, DOI 10.1162/jocn.2007.19.7.1081; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; Samuelsson H, 1998, J CLIN EXP NEUROPSYC, V20, P73, DOI 10.1076/jcen.20.1.73.1481; Schall JD, 2002, NEURON, V36, P309, DOI 10.1016/S0896-6273(02)00964-9; Scheffers MK, 1996, PSYCHOPHYSIOLOGY, V33, P42, DOI 10.1111/j.1469-8986.1996.tb02107.x; SCHENKENBERG T, 1980, NEUROLOGY, V30, P509, DOI 10.1212/WNL.30.5.509; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Sohn MH, 2000, P NATL ACAD SCI USA, V97, P13448, DOI 10.1073/pnas.240460497; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499; Talairach J., 1988, COPLANAR STEREOTAXIC; Tyler LK, 2005, NEUROPSYCHOLOGIA, V43, P771, DOI 10.1016/j.neuropsychologia.2004.07.020; Van Essen DC, 2005, NEUROIMAGE, V28, P635, DOI 10.1016/j.neuroimage.2005.06.058; Van Essen DC, 2001, J AM MED INFORM ASSN, V8, P443, DOI 10.1136/jamia.2001.0080443; Vandenberghe R, 2001, NEUROIMAGE, V14, P37, DOI 10.1006/nimg.2001.0790; Warrington E. K., 1991, VISUAL OBJECT SPACE; Wechsler D, 1998, WECHSLER MEMORY SCAL; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; Zordan L, 2008, BRAIN COGNITION, V66, P57, DOI 10.1016/j.bandc.2007.05.005	77	50	51	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	NOV	2009	47	13					2866	2875		10.1016/j.neuropsychologia.2009.06.012			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	510DB	WOS:000271067100021	19545580				2022-02-06	
J	Hosseini, AH; Lifshitz, J				Hosseini, Ario H.; Lifshitz, Jonathan			Brain Injury Forces of Moderate Magnitude Elicit the Fencing Response	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HEAD INJURY; CONCUSSION; SEVERITY; CONCUSSIVE CONVULSION; TONIC POSTURING; ASYMMETRICAL TONIC NECK	DIFFUSE AXONAL INJURY; CONCUSSIVE CONVULSIONS; AGREEMENT STATEMENT; COMA; SPORT; DAMAGE; MODEL	HOSSEINI, A. H., and J. LIFSHITZ. Brain Injury Forces of Moderate Magnitude Elicit the Fencing Response. Med Sci. Sports Exerc., Vol. 41, No. 9, pp. 1687-1697, 2009. Introduction: Traumatic brain injury is heterogeneous, both in its induction and ensuing neurological sequelae. In this way, medical care depends on accurately identifying the severity of injury-related forces. Clinically, injury severity is determined by a combination of the Glasgow Coma Scale, length of unconsciousness, posttraumatic amnesia, and persistence of neurological sequelae. In the laboratory, injury severity is gauged by the biomechanical forces and the acute suppression of neurological reflexes. The present communication describes and validates the "fencing response" as an overt indicator of injury force magnitude and midbrain localization to aid in injury identification and classification. Methods: Using YouTube (TM), the Internet video database, videos were screened for head injury resulting in unconsciousness and documented for the fencing response. Adult male rats were subjected to midline fluid percussion brain injury at two severities, observed for acute neurological reflexes and the midbrain evaluated histopathologically. Results: Tonic posturing (fencing response) has been observed to precede convulsions in sports injuries at the moment of impact, where extension and flexion of opposite arms occurs despite body position or gravity. Of the 35 videos identified by an impact to the head and period of unconsciousness, 66% showed a fencing response at the moment of impact, regardless of the side of impact, without ensuing convulsion. Similarly, diffuse brain-injured rats demonstrate a fencing response upon injury at moderate (1.9 atm, 39/44 animals) but not mild severity (1.1 atm, 0/19 animals). The proximity of the lateral vestibular nucleus to the cerebellar peduncles makes it vulnerable to mechanical forces that initiate a neurochemical storm to elicit the neuromotor response, disrupt the blood-brain barrier, and alter the nuclear volume. Conclusions: Therefore, the fencing response likely indicates neurological disturbance unique from convulsion associated with mechanical forces of moderate magnitude imparted on the midbrain and can assist in guiding medical care after injury.	[Hosseini, Ario H.; Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, Dept Phys Med & Rehabil, Lexington, KY 40536 USA		Lifshitz, J (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, B463,BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	jlifshitz@uky.edu			University of Kentucky Chandler Medical Center;  [P30 NINDS-NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220] Funding Source: NIH RePORTER	Supported, in part, by the University of Kentucky Chandler Medical Center and P30 NINDS-NS051220. Special thanks to Ms. Amanda M. Lisembee and Ms. Kelley D. Hall for technical assistance. The schematic images of the fencing response were prepared by Mr. Tom Dolan at the Teaching & Academic Support Center, University of Kentucky. The authors thank the reviewers and Dr. Theresa C. Thomas for their constructive comments and suggestions. The results of the present study do not constitute endorsement by the American College of Sports Medicine.	Aghakhani Y, 2004, NEUROLOGY, V62, P2256, DOI 10.1212/WNL.62.12.2256; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Clarke KS, 1998, CLIN SPORT MED, V17, P1, DOI 10.1016/S0278-5919(05)70056-9; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Giza CC, 2001, J ATHL TRAINING, V36, P228; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JENNETT B, 1977, LANCET, V1, P878; JENSEN EBV, 1993, J MICROSC-OXFORD, V170, P35, DOI 10.1111/j.1365-2818.1993.tb03321.x; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Langlois J.A., 2004, TRAUMATIC BRAIN INJU, P1; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LI VG, 1998, NEUROREPORT, V9, P2539; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; LINDSAY KW, 1976, J PHYSIOL-LONDON, V261, P583, DOI 10.1113/jphysiol.1976.sp011575; LUCCARINI P, 1992, ARCH ITAL BIOL, V130, P127; Matsuyama K, 2000, J NEUROPHYSIOL, V84, P2237, DOI 10.1152/jn.2000.84.5.2237; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 1999, NEUROLOGY, V52, P1888, DOI 10.1212/WNL.52.9.1888; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; PAXINOS G, 2007, RAT BRAIN STEREOTAXI, P122; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Sahuquillo J, 2002, ADV TECH STAND NEUR, V27, P23; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Tandrup T, 1997, J MICROSC-OXFORD, V186, P108, DOI 10.1046/j.1365-2818.1997.2070765.x; TEASDALE G, 1974, LANCET, V2, P81; Xiong GX, 2001, EXP BRAIN RES, V141, P204, DOI 10.1007/s002210100867	52	50	50	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	SEP	2009	41	9					1687	1697		10.1249/MSS.0b013e31819fcd1b			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	488GU	WOS:000269338200001	19657303	Bronze			2022-02-06	
J	Sharma, HS; Ali, S; Tian, ZR; Patnaik, R; Patnaik, S; Lek, P; Sharma, A; Lundstedt, T				Sharma, Hari S.; Ali, Syed; Tian, Z. Ryan; Patnaik, Ranjana; Patnaik, S.; Lek, Per; Sharma, Aruna; Lundstedt, Torbjorn			Nano-Drug Delivery and Neuroprotection in Spinal Cord Injury	JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY			English	Article; Proceedings Paper	1st International Symposium on Nanoneuroscience - Nanoeuroprotection and Nanoeurotoxicity	AUG 20-26, 2007	Killithea, GREECE			Nanowiring; Nano-Drug Delivery; Spinal Cord Injury; Neuroprotection; Blood-Spinal Cord Barrier; Functional Paralysis; Myelin Damage; Titanium Dioxide	TITANIUM-DIOXIDE NANOPARTICLES; SEROTONIN SYNTHESIS INHIBITOR; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; ELECTRON-MICROSCOPY; PARTICULATE MATTER; BARRIER DISRUPTION; TRAUMATIC INJURY; OXIDATIVE STRESS; EDEMA FORMATION	Recently nano-drug delivery to the central nervous system (CNS) has been shown to be more effective than the parent compound by itself. An increased availability of the drug for longer periods to the brain or spinal cord and/or a decrease in the drug metabolism altogether could lead to potentiation of the pharmacological activity of the nano-delivered compounds. However, it is still unclear whether the nanocarriers used to deliver the drugs may itself has any potential neurotoxic activity. Although, nanodrug-delivery appears to be a quite promising therapeutic tool for the future clinical therapy, its advantages and limitations for the routine use of patients still needs to be elucidated. Our laboratory is engaged to study a plethora of potential neuroprotective novel compounds delivered to the CNS using nanowiring techniques following brain or spinal cord trauma. Our investigations show that nanowired drugs, if delivered locally following spinal cord injury achieve better neuroprotection than the parent compounds. This effect of nano-drug delivery appears to be very selective in nature. Thus, a clear differentiation based on the compounds used for nano-drug delivery can be seen on various pathological parameters in spinal cord injury. These observations suggest that nanowiring may itself do not induce neuroprotection, but enhance the neuroprotective ability of compounds after trauma. This review describes some recent advances in nano-drug delivery to the CNS in relation to novel neuroprotective strategies with special emphasis on spinal cord trauma based on our own observations and recent findings from our laboratory investigations.	[Sharma, Hari S.; Sharma, Aruna] Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden; [Lek, Per; Lundstedt, Torbjorn] AcurePharma AB, SE-75643 Uppsala, Sweden; [Ali, Syed] US FDA, Neurochem Lab, Div Neurotoxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; [Tian, Z. Ryan] Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; [Patnaik, Ranjana; Patnaik, S.] Banaras Hindu Univ, Inst Technol, Dept Pharm, Varanasi 221005, Uttar Pradesh, India; [Lundstedt, Torbjorn] Uppsala Univ, Div Organ Chem, Dept Med Chem, SE-75105 Uppsala, Sweden		Lundstedt, T (corresponding author), Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden.		Patnaik, Ranjana/AAZ-4440-2020; Patnaik, Ranjana/D-1469-2017; Sharma, Aruna/D-4430-2011; Tian, Z. Ryan/R-6671-2016	Patnaik, Ranjana/0000-0002-8131-177X; Patnaik, Ranjana/0000-0002-8131-177X; Tian, Z. Ryan/0000-0002-5644-8483			Assie MB, 2007, N-S ARCH PHARMACOL, V375, P241, DOI 10.1007/s00210-007-0162-x; BEGGS JL, 1975, EXP NEUROL, V49, P86, DOI 10.1016/0014-4886(75)90196-X; Betbeder D, 2000, PHARM RES-DORDR, V17, P743, DOI 10.1023/A:1007594602449; Boffetta P, 2004, CANCER CAUSE CONTROL, V15, P697, DOI 10.1023/B:CACO.0000036188.23970.22; Brigger I, 2002, J PHARMACOL EXP THER, V303, P928, DOI 10.1124/jpet.102.039669; Brokx RD, 2002, J CONTROL RELEASE, V78, P115, DOI 10.1016/S0168-3659(01)00491-6; Campbell A, 2005, NEUROTOXICOLOGY, V26, P133, DOI 10.1016/j.neuro.2004.08.003; Carty CL, 2003, J ENVIRON MONITOR, V5, P953, DOI 10.1039/b308488d; CHEN JL, 1988, J OCCUP ENVIRON MED, V30, P937, DOI 10.1097/00043764-198812000-00011; Chi B, 2007, J NANOSCI NANOTECHNO, V7, P668, DOI 10.1166/jnn.2007.147; Costigan S., 2006, TOXICOLOGY NANOPARTI; CSERR HF, 1974, EXP NEUROL, V45, P50, DOI 10.1016/0014-4886(74)90099-5; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Dong W, 2006, NANOMED-NANOTECHNOL, V2, P248, DOI 10.1016/j.nano.2006.10.005; Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Dyer AM, 2002, PHARM RES-DORDR, V19, P998, DOI 10.1023/A:1016418523014; ECETOC, 2006, WORKSH TEST STRAT ES; Elder A, 2006, ENVIRON HEALTH PERSP, V114, P1172, DOI 10.1289/ehp.9030; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; *EUR SCI FDN, 2005, 2005 POL BRIEF ESF E; Fabian E, 2008, ARCH TOXICOL, V82, P151, DOI 10.1007/s00204-007-0253-y; Fang C, 2006, EUR J PHARM SCI, V27, P27, DOI 10.1016/j.ejps.2005.08.002; Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038; Gibaud S, 1996, J PHARM SCI, V85, P944, DOI 10.1021/js960032d; Gomes AJ, 2006, PHOTOMED LASER SURG, V24, P514, DOI 10.1089/pho.2006.24.514; Grassian VH, 2007, ENVIRON HEALTH PERSP, V115, P397, DOI 10.1289/ehp.9469; GRIFFITHS IR, 1980, VET CLIN N AM, V10, P131, DOI 10.1016/S0195-5616(80)50008-2; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V43, P205; Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012; Kane RS, 2007, BIOTECHNOL PROGR, V23, P316, DOI 10.1021/bp060388n; Kipp JE, 2004, INT J PHARMACEUT, V284, P109, DOI 10.1016/j.ijpharm.2004.07.019; Kreuter J, 2004, J NANOSCI NANOTECHNO, V4, P484, DOI 10.1166/jnn.2003.077; Kreuter J, 2003, PHARM RES-DORDR, V20, P409, DOI 10.1023/A:1022604120952; Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8; Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936; Lockman PR, 2003, PHARM RES-DORDR, V20, P705, DOI 10.1023/A:1023492015851; Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Muller J, 2005, TOXICOL APPL PHARM, V207, P221, DOI 10.1016/j.taap.2005.01.008; Na K, 2006, EUR J PHARM SCI, V27, P115, DOI 10.1016/j.ejps.2005.08.012; Niidome T, 2006, J CONTROL RELEASE, V114, P343, DOI 10.1016/j.jconrel.2006.06.017; NOBLE LJ, 1987, BRAIN RES, V424, P177, DOI 10.1016/0006-8993(87)91208-X; NOBLE LJ, 1988, EXP NEUROL, V99, P567, DOI 10.1016/0014-4886(88)90173-2; Oberdorster E, 2004, ENVIRON HEALTH PERSP, V112, P1058, DOI 10.1289/ehp.7021; Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Peracchia MT, 1999, J CONTROL RELEASE, V60, P121, DOI 10.1016/S0168-3659(99)00063-2; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Rapoport S. I., 1976, BLOOD BRAIN BARRIER; REULEN HJ, 1976, BRIT J ANAESTH, V48, P741, DOI 10.1093/bja/48.8.741; RHODIN JAG, 1968, J ULTRA MOL STRUCT R, V25, P452, DOI 10.1016/S0022-5320(68)80098-X; Ricci-Junior E, 2006, J MICROENCAPSUL, V23, P523, DOI 10.1080/02652040600775525; ROSS R, 2007, TOWN CTRY MAG, V68; Saez A, 2000, EUR J PHARM BIOPHARM, V50, P379, DOI 10.1016/S0939-6411(00)00125-9; Schins RPF, 2004, TOXICOL APPL PHARM, V195, P1, DOI 10.1016/j.taap.2003.10.002; Schins RPF, 2002, CHEM RES TOXICOL, V15, P1166, DOI 10.1021/tx025558u; Seki J, 2004, INT J PHARM, V273, P75, DOI 10.1016/j.ijpharm.2003.12.022; SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8; SENIOR J, 1982, FEBS LETT, V145, P109, DOI 10.1016/0014-5793(82)81216-7; SHAPIRO K, 1977, SURG NEUROL, V7, P275; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1929; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P437; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5055, DOI 10.1166/jnn.2009.GR09; Sharma HS, 2008, EXPERT OPIN PHARMACO, V9, P2773, DOI 10.1517/14656566.9.16.2773 ; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P197, DOI 10.1196/annals.1403.014; Sharma HS, 2007, NANOMEDICINE-UK, V2, P753, DOI 10.2217/17435889.2.6.753; Sharma HS, 2007, PROG BRAIN RES, V162, P245, DOI 10.1016/S0079-6123(06)62013-X; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1841; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5073, DOI 10.1166/jnn.2009.GR10; Sharma Hari Shanker, 2008, Central Nervous System Agents in Medicinal Chemistry, V8, P143; SHARMA HS, 1995, NEUROSCI RES, V21, P241, DOI 10.1016/0168-0102(94)00855-A; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P407, DOI 10.1196/annals.1344.036; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Sharma HS, 2006, J NEURAL TRANSM, V113, P521, DOI 10.1007/s00702-005-0405-2; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; Sharma HS, 1995, PROG BRAIN RES, V104, P401; Sharma HS, 2000, ACTA NEUROCHIR SUPPL, V76, P297; SHARMA HS, 1995, RESTOR NEUROL NEUROS, V7, P207, DOI 10.3233/RNN-1994-7403; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Tomazic-Jezic VJ, 2001, J BIOMED MATER RES, V55, P523, DOI 10.1002/1097-4636(20010615)55:4<523::AID-JBM1045>3.0.CO;2-G; Umbreit T, 2007, TOXICOLOGIST, V96, P287; Wang JX, 2007, TOXICOL LETT, V168, P176, DOI 10.1016/j.toxlet.2006.12.001; Warheit DB, 2007, TOXICOLOGY, V230, P90, DOI 10.1016/j.tox.2006.11.002; Winkler T, 1998, SPINAL CORD MONITORING, P283; Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k; Yao CP, 2006, EPILEPSIA, V47, P1822, DOI 10.1111/j.1528-1167.2006.00814.x; YASHON D, 1973, J NEUROSURG, V38, P693, DOI 10.3171/jns.1973.38.6.0693; Zhao DB, 2006, SMALL, V2, P879, DOI 10.1002/smll.200500317	94	50	50	3	39	AMER SCIENTIFIC PUBLISHERS	VALENCIA	26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA	1533-4880	1533-4899		J NANOSCI NANOTECHNO	J. Nanosci. Nanotechnol.	AUG	2009	9	8					5014	5037		10.1166/jnn.2009.GR04			24	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	470QO	WOS:000267994100068	19928182				2022-02-06	
J	Hong, X; Miller, C; Savant-Bhonsale, S; Kalkanis, SN				Hong, Xin; Miller, Cathie; Savant-Bhonsale, Smita; Kalkanis, Steven N.			ANTITUMOR TREATMENT USING INTERLEUKIN-12-SECRETING MARROW STROMAL CELLS IN AN INVASIVE GLIOMA MODEL	NEUROSURGERY			English	Article						Animal model; Glioma; Interleukin-12; Invasion; Marrow stromal cells	NEURAL STEM-CELLS; TRAUMATIC BRAIN-INJURY; RATS; MIGRATION; STROKE	OBJECTIVE: Marrow stromal cells (MSCs) have the potential to migrate toward sites of injury or disease in the central nervous system. Encouraging results have been obtained by using MSCs to deliver therapeutic molecules. However, most brain tumor animal models-unlike in actual human disease states-use cells with limited invasion properties. In the present study, C57/B16 mice were implanted with the highly invasive Ast11.9-2 glioma cell line to investigate the potential therapeutic effects of interleukin-12 (IL-12)-secreting MSCs. METHODS: MSCs were infected with adenovirus encoding murine IL-12 (AdIL 12). The infection conditions were optimized by determination of cytotoxicity and IL-12 secretion after AdIL 12 infection in vitro. After implanting Ast11.9-2 tumor into mouse brain, we conducted a survival experiment to compare 4 distinct treatment groups by injecting culture medium control (sham), MSCs alone, MSCs infected with control virus (MSC-adenovirus encoding green fluorescent protein), and MSCs infected with IL-12-expressing virus (MSC-AdIL 12) in the peritumoral region of the brain. Tumor tissues were analyzed by hematoxylin and eosin staining. IL-12 expression was analyzed by immunohistochemistry staining. Y chromosome fluorescent in situ hybridization was used to detect injected MSCs. Cell populations of CD57(+) (natural killer cells), CD3(+) (total T cells), and 7-AAD (dead cells) in whole brain tissue were analyzed by fluorescence-activated cell sorting at days 4 and 7 after therapeutic treatment. RESULTS: Serum IL-12 increased significantly at days 4 and 7 after MSC-AdIL 12 implantation. IL-12-expressing cells were detected by immunohistochemistry staining and Y chromosome-positive staining cells were found in the tumor area, confirming successful IL-12 delivery. MSC-AdIL 12 treatment yielded increased natural killer cell infiltration in brain tissue at day 4, leading to an expected increase in nonspecific cell death, while total T-cell counts remained unchanged. MSC-IL-12 treatment extended animal survival but did not result in a statistically significant difference in comparison to other groups. Because all animals ultimately died of the brain tumors, MSC-AdIL 12 treatment did not completely arrest the invasive growth pattern of these lesions. CONCLUSION: The results indicate that MSCs may serve as useful delivery vehicles for IL-12 and other antineoplastic agents in brain tumor therapy.	[Hong, Xin; Kalkanis, Steven N.] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Miller, Cathie] Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; [Savant-Bhonsale, Smita] Theradigm Inc, Baltimore, MD USA		Kalkanis, SN (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	kalkanis@neuro.hfh.edu					Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Benedetti S, 2000, NAT MED, V6, P447, DOI 10.1038/74710; BOGLER O, 1995, CANCER RES, V55, P2746; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; COHEN J, 1995, SCIENCE, V270, P908; Ehtesham M, 2002, CANCER RES, V62, P5657; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Leonard JP, 1997, BLOOD, V90, P2541; Li Y, 2006, EXP NEUROL, V198, P313, DOI 10.1016/j.expneurol.2005.11.029; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Nakamura K, 2004, GENE THER, V11, P1155, DOI 10.1038/sj.gt.3302276; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 2000, PROG BRAIN RES, V128, P293; Trinchieri G, 1996, J LEUKOCYTE BIOL, V59, P505, DOI 10.1002/jlb.59.4.505; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P237, DOI 10.1016/0167-5699(93)90173-I; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009	20	50	54	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JUN	2009	64	6					1139	1146		10.1227/01.NEU.0000345646.85472.EA			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	452YE	WOS:000266576300029	19487894				2022-02-06	
J	Howard, JL; Cipolle, MD; Horvat, SA; Sabella, VM; Reed, JF; Fulda, G; Tinkoff, G; Pasquale, MD				Howard, Jerry Lee, II; Cipolle, Mark D.; Horvat, Sarah A.; Sabella, Victoria M.; Reed, James F., III; Fulda, Gerard; Tinkoff, Glen; Pasquale, Michael D.			Preinjury Warfarin Worsens Outcome in Elderly Patients Who Fall From Standing	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		CT scan; Elderly; Emergency department triage; Fall from standing; INR correction; Mortality; Outcome; Warfarin	INTRACRANIAL HEMORRHAGE; TRAUMA PATIENTS; ANTICOAGULATION; IMPACT; RISK	Introduction. Fall from standing (FFS) has become one of the most common mechanisms of injury for admission to the trauma center in the elderly population. Many of these patients present anticoagulated with warfarin. This two-center study was designed to examine the effects of preinjury warfarin use on outcome in the elderly. Methods A retrospective review of prospectively collected registry data at two Level I trauma centers was conducted from 2003 to 2006. The study population included patients age 2:65 admitted to the trauma center after an FFS. These centers are relatively close geographically and have similar patient demographics. Data collected included: age, Injury Severity Score, Abbreviated Injury Score (AIS) for head, mortality, admission Glasgow Coma Score, and admission international normalized ratio (INR). Patients were divided into two groups based on the preinjury condition of warfarin use. Statistical differences were determined by impaired t test for continuous variables and chi(2) and odds ratios (ORs) for dichotomous variables. Results. Of the 27,812 patients admitted to these two trauma centers over this time period, 2,791 (10.0%) were of age >= 65 and admitted after an FFS. INR was 2.8 +/- 1.1 in warfarin group (+warf). The number of patients with AIS head 4 and 5 was similar between groups (-warf 22.1 %, +warf 25.9%). Overall, preinjury warfarin use bad a negative effect on the in-hospital mortality rate, +warf 8.6% and -warf 5.7% (OR 1.54,1.09-2.19, p = 0.015). There was no difference in mortality between groups in patients with an AIS head <4. The negative impact of preinjury warfarin use on mortality was most pronounced in patients with an AIS head 4 and 5 who presented awake (Glasgow Coma Score 14 and 15), + warf 13.5 % and -warf 6.4% (OR 2.30, 95% confidence interval 1.12-4.70,p = 0.019). Conclusion. Preinjury warfarin use has an adverse effect on outcome (mortality) in elderly FFS patients. Importantly, this effect is most prominent in patients admitted awake with significant findings on computed tomography scan. This argues for rapid emergency department triage to computed tomography scan and rapid INR correction in this population.	[Howard, Jerry Lee, II; Horvat, Sarah A.; Sabella, Victoria M.; Pasquale, Michael D.] Lehigh Valley Hlth Network, Dept Surg, Div Trauma Surg Crit Care, Allentown, PA 18105 USA; [Cipolle, Mark D.; Reed, James F., III; Fulda, Gerard; Tinkoff, Glen] Christiana Care Hlth Syst, Dept Surg, Div Trauma Surg Crit Care, Newark, DE USA		Pasquale, MD (corresponding author), Lehigh Valley Hlth Network, Dept Surg, Div Trauma Surg Crit Care, Cedar Crest & I-78,POB 689, Allentown, PA 18105 USA.	sally.lutz@lvh.com					*AM COLL SURG, 2006, NAT TRAUM DAT NTDB; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cappuzzo Kimberly A, 2005, Consult Pharm, V20, P601, DOI 10.4140/TCP.n.2005.601; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Fleming B, 2001, CAN FAM PHYSICIAN, V47, P727; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Garvin R, 2006, J FAM PRACTICE, V55, P157; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2006, J TRAUMA, V61, P318, DOI 10.1097/01.ta.0000223944.25922.91; Kalina M, 2008, AM SURGEON, V74, P858; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirsch MJ, 2004, J TRAUMA, V57, P1230, DOI 10.1097/01.TA.0000150839.69648.17; MATTLE H, 1989, J NEUROL NEUROSUR PS, V52, P829, DOI 10.1136/jnnp.52.7.829; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Saab M, 1996, J ACCID EMERG MED, V13, P208; Singer DE, 2004, CHEST, V126, p429S, DOI 10.1378/chest.126.3_suppl.429S; Wellman M, 1999, J Fam Pract, V48, P498; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	23	50	51	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2009	66	6					1518	1524		10.1097/TA.0b013e3181a59728			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	457PN	WOS:000266944500002	19509609				2022-02-06	
J	Bhat, MA; Charoo, BA; Bhat, JI; Ahmad, SM; Ali, SW; Mufti, MUH				Bhat, Mushtaq Ahmad; Charoo, Bashir Ahmad; Bhat, Javeed Iqbal; Ahmad, Sheikh Mushtaq; Ali, Syed Wajid; Mufti, Masood-ul-Hassan			Magnesium Sulfate in Severe Perinatal Asphyxia: A Randomized, Placebo-Controlled Trial	PEDIATRICS			English	Article						asphyxia; perinatal; magnesium sulfate	TRANSIENT HYPOXIA-ISCHEMIA; CEREBRAL ENERGY FAILURE; TRAUMATIC BRAIN-INJURY; NEWBORN PIGLET; BIRTH ASPHYXIA; ENCEPHALOPATHY; INFUSION; PALSY; RISK; TERM	OBJECTIVE. The goal was to study whether postnatal magnesium sulfate infusion could improve neurologic outcomes at discharge for term neonates with severe perinatal asphyxia. METHODS. Forty term (>= 37 weeks of gestation) neonates with severe perinatal asphyxia were studied in a prospective, longitudinal, placebo-controlled trial. Patients were assigned randomly to receive either 3 doses of magnesium sulfate infusion at 250 mg/kg per dose (1 mL/kg per dose) 24 hours apart (treatment group) or 3 doses of normal saline infusion (1 mL/kg per dose) 24 hours apart (placebo group). Both groups also received supportive care according to the unit protocol for perinatal asphyxia. RESULTS. In the treatment group, moderate encephalopathy was present in 35% (7 of 20) of the patients and severe encephalopathy in 65% (13 of 20) of patients at admission. In the placebo group, 40% (8 of 20) of patients had moderate encephalopathy and 60% (12 of 20) of patients had severe encephalopathy. The mean serum magnesium concentration in the treatment group remained at >= 1.2 mmol/L for 72 hours after the first infusion. At discharge, 22% (4 of 18) of infants in the treatment group had neurologic abnormalities, compared with 56% (10 of 18) of infants in the placebo group. Also, neuroimaging (head computed tomography) performed on day 14 yielded abnormal findings for fewer infants in the treatment group than in the placebo group (16% vs 44%). Infants in the treatment group were more likely to be receiving oral feedings (sucking) at discharge than were those in the placebo group (77% vs 37%). Good short-term outcomes at discharge occurred for 77% of the patients in the treatment group, compared with 37% of the patients in the placebo group. CONCLUSION. Postnatal magnesium sulfate treatment improves neurologic outcomes at discharge for term neonates with severe perinatal asphyxia. Pediatrics 2009; 123: e764-e769	[Bhat, Mushtaq Ahmad; Charoo, Bashir Ahmad; Bhat, Javeed Iqbal; Ahmad, Sheikh Mushtaq; Ali, Syed Wajid; Mufti, Masood-ul-Hassan] SKIMS, Dept Pediat, Srinagar 190011, Jammu & Kashmir, India		Bhat, MA (corresponding author), SKIMS, Dept Pediat, Srinagar 190011, Jammu & Kashmir, India.	mbhat47@rediffmail.com	charoo, bashir ahmad/ABB-9310-2020; iqbal, javeed/ABC-1694-2021	iqbal, javeed/0000-0002-4094-4634			ADCOCK LM, 2008, MANUAL NEONATAL CARE, P518; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bhat MA, 2006, J PEDIATR-US, V149, P180, DOI 10.1016/j.jpeds.2006.03.053; CHOI DW, 1993, RES P ARNMD, V71, P23; Dixon G, 2002, PEDIATRICS, V109, P26, DOI 10.1542/peds.109.1.26; DUBOWITZ LMS, 1998, CLINICS DEV MED, V148; Greenwood K, 2000, PEDIATR RES, V48, P346, DOI 10.1203/00006450-200009000-00014; Grether JK, 1998, AM J OBSTET GYNECOL, V178, P1, DOI 10.1016/S0002-9378(98)70617-9; Harrison V, 2007, BJOG-INT J OBSTET GY, V114, P994, DOI 10.1111/j.1471-0528.2007.01409.x; HENNEBERRY RC, 1989, ANN NY ACAD SCI, V568, P225; HOFFMAN DJ, 1994, BRAIN RES, V644, P144, DOI 10.1016/0006-8993(94)90357-3; HORI N, 1994, NEUROSCI LETT, V173, P75, DOI 10.1016/0304-3940(94)90153-8; Ichiba H, 2002, PEDIATR INT, V44, P505, DOI 10.1046/j.1442-200X.2002.01610.x; LEVENE M, 1995, ARCH DIS CHILD-FETAL, V73, pF174, DOI 10.1136/fn.73.3.F174; LOREK A, 1994, PEDIATR RES, V36, P699, DOI 10.1203/00006450-199412000-00003; MARRET S, 1995, DEV MED CHILD NEUROL, V37, P473; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; Natale JE, 2007, PEDIATR CRIT CARE ME, V8, P1, DOI 10.1097/01.pcc.0000256620.55512.5f; NELSON KB, 1995, PEDIATRICS, V95, P263; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PANETH N, 1993, CLIN INVEST MED, V16, P95; Paul V K, 1999, Indian Pediatr, V36, P167; Penrice J, 1997, PEDIATR RES, V41, P443, DOI 10.1203/00006450-199703000-00024; PORTMAN RJ, 1990, AM J OBSTET GYNECOL, V162, P174, DOI 10.1016/0002-9378(90)90844-W; ROBERTSON CMT, 1989, J PEDIATR-US, V114, P753, DOI 10.1016/S0022-3476(89)80132-5; Schendel DE, 1996, JAMA-J AM MED ASSOC, V276, P1805, DOI 10.1001/jama.276.22.1805; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Spandou E, 2007, REPROD SCI, V14, P667, DOI 10.1177/1933719107305864; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Volpe JJ, 2001, NEUROLOGY NEWBORN, P331	30	50	53	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAY	2009	123	5					E764	E769		10.1542/peds.2007-3642			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	438AS	WOS:000265528900029	19349375				2022-02-06	
J	Mamere, AE; Saraiva, LAL; Matos, ALM; Carneiro, AAO; Santos, AC				Mamere, A. E.; Saraiva, L. A. L.; Matos, A. L. M.; Carneiro, A. A. O.; Santos, A. C.			Evaluation of Delayed Neuronal and Axonal Damage Secondary to Moderate and Severe Traumatic Brain Injury Using Quantitative MR Imaging Techniques	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; APPARENT DIFFUSION-COEFFICIENT; WHITE-MATTER LESIONS; CLOSED-HEAD INJURY; MULTIPLE-SCLEROSIS; INVIVO DETERMINATION; ALZHEIMERS-DISEASE; VEGETATIVE STATE; CORPUS-CALLOSUM; TRANSFER RATIO	BACKGROUND AND PURPOSE: Traumatic brain injury (TBI) is a classic model of monophasic neuronal and axonal injury, in which tissue damage mainly occurs at the moment of trauma, There is some evidence of delayed progression of the neuronal and axonal loss. Our purpose was to test the hypothesis that quantitative MR imaging techniques can estimate the biologic changes secondary to delayed neuronal and axonal loss after TBI. MATERIALS AND METHODS: Nine patients (age, 11-28 years; 5 male) who sustained a moderate or severe TBI were evaluated at a mean of 3.1 years after trauma. We applied the following techniques: bicaudate (BCR) and bifrontal (BFR) ventricle-to-brain ratios; T2 relaxometry; magnetization transfer ratio (MTR); apparent diffusion coefficient (ADC); and proton spectroscopy, by using an N-acetylaspartate/creatine (NAA/Cr) ratio measured in normal-appearing white matter (NAWM) and the corpus callosum (CC). The results were compared with those of a control group. RESULTS: BCR and BFR mean values were significantly increased (P <= 05) in patients due to secondary subcortical atrophy; increased T2 relaxation time was observed in the NAWM and CC, reflecting an increase in water concentration secondary to axonal loss. Increased ADC mean values and reduced MTR mean values were found in the NAWM and CC, showing damage in the myelinated axonal fibers; and decreased NAA/Cr ratio mean values were found in the CC, indicating axonal loss. CONCLUSIONS: These quantitative MR imaging techniques could noninvasively demonstrate the neuronal and axonal damage in the NAWM and CC of human brains, secondary to moderate or severe TBI.	[Mamere, A. E.] Canc Hosp Barretos Fundacao Pio XII, Dept Radiol, Sao Paulo, Brazil; [Saraiva, L. A. L.; Matos, A. L. M.; Carneiro, A. A. O.; Santos, A. C.] Univ Sao Paulo, Dept Radiol, Sao Paulo, Brazil		Mamere, AE (corresponding author), R Antenor Duarte Vilella 1331, BR-14784400 Barretos, SP, Brazil.	mamere@uol.com.br	Carneiro, Antonio Adilton O./F-3557-2012; Santos, Antonio/F-5419-2012; Mamere, Augusto/A-4509-2013	Carneiro, Antonio Adilton O./0000-0002-1752-7170; 			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; ARMSPACH JP, 1991, MAGN RESON IMAGING, V9, P107, DOI 10.1016/0730-725X(91)90104-T; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bagley LJ, 1999, AM J NEURORADIOL, V20, P977; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Conti AC, 1998, J NEUROSCI, V18, P5663; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LARSSON HBW, 1989, MAGNET RESON MED, V11, P337, DOI 10.1002/mrm.1910110308; Mascalchi M, 2005, RADIOL MED, V109, P155; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.0.CO;2-6; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Papanikolaou N, 2004, EUR RADIOL, V14, P115, DOI 10.1007/s00330-003-1946-0; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Tievsky AL, 1999, AM J NEURORADIOL, V20, P1491; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	42	50	52	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	2009	30	5					947	952		10.3174/ajnr.A1477			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	446PG	WOS:000266133000014	19193759	hybrid, Green Published			2022-02-06	
J	Baguley, IJ; Nott, MT; Slewa-Younan, S; Heriseanu, RE; Perkes, IE				Baguley, Ian J.; Nott, Melissa T.; Slewa-Younan, Shameran; Heriseanu, Roxana E.; Perkes, Iain E.			Diagnosing Dysautonomia After Acute Traumatic Brain Injury: Evidence for Overresponsiveness to Afferent Stimuli	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Autonomic nervous system; Brain injuries; Diagnosis; Heart rate; Rehabilitation	HEART-RATE-VARIABILITY; PAROXYSMAL AUTONOMIC INSTABILITY; MANAGEMENT; DYSREGULATION; DYSFUNCTION; PREDICTOR; DYSTONIA; DEATH	Baguley IJ, Nott MT, Slewa-Younan S, Heriseanu RE, Perkes IE. Diagnosing dysautonomia after acute traumatic brain injury: evidence for overresponsiveness to afferent stimuli. Arch Phys Med Reliabil 2009:90:580-6. Objective: To differentiate between traumatic brain injury (TBI) subjects with normal and elevated autonomic activity by quantifying cardiac responsivity to nociceptive stimuli and to determine the utility of heart rate variability (HRV) and event-related heart rate changes in diagnosing dysautonomia. Design: Prospective cohort study. Setting: Intensive care unit in a tertiary metropolitan trauma center. Participants: Adults (N=27) with TBI recruited from 79 consecutive TBI admissions comprising 16 autonomically aroused and 11 control subjects matched by age, sex, and injury severity. Interventions: None. Main Outcome Measures: Immediate: pattern of autonomic changes indexed by HRV and event-related heart rate after nociceptive stimuli. Six months: length of stay, Glasgow Coma Scale, and Disability Rating Scale. Results: Heart rate changes (for both HRV and event-related heart rate) were associated with the diagnostic group and 6-month outcome when evaluated pre- and poststimulus but not when evaluated at rest. When assessed on day 7 postinjury, the comparison of HRV and heart rate parameters suggested an overresponsivity to nociceptive stimuli in dysautonomic subjects. These subjects showed a 2-fold increase in mean heart rate relative to subjects with sympathetic arousal of short duration (16% vs 8%), and a 6-fold increase over nonaroused control subjects. Data suggest that post-TBI sympathetic arousal is a spectrum disorder comprising, at one end, a short-duration syndrome and, at the other end, a dramatic, severe sympathetic and motor overactivity syndrome that continued for many months postinjury and associated with a significantly worse 6-month outcome. These findings suggest that it is not the presence of reactivity per se but rather the failure of processes to control for overreactivity that contributes to dysautonomic storming. Conclusions: This study provides empirical evidence that dysautonomic subjects show overresponsiveness to afferent stimuli. Findings from this study suggest an evidence-driven revision of diagnostic criteria and a simple clinical algorithm for the improved identification of cases.	[Baguley, Ian J.; Nott, Melissa T.; Slewa-Younan, Shameran; Heriseanu, Roxana E.] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia; [Baguley, Ian J.; Slewa-Younan, Shameran] Univ Sydney, Rehabil Studies Unit, Fac Med, Sydney, NSW 2006, Australia; [Perkes, Iain E.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge CB2 2QQ, England; [Perkes, Iain E.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia		Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Perkes, Iain/J-7001-2017; Nott, Melissa T/M-6778-2018; Baguley, Ian J/K-6878-2013	Perkes, Iain/0000-0001-8028-9032; Nott, Melissa T/0000-0001-7088-5826; Baguley, Ian J/0000-0001-5650-3705	Motor Accidents Authority of New South wales, Australia [02/836]	Supported by the Motor Accidents Authority of New South wales, Australia (grant no. 02/836).	Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 2008, SEMIN NEUROL, V28, P716, DOI 10.1055/s-0028-1105971; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Bakeman R, 2005, BEHAV RES METHODS, V37, P379, DOI 10.3758/BF03192707; BHIGJEE AI, 1985, J NEUROL SCI, V71, P77, DOI 10.1016/0022-510X(85)90038-3; Bilotta F, 2008, NEUROCRIT CARE, V8, P241, DOI 10.1007/s12028-007-9012-4; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; Camm AJ, 1996, CIRCULATION, V93, P1043; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Diesing TS, 2006, MOVEMENT DISORD, V21, P868, DOI 10.1002/mds.20831; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; JENNETT B, 1981, MANAGEMENT HEAD INJU, P84; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Lemke DM, 2007, CRIT CARE NURSE, V27, P30; Lemke Denise M, 2004, J Neurosci Nurs, V36, P4; Leone M, 2004, ANESTH ANALG, V99, P1193, DOI 10.1213/01.ANE.0000132546.79769.91; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Oh Su Jin, 2007, Korean Journal of Internal Medicine, V22, P51; PENFIELD W, 1954, AUTONOMIC SEIZURES E, P412; Rabinstein AA, 2004, ARCH NEUROL-CHICAGO, V61, P1625, DOI 10.1001/archneur.61.10.1625-a; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; Sacha J, 2005, J ELECTROCARDIOL, V38, P47, DOI 10.1016/j.jelectrocard.2004.09.015; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; Srinivasan S, 2007, CLIN AUTON RES, V17, P378, DOI 10.1007/s10286-007-0428-x; Tabachnick B.G., 2007, USING MULTIVARIATE S, V5; Tong CY, 2000, ANESTH ANALG, V91, P1450, DOI 10.1097/00000539-200012000-00028; Wang VY, 2008, J TRAUMA, V64, P500, DOI 10.1097/TA.0b013e31804a5738; Wijnen VJM, 2006, CLIN NEUROPHYSIOL, V117, P1794, DOI 10.1016/j.clinph.2006.03.006; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	41	50	55	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2009	90	4					580	586		10.1016/j.apmr.2008.10.020			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	432TD	WOS:000265156200007	19345772				2022-02-06	
J	Porcu, P; O'Buckley, TK; Alward, SE; Marx, CE; Shampine, LJ; Girdler, SS; Morrow, AL				Porcu, Patrizia; O'Buckley, Todd K.; Alward, Sarah E.; Marx, Christine E.; Shampine, Lawrence J.; Girdler, Susan S.; Morrow, A. Leslie			Simultaneous quantification of GABAergic 3 alpha,5 alpha/3 alpha,5 beta neuroactive steroids in human and rat serum	STEROIDS			English	Article						GABAergic neuroactive neurosteroid; Pregnenolone; Gas chromatography-mass spectrometry	TRAUMATIC BRAIN-INJURY; CHROMATOGRAPHY-MASS-SPECTROMETRY; MAJOR DEPRESSION; A RECEPTOR; GABA(A) RECEPTORS; CEREBRAL-CORTEX; 3-ALPHA-HYDROXY-5-ALPHA-PREGNAN-20-ONE LEVELS; NEUROSTEROID ALLOPREGNANOLONE; DEHYDROEPIANDROSTERONE LEVELS; PREMENSTRUAL-SYNDROME	The 3 alpha,5 alpha- and 3 alpha,5 beta-reduced derivatives of progesterone, deoxycorticosterone, dehydroepiandrosterone and testosterone enhance GABAergic neurotransmission and produce inhibitory neurobehavioral and anti-inflammatory effects. Despite Substantial information oil the progesterone derivative (3 alpha,5 alpha)-3-hydroxypregnan-20-one (3 alpha,5 alpha-THP, allopregnanolone), the physiological significance of the other endogenous GABAergic neuroactive steroids has remained elusive. Here, we describe the validation of a method using gas chromatography-mass spectrometry to simultaneously identify serum levels of the eight 3 alpha,5 alpha- and 3 alpha,5 beta-reduced derivatives of progesterone, deoxycorticosterone, dehydroepiandrosterone and testosterone. The method shows specificity. sensitivity and enhanced throughput compared to other methods already available for neuroactive steroid quantification. Administration of pregnenolone to rats and progesterone to women produced selective effects on the 3 alpha,5 alpha- and 3 alpha,5 beta-reduced neuroactive steroids, indicating differential regulation of their biosynthetic pathways. Pregnenolone administration increased serum levels of 3 alpha,5 alpha-THP (+1488%, p<0.001), (3 alpha,5 alpha)-3,21-dihydroxypregnan-20-one (3 alpha,5 alpha-THDOC, +205%, p<0.01), (3 alpha,5 alpha)-3-hydroxyandrostan-17-one (3 alpha,5 alpha-A, +216%, p<0.001), (3 alpha,5 alpha,17 beta)-androstane-3,17-diol (3 alpha,5 alpha-A-diol, +190%, p<0.01). (3 alpha,5 beta)-3-hydroxypregnan-20-one (3 alpha,5 beta-THP) and (3 alpha,5 beta)-3-hydroxyandrostan-17-one (3 alpha,5 beta-A) were not altered, while (3 alpha,5 beta)-3,21-dihydroxypregnan-20-one (3 alpha,5 beta-THDOC) and (3 alpha,5 beta,17 beta)-androstane-3,17-diol (3 alpha,5 beta-A-diol) were increased from undetectable levels to 271 +/- 100 and 2.4 +/- 0.9 pg +/- SEM, respectively (5/8 rats). Progesterone administration increased serum levels of 3 alpha,5 beta-THP (+1806%, p<0.0001), 3 alpha,5 beta-THP (+575%, p<0.001), 3 alpha,5 beta-THDOC (+309%, p<0.001). 3 alpha,5 beta-THDOC levels were increased by 307%, although this increase was not significant because this steroid was detected only in 3/16 control Subjects. Levels of 3 alpha,5 alpha-A, 3 alpha,5 beta-A and pregnenolone were not altered. This method can be used to investigate the physiological and pathological role of neuroactive steroids and to develop bioinarkers and new therapeutics for neurological and psychiatric disorders. (C) 2009 Elsevier Inc. All rights reserved.	[Porcu, Patrizia; O'Buckley, Todd K.; Alward, Sarah E.; Girdler, Susan S.; Morrow, A. Leslie] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA; [Porcu, Patrizia; O'Buckley, Todd K.; Alward, Sarah E.; Morrow, A. Leslie] Univ N Carolina, Sch Med, Bowles Ctr Alcahol Studies, Chapel Hill, NC 27599 USA; [Marx, Christine E.; Shampine, Lawrence J.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27705 USA; [Marx, Christine E.; Shampine, Lawrence J.] Dept Vet Affairs Med Ctr, Durham, NC 27705 USA; [Girdler, Susan S.] Univ N Carolina, Sch Med, Dept Psychol, Chapel Hill, NC 27599 USA; [Morrow, A. Leslie] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA		Morrow, AL (corresponding author), Univ N Carolina, Sch Med, Dept Psychiat, 3027 Thurston Bowles Bldg,CB7178, Chapel Hill, NC 27599 USA.	morrow@med.unc.edu	Porcu, Patrizia/B-8400-2015	Porcu, Patrizia/0000-0003-0848-7258; O'Buckley, Todd/0000-0001-8723-734X	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AA010564, U01 AA013515, U01 AA016677]; ALM [R01 MH051246]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH051246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R21AA016677, R37AA010564, U01AA013515, R01AA010564, U01AA016672] Funding Source: NIH RePORTER	The authors wish to express their appreciation to Drs. Synthia H. Mellon (University of California, San Francisco), Robert H. Purdy (The Scripps Research Institute, La Jolla, and Veterans Medical Research Foundation, San Diego, California) and Elena Romeo (Tor Vergata University, Rome, Italy) for many helpful discussions and Suggestions during the course of development and validation of this assay. We also wish to thank Dr. Steven M. Paul (Eli Lilly and Company, Indianapolis, Indiana) for helpful comments on the manuscript.; Source of Funding: This study was supported by the National Institute of Health grants R01 AA010564, U01 AA013515 and U01 AA016677 to ALM and R01 MH051246 to SSG.	Barbaccia ML, 2001, NEUROPSYCHOPHARMACOL, V25, P489, DOI 10.1016/S0893-133X(01)00254-8; BIGGIO G, 2001, INT REV NEUROBIOLOGY, V46; Brambilla F, 2003, PSYCHIAT RES, V118, P107, DOI 10.1016/S0165-1781(03)00077-5; Budzinski H, 2006, ANAL BIOANAL CHEM, V386, P1429, DOI 10.1007/s00216-006-0686-9; Buffet NC, 1998, FRONT NEUROENDOCRIN, V19, P151, DOI 10.1006/frne.1998.0167; CHENEY DL, 1995, J NEUROSCI, V15, P4641; Concas A, 2000, PHARMACOL BIOCHEM BE, V66, P39, DOI 10.1016/S0091-3057(00)00237-9; Concas A, 1998, P NATL ACAD SCI USA, V95, P13284, DOI 10.1073/pnas.95.22.13284; Concas A, 2006, PSYCHOPHARMACOLOGY, V186, P281, DOI 10.1007/s00213-005-0111-7; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; El-Etr M, 2005, J NEUROL SCI, V233, P49, DOI 10.1016/j.jns.2005.03.004; Evans SEG, 2005, GYNECOL ENDOCRINOL, V21, P268, DOI 10.1080/09513590500361747; Follesa P, 2002, NEUROPHARMACOLOGY, V42, P325, DOI 10.1016/S0028-3908(01)00187-3; Frye CA, 1996, BEHAV BRAIN RES, V79, P109, DOI 10.1016/0166-4328(96)00004-6; Genazzani AR, 1998, J CLIN ENDOCR METAB, V83, P2099, DOI 10.1210/jc.83.6.2099; GEORGE MS, 1994, BIOL PSYCHIAT, V35, P775, DOI 10.1016/0006-3223(94)91139-8; Girdler SS, 2001, BIOL PSYCHIAT, V49, P788, DOI 10.1016/S0006-3223(00)01044-1; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Grobin AC, 2005, PSYCHOPHARMACOLOGY, V179, P544, DOI 10.1007/s00213-004-2084-3; Grobin AC, 2001, DEV BRAIN RES, V131, P31; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hill M, 2000, J STEROID BIOCHEM, V75, P237, DOI 10.1016/S0960-0760(00)00192-8; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Kaminski RM, 2005, EPILEPSIA, V46, P819, DOI 10.1111/j.1528-1167.2005.00705.x; Kancheva L, 2007, STEROIDS, V72, P792, DOI 10.1016/j.steroids.2007.06.006; Kim YS, 2000, ANAL BIOCHEM, V277, P187, DOI 10.1006/abio.1999.4384; Klak J, 2003, PHYSIOL RES, V52, P211; Klatzkin RR, 2006, PSYCHONEUROENDOCRINO, V31, P1208, DOI 10.1016/j.psyneuen.2006.09.002; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Liere P, 2000, J CHROMATOGR B, V739, P301, DOI 10.1016/S0378-4347(99)00563-0; Lombardi I, 2004, GYNECOL ENDOCRINOL, V18, P79, DOI 10.1080/09513590310001652955; Maguire JL, 2005, NAT NEUROSCI, V8, P797, DOI 10.1038/nn1469; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Marx CE, 2000, BIOL PSYCHIAT, V47, P1000, DOI 10.1016/S0006-3223(99)00305-4; Marx CE, 2003, NEUROPSYCHOPHARMACOL, V28, P1, DOI 10.1038/sj.npp.1300015; MARX CE, 2008, INT J NEUROPSYCHOPH, P1; Marx CE, 2007, BIOL PSYCHIAT, V61, p13S; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P598, DOI 10.1016/j.pbb.2006.07.026; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P609, DOI 10.1016/j.pbb.2006.07.032; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Morrow A Leslie, 2006, Dialogues Clin Neurosci, V8, P463; Morrow AL, 2007, PHARMACOL THERAPEUT, V116, P1, DOI 10.1016/j.pharmthera.2007.04.003; Morrow AL, 1998, NATURE, V395, P652, DOI 10.1038/27106; Naylor JC, 2008, J CLIN ENDOCR METAB, V93, P3173, DOI 10.1210/jc.2007-1229; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Pieribone VA, 2007, EPILEPSIA, V48, P1870, DOI 10.1111/j.1528-1167.2007.01182.x; Pisu MG, 2004, LIFE SCI, V74, P3181, DOI 10.1016/j.lfs.2003.12.002; Porcu P, 2003, PHARMACOL BIOCHEM BE, V74, P683, DOI 10.1016/S0091-3057(02)01065-1; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; PURDY RH, 2007, HDB NEUROCHEMISTRY M, P1; Rasmusson AM, 2006, BIOL PSYCHIAT, V60, P704, DOI 10.1016/j.biopsych.2006.03.026; Ritsner M, 2007, EUR NEUROPSYCHOPHARM, V17, P358, DOI 10.1016/j.euroneuro.2006.10.001; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; Savitz AJ, 2007, SCHIZOPHRENIA BULL, V33, P458; Schule C, 2006, MOL PSYCHIATR, V11, P261, DOI 10.1038/sj.mp.4001782; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shen H, 2007, NAT NEUROSCI, V10, P469, DOI 10.1038/nn1868; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; STENBERG A, 1976, J ENDOCRINOL, V68, P265, DOI 10.1677/joe.0.0680265; Strohle A, 1999, BIOL PSYCHIAT, V45, P274, DOI 10.1016/S0006-3223(98)00328-X; Strohle A, 2003, ARCH GEN PSYCHIAT, V60, P161, DOI 10.1001/archpsyc.60.2.161; Uzunov DP, 1996, P NATL ACAD SCI USA, V93, P12599, DOI 10.1073/pnas.93.22.12599; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Vallee M, 2000, ANAL BIOCHEM, V287, P153, DOI 10.1006/abio.2000.4841; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2008, BRAIN RES REV, V57, P398, DOI 10.1016/j.brainresrev.2007.08.010; Wang MD, 1996, J CLIN ENDOCR METAB, V81, P1076, DOI 10.1210/jc.81.3.1076; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932	72	50	50	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0039-128X	1878-5867		STEROIDS	Steroids	APR-MAY	2009	74	4-5					463	473		10.1016/j.steroids.2008.12.015			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	429ST	WOS:000264941100010	19171160	Green Accepted, Green Submitted			2022-02-06	
J	Giza, CC; Kolb, B; Harris, NG; Asarnow, RF; Prins, ML				Giza, Christopher C.; Kolb, Bryan; Harris, Neil G.; Asarnow, Robert F.; Prins, Mayumi L.			Hitting a moving target: Basic mechanisms of recovery from acquired developmental brain injury	DEVELOPMENTAL NEUROREHABILITATION			English	Article						experience-dependent plasticity; environmental; age; pediatric; child	CHONDROITIN SULFATE PROTEOGLYCANS; FLUID PERCUSSION INJURY; CEREBRAL HYPOXIA-ISCHEMIA; AGE-DEPENDENT DIFFERENCES; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; CLOSED-HEAD-INJURY; RAT-BRAIN; FUNCTIONAL RECOVERY; ENVIRONMENTAL ENRICHMENT	Acquired brain injuries represent a major cause of disability in the pediatric population. Understanding responses to developmental acquired brain injuries requires knowledge of the neurobiology of normal development, age-at-injury effects and experience-dependent neuroplasticity. In the developing brain, full recovery cannot be considered as a return to the premorbid baseline, since ongoing maturation means that cerebral functioning in normal individuals will continue to advance. Thus, the recovering immature brain has to 'hit a moving target' to achieve full functional recovery, defined as parity with age-matched uninjured peers. This review will discuss the consequences of developmental injuries such as focal lesions, diffuse hypoxia and traumatic brain injury (TBI). Underlying cellular and physiological mechanisms relevant to age-at-injury effects will be described in considerable detail, including but not limited to alterations in neurotransmission, connectivity/network functioning, the extracellular matrix, response to oxidative stress and changes in cerebral metabolism. Finally, mechanisms of experience-dependent plasticity will be reviewed in conjunction with their effects on neural repair and recovery.	[Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Mattel Childrens Hosp UCLA, Div Pediat Neurol, Los Angeles, CA USA; [Kolb, Bryan] Univ Lethbridge, Dept Neurosci, Lethbridge, AB T1K 3M4, Canada; [Asarnow, Robert F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA		Giza, CC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Brain Injury Res Ctr, Room 18-218B Semel Inst,10833 Le Conte Blvd, Los Angeles, CA 90095 USA.	cgiza@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739; Harris, Neil/0000-0002-1965-6750	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057420, NS027544, NS052406, NS055910]; Child Neurology Foundation/Winokur Family Foundation; UCLA FGP; Thrasher Research Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052406, R01NS027544, R01NS055910, K02NS057420] Funding Source: NIH RePORTER	Supported by grants from the National Institutes of Health (C. C. G. NS057420, NS027544, M. L. P. NS052406, N.G.H. NS055910), the Child Neurology Foundation/Winokur Family Foundation (C. C. G.), UCLA FGP (C. C. G., M. L. P.) and the Thrasher Research Foundation (C.C.G.).	Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; ASPBERG A, 1992, DEV BRAIN RES, V66, P55, DOI 10.1016/0165-3806(92)90139-N; Aya-ay J, 2005, EXP NEUROL, V193, P149, DOI 10.1016/j.expneurol.2004.11.021; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bavelier D, 2006, TRENDS COGN SCI, V10, P512, DOI 10.1016/j.tics.2006.09.006; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; BenAri Y, 1997, TRENDS NEUROSCI, V20, P523, DOI 10.1016/S0166-2236(97)01147-8; BERKER EA, 1986, ARCH NEUROL-CHICAGO, V43, P1065, DOI 10.1001/archneur.1986.00520100069017; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Branchi I, 2004, BEHAV PHARMACOL, V15, P353, DOI 10.1097/00008877-200409000-00006; Bredy TW, 2003, EUR J NEUROSCI, V18, P2903, DOI 10.1111/j.1460-9568.2003.02965.x; Broca P., 1865, B SOC ANTHROPOL PAR, P337, DOI DOI 10.3406/BMSAP.1865.9495; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925; CELIO MR, 1994, BRAIN RES REV, V19, P128, DOI 10.1016/0165-0173(94)90006-X; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; CHIRON C, 1992, J NUCL MED, V33, P696; Chou IC, 2001, STROKE, V32, P2192, DOI 10.1161/hs0901.095656; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Cirulli F, 2003, NEUROSCI BIOBEHAV R, V27, P73, DOI 10.1016/S0149-7634(03)00010-1; Cirulli F, 2009, NEUROSCI BIOBEHAV R, V33, P573, DOI 10.1016/j.neubiorev.2008.09.001; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Collignon O, 2009, EXP BRAIN RES, V192, P343, DOI 10.1007/s00221-008-1553-z; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CREMER JE, 1976, BIOCHIM BIOPHYS ACTA, V448, P633, DOI 10.1016/0005-2736(76)90120-6; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Curtiss S, 2001, BRAIN LANG, V79, P379, DOI 10.1006/brln.2001.2487; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Danysz W, 1998, PHARMACOL REV, V50, P597; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Dean JM, 2005, MOL BRAIN RES, V139, P242, DOI 10.1016/j.molbrainres.2005.05.026; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DIAMOND MC, 1983, EXP NEUROL, V81, P1, DOI 10.1016/0014-4886(83)90153-X; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; DIAMOND MC, 1975, BEHAV BIOL, V14, P163, DOI 10.1016/S0091-6773(75)90161-3; Dreiem A, 2005, TOXICOL SCI, V87, P156, DOI 10.1093/toxsci/kfi224; Driscoll I, 2007, BRAIN RES, V1178, P38, DOI 10.1016/j.brainres.2007.08.031; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FIELD TM, 1986, PEDIATRICS, V77, P654; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Finger S, 1999, J Hist Neurosci, V8, P269, DOI 10.1076/jhin.8.3.269.1824; Follett PL, 2000, J NEUROSCI, V20, P9235; Fredriksson A, 2004, BEHAV BRAIN RES, V153, P367, DOI 10.1016/j.bbr.2003.12.026; Fumagalli F, 2007, PROG NEUROBIOL, V81, P197, DOI 10.1016/j.pneurobio.2007.01.002; GIBB, 2009, COMMUNICATION; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Goldman P S, 1974, Neurosci Res Program Bull, V12, P217; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; Gucuyener K, 1999, CLIN NEUROL NEUROSUR, V101, P171, DOI 10.1016/S0303-8467(99)00035-9; GUNN AJ, 2000, CURRENT OPINIONS PED, V12, P115; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; HALLIWELL C, 2009, PRENATAL CHOLI UNPUB; HARRIS N, 2009, J NEUROSCIE IN PRESS; Harris N, 2006, J NEUROTRAUM, V23, P1019; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X; Henderson ST, 2008, NEUROTHERAPEUTICS, V5, P470, DOI 10.1016/j.nurt.2008.05.004; Hotz GA, 2006, BRAIN INJURY, V20, P879, DOI 10.1080/02699050600832635; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; JACOBS B, 1993, J COMP NEUROL, V327, P97, DOI 10.1002/cne.903270108; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; Johnston MV, 2004, BRAIN DEV-JPN, V26, P73, DOI 10.1016/S0387-7604(03)00102-5; Johnston MV, 2003, EXP NEUROL, V184, pS37, DOI 10.1016/S0014-4886(03)00355-8; Kaufman J, 2006, BIOL PSYCHIAT, V60, P669, DOI 10.1016/j.biopsych.2006.09.002; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477, DOI 10.1152/jn.1938.1.6.477; Kennard MA, 1943, J NEUROPHYSIOL, V6, P181, DOI 10.1152/jn.1943.6.3.181; Kennard MA, 1942, ARCH NEURO PSYCHIATR, V48, P227, DOI 10.1001/archneurpsyc.1942.02290080073002; KENNARD MA, 1942, MT SINAI J MED, V9, P594; KENNARD MA, 1940, ARCH NEUROLOGY PSYCH, V48, P227; Kolb B, 1996, BEHAV BRAIN RES, V79, P1, DOI 10.1016/0166-4328(95)00254-5; Kolb B, 1998, BEHAV BRAIN RES, V91, P127, DOI 10.1016/S0166-4328(97)00112-5; Kolb B, 2003, NEUROBIOL LEARN MEM, V79, P1, DOI 10.1016/S1074-7427(02)00021-7; Kolb B, 1997, BEHAV BRAIN RES, V89, P61, DOI 10.1016/S0166-4328(97)00058-2; KOLB B, 1993, BEHAV NEUROSCI, V107, P799, DOI 10.1037/0735-7044.107.5.799; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; KOLB B, 2009, TACTILE STIMUL UNPUB; Koppe G, 1997, CELL TISSUE RES, V288, P33, DOI 10.1007/s004410050790; KOZLOWSKI DA, 1994, RESTOR NEUROL NEUROS, V7, P119, DOI 10.3233/RNN-1994-7207; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Kumar A, 2008, PEDIATRICS, V122, pE722, DOI 10.1542/peds.2008-0269; Lander C, 1997, J NEUROSCI, V17, P1928; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Law AJ, 2003, EUR J NEUROSCI, V18, P1197, DOI 10.1046/j.1460-9568.2003.02850.x; LEONG SF, 1984, BIOCHEM J, V218, P131, DOI 10.1042/bj2180131; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Lewis TL, 2005, DEV PSYCHOBIOL, V46, P163, DOI 10.1002/dev.20055; Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Manning SM, 2008, J NEUROSCI, V28, P6670, DOI 10.1523/JNEUROSCI.1702-08.2008; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Marsh EB, 2009, CORTEX, V45, P677, DOI 10.1016/j.cortex.2008.06.012; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matsui F, 2005, J NEUROSCI RES, V81, P837, DOI 10.1002/jnr.20603; MAVELLI I, 1982, BIOCHEM J, V204, P535, DOI 10.1042/bj2040535; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDonald J W, 1993, NIDA Res Monogr, V133, P185; McLean C, 2004, SEMIN PERINATOL, V28, P425, DOI 10.1053/j.semperi.2004.10.005; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; MILLER B, 1995, J COMP NEUROL, V355, P615, DOI 10.1002/cne.903550410; Mirescu C, 2004, NAT NEUROSCI, V7, P841, DOI 10.1038/nn1290; Monfils MH, 2008, EXP BRAIN RES, V185, P453, DOI 10.1007/s00221-007-1172-0; Monfils MH, 2006, EUR J NEUROSCI, V24, P739, DOI 10.1111/j.1460-9568.2006.04939.x; Monfils MH, 2005, NEUROSCIENCE, V134, P1, DOI 10.1016/j.neuroscience.2005.04.006; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; NEDERGAARD M, 1987, Neurological Research, V9, P241; NEHLIG A, 1991, NEUROSCIENCE, V40, P871, DOI 10.1016/0306-4522(91)90018-J; NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83; NEHLIG A, 1987, NEUROCHEM RES, V12, P641, DOI 10.1007/BF00971014; Okamoto M, 2003, EXP NEUROL, V184, P179, DOI 10.1016/S0014-4886(03)00251-6; Okamoto M, 2001, CELL TISSUE RES, V306, P217, DOI 10.1007/s004410100441; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Papadopoulos CM, 2006, CEREB CORTEX, V16, P529, DOI 10.1093/cercor/bhi132; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Prakash A, 2008, CURR OPIN ANESTHESIO, V21, P565, DOI 10.1097/ACO.0b013e32830f44e4; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Ptito M, 2008, EXP BRAIN RES, V184, P193, DOI 10.1007/s00221-007-1091-0; Pu YL, 2000, AM J NEURORADIOL, V21, P203; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; Qiu DQ, 2008, NEUROIMAGE, V41, P223, DOI 10.1016/j.neuroimage.2008.02.023; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; Rho JM, 2001, J CHILD NEUROL, V16, P271, DOI 10.2310/7010.2001.18013; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; SCHANBERG SM, 1987, CHILD DEV, V58, P1431, DOI 10.1111/j.1467-8624.1987.tb03856.x; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; SCHEETZ AJ, 1994, FASEB J, V8, P745, DOI 10.1096/fasebj.8.10.8050674; Seyfried Thomas N, 2005, Nutr Metab (Lond), V2, P30, DOI 10.1186/1743-7075-2-30; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Sowell ER, 2002, DEV MED CHILD NEUROL, V44, P4, DOI 10.1017/S0012162201001591; Spencer S, 2008, LANCET NEUROL, V7, P525, DOI 10.1016/S1474-4422(08)70109-1; Stefovska VG, 2008, ANN NEUROL, V64, P434, DOI 10.1002/ana.21463; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Towfighi J, 1997, DEV BRAIN RES, V100, P149, DOI 10.1016/S0165-3806(97)00036-9; Trainor LJ, 2005, DEV PSYCHOBIOL, V46, P262, DOI 10.1002/dev.20059; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; Tsujimoto S, 2008, NEUROSCIENTIST, V14, P345, DOI 10.1177/1073858408316002; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Van't Hooft I, 2005, BRAIN INJURY, V19, P511, DOI 10.1080/02699050400025224; Vannucci RC, 1997, PEDIATRICS, V100, P1004, DOI 10.1542/peds.100.6.1004; Vannucci RC, 1997, ANN NY ACAD SCI, V835, P234, DOI 10.1111/j.1749-6632.1997.tb48634.x; VANNUCCI RC, 1993, APMIS, V101, P89; VANNUCCI RC, 1987, PEDIATR RES, V21, P524, DOI 10.1203/00006450-198706000-00002; Vannucci SJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE1127, DOI 10.1152/ajpendo.00187.2003; VOLKMAR FR, 1972, SCIENCE, V176, P1445, DOI 10.1126/science.176.4042.1445; VOORHIES TM, 1986, NEUROLOGY, V36, P1115, DOI 10.1212/WNL.36.8.1115; Voss P, 2008, NEUROIMAGE, V40, P746, DOI 10.1016/j.neuroimage.2007.12.020; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Weiner H. L., 2000, HEAD INJURY, P419; Werker JF, 2005, DEV PSYCHOBIOL, V46, P233, DOI 10.1002/dev.20060; WEST RW, 1972, BEHAV BIOL, V7, P279, DOI 10.1016/S0091-6773(72)80207-4; Wilson MT, 2000, J COMP NEUROL, V424, P532, DOI 10.1002/1096-9861(20000828)424:3<532::AID-CNE10>3.0.CO;2-Z; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; 2005, BRAIN, V128, P1536	199	50	52	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1751-8423	1751-8431		DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	5					255	268		10.3109/17518420903087558			14	Clinical Neurology; Pediatrics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FS	WOS:000207788500002	19956795	Green Accepted			2022-02-06	
J	Levack, WMM; Siegert, RJ; Dean, SG; McPherson, KM				Levack, William M. M.; Siegert, Richard J.; Dean, Sarah G.; McPherson, Kath M.			Goal planning for adults with acquired brain injury: How clinicians talk about involving family	BRAIN INJURY			English	Article						Goal setting; family; rehabilitation; stroke; traumatic brain injury	QUALITY-OF-LIFE; REHABILITATION PROCESS; STROKE REHABILITATION; PATIENT; PARTICIPATION; PROFESSIONALS; CARE; INTERVENTIONS; COMMUNICATION; EXPERIENCES	Primary objective: Although family involvement is frequently identified as a key element of successful rehabilitation, questions remain about 'how' clinicians can best involve them. This study explored how clinicians talk about the involvement of families in goal-planning during rehabilitation of adults with acquired brain injury. Research design: Qualitative study drawing on grounded theory to elicit practitioner perspectives. Methods and procedures: Nine clinicians from a range of professional backgrounds were interviewed. Interview data were transcribed and analysed using the constant comparative method of grounded theory. NVivo software was used to assist with data management. Main outcomes and results: While family were often considered valuable contributors to the goal-planning process, they were also seen as potential barriers to the negotiation of goals between clinicians and patients and to patient-clinician relationships. Clinicians described restricting involvement of family members in situations where such involvement was thought not to be in the best interests of the patient. Conclusions: Goal-planning appeared patient-centred rather than family-centred. Further, clinicians identified concerns about extending family involvement in goal-planning. If clinicians intend to address the needs of family members as well as patients, current approaches to goal-planning (and rehabilitation funding) may need to be reconsidered.	[Levack, William M. M.; Dean, Sarah G.] Univ Otago, Rehabil Teaching & Res Unit, Wellington Sch Med & Hlth Sci, Wellington, New Zealand; [Siegert, Richard J.] Kings Coll London, London, England; [McPherson, Kath M.] Auckland Univ Technol, Div Rehabil & Occupat Studies, Auckland, New Zealand		Levack, WMM (corresponding author), Univ Otago Wellington, Rehabil Teaching & Res Unit, POB 7343, Wellington, New Zealand.	william.levack@otago.ac.nz	Siegert, Richard J./K-2030-2019; Levack, William Mark Magnus/F-9607-2018; Siegert, Richard/C-3241-2009	Levack, William Mark Magnus/0000-0001-6631-908X; Dean, Sarah/0000-0002-3682-5149; Siegert, Richard/0000-0002-3074-0929; McPherson, Kathryn/0000-0003-1240-8882; McPherson, Kath/0000-0003-0487-8497			Abreu BC, 2002, BRAIN INJURY, V16, P691, DOI 10.1080/02699050210128942; Arnetz J, 2004, ADV PHYSIOTHER, V6, P50, DOI DOI 10.1080/14038190310017147; Baker SM, 2001, PHYS THER, V81, P1118, DOI 10.1093/ptj/81.5.1118; BASKETT J, 2003, LIFE STROKE NZ GUIDE; BECKER MC, 1974, ARCH PHYS MED REHAB, V55, P87; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; Boschen K, 2007, NEUROREHABILITATION, V22, P19; *CAN STROK NETW HE, 2006, CAN STROK STRAT CAN; Carswell Anne, 2004, Can J Occup Ther, V71, P210; Conneeley A. L., 2004, BR J OCCUP THER, V67, P248, DOI DOI 10.1177/030802260406700603; Davis A, 1992, CLIN REHABIL, V6, P237; Duff J, 2004, CLIN REHABIL, V18, P275, DOI 10.1191/0269215504cr720oa; Duncan PW, 2005, STROKE, V36, pE100, DOI 10.1161/01.STR.0000180861.54180.FF; ELSWORTH JD, 1999, TOP STROKE REHABIL, V6, P51; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Holliday RC, 2005, NEUROREHAB NEURAL RE, V19, P227, DOI 10.1177/1545968305279206; King RB, 1996, STROKE, V27, P1467, DOI 10.1161/01.STR.27.9.1467; Kuipers P, 2003, DISABIL REHABIL, V25, P154, DOI 10.1080/0963828021000024898; Lefebvre H, 2005, BRAIN INJURY, V19, P585, DOI 10.1080/02699050400025026; Levack WMM, 2006, BRAIN INJURY, V20, P1439, DOI 10.1080/02699050601118422; Levack WMM, 2006, CLIN REHABIL, V20, P739, DOI 10.1177/0269215506070791; Levack WMM, 2006, DISABIL REHABIL, V28, P741, DOI 10.1080/09638280500265961; LEVACK WMM, 2008, THESIS U OTAGO WELLI; Lewin S. A., 2001, COCHRANE DB SYST REV, V4, P3267, DOI DOI 10.1002/14651858.CD003267; Lynch EB, 2008, J REHABIL MED, V40, P518, DOI 10.2340/16501977-0203; MacGregor K, 2006, J AM BOARD FAM MED, V19, P215, DOI 10.3122/jabfm.19.3.215; Macpherson R., 1999, J MENTAL HLTH, V8, P95; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; Man DWK, 2003, BRAIN INJURY, V17, P437, DOI 10.1080/0269905031000070152; Marks JA, 1995, CLIN REHABIL, V9, P320; Mastos M, 2007, CLIN REHABIL, V21, P47, DOI 10.1177/0269215506073494; McCann Terence V, 2003, Nurse Res, V11, P7; McClain Colleen, 2005, Top Stroke Rehabil, V12, P56, DOI 10.1310/ELB1-EGKF-QUQC-VFE9; McMillan TM, 1999, NEUROPSYCHOL REHABIL, V9, P241, DOI 10.1080/096020199389356; Melville LL, 2002, AM J OCCUP THER, V56, P650, DOI 10.5014/ajot.56.6.650; Ministry of Health, 2002, HE KOR OR MAOR HLTH; Monaghan J, 2005, CLIN REHABIL, V19, P194, DOI 10.1191/0269215505cr837oa; Morse J. M., 2002, README 1 USERS GUIDE; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Parry RH, 2004, CLIN REHABIL, V18, P668, DOI 10.1191/0269215504cr745oa; Playford ED, 2000, CLIN REHABIL, V14, P491, DOI 10.1191/0269215500cr343oa; Pollock N., 2005, CANADIAN OCCUPATIONA; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Randall KE, 2000, PHYS THER, V80, P1197, DOI 10.1093/ptj/80.12.1197; Rochette A, 2007, J REHABIL MED, V39, P513, DOI 10.2340/16501977-0082; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Sohlberg MM, 2001, J HEAD TRAUMA REHAB, V16, P498, DOI 10.1097/00001199-200110000-00008; Stern P N, 1980, Image (IN), V12, P20; Strauss A., 1998, BASICS QUALITATIVE R, V2nd Edition; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Turner-Stokes L, 2000, CLIN REHABIL, V14, P468, DOI 10.1191/0269215500cr349oa; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Visser-Meily A, 2006, DISABIL REHABIL, V28, P1557, DOI 10.1080/09638280600648215; WADE DT, 1999, TOP STROKE REHABIL, V6, P1; Wade DT., 1999, TOP STROKE REHABIL, V6, P16; Walker AJ, 2005, BRAIN INJURY, V19, P1237, DOI 10.1080/02699050500309411; Wallace SE, 2007, BRAIN INJURY, V21, P1371, DOI 10.1080/02699050701785088; WEBB PM, 1994, REHABIL PSYCHOL, V39, P179, DOI 10.1037/h0080321; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640; Wressle E, 1999, DISABIL REHABIL, V21, P80, DOI 10.1080/096382899298016	61	50	50	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	3					192	202	PII 908622880	10.1080/02699050802695582			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	406AJ	WOS:000263267100002	19205955				2022-02-06	
J	Batchelor, PE; Tan, S; Wills, TE; Porritt, MJ; Howells, DW				Batchelor, Peter E.; Tan, Simon; Wills, Taryn E.; Porritt, Michelle J.; Howells, David W.			Comparison of Inflammation in the Brain and Spinal Cord following Mechanical Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	International Symposium on Traumatic Brain Injury Research Priorities	OCT 13-16, 2005	Johnstown, PA	John P Murtha Neursci & Pain Inst, Natl Brain Injury Res, Treatments & Training Fdn, Brain Injury Assoc Amer		brain; inflammation; injury; macrophage; spinal cord	CENTRAL-NERVOUS-SYSTEM; ACTIVATED MACROPHAGES; NEUROTROPHIC FACTOR; AXON REGENERATION; CELLULAR REACTION; MICROGLIAL CELLS; MOTOR FUNCTION; OPTIC-NERVE; RAT; METHYLPREDNISOLONE	Inflammation in the CNS predominantly involves microglia and macrophages, and is believed to be a significant cause of secondary injury following trauma. This study compares the microglial and macrophage response in the rat brain and spinal cord following discrete mechanical injury to better appreciate the degree to which these cells could contribute to secondary damage in these areas. We find that, 1 week after injury, the microglial and macrophage response is significantly greater in the spinal cord compared to the brain. This is the case for injuries to both gray and white matter. In addition, we observed a greater inflammatory response in white matter compared to gray matter within both the brain and spinal cord. Because activated microglia and macrophages appear to be effectors of secondary damage, a greater degree of inflammation in the spinal cord is likely to result in more extensive secondary damage. Tissue saving strategies utilizing anti-inflammatory treatments may therefore be more useful in traumatic spinal cord than brain injury.	[Howells, David W.] Austin Hlth, Dept Med, Heidelberg, Vic 3084, Australia; Austin Hlth, Dept Neurol, Heidelberg, Vic 3084, Australia		Howells, DW (corresponding author), Austin Hlth, Dept Med, Heidelberg, Vic 3084, Australia.	david.howells@unimelb.edu.au		Howells, David/0000-0002-2512-7724			Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Batchelor PE, 2000, EUR J NEUROSCI, V12, P3462, DOI 10.1046/j.1460-9568.2000.00239.x; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 2002, EUR J NEUROSCI, V15, P826, DOI 10.1046/j.1460-9568.2002.01914.x; Batchelor PE, 1999, J NEUROSCI, V19, P1708; BIGNAMI A, 1969, BRAIN RES, V13, P444, DOI 10.1016/0006-8993(69)90259-5; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; BLIGHT AR, 1992, J NEUROTRAUMA S, V1, pS83; Bomstein Y, 2003, J NEUROIMMUNOL, V142, P10, DOI 10.1016/S0165-5728(03)00260-1; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; EIDELBERG E, 1977, EXP NEUROL, V56, P312, DOI 10.1016/0014-4886(77)90350-8; FAWCETT JW, 2001, BRAIN DAMAGE BRAIN R, P15; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.3.CO;2-6; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Gomes-Leal W, 2005, BRAIN RES, V1066, P57, DOI 10.1016/j.brainres.2005.10.069; GREEN BA, 1980, SURG NEUROL, V13, P91; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HOLTZ A, 1990, ACTA NEUROL SCAND, V82, P68; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; Lorber B, 2005, EUR J NEUROSCI, V21, P2029, DOI 10.1111/j.1460-9568.2005.04034.x; Mayhan WG, 2001, MICROCIRCULATION, V8, P89, DOI 10.1038/sj.mn.7300154; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Paxinos G, 1986, RAT BRAIN STEREOTAXI; POPOVICH PG, 1993, J NEUROTRAUM, V10, P37, DOI 10.1089/neu.1993.10.37; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Reijerkerk A, 2006, FASEB J, V20, P2550, DOI 10.1096/fj.06-6099fje; RIVADEPATY I, 1994, EXP NEUROL, V128, P77, DOI 10.1006/exnr.1994.1114; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Szczepanik AM, 1996, NEUROSCIENCE, V70, P57, DOI 10.1016/0306-4522(95)00296-U; Takami T, 2002, J NEUROTRAUM, V19, P653, DOI 10.1089/089771502753754118; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; WAKEFIELD CL, 1975, EXP NEUROL, V48, P637, DOI 10.1016/0014-4886(75)90020-5; Watanabe T, 1999, J NEUROTRAUM, V16, P255, DOI 10.1089/neu.1999.16.255; Weaver LC, 2005, J NEUROTRAUM, V22, P1375, DOI 10.1089/neu.2005.22.1375; WINDLE WF, 1958, NEUROLOGY, V8, P518, DOI 10.1212/WNL.8.7.518; Wu JM, 2006, BRAIN RES, V1098, P79, DOI 10.1016/j.brainres.2006.04.074; Yin YQ, 2003, J NEUROSCI, V23, P2284; Young W, 1991, J Neurotrauma, V8 Suppl 1, pS43	58	50	53	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2008	25	10					1217	1225		10.1089/neu.2007.0308			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	370XK	WOS:000260796200010	18986223				2022-02-06	
J	Chen, JR; Cheng, GY; Sheu, CC; Tseng, GF; Wang, TJ; Huang, YS				Chen, Jeng-Rung; Cheng, Guang-Yan; Sheu, Ching-Chung; Tseng, Guo-Fang; Wang, Tsyr-Jiuan; Huang, Yong-San			Transplanted bone marrow stromal cells migrate, differentiate and improve motor function in rats with experimentally induced cerebral stroke	JOURNAL OF ANATOMY			English	Article						astrocyte; bone marrow stromal cells; cerebral stroke; differentiation; migration; oligodendrocyte	TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; SPINAL-CORD; INTRACEREBRAL TRANSPLANTATION; ISCHEMIC BRAIN; GROWTH-FACTOR; THERAPEUTIC BENEFIT; NEURAL PHENOTYPES; FOCAL ISCHEMIA; ADULT RATS	Bone marrow stromal cells are multipotential cells that can be induced to differentiate into osteoblasts, chondrocytes, myocytes and adipocytes in different microenvironments. Recent studies revealed that bone marrow stromal cells could improve neurological deficits of various damages or diseases of the central nervous system such as Parkinson's disease, brain trauma, spinal cord injury and multiple sclerosis, and promote glia-axonal remodeling in animal brain subjected to an experimentally induced stroke. In the present study, bone marrow stromal cells were intracerebrally transplanted into the cerebrum following a transient middle cerebral artery occlusion. Our aim was to find out whether the bone marrow stromal cells could survive and express neural phenotypic proteins and, in addition, whether they could restore the behavioral and functional deficits of the cerebral ischemic rats. Our results demonstrated that transplanted bone marrow stromal cells survived and migrated to areas around the lesion site. Some of them exhibited marker proteins of astrocytes and oligodendrocytes. Bone marrow stromal cell implantation significantly reduced the transient middle cerebral artery occlusion-induced cortical loss and thinning of the white matter and enhanced cortical beta-III-tubulin immunoreactivity. Rats implanted with bone marrow stromal cells showed significant improvement in their performance of elevated body swing test and forelimb footprint analysis and only transient recovery of the adhesive-removal test. Our data support bone marrow stromal cells as a valuable source of autologous or allogenic donor cells for transplantation to improve the outcome following cerebral ischemia.	[Chen, Jeng-Rung; Cheng, Guang-Yan; Sheu, Ching-Chung; Huang, Yong-San] Natl Chung Hsing Univ, Dept Vet Med, Coll Vet Med, Taichung 402, Taiwan; [Tseng, Guo-Fang] Tzu Chi Univ, Dept Anat, Coll Med, Hualien, Taiwan; [Wang, Tsyr-Jiuan] Natl Taichung Nursing Coll, Dept Nursing, Taichung, Taiwan		Huang, YS (corresponding author), Natl Chung Hsing Univ, Dept Vet Med, Coll Vet Med, 250 Kuo Kuang Rd, Taichung 402, Taiwan.	wtj@ntcnc.edu.tw; yshuang@mail.nchu.edu.tw		Wang, Tsyr-Jiuan/0000-0001-5693-2200; Chen, Jeng-Rung/0000-0002-4429-283X	National Science Council of TaiwanMinistry of Science and Technology, Taiwan [NSC-95-2313-B-005-046, NSC-95-2320-B-438-001]	This work was supported by research grants from the National Science Council of Taiwan (NSC-95-2313-B-005-046 and NSC-95-2320-B438-001) to J.-R.C. and T.-J.W.	Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BEDNAR MM, 1994, NEUROL RES, V16, P129; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Borlongan CV, 1998, NEUROREPORT, V9, P3615, DOI 10.1097/00001756-199811160-00012; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Cao Q, 2007, J NEUROSCI RES, V85, P116, DOI 10.1002/jnr.21092; Chen CH, 2007, J NEUROCHEM, V102, P1831, DOI 10.1111/j.1471-4159.2007.04652.x; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chen Y, 2007, J CELL BIOCHEM, V102, P52, DOI 10.1002/jcb.21275; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Dormady SP, 2001, J HEMATOTH STEM CELL, V10, P125, DOI 10.1089/152581601750098372; EAVES CJ, 1991, BLOOD, V78, P110; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; Grassel S, 2007, ORTHOPADE, V36, P227, DOI 10.1007/s00132-007-1058-7; Hermann A, 2006, J NEUROSCI RES, V83, P1502, DOI 10.1002/jnr.20840; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; Ishibashi S, 2003, ACT NEUR S, V86, P159; Ishibashi S, 2003, STROKE, V34, P1501, DOI 10.1161/01.STR.0000074034.32371.13; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kao TK, 2006, NEUROCHEM INT, V48, P166, DOI 10.1016/j.neuint.2005.10.008; Kronenwett R, 2006, MED KLIN, V101, P182; Li Y, 2006, EXP NEUROL, V198, P313, DOI 10.1016/j.expneurol.2005.11.029; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Liao SL, 2004, NEUROSCI LETT, V372, P40, DOI 10.1016/j.neulet.2004.09.013; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mimura T, 2005, J NEUROPATH EXP NEUR, V64, P1108, DOI 10.1097/01.jnen.0000190068.03009.b5; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; OWEN M, 1988, J CELL SCI, P63; OWEN M, 1988, CIBA F SYMP, V136, P42; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Sensebe L, 1997, STEM CELLS, V15, P133, DOI 10.1002/stem.150133; Seyfried D, 2006, J NEUROSURG, V104, P313, DOI 10.3171/jns.2006.104.2.313; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Sughrue ME, 2006, J NEUROSCI METH, V151, P83, DOI 10.1016/j.jneumeth.2005.04.023; Suzuki H, 2004, BIOCHEM BIOPH RES CO, V322, P918, DOI 10.1016/j.bbrc.2004.07.201; TANAKA R, 1995, STROKE, V26, P2154, DOI 10.1161/01.STR.26.11.2154; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Wang ZH, 2002, NEUROSCIENCE, V113, P629, DOI 10.1016/S0306-4522(02)00204-X; Wlodarski Krzysztof H, 2006, Ortop Traumatol Rehabil, V8, P573; Yu S, 2006, BIOCHEM BIOPH RES CO, V344, P1071, DOI 10.1016/j.bbrc.2006.03.231; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	61	50	61	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8782	1469-7580		J ANAT	J. Anat.	SEP	2008	213	3					249	258		10.1111/j.1469-7580.2008.00948.x			10	Anatomy & Morphology	Science Citation Index Expanded (SCI-EXPANDED)	Anatomy & Morphology	341QY	WOS:000258731000005	18647194	Green Published			2022-02-06	
J	Das, A; Belagodu, A; Reiter, RJ; Ray, SK; Banik, NL				Das, Arabinda; Belagodu, Amogh; Reiter, Russel J.; Ray, Swapan K.; Banik, Naren L.			Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress	JOURNAL OF PINEAL RESEARCH			English	Article						apoptosis; C6 astroglial cells; cytoprotective effects; glutamate; H2O2; melatonin	INDUCED APOPTOSIS; REACTIVE OXYGEN; GLIOMA-CELLS; RAT-BRAIN; MITOCHONDRIAL; INHIBITION; INVOLVEMENT; ACTIVATION; PATHWAYS; CALPAIN	To preserve the central nervous system (CNS) function after a traumatic injury, therapeutic agents must be administered to protect neurons as well as glial cells. Cell death in CNS injuries and diseases are attributed to many factors including glutamate toxicity and oxidative stress. We examined whether melatonin, a potent anti-oxidant and free radical scavenger, would attenuate apoptotic death of rat C6 astroglial cells under glutamate excitotoxicity and oxidative stress. Exposure of C6 cells to 500 mu M-glutamic acid (LGA) and 100 mu M hydrogen peroxide (H2O2) for 24 hr caused significant increases in apoptosis. Apoptosis was evaluated by Wright staining and ApopTag assay. Melatonin receptor 1 appeared to be involved in the protection of these cells from excitotoxic and oxidative damage. Cells undergoing excitotoxic and oxidative stress for 15 min were then treated with 150 nM melatonin, which prevented Ca2+ influx and cell death. Western blot analyses showed alterations in Bax and Bcl-2 expression resulting in increased Bax:Bcl-2 ratio during apoptosis. Western blot analyses also showed increases in calpain and caspase-3 activities, which cleaved 270 kD alpha-spectrin at specific sites to generate 145 kD spectrin breakdown product (SBDP) and 120 kD SBDP, respectively. However, 15-min post-treatment of C6 cells with melatonin dramatically reduced Bax:Bcl-2 ratio and proteolytic activities, decreasing LGA or H2O2-induced apoptosis. Our data showed that melatonin prevented proteolysis and apoptosis in C6 astroglial cells. The results suggest that melatonin may be an effective cytoprotective agent against glutamate excitotoxicity and oxidative stress in CNS injuries and diseases.	[Das, Arabinda; Belagodu, Amogh; Banik, Naren L.] Med Univ S Carolina, Dept Neurosci, Div Neurol, Charleston, SC 29425 USA; [Reiter, Russel J.] Univ Texas San Antonio, Dept Cellular & Struct Biol, San Antonio, TX USA; [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA		Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurosci, Div Neurol, 96 Jonathan Lucas St,Suite 309 CSB, Charleston, SC 29425 USA.	baniknl@musc.edu			NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA091460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057811, R01NS031622, R01NS041088, R01NS045967] Funding Source: NIH RePORTER		Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Armstrong KJ, 2002, NEUROREPORT, V13, P473, DOI 10.1097/00001756-200203250-00023; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Castro LMR, 2005, J NEUROCHEM, V95, P1227, DOI 10.1111/j.1471-4159.2005.03457.x; Das A, 2005, J NEUROSCI RES, V81, P551, DOI 10.1002/jnr.20581; Das A, 2007, NEUROCHEM RES, V32, P2167, DOI 10.1007/s11064-007-9413-y; Das A, 2007, CANCER-AM CANCER SOC, V110, P1083, DOI 10.1002/cncr.22888; Fowler G, 2003, FREE RADICAL BIO MED, V34, P77, DOI 10.1016/S0891-5849(02)01186-3; Hardeland R, 2007, J PINEAL RES, V43, P382, DOI 10.1111/j.1600-079X.2007.00489.x; Jou MJ, 2007, J PINEAL RES, V43, P389, DOI 10.1111/j.1600-079X.2007.00490.x; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Li XJ, 2002, J PINEAL RES, V32, P47, DOI 10.1034/j.1600-079x.2002.10831.x; Lin AMY, 2007, J PINEAL RES, V43, P163, DOI 10.1111/j.1600-079X.2007.00456.x; Livrea MA, 1997, FREE RADICAL BIO MED, V23, P706, DOI 10.1016/S0891-5849(97)00018-X; Macias M, 2003, EUR J BIOCHEM, V270, P832, DOI 10.1046/j.1432-1033.2003.03430.x; Martin V, 2006, CANCER RES, V66, P1081, DOI 10.1158/0008-5472.CAN-05-2354; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Polster BM, 2001, J BIOL CHEM, V276, P37887; Radogna F, 2007, J PINEAL RES, V43, P154, DOI 10.1111/j.1600-079X.2007.00455.x; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; SAMANTARAY S, 2007, J PINEAL RE IN PRESS; Sribnick EA, 2006, NEUROSCIENCE, V137, P197, DOI 10.1016/j.neuroscience.2005.08.074; Sur P, 2003, BRAIN RES, V971, P178, DOI 10.1016/S0006-8993(03)02349-7; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4	31	50	50	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	SEP	2008	45	2					117	124		10.1111/j.1600-079X.2008.00582.x			8	Endocrinology & Metabolism; Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	336QT	WOS:000258380400001		Green Accepted			2022-02-06	
J	Rhinn, H; Marchand-Leroux, C; Croci, N; Plotkine, M; Scherman, D; Escriou, V				Rhinn, Herve; Marchand-Leroux, Catherine; Croci, Nicole; Plotkine, Michel; Scherman, Daniel; Escriou, Virginie			Housekeeping while brain's storming validation of normalizing factors for gene expression studies in a murine model of traumatic brain injury	BMC MOLECULAR BIOLOGY			English	Article							REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; UP-REGULATION; NEURONAL SURVIVAL; PROTEIN-LEVELS; RNA; SEVERITY; RATS; INTERLEUKIN-1; PROGESTERONE	Background: Traumatic brain injury models are widely studied, especially through gene expression, either to further understand implied biological mechanisms or to assess the efficiency of potential therapies. A large number of biological pathways are affected in brain trauma models, whose elucidation might greatly benefit from transcriptomic studies. However the suitability of reference genes needed for quantitative RT-PCR experiments is missing for these models. Results: We have compared five potential reference genes as well as total cDNA level monitored using Oligreen reagent in order to determine the best normalizing factors for quantitative RT-PCR expression studies in the early phase (0-48 h post-trauma (PT)) of a murine model of diffuse brain injury. The levels of 18S rRNA, and of transcripts of beta-actin, glyceraldehyde-3P-dehydrogenase (GAPDH), beta-microtubulin and S100 beta were determined in the injured brain region of traumatized mice sacrificed at 30 min, 3 h, 6 h, 12 h, 24 h and 48 h post-trauma. The stability of the reference genes candidates and of total cDNA was evaluated by three different methods, leading to the following rankings as normalization factors, from the most suitable to the less: by using geNorm VBA applet, we obtained the following sequence: cDNA (Oligreen); GAPDH > 18S rRNA > S100 beta > beta-microtubulin > beta-actin; by using NormFinder Excel Spreadsheet, we obtained the following sequence: GAPDH > cDNA(Oligreen) > S100 beta > 18S rRNA > beta-actin > beta-microtubulin; by using a Confidence-Interval calculation, we obtained the following sequence: cDNA(Oligreen) > 18S rRNA; GAPDH > S100 beta > beta-microtubulin > beta-actin. Conclusion: This work suggests that Oligreen cDNA measurements, 18S rRNA and GAPDH or a combination of them may be used to efficiently normalize qRT-PCR gene expression in mouse brain trauma injury, and that beta-actin and beta-microtubulin should be avoided. The potential of total cDNA as measured by Oligreen as a first-intention normalizing factor with a broad field of applications is highlighted. Pros and cons of the three methods of normalization factors selection are discussed. A generic time- and cost-effective procedure for normalization factor validation is proposed.	[Rhinn, Herve; Scherman, Daniel; Escriou, Virginie] INSERM, U640, F-75006 Paris, France; [Rhinn, Herve; Scherman, Daniel; Escriou, Virginie] CNRS, UMR8151, F-75006 Paris, France; Univ Paris 05, Fac Pharmaceut & Biol, Chem & Genet Pharmacol Lab, F-75006 Paris, France; Ecole Natl Super Chim Paris, F-75005 Paris, France; [Marchand-Leroux, Catherine; Croci, Nicole; Plotkine, Michel] Univ Paris 05, Fac Sci Pharmaceut & Biol, Unite Pharmacol Circulat Cerebrale, F-75006 Paris, France		Rhinn, H (corresponding author), INSERM, U640, F-75006 Paris, France.	herve.rhinn@gmail.com; catherine.marchand@univ-paris5.fr; nicole.croci@univ-paris5.fr; michel.plotkine@univ-paris5.fr; daniel.scherman@univ-paris5.fr; virginie.escriou@univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Escriou, Virginie/0000-0001-5686-9301; Scherman, Daniel/0000-0003-1207-1298			Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Argyropoulos D, 2006, FEBS J, V273, P770, DOI 10.1111/j.1742-4658.2006.05109.x; Burbach GJ, 2004, GLIA, V48, P76, DOI 10.1002/glia.20057; Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022; Friedrich DH, 2000, ACTA NEUROCHIR SUPPL, V76, P257; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Haller F, 2004, ANAL BIOCHEM, V335, P1, DOI 10.1016/j.ab.2004.08.024; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Iino M, 2003, INT J LEGAL MED, V117, P153, DOI 10.1007/s00414-003-0370-y; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lundby C, 2005, EUR J APPL PHYSIOL, V95, P351, DOI 10.1007/s00421-005-0022-7; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rhinn H, 2008, ANAL BIOCHEM, V372, P116, DOI 10.1016/j.ab.2007.08.023; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; Rutledge RG, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh177; Sang Q, 2006, J NEUROSCI, V26, P7234, DOI 10.1523/JNEUROSCI.1398-06.2006; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Smith RD, 2003, BIOTECHNIQUES, V34, P88, DOI 10.2144/03341st05; Stahlberg A, 2004, CLIN CHEM, V50, P1678, DOI 10.1373/clinchem.2004.035469; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yoshiya K, 2003, J NEUROTRAUM, V20, P1147, DOI 10.1089/089771503770802844	43	50	51	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2199			BMC MOL BIOL	BMC Mol. Biol.	JUL 8	2008	9								62	10.1186/1471-2199-9-62			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	336EH	WOS:000258346600001	18611280	hybrid, Green Published			2022-02-06	
J	Jin, W; Zhu, L; Guan, Q; Chen, G; Wang, QF; Yin, HX; Hang, CH; Shi, JX; Wang, HD				Jin, Wei; Zhu, Lin; Guan, Qun; Chen, Gang; Wang, Qing Feng; Yin, Hong Xia; Hang, Chun Hua; Shi, Ji Xin; Wang, Han Dong			Influence of Nrf2 genotype on pulmonary NF-kappa B activity and inflammatory response after traumatic brain injury	ANNALS OF CLINICAL AND LABORATORY SCIENCE			English	Article						traumatic brain injury; lung; Nrf2; NF-kappa B; cytokines; pulmonary inflammatory response	TRANSCRIPTION FACTOR; LUNG INJURY; ENHANCES SUSCEPTIBILITY; NRF2-DEFICIENT MICE; HEAD-INJURY; RAT MODEL; ADHESION; PROTECTION; INDUCTION; MECHANISM	Inflammatory response plays an important role in the pathogenesis of acute lung injury (ALI) after traumatic brain injury (TBI). Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcription factor that plays a crucial role in cytoprotection against inflammation. The present study explored the influence of Nrf2 genotype on the production of cytokines and on activation of transcription factors in a murine TBI model. Wild-type Nrf2 (+/+) and Nrf2 (-/-) deficient mice were Subjected to a moderately severe weight-drop impact-acceleration head injury. Lung wet/dry weight ratio, Minor necrosis factor-CA (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1), and nuclear factor kappaB (NF-kappa B) were investigated at 24 hr after TBI. Nrf2 (-/-) mice were shown to have a greater increase in the lung wet/dry weight ratio compared to their wild-type Nrf2 (+/+) counterparts after TBI. This exacerbation Of lung injury in Nrf2 (-/-) mice was associated with increased levels of TNF-alpha, IL-1 beta, IL-6, ICAM-1, and their mediator, NF-kappa B. The results suggest that Nrf2 plays ail important protective role in attenuating the Pulmonary inflammatory response and NF-kappa B activation after TBI.	[Jin, Wei; Zhu, Lin; Chen, Gang; Wang, Qing Feng; Yin, Hong Xia; Hang, Chun Hua; Shi, Ji Xin; Wang, Han Dong] Nanjing Univ, Dept Neurosurg, Sch Med, Jinling Hosp, Nanjing 210002, Jiangsu Prov, Peoples R China; [Guan, Qun] Nanjing Univ, Dept Obstet & Gynecol, Sch Med, Jinling Hosp, Nanjing 210002, Jiangsu Prov, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Dept Neurosurg, Sch Med, Jinling Hosp, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hdwang_nj@yahoo.com.cn	Yin, Hong/AAC-5784-2020		Jinling Hospital of China	This work was supported by grants from Jinling Hospital of China. The authors thank Dr. Bo Wu 15 and Dr. Geng-bao Feng for technical assistance.	Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chen F, 1999, CLIN CHEM, V45, P7; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Cho HY, 2004, FASEB J, V18, P1258, DOI 10.1096/fj.03-1127fje; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Church LD, 2008, NAT CLIN PRACT RHEUM, V4, P34, DOI 10.1038/ncprheum0681; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; DETTBARN CL, 1989, HEART LUNG, V18, P583; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; Guo RF, 2007, ANTIOXID REDOX SIGN, V9, P1991, DOI 10.1089/ars.2007.1785; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kawkitinarong K, 2004, AM J RESP CELL MOL, V31, P517, DOI 10.1165/rcmb.2003-0432OC; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lukacs NW, 1996, ADV IMMUNOL, V62, P257, DOI 10.1016/S0065-2776(08)60432-0; Lv R, 2005, ANN CLIN LAB SCI, V35, P174; Miyao N, 2006, AM J PHYSIOL-LUNG C, V290, pL1059, DOI 10.1152/ajplung.00365.2005; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu S, 2006, EXP NEUROL, V200, P245, DOI 10.1016/j.expneurol.2006.01.027; Zhou ML, 2007, J SURG RES, V137, P103, DOI 10.1016/j.jss.2006.06.023	38	50	52	0	1	ASSOC CLINICAL SCIENTISTS	MIDDLEBURY	PO BOX 1287, MIDDLEBURY, VT 05753 USA	0091-7370	1550-8080		ANN CLIN LAB SCI	Ann. Clin. Lab. Sci.	SUM	2008	38	3					221	227					7	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	339MT	WOS:000258582400004	18715849				2022-02-06	
J	Londos, E; Boschian, K; Linden, A; Persson, C; Minthon, L; Lexell, J				Londos, E.; Boschian, K.; Linden, A.; Persson, C.; Minthon, L.; Lexell, J.			Effects of a goal-oriented rehabilitation program in mild cognitive impairment: A pilot study	AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS			English	Article						mild cognitive impairment; traumatic brain injury; cognitive rehabilitation; memory training; occupational therapy; quality of life	QUALITY-OF-LIFE; ALZHEIMERS-DISEASE; OLDER-ADULTS; DEMENTIA; MEMORY; MCI	Background: Memory disturbance, deficient concentration, and fatigue are symptoms seen in amnestic mild cognitive impairment (MCI) as well as in mild traumatic brain injury (TBI). The aim of this study was to assess if an established rehabilitation program commonly used in TBI can aid MCI patients to develop compensatory memory strategies that can improve their cognition, occupational performance, and quality of life (QoL). Methods: Fifteen patients with MCI participated in the program 2 days per week for 8 weeks. Cognitive function, occupational performance, and self-perceived QoL were assessed at baseline, at the end of the intervention, and at follow-up after 6 months. Results: Significant improvements were seen in cognitive processing speed, occupational performance, and in some of the QoL domains. Conclusion: As this goal-oriented rehabilitation program in MCI resulted in some improvements in cognition, occupational performance, and QoL, further randomized controlled studies are warranted.	[Lexell, J.] Lulea Univ Technol, Dept Hlth Sci, S-95187 Lulea, Sweden; [Lexell, J.] Lund Univ, Clin Sci Lund, Div Rehabil Med, Lund, Sweden; [Boschian, K.; Linden, A.; Lexell, J.] Univ Lund Hosp, Dept Rehabil, S-22185 Lund, Sweden; [Londos, E.; Persson, C.; Minthon, L.] Lund Univ, Clin Sci Malmo, Clin Memory Res Unit, Lund, Sweden		Londos, E (corresponding author), Malmo Univ Hosp, Clin Memory Res Unit, Neuropsychiat Clin, Simrisbanv 14, S-20502 Malmo, Sweden.	elisabet.londos@skane.se		Lexell, Jan/0000-0001-5294-3332	Swedish Alzheimer Foundation, Lund, Sweden	This study was supported by grants from the Swedish Alzheimer Foundation, Lund, Sweden.	Akhtar S, 2006, NEUROPSYCHOL REHABIL, V16, P329, DOI 10.1080/09602010500176674; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Clare L, 2003, COCHRANE DATABASE SY; FLICKER C, 1991, NEUROLOGY, V41, P1006, DOI 10.1212/WNL.41.7.1006; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hanninen T, 2002, ACTA NEUROL SCAND, V106, P148, DOI 10.1034/j.1600-0404.2002.01225.x; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; Larrieu S, 2002, NEUROLOGY, V59, P1594, DOI 10.1212/01.WNL.0000034176.07159.F8; Logsdon RG, 2002, PSYCHOSOM MED, V64, P510, DOI 10.1097/00006842-200205000-00016; Meyers JE., 1995, REY COMPLEX FIGURES; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; Palmer K, 2003, ACTA NEUROL SCAND, V107, P14, DOI 10.1034/j.1600-0404.107.s179.2.x; Perneczky R, 2006, INT J GERIATR PSYCH, V21, P158, DOI 10.1002/gps.1444; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; PETERSEN RC, 1995, JAMA-J AM MED ASSOC, V273, P1274, DOI 10.1001/jama.273.16.1274; Pollock N, 1998, CANADIAN OCCUPATIONA; Rapp S, 2002, AGING MENT HEALTH, V6, P5, DOI 10.1080/13607860120101077; Ready RE, 2004, INT J GERIATR PSYCH, V19, P256, DOI 10.1002/gps.1075; Ready Rebecca E, 2006, Am J Alzheimers Dis Other Demen, V21, P242, DOI 10.1177/1533317506290589; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Shin IS, 2005, AM J GERIAT PSYCHIAT, V13, P469, DOI 10.1176/appi.ajgp.13.6.469; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; Talassi E, 2007, ARCH GERONTOL GERIAT, V44, P391, DOI 10.1016/j.archger.2007.01.055; Thorgrimsen L, 2003, ALZ DIS ASSOC DIS, V17, P201, DOI 10.1097/00002093-200310000-00002; Tuokko H, 2005, NEUROCASE, V11, P40, DOI 10.1080/13554790490896802; WECHSLCR D, 1997, MANUAL WECHSLER ADUL; Wechsler D., 1981, WAIS R MANUAL WECHSL; *WHO, 1997, INT STAT CLASS DIS R; Wiig EH, 2002, ALZHEIMERS QUICK TES; WIIG EH, 2004, AQT SCREENING TEST A; Wressle E., 1999, SCAND J OCCUP THER, V6, P84, DOI [DOI 10.1080/110381299443771, 10.1080/110381299443771]	31	50	54	1	21	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1533-3175	1938-2731		AM J ALZHEIMERS DIS	Am. J. Alzheimers Dis. Other Dement.	APR-MAY	2008	23	2					177	183		10.1177/1533317507312622			7	Geriatrics & Gerontology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	344WC	WOS:000258957000008	18182471				2022-02-06	
J	Harting, MT; Baumgartner, JE; Worth, LL; Ewing-Cobbs, L; Gee, AP; Day, MC; Cox, CS				Harting, Matthew T.; Baumgartner, James E.; Worth, Laura L.; Ewing-Cobbs, Linda; Gee, Adrian P.; Day, Mary-Clare; Cox, Charles S.			Cell therapies for traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						cell therapy; clinical trial; stem cells; traumatic brain injury	MARROW STROMAL CELLS; MESENCHYMAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; NEURAL PROGENITOR CELLS; CORD BLOOD-CELLS; BONE-MARROW; ADULT RATS; COGNITIVE FUNCTION; NEURONAL DIFFERENTIATION; STEM/PROGENITOR CELLS	Preliminary discoveries of the efficacy of cell therapy are currently being translated to clinical trials. Whereas a significant amount of work has been focused on cell therapy applications for a wide array of diseases, including cardiac disease, bone disease, hepatic disease, and cancer, there continues to be extraordinary anticipation that stem cells will advance the current therapeutic regimen for acute neurological disease. Traumatic brain injury is a devastating event for which current therapies are limited. In this report the authors discuss the current status of using adult stem cells to treat traumatic brain injury, including the basic cell types and potential mechanisms of action, preclinical data, and the initiation of clinical trials.	[Harting, Matthew T.; Day, Mary-Clare; Cox, Charles S.] Univ Texas Houston, Sch Med, Dept Pediat Surg, Houston, TX 77030 USA; [Harting, Matthew T.; Cox, Charles S.] Univ Texas Houston, Sch Med, Trauma Res Ctr, Houston, TX 77030 USA; [Baumgartner, James E.] Childrens Mem Hermann Hosp, Houston, TX USA; [Worth, Laura L.] Univ Texas MD Anderson Canc Ctr, Childrens Canc Hosp, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Houston, Sch Med, Dept Pediat, Childrens Learning Inst, Houston, TX USA; [Gee, Adrian P.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA		Cox, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Pediat Surg, 6431 Fannin St,MSB 5-254, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Harting, Matthew/0000-0002-8929-8311	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR002558] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008792-08, T32 GM008792] Funding Source: Medline		Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; Englund U, 2002, EXP NEUROL, V173, P1, DOI 10.1006/exnr.2001.7750; Englund U, 2002, DEV BRAIN RES, V134, P123, DOI 10.1016/S0165-3806(01)00330-3; Englund U, 2002, P NATL ACAD SCI USA, V99, P17089, DOI 10.1073/pnas.252589099; Freyman T, 2006, EUR HEART J, V27, P1114, DOI 10.1093/eurheartj/ehi818; FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Grinnemo KH, 2004, J THORAC CARDIOV SUR, V127, P1293, DOI 10.1016/j.jtcvs.2003.07.037; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KRAUS JF, 1987, PEDIATRICS, V79, P501; Le Blanc K, 2005, CYTOTHERAPY, V7, P36, DOI 10.1080/14653240510018118; Long XX, 2005, STEM CELLS DEV, V14, P65, DOI 10.1089/scd.2005.14.65; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Makinen S, 2006, BRAIN RES, V1123, P207, DOI 10.1016/j.brainres.2006.09.056; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MCKAY R, 1993, CR ACAD SCI III-VIE, V316, P1452; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mezey E, 2003, SCIENCE, V299; Miles DK, 2006, PROG BRAIN RES, V157, P187, DOI 10.1016/S0079-6123(06)57012-8; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Nan ZH, 2005, ANN NY ACAD SCI, V1049, P84, DOI 10.1196/annals.1334.009; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; Schrepfer S, 2007, TRANSPL P, V39, P573, DOI 10.1016/j.transproceed.2006.12.019; Secco M, 2008, STEM CELLS, V26, P146, DOI 10.1634/stemcells.2007-0381; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Sinden JD, 1997, NEUROSCIENCE, V81, P599, DOI 10.1016/S0306-4522(97)00330-8; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03-1100fje; Tao H, 2005, DEV GROWTH DIFFER, V47, P423; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Theise ND, 2003, SCIENCE, V299, p1317A, DOI 10.1126/science.1078412; Tolar J, 2006, BLOOD, V107, P4182, DOI 10.1182/blood-2005-08-3289; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wennersten A, 2006, EXP NEUROL, V199, P339, DOI 10.1016/j.expneurol.2005.12.035; Xiao J, 2005, STEM CELLS DEV, V14, P722, DOI 10.1089/scd.2005.14.722; Xu Y, 2003, J NEUROSCI RES, V74, P533, DOI 10.1002/jnr.10769; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456	79	50	50	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAR	2008	24	3-4							E17	10.3171/FOC/2008/24/3-4/E17			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	308FQ	WOS:000256374100018	18341394	Green Accepted			2022-02-06	
J	Liao, ZB; Zhi, XG; Shi, QH; He, ZH				Liao, Z. B.; Zhi, X. G.; Shi, Q. H.; He, Z. H.			Recombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in rats	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						apoptosis; Bcl-2; EPO receptor; rhEPO; traumatic brain injury	NEONATAL HYPOXIA-ISCHEMIA; CYTOCHROME-C RELEASE; CASPASE ACTIVATION; IN-VITRO; DEATH; APOPTOSIS; NEUROPROTECTION; MODULATION; PATHWAYS; RECOVERY	We explored the regulation of erythropoietin and erythropoietin receptor on traumatic brain injury (TBI), as well as the antiapoptotic effects of recombinant human erythropoietin (rhEPO) treatment. Female Wistar rats were randomly divided into three groups: rhEPO-treated TBI, vehicle-treated TBI, and sham-operated. TBI was induced by the Feeney free falling model. Rats were killed 5, 12, 24, 72, 120, or 168 h after TBI. Regulation of EPO, EPOR and Bcl-2 was detected by reverse transcription-polymerase chain reaction (RT-PCR), western blotting and immunofluorescence. Terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick-end labeling (TUNEL) was used to assess DNA fragmentation after TBI. Induction of EPOR expression persisted for 168 h after TBI, whereas EPO was only slightly elevated for 72 h. In the rhEPO-treated TBI, Bcl-2 mRNA and protein levels were greater than in the vehicle-treated TBI. Bcl-2 mRNA peaked at 24 h and remained stable for 72-120 h. The number of TUNEL-positive cells in the rhEPO-treated TBI was far fewer than in the vehicle-treated TBI. EPOR regulation is enhanced for almost a week after TBI. Administration of rhEPO protects neurons by enhancing Bcl-2 expression, thereby inhibiting TBI-induced neuronal apoptosis.	[Liao, Z. B.; Zhi, X. G.; Shi, Q. H.; He, Z. H.] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China		Liao, ZB (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	liaozhengbu@hotmail.com					Alafaci C, 2000, EUR J PHARMACOL, V406, P219, DOI 10.1016/S0014-2999(00)00691-9; Buki A, 2000, J NEUROSCI, V20, P2825; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chang YS, 2005, PEDIATR RES, V58, P106, DOI 10.1203/01.PDR.0000163616.89767.69; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Demers EJ, 2005, PEDIATR RES, V58, P297, DOI 10.1203/01.PDR.0000169971.64558.5A; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2005, P NATL ACAD SCI USA, V102, P862, DOI 10.1073/pnas.0406008102; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Juul S, 2002, ACTA PAEDIATR, V91, P36, DOI 10.1080/080352502320764184; Kang JQ, 2003, MOL PHARMACOL, V64, P557, DOI 10.1124/mol.64.3.557; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kumral A, 2003, BIOL NEONATE, V83, P224, DOI 10.1159/000068926; Liu CL, 2004, NEUROSCIENCE, V127, P113, DOI 10.1016/j.neuroscience.2004.03.062; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sola A, 2005, PEDIATR RES, V57, P481, DOI 10.1203/01.PDR.0000155760.88664.06; Spandou E, 2004, BRAIN RES, V1021, P167, DOI 10.1016/j.brainres.2004.06.057; Stefanis L, 2005, NEUROSCIENTIST, V11, P50, DOI 10.1177/1073858404271087; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sun Y, 2004, J CEREBR BLOOD F MET, V24, P259, DOI 10.1097/01.WCB.0000110049.43905.AC; Vairano M, 2002, EUR J NEUROSCI, V16, P584, DOI 10.1046/j.1460-9568.2002.02125.x; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wei L, 2004, BRAIN RES, V1022, P54, DOI 10.1016/j.brainres.2004.06.080; Wen TC, 2004, NEUROSCI LETT, V355, P165, DOI 10.1016/j.neulet.2003.10.078; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	30	50	56	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	FEB	2008	15	2					140	149		10.1111/j.1468-1331.2007.02013.x			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	253ZX	WOS:000252557200013	18093155				2022-02-06	
J	Williams, BR; Lazic, SE; Ogilvie, RD				Williams, Benjamin R.; Lazic, Stanley E.; Ogilvie, Robert D.			Polysomnographic and quantitative EEG analysis of subjects with long-term insomnia complaints associated with mild traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						FFT; head injury; insomnia; mild traumatic brain injury; post-concussion syndrome; sleep disorders	SLEEP-ONSET PERIOD; HEAD-INJURY; SPECTRAL-ANALYSIS; DISTURBANCES; ADOLESCENTS; PREVALENCE; DEPRESSION; SYMPTOMS; PATTERNS; RECOVERY	Objective: The aims of this study were (1) to characterise the extent and nature of disrupted sleep in individuals with long-term sleep complaints subsequent to mild traumatic brain injury (MTBI), and (2) to determine whether sleep disturbances in MTBI subjects were more characteristic of psychophysiological, psychiatric, or idiopathic insomnia. Methods: Nine MTBI patients (27.8 months post-injury; SD = 15.5 months) and nine control subjects underwent polysomnographic testing and completed self-report questionnaires on sleep quality. Power spectral (FFT) analysis of the sleep onset period was conducted, with both the power and variability in power being quantified. Results: Individuals with MTBI exhibited long-term sleep difficulties, along with various cognitive and affective abnormalities. The MTBI group had 4% less efficient sleep (p = 0.019), shorter REM onset latencies (p = 0.011), and longer sleep onset latencies, although the latter were highly variable in the MTBI group (F-test: p = 0.012). FFT analysis revealed greater intra-subject variability in the MTBI group in sigma, theta, and delta power during the sleep onset period. Conclusions: MTBI patients with persistent sleep complaints differ significantly from controls on a number of electrophysiological outcomes, but could not be easily classified into existing insomnia subtypes. Significance: Sleep disturbances can persist well after the injury in a subset of patients with MTBI. (c) 2007 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Williams, Benjamin R.; Lazic, Stanley E.; Ogilvie, Robert D.] Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada		Lazic, SE (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3DY, England.	stan.lazic@cantab.net	Lazic, Stanley/F-1160-2011				Alloway CED, 1999, SLEEP, V22, P191, DOI 10.1093/sleep/22.2.191; *AM SLEEP DIS ASS, 1990, INT CLASS SLEEP DIS; Argyropoulos SV, 2005, INT REV PSYCHIATR, V17, P237, DOI 10.1080/09540260500104458; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BIGLER E, 1990, NEUROPATHOLOGY TRAUM, P13; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; DOUGLASS AB, 1994, SLEEP, V17, P160, DOI 10.1093/sleep/17.2.160; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; EIDE PK, 1992, ACTA NEUROL SCAND, V86, P194, DOI 10.1111/j.1600-0404.1992.tb05065.x; GEORGE B, 1986, NEUROCHIRURGIA, V29, P45; GRONWALL D, 1989, CUMULATIVE PERSISTIN, P153; Hori T., 1994, TOPOGRAPHICAL EEG CH, P237; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI 10.2307/1390807; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kristensen M, 2004, ADV PHYSIOL EDUC, V28, P2, DOI 10.1152/advan.00042.2003; Lamarche CH, 1997, SLEEP, V20, P724; LENARD HG, 1970, ACTA PAEDIATR SCAND, V59, P565, DOI 10.1111/j.1651-2227.1970.tb16809.x; LEVIN H, 1987, MINOR HEAD INJURY PO, P262; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCCARTNEY T, 1998, SLEEP S, V21, P267; Mignot E, 2006, BRAIN, V129, P1609, DOI 10.1093/brain/awl079; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morey, 1991, PERSONALITY ASSESSME; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Papadimitriou GN, 2005, INT REV PSYCHIATR, V17, P229, DOI 10.1080/09540260500104524; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PARSONS LC, 1982, NURS RES, V31, P260; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Pinheiro J. C., 2000, MIXED EFFECTS MODELS; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; R Development Core Team,, 2006, R LANG ENV STAT COMP; Rechtschaffen A., 1968, MANUAL STANDARDIZED; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Singh M, 2006, SLEEP, V29, P890, DOI 10.1093/sleep/29.7.890; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006	44	50	52	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	FEB	2008	119	2					429	438		10.1016/j.clinph.2007.11.003			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	260SB	WOS:000253029600021	18083618				2022-02-06	
J	Longhi, L; Pagan, F; Valeriani, V; Magnoni, S; Zanier, E; Conte, V; Branca, V; Stocchetti, N				Longhi, Luca; Pagan, Francesca; Valeriani, Valerio; Magnoni, Sandra; Zanier, ElisaR.; Conte, Valeria; Branca, Vincenzo; Stocchetti, Nino			Monitoring brain tissue oxygen tension in brain-injured patients reveals hypoxic episodes in normal-appearing and in peri-focal tissue	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; brain oxygenation; brain hypoxia; PtiO(2); secondary insults; pathophysiology	CEREBRAL-BLOOD-FLOW; SUBSTRATE DELIVERY; NEUROCRITICAL CARE; HEAD-INJURY; METABOLISM; PERFUSION; MICROCIRCULATION; PRESSURE; ISCHEMIA	Objective: We compared brain tissue oxygen tension (PtiO(2)) measured in peri-focal and in normal-appearing brain parenchyma on computerized tomography (CT) in patients following traumatic brain injury (TBI). Design: Prospective observational study. Setting: Neuro-intensive care unit. Patients and participants: Thirty-two consecutive TBI patients were subjected to PtiO(2) monitoring. Interventions: Peri-focal tissue was identified by the presence of a hypodense area of the contusion and/or within 1 cm from the core of the contusion. The position of the tip of the PtiO(2) probe was assessed at follow-up CT scan. Measurements and results: Mean PtiO2 in the peri-contusional tissue was 19.7 +/- 2.1 mmHg and was lower than PtiO2 in normal-appearing tissue (25.5 +/- 1.5 mmHg, p < 0.05), despite a greater cerebral perfusion pressure (CPP) (73.7 +/- 2.3 mmHg vs. 67.4 +/- 1.4 mmHg, p < 0.05). We observed both in peri-focal tissue and in normal-appearing tissue episodes of brain hypoxia (PtiO(2) < 20 mmHg for at least 10 min), whose median duration was longer in peri-focal tissue than in normal-appearing tissue (51% vs. 34% of monitoring time, p < 0.01). In peri-focal tissue, we observed a progressive PtiO(2) increase from pathologic to normal values ( p < 0.01). Conclusions: Multiple episodes of brain hypoxia occurred over the first 5 days following severe TBI. PtiO(2) was lower in peri-contusional tissue than in normal-appearing tissue. In peri-contusional tissue, a progressive increase of PtiO(2) from pathologic to normal values was observed over time, suggestive of an improvement at microcirculatory level.	Univ Milan, Fdn IRCCS, Osped Maggiore Policlin, Neurosurg Intens Care Unit,Dept Anesthesia & Crit, I-20100 Milan, Italy; Osped Maggiore Policlin Mangiagalli Regina Elena, Fdn IRCCS, Dept Neuroradiol, Milan, Italy		Longhi, L (corresponding author), Univ Milan, Fdn IRCCS, Osped Maggiore Policlin, Neurosurg Intens Care Unit,Dept Anesthesia & Crit, Via Sforza N 35, I-20100 Milan, Italy.	lucalonghi@policlinico.mi.it	Longhi, Luca/AAF-9903-2021; Magnoni, Sandra/AAC-7479-2022; Stocchetti, Nino/O-7444-2017; Zanier, Elisa/AAA-8095-2020	Longhi, Luca/0000-0001-9894-8788; Magnoni, Sandra/0000-0002-1723-0844; Stocchetti, Nino/0000-0003-3250-6834; Zanier, Elisa/0000-0002-3011-8718			Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Longhi L, 2002, ACT NEUR S, V81, P315; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MARSHALL LF, 1991, J NEUROSURG S, V75; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stocchetti N, 2004, CRIT CARE MED, V32, P1429, DOI 10.1097/01.CCM.0000128957.69536.A5; Stocchetti N, 1998, ACT NEUR S, V71, P162; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	33	50	50	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	DEC	2007	33	12					2136	2142		10.1007/s00134-007-0845-2			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234JM	WOS:000251157400015	17846748				2022-02-06	
J	Soriano, FX; Hardingham, GE				Soriano, Francesc X.; Hardingham, Giles E.			Compartmentalized NMDA receptor signalling to survival and death	JOURNAL OF PHYSIOLOGY-LONDON			English	Article; Proceedings Paper	Symposium on Compartmentalized Signalling in Neurons	2007	Glasgow, SCOTLAND				RAT HIPPOCAMPAL-NEURONS; D-ASPARTATE ANTAGONISTS; TRAUMATIC BRAIN-INJURY; CELL-DEATH; GENE-EXPRESSION; CLINICAL-TRIALS; KINASE PATHWAY; DENTATE GYRUS; CREB SHUTOFF; MU-CALPAIN	The ability of Ca2+ influx through the N-methyl D-aspartate subclass of glutamate receptor (NMDA receptor) to both kill neurons and to promote survival under different circumstances is well established. Here we discuss the signal pathways that mediate this dichotomous signalling, and the factors that influence whether an NMDA receptor-dependent Ca2+ signal results in a net pro-survival or pro-death effect. The magnitude of NMDA receptor activation, be it intensity or duration, is of course very important in determining the nature of they response to an episode of NMDA receptor activity, with excitotoxic death pathways requiring higher levels than survival pathways. However, the NMDA receptor is not merely a conduit for Ca2+ influx: the consequences of NMDA receptor activity can be influenced by signalling molecules that physically associate with the NMDA receptor or indeed the location (synaptic versus extrasynaptic) of the receptor. Furthermore, we discuss the possibility that the Ca2+ effectors of survival and death are in different subcellular locations, and thus depend on the spatial characteristics of the Ca2+ transient. A greater understanding of these issues may point to ways of selectively blocking pro-death signalling in neurological disorders such as stroke, where global NMDA receptor antagonists have proved ineffective.	Univ Edinburgh, Ctr Res Neurosci, Edinburgh EH8 9XD, Midlothian, Scotland		Hardingham, GE (corresponding author), Univ Edinburgh, Ctr Res Neurosci, Edinburgh EH8 9XD, Midlothian, Scotland.	giles.hardingham@ed.ac.uk	Soriano, Francesc X/U-7552-2017	Soriano, Francesc X/0000-0003-1678-7162; Hardingham, Giles/0000-0002-7629-5314	BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/D011388/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/D011388/1] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Adams SM, 2004, J NEUROSCI, V24, P9441, DOI 10.1523/JNEUROSCI.3290-04.2004; Albers GV, 2001, JAMA-J AM MED ASSOC, V286, P2673, DOI 10.1001/jama.286.21.2673; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; Chohan MO, 2006, J ALZHEIMERS DIS, V10, P81; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Frizelle PA, 2006, MOL PHARMACOL, V70, P1022, DOI 10.1124/mol.106.024042; GOULD E, 1994, J COMP NEUROL, V340, P551, DOI 10.1002/cne.903400408; Hansen HH, 2004, NEUROBIOL DIS, V16, P440, DOI 10.1016/j.nbd.2004.03.013; Harding JH, 2003, INTERFACE SCI, V11, P81, DOI 10.1023/A:1021539124206; Hardingham GE, 2006, BIOCHEM SOC T, V34, P936, DOI 10.1042/BST0340936; Hardingham GE, 2002, BBA-PROTEINS PROTEOM, V1600, P148, DOI 10.1016/S1570-9639(02)00455-7; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Ivanov A, 2006, J PHYSIOL-LONDON, V572, P789, DOI 10.1113/jphysiol.2006.105510; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Lafon-Cazal M, 2002, EUR J NEUROSCI, V16, P575, DOI 10.1046/j.1460-9568.2002.02124.x; Limback-Stokin K, 2004, J NEUROSCI, V24, P10858, DOI 10.1523/JNEUROSCI.1022-04.2004; Lipton SA, 1999, NAT MED, V5, P270, DOI 10.1038/6481; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Neyton J, 2006, J NEUROSCI, V26, P1331, DOI 10.1523/JNEUROSCI.5242-05.2006; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Pottorf WJ, 2006, J NEUROCHEM, V98, P1646, DOI 10.1111/j.1471-4159.2006.04063.x; Rameau GA, 2007, J NEUROSCI, V27, P3445, DOI 10.1523/JNEUROSCI.4799-06.2007; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Sensi SL, 2004, CURR MOL MED, V4, P87, DOI 10.2174/1566524043479211; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Tashiro A, 2006, NATURE, V442, P929, DOI 10.1038/nature05028; Thomas CG, 2006, J NEUROPHYSIOL, V95, P1727, DOI 10.1152/jn.00771.2005; Tompa P, 1996, J BIOL CHEM, V271, P33161, DOI 10.1074/jbc.271.52.33161; Torok K, 1998, CURR BIOL, V8, P692, DOI 10.1016/S0960-9822(98)70275-1; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025	64	50	51	0	10	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-3751			J PHYSIOL-LONDON	J. Physiol.-London	OCT 15	2007	584	2					381	387		10.1113/jphysiol.2007.138875			7	Neurosciences; Physiology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	227IV	WOS:000250651300007	17690142	Green Published			2022-02-06	
J	Schmidt, JH; Reyes, BJ; Fischer, R; Flaherty, SK				Schmidt, John H.; Reyes, Bernardo J.; Fischer, Roopan; Flaherty, Sarah K.			Use of hinge craniotomy for cerebral decompression - Technical note	JOURNAL OF NEUROSURGERY			English	Article						craniotomy; head trauma; hinge; intracranial pressure	TRAUMATIC BRAIN-INJURY; SUPRATENTORIAL MASS LESIONS; ACUTE SUBDURAL-HEMATOMA; COMA SCALE SCORE; INTRACRANIAL HYPERTENSION; CLINICAL RELEVANCE; CRANIECTOMY; MANAGEMENT; HEMICRANIECTOMY; INFARCTION	v,Decompressive craniectomy to relieve cerebral edema and intracranial hypertension due to traumatic brain injury is a generally accepted practice; however, the procedure remains controversial because of its uncertain effects on outcome, specific complications such as the syndrome of the sinking skin flap, and the need for subsequent cranioplasty. The authors developed a novel craniotomy technique using titanium bone plates in a hinged fashion, which maintains cerebral protection while reducing postoperative complications and eliminating subsequent cranioplasty procedures. The authors conducted a retrospective review of data obtained in all consecutive patients who had undergone post-traumatic cerebral decompression cramotomy using the hinge technique at a Level I trauma facility between 1990 and 2004. Twenty-five patients, most of whom were male (88%) and Caucasian (88%) with a mean age of 38.2 +/- 16.1 years, underwent the hinge craniotomy. The in-hospital mortality rate was 48%, and good cerebral decompression was achieved. None of the patients required surgery for flap replacement. Long-term follow-up data showed that one patient required subsequent cranioplasty due to infection and one patient presented with cranial deformities. None of the patients presented with bone resorption or sinking flap syndrome. The hinge technique effectively prevents procedure-related morbidity and the need for subsequent surgical bone replacement otherwise introduced by traditional decompressive craniectomy. A randomized controlled trial is required to substantiate these findings.	W Virginia Univ, Hlth Sci Ctr, Dept Surg, Sch Med,Charleston Div, Charleston, WV 25304 USA; W Virginia Univ, Dept Internal Med, Charleston, WV 25304 USA; Res Inst, Charleston, WV USA; Charleston Area Med Ctr Hlth Educ, Charleston, WV USA; W Virginia Univ, Sch Med, Morgantown, WV 26506 USA		Reyes, BJ (corresponding author), CCI, 3211 MacCorkle Ave SE, Charleston, WV 25304 USA.	bernardo.reyes@camc.org					BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; Bostrom S, 2005, ACTA NEUROCHIR, V147, P279, DOI 10.1007/s00701-004-0480-4; Buczko W, 2005, J TRAUMA, V58, P40, DOI 10.1097/01.TA.0000149332.17597.36; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; Curry WT, 2005, NEUROSURGERY, V56, P681, DOI 10.1227/01.NEU.0000156604.41886.62; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Hutchinson P J, 2004, Curr Opin Crit Care, V10, P101, DOI 10.1097/00075198-200404000-00004; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; KRIEGER D, 1993, CRIT CARE MED, V21, P1944, DOI 10.1097/00003246-199312000-00024; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MCNEALY DE, 1962, ARCH NEUROL-CHICAGO, V7, P10, DOI 10.1001/archneur.1962.04210010016002; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Poon WS, 2005, ACT NEUR S, V93, P207; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; Schneider GH, 2002, ACT NEUR S, V81, P77; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Stefini R, 1999, NEUROSURGERY, V45, P626, DOI 10.1097/00006123-199909000-00038; TABADDOR K, 1976, J NEUROSURG, V44, P506, DOI 10.3171/jns.1976.44.4.0506; Wada Y, 2002, NEUROL MED-CHIR, V42, P414, DOI 10.2176/nmc.42.414; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	34	50	50	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2007	107	3					678	682		10.3171/JNS-07/09/0678			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	206YZ	WOS:000249220100029	17886572				2022-02-06	
J	Jumisko, E; Lexell, J; Soderberg, S				Jumisko, Eija; Lexell, Jan; Soderberg, Siv			Living with moderate or severe traumatic brain injury - The meaning of family members' experiences	JOURNAL OF FAMILY NURSING			English	Article						family; family members; traumatic; brain injury; phenomenological; hermeneutics; interpretation; responsibility; love; ethics; suffering; hope	CHRONIC ILLNESS; IMPACT	Traumatic brain injury (TBI) has long-lasting consequences not only for the individual with the injury but also for family members. The aim of this study is to elucidate the meaning of family members' experiences of living with an individual with moderate or severe TBI. The data have been collected by means of qualitative research interviews with 8 family member participants. A phenomenological hermeneutic interpretation (Ricouer, 1976) of the data reveal that family members struggle with their own suffering while showing compassion for the injured person. Their willingness to assume care for the injured person is derived from their feeling of natural love and the ethical demand to be responsible for the other. Hope and natural love from close relatives, the afflicted person, and other family members give the family members strength. It is important that professionals pay more attention to the suffering of close relatives.	Lulea Univ Technol, Div Nursing, Dept Hlth Sci, SE-97187 Lulea, Sweden		Jumisko, E (corresponding author), Lulea Univ Technol, Div Nursing, Dept Hlth Sci, SE-97187 Lulea, Sweden.	Eija.Jumisko@ltu.se		Lexell, Jan/0000-0001-5294-3332			Backhouse M, 1999, AUST OCCUP THER J, V46, P99, DOI DOI 10.1046/J.1440-1630.1999.00183.X; BENZEIN E, 1999, THESIS UMEA U SWEDEN; Benzein EG, 2000, WESTERN J NURS RES, V22, P303, DOI 10.1177/01939450022044430; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; Carson P, 1993, J Neurosci Nurs, V25, P165; Chesla CA, 2005, J FAM NURS, V11, P371, DOI 10.1177/1074840705281781; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; CRISHOLM J, 2001, AXON, V23, P12; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Duff Diane, 2002, Axone, V24, P14; Engstrom Asa, 2004, Intensive Crit Care Nurs, V20, P299; Eriksson K, 1994, LIDANDE MANNISKAN; Eriksson K., 1993, MOTEN MED LIDANDEN, P1; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Gill D. J., 2000, REHABILITATION NURSI, V25, P48, DOI [10.1002/j.2048-7940.2000.tb01862.x, DOI 10.1002/J.2048-7940.2000.TB01862.X]; GRANT JS, 1997, J FAMILY NURSING, V1, P36; Guba EG., 1989, 4 GENERATION EVALUAT; Johnson B P, 1995, J Neurosci Nurs, V27, P113; JUMISKO E, 2005, J NEUROSCIENCE NURSI, V36, P20; Kneafsey R, 2004, J CLIN NURS, V13, P601, DOI 10.1111/j.1365-2702.2004.00903.x; Kuyper MB, 1998, QUAL HEALTH RES, V8, P237, DOI 10.1177/104973239800800207; Kvale S, 1997, COMMUNICATION; Lincoln Yvonna S., 1985, NATURALISTIC INQUIRY; Lindholm L, 2002, SCAND J CARING SCI, V16, P248, DOI 10.1046/j.1471-6712.2002.00093.x; Lindseth A, 2004, SCAND J CARING SCI, V18, P145, DOI 10.1111/j.1471-6712.2004.00258.x; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LOGSTRUP KE, 1956, ETISKA KRAVET; Lovasik D, 2001, Crit Care Nurs Q, V23, P24; MAY R, 1975, MODET ATT SKAPA; Naden D., 2000, INT J HUMAN CARING, V4, P23, DOI [10.20467/1091-5710.4.3.23, DOI 10.20467/1091-5710.4.3.23]; Nunkoosing K, 2005, QUAL HEALTH RES, V15, P698, DOI 10.1177/1049732304273903; Ohman M, 2004, QUAL HEALTH RES, V14, P396, DOI 10.1177/1049732303261692; Paterson B, 2001, Rehabil Nurs, V26, P48; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; PUROLA H, 2000, THESIS U OULU FINLAN; Rehnsfeldt A, 2004, SCAND J CARING SCI, V18, P264, DOI 10.1111/j.1471-6712.2004.00281.x; Ricoeur P., 1976, INTERPRETATION THEOR; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Smith J E, 2000, Care Manag J, V2, P27; Soderberg S, 2003, J ADV NURS, V42, P143, DOI 10.1046/j.1365-2648.2003.02597.x; SODERBERG S, 1999, THESIS UMEA U SWEDEN; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380	43	50	53	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1074-8407	1552-549X		J FAM NURS	J. Fam. Nurs.	AUG	2007	13	3					353	369		10.1177/1074840707303842			17	Family Studies; Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Family Studies; Nursing	193AR	WOS:000248246100006	17641113				2022-02-06	
J	Ellis, EF; Willoughby, KA; Sparks, SA; Chen, T				Ellis, Earl F.; Willoughby, Karen A.; Sparks, Sallie A.; Chen, Tao			S100B protein is released from rat neonatal neurons, astrocytes, and microglia by in vitro trauma and anti-S100 increases trauma-induced delayed neuronal injury and negates the protective effect of exogenous S100B on neurons	JOURNAL OF NEUROCHEMISTRY			English	Article						S100B; neuroprotection; traumatic brain injury	STRETCH-INDUCED INJURY; CULTURED ASTROCYTES; COGNITIVE RECOVERY; EXPRESSION; INFUSION; DAMAGE; CELLS; ATP	S100B protein is found in brain, has been used as a marker for brain injury and is neurotrophic. Using a well-characterized in vitro model of brain cell trauma, we have previously shown that strain injury causes S100B release from neonatal rat neuronal plus glial cultures and that exogenous S100B reduces delayed post-traumatic neuronal damage even when given at 6 or 24 h post-trauma. The purpose of the current studies was to measure post-traumatic S100B release by specific brain cell types and to examine the effect of an antibody to S100 on post-traumatic delayed (48 h) neuronal injury and the protective effect of exogenous S100B. Neonatal rat cortical cells grown on a deformable elastic membrane were subjected to a strain (stretch) injury produced by a 50 ms displacement of the membrane. S100B was measured with an ELISA kit. Trauma released S100B from pure cultures of astrocytes, microglia, and neurons. Anti-S100 reduced released S100B to below detectable levels, increased delayed neuronal injury in traumatized cells and negated the protective effect of exogenous S100B on injured cells. Heat denatured anti-S100 did not exacerbate injury. These studies provide further evidence for a protective role for S100B following neuronal trauma.	Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA		Ellis, EF (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.	efellis@vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07288, NS27214] Funding Source: Medline		Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Azmitia EC, 2002, PROG BRAIN RES, V136, P87; BOYES BE, 1986, NEUROSCIENCE, V17, P857, DOI 10.1016/0306-4522(86)90050-3; Brewton LS, 2001, BRAIN RES, V912, P9, DOI 10.1016/S0006-8993(01)02519-7; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hu JR, 1997, J NEUROCHEM, V69, P2294; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; Reali C, 2005, J NEUROSCI RES, V81, P677, DOI 10.1002/jnr.20584; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Schreiber D., 1995, P 1995 INT RES C BIO, P233; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Tran MD, 2006, P NATL ACAD SCI USA, V103, P9321, DOI 10.1073/pnas.0603146103; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; WEBER JT, 2001, J NEUROTRAUM, V18, P1183; Willoughby KA, 2004, J NEUROCHEM, V91, P1284, DOI 10.1111/j.1471-4159.2004.02812.x; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	39	50	56	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2007	101	6					1463	1470		10.1111/j.1471-4159.2007.04515.x			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	177EB	WOS:000247135300003	17403138	Bronze			2022-02-06	
J	Smith, JM; Lunga, P; Story, D; Harris, N; Le Belle, J; James, MF; Pickard, JD; Fawcett, JW				Smith, Justin M.; Lunga, Precious; Story, David; Harris, Neil; Le Belle, Janel; James, Michael F.; Pickard, John D.; Fawcett, James W.			Inosine promotes recovery of skilled motor function in a model of focal brain injury	BRAIN			English	Article						plasticity; head injury; corticospinal tract; spinal cord; behavioural assessment; axon sprouting	PRIMARY SOMATOSENSORY CORTEX; SPINAL-CORD-INJURY; OCULAR DOMINANCE PLASTICITY; INDUCED MOVEMENT THERAPY; VISUAL-CORTEX; ADULT RATS; CORTICOSPINAL AXONS; STAIRCASE TEST; LIMB USE; STROKE	Recovery of function following traumatic brain injury (TBI) is partly through neuronal plasticity. However plasticity is limited in the adult CNS compared with young animals. In order to test whether treatments that enhance CNS plasticity might improve functional recovery after TBI, a new rat head injury model was developed, in which a computer-controlled impactor produced full thickness lesions of the forelimb region of the sensorimotor cortex. Behavioural deficits were seen in several sensorimotor tasks, most of which recovered spontaneously by 21 days. However, skilled paw reaching behaviour, a task that requires corticospinal function, was only similar to 40% recovered by 28 days. In order to promote plasticity inosine was infused into the lateral ventricles for 28 days. This treatment produced an almost complete recovery of skilled paw reaching ability, associated with sprouting of the uninjured corticospinal axons across the midline into the territory of the lesioned pathway. In the cervical spinal cord the number of corticospinal axons originating from the uninjured cortex that innervated the contralateral cervical cord was five times that of controls, and in the red nucleus the number of contralaterally projecting axons was four times control values. Inosine treatment did not affect recovery in unskilled behavioural tasks, most of which recovered to normal levels by 28 days without treatment. Animals were placed in an enriched environment as an alternative method to promote plasticity. This resulted in more rapid recovery in several tasks including skilled paw function, but by 28 days normally housed animals had caught up to the same level of improvement.	Univ Cambridge, Cambridge Ctr Brin Reapir, Cambridge CB1 5RH, England; Univ Calif Los Angeles, Sch Med, Dept Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA USA; GlaxoSmithKline, Neurol & GI Ctr Excellence Drug Discovery, Harlow, Essex, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England		Fawcett, JW (corresponding author), Univ Cambridge, Cambridge Ctr Brin Reapir, ED Adrian Bldg,Robinson Way, Cambridge CB1 5RH, England.	jfl08@cam.ac.uk		Harris, Neil/0000-0002-1965-6750; Fawcett, James/0000-0002-7990-4568	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G9439390] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G9439390, G0001237] Funding Source: UKRI		Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Barbay S, 2006, EXP BRAIN RES, V169, P106, DOI 10.1007/s00221-005-0129-4; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Benowitz LI, 1999, P NATL ACAD SCI USA, V96, P13486, DOI 10.1073/pnas.96.23.13486; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Buchli AD, 2005, ANN MED, V37, P556, DOI 10.1080/07853890500407520; Byl NN, 1996, NEUROLOGY, V47, P508, DOI 10.1212/WNL.47.2.508; Caggiano AO, 2005, J NEUROTRAUM, V22, P226, DOI 10.1089/neu.2005.22.226; CAO Y, 1994, P NATL ACAD SCI USA, V91, P9612, DOI 10.1073/pnas.91.20.9612; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chu D, 2000, NEUROPEDIATRICS, V31, P63, DOI 10.1055/s-2000-7475; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; Farr TD, 2002, STROKE, V33, P1869, DOI 10.1161/01.STR.0000020714.48349.4E; FINGER S, 1988, ARCH NEUROL-CHICAGO, V45, P1136, DOI 10.1001/archneur.1988.00520340090018; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Grill R, 1997, J NEUROSCI, V17, P5560; Grotta JC, 2004, STROKE, V35, P2699, DOI 10.1161/01.STR.0000143320.64953.c4; Hagg T, 2005, NEUROSCIENCE, V130, P875, DOI 10.1016/j.neuroscience.2004.10.018; Hensch TK, 2005, CURR TOP DEV BIOL, V69, P215, DOI 10.1016/S0070-2153(05)69008-4; Hensch TK, 2004, ANNU REV NEUROSCI, V27, P549, DOI 10.1146/annurev.neuro.27.070203.144327; Hummel FC, 2005, CURR OPIN NEUROL, V18, P667, DOI 10.1097/01.wco.0000189876.37475.42; Irwin N, 2006, P NATL ACAD SCI USA, V103, P18320, DOI 10.1073/pnas.0605135103; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; Jones TA, 1999, J NEUROSCI, V19, P10153; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Li Y, 1998, J NEUROSCI, V18, P10514; Liu Y, 1999, EXP BRAIN RES, V128, P149, DOI 10.1007/s002210050830; LORENZ KZ, 1958, SCI AM, V199, P67, DOI 10.1038/scientificamerican1258-67; Lynskey JV, 2006, J NEUROTRAUM, V23, P617, DOI 10.1089/neu.2006.23.617; Mark VW, 2004, RESTOR NEUROL NEUROS, V22, P317; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Papadopoulos CM, 2006, CEREB CORTEX, V16, P529, DOI 10.1093/cercor/bhi132; Piecharka DA, 2005, BRAIN RES BULL, V66, P203, DOI 10.1016/j.brainresbull.2005.04.013; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Pizzorusso T, 2006, P NATL ACAD SCI USA, V103, P8517, DOI 10.1073/pnas.0602657103; Raineteau O, 2001, P NATL ACAD SCI USA, V98, P6929, DOI 10.1073/pnas.111165498; Rittenhouse CD, 2006, J NEUROPHYSIOL, V95, P2947, DOI 10.1152/jn.01328.2005; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert T, 1997, ADV NEUROL, V73, P229; Schwab ME, 2002, PROG BRAIN RES, V137, P351; Shen H, 2005, STROKE, V36, P654, DOI 10.1161/01.STR.0000155747.15679.04; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Vrinten DH, 2003, PAIN, V102, P203, DOI 10.1016/S0304-3959(02)00382-2; Whishaw IQ, 1997, BEHAV BRAIN RES, V89, P167, DOI 10.1016/S0166-4328(97)00057-0; Whishaw IQ, 1998, BEHAV BRAIN RES, V93, P167, DOI 10.1016/S0166-4328(97)00152-6; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Xerri C, 1998, J NEUROPHYSIOL, V79, P2119, DOI 10.1152/jn.1998.79.4.2119; Zhao CS, 2005, BEHAV BRAIN RES, V160, P260, DOI 10.1016/j.bbr.2004.12.007; Zhao JC, 2005, EUR PHYS J E, V16, P49, DOI 10.1140/epje/e2005-00006-1; ZURN AD, 1988, P NATL ACAD SCI USA, V85, P8301, DOI 10.1073/pnas.85.21.8301	63	50	50	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	APR	2007	130		4				915	925		10.1093/brain/awl393			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	165GV	WOS:000246293300005	17293357	Bronze			2022-02-06	
J	Nakashima, T; Nakayama, N; Miwa, K; Okumura, A; Soeda, A; Iwama, T				Nakashima, T.; Nakayama, N.; Miwa, K.; Okumura, A.; Soeda, A.; Iwama, T.			Focal brain glucose hypometabolism in patients with neuropsychologic deficits after diffuse axonal injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							ALZHEIMERS-DISEASE; CINGULATE CORTEX; DEFAULT MODE; HEAD-INJURY; PET; IMAGES; PERFORMANCE; HYPOTHESIS; MEMORY; MONKEY	BACKGROUND AND PURPOSE: Neuropsychologic deficits are well-known sequelae of traumatic brain injury. However, the cerebral correlates of these deficits are still unclear. The aim of the present study was to elucidate the regions of cerebral dysfunction correlated with such neuropsychologic deficits after traumatic brain injury. METHODS: Sets of fluorine-18 fluorodeoxyglucose-positron-emission tomography (FDG-PET) images in the resting state were obtained from 12 patients with neuropsychologic deficits after diffuse axonal injury and from 32 healthy volunteers. The cortical metabolic activity of each subject's PET image sets was extracted using 3D stereotactic surface projection (3D-SSP). A "normal" data base was created using the extracted datasets of the healthy subjects. The patients' datasets were compared with the normal data base by calculating a statistical Z-score on a pixel-by-pixel basis in searches for focal metabolic abnormalities. RESULTS: Group comparisons revealed hypometabolism in the cingulate gyrus with additional involvement of the lingual gyrus and cuneus. Individual case-by-case analyses disclosed differences in the site and extent of the hypometabolism in the cingulate gyrus of each case. Predominant hypometabolism was found in the anterior cingulate gyrus of 6 patients, the middle cingulate gyrus of 2 patients, and the posterior cingulate gyrus of 4 patients. CONCLUSION: Interpretation of FDG-PET using 3D-SSP facilitates the identification of regional hypometabolism in the cerebral cortex of patients after diffuse axonal injury. Dysfunction of the cingulate gyrus, lingual gyrus, and cuneus may play a crucial role in neuropsychologic deficits after traumatic brain injury.	Kizawa Mem Hosp, Dept Neurosurg, Chubu Ryogo Ctr, Gifu 5050034, Japan; Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan		Nakashima, T (corresponding author), Kizawa Mem Hosp, Dept Neurosurg, Chubu Ryogo Ctr, 630 Shimokobi, Gifu 5050034, Japan.	torinaka@quartz.ocn.ne.jp		Iwama, Toru/0000-0002-9426-284X			Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; BALEYDIER C, 1980, BRAIN, V103, P525, DOI 10.1093/brain/103.3.525; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; FINN G, 1996, NATURE, V382, P626; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; GRAHAM DI, 2000, HEAD INJURY, P176; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; ICHISE M, 1994, J NUCL MED, V35, P217; KADEKARO M, 1985, P NATL ACAD SCI USA, V82, P6010, DOI 10.1073/pnas.82.17.6010; Krasnow B, 2003, NEUROIMAGE, V18, P813, DOI 10.1016/S1053-8119(03)00002-8; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; LEROUX PD, 2000, HEAD INJURY, P176; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Marshall LF, 1991, J NEUROSURG S, V75, P14; MATSUNAMI K, 1989, BRAIN RES BULL, V22, P829, DOI 10.1016/0361-9230(89)90026-9; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; MINOSHIMA S, 1994, LANCET, V344, P895, DOI 10.1016/S0140-6736(94)92871-1; Minoshima S, 1998, QUANTITATIVE FUNCTIONAL BRAIN IMAGING WITH POSITRON EMISSION TOMOGRAPHY, P133, DOI 10.1016/B978-012161340-2/50020-2; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, P949; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Mizumura S, 2003, ANN NUCL MED, V17, P289, DOI 10.1007/BF02988523; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Stamatakis EA, 2002, J NUCL MED, V43, P476; Tournoux P, 1998, COPLANAR STEREOTACTI	33	50	53	0	2	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2007	28	2					236	242					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	136ZS	WOS:000244263200013	17296986				2022-02-06	
J	Sakowitz, OW; Stover, JF; Sarrafzadeh, AS; Unterberg, AW; Kiening, KL				Sakowitz, Oliver W.; Stover, John F.; Sarrafzadeh, Asita S.; Unterberg, Andreas W.; Kiening, Karl L.			Effects of mannitol bolus administration on intracranial pressure, cerebral extracellular metabolites, and tissue oxygenation in severely head-injured patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						intracranial pressure; microdialysis; multimodal cerebral monitoring; osmotherapy; traumatic brain injury	BRAIN-INJURY; HYPERTONIC SALINE; MICRODIALYSIS; 7.5-PERCENT; ARTERIOLES; INSULTS; BURDEN; FLUID; COMA; DOGS	Background: Osmotic agents are widely used to lower elevated intracranial pressure (ICP). However, little data are available regarding cerebral oxygenation and metabolism in the traumatized brains studied under clinical conditions. The present prospective, open-labeled clinical study was designed to investigate whether administration of mannitol, with the aim of reducing moderate intracranial hypertension, improves cerebral metabolism and oxygenation in patients after severe traumatic brain injury (TBI). Methods: Multimodal cerebral monitoring (MCM), consisting of intraparenchymal ICP, tissue oxygenation (002), and micro dialysis measurements was initiated in six male TBI patients (mean age 45 years; Glasgow Coma Scale score < 9). A total of 14 mannitol boli (20%, 0.5g/kg, 20 minutes infusion time) were administered to treat ICP exceeding 20 mm Hg (2.7 kPa). Temporal alterations determined by MCM after mannitol infusions were recorded for 120 minutes. Microdialysates were assayed immediately for extracellular glucose, lactate, pyruvate, and glutamate concentrations. Results: Elevated ICP was successfully treated in all cases. This effect was maximal 40 minutes after start of infusion (25 +/- 6 mm Hg [3.3 +/- 0.8 kPa] to 17 +/- 3 mm Hg [2.3 +/- 0.4 kPa], p < 0.05) and lasted up to 100 minutes. Cerebral ptiO(2) remained unaffected (21 5 mm Hg [2.8 +/- 0.7 kPa] to 23 +/- 6 mm Hg [3.1 +/- 0.8 kPa], n.s.). Microdialysate concentrations of all analytes rose unspecifically by 10% to 40% from baseline, reaching maximum concentrations 40 to 60 minutes after start of the infusion. Conclusions: Mannitol efficiently reduces increased ICP. At an ICP of up to 30 mm Hg [4 kPa] it does not affect cerebral oxygenation. Unspecific increases of extracellular fluid metabolites can be explained by transient osmotic dehydration. Additional mechanisms, such as increased cerebral perfusion and blood volume, might explain an accelerated return to baseline.	Heidelberg Univ, Dept Neurosurg, D-69120 Heidelberg, Germany; Univ Zurich Hosp, Div Surg Intens Care Med, CH-8091 Zurich, Switzerland; Med Univ Berlin, Charite, Dept Neurosurg, Berlin, Germany		Sakowitz, OW (corresponding author), Heidelberg Univ, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	oliver.sakowitz@med.uni-heidelberg.de		Sakowitz, Oliver/0000-0003-3248-6335			*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P451; Bateman H, 1910, P CAMB PHILOS SOC, V15, P423; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Berger C, 2005, STROKE, V36, pE4, DOI 10.1161/01.STR.0000151328.70519.e9; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLOYD JC, 1986, J PHARMACOL EXP THER, V236, P301; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Cruz J, 2001, NEUROSURGERY, V49, P864; CSERR HF, 1987, AM J PHYSIOL, V253, pF522, DOI 10.1152/ajprenal.1987.253.3.F522; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; GORDON EL, 1995, J CEREBR BLOOD F MET, V15, P532, DOI 10.1038/jcbfm.1995.66; Hartl R, 1997, ACT NEUR S, V70, P40; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; INAO S, 1990, ACT NEUR S, V51, P401; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KIRKPATRICK PJ, 1994, J NEUROL NEUROSUR PS, V57, P1382, DOI 10.1136/jnnp.57.11.1382; Levenberg K., 1944, Quarterly of Applied Mathematics, V2, P164; MARQUARDT D, 1963, SIAM J APPL MATH, V11, P431, DOI DOI 10.1137/0111030; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Nau R, 1997, EUR J CLIN PHARMACOL, V53, P271, DOI 10.1007/s002280050375; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Polderman KH, 2003, CRIT CARE MED, V31, P584, DOI 10.1097/01.CCM.0000050287.68977.84; RAVUSSIN P, 1986, J NEUROSURG, V64, P104, DOI 10.3171/jns.1986.64.1.0104; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSENBERG GA, 1988, METAB BRAIN DIS, V3, P217, DOI 10.1007/BF00999238; ROSENBLUM WI, 1983, AM J PHYSIOL, V245, pH139, DOI 10.1152/ajpheart.1983.245.1.H139; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; TODD NV, 1990, ACT NEUR S, V51, P296; UNGERSTEDT U, 1998, PATHOPHYSIOLOGICAL P, P83; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wakai A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub5; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	40	50	52	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2007	62	2					292	298		10.1097/01.ta.0000203560.03937.2d			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	137ZY	WOS:000244333300006	17297315				2022-02-06	
J	Coben, JH; Steiner, CA; Miller, TR				Coben, Jeffrey H.; Steiner, Claudia A.; Miller, Ted R.			Characteristics of motorcycle-related hospitalizations: Comparing states with different helmet laws	ACCIDENT ANALYSIS AND PREVENTION			English	Article						motorcycles; injuries; hospitalizations; helmets	ECONOMIC-IMPACT; UNITED-STATES; TRAUMA	This study compares U.S. motorcycle-related hospitalizations across states with differing helmet laws. Cross-sectional analyses of hospital discharge data from 33 states participating in the Healthcare Cost and Utilization Project in 2001 were conducted. Results revealed that motorcyclists hospitalized from states without universal helmet laws are more likely to die during the hospitalization, sustain severe traumatic brain injury, be discharged to long-term care facilities, and lack private health insurance. This study further illustrates and substantiates the increased burden of hospitalization and long-term care seen in states that lack universal motorcycle helmet use laws. (c) 2006 Elsevier Ltd. All rights reserved.	W Virginia Univ, Dept Emergency Med, Injury Control Res Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Community Med, Injury Control Res Ctr, Morgantown, WV 26506 USA; US Dept Hlth & Human Serv, Ctr Delivery Org & Markets, Agcy Healthcare Res & Qual, Rockville, MD USA; Pacific Inst Res & Evaluat, Calverton, MD USA		Coben, JH (corresponding author), W Virginia Univ, Dept Emergency Med, Injury Control Res Ctr, POB 9151, Morgantown, WV 26506 USA.	jcoben@hsc.wvu.edu		Miller, Ted/0000-0002-0958-2639			*AG HEALTHC RES QU, 2006, HCUP REP HEALTHC COS; *AG HEALTHC RES QU, 2004, HCUP OV HEALTHC COST; *AG HEALTHC RES QU, 2006, HCUP TOOLS SOFTW HEA; AGRESTI A, 1990, CATEGORICAL DATA ANA, P54; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Branas CC, 2001, ACCIDENT ANAL PREV, V33, P641, DOI 10.1016/S0001-4575(00)00078-6; BRIED JM, 1987, CLIN ORTHOP RELAT R, P252; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; Coben JH, 2004, AM J PREV MED, V27, P355, DOI 10.1016/j.amepre.2004.08.002; Coben JH, 2003, AM J PREV MED, V24, P1, DOI 10.1016/S0749-3797(02)00578-0; Eastridge BJ, 2006, J TRAUMA, V60, P978, DOI 10.1097/01.ta.0000215582.86115.01; FLEISS JL, 1981, STATISTICAL METHODS, P71; Hotz Gillian A, 2004, Traffic Inj Prev, V5, P87, DOI 10.1080/15389580490269227; Hundley JC, 2004, J TRAUMA, V57, P944, DOI 10.1097/01.TA.0000149497.20065.F4; *INS I HIGH SAF, 2006, Q A MOT HELM US LAWS; *INS I HIGH SAF, 2006, HELM US LAWS; LAWRENCE BA, 2002, HS809242 DOT NAT HIG; Max W, 1998, J TRAUMA, V45, P550, DOI 10.1097/00005373-199809000-00023; Morris CC, 2006, ACCIDENT ANAL PREV, V38, P142, DOI 10.1016/j.aap.2005.08.004; *NAT HIGH TRAFF SA, 2004, MOT RID FAT AR INCR; *NAT HIGH TRAFF SA, 1996, 808347 DOT HS; *NAT HIGH TRAFF SA, 2004, TRAFF SAF FACTS 2004; *NAT HIGH TRAFF SA, 2003, TRAFF SAF FACTS 2003; *NAT HIGH TRAFF SA, 2004, TRAFF SAF FACTS CRAS; ORSAY E, 1995, ANN EMERG MED, V26, P455, DOI 10.1016/S0196-0644(95)70114-1; Paulozzi L. J., 2004, Morbidity and Mortality Weekly Report, V53, P1103; SHULMAN J, 2003, INVESTIGATION UTILIT; Steiner Claudia, 2002, Eff Clin Pract, V5, P143; ULMER RG, 2005, 809849 DOT HS; *US DEP TRANSP FED, 2002, STAT MOT VEH REG 200	30	50	51	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	JAN	2007	39	1					190	196		10.1016/j.aap.2006.06.018			7	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	130UT	WOS:000243825200023	16920053				2022-02-06	
J	Igarashi, T; Potts, MB; Noble-Haeusslein, LJ				Igarashi, Takuji; Potts, Matthew B.; Noble-Haeusslein, Linda J.			Injury severity determines Purkinje cell loss and microglial activation in the cerebellum after cortical contusion injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; controlled cortical impact; neuronal loss; cerebellum; activated microglia; Purkinje cells	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; MORRIS WATER MAZE; IMPACT INJURY; COGNITIVE DEFICITS; HEAD-INJURY; NEURONAL INJURY; TIME-COURSE; RAT; MODEL	Clinical evidence suggests that the cerebellum is damaged after traumatic brain injury (TBI) and experimental studies have validated these observations. We have previously shown cerebellar vulnerability, as demonstrated by Purkinje cell loss and microglial activation, after fluid percussion brain injury. In this study, we examine the effect of graded controlled cortical impact (CCI) injury on the cerebellum in the context of physiologic and anatomical parameters that have been shown by others to be sensitive to injury severity. Adult male rats received mild, moderate, or severe CCI and were euthanized 7 days later. We first validated the severity of the initial injury using physiologic criteria, including apnea and blood pressure, during the immediate postinjury period. Increasing injury severity was associated with an increased incidence of apnea and higher mortality. Severe injury also induced transient hypertension followed by hypotension, while lower grade injuries produced an immediate and sustained hypotension. We next evaluated the pattern of subcortical neuronal loss in response to graded injuries. There was significant neuronal loss in the ipsilateral cortex, hippocampal CA2/CA3, and laterodorsal thalamus that was injury severity-dependent and that paralleled microglial activation. Similarly, there was a distinctive pattern of Purkinje cell loss and microglial activation in the cerebellar vermis that varied with injury severity. Together, these findings emphasize the vulnerability of the cerebellum to TBI. That a selective pattern of Purkinje cell loss occurs regardless of the type of injury suggests a generalized response that is a likely determinant of recovery and a target for therapeutic intervention. (c) 2006 Elsevier Inc. All rights reserved.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA		Noble-Haeusslein, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 521 Parnassus Ave,Room C-224, San Francisco, CA 94143 USA.	linda.noble@ucsf.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER		Ai JL, 2004, PHARMACOLOGY, V71, P192, DOI 10.1159/000078085; Ai JL, 2002, NEUROSCI LETT, V332, P155, DOI 10.1016/S0304-3940(02)00945-X; Alavi A, 1997, J NUCL MED, V38, P1717; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BIARY N, 1989, NEUROLOGY, V39, P103, DOI 10.1212/WNL.39.1.103; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; DAUM I, 1995, BEHAV BRAIN RES, V67, P201, DOI 10.1016/0166-4328(94)00144-5; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; IWADATE Y, 1989, Neurosurgical Review, V12, P500, DOI 10.1007/BF01790695; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; KOCHANEK PM, 1995, J NEUROTRAUM, V12, P1015; KRAUSS JK, 1995, NEUROL RES, V17, P409, DOI 10.1080/01616412.1995.11740353; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Lalonde R, 2003, CEREBELLUM, V2, P300, DOI 10.1080/14734220310017456; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Louis ED, 1996, ARCH NEUROL-CHICAGO, V53, P450, DOI 10.1001/archneur.1996.00550050080027; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Middleton FA, 1998, TRENDS NEUROSCI, V21, P367, DOI 10.1016/S0166-2236(98)01330-7; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MYSIW W J, 1990, Brain Injury, V4, P247, DOI 10.3109/02699059009026174; NAKKI R, 1995, J NEUROSCI, V15, P2097, DOI 10.1523/JNEUROSCI.15-03-02097.1995; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Niimura K, 1999, NEUROLOGY, V52, P792, DOI 10.1212/WNL.52.4.792; OHearn E, 1997, J NEUROSCI, V17, P8828; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Paxinos G, 1995, RAT NERVOUS SYSTEM; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Rapoport M, 2000, J NEUROPSYCH CLIN N, V12, P193, DOI 10.1176/appi.neuropsych.12.2.193; ROSS CA, 1990, TRENDS NEUROSCI, V13, P216, DOI 10.1016/0166-2236(90)90163-5; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SILVERMAN J, 1993, LAB ANIM SCI, V43, P210; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; Tang SL, 1997, J CHART INST WATER E, V11, P14; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tecoult E, 2000, J NEUROSURG ANESTH, V12, P255, DOI 10.1097/00008506-200007000-00010; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth Z, 1997, J NEUROSCI, V17, P8106; Wixson S.K., 1997, ANESTHESIA ANALGESIA; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; YUAN X-Q, 1990, Journal of Neurotrauma, V7, P141, DOI 10.1089/neu.1990.7.141; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; ZIAI MR, 1988, J NEUROCHEM, V51, P1771, DOI 10.1111/j.1471-4159.1988.tb01158.x; ZIAI R, 1986, P NATL ACAD SCI USA, V83, P8420, DOI 10.1073/pnas.83.21.8420	84	50	51	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2007	203	1					258	268		10.1016/j.expneurol.2006.08.030			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	123NU	WOS:000243303400028	17045589				2022-02-06	
J	Kreutzer, JS; Marwitz, JH; Hsu, N; Williams, K; Riddick, A				Kreutzer, Jeffrey S.; Marwitz, Jennifer H.; Hsu, Nancy; Williams, Kelli; Riddick, Amy			Marital stability after brain injury: An investigation and analysis	NEUROREHABILITATION			English	Article						brain injury; marriage; divorce	DYADIC ADJUSTMENT SCALE; HEAD-INJURY; SATISFACTION SCALE	Objective: To examine rates of separation and divorce after traumatic brain injury and identify factors relating to risk of marital breakdown. Participants: 120 persons who sustained a mild, moderate, or severe traumatic brain injury and who were married at the time of injury. Methods: Survivors were contacted between 30 and 96 months postinjury when demographic and marital status information was solicited. Injury information was obtained from medical records. Findings: A majority of patients remained married. The rate of divorce was 17% and 8% was the separation rate. People who were married longer before their injury, victims of non-violent injuries, older persons, and persons with less severe injuries were more likely to remain married. Gender, ethnicity, educational level, time elapsed since injury, and postinjury employment status were unrelated to risk for marital breakdown. Conclusion: Research findings do not support contentions that persons with brain injury are at greater risk for divorce relative to the general population. Nor do findings suggest that males are more likely to leave injured female partners. More research is needed to assess marital quality and the potential benefits of intervention programs designed to develop and maintain mutually supportive relationships.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA		Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.	jskreutz@vcu.edu					Anderson-Parente JK., 1990, COGN REHABIL, V8, P22; BUSBY DM, 1995, J MARITAL FAM THER, V21, P289, DOI 10.1111/j.1752-0606.1995.tb00163.x; Crane DR, 2000, AM J FAM THER, V28, P53, DOI 10.1080/019261800261815; Gosling J, 1999, BRAIN INJURY, V13, P785; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; KIMMEL D, 1974, J MARRIAGE FAM, V36, P57, DOI 10.2307/350994; KREIDER RM, 2005, CURRENT POPULATION R, P70; KREUTZER J, 1987, GEN HLTH HIST PROGRA; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Panting A, 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; RALEY PK, 2003, DEMOGR RES, V8, P245; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SCHUMM WR, 1983, PSYCHOL REP, V53, P567, DOI 10.2466/pr0.1983.53.2.567; STILWELL J, 1997, STUDIES, P1; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Webster G, 1999, BRAIN INJURY, V13, P593; WHITE MB, 1994, FAMILY PERSPECTIVE, V0028, P00053; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	24	50	50	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	1					53	59					7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	150TE	WOS:000245240600006	17379948				2022-02-06	
J	Chiu, WT; Huang, SJ; Hwang, HF; Tsauo, JY; Chen, CF; Tsai, SH; Lin, MR				Chiu, Wen-Ta; Huang, Sheng-Jean; Hwang, Hei-Fen; Tsauo, Jau-Yih; Chen, Chun-Fu; Tsai, Shin-Han; Lin, Mau-Roung			Use of the WHOQOL-BREF for evaluating persons with traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						health-related quality of life; injury severity; reliability; traumatic brain injury; validity	QUALITY-OF-LIFE; HEALTH; VALIDITY; REHABILITATION; INDIVIDUALS; RELIABILITY; INDICATORS; VALIDATION; TELEPHONE; SF-36	This study examined psychometric properties of a brief version of the World Health Organization Quality of Life questionnaire (WHOQOL-BREF) among persons with traumatic brain injury (TBI) and the relations of the WHOQOL-BREF domains, including physical capacity, psychological wellbeing, social relationships, and environment, to different indicators of TBI severity. Of the 354 eligible and available subjects from 22 hospitals in northern Taiwan over a 6-month period, 199 completed telephone interviews during data collection. Three indicators of TBI severity were used: the Glasgow Coma Scale, the presence of post-traumatic amnesia, and the abbreviated injury scale to the head. All domain scores of the WHOQOL-BREF had nearly symmetrical distributions: low percentages of ceiling and floor values (0 similar to 3%), low missing rates (0 similar to 0.5%) for all but one item (43.2%), and very good internal consistency (0.75 similar to 0.89) and test-retest reliability (0.74 similar to 0.95). The WHOQOL-BREF also exhibited excellent known-groups validity, as well as very good responsiveness and convergent validity with regard to employment, independence in daily life activities, social support, and depression. After adjustment for potential confounders, almost none of the domain scores of the WHOQOL-BREF significantly differed in the severity levels of the three severity indicators. In conclusion, the WHOQOL-BREF is an appropriate health-related quality of life (HRQL) instrument for persons with TBI. Furthermore, the initial severity of the TBI might not be suitable for predicting levels of HRQL in persons with TBI.	Taipei Med Univ, Inst Injury Prevent & Control, Taipei 110, Taiwan; Wan Fang Hosp, Dept Surg, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taipei Coll Nursing, Dept Nursing, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Sch & Grad Inst Phys Therapy, Taipei, Taiwan; St Marys Hosp, Dept Neurosurg, Yilan, Taiwan; Taipei Med Univ, Inst Injury Prevent & Control, Taipei, Taiwan		Lin, MR (corresponding author), Taipei Med Univ, Inst Injury Prevent & Control, 250 Wu Hsing St, Taipei 110, Taiwan.	mrlin@tmu.edu.tw		Tsauo, Jau-Yih/0000-0003-4607-4454			Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Cohen J., 1998, STAT POWER ANAL BEHA, V2nd; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Curran D, 1998, OX MED PUBL, P249; de Jager CA, 2003, INT J GERIATR PSYCH, V18, P318, DOI 10.1002/gps.830; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Folstein M, 1988, NEUROPSY NEUROPSY BE, V1, P111; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GUYATT GH, 1989, J CLIN EPIDEMIOL, V42, P403, DOI 10.1016/0895-4356(89)90128-5; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; HUNG JS, 1992, J FORMOS MED ASSOC, V90, P1227; Jackson RJ, 2003, AM J PUBLIC HEALTH, V93, P1382, DOI 10.2105/AJPH.93.9.1382; JENNETT B, 1975, LANCET, V1, P480; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LAZAR RB, 1989, ARCH PHYS MED REHAB, V70, P819; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; Leidy NK, 1999, EPILEPSIA, V40, P97, DOI 10.1111/j.1528-1157.1999.tb01995.x; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MAHONEY F I, 1965, Md State Med J, V14, P61; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McDowell I., 1996, MEASURING HLTH GUIDE; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; OHANICK GJ, 1986, ADV PSYCHOSOM MED, V16, P173; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Revicki DA, 1997, HARVARD REV PSYCHIAT, V5, P75, DOI 10.3109/10673229709034730; Robinette C. D., 1990, Dementia and Geriatric Cognitive Disorders,, V1, P297, DOI [10.1159/000107157, DOI 10.1159/000107157]; Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580; Schipper H., 1996, QUALITY LIFE PHARMAC, V2, P11; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TENNSTEDT SL, 1992, AM J PUBLIC HEALTH, V82, P1541; Unal G, 2001, J CLIN EPIDEMIOL, V54, P587, DOI 10.1016/S0895-4356(00)00372-3; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; WALLER JA, 1988, J TRAUMA, V28, P1632, DOI 10.1097/00005373-198812000-00003; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; WHO, 1996, WHOQOL BREF INTR ADM; *WHO, 1994, MNHPSF944 WHO; *WHO, 1995, MNHPSF951 WHO; *WHOQOL TAIWAN GRO, 2000, MAN TAIW VERS WHOQOL; World Health Organization, 1980, INT CLASS IMP DIS HA; Yao G, 2002, J FORMOS MED ASSOC, V101, P342; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	52	50	51	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2006	23	11					1609	1620		10.1089/neu.2006.23.1609			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	106RK	WOS:000242118200004	17115908				2022-02-06	
J	Schonberger, M; Humle, F; Teasdale, TW				Schonberger, Michael; Humle, Frank; Teasdale, Thomas W.			Subjective outcome of brain injury rehabilitation in relation to the therapeutic working alliance, client compliance and awareness	BRAIN INJURY			English	Article						therapeutic working alliance; awareness; compliance; acquired brain injury; rehabilitation; subjective outcome; process research	CLOSE RELATIVES; HEAD-INJURY; EXPERIENCE; DEFICITS	Objective: To investigate the relationship between working alliance, compliance, awareness and subjective outcome of brain injury rehabilitation. Subjects were 86 patients who were clients in an holistic neuropsychological outpatient rehabilitation programme. They had suffered a traumatic brain injury (n = 27), a cerebrovascular accident (n = 49) or some other neurological insult (n = 10). Measures: The therapeutic alliance, clients' awareness and their compliance were rated four times during the 14-week rehabilitation programme. The therapeutic alliance was rated by both clients and therapist using the Working Alliance Inventory (WAI), awareness and compliance were rated by the therapists. Clients completed the European Brain Injury Questionnaire (EBIQ) at programme start and end. Clients and therapists rated the overall success of their collaboration at programme end. Results: Clients' experience of a good emotional bond between themselves and therapists in mid-therapy was predictive for the reduction of clients' report of depressive symptoms on the EBIQ depression sub-scale (R = 0.68, n = 43, p < 0.001). Good compliance early in the programme was predictive of changes on the EBIQ. Improvement of awareness was related to the amplification of depressive symptoms (r = 0.27, n = 56, p < 0.05). Conclusions: Brain injury rehabilitation should be seen as a dynamic process that develops between clients and therapists. Future research should further investigate the relationship between process and outcome and how the therapeutic process can be optimized.	Univ Copenhagen, Ctr Rehabil Brain Injury, DK-2300 Copenhagen S, Denmark; Univ Copenhagen, Dept Psychol, DK-2300 Copenhagen S, Denmark		Schonberger, M (corresponding author), Univ Copenhagen, Ctr Rehabil Brain Injury, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	michael.schoenberger@psy.ku.dk					BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P33; Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; Bordin ES, 1979, PSYCHOTHER THEORY RE, V16, P252, DOI DOI 10.1037/H0085885; CAETANO C, 2000, INT HDB NEUROPSYCHOL, P259; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; Cohen J., 1975, APPL MULTIPLE REGRES; Constantino M.J., 2002, COUNSELING BASED PRO, P81; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FLEMING J, 1995, BRIT J OCCUPATIONAL, V98, P55; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Fleming JM, 1996, BRAIN INJURY, V10, P1; HENRY WP, 1994, WORKING ALLIANCE THE, P00051; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Norcross, 2002, PSYCHOTHERAPY RELATI, P17; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; Rogers CR, 1952, SCI AM, V187, P66; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; SCHONBERGER M, 2005, NEUROPSYCHOL REHABIL, V16, P298; SCHONBERGER M, 2005, NEUROPSYCHOL REHABIL, V16, P561; Stuss D. T., 1999, COGNITIVE NEUROREHAB, P188; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; Tracey T.J., 1989, J CONSULT CLIN PSYCH, V1, P207, DOI [10.1037/1040-3590.1.3.207, DOI 10.1037/1040-3590.1.3.207, 10.1037/1040-3590.1.3.207.]; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003	34	50	50	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2006	20	12					1271	1282		10.1080/02699050601049395			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	110DF	WOS:000242357800006	17132550				2022-02-06	
J	Wang, R; Foniok, T; Wamsteeker, JI; Qiao, M; Tomanek, B; Vivanco, RA; Tuor, UI				Wang, Rong; Foniok, Tadeusz; Wamsteeker, Jaclyn I.; Qiao, Min; Tomanek, Boguslaw; Vivanco, Rodrigo A.; Tuor, Ursula I.			Transient blood pressure changes affect the functional magnetic resonance imaging detection of cerebral activation	NEUROIMAGE			English	Article						hypertension; hypotension; cerebral blood flow; neural activation; electrical stimulation	TRAUMATIC BRAIN-INJURY; BOLD SIGNAL; FLOW; AUTOREGULATION; STIMULATION; RATS; MRI; HYPOTENSION; BARRIER; REST	Functional magnetic resonance imaging (fMRI) provides an indirect measure of cerebral activation that could be altered by factors directly affecting cerebral blood flow independent of changes in neuronal activation. Presently, we investigate how changes in blood pressure (BP) affect the activation detected with fMRI. fMRI scans were acquired in 33 rats under control conditions and following transient BP increases (norepinephrine, IV) or decreases (arfonad, IV) with and without electrical stimulation of the forepaw. Voxels correlating to either the stimulation or the change in BP time courses were identified. During transient hypertension, irrespective of forepaw stimulation, BP increases (i.e., > 10 mm Hg) produced a transient increase in the blood oxygen level-dependent (BOLD) intensity resulting in a significant numbers of voxels correlating to the BP time courses (P < 0.05), and the number of these voxels increased as BP increased, becoming substantial at BP > 30 mm Hg. The activation patterns with BP increases and stimulation overlapped spatially resulting in an enhanced cerebral activation to simultaneous forepaw stimulation (P < 0.05). BP decreases (> 10 mm Hg) produced corresponding decreases in BOLD intensity, causing significant numbers of voxels correlating to the BP decreases (P < 0.005), and these numbers increased as BP decreased (P < 0.001). The BP decreases and stimulation time courses and responses were distinct, and hypotension did not affect the detection of the activation response to forepaw stimulation. The results indicate that substantial hypertension accompanying a stimulation paradigm produces a BOLD response that enhances the cerebral activation detected, whereas hypotension does not affect the detection of neuronal activation but does produce responses that could be interpreted as a 'deactivation'. Crown Copyright (c) 2005 Published by Elsevier Inc. All rights reserved.	Natl Res Council Canada, Inst Biodiagnost W, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Expt Imaging Ctr, Hotchkiss Brain Inst, Calgary, AB, Canada		Tuor, UI (corresponding author), Natl Res Council Canada, Inst Biodiagnost W, B153,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Ursula.Tuor@nrc-cnrc.ge.ca	Tomanek, Boguslaw/AAD-7594-2019; Tomanek, Boguslaw/J-4720-2014	Tomanek, Boguslaw/0000-0003-2602-0280; 			AASLID R, 1994, STROKE, V25, P1297; Bruhn H, 2001, J MAGN RESON IMAGING, V13, P325, DOI 10.1002/jmri.1047; BRUHN H, 1994, J CEREBR BLOOD F MET, V14, P742, DOI 10.1038/jcbfm.1994.95; BUTCHER KS, 1995, AM J PHYSIOL-REG I, V268, pR214, DOI 10.1152/ajpregu.1995.268.1.R214; Carter JR, 2005, J PHYSIOL-LONDON, V564, P321, DOI 10.1113/jphysiol.2004.079665; Critchley HD, 2000, J PHYSIOL-LONDON, V523, P259, DOI 10.1111/j.1469-7793.2000.t01-1-00259.x; Czisch M, 2004, EUR J NEUROSCI, V20, P566, DOI 10.1111/j.1460-9568.2004.03518.x; Diehl Rolf R, 2002, Eur J Ultrasound, V16, P31, DOI 10.1016/S0929-8266(02)00048-4; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; HARDEBO JE, 1980, ANN NEUROL, V8, P1, DOI 10.1002/ana.410080102; Harper RM, 2000, J COMP NEUROL, V417, P195, DOI 10.1002/(SICI)1096-9861(20000207)417:2<195::AID-CNE5>3.0.CO;2-V; Hempel E, 1999, ROFO-FORTSCHR RONTG, V170, P304; Henderson LA, 2004, J APPL PHYSIOL, V96, P693, DOI 10.1152/japplphysiol.00852.2003; Kalisch R, 2001, NEUROIMAGE, V14, P891, DOI 10.1006/nimg.2001.0890; Kannurpatti SS, 2004, J CEREBR BLOOD F MET, V24, P703, DOI 10.1097/01.WCB.0000121232.04853.46; Kharlamov A, 2004, NEUROSCI LETT, V368, P151, DOI 10.1016/j.neulet.2004.06.079; King AB, 1999, J COMP NEUROL, V413, P572; KONTOS HA, 1978, AM J PHYSIOL, V234, P371; Luo F, 2003, MAGNET RESON MED, V49, P264, DOI 10.1002/mrm.10366; MACKENZIE ET, 1976, CIRC RES, V39, P33, DOI 10.1161/01.RES.39.1.33; Matthews PM, 2004, J NEUROL NEUROSUR PS, V75, P6; MENDELOW AD, 1987, J NEUROSURG, V66, P755, DOI 10.3171/jns.1987.66.5.0755; Menon RS, 2001, CURR OPIN NEUROBIOL, V11, P630, DOI 10.1016/S0959-4388(00)00260-9; Morton DW, 2002, AM J NEURORADIOL, V23, P588; Mulderink TA, 2002, NEUROIMAGE, V15, P37, DOI 10.1006/nimg.2001.0973; OPPENHEIMER SM, 1994, CURR OPIN NEUROL, V7, P20, DOI 10.1097/00019052-199402000-00005; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; Panerai RB, 2003, MED ENG PHYS, V25, P621, DOI 10.1016/S1350-4533(03)00027-4; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Paulson OB, 2002, EUR NEUROPSYCHOPHARM, V12, P495, DOI 10.1016/S0924-977X(02)00098-6; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Prielipp RC, 2001, ANESTH ANALG, V93, P45; Rochette LM, 2005, INT J PSYCHOPHYSIOL, V56, P81, DOI 10.1016/j.ijpsycho.2004.10.003; Stefurak T, 2003, MOVEMENT DISORD, V18, P1508, DOI 10.1002/mds.10593; Tuor UI, 2002, MAGN RESON IMAGING, V20, P707, DOI 10.1016/S0730-725X(02)00599-4; TUOR UI, 1994, AM J PHYSIOL-HEART C, V267, pH2220; TUOR UI, 1986, AM J PHYSIOL, V251, pH824, DOI 10.1152/ajpheart.1986.251.4.H824; Zaharchuk G, 1999, STROKE, V30, P2197, DOI 10.1161/01.STR.30.10.2197	40	50	52	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	MAY 15	2006	31	1					1	11		10.1016/j.neuroimage.2005.12.004			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	049JK	WOS:000238012200001	16460967				2022-02-06	
J	Pohl, M; Mehrholz, J				Pohl, M; Mehrholz, J			Immediate effects of an individually designed functional ankle-foot orthosis on stance and gait in hemiparetic patients	CLINICAL REHABILITATION			English	Article							HEMIPLEGIC GAIT; POSTURAL STABILITY; MUSCLE-ACTIVITY; CEREBRAL-PALSY; WALKING; BALANCE; RELIABILITY; PARAMETERS; SPASTICITY; LONG	Objective: To evaluate the immediate effects of individually designed functional in-shoe ankle-foot orthoses ( AFO) made of soft and hard cast on balance, standing, and gait parameters in hemiparetic patients. Design: Crossover design with randomized order of the intervention. Setting: A rehabilitation centre for adults with neurological disorders. Subjects: Twenty-eight patients with hemiparesis due to stroke or traumatic brain injury. Measures: Postural sway, standing and gait parameters based on ground reaction forces in two conditions: Patients were randomly assigned to varying sequences of wearing AFO in footwear or wearing footwear alone. Results: AFO significantly improved weight-bearing on the affected leg ( affected/unaffected side symmetry: 2.259 +/- 1.5 with AFO versus 3.49 +/- 2.5 without AFO, P < 0.05) and postural sway in stance ( 12.5 mm +/- 5.2 with AFO versus 15.7 mm +/- 6.7 without AFO, P<0.05), double stance duration ( 21.19 +/- 14.4% of gait cycle with AFO versus 25.99 +/- 21.6% of gait cycle without AFO, P < 0.05), and symmetry ratios of gait parameters such as stance duration ( 2.0 +/- 1.5 s with AFO versus 3.3 +/- 3.6 s without AFO, P < 0.05) and deceleration forces ( 1.6 +/- 0.5 with AFO versus 1.9 +/- 0.6 without AFO, P < 0.05) during gait. No significant differences were observed in all other symmetry ratios of gait parameters. Conclusion: An individually designed functional in-shoe AFO can improve stance and gait parameters, even in a single use, in patients with hemiparesis.	Klin Bavaria, Dept Early Neurol Rehabil, Kreischa, Germany; Tech Univ Dresden, Dept Publ Hlth, Dresden, Germany		Pohl, M (corresponding author), Klin Bavaria, Dept Early Rehabil, Wolfsschlucht 1-2, D-01731 Kreischa, Germany.	marcus.pohl@klinik-bavaria.de					BOBATH B, 1990, HEMIPLEGIE ERWACHSEN; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BURDETT RG, 1988, PHYS THER, V68, P1197; Burtner PA, 1999, DEV MED CHILD NEUROL, V41, P748, DOI 10.1017/S0012162299001516; Carr J., 2003, STROKE REHABILITATIO; Chen CL, 1999, ARCH PHYS MED REHAB, V80, P1587, DOI 10.1016/S0003-9993(99)90335-0; Churchill AJG, 2003, CLIN REHABIL, V17, P553, DOI 10.1191/0269215503cr649oa; Corcoran P J, 1970, Arch Phys Med Rehabil, V51, P69; Cross J, 2003, CLIN REHABIL, V17, P817, DOI 10.1191/0269215503cr683oa; DAVIES P, 1990, MITTELPUNKT; DIAMOND MF, 1990, PHYS THER, V70, P423, DOI 10.1093/ptj/70.7.423; EDWARDS S, 2001, NEUROLOGICAL PHYIOTH; Franceschini M, 2003, CLIN REHABIL, V17, P368, DOI 10.1191/0269215503cr622oa; Geboers JF, 2002, ARCH PHYS MED REHAB, V83, P240, DOI 10.1053/apmr.2002.27462; GLANTZ SA, 1998, BIOSTATISTIK; Gok H, 2003, CLIN REHABIL, V17, P137, DOI 10.1191/0269215503cr605oa; Hesse S, 1999, STROKE, V30, P1855, DOI 10.1161/01.STR.30.9.1855; Hesse S, 2003, CNS DRUGS, V17, P1093, DOI 10.2165/00023210-200317150-00004; Hesse S, 1996, INT J REHABIL RES, V19, P133, DOI 10.1097/00004356-199606000-00004; HESSE S, 1993, Z PHYSIOTHER, V45, P827; HESSE SA, 1994, STROKE, V25, P1999, DOI 10.1161/01.STR.25.10.1999; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Iwata M, 2003, ARCH PHYS MED REHAB, V84, P924, DOI 10.1016/S0003-9993(03)00012-1; Kirker SGB, 2000, J NEUROL NEUROSUR PS, V68, P458, DOI 10.1136/jnnp.68.4.458; Laufer Y, 2003, PHYS THER, V83, P112, DOI 10.1093/ptj/83.2.112; LeClair K, 1996, CLIN BIOMECH, V11, P176, DOI 10.1016/0268-0033(95)00027-5; LEHMANN JF, 1987, ARCH PHYS MED REHAB, V68, P763; Leung J, 2002, PHYSIOTHERAPY, V89, P39, DOI DOI 10.1016/S0031-9406(05)60668-2; MEHRHOLZ J, 2001, Z PHYSIOTHER, V53, P1334; Perry J, 1992, GAIT ANAL NORMAL PAT; Pohl M, 2003, ARCH PHYS MED REHAB, V84, P1760, DOI 10.1016/S0003-9993(03)00433-7; Romkes J, 2002, GAIT POSTURE, V15, P18, DOI 10.1016/S0966-6362(01)00178-3; SACHS L, 2004, ANGEWANDTE STAT; SCHUREN J, 1994, ARBEITEN SOFTCAST HD, P104; SIENKO TS, 2002, GAIT POSTURE, V16, P180; Stussi E, 1980, BIOMED TECH, V25, P222, DOI 10.1515/bmte.1980.25.s1.222; Tyson SF, 2001, CLIN REHABIL, V15, P53, DOI 10.1191/026921501673858908	37	50	54	1	36	HODDER ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	APR	2006	20	4					324	330		10.1191/0269215506cr951oa			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	034IZ	WOS:000236923900005	16719030				2022-02-06	
J	Worthington, AD; Melia, Y				Worthington, AD; Melia, Y			Rehabilitation is compromised by arousal and sleep disorders: Results of a survey of rehabilitation centres	BRAIN INJURY			English	Article						arousal; sleep disorder; insomnia; acquired brain injury; rehabilitation	TRAUMATIC BRAIN-INJURY; EXCESSIVE DAYTIME SLEEPINESS; PHARMACOLOGICAL-TREATMENT; INSOMNIA; DISTURBANCES; PHASE; ASSOCIATION; MANAGEMENT; COMPLAINTS; THERAPY	Primary objective: To investigate the impact of disorders of arousal and sleep disturbance on everyday living and participation in rehabilitation. Research design: Survey of rehabilitation centres based on naturalistic observation. Method: One hundred and thirty-five adults with acquired brain injury were reported by rehabilitation staff in seven centres across the UK for presence of arousal and/or sleep disturbance, the impact on rehabilitation and daily living and treatment strategies in use. Outcomes: Disturbance of arousal or sleep patterns was reported in 47% of the sample, with significant adverse effect on activity evident in two-thirds of such cases. Prevalence of disordered arousal was consistent over time for up to 10 years post-injury. Concurrent psychiatric illness, but not epilepsy, was associated with arousal and sleep disorder. Non-pharmacological interventions and benzodiazepine/hypnotic drugs were in use in 34% and 20% of cases respectively. In all cases of prescribed hypnotic drugs, period of use exceeded recommended UK guidelines. Conclusions: Long-term outcome from severe brain injury can be compromised by enduring disturbance of arousal, most commonly evidenced as sleep disorder. Treatment should be based on judicious use of medication ( beyond hypnotic drugs) and greater emphasis on non-pharmacological management.	Brain Injury Rehabil Trust, Birmingham B38 8JW, W Midlands, England		Worthington, AD (corresponding author), Brain Injury Rehabil Trust, W Heath House,54 Ivyhouse Rd,W Heath, Birmingham B38 8JW, W Midlands, England.	aworthington@birt.co.uk		Melia, Yvonne/0000-0003-4430-9379			Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Boivin DB, 2004, SLEEP, V27, P417, DOI 10.1093/sleep/27.3.417; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Busek P, 2000, Sb Lek, V101, P233; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Glenn MB, 2002, J HEAD TRAUMA REHAB, V17, P273, DOI 10.1097/00001199-200208000-00002; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; Happe S, 2003, DRUGS, V63, P2725, DOI 10.2165/00003495-200363240-00003; Hauri PJ, 1997, SLEEP, V20, P1111, DOI 10.1093/sleep/20.12.1111; Ishigooka J, 1999, PSYCHIAT CLIN NEUROS, V53, P515, DOI 10.1046/j.1440-1819.1999.00578.x; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Medicis SW, 1998, J DENT RES, V77, P295; Morgan K, 2003, BRIT J GEN PRACT, V53, P923; Nofzinger EA, 2004, AM J PSYCHIAT, V161, P2126, DOI 10.1176/appi.ajp.161.11.2126; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; RICHTER KJ, 1995, J HEAD TRAUMA REHAB, V10, P7, DOI 10.1097/00001199-199512000-00004; Sateia MJ, 2004, LANCET, V364, P1959, DOI 10.1016/S0140-6736(04)17480-1; Soldatos CR, 2001, CONTEMPORARY NEUROPSYCHIATRY, P405; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Walsh JK, 1999, SLEEP, V22, P371; WROBLEWSKI BA, 1994, J HEAD TRAUMA REHAB, V9, P19, DOI 10.1097/00001199-199409000-00004; [No title captured]; [No title captured]; [No title captured]; [No title captured]	39	50	51	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2006	20	3					327	332		10.1080/02699050500488249			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	021GT	WOS:000235972400012	16537274				2022-02-06	
J	Rech, TH; Vieira, SRR; Nagel, F; Brauner, JS; Scalco, R				Rech, Tatiana H.; Rios Vieira, Silvia Regina; Nagel, Fabiano; Brauner, Janete Salles; Scalco, Rosana			Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN INJURY; ANOXIC-ISCHEMIC COMA; CARDIOPULMONARY-RESUSCITATION; EVOKED-POTENTIALS; POSTANOXIC COMA; PROTEIN S-100; HYPOTHERMIA; SURVIVORS; CONSCIOUSNESS; RECOVERY	Introduction Outcome after cardiac arrest is mostly determined by the degree of hypoxic brain damage. Patients recovering from cardiopulmonary resuscitation are at great risk of subsequent death or severe neurological damage, including persistent vegetative state. The early definition of prognosis for these patients has ethical and economic implications. The main purpose of this study was to investigate the prognostic value of serum neuron-specific enolase (NSE) in predicting outcomes in patients early after in-hospital cardiac arrest. Methods Forty-five patients resuscitated from in-hospital cardiac arrest were prospectively studied from June 2003 to January 2005. Blood samples were collected, at any time between 12 and 36 hours after the arrest, for NSE measurement. Outcome was evaluated 6 months later with the Glasgow outcome scale (GOS). Patients were divided into two groups: group 1 (unfavorable outcome) included GOS 1 and 2 patients; group 2 (favorable outcome) included GOS 3, 4 and 5 patients. The Mann - Whitney U test, Student's t test and Fisher's exact test were used to compare the groups. Results The Glasgow coma scale scores were 6.1 +/- 3 in group 1 and 12.1 +/- 3 in group 2 ( means +/- SD; p < 0.001). The mean time to NSE sampling was 20.2 +/- 8.3 hours in group 1 and 28.4 +/- 8.7 hours in group 2 ( p = 0.013). Two patients were excluded from the analysis because of sample hemolysis. At 6 months, favorable outcome was observed in nine patients (19.6%). Thirty patients (69.8%) died and four (9.3%) remained in a persistent vegetative state. The 34 patients (81.4%) in group 1 had significantly higher NSE levels ( median 44.24 ng/ml, range 8.1 to 370) than those in group 2 (25.26 ng/ml, range 9.28 to 55.41; p = 0.034). Conclusion Early determination of serum NSE levels is a valuable ancillary method for assessing outcome after inhospital cardiac arrest.	Hosp Clin Porto Alegre, Serv Med Intens, BR-90035903 Porto Alegre, RS, Brazil; Complexo Hosp Santa Casa Misericordia Porto Alegr, Serv Med Intens, BR-90020090 Porto Alegre, RS, Brazil; Hosp Clin Porto Alegre, Serv Patol Clin, BR-90035903 Porto Alegre, RS, Brazil		Rech, TH (corresponding author), Hosp Clin Porto Alegre, Serv Med Intens, 2350 Largo Eduardo Z Faraco, BR-90035903 Porto Alegre, RS, Brazil.	tatianarech@terra.com.br	Rech, Tatiana/V-2711-2019				*AM HEART ASS INT, 2000, CIRCULATION S, V102, P105; Anand N, 2005, CEREBROVASC DIS, V20, P213, DOI 10.1159/000087701; BALLEW KA, 1994, ARCH INTERN MED, V154, P2426, DOI 10.1001/archinte.154.21.2426; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Bottiger BW, 2001, CIRCULATION, V103, P2694; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; El-Menyar AA, 2005, CHEST, V128, P2835, DOI 10.1378/chest.128.4.2835; Fernandez RR, 1996, INTENS CARE MED, V22, P1034, DOI 10.1007/s001340050209; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; JENNETT B, 1975, LANCET, V1, P480; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; Madl C, 2000, CRIT CARE MED, V28, P721, DOI 10.1097/00003246-200003000-00020; Madl Christian, 2004, Curr Opin Crit Care, V10, P213, DOI 10.1097/01.ccx.0000127542.32890.fa; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Nakabayashi M, 2001, INTENS CARE MED, V27, P1210, DOI 10.1007/s001340100984; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Safar P, 2002, CRIT CARE MED, V30, pS140, DOI 10.1097/00003246-200204001-00004; Safar PJ, 2002, NEW ENGL J MED, V346, P612, DOI 10.1056/NEJM200202213460811; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Tiainen M, 2005, CRIT CARE MED, V33, P1736, DOI 10.1097/01.CCM.0000171536.63641.D9; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076	33	50	59	0	2	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1466-609X			CRIT CARE	Crit. Care		2006	10	5							R133	10.1186/cc5046			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185NS	WOS:000247718300009	16978415	Green Published, gold			2022-02-06	
J	Warren, MW; Kobeissy, FH; Liu, MC; Hayes, RL; Gold, MS; Wang, KKW				Warren, MW; Kobeissy, FH; Liu, MC; Hayes, RL; Gold, MS; Wang, KKW			Concurrent calpain and caspase-3 mediated proteolysis of alpha II-spectrin and tau in rat brain after methamphetamine exposure: A similar profile to traumatic brain injury	LIFE SCIENCES			English	Article						methamphetamine; drug abuse; traumatic brain injury; caspases; calpain; alpha-spectrin; tau protein; cerebral cortex; hippocampus	BREAKDOWN PRODUCTS; APOPTOSIS; CLEAVAGE; CELLS; ACTIVATION; INCREASES; PROTEASE; NEURONS; DAMAGE	Neurotoxicity in rat cortex and hippocampus following acute methamphetamine administration was characterized and compared to changes following traumatic brain injury. Doses of 10, 20, and 40 mg/kg of methamphetamine produced significant increases in calpain- and caspase-cleaved all-spectrin and tau protein fragments, suggesting cell injury or death. Changes in proteolytic products were significantly increased over vehicle controls. Use of fragment specific biomarkers detected prominent calpain-mediated protein fragments in the cortex and hippocampus while caspase-mediated protein fragments were also detected in the hippocampus. Remarkably, proteolytic product increases at the 40 mg/kg dose after 24 h were as high as those observed in experimental traumatic brain injury. Use of calpain and caspase proteolytic inhibitors may be useful in preventing methamphetamine-induced neurotoxicity. (c) 2005 Elsevier Inc. All rights reserved.	Univ Florida, Coll Med, Dept Psychiat, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Inst Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Div Addict Med, Gainesville, FL 32610 USA		Warren, MW (corresponding author), Univ Florida, Coll Med, Dept Psychiat, McKnight Brain Inst, POB 100183, Gainesville, FL 32610 USA.	warren@ufl.edu; firasko@ufl.edu; liumc@mbi.ufl.edu; hayes@mbi.ufl.edu; msgold@psychiatry.ufl.edu; kwang@psychiatry.ufl.edu	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473			ALI S F, 1991, Biomedical and Environmental Sciences, V4, P207; BERNATH E, 2005, NEUROBIOLOGY AGING; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Canu N, 1998, J NEUROSCI, V18, P7061; Choi HJ, 2002, MOL CELLS, V13, P221; Deng XL, 2002, MOL PHARMACOL, V62, P993, DOI 10.1124/mol.62.5.993; Deng XL, 2002, NEUROPHARMACOLOGY, V42, P837, DOI 10.1016/S0028-3908(02)00034-5; DEVITO MJ, 1989, NEUROPHARMACOLOGY, V28, P1145, DOI 10.1016/0028-3908(89)90130-5; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Gluck MR, 2001, J NEUROCHEM, V79, P152, DOI 10.1046/j.1471-4159.2001.00549.x; Huber A, 1997, J ADDICT DIS, V16, P41, DOI 10.1300/J069v16n04_04; Ishigami Akiko, 2003, Leg Med (Tokyo), V5, P42, DOI 10.1016/S1344-6223(03)00005-1; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Larsen KE, 2002, J NEUROSCI, V22, P8951; Makino Y, 2003, J HEALTH SCI, V49, P129; Martin R, 2003, J ECON GEOGR, V3, P5, DOI 10.1093/jeg/3.1.5; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; *NIDA, 1997, METH AB NIDA CAPS; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; Thiriet N, 2001, MOL BRAIN RES, V90, P202, DOI 10.1016/S0169-328X(01)00093-6; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; WARREN M, 2004, CLUB DRUG USE SELFIN; Xie HQ, 1997, J NEUROCHEM, V69, P1020; YANG LS, 1995, EUR J BIOCHEM, V233, P9, DOI 10.1111/j.1432-1033.1995.009_1.x; Yen S, 1999, FEBS LETT, V461, P91, DOI 10.1016/S0014-5793(99)01427-1; Yuen Po-Wai, 1998, Drugs of the Future, V23, P741, DOI 10.1358/dof.1998.023.07.858362; 2003, DHHS PUBL	40	50	51	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	DEC 5	2005	78	3					301	309		10.1016/j.lfs.2005.04.058			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	984UO	WOS:000233330000012	16125733				2022-02-06	
J	David-West, KS; Wilson, NIL; Sherlock, DA; Bennet, GC				David-West, KS; Wilson, NIL; Sherlock, DA; Bennet, GC			Missed Monteggia injuries	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						missed Monteggia variant injury; ulnar plastic deformation	RADIAL-HEAD DISLOCATION; FRACTURE-DISLOCATION; CHILDREN	The classical Monteggia injury comprises a dislocation of the radial head with an associated fracture of the ulna. In the variant type, there is no ulnar fracture merely plastic deformation. We performed a retrospective study of all Monteggia injuries from 1992 to 2001. A total of 39 were reviewed, of which 8 were missed (1 classical and 7 variant). Of those, five were mate and three female with a mean age of 6.3 years. The mean follow-up was 2.5 years, with a mean interval between injury and diagnosis of 33.5 weeks. Two Monteggia injuries diagnosed within 4 weeks were successfully treated by closed manipulation. The other six required ulnar osteotomy, repair of the annular ligament and stabilisation of the radial head with a transcapitellar pin. A protocol for the diagnosis of Monteggia injuries is described. Doubtful cases require an immediate review since early treatment improves the outcome. Acceptable clinical and radiological results in late diagnosed Monteggia injuries can result from ulnar osteotomy, open reduction of the radial head with repair of the annular ligament and transcapitellar pin stabilisation of the reduced radial head. (c) 2004 Elsevier Ltd. All rights reserved.	Royal Hosp Sick Children, Dept Orthopaed Surg, Glasgow G3 8SJ, Lanark, Scotland		David-West, KS (corresponding author), 14 Kirkiag Ave,Dean Pk, Renfrew PA4 0YH, England.	kd-west@ntlworld.com		Wilson, Neil/0000-0002-0427-766X			Bell Tawse A J, 1965, J Bone Joint Surg Br, V47, P718; Devnani AS, 1997, INJURY, V28, P131, DOI 10.1016/S0020-1383(96)00160-X; DORMANS JP, 1990, ORTHOP CLIN N AM, V21, P251; FREEDMAN L, 1988, J BONE JOINT SURG BR, V70, P846, DOI 10.1302/0301-620X.70B5.3192599; GLEESON AP, 1994, J ACCID EMERG MED, V11, P192; HURST LC, 1983, J PEDIATR ORTHOPED, V3, P227, DOI 10.1097/01241398-198305000-00015; LINCOLN TL, 1994, J PEDIATR ORTHOPED, V14, P454, DOI 10.1097/01241398-199407000-00006; LLOYDROBERTS GC, 1977, J BONE JOINT SURG BR, V59, P402, DOI 10.1302/0301-620X.59B4.925049; MILES KA, 1989, INJURY, V20, P365, DOI 10.1016/0020-1383(89)90016-8; RANG M, 2000, STORY ORTHOPAEDICS, P407; STOLL TM, 1992, J BONE JOINT SURG BR, V74, P436, DOI 10.1302/0301-620X.74B3.1587897; STOREN G, 1969, ACTA CLIN SCAND, V116, P144; Weisman DS, 1999, J PEDIATR ORTHOPED, V19, P523, DOI 10.1097/00004694-199907000-00020	13	50	51	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	OCT	2005	36	10					1206	1209		10.1016/j.injury.2004.12.033			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	978LJ	WOS:000232874500012	16214464				2022-02-06	
J	Zhang, OH; Teo, EC; Ng, HW				Zhang, OH; Teo, EC; Ng, HW			Development and validation of a C0-C7FE complex for biomechanical study	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							HUMAN CERVICAL-SPINE; NONLINEAR FINITE-ELEMENT; MECHANICAL-PROPERTIES; MODEL; HEAD; SIMULATION; COMPONENTS; VERTEBRA; INJURY; DISC	In this study, the digitized geometrical data of the embalmed skull and vertebrae (C0-C7) of a 68-year old male cadaver were processed to develop a comprehensive, geometrically accurate, nonlinear C0-C7 FE model. The biomechanical response of human neck under physiological static loadings, near vertex drop impact and rear-end impact (whiplash) conditions were investigated and compared with published experimental results. Under static loading conditions; the predicted moment-rotation relationships of each motion segment under moments in midsagittal plane and horizontal plane agreed well with experimental data. In addition, the respective predicted head impact force history and the S-shaped kinematics responses of head-neck complex under near-vertex drop impact and rear-end conditions were close to those observed in reported experiments. Although the predicted responses of the head-neck complex under any specific condition cannot perfectly match the experimental observations, the model reasonably reflected the rotation distributions among the motion segments under static moments and basic responses of head and neck under dynamic loadings. The current model may offer potentials to effectively reflect the behavior of human cervical spine suitable for further biomechanics and traumatic studies.	Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore 2263, Singapore			mecteo@ntu.edu.sg	Teo, Ee Chon/F-7308-2010				Camacho DLA, 1999, J BIOMECH, V32, P293, DOI 10.1016/S0021-9290(98)00178-X; DENG YC, 1987, J BIOMECH, V20, P487, DOI 10.1016/0021-9290(87)90249-1; GIBSON LJ, 1997, CELL SOLIDS STRUCTUR; GILAD I, 1986, SPINE, V11, P154, DOI 10.1097/00007632-198603000-00010; GOEL VK, 1988, J BIOMECH, V21, P673, DOI 10.1016/0021-9290(88)90204-7; Goel VK, 1998, SPINE, V23, P684, DOI 10.1097/00007632-199803150-00008; Lee CK, 2000, SPINE, V25, P2431, DOI 10.1097/00007632-200010010-00003; Linder A, 2000, ACCIDENT ANAL PREV, V32, P261, DOI 10.1016/S0001-4575(99)00085-8; Ng HW, 2001, J SPINAL DISORD, V14, P201, DOI 10.1097/00002517-200106000-00003; Nightingale RW, 2002, J BIOMECH, V35, P725, DOI 10.1016/S0021-9290(02)00037-4; ONO K, 1997, 41 STAPP CAR C LAK B; Panjabi M M, 1998, Eur Spine J, V7, P484, DOI 10.1007/s005860050112; Panjabi MM, 1998, CLIN BIOMECH, V13, P239, DOI 10.1016/S0268-0033(98)00033-3; Panjabi MM, 1998, SPINE, V23, P17, DOI 10.1097/00007632-199801010-00005; Panjabi MM, 2001, SPINE, V26, P2692, DOI 10.1097/00007632-200112150-00012; Panjabi MM, 1998, SPINE, V23, P2684, DOI 10.1097/00007632-199812150-00007; Puttlitz CM, 2000, SPINE, V25, P1607, DOI 10.1097/00007632-200007010-00003; Race A, 2000, SPINE, V25, P662, DOI 10.1097/00007632-200003150-00003; SHIRAZIADL SA, 1984, SPINE, V9, P120, DOI 10.1097/00007632-198403000-00003; Silva MJ, 1997, BONE, V21, P191, DOI 10.1016/S8756-3282(97)00100-2; Stemper BD, 2004, MED BIOL ENG COMPUT, V42, P333, DOI 10.1007/BF02344708; Stemper BD, 2000, BIOMED SCI INSTRUM, V395, P331; STEMPER BD, 2004, THESIS MARQUETTE U; Teo EC, 2001, J BIOMECH, V34, P13, DOI 10.1016/S0021-9290(00)00169-X; YANG KH, 1998, 42 STAPP CAR CRASH C; Yoganandan N, 1996, SPINE, V21, P1824, DOI 10.1097/00007632-199608010-00022; Yoganandan N, 2000, J BIOMECH ENG-T ASME, V122, P623, DOI 10.1115/1.1322034; 1998, CERVICAL SPINE	28	50	74	0	10	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	OCT	2005	127	5					729	735		10.1115/1.1992527			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	968WI	WOS:000232193200001	16248301				2022-02-06	
J	Knapp, JM				Knapp, James M.			Hyperosmolar Therapy in the Treatment of Severe Head Injury in Children Mannitol and Hypertonic Saline	AACN ADVANCED CRITICAL CARE			English	Article						hypertonic saline; intracranial hypertension; intracranial pressure; mannitol; traumatic brain injury	ELEVATED INTRACRANIAL-PRESSURE; HYPERTENSION	Traumatic brain injury is the result of a primary, acute injury and is complicated by the development of secondary injury due to hypotension and hypoxia. Cerebral edema due to brain injury compromises the delivery of essential nutrients and alters normal intracranial pressure. The Monroe-Kellie Doctrine defines the principles of intracranial pressure homeostasis. Treatment for intracranial hypertension is aimed at reducing the volume of 1 of the 3 intracranial compartments, brain tissue, blood, and cerebrospinal fluid. Hyperosmolar therapy is one treatment intervention in the care of patients with severe head injury resulting in cerebral edema and intracranial hypertension. The effect of hyperosmolar solutions on brain tissue was first studied nearly 90 years ago. Since that time, mannitol has become the most widely used hyperosmolar solution to treat elevated intracranial pressure. Increasingly, hypertonic saline solutions are being used as an adjunct to mannitol in basic science research and clinical studies. Hyperosmolar solutions are effective in reducing elevated intracranial pressure through 2 distinct mechanisms: plasma expansion with a resultant decrease in blood hematocrit, reduced blood viscosity, and decreased cerebral blood volume; and the creation of an osmotic gradient that draws cerebral edema fluid from brain tissue into the circulation. The pediatric section of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies adapted previously published guidelines for the treatment of adult brain injury into guidelines for the treatment of children with traumatic brain injury. These guidelines offer recommendations for the management of children with severe head injury, including the use of mannitol and hypertonic saline to treat intracranial hypertension. Acute and critical care pediatric advanced practice nurses caring for children with severe head injury should be familiar with management guidelines and the use of hyperosmolar solutions. The purpose of this article is to assist the advanced practice nurse in understanding the role of hyperosmolar therapy in the treatment of pediatric traumatic brain injury and review current guidelines for the use of mannitol and hypertonic saline.	[Knapp, James M.] Childrens Med Ctr, Dallas, TX 75235 USA		Knapp, JM (corresponding author), 2849 Vacherie Lane, Dallas, TX 75227 USA.	james.knapp@childrens.com					Allen CH, 1998, CRIT CARE CLIN, V14, P485, DOI 10.1016/S0749-0704(05)70012-9; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock R, 2000, J NEUROTRAUM, V6-7, P449; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Cruz J, 2001, NEUROSURGERY, V49, P864; Danseco ER, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e27; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Dutton Richard P, 2003, Curr Opin Crit Care, V9, P503, DOI 10.1097/00075198-200312000-00007; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Haden RL, 1919, J AMER MED ASSOC, V73, P983, DOI 10.1001/jama.1919.02610390035011; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Iacono L A, 2000, J Neurosci Nurs, V32, P54; Institute for Safe Medication Practices, ISMPS LIST HIGH AL M; Joint Commission for the Accreditation of Healthcare Organizations, 2004 PAT SAF GOALS F; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Langlois JA., 2004, TRAUMATIC BRAIN INJU; MCGRAW CP, 1983, NEUROSURGERY, V13, P269, DOI 10.1227/00006123-198309000-00009; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; Nau R, 2000, CLIN PHARMACOKINET, V38, P23, DOI 10.2165/00003088-200038010-00002; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Roberts I, 2003, COCHRANE DB SYST REV, V3; SCHWARZ S, 1998, STROKE, V29, P1055; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; THURMAN D, 2001, HEAD TRAUMA BASIC PR; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Weed LH, 1919, AM J PHYSIOL, V48, P512, DOI 10.1152/ajplegacy.1919.48.4.512; WOSTER PS, 1990, CLIN PHARMACY, V9, P762; Yanko J R, 2001, Crit Care Nurs Q, V23, P1; Zafonte R, 1999, TOP SPINAL CORD INJ, V2, P21; [No title captured]	34	50	58	0	1	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1559-7768	1559-7776		AACN ADV CRIT CARE	AACN Adv. Crit. Care	APR-JUN	2005	16	2					199	211		10.1097/00044067-200504000-00011			13	Nursing	Emerging Sources Citation Index (ESCI)	Nursing	VF0BA	WOS:000441617200011	15876888				2022-02-06	
J	Khateb, A; Ammann, J; Annoni, JM; Diserens, K				Khateb, A; Ammann, J; Annoni, JM; Diserens, K			Cognition-enhancing effects of donepezil in traumatic brain injury	EUROPEAN NEUROLOGY			English	Article						brain injury; cognition; donepezil; attention; neuropsychology	ALZHEIMERS-DISEASE; NEUROBEHAVIORAL DEFICITS; ATTENTION; MEMORY; DEPRESSION; CHOLINESTERASE; REHABILITATION; PERFORMANCE; IMPAIRMENT; INHIBITORS	The purpose of this study was to investigate the effects of donepezil, a cholinergic agent, on chronic cognitive impairment due to traumatic brain injury (TBI). Chronic patients underwent two standardized neuropsychological evaluations - one before and the other 3 months following treatment with donepezil. Together with global inventories that appraised behaviour, fatigue, anxiety and depression, these evaluations also assessed executive functioning, memory and attention. Of the 10 patients who followed the therapy, 8 reported subjective improvement in at least one cognitive domain following therapy and most of them reported better functioning in everyday activities. This effect was supported by a slight global improvement when considering the global score of the different affectivo-behavioural scales. At the neuropsychological level, although we could observe a slight improvement in the majority of the considered tests, significant positive changes were mainly found in tests assessing speed of processing, learning and divided attention. These findings suggest that donepezil may lead to better general functioning and improve attentional skills in patients with chronic TBI. Copyright (C) 2005 S. Karger AG, Basel.	Univ Hosp Geneva, Dept Neurol, Lab Expt Neuropsychol, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Dept Neurol, Neuropsychol Unit, CH-1211 Geneva, Switzerland; Univ Lausanne Hosp, Dept Neurol, Lausanne, Switzerland		Khateb, A (corresponding author), Univ Hosp Geneva, Dept Neurol, Lab Expt Neuropsychol, 24 Rue Micheli Crest, CH-1211 Geneva, Switzerland.	Asaid.Khateb@hcuge.ch	Khateb, Asaid/AAF-1609-2020	Khateb, Asaid/0000-0003-4639-1564			Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Beglinger LJ, 2004, J PSYCHOPHARMACOL, V18, P102, DOI 10.1177/0269881104040248; Bourgeois JA, 2002, J NEUROPSYCH CLIN N, V14, P463, DOI 10.1176/appi.neuropsych.14.4.463; Burgess P, 1996, BEHAV ASSESSMENT DYS; CARDEBAT D, 1990, ACTA NEUROL BELG, V90, P207; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; Cummings JL, 2000, AM J PSYCHIAT, V157, P4, DOI 10.1176/ajp.157.1.4; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Giacobini E, 2002, J NEURAL TRANSM, V109, P1053, DOI 10.1007/s007020200089; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; Jackson G, 2004, INT J CLIN PRACT, V58, P1, DOI 10.1111/j.1368-5031.2004.0101.x; Lawrence AD, 1998, NEUROCHEM RES, V23, P787, DOI 10.1023/A:1022419712453; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LEZAK MD, 1989, FRONT CLIN NEUROSCI, V7, P1; Lopez-Pousa S, 2001, NEUROLOGIA, V16, P342; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Muir JL, 1996, COGNITIVE BRAIN RES, V3, P215, DOI 10.1016/0926-6410(96)00008-0; Olazaran-Rodriguez J, 2004, REV NEUROLOGIA, V38, P938, DOI 10.33588/rn.3810.2003573; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Pepeu G, 2004, LEARN MEMORY, V11, P21, DOI 10.1101/lm.68104; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; SCHWARTZ JE, 1993, J PSYCHOSOM RES, V37, P753, DOI 10.1016/0022-3999(93)90104-N; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Staub F, 2001, CEREBROVASC DIS, V12, P75, DOI 10.1159/000047685; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Taverni JP, 1998, BRAIN INJURY, V12, P77; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Whitlock JA, 1999, J HEAD TRAUMA REHAB, V14, P424, DOI 10.1097/00001199-199908000-00010; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zimmermann P., 1994, TEST ATTENTIONAL PER	36	50	51	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-3022	1421-9913		EUR NEUROL	Eur. Neurol.		2005	54	1					39	45		10.1159/000087718			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	963RV	WOS:000231824500007	16118495				2022-02-06	
J	Frederickson, CJ; Burdette, SC; Frederickson, CJ; Sensi, SL; Weiss, JH; Yin, HZ; Balaji, RV; Truong-Tran, AQ; Bedell, E; Prough, DS; Lippard, SJ				Frederickson, CJ; Burdette, SC; Frederickson, CJ; Sensi, SL; Weiss, JH; Yin, HZ; Balaji, RV; Truong-Tran, AQ; Bedell, E; Prough, DS; Lippard, SJ			Method for identifying neuronal cells suffering zinc toxicity by use of a novel fluorescent sensor	JOURNAL OF NEUROSCIENCE METHODS			English	Article						zinc-specific sensor; excitotoxicity; damaged neurons; new cells; dentate gyrus; subgranular strata; brain injury	SYNAPTICALLY-RELEASED ZINC; TRAUMATIC BRAIN-INJURY; INTRACELLULAR ZINC; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; ADULT-RAT; ZN2+; TRANSLOCATION; NEUROGENESIS; ACCUMULATION	During excitotoxic brain damage, injured neurons accumulate an anomalous, pathological burden of weakly bound, rapidly exchangeable Zn2+ that diffusely fills the soma, nucleus and proximal dendrites. Mounting evidence indicates that this Zn2+ is a major contributing factor in the subsequent demise of the damaged neurons. Thus, identifying, imaging, and characterizing zinc-filled cells have become essential steps in understanding excitotoxicity. Here we demonstrate that a new fluorescent stain for zinc can rather selectively and quite vividly label zinc-filled neurons in frozen histologic sections. The method is more sensitive and selective than the existing stain TSQ, and simpler than the Timm-Danscher silver staining techniques. A previously unobserved population of apparently injured cells in the dentate gyrus has been discovered with the new reagent. Whereas cells viewed in situ in normal, healthy tissue virtually never display any perikaryal staining by histochemical methods for zinc [Histochemistry, 71 (1981) 1; Int. Rev. Neurobiol. 31 (1989) 145], injured cells stain intensely for zinc in culture [J. Neurosci. 17 (1997) 9554], acute slice preparations [J. Histochem. Cytochem. 47 (1999) 969; J. Neurosci. 22 (2002) 1273] and in tissue harvested in vivo [Science 272 (1996) 1013; Annu. Rev. Neurosci. 21 (1998) 347]. Thus, the presence of rapidly-exchangeable, "stainable" perikaryal zinc may be taken as an indicator of cell injury [J. Nutr. 130 (2000) 147 IS; Biometals 14 (2001) 353]. (C) 2004 Elsevier B.V. All rights reserved.	MIT, Dept Chem, Cambridge, MA 02139 USA; Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77550 USA; NeuroBioTex Inc, Galveston, TX 77550 USA; Univ G DAnnunzio, Dept Neurol, CESI, Ctr Excellence Aging, I-66013 Chieti, Italy; UCI, I-66013 Chieti, Italy; Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Psychobiol, Irvine, CA 92697 USA; Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77550 USA		Lippard, SJ (corresponding author), MIT, Dept Chem, Room 18-498, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu	weiss, john/B-4283-2008; Prough, Donald S/G-5793-2013; Sensi, Stefano L./J-3164-2016; Sensi, Stefano L./O-1335-2019	weiss, john/0000-0001-9323-7813; Prough, Donald S/0000-0001-7994-532X; Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG00836, AG00919] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM65519] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41682, NS40215, NS38585, NS42894, NS30884] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM065519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038585, R01NS030884, R43NS040215, R44NS041682, R43NS041682] Funding Source: NIH RePORTER		Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; Budde T, 1997, NEUROSCIENCE, V79, P347, DOI 10.1016/S0306-4522(96)00695-1; Burdette SC, 2001, J AM CHEM SOC, V123, P7831, DOI 10.1021/ja010059l; Burdette SC, 2003, J AM CHEM SOC, V125, P1778, DOI 10.1021/ja0287377; Burdette SC, 2002, INORG CHEM, V41, P6816, DOI 10.1021/ic026048q; BURENKOVA O, 2002, UNPUB; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Cuajungco MP, 1998, BRAIN RES, V799, P118, DOI 10.1016/S0006-8993(98)00463-6; Dineley KE, 2002, MOL PHARMACOL, V62, P618, DOI 10.1124/mol.62.3.618; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Frederickson CJ, 2004, NEUROSCIENTIST, V10, P18, DOI 10.1177/1073858403255840; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; Frederickson CJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1659, DOI 10.1177/002215540205001210; Frederickson CJ, 2002, NEUROSCIENCE, V115, P471, DOI 10.1016/S0306-4522(02)00399-8; Frederickson CJ, 2001, BIOMETALS, V14, P353, DOI 10.1023/A:1012934207456; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Kerchner GA, 2000, J PHYSIOL-LONDON, V528, P39, DOI 10.1111/j.1469-7793.2000.00039.x; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Li Y, 2001, J NEUROPHYSIOL, V86, P2597, DOI 10.1152/jn.2001.86.5.2597; Li Y, 2001, J NEUROSCI, V21, P8015, DOI 10.1523/JNEUROSCI.21-20-08015.2001; MARKUSZEWSKI R, 1980, TALANTA, V27, P937, DOI 10.1016/0039-9140(80)80125-1; McCabe BK, 2001, J NEUROSCI, V21, P2094, DOI 10.1523/JNEUROSCI.21-06-02094.2001; MUI BLS, 1994, J BIOL CHEM, V269, P7364; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sharma A, 2002, NEUROBIOL DIS, V11, P246, DOI 10.1006/nbdi.2002.0531; Snitsarev V, 2001, BIOPHYS J, V80, P1538, DOI 10.1016/S0006-3495(01)76126-7; Suh SW, 2000, BRAIN RES, V879, P7, DOI 10.1016/S0006-8993(00)02675-5; Suh SW, 2001, NEUROREPORT, V12, P1523, DOI 10.1097/00001756-200105250-00044; Suh SW, 1999, J HISTOCHEM CYTOCHEM, V47, P969, DOI 10.1177/002215549904700715; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Thompson RB, 1998, ANAL CHEM, V70, P1749, DOI 10.1021/ac971199+; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; Truong-Tran AQ, 2000, AM J PHYSIOL-LUNG C, V279, pL1172, DOI 10.1152/ajplung.2000.279.6.L1172; Walkup GK, 2000, J AM CHEM SOC, V122, P5644, DOI 10.1021/ja000868p; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; Yin HZ, 2002, J NEUROSCI, V22, P1273, DOI 10.1523/JNEUROSCI.22-04-01273.2002	39	50	51	1	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 15	2004	139	1					79	89		10.1016/j.jneumeth.2004.04.033			11	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	856KJ	WOS:000224043800009	15351524				2022-02-06	
J	Li, HH; Lee, SM; Cai, Y; Sutton, RL; Hovda, DA				Li, HH; Lee, SM; Cai, Y; Sutton, RL; Hovda, DA			Differential gene expression in hippocampus following experimental brain trauma reveals distinct features of moderate and severe injuries	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; gene expression; hippocampus; lateral fluid percussion injury; microarray; real-time RT-PCR	CORTICAL IMPACT INJURY; MESSENGER-RNA EXPRESSION; NITRIC-OXIDE SYNTHASE; RAT-BRAIN; CEREBRAL-CORTEX; HEAD-INJURY; SIGNAL-TRANSDUCTION; CYTOKINE EXPRESSION; GROWTH-FACTOR; IN-VITRO	Microarray technology was employed to determine the differential pattern of gene expression within the hippocampus as a result of traumatic brain injury (TBI). The validity of the microarray data was confirmed using real-time RT-PCR. Following either moderate or severe lateral fluid percussion injury, rats were studied 0.5, 4, and 24 h after injury. In general, animals exhibited mRNA up or down regulation of approximately 10% of the genes studied. However, it was clear that the pattern of gene expression was influenced by both the severity of injury and the time after injury at which animals were studied. For example, genes encoding molecules for cellular signaling, synaptic plasticity, metabolism, ion channels and transporters were up regulated following severe injury, but down regulated following moderate injury. Furthermore, moderate injury was associated with an increasing number of responsive genes as a function of time post-injury. However, animals sustaining a severe level of injury exhibited decreasing number of responsive genes during the same post-injury period. The different patterns of gene expression between injury severity and across time after the insult suggests that the pathophysiological cascade induced by TBI is accompanied by a molecular response which, like the other aspects of the cellular response for survival, may indicate a "molecular window" that may offer an opportunity for therapeutic interventions involving gene therapy. Our results also suggest that fundamentally different pathophysiological processes or cascades may be induced by different severities of injury.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA		Hovda, DA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	dhovda@mednet.ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27544, NS 37365, NS 30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544, R01NS037365] Funding Source: NIH RePORTER		Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Allan SM, 2001, MOL BRAIN RES, V93, P180, DOI 10.1016/S0169-328X(01)00211-X; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Blanchard RK, 2001, P NATL ACAD SCI USA, V98, P13507, DOI 10.1073/pnas.251532498; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; CONFERENCE NC, 1999, JAMA-J AM MED ASSOC, V282, P974; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Gong QZ, 1999, J NEUROTRAUM, V16, P893, DOI 10.1089/neu.1999.16.893; GRIESBACH GS, 2002, J NEUROTRAUM, V97, P1045; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Koistinaho J, 2000, NEUROCHEM RES, V25, P645, DOI 10.1023/A:1007559003261; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LOGAN A, 1992, J NEUROSCI, V12, P3828; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Qiu JH, 2002, J NEUROSCI, V22, P3504; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Rao VLR, 1998, J NEUROCHEM, V70, P2020; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Samii A, 2001, HEAD TRAUMA, P203; SLOVITER RS, 1992, J NEUROSCI, V12, P3004, DOI 10.1523/JNEUROSCI.12-08-03004.1992; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SZELE FG, 1995, J NEUROSCI, V15, P4429; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; WANG XK, 1995, J NEUROTRAUM, V12, P825, DOI 10.1089/neu.1995.12.825; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Whitfield PC, 2000, NEUROL RES, V22, P138, DOI 10.1080/01616412.2000.11741050; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Yunoki M, 1998, ACT NEUR S, V71, P142; Zhang L, 2000, MOL BRAIN RES, V79, P174, DOI 10.1016/S0169-328X(00)00124-8	57	50	55	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1141	1153		10.1089/0897715041953777			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900004	15453985				2022-02-06	
J	King, DR; Cohn, SM; Proctor, KG				King, DR; Cohn, SM; Proctor, KG			Changes in intracranial pressure, coagulation, and neurologic outcome after resuscitation from experimental traumatic brain injury with hetastarch	SURGERY			English	Article; Proceedings Paper	65th Annual Meeting of the Society-of-University-Surgeons	FEB 11-14, 2004	St Louis, MO	Soc Univ Surg			HYDROXYETHYL STARCH; HYPERTONIC SALINE; HEXTEND(R); HEMODILUTION; HEMORRHAGE; MANNITOL; SURGERY; TRIAL; PHASE; BLOOD	Background. In a model of traumatic brain injury (TBI), 2 protocols compared changes in intracranial pressure (ICP), coagulation, and neurologic outcome after intravenous fluid (IVF) resuscitation with either Hextend (HEX, 6% hetastarch in lactated electrolyte injection) or standard of care, crystalloid plus mannitol (MAN). Methods. In the nonsurvivor protocol, swine (n = 28) received a fluid percussion TBI and hemorrhage (27 +/- 3 mL/kg). At 30 minutes, resuscitation began with lactated Ringer's (LR) or HEX. After 60 minutes, MAN (1 g/kg) or placebo was given plus supplemental IVF to maintain cerebral perfusion pressure (CPP) greater than or equal to 70 mm Hg for 240 minutes. Swine in the survivor group (n = 15) also underwent TBI and hemorrhage, and resuscitation with HEX was compared to that of normal saline (NS)+MAN. Neurologic outcome and coagulation were evaluated for 72 hours. Results. In the nonsurvivor protocol, HEX, LR+MAN, and HEX+MAN attenuated the time-related rise of ICP and prevented ICP > 20 mm Hg versus LR alone (P < .05). HEX alone maintained CPP (relative to baseline) and decreased total IVF by 50% versus LR MAN (P < .05). XIAN had no additive effect with HEX. Coagulation, measured by thromboelastograph reaction time (R), was 11 +/- 1 and 9 1 minutes at baseline and after TBI (before randomization). At 240 minutes after HEX or LR+MAN, R was 6 +/- 1 or 7 +/- 2 minutes, which indicates a hypercoagulable state, but there was no difference between treatments. In the survivor protocol, ICP and CPP were similar with NS+MAN versus HEX, but IVF requirement was 161 +/- 20 versus 28 +/- 3 mL/kg (P < .05). Motor scores were higher on days 2 and 3 with HEX (P < .05). At 72 hours, R was 28 +/- 14 versus 26 +/- 6 minutes with NS+MAN versus HEX, which indicates a hypocoagulable state, but there was no difference between treatments. Conclusions. Hextend as the sole resuscitation fluid after severe TBI reduces fluid requirement, obviates the need for mannitol, improves neurologic outcome, and has no adverse effect on the coagulation profile relative to the crystalloid plus mannitol standard of care.	Univ Miami, Sch Med, Ryder Trauma Ctr,Trauma & Surg Crit Care Res Inst, Div Trauma,Dewitt Daughtry Family Dept Surg, Miami, FL 33136 USA; Univ Miami, Sch Med,Div Surg Crit Care, Trauma & Surg Crit Care Res Inst, Dewitt Daughtry Family Dept Surg, Miami, FL 33136 USA		Proctor, KG (corresponding author), Univ Miami, Sch Med, Ryder Trauma Ctr,Trauma & Surg Crit Care Res Inst, Div Trauma,Dewitt Daughtry Family Dept Surg, 1800 NW 10th Ave, Miami, FL 33136 USA.		Proctor, Kenneth/AAA-2199-2022	Proctor, Kenneth/0000-0003-1326-6628; King, David/0000-0003-1028-1478	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008749] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM08749-01] Funding Source: Medline		Avorn J, 2003, CHEST, V124, P1437, DOI 10.1378/chest.124.4.1437; Boldt J, 2002, BRIT J ANAESTH, V89, P722, DOI 10.1093/bja/aef242; CROOKES BA, IN PRESS J TRAUMA; Cruz J, 2001, NEUROSURGERY, V49, P864; DAMON L, 1987, NEW ENGL J MED, V317, P964; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; Essell J H, 1993, J Cardiothorac Vasc Anesth, V7, P410, DOI 10.1016/1053-0770(93)90161-D; FIEDMAN Z, 2003, ANESTH ANALG, V96, P39; Gan TJ, 1999, ANESTH ANALG, V88, P992, DOI 10.1097/00000539-199905000-00005; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Hartl R, 1997, ACT NEUR S, V70, P126; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; Holcomb JB, 2003, J TRAUMA, V54, pS46, DOI 10.1097/01.TA.0000051936.91915.A2; JAVID M, 1964, J NEUROSURG, V21, P1059, DOI 10.3171/jns.1964.21.12.1059; Kelly ME, 2003, J TRAUMA, V55, P94, DOI 10.1097/01.TA.0000029042.37577.A6; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; McCammon AT, 2002, ANESTH ANALG, V95, P844, DOI 10.1097/00000539-200210000-00010; McIlroy DR, 2003, ANESTH ANALG, V96, P1572, DOI [10.1213/01.ANE.0000061460.59320B0, 10.1213/01.ANE.0000061460.59320.B0]; Ng KFJ, 2002, BRIT J ANAESTH, V88, P475, DOI 10.1093/bja/88.4.475; Nielsen VG, 2001, ANESTH ANALG, V93, P1106, DOI 10.1097/00000539-200111000-00007; Roberts IG, 2003, COCHRANE DB SYST REV, V2; Roche AM, 2004, BRIT J ANAESTH, V92, pA154, DOI 10.1093/bja/aeh502; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Wilkes NJ, 2002, ANESTH ANALG, V94, P538, DOI 10.1097/00000539-200203000-00011	25	50	51	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	AUG	2004	136	2					355	363		10.1016/j.surg.2004.05.011			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	846LV	WOS:000223318000035	15300202				2022-02-06	
J	Graber, KD; Prince, DA				Graber, KD; Prince, DA			A critical period for prevention of posttraumatic neocortical hyperexcitability in rats	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; PROPHYLACTICALLY ADMINISTERED PHENYTOIN; CORTICAL ACTIVITY; KINDLING MODEL; C-FOS; POSTNATAL BLOCKADE; NEURONAL-ACTIVITY; GENE-EXPRESSION; AMINO-ACIDS; HEAD TRAUMA	Penetrating cortical trauma frequently results in delayed development of epilepsy. In the rat undercut model of neocortical posttraumatic hyperexcitability, suppression of neuronal activity by exposing the injured cortex to tetrodotoxin (TTX) in vivo for approximately 2 weeks prevents the expression of abnormal hypersynchronous discharges in neocortical slices. We examined the relationship between neuronal activity during the latent period after trauma and subsequent expression of hyperexcitability by varying the timing of TTX treatment. Partially isolated islands of rat sensorimotor cortex were treated with Elvax polymer containing TTX to suppress cortical activity and slices obtained for in vitro experiments 10 to 15 days later. TTX treatment was either started immediately after injury and discontinued after a variable number of days or delayed for a variable time after the lesion was placed. Immediate treatment lasting only 2 to 3 days and treatment delayed up to 3 days prevented hyperexcitability. Thus, there is a critical period for development of hyperexcitability in this model that depends on cortical activity. We propose that the hyperexcitability caused by partial cortical isolation may represent an early stage of posttraumatic epileptogenesis. A hypothetical cascade of events leading to subsequent pathophysiological activity is likely initiated at the time of injury but remains plastic during this critical period.	Stanford Univ, Ctr Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA		Graber, KD (corresponding author), Stanford Univ, Ctr Med, Dept Neurol & Neurol Sci, Room M016 Alway, Stanford, CA 94305 USA.	graberk@stanford.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012151, K08NS002167, P50NS012151] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12151, K08 NS02167] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Carmichael ST, 2002, J NEUROSCI, V22, P6062; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; CHIAIA NL, 1994, DEV BRAIN RES, V79, P301, DOI 10.1016/0165-3806(94)90136-8; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; DAMBROSIO R, 2003, BRAIN, V127, P1; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAKE CG, 1948, FED PROC, V7, P29; ECHLIN FA, 1963, ARCH NEUROL-CHICAGO, V9, P154, DOI 10.1001/archneur.1963.00460080064009; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GODDARD GV, 1983, TRENDS NEUROSCI, V6, P275, DOI 10.1016/0166-2236(83)90118-2; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Graber KD, 1999, EPILEPSIA, V40, P31; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; GRIGONIS AM, 1994, DEV BRAIN RES, V77, P251, DOI 10.1016/0165-3806(94)90200-3; HALPERN LM, 1972, EXPT MODELS EPILEPSY, P197; HAMMOND EJ, 1980, EPILEPSIA, V21, P3, DOI 10.1111/j.1528-1157.1980.tb04039.x; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; INNOCENTI G M, 1991, Journal of Neural Transplantation and Plasticity, V2, P29; Kawatsu K, 1997, JPN J MED SCI BIOL, V50, P133, DOI 10.7883/yoken1952.50.133; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; LANGE SC, 1980, EPILEPSIA, V21, P251, DOI 10.1111/j.1528-1157.1980.tb04070.x; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYNCH JJ, 1995, J PHARMACOL EXP THER, V273, P554; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; MCNAMARA JO, 1995, PSYCHIAT CLIN NEUROS, V49, pS175, DOI 10.1111/j.1440-1819.1995.tb02167.x; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Mody I, 1999, Adv Neurol, V79, P631; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MURPHY TH, 1991, J NEUROCHEM, V57, P1862, DOI 10.1111/j.1471-4159.1991.tb06396.x; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nissinen Jari P. T., 2003, Epilepsia, V44, P175; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; Probert AW, 1997, NEUROPHARMACOLOGY, V36, P1031, DOI 10.1016/S0028-3908(97)00072-5; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; SCOVILLE WB, 1960, AM J PSYCHIAT, V117, P525, DOI 10.1176/ajp.117.6.525; Sharpless SK, 1969, BASIC MECH EPILEPSIE, P329; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; SPEHLMANN R, 1971, ARCH NEUROL-CHICAGO, V24, P401, DOI 10.1001/archneur.1971.00480350035003; Stables James P., 2002, Epilepsia, V43, P1410, DOI 10.1046/j.1528-1157.2002.06702.x; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Tanu MB, 2002, TOXICON, V40, P103, DOI 10.1016/S0041-0101(01)00179-9; TAUCK DL, 1985, J NEUROSCI, V5, P1016; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Toth Z, 1997, J NEUROSCI, V17, P8106; Tsui CC, 1996, J NEUROSCI, V16, P2463; Ueda Y, 1998, EXP NEUROL, V153, P123, DOI 10.1006/exnr.1998.6869; WADA JA, 1976, ARCH NEUROL-CHICAGO, V33, P426, DOI 10.1001/archneur.1976.00500060032008; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, CHILD BRAIN, V10, P185	70	50	52	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUN	2004	55	6					860	870		10.1002/ana.20124			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824VW	WOS:000221716300013	15174021				2022-02-06	
J	Liu, DX; Liu, J; Sun, DH; Wen, J				Liu, DX; Liu, J; Sun, DH; Wen, J			The time course of hydroxyl radical formation following spinal cord injury: The possible role of the iron-catalyzed Haber-Weiss reaction	JOURNAL OF NEUROTRAUMA			English	Article						hydrogen peroxide; hydroxyl radical; iron-catalyzed Haber-Weiss/Fenton reaction; microdialysis sampling and administration; reactive oxygen species; secondary spinal cord injury; superoxide anion	MODEL COMBINING MICRODIALYSIS; EXPERIMENTAL HEAD-INJURY; TRAUMATIC BRAIN INJURY; GENERATED IN-VIVO; LIPID-PEROXIDATION; SUPEROXIDE-PRODUCTION; NITRIC-OXIDE; HYDROGEN-PEROXIDE; PROTEIN OXIDATION; IMPACT INJURY	This study explores whether the hydroxyl radical ((OH)-O-.)-one of the most destructive reactive oxygen species-plays a role in secondary spinal cord injury (SCI). First, we measured the time course of (OH)-O-. formation in rat spinal tissue after impact SCI by administering salicylate as a trapping agent into the intrathecal space of the cord and measuring the hydroxylation products of salicylate, 2,3- and 2,5-dihydroxybenzoic acid (2,3- and 2,5-DHBA) by HPLC. The 2,3-DHBA concentration was significantly higher in injured spinal tissue than in sham controls at 5 min, 1 and 3 h, but not at 5 h post-injury. Second, we generated (OH)-O-. by administering H2O2 and FeCl2/EDTA (Fenton's reagents) at the concentrations produced by SCI into the gray matter of the cord for 4 h and found that it induced significant cell loss at 24 h post-(OH)-O-. exposure. Mn (III) tetrakis (4-benzoic acid) porphyrin(MnTBAP)-a broad spectrum reactive species scavenger-significantly reduced (OH)-O-.-induced cell death. Finally, we generated superoxide and administered FeCl3/EDTA in the intrathecal space of the cord at the concentration produced by SCI and measured extracellular (OH)-O-. formation in the gray matter of the cord by microdialysis sampling. We found that the levels of (OH)-O-. significantly increased compared to the pre-administration level, indicating that (OH)-O-. can be produced in vivo by the iron-catalyzed Haber-Weiss reaction. All together, we demonstrated that (OH)-O-. is an endogenous secondary damaging agent following SCI and the metal-catalyzed Haber-Weiss reaction may contribute to early (OH)-O-. formation after SCI.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA		Liu, DX (corresponding author), Univ Texas, Med Branch, Dept Neurol, 301 Univ Blvd, Galveston, TX 77555 USA.	dliu@utmb.edu		liu, danxia/0000-0001-8172-2344	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044324, R01NS035119, R29NS034048] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34048, NS35119, NS44324] Funding Source: Medline		Aksenova M, 2002, J NEUROTRAUM, V19, P491, DOI 10.1089/08977150252932433; Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; BALENTINE JD, 1985, CENTRAL NERVOUS SYST, P455; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Brumby P. E., 1967, METHOD ENZYMOL, V10, P463, DOI [10.1016/0076-6879(67)10078-5, DOI 10.1016/0076-6879(67)10078-5]; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; Chopp M, 1996, STROKE, V27, P363, DOI 10.1161/01.STR.27.3.363; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Ellerby LM, 2000, METHOD ENZYMOL, V322, P413; FLOYD R A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P13, DOI 10.1016/0748-5514(86)90118-2; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, J NEUROSCI RES, V34, P107, DOI 10.1002/jnr.490340111; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1989, ACTA NEUROL SCAND, V80, P23, DOI 10.1111/j.1600-0404.1989.tb01779.x; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; IKEDA Y, 1989, Neurological Research, V11, P213; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KRAUSE GS, 1987, ANN EMERG MED, V16, P1200, DOI 10.1016/S0196-0644(87)80224-X; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; Lipscomb DC, 1998, STROKE, V29, P487, DOI 10.1161/01.STR.29.2.487; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; LIU DX, 1995, FREE RADICAL BIO MED, V18, P861, DOI 10.1016/0891-5849(94)00214-5; LIU DX, 1994, J NEUROCHEM, V62, P37; LIU DX, 1993, J BIOCHEM BIOPH METH, V27, P281, DOI 10.1016/0165-022X(93)90009-D; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; LIU DX, 1995, FREE RADICAL BIO MED, V18, P571, DOI 10.1016/0891-5849(94)00154-C; LIU DX, 1994, MOL CHEM NEUROPATHOL, V23, P77, DOI 10.1007/BF02815402; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Liu DX, 2003, FREE RADICAL BIO MED, V34, P64, DOI 10.1016/S0891-5849(02)01184-X; Liu DX, 2001, J NEUROCHEM, V77, P1036, DOI 10.1046/j.1471-4159.2001.00306.x; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; MAITY S, 1992, ANGIOLOGY, V43, P781, DOI 10.1177/000331979204300908; Marsala M, 1995, J NEUROSCI METH, V62, P43, DOI 10.1016/0165-0270(95)00053-4; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Qian H, 1997, NEUROCHEM RES, V22, P1231, DOI 10.1023/A:1021980929422; Shacter E, 2000, METHOD ENZYMOL, V319, P428; Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR-100102336; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SORKIN LS, 1988, J NEUROSCI METH, V23, P131, DOI 10.1016/0165-0270(88)90185-9; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; SUBBARAO KV, 1990, J NEUROSCI RES, V26, P224, DOI 10.1002/jnr.490260212; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185, DOI 10.1152/jappl.1991.71.4.1185; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; WILLMORE LJ, 1986, BRAIN RES, V382, P422; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	64	50	54	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					805	816		10.1089/0897715041269650			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600014	15253806				2022-02-06	
J	Ekshyyan, O; Aw, TY				Ekshyyan, O; Aw, TY			Apoptosis in acute and chronic neurological disorders	FRONTIERS IN BIOSCIENCE-LANDMARK			English	Article						neuronal apoptosis; apoptosis and neurodegeneration; mitochondrial apoptotic signaling; oxidative stress and apoptosis; apoptosis and cerebrovascular injury; cerebral ischemia/reperfusion; review	TRANSGENIC MOUSE MODEL; HYDROPEROXIDE-INDUCED APOPTOSIS; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; MOTOR-NEURON PROTEIN; SPINAL-CORD-INJURY; CASPASE ACTIVATION; ALPHA-SYNUCLEIN; NITRIC-OXIDE; CELL-DEATH	Programmed cell death or apoptosis is a physiologically important process in neurogenesis wherein similar to50% of the neurons apoptose during maturation of the nervous system. However, premature apoptosis and/or aberrations in apoptosis control contribute to the pathogenesis of a variety of neurological disorders including acute brain injury such as trauma, spinal cord injury, ischemic stroke and ischemia/reperfusion as well as chronic disease states such as Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis, spinal muscular atrophy, and diabetic neuropathy. The current review will focus on two major topics, namely, the general concepts of our current understanding of the apoptosis death machinery, its mediators and regulation, and the relationship between aberrant apoptosis and genesis of neurodegenerative disorders. This knowledge of apoptosis mechanisms will underpin the basis for development of novel therapeutic strategies and treatment modalities that are directed at control of the neuronal apoptotic death program.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA		Aw, TY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA.	taw@lsuhsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P01DK043785, R01DK044510] Funding Source: NIH RePORTER; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK044510, DK 43785, DK 44510, R01 DK044510-11] Funding Source: Medline		Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; ANDERSON AJ, 1995, J NEUROCHEM, V65, P1487; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Aw TY, 2003, MOLECULAR BASIS FOR MICROCIRCULATORY DISORDERS, P297; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Brown RH, 2001, SEMIN NEUROL, V21, P131; Buki A, 2000, J NEUROSCI, V20, P2825; Cabaner C, 1999, BRIT J PHARMACOL, V127, P813, DOI 10.1038/sj.bjp.0702606; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Cassarino DS, 2000, J NEUROCHEM, V74, P1384, DOI 10.1046/j.1471-4159.2000.0741384.x; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Floor E, 1998, J NEUROCHEM, V70, P268; Freemerman AJ, 2000, BIOCHEM BIOPH RES CO, V274, P136, DOI 10.1006/bbrc.2000.3091; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Guo Q, 1999, P NATL ACAD SCI USA, V96, P4125, DOI 10.1073/pnas.96.7.4125; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; JONES BE, 2000, AM J PHYSIOL, V278, pC693; Kalaria RN, 1999, ANN NY ACAD SCI, V893, P113, DOI 10.1111/j.1749-6632.1999.tb07821.x; Kerr DA, 2000, P NATL ACAD SCI USA, V97, P13312, DOI 10.1073/pnas.230364197; Kiechle T, 2002, NEUROMOL MED, V1, P183; Kikuchi S, 1999, J NEUROSCI RES, V57, P280, DOI 10.1002/(SICI)1097-4547(19990715)57:2<280::AID-JNR14>3.3.CO;2-L; Kitagawa A, 2003, J BIOL CHEM, V278, P12130, DOI 10.1074/jbc.M212058200; Kokura S, 1999, CIRC RES, V84, P516, DOI 10.1161/01.RES.84.5.516; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li SH, 2000, HUM MOL GENET, V9, P2859, DOI 10.1093/hmg/9.19.2859; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lovell MA, 1998, NEUROLOGY, V51, P1562, DOI 10.1212/WNL.51.6.1562; Macho A, 1997, J IMMUNOL, V158, P4612; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Marcus DL, 1998, EXP NEUROL, V150, P40, DOI 10.1006/exnr.1997.6750; Marin N, 2000, MECH AGEING DEV, V119, P63, DOI 10.1016/S0047-6374(00)00172-X; Mogi M, 2000, J NEURAL TRANSM, V107, P335, DOI 10.1007/s007020050028; Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Namura S, 1998, J NEUROSCI, V18, P3659; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Pedersen WA, 2000, FASEB J, V14, P913, DOI 10.1096/fasebj.14.7.913; Pias EK, 2002, FASEB J, V16, DOI 10.1096/fj.01-0784com; Pias EK, 2003, J BIOL CHEM, V278, P13294, DOI 10.1074/jbc.M208670200; Pias EK, 2002, CELL DEATH DIFFER, V9, P1007, DOI 10.1038/sj.cdd.4401064; Rigamonti D, 2001, J BIOL CHEM, V276, P14545, DOI 10.1074/jbc.C100044200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Sairanen T, 2001, STROKE, V32, P1750, DOI 10.1161/01.STR.32.8.1750; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Schmeichel AM, 2003, DIABETES, V52, P165, DOI 10.2337/diabetes.52.1.165; Sharp AH, 1996, NEUROBIOL DIS, V3, P3, DOI 10.1006/nbdi.1996.0002; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Su JH, 1997, J NEUROPATH EXP NEUR, V56, P86, DOI 10.1097/00005072-199701000-00009; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Tagami M, 1999, LAB INVEST, V79, P609; Takuma K, 1999, EUR J NEUROSCI, V11, P4204, DOI 10.1046/j.1460-9568.1999.00850.x; Tamagno E, 2003, EXP NEUROL, V180, P144, DOI 10.1016/S0014-4886(02)00059-6; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; Troy CM, 2000, J NEUROSCI, V20, P1386; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Vukosavic S, 1999, J NEUROCHEM, V73, P2460, DOI 10.1046/j.1471-4159.1999.0732460.x; Wang NP, 1999, CIRC RES, V85, P387, DOI 10.1161/01.RES.85.5.387; Wang TG, 2000, FASEB J, V14, P1567, DOI 10.1096/fj.14.11.1567; Weiland U, 2000, CARDIOVASC RES, V45, P671, DOI 10.1016/S0008-6363(99)00347-8; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YOSHIYAMA Y, 1994, ACTA NEUROPATHOL, V88, P207; Young PJ, 2002, J BIOL CHEM, V277, P2852, DOI 10.1074/jbc.M108769200; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	96	50	57	1	13	FRONTIERS IN BIOSCIENCE INC	IRVINE	16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA	1093-9946	1093-4715		FRONT BIOSCI-LANDMRK	Front. Biosci.	MAY	2004	9						1567	1576		10.2741/1357			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	779ZA	WOS:000189333700044	14977568				2022-02-06	
J	Tate, RL				Tate, RL			Assessing support needs for people with traumatic brain injury: the care and needs scale (CANS)	BRAIN INJURY			English	Article							RATING-SCALE; HEAD-INJURY; DISABILITY	Background: After traumatic brain injury (TBI), many individuals have support needs, but the variety, frequency and intensity of such needs vary widely. Currently available scales do not assess all facets of required supports and the eight-category Care and Needs Scale (CANS) was developed in order to capture the range of support needs. The aim of the present study was to examine the sensitivity and validity of the CANS. Method: Using a sample of 67 people who sustained severe TBI 20-26 years previously, the CANS was compared with the Supervision Rating Scale (SRS), five scales from the Craig Handicap Assessment and Reporting Technique (CHART) and the Sydney Psychosocial Reintegration Scale (SPRS). Results: The data showed a spread across all CANS categories: 28.4% of participants were fully independent, 46.3% had support needs on less than a daily basis (25.4% intermittently, 13.4% at least weekly and 7.5% every few days) and the remaining 25.4% had needs on a daily basis (ranging from 11.9% for up to 11 hours per day to 4.5% for 24 hours per day). By contrast, the 13-category SRS classified 61.2% in the best category and five categories did not contain any individuals. The CANS showed strong correlation with the SRS ( r s = 0.75), as well as CHART and SPRS scores (range r s = -0.46 to -0.85) and statistically significant differences were found among participant sub-groups. Logistic regression analyses, using variables collected at the time of discharge from rehabilitation, were able to predict independence on the CANS with classification accuracy of 77% and presence of neuropsychological disability was an individual predictor. Conclusion: These results suggest that the CANS shows promise as a sensitive and valid instrument to measure care and support needs after TBI, particularly in the longer term, and further examination of its psychometric properties is warranted.	Royal Rehabil Ctr Sydney, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Univ Sydney, Dept Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia		Tate, RL (corresponding author), Royal Rehabil Ctr Sydney, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	rtate@med.usyd.edu.au					Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Bowling A., 1997, MEASURING HLTH REV Q; BROE GA, 1982, BRAIN IMPAIR, P59; CAVALLO MM, 1995, J HEAD TRAUMA REHAB, V10, P66, DOI 10.1097/00001199-199504000-00008; Cieza A, 2002, J REHABIL MED, V34, P205, DOI 10.1080/165019702760279189; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Feeney TJ, 2001, J HEAD TRAUMA REHAB, V16, P61, DOI 10.1097/00001199-200102000-00008; Hagen C., 1972, LEVELS COGNITIVE FUN; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kolakowsky-Hayner SA, 2000, NEUROREHABILITATION, V14, P151; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McDowell I., 1996, MEASURING HLTH GUIDE; PONSFORD J, 2003, 26 ANN BRAIN IMP C S; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate RL, 2003, STUD NEUROPSYCHOL DE, P137; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; TATE RL, 2003, 26 ANN BRAIN IMP C S; TATE RL, IN PRESS ARCH PHYS M; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Wade D, 1992, MEASUREMENT NEUROLOG; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; World Health Organization, 2007, INT CLASS FUNCT DIS; [No title captured]	35	50	50	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2004	18	5					445	460		10.1080/02699050310001641183			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	800SS	WOS:000220048600004	15195793				2022-02-06	
J	Mainwaring, LM; Bisschop, SM; Green, REA; Antoniazzi, M; Comper, P; Kristman, V; Provvidenza, C; Richards, DW				Mainwaring, LM; Bisschop, SM; Green, REA; Antoniazzi, M; Comper, P; Kristman, V; Provvidenza, C; Richards, DW			Emotional reaction of varsity athletes to sport-related concussion	JOURNAL OF SPORT & EXERCISE PSYCHOLOGY			English	Article						mild traumatic brain injury; profile of mood states; recovery; athletic injury; depression; confusion; longitudinal	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; POSTCONCUSSION SYMPTOMS; RECOVERY; RESPONSES; CONSEQUENCES; PERFORMANCE; PREDICTION; ADJUSTMENT; ADHERENCE	Despite suggestions that emotions influence recovery from injury, there is little research into the emotional sequelae of mild traumatic brain injury (MTBI), or "concussion," in sport. This examination compares emotional functioning of college athletes with MTBI to that of uninjured teammates and undergraduates. A short version of the Profile of Mood States (POMS; Grove & Prapavessis, 1992) assessed baseline emotions in all groups, and serial emotional functioning in the MTBI and undergraduate groups. Whereas preinjury profiles were similar across groups, the MTBI group showed a significant postinjury spike in depression, confusion, and total mood disturbance that was not seen for the other groups. The elevated mood disturbances subsided within 3 weeks postinjury. Given that concussed athletes were highly motivated to return to play, these data could be used as a benchmark of normal emotional recovery from MTBI. Findings are discussed in relation to current literature on emotional reaction to injury and directions for future research.	Univ Toronto, Fac Phys & Hlth Educ, Toronto, ON M5S 2W6, Canada; Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada		Mainwaring, LM (corresponding author), Univ Toronto, Fac Phys & Hlth Educ, 55 Harbord St, Toronto, ON M5S 2W6, Canada.		Kristman, Vicki/G-8317-2011	Green, Robin/0000-0001-9451-3963; Kristman, Vicki/0000-0001-5508-0552; Bisschop, Sean/0000-0002-3307-292X			Barth JT, 1989, MILD HEAD INJURY, P257; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BREWER BW, 1995, CLIN J SPORT MED, V5, P241, DOI 10.1097/00042752-199510000-00006; Brewer BW, 2000, REHABIL PSYCHOL, V45, P20, DOI 10.1037/0090-5550.45.1.20; BREWER BW, 2001, COPING SPORT INJURIE, P1; CHAN CS, 1988, PERCEPT MOTOR SKILL, V66, P875, DOI 10.2466/pms.1988.66.3.875; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; CHUTE N, 1997, THESIS QUEENS U KING; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; COMPER P, 2002, UNPUB CANADIAN INTER; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; CROSSMAN J, 1985, PERCEPT MOTOR SKILL, V61, P1131, DOI 10.2466/pms.1985.61.3f.1131; DALY JM, 1995, J SPORT REHABIL, V0004, P00023; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Evans L., 1996, J SPORT EXERCISE SCI, V14, P27; FREY JH, 1991, SOCIOL SPORT J, V8, P136, DOI 10.1123/ssj.8.2.136; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Green SL, 2001, J APPL SPORT PSYCHOL, V13, P40, DOI 10.1080/10413200109339003; Grove J., 1990, ANN M AUSTR SPORTS M; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1998, SPORTS RELATED CONCU, V2, P12; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Johnston LH, 1998, J SPORT REHABIL, V7, P206, DOI 10.1123/jsr.7.3.206; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mainwaring L, 1999, CAN J REHABIL, V12, P145; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McDonald SA, 1990, SPORT PSYCHOL, V4, P261; McNair DM, 1971, PROFILE MOOD STATES; MILLER WN, 1998, J APPL SPORT PSYCH S, V10, pS127; Morrey MA, 1999, CLIN J SPORT MED, V9, P63, DOI 10.1097/00042752-199904000-00004; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nixon H. L. II, 1992, Journal of Sport and Social Issues, V16, P127, DOI 10.1177/019372359201600208; Nunnally JC., 1978, PSYCHOMETRIC THEORY, V2; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Pearson L, 1992, PHYSIOTHERAPY, V78, P762, DOI DOI 10.1016/S0031-9406(10)61642-2; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Quackenbush N., 1994, Journal of Sport Behavior, V17, P178; Quinn AM, 1999, J APPL SPORT PSYCHOL, V11, P210, DOI 10.1080/10413209908404201; ROH J, 1998, J APPL SPORT PSYCH S, V10, pS54; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; SMITH AM, 1993, MAYO CLIN PROC, V68, P939, DOI 10.1016/S0025-6196(12)62265-4; Smith AM, 1998, MAYO CLIN PROC, V73, P17; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9; TERRY PC, 1996, J SPORTS SCI, V14, P49; Udry E, 1997, J SPORT EXERCISE PSY, V19, P229, DOI 10.1123/jsep.19.3.229; Udry E, 1997, J SPORT EXERCISE PSY, V19, P71, DOI 10.1123/jsep.19.1.71; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; [No title captured]	65	50	50	2	23	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	0895-2779	1543-2904		J SPORT EXERCISE PSY	J. Sport Exerc. Psychol.	MAR	2004	26	1					119	135		10.1123/jsep.26.1.119			17	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Psychology; Sport Sciences	801CF	WOS:000220073300007					2022-02-06	
J	Peloso, PM; Carroll, LJ; Cassidy, JD; Borg, J; von Holst, H; Holm, L; Yates, D				Peloso, PM; Carroll, LJ; Cassidy, JD; Borg, J; von Holst, H; Holm, L; Yates, D			Critical evaluation of the existing guidelines on mild traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						guidelines; mild traumatic brain injury; critical appraisal; evidence-based medicine	CLINICAL-PRACTICE GUIDELINES; MEDICAL LITERATURE; HEAD-INJURIES; USERS GUIDES; MANAGEMENT GUIDELINES; SYSTEMATIC REVIEWS; SAFE RETURN; CONCUSSION; SPORT; CARE	The purpose of guidelines is to reduce practice variability, but they need to be evidence-based. We examine current mild traumatic brain injury guidelines, critique their basis in evidence and examine their variability in recommendations. A systematic search of the literature found 38,806 abstracts, with 41 guidelines. There were 18 sports-related guidelines, 13 related to admission policies, 12 related to imaging and 5 related to neuropsychological assessment. Some guidelines addressed several areas. Only 5 guidelines reported a methodology for the assembly of evidence used to develop the guideline. After appraising the guidelines against a validated index, we found that 3 of the 41 guidelines could be categorized as evidence-based. Two of these focused on paediatric patients and 1 on adult patients. Limited methodological quality in the current guidelines results in conflicting recommendations amongst them.	Univ Iowa, Ctr Hlth, Dept Internal Med, Iowa City, IA USA; Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden; Uppsala Univ, Dept Neurosci, Uppsala, Sweden; Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; Univ Manchester, Hope Hosp, Emergency Dept, Manchester, Lancs, England		Peloso, PM (corresponding author), Univ Iowa Hlth Care, Room E 330 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	paul-peloso@uiowa.edu		Borg, Jorgen/0000-0002-2372-7478; Carroll, Linda/0000-0003-0876-2336			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bergman DA, 1999, PEDIATRICS, V104, P1407; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BRIGGS M, 1984, BRIT MED J, V288, P983; BRITTON M, 2000, 153 SBU SWED COUNC T; BROCKLEHURST G, 1987, BRIT MED J, V294, P345, DOI 10.1136/bmj.294.6568.345; Brown C, 1999, Nasnewsletter, V14, P6; BROWN C, 1999, NAS NEWSLETTER, V14, P6; BRUNO LA, 1987, CLIN SPORT MED, V6, P17; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1991, SPORTS ADOLESCENT, P17; CANTU RV, 1994, J NEUROSURG, V80, P592; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; *CO MED SOC SPORTS, 1991, GUID MAN CONC SPORTS; Cote P, 2001, Spine (Phila Pa 1976), V26, pE445, DOI 10.1097/00007632-200110010-00020; Cripe LI, 1987, COGNITIVE REHABILITA, V5, P18; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Davis P C, 2000, Radiology, V215 Suppl, P507; de Andrade AF, 2001, WORLD J SURG, V25, P1186; DELACEY G, 1990, BRIT J RADIOL, V63, P14, DOI 10.1259/0007-1285-63-745-14; Dicker G, 1993, Aust Fam Physician, V22, P750; Fernandez R, 1997, ZBL NEUROCHIR, V58, P72; FOWKES FGR, 1986, BRIT J SURG, V73, P891, DOI 10.1002/bjs.1800731112; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; Guyatt GH, 1999, JAMA-J AM MED ASSOC, V281, P1836, DOI 10.1001/jama.281.19.1836; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; Hutchinson PJA, 1998, J ACCID EMERG MED, V15, P84; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; LeBlanc K E, 1998, J La State Med Soc, V150, P312; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; MACLAREN RE, 1993, ARCH EMERG MED, V10, P138; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; *NAT ATHL TRAIN AS, 1994, P MILD BRAIN INJ SPO; OXMAN AD, 1993, ANN NY ACAD SCI, V703, P125, DOI 10.1111/j.1749-6632.1993.tb26342.x; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; Sackett DL., 1991, CLIN EPIDEMIOLOGY BA, V2; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; Spence R A, 1980, Ulster Med J, V49, P65; SPITZER WO, 1990, CLIN INVEST MED, V13, P17; SPITZER WO, 1995, SPINE, V20, P2372; SPITZER WO, 1995, SPINE, V20, pS1; SPITZER WO, 1987, SPINE, V12, pS1; Study Group on Head Injury of the Italian Society for Neurosurgery, 1996, J NEUROSURG SCI, V40, P11; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; Young CC, 1997, CLIN J SPORT MED, V7, P196, DOI 10.1097/00042752-199707000-00008	63	50	50	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			106	112		10.1080/16501960410023868			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	800QR	WOS:000220043300011	15083874	gold			2022-02-06	
J	Johnston, AJ; Steiner, LA; Chatfield, DA; Coleman, MR; Coles, JP; Al-Rawi, PG; Menon, DK; Gupta, AK				Johnston, AJ; Steiner, LA; Chatfield, DA; Coleman, MR; Coles, JP; Al-Rawi, PG; Menon, DK; Gupta, AK			Effects of propofol on cerebral oxygenation and metabolism after head injury	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics i.v., propofol; brain, metabolism; complications, head injury	CARBON-DIOXIDE REACTIVITY; BLOOD-PRESSURE; INTRACRANIAL-PRESSURE; SUPPRESSION; FLOW; AUTOREGULATION; PROTECTION; SATURATION; ANESTHESIA	Background. Flow-metabolism coupling is thought to be deranged after traumatic brain injury, while the effects of propofol on flow-metabolism coupling are controversial. We have used a step increase in target plasma propofol concentration in head injured patients to explore flow-metabolism coupling in these patients. Methods. Ten patients with a moderate to severe head injury received a step increase in propofol target controlled infusion of 2 mug ml(-1). Cerebral tissue gas measurements were recorded using a multimodal sensor, and regional chemistry was assessed using microdialysis. Arterial-jugular venous oxygen differences (AVDO(2)) were measured and all patients had cortical function monitoring (EEG). Results. The step increase in propofol led to a large increase in EEG burst-suppression ratio (0% (range 0-1.1) to 46.1% (range 0-61.7), P<0.05); however, this did not significantly change tissue gas levels, tissue chemistry, or AVDO(2). Conclusions. Flow-metabolism coupling remains intact during a step increase in propofol after traumatic brain injury. The EEG burst-suppression induced by propofol after traumatic brain injury does not appear to be a useful therapeutic tool in reducing the level of regional ischaemic burden.	Univ Cambridge, Dept Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England		Johnston, AJ (corresponding author), Univ Cambridge, Dept Anaesthesia, Box 93, Cambridge CB2 2QQ, England.	ajj29@cam.ac.uk	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011	Coles, Jonathan/0000-0003-4013-679X			Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P527; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Doyle PW, 1999, BRIT J ANAESTH, V83, P580, DOI 10.1093/bja/83.4.580; Ederberg S, 1998, ANESTH ANALG, V86, P1201, DOI 10.1097/00000539-199806000-00011; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Harrison JM, 1999, BRIT J ANAESTH, V83, P839, DOI 10.1093/bja/83.6.839; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Jansen GFA, 1999, ANESTH ANALG, V89, P358, DOI 10.1097/00000539-199908000-00021; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Kazama T, 1999, ANESTHESIOLOGY, V90, P1517, DOI 10.1097/00000542-199906000-00004; Kett-White R, 2002, J NEUROSURG, V96, P1013, DOI 10.3171/jns.2002.96.6.1013; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Lovell AT, 1999, ANESTH ANALG, V88, P554, DOI 10.1097/00000539-199903000-00017; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Nandate K, 2000, BRIT J ANAESTH, V84, P631, DOI 10.1093/bja/84.5.631; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Souter MJ, 1998, ANESTH ANALG, V86, P926, DOI 10.1097/00000539-199805000-00002; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	23	50	51	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	DEC	2003	91	6					781	786		10.1093/bja/aeg256			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	752EQ	WOS:000187147200003	14633744	Bronze			2022-02-06	
J	Li, DZ; Margaill, I; Palmier, B; Pruneau, D; Plotkine, M; Marchand-Verrecchia, C				Li, DZ; Margaill, I; Palmier, B; Pruneau, D; Plotkine, M; Marchand-Verrecchia, C			LF 16-0687 Ms, a bradykinin B-2 receptor antagonist, reduces ischemic brain injury in a murine modelof transient focal cerebral ischemia	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						bradykinin B-2 receptor antagonist; focal cerebral ischemia; mice; neuroprotection; brain edema; inflammation	KALLIKREIN-KININ SYSTEM; PLATELET-ACTIVATING-FACTOR; CLOSED-HEAD TRAUMA; LF 16-0687 MS; TISSUE KALLIKREIN; RAT MODEL; BARRIER DISRUPTION; ENDOTHELIAL-CELLS; SENSORY NEURONS; TRANSGENIC MICE	1 Bradykinin promotes neuronal damage and brain edema through the activation of the B-2 receptor. The neuroprotective effect of LF 16-0687 Ms, a B-2 receptor antagonist, has been described when given prior to induction of transient focal cerebral ischemia in rat, but there are no data regarding the consequence of a treatment when given after injury. Therefore, in a murine model of transient middle cerebral artery occlusion (MCAO), we evaluated the effect of LF 16-0687 Ms given prior to and/or after the onset of ischemia on neurological deficit, infarct volume and inflammatory responses including cerebral edema, blood-brain barrier (BBB) disruption and neutrophil accumulation. 2 LF 16-0687 Ms (1, 2 and 4 mg kg(-1)) administered 0.5 h before and, 1.25 and 6 h after MCAO, decreased the infarct volume by a maximum of 33% and significantly improved the neurological recovery. 3 When given at 0.25 and 6.25 h after MCAO, LF 16-0687 Ms (1.5, 3 and 6 mg kg(-1)) decreased the infarct volume by a maximum of 25% and improved the neurological score. 4 Post-treatment with LF 16-0687 Ms (1.5 mg kg(-1)) significantly decreased brain edema (-28%), BBB disruption (-60%) and neutrophil accumulation (-65%) induced by ischemia. Physiological parameters were not modified by LF 16-0687 Ms. 5 These data emphasize the role of bradykinin B-2 receptor in the development of infarct lesion, neurological deficit and inflammatory responses resulting from transient focal cerebral ischemia. Therefore, B-2 receptor antagonist might represent a new therapeutic approach in the pharmacological treatment of stroke.	Univ Paris 05, Pharmacol Lab, UPRES EA 2510, F-75006 Paris, France; Ctr Rech, Labs Fournier, Daix, France		Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Pharmacol Lab, UPRES EA 2510, 4 Ave Observ, F-75006 Paris, France.	verrecchia@pharmacie.univ-paris5.fr	Margaill, Isabelle/ABA-4362-2020; MARCHAND-LEROUX, Catherine/L-7453-2017	Margaill, Isabelle/0000-0002-7941-6644; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348			BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bhoola K, 2001, BIOL CHEM, V382, P77, DOI 10.1515/BC.2001.013; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bhoola KD, 1996, IMMUNOPHARMACOLOGY, V33, P247, DOI 10.1016/0162-3109(96)00067-7; Bockmann S, 2000, J LEUKOCYTE BIOL, V68, P587; Carl VS, 1996, IMMUNOPHARMACOLOGY, V33, P325, DOI 10.1016/0162-3109(96)00055-0; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; CHERONIS JC, 1992, J MED CHEM, V35, P1563, DOI 10.1021/jm00087a010; CHRISTOPHER TA, 1994, AM J PHYSIOL, V266, pH867, DOI 10.1152/ajpheart.1994.266.3.H867; Costa SKP, 2002, NEUROSCI LETT, V318, P158, DOI 10.1016/S0304-3940(01)02498-3; CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476-5381.1992.tb14503.x; Ding-Zhou L, 2002, EUR J PHARMACOL, V457, P137, DOI 10.1016/S0014-2999(02)02686-9; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1990, NEW TRENDS LIPID MED, P129; FELETOU M, 1994, BRIT J PHARMACOL, V112, P683, DOI 10.1111/j.1476-5381.1994.tb13130.x; FRANSSON LA, 1992, GLYCOCONJUGATE J, V9, P45, DOI 10.1007/BF00731177; Gecse A, 1989, Adv Exp Med Biol, V247A, P249; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Gorlach C, 1996, PEPTIDES, V17, P1373, DOI 10.1016/S0196-9781(96)00223-9; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HAASEMANN M, 1994, BRAZ J MED BIOL RES, V27, P1739; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; HOSLI E, 1993, NEUROREPORT, V4, P159; IKEDA Y, 1994, ACTA NEUROCHIR, P119; Jeftinija SD, 1996, J NEUROCHEM, V66, P676; KAMII H, 1994, BRAIN RES, V662, P240, DOI 10.1016/0006-8993(94)90818-4; KAMIYA T, 1993, STROKE, V24, P571, DOI 10.1161/01.STR.24.4.571; Kaplanski J, 2002, J NEUROTRAUM, V19, P953, DOI 10.1089/089771502320317104; KATUSIC ZS, 1993, STROKE, V24, P392, DOI 10.1161/01.STR.24.3.392; KIZUKI K, 1994, BRAIN RES, V634, P305, DOI 10.1016/0006-8993(94)91934-8; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Lehmberg J, 2000, ACT NEUR S, V76, P39; LEHMBERG J, 1998, CEREBROVASC DIS, V8, P76; Liao SL, 2001, NEUROREPORT, V12, P1943, DOI 10.1097/00001756-200107030-00034; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MAKEVNINA LG, 1994, BRAZ J MED BIOL RES, V27, P1955; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; PRUNEAU D, 2000, RESTOR NEURAL NEUROS, V16, P177; Rachinsky M, 2001, J TRAUMA, V51, P944, DOI 10.1097/00005373-200111000-00020; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V32, P39, DOI 10.1016/0162-3109(96)00007-0; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; Raidoo DM, 1998, PHARMACOL THERAPEUT, V79, P105, DOI 10.1016/S0163-7258(98)00011-4; Regoli D, 1998, EUR J PHARMACOL, V348, P1, DOI 10.1016/S0014-2999(98)00165-4; Relton JK, 1997, STROKE, V28, P1430, DOI 10.1161/01.STR.28.7.1430; ROSENBLUM WI, 1987, CIRC RES, V61, P601, DOI 10.1161/01.RES.61.4.601; Rozsa Z, 1998, GASTROENTEROLOGY, V114, pA411, DOI 10.1016/S0016-5085(98)81664-8; Rydh-Rinder M, 2001, REGUL PEPTIDES, V102, P69, DOI 10.1016/S0167-0115(01)00297-X; SATOH K, 1995, THROMB HAEMOSTASIS, V74, P1335; Schulz J, 2000, ACT NEUR S, V76, P137; Schwaninger M, 1999, J NEUROCHEM, V73, P1461, DOI 10.1046/j.1471-4159.1999.0731461.x; Shigematsu S, 1999, AM J PHYSIOL-HEART C, V277, pH152, DOI 10.1152/ajpheart.1999.277.1.H152; Sobey CG, 1997, STROKE, V28, P2290, DOI 10.1161/01.STR.28.11.2290; SORNAS R, 1972, ARCH NEUROL-CHICAGO, V26, P489, DOI 10.1001/archneur.1972.00490120029002; Stover JF, 2000, ACTA NEUROCHIR SUPPL, V76, P171; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; VERRECCHIA C, 2000, RESTOR NEUROL NEUROS, V16, P177; Wagner S, 2002, J NEUROL SCI, V202, P75, DOI 10.1016/S0022-510X(02)00208-3; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V323, P66, DOI 10.1007/BF00498830; WIRTH K, 1991, EUR J PHARMACOL, V205, P217, DOI 10.1016/0014-2999(91)90824-A; Zausinger S, 2002, BRAIN RES, V950, P268, DOI 10.1016/S0006-8993(02)03053-6	75	50	52	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	AUG	2003	139	8					1539	1547		10.1038/sj.bjp.0705385			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	712JZ	WOS:000184795700021	12922942	Green Published			2022-02-06	
J	Zanier, ER; Lee, SM; Vespa, PM; Giza, CC; Hovda, DA				Zanier, ER; Lee, SM; Vespa, PM; Giza, CC; Hovda, DA			Increased hippocampal CA3 vulnerability to low-level kainic acid following lateral fluid percussion injury	JOURNAL OF NEUROTRAUMA			English	Article						kainic acid; secondary injury; seizures; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; EXCITATORY AMINO-ACIDS; HUMAN HEAD-INJURY; GLUCOSE-UTILIZATION; INTRACRANIAL HYPERTENSION; GLUTAMATE RELEASE; RAT; SEIZURES; HYPOXIA	This study was designed to determine whether a secondary increase in neuronal activity induced by a low dose of kainic acid (KA), a glutamate analogue, exacerbates the anatomical damage in hippocampal regions following a mild lateral fluid percussion (LFP) brain injury. KA (9 mg/kg) was injected intraperitoneally in LFP-injured rats (n = 16) 1 h post-trauma. The neuronal loss in the CA3, CA4, and hilar regions at 7 days was quantified by two-dimensional cell counts. Hippocampal activation 15 min following KA injection was assessed by measuring local glucose metabolic rates (ICMRglc). Following LFP+KA, the ipsilateral side exhibited a 62.7%, 75.7%, and 52.1% decrease in the number of CA3, CA4 and hilar neurons, respectively, compared to naive rats (n = 3). These CA3 and CA4 neuronal counts were also significantly decreased compared to LFP+saline (n = 5) and sham+KA (n = 9) groups. The median Racine Score, used to rate the severity of behavioral seizures, was 4 in LFP+KA and 2 in sham+KA groups (p < 0.015), suggesting a reduction in seizure threshold following injury. lCMR(glc) in CA3 following LFP+KA was 121.8 +/- 2.0 (mean +/- SE) ipsilaterally and 71.5 +/- 5.4 contralaterally (p < 0.0012). No changes were found in the BBB permeability as measured by [C-14]aminoisobutyric acid in CA3, CA4, and hilar regions. We conclude that the presence of low-level KA I h after LFP dramatically increases the extent of hippocampal. activation and induces a striking; loss of ipsilateral CA3 and CA4 pyramidal neurons. Neuronal excitation during a time of cellular vulnerability may trigger or amplify the cycle of secondary damage in functionally impaired, but potentially viable, tissue.	Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg Neurosurg, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat Neurol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA		Lee, SM (corresponding author), Univ Calif Los Angeles, Med Ctr, 18-228 NPI,Box 957039, Los Angeles, CA 90095 USA.		Zanier, Elisa/AAA-8095-2020	Zanier, Elisa/0000-0002-3011-8718	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, NS02089-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER		ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Becker DP, 1989, TXB HEAD INJURY, P1; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; BERGSNEIDER M, 1997, J NEUROSURG, V86, P5241; BLASBERG RONALD, 1966, BRAIN RES, V1, P86, DOI 10.1016/S0006-8993(66)80073-2; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cotman C W, 1986, Adv Exp Med Biol, V203, P237; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERKANY JW, 1982, NATURE, V298, P757, DOI 10.1038/298757a0; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Friedberg MH, 1999, J NEUROPHYSIOL, V81, P2243, DOI 10.1152/jn.1999.81.5.2243; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Goodman JC, 1996, ACT NEUR S, V67, P37; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kudo M, 2001, ANESTHESIOLOGY, V94, P303, DOI 10.1097/00000542-200102000-00021; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller JD, 1996, NEUROTRAUMA, P61; Moore A. H., 2000, Journal of Neurotrauma, V17, P994; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Prough DS, 2001, CRIT CARE MED, V29, P1278, DOI 10.1097/00003246-200106000-00042; RACINE R, 1972, ELECTROEN CLIN NEURO, V32, P295, DOI 10.1016/0013-4694(72)90178-2; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; SATER RA, 1988, NEUROSCI LETT, V84, P73, DOI 10.1016/0304-3940(88)90340-0; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Sommer C, 2001, ACTA NEUROPATHOL, V101, P460; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Suzuki M, 2002, J NEUROTRAUM, V19, P285, DOI 10.1089/08977150252807027; Toth Z, 1997, J NEUROSCI, V17, P8106; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Xiong LZ, 2003, ANESTH ANALG, V96, P233, DOI 10.1097/00000539-200301000-00047; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	67	50	50	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2003	20	5					409	420		10.1089/089771503765355496			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682MY	WOS:000183096900002	12803974				2022-02-06	
J	Mazzini, L; Cossa, FM; Angelino, E; Campini, R; Pastore, I; Monaco, F				Mazzini, L; Cossa, FM; Angelino, E; Campini, R; Pastore, I; Monaco, F			Posttraumatic epilepsy: Neuroradiologic and neuropsychological assessment of long-term outcome	EPILEPSIA			English	Article						posttraumatic epilepsy; MRI; SPECT; cognitive and behavioral disorders	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; CLOSED-HEAD-INJURY; RATING-SCALE; SEIZURES; PERSONALITY; FLUENCY; MEMORY; SPECT; MOOD	Purpose: We sought to detect the incidence and the risk factors of posttraumatic epilepsy (PTE) in rehabilitation patients; to define the influence of PTE for late clinical and functional outcome; and to assess the cognitive and behavioral features of the patients with PTE. Methods: Patients were examined with (a) cognitive and behavioral examinations, which included a clinical interview and psychometric tests performed by an expert clinical psychologist; (b) single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI); and (c) functional evaluation including the Glasgow Outcome Scale (GOS) and the Functional Independence Measure (FIM). Results: Of the 143 patients examined in this study, in 27 (19%), seizures developed after a mean time from trauma of 11.9 +/- 8.6 months. The occurrence of PTE was significantly correlated with the hypoperfusion in temporal lobes (p < 0.004), the degree of hydrocephalus (p < 0.04), the evidence of intracerebral hematoma (p < 0.01), and operative brain injury (p < 0.001). Patients with epilepsy showed a significantly higher incidence of personality disorders than did patients without epilepsy. The disinhibited behavior, irritability, and agitated and aggressive behavior were significantly more frequent and severe in PTE patients. The psychometric tests intended to explore memory, language, intelligence, attention, and spatial cognition did not show any significant difference between those with and without epilepsy. PTE also was significantly correlated with a worse functional outcome 1 year after the trauma. Conclusions: The degrees of hydrocephalus and of hypoperfusion in the temporal lobes are significant risk factors for late PTE. Another main finding of our study is the absence of influence of epilepsy on cognitive disorders; its influence on neurobehavioral disorders and functional outcome is discussed.	San Giovanni Bosco Hosp, Dept Neurol, I-10154 Turin, Italy; Fdn S Maugeri, Neuropsychol Unit, Inst Care & Res IRCCS, Sci Inst Veruno No, Verona, Italy; Univ Amedo Avogadro, Dept Neurol, Novara, Italy		Mazzini, L (corresponding author), San Giovanni Bosco Hosp, Dept Neurol, Largo Donatore Sangue 3, I-10154 Turin, Italy.	mazzini.l@libero.it	Mazzini, Letizia/AAA-2262-2021	Mazzini, Letizia/0000-0003-2479-9120			AMSTRONG KK, 1990, ARCH PHYS MED REHAB, V71, P156; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Basso A, 1987, Funct Neurol, V2, P189; Beck AT, 1987, BECK DEPRESSION INVE; Blumer D, 1999, NEUROLOGY, V53, pS9; Capitani E, 1999, CORTEX, V35, P273, DOI 10.1016/S0010-9452(08)70800-1; Capitani E, 1998, CORTEX, V34, P779, DOI 10.1016/S0010-9452(08)70781-0; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chadwick D, 2000, LANCET, V355, P334, DOI 10.1016/S0140-6736(99)00452-3; Cossa FM, 1999, BRAIN INJURY, V13, P583; DELLASALA S, 1992, PSYCHOL MED, V22, P885, DOI 10.1017/S0033291700038460; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; GIBBS EL, 1948, ARCH NEURO PSYCHIATR, V60, P331, DOI 10.1001/archneurpsyc.1948.02310040002001; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; Haltiner A M, 1996, J Int Neuropsychol Soc, V2, P494; HATHAWAY SR, 1967, MMPI MANUAL; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1975, EPILEPSY NONMISSILE; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Meador KJ, 2000, PHARMACOTHERAPY, V20, p185S, DOI 10.1592/phco.20.12.185S.35253; MENDEZ MF, 1993, NEUROLOGY, V43, P1073, DOI 10.1212/WNL.43.6.1073; MONACO F, 1997, NEUROPSYCHOL REHABIL, P253; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Novelli GLM, 1986, ARCH PSICOL NEUROL P, V2, P278; ORSINI A, 1987, ITAL J NEUROL SCI, V8, P539; Paradiso S, 2001, J NEUROL NEUROSUR PS, V70, P180, DOI 10.1136/jnnp.70.2.180; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; PRAYER L, 1993, ACTA RADIOL, V34, P593; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Robertson MM, 1999, EPILEPSIA, V40, pS1, DOI 10.1111/j.1528-1157.1999.tb00882.x; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Spreen O., 1983, CONTRIBUTION NEUROPS; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SWANSON SJ, 1995, BRAIN, V118, P91, DOI 10.1093/brain/118.1.91; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; van Elst LT, 2000, BRAIN, V123, P234, DOI 10.1093/brain/123.2.234; Van Zomeren A. H., 1981, REACTION TIME ATTENT; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; Wiegartz P, 1999, NEUROLOGY, V53, pS3; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	50	50	55	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	APR	2003	44	4					569	574		10.1046/j.1528-1157.2003.34902.x			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	667UU	WOS:000182253100012	12681007	Bronze			2022-02-06	
J	AbdelMalik, P; Husted, J; Chow, EWC; Bassett, AS				AbdelMalik, P; Husted, J; Chow, EWC; Bassett, AS			Childhood head injury and expression of schizophrenia in multiply affected families	ARCHIVES OF GENERAL PSYCHIATRY			English	Article; Proceedings Paper	8th International Congress on Schizophrenia Research	APR 28-MAY 02, 2001	WHISTLER, CANADA				TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; PSYCHIATRIC-DISORDERS; RISK-FACTORS; PSYCHOSIS; CHILDREN	Background: The etiology of schizophrenia is believed to include genetic and nongenetic factors, with the pathogenesis involving abnormal neurodevelopment. We investigated whether mild head injury during brain maturation plays a role in the expression of schizophrenia in multiply affected families. Methods: We compared the history and severity of head injuries in childhood (age, less than or equal to10 years) and through adolescence (age, less than or equal to17 years) in 67 subjects with narrowly defined schizophrenia and 102 of their unaffected siblings from 23 multiply affected families. In subjects with schizophrenia, only head injuries preceding the onset of psychosis were considered. Results: Subjects in the schizophrenia group (n = 16 [23.9%]) were more likely than the unaffected siblings g. roup (n = 12 [11.8%]) to have a history of childhood head injury (P = .04; odds ratio, 2.35 [95% confidence interval, 1.03-5.36]). Subjects in the schizophrenia group with a history of childhood head injury had a significantly younger median age at onset of psychosis (20 years) compared with those with no such history (25 years; z = -2.98; P = .003). The severity of head injury ranged from minimal to mild, including concussions, but within this narrow range, severity was correlated with younger age at onset (r(s) = -0.66; P = .005). Head injury occurred a median of 12 years before the onset of psychosis. Results were similar if head injuries during adolescence were included, but did not achieve statistical significance. Conclusions: Mild childhood head injury may play a role in the expression of schizophrenia in families with a strong genetic predisposition. Prospective studies of mild head injury should consider genetic predisposition for possible long-term neurobehavioral sequelae.	Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON M6J 1H4, Canada; Univ Toronto, Dept Psychiat, Toronto, ON M6J 1H4, Canada; Univ Waterloo, Dept Hlth Studies & Gerontol, Waterloo, ON, Canada		Bassett, AS (corresponding author), Univ Toronto, Ctr Addict & Mental Hlth, 1001 Queen St W, Toronto, ON M6J 1H4, Canada.		AbdelMalik, Philip S. O./C-8525-2017	AbdelMalik, Philip S. O./0000-0002-7984-2088	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [97800-1] Funding Source: Medline		ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; BASSETT AS, 1993, SCHIZOPHR RES, V11, P9, DOI 10.1016/0920-9964(93)90033-F; Bassett AS, 2001, SCHIZOPHRENIA BULL, V27, P417, DOI 10.1093/oxfordjournals.schbul.a006884; Brzustowicz LM, 2000, SCIENCE, V288, P678, DOI 10.1126/science.288.5466.678; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GUREJE O, 1994, AM J PSYCHIAT, V151, P368; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1989, MILD HEAD INJURY, P8; LEVIN HS, 1989, MILD HEAD INJURY, P189; LISHMAN WA, 1998, ORGANIC PSYCHIAT PSY; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MCGUFFIN P, 1994, BRIT J PSYCHIAT, V164, P593, DOI 10.1192/bjp.164.5.593; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; QUAYLE K, 1997, PEDIATRICS, V99; REISS D, 1991, AM J PSYCHIAT, V148, P283; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; SNOEK JW, 1989, MILD HEAD INJURY, P102; SNOW JH, 1994, PEDIAT TRAUMATIC BRA, V31; Spitzer R. L., 1990, STRUCTURED CLIN INTE; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.0.CO;2-#; WEINBERGER DR, 1995, LANCET, V346, P552, DOI 10.1016/S0140-6736(95)91386-6; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8	29	50	51	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-990X			ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	MAR	2003	60	3					231	236		10.1001/archpsyc.60.3.231			6	Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	655UZ	WOS:000181572200002	12622655	Green Accepted, Bronze			2022-02-06	
J	Hanks, RA; Wood, DL; Millis, S; Harrison-Felix, C; Pierce, CA; Rosenthal, M; Bushnik, T; High, WM; Kreutzer, J				Hanks, RA; Wood, DL; Millis, S; Harrison-Felix, C; Pierce, CA; Rosenthal, M; Bushnik, T; High, WM; Kreutzer, J			Violent traumatic brain injury: Occurrence, patient characteristics, and risk factors from the Traumatic Brain Injury Model Systems project	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; risk factors; violence	COMMUNITY INTEGRATION QUESTIONNAIRE; FUNCTIONAL INDEPENDENCE MEASURE; GLASGOW COMA SCALE; DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; UNITED-STATES; OUTCOMES; REHABILITATION; CONSCIOUSNESS; RELIABILITY	Objectives: To examine the occurrence of and characteristics associated with violent traumatic brain injury (TBI) in the Traumatic Brain Injury Model Systems (TBIMS) project for 4 of the 5 original Model Systems centers and to determine the patient characteristics of this group, as well as the risk factors for sustaining such an injury. Design: Prospective evaluation of individuals with violent TBI over a 10-year period. Setting: Four TBIMS centers. Participants: A total of 1229 individuals who received acute hospitalization and inpatient rehabilitation care for TBI. Interventions: Not applicable. Main Outcome Measure: The occurrence of a violent TBI. Results: Twenty-six percent of the participants in the TBIMS project sustained a violent TBI. This type of injury was more common in African-American men who were single and slightly older than the average TBI patient, were unemployed before injury, and had had a previous TBI. A higher injury rate was noted in the earlier part of the evaluation period. Those who sustained a violent TBI had higher levels of caregiver burden and disability, as well as decreased productivity and community reintegration at rehabilitation discharge and at 1 and 2 years postinjury. Conclusions: The occurrence of violent TBI in the TBIMS project is consistent with national trends of decreasing incidence of violent injuries in the 1990s. These results present a profile of those who have been injured through violence. The relative risks for sustaining such an injury appear to be well defined when considering demographic and temporal factors.	Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Craig Hosp, Englewood, CO USA; Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Baylor Coll Med, Houston, TX 77030 USA; TIRR, Houston, TX 77030 USA; Virginia Commonwealth Univ, Richmond, VA USA		Hanks, RA (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, 261 Mack Blvd, Detroit, MI 48201 USA.			Bushnik, Tamara/0000-0003-3328-257X			Beaman V, 2000, ANN EMERG MED, V35, P258, DOI 10.1016/S0196-0644(00)70077-1; *CDCP, 1997, US INJ MORT STAT; Cherry D, 1998, ANN EMERG MED, V32, P51, DOI 10.1016/S0196-0644(98)70099-X; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Cole TB, 1996, JAMA-J AM MED ASSOC, V275, P1709, DOI 10.1001/jama.1996.03530460013004; *CTR TBIMSND, 2001, TRAUM BRAIN INJ MOD; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; TEASDALE G, 1974, LANCET, V2, P81; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226	31	50	51	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					249	254		10.1053/apmr.2003.50096			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	643QV	WOS:000180872700015	12601657				2022-02-06	
J	Naunheim, RS; Ryden, A; Standeven, J; Genin, G; Lewis, L; Thompson, P; Bayly, P				Naunheim, RS; Ryden, A; Standeven, J; Genin, G; Lewis, L; Thompson, P; Bayly, P			Does soccer headgear attenuate the impact when heading a soccer ball?	ACADEMIC EMERGENCY MEDICINE			English	Article						soccer; head impact; accelerometer; headgear	INJURIES; CONCUSSION; PLAYERS; HELMETS	There is increasing concern that repetitive blows to the head, such as those from heading a soccer ball, can cause measurable cognitive impairment. Reducing acceleration of impact could reduce neurologic sequelae. Objective: To measure the effectiveness of four different types of soccer headgear in reducing the acceleration of impact. Methods: A standard magnesium headform was instrumented with a triaxial accelerometer. A soccer ball was propelled at the headform at three different speeds known to occur in soccer play: 9, 12, and 15 m/sec (20, 26, and 34 mph). The main outcome was the peak acceleration of the headform associated with these impacts with and without protective headgear. Results: Peak accelerations were found in a range from 144 m/s(2) to 289 m/s(2) (14.67-29.5 G, G = 9.81 m/s(2)). Using multivariate analysis of variance (MANOVA) methods to compare the headbands and controls, there was no significant difference in the measured accelerations at the center of gravity with or without headgear (p = 0.50). However, the interaction term of headbands, pressure, and speed was significant at F = 5.51 and p = 0.00001. Using contrasts within conditions, some headbands were found to cause a decrease in peak acceleration at the highest speed and pressure. Conclusions: Currently available headgear for soccer heading shows little ability to attenuate impact during simulated soccer heading. However, statistically significant decreases are present at the highest speeds and pressures tested, suggesting the headbands may play a role in decreasing impact for more forceful blows.	Washington Univ, Sch Med, Div Emergency Med, Dept Emergency Med, St Louis, MO 63110 USA; Washington Univ, Dept Mech Engn, St Louis, MO 63110 USA; Washington Univ, Dept Biostat, St Louis, MO 63110 USA; Washington Univ, Human Performance Lab, St Louis, MO 63110 USA		Naunheim, RS (corresponding author), Washington Univ, Sch Med, Div Emergency Med, Dept Emergency Med, Campus Box 8072,660 S Euclid Ave, St Louis, MO 63110 USA.			Bayly, Philip/0000-0003-4303-0704			*ASTM, 1997, 1997 ANN BOOK ASTM S, P923; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; Gadd C. W., 1966, P 10 STAPP CAR CRASH; GENIN GM, 2001, P BIOM ENG SOC ANN M; GRONWALL D, 1975, LANCET, V2, P995; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MCDERMOTT FT, 1982, MED J AUSTRALIA, V2, P30, DOI 10.5694/j.1326-5377.1982.tb124205.x; OFFNER PJ, 1992, J TRAUMA, V32, P636, DOI 10.1097/00005373-199205000-00016; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; TSYVAER AT, 1991, AM J SPORTS MED, V19, P56; Versace, 1971, P 15 STAPP CAR CRASH, DOI DOI 10.4271/710881; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P104	16	50	50	4	17	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JAN	2003	10	1					85	90		10.1197/aemj.10.1.85			6	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	632YH	WOS:000180252100014	12511322	Bronze			2022-02-06	
J	Chan, RCK				Chan, RCK			Attentional deficits in patients with persisting postconcussive complaints: A general deficit or specific component deficit?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; EXECUTIVE FUNCTION; REACTION-TIME; LOBE LESIONS; CONCUSSION; SYMPTOMS; RECOVERY; BRAIN; QUESTIONNAIRE	This study aimed to examine attentional performance in patients with persisting postconcussive complaints. using a multi-componential perspective. Comparisons of attentional performances of 92 patients with postconcussive complaints and 86 normal controls were conducted using tests of sustained attention (Sustained Attention to Response Task Digit Backward Span). selective attention (Stroop Word-Color Test; Color Trails Test), divided attention (Paced Auditory Serial Addition Test Symbol Digit Modalities Test), and attentional control processing (Six Elements Test: Tower of Hanoi). Questionnaires on daily life inattentive behaviour were also administered to all participants and their significant others. A MANOVA indicated that patients with persisting postconcussive complaints demonstrated a general deficit in attentional performance as compared with their normal controls, F(18, 145)=7.939. p=.005. These patterns still persisted when measures of emotional disturbance were controlled, F(18,143)=5.159, p=.005. Moreover, for sustained attention and selective attention, we were able to statistically control for speed and the differences remained. Future research should be conducted to better control the potential confound of speed for all the attentional components in order to differentiate any specific component deficits in these patients.	Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China		Chan, RCK (corresponding author), Univ Hong Kong, Dept Psychiat, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	rckchan@hkucc.hku.hk	Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BINDER LM, 1997, J CLIN EXPT NEUROPSY, V19, P529; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BRUDER G, 1980, PSYCHOL MED, V10, P549, DOI 10.1017/S0033291700047449; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW., 1996, BEHAV ASSESSMENT DYS; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P1, DOI 10.1162/jocn.1997.9.1.1; CHAN CM, 1984, COGNITIVE THER RES, V8, P501, DOI 10.1007/BF01173287; Chan RCK, 1999, ARCH CLIN NEUROPSYCH, V14, P735, DOI 10.1016/S0887-6177(99)80228-5; Chan RCK, 2001, BRAIN INJURY, V15, P71, DOI 10.1080/02699050150209156; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; DELIA LF, 1996, COLOUR TRAILS TEST P; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1989, FRONTAL LOBE FUNCTIO, P229; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GEOL V, 1995, NEUROPSYCHOLOGIA, V33, P623; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hair JF, 1995, MULTIVARIATE DATA AN; Humes GE, 1997, ASSESSMENT, V4, P249, DOI 10.1177/107319119700400305; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Lee TMC, 2000, J CLIN EXP NEUROPSYC, V22, P465, DOI 10.1076/1380-3395(200008)22:4;1-0;FT465; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEONCARRION J, 1997, NEUROPSYCHOL REHABIL, P47; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MANDEL S, 1989, POSTGRAD MED, V85, P213; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A.F., 1996, ATTENTION MEMORY EXE, P71; Morris RG, 1997, COGN NEUROPSYCHOL, V14, P1007, DOI 10.1080/026432997381330; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Reitan RM, 1997, NEUROPSYCHOL REV, V7, P3, DOI 10.1007/BF02876970; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Wechsler D., 1981, WAIS R MANUAL WECHSL; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940	56	50	54	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2002	24	8					1081	1093		10.1076/jcen.24.8.1081.8371			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	642HA	WOS:000180797100009	12650233				2022-02-06	
J	Johnstone, B; Nossaman, LD; Schopp, LH; Holmquist, L; Rupright, SJ				Johnstone, B; Nossaman, LD; Schopp, LH; Holmquist, L; Rupright, SJ			Distribution of services and supports for people with traumatic brain injury in rural and urban Missouri	JOURNAL OF RURAL HEALTH			English	Article							STRATEGIES	New paradigms of disability suggest that many variables interact to influence the community functioning of people with traumatic brain injury (TBI), including injury severity and social, psychological, and environmental factors. Unfortunately, the majority of TBI outcome research to date has primarily focused on injury severity variables (e.g., neuroradiologic findings, loss of consciousness, posttraumatic amnesia) to the exclusion of environmental variables. Limited environmental resources such as rehabilitation professionals, facilities, and services may be significant barriers that affect outcome for people with TBI, particularly for those in rural areas. Using data from Missouri, where 32% of the population lives in rural counties, this study researched the availability of rehabilitation resources or individuals with TBI, with an emphasis on differences between rural and urban areas. Data indicated that there is a scarcity of rehabilitation professionals (i.e., physiatrists, mental health providers, rehabilitation therapists), facilities (i.e., hospitals offering comprehensive rehabilitation therapies), and services (i.e, support groups) in rural areas of the study state. The results suggest that (1) future rehabilitation researchers need to evaluate the impact of accessibility to rehabilitation services and resources on the outcome of people with TBI and (2) TBI health policy administrators need to consider how to increase rehabilitation resources for people with TBI in rural areas, including the use of rural-based training programs, rural debt-forgiveness training programs, and telehealth systems.	MU Sch Hlth Profess, Dept Hlth Psychol, Columbia, MO 65212 USA		Johnstone, B (corresponding author), MU Sch Hlth Profess, Dept Hlth Psychol, DC04600, Columbia, MO 65212 USA.	johnstoneg@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			*AM HOSP DIR, 2000, AM HOSP DIR ON LIN; Hagglund K., 1998, TOP SPINAL CORD INJ, V4, P28, DOI DOI 10.1310/3502-06MD-F2NK-LBGK; Innes B., 2000, J DISABIL POLICY STU, V10, P207, DOI [10.1177/104420730001000205, DOI 10.1177/104420730001000205]; *MDOH, 2000, DAT STAT REP; *MO BRAIN INJ ASS, 2000, SUPP GROUPS; *MO DEP EC DEV, 2000, LAB MARK INF INF GEO; *MO DEP MENT HLTH, 2000, TREATM CTR; *MO DEP SOC SERV D, 1999, DIR LONG TERM CAR FA; *MO DEP TRANSP CUS, 1999, LIST ORG ZIP PROV TR; *MO DIV VOC REH, 2000, OFF; *MO HOSP ASS, 2000, MISS HOSP COUNT; *MO STAT BOARD REG, 1999, VAR DAT LIST LIC REG; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; *NE MISS COLL CAR, 2000, RESH RUR NURS SERV H; OMOHUNDRO J, 1983, J REHABIL, V49, P19; *RUPRI, 1999, RUPRI RUR POL CONT M; *RUR POL RES I, 2000, BACKGR INF STAT POP; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Schneider M J, 1986, Annu Rev Rehabil, V5, P217; SCHOOTMAN M, 1999, BRAIN INJURY, V48, P70; Schopp L, 2000, PROF PSYCHOL-RES PR, V31, P179, DOI 10.1037/0735-7028.31.2.179; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; SEELMAN KD, 1998, PLEN SESS TIDE 3 C A; *SERV IND LIV, 2000, CIL LOC DIR IND LIV; *U MISS SYST OFF S, 2000, BACKGR INF STAT POP; U.S. Census Bureau, 2000, STAT COUNT QUICK FAC; *US CENS BUR, 1999, MA 98 2 METR AR POP; *US CENS BUR, 1999, MA 98 3B POP EST MET; *US DEP HHS, 1997, N CAR RUR HLTH RES P; WHO, 2000, INT CLASS FUNCT DIS; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	31	50	50	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0890-765X	1748-0361		J RURAL HEALTH	J. Rural Health	WIN	2002	18	1					109	117		10.1111/j.1748-0361.2002.tb00882.x			9	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health	552WJ	WOS:000175642800015	12043749				2022-02-06	
J	Zhang, L; Abreu, BC; Gonzales, V; Seale, G; Masel, B; Ottenbacher, KJ				Zhang, L; Abreu, BC; Gonzales, V; Seale, G; Masel, B; Ottenbacher, KJ			Comparison of the Community Integration Questionnaire, the Craig Handicap Assessment and Reporting Technique, and the disability rating scale in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						correlation; outcome measurement; participation; rehabilitation; traumatic brain injury	SEVERE HEAD-INJURY; FOLLOW-UP; EPIDEMIOLOGY; RELIABILITY; OUTCOMES; VALIDITY; COMA	To examine the concurrent validity of the Community Integration Questionnaire (CIQ) in assessing outcomes in traumatic brain injury (TBI) by comparing it with two widely used and well-validated measurements of rehabilitation outcome. Design: A retrospective relational study of the concurrent validity of the CIQ, Craig Handicap Assessment and Reporting Technique (CHART), and Disability Rating Scale (DRS). Setting: A postacute rehabilitation facility. Participants: Seventy patients with a medical diagnosis of TBI admitted between April 1996 and October 1998 participated in the study. Results: CIQ and CHART provide ratings that are similar in several areas to those provided by the DRS. Correlation (r) among total scores and subscales for all three instruments ranged from 0.021 to 0.671 (P < .01). Correlation between CIQ and CHART is stronger than that between CIQ and DRS or between CHART and DRS, and the correlation between CHART and DRS is stronger than that between CIQ and DRS. Conclusion: The CIQ appears to be the most appropriate instrument in quantifying rehabilitation outcome in patients with TBI at the participatory (handicap) level. The findings of this study can help clinicians gain a greater understanding of the nature, redundancy, and gaps among functional outcome measures. Monitoring outcomes can also help clinicians better understand the effectiveness of interventions.	Transit Learning Ctr, Galveston, TX USA; Univ Texas, Med Branch, Sch Allied Hlth Sci, Galveston, TX 77550 USA; Univ Texas, Med Branch, Sealy Ctr Aging, Galveston, TX 77550 USA					Ottenbacher, Kenneth/0000-0001-5990-3982	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG017638] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG17638] Funding Source: Medline		BEUKELMAN DR, 1991, COMMUNICATION DISORD; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; BROWN ME, 1984, FUNCTIONAL ASSESSMEN, P187; CAREY RG, 1978, ARCH PHYS MED REHAB, V59, P330; Cohen J., 2013, STAT POWER ANAL BEHA; Cope D., 1993, J HEAD TRAUMA REHAB, V8, P1; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER V, 1984, FUNCTIONAL ASSESSMEN, P14; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; Hall K M, 1994, NeuroRehabilitation, V4, P76, DOI 10.3233/NRE-1994-4204; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HEINEMANN A, 1995, J HEAD TRAUMA REHAB, V10, P64; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; Ottenbacher KJ, 1998, AM J EPIDEMIOL, V147, P615; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SARNO JE, 1973, ARCH PHYS MED REHAB, V54, P214; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; Switzer S F, 1991, J Insur Med, V23, P239; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WHITENECK G, 1988, GUIDE USE CHART CRAI; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Willer B., 1993, BRAIN INJURY REHABIL, P355; World Health Organization, 1980, INT CLASS IMP DIS HA	39	50	51	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2002	17	6					497	509		10.1097/00001199-200212000-00002			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	617NN	WOS:000179367900002	12802241				2022-02-06	
J	Mickeviciene, D; Schrader, H; Nestvold, K; Surkiene, D; Kunickas, R; Stovner, LJ; Sand, T				Mickeviciene, D; Schrader, H; Nestvold, K; Surkiene, D; Kunickas, R; Stovner, LJ; Sand, T			A controlled historical cohort study on the post-concussion syndrome	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						concussion; headache; post-concussion syndrome	TRAUMATIC BRAIN INJURY; MINOR HEAD-INJURY; POSTCONCUSSION SYNDROME; POSTTRAUMATIC HEADACHE; EXPECTATION; ETIOLOGY; MIGRAINE; SYMPTOMS; WHIPLASH; PAIN	In Lithuania, expectation of chronic symptoms after minor head injury is less than in western countries and possibilities for monetary compensation are minimal. Therefore, an opportunity exists to study the post-concussion syndrome (PCS) without several confounding factors present in western societies. We sent questionnaires about symptoms attributed to PCS to 200 subjects who had a concussion with loss of consciousness between 35 and 22 months before the study. For each study subject, a sex- and age-matched control person with minor non-head injury was identified. These controls received similar questionnaires. All the responding post-concussion patients stated that they had had acute headache after the trauma but this headache had disappeared in 96% of cases within 1 month. Headache and dizziness at the time of the questioning were not significantly more prevalent in the patients with concussion than in the controls, and there was no significant difference concerning subjective cognitive dysfunction. Scores of visual analogue scales of symptoms attributed to PCS showed no significant differences except for depression, alcohol intolerance and worry about brain injury, which were more frequent in the concussion group. No specific effect of the head injury was detected when various definitions and different constellations of core symptoms of PCS were used. These findings question the validity of the PCS as a useful clinical entity.	Univ Trondheim Hosp, Dept Neurol & Clin Neurophysiol, N-7006 Trondheim, Norway; Red Cross Hosp, Dept Neurol, Kaunas, Lithuania; Red Cross Hosp, Traumatol Emergency Ward, Kaunas, Lithuania; Med Univ Clin, Dept Neurol, Kaunas, Lithuania; Cent Hosp Akershus, Nordbyhagen, Norway		Schrader, H (corresponding author), Univ Trondheim Hosp, Dept Neurol & Clin Neurophysiol, N-7006 Trondheim, Norway.	harald.schrader@medisin.ntnu.no		Schrader, Harald/0000-0001-9975-1960			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALVES WM, 1990, NEUROLOGICAL SURG, P2219; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Guidetti V, 1998, CEPHALALGIA, V18, P455, DOI 10.1046/j.1468-2982.1998.1807455.x; Hasvold T, 1996, SCAND J PRIM HEALTH, V14, P92, DOI 10.3109/02813439608997077; JIN HQ, 1991, INT J EPIDEMIOL, V20, P230, DOI 10.1093/ije/20.1.230; Keidel M, 1997, NERVENARZT, V68, P769, DOI 10.1007/s001150050193; Kelly JP, 1997, NEUROLOGY, V48, P581; Long C J, 1983, Psychiatr Med, V1, P35; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Obelieniene D, 1999, J NEUROL NEUROSUR PS, V66, P279, DOI 10.1136/jnnp.66.3.279; Poole GV, 1997, J TRAUMA, V42, P711, DOI 10.1097/00005373-199704000-00022; *SBU, 2000, LAKARTIDNINGEN, V97, P5493; Schrader H, 1996, LANCET, V347, P1207, DOI 10.1016/S0140-6736(96)90733-3; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0	23	50	51	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	NOV	2002	9	6					581	587		10.1046/j.1468-1331.2002.00497.x			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	620RZ	WOS:000179547400005	12453072				2022-02-06	
